<SEC-DOCUMENT>0001299130-24-000054.txt : 20240228
<SEC-HEADER>0001299130-24-000054.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228162825
ACCESSION NUMBER:		0001299130-24-000054
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		24695895

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pacb-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:pacb="http://www.pacificbiosciences.com/20231231" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pacb-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-32">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001299130</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">False</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-36">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-727">http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-245" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1017">0.0229885</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-221" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1018">0.046512</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pacb-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>pacb:unit</xbrli:measure></xbrli:unit><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OmniomeStockAwardsRelatedToAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-03</xbrli:startDate><xbrli:endDate>2021-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-31</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-31</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-20</xbrli:startDate><xbrli:endDate>2023-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>pacb:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="offering"><xbrli:measure>pacb:offering</xbrli:measure></xbrli:unit><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:ShelfOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-18</xbrli:startDate><xbrli:endDate>2021-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-20</xbrli:startDate><xbrli:endDate>2021-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-22</xbrli:startDate><xbrli:endDate>2022-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">pacb:ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:TwoThousandTenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>pacb:period</xbrli:measure></xbrli:unit><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>pacb:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i02b9487756a44f62beca493d5cd6fd6a_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-34899</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><img src="pacb-20231231_g1.jpg" alt="pacb-20221231x10kg001.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Pacific Biosciences of California, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">16-1590339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">1305 O&#8217;Brien Drive</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">94025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">94025</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">521-8000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">PACB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant on June 30, 2023, based upon the closing price of Common Stock on such date as reported by NASDAQ Global Select Market, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">3,323,701,933</ix:nonFraction>. Shares of voting stock held by each officer and director have been excluded in that such persons may be deemed to be affiliates. This assumption regarding affiliate status is not necessarily a conclusive determination for other purposes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Number of shares outstanding of the registrant&#8217;s common stock as of January&#160;31, 2024: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">267,951,880</ix:nonFraction></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form 10-K </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Fiscal Year Ended December 31, 2023</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_19">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_22">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_517">Item 1</a><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_517">C</a><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_517">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_517">C</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_517">yber</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_517">sec</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_517">urity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_22">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_25">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_28">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_31">55</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_37">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_40">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_43">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_64">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_64">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_64">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_67">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_67">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_130">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_130">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_130">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_133">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_133">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_136">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_136">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_136">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_139">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_139">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_139">113</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_142">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_145">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_145">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_145">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_148">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_148">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_148">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_151">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_151">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_151">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_154">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_154">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_154">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_157">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_157">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_157">113</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_160">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_163">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_163">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_163">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_166">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_166">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_166">116</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_169">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_169">117</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections titled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain or may contain forward-looking statements that are based on the beliefs and assumptions of the management of Pacific Biosciences of California, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) and on information currently available to our management. The statements contained in this Annual Report on Form 10-K that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the availability, uses, accuracy, sensitivity, advantages, compatibility, pricing, specifications, quality, or performance of, or benefits or expected benefits or using, our products or technologies, including the Revio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Onso</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our current and future products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our strategic and commercial plans, including our expectations for Revio and Onso systems; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our market opportunity, including market size and expected market growth;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our expectations regarding the conversion of backlog to revenue and the pricing and gross margin for products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our manufacturing plans including developing and scaling of manufacturing and delivery of our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our research and development plans; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the anticipated impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts, on our business, business plans and results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our product development plans, roadmaps, and objectives, including, among other things, statements relating to future uses, quality, or performance of, or benefits of using, products or technologies, updates, or improvements of our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our intentions regarding seeking regulatory approval for our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our competitive landscape, including competition in the short- and long-read sequencing technologies markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our expectations regarding collaborations and partnerships; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our expectations regarding unrecognized income tax benefits; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our expectations regarding market risk, including interest rate changes and general macroeconomic conditions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the sufficiency of cash, cash equivalents, and investments to fund projected operating requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the effects of recent accounting pronouncements on our financial statements; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">other future events. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by words such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading &#8220;Risk Factors&#8221; in this report and in other documents we file with the Securities and Exchange Commission (SEC). Given these risks and uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent management&#8217;s beliefs and assumptions as of the date of this report. Except as required by law, we assume no obligation to update forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K also contains estimates, projections, and other information concerning our industry, our business, and the markets for our products, including data regarding the estimated size and estimated growth for those markets. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_16"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB</span><span style="background-color:#ffffff;color:#333333;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) short-read sequencing technology. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Methods</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world`s most advanced sequencing systems to provide our customers the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we commercially released two new sequencing platforms, Revio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Onso</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revio is a new long-read sequencing system designed to enable the use of HiFi sequencing for large studies in human genetics, cancer research, and agricultural genomics. Commercial shipments for Revio commenced in the first quarter of 2023, and 173 systems have since been shipped to more than twenty countries as of December 31, 2023. We released SMRT Link 13.0 software on the Revio system which includes the adaptive loading feature for consistent run performance, run preview for improved lab efficiency, and expanded application support with functionality to sequence shorter and longer fragments of DNA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onso, a short-read DNA sequencing system, is designed to deliver industry-leading sensitivity and specificity for novel insights in oncology, disease research, and other applications. We commenced customer shipments of Onso in the third quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we acquired Apton Biosystems to accelerate the development of a high-throughput platform based on the SBB chemistry utilized by Onso. Through acquiring Apton, we obtained expertise in state-of-the-art optics and image processing and a novel clustering method and chemistry designed to enable the sequencing of billions of clusters of DNA on one flow cell. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also develop products used to prepare molecules for sequencing on our platforms. In the fourth quarter of 2023, we commenced commercial shipments for a new Kinnex</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products used to concatenate small molecules into larger fragments to optimize the output on HiFi sequencing systems like Revio. The Kinnex products are designed for various applications in RNA and amplicon sequencing. As of December 31, 2023, we received orders from over 70 customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Mission and Impact</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to enable the promise of genomics to better human health. Genomics is core to all biological processes, and our advanced genomics tools provide scientists and clinical researchers with the insights to better understand biology and health. The &#8220;promise of genomics&#8221; postulates that medicine, agriculture, public health, drug development, and other disciplines will be transformed by incorporating routine genomic information over the coming decades. We see early progress toward this transformation in the applied use of genomics in areas such as genetic disease, oncology, and sustainable food production. However, legacy genomics technologies have fundamental limitations in progressing these fields toward the promise of genomics. We believe that unleashing the full potential of genomics will require a level of accuracy and completeness inaccessible to legacy technologies. Accuracy and completeness are central to our product development strategy; thus, we have created some of the most innovative and high-quality genomics solutions on the market. Our products also have enhanced multi-omic capabilities to look beyond the genome to the transcriptome and epigenome, which we believe is key to understanding a full picture of biology.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Underlying Science</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic inheritance in living organisms is conveyed through a naturally occurring information storage system known as deoxyribonucleic acid, or DNA. DNA stores information in linear chains of the chemical bases adenine, cytosine, guanine, and thymine, represented by the symbols A, C, G, and T respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In humans, the genome is comprised of approximately three billion DNA base pairs, which are divided into 23 chromosomes ranging in size from 50 million to 250 million bases. A human carries two copies of the chromosomes, one inherited from each parent. Approximately 23,000 smaller regions within these chromosomes, called genes, contain the blueprints for protein production. The proteins synthesized from these blueprints essentially underlie the operation of all biological systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genome sequencing reads the bases of long fragments of nucleic acids. Initial genome sequencing studies have shown that mutations in these DNA base pairs play a critical role in human disease, contributing to the burgeoning field of genomics. Since then, recent discoveries have highlighted additional complexities of DNA and RNA. These discoveries include the presence of chemical modifications to the bases, such as methylation, and post-translational modification, or the processing of RNA molecules after they are transcribed from the genome, both of which can affect protein synthesis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Principal Markets </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Researchers utilize our solutions in human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Genomics: Improving rare disease research and understanding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to a World Health Organization publication, it is estimated that 400 million people worldwide are affected by up to 8,000 distinct rare diseases, with 80% of these believed to be genetic in nature. These genetic diseases are DNA differences, called variants, in the affected individuals. Variants range in size from single nucleotide substitutions to large losses or gains of entire chromosomes. Other sequencing technologies applied to rare disease diagnosis are technologically limited to interrogating small variants, representing only a subset of possible genomic variation. Consequently, most genetic disease cases are undiagnosed, leaving families on multi-year diagnostic odysseys. Sequencing the human genome with long and accurate reads enables the potential detection of all known classes of disease-causing variation. In addition, the ability of PacBio&#8217;s long-read sequencing technology to detect 5-Methylcytosine DNA methylation, an epigenetic modification shown to alter gene behavior, may enable further advances in research and development in genetic disease diagnosis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infectious Disease and Microbiology: Understanding and tracking microbes and pathogens in support of global public health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology has increased the scientific community&#8217;s understanding of microorganisms and viruses and their malignancy, transmission, and potential resistance to antibiotics or vaccines. Our sequencing technology delivers highly comprehensive and complete genomes, enabling federal agencies, public health organizations, and healthcare providers to conduct wide-ranging research and surveillance activities to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">generate high quality, complete genome assemblies, revealing variants of all known types, to gain a deeper understanding of community-acquired and hospital-associated infections and transmissions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">identify and characterize pathogens to inform regional, national, and global public health agencies for preparation and response to rapidly evolving microorganisms; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">characterize complex microbial communities to understand their role in human, animal, and environmental health.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology: Enable the discoveries of underlying causes of cancer, progression, and relapse</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Understanding tumor cells` cellular and molecular complexity is critical in developing more effective targeted cancer therapies. Single-cell transcriptomics is particularly impactful in defining cellular identity and function; however, other technologies miss critical information by only sequencing a portion of RNA. Our long-read RNA sequencing method, single-cell Iso-Seq (scIso-Seq), accurately detects molecular events such as RNA isoforms and expressed mutations and provides gene expression information at the single-cell level. We believe scIso-Seq is uniquely positioned to enable discoveries by researchers of the underlying causes of cancer initiation, progression, and relapse, as well as the discovery by researchers of novel diagnostic, prognostic, and predictive biomarkers that may inform future clinical tests. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As novel discoveries continue to be made using our long-read sequencing technology, we believe our SBB short-read sequencing technology will enable us to meet customers` demands in the expanding non-invasive testing market in oncology. Due to the small amounts of circulating tumor DNA (ctDNA) present in the blood of early-stage cancer patients and those with minimal residual disease (MRD), the presence of cancer often goes undetected, and a more sensitive assay will be required. Based on testing internally and at beta customer sites, we believe our SBB technology has the potential to offer higher accuracy than competitor sequencing technologies, which may in the future support our customers&#8217; development of more sensitive tests for the purpose of earlier detection and more robust monitoring of cancer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plant and Animal Sciences: Helping scientists answer biological questions for a healthier world </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Plant and Animal Sciences, academic, government and corporate researchers are using our technology to explore and catalog the genetic and biological diversity of organisms for the breeding, propagation, and production of crops and livestock while conserving the planet&#8217;s natural resources. PacBio HiFi sequencing enables researchers to build high quality de novo reference genomes and transcriptomes to study variations across species enabling improvements to global conservation initiatives and support the breeding and production of resilient and higher yielding crops to meet the world's growing population and demand.   </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Technology, Products, and Solutions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed HiFi long-read sequencing based on Single-Molecule Real-Time (SMRT) technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. We are also expanding our genomic solutions with our short-read SBB chemistry, which offers sensitive sequencing for short-read applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales consist of sequencing instruments, nanofluidic chips (SMRT Cells), and reagents for preparing DNA and performing sequencing based on our SMRT technology; flow cells and reagents for preparing DNA and performing sequencing based on our SBB technology, reagents for DNA extraction based on our Nanobind technology; and the services we perform for customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HiFi Long-Read Sequencing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our HiFi long-read sequencing protocol was built upon our</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SMRT sequencing systems, including consumables and software, and offers customized end-to-end workflows for different sequencing applications. Highly accurate, long sequence reads simplify and accelerate data analysis algorithms, reducing the need for error correction steps and/or assembly aspects, depending on the application.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers use our HiFi long-read sequencing platforms in a wide range of sequencing applications, including whole genome sequencing and </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome assembly, long-range phasing, targeted sequencing, full-length RNA and single-cell sequencing, characterization of metagenomic communities and other mixed DNA samples, viral genome sequencing, and others. Our technology is also capable of detecting epigenetic markers simultaneously by analyzing the kinetics of DNA polymerization that is affected, and thereby detectable, by epigenetic markers such as 5-methylcytosine or N</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">6</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-methyladenine.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SMRT Technology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary SMRT Technology enables the observation of DNA synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which in nature is a highly efficient and accurate process actuated by DNA polymerases. DNA polymerases attach to a strand of DNA to be replicated, examine the individual base at the point it is attached, and then determine which of the four building blocks, or nucleotides (A, C, G, or T), is required to complement that individual base. After determining which nucleotide is required, the polymerases incorporate that nucleotide into the growing strand being produced.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SMRT Sequencing is based on following the activity of DNA polymerase on individual DNA molecules in real time that occurs on our SMRT Cells that are monitored and analyzed within our HiFi long-read sequencing systems: the Revio system, Sequel II system, Sequel IIe system, and Sequel system. Carried out on SMRTbell</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> templates, which attach hairpin adapters to the ends of double-stranded DNA molecules to be sequenced, SMRT sequencing allows for the successive sequencing of both the forward and reverse strands of the individual DNA molecule occurring multiple times, thereby allowing for the same base of the same molecule to be sequenced more than once in a sequencing run. The base calls from the serial observation of the molecule can be processed to generate the final base call in an analytical procedure called circular consensus sequencing, leading to what we have defined as our HiFi sequence reads, which have high accuracy typically being defined as having greater than 99% read accuracy, but often exceeding greater than 99.9% accuracy, according to research we performed in collaboration with other researchers, subsequently published in </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Biotechnology</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019. HiFi reads typically are 15-20 kilobases in size, depending on the input fragments, providing sufficient read length with our accuracy to support a multitude of applications across human health, plant and animal, and microbiology, according to research we performed in collaboration with other researchers, subsequently published in </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scientific Data</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020. The ability to generate single-DNA molecule sequence reads that are both long and highly accurate allows researchers to obtain more contiguous, complete, and accurate genomic data, thereby allowing for greater insights into the complexity of biological systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HiFi Long-Read Sequencing Instruments: Revio system + Sequel systems </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revio, Sequel, Sequel II, and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G, or T base call with associated quality metrics. Once sequencing is started, the real-time data is delivered to the system&#8217;s primary analysis pipeline, which outputs base identity and quality values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HiFi Consumables</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers purchase proprietary consumable products to run their PacBio systems, including our SMRT Cells and reagent kits. One SMRT Cell is consumed per sequencing reaction, and scientists can choose the number of SMRT Cells they use per experiment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SMRTbell double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. Our binding/polymerase kits include our modified DNA polymerase and are used to bind SMRTbell libraries to the polymerase in preparation for sequencing. Our core sequencing kits contain reagents required for on-instrument, real-time sequencing, including phospholinked nucleotides.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and offered a new line of Kinnex kits with companion SMRT Link software to enable high-throughput, scalable, cost-effective RNA applications including bulk RNA, single-cell RNA, and 16S rRNA sequencing. The Kinnex kits are built upon the Multiplexed Array Sequencing (MAS-Seq) method for concatenating smaller amplicons into larger fragments to sequence on PacBio's long read sequencers, increasing the molecular yield by up to 16-fold. Throughput increase in these key RNA applications where the dynamic range of different RNA isoforms (bulk and single-cell) or microbial species (16S) can vary by orders of magnitude, enables characterization of these complex RNA samples while drastically reducing sequencing need.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">S</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BB Short-Read Sequencing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast to SMRT sequencing, SBB reads short fragments of DNA (hundreds of bases instead of kilobases) in a massively parallel manner. Current short-read next generation sequencing technologies available in the market incur various rates of errors in results. Researchers deploy multiple tactics to try to mitigate these effects, including oversampling or implementing complex library preparation methods, yet still face challenges, including missing rare variants.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> believe our proprietary SBB approach will enable researchers to address the gap in detecting rare variants, especially in complex heterogenous samples. Employing a two-phase sequencing chemistry, the SBB approach binds a dye-labeled nucleotide without incorporation into the DNA chain, then removes that base, then blocks and extends with a terminated nucleotide. Using nucleotides with single modifications, we incorporate more native bases, avoiding potential scarring due to fluorescent linker presence. This design helps avoid raw errors and we believe can help us develop a product with substantially greater accuracy than currently marketed short-read sequencing products. SBB enables simplified upfront library preparation, redefines coverage requirements, and reduces bioinformatic workload for downstream analysis. The accuracy of our novel sequencing approach has the potential to advance translational cancer research, drive higher fidelity single-cell applications, and broadly enable clinical sequencing&#8212;even in regions of the genome prone to sequencing errors with other short-read sequencing technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SBB Short-Read Sequencing Instrument: Onso system </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Onso instrument conducts, monitors, and analyzes SBB biochemical reactions. The instrument uses extremely sensitive imaging systems to collect the light emitted by fluorescent reagents allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G, or T base call with associated quality metrics. Once sequencing is started, the imaging data is delivered to the system&#8217;s primary analysis pipeline, which outputs base identity and quality values.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SBB Consumables</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our Onso instrument, we also sell a range of SBB consumable products including flow cells, clustering, and sequencing reagent kits. One flow cell and associated sequencing reagent pack is consumed per sequencing reaction. Each flow cell contains two lanes and scientists can choose to sequence different samples in each lane while additionally combining any number of flow cells needed per experiment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SBB compatible, double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. Additionally for library preparation, our conversion kits include reagents to enable scientists to convert existing sequencing libraries into an SBB compatible format. Finally, our clustering and sequencing kits contain all reagents required for generating sequence ready clusters on flow cell and performing SBB sequencing reactions on instrument, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy for Growth</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enable the promise of genomics, our strategy includes the following key elements:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Increase technology adoption by increasing market share via new customer acquisition, continue Sequel II conversions to Revio, and scale Onso production; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Leverage innovation to complete development of new sequencing platforms and launch on-market system improvements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Build upon clinical momentum by expanding HiFi usage in large-scale programs and translational research projects; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Drive towards positive cash flow through gross margin expansion, disciplined operating expense management, and a focus on working capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing, Sales, Service, and Support </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products through a global sales force and through distribution partners in Asia and Australia, certain parts of Europe, the Middle East and Africa, and Latin America. We plan to continue to invest in growing our marketing, sales, service, and support resources as we drive continued adoption of products, launch new products, and expand our customer base.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to seasonal trends. See the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_442723">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section, specifically the risk factor titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_442724">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock</a>,</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. In general, our customers will isolate, prepare, and analyze genetic samples using PacBio sequencing systems in their own laboratories, or they will send their genetic samples to third-party service providers who in turn will sequence the samples with PacBio systems and provide the sequence data back to the customer for further analysis. For example, customers in academic research institutions may have bacteria, animal, or human DNA samples isolated from various sources while agricultural biology companies may have DNA samples isolated from different strains of rice, corn, or other crops. For the year ended December 31, 2023, no single customer accounted for 10% or more of our total revenue. For the years ended December 31, 2022, and 2021, one customer accounted for approximately 12% and 13% of our total revenue, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the majority of our current customers are early adopters of sequencing technology. By focusing our efforts on high-value applications, and developing whole product solutions around these applications, we seek to drive the adoption of our products across a broader customer base and into numerous large-scale projects. In general, the broader adoption of new technologies by mainstream customers can take a number of years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Backlog </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our product backlog was approximately $18.7 million, compared to $51.5 million as of December 31, 2022. We define backlog as purchase orders or signed contracts from our customers, which we believe are firm and for which we have not yet recognized revenue. We expect to convert the majority of this backlog to revenue during 2024; however, our ability to do so is subject to customers who may seek to cancel or delay their orders even if we are prepared to fulfill them. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture sequencing instruments, SMRT Cells, and reagents. Our key manufacturing and service facility in Menlo Park, California has received ISO 13485 and ISO 9001 certifications for the design, development, manufacture, distribution, installation, and servicing of its nucleic acid sequencing platforms. We utilize subcontract manufacturers for components of the manufacturing process. We purchase both custom and off-the-shelf components from a large number of suppliers and subject them to significant quality specifications. We periodically conduct quality audits of most of our critical suppliers and have established a supplier qualification program. Some of the components required in our products are currently either sole sourced or single sourced. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically made and plan to continue to make significant investments in research and development. Our research and development efforts focus on programs to develop new and existing platforms, as well as increasing throughput and decreasing costs on behalf of our customers. We are currently developing higher throughput platforms that utilize our HiFi long-read sequencing and SBB short-read sequencing technologies. We also are developing a benchtop HiFi platform intended to improve accessibility for smaller laboratories, and we continue to extend our on-market platforms, Revio and Onso. In addition to platform development, we also innovate across end-to-end workflows to improve usability, as well as develop new applications for the advancement of human health. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing and maintaining a strong intellectual property portfolio is an important element of our business. We have sought, and will continue to seek, patent protection for our SMRT and SBB technology, for improvements to our SMRT kit and SBB technology, as well as for any of our other technologies where we believe such protection will be advantageous. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current patent portfolio, including patents exclusively licensed to us, is directed to various technologies, including SMRT nucleic acid sequencing and other methods for analyzing biological samples, zero-mode waveguide (ZMW) arrays, surface treatments, phospholinked nucleotides and other reagents for use in nucleic acid sequencing, optical short-read nucleic acid sequencing, nucleic acid preparation, and purification components and systems, processes for identifying nucleotides within nucleic acid sequences, and processes for analysis and comparison of nucleic acid sequence data. Some of the patents and applications that we own, as well as some of the patents and applications that we have licensed from other parties, are subject to U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government march-in rights, whereby the U.S. government may disregard our exclusive patent rights on its own behalf or on behalf of third parties by imposing licenses in certain circumstances, such as if we fail to achieve practical application of the U.S. government funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government funded inventions must be reported to the government and U.S. government funding must be disclosed in any resulting patent applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we own or hold exclusive licenses to 437 issued U.S. patents, 89 pending U.S. patent applications, 6 pending Patent Cooperation Treaty ("PCT") patent applications, 441 issued foreign patents, and 166 pending foreign patent applications. The full term of the issued U.S. patents will expire between 2024 and 2041. We also have non-exclusive patent licenses with various third parties to supplement our own large and robust patent portfolio.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Sequencing Solutions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of companies offering nucleic acid sequencing equipment or consumables. These include, but are not limited to, Illumina, Inc. (&#8220;Illumina&#8221;), BGI Genomics (also known as MGI or Complete Genomics), Thermo Fisher Scientific Inc. (&#8220;Thermo&#8221;), Oxford Nanopore Technologies Ltd. (&#8220;ONT Ltd.&#8221;), Roche Holding AG (&#8220;Roche&#8221;), Qiagen N.V. (&#8220;Qiagen&#8221;), Element Biosciences, Inc. (&#8220;Element&#8221;), Bionano Genomics, Inc. (&#8220;Bionano&#8221;), Ultima Genomics, Inc. (&#8220;Ultima&#8221;) and Singular Genomics Systems, Inc. (&#8220;Singular&#8221;). These companies may have different levels of financial, technical, manufacturing, administrative, and support resources available to them. We expect the competition to intensify within the overall nucleic acid sequencing market as there are also several companies developing new sequencing technologies, products and/or services. Increased competition may result in pricing pressures, which could harm our sales, profitability, or share of supply.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for us to maintain and increase our sales, we will need to demonstrate that our products deliver superior performance and value as a result of our key differentiators. Our HiFi long-read sequencing will need to continue to deliver very high consensus accuracy and long-read lengths and include single-molecule, real-time resolution, with the ability to detect real-time kinetic information, fast time-to-result and flexibility, as well as support the breadth and depth of current and future applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising, and labeling of certain medical devices, including in vitro diagnostic products and laboratory-developed tests, are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA) and comparable state and foreign regulatory agencies. FDA defines a medical device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component part or accessory, which is (i) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (ii) intended to affect the structure or any function of the body of man or other animals and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. Medical devices to be commercially distributed in the United States must receive from the FDA either clearance of a pre-market notification, known as 510(k), or pre-market approval pursuant to the FDC Act prior to marketing, unless subject to an exemption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to label and sell our products for research use only (&#8220;RUO&#8221;) and expect to sell them to research customers in various settings, including academic institutions, life sciences and research laboratories that conduct research, and biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Our current RUO products are not intended or promoted for use in clinical practice in the diagnosis of disease or other conditions, and they are labeled for research use only, not for use in diagnostic procedures. Accordingly, we believe our products, as we intend to market them, are not subject to regulation by the FDA. Rather, while FDA regulations require that RUO products be labeled for research use only and to market and distribute RUO products in accordance with the FDA RUO guidance, the regulations do not subject RUO products to the FDA&#8217;s jurisdiction or the broader pre- and post-market controls for medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to FDA regulation, or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. If we wish to label and expand product lines to address the diagnosis of disease, regulation by governmental authorities in the United States and other countries will become an increasingly significant factor in development, testing, production, and marketing. In the future, products that we may develop in the molecular </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diagnostic markets, depending on their intended use, may be regulated as medical devices or in vitro diagnostic products (&#8220;IVDs&#8221;) by the FDA and comparable agencies in other countries. In the U.S., if we market our products for use in performing clinical diagnostics, such products would be subject to regulation by the FDA under pre-market and post-market control as medical devices, unless an exemption applies, and we would be required to obtain either prior 510(k) clearance or prior pre-market approval from the FDA before commercializing the product. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. Some countries have regulatory review processes that are substantially longer than U.S. processes. Failure to obtain regulatory approval in a timely manner and meet all of the local regulatory requirements including language and specific safety standards in any foreign country in which we plan to market our products could prevent us from marketing products in such countries or subject us to sanctions and fines. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2013, the FDA issued a final guidance on products labeled for research use only, which, among other things, reaffirmed that a company may not make any clinical or diagnostic claims about an RUO product, stating that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, or other regulatory requirements if the totality of circumstances surrounding the distribution of the product indicates that the manufacturer knows its product is being used by customers for diagnostic uses or the manufacturer intends such a use. These circumstances may include, among other things, written or verbal marketing claims regarding a product&#8217;s performance in clinical diagnostic applications and a manufacturer&#8217;s provision of technical support for such activities. If FDA were to determine, based on the totality of circumstances, that our products labeled and marketed for RUO are intended for diagnostic purposes, they would be considered medical devices that will require clearance or approval prior to commercialization. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation. We continue to monitor the changing legal and regulatory landscape to ensure our compliance with any applicable rules, laws and regulations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risk to the patient are placed in either class I or II, which, unless an exemption applies, requires the manufacturer to submit a pre-market notification requesting FDA clearance for commercial distribution pursuant to Section 510(k) of the FDCA. This process, known as 510(k) clearance, requires that the manufacturer demonstrate that the device is substantially equivalent to a previously cleared and legally marketed 510(k) device or a &#8220;pre-amendment&#8221; class III device for which pre-market approval applications (&#8220;PMAs&#8221;) have not been required by the FDA. This FDA review process typically takes from four to twelve months, although it can take longer. Most Class I devices are exempted from this 510(k) pre-market submission requirement. If no legally marketed predicate can be identified for a new device to enable the use of the 510(k) pathway, the device is automatically classified under the FDCA as Class III, which generally requires pre-market approval, or PMA approval. However, the FDA can reclassify or use &#8220;de novo classification&#8221; for a device that meets the FDCA standards for a Class II device, permitting the device to be marketed without PMA approval. To grant such a reclassification, FDA must determine that the FDCA&#8217;s general controls alone, or general controls and special controls together, are sufficient to provide a reasonable assurance of the device&#8217;s safety and effectiveness. The de novo classification route is generally less burdensome than the PMA approval process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or those deemed not substantially equivalent to a legally marketed predicate device, are placed in class III. Class III devices typically require PMA approval. To obtain PMA approval, an applicant must demonstrate the reasonable safety and effectiveness of the device based, in part, on data obtained in clinical studies. All clinical studies of investigational medical devices to determine safety and effectiveness must be conducted in accordance with FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations, including the requirement for the study sponsor to submit an IDE application to FDA, unless exempt, which must become effective prior to commencing human clinical studies. PMA reviews generally last between one and two years, although they can take longer. Both the 510(k) and the PMA processes can be expensive and lengthy and may not result in clearance or approval. If we are required to submit our products for pre-market review by the FDA, we may be required to delay marketing and commercialization while we obtain pre-market clearance or approval from the FDA. There would be no assurance that we could ever obtain such clearance or approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All medical devices, including IVDs, that are regulated by the FDA are also subject to the quality system regulation. Obtaining the requisite regulatory approvals, including the FDA quality system inspections that are required for PMA approval, can be expensive and may involve considerable delay. The regulatory approval process for such products may be significantly delayed, may be significantly more expensive than anticipated, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may conclude without such products being approved by the FDA. Without timely regulatory approval, we will not be able to launch or successfully commercialize such diagnostic products. Changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products. This may negatively affect our ability to obtain or maintain FDA or comparable regulatory clearance or approval of our products in the future. In addition, regulatory agencies may introduce new requirements that may change the regulatory requirements for us or our customers, or both.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, although our products are currently labeled and sold for research purposes only, the regulatory requirements related to marketing, selling, and supporting such products could be uncertain and depend on the totality of circumstances. This uncertainty exists even if such use by our customers occurs without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in some cases, our customers, including laboratories that offer services as part of our certified service provider program, may use our RUO products in their own laboratory-developed tests (&#8220;LDTs&#8221;) or in other FDA-regulated products for clinical diagnostic use. The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against LDTs and LDT manufacturers. However, on October 3, 2014, the FDA issued two draft guidance documents that set forth the FDA&#8217;s proposed risk-based framework for regulating LDTs, which are designed, manufactured, and used within a single laboratory. In January 2017, the FDA announced that it would not issue final guidance on the oversight of LDTs and LDT manufacturers but would seek further public discussion on an appropriate oversight approach and give Congress an opportunity to develop a legislative solution. The FDA has issued warning letters to genomics labs for illegally marketing genetic tests that claim to predict patients&#8217; responses to specific medications, noting that the FDA has not created a legal &#8220;carve-out&#8221; for LDTs and retains discretion to take action when appropriate, such as when certain genomic tests raise significant public health concerns. As laboratories and manufacturers develop more complex genetic tests and diagnostic software, the FDA may increase its regulation of LDTs. Legislative and administrative proposals to amend the FDA's oversight of LDTs have been introduced in recent years, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the &#8220;VALID Act&#8221;). In September 2022, Congress passed the FDA user fee reauthorization legislation without substantive FDA policy riders, including the VALID Act, but Congress may revisit the policy riders and enact other FDA programmatic reforms in the future. In October 2023, through rulemaking, the FDA proposed to amend the definition of &#8220;in vitro diagnostic products&#8221; in FDA regulations to include laboratories that manufacture such products and to phase out the FDA&#8217;s general enforcement discretion approach for LDTs so that IVDs manufactured by a laboratory would be regulated similarly to IVDs. It is unclear when the FDA will finalize and begin enforcing such rule. Any future legislative or administrative rule making or oversight of LDTs and LDT manufacturers, if and when finalized, may impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with these laws. We would become subject to additional FDA requirements if our products are determined to be medical devices or if we elect to seek 510(k) clearance or pre-market approval. If our products become subject to FDA regulation as medical devices, we would need to invest significant time and resources to ensure ongoing compliance with FDA quality system regulations and other post-market regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products become subject to FDA regulation as medical devices, the regulatory clearance or approval and the maintenance of continued and post-market regulatory compliance for such products will be expensive, time-consuming, and uncertain both in timing and in outcome. Commercialization of such regulated medical devices can increase our exposure under additional laws. For example, medical device companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any medical products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil, and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, to the extent we develop any clinical diagnostic assays, we may pursue payment for such products through a diverse and broad range of channels and seek coverage and reimbursement by government health insurance programs and commercial third-party payors for such products. In the United States, there is no </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uniform coverage for clinical laboratory tests. The extent of coverage and rate of payment for covered services or items vary from payor to payor. Obtaining coverage and reimbursement for such products can be uncertain, time-consuming, and expensive, and, even if favorable coverage and reimbursement status were attained for our tests, to the extent applicable, less favorable coverage policies and reimbursement rates may be implemented in the future. Changes in healthcare regulatory policies could also increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our products, decrease our revenue and adversely impact sales of, and pricing of and reimbursement for, our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country. In the future, if we decide to distribute or market our diagnostic products as IVDs in Europe, such products are subject to regulation under the European Union (&#8220;EU&#8221;) IVD Medical Device Regulation (&#8220;IVDR&#8221;) EU 2017/746. Outside of the EU, regulatory approval needs to be sought on a country-by-country basis in order to market medical devices. Although there is a trend towards harmonization of a quality system, standards and regulations in each country may vary substantially, which can affect timelines of introduction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the protection of our employees and the environment. Our operations require the use of hazardous materials that subject us to various federal, state, and local environmental and safety laws and regulations. We believe that we are in material compliance with current applicable laws and regulations. However, we could be held liable for damages and fines should contamination of the environment or individual exposures to hazardous substances occur. In addition, we cannot predict how changes in these laws and regulations, or the development of new laws and regulations, will affect our business operations or the cost of compliance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we must comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations and sanctions imposed by the U.S. Office of Foreign Assets Control, and other similar laws and regulations. Violations of these laws and regulations could result in fines and penalties, criminal sanctions, restrictions on our business conduct, and on our ability to offer our products in one or more countries, and could also materially affect our brand, our ability to attract and retain employees, our international operations, our business, and our operating results. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our employees, contractors, or agents will not violate our policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our business into multiple international markets, our success will depend, in large part, on our ability to anticipate and effectively manage these and other risks associated with our international operations. Any of these risks could harm our international operations and negatively impact our sales, adversely affecting our business, results of operations, financial condition, and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had 796 full-time employees. Of these employees, 317 were in research and development, 91 were in operations, 45 were in service, 226 were in marketing, sales, and customer support, and 117 were in general and administration. With the exception of our field-based sales, marketing, and service teams, the majority of our employees are in California. None of our employees are represented by labor unions or are covered by a collective bargaining agreement with respect to their employment. We have not experienced any work stoppages, and we consider our relationship with our employees to be good. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Acquisition and Retention</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that our employees largely contribute to our success. To this end, we support business growth by seeking to attract and retain best-in-class talent. Our talent acquisition team uses internal and external resources to recruit highly skilled candidates globally. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards philosophy has been to invest in our workforce by offering competitive and fair compensation and benefits packages. We provide employees with compensation packages that include base salary, short-term incentives such as annual bonuses and commissions, and long-term equity awards. We also offer comprehensive employee benefits, which vary by country and region, such as life, disability, and health insurance, health savings and flexible spending accounts, time off benefits, paid parental leave, Employee Stock Purchase Program, and a 401(k) plan. It is our expressed intent to be an employer of choice in our industry by providing market-competitive compensation and benefits packages.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety, and Wellness</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health, safety, and wellness of our employees is a priority in which we have always invested and will continue to do so. We provide our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being. These programs are highlighted and updated regularly on our internal benefits platform. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe a diverse workforce is critical to our success. Our mission is to value differences in races, ethnicities, religions, nationalities, genders, ages, sexual orientations, as well as education, skill sets and experience. We offer training programs on diversity awareness to help employees understand, recognize, respond, and prevent bias throughout the employee lifecycle. We are focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility, and training and resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Training and Development</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in encouraging employees to becoming lifelong learners by providing ongoing learning and leadership training opportunities. We provide a scaled learning platform of on-demand and virtual classroom learning focused on personal and professional development. While we strive to provide real-time recognition of employee performance, we have a formal annual review process not only to determine pay and equity adjustments tied to individual contributions, but to identify areas where training and development may be needed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website is located at </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.pacb.com</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information posted on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and the inclusion of our website address is an inactive textual reference only. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through the &#8220;Investor Relations&#8221; section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC also maintains a website that contains our SEC filings. The address of the site is www.sec.gov.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we use our website (including the blog section of our website) as well as our X (formerly Twitter) account (</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">@pacbio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as a channel of distribution for important company information and to comply with our disclosure obligations under Regulation FD. Important information, including press releases, analyst presentations, and financial information regarding us, as well as corporate governance information, is routinely posted and accessible on the &#8220;Investor Relations&#8221; section of the website, which is accessible by clicking on the tab labeled &#8220;Company - Investors&#8221; on our website home page. In addition, important information is routinely posted and accessible on the blog section of our website, which is accessible through our website at </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.pacb.com/blog</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as our X account (</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">@pacbio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The contents of our website and our X account are not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website or X account are intended to be inactive textual references only.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;<span id="icf38e81c968145f1b504fbfa29b9ccea_442723"></span>RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below, together with all of the other information in our public filings with the SEC, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects. In addition, any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to successfully market, commercialize, and sell current and future products and related maintenance services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to achieve profitability for our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to repay our debt and fund our long-term operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to successfully leverage and integrate our acquisitions and future acquisitions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to successfully research, develop and timely manufacture our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">recent significant changes to our leadership team and resultant disruptions to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">retention, recruitment, and training of senior management, key personnel, scientists and engineers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our reliance on outsourcing to other companies for manufacturing certain components and sub-assemblies, some of which are sole-sourced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to consistently manufacture our instruments and consumables to meet customers&#8217; specifications, quantity, cost, or performance requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the high amount of competition we face in our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to attract customers and increase sales of current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the complexity of our products giving rise to defects or errors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our unpredictable and lengthy sales cycles;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">adverse effects resulting from political and economic tensions between the United States and other countries, including China and Russia, and other geopolitical uncertainties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">securing and maintaining patent or other intellectual property protection for our products and related improvements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">current and future legal proceedings filed against us claiming intellectual property infringement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the potential adverse impact of health epidemics, including any resurgence of COVID-19 cases or other similar outbreaks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">governmental regulations that burden operations or narrow the market for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">volatility of the price of our common stock; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our stock price falling as a result of future offerings or sales of securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are not guarantees that no such conditions exist as of the date hereof and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and expect to continue making substantial investments to develop new products and enhance our existing products through our acquisitions and research and development efforts. For example, we commenced commercial shipments of Revio, our new long-read sequencing system in the first quarter of 2023, and commenced commercial shipments of Onso, our new SBB short-read platform, in the third quarter of 2023. Our future success is substantially dependent on our ability to successfully develop and commercialize our products, including Revio and Onso, as well as acquired technologies, which are anticipated to be used in demanding scientific research that requires substantial levels of accuracy and precision. In addition, we may not be successful in transitioning our prior generation products to our Revio product, or transitioning users of other third party short-read sequencing platforms to Onso, and could incur related obsolete inventory charges and losses on firm purchase commitments. Customers may also be slower than we anticipate in making new capital equipment acquisitions, especially in the current economic environment. Due to challenges we may experience in developing and marketing our existing products and launching new products, we may not be able to effectively:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">manage the timeliness of our new product introductions and the rate at which sales of our new products may cannibalize sales of our older products or manage sales and marketing of multiple sequencing platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">drive adoption of our current and future products, including the Sequel II/IIe, Revio and Onso systems, and products under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">maintain our competitive position by continuing to attract and retain customers for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">provide appropriate levels of customer training and support for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">implement an effective marketing strategy to promote awareness of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">develop and implement an effective sales and distribution strategy for our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">develop, manufacture and commercialize new products or achieve an acceptable return on our manufacturing or research and development efforts and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">comply with regulatory requirements applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">anticipate and adapt to changes in our market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">accommodate customer expectations and demands with respect to our products, increase product adoption by our existing customers or develop new customer relationships;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">deliver our beta systems to our external beta testing sites or complete our external beta testing program on our currently expected timelines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">overcome unexpected challenges discovered during beta testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">complete the scientific and technical validation of new products on our currently expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">deliver our future products in a timely manner to our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">grow our market share by marketing and selling our products for new and additional applications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">manage the significant burdens that expanding our existing or future products into current and new markets may impose on marketing, compliance, and other administrative and managerial resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">maintain and develop strategic relationships with vendors, manufacturers, and other industry partners to acquire necessary materials for the production of, and to develop, manufacture and commercialize, our existing or future products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">adapt or scale our manufacturing activities to meet performance specifications and potential demand at a reasonable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">avoid infringement and misappropriation of third-party intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">obtain and maintain any necessary licenses to third-party intellectual property on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">obtain valid and enforceable patents that give us a competitive advantage or enforce existing patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">protect our proprietary technology; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks noted above, especially with respect to the marketing, sales, and commercialization of our products, may be heightened by the impact of current uncertain market and other conditions. In addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, we could suffer a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generally incurred net losses each quarter since inception, and we cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved in the future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses since inception and our expectation of incurring substantial losses and negative cash flow for the foreseeable future could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">make it more difficult for us to satisfy our obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">limit our ability to fund future working capital, capital expenditures, research and development and other business opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">increase the volatility of the price of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">limit our flexibility to react to changes in our business and the industry in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">place us at a disadvantage to other companies that offer nucleic acid sequencing equipment or consumables; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">limit our ability to borrow additional funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inflationary pressure, including as a result of supply shortages, has adversely impacted and could continue to adversely impact our financial results, and our operating costs may increase. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our customers may choose to reduce their business with us if we increase our pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of the foregoing may have a material adverse effect on our business, operations, financial condition, and prospects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span id="icf38e81c968145f1b504fbfa29b9ccea_439783"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Additional funds may not be available on terms acceptable to us or at all. We have incurred significant debt, and we may incur additional debt, in the future. As of December 31, 2023, we had outstanding approximately $459.0 million aggregate principal amount of 1.50% convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;) and $441.0 million aggregate principal amount of our 1.375% convertible senior notes due 2030 (the &#8220;2030 Notes&#8221; and, together with the 2028 Notes, the &#8220;Notes&#8221;). We may not have sufficient cash to make required payments under the terms of this debt, and should this occur, debt holders have rights senior to common stockholders to make claims on our assets. We may not be able to issue equity securities due to unacceptable terms and conditions to us in the capital markets. To the extent that we intend to raise additional funds through the sale of our common stock, downward fluctuations in our stock price could adversely affect such fundraising efforts. Furthermore, equity financings normally involve shares sold at a discount to the current market price and fundraising through sales of additional shares of common stock or other equity securities will have a dilutive effect on our existing investors. We may be required to seek equity financing at a time when the market price for our common stock is low, which will further contribute to dilution for existing holders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our growth will depend, in part, on our ability to fund our commercialization efforts and our efforts to develop new products, including any improvements to our existing products. To the extent our existing resources are not sufficient, it may require us to delay, or even not allow us to conduct any or all of these activities that we believe would be beneficial for our future growth. We may need to raise additional funds through public or private debt or equity financing or alternative financing arrangements, which may include collaborations or licensing arrangements. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, launching of new products, or operations, or to increase or maintain the level of our research and development activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of, or eliminating some or all of, our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products, or we may need to cease operations. Any of these actions could materially impede our ability to achieve our business objectives and could materially harm our operating results. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements and we are unable to raise capital, it could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have made acquisitions and, in the future, may continue to acquire businesses, technologies or assets, form joint ventures or make other strategic investments with companies that could adversely affect our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we have acquired and expect to continue to pursue acquisitions of complementary businesses, technologies, or assets. We may also pursue technology license arrangements, strategic alliances or investments that complement our business as we have previously with our acquisitions of Circulomics, Omniome and Apton in July 2021, September 2021 and August 2023, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions and strategic transactions involve numerous risks, any of which could harm our business and negatively affect our financial condition and results of operations, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">intense competition for suitable acquisition targets, which could increase prices and adversely affect our ability to consummate deals on favorable or acceptable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure or material delay in closing a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">transaction-related lawsuits or claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties in integrating the technologies, operations, existing contracts, and personnel of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties in retaining key employees or business partners of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties in retaining suppliers, partners, or customers of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">challenges with integrating the brand identity of an acquired company with our own;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">diversion of financial and management resources from existing operations or alternative acquisition opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure to realize the anticipated benefits or synergies of a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties in developing technology post-acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure to identify the problems, liabilities, or other shortcomings or challenges of an acquired company or technology, including issues related to intellectual property, regulatory compliance practices, litigation, revenue recognition or other accounting practices, or employee or user issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">risks that regulatory bodies may enact new laws or promulgate new regulations that are adverse to an acquired company or business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">risks that regulatory bodies do not approve our acquisitions or business combinations or delay such approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">theft of our trade secrets or confidential information that we share with potential acquisition candidates or other potential strategic partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">risk that an acquired company or investment in new services cannibalizes a portion of our existing business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">adverse market reaction to an acquisition or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or other strategic investments, we may raise additional funds, which could adversely affect our existing stockholders and our business. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to stockholders of companies we acquire could also depress our stock price. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to address the foregoing risks or other problems encountered in connection with past or future acquisitions of businesses, new technologies, services, and other assets and strategic investments, or if we fail to successfully integrate such acquisitions or investments, our business, financial condition, and results of operations could be adversely affected, including potential impairments of goodwill and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and timely manufacture our current and future products, including with respect to SMRT Cells, Sequel II/IIe Systems, Revio, Onso, and other SMRT Cell, HiFi, and SBB products under development, and related products, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the highly complex technologies involved in our products, there can be no assurance that we will be able to manufacture and commercialize our current and future products on a timely basis or continue providing adequate support for our existing products. The commercial success of our products, including the Sequel, Sequel II/IIe, Revio and Onso Systems, and the products under development, including acquired technologies, depends on a number of factors, including performance and reliability of the systems, our anticipating and effectively addressing customer preferences and demands, the success of our sales and marketing efforts, effective forecasting and management of product demand, purchase commitments and inventory levels, effective management of manufacturing and supply costs, and the quality of our products, including consumables such as SMRT Cells and reagents. Should we face delays in or discover unexpected defects during the further development or manufacturing process of instruments or consumables related to our products, including with respect to SMRT Cells, reagents, Sequel II/IIe Systems, Revio, Onso, and other SMRT Cell, HiFi, and SBB products under development, including acquired technologies, and including any delays or defects in software development or product functionality, the timing and success of the continued rollout and scaling of our products may be significantly impacted, which may materially and negatively impact our revenue and gross margin. The ability of our customers to successfully utilize our products will also depend on our ability to deliver high quality SMRT Cells and reagents. We have designed SMRT Cells and other consumables specifically for the Sequel, Sequel II/IIe, and Revio Systems, and may need to develop in the future, other customized SMRT Cells and consumables for our future products. Our production of the SMRT Cells for the Sequel and Sequel II/IIe Systems has been and may in the future, including with respect to the Revio system, be below desired levels and yields, and we have experienced and may experience in the future manufacturing delays, product or quality defects, SMRT Cell variability, and other issues. For example, the COVID&#8211;19 pandemic has impacted and, any resurgence of COVID-19, or the outbreak of other similar health epidemics could result in more pronounced impacts to our manufacturing and our ability to supply products. The performance of our consumables is critical to our customers&#8217; successful utilization of our products, and any defects or performance issues with our consumables would adversely affect our business. All of the foregoing could have a material adverse effect on our ability to sell our products or result in other material adverse effects on our business, operations, financial condition, operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of our products is complex and costly. Problems in the design or quality of our products may have a material and adverse effect on our brand, business, financial condition, and operating results, and could result in us losing our certifications from the International Organization for Standardization (&#8220;ISO&#8221;). If we were to lose ISO certification, then our customers might choose not to purchase products from us and this could adversely impact our ability to develop products approved for clinical uses. Unanticipated problems with our products could divert substantial resources, which may impair our ability to support our new and existing products and could substantially increase our costs. If we encounter development challenges or discover errors in our products late in our development cycle, including during external beta testing, we may be forced to undertake design and/or production changes, delay product shipments or the scaling of manufacturing or supply. The completion of the production and external testing of our beta systems may also take longer than currently planned, cost more than currently expected and the scientific and technical validation may not be completed on our currently expected timelines or at all. Such testing may also expose fundamental flaws in our products that may cause us to abandon the further development of such products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the continued rollout of our current and future products, including with respect to the SMRT Cell, the Sequel II/IIe, Revio, and Onso Systems, is delayed or is not successful or less successful than anticipated, then we may not be able to achieve an acceptable return, if any, on our substantial research and development efforts, and our business may be materially and adversely affected. The expenses or losses associated with delayed or unsuccessful product development or lack of market acceptance of our existing and new products, including the SMRT Cell, Sequel II/IIe Systems, Revio, and Onso, could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development efforts may not result in the benefits that we anticipate, and our failure to successfully market, sell, and commercialize our current and future products could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dedicated significant resources to developing our current products, including sequencing systems and consumables based on our proprietary SMRT sequencing technology and our Sequel and Sequel II/IIe Systems. We are also engaged in substantial and complex research and development efforts, which, if successful, may result in the introduction of new products in the future, including in connection with the SMRT Cell, the Sequel II/IIe Systems, Revio and Onso, in addition to other products currently under development, including acquired technologies. Our research and development efforts are complex and require us to incur substantial expenses and we may not be able to develop, manufacture and commercialize new products or obtain regulatory approval if necessary. We may divert significant resources to research and development initiatives that do not result in commercialized products, and even if these efforts do result in commercialized products, there can be no assurance that such products will compete successfully in the market or achieve an acceptable return, if any, on our research and development efforts and expenses. Moreover, our joint research and development efforts with partners require significant management attention and operational resources. If we are unable to successfully manage such joint research and development efforts, our future results may be adversely impacted. Furthermore, we will need to continue to expand our internal capabilities or seek new partnerships or collaborations, or both, in order to successfully develop, market, sell and commercialize our products for and in the markets we seek to reach. If we are unable to do so or are delayed, then this could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must successfully manage new product introductions and transitions, including with respect to the Revio and Onso Systems and each of their related consumables, and the development of acquired technologies, and we may incur significant costs during these transitions and development, and these efforts may not result in the benefits we anticipate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products and services fail to deliver the performance, scalability or results expected by our current and future customers, or are not delivered on a timely basis, our reputation and credibility may suffer, our current and future sales and revenue may be materially harmed and our business may not succeed. For instance, if we are not able to successfully execute on the commercialization of the Revio HiFi long-read sequencing system, and the Onso SBB short-read sequencing system, and each of their related consumables, and any future products that may be developed for research, medical and clinical uses, including acquired technologies, it could have a material adverse effect on our business, financial condition and results of operations. In addition, the introduction of future products, including with respect to future long-read and short-read products, and related consumables, has and may in the future lead to our limiting or ceasing development of further enhancements to our existing products as we focus our resources on new products, and has resulted and could in the future result in reduced marketplace acceptance and loss of sales of our existing products, materially adversely affecting our revenue and operating results. The introduction of new products, including the recent commercialization of our Revio and Onso systems, has had and may in the future also have a negative impact on our revenue in the near-term as our current and future customers have delayed or cancelled and may in the future delay or cancel orders of existing products in anticipation of new products and we may also be pressured to decrease prices for our existing products. Our experience in managing product transitions is limited, and we have experienced, and may in the future experience, difficulty in managing or forecasting customer reactions, purchasing decisions or transition requirements with respect to newly launched products. We have incurred and may continue to incur significant costs in completing these transitions, including costs of write-downs of our products, as current or future customers transition to new products. If we do not successfully manage these product transitions, including with respect to the Revio and Onso Systems and each of their related consumables, and any future long-read and short-read products, our business, operations, financial condition, and prospects may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by health epidemics, including any resurgence of COVID-19 cases or other similar outbreaks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been and could be further adversely impacted by the effects of COVID-19 or other epidemics or pandemics. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is not possible at this time to estimate the impact that health epidemics, including the results of the COVID-19 pandemic and any future resurgence of COVID-19 cases or other similar outbreaks, could have on our business, any pandemic or public health outbreaks or related disruptions and the measures taken by the governments of countries affected could disrupt the supply chain and the manufacture of our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing partners and suppliers have been and could continue to be disrupted by conditions related to COVID-19 or other epidemics or pandemics, possibly resulting in disruption to the production of our products. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. There is significant uncertainty relating to the long-term effect of COVID-19 or other epidemics or pandemics on our business. Infections may resurge or become more widespread and any ensuing disruptions to business activities or supply chains could have a negative impact on our business, financial condition, and operating results. Because our semiconductor manufacturers are located in a region where immunization rates in certain communities may be low, new and emerging variants of COVID-19 or other epidemics or pandemics could impact workforce availability at those locations and disrupt supply. For example, the Chinese government may re-impose lockdowns or similar measures to combat the spread of health epidemics such as COVID-19 or other similar outbreaks and such measures have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, as well as customer demand for our products and demand through certain distributors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the COVID-19 pandemic caused us to modify our business practices, including limiting certain of our commercial operations and limiting certain employees from working in the office. We offered, and if there is a resurgence of COVID-19 or other similar outbreaks, we may again offer a significant percentage of our employees flexibility in the amount of time they work in an office, which could adversely impact the productivity of certain employees and harm our business, including our future operating results. This may also present risks for our strategy and may present operational, cybersecurity, and workplace culture challenges that may adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after the COVID-19 pandemic has further subsided, we may continue to experience an adverse impact to our business as a result of its global economic impact, including recessionary effects and inflationary pressures. Specifically, difficult macroeconomic conditions, such as decreases in discretionary capital expenditure spending, changes to the government funding environment, a reduction in or the lapsing of COVID-19-related governmental stimulus measures, increased and prolonged unemployment or a decline in consumer confidence as a result of the COVID-19 pandemic or other epidemics or pandemics, as well as limited or significantly reduced points of access of our products, could have a continuing adverse effect on the demand for some of our products and, consequently, related maintenance and support services. The degree of impact of COVID-19 or other epidemics or pandemics on our business will depend on several factors, such as the duration and the extent of the pandemic, the risk of waning immunity among persons already vaccinated and an increase in fatigue or skepticism with respect to initial or booster vaccinations, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant changes to our leadership team and the resulting management transitions might harm our future operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant changes to our leadership team since 2020, including the appointment of our current President and Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Chief Commercial Officer, Vice President and Chief Accounting Officer, and Chair of the Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe these leadership transitions are in the best interest of our stakeholders, these transitions may result in the loss of personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations and relationships with employees, suppliers, partners, and customers due to added costs, operational inefficiencies, decreased employee morale and productivity and increased turnover. We must successfully recruit and integrate our new leadership team members within our organization to achieve our operating objectives; as such, the leadership </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transition</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may temporarily affect our business performance and results of operations while the new members of our leadership team become familiar with our business. In addition, our competitors may seek to use this transition and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes may increase our dependency on the other members of our leadership team that remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such departure could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional management turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. Our future operating results depend substantially upon the continued service of our key personnel and in significant part upon our ability to attract and retain qualified management personnel. If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be materially and adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified scientists, engineers, sales personnel and other employees, our ability to maintain, develop and commercialize our products could be harmed and we may be unable to achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. In particular, our scientists and engineers are critical to our technological and product innovations, and we will need to hire additional qualified personnel. Our industry, is characterized by high demand and intense competition for talent, and the turnover rate has been and may continue to be high. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. This competition had been exacerbated by the increase in employee resignations in 2021 and 2022 that had been experienced by us and reported by employers nationwide. In addition, we have experienced significant turnover in our senior management team in recent periods. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued stock options and restricted stock units that vest over time. The value to employees of stock options and restricted stock units that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. We may face challenges in retaining and recruiting such individuals due to sustained declines in our stock price that could reduce the retention value of equity awards. The loss of qualified employees, or an inability to attract, retain, and motivate employees, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and launches, business growth prospects, results of operations and financial condition. In addition, we will need to continue to recruit, hire and retain sales personnel to support the commercialization of our existing and new products. Our employees could leave our company with little or no prior notice and would be free to work for a competitor. In addition, changes to U.S. immigration policies, particularly to H-1B and other visa programs, could restrain the flow of technical and professional talent into the U.S. and may inhibit our ability to hire qualified personnel. If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have &#8220;key person&#8221; life insurance policies covering any member of our management team or other key personnel. Further, our vaccination and return to office protocols related to COVID-19 or other epidemics or pandemics may also impact the recruitment and retention of key employees. The loss of any of these individuals or any inability to attract or retain qualified personnel, including scientists, engineers, sales personnel and others, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and introductions, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to further penetrate nucleic acid sequencing applications as well as on the growth and expansion of the demand for our products. If our products fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may not succeed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although nucleic acid sequencing technology is well-established, our SMRT Sequencing technology is relatively new and evolving. We cannot be sure that our current or future products will gain acceptance in the marketplace at levels sufficient to support our costs. Our success depends, in part, on our ability to expand overall demand for nucleic acid sequencing to include new applications that are not practicable with other current technologies and to introduce new products that capture a larger share of growing overall demand for sequencing. To accomplish this, we must successfully commercialize, and continue development of, our proprietary SMRT Sequencing technology for use in a variety of life science and other research applications, including uses by academic, government and clinical laboratories, as well as pharmaceutical, diagnostic, biotechnology, and agriculture companies, among others. However, we may be unsuccessful in these efforts and the sale and commercialization of the SMRT Cell, Sequel II/IIe, Revio and Onso Systems, and related products may not grow sufficiently to cover our costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be successful in adding new products or securing additional customers for our current and future products, including with respect to the SMRT Cell, Sequel II/IIe Systems, Revio and Onso. If we are unable to successfully develop acquired technologies and sell acquired technology products, we may fail to achieve our strategic commercial initiatives in connection with the planned release of new products and anticipated entry into new markets. Our ability to further penetrate existing applications and any new applications depends on a number of factors, including the cost, performance and perceived value associated with our products, as well as customers&#8217; willingness to adopt a different approach to nucleic acid sequencing. Potential customers may have already made significant investments in other sequencing technologies and may be unwilling to invest in new technologies. We are experiencing pricing pressures caused by industry competition and increased demand for lower-priced instruments and lower operational costs. We have limited experience commercializing and selling products outside of the academic and research settings, and we cannot guarantee success in acquiring additional customers. Furthermore, we cannot guarantee that our products will be satisfactory to potential customers or that our products will perform in accordance with customer expectations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nucleic acid sequencing applications are new and dynamic, and there can be no assurance that they will develop as quickly as we anticipate, that they will reach their full potential or that our products will be appropriate or competitive for these applications. As a result, we may be required to refocus our marketing efforts, and we may have to make changes to the specifications of our products to enhance our ability to enter particular applications more quickly. We may also need to delay full-scale commercial deployment of new products as we develop them in order to perform quality control and early access user testing. We also need to maintain reliable supply chains for the various components in our new products and consumables to support large-scale commercial production. Even if we are able to implement our technology successfully, we and/or our sales and distribution partners may fail to achieve or sustain market acceptance of our current or future products across the full range of our intended life science and other applications. We need to continue to expand and update our internal capabilities or to collaborate with other partners, or both, in order to successfully expand sales of our products in the applications that we seek to reach, which we may be unable to do at the scale required to support our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the demand for our products grows more slowly than anticipated, if we are unable to successfully scale or otherwise ensure sufficient manufacturing capacity for new products to meet demand, if we are not able to successfully market and sell our products, if competitors develop better or more cost-effective products, if our product launches and commercialization are not successful, or if we are unable to further grow our customer base or do not realize the growth with existing customers that we are expecting, our current and future sales and revenue may be materially and adversely harmed, or we may recognize an impairment loss, and our business may not succeed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on other companies for the manufacture of certain components and sub-assemblies and intend to outsource additional sub-assemblies in the future, some of which are sole sources. We may not be able to successfully scale the manufacturing process necessary to build and test multiple products on a full commercial basis, which could materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are complex and involve a large number of unique components, many of which require precise manufacturing. The nature of our products requires customized components that are currently available only from a limited number of sources, and in some cases, single sources. We have chosen to source certain critical components from a single source, including suppliers for our SMRT Cells, reagents, and instruments. We cannot assure you that product supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or that product supplies will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. We may be unable to negotiate binding agreements with our current and future sole source third-party manufacturing and supply collaborators or, in the event that such collaborators&#8217; services become interrupted for any reason, find replacement manufacturers to support our development and commercial activities at commercially reasonable terms. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or fail to provide sufficient quantities in a timely manner. If we are required to purchase these components from alternative sources, it could take several months or longer to qualify the alternative sources. If we are unable to source these product components from sole-source third-party manufacturing and supply collaborators for any reason, including in connection with acts of terrorism, hostilities, military conflict and acts of war, including between China and Taiwan, or secure a sufficient supply of these product components on a timely basis, or if these components do not meet our expectations or specifications for quality and functionality, our operations and manufacturing would be materially and adversely affected, we could be unable to meet customer demand and our business and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of our third-party manufacturing partners and suppliers have had and may in the future be disrupted by conditions unrelated to our business or operations or that are beyond our control, including but not limited to international trade restrictions, inflation, supply chain disruptions, and conditions related to COVID-19 or other epidemics or pandemics. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. For example, the global shortage of semiconductors, which has been reported since early 2021, has caused challenges for us in our supply chain and resulted in some cost increases that have and may continue to adversely impact margins. During these periods of shortages or delays, the price of components may increase, or the components may not be available at all. Our suppliers have raised their prices and may continue to raise prices that we may not be able to pass on to our customers, which could adversely affect our business, including our competitive position, market share, revenues, and profit margins in material ways. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. For example, the Chinese government may re-impose lockdowns or similar measures to combat the spread of COVID-19 or other similar outbreaks and these measures have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, in addition to customer demand for our products and demand through certain distributors. If as a result of global economic or political instability, such as the political uncertainty in the Middle East associated with the Israel and Hamas conflict, an escalation of the war in Ukraine, potential uncertainty related to Taiwan and its relationship with China, other disease outbreaks, or supply issues, we or our contractors could experience shortages, business disruptions or delays for materials sourced or manufactured in the affected countries, and their ability to supply us with instruments or product components may be affected. From time to time, certain components of our systems and reagents may reach the end of their life cycles or become obsoleted by our suppliers, and we would have to procure alternative sources for these end-of-life products. If we encounter delays or difficulties in securing the quality and quantity of materials we require for our products, our supply chain would be interrupted, which would adversely affect sales. If any of these events occur, our business and operating results could be harmed. Accordingly, if any of the foregoing occurs, our ability to commercialize our products, revenue and gross margins could suffer until lockdowns from COVID-19 or other epidemics or pandemics infections are reduced, supply issues or business disruptions are resolved and/or other sources can be developed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because our semiconductor suppliers are in regions that may have communities with low vaccination rates, any variants of COVID-19 that evolve in the future or other outbreaks could lead to increased infections among workers that could further disrupt the supply chain. Our current manufacturing process is characterized by long lead times between the placement of orders for and delivery of our products. If we do not accurately anticipate our needs or if we receive insufficient components to manufacture our products on a timely basis to meet customer demand, our sales and our gross margin may be adversely affected, and our business could be materially harmed. If we are unable to reduce our manufacturing costs and establish and maintain reliable, high-volume manufacturing suppliers as we scale our operations and expand our product offerings, our business, operations, financial condition, and prospects could be materially and adversely harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to consistently manufacture our instruments and consumables, including SMRT Cells and reagents, to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully generate revenue from our products, we need to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. Our customers have experienced variability in the performance of our products. We have experienced and may continue to experience delays, quality issues or other difficulties leading to customer dissatisfaction with our products. Our production of SMRT Cells, flow cells and of reagents for both our-long and short-read technologies, involve a long and complex manufacturing process and has been and may in the future be below desired yields and resulting output levels. We have experienced and may experience in the future manufacturing delays, product defects, variability in the performance of SMRT Cells, flow cells and other products, inadequate reserves for inventory, or other issues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be able to manufacture our products so that they consistently achieve the product specifications and quality that our customers expect, including any products developed for clinical uses. Problems in the design or quality of our products, including low manufacturing yields of SMRT Cells, flow cells, or sub-performing reagent lots may have a material adverse </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our brand, business, financial condition, and operating results, and could result in us losing our ISO certifications. If we were to lose our ISO certifications, then our customers might choose not to purchase products from us. There is also no assurance that we will be able to increase manufacturing yields and decrease costs, particularly if high rates of inflation continue, or that we will be successful in forecasting customer demand or manufacturing and supply costs, or that product supplies, including reagents or integrated chips, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. Furthermore, while we are undertaking efforts to increase our manufacturing scale and capability, we may not be able to increase manufacturing to meet anticipated demand or may experience downtime in our manufacturing facilities, including, for example, if  our suppliers are unable to meet our increased demand at a time when the supply chain is under duress due to potential dislocations and disruptions in product and employee availability (whether due to health epidemics or pandemics or otherwise). An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs, will have a negative impact, and may have a material adverse effect on our business, product development timelines, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapidly changing technology in life sciences and research diagnostics could make our products obsolete unless we continue to develop, manufacture and commercialize new and improved products and pursue new opportunities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. These new and evolving technologies may be superior to, impair, or render obsolete the products we currently offer or the technologies currently underlying our products. Our future success depends on our ability to continually improve our products, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new opportunities. These new opportunities may be outside the scope of our proven expertise or in areas where demand is unproven, and new products and services developed by us may not gain market acceptance or may not adequately perform to capture market share. Our inability to develop and introduce new products and to gain market acceptance of our existing and new products could harm our future operating results. Unanticipated difficulties or delays in replacing existing products with new products or in commercializing our existing or new products in sufficient quantities and of acceptable quality to meet customer demand, including with respect to the SMRT Cell, Sequel II/IIe Systems, Revio and Onso, could diminish future demand for our products and may materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the markets for our products, including our Revio and Onso instruments, may be smaller than estimated, and new market opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for sequencing systems and consumables products is evolving, making it difficult to accurately predict the size of the markets for our current and future products, including our Revio and Onso instruments. Our estimates of the total addressable market for our current and future products are based on a number of internal and third-party estimates and assumptions that may be incorrect, including the assumptions that academic, governmental, corporate, or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our products. In addition, sales of new products may take time to develop and mature and we cannot be certain that these market opportunities will develop as we expect. While we believe our assumptions and the data underlying our estimates of the total addressable market for our products are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the total addressable market and growth opportunities for our products may be incorrect.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future growth of the market for our current and future products depends on many factors beyond our control, including recognition and acceptance of our products by the research and scientific communities, the growth, prevalence and costs of competing products and solutions and the development of robust ecosystems supporting our products and their methodologies. For example, the market acceptance and growth of long-read sequencing technologies, like our Revio system, depends on a variety of factors, including the availability and cost-effectiveness of related tools for high quality sample collection and preparation and advanced bioinformatic tools to process results; as well as the perceived advantages and disadvantages of long-read sequencing compared to short-read or other sequencing technologies: consequently, if potential customers conclude the costs of adopting long-read sequencing technologies outweigh the benefits, the market for our Revio systems may be negatively impaired. There can be no assurance that our current or future products will gain traction in the market. If the markets for our current and future products are smaller than estimated or do not develop as we expect, our growth may be limited, and it could materially and adversely affect our business, operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased market adoption of our products by customers may depend on the availability of sample preparation and informatics tools, some of which may be developed by third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part upon the development of sample preparation and software and informatics tools by third parties for use with our products. We cannot guarantee that product supplies, including reagents, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices, or that third parties will develop tools that our current and future customers will find useful with our products, or that customers will adopt such third-party tools on a timely basis or at all. A lack of complementary sample preparation and informatics tools, or delayed updates of such tools, may impede the adoption of our products and may materially and adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of companies offering nucleic acid sequencing products and/or services, including Illumina, BGI Genomics (also known as MGI or Complete Genomics), Thermo, ONT Ltd., Roche, Bionano, and Qiagen. Other companies recently entering the market include Ultima, Element and Singular. Many of these companies currently have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater financial, technical, research and/or other resources, more experience in new product development, larger and more established manufacturing capabilities and marketing, sales, and support functions, and/or more established distribution channels to deliver products to customers than we do. These companies may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also several companies that are in the process of developing or have already developed and commercialized new, competing or potentially competing technologies, products and/or services, including ONT Ltd. and its subsidiaries, against whom we have filed complaints for patent infringement in the U.S. District Court for the District of Delaware and, previously, with the U.S. International Trade Commission, in the High Court of England and Wales and in the District Court of Mannheim, Germany. ONT Ltd. previously filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany, also for patent infringement, and its subsidiary, Oxford Nanopore Technologies, Inc. (&#8220;ONT Inc.&#8221;), filed counterclaims against us in the U.S. District Court for the District of Delaware seeking declaratory judgements of non-infringement, invalidity and unenforceability of the asserted patents, as well as antitrust, false advertising and unfair competition counterclaims that were subsequently dismissed by that court. Roche is developing potentially competing sequencing products. Increased competition may result in pricing pressures, which could harm our sales, profitability or market share. Our failure to further enhance our existing products and to introduce new products to compete effectively could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully increase sales of our current products or market and sell our future products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve profitability depends, in part, on our ability to attract customers for our current and future products including Revio and Onso, and we may be unable to effectively market or sell our products or find appropriate partners to do so. To perform sales, marketing, distribution, and customer support functions successfully, we face a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to attract, retain and manage qualified sales, marketing, and service personnel necessary to expand market acceptance for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the performance and commercial availability expectations of our existing and potential customers with respect to new and existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">availability of potential sales and distribution partners to sell our technologies, and our ability to attract and retain such sales and distribution partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the time and cost of maintaining and growing a specialized sales, marketing and service force for a particular application, which may be difficult to justify in light of the revenue generated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have enlisted and may continue to enlist third parties to assist with sales, distribution and customer support. There is no guarantee that we will be successful in attracting desirable sales and distribution partners, that we will be able to enter into arrangements with such partners on terms favorable to us or that we will be able to retain such partners on a going-forward basis. If our sales and marketing efforts, or those of any of our third-party sales and distribution partners, are not successful, or our products do not perform in accordance with customer expectations, our technologies and products may not gain market acceptance, which could materially and adversely impact our business, operations, financial condition, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large purchases by a limited number of customers represent a significant portion of our revenue, and any loss or delay of expected purchases has resulted, and in the future could result, in material quarter-to-quarter fluctuations of our revenue or otherwise adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a significant portion of our revenue from a limited number of customers. For example, for the years ended December 31, 2022 and 2021, one of our customers, who is our primary distributor in China, accounted for approximately 12% and 13% of our total revenue, respectively. For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. Many of these customers make large purchases on a purchase-order basis rather than pursuant to long-term contracts. As a consequence of the concentrated nature of our customer base and their purchasing behavior, our quarterly revenue and results of operations have fluctuated, and may fluctuate in the future, from quarter to quarter and are difficult to forecast. For example, the cancellation of orders or acceleration or delay in anticipated product purchases or the acceptance of shipped products by our larger customers has materially affected, and in the future could materially affect, our revenue and results of operations in any quarterly period. We have been, and may in the future be, unable to sustain or increase our revenue from our larger customers, or offset any discontinuation or decrease of purchases by our larger customers with purchases by new or other existing customers. To the extent one or more of our larger customers experience significant financial difficulty, bankruptcy or insolvency, this could have a material adverse effect on our sales and our ability to collect on receivables, which could materially and adversely harm our financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our customers, including some of our larger customers, have negotiated, or may in the future negotiate, volume-based discounts or other more favorable terms from us or our sales and distribution partners, which can and have had a negative effect on our gross margins or revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that such concentrated purchases will continue to contribute materially to our revenue for the foreseeable future and that our results of operations may fluctuate materially as a result of such larger customers&#8217; buying patterns. In addition, we may see consolidation of our customer base. The loss of one of our larger customers, a significant delay or reduction in its purchases, or any volume-based discount or other more favorable terms that we or our sales and distribution partner(s) may agree to provide, in light of the aggregated purchase volume or buying power resulting from such consolidation, has harmed, and in the future could harm, our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products using our SMRT sequencing and SBB technology are highly complex and may develop or contain undetected defects or errors. Our customers have previously experienced reliability issues with our existing products, including the Sequel System and the Sequel II/IIe Systems. In addition, it is possible our customers could experience reliability issues with current or future products, including the Sequel II/IIe, Revio and Onso Systems. Despite internal and external testing, defects, or errors may arise in our products, which could result in a failure to obtain, maintain, or increase market acceptance of our products, diversion of development resources, injury to our reputation and increased warranty, service, and maintenance costs. New products, including Revio and Onso, or enhancements to our existing products, including the SMRT Cell and Sequel II/IIe Systems, in particular may contain undetected errors or performance problems that are discovered only after delivery to customers. If our products have reliability or other quality issues or require unexpected levels of support in the future, the market acceptance and utilization of our products may not grow to levels sufficient to support our costs and our reputation and business could be harmed. Low utilization rates of our products could cause our revenue and gross margins to be adversely affected. We provide a warranty for our sequencing instruments and consumables, which is generally limited to replacing, repairing, or at our option, giving credit for any sequencing instrument or consumable with defects in material or workmanship. Service contracts for our sequencing instruments may be separately purchased. Defects or errors in our products may also discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may be substantial and could materially and adversely affect our operating margins. If our service and support costs increase, our business and operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such defects or errors could lead to the filing of product liability claims against us or against third parties whom we may have an obligation to indemnify against such claims, which could be costly and time-consuming to defend and result in substantial damages. Although we have product liability insurance, any product liability insurance that we have or procure in the future may not protect our business from the financial impact of a product liability claim. Moreover, we may not be able to obtain adequate insurance coverage on acceptable terms. Any insurance that we have or obtain will be subject to deductibles and coverage limits. A product liability claim could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our sales depends on customers&#8217; spending budgets that may be subject to significant and unexpected variation which could have a negative effect on the demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments represent significant capital expenditures for our customers in research applications. Current and potential customers for our current or future products include academic and government institutions, genome centers, medical research institutions, clinical laboratories, pharmaceutical, agricultural, biotechnology, diagnostic and chemical companies. Their spending budgets can have a significant effect on the demand for our products. Spending budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources which is highly uncertain and subject to change, the spending priorities among various types of research equipment, policies regarding capital expenditures during economically uncertain periods and the potential impacts from health epidemics or pandemics. Any decrease in capital spending or change in spending priorities of our current and potential customers could significantly reduce the demand for our products. Any delay or reduction in purchases by current or potential customers or our inability to forecast fluctuations in demand could materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to convert our orders in backlog into revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and any order backlog we report may not be indicative of our future revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including the potential impacts from health epidemics or pandemics and our suppliers, especially our sole source suppliers, not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales cycles are unpredictable and lengthy, which makes it difficult to forecast revenue and may increase the magnitude of quarterly or annual fluctuations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycles for our sequencing instruments are lengthy because they represent a major capital expenditure and generally require the approval of our customers&#8217; senior management. This may contribute to substantial fluctuations in our quarterly or annual operating results, particularly during periods in which our sales volume is low. Because of these fluctuations, it is likely that in some future quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. Past fluctuations in our quarterly and annual operating results have resulted in decreases in our stock price. Such fluctuations also mean that investors may not be able to rely on our operating results in any particular period as an indication of future performance. Sales to existing customers and the establishment of a business relationship with other potential customers is a lengthy process, generally taking several months and sometimes longer. Following the establishment of the relationship, the negotiation of purchase terms can be time-consuming, including as a result of seasonal factors, as discussed below, and a potential customer may require an extended evaluation and testing period. Our sales cycles may also lengthen, and those sales cycles may result in lower units sold per cycle, as we continue to introduce our Revio and Onso instruments and their associated consumables to the market, as our customers may have additional administrative, technical or other requirements associated with transitioning to new products and technologies. In anticipation of product orders, we may incur substantial costs before the sales cycle is complete and before we receive any customer payments. As a result, if a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results. Even if our selling efforts are successful, the realization of revenue may be substantially delayed, our ability to forecast our future revenue may be more limited and our revenue may fluctuate significantly from quarter to quarter and year over year. For more information on the impact of these fluctuations on our results and stock price, see &#8220;&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_442724">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our customers and suppliers are based in China, our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with political conflicts between the U.S. and China. A significant portion of our revenue is generated from China. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, for the years ended </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 and 2021, one of our customers, who is our primary distributor in China, accounted for approximately 12% and 13%</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our total revenue, respectively. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain c</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">omponents, some of which are critical components, of our products are manufactured in China. These components are either sourced directly from companies in China or indirectly from third parties that source from companies in China.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. Tariffs imposed by the U.S. and China have increased, and may continue to increase, our costs. Additionally, export restrictions imposed by the U.S. may impact our ability to export certain products to customers or distributors in China and restrict our ability to use certain integrated circuits in our products, and it is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. Moreover, the Chinese government may retaliate against U.S. trade restrictions in ways that could impact our business. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional import, export, tax, or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations. For more information, see &#8220;&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_442727">Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_442727">.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks could include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">interruptions to operations in China as a result of potential disease outbreaks, including any further COVID-19 related outbreaks, and natural catastrophic events, which have in the past and can result in the future in business closures, transportation restrictions, import and export complications and cause shortages in the supply of raw materials or disruptions in manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the nationalization or other expropriation of private enterprises or intellectual property by the Chinese government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Difficulties in this relationship may require us to take actions adverse to our business to comply with governmental restrictions on business and trade with China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant risks associated with doing business with Taiwanese suppliers and manufacturers due to the tense relationship between Taiwan and mainland China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our consumable chips are partly manufactured by a company based in Taiwan. Our supply of consumables chips and other critical components may be materially and adversely affected by diplomatic, geopolitical, military and other developments affecting the relationship between China and Taiwan. Recent military exercises in the Taiwan Strait have contributed to geopolitical uncertainty regarding the future of the relationship between China and Taiwan. Current or future diplomatic, geopolitical, military or other tensions between China and Taiwan may lead to circumstances that negatively affect the availability of such consumable chips and other critical components to us, which could limit or prohibit our ability to manufacture consumable chips and other critical components or lead to an increase in our supply costs if we cannot find a similar cost alternative supplier, which could materially and adversely impact our business, operations, prospects, financial condition and results, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span id="icf38e81c968145f1b504fbfa29b9ccea_442724"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate on a December 31st year-end and believe that there are significant seasonal factors which may cause sales of our products, and particularly our sequencing instruments, to vary on a quarterly or yearly basis, contribute to lengthy sales cycles for our sequencing instruments, and increase the magnitude of quarterly or annual fluctuations in our operating results. We believe that this seasonality results from a number of factors, including the procurement and budgeting cycles of many of our customers, especially government-funded customers, which often coincide with government fiscal year ends. For example, the U.S. government&#8217;s fiscal year-end occurs in our third quarter and may result in increased sales of our products during this quarter if government-funded customers have unused funds that may be forfeited, or future budgets that may be reduced if funds remain unspent at fiscal year-end. Furthermore, Lunar New Year celebrations, which occur during our first quarter, and may last for a week or longer, resulting in closure of many of our customers&#8217; offices in China and across the Asia-Pacific region have caused, and may in the future cause, decreased sales of our consumables during our first quarter. These factors have contributed, and in the future may contribute, to substantial fluctuations in our quarterly operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any given period can also be impacted by numerous other factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">market acceptance for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to attract new customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the length of our sales cycles, as discussed above;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to achieve economies of scale and other manufacturing efficiencies at the rate we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">publications of studies by us, our competitors or third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the timing and success of new product introductions by us or our competitors or other changes in the competitive dynamics of our industry, such as consolidation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the amount and timing of our costs and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in our pricing policies or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">general economic, industry and market conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the regulatory environment in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">expenses associated with warranty obligations or unforeseen product quality issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the hiring, training, and retention of key employees, including our ability to grow our sales organization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">litigation or other claims against us for intellectual property infringement or otherwise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to obtain additional financing as necessary; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes or trends in new technologies and industry standards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our common stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially affected, and may in the future materially affect, our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses to offset future taxable income may be subject to substantial limitations, and changes to U.S. tax laws may cause us to make adjustments to our financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (&#8220;NOLs&#8221;) to offset future taxable income. We believe that we have had one or more ownership changes, and as a result our existing NOLs are currently subject to limitation. Future changes in our stock ownership could result in additional ownership changes, including potentially material changes, under Section 382. Consequently, we may not be able to utilize some or all of our NOLs even if we attain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our facilities in California are located near earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in California are located near earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to secure patent or other intellectual property protection for our products and improvements to our products may reduce our ability to maintain any technological or competitive advantage over our current and potential competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to protect and enforce our intellectual property rights is uncertain and depends on complex legal and factual questions. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">we or our licensors might not have been the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that neither our pending patent applications nor the pending patent applications of our licensors will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the scope of the patent protection we or our licensors obtain may not be sufficiently broad to prevent others from practicing our technologies, developing competing products, designing around our patented technologies or independently developing similar or alternative technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our and our licensors&#8217; patent applications or patents have been, are and may in the future be, subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents, those patents being held invalid or the scope of those patents being substantially reduced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our enforcement of patents and proprietary rights in other countries may be problematic or unpredictable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">we or our partners may not adequately protect our trade secrets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may not develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the patents of others may limit our freedom to operate and prevent us from commercializing our technology in accordance with our plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events could impair our ability to operate without infringing upon the proprietary rights of others or prevent us from establishing or maintaining a competitive advantage over our competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variability in intellectual property laws may adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property laws, and patent laws and regulations in particular, have been subject to significant variability either through administrative or legislative changes to such laws or regulations or changes or differences in judicial interpretation, and it is expected that such variability will continue to occur. Additionally, intellectual property laws and regulations differ by country. Variations in the patent laws and regulations or in interpretations of patent laws and regulations in the United States and other countries may diminish the value of our intellectual property and may change the impact of third-party intellectual property on us. Accordingly, we cannot predict the scope of the patents that may be granted to us with certainty, the extent to which we will be able to enforce our patents against third parties or the extent to which third parties may be able to enforce their patents against us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and changes to the rights we have licensed may adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license from third parties some of the intellectual property that is important to our business. If the third parties who license intellectual property to us fail to maintain the intellectual property that we have licensed, or lose rights to that intellectual property, the rights we have licensed may be reduced or eliminated, which would eliminate barriers against our competition. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or could subject us to claims of intellectual property infringement or contract breach in litigation or other administrative proceedings that could result in damage awards against us and injunctions that could prohibit us from selling our products. In addition, some of our licenses from third parties limit the field in which we can use the licensed technology. Therefore, in order for us to use such licensed technology in potential future applications that are outside the licensed field of use, we may be required to negotiate new licenses with our licensors or expand our rights under our existing licenses. We cannot be certain that we will be able to obtain such licenses or expanded rights on reasonable terms or at all. In the event a dispute with our licensors were to occur, our licensors may seek to renegotiate the terms of our licenses, increase the royalty rates that we pay to obtain and maintain those licenses, limit the field or scope of the licenses, or terminate the license agreements. In addition, we have limited rights to participate in the prosecution and enforcement of the patents and patent applications that we have licensed. If we fail to meet our obligations under these licenses, or if we have a dispute regarding the terms of the licenses, these third parties could terminate the licenses, which could subject us to claims of intellectual property infringement. As a result, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. Further, because of the rapid pace of technological change in our industry, we may need to rely on key technologies developed or licensed by third parties, and we may not be able to obtain licenses and technologies from these third parties at all or on reasonable terms. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely upon trademarks, trade secrets, copyrights, and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented, or misappropriated. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees and consultants to enter into confidentiality and assignment of inventions agreements, and by entering into confidentiality agreements with our third-party development, manufacturing, sales, and distribution partners, who may also acquire, develop and/or commercialize alternative or competing products or provide services to our competitors. For example, Roche had certain access to our trade secrets and other proprietary information pursuant to an agreement we had entered into with Roche, subject to the confidentiality provisions thereof (certain of which provisions survive the termination of the agreement); however, Roche is developing potentially competing sequencing products. There can be no assurance that our measures have provided or will provide adequate protection for our intellectual property and proprietary information. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and other proprietary information may be disclosed to others, or others may gain access to or disclose our trade secrets and other proprietary information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Additionally, others may independently develop proprietary information and techniques that are substantially equivalent to ours. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property may be subject to challenges in the United States or foreign jurisdictions that could adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending, issued and granted U.S. and foreign patents and patent applications have been, are and may in the future be, subject to challenges by ONT Ltd., ONT Inc. and Metrichor, Ltd. (&#8220;Metrichor&#8221; and, together with ONT Ltd. and ONT Inc., &#8220;ONT&#8221;) in addition to other parties asserting prior invention by others or invalidity on various grounds, through proceedings, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interferences</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reexaminations, or opposition proceedings. Addressing these challenges to our intellectual property has been, and any future challenges can be, costly and distract management&#8217;s attention and resources. For example, we previously incurred significant legal expenses to litigate and settle a complaint seeking review of a patent interference decision of the U.S. Patent and Trademark Office. Additionally, ONT previously requested that the U.S. Patent and Trademark Office institute </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews of certain patents that we have asserted against ONT Inc. and ONT Ltd. in litigation proceedings for patent infringement. While none of the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews requested by ONT were instituted by the U.S. Patent and Trademark Office, challenges of this nature before the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) in the future could result in determinations that our patents or pending patent applications are unpatentable to us, or are invalidated or unenforceable in whole or in part and could require us to expend significant time, funds, and other resources in litigating such challenges. Accordingly, adverse rulings in such proceedings could negatively impact the scope of our intellectual property protection for our products and technology and could materially and adversely affect our business. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such products. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our technology is subject to &#8220;march-in&#8221; rights by the U.S. government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patented technology was developed with U.S. federal government funding. When new technologies are </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that such action is necessary to (i) achieve practical application of the U.S. government-funded technology, (ii) alleviate health or safety needs, (iii) meet requirements of federal regulations, or (iv) give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and such government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. The U.S. government has generally denied requests to exercise its march-in rights, even to provide access to potentially life-saving medications; however, if the U.S. government were to exercise its march-in rights to our patent technologies funded by the U.S. government, particularly for the benefit of one of more of our competitors, that may have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings to enforce our intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property rights involve complex factual, scientific, and legal questions. We operate in an industry characterized by significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent rights. For example, we were previously involved in legal proceedings with ONT and Harvard University in several United States and European jurisdictions. We have in the past received adverse rulings against us with respect to our complaint with the United States International Trade Commission for one of these proceedings. Legal actions to enforce our patent rights have been, and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and they and others may in the future bring, claims against us and/or our intellectual property. Litigation is a significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for us. Our enforcement actions may not be successful, have given rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the issuance of an injunction against us or our products that could prevent us from selling any products found to be infringing the intellectual property rights of another party.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are based on complex, rapidly developing technologies. We may not be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently uncertain, our belief that our products do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in the future claim, that we infringe their patent rights and have filed, and may in the future file lawsuits or engage in other proceedings against us to enforce their patent rights. For example, we are involved in legal proceedings for alleged patent infringement and related matters in the United States with Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;), Take2 Technologies, Ltd., and the Chinese University of Hong Kong. In addition, ONT Ltd. and Harvard University have, in the past, filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement, and PGI has filed claims against us in the U.S. District Court for the District of Delaware and in the Wuhan People&#8217;s Court in China. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products, and related maintenance and support services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us. In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop or commercialize products or services and could result in the award of substantial damages against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, to defend ourselves or our customers, substantial costs, and the attention of our management and technical personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may from time to time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated technologies of others in our products could result in us paying substantial damage awards or being prevented from further developing or selling some or all of our products, which could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of &#8220;open source&#8221; software could adversely affect our ability to sell our products and subject us to possible litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the products or technologies developed and/or distributed by us incorporate &#8220;open source&#8221; software, and we may incorporate open source software into other products or technologies in the future. Some open source software licenses require that we disclose the source code for any modifications to such open source software that we make and distribute to one or more third parties, and that we license the source code for such modifications to third parties, including our competitors, at no cost. We monitor the use of open source software in our products to avoid uses in a manner that would require us to disclose or grant licenses under our source code that we wish to maintain as proprietary; however, there can be no assurance that such efforts have been or will be successful. In some circumstances, distribution of our software that includes or is linked with open source software could require that we disclose and license some or all of our proprietary source code in that software, which could include permitting the use of such software and source code at no cost to the user. Open source license terms are often ambiguous and there is little legal precedent governing the interpretation of these licenses. Successful claims made by the licensors of open source software that we have violated the terms of these licenses could result in unanticipated obligations, including being subject to significant damages, being enjoined from distributing products that incorporate open source software and being required to make available our proprietary source code pursuant to an open source license, which could substantially help our competitors develop products that are similar to or better than ours or otherwise materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are, and may become, subject to governmental regulations that may impose burdens on our operations, and the markets for our products may be narrowed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject, both directly and indirectly, to the adverse impact of government regulation of our operations and markets. For example, export of our instruments may be subject to strict regulatory control in a number of jurisdictions, and we could experience disruption in our supply chain as a result of certain geopolitical events and conflicts and any related political or economic responses and counter-responses or otherwise by various global actors. Following Russia&#8217;s invasion of Ukraine in February 2022, the United States and other countries imposed certain economic sanctions and severe export control restrictions against Russia and Belarus as well as certain Russian nationals and individuals and entities with ties to Russia, Belarus, and this conflict. These sanctions and restrictions have continued to increase as the conflict has further escalated and now cover the export of our products to Russia, and the United States and other countries could impose even wider sanctions and export restrictions and take other actions in the future that could further limit our ability to provide products in certain locations. Additionally, restrictions on the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China without an export license may impact our ability to provide products to customers or distributors in China. We have expanded and are continuing to expand the international jurisdictions into which we supply products, which increases the risks surrounding governmental regulations relating to our business. The need to or failure to satisfy export control criteria or to obtain necessary clearances could delay or prevent shipment of products, which could materially and adversely affect our revenue and profitability. Moreover, the life sciences industry, which is expected to continue to be one of the primary markets for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which may narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulations that may adversely affect our market opportunities. Additionally, if ethical and other concerns surrounding the use of genetic information, diagnostics or therapies become widespread, there may be less demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with government regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and the cost of operating our business. In addition, changes to laws and government regulations could cause a material adverse effect on our business as we will need to adapt our business to comply with such changes. For example, a governmental prohibition on the use of human </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics or other regulations that negatively impact the research and development activities of our customers would adversely impact our commercialization of products on which we have expended significant research and development resources, which would in turn have a material adverse impact on our business and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products could become subject to government regulation as medical devices by the U.S. Food and Drug Administration or other domestic and international regulatory agencies even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes, which could increase our costs and impede or delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are currently labeled and promoted as research use only (&#8220;RUO&#8221;) products, and are not currently designed, or intended to be used, for clinical diagnostic tests or as medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to regulation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with the FDA&#8217;s guidance on RUO products. For example, our customers may independently elect to use our RUO labeled products in their own laboratory developed tests (&#8220;LDTs&#8221;) for clinical diagnostic use, which could subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming. Regulatory requirements related to marketing, selling, and distribution of RUO products could change or be uncertain, even if clinical uses of our RUO products by our customers were done without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected. In the event that we fail to obtain and maintain necessary regulatory clearances or approvals for products that we develop for clinical uses, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations may be materially harmed. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. We do not have experience in obtaining FDA approvals and no assurance can be given that we will be able to obtain or to maintain such approvals. Furthermore, any approvals that we may obtain can be revoked if safety or efficacy problems develop.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories developing and offering LDTs. In 2017, the FDA announced that it would not issue final guidance on the oversight of LDTs, and manufacturers of products used for LDTs, but would seek further public discussion on an appropriate oversight approach, and give Congress an opportunity to develop a legislative solution. The FDA has issued warning letters to certain genomics labs for illegally marketing genetic tests that claim to predict patients&#8217; responses to specific medications, noting that the FDA has not created a legal &#8220;carve-out&#8221; for LDTs and retains discretion to take action when appropriate, such as when certain genomic tests raise significant public health concerns.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As manufacturers develop more complex diagnostic tests and diagnostic software, the FDA may increase its regulation of LDTs. Any future legislative or administrative rule making or oversight of LDTs, if and when finalized, may impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with these laws. We cannot predict how these various efforts will be resolved, how Congress or the FDA will regulate LDTs in the future, or how that regulatory system will impact our business. Changes to the current regulatory framework, including the imposition of additional or new regulations, including regulation of our products, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2013, the FDA issued Final Guidance &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. The final guidance states that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These circumstances may include written or verbal sales and marketing claims or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical support for clinical applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Department of Health and Human Services ("HHS") announced rescission of guidance and other informal issuances of FDA regarding pre-market review of LDT absent notice-and-comment rulemaking, stating that, absent notice-and-comment rulemaking LDTs are not required to obtain FDA pre-market authorization. In November 2021, HHS under the Biden administration issued a statement that withdrew the August 2020 policy announcement stating that HHS does not have a policy on LDTs that is separate from FDA&#8217;s longstanding approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and administrative proposals to amend the FDA's oversight of LDTs have been introduced in recent years, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the "VALID Act"), which aims to create a new category of medical products separate from medical devices called &#8220;in vitro clinical tests,&#8221; or IVCTs, and bring all such products within the scope of the FDA&#8217;s oversight. To date, Congress has not passed the VALID Act, but may revisit the VALID Act or similar policy riders and enact other FDA programmatic reforms in the future. In October 2023, through rulemaking, the FDA proposed to amend the definition of "in vitro diagnostic products" in FDA regulations to include laboratories that manufacture such products and to phase out the FDA's general enforcement discretion approach for LDTs so that IVDs manufactured by a laboratory would be regulated similarly to IVDs. It is unclear when the FDA will finalize and begin enforcing such rule and how future legislation by federal and state governments and FDA regulation will impact the industry, including our business and that of our customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines our products or related applications should be subject to additional regulation as in vitro diagnostic devices based upon customers&#8217; use of our products for clinical diagnostic or therapeutic decision-making purposes, our ability to market and sell our products could be impeded and our business, prospects, results of operations and financial condition may be adversely affected. In addition, the FDA could consider our products to be misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act and subject to recall and/or other enforcement action.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the FDA or comparable foreign regulatory authority, which could take significant time and expense and could fail to result in a marketing authorization for the intended uses we believe are commercially attractive. Obtaining marketing authorization in one jurisdiction does not mean that we will be successful in obtaining marketing authorization in other jurisdictions where we conduct business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain pre-market 510(k) clearance or pre-market approval from the FDA, unless an exception applies. It is possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome pre-market application, such as a PMA or a </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It generally takes a significant amount of time to prepare a 510(k), including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek pre-market clearance or approval will be approved or cleared by FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable pre-market clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDA&#8217;s QSRs for our development and manufacturing operations. In addition, we would be required to obtain a new 510(k) clearance before we could introduce subsequent material modifications or improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States or if a foreign regulatory authority determines that our products are regulated as medical devices, we would be subject to extensive medical device laws and regulations outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. In Europe, we would need to comply with the Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, which became effective May 26, 2017, with application dates of May 26, 2021 (postponed from 2020) and May 26, 2022, respectively. This will increase the difficulty of regulatory approvals in Europe in the future. In addition, the FDA regulates exports of medical devices. The number and scope of these requirements are increasing. Unlike many of the other companies offering nucleic acid sequencing equipment or consumables, this is an area where we do not have expertise. We, or our other third-party sales and distribution partners, may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining our foreign regulatory approvals. In addition, the export by us of certain of our products, which have not yet been cleared for domestic commercial distribution, may be subject to FDA or other export restrictions. Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances and certifications could impair our ability to commercialize our products for diagnostic use outside of the United States. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span id="icf38e81c968145f1b504fbfa29b9ccea_442727"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations, or other trade barriers may materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, especially the Asia-Pacific region, as discussed above. There is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, government regulations and tariffs. Starting in September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various tariffs of 7.5%, 10%, 15%, and 25% on the import of Chinese products, including non-U.S. components and materials that may be used in our products. Additionally, China also has imposed tariffs on imports into China from the United States. These tariffs have and could continue to raise our costs. Furthermore, tariffs, trade restrictions, or trade barriers that have been, and may in the future be, placed on products such as ours by foreign governments, especially China, have raised, and could further raise, amounts paid for some or all of our products, which may result in the loss of customers and our business, and our financial condition and results of operations may be harmed. Further tariffs may be imposed that could cover imports of additional components and materials used in our products, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to components or materials used in our products or increased amounts that must be paid for our products, which could materially harm our business, financial condition, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. government imposed controls restricting the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China without an export license. These controls also apply to certain hardware containing these specified integrated circuits. In many cases, these licenses are subject to a policy of denial and will not be issued. It is possible that additional restrictions will be put in place. These existing and future controls may impact our ability to export certain products to customers or distributors in China or other locations and restrict our ability to use certain integrated circuits in our products. The U.S. government also continues to add additional entities in China to restricted party lists impacting the ability of U.S. companies to provide items to these entities. Moreover, in November 2018, the U.S. Commerce Department&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) released an advance notice of proposed rulemaking to control the export of emerging technologies. This notice included &#8220;[b]iotechnology, including nanobiology; synthetic biology; genomic and genetic engineering; or neurotech&#8221; as possible areas of increased export controls. The Biden Administration has continued to provide updated lists of emerging technologies subject to national security consents. These lists continue to include biotechnologies including &#8220;[g]enome and protein engineering including design tools&#8221; and &#8220;[b]iomanufacturing and bioprocessing technologies.&#8221; Therefore, it is possible that our ability to export our products to customers or distributors may be further restricted in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Chinese government will retaliate in response to existing or future U.S. export controls or trade restrictions in ways that could impact our business. It also is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. The continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international business could expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engaging in international business inherently involves a number of difficulties and risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">required compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;) and other data privacy requirements, labor and employment regulations, anti-competition regulations, the U.K. Bribery Act of 2010 and other anti-corruption laws, regulations relating to the use of certain hazardous substances or chemicals in commercial products, and require the collection, reuse, and recycling of waste from products we manufacture;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and trade and economic sanctions and other regulations established by the Office of Foreign Asset Control;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">export requirements and import or trade restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">laws and business practices favoring local companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">restrictions on both inbound and outbound cross-border investment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of the separation of the United Kingdom from the European Union (&#8220;Brexit&#8221;) and ongoing geopolitical tensions related to the political uncertainty and military actions associated with the war in Ukraine, resulting sanctions imposed by the U.S. and other countries, and retaliatory actions taken by Russia in response to such sanctions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties and costs of staffing and managing foreign operations; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties protecting, maintaining, enforcing, or procuring intellectual property rights and defending against intellectual property claims under the law and judicial systems of other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations involve the use of hazardous materials, and we must comply with environmental, health and safety laws, which can be expensive and may adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities involve the use of hazardous materials, including chemicals and biological materials, and some of our products include hazardous materials. Accordingly, we are subject to federal, state, local and foreign laws, regulations, and permits relating to environmental, health and safety matters, including, among others, those governing the use, storage, handling, exposure to and disposal of hazardous materials and wastes, the health and safety of our employees, and the shipment, labeling, collection, recycling, treatment, and disposal of products containing hazardous materials. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. For example, under certain circumstances and under certain environmental laws, we could be held liable for costs relating to contamination at our or our predecessors&#8217; past or present facilities and at third-party waste disposal sites. We could also be held liable for damages arising out of human exposure to hazardous materials. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, investigations, the suspension of production or product sales, loss of permits or a cessation of operations. Any of these events could harm our business, operating results, and financial condition. We also expect that our operations will be affected by new environmental, health and safety laws and regulations on an ongoing basis, or more stringent enforcement of existing laws and regulations. New laws or changes to existing laws may result in additional costs and may increase penalties associated with violations or require us to change the content of our products or how we manufacture them, which could have a material adverse effect on our business, operating results, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information could reduce demand for our technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may be used to provide genetic information about humans, agricultural crops and other living organisms. The information obtained from our products could be used in a variety of applications which may have underlying ethical, legal, privacy, data protection and social concerns, including the genetic engineering or modification of agricultural products or testing for genetic predisposition for certain medical conditions. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of the use of genetic testing, and may consider or adopt such regulations or other restrictions. Such concerns or governmental restrictions could limit the use of our products or be costly and burdensome to comply with, and actual or perceived violations of any such restrictions may lead to the imposition of substantial fines and penalties, remediation costs, claims and litigation, regulatory investigations and proceedings, and other liability, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations related to conflict minerals has caused us to incur, and will continue to cause us to incur, additional expenses and could limit the supply and increase the costs of certain materials used in the manufacture of our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 that require us to conduct diligence and report on whether or not our products contain conflict minerals. The implementation of these requirements could adversely affect the sourcing, availability and pricing of the materials used in the manufacture of components used in our products. Furthermore, the complex nature of our products requires components and materials that may be available only from a limited number of sources and, in some cases, from only a single source. We have incurred, and will continue to incur, additional costs to comply with the disclosure requirements, including costs related to conducting diligence procedures to determine the sources of conflict minerals that may be used or necessary to the production of our products and, if applicable, potential changes to components, processes, or sources of supply as a consequence of such verification activities. We may face reputational harm if we determine that certain of our products contain minerals that are not determined to be conflict free or if we are unable to alter our processes or sources of supply to avoid using such materials. In such circumstances, the reputational harm could materially and adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Owning Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been, is, and may continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is highly volatile, and we expect it to continue to be volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">actual or anticipated fluctuations in our financial condition and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">announcements of new products, technological innovations or strategic partnerships by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">announcements by us, our customers, partners, or suppliers relating directly or indirectly to our products, services or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">overall conditions in our industry and market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">addition or loss of significant customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in laws or regulations applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">competition from existing products or new products that may emerge;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">issuance of new or updated research or reports by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">sales of our common stock by us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">reports, guidance and ratings issued by securities or industry analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">operating results below the expectations of securities analysts or investors; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">general economic and market conditions, which could be impacted by various events including health epidemics or pandemics, interest rate fluctuations, increases in fuel prices, foreign currency fluctuations, international tariffs, acts of terrorism, hostilities or the perception that hostilities may be imminent, military conflict and acts of war, including further political uncertainty and military actions associated with the war in Ukraine and the related response, including sanctions or other restrictive actions, by the United States and/or other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the forgoing occurs, it would cause our stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations, which were exacerbated by the COVID-19 pandemic, and current macroeconomic trends and geopolitical events, and have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, companies that </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the market price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for existing stockholders to sell their common stock at a time and price that they deem appropriate and may dilute their voting power and ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our stockholders sell, or indicate an intent to sell, a large number of shares of our common stock in the public market, it could cause our stock price to fall, particularly if such sales occur over a short period time (for example, following delivery of shares upon achievement of milestones in our acquisition agreements). We may also issue shares of common stock or securities convertible into our common stock in connection with a financing, acquisition, our equity incentive plans, or otherwise. Any such issuances would result in dilution to our existing stockholders and the market price of our common stock may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing principal stockholders, executive officers, directors, and their affiliates beneficially own a significant number of our outstanding shares of common stock. In addition, such parties may acquire additional control by purchasing stock that we issue in connection with our future fundraising efforts. These parties may now and in the future be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued shares of common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">specify that special meetings of our stockholders can be called only by our board of directors, the Chair of the Board, the Chief Executive Officer or the President;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">establish advance notice procedures for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">provide that our directors may be removed only for cause; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain stockholder litigation matters, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, each of which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, stockholders, or employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf&#894; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, stockholders, officers, or other employees to us or our stockholders&#894; (iii) any action arising pursuant to any provision of the Delaware General Corporation Law; (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws&#894; or (v) any action asserting a claim governed by the internal affairs doctrine, except as to each of (i) through (v) above, for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing, holding or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, stockholders, officers or other employees, which may discourage lawsuits with respect to such claims against us and our current and former directors, stockholders, officers or other employees. In addition, a stockholder that is unable to bring a claim in the judicial forum of its choosing may be required to incur additional costs in the pursuit of actions which are subject to the exclusive forum provisions described above. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds either exclusive forum provision contained in our bylaws to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders&#8217; stockholdings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had outstanding approximately $459.0 million aggregate principal amount of our 2028 Notes and $441.0 million aggregate principal amount of our 2030 Notes. The 2028 Notes will mature on February 15, 2028, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2030 Notes and 2028 Notes are collectively referred to as the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change before the maturity date at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus unpaid interest to, but excluding, the maturity date. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to settle a portion or all of our conversion obligation in cash in respect of the Notes being converted. Moreover, we will be required to repay the Notes in cash at their maturity unless earlier converted, redeemed, or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or pay cash with respect to Notes being converted or at their maturity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to repurchase Notes or to pay cash upon conversions of Notes or at their maturity may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the indenture or to pay cash upon conversions of Notes or at their maturity as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under the indenture could constitute an event of default under any such agreement. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness or to pay cash amounts due upon conversion, upon required repurchase or at maturity of the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Notes are converted, it may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes are entitled to convert their Notes at any time at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, issuances of shares of common stock upon conversion of our Notes could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. The existence of the Notes may encourage short selling by market participants because the conversion of the Notes could depress the price of our common stock. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General conditions in the global economy and in the global financial markets could adversely affect our results of operations, including the potential effects from the COVID-19 pandemic or other similar outbreaks as discussed above, and the overall demand for nucleic acid sequencing products may be particularly vulnerable to unfavorable economic conditions. A global financial crisis, inflation or a global or regional political disruption, as well as acts of terrorism, hostilities, military conflict and acts of war, including any further political uncertainty and military actions in the Middle East associated with the Israel and Hamas conflict and the war in Ukraine, as well as the related responses, could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our product and services. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control. Any failure to deliver products to our customers in a safe and timely manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these carriers are unable to deliver our products, the delivery of our products by our customers may be delayed, which could harm our business and financial results. The failure to deliver our products in a safe and timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently conduct operations in various countries and jurisdictions, and continue to expand to new international jurisdictions as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the U.S. We sell directly and through distribution partners throughout Europe, the Asia-Pacific region, Mexico, Brazil, and South Africa and have a significant portion of our sales and customer support personnel in Europe and the Asia-Pacific region. As a result, we or our distribution partners may be subject to additional regulations and increased diversion of management time and efforts. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in foreign jurisdictions may also subject us to significant liabilities and other penalties. International operations entail a variety of other risks, including, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">potential limits to travel as a result of COVID-19 or other epidemics or pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">challenges in staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our platform outside of the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the potential need for localized software and documentation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">defending against intellectual property claims in other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">restrictions on both inbound and outbound cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and substantial restrictions on investment from China;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">U.S. and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components, and/or services to foreign persons;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs by the U.S. government on various imports from China, Canada, Mexico, and the European Union (&#8220;E.U.&#8221;) and by the governments of these jurisdictions on certain U.S. goods, and any other possible tariffs that may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">deterioration of political relations between the U.S. and Russia, China, Japan, Korea, Canada, the United Kingdom (&#8220;U.K.&#8221;), and the E.U., which could have a material adverse effect on our sales and operations in these countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in social, political, and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions into which we sell our products, including as a result of the withdrawal of the U.K. from the E.U.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">fluctuations in currency exchange rates and the related effect on our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">disruptions to global trade due to disease outbreaks or conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">potential increases on tariffs or restrictions on trade generally; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">significant taxes or other burdens of complying with a variety of foreign laws and regulations, including laws and regulations relating to privacy and data protection such as the E.U. General Data Protection Regulation which took effect in the E.U. in 2018.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conducting our international operations, we are subject to U.S. laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, the inclusion of one of our foreign customers on any U.S. Government sanctioned persons list, including but not limited to the U.S. Department of Commerce&#8217;s List of Denied Persons and the U.S. Department of Treasury&#8217;s List of Specially Designated Nationals and Blocked Persons List, could be material to our earnings. Failure to comply with these laws may subject us to claims or financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition. These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to the current global economic environment, which could delay or prevent our customers from purchasing our products, which could in turn harm our business, financial condition, and results of operations. The state of the global economy continues to be uncertain. The current global economic conditions and uncertain credit markets and concerns regarding the availability of credit pose a risk that could impact customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers, and creditors, including financial institutions. If the current global economic environment deteriorates, our business could be negatively affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers&#8217; local currencies could make our products more expensive, impacting our ability to compete or as a result of financial or other instability in such locations which could result in decreased sales of our products. Our costs of materials from international suppliers may also increase as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Such actions may materially and adversely impact our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of complex foreign and U.S. laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors, or agents will not violate our policies and subject us to potential claims or penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business and our stock price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Operating as a public company requires sufficient resources within the accounting and finance functions in order to produce timely financial information, ensure the level of segregation of duties, and maintain adequate internal control over financial reporting customary for a U.S. public company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, we perform periodic evaluations of our internal control over financial reporting. While we have in the past performed this evaluation and concluded that our internal control over financial reporting was operating effectively, there can be no assurance that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by changes in the United States political environment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant ongoing uncertainty with respect to potential legislation, regulation and government policy at the federal level, as well as the state and local levels. Any such changes could significantly impact our business as well as the markets in which we compete. Specific legislative and regulatory proposals discussed during election campaigns and more recently that might materially impact us include, but are not limited to, changes to spending priorities and potential reductions in research funding. Uncertainty about U.S. government funding has posed, and may continue to pose, a risk as customers may choose to postpone or reduce spending in response to actual or anticipated restraints on funding. To the extent changes in the political environment have a negative impact on us or on our markets, our business, results of operation and financial condition could be materially and adversely impacted in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruption of critical information technology systems or material breaches in the security of our systems could harm our business, customer relations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information technology (&#8220;IT&#8221;) helps us to operate efficiently, interface with customers, maintain financial accuracy and efficiently and accurately produce our financial statements. IT systems are used extensively in virtually all aspects of our business, including in our products, sales forecast, order fulfillment and billing, customer service, logistics, and management of data from running samples on our products. Our success depends, in part, on the continued and uninterrupted performance of our IT systems. Our IT systems, including those used in our products, may be vulnerable to damage from a variety of sources, including telecommunications or network failures, power loss, natural disasters, human acts, computer viruses, ransomware, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Furthermore, there may be a heightened risk of potential cybersecurity incidents and security breaches to which we could be vulnerable by state-sponsored or affiliated actors or others in connection with the political uncertainty and military actions in the Middle East associated with the Israel and Hamas conflict and the war in Ukraine. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, disruption of our operations, which could harm our reputation and financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, including those used in our products, we could be subject to transaction errors, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property. If our data management systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our reputation, financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personal information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our IT infrastructure may be vulnerable to attacks by hackers, computer viruses, malicious codes, ransomware, unauthorized access attempts, and cyber- or phishing-attacks, or breached or otherwise disrupted due to employee error, malfeasance, faulty password management or other disruptions. Third parties may attempt to fraudulently induce employees or other persons into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our IT systems, commit identity theft or carry out other unauthorized or illegal activities. Any such breach or incident could compromise our systems and networks and the information stored or otherwise processed there could be accessed, publicly disclosed, lost, stolen or otherwise processed in an unauthorized manner. We engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, including cyber-attacks, malicious software, ransomware, phishing schemes, and fraud. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure, other processing, or loss or unavailability of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure, other processing, or loss or unavailability of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, and data integrity issues, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches and security incidents, which could cause us to incur significant additional expenses. Retaliatory acts by Russia in response to Western sanctions or otherwise in connection with the war in Ukraine could include cyber-attacks that could disrupt the economy generally or that may either directly or indirectly impact our operations specifically.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our insurance may be insufficient to cover our losses resulting from cyber-attacks, breaches, or other interruptions, and any incidents may result in loss of, or increased costs of, such insurance. The successful assertion of one or more large claims against us that exceed available insurance coverage, the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, or denials of coverage, could have a material adverse effect on our business, including our financial condition, results of operations and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of artificial intelligence and machine learning technologies may result in reputational harm or liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incorporated and may continue to incorporate additional artificial intelligence and machine learning, or AIML, technologies into our sequencing platforms, marketing programs, and analysis software, including Revio and otherwise within our business, and these solutions and features are advantageous to describing, enhancing, and maximizing the capabilities of our differentiated technologies and to our future growth over time. We rely and expect to rely on AIML technologies such as basecalling, variant calling, epigenetic analysis and tertiary analysis, but there can be no assurance that we will realize the desired or anticipated benefits from AIML or any at all. We may also fail to properly implement or utilize AIML technologies. Our competitors or other third parties may incorporate AIML into their products, platforms, software and services or otherwise within their business more quickly or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations. Additionally, our use of AIML technologies may expose us to additional claims, demands and proceedings by private parties and regulatory authorities and subject us to legal liability as well as brand and reputational harm. For example, if output from AIML technologies or that they assist in producing are or are alleged to be deficient, inaccurate, or biased, or for such output, or such technologies or their development or deployment, including the collection, use, or other processing of data used to train or create such AIML technologies, to alleged to infringe upon or to have misappropriated third-party intellectual property rights or to violate applicable laws, regulations, or other actual or asserted legal obligations to which we are or may become subject, then our business, financial condition, and results of operations may be adversely affected. The legal, regulatory, and policy environments around AIML are evolving rapidly, and we may become subject to new and evolving legal and other obligations. These and other developments may require us to make significant changes to our use of AIML, including by limiting or restricting our use of AIML, and may require us to make significant changes to our policies and practices, which may necessitate expenditure of significant time, expense, and other resources, AIML also presents emerging ethical issues, and if our use of AIML becomes controversial, we may experience brand or reputational harm.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we currently, and in the future will, collect, store, transfer, use or process sensitive data, including personal information of employees, and intellectual property and proprietary business information owned or controlled by ourselves and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bureau</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California also passed the California Privacy Rights Act, or (&#8220;CPRA&#8221;), which significantly expanded the CCPA as of January 1, 2023, including by introducing additional obligations such as data minimization and storage limitations and granting additional rights to consumers, among others. The enactment of the CCPA has prompted similar legislative developments in other states, and numerous other states have proposed, and in certain cases enacted, legislation relating to privacy and data security, many of which are similar to the CCPA and CPRA. Similar laws are being considered by other state legislatures. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law. These and future laws and regulations may increase our compliance costs and potential liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), establish privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;protected health information&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or disrupted, breached or otherwise compromised due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or disruption could compromise our networks and the information stored there could be accessed, manipulated, publicly disclosed, lost, stolen, made unavailable, or otherwise processed without authorization. Any such disruption, access, breach, unavailability, theft, loss or other unauthorized processing of information, or the perception that any of these has occurred could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need to be made to the media or state attorneys general. Such a notice could harm our reputation and our ability to compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have in place formal policies and procedures related to the storage, collection, and processing of information, and have conducted data privacy audits, we continue to evaluate our compliance needs, including the need to conduct additional internal and external data privacy audits or adopt additional policies and procedures, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendors&#8217; compliance with applicable data protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security, could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and customers are increasingly focused on environmental, social, and governance (&#8220;ESG&#8221;) practices of companies. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow. If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, board and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us. In addition, as we work to align our ESG practices with industry standards, we will likely continue to expand our disclosures in these areas and doing so may result in additional costs and require additional resources to monitor, report, and comply with our various ESG practices. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, our reputation, business, financial performance, and growth may be adversely impacted.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_22"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_517"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C.&#160;&#160;&#160;&#160;CYBERSECURITY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.  We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats.  These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following these risk assessments, we evaluate whether and how to re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards.  We devote significant resources and designate high-level personnel, including our Senior Director and Head of Information Technology who reports to our Chief Operating Officer, to manage the risk assessment and mitigation process. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our overall risk management system, we monitor and test our safeguards, including through annual third-party vulnerability assessments. We train our employees on these safeguards, in collaboration with human resources, IT, and departmental management.  Personnel at all levels and departments are made aware of our cybersecurity policies through trainings. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage assessors, consultants, auditors, or other third parties in connection with our risk assessment processes. These service providers assist us to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require each third-party infrastructure and applications service provider that has access to our system to certify that it has the ability to implement and maintain appropriate security measures, consistent with all applicable laws, to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of its security measures that may affect our company. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously experienced a cybersecurity incident that was determined to be material. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this annual report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Senior Director and Head of Information Technology and our management committee on cybersecurity, which includes Facilities, HR, IT, Legal, and Management, are primarily responsible to assess and manage our material risks from cybersecurity threats.  Our cybersecurity team and IT management have years of cybersecurity experience and expertise including holding numerous applicable cybersecurity certifications, such as ISC2 Certified Information Systems Security Professional (CISSP).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Senior Director and Head of Information Technology and our management committee on cybersecurity oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.  Our Senior Director and Head of Information Technology is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents by leading the implantation of the cybersecurity risk management program and working directly with our security team. The Senior Director and Head of Information Technology also provides appropriate information and updates to our management committee on cybersecurity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Senior Director and Head of Information Technology and representatives from our management committee on cybersecurity provide annual briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  Our audit committee provides regular updates to the board of directors on such reports. </span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_25"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, research and development facilities, and manufacturing and distribution centers are located in Menlo Park, California, where we lease approximately 180,200 square feet under a lease expiring on October 31, 2027. We operate additional research, development, and support functions in San Diego, where we lease approximately 73,500 square feet under a lease expiring on September 30, 2027. Additionally, our European headquarters is located in London, where we lease approximately 7,300 square feet under a lease expiring November 30, 2026. Including these leases, we lease approximately 270,000 square feet globally. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities, together with suitable additional or alternative space available on commercially reasonable terms, will be sufficient to meet our needs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. District Court Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;). We plan to vigorously defend in this matter. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the &#8216;441 Patent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, we filed a petition requesting institution of an inter-partes review ("IPR") to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions be instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs. In one IPR, all challenged claims were found unpatentable, including PGI&#8217;s core device claims. In the second IPR, the Board did not find the disputed claims unpatentable. We appealed the decision in the second IPR to the U.S. Court of Appeals for the Federal Circuit, which held a hearing on December 7, 2023. On January 9, 2024, the U.S. Court of Appeals for the Federal Circuit affirmed the decisions of the Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final decision on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. However, in a subsequent order dated September 15, 2022, the judge stayed the PGI District Court matter pending a final decision by the U.S. Court of Appeals for the Federal Circuit regarding the appeal described above. We plan to vigorously defend against the remaining claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, Take2 Technologies, Ltd. (&#8220;Take2&#8221;) and the Chinese University of Hong Kong filed a complaint in the U.S. District Court for Delaware against us alleging infringement of U.S. Patent No. 11,091,794 (the &#8220;&#8217;794 Patent&#8221;) (C.A. No. 22- cv-01595). The complaint alleges that our Sequel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II systems, Sequel IIe Systems, and Revio</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Systems that operate version 11.0 or later of the SMRT</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Link software, infringe the &#8216;794 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;794 Patent. We believe the infringement allegations in the complaint lack merit and we intend to vigorously defend in this matter. We filed a motion to dismiss on February 14, 2023. We also filed a motion to transfer the case to the Northern District of California which was granted on August 2, 2023 and the case was transferred on August 16, 2023 (C.A. No. 5:23-cv-04166). A hearing occurred on February 22, 2024 on the motion to dismiss the case and the motion was taken under submission for future decision. Take2 filed a motion to disqualify our in-house legal department from representing PacBio in the district court action on September 20, 2023. We opposed Take2&#8217;s disqualification motion on October 4, 2023. An oral hearing on the disqualification motion was held on October 26, 2023 and the court issued orders November 6 and December 4 of 2023 partially granting the motion.  While some members of the in-house legal department were disqualified, General Counsel for PacBio was not disqualified and continues to represent PacBio in the district court action. On October 17, 2023, we filed a petition requesting institution of an IPR requesting the Board to find all claims of the &#8217;794 patent invalid. We anticipate a decision by the United States Patent and Trademark Office on whether to institute a trial on the validity of the claims of the '794 patent on or before April 26, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceedings in China</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#8217;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#8220;CN321 Patent&#8221;), which is related to the &#8216;441 Patent. On November 23, 2020, we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision. We filed a petition with the Wuhan Intermediate People&#8217;s court requesting dismissal of the infringement action based on the CNIPA invalidation decision, and PGI filed a petition to withdraw its complaint. The Wuhan Intermediate People&#8217;s court granted PGI&#8217;s petition and dismissed the infringement action in May 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment, and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_31"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_37"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;PACB.&#8221; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of Record </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2024, there were approximately 76 stockholders of record of our common stock, although we believe that there are a significantly larger number of beneficial owners of our common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our common stock and have no present plans to do so. We intend to retain earnings for use in the operation and expansion of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph included in this Annual Report on Form 10-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference into any filing of Pacific Biosciences under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows a comparison from December 31, 2018 through December 31, 2023 of the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. Such returns are based on historical results and are not intended to suggest future performance. Data for The Nasdaq Composite Index and the Nasdaq Biotechnology Index assume reinvestment of dividends. </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Among Pacific Biosciences, Inc, the NASDAQ Composite Index</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the NASDAQ Biotechnology Index</span></div><div style="margin-top:6pt;text-align:center"><img src="pacb-20231231_g2.gif" alt="Screenshot 2024-01-26 115201.gif" style="height:392px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:6pt;padding-left:162pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*$100 invested on 12/31/2018 in stock or index, including reinvestment of dividends.</span></div><div style="padding-left:162pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fiscal year ending December 31.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as previously reported on our Current Reports on Form 8-K filed with the SEC on June 26, 2023 and August 2, 2023, there were no unregistered sales of equity securities by us during 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;[Reserved]</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_43"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes included in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management&#8217;s Discussion and Analysis (MD&amp;A) is organized in the following sections: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Overview and Outlook </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Results of Operations </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Quantitative and Qualitative Disclosure of Market Risk</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Contractual Obligations</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Off Balance Sheet Arrangements</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_46"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Outlook</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">About PacBio</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) short-read sequencing technology. Our products address solutions across a broad set of research applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world&#8217;s most advanced sequencing systems to provide our customers the most complete and accurate view of genomes, transcriptomes, and epigenomes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our commercial team is comprised of approximately 215 employees, including 71 quota-carrying representatives, many with advanced degrees in biology and significant experience in the genomics industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Objectives</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 exceeded our expectations as we drove adoption of our advanced sequencing technologies, demonstrated short-read accuracy with our Onso platform, and progressed development of our pipeline technologies and products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2024 strategic objectives are to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Increase technology adoption by increasing market share via new customer acquisition, continue Sequel II conversions to Revio, and scale Onso production; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Leverage innovation to complete development of new sequencing platforms and launch on-market system improvements;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Build upon clinical momentum by expanding HiFi usage in large-scale programs and translational research projects; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Drive towards positive cash flow through gross margin expansion, disciplined operating expense management, and a focus on working capital. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to leverage our commercial organization and make significant improvements in the efficiency and usability of our products in pursuit of a broader customer base. We believe the commercial investments we have recently made will further help drive growth in our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To increase the adoption of HiFi sequencing, we have various development programs in progress to expand our product portfolio as well as increase the throughput and improve the usability of our existing sequencing technologies. We continue to focus on programs to accelerate new platform launches in the near to mid-term as well as increase applications for our technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that with the capabilities of our HiFi chemistry and SMRT technology, we can be a market leader in whole-genome clinical sequencing. Leading institutions have adopted our products to study rare and inherited disease. We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the company. We plan to continue to pursue partner collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing. Collaborative arrangements add to the awareness of our products and service offerings and may drive new applications for use of our technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key highlights of our 2023 consolidated financial results include the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Revenue increased $72.2 million, or 56%, to $200.5 million for the year ended December&#160;31, 2023, as compared to $128.3 million for the year ended December&#160;31, 2022. Revenue was comprised of $120.5 million in instrument revenue, $63.4 million in consumables revenue and $16.6 million in service and other revenue for the year ended December&#160;31, 2023. The increase was primarily driven by the launch of Revio in the first quarter of 2023, which is sold at a higher average selling price than our previous Sequel II and IIe platforms. We ended the year with an installed base of 173 Revio systems.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Gross profit as a percentage of revenue (gross margin) was 26.3% for the year ended December&#160;31, 2023, compared to 38.2% for the year ended December&#160;31, 2022. Gross margin declined due primarily to the instrument mix, as Revio instruments sold during the period had a lower margin than the Sequel II/IIe system, primarily due to loyalty discounts provided and higher initial manufacturing costs, including warranty costs as well as charges for scrap inventory. In addition, we recognized an adjustment during the year ended December&#160;31, 2023 primarily related to excess instrument and consumables inventory. The excess instrument adjustment was primarily due to a change in the Sequel II demand primarily from one customer. The consumables inventory adjustment was primarily resulting from a faster-than-expected decline in demand of Sequel II/IIe consumables due primarily to a faster than expected ramp on the Revio system.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Loss from operations increased $27.3 million or 9%, to $334.5 million for the year ended December&#160;31, 2023, as compared to $307.2 million for the year ended December&#160;31, 2022, driven primarily by an increase of $31.0 million of operating expenses, including a $12.7 million increase in the change in the fair value of the contingent consideration, a $9.0 million increase in non-recurring merger-related costs incurred, and a $9.0 million increase in sales, general, and administrative expenses, partially offset by a $5.8 million decrease in research and development expenses. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_94">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Cash, cash equivalents, and short-term investments were $631.4 million at December&#160;31, 2023, which represents an 18% decrease compared to the balance at December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic dynamics including inflation, exchange rates and concerns about an economic downturn, have impacted both the Company and our customers&#8217; behavior. For example, some customers and potential customers are managing capital more conservatively, resulting in lengthened sales cycles, and capital funding in China is being deferred, resulting in less capital equipment purchases. These factors could continue to impact our revenues and results of operations in 2024; however, as the size and duration of these impacts is uncertain, we cannot reasonably estimate the future impact to our operations and financial results. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_442723">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section for further discussion of the possible impact of macroeconomic factors on our business.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_52"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> detailed discussion of our consolidated financial results comparison between 2023 and 2022 is presented below. A discussion of the changes in our results of operations between the years ended December 31, 2022 and December 31, 2021, has been omitted from this Annual Report on Form 10-K but may be found in </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Report on </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1299130/000129913023000032/pacb-20221231x10k.htm">Form 10-K</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2022, filed with the Securities and Exchange Commission on February 28, 2023, which is incorporated herein by reference, and is available free of charge on the SEC&#8217;s website at www.sec.gov and our corporate website (www.pacb.com).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2023 and 2022</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on purchase commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 64pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expense </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(334,467)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(307,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(318,159)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product revenue resulted primarily from an increase of $71.7 million in instrument revenue, as well as an increase of $3.4 million in consumable revenue. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in instrument revenue was primarily due to the sale of 173 Revio systems that have a higher average selling price as compared to the Sequel II/IIe platform. We expect the installed base of Revio instruments to grow, reflecting customer demand for the new product. As a result of this new product launch, we anticipate the installed base and sales volumes of Sequel II/IIe to continue to decline compared to recent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarters.  Additionally, we commenced the shipment of Onso products during the year ended December 31, 2023 and expect the installed base to continue to grow. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in consumable sales was primarily due to higher Revio consumables sales attributable to the growth in the Revio instrument installed base, partially offset by a decline in Sequel consumables as customers transition to the new platform. As the Revio installed base continues to grow, we anticipate the related consumable sales to continue to increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in service and other revenue was primarily due to the change in our terms of the warranty provided with the instrument during the first quarter of 2022 to remove the service component.  As a result, the warranty is no longer a separate performance obligation and, accordingly, we accrue for the cost of the assurance warranty when revenue of the instrument is recognized, and no longer recognize a component of the instrument revenue in service and other revenue over the warranty period. Service revenue also declined as customers transition to Revio, which includes a first-year warranty, and opt to not renew their Sequel II/IIe plans. As the Revio installed base begins to surpass the warranty period in 2024 and customers transition to service plans, we expect the retrospective decline in growth trend to reverse within the year and service revenues to potentially exceed 2023 levels.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue, Gross Profit, and Gross Margin</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the cost of product revenue was driven primarily by an increase in system placements and higher overall product costs on the Revio platform, including warranty costs, as well as an increase in adjustments of approximately $4.6 million as compared to the prior year primarily relating to excess consumables inventory resulting from faster-than-expected decline in demand of Sequel II/IIe consumables due primarily to a faster than expected ramp on the Revio system. Cost of revenue included share-based compensation expense of $5.4 million and $4.8 million during the years ended December&#160;31, 2023 and 2022 respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on purchase commitment was $3.4 million and $3.7 million for the years ended December 31, 2023 and 2022, respectively. The purchase commitment loss is based on an estimate of future excess inventory related to supply agreements, for which we do not expect to have related sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased $3.7 million, or 8%. Gross margin was 26.3% for the year ended December&#160;31, 2023 compared to 38.2% for the year ended December&#160;31, 2022. The decrease in gross margin percentage was primarily due to instrument mix, in addition to charges for scrap inventory and an increase in adjustments primarily relating to excess consumables inventory resulting from a faster-than-expected decline in demand of Sequel II/IIe consumables due primarily to a faster than expected ramp on the Revio system. Revio instruments sold during the period had a lower margin primarily due to loyalty discounts provided and higher initial manufacturing costs, including warranty costs. Gross margin could fluctuate depending on the pace at which Sequel II/IIe revenue declines, Revio consumable revenue ramps, manufacturing efficiencies and warranty costs improve, as well as fluctuation in average selling prices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expense was primarily driven by the transition of Revio from development to commercialization. Research and development expense included share-based compensation of $22.4 million and $30.7 million during the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales, General, and Administrative Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in sales, general, and administrative expense was primarily driven by an increase in sales and marketing headcount as we continue to grow our commercial footprint. Sales, general, and administrative expense included share-based compensation expenses of $44.3 million and $43.1 million during the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger-Related Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger-related expenses of $9.0 million during the year ended December&#160;31, 2023, consist of $4.9 million of transaction costs arising from the acquisition of Apton, $2.8 million of compensation expense resulting from the liquidity event bonus plan in connection with the Apton acquisition, and $1.3 million of share-based compensation expense resulting from the acceleration of certain equity awards in connection with the Apton acquisition. We recognized $1.3 million of share-based compensation expense for the acceleration that was not attributable to pre-combination services.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets of $6.2 million during the year ended December&#160;31, 2023 consists of amortization expense attributable to acquired intangible assets that are not directly related to sales generating activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration during the year ended December&#160;31, 2023, represents the remeasurement impact of the Omniome and Apton contingent consideration due upon the achievement of the respective milestone. The increase in the change in fair value of contingent consideration during the year was primarily due to the Omniome contingent consideration and was primarily attributable to the passage of time, changes in the discount rates and probabilities of milestone achievement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration milestone for the Omniome acquisition was defined as the first commercial shipment to a customer of both an instrument and related consumables, utilizing SBB technology. As a result of the milestone achievement in September 2023, former Omniome securityholders received as milestone consideration, among other things, an aggregate of approximately $100.9 million in cash and approximately 9.0 million shares of our common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt of $2.0 million during the year ended December&#160;31, 2023, represents the loss resulting from the difference in the fair value of the 2030 Notes and the principal, in addition to the write-off of the unamortized debt issuance costs on the portion of the 2028 Notes that were exchanged as part of the debt modification during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the year ended December 31, 2023 was $14.3 million compared to $14.7 million for the year ended December&#160;31, 2022 and was primarily comprised of interest on the Convertible Senior Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other income, net was primarily driven by investment income. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred income tax benefit of $11.4&#160;million for the year ended December&#160;31, 2023, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_55"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity, other than our holdings of cash, cash equivalents, and investments, has primarily been through the issuance of debt or equity securities, together with cash flow from operating activities. For example, in January 2023, as discussed above, we issued and sold an aggregate of 20,125,000 shares of our common stock in a follow-on public offering for aggregate gross proceeds of approximately $201.3 million. We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis due to the investments we intend to make as described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_52">Results of Operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $631.4 million in cash, cash equivalents, and investments, compared to $772.3 million at December&#160;31, 2022. The decrease was primarily attributable to $259.2 million cash used in operating activities for the twelve months ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, we had $900 million of principal Convertible Senior Notes outstanding resulting from our February 9, 2021, issuance of convertible notes due 2028 (the &#8220;2028 Notes&#8221;) with an aggregate principal of $900 million. The Notes bear interest at a rate of 1.50% per annum. Interest on the 2028 Notes is payable semi-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annually in arrears on February 15 and August 15 commencing on August 15, 2021. The 2028 Notes will mature on February 15, 2028, subject to earlier conversion, redemption, or repurchase. The proceeds from the issuance of the convertible notes are being used to fund operations, strategic investments, and capital requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by us. The 2028 Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the 2028 Notes (which is equal to an initial conversion price of $43.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2028 Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with the holder of our outstanding 2028 Notes, pursuant to which we issued $441.0 million in aggregate principal amount of our 1.375% Convertible Senior Notes due in 2030 (the "2030 Notes") in exchange for $441.0 million principal amount of the 2028 Notes. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15 commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption, or repurchase. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of $21.50 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in shares, cash or a combination of shares and cash. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With certain exceptions, upon a change of control of our company or the failure of our common stock to be listed on certain stock exchanges, the holders of the 2028 Notes and 2030 notes may require that we repurchase all or part of the principal amount of those Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the Notes under the Indenture. The Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_109">Note 7. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Capital Requirements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, and investments will be sufficient to fund our projected operating and capital requirements for at least the next 12 months from the date of filing of this Annual Report on Form 10-K for the year ended December&#160;31, 2023. Operating needs include planned costs to operate our business, including costs to fund working capital and capital expenditures. Recent and expected working and other capital requirements, in addition to the above matters, include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Our purchase orders and contractual obligations of approximately $109.9 million as of December&#160;31, 2023, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">As described in more detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_112">Note 8 - Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to the Consolidated Financial Statements, we signed a Supply Agreement, which was amended in October 2022, with a supplier for the purchase of certain products over the period of 2023 through 2026. As part of the Supply Agreement, we made a $9.0 million deposit during the year ended December 31, 2022, and an additional deposit of $6.0 million in 2023, to secure the supply of certain products through the term of the contract. If we breach the minimum volume purchase commitment during any applicable year, the supplier is entitled to retain a portion or all of the deposit corresponding to that year. If we terminate the Supply Agreement before January 15, 2027, Supplier will refund the remaining balance of the Deposit. If the supplier breaches its minimum volume supply commitment during any applicable year or portions thereof, our remedies include termination, pursuit of damages, or pursuit of specific </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance. If, on or before October 31, 2024, we commit to purchasing a set amount of additional products during the calendar year 2026, Supplier will increase its maximum capacity guarantee to meet the additional demand. Should we exercise this option, we will be required to make an additional deposit of $5.0 million to Supplier within 30 days of the exercise.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Our research and development expenditures of $187.2 million in 2023 and $193.0 million in 2022. While we expect to continue our investment in research and development in 2024, including enhancements of our existing products, and continued development of other new technology and products, we expect research and development expenses to decline slightly in 2024 as compared to the year ended December 31, 2023 due to recent product transitions. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Cash outflows for capital expenditures of $8.8 million in 2023 and $16.8 million in 2022. We expect to continue to invest in capital expenditures in fiscal 2024 to continue to support manufacturing and expansion of our business, and anticipate a slight increase in 2024 as compared to the year ended December&#160;31, 2023. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Amounts related to future lease payments for operating lease obligations at December&#160;31, 2023, totaling $46.7 million, with $12.1 million expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Amounts due under the term loan acquired in connection with Omniome at December 31, 2023, totaling $0.5 million, the remainder of which is expected to be paid within the next 12 months. Please see </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_106">Note 6. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Payments made to third party collaborators to help advance our technologies and the capabilities of our products. We may also choose to drive investments to help create an ecosystem of customers, partners, and collaborators whose expertise and offerings complement and enhance the capabilities and utility of our technology and increase genomic data available on our platforms.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Payments related to licensing and other arrangements, which are cancellable license agreements with third parties for certain patent rights and technology. Under the terms of these agreements, we may be obligated to pay royalties based on revenue from the sales of licensed products, or minimum royalties, whichever is greater, and license maintenance fees. The future license maintenance fees and minimum royalty payments under the license agreements are not deemed to be material.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements and the adequacy of our available funds will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to successfully commercialize and develop products and solutions that address customer needs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the pace of adoption of our products and our ability to obtain new customers in markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the progress of our research and development programs and our ability to initiate or expand research programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to manage manufacturing and production costs, including purchase obligations, and litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">the extent to which we engage in collaborations with partners and acquire other businesses or technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If economic, financial, business, or other factors adversely affect our ability to fund our projected operating cash requirements, we may be required to obtain funding through traditional or alternative sources of financing. We cannot be certain that funds will be available on favorable terms, or at all. If we are required and unable to raise additional capital when desired, our business, operating results, and financial condition may be adversely affected. See our risk factor captioned &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_439783">We are not cash flow positive</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#icf38e81c968145f1b504fbfa29b9ccea_439783"> and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259,173)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263,211)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,678)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash in operating activities include the development of future products and product enhancements, manufacturing, and support functions related to our sales, general, and administrative activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December&#160;31, 2023, of $259.2 million was due primarily to a $306.7 million net loss that was partially offset by non-cash items such as share-based compensation of $72.1 million, a change in the estimated fair value of contingent consideration of $15.1 million, depreciation of $11.5 million, inventory provision of $10.6 million, amortization of intangible assets of $8.3 million, and amortization of right-of-use assets of $6.8 million, offset by accretion of discount and amortization of premium on marketable securities, net of $12.8 million, and deferred income taxes of $11.4 million. Cash flow impact from changes in net operating assets and liabilities of $59.0 million, was primarily attributable to increases of $17.8 million in accounts receivable, net, $13.8 million in inventory, net, $9.0 million in prepaid expenses and other assets, and decreases of $14.9 million in contingent consideration liability, $10.4 million in deferred revenue, and $8.8 million in operating lease liabilities, partially offset by increases of $13.1 million in accrued expenses, and $2.4 million in other liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December 31, 2022, of $263.2 million was due primarily to a $314.2 million net loss that was partially offset by non-cash items such as share-based compensation of $78.6 million, depreciation of $9.5 million, amortization of right-of-use assets of $6.9 million, inventory provision of $6.0 million, and a change in the estimated fair value of contingent consideration of $2.4 million. Cash flow impact from changes in net operating assets and liabilities of $54.0 million, was primarily attributable to increases of $33.9 million in inventory, net, $12.3 million in prepaid expenses and other assets, and decreases of $7.7 million in operating lease liabilities, $3.7 million in accrued expenses, and $3.7 million in deferred revenue, partially offset by a decrease of $5.5 million in accounts receivable, net, an increase of $1.0 million in accounts payable, and $0.9 million in other liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities consist primarily of capital expenditures and investment purchases and maturities. Cash provided by investing activities for the year ended December&#160;31, 2023, was due primarily to capital expenditures of $8.8 million and purchases of investments of $756.6 million offset by maturities of investments of $769.5 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the year ended December 31, 2022, was due primarily to capital expenditures of $16.8 million and purchases of investments of $442.8 million offset by maturities of investments of $575.8 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the year ended December&#160;31, 2023, resulted from net proceeds from issuance of common stock under equity offerings of $189.2 million, net proceeds of $15.3 million from the issuance of common stock through our equity compensation plans, partially offset by $86.4 million due to the payment of contingent consideration, $7.4 million due to the payment of debt issuance costs, and $1.8 million due to the payment of notes payable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the year ended December 31, 2022, resulted from net proceeds of $11.2 million from the issuance of common stock through our equity compensation plans, partially offset by $1.6 million due to the payment of notes payable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we did not have any off-balance sheet arrangements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract, any defective products supplied by us, or any acts or omissions, or willful misconduct, committed by us or any of our employees, agents or representatives. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. To the extent that such indemnification obligations apply to the lawsuits described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_28">Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 3 of this Annual Report on Form 10-K, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification agreements has been recorded as of December 31, 2023.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_58"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon our Consolidated Financial Statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, cost of revenue, and operating expenses, and related disclosure of contingent assets and liabilities. Management based its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. The fair values assigned, defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between willing market participants, are based on estimates and assumptions determined by management. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. Changes in the fair value of contingent consideration subsequent to the acquisition date are recognized in operating expenses in our consolidated statements of operations and comprehensive loss.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use the discounted cash flow method to value our acquired intangible assets. This method requires significant management judgment to forecast future operating results and utilizes significant assumptions such as assumed revenue projections, discount rates and obsolescence factors. The estimates we use to value and amortize intangible assets are consistent with the plans and estimates that we use to manage our business and are based on available historical information and industry estimates and averages. If the subsequent actual results and updated projections of the underlying business activity change compared with the assumptions and projections used to develop these values, we could experience impairment charges. In addition, we have estimated the economic lives of certain acquired assets and these lives are used to calculate depreciation and amortization expense. If our estimates of the economic lives change, depreciation or amortization expense could be accelerated or extended. We capitalize in-process research and development (IPR&amp;D), which is considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired $55.0 million of IPR&amp;D, and $52.3 million of goodwill in connection with the acquisition of Apton Biosystems, Inc. in the third quarter of 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets with Indefinite Lives &#8212; Impairment Assessment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite useful lives (i.e., IPR&amp;D) are not amortized, however they are tested annually for impairment, in the second and fourth quarter of our fiscal year, respectively, and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments or courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies. Key assumptions include, but are not limited to, revenue and operating income growth rates, discount rates and other factors. We consider peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the asset under measurement and estimated weighted-average costs of capital. Different assumptions from those made in our analysis could materially affect projected cash flows and the evaluation of assets for impairment. We also consider our market capitalization as a part of our analysis. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections. Key assumptions include, but are not limited to, revenue projections, revenue growth rates, discount rates and other factors. We consider peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the asset under measurement and estimated weighted-average costs of capital. Different assumptions from those made in our analysis could materially affect projected cash flows and the evaluation of assets for impairment. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets &#8212; Impairment Assessment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that the carrying values of our intangible assets with finite lives and other long-lived assets are impaired. If indicators of impairment exist, we assess the recoverability of the affected assets by determining whether their carrying amounts exceed their undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair values of identifiable intangible assets with finite lives and other long-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Omniome in the third quarter of 2021, we entered into an arrangement where we were obligated to pay $200 million in cash and equity dependent upon the achievement of a milestone event upon the first commercial shipment of products developed from our acquired sequencing technology. In the third quarter of 2023, we commenced customer shipments of the Onso short-read sequencing instrument. The milestone payment associated with PacBio&#8217;s acquisition of Omniome was triggered in September 2023 once both the Onso instrument and related consumables had been shipped to one customer. Consequently, we paid the former Omniome security holders milestone consideration of an aggregate of approximately $100.9 million in cash and approximately 9.0 million shares of our common stock in October 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Apton, we entered into an arrangement where we are obligated to pay former holders of Apton's outstanding equity interests $25.0 million upon the achievement of $50 million in revenue associated with a high throughput sequencer using Apton's technology, provided that the milestone event occurs prior to the 5-year anniversary of the closing date of the acquisition, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_94">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability was measured at fair value as of the acquisition date and is remeasured periodically at each reporting date, with changes in fair value recorded as change in fair value of contingent consideration in the consolidated statements of operations and comprehensive loss. For the Omniome contingent consideration, the initial measurement and post-acquisition remeasurement required estimates and assumptions using a scenario-based method that considers a range of potential outcomes of milestone achievement dates and assigned probabilities of occurrence for each outcome. Outcomes were discounted to present value, which was then weighted by the probability of each scenario to determine the total fair value of the contingent consideration payment as of each reporting period. This method requires significant management judgment, including the probability of achieving certain future milestones and discount rates. For the Apton contingent consideration, the initial measurement and post-acquisition remeasurement required estimates and assumptions using a Monte Carlo Simulation to estimate the volatility and systematic relative </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate to determine the total fair value of the contingent consideration payment as of each reporting period. This method requires significant management judgment, including risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread. Future changes in our estimates could result in expenses or gains. Refer to </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_103">Note 5. Financial Instruments</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion on valuation assumptions.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_61"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_91">Note 1. Organization and Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Recent Accounting Pronouncements&#8221;, in Part II, Item 8 of this Annual Report on Form 10-K for information regarding applicable recent accounting pronouncements.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_64"></div><div style="margin-top:6pt;padding-left:55.44pt;text-align:justify;text-indent:-55.44pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio is exposed to market risk from changes in interest rates. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and cash equivalents and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. The securities in our investment portfolio are not leveraged, are classified as available for sale and are, due to their short-term nature, subject to minimal interest rate risk. The fair market value of our fixed rate securities may be adversely impacted by increases in interest rates while income earned may decline as a result of decreases in interest rates. A hypothetical 100 basis-point (one percentage point) increase or decrease in interest rates compared to rates on December&#160;31, 2023 would have affected the fair value of our investment portfolio by approximately $2.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes were recorded at fair value as of the closing date of the Exchange Transaction, less debt issuance costs, on our consolidated balance sheets. We carry our remaining 2028 Notes at the principal amount, less unamortized debt issuance costs, on our consolidated balance sheets. Because the 2030 Notes and 2028 Notes have fixed annual interest rates of 1.375% and 1.50%, respectively, we do not have any economic interest rate exposure or financial statement risk associated with changes in interest rates. The fair value of the notes, however, may fluctuate when interest rates and the market price of our stock changes. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_109">Note 7. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of this Annual Form 10-K for additional information. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, expense, and capital purchasing activities are primarily transacted in U.S. dollars; however, a portion of our operations is conducted in foreign currencies. As a result, we have foreign exchange exposures relating to non-U.S. dollar denominated cash flows and monetary assets and liabilities that are denominated in currencies other than U.S. dollars. The value of the amounts is exposed to changes in currency exchange rates from the time the transactions are originated, until the time the cash settlement is converted into U.S. dollars. Our foreign currency exposure is primarily concentrated in the Euro. A 10% strengthening of the U.S. dollar exchange rate against all currencies with which we have exposure, after taking into account offsetting positions at December&#160;31, 2023 would have resulted in a $0.9 million decrease in the carrying amounts of those net assets. Actual gains and losses in the future may differ materially from these hypothetical gains and losses based on changes in the timing and amount of foreign currency exchange rate movements and our actual exposure. Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page(s)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_70">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-37">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_70">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_70">71</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_76">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_76">74</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_79">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_79">Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_79">75</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_82">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_82">76</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_85">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_85">77</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i02b9487756a44f62beca493d5cd6fd6a_88">78</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Pacific Biosciences of California, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Pacific Biosciences of California, Inc. (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control&#8211;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;28, 2024, expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognition - Identification of performance obligations and allocation of contract consideration</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Description of the Matter </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, the Company recognized revenue of $200.5 million, including $183.9 million of product revenue, which consists primarily of instrument sales and related consumables. As described in Note 1 to the consolidated financial statements, the Company may enter into contracts with customers that includes a combination of promised products and services, resulting in arrangements containing multiple performance obligations. The Company identifies a performance obligation for each promise to transfer to the customer, a product or service that is distinct. The consideration is allocated between each performance obligation based on its individual standalone selling price, which is estimated by the Company, using historical sales data, as well as management judgment.</span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into, or periodically modifies, revenue contracts with non-standard terms, requiring management to evaluate whether these non-standard terms represent a performance obligation. For example, the Company may offer specified discounts on current products within an arrangement and on future purchase options, for which historical information may not be available. As part of the Company's identification of performance obligations and the resulting determination of the allocation of contract consideration, the Company considers if these specified discounts represent a material right when compared to the estimated standalone selling price and, therefore, a performance obligation to be included in the allocation of the contract value.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s identification of the performance obligations and the resulting determination of the allocation of contract consideration in certain contracts involved a higher degree of judgment due to the subjective nature of identifying certain performance obligations and the related determination of standalone selling price when it is not based on historical information.</span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How We Addressed the Matter in Our Audit </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s internal controls addressing management&#8217;s identification of performance obligations and allocation of contract consideration, including standalone selling price determination.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, reading executed contracts for a sample of arrangements and evaluating whether terms of the contracts (including specified discounts on current and future purchase options) resulted in additional performance obligations. Additionally, we tested the completeness and accuracy of the information used in management&#8217;s allocation of contract consideration, including the data incorporated in underlying calculations to determine standalone selling price.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business combination - Valuation of intangible asset</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Description of the Matter </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the Company completed its acquisition of Apton Biosystems, Inc. during 2023. The transaction was accounted for as a business combination, and the Company recorded an indefinite-lived intangible asset of $55.0 million.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accounting for the acquisition was challenging because the determination of the fair value of the identified intangible asset, which consisted of in-process research and development (IPR&amp;D), required management to make certain subjective estimates and assumptions. The Company used an income approach to measure the intangible asset. The valuation of the intangible asset is subject to higher estimation uncertainty due to management&#8217;s judgments in determining significant assumptions, which included certain components of the revenue projection and the discount rate. A change in these significant assumptions could have a significant effect on the fair value of the intangible asset.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How We Addressed the Matter in Our Audit </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls addressing the identified audit risk. For example, we tested controls over management&#8217;s review of the significant assumptions used to develop the fair value estimate of the intangible asset. We also tested management&#8217;s controls to validate that data used in the fair value estimate was complete and accurate.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the intangible asset, we performed audit procedures that included, among others, evaluating the Company&#8217;s valuation model with the assistance of valuation specialists, performing sensitivity analyses to determine which assumptions had the greatest impact on the overall determination of value, and testing the completeness and accuracy of the underlying data used to develop the assumptions. We also evaluated the assumptions by comparing them to market and economic trends, historical results of the Company&#8217;s business and other guideline companies within the same industry.</span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-38">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2011.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-39">San Mateo, California</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2024</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_73"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">179,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-41">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-42">451,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-43">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">36,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">18,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-46">56,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-47">50,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">17,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">10,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-50">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-51">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">742,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">852,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-54">36,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-55">41,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-56">32,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-57">39,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-60">456,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-61">410,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-62">462,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-63">409,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">10,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-66">1,746,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-67">1,767,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">15,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">12,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">32,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">16,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">30,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">9,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">8,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities, current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">8,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">7,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">95,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">263,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration liability, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">31,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">41,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible senior notes, net, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-88">892,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-89">896,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities, non-current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-90">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">1,044,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-93">1,204,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-94"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-95"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-97">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-99">50,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-103">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-106"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-107">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-109">1,000,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-111">267,744</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-113">226,505</ix:nonFraction></ix:nonFraction> shares at December&#160;31, 2023 and December&#160;31, 2022, respectively </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-114">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-115">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-116">2,539,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-117">2,099,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-118">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-119">4,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-120">1,839,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-121">1,532,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">701,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">562,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-124">1,746,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-125">1,767,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_88">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-126">183,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-127">108,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-128">113,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service and other revenue </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-129">16,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-130">19,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-131">17,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-132">200,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-133">128,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-134">130,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-135">127,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-136">60,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-137">56,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherCostOfOperatingRevenue" format="ixt:num-dot-decimal" scale="3" id="f-138">14,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherCostOfOperatingRevenue" format="ixt:num-dot-decimal" scale="3" id="f-139">13,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherCostOfOperatingRevenue" format="ixt:num-dot-decimal" scale="3" id="f-140">14,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-141">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="f-142">733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="f-143">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on purchase commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LossOnContracts" format="ixt:num-dot-decimal" scale="3" id="f-144">3,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LossOnContracts" format="ixt:num-dot-decimal" scale="3" id="f-145">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LossOnContracts" format="ixt:fixed-zero" scale="3" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of revenue </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-147">147,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-148">79,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-149">71,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-150">52,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-151">49,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-152">58,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating Expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">187,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">193,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">112,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">169,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-157">160,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-158">124,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merger-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-159">9,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-161">31,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-162">15,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-163">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-164">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-165">6,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expense </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-168">387,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-169">356,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-170">269,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">334,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">307,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">210,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from Continuation Advances from Illumina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="f-174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="f-175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:GainLossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="f-176">52,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-177">2,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-180">14,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-181">14,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-182">12,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-183">32,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-184">7,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-185">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-186">318,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-187">314,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-188">274,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-189">11,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-191">93,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-192">306,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">314,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-194">181,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-195">4,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-196">3,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-197">1,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-198">301,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-199">317,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-200">182,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-201">1.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-202">1.40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-203">0.89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-204">1.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-205">1.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-206">0.89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding used in calculating net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-207">253,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-208">224,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-209">204,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-210">253,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-211">224,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-212">204,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_88">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.024%"/><td style="width:0.1%"/></tr><tr style="height:25pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Common Stock </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7.5pt;font-weight:400;line-height:108%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-213">192,294</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-214">192</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-215">1,372,083</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-216">85</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-217">1,036,869</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">335,491</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">181,223</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-220">181,223</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-221">1,172</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-222">1,172</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-223">8,557</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-224">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-225">31,797</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-226">31,806</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in Private Placement, net of issuance costs</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-227">11,215</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-228">11</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-229">294,834</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-230">294,845</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in acquisition of Omniome</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-231">8,912</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-232">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-233">237,876</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-234">237,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-235">73,355</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-236">73,355</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-237">220,978</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-238">221</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">2,009,945</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">1,087</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">1,218,092</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">790,987</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net loss</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">314,248</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">314,248</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other comprehensive loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-245">3,678</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-246">3,678</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-247">5,527</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-248">6</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-249">11,224</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-250">11,230</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Share-based compensation expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-251">78,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">78,613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-253">226,505</ix:nonFraction></span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-254">227</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-255">2,099,782</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-256">4,765</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">1,532,340</ix:nonFraction>)</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"/><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">562,904</ix:nonFraction>&#160;</span></td><td style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-259">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-260">306,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-261">4,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-262">4,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock following milestone achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-263">8,988</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-264">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-265">84,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-266">84,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in acquisition of Apton</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-267">6,121</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-268">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-269">76,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-270">76,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in connection with Apton liquidity event bonus plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" scale="3" id="f-271">169</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="3" id="f-272">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="3" id="f-273">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-274">20,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-275">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-276">189,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-277">189,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-278">5,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-279">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-280">15,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-281">15,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-282">72,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-283">72,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-284">267,744</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-285">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-286">2,539,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-287">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-288">1,839,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">701,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_88">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-290">306,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-291">314,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-292">181,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss (gain) from Continuation Advances </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:GainLossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="f-295">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-296">11,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-297">9,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-298">7,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-299">8,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" scale="3" id="f-300">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" scale="3" id="f-301">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-302">6,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-303">6,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-304">4,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-305">72,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-306">78,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-307">73,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Merger-related compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashMergerRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-308">3,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NoncashMergerRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NoncashMergerRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-311">2,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of premium and accretion of discount on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-314">12,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-315">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-316">4,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in the estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-317">15,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-318">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-319">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventory provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-320">10,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-321">6,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="f-322">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-323">11,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-325">93,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-326">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-327">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-328">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in assets and liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-329">17,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-330">5,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-331">7,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-332">13,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-333">33,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-334">13,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses and other assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-335">8,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-336">12,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-337">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-338">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-339">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-340">6,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-341">13,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-342">3,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-343">15,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="f-344">10,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="f-345">3,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="f-346">25,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-347">8,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-348">7,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-349">4,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:IncreaseDecreaseInContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-350">14,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="pacb:IncreaseDecreaseInContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="pacb:IncreaseDecreaseInContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-353">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-354">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-355">803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash used in operating activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-356">259,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-357">263,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-358">111,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of property and equipment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-359">8,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-360">16,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-361">5,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-363">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash paid for purchases of acquired entities, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="f-365">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-367">319,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of investments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-368">756,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-369">442,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-370">988,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales of investments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="f-371">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-373">212,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maturities of investments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-374">769,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-375">575,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-376">422,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by (used in) in investing activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-377">4,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-378">116,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-379">678,531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Continuation Advances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:ProceedsFromRepaymentsOfContractTermination" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="pacb:ProceedsFromRepaymentsOfContractTermination" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="pacb:ProceedsFromRepaymentsOfContractTermination" format="ixt:num-dot-decimal" scale="3" id="f-382">52,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from issuance of Convertible Senior Notes, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-385">895,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-386">189,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-388">294,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock from equity plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-389">15,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-390">11,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-391">31,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-392">7,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-395">86,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Notes payable principal payoff </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-398">1,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-399">1,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-400">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="f-403">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-404">108,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-405">9,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-406">1,169,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-407">145,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-408">137,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-409">379,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-410">328,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-411">465,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-412">85,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-413">182,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-414">328,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-415">465,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period </span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-416">179,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-417">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-418">460,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restricted cash at end of period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-419">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-420">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-421">5,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-422">182,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-423">328,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-424">465,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-425">15,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-426">14,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-427">6,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventory transferred to property and equipment </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="pacb:TransferOfInventoryToPropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-428">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="pacb:TransferOfInventoryToPropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-429">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="pacb:TransferOfInventoryToPropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-430">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property and equipment transferred to inventory</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="3" id="f-431">7,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="3" id="f-432">715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="3" id="f-433">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use asset and liability additions and modifications</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-436">2,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock in acquisition of Apton and Omniome</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-437">76,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-439">237,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock in connection with Apton liquidity event bonus plan</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-440">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Convertible Senior Notes exchange</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:num-dot-decimal" scale="3" id="f-443">441,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock following milestone achievement</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-446">84,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_88">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_91"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-449" continuedAt="f-449-1" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-449-1" continuedAt="f-449-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB</span><span style="background-color:#ffffff;color:#333333;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on creating some of the world's most advanced sequencing systems to provide our customers the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-450" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-451" continuedAt="f-451-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-451-1">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the fair value of contingent consideration, the valuation of acquired intangible assets, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2023. Actual results could differ materially from these estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-452" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Functional Currency</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-453" continuedAt="f-453-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-2" continuedAt="f-449-3"><ix:continuation id="f-453-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-454" continuedAt="f-454-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2023, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. For the years ended December&#160;31, 2022 and 2021, one customer accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-455">12</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-60" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-456">13</ix:nonFraction>% of our total revenue, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, <ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-457">49</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-62" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-458">57</ix:nonFraction>% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2023, one customer represented approximately <ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-459">10</ix:nonFraction>% of our net accounts receivable. As of December&#160;31, 2022, one customer represented approximately <ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-460">10</ix:nonFraction>% of our net accounts receivable. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-454-1">We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-461" continuedAt="f-461-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory, Net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-3" continuedAt="f-449-4"><ix:continuation id="f-461-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-462" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-463" continuedAt="f-463-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-464">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-66" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-465">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-67" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-466">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-68" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-467">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-69" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-468">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-70" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-469">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-71" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-470">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-72" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-471">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-472">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-473" continuedAt="f-473-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-473-1">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-474" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense in our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-4" continuedAt="f-449-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-475" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, and Other Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and capitalized in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill in the second quarter of each year, or more frequently if indicators of potential impairment exist. We generally perform annual impairment testing of IPR&amp;D in the fourth quarter of each year, or more frequently if indicators of potential impairment exist.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have <ix:nonFraction unitRef="unit" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-476">one</ix:nonFraction> reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-477" continuedAt="f-477-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-5" continuedAt="f-449-6"><ix:continuation id="f-477-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a <ix:nonNumeric contextRef="c-1" name="pacb:StandardProductWarrantyPeriod" format="ixt-sec:durwordsen" id="f-478">one-year</ix:nonNumeric> warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-479" continuedAt="f-479-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-6" continuedAt="f-449-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-480" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-481" continuedAt="f-481-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale debt securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-481-1">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of COVID-19 or other epidemics or pandemics, or other customer-specific factors.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-482" continuedAt="f-482-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-482-1">We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-483" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP")  based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_118">Note 10. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding share-based compensation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-484" continuedAt="f-484-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-484-1">Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.</ix:continuation> </span></div><ix:continuation id="f-479-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-449-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-485" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="pacb:RecentlyAdoptedAccountingStandardsPolicyTextBlock" id="f-486" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-487" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires entities to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. This authoritative guidance will be effective for us in fiscal year 2025, with early adoption permitted. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_94"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-488" continuedAt="f-488-1" escape="true">BUSINESS ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="f-488-1" continuedAt="f-488-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apton Biosystems</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, we acquired Apton Biosystems, Inc. (&#8220;Apton&#8221;), a California-based genomics company focused on developing a high throughput short-read sequencer using highly differentiated optics and image processing, paired with novel clustering and chemistry (the &#8220;Apton acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, all outstanding equity securities of Apton were cancelled in exchange for shares of our common stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-489">76.6</ix:nonFraction> million, cash of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-490">0.2</ix:nonFraction> million, and contingent consideration with a preliminary estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-491">18.5</ix:nonFraction> million. Excluded from consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-492">1.3</ix:nonFraction> million attributable to accelerated share-based compensation expense. The fair value of the <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-493">6,121,571</ix:nonFraction> common shares issued was determined based on the closing market price of our common stock on the acquisition date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-494">25.0</ix:nonFraction>&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" format="ixt:num-dot-decimal" scale="6" id="f-495">50.0</ix:nonFraction>&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the <ix:nonNumeric contextRef="c-75" name="pacb:BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" format="ixt-sec:durwordsen" id="f-496">5-year</ix:nonNumeric> anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <ix:nonFraction unitRef="d" contextRef="c-74" decimals="INF" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" format="ixt-sec:numwordsen" scale="0" id="f-497">twenty</ix:nonFraction> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed <ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" scale="-2" id="f-498">19.9</ix:nonFraction>% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on preliminary estimates of their respective fair values at the date of the completion of the Apton acquisition, and such allocation is subject to adjustment for up to one year after the close of the acquisition as additional </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-488-2" continuedAt="f-488-3"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information is obtained. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-499" continuedAt="f-499-1" escape="true">The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred, based on the preliminary estimated fair values were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-499-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-500">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-501">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-502">52,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="f-503">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-504">11,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-505">2,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-506">94,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation is preliminary, primarily due to the pending finalization of review of various tax attributes. We continue to collect information regarding certain estimates and assumptions, including potential liabilities and contingencies. We will record adjustments to the fair value of the assets acquired, liabilities assumed and goodwill within the twelve months measurement period, if necessary. During the year ended December&#160;31, 2023, we recorded a measurement period adjustment of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-507">1.6</ix:nonFraction>&#160;million to decrease goodwill, and a corresponding $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-508">2.0</ix:nonFraction>&#160;million increase in intangible assets and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" sign="-" name="pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="f-509">0.4</ix:nonFraction>&#160;million decrease in the deferred tax liability on the consolidated balance sheets, and a $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" sign="-" name="pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-510">0.7</ix:nonFraction>&#160;million increase to our benefit from income taxes on the consolidated statements of operations and comprehensive loss. The measurement period adjustment was due to new information that became available to us upon the completion of the valuation assessment of the in-process research and development and the tax provision.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred costs related to the Apton acquisition of approximately $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-511">9.0</ix:nonFraction>&#160;million during the year ended December&#160;31, 2023, which are included in merger-related expenses on the consolidated statement of operations and comprehensive loss. Merger-related expenses include $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="f-512">2.8</ix:nonFraction>&#160;million relating to a liquidity event bonus plan that was treated as a separate transaction and included the issuance of <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="0" name="pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="0" id="f-513">168,621</ix:nonFraction> shares of common stock that were issued with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" format="ixt:num-dot-decimal" scale="6" id="f-514">2.1</ix:nonFraction>&#160;million based on the closing market price of our common stock on the acquisition date. As a result, the total shares issued in connection with the Apton acquisition were <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-515">6.3</ix:nonFraction>&#160;million shares of common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-516">52.3</ix:nonFraction>&#160;million, based on preliminary estimates, which is primarily attributable to the synergies expected to occur from the integration of Apton and is not deductible for income tax purposes. We preliminarily allocated $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-517">55.0</ix:nonFraction> million of the purchase price to acquired in-process research and development ("IPR&amp;D"). The fair value of the IPR&amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as assumed revenue projections and discount rate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omniome, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021, we completed our acquisition of Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company, to obtain their proprietary short-read DNA sequencing platform capable of delivering high accuracy (the &#8220;Omniome acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Omniome acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-518">315.7</ix:nonFraction>&#160;million in cash, <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-519">8,911,580</ix:nonFraction> shares of our common stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-520">249.4</ix:nonFraction>&#160;million and contingent consideration with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-521">168.6</ix:nonFraction>&#160;million. The fair value of the <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-522">8,911,580</ix:nonFraction> common shares issued was determined based on the closing market price of PacBio&#8217;s common shares on the acquisition date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-523">18.9</ix:nonFraction>&#160;million, comprised of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-524">7.4</ix:nonFraction>&#160;million of cash, <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-525">226,811</ix:nonFraction> shares of our common stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-526">6.3</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-527">5.2</ix:nonFraction>&#160;million related to contingent consideration, was accounted for as a one-time post-acquisition share-based compensation expense. This share-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-488-3" continuedAt="f-488-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition the contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-528">200</ix:nonFraction>&#160;million (composed of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-529">100</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-530">100</ix:nonFraction>&#160;million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the <ix:nonFraction unitRef="d" contextRef="c-74" decimals="INF" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" format="ixt-sec:numwordsen" scale="0" id="f-531">twenty</ix:nonFraction> trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-532">100</ix:nonFraction>&#160;million in shares of our common stock to be issued as part of the milestone, $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-533">4.1</ix:nonFraction>&#160;million was attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction. Upon achievement of the milestone, shares will be issued not in excess of an amount equal to <ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" scale="-2" id="f-534">19.9</ix:nonFraction>% of our outstanding shares of common stock on the date of closing (prior to the issuance of any shares issued in connection with the transaction or the related private placement), less <ix:nonFraction unitRef="usd" contextRef="c-84" decimals="INF" name="pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-535">11,500,000</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive Loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a scenario-based method that considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio&#8217;s credit spread. On September 20, 2023, we achieved the commercial milestone in connection with the acquisition of Omniome. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_103">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_103">5. Financial Instruments</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on amounts paid and shares issued to former Omniome securityholders during the year ended December&#160;31, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" id="f-536" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition is as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash paid</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-537">315,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of share consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-538">249,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-539">168,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Share-based compensation expense excluded from consideration transferred</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-540">18,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-541">714,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-542" continuedAt="f-542-1" escape="true">As of December&#160;31, 2021, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-543">15,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-544">6,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="pacb:BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-545">18,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-546">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-547">390,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-548">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-549">91,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-550">26,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-551">714,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we recorded a measurement period adjustment of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-552">1.6</ix:nonFraction>&#160;million to decrease goodwill and a corresponding $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" sign="-" name="pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="f-553">0.4</ix:nonFraction>&#160;million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-554">1.2</ix:nonFraction>&#160;million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to Note 9 &#8211; Income Taxes, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2021 for more information. There were no measurement period adjustments recorded in the year ended December&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-488-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred costs related to the Omniome acquisition of approximately $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-555">12.0</ix:nonFraction>&#160;million during the twelve months ended December&#160;31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income. No significant merger-related costs were incurred during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of 2020, giving effect on a pro forma basis to the purchase accounting adjustments such as $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-556">12.0</ix:nonFraction>&#160;million of PacBio acquisition-related costs, $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-557">18.9</ix:nonFraction>&#160;million of share-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="pacb:IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-558">91.0</ix:nonFraction>&#160;million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="pacb:ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-559">16.7</ix:nonFraction>&#160;million of Omniome&#8217;s acquisition-related costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of 2020 or the results of future operations of the combined business.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-560" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the unaudited pro forma financial information:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma total revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-561">130,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-562">78,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma net (loss) income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-563">278,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-564">17,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma net (loss) income per share - basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-565"><ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-566">1.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-567"><ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-568">0.09</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Revenues of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="0" id="f-569">0</ix:nonFraction> and a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-570">15.6</ix:nonFraction>&#160;million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Circulomics, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, we acquired Circulomics Inc. (&#8220;Circulomics&#8221;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows (the &#8220;Circulomics acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-571">29.5</ix:nonFraction>&#160;million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the Circulomics acquisition. <ix:continuation id="f-542-2" continuedAt="f-542-3">The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="f-542-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-572">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="f-573">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-574">11,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-575">19,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="f-576">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-577">2,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="f-578">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-579">29,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-580">19.3</ix:nonFraction>&#160;million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes. We recorded $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-581">11.4</ix:nonFraction>&#160;million for the fair value of acquired intangible assets, which consists of developed technology and customer relationships.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="c-1" name="pacb:InvitaeCollaborationTextBlock" id="f-582" continuedAt="f-582-1" escape="true">INVITAE COLLABORATION</ix:nonNumeric></span></div><ix:continuation id="f-582-1"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Invitae Corporation (&#8220;Invitae&#8221;). The Amended and Restated Agreement amended and restated the existing Development and Commercialization Agreement, effective as of January 12, 2021, as amended by Amendment No. 1 to Development and Commercialization Agreement, entered into on June 3, 2021, by and between us and Invitae (together, the &#8220;Original Agreement&#8221;). Unless otherwise agreed in writing or terminated in accordance with the Amended and Restated Agreement, the term of the Amended and Restated Agreement shall continue until June 30, 2028 (&#8220;Term&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Original Agreement, Invitae provided certain funding to us to develop products relating to production-scale high-throughput sequencing (&#8220;Program Products&#8221;). If Program Products were to become commercially available, Invitae had the right to purchase the Program Products at preferred pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended and Restated Agreement, we will continue to receive feedback, input and insight from Invitae in connection with the intended development of our new sequencing systems; however, such feedback will not be contractually required, and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. Our development plans for such new sequencing systems will be at our discretion and pursuant to our own internal processes and programs. Invitae will not be contractually obligated to reimburse us for development costs under the Amended and Restated Agreement. There can be no assurances that the in-development sequencing systems will continue to be developed, be successfully developed or become available for commercial sale.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the non-refundable payments received from Invitae pursuant to the Original Agreement of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="pacb:AmountOfAgreementPaymentReceivedUponExecution" format="ixt:num-dot-decimal" scale="6" id="f-583">23.5</ix:nonFraction> million, we will provide Invitae with credits in connection with Invitae&#8217;s anticipated purchase of certain currently sequencing systems (instruments, consumables and service contracts). The credits will expire on June 30, 2025 (&#8220;Credit Expiration Date&#8221;). Subject to certain conditions, Invitae will also be entitled to most favored pricing for the Company&#8217;s Sequel IIe systems and certain in-development systems through the Term. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Invitae may terminate the Amended and Restated Agreement if the other party remains in material breach of the Amended and Restated Agreement following a cure period to remedy the material breach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated Agreement was deemed a contract modification and accounted for on a prospective basis in accordance with ASC Topic 606. We will recognize proportionate amounts of the transaction price, including payments made by Invitae to us pursuant to the Original Agreement, in revenue as the remaining performance obligations are s</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atisfied, which is when Invitae places purchase orders for certain sequencing platforms and the associated goods or services are delivered. Any remaining unused credits will be recognized when they expire.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invitae purchased certain instruments and consumables under the terms of the Amended and Restated Agreement, for which $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-584">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-585">3.7</ix:nonFraction> million of revenue was recognized as product revenue during the years ended December&#160;31, 2023 and 2022, respectively, on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-586">8.0</ix:nonFraction> million of deferred revenue, current, and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="pacb:ContractWithCustomerLiabilityNoncurrentReclassification" format="ixt:num-dot-decimal" scale="6" id="f-587">2.9</ix:nonFraction> million of deferred revenue, non-current, is recorded on the consolidated balance sheet relating to all future performance obligations under the Amended and Restated Agreement.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_100"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="c-1" name="pacb:MergerTerminationTextBlock" id="f-588" continuedAt="f-588-1" escape="true">TERMINATION OF MERGER WITH ILLUMINA</ix:nonNumeric></span></div><ix:continuation id="f-588-1" continuedAt="f-588-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the &#8220;Illumina Merger Agreement&#8221;) with Illumina, Inc. (&#8220;Illumina&#8221;) and FC Ops Corp., a wholly owned subsidiary of Illumina (&#8220;Illumina Merger Sub&#8221;). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the &#8220;Termination Agreement&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Continuation Advances from Illumina</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Termination Agreement, Illumina paid us cash payments (&#8220;Continuation Advances&#8221;) totaling $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" sign="-" name="us-gaap:GainLossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="f-589">52</ix:nonFraction> million. Up to the full $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" format="ixt:num-dot-decimal" scale="6" id="f-590">52.0</ix:nonFraction> million of Continuation Advances paid to us were repayable without interest to Illumina if, within <ix:nonNumeric contextRef="c-97" name="pacb:MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" format="ixt-sec:durwordsen" id="f-591">two years</ix:nonNumeric> of March&#160;31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-8" name="pacb:MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" format="ixt:num-dot-decimal" scale="6" id="f-592">100</ix:nonFraction> million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Resulting from the issuance and sale of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-593">900</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-594">1.50</ix:nonFraction>% Convertible Senior Notes due February&#160;15, 2028, $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" sign="-" name="us-gaap:GainLossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="f-595">52.0</ix:nonFraction>&#160;million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-588-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-operating expense in the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_103"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-596" continuedAt="f-596-1" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="f-596-1" continuedAt="f-596-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-597" continuedAt="f-597-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-597-1">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-596-2" continuedAt="f-596-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-598" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-599">70,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-602">70,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-603">137,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-606">137,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-612">166,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-614">166,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-616">109,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-618">109,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-620">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-622">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-623">70,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-624">109,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-626">179,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-627">137,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-628">187,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-630">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-632">9,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-634">9,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-636">127,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-638">127,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-640">88,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-642">88,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-644">49,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-646">49,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-648">352,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-650">352,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-652">270,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-654">270,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-656">451,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-658">451,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-660">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-662">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-663">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-666">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-667">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-670">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-671">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-674">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-675">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-678">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-679">72,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-680">561,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-682">634,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-683">140,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-684">634,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-686">775,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Omniome acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-693">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-694">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Apton acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-697">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-698">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities measured at fair value </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-705">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-706">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-709">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-710">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration, which was incurred in connection with the acquisition of Apton, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the <ix:nonNumeric contextRef="c-4" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:duryear" id="f-711">5</ix:nonNumeric>-year anniversary of the closing date of the acquisition. As of December 31, 2023, the key input used in the determination of the fair value included projected revenues of the Company relating to the high-throughput short-read products and services leveraging Apton's technology. A decrease in the projected revenues would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- credit rating, which ranges from <ix:nonFraction unitRef="number" contextRef="c-169" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-712">7.8</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-170" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-713">8.2</ix:nonFraction>%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2023, we achieved the commercial milestone in connection with the acquisition of Omniome. Consequently, former Omniome securityholders were entitled to receive as milestone consideration, among other things, an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-714">100.9</ix:nonFraction>&#160;million in cash and approximately <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-715">9.0</ix:nonFraction>&#160;million shares of our common stock, representing $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-716">95.9</ix:nonFraction>&#160;million divided by the volume-weighted average of the trading prices of our common stock for the <ix:nonFraction unitRef="d" contextRef="c-74" decimals="INF" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" format="ixt-sec:numwordsen" scale="0" id="f-717">twenty</ix:nonFraction> trading days ending with and including the trading day that was two days </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-596-3" continuedAt="f-596-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediately prior to the achievement of the milestone. The $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-718">95.9</ix:nonFraction>&#160;million represents the $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-719">100.0</ix:nonFraction>&#160;million that was to be paid in shares of our common stock offset by $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="f-720">4.1</ix:nonFraction>&#160;million attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the achievement of the commercial milestone, $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="pacb:PaymentsForContingentConsiderationRevenueAchievementMilestone" format="ixt:num-dot-decimal" scale="6" id="f-721">101.3</ix:nonFraction>&#160;million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December&#160;31, 2023. Additionally, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-722">8,988,391</ix:nonFraction> shares were issued at a value of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="f-723">84.8</ix:nonFraction>&#160;million to the former Omniome securityholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the achievement of the milestone, the contingent consideration liability incurred in connection with the acquisition of Omniome was no longer considered a Level 3 liability at December&#160;31, 2023. There were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis for the year ended December&#160;31, 2023, and our valuation techniques did not change compared to the prior year. </span></div><ix:nonNumeric contextRef="c-1" name="pacb:ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" id="f-724" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the year ended December&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-725">172,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="f-726">18,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-727">Change in estimated fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-728">15,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Achievement of milestone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="pacb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-729">186,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-730">19,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as the Change in fair value of contingent consideration in the consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-596-4" continuedAt="f-596-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-731" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-732">70,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-735">70,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-736">109,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-737">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-738">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-739">109,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-740">179,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-741">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-742">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-743">179,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-744">9,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-747">9,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-748">88,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-749">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-750">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-751">88,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-752">353,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-753">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-754">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-755">352,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-756">451,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-757">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-758">585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-759">451,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-760">631,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-761">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-762">645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-763">631,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-764">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-765">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-766">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-767">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-768">137,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-771">137,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-772">166,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-774">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-775">166,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-776">20,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-777">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-779">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-780">325,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-781">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-782">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-783">325,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-784">127,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-785">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-786">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-787">127,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-788">49,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-790">507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-791">49,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-792">274,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-793">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-794">3,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-795">270,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-796">451,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-797">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-798">4,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-799">447,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-800">777,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-801">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-802">4,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-803">772,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-804">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-805">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-806">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-807">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-808" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-809">465,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through 5 years </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-810">96,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-811">561,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-596-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net on the consolidated statement of operations and comprehensive loss was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-812">32.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="6" id="f-813">9.2</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_106"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-814" continuedAt="f-814-1" escape="true">BALANCE SHEET COMPONENTS</ix:nonNumeric></span><ix:continuation id="f-814-1" continuedAt="f-814-2"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-814-2" continuedAt="f-814-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-815" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-816">20,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-817">24,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-818">23,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-819">14,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-820">13,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-821">12,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-822">56,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-823">50,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:continuation id="f-463-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-824">44,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-825">38,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-826">35,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-827">34,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-828">19,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-829">18,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-830">6,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-831">6,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-832">3,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-833">3,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-834">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-835">4,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-836">111,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-837">106,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-838">74,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-839">64,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-840">36,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-841">41,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of capitalizable costs that have been incurred for the construction of long-lived assets and is primarily comprised of amounts that will be classified as lab equipment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense during the years ended December&#160;31, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-842">11.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-843">9.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-844">7.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the goodwill balance was $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-845">462.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-846">410.0</ix:nonFraction> million, respectively. Goodwill preliminarily increased by $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-847">52.3</ix:nonFraction> million, due to the Apton acquisition, of which $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-848">11.3</ix:nonFraction> million relates to a deferred income tax liability. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2023, noting no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include acquired IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-849">55.0</ix:nonFraction> million as a result of the Apton acquisition in August 2023. As of December&#160;31, 2023, the research and development project had not been completed or abandoned and, therefore, the IPR&amp;D intangible asset is not currently subject to amortization. During the year ended December&#160;31, 2023, acquired IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-850">400.0</ix:nonFraction> million as a result of the Omniome acquisition in September 2021 was completed and became subject to amortization. IPR&amp;D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for IPR&amp;D impairment in the third quarter of 2023, noting no impairment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-814-3" continuedAt="f-814-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-851" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired definite-lived intangible assets as of December&#160;31, 2023 (in thousands, except years):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated <br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-209" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-852">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-853">411,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-854">9,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-855">401,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-210" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-856">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-857">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-858">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-860">411,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-861">9,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-862">401,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangibles was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="f-863">8.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="f-864">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="f-865">0.4</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. For the years ended December&#160;31, 2023,  2022, and 2021 amortization expense of intangibles in cost of revenue was $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-866">2.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-867">0.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-868">0.3</ix:nonFraction>&#160;million, respectively.  For the years ended December&#160;31, 2023, 2022, and 2021, amortization expense of intangibles in operating expenses was $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-869">6.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-870">0.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-871">0.1</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The definite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-872" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-873">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-874">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-875">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-876">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-877">27,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-878">264,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-879">401,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="f-880" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-881">29,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-882">17,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:AccruedTenantImprovementsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-883">2,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:AccruedTenantImprovementsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-884">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-885">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-886">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:AccruedProductDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-887">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:AccruedProductDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-888">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional services and legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-889">2,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-890">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductLiabilityContingencyAccrualPresentValue" scale="3" id="f-891">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductLiabilityContingencyAccrualPresentValue" scale="3" id="f-892">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-893">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-894">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-895">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-896">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-897">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-898">32,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-814-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-899" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-900">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProductWarrantyAccrual" scale="3" id="f-901">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-902">8,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-903">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-904">5,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-905">2,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-906">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-907">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had a total of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-908">21.9</ix:nonFraction> million of deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-909">16.3</ix:nonFraction> million of which was recorded as deferred revenue, current and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae, as described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_97">Note 3. Invitae Collaboration</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as deferred service contract revenues. The deferred revenue, non-current balance of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-910">5.6</ix:nonFraction> million primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae and deferred service contract revenues and is scheduled to be recognized in the next <ix:nonNumeric contextRef="c-218" name="pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" format="ixt-sec:duryear" id="f-911">5</ix:nonNumeric> years. The deferred revenue, non-current balance includes $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="pacb:ContractWithCustomerLiabilityNoncurrentReclassification" format="ixt:num-dot-decimal" scale="6" id="f-912">2.9</ix:nonFraction> million that was reclassified from deferred revenue, current to deferred revenue, non-current following receipt of a non-cancellable order from Invitae during the year ended December&#160;31, 2023 for partial utilization of the available credits, which is expected to be recognized in revenue after 12 months from December&#160;31, 2023. Revenue recorded in the year ended December&#160;31, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-913">18.9</ix:nonFraction> million of previously deferred revenue that was included in deferred revenue, current as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Omniome, we acquired $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-914">1.3</ix:nonFraction> million in short-term debt and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-915">3.0</ix:nonFraction> million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#8217;s purchases of equipment, which serves as collateral. Each term loan has a term of <ix:nonNumeric contextRef="c-81" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="f-916">43</ix:nonNumeric> months and bears a fixed interest rate of approximately <ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-917">17</ix:nonFraction>% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month and before the 43</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month after the commencement date, is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="pacb:PercentageOfFeeToPrepayDebt" scale="-2" id="f-918">4</ix:nonFraction>% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the carrying value of term loans outstanding was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-919">0.5</ix:nonFraction> million, recorded as part of other liabilities, current on the consolidated balance sheet. The interest expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-920">0.3</ix:nonFraction> million for the year ended December&#160;31, 2023, which was included as part of interest expense in the consolidated statements of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="c-1" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="f-921" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the future principal payments remaining on term loans was the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="f-922">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="f-923">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Liabilities, Current</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-924" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities, current, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-925">3,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-926">3,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermBorrowings" scale="3" id="f-927">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-928">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-929">4,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-930">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-931">8,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-932">7,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-933" continuedAt="f-933-1" escape="true">CONVERTIBLE SENIOR NOTES</ix:nonNumeric></span></div><ix:continuation id="f-933-1" continuedAt="f-933-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2030 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding <ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-934">1.50</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), pursuant to which we issued $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-935">441.0</ix:nonFraction>&#160;million in aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="c-220" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-936">1.375</ix:nonFraction>% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221;) in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-937">441.0</ix:nonFraction> million principal amount of the 2028 Notes (the &#8220;Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-220" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-938">1.375</ix:nonFraction>% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December&#160;15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-939">21.50</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-221" decimals="2" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" scale="-2" id="f-940">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="c-221" name="pacb:DebtInstrumentRedemptionPriceTradingDays" format="ixt-sec:durday" id="f-941">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="c-221" name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" format="ixt-sec:durday" id="f-942">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-221" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-943">100</ix:nonFraction>% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="c-221" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-944">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-221" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-945">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-221" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-946">0.25</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-222" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-947">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-221" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-948">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-221" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-949">0.50</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-223" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-950">181</ix:nonNumeric>st calendar day to, and including, the <ix:nonNumeric contextRef="c-221" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-951">360</ix:nonNumeric>th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the <ix:nonNumeric contextRef="c-224" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-952">361</ix:nonNumeric>st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-224" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-953">361</ix:nonNumeric>st day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-933-2" continuedAt="f-933-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-954">2.0</ix:nonFraction> million in connection with the Exchange Transaction during the year ended December&#160;31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-955">1.5</ix:nonFraction> million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-956">7.3</ix:nonFraction> million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our consolidated balance sheets and are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-228" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-957">1.6</ix:nonFraction>%. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-958">2.5</ix:nonFraction> million on the 2028 Notes in connection with the Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the Exchange Transaction, $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-959">459.0</ix:nonFraction> million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-960" continuedAt="f-960-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-961">441,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt premium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-963">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-965">6,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-967">434,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="f-968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfInterestExpenseTableTextBlock" id="f-969" continuedAt="f-969-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes for the years ended December&#160;31, 2023, 2022, and 2021 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-970">3,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-973">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-976">3,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the estimated fair value (Level 2) of the 2030 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-979">410.5</ix:nonFraction> million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;9, 2021, we entered into an investment agreement (the &#8220;Investment Agreement&#8221;) with SB Northstar LP (the &#8220;Purchaser&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-980">900.0</ix:nonFraction> million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021. As discussed above, in June 2023 we completed an exchange of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-981">441.0</ix:nonFraction> million in aggregate principal amount of our 2028 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-982">441.0</ix:nonFraction> million aggregate principal amount of the 2030 Notes, leaving approximately $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-983">459.0</ix:nonFraction> million in aggregate principal amount of 2028 Notes outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are governed by an indenture (the &#8220;2028 Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The 2028 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-235" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-984">1.50</ix:nonFraction>% per annum. Interest on the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-933-3" continuedAt="f-933-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028 Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The 2028 Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption, or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2028 Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the 2028 Notes (which is equal to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-235" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-985">43.50</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2028 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 20, 2026, the 2028 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" scale="-2" id="f-986">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="c-236" name="pacb:DebtInstrumentRedemptionPriceTradingDays" format="ixt-sec:durday" id="f-987">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="c-236" name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" format="ixt-sec:durday" id="f-988">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-989">100</ix:nonFraction>% of the principal amount of such 2028 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2028 Indenture), the holders of the 2028 Notes may require that we repurchase all or part of the principal amount of the 2028 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2028 Notes under the 2028 Indenture. The 2028 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-237" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-990">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2028 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-237" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-991">0.25</ix:nonFraction>% per annum of the principal amount of the 2028 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-238" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-992">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-237" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-993">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-237" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-994">0.50</ix:nonFraction>% per annum of the principal amount of the 2028 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-239" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-995">181</ix:nonNumeric>st calendar day to, and including, the <ix:nonNumeric contextRef="c-237" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-996">360</ix:nonNumeric>th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2028 Indenture). On the <ix:nonNumeric contextRef="c-240" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-997">361</ix:nonNumeric>st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-240" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-998">361</ix:nonNumeric>st day), the 2028 Notes shall be subject to acceleration as provided for in the 2028 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2028 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2028 Notes were not issued at a premium; therefore, the 2028 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2028 Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-999">4.5</ix:nonFraction> million, which were recorded as debt issuance cost and are presented as a reduction to the 2028 Notes on our consolidated balance sheets and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-933-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-230" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1000">1.6</ix:nonFraction>%. </span></div><ix:continuation id="f-960-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1001">459,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1002">900,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-1003">1,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-1004">3,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1005">457,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1006">896,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:continuation id="f-969-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1007">10,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1008">13,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1009">11,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-1010">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-1011">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-1012">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1013">10,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1014">14,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1015">12,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the estimated fair value (Level 2) of the 2028 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-1016">395.4</ix:nonFraction> million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_112"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-1019" continuedAt="f-1019-1" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="f-1019-1" continuedAt="f-1019-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1020"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1021">18.1</ix:nonFraction></ix:nonFraction> million in right-of-use assets and liabilities on our consolidated balance sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1019-2" continuedAt="f-1019-3"><ix:nonNumeric contextRef="c-1" name="pacb:LesseeOperatingLeaseDescriptionTableTextBlock" id="f-1022" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1023">12,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1024">12,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1025">12,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1026">9,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-1027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1029">46,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1030">5,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1031">41,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1032">9,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1033">31,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1034">41,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1035">6.8</ix:nonFraction>%. The weighted-average remaining lease term for our operating leases as of December&#160;31, 2023 was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1036">3.8</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="f-1037">12.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="f-1038">11.2</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, and were included in operating cash flows. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1039">10.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1040">10.5</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_28">Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1019-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" format="ixt:fixed-zero" scale="0" id="f-1041">No</ix:nonFraction> additional liability associated with such indemnification obligations has been recorded as of December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancellable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchase orders and contractual obligations are approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-1042">109.9</ix:nonFraction> million as of December&#160;31, 2023, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a loss on purchase commitment of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1043">3.4</ix:nonFraction> million for the year ended December&#160;31, 2023, which was recorded as part of accrued expenses on the consolidated balance sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to a supply agreement with a third-party vendor, for which we do not expect to have related sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-term supply agreement, which was amended in October 2022 (the &#8220;Supply Agreement&#8221;), for the purchase of certain products with a semiconductor manufacturer (&#8220;Supplier&#8221;). The Supply Agreement provides for minimum purchase commitments through 2026 on our part in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid our Supplier a deposit of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:PaymentsForDeposits" format="ixt:num-dot-decimal" scale="6" id="f-1044">9.0</ix:nonFraction> million in November 2022 and an additional deposit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForDeposits" format="ixt:num-dot-decimal" scale="6" id="f-1045">6.0</ix:nonFraction> million in 2023, for a total of $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:PaymentsForDeposits" format="ixt:num-dot-decimal" scale="6" id="f-1046">15.0</ix:nonFraction> million (the &#8220;Deposit&#8221;). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1047">3.0</ix:nonFraction> million related to the Deposit was included in prepaid expenses and other current assets in the consolidated balance sheets and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1048">12.0</ix:nonFraction> million related to the Deposit was included in other long-term assets in the consolidated balance sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_115"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1049" continuedAt="f-1049-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-1049-1" continuedAt="f-1049-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes both in the United States and certain foreign jurisdictions in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" scale="-2" id="f-1050">50</ix:nonFraction>% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for Global Intangible Low-taxed Income as a period cost.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1049-2" continuedAt="f-1049-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022, and 2021 income/(loss) before taxes from U.S. operations were ($<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1051">318.9</ix:nonFraction>) million, ($<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1052">315.7</ix:nonFraction>) million, and ($<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1053">275.4</ix:nonFraction>) million, respectively, and income/(loss) before taxes from foreign operations was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1054">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1055">1.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="f-1056">0.8</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision (Benefit) for Income Taxes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1057" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1061">9,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1063">83,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1064">1,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1066">9,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1070">11,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1072">93,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit) Provision for Income Taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1073">11,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1075">93,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1076" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory tax rate </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1077">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1078">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1079">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State tax rate, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1080">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1081">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1082">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1083">20.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1084">25.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1085">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" scale="-2" id="f-1086">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" scale="-2" id="f-1087">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="pacb:EffectiveIncomeTaxRateReconciliationTaxCredit" scale="-2" id="f-1088">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1089">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1090">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1091">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" scale="-2" id="f-1092">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" format="ixt:fixed-zero" scale="-2" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" scale="-2" id="f-1094">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1095">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1096">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1097">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1098">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1099">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1100">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1049-3" continuedAt="f-1049-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1101" continuedAt="f-1101-1" escape="true">Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): </ix:nonNumeric></span></div><ix:continuation id="f-1101-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1102">435,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1103">400,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1104">83,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1105">71,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and experimental expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1106">63,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1107">34,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="f-1108">16,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="f-1109">13,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of indebtedness income and interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1110">14,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1111">4,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1112">18,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1113">17,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1114">9,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1115">11,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1116">642,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1117">554,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1118">525,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1119">445,574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1120">116,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1121">108,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1122">109,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1123">98,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-1124">548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1125">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1126">7,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="pacb:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1127">9,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1128">117,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1129">109,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-1130">751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-1131">835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we maintained a valuation allowance against our net deferred tax assets which totaled $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1132">525.7</ix:nonFraction> million, including net operating loss carryforwards and research and development credits of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1133">435.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1134">83.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. A deferred income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1135">11.4</ix:nonFraction>&#160;million for the year ended December&#160;31, 2023, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company's valuation allowance increased to $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1136">525.7</ix:nonFraction> million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. For the year ended December&#160;31, 2022, the Company's valuation allowance increased to $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1137">445.6</ix:nonFraction> million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had a net operating loss carryforward for federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1138">1,709.3</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="pacb:OperatingLossCarryforwardsAmountSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-1139">788.1</ix:nonFraction> million is subject to expiration beginning in 2024. We had a total state net operating loss carryforward of approximately $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1140">1,171.8</ix:nonFraction> million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1049-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have federal credits of approximately $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1141">57.7</ix:nonFraction> million, which will begin to expire in 2024 if not utilized and state research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1142">49.8</ix:nonFraction> million, which have no expiration date. These tax credits are subject to the same limitations discussed above. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1143" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our total unrecognized tax benefit was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1144">14.6</ix:nonFraction> million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1145">5,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1146">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1147">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1148">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1149">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1150">2,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1151">10,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1152">2,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1153">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1154">14,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2023 and 2022, we had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" scale="0" id="f-1155"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" scale="0" id="f-1156">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December&#160;31, 2020 to present and December 31, 2019 to present, respectively. In addition, all the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_118"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1157" continuedAt="f-1157-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-1157-1" continuedAt="f-1157-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1158">1,000,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-250" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1159">0.001</ix:nonFraction> par value common stock and <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1160">50,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-250" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1161">0.001</ix:nonFraction> par value preferred stock. As of December&#160;31, 2023 and 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1162"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1163"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1164"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1165">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued or outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to dividends when and if declared by our board of directors. There have been <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="f-1166">no</ix:nonFraction> dividends declared to date. The holder of each share of common stock is entitled to <ix:nonNumeric contextRef="c-1" name="us-gaap:CommonStockVotingRights" id="f-1167"><ix:nonFraction unitRef="vote" contextRef="c-1" decimals="INF" name="pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned" format="ixt-sec:numwordsen" scale="0" id="f-1168">one</ix:nonFraction></ix:nonNumeric> vote. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Underwritten Public Equity Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an underwriting agreement, relating to the public offering of <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-4" name="pacb:PublicOfferingShares" format="ixt:num-dot-decimal" scale="0" id="f-1169">19,430,000</ix:nonFraction> shares of our common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-252" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1170">0.001</ix:nonFraction> par value per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-252" decimals="2" name="pacb:OfferingShareAmountMaximum" scale="0" id="f-1171">4.47</ix:nonFraction> per share. Under the terms of the underwriting agreement, we also granted the underwriters a <ix:nonNumeric contextRef="c-251" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" format="ixt-sec:durday" id="f-1172">30</ix:nonNumeric>-day option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-2" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" format="ixt:num-dot-decimal" scale="0" id="f-1173">2,914,500</ix:nonFraction> shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in August 2020. In total, we sold <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-1174">22.3</ix:nonFraction>&#160;million shares of our common stock. We paid a commission equal to <ix:nonFraction unitRef="number" contextRef="c-251" decimals="2" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" scale="-2" id="f-1175">6</ix:nonFraction>% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1176">93.9</ix:nonFraction>&#160;million, excluding approximately $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1177">0.3</ix:nonFraction>&#160;million of offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into an underwriting agreement, relating to the public offering of <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="0" name="pacb:PublicOfferingShares" format="ixt:num-dot-decimal" scale="0" id="f-1178">6,096,112</ix:nonFraction> shares of our common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-254" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1179">0.001</ix:nonFraction> par value per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-254" decimals="2" name="pacb:OfferingShareAmountMaximum" scale="0" id="f-1180">14.25</ix:nonFraction> per share. Under the terms of the underwriting agreement, we also granted the underwriters a <ix:nonNumeric contextRef="c-253" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" format="ixt-sec:durday" id="f-1181">30</ix:nonNumeric>-day option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="0" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" format="ixt:num-dot-decimal" scale="0" id="f-1182">914,416</ix:nonFraction> shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in November 2020. In total, we sold <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-1183">7.0</ix:nonFraction>&#160;million shares of our common stock. We paid a commission equal to <ix:nonFraction unitRef="number" contextRef="c-253" decimals="2" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" scale="-2" id="f-1184">6</ix:nonFraction>% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1157-2" continuedAt="f-1157-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deducting the underwriting discount were approximately $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1185">93.9</ix:nonFraction>&#160;million, excluding approximately $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1186">0.3</ix:nonFraction> million of offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, for the year ended December&#160;31, 2021, we issued <ix:nonFraction unitRef="shares" contextRef="c-255" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-1187">29.4</ix:nonFraction> million shares of our common stock through our <ix:nonFraction unitRef="offering" contextRef="c-255" decimals="INF" name="pacb:NumberOfOfferings" format="ixt-sec:numwordsen" scale="0" id="f-1188">two</ix:nonFraction> underwritten public offerings with an average offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-256" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-1189">6.40</ix:nonFraction>. The total net proceeds to us from the <ix:nonFraction unitRef="offering" contextRef="c-257" decimals="INF" name="pacb:NumberOfOfferings" format="ixt-sec:numwordsen" scale="0" id="f-1190">two</ix:nonFraction> offerings, after deducting the underwriting commission and offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1191">187.2</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into an underwriting agreement, relating to the public offering of <ix:nonFraction unitRef="shares" contextRef="c-258" decimals="-5" name="pacb:PublicOfferingShares" format="ixt:num-dot-decimal" scale="6" id="f-1192">17.5</ix:nonFraction>&#160;million shares of our common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-259" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1193">0.001</ix:nonFraction> par value per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-259" decimals="2" name="pacb:OfferingShareAmountMaximum" scale="0" id="f-1194">10.00</ix:nonFraction> per share. Under the terms of the underwriting agreement, we also granted the underwriters a <ix:nonNumeric contextRef="c-258" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod" format="ixt-sec:durday" id="f-1195">30</ix:nonNumeric>-day option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="c-258" decimals="-5" name="pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares" format="ixt:num-dot-decimal" scale="6" id="f-1196">2.6</ix:nonFraction>&#160;million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold <ix:nonFraction unitRef="shares" contextRef="c-260" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1197">20.1</ix:nonFraction>&#160;million shares of our common stock. We paid a commission equal to <ix:nonFraction unitRef="number" contextRef="c-258" decimals="4" name="pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" scale="-2" id="f-1198">5.75</ix:nonFraction>% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1199">189.7</ix:nonFraction>&#160;million, excluding approximately $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1200">0.5</ix:nonFraction>&#160;million of offering expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement of Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1201">11,214,953</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-261" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-1202">26.75</ix:nonFraction> per share, for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1203">300</ix:nonFraction> million. The transaction closed on September&#160;20, 2021. We registered the private placement shares for resale following the closing of the merger.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) allow for the issuance of stock options, restricted units and awards, and performance-based awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2020, the Board of Directors (the &#8220;Board&#8221;) adopted the Inducement Plan and reserved <ix:nonFraction unitRef="shares" contextRef="c-263" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1204">2,500,000</ix:nonFraction> shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April&#160;18, 2021 and November&#160;22, 2021, the Board amended the Inducement Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1205">750,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-265" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1206">360,000</ix:nonFraction> shares, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, was assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio&#8217;s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to <ix:nonFraction unitRef="number" contextRef="c-266" decimals="INF" name="pacb:ExchangeRatio" scale="0" id="f-1207">0.259204639</ix:nonFraction>. We reserved <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1208">2,494,128</ix:nonFraction> shares of our common stock for issuance pursuant to equity awards under the Omniome Plan. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, stockholders approved an amendment to the 2020 Plan, and we reserved an additional <ix:nonFraction unitRef="shares" contextRef="c-268" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1209">18,000,000</ix:nonFraction> shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had <ix:nonFraction unitRef="shares" contextRef="c-269" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1210">12.8</ix:nonFraction>&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1157-3" continuedAt="f-1157-4"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-based stock options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1211" continuedAt="f-1211-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1212">14,618</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1213">10.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1214">419</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1215">11.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-271" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-1216">1,119</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1217">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-271" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1218">910</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1219">17.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1220">13,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1221">10.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based stock options</span></div><ix:continuation id="f-1211-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1222">258</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1223">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="f-1224">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1226">251</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1227">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-275" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1228">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-275" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1229">4.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1230">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-276" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1231">4.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance condition was achieved during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of the outstanding options presented in the tables above as of December&#160;31, 2023, totaled $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1232">31.8</ix:nonFraction> million, and had a weighted-average remaining contractual life of <ix:nonNumeric contextRef="c-278" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1233">5.9</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $<ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-1234">9.81</ix:nonFraction>, our closing stock price on the last trading day of our fourth quarter of 2023 and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2023. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and exercisable options as of December&#160;31, 2023, totaled <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1235">10,039,742</ix:nonFraction> shares, had an aggregate intrinsic value of $<ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="6" id="f-1236">30.0</ix:nonFraction>&#160;million, a weighted-average exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1237">9.70</ix:nonFraction>, and a weighted-average remaining contractual life of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1238">5.2</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and expected to vest options as of December&#160;31, 2023, totaled <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1239">13,026,464</ix:nonFraction> shares, had an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1240">31.6</ix:nonFraction> million, a weighted-average exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1241">10.81</ix:nonFraction>, and a weighted-average remaining contractual life of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1242">5.8</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1243">8.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1244">5.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1245">146.1</ix:nonFraction> million, respectively. The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1246">7.32</ix:nonFraction> in 2023, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1247">5.93</ix:nonFraction> in 2022, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1248">18.36</ix:nonFraction> in 2021, each determined by the Black-Scholes option valuation method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Restricted Stock Unit (RSU) represents <ix:nonFraction unitRef="shares" contextRef="c-280" decimals="0" name="pacb:ShareInstrumentNumberOfSharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1249">one</ix:nonFraction> equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs are time-based and vest over <ix:nonNumeric contextRef="c-280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1250">four years</ix:nonNumeric> at a rate of <ix:nonFraction unitRef="number" contextRef="c-281" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1251">25</ix:nonFraction>% annually. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. The fair value of these RSUs is </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1157-4" continuedAt="f-1157-5"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis.  RSUs that are expected to vest are net of estimated future forfeitures. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue PSUs for which the number of shares issuable in the third year of the performance period is based on performance relative to specified revenue targets and continued employment through the vesting period.  Maximum achievement of the revenue goal under the PSUs will result in up to <ix:nonFraction unitRef="number" contextRef="c-282" decimals="2" name="pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" scale="-2" id="f-1252">200</ix:nonFraction>% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under PSUs will result in no shares subject to the PSUs becoming eligible to vest.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-1253" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the time-based RSUs and PSUs activity for the year ended December&#160;31, 2023 (shares in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units (RSUs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Stock Units (PSUs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1254">8,535</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="f-1255">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1256">15.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-284" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1258">7,141</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1259">564</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1260">9.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1261">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-280" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1262">2,730</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="f-1263">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1264">14.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-280" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1266">1,638</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1267">23</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1268">13.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1269">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1270">11,308</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1271">541</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1272">12.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1273">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested related to RSUs and PSUs during the years ended December&#160;31, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1274">39.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1275">39.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1276">9.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all RSUs and PSUs granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-287" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1277">9.65</ix:nonFraction> in 2023, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1278">10.15</ix:nonFraction> in 2022, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-289" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1279">35.33</ix:nonFraction> in 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, a total of <ix:nonFraction unitRef="shares" contextRef="c-290" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1280">29.5</ix:nonFraction>&#160;million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of <ix:nonFraction unitRef="period" contextRef="c-291" decimals="INF" name="pacb:NumberOfPurchasePeriods" format="ixt-sec:numwordsen" scale="0" id="f-1281">four</ix:nonFraction> purchase periods, each purchase period being approximately <ix:nonNumeric contextRef="c-292" name="pacb:PurchasePeriodOfEmployeeStockPurchasePlan" format="ixt-sec:durwordsen" id="f-1282">six months</ix:nonNumeric>. The price at which the stock is purchased is equal to the lower of <ix:nonFraction unitRef="number" contextRef="c-292" decimals="2" name="pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased" scale="-2" id="f-1283">85</ix:nonFraction>% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will be terminated and a new offering period will come into place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lesser of <ix:nonFraction unitRef="number" contextRef="c-292" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1284">2</ix:nonFraction>% of the common shares then outstanding, <ix:nonFraction unitRef="shares" contextRef="c-291" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1285">4,000,000</ix:nonFraction> shares, or an amount determined by the ESPP&#8217;s administrator. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-1286">1,735,058</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, <ix:nonFraction unitRef="shares" contextRef="c-293" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-1287">1,878,168</ix:nonFraction> shares, and <ix:nonFraction unitRef="shares" contextRef="c-294" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-1288">1,913,968</ix:nonFraction> shares of common stock were purchased under the ESPP, respectivel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y. As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-291" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-1289">12,197,447</ix:nonFraction> sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares of our common stock remain available for issuance under our ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1157-5" continuedAt="f-1157-6"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1290" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense consists of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1291">5,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1292">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1293">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1294">22,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1295">30,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1296">20,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1297">44,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1298">43,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1299">35,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - stock-settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1302">6,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1305">5,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1306">72,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1307">78,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1308">73,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - cash-settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-1310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1311">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1312">72,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1313">78,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1314">80,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1315">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1316">0.7</ix:nonFraction> million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit of share-based compensation expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Fair Value</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term &#8211; The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Volatility &#8211; The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Dividend &#8211; We have never paid dividends on our shares and, accordingly, the dividend yield percentage is <ix:nonFraction unitRef="number" contextRef="c-13" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1317"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1318"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1319">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction> for all periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-Free Interest Rate &#8211; The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1157-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1320" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-316" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1321">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1322">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-318" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1323">2.1</ix:nonNumeric> - <ix:nonNumeric contextRef="c-319" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1324">4.6</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-320" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1325">77</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-321" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1326">78</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1327">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1328">76</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-318" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1329">67</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-319" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1330">80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-316" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1331">3.73</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-316" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1332">4.60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-317" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1333">0.41</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-317" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1334">3.66</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1335">0.05</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-324" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1336">1.10</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1337">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1338">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1339">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-316" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1340">7.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-317" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1341">5.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-324" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1342">15.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from option exercises for the years ended December&#160;31, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1343">6.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1344">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1345">25.4</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESPP </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-1346" continuedAt="f-1346-1" escape="true">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-1346-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1347">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-326" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1348">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1349">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-328" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1350">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-329" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1351">0.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-330" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1352">2.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-325" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1353">79</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-326" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1354">97</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-327" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1355">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-328" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1356">97</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-329" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1357">67</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-330" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1358">68</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1359">4.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1360">5.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-293" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1361">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-293" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1362">3.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1363">0.1</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-294" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1364">0.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1365">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1366">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1367">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-292" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1368">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-293" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1369">4.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1370">25.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received through the ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1371">8.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1372">7.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1373">6.4</ix:nonFraction> million, respectively.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1374">101.9</ix:nonFraction> million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1375">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_121"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1376" continuedAt="f-1376-1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-1376-1" continuedAt="f-1376-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the convertible senior notes, using the if-converted method, and outstanding equity awards using the treasury stock method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the consolidated statements of operations and comprehensive loss (in thousands, except per share amounts): </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1377" escape="true"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1378">306,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1379">314,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1380">181,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1381">253,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1382">224,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1383">204,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1384">1.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1385">1.40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1386">0.89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1387">253,629</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1388">224,550</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1389">204,136</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1390">1.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1391">1.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1392">0.89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><ix:continuation id="f-1376-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1393" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-332" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1394">31,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1395">20,690</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1396">20,690</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1397">27,246</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-336" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1398">27,291</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1399">21,419</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_94">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the contingently issuable shares would be due upon the achievement of a milestone. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_118">Note 10. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on RSUs with time-based vesting and RSUs with performance-based vesting.</span></div></ix:continuation><div id="i02b9487756a44f62beca493d5cd6fd6a_124"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1400" continuedAt="f-1400-1" escape="true">SEGMENT AND GEOGRAPHIC INFORMATION</ix:nonNumeric></span></div><ix:continuation id="f-1400-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1401">one</ix:nonFraction> reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1402" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1403">105,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1404">69,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1405">64,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East, and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1406">40,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1407">22,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1408">30,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1409">54,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1410">36,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1411">35,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1412">200,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1413">128,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1414">130,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-1415" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1416">120,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1417">48,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1418">61,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1419">63,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1420">59,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1421">52,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1422">183,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1423">108,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1424">113,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1425">16,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1426">19,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1427">17,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1428">200,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1429">128,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1430">130,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_133"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive officer, our chief financial officer, and our principal accounting officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a&#8211;15(e) and 15d&#8211;15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10&#8211;K. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer, chief financial officer and our principal accounting officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Pacific Biosciences of California, Inc&#8217;s internal control over financial reporting is designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the preparation and fair presentation of published financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). Based on our assessment, we concluded that, as of December&#160;31, 2023, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s internal control over financial reporting as of December&#160;31, 2023 has been audited by Ernst &amp; Young LLP, the independent registered public accounting firm who also audited the Company&#8217;s financial statements. Ernst &amp; Young&#8217;s attestation report on the Company&#8217;s internal control over financial reporting appears on page </span><span style="color:#0070c0;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0070c0;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_530">112</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December&#160;31, 2023, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_530"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Pacific Biosciences of California, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Pacific Biosciences of California, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Pacific Biosciences of California, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2023, based on the COSO criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2023 consolidated financial statements of the Company and our report dated February&#160;28, 2024, expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Mateo, California </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Trading Plans of Directors and Executive Officers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-353" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1431"><ix:nonNumeric contextRef="c-353" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1432">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-353" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1433"><ix:nonNumeric contextRef="c-353" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1434">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; each as defined in Item 408 of Regulation S-K.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_139"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_142"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_145"></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_148"></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2024 Annual Meeting of Stockholder to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_151"></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_154"></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_157"></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information responsive to this item is incorporated herein by reference to our definitive proxy statement with respect to our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. </span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_160"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i02b9487756a44f62beca493d5cd6fd6a_163"></div><div style="-sec-extract:summary;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.69pt">The following documents are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K: </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.76pt">Financial Statements</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: See Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.76pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: All schedules are omitted because they are not required, are not applicable or the information is included in the consolidated financial statements or notes thereto. </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.76pt">Exhibits</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have filed or incorporated by reference into this Annual Report on Form 10-K, the exhibits listed on the accompanying Exhibit Index immediately below. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.51pt">Financial Statement Schedules: See Item 15(a)(2), above. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.89pt">Exhibits: Refer to the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6d2637ba40454828a8c5f263da80966e_1585">Exhibit Index</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that follows. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span id="i6d2637ba40454828a8c5f263da80966e_1585"></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by reference herein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">3.1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 23, 2011</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103xex3_1.htm">Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 7, 2022</span></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510221497/dex41.htm">Specimen Common Stock Certificate</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 1, 2010</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000008/pacb-20191231xex4_2.htm">Description of Registrant&#8217;s securities registered under Section 12 of the Exchange Act</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2020</span></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm">Indenture, dated February 16, 2021, between Pacific Biosciences of California, Inc., and U.S. Bank National Association, as Trustee</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 4, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000049/pacb-20210216xex4_1.htm">Form of 1.50% Convertible Senior Notes due 2028 (included in Exhibit 4.3)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 4, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/tm2320097d1_ex4-1.htm">Indenture, dated as of June 30, 2023, by and between Pacific Biosciences of California, Inc. and U.S. Bank Trust Company, National Association, as Trustee</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/tm2320097d1_ex4-1.htm">Form of 1.375% Convertible Senior Note due 2030</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.1+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex101.htm">Form of Director and Executive Officer Indemnification Agreement</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.2+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex104.htm">2010 Equity Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.3+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_1.htm">2010 Equity Incentive Plan forms of agreement</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.4+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex105.htm">2010 Employee Stock Purchase Plan and forms of agreement thereunder</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.5+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/dex106.htm">2010 Outside Director Equity Incentive Plan </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 16, 2010</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.6+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913018000031/pacb-20180331xex10_2.htm">2010 Outside Director Equity Incentive Plan forms of agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.7+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-1.htm">2020 Equity Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-1.htm">, as amended</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.8+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-2.htm">Form of Global Stock Option Agreement under the Pacific Biosciences of California, Inc., 2020 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.9+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000110465922065284/tm2216796d1_ex10-3.htm">Form of Global Restricted Stock Unit Agreement under the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.10+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000216/pacb-20210930xex10_4.htm">Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc., and related forms of agreement thereunder</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 5, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.11+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000223/pacb-20211119xex10_1.htm">Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.12+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913020000148/pacb-20200930xex10_2.htm">Letter Relating to Employment Terms by and between the Registrant and Susan G. Kim effective September 28, 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 3, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.13+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_14.htm">Form of Change in Control and Severance Agreement for executive officers</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.14+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_15.htm">Letter Relating to Employment Terms by and between the Registrant and Christian O. Henry effective September 14, 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.15+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_17.htm">Amended Change in Control and Severance Agreement by and between the Registrant and Christian O. Henry dated February 3, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.16+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000098/pacb-20201231xex10_18.htm">Letter Relating to Employment Terms by and between the Registrant and Mark Van Oene effective January 8, 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.17+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913015000128/pacb-20150630ex1026040de.htm">Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated July 22, 2015</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.18&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913017000016/pacb-20161231xex10_50.htm">First Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated December 23, 2016</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 6, 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521035435/d121704dex101.htm">Investment Agreement, dated as of February 9, 2021, between Pacific Biosciences of California, Inc. and SB Northstar LP.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 10, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.20&#8224;&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312510234059/dex108.htm">Exclusive License Agreement by and between the Registrant and Cornell Research Foundation, Inc., dated as of February 1, 2004</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 22, 2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.21+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000129913021000192/pacb-20210630xex10_2.htm">Letter Relating to Employment Terms by and between the Registrant and Michele Farmer effective May 17, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 6, 2021</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.22</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex101.htm">Agreement and Plan of Merger of Reorganization among Pacific Biosciences of California, Inc., Apollo Acquisition Corp., Apollo Acquisition Sub, LLC, Omniome, Inc. and Shareholder Representative Services, LLC, as securityholder representative, dated as of July 19, 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 20, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.23</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex102.htm">Securities Purchase Agreement, dated as of July 19, 2021, by and between Pacific Biosciences of California, Inc., and each of the Investors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 20, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.24</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000119312521219136/d198514dex103.htm">Registration Rights Agreement, dated as of July 19, 2021, by and between Pacific Biosciences of California, Inc., and each of the Investors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 20, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.25+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000110465923006228/tm234149d1_ex99-3.htm">Letter Relating to Employment Terms by and between the Registrant and Jeff Eidel effective August 16, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 24, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.26+</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1299130/000110465923006228/tm234149d1_ex99-4.htm">Change in Control and Severance Agreement by and between the Registrant and Susan G. Kim effective February 3, 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 24, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.27</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000110465923074397/tm2319528d1_ex10-1.htm">Letter Agreement, dated June 23, 2023, between the Company and Chimera Investment LLC</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 23, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">10.28+</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx1028.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">21.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx211.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx311.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx312.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">32.1*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">32.2*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furnished herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">97.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx971.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx971.htm">ompensation Re</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="pacb-20231231xexx971.htm">covery Policy</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:108%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan. </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and have been filed separately with the Securities and Exchange Commission.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain confidential information contained in this Exhibit was omitted by means of marking such portions with brackets because the identified confidential information (i) is not material and (ii) would be competitively harmful if publicly disclosed.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div></div></div><div id="i02b9487756a44f62beca493d5cd6fd6a_169"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pacific Biosciences of California, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;28, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christian O. Henry </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christian O. Henry</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;28, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Susan G. Kim </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Susan G. Kim</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Financial Officer </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;28, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michele Farmer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michele Farmer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vice President and Chief Accounting Officer </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christian O. Henry, Susan G. Kim, Brett Atkins, and Michele Farmer, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for each individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or the individual&#8217;s substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i02b9487756a44f62beca493d5cd6fd6a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Christian O. Henry </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian O. Henry</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Susan G. Kim</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer <br/>(Principal Financial Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan G. Kim</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Michele Farmer</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and Chief Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michele Farmer</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ John F. Milligan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Milligan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ William W. Ericson</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William W. Ericson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Hannah A. Valantine</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hannah A. Valantine</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Randall S. Livingston</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randall S. Livingston</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Marshall L. Mohr</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marshall L. Mohr</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Kathy Ordo&#241;ez</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathy Ordo&#241;ez</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Lucy Shapiro</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lucy Shapiro</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ David Meline</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Meline </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>2
<FILENAME>pacb-20231231xexx1028.htm
<DESCRIPTION>EX-10.28
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>pacb-20231231xexx1028</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- pacb-20231231xexx1028001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pacb-20231231xexx1028001.jpg" title="slide1" width="1055" height="5460">
<DIV><FONT size="1" style="font-size:1pt;color:white">  4853-9957-6739.4  PACIFIC BIOSCIENCES OF CALIFORNIA, INC.  2020 EQUITY INCENTIVE PLAN  PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT  NOTICE OF RESTRICTED STOCK UNIT GRANT  Unless otherwise defined herein, the terms defined in the Pacific Biosciences of  California, Inc. 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) will have the same defined meanings in  this Performance-Based Restricted Stock Unit Agreement which includes the Notice of Restricted  Stock Unit Grant (the &#8220;Notice of Grant&#8221;), the Terms and Conditions of Restricted Stock Unit Grant  attached hereto as Exhibit A, the Country Addendum attached hereto as Exhibit B, the Vesting  Criteria attached hereto as Exhibit C, and all other exhibits, appendices, and addenda attached  hereto (the &#8220;Award Agreement&#8221;).  Participant Name:   Address:   The undersigned Participant has been granted an Award of Restricted Stock Units, subject  to the terms and conditions of the Plan and this Award Agreement, as follows:  Grant Number: ______________________________  Date of Grant: ______________________________  Vesting Commencement Date: ______________________________  Target Number of Restricted Stock Units: ______________________________  Maximum Number of Restricted Stock Units: ______________________________  Vesting Schedule:  Subject to any acceleration provisions contained in the Plan or this Award Agreement or  any other written agreement between Participant and the Company or any applicable Subsidiary  of the Company governing the terms of this Award, the Restricted Stock Units (the &#8220;RSUs&#8221;) will  be scheduled to vest in accordance with the specified criteria set forth in the Vesting Criteria  attached hereto as Exhibit C.   By Participant&#8217;s signature and the signature of the representative of Pacific Biosciences of  California, Inc. (the &#8220;Company&#8221;) below, Participant and the Company agree that this Award of  Restricted Stock Units is granted under and governed by the terms and conditions of the Plan and  this Award Agreement, including the Terms and Conditions of Restricted Stock Unit Grant,  attached hereto as Exhibit A, and all other exhibits, appendices and addenda attached hereto, all of  which are made a part of this document.  Participant acknowledges receipt of a copy of the Plan.   Participant has reviewed the Plan and this Award Agreement in their entirety, has had an  opportunity to obtain the advice of counsel prior to executing this Award Agreement and fully  understands all provisions of the Plan and this Award Agreement.  Participant hereby agrees to  - 2 -  accept as binding, conclusive and final all decisions or interpretations of the Administrator upon  any questions relating to the Plan and Award Agreement.  Participant further agrees to notify the  Company upon any change in the residence address indicated below.    PARTICIPANT  PACIFIC BIOSCIENCES OF CALIFORNIA, INC.          Signature  By           Print Name  Title       Residence Address:                     EXHIBIT A  PACIFIC BIOSCIENCES OF CALIFORNIA, INC.  2020 EQUITY INCENTIVE PLAN  PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT  TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT GRANT  1. Grant of Restricted Stock Units.  The Company hereby grants to the individual  (&#8220;Participant&#8221;) named in the Notice of Grant of Restricted Stock Units of this Award Agreement (the  &#8220;Notice of Grant&#8221;) under the Plan an Award of Restricted Stock Units, and subject to all of the terms  and conditions of this Award Agreement, including any country-specific provisions set forth in  Exhibit B, vesting criteria set forth in Exhibit C, and the Plan, which is incorporated herein by  reference.  Subject to Section 19(c) of the Plan, in the event of a conflict between the terms and  conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.  2. Company&#8217;s Obligation to Pay.  Each Restricted Stock Unit represents the right to  receive a Share on the date it vests.  Unless and until the Restricted Stock Units will have vested in  the manner set forth in Section 3 or 4, Participant will have no right to payment of any such Restricted  Stock Units.  Prior to actual payment of any vested Restricted Stock Units, such Restricted Stock Unit  will represent an unsecured obligation of the Company, payable (if at all) only from the general assets  of the Company.  3. Vesting Schedule.  Except as provided in Section 4, and subject to Section 5, the  Restricted Stock Units awarded by this Award Agreement will vest in accordance with the vesting  provisions set forth in the Notice of Grant.  Unless specifically provided otherwise in this Award  Agreement or other written agreement between Participant and the Company or any applicable  Subsidiary of the Company governing the terms of this Award, Restricted Stock Units that are  scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in  accordance with any of the provisions of this Award Agreement, unless Participant will have been  continuously a Service Provider from the Date of Grant through the applicable vesting date.  The  Administrator will have the exclusive discretion to determine when Participant no longer is providing  services for purposes of determining Service Provider status under this Award of Restricted Stock  Units (including without limitation whether Participant will be considered to be providing services  while on a leave of absence).   4. Payment after Vesting.  (a) General Rule.  Subject to Section 8, any Restricted Stock Units that vest will be  paid to Participant (or in the event of Participant&#8217;s death, to his or her properly designated beneficiary  or estate) in whole Shares.  Subject to the provisions of this Section 4, such vested Restricted Stock  Units shall be paid in whole Shares as soon as practicable after vesting, but in each such case within  sixty (60) days following the vesting date.  In no event will Participant be permitted, directly or  indirectly, to specify the taxable year of payment of any Restricted Stock Units payable under this  Award Agreement.  (b) Acceleration.  -2-  (i) Discretionary Acceleration.  The Administrator, in its discretion, may  accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Restricted  Stock Units at any time, subject to the terms of the Plan.  If so accelerated, such Restricted Stock Units  will be considered as having vested as of the date specified by the Administrator.  If Participant is a  U.S. taxpayer, the payment of Shares vesting pursuant to this Section 4 in all cases shall be paid at a  time or in a manner that is exempt from, or complies with, Section 409A.  The prior sentence may be  superseded in a future agreement or amendment to this Award Agreement only by direct and specific  reference to such sentence.   (ii) Notwithstanding anything in the Plan or this Award Agreement or any  other agreement (whether entered into before, on or after the Date of Grant) to the contrary, if the  vesting of the balance, or some lesser portion of the balance, of the Restricted Stock Units is  accelerated in connection with the cessation of Participant&#8217;s status as an Employee or other Service  Provider (provided that such termination is a &#8220;separation from service&#8221; within the meaning of  Section 409A, as determined by the Company), other than due to Participant&#8217;s death, and if (x)  Participant is a U.S. taxpayer and a &#8220;specified employee&#8221; within the meaning of Section 409A at the  time of such termination as a Service Provider and (y) the payment of such accelerated Restricted  Stock Units will result in the imposition of additional tax under Section 409A if paid to Participant on  or within the six (6) month period following the cessation of Participant&#8217;s status as a Service Provider,  then the payment of such accelerated Restricted Stock Units will not be made until the date six (6)  months and one (1) day following the date of cessation of such Participant&#8217;s status, unless Participant  dies following cessation of such Participant&#8217;s status, in which case, the Restricted Stock Units will be  paid in Shares to Participant&#8217;s estate as soon as practicable following his or her death.   (c) Section 409A.  It is the intent of this Award Agreement that it and all payments  and benefits to U.S. taxpayers hereunder be exempt from, or comply with, the requirements of Section  409A so that none of the Restricted Stock Units provided under this Award Agreement or Shares  issuable thereunder will be subject to the additional tax imposed under Section 409A, and any  ambiguities or ambiguous terms herein will be interpreted to be so exempt or to so comply.  Each  payment payable under this Award Agreement is intended to constitute a separate payment for  purposes of Treasury Regulation Section 1.409A-2(b)(2).  However, in no event will the Company or  any of its Parents or Subsidiaries have any liability, responsibility or obligation to reimburse,  indemnify, or hold harmless Participant for any taxes, penalties and interest that may be imposed, or  other costs that may be incurred, as a result of Section 409A.  5. Forfeiture Upon Termination as a Service Provider.  Unless specifically provided  otherwise in this Award Agreement or other written agreement between Participant and the Company  or any of its Subsidiaries or Parents, as applicable, if Participant ceases to be a Service Provider for  any or no reason, the then-unvested Restricted Stock Units awarded by this Award Agreement will  thereupon be forfeited at no cost to the Company and Participant will have no further rights thereunder.  6. Death of Participant.  Any distribution or delivery to be made to Participant under this  Award Agreement, if Participant is then deceased, will be made to Participant&#8217;s designated beneficiary  (if applicable and to the extent the Administrator has permitted such beneficiary designation with  respect to this Award) or, absent a designated beneficiary or if no beneficiary survives Participant, the  administrator or executor of Participant&#8217;s estate.  Any such transferee must furnish the Company with  (a) written notice of his or her status as transferee, and (b) evidence satisfactory to the Company to  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pacb-20231231xexx1028002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pacb-20231231xexx1028002.jpg" title="slide2" width="1055" height="5460">
<DIV><FONT size="1" style="font-size:1pt;color:white">-3-  establish the validity of the transfer and compliance with any laws or regulations pertaining to said  transfer.    7. Tax Obligations  (a) Responsibility for Taxes.  Participant acknowledges that, regardless of any  action taken by the Company or, if different, Participant&#8217;s employer (the &#8220;Employer&#8221;) or any Parent  or Subsidiary of the Company to which Participant is providing services (together, the &#8220;Service  Recipients&#8221;), the ultimate liability for any tax and/or social insurance liability obligations and  requirements in connection with the Restricted Stock Units, including, without limitation, (i) all  federal, state, and local taxes (including Participant&#8217;s Federal Insurance Contributions Act (FICA)  obligations) that are required to be withheld by any Service Recipient or other payment of tax-related  items related to Participant&#8217;s participation in the Plan and legally applicable to Participant, (ii)  Participant&#8217;s and, to the extent required by any Service Recipient, the Service Recipient&#8217;s fringe  benefit tax liability, if any, associated with the grant, vesting, or settlement of the Restricted Stock  Units or sale of Shares, and (iii) any other Service Recipient taxes the responsibility for which  Participant has, or has agreed to bear, with respect to the Restricted Stock Units (or settlement thereof  or issuance of Shares thereunder) (collectively, the &#8220;Tax Obligations&#8221;), is and remains Participant&#8217;s  sole responsibility and may exceed the amount actually withheld by the applicable Service  Recipient(s).  Participant further acknowledges that no Service Recipient (A) makes any  representations or undertakings regarding the treatment of any Tax Obligations in connection with any  aspect of the Restricted Stock Units, including, but not limited to, the grant, vesting or settlement of  the Restricted Stock Units, the subsequent sale of Shares acquired pursuant to such settlement and the  receipt of any dividends or other distributions, and (B) makes any commitment to and is under any  obligation to structure the terms of the grant or any aspect of the Restricted Stock Units to reduce or  eliminate Participant&#8217;s liability for Tax Obligations or achieve any particular tax result.    (b) Tax Withholding.  Pursuant to such procedures as the Administrator may  specify from time to time, the Service Recipient shall withhold the amount required to be withheld for  the payment of Tax Obligations.  The Administrator, in its sole discretion and pursuant to such  procedures as it may specify from time to time, may permit Participant to satisfy such Tax Obligations,  in whole or in part (without limitation), if permissible by applicable local law, by (i) paying cash in  U.S. dollars, (ii) electing to have the Company withhold otherwise deliverable Shares having a fair  market value equal to the minimum amount that is necessary to meet the withholding requirement for  such Tax Obligations (or such greater amount as Participant may elect if permitted by the  Administrator, if such greater amount would not result in adverse financial accounting consequences),  (iii) withholding the amount of such Tax Obligations from Participant&#8217;s wages or other cash  compensation paid to Participant by the applicable Service Recipient(s), (iv) delivering to the  Company Shares that Participant owns and that already have vested with a fair market value equal to  the Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator,  if such greater amount would not result in adverse financial accounting consequences), (v) selling a  sufficient number of such Shares otherwise deliverable to Participant, through such means as the  Company may determine in its sole discretion (whether through a broker or otherwise) equal to the  minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or  such greater amount as Participant may elect if permitted by the Administrator, if such greater amount  would not result in adverse financial accounting consequences), or (v) such other means as the  Administrator deems appropriate.  Further, if Participant is subject to Tax Obligations in more than  -4-  one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding  event, as applicable, Participant acknowledges that the applicable Service Recipient(s) (or former  employer, as applicable) may be required to withhold or account for Tax Obligations in more than one  jurisdiction.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes, Participant  is deemed to have been issued the full number of Shares subject to the vested Restricted Stock Units,  notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax  Obligations.  If Participant is an officer of the Company within the meaning of Section 16 of the  Exchange Act, then the Company will withhold from proceeds of the sale of a sufficient number  of Shares otherwise deliverable to Participant to satisfy the Tax Obligations and any associated  broker or other fees upon the relevant taxable or tax withholding event, as applicable, and  Participant agrees and acknowledges that Participant may not satisfy them by any means other  than such sale of Shares, unless required to do so by the Administrator.  To the extent the use of  such withholding method is problematic under Applicable Laws or has materially adverse accounting  consequences, then the Tax Obligations may be satisfied by one or a combination of the methods  specified under clauses (i), (ii), (iii) and (v) above.   (c) No Representations.  Participant has reviewed with his or her own tax advisers  the U.S. federal, state, local and non-U.S. tax consequences of this investment and the transactions  contemplated by this Award Agreement.  With respect to such matters, Participant relies solely on  such advisers and not on any statements or representations of the Company or any of its agents, written  or oral.  Participant understands that Participant (and not the Company) shall be responsible for  Participant&#8217;s own tax liability that may arise as a result of this investment or the transactions  contemplated by this Award Agreement.  (d) Company&#8217;s Obligation to Deliver Shares.  For clarification purposes, in no  event will the Company issue Participant any Shares unless and until arrangements satisfactory to the  Administrator have been made for the payment of Participant&#8217;s Tax Obligations.  If Participant fails  to make satisfactory arrangements for the payment of such Tax Obligations hereunder at the time any  applicable Restricted Stock Units otherwise are scheduled to vest pursuant to Sections 3 or 4 or  Participant&#8217;s Tax Obligations otherwise become due, Participant will permanently forfeit such  Restricted Stock Units to which Participant&#8217;s Tax Obligation relates and any right to receive Shares  thereunder and such Restricted Stock Units will be returned to the Company at no cost to the Company.   Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares if  such Tax Obligations are not delivered at the time they are due.  8. Rights as Stockholder.  Neither Participant nor any person claiming under or through  Participant will have any of the rights or privileges of a stockholder of the Company in respect of any  Shares deliverable hereunder unless and until certificates representing such Shares (which may be in  book entry form) will have been issued, recorded on the records of the Company or its transfer agents  or registrars, and delivered to Participant (including through electronic delivery to a brokerage  account).  After such issuance, recordation and delivery, Participant will have all the rights of a  stockholder of the Company with respect to voting such Shares and receipt of dividends and  distributions on such Shares.  9. No Guarantee of Continued Service.  PARTICIPANT ACKNOWLEDGES AND  AGREES THAT THE VESTING OF THE RESTRICTED STOCK UNITS PURSUANT TO THE  VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE  -5-  PROVIDER, WHICH UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW IS AT  THE WILL OF THE APPLICABLE SERVICE RECIPIENT AND NOT THROUGH THE ACT OF  BEING HIRED, BEING GRANTED THIS RESTRICTED STOCK UNIT AWARD OR  ACQUIRING SHARES HEREUNDER.  PARTICIPANT FURTHER ACKNOWLEDGES AND  AGREES THAT THIS AWARD AGREEMENT, THE TRANSACTIONS CONTEMPLATED  HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE  AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE  PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT  INTERFERE IN ANY WAY WITH PARTICIPANT&#8217;S RIGHT OR THE RIGHT OF ANY SERVICE  RECIPIENT TO TERMINATE PARTICIPANT&#8217;S RELATIONSHIP AS A SERVICE PROVIDER,  SUBJECT TO APPLICABLE LAW, WHICH TERMINATION, UNLESS PROVIDED  OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT  CAUSE.  10. Grant is Not Transferable.  Except to the limited extent provided in Section 7, this grant  and the rights and privileges conferred hereby will not be transferred, assigned, pledged or  hypothecated in any way (whether by operation of law or otherwise) and will not be subject to sale  under execution, attachment or similar process.  Upon any attempt to transfer, assign, pledge,  hypothecate or otherwise dispose of this grant, or any right or privilege conferred hereby, or upon any  attempted sale under any execution, attachment or similar process, this grant and the rights and  privileges conferred hereby immediately will become null and void.  11. Insider Trading Restrictions/Market Abuses.  Participant acknowledges that Participant  may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions,  including the United States and Participant&#8217;s country of residence, which may affect Participant&#8217;s  ability, directly or indirectly, for Participant or for a third party, to acquire or sell, or attempt to sell,  Shares or rights to Shares under the Plan during such times as Participant is considered to have &#8220;inside  information&#8221; regarding the Company (as defined by the laws in the applicable jurisdiction, including  the United States and Participant&#8217;s country of residence).  Any restrictions under these laws or  regulations are separate from and in addition to any restrictions that may be imposed under any  applicable Company insider trading policy.  Participant acknowledges that it is Participant&#8217;s  responsibility to be compliant with all such requirements and Participant should consult Participant&#8217;s  personal legal advisers to ensure compliance.  12. Foreign Asset/Account Reporting Requirements; Exchange Controls.  Participant&#8217;s  country may have certain foreign asset and/or account reporting requirements and exchange controls  which may affect Participant&#8217;s ability to acquire or hold Shares under the Plan or cash received from  participating in the Plan (including from any dividends received or sale proceeds arising from the sale  of Shares) in a brokerage or bank account outside Participant&#8217;s country.  Participant understands that  Participant may be required to report such accounts, assets or transactions to the tax or other authorities  in Participant&#8217;s country.  Participant also may be required to repatriate sale proceeds or other funds  received as a result of participation in the Plan to Participant&#8217;s country through a designated bank or  broker and/or within a certain time after receipt.  In addition, Participant may be subject to tax payment  and/or reporting obligations in connection with any income realized under the Plan and/or from the  sale of Shares.  Participant acknowledges that it is Participant&#8217;s responsibility to be compliant with all  such requirements, and that Participant should consult Participant&#8217;s personal legal and tax advisers, as  applicable, to ensure compliance.   -6-  13. Nature of Grant.  In accepting this Award of Restricted Stock Units, Participant  acknowledges, understands and agrees that:  (a) the grant of the Restricted Stock Units is voluntary and occasional and does not  create any contractual or other right to receive future grants of restricted stock units, or benefits in lieu  of restricted stock units, even if restricted stock units have been granted in the past;   (b) all decisions with respect to future restricted stock units or other grants, if any,  will be at the sole discretion of the Administrator;   (c) Participant is voluntarily participating in the Plan;   (d) the Restricted Stock Units and the Shares subject to the Restricted Stock Units  are not intended to replace any pension rights or compensation;  (e) the Restricted Stock Units and the Shares subject to the Restricted Stock Units,  and the income and value of same, are not part of normal or expected compensation for purposes of  calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments,  bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar  payments;   (f) the future value of the Shares underlying the Restricted Stock Units is unknown,  indeterminable and cannot be predicted with certainty;   (g) for purposes of the Restricted Stock Units, Participant&#8217;s status as a Service  Provider will be considered terminated as of the date Participant is no longer actively providing  services to the Company or any Parent or Subsidiary of the Company (regardless of the reason for  such termination and whether or not later found to be invalid or in breach of employment laws in the  jurisdiction where Participant is a Service Provider or the terms of Participant&#8217;s employment or service  agreement, if any), and unless otherwise expressly provided in this Award Agreement (including by  reference in the Notice of Grant to other arrangements or contracts) or determined by the  Administrator, Participant&#8217;s right to vest in the Restricted Stock Units under the Plan, if any, will  terminate as of such date and will not be extended by any notice period (e.g., Participant&#8217;s period of  service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar  period mandated under employment laws in the jurisdiction where Participant is a Service Provider or  the terms of Participant&#8217;s employment or service agreement, if any, unless Participant is providing  bona fide services during such time); the Administrator shall have the exclusive discretion to  determine when Participant is no longer actively providing services for purposes of the Restricted  Stock Units grant (including whether Participant may still be considered to be providing services while  on a leave of absence and consistent with local law);   (h) unless otherwise provided in the Plan or by the Administrator in its discretion,  the Restricted Stock Units and the benefits evidenced by this Award Agreement do not create any  entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by,  another company nor be exchanged, cashed out or substituted for, in connection with any corporate  transaction affecting the Shares; and  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pacb-20231231xexx1028003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pacb-20231231xexx1028003.jpg" title="slide3" width="1055" height="5460">
<DIV><FONT size="1" style="font-size:1pt;color:white">-7-  (i) the following provisions apply only if Participant is providing services outside  the United States:  (i) the Restricted Stock Units and the Shares subject to the Restricted Stock  Units are not part of normal or expected compensation or salary for any purpose;  (ii) Participant acknowledges and agrees that no Service Recipient shall be  liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United  States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to  Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares  acquired upon settlement; and  (iii) no claim or entitlement to compensation or damages shall arise from  forfeiture of the Restricted Stock Units resulting from the termination of Participant&#8217;s status as a  Service Provider (for any reason whatsoever whether or not later found to be invalid or in breach of  employment laws in the jurisdiction where Participant is a Service Provider or the terms of  Participant&#8217;s employment or service agreement, if any), and in consideration of the grant of the  Restricted Stock Units to which Participant is otherwise not entitled, Participant irrevocably agrees  never to institute any claim against any Service Recipient, waives his or her ability, if any, to bring  any such claim, and releases each Service Recipient from any such claim; if, notwithstanding the  foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the  Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to  execute any and all documents necessary to request dismissal or withdrawal of such claim.  14. No Advice Regarding Grant.  The Company is not providing any tax, legal or financial  advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the  Plan, or Participant&#8217;s acquisition or sale of the Shares underlying the Restricted Stock Units.   Participant is hereby advised to consult with his or her own personal tax, legal and financial advisers  regarding his or her participation in the Plan before taking any action related to the Plan.  15. Data Privacy.  Participant hereby explicitly and unambiguously consents to the  collection, use and transfer, in electronic or other form, of Participant&#8217;s personal data as described  in this Award Agreement and any other Restricted Stock Unit grant materials by and among, as  applicable, the Service Recipients for the exclusive purpose of implementing, administering and  managing Participant&#8217;s participation in the Plan.  Participant understands that the Company and the Service Recipient may hold certain  personal information about Participant, including, but not limited to, Participant&#8217;s name, home  address, email address and telephone number, date of birth, social insurance number, passport or  other identification number (e.g., resident registration number), salary, nationality, job title, any  Shares or directorships held in the Company, details of all equity awards or any other entitlement  to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor  (&#8220;Data&#8221;), for the exclusive purpose of implementing, administering and managing the Plan.    Participant understands that Data may be transferred to a stock plan service provider, as  may be selected by the Company in the future, assisting the Company with the implementation,  administration and management of the Plan.  Participant understands that the recipients of the  -8-  Data may be located in the United States or elsewhere, and that the recipients&#8217; country of operation  (e.g., the United States) may have different data privacy laws and protections than Participant&#8217;s  country.  Participant understands that if he or she resides outside the United States, he or she may  request a list with the names and addresses of any potential recipients of the Data by contacting his  or her local human resources representative.  Participant authorizes the Company, any stock plan  service provider selected by the Company and any other possible recipients which may assist the  Company (presently or in the future) with implementing, administering and managing the Plan to  receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose  of implementing, administering and managing his or her participation in the Plan.  Participant  understands that Data will be held only as long as is necessary to implement, administer and  manage Participant&#8217;s participation in the Plan.  Participant understands if he or she resides outside  the United States, he or she may, at any time, view Data, request additional information about the  storage and processing of Data, require any necessary amendments to Data or refuse or withdraw  the consents herein, in any case without cost, by contacting in writing his or her local human  resources representative.  Further, Participant understands that he or she is providing the consents  herein on a purely voluntary basis.  If Participant does not consent, or if Participant later seeks to  revoke his or her consent, his or her status as a Service Provider and career with the Service  Recipient will not be adversely affected.  The only adverse consequence of refusing or withdrawing  Participant&#8217;s consent is that the Company would not be able to grant Participant Restricted Stock  Units or other equity awards or administer or maintain such awards.  Therefore, Participant  understands that refusing or withdrawing his or her consent may affect Participant&#8217;s ability to  participate in the Plan.  For more information on the consequences of Participant&#8217;s refusal to  consent or withdrawal of consent, Participant understands that he or she may contact his or her  local human resources representative.  16. Address for Notices.  Any notice to be given to the Company under the terms of this  Award Agreement will be addressed to the Company, in care of its Chief Financial Officer at Pacific  Biosciences of California, Inc., 1305 O&#8217;Brien Drive, Menlo Park, CA 94025, U.S.A., or at such other  address as the Company may hereafter designate in writing.  17. Electronic Delivery and Acceptance.  The Company may, in its sole discretion, decide  to deliver any documents related to the Restricted Stock Units awarded under the Plan or future  Restricted Stock Units that may be awarded under the Plan by electronic means or require Participant  to participate in the Plan by electronic means.  Participant hereby consents to receive such documents  by electronic delivery and agrees to participate in the Plan through any on-line or electronic system  established and maintained by the Company or a third party designated by the Company.  18. No Waiver.  Either party&#8217;s failure to enforce any provision or provisions of this Award  Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor  prevent that party from thereafter enforcing each and every other provision of this Award Agreement.   The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#8217;s  right to assert all other legal remedies available to it under the circumstances.  19. Successors and Assigns.  The Company may assign any of its rights under this Award  Agreement to single or multiple assignees, and this Award Agreement shall inure to the benefit of the  successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth, this  Award Agreement shall be binding upon Participant and his or her heirs, executors, administrators,  -9-  successors and assigns.  The rights and obligations of Participant under this Award Agreement may  be assigned only with the prior written consent of the Company.  Subject to the limitation on  transferability of this Award contained herein, this Award Agreement will be binding upon and inure  to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.  20. Additional Conditions to Issuance of Stock.  If at any time the Company will determine,  in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any  securities exchange or under any U.S. federal, state, local or non-U.S. law, the tax code and related  regulations or under the rulings or regulations of the United States Securities and Exchange  Commission or any other governmental regulatory body or the clearance, consent or approval of the  United States Securities and Exchange Commission or any other governmental regulatory authority is  necessary or desirable as a condition to the issuance of Shares to Participant (or his or her estate)  hereunder, such issuance will not occur unless and until such listing, registration, qualification, rule  compliance, clearance, consent or approval will have been completed, effected or obtained free of any  conditions not acceptable to the Company.  Subject to the terms of the Award Agreement and the Plan,  the Company shall not be required to issue any certificate or certificates for (or make any entry on the  books of the Company or of a duly authorized transfer agent of the Company of) the Shares hereunder  prior to the lapse of such reasonable period of time following the date of vesting of the Restricted  Stock Units as the Administrator may establish from time to time for reasons of administrative  convenience.  The Company will make all reasonable efforts to meet the requirements of any such  Applicable Laws and to obtain any such registration, qualification, rule compliance, clearance, consent  or approval of any such governmental regulatory authority.   21. Language.  If Participant has received this Award Agreement or any other document  related to the Plan translated into a language other than English and if the meaning of the translated  version is different than the English version, the English version will control.  22. Interpretation.  The Administrator will have the power to interpret the Plan and this  Award Agreement and to adopt such rules for the administration, interpretation and application of the  Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited  to, the determination of whether or not any Restricted Stock Units have vested).  All actions taken and  all interpretations and determinations made by the Administrator in good faith will be final and binding  upon Participant, the Company and all other interested persons.  Neither the Administrator nor any  person acting on behalf of the Administrator will be personally liable for any action, determination or  interpretation made in good faith with respect to the Plan or this Award Agreement.  23. Captions.  Captions provided herein are for convenience only and are not to serve as a  basis for interpretation or construction of this Award Agreement.  24. Amendment, Suspension or Termination of the Plan.  By accepting this Award,  Participant expressly warrants that he or she has received an Award of Restricted Stock Units under  the Plan, and has received, read and understood a description of the Plan.  Participant understands that  the Plan is discretionary in nature and may be amended, suspended or terminated by the Administrator  at any time.  25. Modifications to the Award Agreement.  This Award Agreement constitutes the entire  understanding of the parties on the subjects covered.  Participant expressly warrants that he or she is  -10-  not accepting this Award Agreement in reliance on any promises, representations, or inducements  other than those contained herein.  Modifications to this Award Agreement or the Plan can be made  only in an express written contract executed by a duly authorized officer of the Company.   Notwithstanding anything to the contrary in the Plan or this Award Agreement, the Company reserves  the right to revise this Award Agreement as it deems necessary or advisable, in its sole discretion and  without the consent of Participant, to comply with Section 409A or to otherwise avoid imposition of  any additional tax or income recognition under Section 409A in connection with this Award of  Restricted Stock Units.  Further, the Company reserves the right to impose other requirements on  Participant&#8217;s participation in the Plan, on this Award of Restricted Stock Units and on any Shares  acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or  administrative reasons, and to require Participant to execute any additional agreements or undertakings  that may be necessary to accomplish the foregoing.  26. Governing Law; Venue; Severability.  This Award Agreement and the Restricted Stock  Units are governed by the internal substantive laws, but not the choice of law rules, of the State of  California.  For purposes of litigating any dispute that arises under these Restricted Stock Units or this  Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of  California, and agree that such litigation will be conducted in the courts of San Mateo County,  California, or the United States federal courts for the Northern District of California, and no other  courts, where this Award Agreement is made and/or to be performed.  In the event that any provision  of this Award Agreement, including the country-specific provisions set forth in an attachment to this  Award Agreement (if any), will be held invalid or unenforceable, such provision will be severable  from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining  provisions of this Award Agreement.   27. Entire Agreement.  The Plan is incorporated herein by this reference.  The Plan and this  Award Agreement (including the appendices and exhibits referenced herein) constitute the entire  agreement of the parties with respect to the subject matter hereof and supersede in their entirety all  prior undertakings and agreements of the Company and Participant with respect to the subject matter  hereof, and may not be modified adversely to the Participant&#8217;s interest except by means of a writing  signed by the Company and Participant.  28. Country Addendum.  The Restricted Stock Unit grant shall be subject to any special  terms and conditions set forth in an exhibit, appendix, addendum or other attachment (if any) to this  Award Agreement for any country whose laws are applicable to Participant and this Award of  Restricted Stock Units (as determined by the Administrator in its sole discretion) (the &#8220;Country  Addendum&#8221;).  Moreover, if Participant relocates to one of the countries included in the Country  Addendum (if any), the special terms and conditions for such country will apply to Participant, to the  extent the Company determines that the application of such terms and conditions is necessary or  advisable for legal or administrative reasons.  The Country Addendum constitutes part of this Award  Agreement.  *          *          *    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pacb-20231231xexx1028004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pacb-20231231xexx1028004.jpg" title="slide4" width="1055" height="5460">
<DIV><FONT size="1" style="font-size:1pt;color:white">    EXHIBIT B  PACIFIC BIOSCIENCES OF CALIFORNIA, INC.  2020 EQUITY INCENTIVE PLAN  PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT     COUNTRY ADDENDUM    This Country Addendum includes additional terms and conditions that govern the Award of Restricted  Stock Units granted pursuant to the terms and conditions of the Pacific Biosciences of California, Inc.  2020 Equity Incentive Plan (the &#8220;Plan&#8221;) and the Performance-Based Restricted Stock Unit Agreement  to which this Country Addendum is attached (the &#8220;Award Agreement&#8221;) to the extent the individual to  whom the Restricted Stock Units were granted (&#8220;Participant&#8221;) resides in one of the countries listed  below.  Capitalized terms used but not defined herein will have the meanings set forth in the Award  Agreement or the Plan, as applicable.  This Country Addendum also includes information regarding exchange controls and certain other  issues of which Participant should be aware with respect to Participant&#8217;s participation in the Plan.  The  information is based on the securities, exchange control and other laws in effect in the respective  countries as of August 2020.  Such laws often are complex and change frequently.  As a result, the  Company strongly recommends that Participant not rely on the information in this Country Addendum  as the only source of information relating to the consequences of Participant&#8217;s participation in the Plan  because the information may be out of date at the time Participant vest in or receives or sells the Shares  covered by the Restricted Stock Units.   In addition, the information contained herein is general in nature and may not apply to Participant&#8217;s  particular situation and the Company is not in a position to assure Participant of any particular result.   Accordingly, Participant is advised to seek appropriate professional advice as to how the relevant laws  of Participant&#8217;s country may apply to Participant&#8217;s situation.    Finally, if Participant is a citizen or resident of a country other than the one in which Participant  currently is working or transfers to another country after the grant of the Restricted Stock Units, or is  considered a resident of another country for local law purposes, the information contained herein may  not be applicable to Participant in the same manner.  In addition, the Company, in its sole discretion,  shall determine the extent to which the terms and conditions contained herein shall apply to Participant  under these circumstances.    Australia  Notifications  Tax Information.  The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment  Act 1997 (Cth) applies (subject to the conditions in that Act).  -2-  Canada  Terms and Conditions  Company&#8217;s Obligation to Pay.  This provision supplements Section 2 of the Award Agreement:  Notwithstanding any discretion set out in Section 8(d) of the Plan, vested Restricted Stock Units will  be paid in Shares and not in cash or a combination of Shares and cash.  Nature of Grant.  This provision replaces Section 13(g) of the Award Agreement:  For purposes of the Award of Restricted Stock Units, Participant&#8217;s employment or service relationship  will be considered terminated as of the date that is the earlier of: (i) the date Participant&#8217;s employment  is terminated, (ii) the date Participant receives notice of termination, and (iii) the date Participant is no  longer actively providing services to the Company or any Parent or Subsidiary of the Company  (regardless of the reason for such termination and whether or not later found to be invalid or in breach  of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s  employment agreement, if any) and, unless otherwise expressly provided in this Award Agreement or  determined by the Company, Participant&#8217;s right to vest in the Restricted Stock Units will terminate as  of such date and will not be extended by any notice period (e.g., Participant&#8217;s period of service would  not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated  under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s  employment agreement, if any).  The following provisions will apply to Participant if he or she is a resident of Quebec:  Language Consent.  The parties acknowledge that it is their express wish that the Award Agreement,  including this Exhibit B, as well as all documents, notices, and legal proceedings entered into, given  or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.  Consentement Relatif &agrave; la Langue Utilis&eacute;e.  Les parties reconnaissent avoir express&eacute;ment souhait&eacute;  que la convention (&laquo;Award Agreement&raquo;) ainsi que cette Annexe B, ainsi que tous les documents, avis  et proc&eacute;dures judiciares, &eacute;x&eacute;cut&eacute;s, donn&eacute;s ou intent&eacute;s en vertu de, ou li&eacute;s directement ou indirectement  &agrave; la pr&eacute;sente convention, soient r&eacute;dig&eacute;s en langue anglaise.  Data Privacy.  This provision supplements Section 15 of the Award Agreement:   Participant hereby authorizes the Company and the Company&#8217;s representatives to discuss with and  obtain all relevant information from all personnel, professional or not, involved in the administration  and operation of the Plan.  Participant further authorizes the Company and the Company&#8217;s Parent or  Subsidiary employing or retaining Participant to disclose and discuss Participant&#8217;s participation in the  Plan with their respective advisers.  Participant further authorizes the Company and the Company&#8217;s  Parent or Subsidiary employing or retaining Participant to record such information and to keep such  information in Participant&#8217;s employee file.  Notifications  Securities Law Information.  Participant understands that Participant is permitted to sell Shares  -3-  acquired pursuant to the Plan through the designated broker appointed under the Plan, if any, provided  the sale of the Shares acquired pursuant to the Plan takes place outside of Canada through the facilities  of a stock exchange on which the Shares are listed.  The Company&#8217;s common stock are currently  traded on the NASDAQ Global Select Market, which is located outside of Canada, under the ticker  symbol &#8220;PACB&#8221; and Shares acquired under the Plan may be sold through this exchange.  Foreign Asset/Account Reporting Information.  Foreign specified property, including Shares and  rights to Shares (e.g., Restricted Stock Units), held by a Canadian resident must be reported annually  on Form T1135 (Foreign Income Verification Statement) if the total cost of such foreign specified  property exceeds C$100,000 at any time during the year.  If applicable, Form T1135 is due by April  30th of the following year.  Restricted Stock Units must be reported &#8211; generally at a nil cost &#8211; if the  C$100,000 cost threshold is exceeded because of other foreign specified property held by Participant.   When Shares are acquired, their cost generally is the adjusted cost base (&#8220;ACB&#8221;) of the Shares.  The  ACB would ordinarily equal the fair market value of the Shares at the time of acquisition, but if other  Shares are owned, this ACB may have to be averaged with the ACB of the other Shares.  Participant  is responsible for ensuring his or her compliance with any applicable reporting obligations and should  speak to his or her personal legal adviser on this matter.  France  Terms and Conditions  Type of Restricted Stock Units.  The Restricted Stock Units are not intended to qualify for specific  tax or social security treatment in France.  Language Consent.  By accepting the Award Agreement providing for the terms and conditions of  the grant, Participant confirms having read and understood the documents relating to this grant (the  Plan and this Award Agreement) which were provided in English language.  Participant accepts the  terms of those documents accordingly.  Consentement Relatif &agrave; la Langue Utilis&eacute;e.  En acceptant le Contrat d'Attribution d&eacute;crivant les  termes et conditions de l&#8217;attribution, le Participant confirme avoir lu et compris les documents relatifs  &agrave; cette attribution (le Plan et ce Contrat d'Attribution) qui ont &eacute;t&eacute; communiqu&eacute;s en langue  anglaise.  Le Participant accepte les termes de ces documents en connaissance de cause.  Notifications  Foreign Asset/Account Reporting Information.  Participant may hold Shares acquired under the  Plan outside of France provided Participant annually declares all foreign bank and stock accounts,  whether open, current, or closed, together with Participant&#8217;s personal income tax returns.  Germany  Notifications  Exchange Control Information.  Cross-border payments in excess of &#8364;12,500 must be reported electronically, on a monthly basis, to  -4-  the Servicezentrum Au&szlig;enwirtschaftsstatistik, which is the competent federal office of the Deutsche  Bundesbank (the German Central Bank) for such notifications in Germany.  The Allgemeinesc  Meldeportal Statistik (General Statistics Reporting Portal) can be accessed at www.bundesbank.de.  Japan  Notifications  Foreign Asset / Account Reporting Information.  Participant will be required to report details of  any assets held outside of Japan as of December 31st to the extent such assets have a total net fair  market value exceeding &yen;50,000,000.  Such report will be due by March 15th each year.  Participant  should consult with his or her personal tax adviser as to whether the reporting obligation applies to  him or her and whether the requirement extends to any outstanding Restricted Stock Units, Shares  and/or cash acquired under the Plan.  Netherlands  There are no country-specific provisions.  Singapore  Notifications  Securities Law Information.  The Award of Restricted Stock Units under the Plan is being made  pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the Securities and Futures  Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;).  The Plan has not been lodged or registered as a prospectus with  the Monetary Authority of Singapore.  Participant should note that the Restricted Stock Units are  subject to section 257 of the SFA and the Participant should not make (i) any subsequent sale of the  Shares in Singapore or (ii) any offer of such subsequent sale of the Shares subject to the Restricted  Stock Units in Singapore, unless such sale or offer is made more than six (6) months after the Date of  Grant or pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280)  of the SFA.  The Company&#8217;s common stock is traded on the Nasdaq Global Select Market, which is  located outside of Singapore, under the ticker symbol &#8220;PACB&#8221; and Shares acquired under the Plan  may be sold through this exchange.  CEO and Director Notification Information.  If Participant is the Chief Executive Officer (&#8220;CEO&#8221;)  or a director, associate director or shadow director1 of a Singaporean Parent or Subsidiary, Participant  is subject to certain notification requirements under the Singapore Companies Act.  Among these  requirements is an obligation to notify the Singaporean Parent or Subsidiary in writing when  Participant receives an interest in the Company (e.g., Restricted Stock Units or Shares).  In addition,  Participant must notify the Singaporean Parent or Subsidiary when Participant disposes of an interest  in the Company (including when Participant sells Shares acquired at vesting of the Restricted Stock    1 A shadow director is an individual who is not on the board of directors of the Singapore  Parent or Subsidiary but who has sufficient control so that the board of directors of the Singapore  Parent or Subsidiary acts in accordance with the directions and instructions of the individual.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- pacb-20231231xexx1028005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="pacb-20231231xexx1028005.jpg" title="slide5" width="1055" height="4095">
<DIV><FONT size="1" style="font-size:1pt;color:white">-5-  Units).  These notifications must be made within two (2) business days of (i) acquiring or disposing  of any interest in the Company, (ii) any change in a previously-disclosed interest (e.g., upon vesting  of the Restricted Stock Units or when Shares acquired under the Plan are subsequently sold), or  (iii) becoming the CEO or a director, associate director or shadow director if such an interest exists at  such time.  Switzerland  Notifications  Securities Law Information.  The Award of Restricted Stock Units under the Plan is considered a  private offering in Switzerland and is therefore not subject to registration in Switzerland.  Neither this  document nor any other materials relating to the Restricted Stock Units constitutes a prospectus as  such term is understood pursuant to article 652a of the Swiss Code of Obligations, and neither this  document nor any other materials relating to the Restricted Stock Units may be publicly distributed  nor otherwise made publicly available in Switzerland.  Neither this document nor any other offering  or marketing material relating to the Restricted Stock Units has been filed with, approved, or  supervised by any Swiss regulatory authority (in particular, the Swiss Financial Market Supervisory  Authority (FINMA)).  Taiwan  Notifications  Securities Law Information.  The Award of Restricted Stock Units and the Shares to be issued upon  vesting of the Restricted Stock Units is available only for employees of the Company and any Parent  or Subsidiary.  It is not a public offer of securities by a Taiwanese company; therefore, it is exempt  from registration in Taiwan.  Exchange Control Information.  Participant may acquire and remit foreign currency (including funds  for the purchase of Shares and proceeds from the sale of Shares) up to US$5,000,000 per year without  justification.  If the transaction amount is TWD500,000 or more in a single transaction, Participant  must submit a Foreign Exchange Transaction Form.  If the transaction amount is US$500,000 or more  in a single transaction, Participant must also provide supporting documentation to the satisfaction of  the remitting bank.  United Kingdom  Terms and Conditions  Taxes.  The following provision supplements Section 7 of the Award Agreement:  Without limitation to Section 7 of the Award Agreement, Participant agrees that Participant is liable  for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when  requested by the Company or the Parent or Subsidiary employing or retaining Participant or by Her  Majesty's Revenue and Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant  authority).  Participant also agrees to indemnify and keep indemnified the Company and  the Company&#8217;s Parent or Subsidiary employing or retaining Participant against any Tax&#8211;Related Items  -6-  that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority  or any other relevant authority) on Participant&#8217;s behalf.  *          *          *      EXHIBIT C  PACIFIC BIOSCIENCES OF CALIFORNIA, INC.  2020 EQUITY INCENTIVE PLAN  PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT  VESTING CRITERIA  A. General.  This Award of performance-based Restricted Stock Units is subject to vesting  requirements relating to both Participant&#8217;s continued status as a Service Provider through a specified  date and achievement of specified performance-based criteria (the &#8220;Performance Goal&#8221;).  Any  capitalized terms not defined in this Award Agreement will have the meaning ascribed to such term  in the Plan.  B. Performance Goal.  [INSERT PERFORMANCE GOAL]  C. Certification, Vesting, and Forfeiture.  [INSERT APPLICABLE DETAILS HERE]  D. Change in Control.  [INSERT TREATMENT ON CHANGE IN CONTROL]  E. Maximum Shares That May Vest.  In no event will the number of Shares subject to this  Award that vest exceed the Maximum Number of Restricted Stock Units (as specified in the Notice  of Grant).   *          *          *  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>pacb-20231231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i30ebff0a96ce4481b3904d6869faa1f6_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 21.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LIST OF SUBSIDIARIES</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.420%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Subsidiary name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jurisdiction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Type</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences International LLC</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences Canada Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Canada (Ontario)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences Germany GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Germany (Munich)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences Japan GK</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan (Tokyo)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences (Shanghai) Co., Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">China (Shanghai)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio Singapore Pte. Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Singapore</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pacific Biosciences UK, Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United Kingdom (London)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Omniome, LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Circulomics Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maryland</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio B.V.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Netherlands (Amsterdam)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio of Korea, Yuhan Hoesa</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Korea</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apton Biosystems LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Domestic</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>pacb-20231231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ied4a74b1d8e64baab52633cc152f01a8_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statements (Forms S-8 Nos. 333-170211, 333-179810, 333-186065, 333-193437, 333-201678, 333-209157, 333-215746, 333-222696, 333-229368, 333-236061, 333-241687, 333-170211, 333-179810, 333-186065, 333-193437, 333-201678, 333-209157, 333-215746, 333-222696, 333-229368, 333-236061, 333-251153, 333-253669, 333-255342, 333-259671, 333-261251, 333-263101, 333-265249 and 333-270122) pertaining to the Pacific Biosciences of California, Inc. 2010 Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2010 Employee Stock Purchase Plan, the Pacific Biosciences of California, Inc. 2010 Outside Director Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, the Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, and the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc., and</font></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statements (Forms S-3 Nos. 333-255324, 333-259670, 333-259672 and 333-274846) and related Prospectuses of Pacific Biosciences of California, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February 28, 2024, with respect to the consolidated financial statements of Pacific Biosciences of California, Inc. and the effectiveness of internal control over financial reporting of Pacific Biosciences of California, Inc. included in this Annual Report (Form 10-K) of Pacific Biosciences of California, Inc. for the year ended December 31, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Mateo, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>pacb-20231231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iee3e0abf903a4e13a6ed6ef9b611b30d_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT RULES 13a-14(a)&#47;15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christian Henry, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this annual report on Form 10-K of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2024</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>pacb-20231231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7825a052bca24306b7b356d603b7cac3_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT RULES 13a-14(a)&#47;15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Susan Kim, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this annual report on Form 10-K of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:0.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2024</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Susan Kim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan Kim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer <br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>pacb-20231231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0fdabaf88ed847339c7a371a93fcbd8e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Annual Report of the Company on Form 10-K for the period ended December&#160;31, 2023 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christian Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>pacb-20231231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibb4180b8de464b17a794fbbd813f5d87_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:6pt;padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Susan Kim, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Annual Report of the Company on Form 10-K for the period ended December&#160;31, 2023 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Susan Kim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan Kim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer <br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>pacb-20231231xexx971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idabccc6ef1ab49ee8095f3684c26765d_35"></div><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 97.1 </font></div><div style="margin-top:1.3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:188%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. </font></div><div style="margin-top:1.3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:188%">COMPENSATION RECOVERY POLICY</font></div><div style="margin-top:0.1pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As most recently amended on October 24, 2023</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is committed to strong corporate governance. As part of this commitment, the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) has adopted this clawback policy called the Compensation Recovery Policy (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Policy is intended to further the Company&#8217;s pay-for- performance philosophy and to comply with applicable laws by providing rules relating to the reasonably prompt recovery of certain compensation received by Covered Executives in the event of an Accounting Restatement. The application of the Policy to Covered Executives is not discretionary, except to the limited extent provided below, and applies without regard to whether a Covered Executive was at fault. Capitalized terms used in the Policy are defined below, and the definitions have substantive impact on its application so reviewing them carefully is important to your understanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Policy is intended to comply with, and will be interpreted in a manner consistent with, Section 10D of the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with Exchange Act Rule 10D-1 and with the listing standards of the national securities exchange (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) on which the securities of the Company are listed.</font></div><div style="margin-top:12pt;text-indent:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Persons Covered by the Policy</font></div><div style="margin-top:12pt;text-align:justify;text-indent:42pt"><font style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Policy is binding and enforceable against all &#8220;</font><font style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Covered Executives.</font><font style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; A Covered Executive is each individual who is or was ever designated as an &#8220;officer&#8221; by the Board in accordance with Exchange Act Rule 16a- 1(f) (a &#8220;</font><font style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 16 Officer</font><font style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Committee may (but is not obligated to) require a Covered Executive to sign and return to the Company an acknowledgement that such Covered Executive will be bound by the terms and comply with the Policy. The Policy is binding on each Covered Executive whether or not the Covered Executive signs and&#47;or returns any acknowledgment.</font></div><div style="margin-top:12pt;text-indent:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Administration of the Policy</font></div><div style="margin-top:12pt;text-align:justify;text-indent:42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) has full delegated authority to administer the Policy. The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer to the independent members of the Board or the other Board committee. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law.</font></div><div style="margin-top:12pt;text-indent:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Restatements Requiring Application of the Policy</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the Committee must determine the Excess Compensation, if any, that must be recovered. The Company&#8217;s obligation to recover Excess Compensation is not dependent on if or when restated financial statements are filed.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Compensation Covered by the Policy</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Policy applies to certain </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive-Based Compensation </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(certain terms used in this Section are defined below) that is </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Received </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), during the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Covered Period </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">while the Company has a class of securities listed on a national securities exchange. Incentive-Based Compensation is considered &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clawback Eligible Incentive-Based Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; if the Incentive-Based Compensation is Received by a person after such person became a Section 16 Officer and the person served as a Section 16 Officer at any time during the performance period for the Incentive-Based Compensation. &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Excess Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based Compensation that otherwise would have been Received had such Clawback Eligible Incentive-Based Compensation been determined based on the restated amounts. Excess Compensation must be computed without regard to any taxes paid and is referred to in the listings standards as &#8220;erroneously awarded incentive-based compensation&#8221;.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide that documentation to the Exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company&#8217;s right to recover under the Policy has lapsed. The following items of compensation are not Incentive-Based Compensation under the Policy&#58; salaries, bonuses paid solely at the discretion of the Committee or Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure, bonuses paid solely upon satisfying one or more subjective standards and&#47;or completion of a specified employment period, non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures, and equity awards for which the grant is not contingent upon achieving any Financial Reporting Measure performance goal and vesting is contingent solely upon completion of a specified employment period (e.g., time-based vesting equity awards) and&#47;or attaining one or more non-Financial Reporting Measures.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; are measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Incentive-Based Compensation is &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Received</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; under the Policy in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment, vesting, settlement or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to the Effective Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Covered Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Determination Date. In addition, Covered Period can include certain transition periods resulting from a change in the Company&#8217;s fiscal year.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Restatement Determination Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earliest to occur of&#58; (a) the date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement&#59; and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:5.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Repayment of Excess Compensation</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company must recover Excess Compensation reasonably promptly and Covered Executives are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Covered Executive to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not need to be identical as to each Covered Executive). These means include (but are not limited to)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">requiring reimbursement of cash Incentive-Based Compensation previously paid&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation or vest based on the achievement of performance goals&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.58pt">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Covered Executive, including (but not limited to) payments of severance that might otherwise be due in connection with a Covered Executive&#8217;s termination of employment and without regard to whether such amounts are Incentive-Based Compensation&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">cancelling outstanding vested or unvested equity awards (including, but not limited to, time- based vesting awards), without regard to whether such awards are Incentive-Based Compensation&#59; and&#47;or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.76pt">taking any other remedial and recovery action permitted by law, as determined by the Committee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The repayment of Excess Compensation must be made by a Covered Executive notwithstanding any Covered Executive&#8217;s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore is not subject to clawback.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce a Covered Executive&#8217;s obligations to the Company or to discipline a Covered Executive. Failure of a Covered Executive to comply with their obligations under the Policy may result in (without limitation) termination of that Covered Executive&#8217;s employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities or change in role. The decision to take any actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company. For avoidance of doubt, any decisions of the Company or the Covered Executive&#8217;s employer to discipline a Covered Executive or terminate the employment of a Covered Executive are independent of determinations under this Policy. For example, if a Covered Executive was involved in activities that led to an Accounting Restatement, the Company&#8217;s decision as to whether to not to terminate such Covered Executive&#8217;s employment would be made under its employment arrangements with such Covered Executive and the requirement to apply this no-fault and non-discretionary clawback policy will not be determinative of whether any such termination is for cause, although failure to comply with the Policy might be something that could result in a termination for cause depending on the terms of such arrangements.</font></div><div style="margin-top:12pt;text-indent:5.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Limited Exceptions to the Policy</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company must recover the Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below is met, and the Committee determines that recovery of the Excess Compensation would be impracticable&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.97pt">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover such Excess Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange&#59; or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.46pt">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such.</font></div><div style="margin-top:12pt;text-indent:5.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Important Information in the Policy</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer, as well as any other applicable laws, regulatory requirements, rules, or pursuant to the terms of any existing Company policy or agreement providing for the recovery of compensation. With the exception of any compensation that is Received prior to the Effective Date, which compensation will remain subject to the Company&#8217;s previously adopted clawback policy providing for recovery of compensation as applicable pursuant to the terms of such policy, this Policy supersedes in full all of the clawback policies of the Company that were in effect prior to the Effective Date to the extent such policies were applicable with respect to Executive Officers and the operative portions of such policies will have no further force or effect on or after the Effective Date.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the terms of any of the Company&#8217;s organizational documents (including, but not limited to, the Company&#8217;s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide advancement for any Covered Executive against any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that the Company is required to recover Excess Compensation pursuant to the Policy from a Covered Executive who is no longer an employee pursuant to the Policy, the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement that individual may have signed.</font></div><div style="margin-top:12pt;text-indent:42pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Committee or Board may review and modify the Policy from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any provision of the Policy or the application of any such provision to any Covered Executive is adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Covered Executive, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Policy will terminate and no longer be enforceable when the Company ceases to be listed issuer within the meaning of Section 10D of the Exchange Act.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt;text-align:center;text-indent:124.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ACKNOWLEDGEMENT</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I acknowledge that I have received and read the Compensation Recovery Policy (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Pacific Biosciences of California, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I understand and acknowledge that the Policy applies to me, and all of my beneficiaries, heirs, executors, administrators or other legal representatives and that the Company&#8217;s right to recovery in order to comply with applicable law will apply, regardless of the terms of any release of claims or separation agreement I have signed or will sign in the future.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I agree to be bound by and to comply with the Policy and understand that determinations of the Committee (as such term is used in the Policy) will be final and binding and will be given the maximum deference permitted by law.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I understand and agree that my current indemnification rights, whether in an individual agreement or the Company&#8217;s organizational documents, exclude the right to be indemnified for amounts required to be recovered under the Policy.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I understand that my failure to comply in all respects with the Policy is a basis for termination of my employment with the Company and any affiliate of the Company as well as any other appropriate discipline.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I understand that neither the Policy, nor the application of the Policy to me, gives rise to a resignation for good reason (or similar concept) by me under any applicable employment agreement or arrangement.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I acknowledge that if I have questions concerning the meaning or application of the Policy, it is my responsibility to seek guidance from the Company&#8217;s General Counsel, Human Resources or my own personal advisers.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">I acknowledge that neither this Acknowledgement nor the Policy is meant to constitute an employment contract.</font></div><div style="margin-top:6pt;text-indent:6pt"><font><br></font></div><div style="margin-top:6pt;text-indent:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.04pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-indent:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please review, sign and return this form to Human Resources.</font></div><div style="margin-top:6pt;text-indent:6pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.041%"><tr><td style="width:1.0%"></td><td style="width:5.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:102%">Covered Executive<br></font><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:102%"><br></font></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">print nam</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">e)</font></div><div><font><br></font></div><div><font><br></font></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">signature</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">)</font></div><div><font><br></font></div><div><font><br></font></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:111%">(date)<br></font><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:111%"><br></font></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>pacb-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4809e9eb-ee6c-40c5-b267-06eb948f47bd,g:8f5aae7b-78f1-4a80-ad95-b1556c05246b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacificbiosciences.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pacificbiosciences.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.pacificbiosciences.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000008 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONS" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS">
        <link:definition>0000009 - Disclosure - BUSINESS ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVITAECOLLABORATION" roleURI="http://www.pacificbiosciences.com/role/INVITAECOLLABORATION">
        <link:definition>0000010 - Disclosure - INVITAE COLLABORATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TERMINATIONOFMERGERWITHILLUMINA" roleURI="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINA">
        <link:definition>0000011 - Disclosure - TERMINATION OF MERGER WITH ILLUMINA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS">
        <link:definition>0000012 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTS" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS">
        <link:definition>0000013 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTES" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES">
        <link:definition>0000014 - Disclosure - CONVERTIBLE SENIOR NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXES">
        <link:definition>0000016 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.pacificbiosciences.com/role/StockholdersEquity">
        <link:definition>0000017 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE">
        <link:definition>0000018 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATION" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION">
        <link:definition>0000019 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy">
        <link:definition>9954471 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSTables" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables">
        <link:definition>9954473 - Disclosure - BUSINESS ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9954474 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSTables" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables">
        <link:definition>9954475 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESTables" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables">
        <link:definition>9954476 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9954477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESTables">
        <link:definition>9954478 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954479 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables">
        <link:definition>9954480 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONTables" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables">
        <link:definition>9954481 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954482 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails">
        <link:definition>9954483 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails">
        <link:definition>9954484 - Disclosure - BUSINESS ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails">
        <link:definition>9954485 - Disclosure - BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails">
        <link:definition>9954486 - Disclosure - BUSINESS ACQUISITIONS - Total Consideration Transferred for The Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails" roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails">
        <link:definition>9954487 - Disclosure - BUSINESS ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVITAECOLLABORATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails">
        <link:definition>9954488 - Disclosure - INVITAE COLLABORATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TERMINATIONOFMERGERWITHILLUMINANarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails">
        <link:definition>9954489 - Disclosure - TERMINATION OF MERGER WITH ILLUMINA - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954490 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>9954491 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails">
        <link:definition>9954492 - Disclosure - FINANCIAL INSTRUMENTS - Changes in Estimated Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails">
        <link:definition>9954493 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails">
        <link:definition>9954494 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSComponentsofInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails">
        <link:definition>9954495 - Disclosure - BALANCE SHEET COMPONENTS - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails">
        <link:definition>9954496 - Disclosure - BALANCE SHEET COMPONENTS - Components of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails">
        <link:definition>9954497 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails">
        <link:definition>9954498 - Disclosure - BALANCE SHEET COMPONENTS - Definite-Lived Intangible Assets from Business Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails">
        <link:definition>9954499 - Disclosure - BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSAccruedExpensesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails">
        <link:definition>9954500 - Disclosure - BALANCE SHEET COMPONENTS - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails">
        <link:definition>9954501 - Disclosure - BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails">
        <link:definition>9954502 - Disclosure - BALANCE SHEET COMPONENTS - Future Principal Payments , Fiscal Year Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails">
        <link:definition>9954503 - Disclosure - BALANCE SHEET COMPONENTS - Other Liabilities, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails">
        <link:definition>9954504 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails">
        <link:definition>9954505 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails">
        <link:definition>9954506 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>9954507 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails">
        <link:definition>9954508 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1">
        <link:definition>9954508 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9954509 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESProvisionBenefitforIncomeTaxesDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails">
        <link:definition>9954510 - Disclosure - INCOME TAXES - Provision (Benefit) for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofFederalIncomeTaxRateDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails">
        <link:definition>9954511 - Disclosure - INCOME TAXES - Reconciliation of Federal Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954512 - Disclosure - INCOME TAXES - Reconciliation of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails" roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails">
        <link:definition>9954513 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefit Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9954514 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails">
        <link:definition>9954515 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails">
        <link:definition>9954516 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of RSUs and PSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9954517 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails">
        <link:definition>9954518 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails">
        <link:definition>9954519 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9954520 - Disclosure - NET LOSS PER SHARE - Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails">
        <link:definition>9954521 - Disclosure - NET LOSS PER SHARE - Antidilutive Shares Excluded From Computation Of Diluted Net Loss Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails">
        <link:definition>9954522 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails">
        <link:definition>9954523 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails">
        <link:definition>9954524 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Summary of Revenue by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" abstract="false" name="ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_MergerTerminationAbstract" abstract="true" name="MergerTerminationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" abstract="false" name="DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_PrivatePlacementOfCommonStockMember" abstract="false" name="PrivatePlacementOfCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_StandardProductWarrantyPeriod" abstract="false" name="StandardProductWarrantyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" abstract="false" name="AdditionalLiabilityAssociatedWithIndemnificationObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_FinancialInstrumentsLineItems" abstract="true" name="FinancialInstrumentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_CostOfRevenueMember" abstract="true" name="CostOfRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_CashAndMoneyMarketFundsMember" abstract="true" name="CashAndMoneyMarketFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" abstract="false" name="CommonStockVotingRightsNumberOfVotesPerShareOwned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:positiveIntegerItemType"/>
  <xs:element id="pacb_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsAmountSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" abstract="false" name="AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_MergerTerminationTable" abstract="true" name="MergerTerminationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" abstract="true" name="ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" abstract="false" name="PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_ContractWithCustomerLiabilityNoncurrentReclassification" abstract="false" name="ContractWithCustomerLiabilityNoncurrentReclassification" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DomesticCustomersMember" abstract="false" name="DomesticCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_NumberOfPurchasePeriods" abstract="false" name="NumberOfPurchasePeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pacb_MergerTerminationLineItems" abstract="true" name="MergerTerminationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_BalanceSheetComponentsLineItems" abstract="true" name="BalanceSheetComponentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" abstract="false" name="ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_TimeBasedAndPerformanceBasedOptionsMember" abstract="false" name="TimeBasedAndPerformanceBasedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_FinancialInstrumentsTable" abstract="true" name="FinancialInstrumentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" abstract="false" name="PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" abstract="false" name="DebtInstrumentRedemptionPricePercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_CashCashEquivalentsAndInvestmentsMember" abstract="false" name="CashCashEquivalentsAndInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_EquityIncentivePlan2020Member" abstract="false" name="EquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" abstract="false" name="BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_NumberOfOfferings" abstract="false" name="NumberOfOfferings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:positiveIntegerItemType"/>
  <xs:element id="pacb_AccruedTenantImprovementsCurrent" abstract="false" name="AccruedTenantImprovementsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_SignificantAgreementsAbstract" abstract="true" name="SignificantAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_OmniomeIncMember" abstract="false" name="OmniomeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" abstract="false" name="StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_PublicOfferingShares" abstract="false" name="PublicOfferingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_AccruedProductDevelopmentCostsCurrent" abstract="false" name="AccruedProductDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DebtInstrumentDebtDefaultCalendarDays" abstract="false" name="DebtInstrumentDebtDefaultCalendarDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" abstract="false" name="StockBasedCompensationExpenseExcludedFromConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_TwoThousandTenEquityIncentivePlanMember" abstract="false" name="TwoThousandTenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_LiquidityBonusEventMember" abstract="true" name="LiquidityBonusEventMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_AchievementOfMilestoneMember" abstract="false" name="AchievementOfMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_IlluminaFcOpsCorpMember" abstract="false" name="IlluminaFcOpsCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" abstract="false" name="StockIssuedDuringPeriodAverageTradingPeriodAcquisition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" abstract="false" name="UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_InvitaeCorporationMember" abstract="false" name="InvitaeCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ExchangeTransactionMember" abstract="true" name="ExchangeTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_LongTermRestrictedCashMember" abstract="false" name="LongTermRestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalInterestInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_CirculomicsIncMember" abstract="false" name="CirculomicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_InvitaeCollaborationTextBlock" abstract="false" name="InvitaeCollaborationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_MergerRelatedExpensesCashSettledMember" abstract="false" name="MergerRelatedExpensesCashSettledMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_OmniomePlanMember" abstract="false" name="OmniomePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" abstract="false" name="RecentlyAdoptedAccountingStandardsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" abstract="false" name="ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" abstract="false" name="ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ProceedsFromRepaymentsOfContractTermination" abstract="false" name="ProceedsFromRepaymentsOfContractTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_LesseeOperatingLeaseDescriptionTableTextBlock" abstract="false" name="LesseeOperatingLeaseDescriptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" abstract="false" name="InProcessResearchAndDevelopmentIndefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AmountOfAgreementPaymentReceivedUponExecution" abstract="false" name="AmountOfAgreementPaymentReceivedUponExecution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" abstract="true" name="TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_OfferingShareAmountMaximum" abstract="false" name="OfferingShareAmountMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="pacb_IncomeLossPerShareAbstract" abstract="true" name="IncomeLossPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_AptonMember" abstract="true" name="AptonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_MergerRelatedExpensesMilestoneMember" abstract="false" name="MergerRelatedExpensesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" abstract="false" name="MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_ShortTermRestrictedCashMember" abstract="false" name="ShortTermRestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_LongTermRestrictedCashFairValueDisclosure" abstract="false" name="LongTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_StockBasedCompensationMember" abstract="false" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" abstract="false" name="StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ExchangeRatio" abstract="false" name="ExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ShortTermRestrictedCashFairValueDisclosure" abstract="false" name="ShortTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" abstract="false" name="PublicOfferingOptionToPurchaseAdditionalSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_PercentageOfFeeToPrepayDebt" abstract="false" name="PercentageOfFeeToPrepayDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsTable" abstract="true" name="ScheduleOfBalanceSheetComponentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_InstrumentMember" abstract="false" name="InstrumentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsRsusMember" abstract="false" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" abstract="true" name="DevelopmentAndCommercializationAgreementTransactionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_A2030ConvertibleSeniorNotesMember" abstract="true" name="A2030ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ConsumableMember" abstract="false" name="ConsumableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_AptonAndOmniomeMember" abstract="true" name="AptonAndOmniomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_TimeBasedStockOptionMember" abstract="false" name="TimeBasedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ConvertibleSeniorNotesMember" abstract="false" name="ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_OptionsToPurchaseCommonStockMember" abstract="false" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" abstract="false" name="PercentageOfFairMarketValueAtWhichStockCanBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" abstract="false" name="ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_LaboratoryEquipmentAndMachineryMember" abstract="false" name="LaboratoryEquipmentAndMachineryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" abstract="false" name="AccruedEmployeeStockPurchasePlanLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" abstract="false" name="ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BusinessCombinationMember" abstract="true" name="BusinessCombinationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InducementEquityIncentivePlan2020Member" abstract="false" name="InducementEquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentInterestInTheEventOfDefault" abstract="false" name="DebtInstrumentInterestInTheEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_ShareInstrumentNumberOfSharesConversionRatio" abstract="false" name="ShareInstrumentNumberOfSharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" abstract="false" name="PaymentsForContingentConsiderationRevenueAchievementMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PurchasePeriodOfEmployeeStockPurchasePlan" abstract="false" name="PurchasePeriodOfEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_TransferOfInventoryToPropertyAndEquipment" abstract="false" name="TransferOfInventoryToPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ShelfOfferingMember" abstract="true" name="ShelfOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" abstract="false" name="MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncreaseDecreaseInContingentConsiderationLiability" abstract="false" name="IncreaseDecreaseInContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_MergerTerminationTextBlock" abstract="false" name="MergerTerminationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" abstract="true" name="SupplementalBalanceSheetComponentsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" abstract="false" name="PublicOfferingOptionToPurchaseAdditionalSharesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCredit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_MergerRelatedExpensesStockSettledMember" abstract="false" name="MergerRelatedExpensesStockSettledMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_BalanceSheetClassificationAbstract" abstract="true" name="BalanceSheetClassificationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ServiceAndOtherMember" abstract="false" name="ServiceAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsPSUMember" abstract="true" name="TimeBasedRestrictedStockUnitsPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" abstract="false" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" abstract="false" name="IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_OmniomeStockAwardsRelatedToAcquisitionMember" abstract="false" name="OmniomeStockAwardsRelatedToAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_A2028ConvertibleSeniorNotesMember" abstract="false" name="A2028ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>pacb-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4809e9eb-ee6c-40c5-b267-06eb948f47bd,g:8f5aae7b-78f1-4a80-ad95-b1556c05246b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8facd29e-6443-4d45-9e2e-9cbd57dd7f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b44136c0-3f25-436c-afe6-6fbd8d88e8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8facd29e-6443-4d45-9e2e-9cbd57dd7f30" xlink:to="loc_us-gaap_PreferredStockValue_b44136c0-3f25-436c-afe6-6fbd8d88e8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_419b6a8d-8929-4b34-a58f-7c65af1e8195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8facd29e-6443-4d45-9e2e-9cbd57dd7f30" xlink:to="loc_us-gaap_CommonStockValue_419b6a8d-8929-4b34-a58f-7c65af1e8195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b88ca6f5-d04d-4d4a-bb47-926e45474ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8facd29e-6443-4d45-9e2e-9cbd57dd7f30" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b88ca6f5-d04d-4d4a-bb47-926e45474ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0167ddc-d04f-48c1-8e38-c3a4f0b71529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8facd29e-6443-4d45-9e2e-9cbd57dd7f30" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0167ddc-d04f-48c1-8e38-c3a4f0b71529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d661aaa-7104-4cbb-9161-b4bdf1792cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8facd29e-6443-4d45-9e2e-9cbd57dd7f30" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d661aaa-7104-4cbb-9161-b4bdf1792cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8b42b5f-eef8-427d-9dfb-8f3e5e638039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8b42b5f-eef8-427d-9dfb-8f3e5e638039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_cd8f69d7-01d7-475b-b998-cd65c3fcb288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:to="loc_us-gaap_ShortTermInvestments_cd8f69d7-01d7-475b-b998-cd65c3fcb288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_91d4e374-0344-479f-8e11-8f663500cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_91d4e374-0344-479f-8e11-8f663500cf97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dfe9c993-20ac-45a6-a139-0cebcb51c496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:to="loc_us-gaap_InventoryNet_dfe9c993-20ac-45a6-a139-0cebcb51c496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42d219b1-d42c-4901-bcba-578f0fa6d132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42d219b1-d42c-4901-bcba-578f0fa6d132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_8d0ebe0f-7429-4e74-a29d-784293282cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cdfebf16-7b6b-4252-af9b-ec2706dedb98" xlink:to="loc_us-gaap_RestrictedCashCurrent_8d0ebe0f-7429-4e74-a29d-784293282cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ae83e956-c3ad-43cb-b331-98d79f305d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_AssetsCurrent_ae83e956-c3ad-43cb-b331-98d79f305d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a6eac7dc-327e-4073-813f-6399211906a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a6eac7dc-327e-4073-813f-6399211906a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a00a2753-2c0a-4981-9826-449acd56fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a00a2753-2c0a-4981-9826-449acd56fd86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1cfa225a-7b22-40d4-b657-65e88e968353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1cfa225a-7b22-40d4-b657-65e88e968353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_921d3564-e5f0-4db5-926f-027a511656e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_921d3564-e5f0-4db5-926f-027a511656e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f79bc59-c9bc-48af-9105-862ff9ac295f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f79bc59-c9bc-48af-9105-862ff9ac295f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_69a4a578-1c4a-424a-ad52-94aa844e9b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c723626-f5b0-424a-b12b-9bca3becf816" xlink:to="loc_us-gaap_Goodwill_69a4a578-1c4a-424a-ad52-94aa844e9b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f21a7842-c6d4-4d0a-826c-f4daa79bc119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5d1a1f0c-9e69-4b66-9956-f2e338223b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f21a7842-c6d4-4d0a-826c-f4daa79bc119" xlink:to="loc_us-gaap_Liabilities_5d1a1f0c-9e69-4b66-9956-f2e338223b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1a3fa87-e58a-434f-a26b-094703611902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f21a7842-c6d4-4d0a-826c-f4daa79bc119" xlink:to="loc_us-gaap_StockholdersEquity_b1a3fa87-e58a-434f-a26b-094703611902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_818cb1dd-02de-4b3b-8d2c-28add1af5c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f21a7842-c6d4-4d0a-826c-f4daa79bc119" xlink:to="loc_us-gaap_CommitmentsAndContingencies_818cb1dd-02de-4b3b-8d2c-28add1af5c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cf72f940-4e1b-4921-8851-b878ca1e2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:to="loc_us-gaap_LiabilitiesCurrent_cf72f940-4e1b-4921-8851-b878ca1e2ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0937cd59-03f0-4222-8f6e-5c46d0bfb066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0937cd59-03f0-4222-8f6e-5c46d0bfb066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab5fa15b-3881-481f-b7ff-4b64f1296305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab5fa15b-3881-481f-b7ff-4b64f1296305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_5fecc783-bedb-42a0-ba33-e9c86814e993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_5fecc783-bedb-42a0-ba33-e9c86814e993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7d3dde17-93aa-4afb-96bd-0fb67780b64e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7d3dde17-93aa-4afb-96bd-0fb67780b64e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d8827598-6636-4508-b764-d8e92e45c5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6c88430e-d8a8-42a6-98fb-921e4f6b0aeb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d8827598-6636-4508-b764-d8e92e45c5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_68a20be5-5ca4-412f-b31a-93f4a22765ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:to="loc_us-gaap_AccountsPayableCurrent_68a20be5-5ca4-412f-b31a-93f4a22765ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_30ee9e18-de89-4465-a6f5-5b04040063b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_30ee9e18-de89-4465-a6f5-5b04040063b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f35df8cc-fa16-435d-8475-b4702116feb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f35df8cc-fa16-435d-8475-b4702116feb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ae50a70-ad84-4d4e-8de6-450cb1f94d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ae50a70-ad84-4d4e-8de6-450cb1f94d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6bb3f812-3136-4ac8-8b5b-896514eb9ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6bb3f812-3136-4ac8-8b5b-896514eb9ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_52d73dd8-df1e-4747-81e9-a0f7b12fe5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ebacad6-c5ea-4321-8fa1-2d59cedf67f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_52d73dd8-df1e-4747-81e9-a0f7b12fe5e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c0350ba-142b-4553-ac94-37d3fccdd0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_2d0d3fa8-8815-44dc-b5c9-00cb0c055b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c0350ba-142b-4553-ac94-37d3fccdd0c3" xlink:to="loc_us-gaap_GainLossOnContractTermination_2d0d3fa8-8815-44dc-b5c9-00cb0c055b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fe6461de-dcae-4b93-8881-ac362243d8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c0350ba-142b-4553-ac94-37d3fccdd0c3" xlink:to="loc_us-gaap_InterestExpense_fe6461de-dcae-4b93-8881-ac362243d8f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fbe7067a-b74a-450d-a068-318a373db2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c0350ba-142b-4553-ac94-37d3fccdd0c3" xlink:to="loc_us-gaap_OperatingIncomeLoss_fbe7067a-b74a-450d-a068-318a373db2f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_938bb9e8-5950-4d71-8fd3-82ef2cbb85d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c0350ba-142b-4553-ac94-37d3fccdd0c3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_938bb9e8-5950-4d71-8fd3-82ef2cbb85d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e937ea7-7e88-45dd-b433-93fcfdf61d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c0350ba-142b-4553-ac94-37d3fccdd0c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4e937ea7-7e88-45dd-b433-93fcfdf61d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dd13f06-50a0-4fc3-976c-bb85f7a873b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e9a69e42-e136-4838-9165-b4d821eeb67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dd13f06-50a0-4fc3-976c-bb85f7a873b8" xlink:to="loc_us-gaap_NetIncomeLoss_e9a69e42-e136-4838-9165-b4d821eeb67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_36783af4-6ea3-4e19-ab4d-03449988a105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dd13f06-50a0-4fc3-976c-bb85f7a873b8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_36783af4-6ea3-4e19-ab4d-03449988a105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fb08befa-3191-4ec6-a13e-0d2093d8a555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d7ab500a-557f-4aff-929a-ec3345e11078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fb08befa-3191-4ec6-a13e-0d2093d8a555" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d7ab500a-557f-4aff-929a-ec3345e11078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_efa84251-9951-45a2-8028-d0475eabf5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fb08befa-3191-4ec6-a13e-0d2093d8a555" xlink:to="loc_us-gaap_CostOfRevenue_efa84251-9951-45a2-8028-d0475eabf5a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f38751a9-fc7a-4abb-b555-83291125c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d323ecbe-dcfe-4e4d-a5b9-de534f714870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f38751a9-fc7a-4abb-b555-83291125c13a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d323ecbe-dcfe-4e4d-a5b9-de534f714870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_96348915-3332-4aa9-8347-9617d08abc02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f38751a9-fc7a-4abb-b555-83291125c13a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_96348915-3332-4aa9-8347-9617d08abc02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_791780ad-dcba-47ef-8509-21aaac217d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f38751a9-fc7a-4abb-b555-83291125c13a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_791780ad-dcba-47ef-8509-21aaac217d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_956b2e1b-1fd6-4a05-afb7-212023dba92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f38751a9-fc7a-4abb-b555-83291125c13a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_956b2e1b-1fd6-4a05-afb7-212023dba92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cac183a4-2b40-4a34-83f5-01d784b630c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f38751a9-fc7a-4abb-b555-83291125c13a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cac183a4-2b40-4a34-83f5-01d784b630c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_facc1da7-ac68-4b4b-a35e-07cd9b22c627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f90fdc63-f2d4-49d5-8c40-f7cf3612cee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_facc1da7-ac68-4b4b-a35e-07cd9b22c627" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f90fdc63-f2d4-49d5-8c40-f7cf3612cee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts_be384bef-6e26-4345-b4eb-85e82ee9b113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContracts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_facc1da7-ac68-4b4b-a35e-07cd9b22c627" xlink:to="loc_us-gaap_LossOnContracts_be384bef-6e26-4345-b4eb-85e82ee9b113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue_585ffb48-51a6-4fd3-8b23-fc317590c68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_facc1da7-ac68-4b4b-a35e-07cd9b22c627" xlink:to="loc_us-gaap_OtherCostOfOperatingRevenue_585ffb48-51a6-4fd3-8b23-fc317590c68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b5eb5629-01f1-47b1-ad60-e5bc7ab9a839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_facc1da7-ac68-4b4b-a35e-07cd9b22c627" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b5eb5629-01f1-47b1-ad60-e5bc7ab9a839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8bf2b4de-8ec2-4b2c-989d-47ff63a69e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7407fc87-424c-42e3-98ea-a0228076193c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8bf2b4de-8ec2-4b2c-989d-47ff63a69e43" xlink:to="loc_us-gaap_GrossProfit_7407fc87-424c-42e3-98ea-a0228076193c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_820728c3-23a2-407b-8b86-07198040809e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8bf2b4de-8ec2-4b2c-989d-47ff63a69e43" xlink:to="loc_us-gaap_OperatingExpenses_820728c3-23a2-407b-8b86-07198040809e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49a64d3b-1017-49ed-9950-b8f9f6d8090f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef25c947-bf1e-4e8d-b18f-cf1118ff558a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49a64d3b-1017-49ed-9950-b8f9f6d8090f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef25c947-bf1e-4e8d-b18f-cf1118ff558a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_041984de-e761-41d1-ab6c-04457eabf4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49a64d3b-1017-49ed-9950-b8f9f6d8090f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_041984de-e761-41d1-ab6c-04457eabf4eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_44c19e80-1bbb-4183-b8e1-677061a27bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_44c19e80-1bbb-4183-b8e1-677061a27bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cfd91231-973b-4484-b3ac-2ad4b0dd5214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cfd91231-973b-4484-b3ac-2ad4b0dd5214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromRepaymentsOfContractTermination_f268d715-48ef-483f-8193-b58f0f6c1b12" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_pacb_ProceedsFromRepaymentsOfContractTermination_f268d715-48ef-483f-8193-b58f0f6c1b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e92abcdc-ead5-4dfc-8b3e-b6e5bf671788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e92abcdc-ead5-4dfc-8b3e-b6e5bf671788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_fd420c82-a7de-4ee1-b8c9-a7af73916bdd" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_fd420c82-a7de-4ee1-b8c9-a7af73916bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b65a93b9-89ac-494a-a14b-fca90b61b930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b65a93b9-89ac-494a-a14b-fca90b61b930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7c7e6912-1e1b-4f6a-9c8f-2f5c4dcbb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7c7e6912-1e1b-4f6a-9c8f-2f5c4dcbb7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_5f0edd3b-a86f-4f93-b040-4d8ab82e96a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4af37f36-9671-4ad8-8601-577fba6521cb" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_5f0edd3b-a86f-4f93-b040-4d8ab82e96a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2cd70476-0c16-41c5-8539-3ce5035c29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b27141b-6153-4473-b71d-4845f8c62c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2cd70476-0c16-41c5-8539-3ce5035c29f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b27141b-6153-4473-b71d-4845f8c62c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_235d9bc5-86fb-4445-8bf6-01b83be74176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2cd70476-0c16-41c5-8539-3ce5035c29f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_235d9bc5-86fb-4445-8bf6-01b83be74176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8ca920-b5da-4e22-a321-011544de8e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2cd70476-0c16-41c5-8539-3ce5035c29f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8ca920-b5da-4e22-a321-011544de8e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b839abd1-37fb-4ad5-b0b4-413a1f2309eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_InventoryWriteDown_b839abd1-37fb-4ad5-b0b4-413a1f2309eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cd3e55ac-6407-43fb-9cca-0ef3a5e9adc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cd3e55ac-6407-43fb-9cca-0ef3a5e9adc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_35044d0d-698e-4710-9ec8-f91ba4affbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_35044d0d-698e-4710-9ec8-f91ba4affbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5eeef6f5-5ac0-41f0-b193-e7a928b44342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_OperatingLeasePayments_5eeef6f5-5ac0-41f0-b193-e7a928b44342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_919beb86-e330-416f-8498-6f4f917b111b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_919beb86-e330-416f-8498-6f4f917b111b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_58d4dff3-f35f-4c02-b675-b9124d35befb" xlink:href="pacb-20231231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_58d4dff3-f35f-4c02-b675-b9124d35befb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6992d311-d981-46c1-8c9b-aceb1020acac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6992d311-d981-46c1-8c9b-aceb1020acac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8f134a5a-27e8-426d-9643-077d36fec484" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8f134a5a-27e8-426d-9643-077d36fec484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_45210952-7ad6-4251-b51c-1f3c1c0d871c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_45210952-7ad6-4251-b51c-1f3c1c0d871c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8ad43ee2-2c72-4cbe-99ef-e616666204f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8ad43ee2-2c72-4cbe-99ef-e616666204f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_46c04a5e-1dc9-4183-b83c-49f6c85c6827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_46c04a5e-1dc9-4183-b83c-49f6c85c6827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2b065986-89e7-481e-b576-603ec6c062a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_ShareBasedCompensation_2b065986-89e7-481e-b576-603ec6c062a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability_0be6075f-4cc3-4222-8d74-c396dc3801ee" xlink:href="pacb-20231231.xsd#pacb_IncreaseDecreaseInContingentConsiderationLiability"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability_0be6075f-4cc3-4222-8d74-c396dc3801ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a04f7dd1-4688-451c-b80b-771aa40244fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_NetIncomeLoss_a04f7dd1-4688-451c-b80b-771aa40244fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_576b25ee-fa39-44d6-8fed-8d579cbde209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_576b25ee-fa39-44d6-8fed-8d579cbde209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_14ed6dbc-cad8-42ab-8997-92d047020f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_Depreciation_14ed6dbc-cad8-42ab-8997-92d047020f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_1b946ab7-2f14-414f-bb1f-83a25d7b78df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_1b946ab7-2f14-414f-bb1f-83a25d7b78df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fdd68b3b-8d01-433d-b6ba-7dd54e403921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fdd68b3b-8d01-433d-b6ba-7dd54e403921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_24ccc633-d4e6-4b50-845c-c8cecfef2fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_24ccc633-d4e6-4b50-845c-c8cecfef2fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_db0a6e22-9da2-48d0-bcae-62822cb9fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_db0a6e22-9da2-48d0-bcae-62822cb9fa8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9817d564-9cde-486e-b27c-1e912e67ceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9817d564-9cde-486e-b27c-1e912e67ceb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_0637a5c3-31f0-42ab-925a-3d8a5cb82170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3668c94b-03c2-44e0-97ea-6ba9a17fe00f" xlink:to="loc_us-gaap_GainLossOnContractTermination_0637a5c3-31f0-42ab-925a-3d8a5cb82170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a32411e9-0014-41dc-96d6-37bc0e947e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a32411e9-0014-41dc-96d6-37bc0e947e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_ef0faed6-f9d9-4409-a945-3d6da2163b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_ef0faed6-f9d9-4409-a945-3d6da2163b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b143529a-6e63-4287-bbe8-f11e170abefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b143529a-6e63-4287-bbe8-f11e170abefd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d3dfc28d-4dd9-4cdc-9e71-20f423017d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d3dfc28d-4dd9-4cdc-9e71-20f423017d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea0d9fbf-d98c-4b70-a12f-bbc7f83c90cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ea0d9fbf-d98c-4b70-a12f-bbc7f83c90cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88a5bbe1-7a64-45c9-a853-fc19b5873073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f387672-5ad3-4b12-90d5-8560ced207da" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_88a5bbe1-7a64-45c9-a853-fc19b5873073" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_44d499a2-47f6-4a96-a7d1-4d131f39d19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_Goodwill_44d499a2-47f6-4a96-a7d1-4d131f39d19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_7199119c-5583-4d93-95b6-62bcd13fbfe9" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_7199119c-5583-4d93-95b6-62bcd13fbfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_30c3c24b-9785-4f2f-90f3-ca8d2c9e2d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_30c3c24b-9785-4f2f-90f3-ca8d2c9e2d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_02d2d6fe-d870-471c-a90a-0f35eee24f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_02d2d6fe-d870-471c-a90a-0f35eee24f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d5f555f4-e739-463d-b54d-d9de464d2953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d5f555f4-e739-463d-b54d-d9de464d2953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4c3268eb-3e73-4526-bd84-c0d00f4d73e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4c3268eb-3e73-4526-bd84-c0d00f4d73e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4dbe97dd-47af-41dc-8f2c-2c309b14530e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4dbe97dd-47af-41dc-8f2c-2c309b14530e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_787a9c98-284b-45d1-833a-ec09c47d5ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_787a9c98-284b-45d1-833a-ec09c47d5ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_9a95df0a-816b-47ba-9eeb-3351a35d7e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_9a95df0a-816b-47ba-9eeb-3351a35d7e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f3ca3e52-ad23-48e8-8cd8-bf7022c11d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_05eab9a5-3692-4010-b527-0acac4403ed1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f3ca3e52-ad23-48e8-8cd8-bf7022c11d6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b515a48-457f-43d9-818d-3680d2124a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c5ea1270-357c-4d15-b06c-bee6d49bf34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b515a48-457f-43d9-818d-3680d2124a4e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c5ea1270-357c-4d15-b06c-bee6d49bf34a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1384e6e6-90e8-45f5-8cf3-5a0a1575a63a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b515a48-457f-43d9-818d-3680d2124a4e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1384e6e6-90e8-45f5-8cf3-5a0a1575a63a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_83356cc6-4776-4903-80f7-c3393410a0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b515a48-457f-43d9-818d-3680d2124a4e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_83356cc6-4776-4903-80f7-c3393410a0bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_78edd3ec-1f3f-4ffb-adba-8b7d0ffecec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2b515a48-457f-43d9-818d-3680d2124a4e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_78edd3ec-1f3f-4ffb-adba-8b7d0ffecec2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6f5f06bc-c348-429d-9d6d-969f0428bb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2f7613aa-de7b-4e18-9d33-4cf37c632ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6f5f06bc-c348-429d-9d6d-969f0428bb0f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2f7613aa-de7b-4e18-9d33-4cf37c632ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8ac3e018-a39a-46eb-867e-1961e85eeb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f8f369c8-e1b3-4bb8-884a-ef5b0a43fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac3e018-a39a-46eb-867e-1961e85eeb09" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f8f369c8-e1b3-4bb8-884a-ef5b0a43fc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c2266913-3e7e-4a1e-91d0-2b1610525651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac3e018-a39a-46eb-867e-1961e85eeb09" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c2266913-3e7e-4a1e-91d0-2b1610525651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_73f0cdb1-14c7-4ede-bb7b-a7615cd1a802" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac3e018-a39a-46eb-867e-1961e85eeb09" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_73f0cdb1-14c7-4ede-bb7b-a7615cd1a802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_560d1f29-2384-4d57-b64e-af5874c550a5" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac3e018-a39a-46eb-867e-1961e85eeb09" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_560d1f29-2384-4d57-b64e-af5874c550a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a371ba8e-b031-4e9b-bf50-6c84c73518dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_007e4c84-97c3-401a-bb0a-c711a9e668a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a371ba8e-b031-4e9b-bf50-6c84c73518dc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_007e4c84-97c3-401a-bb0a-c711a9e668a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f2adb704-4012-4207-aadd-e37d7a047325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a371ba8e-b031-4e9b-bf50-6c84c73518dc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f2adb704-4012-4207-aadd-e37d7a047325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7deeb054-e521-49f7-95d9-ea437c302d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a371ba8e-b031-4e9b-bf50-6c84c73518dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7deeb054-e521-49f7-95d9-ea437c302d78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31037252-457d-439d-9793-12cb8e78ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_aa84b578-40c6-45a4-a59f-5da90e7d44ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31037252-457d-439d-9793-12cb8e78ce02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_aa84b578-40c6-45a4-a59f-5da90e7d44ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5f680340-eaa8-4d01-a393-282763bb053e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31037252-457d-439d-9793-12cb8e78ce02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5f680340-eaa8-4d01-a393-282763bb053e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5b79683a-3bc1-490d-8383-b118b94bc479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0021a7e3-f4c0-43db-8d6c-35487e92d516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_5b79683a-3bc1-490d-8383-b118b94bc479" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0021a7e3-f4c0-43db-8d6c-35487e92d516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e8a2811c-0c22-43f3-81a3-aae0166b02c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_5b79683a-3bc1-490d-8383-b118b94bc479" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e8a2811c-0c22-43f3-81a3-aae0166b02c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cbc80920-ba86-4af3-a579-4cfe0968c05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_5b79683a-3bc1-490d-8383-b118b94bc479" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cbc80920-ba86-4af3-a579-4cfe0968c05c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3cb099a5-1b9b-4231-a954-b2f5de689938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3173cca8-8478-4843-86c3-2ac54bc90196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3cb099a5-1b9b-4231-a954-b2f5de689938" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3173cca8-8478-4843-86c3-2ac54bc90196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f17805de-7102-4d8b-a21d-8d39702d8af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3cb099a5-1b9b-4231-a954-b2f5de689938" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f17805de-7102-4d8b-a21d-8d39702d8af2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7340b2be-001a-42e8-bdbc-18a7212d0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7340b2be-001a-42e8-bdbc-18a7212d0ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedProductDevelopmentCostsCurrent_08e972ee-00a0-44b0-af79-21c21ad58051" xlink:href="pacb-20231231.xsd#pacb_AccruedProductDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_pacb_AccruedProductDevelopmentCostsCurrent_08e972ee-00a0-44b0-af79-21c21ad58051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0e488fdb-bf7e-4ec9-abb6-fddd9b93b00a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0e488fdb-bf7e-4ec9-abb6-fddd9b93b00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedTenantImprovementsCurrent_36b5dfe6-d566-4841-9c1b-27733caa0793" xlink:href="pacb-20231231.xsd#pacb_AccruedTenantImprovementsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_pacb_AccruedTenantImprovementsCurrent_36b5dfe6-d566-4841-9c1b-27733caa0793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_279db131-d56f-4bdf-81bf-92efed617f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_279db131-d56f-4bdf-81bf-92efed617f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualPresentValue_f538afe6-5356-4e57-bbe1-3076de5e04cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualPresentValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_us-gaap_ProductLiabilityContingencyAccrualPresentValue_f538afe6-5356-4e57-bbe1-3076de5e04cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_5fd11b87-d441-4e07-810d-244dd13d22da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_5fd11b87-d441-4e07-810d-244dd13d22da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_d0ea8717-e3aa-4131-8df3-c9e045a40605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639aa849-e56b-461b-b352-b34fb36665a9" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_d0ea8717-e3aa-4131-8df3-c9e045a40605" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_eeefa1cd-5fd4-4cc3-9c4d-2ad89e0a909e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_1fe7b496-36c1-4c8f-9ad0-c6936deb10e7" xlink:href="pacb-20231231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eeefa1cd-5fd4-4cc3-9c4d-2ad89e0a909e" xlink:to="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_1fe7b496-36c1-4c8f-9ad0-c6936deb10e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_c7e6fb89-c793-4d3b-ad14-75c0cbf76322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eeefa1cd-5fd4-4cc3-9c4d-2ad89e0a909e" xlink:to="loc_us-gaap_ShortTermBorrowings_c7e6fb89-c793-4d3b-ad14-75c0cbf76322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_2d930b99-36c6-40a3-bbf4-b3d137cf08b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eeefa1cd-5fd4-4cc3-9c4d-2ad89e0a909e" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_2d930b99-36c6-40a3-bbf4-b3d137cf08b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ca367160-71f5-4d41-b977-66f8f8c18c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_fcfa2d0b-8d2b-40c5-b819-d27e45d04e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ca367160-71f5-4d41-b977-66f8f8c18c14" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_fcfa2d0b-8d2b-40c5-b819-d27e45d04e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_bb2231ce-d779-40b8-bd04-f73bfb5f8b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ca367160-71f5-4d41-b977-66f8f8c18c14" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_bb2231ce-d779-40b8-bd04-f73bfb5f8b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_76d49521-c501-4704-816c-5966d1fbd28b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ca367160-71f5-4d41-b977-66f8f8c18c14" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_76d49521-c501-4704-816c-5966d1fbd28b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6000ca21-83a5-455a-905b-e5262efeb5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_12bcb6fe-1c36-45b7-bdef-77083fe39526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_6000ca21-83a5-455a-905b-e5262efeb5a1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_12bcb6fe-1c36-45b7-bdef-77083fe39526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_5514affc-70a9-43b1-82ca-befc80f8e52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_6000ca21-83a5-455a-905b-e5262efeb5a1" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_5514affc-70a9-43b1-82ca-befc80f8e52d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_227432ba-d2b0-40a0-ba5d-a8df05664922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_04f0229c-864a-4a5d-8662-790fc4f917c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_227432ba-d2b0-40a0-ba5d-a8df05664922" xlink:to="loc_us-gaap_OperatingLeaseLiability_04f0229c-864a-4a5d-8662-790fc4f917c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2a4c6cda-7f4f-40b1-8677-fb829483c669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_227432ba-d2b0-40a0-ba5d-a8df05664922" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2a4c6cda-7f4f-40b1-8677-fb829483c669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a25cb81f-e9b4-4a72-97a7-bb95d5f83b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_604c911f-a57a-4fed-a8ee-4b4b0348c3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a25cb81f-e9b4-4a72-97a7-bb95d5f83b5c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_604c911f-a57a-4fed-a8ee-4b4b0348c3be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d4766c5-58ab-430f-89b3-d30b208d1c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a25cb81f-e9b4-4a72-97a7-bb95d5f83b5c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d4766c5-58ab-430f-89b3-d30b208d1c69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e3f163ec-b60c-4654-ae61-f1b9bf2cb56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e3f163ec-b60c-4654-ae61-f1b9bf2cb56a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f5e47b9-d027-4b25-afc4-2aa4fd1cc559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f5e47b9-d027-4b25-afc4-2aa4fd1cc559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ca21001f-3581-4dc6-be26-e99299740855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ca21001f-3581-4dc6-be26-e99299740855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3732cda5-c082-4736-8213-7f3023edac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3732cda5-c082-4736-8213-7f3023edac9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8c660b6d-7780-4dfe-92f1-be3cd298a608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8c660b6d-7780-4dfe-92f1-be3cd298a608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_754e6c4d-1968-4535-ac7b-3de69c1245bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ea0d730-2e89-47c6-ae9c-736fb0da19d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_754e6c4d-1968-4535-ac7b-3de69c1245bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESProvisionBenefitforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7c28e1cf-8f41-4085-bc69-8e740a97664d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fc288b56-2bcf-46d0-90c8-6101aba53fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7c28e1cf-8f41-4085-bc69-8e740a97664d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_fc288b56-2bcf-46d0-90c8-6101aba53fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e33db307-d75b-4201-8c6f-450c98f5f146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7c28e1cf-8f41-4085-bc69-8e740a97664d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e33db307-d75b-4201-8c6f-450c98f5f146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_101c8522-e555-462c-8fe9-b3ef04feced2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b10cdeff-b14b-4a37-a171-5adf45d74381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_101c8522-e555-462c-8fe9-b3ef04feced2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b10cdeff-b14b-4a37-a171-5adf45d74381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ab569a62-f82a-43bb-a7eb-eacdb3a24a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_101c8522-e555-462c-8fe9-b3ef04feced2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ab569a62-f82a-43bb-a7eb-eacdb3a24a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_132d2a72-070d-4951-b9c8-f72ae58639cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_101c8522-e555-462c-8fe9-b3ef04feced2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_132d2a72-070d-4951-b9c8-f72ae58639cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8bbea4fd-8255-48f6-ae97-a09bcaa714fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8bbea4fd-8255-48f6-ae97-a09bcaa714fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e98d38ac-2a8f-49e4-bdd3-3482ab379795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e98d38ac-2a8f-49e4-bdd3-3482ab379795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a4d99822-9952-43da-a47c-bcc07a394708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a4d99822-9952-43da-a47c-bcc07a394708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_e6ec50d8-eb8e-406a-8aff-7f4b1d600ff2" xlink:href="pacb-20231231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_e6ec50d8-eb8e-406a-8aff-7f4b1d600ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_979c83d4-8ca0-4046-9e52-1d603ab44090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_979c83d4-8ca0-4046-9e52-1d603ab44090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_337caa32-fa07-4631-a481-c943d8c877f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_337caa32-fa07-4631-a481-c943d8c877f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_d861d9f1-2243-4cdd-943d-e409ea06fca2" xlink:href="pacb-20231231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2bf42d03-21af-4e5d-b46c-976f9693fc7b" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_d861d9f1-2243-4cdd-943d-e409ea06fca2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fb85406d-ff7d-484b-b11b-824ce42e5a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_71eee94b-4623-4d0e-95de-10eacae3b4c5" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_fb85406d-ff7d-484b-b11b-824ce42e5a80" xlink:to="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_71eee94b-4623-4d0e-95de-10eacae3b4c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d46fef97-1beb-4094-b0f1-69fba971fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_fb85406d-ff7d-484b-b11b-824ce42e5a80" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d46fef97-1beb-4094-b0f1-69fba971fa79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2fcee6d4-4d3e-4f9c-8486-e9ec2396e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_fb85406d-ff7d-484b-b11b-824ce42e5a80" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2fcee6d4-4d3e-4f9c-8486-e9ec2396e3f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_d0eb78c1-29d3-4ef8-9f61-5145c438dccb" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_d0eb78c1-29d3-4ef8-9f61-5145c438dccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_59464a84-bfb4-4f25-8c41-48c9c5217f10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_59464a84-bfb4-4f25-8c41-48c9c5217f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_c06e65b4-8ed2-45b8-a7f4-40cbb5ad1ff3" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_c06e65b4-8ed2-45b8-a7f4-40cbb5ad1ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_32b2a1b3-286a-4c15-9267-c52fc92ff3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_32b2a1b3-286a-4c15-9267-c52fc92ff3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_06906a49-45bc-46fd-9185-941392d4f338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_06906a49-45bc-46fd-9185-941392d4f338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_04d56239-e10e-4447-a8f9-b3c6d252e84d" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_04d56239-e10e-4447-a8f9-b3c6d252e84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_52e0c041-58fd-4457-96c6-425b6131b9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e45ce0ea-be2a-4b28-b409-4a72c4f0c54c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_52e0c041-58fd-4457-96c6-425b6131b9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9ca308ed-77c1-4383-b59e-76f3cec82d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b7fbc6de-7c4c-4d95-8a36-ec0272a16959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_9ca308ed-77c1-4383-b59e-76f3cec82d85" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b7fbc6de-7c4c-4d95-8a36-ec0272a16959" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fd94cc8a-f18d-4193-b5f5-e57e5703cd60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_9ca308ed-77c1-4383-b59e-76f3cec82d85" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fd94cc8a-f18d-4193-b5f5-e57e5703cd60" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>pacb-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4809e9eb-ee6c-40c5-b267-06eb948f47bd,g:8f5aae7b-78f1-4a80-ad95-b1556c05246b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:to="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90784abb-5f0d-4dc6-a25d-0430bc0c3f36_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:to="loc_srt_ProductsAndServicesDomain_90784abb-5f0d-4dc6-a25d-0430bc0c3f36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:to="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_235609d7-48a1-42ac-94f3-0566b7291ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:to="loc_us-gaap_ProductMember_235609d7-48a1-42ac-94f3-0566b7291ff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_625a52d9-2675-46a0-9159-d4ecab7d2f5a" xlink:href="pacb-20231231.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:to="loc_pacb_ServiceAndOtherMember_625a52d9-2675-46a0-9159-d4ecab7d2f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_07fcebc1-2771-4772-9fd4-b0b4979a9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_RevenuesAbstract_07fcebc1-2771-4772-9fd4-b0b4979a9e98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_94cc024f-3abc-43d0-9e82-ebce1fac4c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_07fcebc1-2771-4772-9fd4-b0b4979a9e98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_94cc024f-3abc-43d0-9e82-ebce1fac4c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_0339b7cd-f19a-4b8e-9c42-ef33e54bcaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_0339b7cd-f19a-4b8e-9c42-ef33e54bcaa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue_352f795a-9454-452b-9625-8955e60b7aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_OtherCostOfOperatingRevenue_352f795a-9454-452b-9625-8955e60b7aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_2839713d-2ad0-4dea-85c2-b6de126df3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_2839713d-2ad0-4dea-85c2-b6de126df3e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts_57f0d264-c78d-46a0-8332-2db00568b251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_LossOnContracts_57f0d264-c78d-46a0-8332-2db00568b251" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ef61df9b-8aff-4837-8aec-06ece186d84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_CostOfRevenue_ef61df9b-8aff-4837-8aec-06ece186d84d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f08c8818-473b-477d-91f8-821c72059ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_GrossProfit_f08c8818-473b-477d-91f8-821c72059ec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c37023fa-ee3a-45b6-b435-f5bb989e6a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c37023fa-ee3a-45b6-b435-f5bb989e6a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ccebdac-15ef-406d-805a-7b659e1da108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ccebdac-15ef-406d-805a-7b659e1da108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e0df685-1aae-4da3-88d1-1f1b9b890415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e0df685-1aae-4da3-88d1-1f1b9b890415" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ba94d308-5f91-4db4-b050-ae1f3240b2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ba94d308-5f91-4db4-b050-ae1f3240b2f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3dfe02dd-6e6d-4906-ab2f-140c08261f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3dfe02dd-6e6d-4906-ab2f-140c08261f6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_196bab16-060e-44fa-b36c-c169160f0473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_OperatingExpenses_196bab16-060e-44fa-b36c-c169160f0473" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6127a3a5-c50c-4cb2-a362-5d9b3e960280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OperatingIncomeLoss_6127a3a5-c50c-4cb2-a362-5d9b3e960280" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_8d478907-8ff8-4307-bca2-9a6de349bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_GainLossOnContractTermination_8d478907-8ff8-4307-bca2-9a6de349bd7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_135746e2-8ab5-4fcd-bc97-a04b20af60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_135746e2-8ab5-4fcd-bc97-a04b20af60b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_baf511c6-6a2f-4767-a4da-570e621ba78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_InterestExpense_baf511c6-6a2f-4767-a4da-570e621ba78a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dd8c33ea-ac13-490a-880b-422583ad90a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dd8c33ea-ac13-490a-880b-422583ad90a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cebd090d-ecd4-4e70-a5d7-3cae186cac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cebd090d-ecd4-4e70-a5d7-3cae186cac6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0c97b5fe-2905-4543-bf56-69ca31b329f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0c97b5fe-2905-4543-bf56-69ca31b329f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db45801c-50b1-4aab-b235-5c26f304eb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_NetIncomeLoss_db45801c-50b1-4aab-b235-5c26f304eb4d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b84a9e4a-d19d-4147-9c94-eecde0ab8971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b84a9e4a-d19d-4147-9c94-eecde0ab8971" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f18e7a7c-28bb-41a8-a9c3-ea37e8ada38f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b84a9e4a-d19d-4147-9c94-eecde0ab8971" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f18e7a7c-28bb-41a8-a9c3-ea37e8ada38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_55932567-6f2e-447d-bc7f-46ce863ed95b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_55932567-6f2e-447d-bc7f-46ce863ed95b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:href="pacb-20231231.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9c1ae31-2f55-4a3f-9cbe-7a2e708c2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9c1ae31-2f55-4a3f-9cbe-7a2e708c2d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ef52b7d-eb54-4284-841f-b98af54513bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4ef52b7d-eb54-4284-841f-b98af54513bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c225c346-4baa-415b-82ca-45b2080228ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c225c346-4baa-415b-82ca-45b2080228ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c5e1ee6-7575-4311-8072-7e3dcb810ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c5e1ee6-7575-4311-8072-7e3dcb810ef0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e5dcdb5-06f8-442e-a538-eaa251379f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0e5dcdb5-06f8-442e-a538-eaa251379f19" xlink:to="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c58e55d4-c299-4c7c-ad96-c37299cb245b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:to="loc_us-gaap_EquityComponentDomain_c58e55d4-c299-4c7c-ad96-c37299cb245b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:to="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b901f4f5-6c10-44dd-ad58-73804276c178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_CommonStockMember_b901f4f5-6c10-44dd-ad58-73804276c178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f313405f-c6fc-4db3-b18b-142bf1df4472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f313405f-c6fc-4db3-b18b-142bf1df4472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f579426c-6b0b-449a-86ab-b56c8e8ca537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f579426c-6b0b-449a-86ab-b56c8e8ca537" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5c03f5a7-a6e4-4e0a-883d-5521cfda7dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_RetainedEarningsMember_5c03f5a7-a6e4-4e0a-883d-5521cfda7dd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e5dcdb5-06f8-442e-a538-eaa251379f19" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b601ff6f-3498-4d57-99e0-821e9cd30cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b601ff6f-3498-4d57-99e0-821e9cd30cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f048c31b-eab7-4ae5-868c-917038985186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockholdersEquity_f048c31b-eab7-4ae5-868c-917038985186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c55a046d-c281-4963-b53c-e666f2bfe65a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_NetIncomeLoss_c55a046d-c281-4963-b53c-e666f2bfe65a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9f9ba78f-98a4-4975-83bc-908022b5bf75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9f9ba78f-98a4-4975-83bc-908022b5bf75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a856e7c8-5eb9-4788-96a7-d1e664ec1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a856e7c8-5eb9-4788-96a7-d1e664ec1fb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_77d40d7e-e3e0-45e5-b4ce-33dd0c1933a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_77d40d7e-e3e0-45e5-b4ce-33dd0c1933a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a01506a2-8929-4bd8-b3bb-9137bcf38d58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a01506a2-8929-4bd8-b3bb-9137bcf38d58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66e2f6c8-6c7f-4948-ae44-4628b9ece360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66e2f6c8-6c7f-4948-ae44-4628b9ece360" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1d4bc509-6730-419c-ba30-7333c9daf88e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1d4bc509-6730-419c-ba30-7333c9daf88e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_217dff1e-8f93-4447-a343-b16f6cd00f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_217dff1e-8f93-4447-a343-b16f6cd00f9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ab81ada8-7236-4812-9023-74bf6d39eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ab81ada8-7236-4812-9023-74bf6d39eda0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9ccfdde8-e966-45fa-bb40-01b21af8611d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9ccfdde8-e966-45fa-bb40-01b21af8611d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_280ec70b-2880-4040-ad78-1e2bba30bff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_280ec70b-2880-4040-ad78-1e2bba30bff9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_c478046f-7e64-4bb1-9cc0-01f822641715" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_c478046f-7e64-4bb1-9cc0-01f822641715" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_d6f42ac3-4360-4375-aeda-9ff05af44a96" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_d6f42ac3-4360-4375-aeda-9ff05af44a96" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d0abee7-48e0-4d9a-b42f-a6915aafb120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d7859c5-ef60-450e-b85f-57dc30e5ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7a31209-fe8c-4637-82c0-3557e9b34fa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7a31209-fe8c-4637-82c0-3557e9b34fa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember_46d79e26-762e-4097-903e-aaa3ad9c03ff" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:to="loc_pacb_CirculomicsIncMember_46d79e26-762e-4097-903e-aaa3ad9c03ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_b3b34a5a-e0b6-448d-9e7a-be8d80f5d527" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:to="loc_pacb_OmniomeIncMember_b3b34a5a-e0b6-448d-9e7a-be8d80f5d527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonAndOmniomeMember_73f4ce17-f0fb-4e31-997f-a61a0fa786c3" xlink:href="pacb-20231231.xsd#pacb_AptonAndOmniomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:to="loc_pacb_AptonAndOmniomeMember_73f4ce17-f0fb-4e31-997f-a61a0fa786c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284d9af4-fa9d-4a87-b40f-e586f9a076e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_284d9af4-fa9d-4a87-b40f-e586f9a076e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationMember_8b9792ec-3b4b-42f4-a7bb-834059daeab0" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:to="loc_pacb_BusinessCombinationMember_8b9792ec-3b4b-42f4-a7bb-834059daeab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LiquidityBonusEventMember_cd150451-979c-4ea1-a72f-b5e9c752a9b5" xlink:href="pacb-20231231.xsd#pacb_LiquidityBonusEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:to="loc_pacb_LiquidityBonusEventMember_cd150451-979c-4ea1-a72f-b5e9c752a9b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MilestoneAchievementMember_a4ca4351-9adc-4860-a56a-de108f0fd256" xlink:href="pacb-20231231.xsd#pacb_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:to="loc_pacb_MilestoneAchievementMember_a4ca4351-9adc-4860-a56a-de108f0fd256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ba0878f-31db-4f2e-b41f-4ce2e4f8df97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_NetIncomeLoss_8ba0878f-31db-4f2e-b41f-4ce2e4f8df97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_3d09dd5c-ef87-4602-9cbd-d503604abc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_GainLossOnContractTermination_3d09dd5c-ef87-4602-9cbd-d503604abc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bb44c3cf-b52b-4cf1-a360-5a23247f8b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_Depreciation_bb44c3cf-b52b-4cf1-a360-5a23247f8b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_c194942a-010d-4e20-a8ee-59119da7fac4" xlink:href="pacb-20231231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_c194942a-010d-4e20-a8ee-59119da7fac4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_13e4248e-77d7-4655-9a15-ac882a12651b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_13e4248e-77d7-4655-9a15-ac882a12651b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1bd4b8b2-a4cf-4757-9345-3c36336a8861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_ShareBasedCompensation_1bd4b8b2-a4cf-4757-9345-3c36336a8861" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_8d422af2-cafb-462c-b08f-9c15adbd7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_8d422af2-cafb-462c-b08f-9c15adbd7fee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_83634719-006f-4a8e-98e5-9efa0e927213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_83634719-006f-4a8e-98e5-9efa0e927213" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2cd485fb-7e09-4c16-b489-5a01449a086d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2cd485fb-7e09-4c16-b489-5a01449a086d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_54053b8c-e622-4359-9932-07a3c27f3c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_54053b8c-e622-4359-9932-07a3c27f3c46" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_87ba2f2f-423d-4d59-87f2-8591dcb6d448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_InventoryWriteDown_87ba2f2f-423d-4d59-87f2-8591dcb6d448" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ac30c12-d817-48eb-a046-c5f6dcb90fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ac30c12-d817-48eb-a046-c5f6dcb90fd7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_35b7e07c-6b2a-4d5d-9d30-607b79587e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_35b7e07c-6b2a-4d5d-9d30-607b79587e5b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f77f5fd5-3621-43ff-be1a-64d8de0f7f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f77f5fd5-3621-43ff-be1a-64d8de0f7f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1964d5f0-0a60-4004-8fa0-4a98bbb84941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1964d5f0-0a60-4004-8fa0-4a98bbb84941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a445212-2ee0-4987-8fc3-71a2ae18477b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a445212-2ee0-4987-8fc3-71a2ae18477b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f329fc92-56b9-45c0-9ff1-71afb9c89926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f329fc92-56b9-45c0-9ff1-71afb9c89926" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_daf363cf-dbc2-4bf4-8af2-eeb41d4e25f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_daf363cf-dbc2-4bf4-8af2-eeb41d4e25f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4de245f7-6300-45ab-a778-6942b803fe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4de245f7-6300-45ab-a778-6942b803fe8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bb8c8025-b35c-4a70-8ece-c1ec483678c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_OperatingLeasePayments_bb8c8025-b35c-4a70-8ece-c1ec483678c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability_18bcde45-07a2-4746-a0a3-0e7612edcd49" xlink:href="pacb-20231231.xsd#pacb_IncreaseDecreaseInContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability_18bcde45-07a2-4746-a0a3-0e7612edcd49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_fb73a01b-8028-4464-9643-8fe9617f731d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_fb73a01b-8028-4464-9643-8fe9617f731d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe4cabad-976a-4338-85bb-c9b27145f423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe4cabad-976a-4338-85bb-c9b27145f423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_570f96d0-4a32-49e8-b65d-2316f14077f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_570f96d0-4a32-49e8-b65d-2316f14077f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e38894d6-57a6-43e2-8c28-3b94676961a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e38894d6-57a6-43e2-8c28-3b94676961a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cffd0257-59fe-446f-b94b-ecafbeff42c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cffd0257-59fe-446f-b94b-ecafbeff42c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f540bc72-e71c-4114-a47f-349d66ef9b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f540bc72-e71c-4114-a47f-349d66ef9b75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_26a5597a-01cd-46a1-8326-0bdc3f7c7953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_26a5597a-01cd-46a1-8326-0bdc3f7c7953" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_483f2d9d-bb10-47ed-812b-c96ee6444150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_483f2d9d-bb10-47ed-812b-c96ee6444150" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_73bca135-8d31-4e7a-a641-2d310cba4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_73bca135-8d31-4e7a-a641-2d310cba4ce4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromRepaymentsOfContractTermination_1f32c85d-2be8-470b-a293-d9ef0596c7da" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_pacb_ProceedsFromRepaymentsOfContractTermination_1f32c85d-2be8-470b-a293-d9ef0596c7da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6bea8c00-f573-49d7-8eb3-7624cda45c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6bea8c00-f573-49d7-8eb3-7624cda45c8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_601b9fff-0c1d-4199-a47e-44e5ce97df65" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_601b9fff-0c1d-4199-a47e-44e5ce97df65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ea5e0f71-bae8-4eaa-86c7-59399e549e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ea5e0f71-bae8-4eaa-86c7-59399e549e17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_313bd4f8-78c1-46cf-9a1c-1a74fd103c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_313bd4f8-78c1-46cf-9a1c-1a74fd103c96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7b54e412-3c34-4b14-9949-a4c86d140271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7b54e412-3c34-4b14-9949-a4c86d140271" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_242bf33b-5735-4c81-9778-280d4fdace68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_242bf33b-5735-4c81-9778-280d4fdace68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_55718ad2-0f64-4dfd-8b66-ea28bf05b6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_55718ad2-0f64-4dfd-8b66-ea28bf05b6ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a7218a5-ff23-4399-a211-407e4d29eb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a7218a5-ff23-4399-a211-407e4d29eb2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72fa8192-e517-4679-8ae7-278a099186ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72fa8192-e517-4679-8ae7-278a099186ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05015919-38ce-424c-b71c-47ceb346efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05015919-38ce-424c-b71c-47ceb346efdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_559bfee3-8723-448d-9456-cf37c0658b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a6cf0c1-a720-4479-af7f-f910243eadbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a6cf0c1-a720-4479-af7f-f910243eadbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_86a6051e-9e2c-4ab5-a06f-b8699b6191f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_86a6051e-9e2c-4ab5-a06f-b8699b6191f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6c31e6ca-2e22-4cef-bb3d-73edd748deb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6c31e6ca-2e22-4cef-bb3d-73edd748deb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a92a701b-a964-4e2a-babe-545dd51a1e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6c31e6ca-2e22-4cef-bb3d-73edd748deb8" xlink:to="loc_us-gaap_InterestPaidNet_a92a701b-a964-4e2a-babe-545dd51a1e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TransferOfInventoryToPropertyAndEquipment_22e043e0-cf30-46bc-9ed1-eb304b83ce9f" xlink:href="pacb-20231231.xsd#pacb_TransferOfInventoryToPropertyAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_pacb_TransferOfInventoryToPropertyAndEquipment_22e043e0-cf30-46bc-9ed1-eb304b83ce9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_b5e098fc-79e2-4a05-80cc-f892c0131f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_b5e098fc-79e2-4a05-80cc-f892c0131f31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_48f5dd0b-a55c-475b-a091-4b207ce6bcee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_48f5dd0b-a55c-475b-a091-4b207ce6bcee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_f4832fed-facd-4f07-aea7-d94b09751ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_StockIssued1_f4832fed-facd-4f07-aea7-d94b09751ff4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_1fe22fd6-7fd9-4e06-b572-158c3d3d9e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_NotesIssued1_1fe22fd6-7fd9-4e06-b572-158c3d3d9e24" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:href="pacb-20231231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:href="pacb-20231231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41e6a007-af41-4386-b4e1-2e3d4c8767b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_41e6a007-af41-4386-b4e1-2e3d4c8767b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0f35cd4e-3c1e-4626-9d3b-81711d907299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:to="loc_us-gaap_SalesRevenueNetMember_0f35cd4e-3c1e-4626-9d3b-81711d907299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_decabbbb-0790-4bef-ad86-bd902b05d326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:to="loc_us-gaap_AccountsReceivableMember_decabbbb-0790-4bef-ad86-bd902b05d326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_53d018eb-3ef2-428a-9b85-e306e8e01b77_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:to="loc_srt_NameOfMajorCustomerDomain_53d018eb-3ef2-428a-9b85-e306e8e01b77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:to="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_db7d8233-70b0-47ea-887d-50a31b5b25de" xlink:href="pacb-20231231.xsd#pacb_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:to="loc_pacb_CustomerOneMember_db7d8233-70b0-47ea-887d-50a31b5b25de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_6e0f6aee-1409-4f66-aa4f-9133b23e4796" xlink:href="pacb-20231231.xsd#pacb_DomesticCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:to="loc_pacb_DomesticCustomersMember_6e0f6aee-1409-4f66-aa4f-9133b23e4796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_39349aad-2c7f-4b36-a6c7-76eb914c939a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_39349aad-2c7f-4b36-a6c7-76eb914c939a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2f84804-48d1-4c18-a1c3-05cd92192f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_39349aad-2c7f-4b36-a6c7-76eb914c939a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2f84804-48d1-4c18-a1c3-05cd92192f99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_65f32fab-4a96-41a5-be0b-605ea9839590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_65f32fab-4a96-41a5-be0b-605ea9839590" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4b4af640-faa0-46cc-958f-53507f2ade34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_us-gaap_NumberOfReportableSegments_4b4af640-faa0-46cc-958f-53507f2ade34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_31d59e9d-0c0d-48fe-8b76-bf8af70f9b99" xlink:href="pacb-20231231.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_pacb_StandardProductWarrantyPeriod_31d59e9d-0c0d-48fe-8b76-bf8af70f9b99" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44178573-aa97-4c14-8b25-fc0bbbec3fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44178573-aa97-4c14-8b25-fc0bbbec3fb3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:to="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c614296e-ffd1-40f7-9c12-93c3524e6c16_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:to="loc_srt_RangeMember_c614296e-ffd1-40f7-9c12-93c3524e6c16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:to="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e35d480b-4ab8-4a06-9e10-5b0a2fa1ba94" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:to="loc_srt_MinimumMember_e35d480b-4ab8-4a06-9e10-5b0a2fa1ba94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_968376fe-55a9-48d0-bd31-c11c72fadb9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:to="loc_srt_MaximumMember_968376fe-55a9-48d0-bd31-c11c72fadb9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1c2dc973-03ae-4ced-b703-25df5db7d026_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1c2dc973-03ae-4ced-b703-25df5db7d026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_010381b6-e0cf-4f7d-8a7a-dc77edc8234f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_010381b6-e0cf-4f7d-8a7a-dc77edc8234f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d4806fb1-3e84-4306-8232-fc226ae29d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_EquipmentMember_d4806fb1-3e84-4306-8232-fc226ae29d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4aa9e86a-4e60-484e-bc88-3ada54eeb57f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_ComputerEquipmentMember_4aa9e86a-4e60-484e-bc88-3ada54eeb57f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_59f64fc0-9ca3-43f4-b825-1993f29343de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_59f64fc0-9ca3-43f4-b825-1993f29343de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e75b157b-a779-4b86-81ff-1f4943aed957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e75b157b-a779-4b86-81ff-1f4943aed957" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f1f01b0c-1a17-490e-85ae-7be49e4c44c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44178573-aa97-4c14-8b25-fc0bbbec3fb3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f1f01b0c-1a17-490e-85ae-7be49e4c44c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e306f6b-e17f-4708-9661-676040593dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e306f6b-e17f-4708-9661-676040593dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_ba9a8554-1c8b-40d1-b679-9b3332b5262d" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:to="loc_pacb_AptonMember_ba9a8554-1c8b-40d1-b679-9b3332b5262d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c5247b91-adcd-4d80-8621-6515bf0f7c88" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:to="loc_pacb_OmniomeIncMember_c5247b91-adcd-4d80-8621-6515bf0f7c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember_09568ba2-646f-4e3f-93eb-d3cad6c3712b" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:to="loc_pacb_CirculomicsIncMember_09568ba2-646f-4e3f-93eb-d3cad6c3712b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_02370c0a-d941-497e-8a07-dcc69fb3ab35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_02370c0a-d941-497e-8a07-dcc69fb3ab35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_ca8c9d5a-63cd-4cc7-9b81-b0b8041a3281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_ca8c9d5a-63cd-4cc7-9b81-b0b8041a3281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_b50de746-34f9-4769-bb5d-eccb10561761" xlink:href="pacb-20231231.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ca8c9d5a-63cd-4cc7-9b81-b0b8041a3281" xlink:to="loc_pacb_AchievementOfMilestoneMember_b50de746-34f9-4769-bb5d-eccb10561761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fd963de-ec2a-4692-85b2-bd4f5c310ccb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:to="loc_srt_RangeMember_2fd963de-ec2a-4692-85b2-bd4f5c310ccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3800b0c3-4bc1-4c4b-a608-1a08e9e404fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:to="loc_srt_RangeMember_3800b0c3-4bc1-4c4b-a608-1a08e9e404fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd70ac8c-d62b-4f14-aac5-c4dfc5fccfda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3800b0c3-4bc1-4c4b-a608-1a08e9e404fe" xlink:to="loc_srt_MaximumMember_cd70ac8c-d62b-4f14-aac5-c4dfc5fccfda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_175f6af2-0cd3-4076-88ac-8c9ef6f573f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:to="loc_us-gaap_EquityComponentDomain_175f6af2-0cd3-4076-88ac-8c9ef6f573f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30b1ae13-8e35-41b7-bdc2-2be59cf6d007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:to="loc_us-gaap_EquityComponentDomain_30b1ae13-8e35-41b7-bdc2-2be59cf6d007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_585fd914-eae1-4d97-a72a-3adc7d055ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_30b1ae13-8e35-41b7-bdc2-2be59cf6d007" xlink:to="loc_us-gaap_CommonStockMember_585fd914-eae1-4d97-a72a-3adc7d055ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2c496e3-3547-418a-820f-e658c5e1d4c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2c496e3-3547-418a-820f-e658c5e1d4c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_996b5796-7946-4a6f-a275-c1273e6a9f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_996b5796-7946-4a6f-a275-c1273e6a9f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_a37fc575-7fe5-467a-bd34-f270391049c9" xlink:href="pacb-20231231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_996b5796-7946-4a6f-a275-c1273e6a9f39" xlink:to="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_a37fc575-7fe5-467a-bd34-f270391049c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7d7c6c3b-97ce-4b1d-8b04-9263b4946c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7d7c6c3b-97ce-4b1d-8b04-9263b4946c19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2752554d-19bf-4a9b-9182-3e5d302119fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2752554d-19bf-4a9b-9182-3e5d302119fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51b73982-1a79-4824-a314-d02c814d15e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51b73982-1a79-4824-a314-d02c814d15e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_cd0614ff-4c5d-42bc-b1d8-5e72a0a41581" xlink:href="pacb-20231231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_cd0614ff-4c5d-42bc-b1d8-5e72a0a41581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef7955b9-a40e-4aad-a50f-441e166a87a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef7955b9-a40e-4aad-a50f-441e166a87a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_e5211237-5b71-4d10-be65-368529de3be3" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_e5211237-5b71-4d10-be65-368529de3be3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_eb12b2f2-678f-483b-be0a-ec31c2d82307" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_eb12b2f2-678f-483b-be0a-ec31c2d82307" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_6120fafb-ca4a-4228-8b51-9316dfaafd8c" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_6120fafb-ca4a-4228-8b51-9316dfaafd8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_974dbbf4-c585-4dd3-a352-11e6e80b2f35" xlink:href="pacb-20231231.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_974dbbf4-c585-4dd3-a352-11e6e80b2f35" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e744c160-7ce3-4585-bf5b-e05a21b8fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e744c160-7ce3-4585-bf5b-e05a21b8fe53" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_052eedaf-976b-4e84-98e9-2b9880811bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_052eedaf-976b-4e84-98e9-2b9880811bf5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_79cbfd42-ab5b-4231-83cf-7896d711d5bd" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_79cbfd42-ab5b-4231-83cf-7896d711d5bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_b4a4ea34-8743-4222-a469-b71fb5ae0890" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_b4a4ea34-8743-4222-a469-b71fb5ae0890" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_76aa3ae3-75dd-4c4c-a057-1238fae1d3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_76aa3ae3-75dd-4c4c-a057-1238fae1d3f1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_32889442-550e-4592-9ef6-14b290ccf77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_32889442-550e-4592-9ef6-14b290ccf77c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_76d136a4-79d3-4407-bb5c-2f96fcd1ab03" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_76d136a4-79d3-4407-bb5c-2f96fcd1ab03" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_99afb7db-4198-439b-b8d6-88790aaba9a7" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_99afb7db-4198-439b-b8d6-88790aaba9a7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_09046f05-47d1-419a-bc94-8b2d144b4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_09046f05-47d1-419a-bc94-8b2d144b4fcd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8b8692c9-3072-4871-9768-e23abf7c49b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8b8692c9-3072-4871-9768-e23abf7c49b3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a93837eb-1e14-4fb2-b83b-8547076a6141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a93837eb-1e14-4fb2-b83b-8547076a6141" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f2fffc44-3b3d-47b4-a9ba-9bce6565456f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f2fffc44-3b3d-47b4-a9ba-9bce6565456f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8a192fd8-ef24-4823-b2d1-8df7d7d12b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8a192fd8-ef24-4823-b2d1-8df7d7d12b6f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_8f3c9b07-f2af-40e8-93f7-8efa255b12e7" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_8f3c9b07-f2af-40e8-93f7-8efa255b12e7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_eeee80d1-5a2c-471c-b3fe-e4bb21dc01e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_eeee80d1-5a2c-471c-b3fe-e4bb21dc01e5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8679932f-ce54-495a-b3fa-7c234555e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8679932f-ce54-495a-b3fa-7c234555e8fc" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_fe5a7d66-643a-4829-a97c-22605e603018" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_fe5a7d66-643a-4829-a97c-22605e603018" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_a118d56d-6221-4e45-9ce8-69a85f159265" xlink:href="pacb-20231231.xsd#pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_a118d56d-6221-4e45-9ce8-69a85f159265" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b124a303-ac99-4327-9050-a33489d32d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b124a303-ac99-4327-9050-a33489d32d76" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_48f156f5-b1fd-4149-acba-d630d5122d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_48f156f5-b1fd-4149-acba-d630d5122d52" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d6c3af06-8b8f-4ea9-a2f7-db5d131ba05f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d6c3af06-8b8f-4ea9-a2f7-db5d131ba05f" xlink:type="arc" order="29"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de34c95d-1394-43f0-8dc3-5fcb0b3b27df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de34c95d-1394-43f0-8dc3-5fcb0b3b27df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_994db344-1ac5-4e6f-922f-b866a15a2f13" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:to="loc_pacb_AptonMember_994db344-1ac5-4e6f-922f-b866a15a2f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_30027585-9146-430a-8cbc-e4be257542ec" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:to="loc_pacb_OmniomeIncMember_30027585-9146-430a-8cbc-e4be257542ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember_037e667b-58a0-45f9-9c8d-585af780ca3d" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:to="loc_pacb_CirculomicsIncMember_037e667b-58a0-45f9-9c8d-585af780ca3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0d83c809-2378-4a73-934d-1ce7fbb11ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0d83c809-2378-4a73-934d-1ce7fbb11ce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b5841c1f-4513-4b16-ada3-14597f62b225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b5841c1f-4513-4b16-ada3-14597f62b225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_591e3178-8306-4410-9f11-37e1e3f936ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_Goodwill_591e3178-8306-4410-9f11-37e1e3f936ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_af5ae18d-0be1-4db7-961d-de01801a3482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_af5ae18d-0be1-4db7-961d-de01801a3482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9b9b6463-c48c-481e-8392-7242d624c8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9b9b6463-c48c-481e-8392-7242d624c8a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d4db633b-835a-4d96-b26c-8f120c7ddb92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d4db633b-835a-4d96-b26c-8f120c7ddb92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e389c578-370a-4efa-8337-6f54ee374e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e389c578-370a-4efa-8337-6f54ee374e48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_310e5f25-ac0e-4239-a670-8b57a141fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_310e5f25-ac0e-4239-a670-8b57a141fef1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_aadf35cb-7f23-4750-8dbc-1832ae5a5918" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_aadf35cb-7f23-4750-8dbc-1832ae5a5918" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_46db87cc-d400-4fc9-b3b2-f15ad39969b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_46db87cc-d400-4fc9-b3b2-f15ad39969b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3baf6d4f-4b21-4d59-a576-dc9ef5e30d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3baf6d4f-4b21-4d59-a576-dc9ef5e30d31" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557af35e-404a-4d84-8c22-fb28bab5d180_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_557af35e-404a-4d84-8c22-fb28bab5d180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6b6c033-e4c0-4e54-9ef3-e07f09009e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6b6c033-e4c0-4e54-9ef3-e07f09009e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c6a9a515-fce3-4a7e-b222-f770a82af1f5" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6b6c033-e4c0-4e54-9ef3-e07f09009e2b" xlink:to="loc_pacb_OmniomeIncMember_c6a9a515-fce3-4a7e-b222-f770a82af1f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f1a88f35-bff6-4b5e-bf26-453fcca54619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f1a88f35-bff6-4b5e-bf26-453fcca54619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d3a20eab-945b-43b9-a443-41ed5a5e99b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d3a20eab-945b-43b9-a443-41ed5a5e99b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_73f3ffb6-5ef1-47f4-9dfd-faded44be23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_73f3ffb6-5ef1-47f4-9dfd-faded44be23a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fad9e945-01fc-4824-a486-0e7ddfe7bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fad9e945-01fc-4824-a486-0e7ddfe7bdf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73f56c93-ae05-4711-b11e-815f4aa03b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73f56c93-ae05-4711-b11e-815f4aa03b69" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db201b63-61f1-4f7b-a78e-efea376d2342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db201b63-61f1-4f7b-a78e-efea376d2342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_d084eb26-6195-400d-86dc-4b956f03a11d" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db201b63-61f1-4f7b-a78e-efea376d2342" xlink:to="loc_pacb_OmniomeIncMember_d084eb26-6195-400d-86dc-4b956f03a11d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3b6fdce9-09f5-452f-85e0-a73ed163cee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3b6fdce9-09f5-452f-85e0-a73ed163cee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b52bc2a3-f887-4765-8782-0df9611bf25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b52bc2a3-f887-4765-8782-0df9611bf25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_083e88db-f074-4495-a6a4-7e85ffd06297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_083e88db-f074-4495-a6a4-7e85ffd06297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_483f5fef-f23f-4e1b-a0ba-14edb2aff178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_483f5fef-f23f-4e1b-a0ba-14edb2aff178" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INVITAECOLLABORATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:href="pacb-20231231.xsd#pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:to="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_332f6b79-bf37-4de1-a216-2c804810a6b6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_332f6b79-bf37-4de1-a216-2c804810a6b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1353d9ea-a8b9-4db7-8bf4-547867002a58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_1353d9ea-a8b9-4db7-8bf4-547867002a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember_6d73c86e-3ec6-486b-b281-bde2de3afbe2" xlink:href="pacb-20231231.xsd#pacb_InvitaeCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1353d9ea-a8b9-4db7-8bf4-547867002a58" xlink:to="loc_pacb_InvitaeCorporationMember_6d73c86e-3ec6-486b-b281-bde2de3afbe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:to="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d836f42-fa08-4c69-96b3-146ba69468ad_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:to="loc_srt_ProductsAndServicesDomain_0d836f42-fa08-4c69-96b3-146ba69468ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5eb56d2-1ace-40ac-a8f5-a7d660cf2971" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:to="loc_srt_ProductsAndServicesDomain_e5eb56d2-1ace-40ac-a8f5-a7d660cf2971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_946ea379-b7ff-4622-ba6c-e1a3eb81a68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5eb56d2-1ace-40ac-a8f5-a7d660cf2971" xlink:to="loc_us-gaap_ProductMember_946ea379-b7ff-4622-ba6c-e1a3eb81a68e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmountOfAgreementPaymentReceivedUponExecution_2797d668-cf56-4f8c-b283-b7755ace907a" xlink:href="pacb-20231231.xsd#pacb_AmountOfAgreementPaymentReceivedUponExecution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_pacb_AmountOfAgreementPaymentReceivedUponExecution_2797d668-cf56-4f8c-b283-b7755ace907a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cefe1c2a-a97d-4f5d-a100-60c9ebfad6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cefe1c2a-a97d-4f5d-a100-60c9ebfad6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f9036c3-503b-45e8-aff2-f171cdaf165a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f9036c3-503b-45e8-aff2-f171cdaf165a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6937ae96-9a7d-4f3b-a2e0-43fcd0b54a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6937ae96-9a7d-4f3b-a2e0-43fcd0b54a1c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:to="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_57e592ab-5639-4bc3-af2e-181bf4ac62a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_57e592ab-5639-4bc3-af2e-181bf4ac62a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f20e8163-9148-4bc2-a579-707198dd49dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f20e8163-9148-4bc2-a579-707198dd49dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_7676c5d9-33cb-46d8-8f24-b5f58a29d762" xlink:href="pacb-20231231.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f20e8163-9148-4bc2-a579-707198dd49dc" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_7676c5d9-33cb-46d8-8f24-b5f58a29d762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:to="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d9cf5c75-aa39-4a80-8336-c75db2fff0a7_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:to="loc_dei_EntityDomain_d9cf5c75-aa39-4a80-8336-c75db2fff0a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ba4635a6-b3f8-48fb-a451-7a3fff7a48ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:to="loc_dei_EntityDomain_ba4635a6-b3f8-48fb-a451-7a3fff7a48ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IlluminaFcOpsCorpMember_ceff0221-8a27-4a6d-aefb-f9bc4bd4e658" xlink:href="pacb-20231231.xsd#pacb_IlluminaFcOpsCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ba4635a6-b3f8-48fb-a451-7a3fff7a48ef" xlink:to="loc_pacb_IlluminaFcOpsCorpMember_ceff0221-8a27-4a6d-aefb-f9bc4bd4e658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_59f84cef-0bd6-4542-b844-70200edaada1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_us-gaap_GainLossOnContractTermination_59f84cef-0bd6-4542-b844-70200edaada1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_c940499e-74b5-4566-bbe5-8860d1dcba9d" xlink:href="pacb-20231231.xsd#pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_c940499e-74b5-4566-bbe5-8860d1dcba9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_6261c9dd-c9b0-4adc-867d-af596cd4b7a9" xlink:href="pacb-20231231.xsd#pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_6261c9dd-c9b0-4adc-867d-af596cd4b7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_e2f8d3e0-7929-4a2d-aaba-6bfebeee974d" xlink:href="pacb-20231231.xsd#pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_e2f8d3e0-7929-4a2d-aaba-6bfebeee974d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_198874a6-e574-401a-8cc0-8b4784ef0457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_198874a6-e574-401a-8cc0-8b4784ef0457" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11e06fbd-8580-4b2b-b43c-68cc265b1488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11e06fbd-8580-4b2b-b43c-68cc265b1488" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b51375aa-2fdf-4797-a217-e03bada693d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b51375aa-2fdf-4797-a217-e03bada693d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_59c36c6a-a4cf-464d-bf43-c5d852a72beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_59c36c6a-a4cf-464d-bf43-c5d852a72beb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a948f409-f543-4061-84b8-0c805451d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a948f409-f543-4061-84b8-0c805451d96d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f6f6264a-aed3-41d3-adeb-d0d96555e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f6f6264a-aed3-41d3-adeb-d0d96555e4e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_52985d16-bd3c-426f-be7b-cd39e26b515c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_52985d16-bd3c-426f-be7b-cd39e26b515c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_58b6eafb-d29b-4efc-8d95-66098172abdb" xlink:href="pacb-20231231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_58b6eafb-d29b-4efc-8d95-66098172abdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_42ec69fb-049a-4ec8-8ca8-61684257cde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:to="loc_us-gaap_CommercialPaperMember_42ec69fb-049a-4ec8-8ca8-61684257cde0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_516edccb-769f-4c9b-b649-84ee6fd67d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_516edccb-769f-4c9b-b649-84ee6fd67d0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:to="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f4ccf277-5ae9-4c51-be53-6491edd5da32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f4ccf277-5ae9-4c51-be53-6491edd5da32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3d0d5914-faed-49ae-9994-b5b8b78f0611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3d0d5914-faed-49ae-9994-b5b8b78f0611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_cc5d917a-45bc-4516-a369-61dcfdb5bf27" xlink:href="pacb-20231231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_cc5d917a-45bc-4516-a369-61dcfdb5bf27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6911c9b2-402b-4261-8bb9-9538cbb70791_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6911c9b2-402b-4261-8bb9-9538cbb70791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_77728139-1be6-4456-b68d-4ec2d23c76ed" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:to="loc_pacb_OmniomeIncMember_77728139-1be6-4456-b68d-4ec2d23c76ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_2a6a6045-09f7-42cc-a9e4-c402f89a50ae" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:to="loc_pacb_AptonMember_2a6a6045-09f7-42cc-a9e4-c402f89a50ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:to="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f5829ef7-9bb6-485a-ab07-15dd6c2ddd51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f5829ef7-9bb6-485a-ab07-15dd6c2ddd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3bc4ebc1-7f8d-49fd-9f3f-68d4f5791ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_3bc4ebc1-7f8d-49fd-9f3f-68d4f5791ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_7036ce23-1e7e-4240-924b-4885ea30cb1a" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_7036ce23-1e7e-4240-924b-4885ea30cb1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_c7418d38-5c04-4c06-b4b8-252705cb315f" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_c7418d38-5c04-4c06-b4b8-252705cb315f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d6a2180b-2656-4deb-a662-c1adbe58c806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d6a2180b-2656-4deb-a662-c1adbe58c806" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:to="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9e66c6-053f-4d88-9b15-00f9dd386188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9e66c6-053f-4d88-9b15-00f9dd386188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cb3635cd-221b-4a3c-b2e8-1c3f4825447a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_cb3635cd-221b-4a3c-b2e8-1c3f4825447a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:href="pacb-20231231.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:href="pacb-20231231.xsd#pacb_FinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:to="loc_srt_RangeMember_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:to="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44c16c6e-ac10-4243-af7b-684950b8ba87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:to="loc_srt_MinimumMember_44c16c6e-ac10-4243-af7b-684950b8ba87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6be19c8-ed2b-4c04-a715-6cb94ac097cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:to="loc_srt_MaximumMember_f6be19c8-ed2b-4c04-a715-6cb94ac097cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_943378e3-35c3-4524-a081-170ef87ec56f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_943378e3-35c3-4524-a081-170ef87ec56f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_6ff200a3-23b8-46fe-8800-93fccd428968" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:to="loc_pacb_OmniomeIncMember_6ff200a3-23b8-46fe-8800-93fccd428968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_85335896-a6f2-4add-bffa-37729e1c7158" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:to="loc_pacb_AptonMember_85335896-a6f2-4add-bffa-37729e1c7158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796b6965-d39c-4ba0-af51-10604bf6f3a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796b6965-d39c-4ba0-af51-10604bf6f3a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_157159fa-cfed-4e40-9640-cf243d217215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:to="loc_us-gaap_CommonStockMember_157159fa-cfed-4e40-9640-cf243d217215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0eb0360-133a-4a32-ba88-5a370a332015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0eb0360-133a-4a32-ba88-5a370a332015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_006188b5-3277-42e5-bcf2-77d2b25842c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:to="loc_us-gaap_ValuationTechniqueDomain_006188b5-3277-42e5-bcf2-77d2b25842c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_62f79a33-e047-4cb7-8368-b9208824d2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:to="loc_us-gaap_ValuationTechniqueDomain_62f79a33-e047-4cb7-8368-b9208824d2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_b4c580de-6b20-4729-8b1f-4663aa6a3d99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_62f79a33-e047-4cb7-8368-b9208824d2e5" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_b4c580de-6b20-4729-8b1f-4663aa6a3d99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7b539bd6-25fe-490e-a198-1212d7d7bd62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7b539bd6-25fe-490e-a198-1212d7d7bd62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_39055154-27d8-481f-9fb1-a7a4955b020c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_39055154-27d8-481f-9fb1-a7a4955b020c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6a063605-e501-4463-9583-583b35d227af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_39055154-27d8-481f-9fb1-a7a4955b020c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6a063605-e501-4463-9583-583b35d227af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_e1a0d024-7a60-4422-a057-860acfa1e3da" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_e1a0d024-7a60-4422-a057-860acfa1e3da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5c402b8b-ef1a-4239-b6ae-1df857b255d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5c402b8b-ef1a-4239-b6ae-1df857b255d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5e672c0-9b08-43a1-aa55-c49dbcfc42e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5e672c0-9b08-43a1-aa55-c49dbcfc42e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c2ec9b5b-b0ca-4f57-9a34-7901bd224a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c2ec9b5b-b0ca-4f57-9a34-7901bd224a07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_68e6b53e-1d44-44ff-a6de-33d91937d910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_68e6b53e-1d44-44ff-a6de-33d91937d910" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_63050780-493a-41f0-a5cb-7e8a34b7e9b1" xlink:href="pacb-20231231.xsd#pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_63050780-493a-41f0-a5cb-7e8a34b7e9b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9b114751-42f5-4537-ad46-72593e84b563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9b114751-42f5-4537-ad46-72593e84b563" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_a879e73f-3bb5-41df-bd61-92db663c5f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_a879e73f-3bb5-41df-bd61-92db663c5f13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_f6418800-05bf-4e28-bf57-acdc62110ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_InvestmentIncomeNet_f6418800-05bf-4e28-bf57-acdc62110ac3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_22d4d015-99b0-469b-b756-78144f498eb1" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_22d4d015-99b0-469b-b756-78144f498eb1" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18d9c63a-2780-41e7-bb80-bcdc7483ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18d9c63a-2780-41e7-bb80-bcdc7483ef85" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a0d0534-931a-4580-885b-b6ba79e76a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a0d0534-931a-4580-885b-b6ba79e76a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c34c093b-e76f-44fb-b3ba-db1312bfcba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a0d0534-931a-4580-885b-b6ba79e76a5c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c34c093b-e76f-44fb-b3ba-db1312bfcba9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18d9c63a-2780-41e7-bb80-bcdc7483ef85" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_392dd0d1-b781-4673-8fff-8da32806bc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_392dd0d1-b781-4673-8fff-8da32806bc6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_022eb11f-be95-4e46-a385-5c5008f1a593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_022eb11f-be95-4e46-a385-5c5008f1a593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_98c92960-2275-495d-85b2-2e42819a845a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_98c92960-2275-495d-85b2-2e42819a845a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5b7db529-e355-463b-81cf-ee7433ff6a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5b7db529-e355-463b-81cf-ee7433ff6a3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_744383cf-7eb3-4afd-b3c0-90cdbf1d5455" xlink:href="pacb-20231231.xsd#pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_744383cf-7eb3-4afd-b3c0-90cdbf1d5455" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ee0ac79-d146-467a-a4b1-2dd2e273cb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:href="pacb-20231231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:to="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_ede14b13-1c67-49a8-a0e8-20c843b7e56b" xlink:href="pacb-20231231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_ede14b13-1c67-49a8-a0e8-20c843b7e56b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14d87449-5e54-450b-9759-71a54fbff382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:to="loc_us-gaap_CommercialPaperMember_14d87449-5e54-450b-9759-71a54fbff382" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_536483c5-1e89-44b1-a08b-45c33961f610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_536483c5-1e89-44b1-a08b-45c33961f610" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:to="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_17d1f718-752e-4e50-a436-83a25410527c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_17d1f718-752e-4e50-a436-83a25410527c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b3636fb2-08d3-4601-b3ae-76fcb078f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b3636fb2-08d3-4601-b3ae-76fcb078f1a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_6fbc91cb-adf8-438b-99b1-35c67015d664" xlink:href="pacb-20231231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_6fbc91cb-adf8-438b-99b1-35c67015d664" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashMember_4e6dac46-a0e6-4eb9-bab1-0ac6733f3242" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:to="loc_pacb_ShortTermRestrictedCashMember_4e6dac46-a0e6-4eb9-bab1-0ac6733f3242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashMember_b3d0ca77-16f7-4df3-8fe8-5e651039513a" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:to="loc_pacb_LongTermRestrictedCashMember_b3d0ca77-16f7-4df3-8fe8-5e651039513a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b4e58d-51a9-4b96-9f8a-c355025e34aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b4e58d-51a9-4b96-9f8a-c355025e34aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c16e5c4e-ee1b-4b05-9889-5d0614a36656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c16e5c4e-ee1b-4b05-9889-5d0614a36656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f65670ff-bab3-43a6-a4b0-2af56bab0542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f65670ff-bab3-43a6-a4b0-2af56bab0542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fccf307e-bd62-4284-87b5-ada5eeb38081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fccf307e-bd62-4284-87b5-ada5eeb38081" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1eeb6aac-65d7-4686-b802-5f6aa825ab8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1eeb6aac-65d7-4686-b802-5f6aa825ab8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LaboratoryEquipmentAndMachineryMember_a9608073-4bcb-407d-a38c-43d1b983014e" xlink:href="pacb-20231231.xsd#pacb_LaboratoryEquipmentAndMachineryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_pacb_LaboratoryEquipmentAndMachineryMember_a9608073-4bcb-407d-a38c-43d1b983014e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a8e56d2e-8c67-44dc-8bdf-4f4f4927a0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a8e56d2e-8c67-44dc-8bdf-4f4f4927a0c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_6135d659-1d40-4657-8ff4-7fd93aca454d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_ComputerEquipmentMember_6135d659-1d40-4657-8ff4-7fd93aca454d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_323ad257-52d4-4a49-bf62-3c6db4a86a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_323ad257-52d4-4a49-bf62-3c6db4a86a77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_48a6f469-a686-4828-b7c8-efc75acef0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_48a6f469-a686-4828-b7c8-efc75acef0c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_469bf743-f6f6-4750-b4e6-4a6ad7f25e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_ConstructionInProgressMember_469bf743-f6f6-4750-b4e6-4a6ad7f25e77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5163d999-9be7-479c-b4ca-fd08561e1f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5163d999-9be7-479c-b4ca-fd08561e1f90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5321567b-05a4-4fde-b2ff-b2b59bdff633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5321567b-05a4-4fde-b2ff-b2b59bdff633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5dca4c1b-28cd-4181-814a-f725b2ee2b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5dca4c1b-28cd-4181-814a-f725b2ee2b71" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:href="pacb-20231231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bfc271b9-e5f9-4243-8c28-c8a2f686e21b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:to="loc_srt_ProductsAndServicesDomain_bfc271b9-e5f9-4243-8c28-c8a2f686e21b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4952c52a-6987-4471-9a9d-d76e239d025d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:to="loc_srt_ProductsAndServicesDomain_4952c52a-6987-4471-9a9d-d76e239d025d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3a3e8a96-9503-4e77-b439-6ee9a315223d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4952c52a-6987-4471-9a9d-d76e239d025d" xlink:to="loc_us-gaap_ServiceMember_3a3e8a96-9503-4e77-b439-6ee9a315223d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_9916c03e-90cf-4924-852d-0cc52c837655" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:to="loc_pacb_OmniomeIncMember_9916c03e-90cf-4924-852d-0cc52c837655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_96fd137a-7f24-4867-ad35-97ee98df6738" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:to="loc_pacb_AptonMember_96fd137a-7f24-4867-ad35-97ee98df6738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba91c527-4e96-4d92-9512-5f7ffa4f4345_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba91c527-4e96-4d92-9512-5f7ffa4f4345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2a923460-9b98-40f8-802f-e6e0f3f6c4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2a923460-9b98-40f8-802f-e6e0f3f6c4d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_b3bf5ada-efe0-412d-a205-a5041f9063b9" xlink:href="pacb-20231231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2a923460-9b98-40f8-802f-e6e0f3f6c4d7" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_b3bf5ada-efe0-412d-a205-a5041f9063b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0d8a8f56-9911-4f63-8f01-778de1686b9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0d8a8f56-9911-4f63-8f01-778de1686b9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember_f902e068-8a72-4efe-bbc5-39bd225d1df6" xlink:href="pacb-20231231.xsd#pacb_CostOfRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:to="loc_pacb_CostOfRevenueMember_f902e068-8a72-4efe-bbc5-39bd225d1df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_a7db1268-2fe6-4734-a0d5-94372dd9aaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:to="loc_us-gaap_OperatingExpenseMember_a7db1268-2fe6-4734-a0d5-94372dd9aaff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a6603d79-56c3-466d-a8f2-5d33937b97a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_Depreciation_a6603d79-56c3-466d-a8f2-5d33937b97a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4d30116c-f107-47ce-8a0a-9da73c89c798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_Goodwill_4d30116c-f107-47ce-8a0a-9da73c89c798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3a53267-8815-4275-bc6e-88bb0235e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3a53267-8815-4275-bc6e-88bb0235e4b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f86efea-e44c-468e-a07a-58aa006b5c62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f86efea-e44c-468e-a07a-58aa006b5c62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b2692b24-dfd9-4bc8-bf90-edd68485d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b2692b24-dfd9-4bc8-bf90-edd68485d5b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_ef3c4e8e-f56b-472e-b45b-dbd503fe79be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_AdjustmentForAmortization_ef3c4e8e-f56b-472e-b45b-dbd503fe79be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e49c0488-02d3-442e-b489-b2946abc5e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e49c0488-02d3-442e-b489-b2946abc5e5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_394f7367-5d37-440f-bd1d-75a01aa25017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_394f7367-5d37-440f-bd1d-75a01aa25017" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c793609-63eb-48b8-ad59-5d1c95eb4e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c793609-63eb-48b8-ad59-5d1c95eb4e16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf59216b-f5f0-4653-a742-6aa16c2b0452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf59216b-f5f0-4653-a742-6aa16c2b0452" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_84e72260-7828-4480-a9cc-b7279128e9e8" xlink:href="pacb-20231231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_84e72260-7828-4480-a9cc-b7279128e9e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_12f10c08-c950-4b91-890e-c05b3d8ff227" xlink:href="pacb-20231231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentReclassification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_12f10c08-c950-4b91-890e-c05b3d8ff227" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fcbb16eb-f54f-4a3b-b977-c96d2742e8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fcbb16eb-f54f-4a3b-b977-c96d2742e8bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_11977a41-3afa-4dd1-898e-1bb79744358b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_11977a41-3afa-4dd1-898e-1bb79744358b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9c15a74a-6c07-4516-afb5-c46b5c225024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9c15a74a-6c07-4516-afb5-c46b5c225024" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_71ba51dd-34da-47da-8d81-429e7d164aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_DebtInstrumentTerm_71ba51dd-34da-47da-8d81-429e7d164aba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5e7c9a-387c-4acc-99f4-c53705f8bbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5e7c9a-387c-4acc-99f4-c53705f8bbb8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt_320e9531-6b6a-41a7-8533-440399db39ee" xlink:href="pacb-20231231.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_PercentageOfFeeToPrepayDebt_320e9531-6b6a-41a7-8533-440399db39ee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_4f13e6bf-f6d8-4a15-80a5-d1facdfbee12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_NotesPayable_4f13e6bf-f6d8-4a15-80a5-d1facdfbee12" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_00b01620-933b-4724-ba07-2f7ca3db6e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_InterestExpenseBorrowings_00b01620-933b-4724-ba07-2f7ca3db6e89" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1ffd05a4-2ff7-4f9c-ab5a-a6d646ff231a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1ffd05a4-2ff7-4f9c-ab5a-a6d646ff231a" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b76115f-0717-41ec-9109-884a6777e114_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b76115f-0717-41ec-9109-884a6777e114_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_8f96676d-1db7-4f8a-8ad8-d79f0024e990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_8f96676d-1db7-4f8a-8ad8-d79f0024e990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_baace4aa-d45f-4a14-9ab3-7ada42a94222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:to="loc_us-gaap_CustomerRelationshipsMember_baace4aa-d45f-4a14-9ab3-7ada42a94222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2cd8e2c-c3a7-4077-b710-1ab919e4206f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2cd8e2c-c3a7-4077-b710-1ab919e4206f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1bb4007-5a44-40bb-bcc8-8f7b924dfaed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1bb4007-5a44-40bb-bcc8-8f7b924dfaed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0be38e01-1081-48c4-807e-e22e14fbf980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0be38e01-1081-48c4-807e-e22e14fbf980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268b1419-1f9f-4f94-beb5-3218e95719b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268b1419-1f9f-4f94-beb5-3218e95719b1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_79ba1ba4-b0d0-48d4-b755-c889f7b040f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_79ba1ba4-b0d0-48d4-b755-c889f7b040f5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59e77672-e17e-4328-ba83-64a1e1617d92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59e77672-e17e-4328-ba83-64a1e1617d92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f8053e6-63d0-46e1-ac21-87a1976efc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f8053e6-63d0-46e1-ac21-87a1976efc08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_9124816b-07d5-4408-97d5-0c7b55d55e9b" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f8053e6-63d0-46e1-ac21-87a1976efc08" xlink:to="loc_pacb_OmniomeIncMember_9124816b-07d5-4408-97d5-0c7b55d55e9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_79ba1ba4-b0d0-48d4-b755-c889f7b040f5" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df3b53ce-8ce3-4886-bb21-72a7ecf5d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df3b53ce-8ce3-4886-bb21-72a7ecf5d0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d28ff87-35d9-460f-a697-7067b41c5e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:to="loc_us-gaap_LongTermDebt_6d28ff87-35d9-460f-a697-7067b41c5e01" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1b67d8d2-12cc-417b-8a30-46831f8eade9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1b67d8d2-12cc-417b-8a30-46831f8eade9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_591f2fcb-3a90-4547-9c63-5497de26bacc" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_591f2fcb-3a90-4547-9c63-5497de26bacc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_6b50d31d-cafd-42cb-9116-4a33f4515530" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_6b50d31d-cafd-42cb-9116-4a33f4515530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_70223711-23e7-44dd-9e77-1a66e1ce6dfc" xlink:href="pacb-20231231.xsd#pacb_ExchangeTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_ExchangeTransactionMember_70223711-23e7-44dd-9e77-1a66e1ce6dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_a80a7f7e-ef9a-4eb5-b074-2b9807857fee" xlink:href="pacb-20231231.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_a80a7f7e-ef9a-4eb5-b074-2b9807857fee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_aa2e1018-3480-44a7-bf8a-0dddde182414_default" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_aa2e1018-3480-44a7-bf8a-0dddde182414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_25c9efa8-a05f-4756-a043-53785f15ad87" xlink:href="pacb-20231231.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:to="loc_pacb_DebtConversionTermsOneMember_25c9efa8-a05f-4756-a043-53785f15ad87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_88c10815-bca4-4fc6-a13e-1d3fa823051a" xlink:href="pacb-20231231.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:to="loc_pacb_DebtConversionTermsTwoMember_88c10815-bca4-4fc6-a13e-1d3fa823051a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ad899174-56ce-43a2-a1b5-4def402316ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ad899174-56ce-43a2-a1b5-4def402316ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a2c5435c-3ead-45be-810c-31ecaa78682b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a2c5435c-3ead-45be-810c-31ecaa78682b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_eec10506-bd49-4a5f-a96b-abeab8144d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a2c5435c-3ead-45be-810c-31ecaa78682b" xlink:to="loc_us-gaap_ConvertibleDebtMember_eec10506-bd49-4a5f-a96b-abeab8144d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_120842a6-7ee2-4877-9caf-31e7055e6a7b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:to="loc_srt_RangeMember_120842a6-7ee2-4877-9caf-31e7055e6a7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:to="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_00832f48-de90-4fd6-8ff4-7093c500a676" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:to="loc_srt_MinimumMember_00832f48-de90-4fd6-8ff4-7093c500a676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e87320f-c7a4-4bf9-adea-45b14f9061dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:to="loc_srt_MaximumMember_5e87320f-c7a4-4bf9-adea-45b14f9061dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_538da044-bc29-488f-bf35-2fe718cac1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_538da044-bc29-488f-bf35-2fe718cac1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bd62c893-94ef-473d-b3bc-dc6271513e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bd62c893-94ef-473d-b3bc-dc6271513e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_85242e63-5e29-4b6d-a013-3485b71cfc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_85242e63-5e29-4b6d-a013-3485b71cfc73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cf2a4e4e-eb05-4d65-8c5a-399ea73b6540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cf2a4e4e-eb05-4d65-8c5a-399ea73b6540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_adc2d2b2-99ac-43c2-ae62-fa9491c02868" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_adc2d2b2-99ac-43c2-ae62-fa9491c02868" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_77d3bdd1-89e7-4528-a7fa-222417d0505b" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_77d3bdd1-89e7-4528-a7fa-222417d0505b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_43f1b774-5810-4fdc-a023-c310cf6ebf00" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_43f1b774-5810-4fdc-a023-c310cf6ebf00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bf1db934-1f8d-427b-b2f5-68a31063540c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bf1db934-1f8d-427b-b2f5-68a31063540c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_1f68c22d-a63a-4ea2-a19a-ee304812b8a2" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_1f68c22d-a63a-4ea2-a19a-ee304812b8a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_d4ca5b1f-ec34-4d9c-bf0a-84b46c522f83" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_d4ca5b1f-ec34-4d9c-bf0a-84b46c522f83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_868e1adb-de5f-4200-b07b-bb72469956dc" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_868e1adb-de5f-4200-b07b-bb72469956dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_93da360d-2ba9-4235-aea7-d79c950fe9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_93da360d-2ba9-4235-aea7-d79c950fe9d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e49acd30-ad85-4f30-8320-10a9e065365b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e49acd30-ad85-4f30-8320-10a9e065365b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_92aeda80-a170-4d8e-bf15-235afd4ec0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_92aeda80-a170-4d8e-bf15-235afd4ec0c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_e196af1a-2548-40d0-8ca6-32ced7e3b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_e196af1a-2548-40d0-8ca6-32ced7e3b8c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d3cd1137-0f52-4c56-86ba-69d3a25e7272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_LongTermDebt_d3cd1137-0f52-4c56-86ba-69d3a25e7272" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_06af1150-f21a-4e8a-bdac-c56caf2cd756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_06af1150-f21a-4e8a-bdac-c56caf2cd756" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed08d072-e37a-463a-9346-ab569f34d1a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed08d072-e37a-463a-9346-ab569f34d1a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_2bc547b4-3434-4d43-b1cf-2fed72bca1fb" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_2bc547b4-3434-4d43-b1cf-2fed72bca1fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_98472a39-21d9-46cc-a114-64c2c248e0ea" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_98472a39-21d9-46cc-a114-64c2c248e0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4211dbb4-f5d6-4aca-b7c6-1fdfa6a30a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4211dbb4-f5d6-4aca-b7c6-1fdfa6a30a4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_ab534fcc-75b8-4f08-8a4c-bc54815686fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_ab534fcc-75b8-4f08-8a4c-bc54815686fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_c3edf00c-3cfb-4c2a-b40c-b89b8138d0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_c3edf00c-3cfb-4c2a-b40c-b89b8138d0b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b6172922-8b77-4817-b9b3-1929ec0a0645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_LongTermDebt_b6172922-8b77-4817-b9b3-1929ec0a0645" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:to="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7209dda8-3122-4172-b4a7-966824b06940_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7209dda8-3122-4172-b4a7-966824b06940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_7835afc5-17de-45b5-bb06-9f260c4b54d8" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_7835afc5-17de-45b5-bb06-9f260c4b54d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_f1e23448-1ca8-45b7-82d5-b2854593f026" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_f1e23448-1ca8-45b7-82d5-b2854593f026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_80d04504-5743-40ea-bb01-cd19ae5a63fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_80d04504-5743-40ea-bb01-cd19ae5a63fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4485ad63-5b35-4113-b603-b65d142c9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4485ad63-5b35-4113-b603-b65d142c9cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b4e493c3-9c58-41f1-babd-39aed85efda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_InterestExpenseDebt_b4e493c3-9c58-41f1-babd-39aed85efda3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:href="pacb-20231231.xsd#pacb_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:href="pacb-20231231.xsd#pacb_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1599c395-ddd6-4cb9-8b31-19e40613baff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1599c395-ddd6-4cb9-8b31-19e40613baff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02d82b41-a9f7-44a4-bbd5-2142546375b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02d82b41-a9f7-44a4-bbd5-2142546375b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c6df5a28-e32e-4e8d-aadd-f635b889f03a" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02d82b41-a9f7-44a4-bbd5-2142546375b4" xlink:to="loc_pacb_OmniomeIncMember_c6df5a28-e32e-4e8d-aadd-f635b889f03a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6161bc03-71ee-4072-b625-e4543cf28cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6161bc03-71ee-4072-b625-e4543cf28cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56ad7d0f-d057-4b6b-8b56-7280677ec061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56ad7d0f-d057-4b6b-8b56-7280677ec061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8dd579fb-e10c-4de9-a294-9009bd42821b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8dd579fb-e10c-4de9-a294-9009bd42821b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_c13de5d8-5ba5-4b03-bc46-039601aaafae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_PaymentsForRent_c13de5d8-5ba5-4b03-bc46-039601aaafae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_86110f8b-085f-4c14-b68d-25fc198e7fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseCost_86110f8b-085f-4c14-b68d-25fc198e7fb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5ff1aef1-0b20-4699-aea9-afda291f83cb" xlink:href="pacb-20231231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5ff1aef1-0b20-4699-aea9-afda291f83cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_f6e46f2f-7edb-4f1a-9142-061002dbe879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_PurchaseObligation_f6e46f2f-7edb-4f1a-9142-061002dbe879" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_24e8d73d-690a-4608-af10-cae9dc8adc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseLiability_24e8d73d-690a-4608-af10-cae9dc8adc89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f34786d3-9d1c-4619-a25d-df4ef767738d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f34786d3-9d1c-4619-a25d-df4ef767738d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_54a7433e-b93b-420a-808a-c92ee89b6e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_PaymentsForDeposits_54a7433e-b93b-420a-808a-c92ee89b6e68" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5bb0b3ae-f925-464e-9686-2ff078094716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5bb0b3ae-f925-464e-9686-2ff078094716" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_900be459-fc09-41cc-8dfb-27eb2fc2978d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_900be459-fc09-41cc-8dfb-27eb2fc2978d" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a106f1f4-0951-4da1-8da3-f76022d24d0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a106f1f4-0951-4da1-8da3-f76022d24d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_55907a43-bc84-45ec-aa60-0661af1a20da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:to="loc_us-gaap_DomesticCountryMember_55907a43-bc84-45ec-aa60-0661af1a20da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e7194235-fb80-44bf-aef5-aa92afa06d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e7194235-fb80-44bf-aef5-aa92afa06d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_61654fbd-269a-4774-adca-a370b7dc826e" xlink:href="pacb-20231231.xsd#pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_61654fbd-269a-4774-adca-a370b7dc826e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_395fdbf5-e361-426d-abe9-0b8ed6fcc554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_395fdbf5-e361-426d-abe9-0b8ed6fcc554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e3473ee8-2502-478c-ad95-913669a51b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e3473ee8-2502-478c-ad95-913669a51b1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_10671c24-66d7-4d18-ae5e-f9548055765a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_10671c24-66d7-4d18-ae5e-f9548055765a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_c4088453-f90a-42e1-9a6c-2241456504f4" xlink:href="pacb-20231231.xsd#pacb_OperatingLossCarryforwardsAmountSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_c4088453-f90a-42e1-9a6c-2241456504f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_54c81eaa-6805-44ff-ab75-6a94afa10158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_54c81eaa-6805-44ff-ab75-6a94afa10158" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ad6d1de-95ce-4f7e-aa4c-650c7027542f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ad6d1de-95ce-4f7e-aa4c-650c7027542f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b08b7080-945e-4d85-afc3-fbfd720c559b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b08b7080-945e-4d85-afc3-fbfd720c559b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_de4453f1-bed5-4cce-9f62-beee29c29aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_de4453f1-bed5-4cce-9f62-beee29c29aa9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd93b9cf-65ae-4d98-a59a-c7af53f80fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd93b9cf-65ae-4d98-a59a-c7af53f80fbf" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:href="pacb-20231231.xsd#pacb_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:href="pacb-20231231.xsd#pacb_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0203af0c-4a8b-4e8d-bc89-279d08afbc7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:to="loc_us-gaap_EquityComponentDomain_0203af0c-4a8b-4e8d-bc89-279d08afbc7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:to="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PrivatePlacementOfCommonStockMember_2b98dfef-5382-40e7-95d5-3c04a633527e" xlink:href="pacb-20231231.xsd#pacb_PrivatePlacementOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:to="loc_pacb_PrivatePlacementOfCommonStockMember_2b98dfef-5382-40e7-95d5-3c04a633527e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7c8fa692-7284-4eaf-aa0b-338f3b6b46bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:to="loc_us-gaap_CommonStockMember_7c8fa692-7284-4eaf-aa0b-338f3b6b46bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_3d2e6307-0a81-4873-a9d1-54ad765972b0" xlink:href="pacb-20231231.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_EquityIncentivePlan2020Member_3d2e6307-0a81-4873-a9d1-54ad765972b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InducementEquityIncentivePlan2020Member_66cce5c7-20b4-43a8-90aa-33ee6228cbfc" xlink:href="pacb-20231231.xsd#pacb_InducementEquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_InducementEquityIncentivePlan2020Member_66cce5c7-20b4-43a8-90aa-33ee6228cbfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomePlanMember_4f29e984-5e6f-4796-b97a-b01a9ce310e5" xlink:href="pacb-20231231.xsd#pacb_OmniomePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_OmniomePlanMember_4f29e984-5e6f-4796-b97a-b01a9ce310e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TwoThousandTenEquityIncentivePlanMember_af89e4d2-ed8e-4cbd-83ca-ecc3b0769204" xlink:href="pacb-20231231.xsd#pacb_TwoThousandTenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_TwoThousandTenEquityIncentivePlanMember_af89e4d2-ed8e-4cbd-83ca-ecc3b0769204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_951c5144-8dc6-4c36-8191-74122a003c4a" xlink:href="pacb-20231231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_951c5144-8dc6-4c36-8191-74122a003c4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_947a5fd5-fa4b-4494-b97b-af3d591a33a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_947a5fd5-fa4b-4494-b97b-af3d591a33a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_78ce0d5e-69fd-48ee-aa48-1d9b3285e28a" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_78ce0d5e-69fd-48ee-aa48-1d9b3285e28a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_98c680a3-ed0c-41e5-a59a-6e341693e755" xlink:href="pacb-20231231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_98c680a3-ed0c-41e5-a59a-6e341693e755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b4699c3-f0cc-4835-94de-43efa554274a" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b4699c3-f0cc-4835-94de-43efa554274a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_0b4f1316-4bf0-4544-b168-591556bdcdad" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_0b4f1316-4bf0-4544-b168-591556bdcdad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_15976233-ff73-45d2-811e-7360339165ca" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_15976233-ff73-45d2-811e-7360339165ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_746af636-a273-42c4-a962-d85a7053d996_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:to="loc_us-gaap_VestingDomain_746af636-a273-42c4-a962-d85a7053d996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9d757ffd-1d42-4fe1-afa1-ee2b92fa392e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:to="loc_us-gaap_VestingDomain_9d757ffd-1d42-4fe1-afa1-ee2b92fa392e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_2d6095eb-5047-471c-a8b3-3f58fdbd5553" xlink:href="pacb-20231231.xsd#pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9d757ffd-1d42-4fe1-afa1-ee2b92fa392e" xlink:to="loc_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_2d6095eb-5047-471c-a8b3-3f58fdbd5553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicStockOfferingMember_e00c5620-3b96-4667-b8f2-662113d69de6" xlink:href="pacb-20231231.xsd#pacb_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:to="loc_pacb_PublicStockOfferingMember_e00c5620-3b96-4667-b8f2-662113d69de6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember_ec20ee9d-ef6e-4ab1-901c-3de88fe760c3" xlink:href="pacb-20231231.xsd#pacb_ShelfOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:to="loc_pacb_ShelfOfferingMember_ec20ee9d-ef6e-4ab1-901c-3de88fe760c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_aa9dfd07-38f3-4462-b41d-f1afd105a5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_aa9dfd07-38f3-4462-b41d-f1afd105a5b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_679f4752-5295-42d9-beb2-2c4ee550dec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_679f4752-5295-42d9-beb2-2c4ee550dec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fefb95c1-0d9b-4494-af1b-83f02d1c5acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fefb95c1-0d9b-4494-af1b-83f02d1c5acd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6326bf9c-ef5c-40a5-bb62-9cd5d1bad6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6326bf9c-ef5c-40a5-bb62-9cd5d1bad6ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f7cd836a-d371-4ccf-9f89-4c1f2fcc719a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f7cd836a-d371-4ccf-9f89-4c1f2fcc719a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2091fa8c-aaf1-4c68-bf1b-add4756679e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2091fa8c-aaf1-4c68-bf1b-add4756679e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_406ca7e0-9da1-432b-a124-e2dd10b457a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_406ca7e0-9da1-432b-a124-e2dd10b457a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights_0f7146ec-c8bb-44a5-a73e-17ef5582d496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockVotingRights_0f7146ec-c8bb-44a5-a73e-17ef5582d496" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_d2e528eb-3362-43dd-b146-63dd7fed580e" xlink:href="pacb-20231231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_d2e528eb-3362-43dd-b146-63dd7fed580e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares_18afb409-738c-41b8-bfb4-2d913cb36c34" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PublicOfferingShares_18afb409-738c-41b8-bfb4-2d913cb36c34" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum_4e8a9a9c-7596-474b-9c74-eeca753c628f" xlink:href="pacb-20231231.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_OfferingShareAmountMaximum_4e8a9a9c-7596-474b-9c74-eeca753c628f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_622a1655-90dd-4cee-9dd6-3f7f8f7117fe" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_622a1655-90dd-4cee-9dd6-3f7f8f7117fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_5aeca26a-49a7-4944-ab93-496de8e3f1b3" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_5aeca26a-49a7-4944-ab93-496de8e3f1b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a591156a-c28d-48ee-95f0-aae5cd2f52dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a591156a-c28d-48ee-95f0-aae5cd2f52dd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_803b6bfd-c303-4d54-8103-ff54165a5fcb" xlink:href="pacb-20231231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_803b6bfd-c303-4d54-8103-ff54165a5fcb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_b9617559-0501-42a2-b1b3-884776a571da" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_b9617559-0501-42a2-b1b3-884776a571da" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_eb27108d-9162-4ed6-a9e9-9c7c9c8f440a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_DeferredOfferingCosts_eb27108d-9162-4ed6-a9e9-9c7c9c8f440a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfOfferings_df090453-22f2-4c8e-b909-73bb09938462" xlink:href="pacb-20231231.xsd#pacb_NumberOfOfferings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_NumberOfOfferings_df090453-22f2-4c8e-b909-73bb09938462" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_a666da38-cd55-4ff8-93d8-0f7c16aef165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_a666da38-cd55-4ff8-93d8-0f7c16aef165" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ba8d6e8-85a1-49a2-9f18-339ce211671e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ba8d6e8-85a1-49a2-9f18-339ce211671e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_67b8d239-7514-451d-86a7-e8c31c3343e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_67b8d239-7514-451d-86a7-e8c31c3343e2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1a69290f-af01-4290-a0be-67e17092377f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockSharesIssued_1a69290f-af01-4290-a0be-67e17092377f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3094304a-c030-4bab-bf64-f64ac0cd1a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3094304a-c030-4bab-bf64-f64ac0cd1a97" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_090b9bf0-3132-4e4a-bb97-5b4cfb567188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_090b9bf0-3132-4e4a-bb97-5b4cfb567188" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e889373f-e6a6-41e7-9f22-bcc81d8c56cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e889373f-e6a6-41e7-9f22-bcc81d8c56cf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeRatio_3f979a97-c250-4a6e-a336-68e31e1a9dae" xlink:href="pacb-20231231.xsd#pacb_ExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ExchangeRatio_3f979a97-c250-4a6e-a336-68e31e1a9dae" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af033f52-24a4-4d6a-8213-864e69fb588d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af033f52-24a4-4d6a-8213-864e69fb588d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_dd999f36-2419-4808-89ba-ba32473772ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharePrice_dd999f36-2419-4808-89ba-ba32473772ce" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5471f1ac-8d1c-4f4c-8706-5249ad3cd129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5471f1ac-8d1c-4f4c-8706-5249ad3cd129" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_509910fd-7ffe-4984-95d1-df8af66a0d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_509910fd-7ffe-4984-95d1-df8af66a0d1c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_34cf27f4-3a46-4b0b-93da-81ac26948f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_34cf27f4-3a46-4b0b-93da-81ac26948f95" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_083d3e16-ed7c-44b3-96ee-cbd96e3027be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_083d3e16-ed7c-44b3-96ee-cbd96e3027be" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8c5315bf-c805-453a-937a-1989cdad7ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8c5315bf-c805-453a-937a-1989cdad7ef2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c69f75a-a443-45c9-a84e-f45e6c54b6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c69f75a-a443-45c9-a84e-f45e6c54b6c5" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41a42c23-537f-48ff-86f0-9063569c2e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41a42c23-537f-48ff-86f0-9063569c2e26" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d83ae64b-b537-4d6d-a5f5-1a2bfccbadb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d83ae64b-b537-4d6d-a5f5-1a2bfccbadb3" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2101f82d-2b65-4c27-8795-11f7d7af968b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2101f82d-2b65-4c27-8795-11f7d7af968b" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_002a484e-cca3-4025-b521-6331abc80268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_002a484e-cca3-4025-b521-6331abc80268" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5515afd6-a5a0-4107-9a36-43d1434ea93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5515afd6-a5a0-4107-9a36-43d1434ea93d" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f189d077-7f34-444d-aeea-1a154c6d1d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f189d077-7f34-444d-aeea-1a154c6d1d40" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_8d59f60c-69bb-4b80-b66f-947c177957a4" xlink:href="pacb-20231231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_8d59f60c-69bb-4b80-b66f-947c177957a4" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55fd0960-c8e5-41fb-84b9-50b69d7f3321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55fd0960-c8e5-41fb-84b9-50b69d7f3321" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c89c092e-1278-4533-8154-912be9690d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c89c092e-1278-4533-8154-912be9690d90" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_69665528-984e-4cbd-b2d0-1ab1fd9453c1" xlink:href="pacb-20231231.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_69665528-984e-4cbd-b2d0-1ab1fd9453c1" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_32a98dd8-2a30-4c3c-99bb-eddc6fffaff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_32a98dd8-2a30-4c3c-99bb-eddc6fffaff9" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da02b2a0-6172-44f2-91a1-040225b2c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da02b2a0-6172-44f2-91a1-040225b2c5c9" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfPurchasePeriods_e9b7a462-fac9-4c47-b93b-5988809c665b" xlink:href="pacb-20231231.xsd#pacb_NumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_NumberOfPurchasePeriods_e9b7a462-fac9-4c47-b93b-5988809c665b" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_611e796a-7bee-4c28-a956-14a04bd3d8e0" xlink:href="pacb-20231231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_611e796a-7bee-4c28-a956-14a04bd3d8e0" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_34080944-ea69-422a-95fb-a4bad606fc70" xlink:href="pacb-20231231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_34080944-ea69-422a-95fb-a4bad606fc70" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2972fec1-07f1-43da-afa4-2fd296460f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2972fec1-07f1-43da-afa4-2fd296460f42" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_e8aac78f-c110-497e-aade-be8005b7c500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_e8aac78f-c110-497e-aade-be8005b7c500" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5285e9f2-d54c-4289-9cc9-45050a29ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5285e9f2-d54c-4289-9cc9-45050a29ec95" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_675aa9cf-e904-45ce-b247-d54ebe3b64cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_675aa9cf-e904-45ce-b247-d54ebe3b64cc" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_efb00435-11f9-4d7c-9b7c-bf5803751821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_efb00435-11f9-4d7c-9b7c-bf5803751821" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f49f9a4-f5cb-4875-a416-8598f76afd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f49f9a4-f5cb-4875-a416-8598f76afd9e" xlink:type="arc" order="54"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:to="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_b882c911-9dc0-4d2a-9742-52bddf60b080" xlink:href="pacb-20231231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:to="loc_pacb_TimeBasedStockOptionMember_b882c911-9dc0-4d2a-9742-52bddf60b080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bd14b166-ef91-4437-8c2d-8adc795246bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:to="loc_us-gaap_PerformanceSharesMember_bd14b166-ef91-4437-8c2d-8adc795246bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_b60b7efc-a4f8-456d-aa8e-40cb43ec23be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_b60b7efc-a4f8-456d-aa8e-40cb43ec23be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_7796ae81-7698-4e2a-aeb7-d7dbb52ec983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_7796ae81-7698-4e2a-aeb7-d7dbb52ec983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomePlanMember_c55977a3-7521-4801-b31b-720012ec92fd" xlink:href="pacb-20231231.xsd#pacb_OmniomePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_7796ae81-7698-4e2a-aeb7-d7dbb52ec983" xlink:to="loc_pacb_OmniomePlanMember_c55977a3-7521-4801-b31b-720012ec92fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f903be-c640-448f-a240-db1802bdf321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f903be-c640-448f-a240-db1802bdf321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7110bdf5-2064-4630-bbd5-b655239629b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7110bdf5-2064-4630-bbd5-b655239629b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e3c7b0d-33b4-4ea5-a8c4-e9bc1d920951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e3c7b0d-33b4-4ea5-a8c4-e9bc1d920951" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5270e5c8-b557-4c71-9446-7a806b4770bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5270e5c8-b557-4c71-9446-7a806b4770bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f9e072f-8435-488e-865c-88315ace2c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b33a2221-3a89-4860-ba4c-abd5dafdcec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b33a2221-3a89-4860-ba4c-abd5dafdcec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1f648cec-44d7-4981-8fb9-b0c4abb2a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1f648cec-44d7-4981-8fb9-b0c4abb2a60c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42fa7105-cb2f-48bb-9dc4-6ec62315ec58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42fa7105-cb2f-48bb-9dc4-6ec62315ec58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_76c9fbf7-0713-462e-9201-f1081a79b507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_76c9fbf7-0713-462e-9201-f1081a79b507" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6d415dfd-430c-4c10-a2ad-849bf7be463f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6d415dfd-430c-4c10-a2ad-849bf7be463f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d25fd01f-0fff-4e12-923b-38bf9ebc048c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:to="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfeba494-b55b-40de-921d-b7e097e40b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfeba494-b55b-40de-921d-b7e097e40b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_7bf89ddc-60cd-4f8a-9562-dd3fd116b524" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_7bf89ddc-60cd-4f8a-9562-dd3fd116b524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_107dfe7f-93ed-4edd-b2b2-8610e0126e99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:to="loc_us-gaap_PerformanceSharesMember_107dfe7f-93ed-4edd-b2b2-8610e0126e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4191ee79-657b-419f-a209-c0110bbe3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4191ee79-657b-419f-a209-c0110bbe3ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4bff193-1f99-46d3-8739-a9fc6126da00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4bff193-1f99-46d3-8739-a9fc6126da00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99555c46-d620-42d8-aa57-cbaba213811e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99555c46-d620-42d8-aa57-cbaba213811e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2e0f06a-c350-4603-9166-64249f5d789e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2e0f06a-c350-4603-9166-64249f5d789e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c2b45e9-c5e7-45df-8ae7-54364a5a7ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad00512-b827-426a-a81b-460c57970483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad00512-b827-426a-a81b-460c57970483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3fe443d2-d9a9-48e8-b7bc-fa61955f92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3fe443d2-d9a9-48e8-b7bc-fa61955f92ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cb274ce2-e8f2-48e8-9b47-0e596ef0a464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cb274ce2-e8f2-48e8-9b47-0e596ef0a464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e7effe0-c4f6-41d3-9190-3800aced2539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e7effe0-c4f6-41d3-9190-3800aced2539" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5af0ec-d85b-4d39-8f5a-cc710ebfd757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f37d15b7-ad02-4ce6-8669-51a98621fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f37d15b7-ad02-4ce6-8669-51a98621fb9a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8dbe677-3e93-4a40-ac74-661f462f2901_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8dbe677-3e93-4a40-ac74-661f462f2901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_27748b4c-268b-46b7-a97c-4122c0b6dd04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_us-gaap_CostOfSalesMember_27748b4c-268b-46b7-a97c-4122c0b6dd04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7c7f075-1857-4847-8ecc-08dffdf791ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7c7f075-1857-4847-8ecc-08dffdf791ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eac60fef-274c-43bc-a7f9-617071b13432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eac60fef-274c-43bc-a7f9-617071b13432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesStockSettledMember_928e32e1-9502-49c8-aa67-c65d83b36323" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesStockSettledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_MergerRelatedExpensesStockSettledMember_928e32e1-9502-49c8-aa67-c65d83b36323" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesMilestoneMember_9e11e76c-1e83-47e5-a33e-4d14da25facb" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_MergerRelatedExpensesMilestoneMember_9e11e76c-1e83-47e5-a33e-4d14da25facb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_4d03d8a2-f62a-4c05-9cee-bc5c49a01452" xlink:href="pacb-20231231.xsd#pacb_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_StockBasedCompensationMember_4d03d8a2-f62a-4c05-9cee-bc5c49a01452" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesCashSettledMember_2ec2fc51-3d75-411b-b489-0ea68c325359" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesCashSettledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_MergerRelatedExpensesCashSettledMember_2ec2fc51-3d75-411b-b489-0ea68c325359" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f7192022-1a0b-444b-beb7-a254b810cf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f37d15b7-ad02-4ce6-8669-51a98621fb9a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f7192022-1a0b-444b-beb7-a254b810cf1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:to="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44c979a-3dbf-4c91-b730-0762fab1d6ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44c979a-3dbf-4c91-b730-0762fab1d6ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb9fe654-5323-4129-8426-40b6416b66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb9fe654-5323-4129-8426-40b6416b66e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_060d0af3-4ce2-4e25-b340-1e5f339a772f" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb9fe654-5323-4129-8426-40b6416b66e8" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_060d0af3-4ce2-4e25-b340-1e5f339a772f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:to="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96a46ae4-a867-455d-b135-d0a16e7ec4fe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:to="loc_srt_RangeMember_96a46ae4-a867-455d-b135-d0a16e7ec4fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:to="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7fb57334-36d3-435c-82b3-41a5d407beb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:to="loc_srt_MinimumMember_7fb57334-36d3-435c-82b3-41a5d407beb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ea1f466-9b4c-492e-a2a5-e747541f6341" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:to="loc_srt_MaximumMember_0ea1f466-9b4c-492e-a2a5-e747541f6341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4717ebf-9250-4023-8186-1f87a54fb247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4717ebf-9250-4023-8186-1f87a54fb247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b55bf9ff-e0ac-49e1-b8d9-8fb57429724c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b55bf9ff-e0ac-49e1-b8d9-8fb57429724c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2b81e957-75a5-4fd8-9786-ad3905061286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2b81e957-75a5-4fd8-9786-ad3905061286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_48e38492-b171-40cd-9433-f5a4e8015ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_48e38492-b171-40cd-9433-f5a4e8015ff1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8c0d0b51-3aef-43f3-bcfe-2c9a1d1ba4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8c0d0b51-3aef-43f3-bcfe-2c9a1d1ba4d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82cc9882-38fb-4ced-b049-c51c9a40a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82cc9882-38fb-4ced-b049-c51c9a40a94a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_95403652-ccc0-4413-b429-865e7170a3dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_95403652-ccc0-4413-b429-865e7170a3dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_33c29cb5-7b2e-4c11-b7e3-bd78f9e18eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_33c29cb5-7b2e-4c11-b7e3-bd78f9e18eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_d8b126f9-13c8-4d22-86b6-377942bdc186" xlink:href="pacb-20231231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_33c29cb5-7b2e-4c11-b7e3-bd78f9e18eb8" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_d8b126f9-13c8-4d22-86b6-377942bdc186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:to="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_497b2a4c-9bfe-4117-b439-510c4968860e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:to="loc_srt_RangeMember_497b2a4c-9bfe-4117-b439-510c4968860e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:to="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a4773f8-4714-4f94-9869-6fe2a5072a70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:to="loc_srt_MinimumMember_4a4773f8-4714-4f94-9869-6fe2a5072a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef6291e4-7341-4ad5-a6d4-893e72716b80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:to="loc_srt_MaximumMember_ef6291e4-7341-4ad5-a6d4-893e72716b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3bd07397-6712-43b1-8a3b-3047365753ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3bd07397-6712-43b1-8a3b-3047365753ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03d53171-c139-4e6a-98bd-e8cc7e5533f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03d53171-c139-4e6a-98bd-e8cc7e5533f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_87d5d926-8a88-477e-8b4e-f09d43d505d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_87d5d926-8a88-477e-8b4e-f09d43d505d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a5150215-fe66-49d1-8f5a-6727c4512da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a5150215-fe66-49d1-8f5a-6727c4512da5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_180ec03e-b17b-4dcf-a103-6c33a803344e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_180ec03e-b17b-4dcf-a103-6c33a803344e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af92e8e7-a3ac-4263-80fa-2376def305a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af92e8e7-a3ac-4263-80fa-2376def305a4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bf7be14c-00fa-4134-8899-6ffa5a7b8fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bf7be14c-00fa-4134-8899-6ffa5a7b8fc2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f64d95a9-aaf4-4537-b793-79255397c99a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f64d95a9-aaf4-4537-b793-79255397c99a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_c15687a3-bcb1-468f-a71d-2d522b655708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_c15687a3-bcb1-468f-a71d-2d522b655708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_52db9430-4568-4e99-89a4-876bffe8863a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:to="loc_us-gaap_StockCompensationPlanMember_52db9430-4568-4e99-89a4-876bffe8863a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cb6f4a0-29da-4ba6-b7e9-ef80ea710e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bf7be14c-00fa-4134-8899-6ffa5a7b8fc2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cb6f4a0-29da-4ba6-b7e9-ef80ea710e83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5bf7799d-bc3e-4dc4-b7a7-e074de8cf2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5bf7799d-bc3e-4dc4-b7a7-e074de8cf2b0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:to="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_25b3ac1d-f146-45a6-9699-3651818a1823_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:to="loc_srt_SegmentGeographicalDomain_25b3ac1d-f146-45a6-9699-3651818a1823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:to="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_21f95aae-30fa-4b06-9139-9948f4b66dba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:to="loc_srt_NorthAmericaMember_21f95aae-30fa-4b06-9139-9948f4b66dba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d774e393-6e18-4874-b991-f2fd8fa7827d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:to="loc_srt_EuropeMember_d774e393-6e18-4874-b991-f2fd8fa7827d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_c6e8b36e-ece7-44ba-8557-020ab9799ec2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:to="loc_srt_AsiaPacificMember_c6e8b36e-ece7-44ba-8557-020ab9799ec2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d7f70e67-7dd1-4cdc-aea0-24380a1486ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5bf7799d-bc3e-4dc4-b7a7-e074de8cf2b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d7f70e67-7dd1-4cdc-aea0-24380a1486ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_947cd09a-34f4-434d-88b4-9d9c1d25b7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_947cd09a-34f4-434d-88b4-9d9c1d25b7cf" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:to="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40f481a4-687b-434b-988d-4272d9781ca5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:to="loc_srt_ProductsAndServicesDomain_40f481a4-687b-434b-988d-4272d9781ca5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:to="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:to="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_2c5d0869-cb3a-4844-ab58-a9555d1eaf00" xlink:href="pacb-20231231.xsd#pacb_InstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:to="loc_pacb_InstrumentMember_2c5d0869-cb3a-4844-ab58-a9555d1eaf00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_64418298-2676-4c77-9f37-d5fe62bb3b44" xlink:href="pacb-20231231.xsd#pacb_ConsumableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:to="loc_pacb_ConsumableMember_64418298-2676-4c77-9f37-d5fe62bb3b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_5bfa544a-ddb5-4a4d-a4a9-99930b1897ec" xlink:href="pacb-20231231.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:to="loc_pacb_ServiceAndOtherMember_5bfa544a-ddb5-4a4d-a4a9-99930b1897ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6549e420-f7a4-40c2-a8de-8b56994efe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_947cd09a-34f4-434d-88b4-9d9c1d25b7cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6549e420-f7a4-40c2-a8de-8b56994efe5f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_2b2da49b-19f9-4281-8aeb-a6d57933a58d" xlink:href="pacb-20231231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_2b2da49b-19f9-4281-8aeb-a6d57933a58d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_d24119b9-187e-425d-9994-2b07391be747" xlink:href="pacb-20231231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedStockOptionMember_d24119b9-187e-425d-9994-2b07391be747" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_c09774d5-c3b2-4612-b26d-9ab65504f23f" xlink:href="pacb-20231231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_c09774d5-c3b2-4612-b26d-9ab65504f23f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_7e349ab0-d060-44f4-963a-c55331284790" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_7e349ab0-d060-44f4-963a-c55331284790" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_fd6dea1c-24fd-43d9-b358-b3655251c527" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_fd6dea1c-24fd-43d9-b358-b3655251c527" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_d1ad3b89-b63e-4ff7-b16f-e0b6c0618c3c" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_d1ad3b89-b63e-4ff7-b16f-e0b6c0618c3c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_fcc758f6-33a7-44cb-ba63-db3583bbfb07" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_fcc758f6-33a7-44cb-ba63-db3583bbfb07" xlink:type="arc" order="12"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>pacb-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4809e9eb-ee6c-40c5-b267-06eb948f47bd,g:8f5aae7b-78f1-4a80-ad95-b1556c05246b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_787930a9-c503-4342-b111-1885ebe1db2c_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units Rsus [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f79ad859-b58d-4037-9169-10a98181ee4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_05fee65e-a470-492b-9112-ffd4ff28407a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_201112f1-a5ff-4ed4-8d47-10f122647069_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ada4d8af-b05d-47d0-a412-3b80934394f2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_83576daf-ef64-4360-8c60-d933df5fea1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f4e1ef51-1852-4f2b-861f-63b91d850def_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_63d3a131-9317-49f3-97a6-77a01e982772_terseLabel_en-US" xlink:label="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Stock Purchase Plan</link:label>
    <link:label id="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_label_en-US" xlink:label="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Stock Purchase Plan Liability, Current</link:label>
    <link:label id="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_documentation_en-US" xlink:label="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Stock Purchase Plan Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:href="pacb-20231231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:to="lab_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_d21ba9fa-fd9d-4ce0-a154-1da830a99ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue by Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b99a7523-2e3d-4113-8d41-466fcbb1ec2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c622ab16-d649-417b-b1d3-52dcb3278da8_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium and accretion of discount on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8ef1834b-1462-4340-bfe0-d1d9ce8cd530_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5c9b8096-760d-4579-bfd8-f2f26c9a374f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Classes of Assets and Liabilities Allocated to Total Fair Value of The Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerTerminationAbstract_b705d800-99c7-4869-bdcf-dbafb37a7639_terseLabel_en-US" xlink:label="lab_pacb_MergerTerminationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of Merger with Illumina [Abstract]</link:label>
    <link:label id="lab_pacb_MergerTerminationAbstract_label_en-US" xlink:label="lab_pacb_MergerTerminationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of Merger with Illumina [Abstract]</link:label>
    <link:label id="lab_pacb_MergerTerminationAbstract_documentation_en-US" xlink:label="lab_pacb_MergerTerminationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationAbstract" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerTerminationAbstract" xlink:to="lab_pacb_MergerTerminationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_65d93dc5-0f77-406f-a584-2f6fc30ffa48_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units PSU [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cc641b9e-a81b-4dcd-a3ee-b239fb49d165_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_64e98090-9662-4501-8d0c-39d1fd7b9e77_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_9c7fb7bd-8603-47cc-b0de-c61a4337a6fd_terseLabel_en-US" xlink:label="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of benefit realized upon settlement uncertain tax position</link:label>
    <link:label id="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_label_en-US" xlink:label="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Of Benefit Realized Upon Settlement Uncertain Tax Position</link:label>
    <link:label id="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_documentation_en-US" xlink:label="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of benefit Realized Upon Settlement Uncertain Tax Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:href="pacb-20231231.xsd#pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:to="lab_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_006c9b58-5179-45bf-95d9-769746265f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_9b3b37d9-e552-4b72-8d42-9015c589731b_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4f2db604-d68c-4b4f-9357-de04d476b354_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_ff01df5c-f0de-443a-a532-ef3b58645348_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_624b465c-5909-4715-82dc-8b0bf4922556_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e453df57-f309-45cf-814d-37ed6bb4e358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_dcb50325-6e0d-474f-bf4a-c0d27c7cc2ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory provision</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ExchangeTransactionMember_4f63c6e3-7a74-4dad-a1e8-fe2b58c10389_terseLabel_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Transaction</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_label_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Transaction [Member]</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_documentation_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember" xlink:href="pacb-20231231.xsd#pacb_ExchangeTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ExchangeTransactionMember" xlink:to="lab_pacb_ExchangeTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_0c194660-253d-4897-a098-62b279bd93ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repairs and replacements</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_af71e615-39d4-4d6e-b2f0-ba4026210b13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e590b569-d349-4e12-b408-f058abbe75e2_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1e8ae340-e85c-4447-a7fa-efb173f07169_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5cf94c80-7a9d-4d17-bd48-67c75f7df3cc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_68345844-3ac3-4d63-acb3-6591821ecbbf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized 50,000 shares; No shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b34b0587-cc8e-4b9a-9196-718675ebfbe2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_48bbc5e3-1495-4935-838d-8802a2f8b878_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net (loss) income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_c449b7d0-caa4-4f4d-b0bb-9b981d84b30d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e325e038-83fd-4d42-a12d-e764e11e224b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AccruedTenantImprovementsCurrent_8c5e4257-a3db-4b1a-878a-cd9b020635f3_terseLabel_en-US" xlink:label="lab_pacb_AccruedTenantImprovementsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_pacb_AccruedTenantImprovementsCurrent_label_en-US" xlink:label="lab_pacb_AccruedTenantImprovementsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Tenant Improvements, Current</link:label>
    <link:label id="lab_pacb_AccruedTenantImprovementsCurrent_documentation_en-US" xlink:label="lab_pacb_AccruedTenantImprovementsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Tenant Improvements, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedTenantImprovementsCurrent" xlink:href="pacb-20231231.xsd#pacb_AccruedTenantImprovementsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AccruedTenantImprovementsCurrent" xlink:to="lab_pacb_AccruedTenantImprovementsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_bb55623d-1753-4f90-8520-75ec118b732d_terseLabel_en-US" xlink:label="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_label_en-US" xlink:label="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Contingent Consideration, Revenue Achievement Milestone</link:label>
    <link:label id="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_documentation_en-US" xlink:label="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Contingent Consideration, Revenue Achievement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:href="pacb-20231231.xsd#pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:to="lab_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_32ad07ba-cc2b-4c8c-9539-989e6993b412_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48d35d0d-36b2-4e13-94ff-799d1c8c6e23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c5ff42e7-432c-4f15-867d-4b2c5fd3a4bd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ec6232e4-d7ad-413a-8bfd-8b8d767009ad_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_b7945f95-5a4d-479d-8dbb-e9e215d57047_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9a08c94d-92fa-45de-a3d5-e8870a2767cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_673f9370-d93d-4667-981c-ee3c1af48f44_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefit Accounts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_15e9aaa0-7aba-4fd5-b9c3-6f43ec10d13e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_64887d17-345f-4de7-a9d6-bce85f2505ef_terseLabel_en-US" xlink:label="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche One, Two, Three and Four</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_label_en-US" xlink:label="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Award Tranche One Two Three And Four [Member]</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_documentation_en-US" xlink:label="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche One, Two, Three and Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:href="pacb-20231231.xsd#pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:to="lab_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_bd055d04-2670-4c7c-8f0d-aadbce20034d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a843cb6e-73e2-4f56-8038-b2b32de3cd6b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_9e674b96-27b0-43a9-8b4b-5a0c0fadc899_terseLabel_en-US" xlink:label="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_label_en-US" xlink:label="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards [Policy Text Block]</link:label>
    <link:label id="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_documentation_en-US" xlink:label="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:href="pacb-20231231.xsd#pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:to="lab_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_39f85715-8388-49ea-a406-68b2c65ccd44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d9619567-0c48-4e15-b403-c0257380933d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_37d39389-87f9-407b-88f6-e5fcdd894b76_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_abd1872f-9c1a-453a-a674-2c7331fc1b30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f3cab1a3-96ad-4815-a551-1af28929e7f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of The Major Classes of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8c34b55a-bc19-4edf-8cad-71977cdf6c36_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8f354cb4-43a5-4fdc-b108-3fd05169be4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_913c3fff-2c5c-4671-952e-121943c63750_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Eligible Item or Group [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_afdaa508-8d73-4e6e-a811-a0f227607679_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_cee196bf-11d6-49b3-9678-f1eb9afa24de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4b225e2d-47e8-4124-8218-306d401e558e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock remain available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2e191709-6b9c-401b-86e7-c292252e0356_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4348b87f-d391-49bb-9f2d-e4ea0a609bd7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ab6906f0-cd20-4e1d-b0f7-efbeb6e3d98e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a83dfce1-606f-49a1-ae86-64b49c376995_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_782fb38e-7ac3-4eec-a4f5-ae2f494c8b55_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_NumberOfPurchasePeriods_b4c5c705-72bb-43c9-98af-093d36c0797d_terseLabel_en-US" xlink:label="lab_pacb_NumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase periods</link:label>
    <link:label id="lab_pacb_NumberOfPurchasePeriods_label_en-US" xlink:label="lab_pacb_NumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Purchase Periods</link:label>
    <link:label id="lab_pacb_NumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_pacb_NumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfPurchasePeriods" xlink:href="pacb-20231231.xsd#pacb_NumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_NumberOfPurchasePeriods" xlink:to="lab_pacb_NumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1f3147fe-57ad-4693-949f-ce305bcef835_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicStockOfferingMember_9c67dc72-b66b-49dc-b34a-f7bffa8ea520_terseLabel_en-US" xlink:label="lab_pacb_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_pacb_PublicStockOfferingMember_label_en-US" xlink:label="lab_pacb_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_pacb_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_pacb_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicStockOfferingMember" xlink:href="pacb-20231231.xsd#pacb_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicStockOfferingMember" xlink:to="lab_pacb_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_92ee5cb7-90a7-4d85-af27-56c92c36a3d9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_6d3aa045-d572-42a1-be28-d345c6a53695_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_5a2fe175-fecd-4bf8-8289-72514487277f_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Principal Payments , Fiscal Year Maturity</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_60c48cb4-aec0-4291-bd2a-4ca55758c8f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_ea3cbdfb-cf37-4859-82ad-083de20d118d_terseLabel_en-US" xlink:label="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which company must repay continuation advances if change-of-control transaction is entered into with third party</link:label>
    <link:label id="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_label_en-US" xlink:label="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Period in Which Company must Repay Continuation Advances if Change-of-Control Transaction is Entered into with Third Party</link:label>
    <link:label id="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_documentation_en-US" xlink:label="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Period in Which Company must Repay Continuation Advances if Change-of-Control Transaction is Entered into with Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" xlink:href="pacb-20231231.xsd#pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" xlink:to="lab_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_2d7af375-9771-4464-a7ea-e32e44cd3161_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8f829227-6f22-4659-8cde-1b411271a6ab_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_81035589-c34e-45a0-ac97-e4d5331f5c04_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_5301d9ee-9c33-4950-90bf-2dbfaa4be134_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a506f483-c6e2-4fa4-bb8d-818d89a26899_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_edb08443-d85d-4703-8adc-2c1ee2d7744d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9850f04b-0e73-4b0c-863f-116e83b8caca_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1ba07f51-b64c-49ed-af63-ce5a36ced0e1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_afa7860b-d6bf-47c7-95e4-dd54b193a9de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_630eb64a-adf4-4690-bb75-058c927634ce_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7983de6-2f2d-40f6-9ad7-c049046210b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_bee584ea-ef52-4a84-9b74-389686bd4bed_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_061326bd-528d-4d7c-8963-c35b6835ea46_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_da3d71a6-38b0-4743-bef4-1e3885bca6c8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset and liability additions and modifications</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_79e212ca-af20-4681-bc6f-964418ec9ce7_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_719b90c2-51b7-4888-a562-d19928ca4a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_107e6aaa-f817-4a93-819b-b17ab5a114d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_50720623-c7a0-47c9-b73e-3ff794b1c72e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_39f87af9-371c-4a2d-a8fb-a6fb3ee02cf6_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e19a24fd-b9be-4b21-9c71-71605eb71c4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_111e3344-dc3e-4b0f-b442-390a9e2fca41_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e202e428-a55e-4f48-a4cc-b9c455e93952_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6af5b1cc-8f0b-49be-9af7-252b617e09c5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements Pending Adoption</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FinancialInstrumentsTable_d0219f08-c166-42bb-a2c0-d78e0f2f4f7e_terseLabel_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsTable_label_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsTable_documentation_en-US" xlink:label="lab_pacb_FinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable" xlink:href="pacb-20231231.xsd#pacb_FinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FinancialInstrumentsTable" xlink:to="lab_pacb_FinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90d6ce2f-5b18-484b-a3ca-ebd6737ca393_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e3b1ce45-cd10-469b-9395-60f5fc05fd2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_62e278f3-d4a9-4836-8325-432e2c8eab6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before taxes from foreign operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_65fe7e9e-f0c7-401e-a99a-dbaf2a4e491f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_16ef4769-2478-4b23-97f5-939e90931be1_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f9c41b57-6ea8-4d60-8336-e336d27c5a0b_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f8725112-6a02-401b-988f-e7673896d244_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a0a85f4a-af5f-48b0-8a66-cf85c01c7a96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e9d5e425-6e6b-4208-9465-c769338fa0e8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_de8e2ebc-6872-4627-a147-7f55e06d9bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_665f60a7-3c08-4fe5-9f11-f4ec9d22e94b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e2f4f51-7210-425e-8aee-d95fd27093b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cbab0fb0-a3f5-4654-b9f9-3d27d3351822_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a016b335-0071-4ebd-9a6e-a0c7cfa59b2b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f6e45e28-0dc2-40c4-b80b-58d2ab0d8af0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_313a9cf5-5407-4e2a-a0ca-f1c458fc867f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_5884ac01-7bba-43cc-8621-37f506978e6d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, acquired during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AptonAndOmniomeMember_3df19fcc-0270-4bf3-82ca-cca66befd029_terseLabel_en-US" xlink:label="lab_pacb_AptonAndOmniomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apton And Omniome</link:label>
    <link:label id="lab_pacb_AptonAndOmniomeMember_label_en-US" xlink:label="lab_pacb_AptonAndOmniomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apton And Omniome [Member]</link:label>
    <link:label id="lab_pacb_AptonAndOmniomeMember_documentation_en-US" xlink:label="lab_pacb_AptonAndOmniomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apton And Omniome</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonAndOmniomeMember" xlink:href="pacb-20231231.xsd#pacb_AptonAndOmniomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AptonAndOmniomeMember" xlink:to="lab_pacb_AptonAndOmniomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_7e51d9c1-2535-4367-9789-e178c3dacafc_terseLabel_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_label_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_BalanceSheetComponentsLineItems_documentation_en-US" xlink:label="lab_pacb_BalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems" xlink:href="pacb-20231231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BalanceSheetComponentsLineItems" xlink:to="lab_pacb_BalanceSheetComponentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_31769a12-03bf-4860-b49b-bf1dc6ab3dad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_67c7e941-5e7f-48ed-aca1-1305a31084d5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e81449b7-ad88-4d2f-bd90-b6db47896cbf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d6f3bc59-5cd7-4feb-a89b-1e92757a2d11_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_72722b31-9dd4-4211-9909-72ae8ac0cfc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_b81f0981-5b5f-4d06-bd05-298747b520a0_terseLabel_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_label_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_documentation_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:href="pacb-20231231.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:to="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_28aa72c5-3099-4fa0-b416-06f1d4699fe9_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="pacb-20231231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_599cc028-ebea-43b0-af12-516db962a670_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6ddcd582-a5e2-4d24-9404-b194cfc94a23_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_26b6a8ac-6d39-43e3-b565-2448df79b942_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits, current</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_d3039cd3-eec8-41ba-894f-2b89cc48a595_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ff68cc22-fce7-41ca-aa98-79130f377d39_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_539e3bfc-0db9-4159-a52c-3965d1ca2ef0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6a8bcef2-990f-4591-8c46-32cfefb43325_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3a814f89-6360-4f7e-b7e8-b782c81a9c14_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfFeeToPrepayDebt_936a6dab-010f-42a8-990e-822487e1d854_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fee to prepay debt</link:label>
    <link:label id="lab_pacb_PercentageOfFeeToPrepayDebt_label_en-US" xlink:label="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fee to prepay debt</link:label>
    <link:label id="lab_pacb_PercentageOfFeeToPrepayDebt_documentation_en-US" xlink:label="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fee of the outstanding debt to prepay the debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt" xlink:href="pacb-20231231.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfFeeToPrepayDebt" xlink:to="lab_pacb_PercentageOfFeeToPrepayDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_a765b97a-4650-4d6a-9e46-0d66427a8201_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5cdf4b1e-2cae-4cd8-86b0-64096c086bc2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets include acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_f7233a2f-e83a-40d5-95f6-30d1bf702c2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2efb7d8e-2693-4eb4-b2f0-f2c98308f0c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d308b39-5892-4d8b-9e64-5072689094de_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_74f36f3e-0941-413d-b418-6197f9d26ff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da254702-25ac-4aac-9c5c-580fc3102023_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_63a5dffd-a602-4e10-85b9-2603879c5264_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_792c8f89-11a0-4dae-a0fe-db08f6c548d0_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c179c859-5b4d-4a5e-8deb-ebdc093ac292_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation cost capitalized in inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2c8c3173-3718-456e-8198-a5ff2667765a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShortTermRestrictedCashMember_52181c77-a06e-4ae2-841a-41654ac79871_terseLabel_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashMember_label_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Restricted Cash [Member]</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashMember_documentation_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Restricted Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashMember" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShortTermRestrictedCashMember" xlink:to="lab_pacb_ShortTermRestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_935428e5-f9e7-47e0-a384-131f97864ee5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_66117eb6-29a0-417c-8489-f0c277e94e42_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CashCashEquivalentsAndInvestmentsMember_fdc6343a-a401-4959-b61f-945793d91c77_terseLabel_en-US" xlink:label="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and investments</link:label>
    <link:label id="lab_pacb_CashCashEquivalentsAndInvestmentsMember_label_en-US" xlink:label="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments [Member]</link:label>
    <link:label id="lab_pacb_CashCashEquivalentsAndInvestmentsMember_documentation_en-US" xlink:label="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:href="pacb-20231231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:to="lab_pacb_CashCashEquivalentsAndInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_9735c03c-0600-478a-bbf8-40a6972c3525_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0ce2f3cd-631d-4c47-8af2-15d881f05d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_46cae79d-38eb-4a06-a955-ff65919808e3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets, and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5acd0d7c-8b1e-4bac-9ad7-f72cea9d5141_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_673c1a70-fd1a-484b-9903-990e116fc67d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_d9b6a60e-67d7-4083-ae77-fb472a3a6a6c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from Continuation Advances from Illumina</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_1e3f79da-4fb1-4349-b028-2042c087da0b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) from Continuation Advances</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination" xlink:to="lab_us-gaap_GainLossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac3d5b24-4beb-4a75-86ff-8e3f895757db_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_26fb7ce8-4a03-485b-a01f-da57b9cf850d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_6c4d2b03-91fc-4224-9e82-35ad9e87e4e0_terseLabel_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount eligible to vest upon achievement of goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_label_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_documentation_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:href="pacb-20231231.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:to="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_19619a7a-9711-4ee4-ac35-b3851f783252_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption, trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_122de92b-9668-40db-a0f0-ce4769760f7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5dc87568-d6c2-4fa9-aa22-3672f765351b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2eb0e6a1-e1cd-49ff-9059-418b5679e712_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_485af2ea-b0a1-48b7-a512-e012c22ef906_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dd7ad590-390e-4113-be59-225e1d4e549e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2f3be699-5ea0-418e-8a13-185e83043745_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_644f5eb8-c285-4797-9dd3-9ac3db228461_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DomesticCustomersMember_5148f5dd-28d2-40da-a819-96da28c81715_terseLabel_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Customers</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_label_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_documentation_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember" xlink:href="pacb-20231231.xsd#pacb_DomesticCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DomesticCustomersMember" xlink:to="lab_pacb_DomesticCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_bcab2a90-599b-4c09-ae0e-5b774249f316_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_d544eaa8-bf65-4933-ab05-8be02e6cc63f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration and Other Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_00645181-72ef-45fc-836c-7448c2af5d82_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_5ecc4e9d-204d-4106-8e31-bec24bc3d2c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InvitaeCollaborationTextBlock_a08927aa-a85d-48c3-a70d-6a6fa38c0c71_terseLabel_en-US" xlink:label="lab_pacb_InvitaeCollaborationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVITAE COLLABORATION</link:label>
    <link:label id="lab_pacb_InvitaeCollaborationTextBlock_label_en-US" xlink:label="lab_pacb_InvitaeCollaborationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Collaboration [Text Block]</link:label>
    <link:label id="lab_pacb_InvitaeCollaborationTextBlock_documentation_en-US" xlink:label="lab_pacb_InvitaeCollaborationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization Of Significant Agreements Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCollaborationTextBlock" xlink:href="pacb-20231231.xsd#pacb_InvitaeCollaborationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InvitaeCollaborationTextBlock" xlink:to="lab_pacb_InvitaeCollaborationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f144b1d7-a410-41c6-9cb1-a724ed326927_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_655bb6dc-2f91-4e15-8542-ba7a6aa31de8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_139c55a7-4b54-4e58-806c-56f4ffe39433_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d220d60a-2ec0-491c-bb1d-1ffe83d25ea4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d1797af3-5b61-4e1b-9d06-5531e7f9f9d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_25fd49fa-c5cb-4934-9be7-71d71b215216_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with liquidity event bonus plan (in shares)</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:to="lab_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_89fc34ae-a736-4c25-8ff3-fbe22547ceb2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_8cf762e3-569e-4634-81a9-3694c6a4fa59_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Since the date of acquisition, revenues</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_ffd52209-5bcd-48af-ad4d-b0569c48b7d0_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_2d4c305e-e7f5-4b57-be17-0713aff80dc3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_24bdc0ba-18b6-427a-ab2f-bd4c01d53271_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_86ac7435-52df-4d1b-9519-ad739806caba_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashMergerRelatedCosts_95b1bc1b-9226-48b1-b168-a7f15e016f42_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related compensation expense</link:label>
    <link:label id="lab_us-gaap_NoncashMergerRelatedCosts_label_en-US" xlink:label="lab_us-gaap_NoncashMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Merger Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashMergerRelatedCosts" xlink:to="lab_us-gaap_NoncashMergerRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_5c9f3d44-a129-46e7-892e-5ae122bd993b_terseLabel_en-US" xlink:label="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit from reduction in deferred tax assets valuation allowance</link:label>
    <link:label id="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit from reduction in deferred tax assets valuation allowance</link:label>
    <link:label id="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit from reduction in deferred tax assets valuation allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:to="lab_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_f01c7bcd-0a36-4a93-b8d7-826ba90dc57a_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0176c918-7d53-41fd-8c5d-46583beee3e3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_6bb3548f-470f-4b9b-82b4-9902d9611609_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair market value at which stock can be purchased</link:label>
    <link:label id="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_label_en-US" xlink:label="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Fair Market Value At Which Stock Can Be Purchased</link:label>
    <link:label id="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_documentation_en-US" xlink:label="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair market value at which stock can be purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:href="pacb-20231231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:to="lab_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3f8e88fa-cdb5-4bde-af51-65019df785f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services and legal fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_d529b763-f969-4f20-9f58-7e6beecc144d_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CommitmentsAndContingenciesTable_29d85532-ab78-4a8e-b9e1-bf0e89dfd98b_terseLabel_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesTable" xlink:href="pacb-20231231.xsd#pacb_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CommitmentsAndContingenciesTable" xlink:to="lab_pacb_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6270b6d4-d37b-4290-8c21-47bb73063c48_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_ac6612e4-2c5f-46e6-ba62-8436e038dc5f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_115cae1c-526e-4636-a45e-e994efefedd1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0acd67aa-d860-4ac8-abe6-59aff4e51837_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3af056c0-e654-407a-8e7b-1aa2c4e3c545_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance as of December 31, 2022</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cf06a0c0-1fbf-423a-8016-2810f6f29cd1_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance as of December 31, 2023</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_280c397f-5298-4196-bbcc-9e51edd79dd1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_21f8b72f-1bed-4409-82a5-1ccb2812ad26_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_75e05eb9-13f6-42ad-a200-db76de29c64a_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7c8aa01f-5651-49c3-9f91-e146228f22ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d0da1759-4fb2-44a1-aa3f-906ec845310c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0e5a4077-e054-45ac-b1a5-5c59c0e15dd3_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bdbc9fd-c5ea-4671-ad3f-89b86f8ef780_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_79c204eb-1c23-4f23-a97a-ebbbabfaebce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_6a2d82e1-6519-434e-b0bb-93aa78cdb12f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9a8a234-0b38-4367-9352-dec341bf0137_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8f206cf1-cd5f-48b6-8044-f9742ccff2da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9579541e-b609-42f7-b846-8e4bf4adbe44_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_17b79d20-9cb5-4825-8b4f-9ddb1405d331_terseLabel_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember" xlink:href="pacb-20231231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeStockPurchasePlanMember" xlink:to="lab_pacb_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_11a64c0e-9e1a-4eb3-a1ae-3d09e15ca595_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, anniversary</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_label_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:to="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_9101311b-54b3-43ad-b6f8-4a8df6c1d5f4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LongTermRestrictedCashMember_0c042121-2e01-4df8-9c26-6a309cd9599d_terseLabel_en-US" xlink:label="lab_pacb_LongTermRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashMember_label_en-US" xlink:label="lab_pacb_LongTermRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Restricted Cash [Member]</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashMember_documentation_en-US" xlink:label="lab_pacb_LongTermRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Restricted Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashMember" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LongTermRestrictedCashMember" xlink:to="lab_pacb_LongTermRestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_NumberOfOfferings_c3a31caf-031d-41f2-9da1-a78dc259ecd4_terseLabel_en-US" xlink:label="lab_pacb_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offerings</link:label>
    <link:label id="lab_pacb_NumberOfOfferings_label_en-US" xlink:label="lab_pacb_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offerings</link:label>
    <link:label id="lab_pacb_NumberOfOfferings_documentation_en-US" xlink:label="lab_pacb_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfOfferings" xlink:href="pacb-20231231.xsd#pacb_NumberOfOfferings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_NumberOfOfferings" xlink:to="lab_pacb_NumberOfOfferings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7bc763a4-c22d-4933-ad65-040167f0837a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_6b01c12c-f126-43f4-b63e-a7faf7112a72_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c88706fb-0850-4da5-9e8a-60cb2cc4f37c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_72cdc43e-e307-4e85-8f16-af87725684bb_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a77f0fd2-8971-4c84-9603-09ac82eb15ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeTaxesTable_ecf1dc5f-4dad-4793-9873-6fc222869706_terseLabel_en-US" xlink:label="lab_pacb_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pacb_IncomeTaxesTable_label_en-US" xlink:label="lab_pacb_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pacb_IncomeTaxesTable_documentation_en-US" xlink:label="lab_pacb_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesTable" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeTaxesTable" xlink:to="lab_pacb_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3c0ca62a-ed63-4cd2-9c80-5b86e253458a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_2c404156-5655-4ccb-8fe3-9956f34658bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3a5fd1a7-5474-4c75-b134-cc1d8683e1e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e489491c-9c73-46aa-8036-413a763abab2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6b24853c-801a-4b72-8178-c0c1a57b001e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f186f67d-df72-4614-af82-a01c5902ba94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d97429b4-46ee-4bbb-8f32-919f5fe627f9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationMember_d8264995-4f38-422b-8962-3f1ba58412a3_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_pacb_BusinessCombinationMember_label_en-US" xlink:label="lab_pacb_BusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination [Member]</link:label>
    <link:label id="lab_pacb_BusinessCombinationMember_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationMember" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationMember" xlink:to="lab_pacb_BusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bab08039-7635-4913-91c6-0b6283bc20f4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_86f7a171-a1b4-4b66-8310-b405bc1970b3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c8dfc0e0-72eb-456b-bed3-f4514b7b1e0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of purchase price to intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_259adac5-e5da-439f-80ce-388b12655887_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c12d9d7-f4d1-46be-b268-bb328aefcfe5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesIssued1_5ffdc4ca-eed2-45de-8d9d-e8b03c5a763c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes exchange</link:label>
    <link:label id="lab_us-gaap_NotesIssued1_label_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_81d7bfb5-d3ce-42a3-9380-b3c83a111b99_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_cf298559-c3aa-459e-a3f0-f5b5a40fd7cd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through 5 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_97663f1e-a016-4120-bdb9-c60275b254e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_114b3bc9-49c9-42b9-b563-ff8869bb81bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4cb9376a-639c-48a8-b767-ef13176b4c60_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_53b42aeb-d82b-493b-a11b-9e22ead7b9dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_a2d22056-6b53-4e3e-b4e7-8bf66367d825_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the components of accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c1e94966-e8d7-451c-aa0b-82714e56a64d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_69c9aea6-be7a-4490-b398-cfd4c98b6add_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_65acab16-74a0-44d4-880d-935c9d82ada6_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_bb736c8e-3e8c-4f3a-9979-1cbc8e0ff4ed_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Rate of Time Deposits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:to="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d7ad53ef-1005-469a-90a0-2107eed1d1d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c46fe0a8-ec86-4082-ae1d-b93a7d09b6b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_97d020ec-977b-4542-aad0-9ad3baeb85da_terseLabel_en-US" xlink:label="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma adjustment related to acquiree's acquisition-related costs</link:label>
    <link:label id="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_label_en-US" xlink:label="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma adjustment related to acquiree's acquisition-related costs</link:label>
    <link:label id="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_documentation_en-US" xlink:label="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma adjustment to reflect acquiree's acquisition-related costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:href="pacb-20231231.xsd#pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:to="lab_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_cf52e4f5-f772-4997-8217-a67622c8b45e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_98056879-385e-4703-826c-7b703c244ed3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8d7a212-c3d2-4e2c-987f-7d5480d14891_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_1cbd730c-3dbd-4e58-925b-d77cc265658f_terseLabel_en-US" xlink:label="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_label_en-US" xlink:label="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets and research development expense</link:label>
    <link:label id="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_documentation_en-US" xlink:label="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) and research development expense in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:href="pacb-20231231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:to="lab_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9d9f742e-b7b7-40b9-8e58-7a89ea5c1b13_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_fb6293c0-187e-417a-9320-3a74bdac586a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_20221878-298e-42bf-ba2e-0e8d15a2b09e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_20558736-1636-4c0e-be3b-da04266932ca_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net (loss) income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ff06a2ea-e121-451e-89b7-fcaaa076ddab_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a879df73-11d7-40be-b2cf-5bebf96c98f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_af7f7567-f47c-47e6-b1df-29bb5b0471e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_ad469b53-8c52-4951-9686-c62ac94496a0_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering, option to purchase additional shares (in shares)</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_label_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_documentation_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:to="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fcb0c75d-5f2c-441a-a3c6-68dcdb9735b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConvertibleSeniorNotesMember_4dfa5e76-6cbf-4eac-ac1c-fc52da37a3ae_terseLabel_en-US" xlink:label="lab_pacb_ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember" xlink:href="pacb-20231231.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConvertibleSeniorNotesMember" xlink:to="lab_pacb_ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_c3b2cd20-1a6c-4417-8578-f9146d814ee2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2bba698f-7711-4e3e-9f34-089d080fc891_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShelfOfferingMember_c20bf307-5719-416c-8372-dc07b581dc6b_terseLabel_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Offering</link:label>
    <link:label id="lab_pacb_ShelfOfferingMember_label_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Offering [Member]</link:label>
    <link:label id="lab_pacb_ShelfOfferingMember_documentation_en-US" xlink:label="lab_pacb_ShelfOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember" xlink:href="pacb-20231231.xsd#pacb_ShelfOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShelfOfferingMember" xlink:to="lab_pacb_ShelfOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingShares_f17db764-1983-48fe-8295-894531c9d91d_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering (in shares)</link:label>
    <link:label id="lab_pacb_PublicOfferingShares_label_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Shares</link:label>
    <link:label id="lab_pacb_PublicOfferingShares_documentation_en-US" xlink:label="lab_pacb_PublicOfferingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingShares" xlink:to="lab_pacb_PublicOfferingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_ede62c61-60a3-4b27-a9b9-2fc75cf0319a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock following milestone achievement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1b30ea41-8f84-420a-a225-4e7099e44658_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_8a041a3e-aa14-410c-b1c9-14d8b275d744_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b347d80-becf-4340-b6ac-5c36e9423a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_d7b7436b-e860-464c-9593-064470020227_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_b66e767a-ad4c-45f7-a79f-ae94b7d895d3_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest in the event of default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:to="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_86403569-70d7-4639-b046-62c3fbe70614_terseLabel_en-US" xlink:label="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity or debt financing that must be raised in a single transaction</link:label>
    <link:label id="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_label_en-US" xlink:label="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction</link:label>
    <link:label id="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_documentation_en-US" xlink:label="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:href="pacb-20231231.xsd#pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:to="lab_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_67247806-5800-4aca-9cba-72da5da88abe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_96d5afa4-025e-46bb-ab9e-39cbc939787f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_39649585-21bf-46c0-8023-255fb5a5824c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_e23c47d3-12ec-4ed9-94fa-04b5e2c3001a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid accrued but unpaid interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CommitmentsAndContingenciesLineItems_875affdb-9088-454e-a4aa-bc6c5ad2068a_terseLabel_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_pacb_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesLineItems" xlink:href="pacb-20231231.xsd#pacb_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems" xlink:to="lab_pacb_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6975551b-d80e-41db-997a-9fa57a0f177b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CustomerOneMember_d03ffb0b-b276-4825-9444-e94e8bec3c58_terseLabel_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_pacb_CustomerOneMember_label_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_pacb_CustomerOneMember_documentation_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember" xlink:href="pacb-20231231.xsd#pacb_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CustomerOneMember" xlink:to="lab_pacb_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_cb44eabd-7866-4861-be4d-6f130f7e895a_verboseLabel_en-US" xlink:label="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of milestone</link:label>
    <link:label id="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_label_en-US" xlink:label="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration</link:label>
    <link:label id="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_documentation_en-US" xlink:label="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" xlink:href="pacb-20231231.xsd#pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" xlink:to="lab_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_d21b5c62-4b83-4754-83c0-e640ed15dbfd_terseLabel_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity offerings, net of issuance costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_label_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity offerings, net of issuance costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity offerings, net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" xlink:to="lab_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PrivatePlacementOfCommonStockMember_6225e2d7-db81-488a-9283-7a9b96372f29_terseLabel_en-US" xlink:label="lab_pacb_PrivatePlacementOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement of Common Stock</link:label>
    <link:label id="lab_pacb_PrivatePlacementOfCommonStockMember_label_en-US" xlink:label="lab_pacb_PrivatePlacementOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Of Common Stock [Member]</link:label>
    <link:label id="lab_pacb_PrivatePlacementOfCommonStockMember_documentation_en-US" xlink:label="lab_pacb_PrivatePlacementOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PrivatePlacementOfCommonStockMember" xlink:href="pacb-20231231.xsd#pacb_PrivatePlacementOfCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PrivatePlacementOfCommonStockMember" xlink:to="lab_pacb_PrivatePlacementOfCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CostOfRevenueMember_6998237d-2492-470a-93d8-378062a69250_terseLabel_en-US" xlink:label="lab_pacb_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue</link:label>
    <link:label id="lab_pacb_CostOfRevenueMember_label_en-US" xlink:label="lab_pacb_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue [Member]</link:label>
    <link:label id="lab_pacb_CostOfRevenueMember_documentation_en-US" xlink:label="lab_pacb_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember" xlink:href="pacb-20231231.xsd#pacb_CostOfRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CostOfRevenueMember" xlink:to="lab_pacb_CostOfRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b8d0ba24-9175-452b-85f5-fe0280df319b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_94a0279d-bdec-4a9c-ab7e-c0a5bfaa60cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7912c4c3-b49e-4582-9a41-283fcfdfaf9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0b01e783-8794-4107-8d39-b9f18054d9e7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_48afe672-aaec-45b1-9086-cf998b1369d1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_86cb64c3-5e71-4131-8efc-f1cf4b2023f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_a3057f3c-081b-4820-bf83-18953ee54b9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_f604c621-d392-437b-821a-2be751eb41ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ff0b5107-b4d7-4f01-92bf-8f13a6b8d17a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AptonMember_0f204f2b-3fe2-439a-9c79-c105b3af2c32_terseLabel_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apton</link:label>
    <link:label id="lab_pacb_AptonMember_label_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apton [Member]</link:label>
    <link:label id="lab_pacb_AptonMember_documentation_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AptonMember" xlink:to="lab_pacb_AptonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_531df4b1-d15a-4639-9a07-48be7d640737_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_88cfbac9-dda5-46c4-b0c3-c9832e8cd822_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_17e8ce9c-ef6c-40ea-a787-9ba956a8536a_terseLabel_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_label_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Reclassification</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_documentation_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Reclassification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentReclassification" xlink:href="pacb-20231231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentReclassification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ContractWithCustomerLiabilityNoncurrentReclassification" xlink:to="lab_pacb_ContractWithCustomerLiabilityNoncurrentReclassification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_cb5768ac-5838-4132-bf19-c428eee5aeef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-Lived Intangible Assets from Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_af84f016-08b7-44c0-ae36-5399d7d44318_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_ca9e7907-4fa9-407b-904e-ee56b3afc4d3_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_55b5c7f2-52fb-4940-9253-a067eb0185ba_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_label_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_documentation_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:href="pacb-20231231.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:to="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_877152af-b569-456b-8a3c-53d9d500ca93_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_a0343c15-9fcb-41c5-9c3a-bd58bab40bc9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_321ac379-44c6-4e91-9c36-56e57f589fae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_86d902a0-0fdf-427c-aa83-fae10a432594_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_80234de2-f678-436b-a39f-48279669a022_negatedTerseLabel_en-US" xlink:label="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Share-based compensation expense excluded from consideration transferred</link:label>
    <link:label id="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_label_en-US" xlink:label="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense excluded from consideration transferred</link:label>
    <link:label id="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_documentation_en-US" xlink:label="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense excluded from consideration transferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:href="pacb-20231231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:to="lab_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_ae50aec1-5ae0-425d-b83d-d49395c05000_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Pro Forma Financial Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InvitaeCorporationMember_cc9c23e0-5d37-493e-a6e1-92913f788ca3_terseLabel_en-US" xlink:label="lab_pacb_InvitaeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Corporation</link:label>
    <link:label id="lab_pacb_InvitaeCorporationMember_label_en-US" xlink:label="lab_pacb_InvitaeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Corporation [Member]</link:label>
    <link:label id="lab_pacb_InvitaeCorporationMember_documentation_en-US" xlink:label="lab_pacb_InvitaeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember" xlink:href="pacb-20231231.xsd#pacb_InvitaeCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InvitaeCorporationMember" xlink:to="lab_pacb_InvitaeCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ae364b2a-d9e5-40dd-8fdf-6e143d279a7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dbcb07a2-ca9d-4127-a2de-072b73929413_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit) Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_5f50ea6a-49b0-4c7b-8462-9628e8f0eedb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net (loss) income per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_5ee81ad8-822c-4a27-858b-ff4716461134_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_592756d5-7562-47e5-a8da-62e233d5515e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProceedsFromRepaymentsOfContractTermination_4e1bed55-25cb-49c9-9072-fc27b62a64e0_terseLabel_en-US" xlink:label="lab_pacb_ProceedsFromRepaymentsOfContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuation Advances</link:label>
    <link:label id="lab_pacb_ProceedsFromRepaymentsOfContractTermination_label_en-US" xlink:label="lab_pacb_ProceedsFromRepaymentsOfContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Contract Termination</link:label>
    <link:label id="lab_pacb_ProceedsFromRepaymentsOfContractTermination_documentation_en-US" xlink:label="lab_pacb_ProceedsFromRepaymentsOfContractTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromRepaymentsOfContractTermination" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProceedsFromRepaymentsOfContractTermination" xlink:to="lab_pacb_ProceedsFromRepaymentsOfContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_20532e73-5594-4d2f-a12f-b77079f4fd50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f72553c-b8f9-412d-b12e-d3ff48db25b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_054ffac1-9ed5-4465-bddc-347cea8e85d9_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_00da0982-087a-4fcb-8b80-3aace0d03313_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_def6dac0-5568-4300-81b5-fb8e51248a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_b8dee109-25a8-4e83-b08f-62688c847518_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDeposits_6ccb368d-8a85-4753-9718-755fda92a348_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for deposits to Supplier</link:label>
    <link:label id="lab_us-gaap_PaymentsForDeposits_label_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDeposits" xlink:to="lab_us-gaap_PaymentsForDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_71a1520d-4dd7-4a9e-8f94-eb4165ee15cf_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5ba842d8-c71e-46d6-ada4-c5947ed1f1fa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_ee6623b7-42b0-4d7c-8495-199c1137dd2a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable principal payoff</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_484a0555-7337-4daa-8604-6fb70303a0c0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for purchase of business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ffa3f57e-4c65-476c-9c5a-979fbb173706_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TwoThousandTenEquityIncentivePlanMember_e953e593-437c-4386-99e0-e752dadc4e16_terseLabel_en-US" xlink:label="lab_pacb_TwoThousandTenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Plan</link:label>
    <link:label id="lab_pacb_TwoThousandTenEquityIncentivePlanMember_label_en-US" xlink:label="lab_pacb_TwoThousandTenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Ten Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_pacb_TwoThousandTenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_pacb_TwoThousandTenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Ten Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TwoThousandTenEquityIncentivePlanMember" xlink:href="pacb-20231231.xsd#pacb_TwoThousandTenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TwoThousandTenEquityIncentivePlanMember" xlink:to="lab_pacb_TwoThousandTenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dc1c3142-cadc-4b20-b90a-9a61ff25df37_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_7ec5ec44-3f4e-4b94-8445-d76fbae38e25_terseLabel_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options To Purchase Common Stock</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_label_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_documentation_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:to="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_23d43983-4658-4a8f-bd2f-76d97214e95b_terseLabel_en-US" xlink:label="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_pacb_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e94c9bf0-650d-47d5-aff4-907be19a67e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b976a560-0a31-4db4-9b80-f36ec9d5776f_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_cdae6dba-1ab0-4fcd-ab50-e0983acc0213_terseLabel_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CirculomicsIncMember_3b632fc9-4b5e-4a0c-a14a-1d15a7c3c1cb_terseLabel_en-US" xlink:label="lab_pacb_CirculomicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Circulomics, Inc</link:label>
    <link:label id="lab_pacb_CirculomicsIncMember_label_en-US" xlink:label="lab_pacb_CirculomicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Circulomics Inc [Member]</link:label>
    <link:label id="lab_pacb_CirculomicsIncMember_documentation_en-US" xlink:label="lab_pacb_CirculomicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Circulomics Inc. (&#8220;Circulomics&#8221;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CirculomicsIncMember" xlink:to="lab_pacb_CirculomicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_be10b6b1-b9ce-41b6-a96f-342bfd6d3536_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_d28eafa1-dc14-4552-a8d9-b3603891417c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_ddd01969-0728-44b7-98d0-d2f9db3b2fd7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InstrumentMember_fbe285ad-c608-41d0-a77d-538decfb380e_terseLabel_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument revenue</link:label>
    <link:label id="lab_pacb_InstrumentMember_label_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument [Member]</link:label>
    <link:label id="lab_pacb_InstrumentMember_documentation_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember" xlink:href="pacb-20231231.xsd#pacb_InstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InstrumentMember" xlink:to="lab_pacb_InstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_48f7effd-455c-4c28-879c-a9b577605a68_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7c6cad82-17cf-430d-8ebc-281fb47f8854_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812d1d9c-79ed-4b95-88a7-5b52b309045b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_b4607fe3-07fc-4561-bc37-8cd34551088c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7d31e85f-e73a-4628-8818-510a93c50656_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_d0c510c6-b6ce-4a1f-aec9-af3eb737f86a_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_423de117-f29d-42af-b686-caf94f44024c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9943245-3a7e-4e35-8af7-f3a886a551b1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_f21e3057-04a4-416b-81a0-9ecea2e329d4_terseLabel_en-US" xlink:label="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period of ESPP</link:label>
    <link:label id="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Period Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period of employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:href="pacb-20231231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:to="lab_pacb_PurchasePeriodOfEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_401d1a9b-5765-4fbe-a8a1-3b099d498eae_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_11397f31-faae-4147-b853-a666341eb0ba_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_b541bf6d-0478-4ff7-90cc-88695a73f4ff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_aa3a84df-4e9e-4313-bb9a-0e60fc389cc2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_2e9000dc-0412-496c-9179-98868d9541c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_67e51f7a-c224-4f2f-a445-0ea87e1d32c1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_766452ce-d36e-44cc-8f3e-c7be107858c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_6aeba4a6-6e93-4d9f-9cce-c283a3706568_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeTaxesLineItems_db9e1e6a-8a68-4fad-9538-e40dcb59243c_terseLabel_en-US" xlink:label="lab_pacb_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pacb_IncomeTaxesLineItems_label_en-US" xlink:label="lab_pacb_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pacb_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_pacb_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesLineItems" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeTaxesLineItems" xlink:to="lab_pacb_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_c8ebeb82-1cce-4992-bf2b-144c427b4868_terseLabel_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offering price (in usd per share)</link:label>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_label_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Share Amount Maximum</link:label>
    <link:label id="lab_pacb_OfferingShareAmountMaximum_documentation_en-US" xlink:label="lab_pacb_OfferingShareAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Share Amount Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum" xlink:href="pacb-20231231.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OfferingShareAmountMaximum" xlink:to="lab_pacb_OfferingShareAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3dd77de4-fe32-48ac-8553-56a9756fab3f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_a8ab319f-b7a6-4825-87e5-12e8ed231cc9_terseLabel_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred service revenue, noncurrent, recognition period</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_label_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_documentation_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:href="pacb-20231231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:to="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_d2d5470d-3d62-4d48-8973-47a86da4f205_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_85c2496b-a599-4435-abc4-1874ae087a6f_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with Apton liquidity event bonus plan</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:to="lab_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7db4fe2b-6ade-4e9e-aace-21eb1d195e65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_1e4e4d35-bb1b-4f31-b553-75835d7f6d30_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_88de7b4d-f855-43d4-84b5-a0866903a83d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_8461189e-30a4-455d-abc1-34ecf8317b6c_terseLabel_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Expenses</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_label_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_documentation_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:href="pacb-20231231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:to="lab_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_089c176a-2d2f-4f8a-aea7-38fa04090451_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_8f8a5ea3-c3c4-4cd5-8450-a0cdaa639038_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c271ace2-1f15-4f41-8b3b-5c8df9348ef3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5b5e1a4-0cfb-445a-98bb-116319aeb078_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8e2196ea-70ca-49e0-9e4d-5e05e05773d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONVERTIBLE SENIOR NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_79735397-b61b-4515-a60f-3f8f8d6d3df3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_8785a0b2-511b-42f3-a2ea-f5bc8bd89373_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, debt default, calendar days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:to="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4c878e14-cb11-4aa2-8d32-01f5792d8b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OmniomeIncMember_51f1cd45-4ab7-4a3d-9b73-f9e1deb9c922_terseLabel_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome, Inc</link:label>
    <link:label id="lab_pacb_OmniomeIncMember_label_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Inc [Member]</link:label>
    <link:label id="lab_pacb_OmniomeIncMember_documentation_en-US" xlink:label="lab_pacb_OmniomeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OmniomeIncMember" xlink:to="lab_pacb_OmniomeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f561fed3-953d-4052-bf4b-4b4708861b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockholdersEquityLineItems_6ef32b6a-1113-4d1a-8a5b-f762bf3df4cb_terseLabel_en-US" xlink:label="lab_pacb_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:label id="lab_pacb_StockholdersEquityLineItems_label_en-US" xlink:label="lab_pacb_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:label id="lab_pacb_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_pacb_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityLineItems" xlink:href="pacb-20231231.xsd#pacb_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockholdersEquityLineItems" xlink:to="lab_pacb_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_28c30881-c8fe-4681-b0bd-a990b4ebe6ea_terseLabel_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_de90159f-3a0f-4e34-96dd-87b6c84f2199_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units (PSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_e145f71b-2964-487f-ba2b-edf8b14b075a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_af2d3795-88d1-4dca-9ee9-7e4d0a402cae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ea257fbc-e300-469b-b875-3396729f70c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_9aee482f-7b1b-4622-b61b-47fa0b3dd85c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_5f255916-9f6c-4ec0-adb2-eadd5043d459_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Since the date of acquisition, net loss</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0c8029e8-e21d-4946-a972-c1e47d7c2af9_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_da715b90-1afc-45d5-9a6c-9913a3d9bf99_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3de6c503-1d0b-460e-90d0-d457261a0313_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e8b88c5e-168d-4166-b7dd-553d7d0559f6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_96d6533e-5d5b-4c17-8007-cc756393fd0b_terseLabel_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_label_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_documentation_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Components Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_dc8f3259-e1ee-4752-bb9a-7c794a9f34d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1971ec35-aced-4125-b903-ad18d92ef2f9_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_450b8859-4803-4f45-acff-f333c237bea9_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units RSUs and Performance Units</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units RSUs And Performance Units [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Restricted Stock Units RSUs And Performance Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f4f6f854-8a0e-42ee-82c3-9198d22f3049_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_8dc77418-36bb-4979-ac37-408da161f00b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions charged to cost of product revenue</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_36a1e475-6658-41fa-8d7c-76f5c4e791d7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_173d5610-80c1-49ff-9340-2eca8f2bc599_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d39cfb44-5856-4c7f-9145-af88e7960dfb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_2263e94d-0b14-449e-9dcb-50c19169985c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3f326f84-d30b-4d22-911a-ddd17e5c2217_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_16648483-67c1-426a-858a-b26b9af4313d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8b30049d-69fe-4368-94bd-f925ff368633_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e28d7d0b-765a-4c87-b7ba-4cf9e692b2d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_245d02b5-6870-4673-98d7-e29200649121_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_99037d4a-0eec-4f05-ac0f-c2c5a13d4195_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4f429443-657e-4ad6-aca7-ef73793a2062_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockBasedCompensationMember_4c67fd68-0da8-4ea4-83e8-0bc0155facf4_terseLabel_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_label_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember" xlink:href="pacb-20231231.xsd#pacb_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockBasedCompensationMember" xlink:to="lab_pacb_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b3f5d829-fbcb-4073-91d2-deffd641c762_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4840db2-66cb-4c63-aaa4-e97ec825f156_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3087dd21-8686-4f04-9cd5-52bca046606a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_07802e60-1888-40f9-8907-c58c0c432fd3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_6001d40b-2437-44c1-9255-8b049e61a1fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContracts_57335e01-0edd-47ee-bc00-23847ffb09e4_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on purchase commitment</link:label>
    <link:label id="lab_us-gaap_LossOnContracts_label_en-US" xlink:label="lab_us-gaap_LossOnContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContracts" xlink:to="lab_us-gaap_LossOnContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7a5d51d5-befc-4676-892d-0a50cd9b6ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution_06e2e488-8218-49fd-99c4-5a59d3976442_terseLabel_en-US" xlink:label="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of agreement payment received upon execution</link:label>
    <link:label id="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution_label_en-US" xlink:label="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Agreement Payment Received Upon Execution</link:label>
    <link:label id="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution_documentation_en-US" xlink:label="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of agreement payment received upon execution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmountOfAgreementPaymentReceivedUponExecution" xlink:href="pacb-20231231.xsd#pacb_AmountOfAgreementPaymentReceivedUponExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AmountOfAgreementPaymentReceivedUponExecution" xlink:to="lab_pacb_AmountOfAgreementPaymentReceivedUponExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_001ae2ec-82ce-4481-ac1e-7eeabdc2d9d7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d314b8b4-f1a5-4c39-a27a-a35a9953a3ff_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3a622edb-a429-4932-801e-9be3dd9e3218_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1314bd5f-807e-4ee9-b579-84ed482b30a5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SignificantAgreementsAbstract_e3492686-5c59-4d23-9694-c6682c0167f5_terseLabel_en-US" xlink:label="lab_pacb_SignificantAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Collaboration Arrangement [Abstract]</link:label>
    <link:label id="lab_pacb_SignificantAgreementsAbstract_label_en-US" xlink:label="lab_pacb_SignificantAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invitae Collaboration Arrangement [Abstract]</link:label>
    <link:label id="lab_pacb_SignificantAgreementsAbstract_documentation_en-US" xlink:label="lab_pacb_SignificantAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization Of Significant Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SignificantAgreementsAbstract" xlink:href="pacb-20231231.xsd#pacb_SignificantAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SignificantAgreementsAbstract" xlink:to="lab_pacb_SignificantAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e96dec8b-00cd-4700-8495-0773a880519d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Functional Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_523625b1-496f-4d0a-8121-e9074bb905ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eea8d66-c7d4-4f5e-a478-94699323be85_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_00cb131e-59fb-4a56-90ad-d538da28c41d_terseLabel_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranty period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_label_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_documentation_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod" xlink:href="pacb-20231231.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StandardProductWarrantyPeriod" xlink:to="lab_pacb_StandardProductWarrantyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f1254110-62e6-43e9-a1ce-c880f6517233_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1ff3ecba-d2b8-4bdd-bf91-03eef4c48714_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9966ff6a-d1ec-4dc6-aa85-19d511b716d9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_c42d9ee8-23db-4915-a51f-d459e168c2e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net, non-current</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_408e91c5-c4f5-41e4-afd9-7b6c603dea4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before taxes from U.S. operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5567672c-f227-46c6-ba4c-b669c5de2ab2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_89ecf8fb-6ebc-4b8a-ad1b-fbf850bdba16_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_f0d7ac30-4a7f-40c2-8ed8-c63df36f6fb6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_653cf70f-9ab8-4561-85a8-0d2aff94bd0b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2d41cb48-65aa-4089-8358-638700654c52_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in balance related to tax positions taken in prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_07545ca7-5768-47d8-b3ac-692f166b5334_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption, consecutive trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_b4f6e848-a992-4f3b-be31-41bf856290e8_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IlluminaFcOpsCorpMember_a9dd9db5-aedc-465c-b3ea-dbfd6b318d8a_terseLabel_en-US" xlink:label="lab_pacb_IlluminaFcOpsCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illumina, FC Ops Corp</link:label>
    <link:label id="lab_pacb_IlluminaFcOpsCorpMember_label_en-US" xlink:label="lab_pacb_IlluminaFcOpsCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illumina Fc Ops Corp [Member]</link:label>
    <link:label id="lab_pacb_IlluminaFcOpsCorpMember_documentation_en-US" xlink:label="lab_pacb_IlluminaFcOpsCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illumina, FC Ops Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IlluminaFcOpsCorpMember" xlink:href="pacb-20231231.xsd#pacb_IlluminaFcOpsCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IlluminaFcOpsCorpMember" xlink:to="lab_pacb_IlluminaFcOpsCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6f44e061-063f-43dc-9500-a550a29a7a84_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_af64deaa-f93b-406f-bf69-24e67fbaf296_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_5e5d70f2-e854-462a-9a62-945d77d0380a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_0c7a47ed-995c-407f-b0e4-43757ae7a3cc_terseLabel_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_label_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:label id="lab_pacb_FinancialInstrumentsLineItems_documentation_en-US" xlink:label="lab_pacb_FinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems" xlink:href="pacb-20231231.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FinancialInstrumentsLineItems" xlink:to="lab_pacb_FinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_504208f5-c12e-4f4c-b285-88e8095475a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f77cae0a-540b-4e37-9b30-fddb654364a8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of offering expense</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_75c67a82-32eb-4f2f-9062-68e20e568b3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4b2ca128-8dee-4d30-b2b5-9af49ea580b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4c14322b-4dbb-4062-afc0-ae76c7825e68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0347fda8-7f6a-4a37-8531-1512554978fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_215a2c20-f97c-49c2-8f11-6a405a6ea5d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_64b7efe5-0693-4c8c-9aff-8c4ebf0b161d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio_3ece50e1-b805-4bad-bb28-e8886c7ce619_terseLabel_en-US" xlink:label="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of number of shares into which the share instrument may be converted</link:label>
    <link:label id="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio_label_en-US" xlink:label="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Instrument, Number of Shares, Conversion Ratio</link:label>
    <link:label id="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio_documentation_en-US" xlink:label="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which the share instrument may be converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:href="pacb-20231231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:to="lab_pacb_ShareInstrumentNumberOfSharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_b7b3f777-f2cc-43e8-9297-55f9099ee6fa_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East, and Africa</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_25964911-067e-460d-9c91-ec22e0616c72_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_c62dd43c-68f1-401f-bd51-7d763477006d_verboseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) to our benefit from income taxes</link:label>
    <link:label id="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" xlink:to="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_42bfba79-0ba1-4004-a774-55a3fca2f0c6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue and Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_4c38d279-8a09-41d2-b4fc-0f1a571c44f0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_922b6d7c-902a-4c97-9f10-c599374f57a2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_06a75824-631f-4afb-a6c2-46de38163301_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_50f8ab83-4504-468c-b285-58fba3e6b5a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ee6f5599-d29e-48e0-98ad-8b4857d6ebfe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bbb210fa-3bd4-4156-9114-f7fb18937d0b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyAccrualPresentValue_f2f29009-28e8-4829-a129-17bea4fac4ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory accrual</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyAccrualPresentValue_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency, Accrual, Present Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualPresentValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:to="lab_us-gaap_ProductLiabilityContingencyAccrualPresentValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_bb405962-3748-432a-917f-8319704f5e2b_terseLabel_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering, option to purchase additional shares, period</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_label_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</link:label>
    <link:label id="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_documentation_en-US" xlink:label="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering, Option to Purchase Additional Shares, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:to="lab_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7c565f46-fddd-48e5-ab30-acb0027c518b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4ad02cb-2880-4bf1-bba1-353d72f71cc5_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3f2a30e6-fae2-499b-a66c-527a21c80db2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_55a5e4a5-ca2a-411a-b7ef-546fd43b8ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1fb20c39-8c11-4998-adac-fa27efbbf759_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rates</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_412ea962-9d3f-4f9b-abbe-81a5a0047f28_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ServiceAndOtherMember_14d54566-c6ab-4361-b792-fea020268462_terseLabel_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_label_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service And Other [Member]</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_documentation_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember" xlink:href="pacb-20231231.xsd#pacb_ServiceAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ServiceAndOtherMember" xlink:to="lab_pacb_ServiceAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_24467fb0-9912-4d55-9af7-6886044b2a97_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a8ac673a-9cc7-453a-830f-ef8c71adea86_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TransferOfInventoryToPropertyAndEquipment_025951c4-cde9-494f-b25e-bad313658057_terseLabel_en-US" xlink:label="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory transferred to property and equipment</link:label>
    <link:label id="lab_pacb_TransferOfInventoryToPropertyAndEquipment_label_en-US" xlink:label="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Inventory to Property and Equipment</link:label>
    <link:label id="lab_pacb_TransferOfInventoryToPropertyAndEquipment_documentation_en-US" xlink:label="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Inventory to Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:href="pacb-20231231.xsd#pacb_TransferOfInventoryToPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:to="lab_pacb_TransferOfInventoryToPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerRelatedExpensesMilestoneMember_920882a1-1d6e-4ac1-9706-b7714490cb3d_terseLabel_en-US" xlink:label="lab_pacb_MergerRelatedExpensesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses - milestone</link:label>
    <link:label id="lab_pacb_MergerRelatedExpensesMilestoneMember_label_en-US" xlink:label="lab_pacb_MergerRelatedExpensesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Related Expenses Milestone [Member]</link:label>
    <link:label id="lab_pacb_MergerRelatedExpensesMilestoneMember_documentation_en-US" xlink:label="lab_pacb_MergerRelatedExpensesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses - milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesMilestoneMember" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerRelatedExpensesMilestoneMember" xlink:to="lab_pacb_MergerRelatedExpensesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f8e59ed-423e-4317-b681-0d7b1e9c52bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4b3653ce-eb55-4e82-9e7e-cb625425ecda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Time-Based RSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_64f4e862-e01d-475f-bec5-f75db55ce6e4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2997939a-53a1-4a4d-b895-54f6bbda8179_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty accrual</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_04de10aa-86ac-49a0-b379-3472663502ce_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in balance related to tax positions taken in prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_9d485b2d-b97c-4e1b-a4c5-2bf2dfb945c5_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_40d1301d-a847-45f1-b75d-59b2f6a05ed1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1065ecac-da5a-4bf6-a8d1-7bc092b1af5b_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_242b1ac1-1b35-459c-9135-04b25b4dac61_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d9bb7ec1-7676-4ee3-ae85-ed878705cc01_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fdfe0531-ff82-484b-b329-07c5c5515572_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_fe38eaed-2e50-4d11-9e9f-cd538683ab47_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in balance related to tax positions taken during current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_a1c62947-4856-487e-8f12-c45c8a5bc00a_terseLabel_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_label_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit</link:label>
    <link:label id="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_documentation_en-US" xlink:label="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:href="pacb-20231231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:to="lab_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80380acf-40f8-40c9-83d5-4372c136f685_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb54769d-0306-4a4f-91e4-31c6fd857790_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8abc434c-d5d4-49ae-aff0-fbb0f3f408db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_970e2656-a241-40d4-961b-bc602fc46176_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e651560d-570d-47c3-b6d2-c1808a5ef491_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a2c4c46c-54cf-43ec-bb05-112da08c167f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9f091456-bde7-458d-8dfb-26857411bd42_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ef8324b1-0063-4da6-8795-ece19202980f_netLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_84285ed9-e35d-41a6-8151-524e751b8cda_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate outstanding balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0974cf19-a3ff-44c5-ab84-2cce2b7d4136_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a1ff87ae-f224-4906-906a-d479892f661a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LiquidityBonusEventMember_7f06dd24-424d-4cab-aab8-c5e6d1118470_terseLabel_en-US" xlink:label="lab_pacb_LiquidityBonusEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Bonus Event</link:label>
    <link:label id="lab_pacb_LiquidityBonusEventMember_label_en-US" xlink:label="lab_pacb_LiquidityBonusEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Bonus Event [Member]</link:label>
    <link:label id="lab_pacb_LiquidityBonusEventMember_documentation_en-US" xlink:label="lab_pacb_LiquidityBonusEventMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Bonus Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LiquidityBonusEventMember" xlink:href="pacb-20231231.xsd#pacb_LiquidityBonusEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LiquidityBonusEventMember" xlink:to="lab_pacb_LiquidityBonusEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ef3149e6-35ee-4533-a450-09234745165c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e0ccc98c-7e89-4ff7-bb70-0715d20c6fc7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_ab570e0e-b503-4afb-bf3c-de91a3021b07_terseLabel_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development Indefinite Lived</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_label_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Indefinite Lived [Member]</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_documentation_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development indefinite lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:href="pacb-20231231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:to="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4f0d170f-5cca-438c-b0fc-2b158552d0b6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_15c349ce-8159-4ef3-b617-b76ba81e5594_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net (loss) income per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_b9a66afc-8d79-45eb-aabb-0aa13ccd1e52_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_2d76f2ac-f4bd-4623-b5f2-261b6754965f_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest in the event of default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:to="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_97274d56-ee3a-4c20-8322-31cad0516f24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5c744c75-b994-494e-b8a8-ffd3e78bb190_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_23830a90-dabb-4820-8996-f5ed25242280_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember" xlink:href="pacb-20231231.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsTwoMember" xlink:to="lab_pacb_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_a0142b30-41c9-405c-991f-c98a059a51d7_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b10d7dc-12ec-4e39-8c71-d67418e8702f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_123a362b-85e6-46ba-8a90-9536069acbf9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_139921fc-9e82-487a-9279-fbd579ed0175_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_83a87e8e-5854-4994-beef-362843e8f31a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_fee00065-3811-40c0-bcb0-e8d14973e045_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockholdersEquityTable_8e8fb049-df5a-43cb-b5a0-e59cc0d8432b_terseLabel_en-US" xlink:label="lab_pacb_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:label id="lab_pacb_StockholdersEquityTable_label_en-US" xlink:label="lab_pacb_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:label id="lab_pacb_StockholdersEquityTable_documentation_en-US" xlink:label="lab_pacb_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityTable" xlink:href="pacb-20231231.xsd#pacb_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockholdersEquityTable" xlink:to="lab_pacb_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7852a424-aaac-44d6-a517-a7c6da117968_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1d5fad25-9005-47ae-b018-8fd907f61a08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f2c0ff9-51d7-4932-8037-28d54fbe3e7e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21a09037-2401-4043-acd6-c6e2178a37b8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24d509ce-3fbb-486e-b16b-467e51a5edc2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in Private Placement, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_60472af3-221e-4738-91b9-b17cc1453ccd_terseLabel_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_label_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan2020 [Member]</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member" xlink:href="pacb-20231231.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EquityIncentivePlan2020Member" xlink:to="lab_pacb_EquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_b92ab7f6-141d-42ab-957f-c0cf0a59b8a6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1916550c-a056-4612-a1d4-356e823322d0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_85ce0423-c946-43b3-83a3-ad05ef3512a0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_0d60c75d-13a4-45a3-a932-4d00df2395f6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5f93e966-2576-456a-824d-eeaddf327759_terseLabel_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability associated with indemnification obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_label_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_documentation_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:href="pacb-20231231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:to="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_74072144-775a-40bd-8c12-ef688cd5fbb3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in conjunction with equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_0160dfe5-63dc-4d30-89ac-09bb1c7b2cdf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_7ad12286-16ad-4a7f-9cde-981a38993a69_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_97c46c39-5fb7-419a-9cd2-a064a30665fe_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_865b6e51-5ce2-4935-9670-975dcf013bba_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a6bdf58b-e22c-4ebd-a4d9-877185644e31_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a0aabe52-5e53-4b76-aaff-70a5e08cdf9f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_91a2f305-45e8-4d28-a631-18e568e45b91_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_423559ed-39cd-44b9-98f3-a60575dc9ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_63444583-9581-4f00-a8bf-bd4fc1c6b3ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_86dfcc1b-bb02-401f-a7c1-b6278da12a23_terseLabel_en-US" xlink:label="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in The Estimated Fair Value of Contingent Consideration Liabilities</link:label>
    <link:label id="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the estimated fair value of contingent consideration liabilities [Table Text Block]</link:label>
    <link:label id="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the estimated fair value of contingent consideration liabilities table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:href="pacb-20231231.xsd#pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:to="lab_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad3a578a-ea11-4bd8-9e56-fd7da0ca0ef9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_e9bb6c80-c7ee-4d36-931c-47c26027e0ec_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_label_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue Achievement Milestone</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:to="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b53ec75f-38a6-48ea-b9c9-cebb071e178f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ad0240c1-8cdb-4987-a87f-fddf466498b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_fe34458d-8500-40e0-8229-b2d7d4c2e9a5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cb3633bc-32c6-4ad9-9138-a52b40a940bb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_67a60cc3-52f1-49f4-ab8f-30464e214a8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40a3a1e6-dc51-46e8-b574-ca266ac1b8d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f7ecfbc3-256e-4516-ad76-de2526fa9fac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_c9e59d4a-2e5d-4db6-9417-d05cf248d375_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ce033e3a-47e8-4941-8df7-67d4496b4490_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_cc352fb7-2bfc-46f3-920f-1cafba435a1f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_24947f31-7659-40af-b199-44be76b1af60_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loans outstanding</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_89382bde-2b9e-45a9-a383-ba48e6e84c4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5b12c600-9a29-4283-8bc0-a5115f9135eb_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ee5d8c20-89d7-4795-b59a-18b89633402d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9a5d177a-d033-42d3-9ca0-f8ee3ad9a437_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_333e06fe-6df6-4a7a-a2c1-8331bf257361_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7759455e-cd33-471f-8323-7d3b77946b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a9e01b42-658f-45f9-afd2-98ae93cb9364_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cc618a3e-0619-4cd3-bb7d-498325aaa472_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_15d2c07c-27ba-4e8c-aa19-68246d1e8918_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6cb9345b-27ba-46ef-b1f4-b34e6124f0c8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_2b1ac89e-a382-4d38-8915-5f681de379d0_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in Private Placement, net of issuance costs</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in Private Placement, net of issuance costs</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued in private placement net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:to="lab_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_1ec67a24-a911-4867-97ec-ca65af7a9734_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ExchangeRatio_ea7e98c7-407c-4924-a128-92814f3f2778_terseLabel_en-US" xlink:label="lab_pacb_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_pacb_ExchangeRatio_label_en-US" xlink:label="lab_pacb_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Ratio</link:label>
    <link:label id="lab_pacb_ExchangeRatio_documentation_en-US" xlink:label="lab_pacb_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The relative number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeRatio" xlink:href="pacb-20231231.xsd#pacb_ExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ExchangeRatio" xlink:to="lab_pacb_ExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3843c16c-9817-43ce-9d56-01137dda63ba_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8a41d642-c533-464e-9cc0-4cdde6a6c466_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_ee979c97-fcf8-4b5f-b1ec-ec2908e1430b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dd3a7934-2f9b-45e9-a0b5-2b0dd25ba32a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0bb89794-3ee5-4b9c-9852-9b53e46988af_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_acb058f5-6a25-4502-9171-0272ec5b566f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_7ecf8e26-142a-4229-9fbb-6ce5d09f22ab_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Stock Option</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_label_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based Stock Option [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedStockOptionMember" xlink:to="lab_pacb_TimeBasedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_b6863466-861a-46d4-bcef-706554d93d40_terseLabel_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_54c9b97a-3c9b-4f6a-b8b3-5eae78741011_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_53af2455-6104-4f2a-97c6-1d95817055e0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2729b324-7e07-42cf-b5c6-6842b2b3f995_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e3db1719-9a34-4e09-960b-7d1b9748e46f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_038ca287-0367-447e-90d3-2f4eea162e57_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized 1,000,000 shares; issued and outstanding 267,744 and 226,505 shares at December&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_05099ce4-9ee6-4066-968d-33bac6a65ac5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_318fe0dc-8c88-47bc-9ecf-50ee203aa00c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_c6c0b37e-2a2e-43bc-a7d7-2d50baebc57c_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Development and Commercialization Agreement Transactions [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_label_en-US" xlink:label="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Development and Commercialization Agreement Transactions [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_documentation_en-US" xlink:label="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Development and Commercialization Agreement Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:to="lab_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4e3eb501-91d6-49fd-a3f4-ab3011931aec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRent_dcb8910e-efbf-4847-bf42-e7a737b91548_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRent_label_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d5e42a2c-835e-4636-bb90-9dd2d3b9348c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_50c8cb6d-ae6e-419d-b69f-68f1044e3a15_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_102abbf5-0ece-4472-be84-81f4617c5616_terseLabel_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Classification</link:label>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_label_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Classification [Abstract]</link:label>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_documentation_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Classification [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetClassificationAbstract" xlink:href="pacb-20231231.xsd#pacb_BalanceSheetClassificationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BalanceSheetClassificationAbstract" xlink:to="lab_pacb_BalanceSheetClassificationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_78fd4afe-0d59-4658-8461-76bf67ec01b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_116f850c-47d2-470a-9501-fc88521ea07a_terseLabel_en-US" xlink:label="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Us Government Corporations And Agencies Securities Not Included With Cash And Cash Equivalents [Member]</link:label>
    <link:label id="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_documentation_en-US" xlink:label="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities, , Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:href="pacb-20231231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d4fd1718-ae35-4da7-99ab-fa6b4b0f7ac9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ee18eea5-79ce-4b23-a821-8a8edc9746cc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_2b161ab1-91e2-4498-90f4-c6f891f4d889_terseLabel_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions, percentage of gross proceeds</link:label>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_label_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</link:label>
    <link:label id="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_documentation_en-US" xlink:label="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:href="pacb-20231231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:to="lab_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3db036be-e170-45d4-a15f-4cf3176bce3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b3f3e0aa-e422-4802-9a28-7a91168662b6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_896487cc-43d4-4881-bed9-7ef3b6310283_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_343161c2-92b4-4962-a935-14e9650478b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b545dd1f-c993-4f1b-bd2b-007ee993b779_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_10b3e58f-707d-4f1e-8f86-df4965f362e1_terseLabel_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_label_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Milestone [Member]</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_documentation_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon achievement of a milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember" xlink:href="pacb-20231231.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AchievementOfMilestoneMember" xlink:to="lab_pacb_AchievementOfMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_140d4e40-1ac5-495b-884c-4c1ed30f83a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_2546f68e-ba68-4379-a67e-b177996212f7_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019bd5f4-9ac9-4361-b676-63339be7ba5e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_343e05d1-24ea-4b0e-ac95-c89b2d4711a6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchase commitments</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ed09abe8-67ad-4f1f-b6b1-227d9498cdd0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_808ae26a-5b15-434e-a7e3-22dcea1774d5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aa0c27f7-4438-47bc-859f-6fbe206a7998_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_def69217-3bec-4d5e-9920-26465223bccf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0f71ed5a-c611-45bb-8ac4-8f34eb8fe207_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0058f4dd-25da-498a-beb7-af9345dc763b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_25b61664-6b7a-4fad-8e9d-729905e80d3f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_21815a9c-2f0e-4184-9690-70246f2af031_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5d984599-1c85-4053-abc7-ac650b812991_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_52002d3e-fe81-4f96-81bd-2e426606fffe_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_575fabc9-7ac4-48ec-8857-6519fa52e659_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6fe481f1-0c0c-4a13-9652-f6e17e5030ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_525769ca-1bee-4ad4-b7ba-b77b73387f37_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_34d1246a-ce9e-4d79-a616-1dfd6b492bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1a0880b7-0c8a-4801-a7f1-88af68194976_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39b12589-6338-475c-a827-a6db658e2d67_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerRelatedExpensesCashSettledMember_6810b3aa-8713-45c8-92f6-d64653a06ebf_terseLabel_en-US" xlink:label="lab_pacb_MergerRelatedExpensesCashSettledMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses - cash-settled</link:label>
    <link:label id="lab_pacb_MergerRelatedExpensesCashSettledMember_label_en-US" xlink:label="lab_pacb_MergerRelatedExpensesCashSettledMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Related Expenses Cash Settled [Member]</link:label>
    <link:label id="lab_pacb_MergerRelatedExpensesCashSettledMember_documentation_en-US" xlink:label="lab_pacb_MergerRelatedExpensesCashSettledMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses - cash-settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesCashSettledMember" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesCashSettledMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerRelatedExpensesCashSettledMember" xlink:to="lab_pacb_MergerRelatedExpensesCashSettledMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_8d029bce-5094-4022-8415-2bf066a666f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_f3177ef7-aa00-497c-8f5f-7f893b2feb5a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_659b7c6e-224c-46e2-80ea-a1a0af259cda_terseLabel_en-US" xlink:label="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Stock Awards Related to Acquisition</link:label>
    <link:label id="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_label_en-US" xlink:label="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Stock Awards Related To Acquisition [Member]</link:label>
    <link:label id="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_documentation_en-US" xlink:label="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome stock awards in connection with the acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:href="pacb-20231231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:to="lab_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_f8d67dc4-74cc-48e4-9982-9db434f89f71_terseLabel_en-US" xlink:label="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_label_en-US" xlink:label="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Amount Subject To Expiration</link:label>
    <link:label id="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_documentation_en-US" xlink:label="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Amount Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:href="pacb-20231231.xsd#pacb_OperatingLossCarryforwardsAmountSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:to="lab_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_8f2094fb-579d-421e-ae73-72dc0e08cce2_terseLabel_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Issuance Costs</link:label>
    <link:label id="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity, net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_143f0f1e-9c63-4c4b-b61b-0770c1634178_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_4adea3fb-8ec0-46d5-a4e2-0e2943d33faf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CashAndMoneyMarketFundsMember_61d3ee36-db1e-4470-9adb-c8d8c0b6309b_terseLabel_en-US" xlink:label="lab_pacb_CashAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_pacb_CashAndMoneyMarketFundsMember_label_en-US" xlink:label="lab_pacb_CashAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Funds [Member]</link:label>
    <link:label id="lab_pacb_CashAndMoneyMarketFundsMember_documentation_en-US" xlink:label="lab_pacb_CashAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember" xlink:href="pacb-20231231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CashAndMoneyMarketFundsMember" xlink:to="lab_pacb_CashAndMoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_f282d24a-874a-40a1-be34-a23d742ae81c_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average trading period</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:to="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_fc34d247-6936-43d7-96e2-689e9cdb9f77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Reserve for Product Warranties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3cb6b934-7282-42e6-942e-ae670bfc2c65_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_15d653e1-73e3-40f6-86e1-ece806b73782_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:href="pacb-20231231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2eafada9-d2b7-49aa-84aa-d92a5782f19d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d258ccc3-fa73-474d-bc1e-9c368eda2cda_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember_4cecf01b-fca9-43f5-a291-1e15d64b20bd_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based and Performance-Based Options</link:label>
    <link:label id="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember_label_en-US" xlink:label="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based And Performance Based Options [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based and performance-based options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:to="lab_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99860e93-11c4-43f8-9ad2-7caf37f63370_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_fc55f77f-35db-4211-8f70-5f1188f7c93b_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_33829887-6a3e-43f8-929f-efe130ad1b9c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dae35bc0-7ceb-40f0-88b2-0bfdf1c95216_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3ada404-966f-47c0-bafb-627281dacb82_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4b188a43-022b-4042-8eb3-ee4a2d2dfa43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_bba764e5-1de5-411d-80f9-036e453e404b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Location</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostOfOperatingRevenue_e0e6771e-c745-426b-ae2f-3b6977d71536_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostOfOperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service and other revenue</link:label>
    <link:label id="lab_us-gaap_OtherCostOfOperatingRevenue_label_en-US" xlink:label="lab_us-gaap_OtherCostOfOperatingRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost of Operating Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostOfOperatingRevenue" xlink:to="lab_us-gaap_OtherCostOfOperatingRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AccruedProductDevelopmentCostsCurrent_ad34836a-e956-4440-ab02-dc282fe95e61_terseLabel_en-US" xlink:label="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product development costs</link:label>
    <link:label id="lab_pacb_AccruedProductDevelopmentCostsCurrent_label_en-US" xlink:label="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Development Costs, Current</link:label>
    <link:label id="lab_pacb_AccruedProductDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedProductDevelopmentCostsCurrent" xlink:href="pacb-20231231.xsd#pacb_AccruedProductDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AccruedProductDevelopmentCostsCurrent" xlink:to="lab_pacb_AccruedProductDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_377c0583-6583-4340-b9b3-0a3a35d5dc49_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_aa9b8fcd-2ccd-42a8-ac13-c78313f7fdd6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ab3876fc-2e18-4569-94eb-5065916e5725_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_5e6c8488-7ce5-4309-8347-c9371fa5a09d_negatedLabel_en-US" xlink:label="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred tax liability</link:label>
    <link:label id="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_label_en-US" xlink:label="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:label id="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:to="lab_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_a6177ab0-1d6e-4d86-b42d-cc3e3927f4de_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anniversary</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_label_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Closing Date Period</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Closing Date Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:to="lab_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2c2cfcf3-694a-40e0-8045-882adc428c31_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e96035b5-b989-4636-8bd1-411e51e79ad7_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_19ff4709-45d5-4077-b5d6-977096be5175_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment transferred to inventory</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Transfers and Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f0f6ce9b-52de-489b-9bb7-69b590b0e5ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21532b68-670e-4b2e-8fbe-63c85e7c4ce6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockVotingRights_2786e7c9-dc1e-46eb-9cdb-d99d7a9e6d55_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockVotingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting right of common stock share holders</link:label>
    <link:label id="lab_us-gaap_CommonStockVotingRights_label_en-US" xlink:label="lab_us-gaap_CommonStockVotingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d7e6ac24-df21-49c4-9426-3fb5970d3085_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_9a05790a-01ed-4011-b200-1c090262dc9a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_13508874-e605-411e-a5d2-c9c3769b5455_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b53375ac-debc-4ac9-8278-eff74e92a484_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_dda3a0b3-5709-451d-b10a-c0917b199b7d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_93bc44d5-a64d-4422-905a-55b6440c4b62_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7fb905a6-4ba9-45c5-aca7-2d90859bd642_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d6463fdd-9405-4ad6-8e0b-c175de6ae3aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_07f259c4-16c6-4235-a70a-2d9c95e997e5_terseLabel_en-US" xlink:label="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of indebtedness income and interest expense</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_label_en-US" xlink:label="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_documentation_en-US" xlink:label="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:to="lab_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0b6ad940-67b2-4834-9d28-577f3f4a8335_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerRelatedExpensesStockSettledMember_44c7e127-7b24-4e68-bd2c-45d659da92e2_terseLabel_en-US" xlink:label="lab_pacb_MergerRelatedExpensesStockSettledMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses - stock-settled</link:label>
    <link:label id="lab_pacb_MergerRelatedExpensesStockSettledMember_label_en-US" xlink:label="lab_pacb_MergerRelatedExpensesStockSettledMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Related Expenses Stock Settled [Member]</link:label>
    <link:label id="lab_pacb_MergerRelatedExpensesStockSettledMember_documentation_en-US" xlink:label="lab_pacb_MergerRelatedExpensesStockSettledMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger-related expenses - stock-settled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesStockSettledMember" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesStockSettledMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerRelatedExpensesStockSettledMember" xlink:to="lab_pacb_MergerRelatedExpensesStockSettledMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_05c1ae17-fdef-4e89-a2f5-f3c324e32bc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock_8f98fc6b-97f4-4f71-bea7-d1576aaf56b6_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Consideration Transferred for Acquisition</link:label>
    <link:label id="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition Consideration Transferred [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of a material business combination completed during the period, details of total considerations transferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" xlink:to="lab_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability_3c9d31b0-0484-4d82-b91b-67a6ae49baa1_negatedTerseLabel_en-US" xlink:label="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability_label_en-US" xlink:label="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Contingent Consideration Liability</link:label>
    <link:label id="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability_documentation_en-US" xlink:label="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Contingent Consideration Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability" xlink:href="pacb-20231231.xsd#pacb_IncreaseDecreaseInContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability" xlink:to="lab_pacb_IncreaseDecreaseInContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a7014be9-86ae-4594-afbe-c4f602678753_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c3922c0d-acb7-4cd1-9cff-601d9af7628a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_56e75a10-fdd1-40da-99a8-5656f8761646_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_2e929420-16ed-48b7-8874-d9be3cc27479_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember" xlink:href="pacb-20231231.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsOneMember" xlink:to="lab_pacb_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AuditInformationAbstract_label_en-US" xlink:label="lab_pacb_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_pacb_AuditInformationAbstract_documentation_en-US" xlink:label="lab_pacb_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AuditInformationAbstract" xlink:href="pacb-20231231.xsd#pacb_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AuditInformationAbstract" xlink:to="lab_pacb_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_7d661e18-d31f-4055-98da-4f95af1477c7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseBorrowings_label_en-US" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings" xlink:to="lab_us-gaap_InterestExpenseBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_bbf52d96-d0c9-4ceb-9cb3-24a73071d031_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_df504071-90fd-4aef-a116-c21844d20f35_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger related transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_3d4d9b62-cdbe-4107-93d8-43a22f27cdb5_terseLabel_en-US" xlink:label="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization of Significant Agreements Transactions [Line Items]</link:label>
    <link:label id="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_label_en-US" xlink:label="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization of Significant Agreements Transactions [Line Items]</link:label>
    <link:label id="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_documentation_en-US" xlink:label="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization Agreement Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:href="pacb-20231231.xsd#pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:to="lab_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3695e210-0f2c-470f-a2d0-0a88be2c3bcf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets_e7f1b840-c629-4140-9e7f-60a32e391d7b_negatedLabel_en-US" xlink:label="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</link:label>
    <link:label id="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_pacb_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d16dde71-75db-4b34-9dee-78814522a052_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56cbcb18-118b-4aba-8f26-0dbf25b38e86_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_a60052a2-4f28-4ed2-be4e-9ea19675db31_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term loan</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5861569b-47c6-4efb-8b15-ddb039dc58ff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InducementEquityIncentivePlan2020Member_fe80872d-ad7e-4fca-95e9-bfb8d894efaa_terseLabel_en-US" xlink:label="lab_pacb_InducementEquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_pacb_InducementEquityIncentivePlan2020Member_label_en-US" xlink:label="lab_pacb_InducementEquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Equity Incentive Plan2020 [Member]</link:label>
    <link:label id="lab_pacb_InducementEquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_pacb_InducementEquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InducementEquityIncentivePlan2020Member" xlink:href="pacb-20231231.xsd#pacb_InducementEquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InducementEquityIncentivePlan2020Member" xlink:to="lab_pacb_InducementEquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LaboratoryEquipmentAndMachineryMember_1d2dd65a-d543-41bf-87a0-7caccf402d02_terseLabel_en-US" xlink:label="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment and machinery</link:label>
    <link:label id="lab_pacb_LaboratoryEquipmentAndMachineryMember_label_en-US" xlink:label="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</link:label>
    <link:label id="lab_pacb_LaboratoryEquipmentAndMachineryMember_documentation_en-US" xlink:label="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment And Machinery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LaboratoryEquipmentAndMachineryMember" xlink:href="pacb-20231231.xsd#pacb_LaboratoryEquipmentAndMachineryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LaboratoryEquipmentAndMachineryMember" xlink:to="lab_pacb_LaboratoryEquipmentAndMachineryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7fcfdad1-efb0-406b-bd80-07beb0376e36_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b1741ef-9940-4424-983d-d9cb9bda9723_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b8bf8901-ad64-46d0-aeb6-c32b88a57e31_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerTerminationTextBlock_5d687f53-2702-42d3-928f-d55bcabe9725_terseLabel_en-US" xlink:label="lab_pacb_MergerTerminationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TERMINATION OF MERGER WITH ILLUMINA</link:label>
    <link:label id="lab_pacb_MergerTerminationTextBlock_label_en-US" xlink:label="lab_pacb_MergerTerminationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Text Block]</link:label>
    <link:label id="lab_pacb_MergerTerminationTextBlock_documentation_en-US" xlink:label="lab_pacb_MergerTerminationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationTextBlock" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerTerminationTextBlock" xlink:to="lab_pacb_MergerTerminationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_091523a2-38b3-4eff-8902-af3d53c5b260_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding common stock used to determine annual plan increase</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MilestoneAchievementMember_6ed327c3-d5ef-468d-9c19-5274bf382f3b_terseLabel_en-US" xlink:label="lab_pacb_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_pacb_MilestoneAchievementMember_label_en-US" xlink:label="lab_pacb_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_pacb_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_pacb_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MilestoneAchievementMember" xlink:href="pacb-20231231.xsd#pacb_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MilestoneAchievementMember" xlink:to="lab_pacb_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_08963441-9d82-42a0-b7dc-8fb7460c6e01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested related to RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d3f14e84-4b0b-4ff1-b049-63f4f5a5de2d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_e9de7f50-ce76-4932-937d-876741559f97_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_36f3f445-bc2f-4064-8568-a757b12c9091_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6c7c1f-03e9-48fc-aa73-7c0d7a7527ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7385742b-5052-4475-9d3d-f194e3e88087_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02b1b615-bff5-4362-aa1e-a3de3c2a9532_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d6c8dd5b-20e7-4c47-b6a5-f1587a8c3a53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConsumableMember_747c2c36-88a6-4a75-a04e-744391c070c1_terseLabel_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable revenue</link:label>
    <link:label id="lab_pacb_ConsumableMember_label_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable [Member]</link:label>
    <link:label id="lab_pacb_ConsumableMember_documentation_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember" xlink:href="pacb-20231231.xsd#pacb_ConsumableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConsumableMember" xlink:to="lab_pacb_ConsumableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_93ea7a86-80f7-43b2-bd63-425f0995ac65_terseLabel_en-US" xlink:label="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible Continuation Advances payable</link:label>
    <link:label id="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_label_en-US" xlink:label="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place</link:label>
    <link:label id="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_documentation_en-US" xlink:label="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:href="pacb-20231231.xsd#pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:to="lab_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e96fbd2-5e6a-4f9b-97ec-990cd08c69ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_a939e142-ca43-4077-8537-d1b2dd0e80de_terseLabel_en-US" xlink:label="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and experimental expenses</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label id="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_53cd31e5-2109-4baa-ab6e-33b28d7198c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in conjunction with equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b391865d-fb91-4208-9aee-104cf97ed5a5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5c7ac27f-ae98-4e9e-b010-e71f71c217d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0593099e-823e-4211-bf8d-52128f05e826_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_9106b0cd-21f5-48e0-ade7-6bd2072b6241_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_238b1eb2-fee5-4888-a2eb-6f412a1d7515_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_be948e53-b105-4bf8-b937-71591904f660_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cae5a9fc-dfe5-4c3e-b597-61f4ed788c2f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2f1d3779-a707-4985-9dc1-ddf2c2fd4180_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_67d038b9-4ec9-456a-906d-8112c67fe163_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_44c51716-ffd2-49c5-a59b-4d12da1a3c79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Share-based compensation expense excluded from consideration transferred</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e216c88d-6783-4964-8552-1bd6bd995b41_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_cb27c551-b0f6-4eaf-9e30-a7722796f492_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a919f8ef-49f5-4c00-a171-7aed58e17079_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_9b72b9a4-0b9e-4593-a095-6070524f6246_terseLabel_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e941d3ce-b81d-4bfd-b971-c7c48b3cadd1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_4f92efe0-3348-4990-b4a5-ba0ec8146c71_terseLabel_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_label_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss per Share Abstrct</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_documentation_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss per Share Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract" xlink:href="pacb-20231231.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeLossPerShareAbstract" xlink:to="lab_pacb_IncomeLossPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_488b5a4b-a532-41a0-be6a-18c8bc7656eb_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e25e301c-ec51-4e7a-9035-62de222ba67a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_35d89330-b479-4e99-918a-ecbf31613e1a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_2838936c-dd22-41e1-83b5-8df98adb0b30_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6e9aeb37-bea0-48ba-a441-66022486cf3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerTerminationTable_82cdcd77-7bbb-45a2-b4da-5a781a60d6e6_terseLabel_en-US" xlink:label="lab_pacb_MergerTerminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Table]</link:label>
    <link:label id="lab_pacb_MergerTerminationTable_label_en-US" xlink:label="lab_pacb_MergerTerminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Table]</link:label>
    <link:label id="lab_pacb_MergerTerminationTable_documentation_en-US" xlink:label="lab_pacb_MergerTerminationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationTable" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerTerminationTable" xlink:to="lab_pacb_MergerTerminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fd2c5d75-d32f-4de0-a7af-54de8021f34a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_51977f9f-711a-46bd-a722-a629bea00a99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_c4c380e9-0ee1-48d9-8476-9621975b9223_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2c3de179-c146-48df-bf54-c50e5fffbe7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e1d97ceb-4b2f-4189-a23a-fb055f69f556_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_a22fff59-ef6f-4163-8201-340b89f58497_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d3a282e7-7f8c-42d2-8667-918b55f3dd99_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock following milestone achievement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_5dd229e1-f832-4be9-93d8-25fa602443f5_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7f2771b4-6785-4459-9851-c9088bdb79ba_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_10661a1a-e605-46b7-91a0-0d155e0c94d5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_203d0f83-a4d1-4d0a-86b6-61526b88c9bc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_95a2cc72-f41f-4a3f-81fd-4ea7b4b18126_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_aaa43d0b-e5a5-4a2b-a63a-04337044015c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_97794110-5612-4583-a767-5c33177af8a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9a24738-3468-432a-8667-15b7893af2ab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_567b0633-c090-43c3-9e23-6a5cc00c748a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_611f7c84-48a1-4835-866c-2e75c2d34b76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expired, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_45fd565b-1477-4757-b3c7-ae78cfee4d0b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0556a10f-29a2-4cf3-8705-8047e0181e38_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_b4302a3e-e103-43a7-9bf4-a6edbfcfe48c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_MergerTerminationLineItems_20a7094d-b846-427b-bfe9-7991308b1af2_terseLabel_en-US" xlink:label="lab_pacb_MergerTerminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Line Items]</link:label>
    <link:label id="lab_pacb_MergerTerminationLineItems_label_en-US" xlink:label="lab_pacb_MergerTerminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Line Items]</link:label>
    <link:label id="lab_pacb_MergerTerminationLineItems_documentation_en-US" xlink:label="lab_pacb_MergerTerminationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Termination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationLineItems" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_MergerTerminationLineItems" xlink:to="lab_pacb_MergerTerminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_d20783f7-5c65-4299-a5b1-676a44434646_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_e5c5dd7f-686d-4097-a95c-6b46f0505e29_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Convertible Senior Notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ce1e1467-a601-4a30-a6a4-922251e7124f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6a0251e5-704f-49e3-bd53-1e1f1a90e00b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_608d51ad-3d75-4659-b391-bd6173969612_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption, percentage of conversion price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:to="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_f25201be-4772-4fd9-b8f6-39c3e61a735b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_d9beb56e-2c62-4740-b3c6-2de6269d724f_terseLabel_en-US" xlink:label="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting right of common stock share holders, number of votes</link:label>
    <link:label id="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_label_en-US" xlink:label="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share Owned</link:label>
    <link:label id="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_documentation_en-US" xlink:label="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes Per Share Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:href="pacb-20231231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:to="lab_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_080bc270-a92f-4d6f-9e71-4f0e290bc811_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9eacb372-100f-4c8b-ada6-c5cef18fe1b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term debt acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_598a4af5-a1b1-427e-aedb-f9f8cab6e927_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_00c36591-04b6-4968-ac70-d8de07192d6d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b8cf2a9b-9af2-4258-904c-b019df6a90fd_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_bb2ce72f-78c5-4b2f-a691-e7b5e902cc23_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of share consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e6bfd508-62ff-4f02-915e-8cae73ea8b16_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c3c8b4c8-5b90-4cc0-9bbe-9eeb81701a7a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d75e89d9-cb64-4795-b87c-37d7166f0584_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a452244e-74b0-4c77-96b4-06f8b7f6d06d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing basic net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_dbb140ec-17a3-453a-9453-91cb68dbb53b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3752f70d-d8c6-46fe-a8b6-eb5eac1648ba_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c769d43d-c890-4fb2-be51-44c3b240907e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OmniomePlanMember_dadf1d5e-e0b4-46e7-9a49-c7314308754c_terseLabel_en-US" xlink:label="lab_pacb_OmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Plan</link:label>
    <link:label id="lab_pacb_OmniomePlanMember_label_en-US" xlink:label="lab_pacb_OmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Plan [Member]</link:label>
    <link:label id="lab_pacb_OmniomePlanMember_documentation_en-US" xlink:label="lab_pacb_OmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniome Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomePlanMember" xlink:href="pacb-20231231.xsd#pacb_OmniomePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OmniomePlanMember" xlink:to="lab_pacb_OmniomePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4ba89c55-73bc-45a1-8382-34c5a6649b4a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_0804dff5-1c1e-4052-9643-fcdcab488a2f_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_16dd14d4-2f25-494c-8931-f6a2dceca362_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on purchase commitment</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5a67560b-4d6a-47c1-bad5-1ae4330db962_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0981376e-4ae1-4c9f-ab04-86ce5833580d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4db9b8c7-a5c2-4dad-bfec-e5927c493bcb_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_58c6efe8-4cc2-49d0-b961-fb036d092746_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_label_en-US" xlink:label="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Operating lease right-of-use assets, net Acquired and Liabilities Assumed Operating Lease Right of use assets Net</link:label>
    <link:label id="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of property, operating lease right of use assets net recognized as of the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:to="lab_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>pacb-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4809e9eb-ee6c-40c5-b267-06eb948f47bd,g:8f5aae7b-78f1-4a80-ad95-b1556c05246b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/Cover" xlink:type="simple" xlink:href="pacb-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_94a5db38-3b6a-4200-b248-d93bbd28a752" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentType_94a5db38-3b6a-4200-b248-d93bbd28a752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a59555f3-9956-4e6b-ae1d-1d316c8aeba8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentAnnualReport_a59555f3-9956-4e6b-ae1d-1d316c8aeba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a21ec7c6-3c3d-4a52-9f64-38fa7f645c05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_CurrentFiscalYearEndDate_a21ec7c6-3c3d-4a52-9f64-38fa7f645c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3d6dce9c-7052-42cf-9be6-a1423f86fc56" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentPeriodEndDate_3d6dce9c-7052-42cf-9be6-a1423f86fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3611d99e-15dd-4331-991d-136a76b1b634" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentTransitionReport_3611d99e-15dd-4331-991d-136a76b1b634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8050b339-37af-4b96-bfc1-44070c964a7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityFileNumber_8050b339-37af-4b96-bfc1-44070c964a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bbd839d2-0b47-4a2e-b4dc-299375a787d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityRegistrantName_bbd839d2-0b47-4a2e-b4dc-299375a787d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_11f7cbe1-3a0f-4e19-ac38-03e2cf518e95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_11f7cbe1-3a0f-4e19-ac38-03e2cf518e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f1a6c618-17ad-40ce-a394-e44620eb22e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityTaxIdentificationNumber_f1a6c618-17ad-40ce-a394-e44620eb22e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5a4eda93-1ddc-4fea-85b4-243154351dd2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityAddressAddressLine1_5a4eda93-1ddc-4fea-85b4-243154351dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e88bd9a5-5991-4eb5-9fcc-51709a360f31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityAddressCityOrTown_e88bd9a5-5991-4eb5-9fcc-51709a360f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8d058d11-d7f6-42da-bce5-986423895e26" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityAddressStateOrProvince_8d058d11-d7f6-42da-bce5-986423895e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ccbd1c50-5865-4ab1-b861-8d838036a3ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityAddressPostalZipCode_ccbd1c50-5865-4ab1-b861-8d838036a3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_763145b2-7804-4d0e-b01a-26b540698ff1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_CityAreaCode_763145b2-7804-4d0e-b01a-26b540698ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4c92c8a5-551b-40c1-a0d1-877e6ce49621" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_LocalPhoneNumber_4c92c8a5-551b-40c1-a0d1-877e6ce49621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fe34eb2e-990a-4bdd-be21-b18574c7a2ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_Security12bTitle_fe34eb2e-990a-4bdd-be21-b18574c7a2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f2c74c12-3b96-4529-b107-e45bac68e983" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_TradingSymbol_f2c74c12-3b96-4529-b107-e45bac68e983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bfebb4f2-88f2-4064-a0ee-106e995b90b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_SecurityExchangeName_bfebb4f2-88f2-4064-a0ee-106e995b90b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1f1f1167-1408-4ba2-97b1-6543d21b7758" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1f1f1167-1408-4ba2-97b1-6543d21b7758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ac264535-e195-457d-9e3e-b82ab217f20a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityVoluntaryFilers_ac264535-e195-457d-9e3e-b82ab217f20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_09008cde-3173-4a6d-8f43-67dbf070c69d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityCurrentReportingStatus_09008cde-3173-4a6d-8f43-67dbf070c69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0ccee6cf-fe11-46cf-9482-7d3deb1421f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityInteractiveDataCurrent_0ccee6cf-fe11-46cf-9482-7d3deb1421f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6fa2ee22-68dd-4da1-a91a-00069466e342" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityFilerCategory_6fa2ee22-68dd-4da1-a91a-00069466e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7e4a3775-3ef4-435d-8e5b-850e8fed369f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntitySmallBusiness_7e4a3775-3ef4-435d-8e5b-850e8fed369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_95bc591f-41ed-40db-a1b0-407169818566" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityEmergingGrowthCompany_95bc591f-41ed-40db-a1b0-407169818566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_dc7eb7ee-e324-4479-bfc4-0558f06c405b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_dc7eb7ee-e324-4479-bfc4-0558f06c405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_2634952f-77f1-40b4-8037-e0ced4aa0697" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_2634952f-77f1-40b4-8037-e0ced4aa0697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d5a868bf-651a-456f-b694-3f6628a29400" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityShellCompany_d5a868bf-651a-456f-b694-3f6628a29400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_63c68e82-cf03-4a12-81d1-14dd5c7648bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityPublicFloat_63c68e82-cf03-4a12-81d1-14dd5c7648bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_77f7a24a-d880-4bfd-8807-3d5896f48460" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_77f7a24a-d880-4bfd-8807-3d5896f48460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_19712cd0-2892-4d4c-af9c-7d801b46c7af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_19712cd0-2892-4d4c-af9c-7d801b46c7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9f838846-edab-4dd5-9589-6f6e1b46905c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9f838846-edab-4dd5-9589-6f6e1b46905c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_aa65a953-6765-483f-bd8e-6c641668fb3f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_EntityCentralIndexKey_aa65a953-6765-483f-bd8e-6c641668fb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_905b4f4b-1378-4903-a990-c7a76c4d408b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_AmendmentFlag_905b4f4b-1378-4903-a990-c7a76c4d408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8336cf46-4dba-4ee9-92e2-39a19782e080" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecad1d90-a95c-4605-9e0f-4045e101460a" xlink:to="loc_dei_DocumentFiscalYearFocus_8336cf46-4dba-4ee9-92e2-39a19782e080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/AuditInformation" xlink:type="simple" xlink:href="pacb-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AuditInformationAbstract_b8c76bc9-47ab-4bae-b063-9f3612969d98" xlink:href="pacb-20231231.xsd#pacb_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_7cd6953e-138e-440a-8cd5-98c4aabdc0eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_AuditInformationAbstract_b8c76bc9-47ab-4bae-b063-9f3612969d98" xlink:to="loc_dei_AuditorName_7cd6953e-138e-440a-8cd5-98c4aabdc0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_8af07be6-db73-4f77-8905-9f84c3925714" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_AuditInformationAbstract_b8c76bc9-47ab-4bae-b063-9f3612969d98" xlink:to="loc_dei_AuditorLocation_8af07be6-db73-4f77-8905-9f84c3925714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ec9a4e23-d6f1-4d5a-91ad-ae49d7ef2953" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_AuditInformationAbstract_b8c76bc9-47ab-4bae-b063-9f3612969d98" xlink:to="loc_dei_AuditorFirmId_ec9a4e23-d6f1-4d5a-91ad-ae49d7ef2953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0e72b4c6-c21a-4110-aff4-69363228c76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e72b4c6-c21a-4110-aff4-69363228c76d" xlink:to="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_60abc8c0-0ed1-4869-8f83-90e403cbab28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_60abc8c0-0ed1-4869-8f83-90e403cbab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_be24cec2-d0ed-4836-a729-6cadb94fc368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_ShortTermInvestments_be24cec2-d0ed-4836-a729-6cadb94fc368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_05e7c58e-0148-465a-9f96-1e29515826d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_05e7c58e-0148-465a-9f96-1e29515826d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a31b2dab-2c84-466a-ad7a-ec5ef59e81f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_InventoryNet_a31b2dab-2c84-466a-ad7a-ec5ef59e81f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c864dea0-3d84-4e47-8f7a-b1c37f7f294d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c864dea0-3d84-4e47-8f7a-b1c37f7f294d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_a798bdf7-95d8-4a60-9e49-40a02951fccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_RestrictedCashCurrent_a798bdf7-95d8-4a60-9e49-40a02951fccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_18b1173f-8e5f-4adc-a9ac-1216516f5b66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5c492807-cef6-44fa-b05a-10051a506948" xlink:to="loc_us-gaap_AssetsCurrent_18b1173f-8e5f-4adc-a9ac-1216516f5b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a83dc38-7608-4708-99e6-0be1be2a43c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1a83dc38-7608-4708-99e6-0be1be2a43c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_af299fff-689d-4352-8083-1ff4da08b7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_af299fff-689d-4352-8083-1ff4da08b7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7a587bd8-bb86-4265-b182-4f155b1ab6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7a587bd8-bb86-4265-b182-4f155b1ab6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f63c6505-b0b0-4e24-a522-9dfc040d8141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f63c6505-b0b0-4e24-a522-9dfc040d8141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c21440e6-28ed-453f-92dd-a36a444554e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_Goodwill_c21440e6-28ed-453f-92dd-a36a444554e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b4d489a7-7bba-47b1-b7e1-c9e880f11d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b4d489a7-7bba-47b1-b7e1-c9e880f11d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e9450b47-0a90-46da-aad4-f1d9628f2645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4129b408-fe5c-42a7-ac38-2e48fb0f67db" xlink:to="loc_us-gaap_Assets_e9450b47-0a90-46da-aad4-f1d9628f2645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e72b4c6-c21a-4110-aff4-69363228c76d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2eead493-e6c0-4c27-9343-8eb168816907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_AccountsPayableCurrent_2eead493-e6c0-4c27-9343-8eb168816907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5c4acb1e-6933-4700-9eb6-d4b2e0769f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5c4acb1e-6933-4700-9eb6-d4b2e0769f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e879d91-1509-48fc-b639-8933d67efcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e879d91-1509-48fc-b639-8933d67efcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0208ab0b-e6b8-4ff7-9621-92888a222e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0208ab0b-e6b8-4ff7-9621-92888a222e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_604e6ccf-f4b4-4fe1-a1a5-99a257626bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_604e6ccf-f4b4-4fe1-a1a5-99a257626bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_624e45dc-8986-4db1-b9dd-8ef7c0c54671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_624e45dc-8986-4db1-b9dd-8ef7c0c54671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3147957f-08ba-446a-ac25-b1892fc24799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bfd799cc-e25a-4844-88dc-ab771c3804f0" xlink:to="loc_us-gaap_LiabilitiesCurrent_3147957f-08ba-446a-ac25-b1892fc24799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ae225cc5-49c4-4602-a97c-124fba6523f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ae225cc5-49c4-4602-a97c-124fba6523f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e720a090-33a5-448b-bb77-eb9c4ba58b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e720a090-33a5-448b-bb77-eb9c4ba58b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b4e715c-237d-4542-9b98-6dc0f435daa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b4e715c-237d-4542-9b98-6dc0f435daa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_4b90bc94-fb94-49fb-bd95-32ccebb3b3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_4b90bc94-fb94-49fb-bd95-32ccebb3b3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e8788133-a4d5-4574-8c2b-267006277d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e8788133-a4d5-4574-8c2b-267006277d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3ff68e15-6336-4756-bd59-ae93e53698d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_Liabilities_3ff68e15-6336-4756-bd59-ae93e53698d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9523b70e-191b-4b7a-9e79-d64e0356695b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9523b70e-191b-4b7a-9e79-d64e0356695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_39866567-bff6-409f-97a0-f9cad0ae0373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:to="loc_us-gaap_PreferredStockValue_39866567-bff6-409f-97a0-f9cad0ae0373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c5cd67ec-f10d-41db-af51-a30f868f0bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:to="loc_us-gaap_CommonStockValue_c5cd67ec-f10d-41db-af51-a30f868f0bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dc634a47-bffc-44aa-9261-341ccba1b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dc634a47-bffc-44aa-9261-341ccba1b8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c53d17b6-7144-4e28-86a1-ffacd6a97b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c53d17b6-7144-4e28-86a1-ffacd6a97b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cc622b80-79eb-442e-91ea-d84707a02add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cc622b80-79eb-442e-91ea-d84707a02add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2fe49b07-9e7a-46c2-b488-2048b7ac25a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a33dacf5-8bcb-4df3-ae1e-d29166dcd1c8" xlink:to="loc_us-gaap_StockholdersEquity_2fe49b07-9e7a-46c2-b488-2048b7ac25a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_acd7b7d5-19c0-4472-ace4-65f9f092334a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b7c3879-bcb3-426b-8ec5-ead5e485a55e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_acd7b7d5-19c0-4472-ace4-65f9f092334a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8a0c6989-a9ee-4741-8ad7-1c870374e7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8a0c6989-a9ee-4741-8ad7-1c870374e7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_62ab710a-3efb-4e7d-ab06-1dc41866aca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_62ab710a-3efb-4e7d-ab06-1dc41866aca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b6435ba5-f693-44f5-aa87-91f24fe548f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b6435ba5-f693-44f5-aa87-91f24fe548f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a55367a9-184d-4d59-bb7f-62cba4d984fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a55367a9-184d-4d59-bb7f-62cba4d984fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_47af56d9-9280-4470-87d6-73bdd2754421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_47af56d9-9280-4470-87d6-73bdd2754421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_67c95fe5-0fb5-404d-a14c-c68083a92456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_67c95fe5-0fb5-404d-a14c-c68083a92456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3ce7b24d-20c2-4946-9287-abb6d470dd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_CommonStockSharesIssued_3ce7b24d-20c2-4946-9287-abb6d470dd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5391cad0-5891-4284-8acb-53301f56b981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3deb64e2-6084-4434-94f1-b3168d4cf76e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5391cad0-5891-4284-8acb-53301f56b981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3f6b1b06-7db0-4233-bd40-4289cc35861d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3f6b1b06-7db0-4233-bd40-4289cc35861d" xlink:to="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:to="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_90784abb-5f0d-4dc6-a25d-0430bc0c3f36" xlink:to="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_235609d7-48a1-42ac-94f3-0566b7291ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:to="loc_us-gaap_ProductMember_235609d7-48a1-42ac-94f3-0566b7291ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_625a52d9-2675-46a0-9159-d4ecab7d2f5a" xlink:href="pacb-20231231.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9a30e98-d52f-4b0c-b131-a5e1e9d15406" xlink:to="loc_pacb_ServiceAndOtherMember_625a52d9-2675-46a0-9159-d4ecab7d2f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fcb99452-adcc-4134-b730-861a328bb790" xlink:to="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_07fcebc1-2771-4772-9fd4-b0b4979a9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_RevenuesAbstract_07fcebc1-2771-4772-9fd4-b0b4979a9e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_94cc024f-3abc-43d0-9e82-ebce1fac4c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_07fcebc1-2771-4772-9fd4-b0b4979a9e98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_94cc024f-3abc-43d0-9e82-ebce1fac4c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_0339b7cd-f19a-4b8e-9c42-ef33e54bcaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_0339b7cd-f19a-4b8e-9c42-ef33e54bcaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostOfOperatingRevenue_352f795a-9454-452b-9625-8955e60b7aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_OtherCostOfOperatingRevenue_352f795a-9454-452b-9625-8955e60b7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_2839713d-2ad0-4dea-85c2-b6de126df3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_2839713d-2ad0-4dea-85c2-b6de126df3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContracts_57f0d264-c78d-46a0-8332-2db00568b251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContracts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_LossOnContracts_57f0d264-c78d-46a0-8332-2db00568b251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ef61df9b-8aff-4837-8aec-06ece186d84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_6777ba15-be1c-4144-bc4d-d887052939e6" xlink:to="loc_us-gaap_CostOfRevenue_ef61df9b-8aff-4837-8aec-06ece186d84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f08c8818-473b-477d-91f8-821c72059ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_GrossProfit_f08c8818-473b-477d-91f8-821c72059ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c37023fa-ee3a-45b6-b435-f5bb989e6a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c37023fa-ee3a-45b6-b435-f5bb989e6a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ccebdac-15ef-406d-805a-7b659e1da108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3ccebdac-15ef-406d-805a-7b659e1da108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e0df685-1aae-4da3-88d1-1f1b9b890415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_8e0df685-1aae-4da3-88d1-1f1b9b890415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ba94d308-5f91-4db4-b050-ae1f3240b2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ba94d308-5f91-4db4-b050-ae1f3240b2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3dfe02dd-6e6d-4906-ab2f-140c08261f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3dfe02dd-6e6d-4906-ab2f-140c08261f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_196bab16-060e-44fa-b36c-c169160f0473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7180e318-9c42-4178-88b5-ce76e8a8e58f" xlink:to="loc_us-gaap_OperatingExpenses_196bab16-060e-44fa-b36c-c169160f0473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6127a3a5-c50c-4cb2-a362-5d9b3e960280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OperatingIncomeLoss_6127a3a5-c50c-4cb2-a362-5d9b3e960280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_8d478907-8ff8-4307-bca2-9a6de349bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_GainLossOnContractTermination_8d478907-8ff8-4307-bca2-9a6de349bd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_135746e2-8ab5-4fcd-bc97-a04b20af60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_135746e2-8ab5-4fcd-bc97-a04b20af60b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_baf511c6-6a2f-4767-a4da-570e621ba78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_InterestExpense_baf511c6-6a2f-4767-a4da-570e621ba78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dd8c33ea-ac13-490a-880b-422583ad90a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dd8c33ea-ac13-490a-880b-422583ad90a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cebd090d-ecd4-4e70-a5d7-3cae186cac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cebd090d-ecd4-4e70-a5d7-3cae186cac6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0c97b5fe-2905-4543-bf56-69ca31b329f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0c97b5fe-2905-4543-bf56-69ca31b329f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db45801c-50b1-4aab-b235-5c26f304eb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_NetIncomeLoss_db45801c-50b1-4aab-b235-5c26f304eb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b84a9e4a-d19d-4147-9c94-eecde0ab8971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b84a9e4a-d19d-4147-9c94-eecde0ab8971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f18e7a7c-28bb-41a8-a9c3-ea37e8ada38f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b84a9e4a-d19d-4147-9c94-eecde0ab8971" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f18e7a7c-28bb-41a8-a9c3-ea37e8ada38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_55932567-6f2e-447d-bc7f-46ce863ed95b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_55932567-6f2e-447d-bc7f-46ce863ed95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:href="pacb-20231231.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9c1ae31-2f55-4a3f-9cbe-7a2e708c2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9c1ae31-2f55-4a3f-9cbe-7a2e708c2d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ef52b7d-eb54-4284-841f-b98af54513bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_7aa9c4b4-c52e-4c3a-9d77-2dafe1aae2ee" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4ef52b7d-eb54-4284-841f-b98af54513bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17266535-526a-40fa-aa59-a86976d82f75" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c225c346-4baa-415b-82ca-45b2080228ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c225c346-4baa-415b-82ca-45b2080228ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c5e1ee6-7575-4311-8072-7e3dcb810ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_fb08f8f3-88db-4bc7-9f4c-9e6d746f26c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c5e1ee6-7575-4311-8072-7e3dcb810ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b5f18d90-09ca-4096-8df8-567c83011a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b5f18d90-09ca-4096-8df8-567c83011a1e" xlink:to="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c58e55d4-c299-4c7c-ad96-c37299cb245b" xlink:to="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b901f4f5-6c10-44dd-ad58-73804276c178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_CommonStockMember_b901f4f5-6c10-44dd-ad58-73804276c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f313405f-c6fc-4db3-b18b-142bf1df4472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f313405f-c6fc-4db3-b18b-142bf1df4472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f579426c-6b0b-449a-86ab-b56c8e8ca537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f579426c-6b0b-449a-86ab-b56c8e8ca537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5c03f5a7-a6e4-4e0a-883d-5521cfda7dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57469fe6-61e1-4575-bea9-363ef97b8e25" xlink:to="loc_us-gaap_RetainedEarningsMember_5c03f5a7-a6e4-4e0a-883d-5521cfda7dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e5dcdb5-06f8-442e-a538-eaa251379f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b075f7eb-f20f-4e10-b87c-9e9459bba0b0" xlink:to="loc_us-gaap_StatementLineItems_0e5dcdb5-06f8-442e-a538-eaa251379f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e5dcdb5-06f8-442e-a538-eaa251379f19" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b601ff6f-3498-4d57-99e0-821e9cd30cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b601ff6f-3498-4d57-99e0-821e9cd30cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f048c31b-eab7-4ae5-868c-917038985186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockholdersEquity_f048c31b-eab7-4ae5-868c-917038985186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c55a046d-c281-4963-b53c-e666f2bfe65a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_NetIncomeLoss_c55a046d-c281-4963-b53c-e666f2bfe65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9f9ba78f-98a4-4975-83bc-908022b5bf75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9f9ba78f-98a4-4975-83bc-908022b5bf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a856e7c8-5eb9-4788-96a7-d1e664ec1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a856e7c8-5eb9-4788-96a7-d1e664ec1fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_77d40d7e-e3e0-45e5-b4ce-33dd0c1933a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_77d40d7e-e3e0-45e5-b4ce-33dd0c1933a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a01506a2-8929-4bd8-b3bb-9137bcf38d58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a01506a2-8929-4bd8-b3bb-9137bcf38d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66e2f6c8-6c7f-4948-ae44-4628b9ece360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66e2f6c8-6c7f-4948-ae44-4628b9ece360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1d4bc509-6730-419c-ba30-7333c9daf88e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1d4bc509-6730-419c-ba30-7333c9daf88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_217dff1e-8f93-4447-a343-b16f6cd00f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_217dff1e-8f93-4447-a343-b16f6cd00f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ab81ada8-7236-4812-9023-74bf6d39eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ab81ada8-7236-4812-9023-74bf6d39eda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9ccfdde8-e966-45fa-bb40-01b21af8611d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9ccfdde8-e966-45fa-bb40-01b21af8611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_280ec70b-2880-4040-ad78-1e2bba30bff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_280ec70b-2880-4040-ad78-1e2bba30bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_c478046f-7e64-4bb1-9cc0-01f822641715" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_c478046f-7e64-4bb1-9cc0-01f822641715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_d6f42ac3-4360-4375-aeda-9ff05af44a96" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_d6f42ac3-4360-4375-aeda-9ff05af44a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6d0abee7-48e0-4d9a-b42f-a6915aafb120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_StockholdersEquity_6d0abee7-48e0-4d9a-b42f-a6915aafb120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0d7859c5-ef60-450e-b85f-57dc30e5ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4614694f-ec18-44c4-b0d9-f1655642a6b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0d7859c5-ef60-450e-b85f-57dc30e5ea1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pacb-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f640d90f-04fe-44a1-b385-2267800eb420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f640d90f-04fe-44a1-b385-2267800eb420" xlink:to="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7a31209-fe8c-4637-82c0-3557e9b34fa2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember_46d79e26-762e-4097-903e-aaa3ad9c03ff" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:to="loc_pacb_CirculomicsIncMember_46d79e26-762e-4097-903e-aaa3ad9c03ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_b3b34a5a-e0b6-448d-9e7a-be8d80f5d527" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:to="loc_pacb_OmniomeIncMember_b3b34a5a-e0b6-448d-9e7a-be8d80f5d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonAndOmniomeMember_73f4ce17-f0fb-4e31-997f-a61a0fa786c3" xlink:href="pacb-20231231.xsd#pacb_AptonAndOmniomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3a27f9a-51e3-42b9-b02c-f102d3e36589" xlink:to="loc_pacb_AptonAndOmniomeMember_73f4ce17-f0fb-4e31-997f-a61a0fa786c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_284d9af4-fa9d-4a87-b40f-e586f9a076e0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationMember_8b9792ec-3b4b-42f4-a7bb-834059daeab0" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:to="loc_pacb_BusinessCombinationMember_8b9792ec-3b4b-42f4-a7bb-834059daeab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LiquidityBonusEventMember_cd150451-979c-4ea1-a72f-b5e9c752a9b5" xlink:href="pacb-20231231.xsd#pacb_LiquidityBonusEventMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:to="loc_pacb_LiquidityBonusEventMember_cd150451-979c-4ea1-a72f-b5e9c752a9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MilestoneAchievementMember_a4ca4351-9adc-4860-a56a-de108f0fd256" xlink:href="pacb-20231231.xsd#pacb_MilestoneAchievementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b58c6f58-c7ec-4ba9-845e-b3a96c288159" xlink:to="loc_pacb_MilestoneAchievementMember_a4ca4351-9adc-4860-a56a-de108f0fd256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_729ff890-efb1-4703-81c9-f749ef19661d" xlink:to="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ba0878f-31db-4f2e-b41f-4ce2e4f8df97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_NetIncomeLoss_8ba0878f-31db-4f2e-b41f-4ce2e4f8df97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_3d09dd5c-ef87-4602-9cbd-d503604abc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_GainLossOnContractTermination_3d09dd5c-ef87-4602-9cbd-d503604abc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bb44c3cf-b52b-4cf1-a360-5a23247f8b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_Depreciation_bb44c3cf-b52b-4cf1-a360-5a23247f8b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_c194942a-010d-4e20-a8ee-59119da7fac4" xlink:href="pacb-20231231.xsd#pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense_c194942a-010d-4e20-a8ee-59119da7fac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_13e4248e-77d7-4655-9a15-ac882a12651b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_13e4248e-77d7-4655-9a15-ac882a12651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1bd4b8b2-a4cf-4757-9345-3c36336a8861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_ShareBasedCompensation_1bd4b8b2-a4cf-4757-9345-3c36336a8861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_8d422af2-cafb-462c-b08f-9c15adbd7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashMergerRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_8d422af2-cafb-462c-b08f-9c15adbd7fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_83634719-006f-4a8e-98e5-9efa0e927213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_83634719-006f-4a8e-98e5-9efa0e927213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2cd485fb-7e09-4c16-b489-5a01449a086d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2cd485fb-7e09-4c16-b489-5a01449a086d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_54053b8c-e622-4359-9932-07a3c27f3c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_54053b8c-e622-4359-9932-07a3c27f3c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_87ba2f2f-423d-4d59-87f2-8591dcb6d448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_InventoryWriteDown_87ba2f2f-423d-4d59-87f2-8591dcb6d448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ac30c12-d817-48eb-a046-c5f6dcb90fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ac30c12-d817-48eb-a046-c5f6dcb90fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_35b7e07c-6b2a-4d5d-9d30-607b79587e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ac1673b-794e-4d9e-aaf2-dca39886262d" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_35b7e07c-6b2a-4d5d-9d30-607b79587e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f77f5fd5-3621-43ff-be1a-64d8de0f7f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f77f5fd5-3621-43ff-be1a-64d8de0f7f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1964d5f0-0a60-4004-8fa0-4a98bbb84941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1964d5f0-0a60-4004-8fa0-4a98bbb84941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a445212-2ee0-4987-8fc3-71a2ae18477b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a445212-2ee0-4987-8fc3-71a2ae18477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f329fc92-56b9-45c0-9ff1-71afb9c89926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f329fc92-56b9-45c0-9ff1-71afb9c89926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_daf363cf-dbc2-4bf4-8af2-eeb41d4e25f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_daf363cf-dbc2-4bf4-8af2-eeb41d4e25f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4de245f7-6300-45ab-a778-6942b803fe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4de245f7-6300-45ab-a778-6942b803fe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bb8c8025-b35c-4a70-8ece-c1ec483678c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_OperatingLeasePayments_bb8c8025-b35c-4a70-8ece-c1ec483678c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability_18bcde45-07a2-4746-a0a3-0e7612edcd49" xlink:href="pacb-20231231.xsd#pacb_IncreaseDecreaseInContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_pacb_IncreaseDecreaseInContingentConsiderationLiability_18bcde45-07a2-4746-a0a3-0e7612edcd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_fb73a01b-8028-4464-9643-8fe9617f731d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1ab11eee-ca33-49e2-a804-2e0741abfc05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_fb73a01b-8028-4464-9643-8fe9617f731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe4cabad-976a-4338-85bb-c9b27145f423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c3b107f-7505-4209-8e7a-c2ea25ab22ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe4cabad-976a-4338-85bb-c9b27145f423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_570f96d0-4a32-49e8-b65d-2316f14077f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_570f96d0-4a32-49e8-b65d-2316f14077f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e38894d6-57a6-43e2-8c28-3b94676961a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e38894d6-57a6-43e2-8c28-3b94676961a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cffd0257-59fe-446f-b94b-ecafbeff42c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cffd0257-59fe-446f-b94b-ecafbeff42c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f540bc72-e71c-4114-a47f-349d66ef9b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f540bc72-e71c-4114-a47f-349d66ef9b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_26a5597a-01cd-46a1-8326-0bdc3f7c7953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_26a5597a-01cd-46a1-8326-0bdc3f7c7953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_483f2d9d-bb10-47ed-812b-c96ee6444150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_483f2d9d-bb10-47ed-812b-c96ee6444150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_73bca135-8d31-4e7a-a641-2d310cba4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d5f97218-6f55-4292-aeb3-aab51bbf5e61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_73bca135-8d31-4e7a-a641-2d310cba4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromRepaymentsOfContractTermination_1f32c85d-2be8-470b-a293-d9ef0596c7da" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromRepaymentsOfContractTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_pacb_ProceedsFromRepaymentsOfContractTermination_1f32c85d-2be8-470b-a293-d9ef0596c7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6bea8c00-f573-49d7-8eb3-7624cda45c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6bea8c00-f573-49d7-8eb3-7624cda45c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_601b9fff-0c1d-4199-a47e-44e5ce97df65" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts_601b9fff-0c1d-4199-a47e-44e5ce97df65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ea5e0f71-bae8-4eaa-86c7-59399e549e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ea5e0f71-bae8-4eaa-86c7-59399e549e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_313bd4f8-78c1-46cf-9a1c-1a74fd103c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_313bd4f8-78c1-46cf-9a1c-1a74fd103c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7b54e412-3c34-4b14-9949-a4c86d140271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7b54e412-3c34-4b14-9949-a4c86d140271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_242bf33b-5735-4c81-9778-280d4fdace68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_242bf33b-5735-4c81-9778-280d4fdace68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_55718ad2-0f64-4dfd-8b66-ea28bf05b6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_55718ad2-0f64-4dfd-8b66-ea28bf05b6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a7218a5-ff23-4399-a211-407e4d29eb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4f3de5e-7570-49cc-bfd9-1cc5f813bb20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a7218a5-ff23-4399-a211-407e4d29eb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72fa8192-e517-4679-8ae7-278a099186ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72fa8192-e517-4679-8ae7-278a099186ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05015919-38ce-424c-b71c-47ceb346efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05015919-38ce-424c-b71c-47ceb346efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_559bfee3-8723-448d-9456-cf37c0658b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_559bfee3-8723-448d-9456-cf37c0658b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a6cf0c1-a720-4479-af7f-f910243eadbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a6cf0c1-a720-4479-af7f-f910243eadbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_86a6051e-9e2c-4ab5-a06f-b8699b6191f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_86a6051e-9e2c-4ab5-a06f-b8699b6191f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6c31e6ca-2e22-4cef-bb3d-73edd748deb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6c31e6ca-2e22-4cef-bb3d-73edd748deb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a92a701b-a964-4e2a-babe-545dd51a1e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6c31e6ca-2e22-4cef-bb3d-73edd748deb8" xlink:to="loc_us-gaap_InterestPaidNet_a92a701b-a964-4e2a-babe-545dd51a1e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8625ec90-8a04-4835-9cdd-dacf6985f9eb" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TransferOfInventoryToPropertyAndEquipment_22e043e0-cf30-46bc-9ed1-eb304b83ce9f" xlink:href="pacb-20231231.xsd#pacb_TransferOfInventoryToPropertyAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_pacb_TransferOfInventoryToPropertyAndEquipment_22e043e0-cf30-46bc-9ed1-eb304b83ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_b5e098fc-79e2-4a05-80cc-f892c0131f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_b5e098fc-79e2-4a05-80cc-f892c0131f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_48f5dd0b-a55c-475b-a091-4b207ce6bcee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_48f5dd0b-a55c-475b-a091-4b207ce6bcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_f4832fed-facd-4f07-aea7-d94b09751ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_StockIssued1_f4832fed-facd-4f07-aea7-d94b09751ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_1fe22fd6-7fd9-4e06-b572-158c3d3d9e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_03628772-3303-4ce8-afea-f8929b0df4f6" xlink:to="loc_us-gaap_NotesIssued1_1fe22fd6-7fd9-4e06-b572-158c3d3d9e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dc6fcb8-1666-4e3c-b582-0a27fd75b349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_be853600-3d73-45f4-845e-1a82186e1145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dc6fcb8-1666-4e3c-b582-0a27fd75b349" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_be853600-3d73-45f4-845e-1a82186e1145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7f76c972-f9b4-45bb-b155-a3ba8a5c772b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_93d1cef5-71af-44ae-8058-8ba18f7e14a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7f76c972-f9b4-45bb-b155-a3ba8a5c772b" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_93d1cef5-71af-44ae-8058-8ba18f7e14a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INVITAECOLLABORATION" xlink:type="simple" xlink:href="pacb-20231231.xsd#INVITAECOLLABORATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INVITAECOLLABORATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SignificantAgreementsAbstract_dd1d0234-dbbe-43a2-9a89-b2d07c24e271" xlink:href="pacb-20231231.xsd#pacb_SignificantAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCollaborationTextBlock_8fef5757-1fa6-4d80-b46c-0130c04451dc" xlink:href="pacb-20231231.xsd#pacb_InvitaeCollaborationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SignificantAgreementsAbstract_dd1d0234-dbbe-43a2-9a89-b2d07c24e271" xlink:to="loc_pacb_InvitaeCollaborationTextBlock_8fef5757-1fa6-4d80-b46c-0130c04451dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINA" xlink:type="simple" xlink:href="pacb-20231231.xsd#TERMINATIONOFMERGERWITHILLUMINA"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINA" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationAbstract_06e0b9dc-92b4-4827-8762-de5214c2d988" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationTextBlock_458a4b7b-71ad-43e5-8445-2fba71c972db" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationAbstract_06e0b9dc-92b4-4827-8762-de5214c2d988" xlink:to="loc_pacb_MergerTerminationTextBlock_458a4b7b-71ad-43e5-8445-2fba71c972db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1db44679-a76e-4fc2-ae02-72bb06dc229a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8919e239-8f90-41ba-b277-0381f14fe430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1db44679-a76e-4fc2-ae02-72bb06dc229a" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_8919e239-8f90-41ba-b277-0381f14fe430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6518ca39-7569-4f75-95c1-b39000ac4569" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_903ab373-0fe1-48ec-bac9-6b88a90d9c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_6518ca39-7569-4f75-95c1-b39000ac4569" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_903ab373-0fe1-48ec-bac9-6b88a90d9c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ae2afefa-57dc-40d3-92ce-a4d6a9efac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_501cc375-f5c2-4ee9-98fd-c9476bb5d346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ae2afefa-57dc-40d3-92ce-a4d6a9efac6c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_501cc375-f5c2-4ee9-98fd-c9476bb5d346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba577c19-66fe-42ac-9045-53bfcb035e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_eff86f3e-4ecd-4351-ba96-02cd17ebbe62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba577c19-66fe-42ac-9045-53bfcb035e5d" xlink:to="loc_us-gaap_LossContingencyDisclosures_eff86f3e-4ecd-4351-ba96-02cd17ebbe62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXES" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_59c23594-89e3-42fe-a96b-d96f835e6635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_50a23db3-e139-471a-8b29-1312f678d7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59c23594-89e3-42fe-a96b-d96f835e6635" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_50a23db3-e139-471a-8b29-1312f678d7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/StockholdersEquity" xlink:type="simple" xlink:href="pacb-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c00aa6-6563-4c0d-bc23-11c9ca7a53d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6697fef4-9669-4b96-8b0f-18e5029803a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99c00aa6-6563-4c0d-bc23-11c9ca7a53d8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6697fef4-9669-4b96-8b0f-18e5029803a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="pacb-20231231.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fb566406-9739-4f2d-8d29-031f26f8d1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_94ba2786-0a61-40ba-a46f-156e671b904a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb566406-9739-4f2d-8d29-031f26f8d1f1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_94ba2786-0a61-40ba-a46f-156e671b904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f1d9dc63-232b-4223-b1b9-d518cc881a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b9736de6-bdf8-44cf-9f88-7c18406effc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f1d9dc63-232b-4223-b1b9-d518cc881a61" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b9736de6-bdf8-44cf-9f88-7c18406effc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d42c4285-7292-427c-99e4-ccdb77f615d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d42c4285-7292-427c-99e4-ccdb77f615d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_88f8f956-2e46-4972-ade1-e1b42071e003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_UseOfEstimates_88f8f956-2e46-4972-ade1-e1b42071e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0c645317-7f76-4a6e-ab17-c029236812fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0c645317-7f76-4a6e-ab17-c029236812fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_367493b9-9662-48a9-aa9a-62c2d562eb91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_367493b9-9662-48a9-aa9a-62c2d562eb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b57fa753-09e8-48a3-8203-9cbe7f384619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b57fa753-09e8-48a3-8203-9cbe7f384619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7be94e3a-18d6-4f3a-abec-aac427c5c66b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7be94e3a-18d6-4f3a-abec-aac427c5c66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_708e5479-b9f3-4c52-b0eb-697d84e56c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_708e5479-b9f3-4c52-b0eb-697d84e56c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f5dee664-1f9e-48f8-a78a-ed33578c9213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f5dee664-1f9e-48f8-a78a-ed33578c9213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_f4cb9575-4387-4e84-be55-f872bf30791b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_f4cb9575-4387-4e84-be55-f872bf30791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_161728bc-137f-44fc-846b-1663d83f5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_161728bc-137f-44fc-846b-1663d83f5fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_54d9f11d-2a50-4a31-a258-a8dc1922a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_54d9f11d-2a50-4a31-a258-a8dc1922a9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_755c692f-5faf-48ff-bc58-d2635a43decb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_755c692f-5faf-48ff-bc58-d2635a43decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5b542322-1a7c-475b-ad3f-fb122d6bc670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5b542322-1a7c-475b-ad3f-fb122d6bc670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_725d7758-8092-4846-91e2-87d96c08e13a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_725d7758-8092-4846-91e2-87d96c08e13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_07b787c3-321b-43f7-9133-6629d7a7ae64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_07b787c3-321b-43f7-9133-6629d7a7ae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c98c9456-96ce-4063-8361-825146e73837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c98c9456-96ce-4063-8361-825146e73837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_248f1029-eff4-40e9-8b47-93edb411bba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_248f1029-eff4-40e9-8b47-93edb411bba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_bd24c56e-7446-4979-8777-d5238ba40c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_bd24c56e-7446-4979-8777-d5238ba40c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_a8193215-f0e2-4566-b314-cfda4e9dce21" xlink:href="pacb-20231231.xsd#pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock_a8193215-f0e2-4566-b314-cfda4e9dce21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aef69a4f-e055-4b91-96d9-31ac5d1181b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_aef69a4f-e055-4b91-96d9-31ac5d1181b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_185b03f6-3077-40d2-a179-60d9f3f0a869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fa8fe86-9422-4cd9-9c26-2233431606ac" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_185b03f6-3077-40d2-a179-60d9f3f0a869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2bc8a34c-5cf8-4a24-892b-a7f34cd4948a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef92a84e-1dbc-4570-846b-b24fb18b4814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2bc8a34c-5cf8-4a24-892b-a7f34cd4948a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef92a84e-1dbc-4570-846b-b24fb18b4814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bab026d8-4835-4c2d-b6f4-27c9ea28753b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_2443db4b-abd7-41b2-8aa5-ef710a1dae11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bab026d8-4835-4c2d-b6f4-27c9ea28753b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_2443db4b-abd7-41b2-8aa5-ef710a1dae11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_36344e30-1748-4910-a750-3a8a77fb60ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bab026d8-4835-4c2d-b6f4-27c9ea28753b" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_36344e30-1748-4910-a750-3a8a77fb60ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock_388486f2-22f6-41b2-abbc-b8bc272881cd" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bab026d8-4835-4c2d-b6f4-27c9ea28753b" xlink:to="loc_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock_388486f2-22f6-41b2-abbc-b8bc272881cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_28bc1298-77ac-478f-8530-4d327cbea750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bab026d8-4835-4c2d-b6f4-27c9ea28753b" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_28bc1298-77ac-478f-8530-4d327cbea750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_db9ca4bc-9b33-4ad3-b743-cd9e8ffae79b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3412d124-75a7-46fc-b4a9-90770c7cda8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_db9ca4bc-9b33-4ad3-b743-cd9e8ffae79b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3412d124-75a7-46fc-b4a9-90770c7cda8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_e80b31ff-e6e1-41f1-9d32-89ceb5cdc016" xlink:href="pacb-20231231.xsd#pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_db9ca4bc-9b33-4ad3-b743-cd9e8ffae79b" xlink:to="loc_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock_e80b31ff-e6e1-41f1-9d32-89ceb5cdc016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3cffa3cd-91d2-4e7b-84dd-10c20abed2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_db9ca4bc-9b33-4ad3-b743-cd9e8ffae79b" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3cffa3cd-91d2-4e7b-84dd-10c20abed2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_f3591f73-bd5b-4f19-baae-4a41df5e7412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_db9ca4bc-9b33-4ad3-b743-cd9e8ffae79b" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_f3591f73-bd5b-4f19-baae-4a41df5e7412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_96586250-11db-4b34-ad5b-d08e7e5e3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_96586250-11db-4b34-ad5b-d08e7e5e3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_97f38886-cc95-4cf3-bd53-c7431edd5d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_97f38886-cc95-4cf3-bd53-c7431edd5d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_949802e2-90ea-42d9-a70f-9e89b055df59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_949802e2-90ea-42d9-a70f-9e89b055df59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0cedafbd-fb3d-41aa-b134-386f5225d88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0cedafbd-fb3d-41aa-b134-386f5225d88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_3b035c6e-e0bb-4e10-98e2-58d99d7f6c82" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_3b035c6e-e0bb-4e10-98e2-58d99d7f6c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_1b18ffd8-06c4-4a53-bd8a-01d6baa57d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_1b18ffd8-06c4-4a53-bd8a-01d6baa57d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_7e86ca03-657b-4a3b-bd76-273a5d4bec81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_7e86ca03-657b-4a3b-bd76-273a5d4bec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_7d71aa6c-fd5e-48fd-8995-cc80e5e62b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_a8ec0870-e4c3-4e19-a6e1-569151387401" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_7d71aa6c-fd5e-48fd-8995-cc80e5e62b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_49046252-4088-4668-9800-902de899e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e0b1d8a9-f111-4235-b9af-01fa03e7c440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_49046252-4088-4668-9800-902de899e50d" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e0b1d8a9-f111-4235-b9af-01fa03e7c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_1bbc778b-a616-4bd8-bfb8-40ff2627ba11" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_49046252-4088-4668-9800-902de899e50d" xlink:to="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_1bbc778b-a616-4bd8-bfb8-40ff2627ba11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b04efc0-4169-4061-ad9f-44c43458ad75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_e02e3e48-eed2-4368-93ee-fc29d203d009" xlink:href="pacb-20231231.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b04efc0-4169-4061-ad9f-44c43458ad75" xlink:to="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_e02e3e48-eed2-4368-93ee-fc29d203d009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18d0e57e-8fcb-4e96-8b14-0ef7ea0a3ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c7f857da-886a-4a8f-a53a-bc7f7664ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18d0e57e-8fcb-4e96-8b14-0ef7ea0a3ccd" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c7f857da-886a-4a8f-a53a-bc7f7664ad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b7fa430-c571-4cf8-9618-f8aaa94c4f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18d0e57e-8fcb-4e96-8b14-0ef7ea0a3ccd" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9b7fa430-c571-4cf8-9618-f8aaa94c4f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9dd4c352-b946-4fbd-a950-68907917b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18d0e57e-8fcb-4e96-8b14-0ef7ea0a3ccd" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9dd4c352-b946-4fbd-a950-68907917b40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1ae53f82-f8eb-419a-aec7-bc49753fc328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18d0e57e-8fcb-4e96-8b14-0ef7ea0a3ccd" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1ae53f82-f8eb-419a-aec7-bc49753fc328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1aca403-11f8-4440-b07f-3bfde8cabeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9c78b036-db78-48f3-a68f-12c986e660da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1aca403-11f8-4440-b07f-3bfde8cabeb6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9c78b036-db78-48f3-a68f-12c986e660da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_231994d8-cd8a-4e3e-98d3-6f803ad1741c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1aca403-11f8-4440-b07f-3bfde8cabeb6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_231994d8-cd8a-4e3e-98d3-6f803ad1741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_587c0a37-e110-4f01-b8fd-fe55179c30f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1aca403-11f8-4440-b07f-3bfde8cabeb6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_587c0a37-e110-4f01-b8fd-fe55179c30f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1183acd3-d286-4d50-9023-6f4c0fc1d865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1aca403-11f8-4440-b07f-3bfde8cabeb6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1183acd3-d286-4d50-9023-6f4c0fc1d865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_d45ecb02-5dbb-4cfb-ab70-91f4158cafe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a1aca403-11f8-4440-b07f-3bfde8cabeb6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_d45ecb02-5dbb-4cfb-ab70-91f4158cafe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="pacb-20231231.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_09eb7317-7cef-47b8-94a9-85e357d7c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ab2296c9-8dc1-4a71-9f14-59d0f1702832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09eb7317-7cef-47b8-94a9-85e357d7c41d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ab2296c9-8dc1-4a71-9f14-59d0f1702832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8ba49b99-09f6-461a-8eb9-452d91aef686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09eb7317-7cef-47b8-94a9-85e357d7c41d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8ba49b99-09f6-461a-8eb9-452d91aef686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4effbecd-52a3-4bd9-944b-97730de22176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a5c893d2-f690-44f1-89bb-6b252fa9ae78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4effbecd-52a3-4bd9-944b-97730de22176" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a5c893d2-f690-44f1-89bb-6b252fa9ae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5845fd46-2cf6-4a38-98e2-d54b52c7e1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4effbecd-52a3-4bd9-944b-97730de22176" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5845fd46-2cf6-4a38-98e2-d54b52c7e1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68b74599-e627-409a-8a42-4580f05eef08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:href="pacb-20231231.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68b74599-e627-409a-8a42-4580f05eef08" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41e6a007-af41-4386-b4e1-2e3d4c8767b3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0f35cd4e-3c1e-4626-9d3b-81711d907299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:to="loc_us-gaap_SalesRevenueNetMember_0f35cd4e-3c1e-4626-9d3b-81711d907299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_decabbbb-0790-4bef-ad86-bd902b05d326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10f5322d-3cee-4847-8cf5-d4482e7b30d0" xlink:to="loc_us-gaap_AccountsReceivableMember_decabbbb-0790-4bef-ad86-bd902b05d326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_53d018eb-3ef2-428a-9b85-e306e8e01b77" xlink:to="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_db7d8233-70b0-47ea-887d-50a31b5b25de" xlink:href="pacb-20231231.xsd#pacb_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:to="loc_pacb_CustomerOneMember_db7d8233-70b0-47ea-887d-50a31b5b25de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_6e0f6aee-1409-4f66-aa4f-9133b23e4796" xlink:href="pacb-20231231.xsd#pacb_DomesticCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e220e010-26db-471f-a761-589b785db878" xlink:to="loc_pacb_DomesticCustomersMember_6e0f6aee-1409-4f66-aa4f-9133b23e4796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_39349aad-2c7f-4b36-a6c7-76eb914c939a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a416f30b-a2fa-4219-858d-1a0ec0f8cd2a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_39349aad-2c7f-4b36-a6c7-76eb914c939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2f84804-48d1-4c18-a1c3-05cd92192f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_39349aad-2c7f-4b36-a6c7-76eb914c939a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2f84804-48d1-4c18-a1c3-05cd92192f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:href="pacb-20231231.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6813aba5-4de3-4e5a-805f-b039fc3d9345" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_65f32fab-4a96-41a5-be0b-605ea9839590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_65f32fab-4a96-41a5-be0b-605ea9839590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4b4af640-faa0-46cc-958f-53507f2ade34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_us-gaap_NumberOfReportableSegments_4b4af640-faa0-46cc-958f-53507f2ade34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_31d59e9d-0c0d-48fe-8b76-bf8af70f9b99" xlink:href="pacb-20231231.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f20aa371-6ac4-4b4f-9179-d7390da24fcb" xlink:to="loc_pacb_StandardProductWarrantyPeriod_31d59e9d-0c0d-48fe-8b76-bf8af70f9b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e17948d5-5f76-4fb0-a9b5-1448d4d9849c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e17948d5-5f76-4fb0-a9b5-1448d4d9849c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:to="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c614296e-ffd1-40f7-9c12-93c3524e6c16" xlink:to="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e35d480b-4ab8-4a06-9e10-5b0a2fa1ba94" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:to="loc_srt_MinimumMember_e35d480b-4ab8-4a06-9e10-5b0a2fa1ba94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_968376fe-55a9-48d0-bd31-c11c72fadb9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2891a844-f4c7-4935-90dc-efdd27ff861b" xlink:to="loc_srt_MaximumMember_968376fe-55a9-48d0-bd31-c11c72fadb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c2dc973-03ae-4ced-b703-25df5db7d026" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_010381b6-e0cf-4f7d-8a7a-dc77edc8234f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_010381b6-e0cf-4f7d-8a7a-dc77edc8234f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d4806fb1-3e84-4306-8232-fc226ae29d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_EquipmentMember_d4806fb1-3e84-4306-8232-fc226ae29d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4aa9e86a-4e60-484e-bc88-3ada54eeb57f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_ComputerEquipmentMember_4aa9e86a-4e60-484e-bc88-3ada54eeb57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_59f64fc0-9ca3-43f4-b825-1993f29343de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_59f64fc0-9ca3-43f4-b825-1993f29343de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e75b157b-a779-4b86-81ff-1f4943aed957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ca9596a-9177-4b71-ae62-0a1720827619" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e75b157b-a779-4b86-81ff-1f4943aed957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44178573-aa97-4c14-8b25-fc0bbbec3fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c25fb245-a099-442a-8e0b-7d1c5b5be15b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44178573-aa97-4c14-8b25-fc0bbbec3fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f1f01b0c-1a17-490e-85ae-7be49e4c44c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44178573-aa97-4c14-8b25-fc0bbbec3fb3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f1f01b0c-1a17-490e-85ae-7be49e4c44c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d23bbe98-3f4f-4bed-ba99-0e2474587a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d23bbe98-3f4f-4bed-ba99-0e2474587a99" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e306f6b-e17f-4708-9661-676040593dc1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_ba9a8554-1c8b-40d1-b679-9b3332b5262d" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:to="loc_pacb_AptonMember_ba9a8554-1c8b-40d1-b679-9b3332b5262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c5247b91-adcd-4d80-8621-6515bf0f7c88" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:to="loc_pacb_OmniomeIncMember_c5247b91-adcd-4d80-8621-6515bf0f7c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember_09568ba2-646f-4e3f-93eb-d3cad6c3712b" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36a1f7cb-54f8-4ea9-aa2f-694e7d14f526" xlink:to="loc_pacb_CirculomicsIncMember_09568ba2-646f-4e3f-93eb-d3cad6c3712b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_ca8c9d5a-63cd-4cc7-9b81-b0b8041a3281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_02370c0a-d941-497e-8a07-dcc69fb3ab35" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_ca8c9d5a-63cd-4cc7-9b81-b0b8041a3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_b50de746-34f9-4769-bb5d-eccb10561761" xlink:href="pacb-20231231.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ca8c9d5a-63cd-4cc7-9b81-b0b8041a3281" xlink:to="loc_pacb_AchievementOfMilestoneMember_b50de746-34f9-4769-bb5d-eccb10561761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3800b0c3-4bc1-4c4b-a608-1a08e9e404fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2fd963de-ec2a-4692-85b2-bd4f5c310ccb" xlink:to="loc_srt_RangeMember_3800b0c3-4bc1-4c4b-a608-1a08e9e404fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd70ac8c-d62b-4f14-aac5-c4dfc5fccfda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3800b0c3-4bc1-4c4b-a608-1a08e9e404fe" xlink:to="loc_srt_MaximumMember_cd70ac8c-d62b-4f14-aac5-c4dfc5fccfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30b1ae13-8e35-41b7-bdc2-2be59cf6d007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175f6af2-0cd3-4076-88ac-8c9ef6f573f7" xlink:to="loc_us-gaap_EquityComponentDomain_30b1ae13-8e35-41b7-bdc2-2be59cf6d007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_585fd914-eae1-4d97-a72a-3adc7d055ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_30b1ae13-8e35-41b7-bdc2-2be59cf6d007" xlink:to="loc_us-gaap_CommonStockMember_585fd914-eae1-4d97-a72a-3adc7d055ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_996b5796-7946-4a6f-a275-c1273e6a9f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f2c496e3-3547-418a-820f-e658c5e1d4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_996b5796-7946-4a6f-a275-c1273e6a9f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_a37fc575-7fe5-467a-bd34-f270391049c9" xlink:href="pacb-20231231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_996b5796-7946-4a6f-a275-c1273e6a9f39" xlink:to="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember_a37fc575-7fe5-467a-bd34-f270391049c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9d53581-0624-4e23-b602-8a3f2501dc00" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7d7c6c3b-97ce-4b1d-8b04-9263b4946c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7d7c6c3b-97ce-4b1d-8b04-9263b4946c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2752554d-19bf-4a9b-9182-3e5d302119fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2752554d-19bf-4a9b-9182-3e5d302119fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51b73982-1a79-4824-a314-d02c814d15e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51b73982-1a79-4824-a314-d02c814d15e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_cd0614ff-4c5d-42bc-b1d8-5e72a0a41581" xlink:href="pacb-20231231.xsd#pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred_cd0614ff-4c5d-42bc-b1d8-5e72a0a41581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef7955b9-a40e-4aad-a50f-441e166a87a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_ef7955b9-a40e-4aad-a50f-441e166a87a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_e5211237-5b71-4d10-be65-368529de3be3" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_e5211237-5b71-4d10-be65-368529de3be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_eb12b2f2-678f-483b-be0a-ec31c2d82307" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod_eb12b2f2-678f-483b-be0a-ec31c2d82307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_6120fafb-ca4a-4228-8b51-9316dfaafd8c" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_6120fafb-ca4a-4228-8b51-9316dfaafd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_974dbbf4-c585-4dd3-a352-11e6e80b2f35" xlink:href="pacb-20231231.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_974dbbf4-c585-4dd3-a352-11e6e80b2f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e744c160-7ce3-4585-bf5b-e05a21b8fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_e744c160-7ce3-4585-bf5b-e05a21b8fe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_052eedaf-976b-4e84-98e9-2b9880811bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_052eedaf-976b-4e84-98e9-2b9880811bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_79cbfd42-ab5b-4231-83cf-7896d711d5bd" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_79cbfd42-ab5b-4231-83cf-7896d711d5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_b4a4ea34-8743-4222-a469-b71fb5ae0890" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit_b4a4ea34-8743-4222-a469-b71fb5ae0890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_76aa3ae3-75dd-4c4c-a057-1238fae1d3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_76aa3ae3-75dd-4c4c-a057-1238fae1d3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_32889442-550e-4592-9ef6-14b290ccf77c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_32889442-550e-4592-9ef6-14b290ccf77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_76d136a4-79d3-4407-bb5c-2f96fcd1ab03" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan_76d136a4-79d3-4407-bb5c-2f96fcd1ab03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_99afb7db-4198-439b-b8d6-88790aaba9a7" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan_99afb7db-4198-439b-b8d6-88790aaba9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_09046f05-47d1-419a-bc94-8b2d144b4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_09046f05-47d1-419a-bc94-8b2d144b4fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8b8692c9-3072-4871-9768-e23abf7c49b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8b8692c9-3072-4871-9768-e23abf7c49b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a93837eb-1e14-4fb2-b83b-8547076a6141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a93837eb-1e14-4fb2-b83b-8547076a6141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f2fffc44-3b3d-47b4-a9ba-9bce6565456f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f2fffc44-3b3d-47b4-a9ba-9bce6565456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8a192fd8-ef24-4823-b2d1-8df7d7d12b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8a192fd8-ef24-4823-b2d1-8df7d7d12b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_8f3c9b07-f2af-40e8-93f7-8efa255b12e7" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts_8f3c9b07-f2af-40e8-93f7-8efa255b12e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_eeee80d1-5a2c-471c-b3fe-e4bb21dc01e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_eeee80d1-5a2c-471c-b3fe-e4bb21dc01e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8679932f-ce54-495a-b3fa-7c234555e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8679932f-ce54-495a-b3fa-7c234555e8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_fe5a7d66-643a-4829-a97c-22605e603018" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance_fe5a7d66-643a-4829-a97c-22605e603018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_a118d56d-6221-4e45-9ce8-69a85f159265" xlink:href="pacb-20231231.xsd#pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts_a118d56d-6221-4e45-9ce8-69a85f159265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b124a303-ac99-4327-9050-a33489d32d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_b124a303-ac99-4327-9050-a33489d32d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_48f156f5-b1fd-4149-acba-d630d5122d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_48f156f5-b1fd-4149-acba-d630d5122d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d6c3af06-8b8f-4ea9-a2f7-db5d131ba05f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a030b9fb-2e36-43bc-8416-a69f1d85352a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d6c3af06-8b8f-4ea9-a2f7-db5d131ba05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_898322a9-34cf-49ae-b89c-2415398bf09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_898322a9-34cf-49ae-b89c-2415398bf09c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_de34c95d-1394-43f0-8dc3-5fcb0b3b27df" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_994db344-1ac5-4e6f-922f-b866a15a2f13" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:to="loc_pacb_AptonMember_994db344-1ac5-4e6f-922f-b866a15a2f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_30027585-9146-430a-8cbc-e4be257542ec" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:to="loc_pacb_OmniomeIncMember_30027585-9146-430a-8cbc-e4be257542ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CirculomicsIncMember_037e667b-58a0-45f9-9c8d-585af780ca3d" xlink:href="pacb-20231231.xsd#pacb_CirculomicsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93a864dc-c65b-470b-8792-016d3f3b04cc" xlink:to="loc_pacb_CirculomicsIncMember_037e667b-58a0-45f9-9c8d-585af780ca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a564240f-4be0-49e1-b204-6fbd4cd4d17f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0d83c809-2378-4a73-934d-1ce7fbb11ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0d83c809-2378-4a73-934d-1ce7fbb11ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b5841c1f-4513-4b16-ada3-14597f62b225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b5841c1f-4513-4b16-ada3-14597f62b225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_591e3178-8306-4410-9f11-37e1e3f936ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_Goodwill_591e3178-8306-4410-9f11-37e1e3f936ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_af5ae18d-0be1-4db7-961d-de01801a3482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_af5ae18d-0be1-4db7-961d-de01801a3482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9b9b6463-c48c-481e-8392-7242d624c8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9b9b6463-c48c-481e-8392-7242d624c8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d4db633b-835a-4d96-b26c-8f120c7ddb92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d4db633b-835a-4d96-b26c-8f120c7ddb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e389c578-370a-4efa-8337-6f54ee374e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e389c578-370a-4efa-8337-6f54ee374e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_310e5f25-ac0e-4239-a670-8b57a141fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_310e5f25-ac0e-4239-a670-8b57a141fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_aadf35cb-7f23-4750-8dbc-1832ae5a5918" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet_aadf35cb-7f23-4750-8dbc-1832ae5a5918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_46db87cc-d400-4fc9-b3b2-f15ad39969b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_46db87cc-d400-4fc9-b3b2-f15ad39969b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3baf6d4f-4b21-4d59-a576-dc9ef5e30d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e74738-9e7b-443e-99e1-0623bafa76f7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3baf6d4f-4b21-4d59-a576-dc9ef5e30d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_12dbe6db-c08a-43d3-b360-4f29790f1b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_12dbe6db-c08a-43d3-b360-4f29790f1b09" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6b6c033-e4c0-4e54-9ef3-e07f09009e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_557af35e-404a-4d84-8c22-fb28bab5d180" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6b6c033-e4c0-4e54-9ef3-e07f09009e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c6a9a515-fce3-4a7e-b222-f770a82af1f5" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6b6c033-e4c0-4e54-9ef3-e07f09009e2b" xlink:to="loc_pacb_OmniomeIncMember_c6a9a515-fce3-4a7e-b222-f770a82af1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_403e186c-15e4-4a2b-9f53-14df3001ad75" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f1a88f35-bff6-4b5e-bf26-453fcca54619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f1a88f35-bff6-4b5e-bf26-453fcca54619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d3a20eab-945b-43b9-a443-41ed5a5e99b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d3a20eab-945b-43b9-a443-41ed5a5e99b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_73f3ffb6-5ef1-47f4-9dfd-faded44be23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_73f3ffb6-5ef1-47f4-9dfd-faded44be23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fad9e945-01fc-4824-a486-0e7ddfe7bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fad9e945-01fc-4824-a486-0e7ddfe7bdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73f56c93-ae05-4711-b11e-815f4aa03b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a793e49d-8e2f-4884-9218-d89cd5dbe5b5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_73f56c93-ae05-4711-b11e-815f4aa03b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6a683977-eb1e-43ac-aa7f-fb1f797fe9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6a683977-eb1e-43ac-aa7f-fb1f797fe9a7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db201b63-61f1-4f7b-a78e-efea376d2342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8fc9f8ef-80e6-42d4-b17f-fd032dbe323b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db201b63-61f1-4f7b-a78e-efea376d2342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_d084eb26-6195-400d-86dc-4b956f03a11d" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db201b63-61f1-4f7b-a78e-efea376d2342" xlink:to="loc_pacb_OmniomeIncMember_d084eb26-6195-400d-86dc-4b956f03a11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_420ae1f2-7762-4c67-8de4-4f7e0154f3bd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3b6fdce9-09f5-452f-85e0-a73ed163cee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3b6fdce9-09f5-452f-85e0-a73ed163cee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b52bc2a3-f887-4765-8782-0df9611bf25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b52bc2a3-f887-4765-8782-0df9611bf25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_083e88db-f074-4495-a6a4-7e85ffd06297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_083e88db-f074-4495-a6a4-7e85ffd06297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_483f5fef-f23f-4e1b-a0ba-14edb2aff178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34396065-5ad6-4c6d-90d2-3984512a7b98" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_483f5fef-f23f-4e1b-a0ba-14edb2aff178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INVITAECOLLABORATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SignificantAgreementsAbstract_8404cbec-289b-4913-b8a0-f37b0560a453" xlink:href="pacb-20231231.xsd#pacb_SignificantAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SignificantAgreementsAbstract_8404cbec-289b-4913-b8a0-f37b0560a453" xlink:to="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:to="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1353d9ea-a8b9-4db7-8bf4-547867002a58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_332f6b79-bf37-4de1-a216-2c804810a6b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_1353d9ea-a8b9-4db7-8bf4-547867002a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InvitaeCorporationMember_6d73c86e-3ec6-486b-b281-bde2de3afbe2" xlink:href="pacb-20231231.xsd#pacb_InvitaeCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1353d9ea-a8b9-4db7-8bf4-547867002a58" xlink:to="loc_pacb_InvitaeCorporationMember_6d73c86e-3ec6-486b-b281-bde2de3afbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:to="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5eb56d2-1ace-40ac-a8f5-a7d660cf2971" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0d836f42-fa08-4c69-96b3-146ba69468ad" xlink:to="loc_srt_ProductsAndServicesDomain_e5eb56d2-1ace-40ac-a8f5-a7d660cf2971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_946ea379-b7ff-4622-ba6c-e1a3eb81a68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5eb56d2-1ace-40ac-a8f5-a7d660cf2971" xlink:to="loc_us-gaap_ProductMember_946ea379-b7ff-4622-ba6c-e1a3eb81a68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:href="pacb-20231231.xsd#pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable_d7ef228a-d643-453f-811c-d4f4b0549466" xlink:to="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmountOfAgreementPaymentReceivedUponExecution_2797d668-cf56-4f8c-b283-b7755ace907a" xlink:href="pacb-20231231.xsd#pacb_AmountOfAgreementPaymentReceivedUponExecution"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_pacb_AmountOfAgreementPaymentReceivedUponExecution_2797d668-cf56-4f8c-b283-b7755ace907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cefe1c2a-a97d-4f5d-a100-60c9ebfad6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cefe1c2a-a97d-4f5d-a100-60c9ebfad6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f9036c3-503b-45e8-aff2-f171cdaf165a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f9036c3-503b-45e8-aff2-f171cdaf165a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6937ae96-9a7d-4f3b-a2e0-43fcd0b54a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems_31d8ebd4-c4a6-4f48-862e-4a24ab4e5fbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6937ae96-9a7d-4f3b-a2e0-43fcd0b54a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationAbstract_6d0c305c-28be-4dd1-a323-cfb15f8e55fe" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationAbstract_6d0c305c-28be-4dd1-a323-cfb15f8e55fe" xlink:to="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:to="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f20e8163-9148-4bc2-a579-707198dd49dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_57e592ab-5639-4bc3-af2e-181bf4ac62a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f20e8163-9148-4bc2-a579-707198dd49dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_7676c5d9-33cb-46d8-8f24-b5f58a29d762" xlink:href="pacb-20231231.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f20e8163-9148-4bc2-a579-707198dd49dc" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_7676c5d9-33cb-46d8-8f24-b5f58a29d762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:to="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ba4635a6-b3f8-48fb-a451-7a3fff7a48ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d9cf5c75-aa39-4a80-8336-c75db2fff0a7" xlink:to="loc_dei_EntityDomain_ba4635a6-b3f8-48fb-a451-7a3fff7a48ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IlluminaFcOpsCorpMember_ceff0221-8a27-4a6d-aefb-f9bc4bd4e658" xlink:href="pacb-20231231.xsd#pacb_IlluminaFcOpsCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ba4635a6-b3f8-48fb-a451-7a3fff7a48ef" xlink:to="loc_pacb_IlluminaFcOpsCorpMember_ceff0221-8a27-4a6d-aefb-f9bc4bd4e658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:href="pacb-20231231.xsd#pacb_MergerTerminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationTable_6e73e8e1-d542-444b-b627-98d288798abe" xlink:to="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_59f84cef-0bd6-4542-b844-70200edaada1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_us-gaap_GainLossOnContractTermination_59f84cef-0bd6-4542-b844-70200edaada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_c940499e-74b5-4566-bbe5-8860d1dcba9d" xlink:href="pacb-20231231.xsd#pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace_c940499e-74b5-4566-bbe5-8860d1dcba9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_6261c9dd-c9b0-4adc-867d-af596cd4b7a9" xlink:href="pacb-20231231.xsd#pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty_6261c9dd-c9b0-4adc-867d-af596cd4b7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_e2f8d3e0-7929-4a2d-aaba-6bfebeee974d" xlink:href="pacb-20231231.xsd#pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction_e2f8d3e0-7929-4a2d-aaba-6bfebeee974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_198874a6-e574-401a-8cc0-8b4784ef0457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_198874a6-e574-401a-8cc0-8b4784ef0457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11e06fbd-8580-4b2b-b43c-68cc265b1488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_MergerTerminationLineItems_daa0bf65-1917-47ed-beff-2a86c33ec674" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11e06fbd-8580-4b2b-b43c-68cc265b1488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7cd26a4a-7e85-4438-ada8-a79802886d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7cd26a4a-7e85-4438-ada8-a79802886d50" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51375aa-2fdf-4797-a217-e03bada693d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_59c36c6a-a4cf-464d-bf43-c5d852a72beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_59c36c6a-a4cf-464d-bf43-c5d852a72beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a948f409-f543-4061-84b8-0c805451d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a948f409-f543-4061-84b8-0c805451d96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f6f6264a-aed3-41d3-adeb-d0d96555e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f87563d5-6528-4ae5-9a8c-db46f675863b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f6f6264a-aed3-41d3-adeb-d0d96555e4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_52985d16-bd3c-426f-be7b-cd39e26b515c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_58b6eafb-d29b-4efc-8d95-66098172abdb" xlink:href="pacb-20231231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_58b6eafb-d29b-4efc-8d95-66098172abdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_42ec69fb-049a-4ec8-8ca8-61684257cde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:to="loc_us-gaap_CommercialPaperMember_42ec69fb-049a-4ec8-8ca8-61684257cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_516edccb-769f-4c9b-b649-84ee6fd67d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_c043e94f-ae94-4056-b6c3-89bce69920b4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_516edccb-769f-4c9b-b649-84ee6fd67d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_96e3a2e5-0b1a-4ee9-a381-1349afbc0344" xlink:to="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f4ccf277-5ae9-4c51-be53-6491edd5da32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f4ccf277-5ae9-4c51-be53-6491edd5da32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3d0d5914-faed-49ae-9994-b5b8b78f0611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3d0d5914-faed-49ae-9994-b5b8b78f0611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_cc5d917a-45bc-4516-a369-61dcfdb5bf27" xlink:href="pacb-20231231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_caa96bd7-f9d6-4c59-b26c-b63cf883b1f9" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_cc5d917a-45bc-4516-a369-61dcfdb5bf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6911c9b2-402b-4261-8bb9-9538cbb70791" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_77728139-1be6-4456-b68d-4ec2d23c76ed" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:to="loc_pacb_OmniomeIncMember_77728139-1be6-4456-b68d-4ec2d23c76ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_2a6a6045-09f7-42cc-a9e4-c402f89a50ae" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3108f3e-2b68-4405-8ef8-7d3ba8c04230" xlink:to="loc_pacb_AptonMember_2a6a6045-09f7-42cc-a9e4-c402f89a50ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4ebda2e5-d7c8-4186-8c6a-f519f77066d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:to="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f5829ef7-9bb6-485a-ab07-15dd6c2ddd51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f5829ef7-9bb6-485a-ab07-15dd6c2ddd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3bc4ebc1-7f8d-49fd-9f3f-68d4f5791ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_3bc4ebc1-7f8d-49fd-9f3f-68d4f5791ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_7036ce23-1e7e-4240-924b-4885ea30cb1a" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_7036ce23-1e7e-4240-924b-4885ea30cb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_c7418d38-5c04-4c06-b4b8-252705cb315f" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_c7418d38-5c04-4c06-b4b8-252705cb315f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d6a2180b-2656-4deb-a662-c1adbe58c806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24b0c0ec-2ab3-43e1-84cf-f7d81287c2e9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d6a2180b-2656-4deb-a662-c1adbe58c806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_44c73524-ec27-45ed-bed5-37d14e4edf06" xlink:to="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9e66c6-053f-4d88-9b15-00f9dd386188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7d9e66c6-053f-4d88-9b15-00f9dd386188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cb3635cd-221b-4a3c-b2e8-1c3f4825447a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cefe3fc2-3ded-4919-a85d-2677c3db83cc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_cb3635cd-221b-4a3c-b2e8-1c3f4825447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4eb8aa29-3f1e-4cbd-85d9-898466923b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:href="pacb-20231231.xsd#pacb_FinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4eb8aa29-3f1e-4cbd-85d9-898466923b6c" xlink:to="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdde3f38-0551-4ce3-bc95-35cba5f2a4d8" xlink:to="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44c16c6e-ac10-4243-af7b-684950b8ba87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:to="loc_srt_MinimumMember_44c16c6e-ac10-4243-af7b-684950b8ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6be19c8-ed2b-4c04-a715-6cb94ac097cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f2b54e2-eed9-46f9-9c7a-7b14670c4f00" xlink:to="loc_srt_MaximumMember_f6be19c8-ed2b-4c04-a715-6cb94ac097cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_943378e3-35c3-4524-a081-170ef87ec56f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_6ff200a3-23b8-46fe-8800-93fccd428968" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:to="loc_pacb_OmniomeIncMember_6ff200a3-23b8-46fe-8800-93fccd428968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_85335896-a6f2-4add-bffa-37729e1c7158" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_21b27744-50ee-4af9-a45e-974e246c3f34" xlink:to="loc_pacb_AptonMember_85335896-a6f2-4add-bffa-37729e1c7158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_796b6965-d39c-4ba0-af51-10604bf6f3a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_157159fa-cfed-4e40-9640-cf243d217215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:to="loc_us-gaap_CommonStockMember_157159fa-cfed-4e40-9640-cf243d217215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0eb0360-133a-4a32-ba88-5a370a332015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ce08424-dc59-4bbb-b3b9-4ba36cf68abc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0eb0360-133a-4a32-ba88-5a370a332015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_62f79a33-e047-4cb7-8368-b9208824d2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_006188b5-3277-42e5-bcf2-77d2b25842c4" xlink:to="loc_us-gaap_ValuationTechniqueDomain_62f79a33-e047-4cb7-8368-b9208824d2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_b4c580de-6b20-4729-8b1f-4663aa6a3d99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_62f79a33-e047-4cb7-8368-b9208824d2e5" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_b4c580de-6b20-4729-8b1f-4663aa6a3d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_39055154-27d8-481f-9fb1-a7a4955b020c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7b539bd6-25fe-490e-a198-1212d7d7bd62" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_39055154-27d8-481f-9fb1-a7a4955b020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6a063605-e501-4463-9583-583b35d227af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_39055154-27d8-481f-9fb1-a7a4955b020c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_6a063605-e501-4463-9583-583b35d227af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:href="pacb-20231231.xsd#pacb_FinancialInstrumentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsTable_af08b1c6-2a7d-4166-b228-e78b87479cfb" xlink:to="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_e1a0d024-7a60-4422-a057-860acfa1e3da" xlink:href="pacb-20231231.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_e1a0d024-7a60-4422-a057-860acfa1e3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5c402b8b-ef1a-4239-b6ae-1df857b255d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5c402b8b-ef1a-4239-b6ae-1df857b255d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5e672c0-9b08-43a1-aa55-c49dbcfc42e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b5e672c0-9b08-43a1-aa55-c49dbcfc42e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c2ec9b5b-b0ca-4f57-9a34-7901bd224a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c2ec9b5b-b0ca-4f57-9a34-7901bd224a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_68e6b53e-1d44-44ff-a6de-33d91937d910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_68e6b53e-1d44-44ff-a6de-33d91937d910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_63050780-493a-41f0-a5cb-7e8a34b7e9b1" xlink:href="pacb-20231231.xsd#pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone_63050780-493a-41f0-a5cb-7e8a34b7e9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9b114751-42f5-4537-ad46-72593e84b563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9b114751-42f5-4537-ad46-72593e84b563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_a879e73f-3bb5-41df-bd61-92db663c5f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_a879e73f-3bb5-41df-bd61-92db663c5f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_f6418800-05bf-4e28-bf57-acdc62110ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_us-gaap_InvestmentIncomeNet_f6418800-05bf-4e28-bf57-acdc62110ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_22d4d015-99b0-469b-b756-78144f498eb1" xlink:href="pacb-20231231.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_FinancialInstrumentsLineItems_807965cc-91a6-4ba8-b2ec-3924c478b2ff" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_22d4d015-99b0-469b-b756-78144f498eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_391fbf1f-3b32-4cf3-a6d0-ddc6c58d7e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_391fbf1f-3b32-4cf3-a6d0-ddc6c58d7e5a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a0d0534-931a-4580-885b-b6ba79e76a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08e42c5d-d0c6-4618-ad74-8c8e12c09b6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a0d0534-931a-4580-885b-b6ba79e76a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c34c093b-e76f-44fb-b3ba-db1312bfcba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a0d0534-931a-4580-885b-b6ba79e76a5c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c34c093b-e76f-44fb-b3ba-db1312bfcba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18d9c63a-2780-41e7-bb80-bcdc7483ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23e5426b-a4cd-4395-b607-9e379765c8a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18d9c63a-2780-41e7-bb80-bcdc7483ef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_18d9c63a-2780-41e7-bb80-bcdc7483ef85" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_392dd0d1-b781-4673-8fff-8da32806bc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_392dd0d1-b781-4673-8fff-8da32806bc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_022eb11f-be95-4e46-a385-5c5008f1a593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_022eb11f-be95-4e46-a385-5c5008f1a593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_98c92960-2275-495d-85b2-2e42819a845a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_98c92960-2275-495d-85b2-2e42819a845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5b7db529-e355-463b-81cf-ee7433ff6a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5b7db529-e355-463b-81cf-ee7433ff6a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_744383cf-7eb3-4afd-b3c0-90cdbf1d5455" xlink:href="pacb-20231231.xsd#pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration_744383cf-7eb3-4afd-b3c0-90cdbf1d5455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ee0ac79-d146-467a-a4b1-2dd2e273cb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3a7d434a-853f-4814-979c-9374d4094f35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7ee0ac79-d146-467a-a4b1-2dd2e273cb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1d471378-9efd-41eb-88c4-e7f6053cb08e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1d471378-9efd-41eb-88c4-e7f6053cb08e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_46a968fe-bb7c-4e64-9b8c-c67b13f3dee4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:href="pacb-20231231.xsd#pacb_CashCashEquivalentsAndInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:to="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CashAndMoneyMarketFundsMember_ede14b13-1c67-49a8-a0e8-20c843b7e56b" xlink:href="pacb-20231231.xsd#pacb_CashAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:to="loc_pacb_CashAndMoneyMarketFundsMember_ede14b13-1c67-49a8-a0e8-20c843b7e56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14d87449-5e54-450b-9759-71a54fbff382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:to="loc_us-gaap_CommercialPaperMember_14d87449-5e54-450b-9759-71a54fbff382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_536483c5-1e89-44b1-a08b-45c33961f610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember_e5f01f22-4fdc-48ed-8ba6-a4724858b740" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_536483c5-1e89-44b1-a08b-45c33961f610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CashCashEquivalentsAndInvestmentsMember_01b0595a-e797-4e47-b0d7-68c8e448d5e7" xlink:to="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_17d1f718-752e-4e50-a436-83a25410527c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_17d1f718-752e-4e50-a436-83a25410527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b3636fb2-08d3-4601-b3ae-76fcb078f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b3636fb2-08d3-4601-b3ae-76fcb078f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_6fbc91cb-adf8-438b-99b1-35c67015d664" xlink:href="pacb-20231231.xsd#pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_d5b2f3b3-8fcc-433c-829b-bf19dc4a9e41" xlink:to="loc_pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember_6fbc91cb-adf8-438b-99b1-35c67015d664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashMember_4e6dac46-a0e6-4eb9-bab1-0ac6733f3242" xlink:href="pacb-20231231.xsd#pacb_ShortTermRestrictedCashMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:to="loc_pacb_ShortTermRestrictedCashMember_4e6dac46-a0e6-4eb9-bab1-0ac6733f3242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashMember_b3d0ca77-16f7-4df3-8fe8-5e651039513a" xlink:href="pacb-20231231.xsd#pacb_LongTermRestrictedCashMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53972a51-b833-4887-ae2f-11e4303d5a17" xlink:to="loc_pacb_LongTermRestrictedCashMember_b3d0ca77-16f7-4df3-8fe8-5e651039513a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a936cee-046a-4205-84f1-94b4ba3e5d2f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b4e58d-51a9-4b96-9f8a-c355025e34aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e0b4e58d-51a9-4b96-9f8a-c355025e34aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c16e5c4e-ee1b-4b05-9889-5d0614a36656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c16e5c4e-ee1b-4b05-9889-5d0614a36656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f65670ff-bab3-43a6-a4b0-2af56bab0542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f65670ff-bab3-43a6-a4b0-2af56bab0542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fccf307e-bd62-4284-87b5-ada5eeb38081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b57173a9-3d03-46b4-838c-6b4e4b4b4687" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fccf307e-bd62-4284-87b5-ada5eeb38081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f944ea31-f0d7-474a-a15b-dd7e27972f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d44e3c9b-f2a3-4648-87c1-2c3fb035610c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f944ea31-f0d7-474a-a15b-dd7e27972f6b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d44e3c9b-f2a3-4648-87c1-2c3fb035610c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_11a5667d-e20c-4aa0-948f-bacb84e348f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f944ea31-f0d7-474a-a15b-dd7e27972f6b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_11a5667d-e20c-4aa0-948f-bacb84e348f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8696264c-05eb-4527-8783-0f992f05c4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f944ea31-f0d7-474a-a15b-dd7e27972f6b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8696264c-05eb-4527-8783-0f992f05c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_11664ddd-4605-4621-b6ce-3cd83c52714f" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_33c4db14-f37d-482a-863c-b16af6559c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_11664ddd-4605-4621-b6ce-3cd83c52714f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_33c4db14-f37d-482a-863c-b16af6559c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ab27ae6b-553f-42f1-bd60-4d5650bbee39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_11664ddd-4605-4621-b6ce-3cd83c52714f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ab27ae6b-553f-42f1-bd60-4d5650bbee39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_30bb3b12-6699-4150-8a6e-0e6501bb261e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_11664ddd-4605-4621-b6ce-3cd83c52714f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_30bb3b12-6699-4150-8a6e-0e6501bb261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fea33b95-e871-48c2-b112-f94aba68c1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_11664ddd-4605-4621-b6ce-3cd83c52714f" xlink:to="loc_us-gaap_InventoryNet_fea33b95-e871-48c2-b112-f94aba68c1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_fa877891-35de-4e6c-89ee-71415c111c5b" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_fa877891-35de-4e6c-89ee-71415c111c5b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1eeb6aac-65d7-4686-b802-5f6aa825ab8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LaboratoryEquipmentAndMachineryMember_a9608073-4bcb-407d-a38c-43d1b983014e" xlink:href="pacb-20231231.xsd#pacb_LaboratoryEquipmentAndMachineryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_pacb_LaboratoryEquipmentAndMachineryMember_a9608073-4bcb-407d-a38c-43d1b983014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a8e56d2e-8c67-44dc-8bdf-4f4f4927a0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a8e56d2e-8c67-44dc-8bdf-4f4f4927a0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_6135d659-1d40-4657-8ff4-7fd93aca454d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_ComputerEquipmentMember_6135d659-1d40-4657-8ff4-7fd93aca454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_323ad257-52d4-4a49-bf62-3c6db4a86a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_323ad257-52d4-4a49-bf62-3c6db4a86a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_48a6f469-a686-4828-b7c8-efc75acef0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_48a6f469-a686-4828-b7c8-efc75acef0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_469bf743-f6f6-4750-b4e6-4a6ad7f25e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2556ee9-2c47-4f2e-9738-3fb37e66bca6" xlink:to="loc_us-gaap_ConstructionInProgressMember_469bf743-f6f6-4750-b4e6-4a6ad7f25e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4546227-a81c-4bea-acf8-4743434f193a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5163d999-9be7-479c-b4ca-fd08561e1f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5163d999-9be7-479c-b4ca-fd08561e1f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5321567b-05a4-4fde-b2ff-b2b59bdff633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5321567b-05a4-4fde-b2ff-b2b59bdff633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5dca4c1b-28cd-4181-814a-f725b2ee2b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e25a6ae-347e-4f30-b3e6-6040c63b80b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5dca4c1b-28cd-4181-814a-f725b2ee2b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b2ee9083-1d93-4b92-a677-e21a841c8177" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:href="pacb-20231231.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b2ee9083-1d93-4b92-a677-e21a841c8177" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4952c52a-6987-4471-9a9d-d76e239d025d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bfc271b9-e5f9-4243-8c28-c8a2f686e21b" xlink:to="loc_srt_ProductsAndServicesDomain_4952c52a-6987-4471-9a9d-d76e239d025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3a3e8a96-9503-4e77-b439-6ee9a315223d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4952c52a-6987-4471-9a9d-d76e239d025d" xlink:to="loc_us-gaap_ServiceMember_3a3e8a96-9503-4e77-b439-6ee9a315223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c74be71d-dc3b-467c-bfa8-ff907a1a8e0d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_9916c03e-90cf-4924-852d-0cc52c837655" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:to="loc_pacb_OmniomeIncMember_9916c03e-90cf-4924-852d-0cc52c837655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_96fd137a-7f24-4867-ad35-97ee98df6738" xlink:href="pacb-20231231.xsd#pacb_AptonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94e47d5e-9b6a-4ce5-9b99-a5fc29d44c1f" xlink:to="loc_pacb_AptonMember_96fd137a-7f24-4867-ad35-97ee98df6738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2a923460-9b98-40f8-802f-e6e0f3f6c4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba91c527-4e96-4d92-9512-5f7ffa4f4345" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2a923460-9b98-40f8-802f-e6e0f3f6c4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_b3bf5ada-efe0-412d-a205-a5041f9063b9" xlink:href="pacb-20231231.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2a923460-9b98-40f8-802f-e6e0f3f6c4d7" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_b3bf5ada-efe0-412d-a205-a5041f9063b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0d8a8f56-9911-4f63-8f01-778de1686b9c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CostOfRevenueMember_f902e068-8a72-4efe-bbc5-39bd225d1df6" xlink:href="pacb-20231231.xsd#pacb_CostOfRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:to="loc_pacb_CostOfRevenueMember_f902e068-8a72-4efe-bbc5-39bd225d1df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_a7db1268-2fe6-4734-a0d5-94372dd9aaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7e32af3-e4b8-46f9-a798-98da959a0ca4" xlink:to="loc_us-gaap_OperatingExpenseMember_a7db1268-2fe6-4734-a0d5-94372dd9aaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:href="pacb-20231231.xsd#pacb_BalanceSheetComponentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_db8deb7f-3267-4bb5-aa13-f605f9174a2a" xlink:to="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a6603d79-56c3-466d-a8f2-5d33937b97a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_Depreciation_a6603d79-56c3-466d-a8f2-5d33937b97a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4d30116c-f107-47ce-8a0a-9da73c89c798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_Goodwill_4d30116c-f107-47ce-8a0a-9da73c89c798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3a53267-8815-4275-bc6e-88bb0235e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c3a53267-8815-4275-bc6e-88bb0235e4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f86efea-e44c-468e-a07a-58aa006b5c62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f86efea-e44c-468e-a07a-58aa006b5c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b2692b24-dfd9-4bc8-bf90-edd68485d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b2692b24-dfd9-4bc8-bf90-edd68485d5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_ef3c4e8e-f56b-472e-b45b-dbd503fe79be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_AdjustmentForAmortization_ef3c4e8e-f56b-472e-b45b-dbd503fe79be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e49c0488-02d3-442e-b489-b2946abc5e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e49c0488-02d3-442e-b489-b2946abc5e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_394f7367-5d37-440f-bd1d-75a01aa25017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_394f7367-5d37-440f-bd1d-75a01aa25017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c793609-63eb-48b8-ad59-5d1c95eb4e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2c793609-63eb-48b8-ad59-5d1c95eb4e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf59216b-f5f0-4653-a742-6aa16c2b0452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf59216b-f5f0-4653-a742-6aa16c2b0452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_84e72260-7828-4480-a9cc-b7279128e9e8" xlink:href="pacb-20231231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_84e72260-7828-4480-a9cc-b7279128e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_12f10c08-c950-4b91-890e-c05b3d8ff227" xlink:href="pacb-20231231.xsd#pacb_ContractWithCustomerLiabilityNoncurrentReclassification"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentReclassification_12f10c08-c950-4b91-890e-c05b3d8ff227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fcbb16eb-f54f-4a3b-b977-c96d2742e8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fcbb16eb-f54f-4a3b-b977-c96d2742e8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_11977a41-3afa-4dd1-898e-1bb79744358b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_11977a41-3afa-4dd1-898e-1bb79744358b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9c15a74a-6c07-4516-afb5-c46b5c225024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9c15a74a-6c07-4516-afb5-c46b5c225024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_71ba51dd-34da-47da-8d81-429e7d164aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_DebtInstrumentTerm_71ba51dd-34da-47da-8d81-429e7d164aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5e7c9a-387c-4acc-99f4-c53705f8bbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5e7c9a-387c-4acc-99f4-c53705f8bbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFeeToPrepayDebt_320e9531-6b6a-41a7-8533-440399db39ee" xlink:href="pacb-20231231.xsd#pacb_PercentageOfFeeToPrepayDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_pacb_PercentageOfFeeToPrepayDebt_320e9531-6b6a-41a7-8533-440399db39ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_4f13e6bf-f6d8-4a15-80a5-d1facdfbee12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_NotesPayable_4f13e6bf-f6d8-4a15-80a5-d1facdfbee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseBorrowings_00b01620-933b-4724-ba07-2f7ca3db6e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_InterestExpenseBorrowings_00b01620-933b-4724-ba07-2f7ca3db6e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1ffd05a4-2ff7-4f9c-ab5a-a6d646ff231a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetComponentsLineItems_dcd9265e-5505-4c06-8634-e618cfbe696b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1ffd05a4-2ff7-4f9c-ab5a-a6d646ff231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_68bd2382-af63-4998-a44b-3630b82e26fb" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_68bd2382-af63-4998-a44b-3630b82e26fb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b76115f-0717-41ec-9109-884a6777e114" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_8f96676d-1db7-4f8a-8ad8-d79f0024e990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_8f96676d-1db7-4f8a-8ad8-d79f0024e990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_baace4aa-d45f-4a14-9ab3-7ada42a94222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f7f0384-3fc7-4a03-b16d-3e2ee00100a4" xlink:to="loc_us-gaap_CustomerRelationshipsMember_baace4aa-d45f-4a14-9ab3-7ada42a94222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8dac922b-deda-4022-b708-864f1951d711" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2cd8e2c-c3a7-4077-b710-1ab919e4206f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2cd8e2c-c3a7-4077-b710-1ab919e4206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1bb4007-5a44-40bb-bcc8-8f7b924dfaed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1bb4007-5a44-40bb-bcc8-8f7b924dfaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0be38e01-1081-48c4-807e-e22e14fbf980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0be38e01-1081-48c4-807e-e22e14fbf980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268b1419-1f9f-4f94-beb5-3218e95719b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_af96a143-6773-4d87-b807-c69f4a5a284a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_268b1419-1f9f-4f94-beb5-3218e95719b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_63d57075-c1bf-4557-8cd8-77dd058e7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_63d57075-c1bf-4557-8cd8-77dd058e7fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_38ba8623-c27c-4a8a-89a2-a30e40923aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_38ba8623-c27c-4a8a-89a2-a30e40923aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c0c6b680-64ba-4ecb-a8cd-530d6f2a2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c0c6b680-64ba-4ecb-a8cd-530d6f2a2bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2d40cd61-ca9a-4cc5-b8e5-bebd8bbd4abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2d40cd61-ca9a-4cc5-b8e5-bebd8bbd4abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c05ec68e-b9ca-4cb7-b9fa-a36174adebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c05ec68e-b9ca-4cb7-b9fa-a36174adebe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5a02468b-7f2b-4158-98bf-045e9b1b3371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5a02468b-7f2b-4158-98bf-045e9b1b3371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2e5e045-fa94-47e9-92e7-11f0ec42b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_182879ec-d2ba-4c05-935a-73082899783d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2e5e045-fa94-47e9-92e7-11f0ec42b10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2562c74a-6527-48f9-91f3-554a9ee9486d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2562c74a-6527-48f9-91f3-554a9ee9486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedTenantImprovementsCurrent_b6fe8cd0-e476-4cc0-ad1d-001c5b610cee" xlink:href="pacb-20231231.xsd#pacb_AccruedTenantImprovementsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_pacb_AccruedTenantImprovementsCurrent_b6fe8cd0-e476-4cc0-ad1d-001c5b610cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_716cec60-b028-47ed-922d-c579de6a739c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_716cec60-b028-47ed-922d-c579de6a739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedProductDevelopmentCostsCurrent_8884394f-7287-4d2d-a819-a9ae931fd180" xlink:href="pacb-20231231.xsd#pacb_AccruedProductDevelopmentCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_pacb_AccruedProductDevelopmentCostsCurrent_8884394f-7287-4d2d-a819-a9ae931fd180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_58642886-c350-4cd1-92e4-dda85a8ce124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_58642886-c350-4cd1-92e4-dda85a8ce124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualPresentValue_f6c8ea7d-3e86-41c3-8056-03d673013972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualPresentValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_ProductLiabilityContingencyAccrualPresentValue_f6c8ea7d-3e86-41c3-8056-03d673013972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2f8cb4a9-82ae-4552-afd3-bac04372f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2f8cb4a9-82ae-4552-afd3-bac04372f0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7bbd0697-a532-47c7-a7d7-4a14c8090ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7bbd0697-a532-47c7-a7d7-4a14c8090ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fbad6450-d81d-4352-ad01-898ab22b59ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_b156eaeb-729a-47b3-9135-6e54c6370985" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fbad6450-d81d-4352-ad01-898ab22b59ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_fd23a883-cae5-4e8a-b73e-fdafcff01b80" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_6696825b-2f50-42ea-9207-0124b898eefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_fd23a883-cae5-4e8a-b73e-fdafcff01b80" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_6696825b-2f50-42ea-9207-0124b898eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_cfda35ec-cf8f-4028-8bca-7770c6d225e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_6696825b-2f50-42ea-9207-0124b898eefd" xlink:to="loc_us-gaap_ProductWarrantyAccrual_cfda35ec-cf8f-4028-8bca-7770c6d225e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_d561bbf2-6b48-4f74-ba1b-448108513632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_6696825b-2f50-42ea-9207-0124b898eefd" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_d561bbf2-6b48-4f74-ba1b-448108513632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_5b5203e1-8389-46f9-b255-3326cdc1523a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_6696825b-2f50-42ea-9207-0124b898eefd" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_5b5203e1-8389-46f9-b255-3326cdc1523a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_b29e54eb-459d-4af1-9378-947de8e0c9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_6696825b-2f50-42ea-9207-0124b898eefd" xlink:to="loc_us-gaap_ProductWarrantyAccrual_b29e54eb-459d-4af1-9378-947de8e0c9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_2c84c56a-3943-4e85-9f2d-a06cdb628855" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_2c84c56a-3943-4e85-9f2d-a06cdb628855" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f8053e6-63d0-46e1-ac21-87a1976efc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59e77672-e17e-4328-ba83-64a1e1617d92" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f8053e6-63d0-46e1-ac21-87a1976efc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_9124816b-07d5-4408-97d5-0c7b55d55e9b" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f8053e6-63d0-46e1-ac21-87a1976efc08" xlink:to="loc_pacb_OmniomeIncMember_9124816b-07d5-4408-97d5-0c7b55d55e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_79ba1ba4-b0d0-48d4-b755-c889f7b040f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_dd66b8e5-6747-4463-ad85-baed9623f98b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_79ba1ba4-b0d0-48d4-b755-c889f7b040f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_79ba1ba4-b0d0-48d4-b755-c889f7b040f5" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df3b53ce-8ce3-4886-bb21-72a7ecf5d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_df3b53ce-8ce3-4886-bb21-72a7ecf5d0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d28ff87-35d9-460f-a697-7067b41c5e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_dfcbd3ea-9e01-498d-8d26-39b771b533e3" xlink:to="loc_us-gaap_LongTermDebt_6d28ff87-35d9-460f-a697-7067b41c5e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7782613d-5edb-49a8-bb15-c3217f779b9b" xlink:href="pacb-20231231.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_a001eeff-9ae6-42b0-8aca-de47f39b5f34" xlink:href="pacb-20231231.xsd#pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7782613d-5edb-49a8-bb15-c3217f779b9b" xlink:to="loc_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent_a001eeff-9ae6-42b0-8aca-de47f39b5f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4e00efb7-62f0-4581-ad22-215fcc8899be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7782613d-5edb-49a8-bb15-c3217f779b9b" xlink:to="loc_us-gaap_ShortTermBorrowings_4e00efb7-62f0-4581-ad22-215fcc8899be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_bae667b4-0556-416e-8a2f-4752b880941c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7782613d-5edb-49a8-bb15-c3217f779b9b" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_bae667b4-0556-416e-8a2f-4752b880941c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1812f91f-8dd4-462c-8e95-0d07769a7e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_7782613d-5edb-49a8-bb15-c3217f779b9b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1812f91f-8dd4-462c-8e95-0d07769a7e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_edaf20d7-9ca3-451c-81c4-6777338d818c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_edaf20d7-9ca3-451c-81c4-6777338d818c" xlink:to="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1b67d8d2-12cc-417b-8a30-46831f8eade9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_591f2fcb-3a90-4547-9c63-5497de26bacc" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_591f2fcb-3a90-4547-9c63-5497de26bacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_6b50d31d-cafd-42cb-9116-4a33f4515530" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_6b50d31d-cafd-42cb-9116-4a33f4515530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_70223711-23e7-44dd-9e77-1a66e1ce6dfc" xlink:href="pacb-20231231.xsd#pacb_ExchangeTransactionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_ExchangeTransactionMember_70223711-23e7-44dd-9e77-1a66e1ce6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConvertibleSeniorNotesMember_a80a7f7e-ef9a-4eb5-b074-2b9807857fee" xlink:href="pacb-20231231.xsd#pacb_ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9138c99b-8094-4e17-a89e-10e08c3232b2" xlink:to="loc_pacb_ConvertibleSeniorNotesMember_a80a7f7e-ef9a-4eb5-b074-2b9807857fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_aa2e1018-3480-44a7-bf8a-0dddde182414" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_25c9efa8-a05f-4756-a043-53785f15ad87" xlink:href="pacb-20231231.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:to="loc_pacb_DebtConversionTermsOneMember_25c9efa8-a05f-4756-a043-53785f15ad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_88c10815-bca4-4fc6-a13e-1d3fa823051a" xlink:href="pacb-20231231.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_d6b7e505-38f4-434a-91e3-d52ca3e2c719" xlink:to="loc_pacb_DebtConversionTermsTwoMember_88c10815-bca4-4fc6-a13e-1d3fa823051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a2c5435c-3ead-45be-810c-31ecaa78682b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ad899174-56ce-43a2-a1b5-4def402316ba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a2c5435c-3ead-45be-810c-31ecaa78682b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_eec10506-bd49-4a5f-a96b-abeab8144d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a2c5435c-3ead-45be-810c-31ecaa78682b" xlink:to="loc_us-gaap_ConvertibleDebtMember_eec10506-bd49-4a5f-a96b-abeab8144d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_120842a6-7ee2-4877-9caf-31e7055e6a7b" xlink:to="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_00832f48-de90-4fd6-8ff4-7093c500a676" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:to="loc_srt_MinimumMember_00832f48-de90-4fd6-8ff4-7093c500a676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e87320f-c7a4-4bf9-adea-45b14f9061dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86d85137-ffc1-4404-b9b5-65241401f623" xlink:to="loc_srt_MaximumMember_5e87320f-c7a4-4bf9-adea-45b14f9061dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f74ba4e-2acb-4e8d-8ad6-d25a324822df" xlink:to="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_538da044-bc29-488f-bf35-2fe718cac1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_538da044-bc29-488f-bf35-2fe718cac1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bd62c893-94ef-473d-b3bc-dc6271513e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bd62c893-94ef-473d-b3bc-dc6271513e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_85242e63-5e29-4b6d-a013-3485b71cfc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_85242e63-5e29-4b6d-a013-3485b71cfc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cf2a4e4e-eb05-4d65-8c5a-399ea73b6540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cf2a4e4e-eb05-4d65-8c5a-399ea73b6540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_adc2d2b2-99ac-43c2-ae62-fa9491c02868" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_adc2d2b2-99ac-43c2-ae62-fa9491c02868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_77d3bdd1-89e7-4528-a7fa-222417d0505b" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_77d3bdd1-89e7-4528-a7fa-222417d0505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_43f1b774-5810-4fdc-a023-c310cf6ebf00" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_43f1b774-5810-4fdc-a023-c310cf6ebf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bf1db934-1f8d-427b-b2f5-68a31063540c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bf1db934-1f8d-427b-b2f5-68a31063540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_1f68c22d-a63a-4ea2-a19a-ee304812b8a2" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_1f68c22d-a63a-4ea2-a19a-ee304812b8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_d4ca5b1f-ec34-4d9c-bf0a-84b46c522f83" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_d4ca5b1f-ec34-4d9c-bf0a-84b46c522f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_868e1adb-de5f-4200-b07b-bb72469956dc" xlink:href="pacb-20231231.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_868e1adb-de5f-4200-b07b-bb72469956dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_93da360d-2ba9-4235-aea7-d79c950fe9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_93da360d-2ba9-4235-aea7-d79c950fe9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e49acd30-ad85-4f30-8320-10a9e065365b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e49acd30-ad85-4f30-8320-10a9e065365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_92aeda80-a170-4d8e-bf15-235afd4ec0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_92aeda80-a170-4d8e-bf15-235afd4ec0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_e196af1a-2548-40d0-8ca6-32ced7e3b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_e196af1a-2548-40d0-8ca6-32ced7e3b8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d3cd1137-0f52-4c56-86ba-69d3a25e7272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_LongTermDebt_d3cd1137-0f52-4c56-86ba-69d3a25e7272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_06af1150-f21a-4e8a-bdac-c56caf2cd756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43307265-ddc5-49e1-accb-4af481d17f45" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_06af1150-f21a-4e8a-bdac-c56caf2cd756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b2fa698-91c5-4bb3-b520-892b1ead672d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b2fa698-91c5-4bb3-b520-892b1ead672d" xlink:to="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed08d072-e37a-463a-9346-ab569f34d1a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_2bc547b4-3434-4d43-b1cf-2fed72bca1fb" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_2bc547b4-3434-4d43-b1cf-2fed72bca1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_98472a39-21d9-46cc-a114-64c2c248e0ea" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75b56c9b-3000-47e1-91d7-8695c77b1ce8" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_98472a39-21d9-46cc-a114-64c2c248e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2228a3a6-0abb-4a9c-8d24-39c2b42b1661" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4211dbb4-f5d6-4aca-b7c6-1fdfa6a30a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4211dbb4-f5d6-4aca-b7c6-1fdfa6a30a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_ab534fcc-75b8-4f08-8a4c-bc54815686fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_ab534fcc-75b8-4f08-8a4c-bc54815686fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_c3edf00c-3cfb-4c2a-b40c-b89b8138d0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_c3edf00c-3cfb-4c2a-b40c-b89b8138d0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b6172922-8b77-4817-b9b3-1929ec0a0645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d7d023f2-f581-47b4-8b72-410e23401c80" xlink:to="loc_us-gaap_LongTermDebt_b6172922-8b77-4817-b9b3-1929ec0a0645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7776d1e4-bbfc-4186-b5a3-538400c285b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7776d1e4-bbfc-4186-b5a3-538400c285b5" xlink:to="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:to="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7209dda8-3122-4172-b4a7-966824b06940" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_7835afc5-17de-45b5-bb06-9f260c4b54d8" xlink:href="pacb-20231231.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_7835afc5-17de-45b5-bb06-9f260c4b54d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_f1e23448-1ca8-45b7-82d5-b2854593f026" xlink:href="pacb-20231231.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c51aa5ab-a43a-4e41-81fc-f7a79eeeed0a" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_f1e23448-1ca8-45b7-82d5-b2854593f026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4fe092b1-b222-4c4a-9298-4a9615dc0c96" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_80d04504-5743-40ea-bb01-cd19ae5a63fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_80d04504-5743-40ea-bb01-cd19ae5a63fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4485ad63-5b35-4113-b603-b65d142c9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4485ad63-5b35-4113-b603-b65d142c9cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b4e493c3-9c58-41f1-babd-39aed85efda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3dd854ed-34f2-48a4-ad6c-4ff213527a4b" xlink:to="loc_us-gaap_InterestExpenseDebt_b4e493c3-9c58-41f1-babd-39aed85efda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373b36f3-4479-4a08-a0c5-5a5fefe2382a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:href="pacb-20231231.xsd#pacb_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373b36f3-4479-4a08-a0c5-5a5fefe2382a" xlink:to="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02d82b41-a9f7-44a4-bbd5-2142546375b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1599c395-ddd6-4cb9-8b31-19e40613baff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02d82b41-a9f7-44a4-bbd5-2142546375b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeIncMember_c6df5a28-e32e-4e8d-aadd-f635b889f03a" xlink:href="pacb-20231231.xsd#pacb_OmniomeIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02d82b41-a9f7-44a4-bbd5-2142546375b4" xlink:to="loc_pacb_OmniomeIncMember_c6df5a28-e32e-4e8d-aadd-f635b889f03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:href="pacb-20231231.xsd#pacb_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesTable_5221a501-10e1-4037-8c4d-e9ac02d2ddde" xlink:to="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6161bc03-71ee-4072-b625-e4543cf28cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6161bc03-71ee-4072-b625-e4543cf28cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56ad7d0f-d057-4b6b-8b56-7280677ec061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_56ad7d0f-d057-4b6b-8b56-7280677ec061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8dd579fb-e10c-4de9-a294-9009bd42821b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8dd579fb-e10c-4de9-a294-9009bd42821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_c13de5d8-5ba5-4b03-bc46-039601aaafae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_PaymentsForRent_c13de5d8-5ba5-4b03-bc46-039601aaafae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_86110f8b-085f-4c14-b68d-25fc198e7fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseCost_86110f8b-085f-4c14-b68d-25fc198e7fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5ff1aef1-0b20-4699-aea9-afda291f83cb" xlink:href="pacb-20231231.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5ff1aef1-0b20-4699-aea9-afda291f83cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_f6e46f2f-7edb-4f1a-9142-061002dbe879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_PurchaseObligation_f6e46f2f-7edb-4f1a-9142-061002dbe879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_24e8d73d-690a-4608-af10-cae9dc8adc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_OperatingLeaseLiability_24e8d73d-690a-4608-af10-cae9dc8adc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f34786d3-9d1c-4619-a25d-df4ef767738d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f34786d3-9d1c-4619-a25d-df4ef767738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_54a7433e-b93b-420a-808a-c92ee89b6e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDeposits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_PaymentsForDeposits_54a7433e-b93b-420a-808a-c92ee89b6e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5bb0b3ae-f925-464e-9686-2ff078094716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5bb0b3ae-f925-464e-9686-2ff078094716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_900be459-fc09-41cc-8dfb-27eb2fc2978d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_CommitmentsAndContingenciesLineItems_5ec129e5-8395-4550-8bc4-e34f5c089b19" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_900be459-fc09-41cc-8dfb-27eb2fc2978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b5c878d-8d6c-452e-a27f-4aa63599927f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b5c878d-8d6c-452e-a27f-4aa63599927f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5da1746d-f0b4-4f4e-8fda-8ed7b05a4e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5da1746d-f0b4-4f4e-8fda-8ed7b05a4e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_74a20566-af3c-4a2c-badf-6de1b47bbab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_74a20566-af3c-4a2c-badf-6de1b47bbab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_16288780-5447-41ae-8c7f-7b267796de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_16288780-5447-41ae-8c7f-7b267796de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9b805f36-1a54-4b80-8eff-74008196345e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9b805f36-1a54-4b80-8eff-74008196345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4095f022-06fc-4e52-9d24-bac096026c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4095f022-06fc-4e52-9d24-bac096026c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fa344a31-47b9-4556-ac45-592ca7a68c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fa344a31-47b9-4556-ac45-592ca7a68c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00e0be6d-f918-46b5-afbb-1afa82cb7655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00e0be6d-f918-46b5-afbb-1afa82cb7655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bddea134-d424-4d9e-b83d-e68ec1086a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bddea134-d424-4d9e-b83d-e68ec1086a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0684f365-70df-45c9-8b04-781289c85adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a10480b1-fa02-4475-9a32-057599735de7" xlink:to="loc_us-gaap_OperatingLeaseLiability_0684f365-70df-45c9-8b04-781289c85adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetClassificationAbstract_e8c7997f-c20a-4f7c-93ee-dd11a0e6fdcf" xlink:href="pacb-20231231.xsd#pacb_BalanceSheetClassificationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b5c878d-8d6c-452e-a27f-4aa63599927f" xlink:to="loc_pacb_BalanceSheetClassificationAbstract_e8c7997f-c20a-4f7c-93ee-dd11a0e6fdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dac64d8a-70ae-407f-87f0-21853c2d958d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_e8c7997f-c20a-4f7c-93ee-dd11a0e6fdcf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dac64d8a-70ae-407f-87f0-21853c2d958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_00d8afd8-b4ed-419e-a6f5-f857cc356fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_e8c7997f-c20a-4f7c-93ee-dd11a0e6fdcf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_00d8afd8-b4ed-419e-a6f5-f857cc356fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6a7ede04-55bd-466f-8c87-b948890676c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_e8c7997f-c20a-4f7c-93ee-dd11a0e6fdcf" xlink:to="loc_us-gaap_OperatingLeaseLiability_6a7ede04-55bd-466f-8c87-b948890676c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" xlink:type="simple" xlink:href="pacb-20231231.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2a51f01a-215b-4b7b-8146-ed6cdf957d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a51f01a-215b-4b7b-8146-ed6cdf957d5e" xlink:to="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a106f1f4-0951-4da1-8da3-f76022d24d0a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_55907a43-bc84-45ec-aa60-0661af1a20da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:to="loc_us-gaap_DomesticCountryMember_55907a43-bc84-45ec-aa60-0661af1a20da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e7194235-fb80-44bf-aef5-aa92afa06d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_742a59c2-85da-4994-b971-c02696074ade" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e7194235-fb80-44bf-aef5-aa92afa06d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:href="pacb-20231231.xsd#pacb_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesTable_0904b621-4fcc-43e7-92b8-c5c6fe3ad6a1" xlink:to="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_61654fbd-269a-4774-adca-a370b7dc826e" xlink:href="pacb-20231231.xsd#pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition_61654fbd-269a-4774-adca-a370b7dc826e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_395fdbf5-e361-426d-abe9-0b8ed6fcc554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_395fdbf5-e361-426d-abe9-0b8ed6fcc554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e3473ee8-2502-478c-ad95-913669a51b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e3473ee8-2502-478c-ad95-913669a51b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_10671c24-66d7-4d18-ae5e-f9548055765a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_10671c24-66d7-4d18-ae5e-f9548055765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_c4088453-f90a-42e1-9a6c-2241456504f4" xlink:href="pacb-20231231.xsd#pacb_OperatingLossCarryforwardsAmountSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration_c4088453-f90a-42e1-9a6c-2241456504f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_54c81eaa-6805-44ff-ab75-6a94afa10158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_54c81eaa-6805-44ff-ab75-6a94afa10158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ad6d1de-95ce-4f7e-aa4c-650c7027542f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ad6d1de-95ce-4f7e-aa4c-650c7027542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b08b7080-945e-4d85-afc3-fbfd720c559b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b08b7080-945e-4d85-afc3-fbfd720c559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_de4453f1-bed5-4cce-9f62-beee29c29aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_de4453f1-bed5-4cce-9f62-beee29c29aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd93b9cf-65ae-4d98-a59a-c7af53f80fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeTaxesLineItems_5b8386d2-2012-4c2b-bab3-c2897011c56e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd93b9cf-65ae-4d98-a59a-c7af53f80fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESProvisionBenefitforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cf0c1152-a5d9-478a-a8cc-2c1d19103e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0ce0585f-6bba-4bf5-8f7a-dfeed83d0310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf0c1152-a5d9-478a-a8cc-2c1d19103e4c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0ce0585f-6bba-4bf5-8f7a-dfeed83d0310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eeea2baf-e940-4c3b-a53e-3a1710e211b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf0c1152-a5d9-478a-a8cc-2c1d19103e4c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eeea2baf-e940-4c3b-a53e-3a1710e211b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_84d68f40-db10-47fd-b434-2a6a8cb6d746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eeea2baf-e940-4c3b-a53e-3a1710e211b0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_84d68f40-db10-47fd-b434-2a6a8cb6d746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9ab317c3-2b9c-4788-93cf-d2d2420addb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eeea2baf-e940-4c3b-a53e-3a1710e211b0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9ab317c3-2b9c-4788-93cf-d2d2420addb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9a737d49-d182-4bd2-b597-78a37bf3f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eeea2baf-e940-4c3b-a53e-3a1710e211b0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9a737d49-d182-4bd2-b597-78a37bf3f23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_176c51ff-02be-458e-949a-528c3d421e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eeea2baf-e940-4c3b-a53e-3a1710e211b0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_176c51ff-02be-458e-949a-528c3d421e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7e7957bd-e3c4-40db-8280-755998c4bcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cf0c1152-a5d9-478a-a8cc-2c1d19103e4c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7e7957bd-e3c4-40db-8280-755998c4bcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5030bd75-2b3e-4a05-acfb-9f412f21a549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5030bd75-2b3e-4a05-acfb-9f412f21a549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e87db497-1354-4862-a523-4f9a2f429272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e87db497-1354-4862-a523-4f9a2f429272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_619a1f4d-f8f9-41c5-8c14-f4b6b40492eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_619a1f4d-f8f9-41c5-8c14-f4b6b40492eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_6ab9de3e-e3f1-4e02-a438-e46266d89a0f" xlink:href="pacb-20231231.xsd#pacb_EffectiveIncomeTaxRateReconciliationTaxCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit_6ab9de3e-e3f1-4e02-a438-e46266d89a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f6643150-bade-4407-ae66-d3ab452c8a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f6643150-bade-4407-ae66-d3ab452c8a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_ca982d2c-42c4-4ffc-8851-ed196a1e70ea" xlink:href="pacb-20231231.xsd#pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent_ca982d2c-42c4-4ffc-8851-ed196a1e70ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_776b0e54-d363-477c-9f73-e772e948d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_776b0e54-d363-477c-9f73-e772e948d46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_87dfc7d1-3e5a-48c1-a63d-3debbbcb5e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02417883-747b-41a5-a094-bbb03c6de4af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_87dfc7d1-3e5a-48c1-a63d-3debbbcb5e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_15f3216d-6ca5-457a-9f9c-d9cbdcbdcf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_15f3216d-6ca5-457a-9f9c-d9cbdcbdcf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1c91d996-ee9e-41c3-b05f-58e617c3b3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1c91d996-ee9e-41c3-b05f-58e617c3b3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_9481365a-c14e-445b-9b3c-ef895db14868" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_9481365a-c14e-445b-9b3c-ef895db14868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_e0a1ff57-707b-461a-8888-12f9b01d87c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_e0a1ff57-707b-461a-8888-12f9b01d87c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_388f8caa-53ef-4986-b4b9-4f883c38f6e6" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense_388f8caa-53ef-4986-b4b9-4f883c38f6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_44d3f34a-3a71-4f31-a14a-5de26958efe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_44d3f34a-3a71-4f31-a14a-5de26958efe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_7b42a2c4-010e-4b8d-b361-6941d12a69fd" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_pacb_DeferredTaxAssetsOperatingLeaseLiabilities_7b42a2c4-010e-4b8d-b361-6941d12a69fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_df817bf2-7caa-4d41-bd0e-b6461773fbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_df817bf2-7caa-4d41-bd0e-b6461773fbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_99af3177-99c6-49e1-b154-6d973aa01546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_99af3177-99c6-49e1-b154-6d973aa01546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b78b0aa3-7a6f-4c60-b3be-0155bb698d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c547c2b4-29ca-4248-ac14-f6ac7a0e9ef7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b78b0aa3-7a6f-4c60-b3be-0155bb698d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8e04df3f-3e7b-4145-a90c-6a1c1cc1c551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8e04df3f-3e7b-4145-a90c-6a1c1cc1c551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_67ce0eab-aa5a-41d5-9106-8f5feb4c644e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_67ce0eab-aa5a-41d5-9106-8f5feb4c644e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_ea8e65ee-68dc-4f7d-8d83-83ad4620e09d" xlink:href="pacb-20231231.xsd#pacb_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:to="loc_pacb_DeferredTaxLiabilitiesRightOfUseAssets_ea8e65ee-68dc-4f7d-8d83-83ad4620e09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7cd61609-f0a0-4817-9bd0-6020cf91dead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7cd61609-f0a0-4817-9bd0-6020cf91dead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5c4b65c2-4732-4b86-8808-c258436acba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be81b7b-71ef-4d24-819f-579274dbe900" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5c4b65c2-4732-4b86-8808-c258436acba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b0f0ed0e-2bc7-437f-acee-7f0765216ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b0f0ed0e-2bc7-437f-acee-7f0765216ed3" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3ea4c6db-4970-44b8-9306-f95dd92b8650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3ea4c6db-4970-44b8-9306-f95dd92b8650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7caae438-fd53-4421-b23a-ef57cc81cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7caae438-fd53-4421-b23a-ef57cc81cffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c72c541b-7432-475f-9b4d-a20cc561e0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c72c541b-7432-475f-9b4d-a20cc561e0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a5c0f07e-36f8-4d18-930d-161e1d7101de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a5c0f07e-36f8-4d18-930d-161e1d7101de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3bf3977c-4b05-49d7-921d-5a3caaaff842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_163855cc-c1aa-4e83-a1e1-928f83f2e94c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3bf3977c-4b05-49d7-921d-5a3caaaff842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c705627-f025-42ec-911b-621122fdd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:href="pacb-20231231.xsd#pacb_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c705627-f025-42ec-911b-621122fdd1fd" xlink:to="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0203af0c-4a8b-4e8d-bc89-279d08afbc7e" xlink:to="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PrivatePlacementOfCommonStockMember_2b98dfef-5382-40e7-95d5-3c04a633527e" xlink:href="pacb-20231231.xsd#pacb_PrivatePlacementOfCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:to="loc_pacb_PrivatePlacementOfCommonStockMember_2b98dfef-5382-40e7-95d5-3c04a633527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7c8fa692-7284-4eaf-aa0b-338f3b6b46bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95fb3762-22c9-485b-aed8-1c57bdd2268c" xlink:to="loc_us-gaap_CommonStockMember_7c8fa692-7284-4eaf-aa0b-338f3b6b46bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_3db9b1ee-3f01-4b16-bd9f-fc1502ee2361" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_3d2e6307-0a81-4873-a9d1-54ad765972b0" xlink:href="pacb-20231231.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_EquityIncentivePlan2020Member_3d2e6307-0a81-4873-a9d1-54ad765972b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InducementEquityIncentivePlan2020Member_66cce5c7-20b4-43a8-90aa-33ee6228cbfc" xlink:href="pacb-20231231.xsd#pacb_InducementEquityIncentivePlan2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_InducementEquityIncentivePlan2020Member_66cce5c7-20b4-43a8-90aa-33ee6228cbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomePlanMember_4f29e984-5e6f-4796-b97a-b01a9ce310e5" xlink:href="pacb-20231231.xsd#pacb_OmniomePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_OmniomePlanMember_4f29e984-5e6f-4796-b97a-b01a9ce310e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TwoThousandTenEquityIncentivePlanMember_af89e4d2-ed8e-4cbd-83ca-ecc3b0769204" xlink:href="pacb-20231231.xsd#pacb_TwoThousandTenEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_TwoThousandTenEquityIncentivePlanMember_af89e4d2-ed8e-4cbd-83ca-ecc3b0769204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_951c5144-8dc6-4c36-8191-74122a003c4a" xlink:href="pacb-20231231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_79fb5d9a-98e8-4e4b-872e-fa3cd0828222" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_951c5144-8dc6-4c36-8191-74122a003c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_947a5fd5-fa4b-4494-b97b-af3d591a33a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_78ce0d5e-69fd-48ee-aa48-1d9b3285e28a" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_78ce0d5e-69fd-48ee-aa48-1d9b3285e28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_98c680a3-ed0c-41e5-a59a-6e341693e755" xlink:href="pacb-20231231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember_98c680a3-ed0c-41e5-a59a-6e341693e755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b4699c3-f0cc-4835-94de-43efa554274a" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_9b4699c3-f0cc-4835-94de-43efa554274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_0b4f1316-4bf0-4544-b168-591556bdcdad" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_0b4f1316-4bf0-4544-b168-591556bdcdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_15976233-ff73-45d2-811e-7360339165ca" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50be74e4-e165-4e6d-be75-28a18d271ae0" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember_15976233-ff73-45d2-811e-7360339165ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9d757ffd-1d42-4fe1-afa1-ee2b92fa392e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_746af636-a273-42c4-a962-d85a7053d996" xlink:to="loc_us-gaap_VestingDomain_9d757ffd-1d42-4fe1-afa1-ee2b92fa392e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_2d6095eb-5047-471c-a8b3-3f58fdbd5553" xlink:href="pacb-20231231.xsd#pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9d757ffd-1d42-4fe1-afa1-ee2b92fa392e" xlink:to="loc_pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember_2d6095eb-5047-471c-a8b3-3f58fdbd5553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3d02b8fc-cc68-42db-b638-9dd3a0fff4ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicStockOfferingMember_e00c5620-3b96-4667-b8f2-662113d69de6" xlink:href="pacb-20231231.xsd#pacb_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:to="loc_pacb_PublicStockOfferingMember_e00c5620-3b96-4667-b8f2-662113d69de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShelfOfferingMember_ec20ee9d-ef6e-4ab1-901c-3de88fe760c3" xlink:href="pacb-20231231.xsd#pacb_ShelfOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33cdbdca-0546-4c50-ae98-fe3e5e3f0e21" xlink:to="loc_pacb_ShelfOfferingMember_ec20ee9d-ef6e-4ab1-901c-3de88fe760c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:href="pacb-20231231.xsd#pacb_StockholdersEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityTable_bd174fc1-9aa5-4642-8b6a-c3dade65a032" xlink:to="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_aa9dfd07-38f3-4462-b41d-f1afd105a5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_aa9dfd07-38f3-4462-b41d-f1afd105a5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_679f4752-5295-42d9-beb2-2c4ee550dec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_679f4752-5295-42d9-beb2-2c4ee550dec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fefb95c1-0d9b-4494-af1b-83f02d1c5acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fefb95c1-0d9b-4494-af1b-83f02d1c5acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6326bf9c-ef5c-40a5-bb62-9cd5d1bad6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6326bf9c-ef5c-40a5-bb62-9cd5d1bad6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f7cd836a-d371-4ccf-9f89-4c1f2fcc719a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f7cd836a-d371-4ccf-9f89-4c1f2fcc719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2091fa8c-aaf1-4c68-bf1b-add4756679e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2091fa8c-aaf1-4c68-bf1b-add4756679e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_406ca7e0-9da1-432b-a124-e2dd10b457a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_406ca7e0-9da1-432b-a124-e2dd10b457a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights_0f7146ec-c8bb-44a5-a73e-17ef5582d496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockVotingRights_0f7146ec-c8bb-44a5-a73e-17ef5582d496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_d2e528eb-3362-43dd-b146-63dd7fed580e" xlink:href="pacb-20231231.xsd#pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned_d2e528eb-3362-43dd-b146-63dd7fed580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingShares_18afb409-738c-41b8-bfb4-2d913cb36c34" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PublicOfferingShares_18afb409-738c-41b8-bfb4-2d913cb36c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OfferingShareAmountMaximum_4e8a9a9c-7596-474b-9c74-eeca753c628f" xlink:href="pacb-20231231.xsd#pacb_OfferingShareAmountMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_OfferingShareAmountMaximum_4e8a9a9c-7596-474b-9c74-eeca753c628f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_622a1655-90dd-4cee-9dd6-3f7f8f7117fe" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod_622a1655-90dd-4cee-9dd6-3f7f8f7117fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_5aeca26a-49a7-4944-ab93-496de8e3f1b3" xlink:href="pacb-20231231.xsd#pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares_5aeca26a-49a7-4944-ab93-496de8e3f1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a591156a-c28d-48ee-95f0-aae5cd2f52dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a591156a-c28d-48ee-95f0-aae5cd2f52dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_803b6bfd-c303-4d54-8103-ff54165a5fcb" xlink:href="pacb-20231231.xsd#pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering_803b6bfd-c303-4d54-8103-ff54165a5fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_b9617559-0501-42a2-b1b3-884776a571da" xlink:href="pacb-20231231.xsd#pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_b9617559-0501-42a2-b1b3-884776a571da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_eb27108d-9162-4ed6-a9e9-9c7c9c8f440a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_DeferredOfferingCosts_eb27108d-9162-4ed6-a9e9-9c7c9c8f440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfOfferings_df090453-22f2-4c8e-b909-73bb09938462" xlink:href="pacb-20231231.xsd#pacb_NumberOfOfferings"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_NumberOfOfferings_df090453-22f2-4c8e-b909-73bb09938462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_a666da38-cd55-4ff8-93d8-0f7c16aef165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_a666da38-cd55-4ff8-93d8-0f7c16aef165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ba8d6e8-85a1-49a2-9f18-339ce211671e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ba8d6e8-85a1-49a2-9f18-339ce211671e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_67b8d239-7514-451d-86a7-e8c31c3343e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_67b8d239-7514-451d-86a7-e8c31c3343e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1a69290f-af01-4290-a0be-67e17092377f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_CommonStockSharesIssued_1a69290f-af01-4290-a0be-67e17092377f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3094304a-c030-4bab-bf64-f64ac0cd1a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3094304a-c030-4bab-bf64-f64ac0cd1a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_090b9bf0-3132-4e4a-bb97-5b4cfb567188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_090b9bf0-3132-4e4a-bb97-5b4cfb567188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e889373f-e6a6-41e7-9f22-bcc81d8c56cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e889373f-e6a6-41e7-9f22-bcc81d8c56cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeRatio_3f979a97-c250-4a6e-a336-68e31e1a9dae" xlink:href="pacb-20231231.xsd#pacb_ExchangeRatio"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ExchangeRatio_3f979a97-c250-4a6e-a336-68e31e1a9dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af033f52-24a4-4d6a-8213-864e69fb588d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af033f52-24a4-4d6a-8213-864e69fb588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_dd999f36-2419-4808-89ba-ba32473772ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharePrice_dd999f36-2419-4808-89ba-ba32473772ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5471f1ac-8d1c-4f4c-8706-5249ad3cd129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5471f1ac-8d1c-4f4c-8706-5249ad3cd129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_509910fd-7ffe-4984-95d1-df8af66a0d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_509910fd-7ffe-4984-95d1-df8af66a0d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_34cf27f4-3a46-4b0b-93da-81ac26948f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_34cf27f4-3a46-4b0b-93da-81ac26948f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_083d3e16-ed7c-44b3-96ee-cbd96e3027be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_083d3e16-ed7c-44b3-96ee-cbd96e3027be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8c5315bf-c805-453a-937a-1989cdad7ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8c5315bf-c805-453a-937a-1989cdad7ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c69f75a-a443-45c9-a84e-f45e6c54b6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c69f75a-a443-45c9-a84e-f45e6c54b6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41a42c23-537f-48ff-86f0-9063569c2e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41a42c23-537f-48ff-86f0-9063569c2e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d83ae64b-b537-4d6d-a5f5-1a2bfccbadb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d83ae64b-b537-4d6d-a5f5-1a2bfccbadb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2101f82d-2b65-4c27-8795-11f7d7af968b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2101f82d-2b65-4c27-8795-11f7d7af968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_002a484e-cca3-4025-b521-6331abc80268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_002a484e-cca3-4025-b521-6331abc80268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5515afd6-a5a0-4107-9a36-43d1434ea93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5515afd6-a5a0-4107-9a36-43d1434ea93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f189d077-7f34-444d-aeea-1a154c6d1d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f189d077-7f34-444d-aeea-1a154c6d1d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_8d59f60c-69bb-4b80-b66f-947c177957a4" xlink:href="pacb-20231231.xsd#pacb_ShareInstrumentNumberOfSharesConversionRatio"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ShareInstrumentNumberOfSharesConversionRatio_8d59f60c-69bb-4b80-b66f-947c177957a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55fd0960-c8e5-41fb-84b9-50b69d7f3321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55fd0960-c8e5-41fb-84b9-50b69d7f3321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c89c092e-1278-4533-8154-912be9690d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c89c092e-1278-4533-8154-912be9690d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_69665528-984e-4cbd-b2d0-1ab1fd9453c1" xlink:href="pacb-20231231.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_69665528-984e-4cbd-b2d0-1ab1fd9453c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_32a98dd8-2a30-4c3c-99bb-eddc6fffaff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_32a98dd8-2a30-4c3c-99bb-eddc6fffaff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da02b2a0-6172-44f2-91a1-040225b2c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da02b2a0-6172-44f2-91a1-040225b2c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_NumberOfPurchasePeriods_e9b7a462-fac9-4c47-b93b-5988809c665b" xlink:href="pacb-20231231.xsd#pacb_NumberOfPurchasePeriods"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_NumberOfPurchasePeriods_e9b7a462-fac9-4c47-b93b-5988809c665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_611e796a-7bee-4c28-a956-14a04bd3d8e0" xlink:href="pacb-20231231.xsd#pacb_PurchasePeriodOfEmployeeStockPurchasePlan"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PurchasePeriodOfEmployeeStockPurchasePlan_611e796a-7bee-4c28-a956-14a04bd3d8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_34080944-ea69-422a-95fb-a4bad606fc70" xlink:href="pacb-20231231.xsd#pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased_34080944-ea69-422a-95fb-a4bad606fc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2972fec1-07f1-43da-afa4-2fd296460f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2972fec1-07f1-43da-afa4-2fd296460f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_e8aac78f-c110-497e-aade-be8005b7c500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_e8aac78f-c110-497e-aade-be8005b7c500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5285e9f2-d54c-4289-9cc9-45050a29ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_5285e9f2-d54c-4289-9cc9-45050a29ec95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_675aa9cf-e904-45ce-b247-d54ebe3b64cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_675aa9cf-e904-45ce-b247-d54ebe3b64cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_efb00435-11f9-4d7c-9b7c-bf5803751821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_efb00435-11f9-4d7c-9b7c-bf5803751821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f49f9a4-f5cb-4875-a416-8598f76afd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_StockholdersEquityLineItems_8ad46ae9-d2c0-47bc-b8e1-d8ff6ac6d0a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6f49f9a4-f5cb-4875-a416-8598f76afd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7928964-7c73-4dca-beb1-b5d2a6b76b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7928964-7c73-4dca-beb1-b5d2a6b76b33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:to="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6ec046a8-8ce9-4f2a-8f21-58fbfacc2146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_b882c911-9dc0-4d2a-9742-52bddf60b080" xlink:href="pacb-20231231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:to="loc_pacb_TimeBasedStockOptionMember_b882c911-9dc0-4d2a-9742-52bddf60b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bd14b166-ef91-4437-8c2d-8adc795246bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a04f627-3d10-441a-abdc-7b8439dfd000" xlink:to="loc_us-gaap_PerformanceSharesMember_bd14b166-ef91-4437-8c2d-8adc795246bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_7796ae81-7698-4e2a-aeb7-d7dbb52ec983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_b60b7efc-a4f8-456d-aa8e-40cb43ec23be" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_7796ae81-7698-4e2a-aeb7-d7dbb52ec983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomePlanMember_c55977a3-7521-4801-b31b-720012ec92fd" xlink:href="pacb-20231231.xsd#pacb_OmniomePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_7796ae81-7698-4e2a-aeb7-d7dbb52ec983" xlink:to="loc_pacb_OmniomePlanMember_c55977a3-7521-4801-b31b-720012ec92fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_532f8842-b192-4306-828f-d3ae302e2036" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f903be-c640-448f-a240-db1802bdf321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f903be-c640-448f-a240-db1802bdf321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7110bdf5-2064-4630-bbd5-b655239629b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7110bdf5-2064-4630-bbd5-b655239629b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e3c7b0d-33b4-4ea5-a8c4-e9bc1d920951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e3c7b0d-33b4-4ea5-a8c4-e9bc1d920951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5270e5c8-b557-4c71-9446-7a806b4770bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5270e5c8-b557-4c71-9446-7a806b4770bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f9e072f-8435-488e-865c-88315ace2c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d164ecb1-4d24-4d16-b05c-3db8888e249b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f9e072f-8435-488e-865c-88315ace2c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_b7f6de72-a4bb-470b-b495-67636321a6f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b33a2221-3a89-4860-ba4c-abd5dafdcec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b33a2221-3a89-4860-ba4c-abd5dafdcec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1f648cec-44d7-4981-8fb9-b0c4abb2a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1f648cec-44d7-4981-8fb9-b0c4abb2a60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42fa7105-cb2f-48bb-9dc4-6ec62315ec58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42fa7105-cb2f-48bb-9dc4-6ec62315ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_76c9fbf7-0713-462e-9201-f1081a79b507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_76c9fbf7-0713-462e-9201-f1081a79b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6d415dfd-430c-4c10-a2ad-849bf7be463f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6d415dfd-430c-4c10-a2ad-849bf7be463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d25fd01f-0fff-4e12-923b-38bf9ebc048c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_58fcebe7-0220-4751-aaa2-61238f26575a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d25fd01f-0fff-4e12-923b-38bf9ebc048c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f384744-05b2-48c8-8a80-5e600f7cec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f384744-05b2-48c8-8a80-5e600f7cec2e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:to="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bfeba494-b55b-40de-921d-b7e097e40b28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_7bf89ddc-60cd-4f8a-9562-dd3fd116b524" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_7bf89ddc-60cd-4f8a-9562-dd3fd116b524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_107dfe7f-93ed-4edd-b2b2-8610e0126e99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84368945-3c1c-4777-8c3e-c749fdad0d54" xlink:to="loc_us-gaap_PerformanceSharesMember_107dfe7f-93ed-4edd-b2b2-8610e0126e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38f4fc1e-ca21-41d3-8f9b-445025c932f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4191ee79-657b-419f-a209-c0110bbe3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4191ee79-657b-419f-a209-c0110bbe3ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4bff193-1f99-46d3-8739-a9fc6126da00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f4bff193-1f99-46d3-8739-a9fc6126da00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99555c46-d620-42d8-aa57-cbaba213811e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99555c46-d620-42d8-aa57-cbaba213811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2e0f06a-c350-4603-9166-64249f5d789e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2e0f06a-c350-4603-9166-64249f5d789e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c2b45e9-c5e7-45df-8ae7-54364a5a7ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_c87b053f-ca7f-4b8c-a5a7-2e47d6b7ebc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c2b45e9-c5e7-45df-8ae7-54364a5a7ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d58fe1d3-5c3f-4882-bd82-e337057632c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad00512-b827-426a-a81b-460c57970483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad00512-b827-426a-a81b-460c57970483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3fe443d2-d9a9-48e8-b7bc-fa61955f92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3fe443d2-d9a9-48e8-b7bc-fa61955f92ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cb274ce2-e8f2-48e8-9b47-0e596ef0a464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cb274ce2-e8f2-48e8-9b47-0e596ef0a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e7effe0-c4f6-41d3-9190-3800aced2539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e7effe0-c4f6-41d3-9190-3800aced2539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5af0ec-d85b-4d39-8f5a-cc710ebfd757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d8a40b14-a57f-4577-a2bf-d6fb9e0d44ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc5af0ec-d85b-4d39-8f5a-cc710ebfd757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_050139d4-926a-4a9e-a027-f333959c45c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_050139d4-926a-4a9e-a027-f333959c45c5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a8dbe677-3e93-4a40-ac74-661f462f2901" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_27748b4c-268b-46b7-a97c-4122c0b6dd04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_us-gaap_CostOfSalesMember_27748b4c-268b-46b7-a97c-4122c0b6dd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7c7f075-1857-4847-8ecc-08dffdf791ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7c7f075-1857-4847-8ecc-08dffdf791ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eac60fef-274c-43bc-a7f9-617071b13432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eac60fef-274c-43bc-a7f9-617071b13432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesStockSettledMember_928e32e1-9502-49c8-aa67-c65d83b36323" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesStockSettledMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_MergerRelatedExpensesStockSettledMember_928e32e1-9502-49c8-aa67-c65d83b36323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesMilestoneMember_9e11e76c-1e83-47e5-a33e-4d14da25facb" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_MergerRelatedExpensesMilestoneMember_9e11e76c-1e83-47e5-a33e-4d14da25facb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_4d03d8a2-f62a-4c05-9cee-bc5c49a01452" xlink:href="pacb-20231231.xsd#pacb_StockBasedCompensationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_StockBasedCompensationMember_4d03d8a2-f62a-4c05-9cee-bc5c49a01452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_MergerRelatedExpensesCashSettledMember_2ec2fc51-3d75-411b-b489-0ea68c325359" xlink:href="pacb-20231231.xsd#pacb_MergerRelatedExpensesCashSettledMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677255e4-7615-46da-bd03-15e496324f08" xlink:to="loc_pacb_MergerRelatedExpensesCashSettledMember_2ec2fc51-3d75-411b-b489-0ea68c325359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f37d15b7-ad02-4ce6-8669-51a98621fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad8768ad-bc8a-4408-9316-635d47a57fa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f37d15b7-ad02-4ce6-8669-51a98621fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f7192022-1a0b-444b-beb7-a254b810cf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f37d15b7-ad02-4ce6-8669-51a98621fb9a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f7192022-1a0b-444b-beb7-a254b810cf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe1380a-ac17-4673-8a30-877ed3935041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe1380a-ac17-4673-8a30-877ed3935041" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:to="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb9fe654-5323-4129-8426-40b6416b66e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f44c979a-3dbf-4c91-b730-0762fab1d6ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb9fe654-5323-4129-8426-40b6416b66e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_060d0af3-4ce2-4e25-b340-1e5f339a772f" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb9fe654-5323-4129-8426-40b6416b66e8" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_060d0af3-4ce2-4e25-b340-1e5f339a772f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:to="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_96a46ae4-a867-455d-b135-d0a16e7ec4fe" xlink:to="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7fb57334-36d3-435c-82b3-41a5d407beb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:to="loc_srt_MinimumMember_7fb57334-36d3-435c-82b3-41a5d407beb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ea1f466-9b4c-492e-a2a5-e747541f6341" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e854b64-f0ec-4eca-821f-e35603800e1a" xlink:to="loc_srt_MaximumMember_0ea1f466-9b4c-492e-a2a5-e747541f6341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbb07d32-bc56-49bb-b554-5fa766a74f29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4717ebf-9250-4023-8186-1f87a54fb247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4717ebf-9250-4023-8186-1f87a54fb247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b55bf9ff-e0ac-49e1-b8d9-8fb57429724c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b55bf9ff-e0ac-49e1-b8d9-8fb57429724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2b81e957-75a5-4fd8-9786-ad3905061286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2b81e957-75a5-4fd8-9786-ad3905061286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_48e38492-b171-40cd-9433-f5a4e8015ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_48e38492-b171-40cd-9433-f5a4e8015ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8c0d0b51-3aef-43f3-bcfe-2c9a1d1ba4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8c0d0b51-3aef-43f3-bcfe-2c9a1d1ba4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82cc9882-38fb-4ced-b049-c51c9a40a94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f65814f7-8656-4c48-b2f6-6344f2e3d0e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_82cc9882-38fb-4ced-b049-c51c9a40a94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dec9059-8514-475f-b736-a4725d5e8b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dec9059-8514-475f-b736-a4725d5e8b24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_33c29cb5-7b2e-4c11-b7e3-bd78f9e18eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_95403652-ccc0-4413-b429-865e7170a3dc" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_33c29cb5-7b2e-4c11-b7e3-bd78f9e18eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_d8b126f9-13c8-4d22-86b6-377942bdc186" xlink:href="pacb-20231231.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_33c29cb5-7b2e-4c11-b7e3-bd78f9e18eb8" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_d8b126f9-13c8-4d22-86b6-377942bdc186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:to="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_497b2a4c-9bfe-4117-b439-510c4968860e" xlink:to="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a4773f8-4714-4f94-9869-6fe2a5072a70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:to="loc_srt_MinimumMember_4a4773f8-4714-4f94-9869-6fe2a5072a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef6291e4-7341-4ad5-a6d4-893e72716b80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a613ef12-7024-4db0-b42a-093342a17ef1" xlink:to="loc_srt_MaximumMember_ef6291e4-7341-4ad5-a6d4-893e72716b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1337c69d-9379-40e6-89a6-cee34cf6420d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3bd07397-6712-43b1-8a3b-3047365753ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3bd07397-6712-43b1-8a3b-3047365753ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03d53171-c139-4e6a-98bd-e8cc7e5533f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03d53171-c139-4e6a-98bd-e8cc7e5533f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_87d5d926-8a88-477e-8b4e-f09d43d505d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_87d5d926-8a88-477e-8b4e-f09d43d505d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a5150215-fe66-49d1-8f5a-6727c4512da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a5150215-fe66-49d1-8f5a-6727c4512da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_180ec03e-b17b-4dcf-a103-6c33a803344e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_180ec03e-b17b-4dcf-a103-6c33a803344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af92e8e7-a3ac-4263-80fa-2376def305a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2775ccad-f5a6-4d7b-a533-e0d3d6d3822a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af92e8e7-a3ac-4263-80fa-2376def305a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_31195225-ed03-4042-8414-335aecb66ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16f2297-cab2-416a-b5d3-d4a6065fdcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_31195225-ed03-4042-8414-335aecb66ad2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16f2297-cab2-416a-b5d3-d4a6065fdcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_bec49421-cc4a-48c5-a0dc-c0305118e753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16f2297-cab2-416a-b5d3-d4a6065fdcd8" xlink:to="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_bec49421-cc4a-48c5-a0dc-c0305118e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3d32bc93-712f-4fa1-b44e-d68bf3d2e994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_bec49421-cc4a-48c5-a0dc-c0305118e753" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3d32bc93-712f-4fa1-b44e-d68bf3d2e994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d6277d3-4d2d-40f3-b42a-1a9ef456bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3d32bc93-712f-4fa1-b44e-d68bf3d2e994" xlink:to="loc_us-gaap_NetIncomeLoss_7d6277d3-4d2d-40f3-b42a-1a9ef456bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_89039d6e-7ad2-4fb2-a166-1950066bc9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_bec49421-cc4a-48c5-a0dc-c0305118e753" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_89039d6e-7ad2-4fb2-a166-1950066bc9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_60b7aa42-5ada-4052-b113-43e2112bf582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_89039d6e-7ad2-4fb2-a166-1950066bc9e3" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_60b7aa42-5ada-4052-b113-43e2112bf582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c60bcc8-5728-4538-8dea-6e8a8138969c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_60b7aa42-5ada-4052-b113-43e2112bf582" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c60bcc8-5728-4538-8dea-6e8a8138969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_24d0bca8-062d-4741-9844-45c1f7e7f20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_60b7aa42-5ada-4052-b113-43e2112bf582" xlink:to="loc_us-gaap_EarningsPerShareBasic_24d0bca8-062d-4741-9844-45c1f7e7f20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_a0af19e2-d6e6-4f31-895d-cae020bc8fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_89039d6e-7ad2-4fb2-a166-1950066bc9e3" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_a0af19e2-d6e6-4f31-895d-cae020bc8fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24b23da4-17e1-44d2-b7d5-a2f6d513d861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a0af19e2-d6e6-4f31-895d-cae020bc8fa6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24b23da4-17e1-44d2-b7d5-a2f6d513d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_72bcdbc9-7694-421b-8c32-0d13085c3d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_a0af19e2-d6e6-4f31-895d-cae020bc8fa6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_72bcdbc9-7694-421b-8c32-0d13085c3d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_62ec810f-6465-4667-a51e-1be9de4e3c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_62ec810f-6465-4667-a51e-1be9de4e3c5f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f64d95a9-aaf4-4537-b793-79255397c99a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_c15687a3-bcb1-468f-a71d-2d522b655708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_c15687a3-bcb1-468f-a71d-2d522b655708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_52db9430-4568-4e99-89a4-876bffe8863a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c8fa630-37a4-481b-8564-0dde18586ddd" xlink:to="loc_us-gaap_StockCompensationPlanMember_52db9430-4568-4e99-89a4-876bffe8863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bf7be14c-00fa-4134-8899-6ffa5a7b8fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f8053046-8dc1-4caa-bbe5-0ea4ea10a962" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bf7be14c-00fa-4134-8899-6ffa5a7b8fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cb6f4a0-29da-4ba6-b7e9-ef80ea710e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bf7be14c-00fa-4134-8899-6ffa5a7b8fc2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3cb6f4a0-29da-4ba6-b7e9-ef80ea710e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_976fa43c-d73d-446f-b5cd-d007bbc82829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_2e0283d2-bf27-4af6-919a-8ec602335dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_976fa43c-d73d-446f-b5cd-d007bbc82829" xlink:to="loc_us-gaap_NumberOfReportableSegments_2e0283d2-bf27-4af6-919a-8ec602335dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d6ed555a-c3a4-4cac-bf35-636e2bccc2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d6ed555a-c3a4-4cac-bf35-636e2bccc2bd" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:to="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_25b3ac1d-f146-45a6-9699-3651818a1823" xlink:to="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_21f95aae-30fa-4b06-9139-9948f4b66dba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:to="loc_srt_NorthAmericaMember_21f95aae-30fa-4b06-9139-9948f4b66dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d774e393-6e18-4874-b991-f2fd8fa7827d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:to="loc_srt_EuropeMember_d774e393-6e18-4874-b991-f2fd8fa7827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_c6e8b36e-ece7-44ba-8557-020ab9799ec2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca3543f0-8dbf-4a72-af24-bf3db2ec7cc7" xlink:to="loc_srt_AsiaPacificMember_c6e8b36e-ece7-44ba-8557-020ab9799ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5bf7799d-bc3e-4dc4-b7a7-e074de8cf2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_48d95ae5-3060-4c44-9d5b-759d2391b635" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5bf7799d-bc3e-4dc4-b7a7-e074de8cf2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d7f70e67-7dd1-4cdc-aea0-24380a1486ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_5bf7799d-bc3e-4dc4-b7a7-e074de8cf2b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d7f70e67-7dd1-4cdc-aea0-24380a1486ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20231231.xsd#SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c931af9a-1208-4dc9-ae61-1a15aeef0620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c931af9a-1208-4dc9-ae61-1a15aeef0620" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:to="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_40f481a4-687b-434b-988d-4272d9781ca5" xlink:to="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:to="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_2c5d0869-cb3a-4844-ab58-a9555d1eaf00" xlink:href="pacb-20231231.xsd#pacb_InstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:to="loc_pacb_InstrumentMember_2c5d0869-cb3a-4844-ab58-a9555d1eaf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_64418298-2676-4c77-9f37-d5fe62bb3b44" xlink:href="pacb-20231231.xsd#pacb_ConsumableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_266c646b-bdf1-4238-834f-2b9fb3382123" xlink:to="loc_pacb_ConsumableMember_64418298-2676-4c77-9f37-d5fe62bb3b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_5bfa544a-ddb5-4a4d-a4a9-99930b1897ec" xlink:href="pacb-20231231.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_921a329a-f424-4b2e-9a02-65389ced498b" xlink:to="loc_pacb_ServiceAndOtherMember_5bfa544a-ddb5-4a4d-a4a9-99930b1897ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_947cd09a-34f4-434d-88b4-9d9c1d25b7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8f412295-f432-4a9f-9475-323cc9021348" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_947cd09a-34f4-434d-88b4-9d9c1d25b7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6549e420-f7a4-40c2-a8de-8b56994efe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_947cd09a-34f4-434d-88b4-9d9c1d25b7cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6549e420-f7a4-40c2-a8de-8b56994efe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:href="pacb-20231231.xsd#pacb_OmniomeStockAwardsRelatedToAcquisitionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_OmniomeStockAwardsRelatedToAcquisitionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_CommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedAndPerformanceBasedOptionsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedAndPerformanceBasedOptionsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:href="pacb-20231231.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:href="pacb-20231231.xsd#pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pacb-20231231_g1.jpg
<TEXT>
begin 644 pacb-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
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M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
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M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pacb-20231231_g2.gif
<TEXT>
begin 644 pacb-20231231_g2.gif
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M,93O,3$9C @9.L[O4E+OYE*EYO<ZYO<ZK?<0YO<0K5HZC-;%[UH0C$(00AD
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MTZA3GRS 0;7KU["'$@A >T#! P$(#J M8.#N +UC"Q].?..! _%  !_(@?;
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M&P?P7^;E;VZ"9-L4,:3CB')1@ML1>L3G%BEC+DAS &78%$CV,,QA<6?29@<
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MA'01"*( "!"!G'P1AD.0]R#(< +$EI$ ,?H01L.2;+6AN%(AB4P0YA+"W@'
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M@R10_R,02X6MI+&,SP.8KIT3C2D !1#?3]ZB#%"E#^  (&"$U(T6L+V>^^
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M*G$R9\/."Y'1&-$_5\D:XHXK:4GN/$/< !% 8( # P8\  % X4*&#1M*()&
M80(2$AQ>Q)A1X\:%"1(06+!  @>)"Q=T.$!BX,J!)0' $^B+1(<.!Q\P*""
M)$>'"").K,A3Z%"B11<6X&#4J "E39T^A1J58P(.!WS= ^! P *A @)T:)I
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M)M$PG!2.!!X949*VZ5ZL R2Y%LH[$MBGI$7YXH[&$K!7#2T4F%HD I8Y&(:
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MR1<6!,9ZU"\'(UPU+K7LRX\V"E,EX&'R.0 $"]CR5+XF@$FI^6$.:#-!B3.
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M +\.@1FU<0S\TL-#/"L^A I]Z,!ULL#KF)B3^"5#1,1*+"DRM(X%L"_+"Y$
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MZ[(VZ[-&Z[16)NNU9NNV=NNWANNXENNYINNZMNN[QNN\UNN]YNN^]NN_!NS
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#$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pacb-20231231xexx1028001.jpg
<TEXT>
begin 644 pacb-20231231xexx1028001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"!54!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM/LVIW"-'/&>L861\1GUVY(KS'XEW+ZK\:_!_AR^YTE3'<F%ONRR%V'([_<
M_$^M 'I:>.O#AMA=2:@;>V892>YMY88Y._R,Z@.?0*3GM70LRHI9B%4#))/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG8\F[2/>C '.UT)&5Y/?N>M:]O9^(;B2'^T]1LXXHV#NEA RM*0<X+.QPOJ
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M]JNFF@\U<>0A_A')_(8'' KHZ** "BBB@ HHHH **** "BBB@ HHHH ****
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M.&EF9NH4+D$_[0'H*MZ9\,(K23P_#=ZC]JT_P_++-80^3M<L[;E,C;B&V]L
M9XSZ56USX;^)-7\276LP>/KS3VF C2*VM2HCB!R$R).>N2>Y.: ,/Q+!)IWQ
M;^&VBB1Y+6RMBL;-_$P4J2??"+5GX17$Q\<_$BUR?LZ:NTBCL&,DP/Z*OY5U
M5YX"CGMO#<L=^W]K:"0T5Y-&7\\D 2>8-P)WD9ZY!]>^AX2\)0>%HM0D$WVB
M^U*[>\NY]FP,[$G"KDX49.!D]3S0!YO^T*2(/"I49/VYL#/7A:]#\/SWFKW6
MHSZY8"TGT_5"MI&9 ^Q3;H P8<'=YC_]]8ZBLWXA?#Z;QXVFC^UTL8[&0RH!
M:^868XZG>../2M2XT+7KZ_L9+S7;1;.WN%GEM[73S&;@KRH9FE; ! / ["@#
MS?X4SRZK\8/'&H:B2U[$[0)OZH@E(VCV 111\3)YM+^-_@B]T\E;N<I;RA.K
MQF7:0?;#-_D5VFL^#+C3?$-YXQ\*E$UF2 I<64HS#>]#@\@H_ ^;.,CD<DUS
MG@E[3Q/XP'B/Q2MQ;^*( ;:#3)K9XH[103@IG.\D$G<3QD\=#0!2M/\ DZF_
M_P"O ?\ HE*].D_Y'FW_ .P;+_Z-2L/6_ ,MSXYMO&.B:FECJL<7DS)/;^=%
M.F,<@,I!QW!["NAT[2KN"ZGU"_O([G4)8A$&CA,<42 D@*A8GDG));)XZ8H
M\I^&D23?&/XAQ2+N1Y9%8>H,K TOQRC2'6? ,4:A(TOF55 P  T.!78>%OA[
M<^&_&6L^(CK$5RVK.SS0?8R@7+;OE/F'U[@T[QW\/I_&VI:1=?VO'9+I<IFB
M3[(9"S$J?F.\<?(.@[T ==<Z9978NA<6R2"[@%O/N'^LC&["GV^=OSKQ#P3+
MJW@KQMK/PTBD=H[Q_.T^Z)'[A",L_P!?+!X_OJ.Q)KWB,.(U$K*SX^8JNT$^
MPR<?G7"R_#V\D^)D7C7^VH1/'%Y0MOL1V[=A7KYF<\YH [6SM(+"RAM+:,1P
M0H(T4=@!@5X[XX_Y.,\&?]>R_P#H4M>TUPFN_#VZUKXA:9XM&LQ0R:<H2*W^
MQE@R@L?F;S!S\YZ 4 9OQ$\ P^.]1U*.-A#JMI86LEE.3C#>9<94^S8'T(![
M5E_#KQS=^(-4TSP_KT<D7B'29)DN/,',J"-EW'_:!X/KP>_'I5OIFH1>)+K4
MY+^W>WG@C@^SK;%64(7(._>><R'/'8=*J3>#M/;QS:^+(1Y-_' \$^U>)U(P
M"?<8Z^G'84 >9_"JX?6_B]XUU34OFO[=C!"'ZQ1^8R[1Z8"*/_UU[)/I]M<W
MUI>2Q@W%H6,,G==R[6'T/'Y"N3O/A^;?QE)XK\.:B-,U*="EW%+!YT%R./O*
M&4@\ Y!ZCZYZ"SL=5\\W.H:G%+(J%8X;> Q0J3_$P+,SG_@0'MGF@#PSPQJ6
MJZ7XW^)D^DV/VF7[6X=Q*%,*^?("X'\6!DX]J]H\2V-I'X6UR-(DQ<QM),G4
M,2H4DCW"_P ZYWP_\.=3\-^(]<UJTU^SEEUB1I)XI]-9D4ERWRXF!Q\Q'-:W
M_"+:S)H^KV]SX@BGOM2ERURUCA8HPH C2,2=!@G)/\1H \QGBN_@9XY%U"LL
MW@S5Y,2(,M]G;_%>W]Y<CJ,UZYX1BMKCPOH5\JJ[BP58I/1'"DX^NU?RJWJ^
MA6OB+0)](UE([B&X3;(47:,]F4$G!!Y')HT/26T/PS8:1#.)&L[9+=973AMJ
M@ E0?;IF@#RGX'HDOB/X@QNH9&OD5E(R""\_%-^)<,=O\7_AU#$NV..:-$7T
M E4 5V7@7X?3^"]6UB]_MB.\7591--']D,95@7(VG>>/G/4=J3Q5\/;GQ+XQ
MT;Q"-8BMFTEU>&#[(7#$.&^8^8/3L!0!SWQST:XAT_2_&>F#;J&B7"LS =8R
MP(SZ@-C\&-=CH&L6WC.XL=8M?FL;6W61!UQ<R)R#[HAQ_P!M#Z5OZCIT&K:1
M<Z;?*)(;J%H9@!C(88./2J/A+PW;>$O"]CHEJV]+9,-)MP9')RS8]R30!Y-K
MD]W;?M,V\UC9B\N5TXF. RB/>?)?C<>!7JWA4M=Z'INK7D835+RP@^TD\,<
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M0V">>0.%DVKN./4/M;Z.:D\26DUM\:? LMTFV\NR+FX!ZJ[2,=OOM&U![**
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M\/#7KFYN(M,+;?/>RF !SMY&S(&3C)&*5?&VA/9Z==1SW4D6I9^R>78SNTP
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M5RQ8.5Z#DG:JUT'ASQ-X7\1:SJLVARR37RI'%>M]EEC V%]H8LH&>6'KQ[4
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M=R"5S<6&XJP&,KB0?KFNK\/Z/-HVF&WN[^34;J29YIKJ5 I=F.>@X  P !V
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MN$V;57@[\@X0<\]^*[BB@#COB%X#_P"%@:9;:=-J1L[:"83_ "0;V9P&7J6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8>!ZG@_E7M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*45Z/10!YPWAKXENQ9O%^D,3U)TI33_^$>^)VS9_PF>E;<8V_P!EKC%>B44
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M%B=_O,FD(I/U(KTJB@#SS^P?BA_T.FE_^"Q:@B\*?$:"9IH?%>BQRM]YTTA
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M.FZ9<6EO>WD4,UY*(;>-C\TCGH *O4 %%5K[4+73HEDNI=@9MJ*%+,YP3A5
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M HHHH **I_VK8_VR-(^TI_:!M_M/D<[O*W;=WTSQ5R@ HHHH **** "BBB@
MHHILDB11M)(ZHB LS,<  =230 ZBLS3_ !#I.JWLUE9WBR74*+(\)5D;8>C@
M,!E3_>&16G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY\(7?B[3+>TFTJW:5UM75O-G@B<J[A]V%)VL0NT\ <\\1Q:UJ>J_$S2A8WT
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M<\5'\::VNC>'+J\T..SN+[5XM/NHKD.I3<Q'F1@@'! R">F>^*O>(/#>N_\
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M 6[64\ING0 NJR)\J')VC.[D<X%54\$:Q'X/\+Z*LU@9=%O8+EY#(^V41$D
M#;P3G\,=ZLKX9\4Z-XBU*Y\.ZEIBZ9JDWVFX@OHG=K>8@!WCVD;LXS@D4 7X
M/$MYK.L+I6FPQV=Q%8Q7EX;V)F,!E^Y$4#*=W#$G/&!P<\9_PJ\X^&]2-PJ+
M/_;-[YBQG*AO-.<>V:FF\+:SIOBY=>T.\MIC<VD=I?P7Y8>;Y?W90R@_-ZC&
M#5[P5X?U#P[I]_;ZA<VT[7%_/=H;=&4*)'+8.3[_ (>IZT =-7+QZ]J#^/M0
MT$6EH$ATU+N&7>VYRSLH#'' X/ !ZUU%<PNA:G%X_N_$*_9&MY=.6R2(R,'R
MKLX8_*1R6QCMUYZ4 <U9>/\ Q#-X6T3Q+<6.FI87=ZMK<0HSF0!IC&&0YP,<
M<'.?;I7IE><Q>!-:B^'>F>&O/L#/9WB7)GWN%8+,90,;<@G./U]J]%7<5&X
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MJ ,75=+U#7_B1X9U2PTZXL[?2UE-Y>S*(S*K* (E&<MSGM@9ZU+/XUU6PO\
M2$OX+*)M0U/[#)IP)-Q;HQ<1R,X8KR%!QM'#<'BNXM_.-LGVA8TFQ\PC8LH/
ML2!_*O.(? 7B:/1=*T]M2TMVTS5UU!)VBD+W.&8EI#G[WS=LYP.10!O3>(=;
MU*+6YO#EM:3?V5<-:K!.#NNY4 +JK;@(Q\VT$YR0>@J67Q!?Q^.=&T>:QMXH
M;VQEN&8N6EC9-F4XXQENV<XK.@\+^)]$\0ZG/H&IZ:-,U6?[5<1WD+L]O,0
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M-!CAT1]9L)O#]LV()O*<7GE Y$1.=H';=R<=,<8 *MQXQ\4/;>*YK6RTE/[
MF?/FO(WFHL0D*C&/F()YX XX/6MN'Q3-J]]INGZ6L,-Q=Z8NIR27"F188VP%
M7:"I8DD]Q@*?6J">$]76T\90E['.OM(T1\Q_W.Z(1_-\O. ,\?3WJL_@SQ!8
M3:#JVBWNGQZOI^G+IES%<[VM[F%<8.0 RD$9''?';D T#XIU:TLM,M=5TY+3
M6;ZXEA"QJUQ&$C!)E"IEB" N%SD;N3QFJ4GCC5=-TG6+C5=+>);"Y@C2_P#L
M<T<,L,C &7RV^;Y 3N4'L.><U:USPGKFIV6FW]OJ\$7B33[AKF*8Q'[.=R[6
MBVY)"%<#.2>,]35Z.R\5OIK37=YIC:DTD>;>)76U$2D[EYRQ+ G+8_N\<<@%
M[P_J5QJD,UPUU87EH64VMU9?<E4CG(W-@@Y'6MBN8\*^%5\/:CK-Y'#;VD>H
MR1N+&U8F&$JI!89"\L3DX ' KIZ .<EUV[O_ !/>Z#I+6T4MA;QS7,]Q&T@#
M29V(%#+V4DG/IP<\<;XJ\3WOB#X0^)I D5E>V#S6&HPX+C<I ;RVR."&!R0>
M"1[UU=QX=U"Q\:S>)-'>VD^VVRV][:7+M&'*?<D5U5L$ D8(P1Z5G:CX$NY_
M VMZ+:W%M]OUNXDN;JXDW*BN[ G: "2 %"C/IGVH ZS3;21(8I[L6LEYY8C\
MZ&#9\G4+R2<?CBK]06@G6TB6Y6-9@H#"-BRY]B0/Y5/0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2$A022 !R2:6O/OB]>3Q>'-+TV.1HH=6U:WL+EU."(G)+#/;.W'TS0!U"^+-
M!8%QJ</D X^T'(ASTQYN-F?QK5@GBN;>.>%P\4JAT<=&4C(-,^QVWV'[#]GB
M^R>7Y7D[1LV8QMQTQCC%<QJ=YJ.@&WTRP:TM-.MM/ @N;H&9IIE^58EC5E8G
M:NXD YSQB@#>U+6]-T>2SCO[M('O)UM[=2"3)(QP%&!_]:GC5K%M:;1Q./MZ
MVXN3#M/$9;:&SC'48QG->>ZWK;^)/!G@/69(5ADN];L)'C4Y"MN.<>V:ZA-=
MU%_B)=^'F2U6V72EO890K%]QD*8;D C@G QUZT 7]0\4Z+I=TMO>WHB8RK"6
M\MS&DC#*J[@;4)!! 8CJ/6MBO*= U:;0=#\<ZSK$MK=V=GK-RTD*VQ#22J(P
MN&+D*,[0 0<>M=)J'B/6?#UWH4NK"RGL=4N4LI/L\3(]M-(,IR6(=<@@\ ]_
M:@#LJ*X72=>\7:UK&JVUO'HT4&F:G]FE,@E)DBV*WRX/##=U/!SVQSDP^._$
MY\&VGBB>#2A:K?\ V:ZMT20NZ&X,.Y&W84CC@AL]>.E 'H9U:Q&M#1S./[0-
MN;H0[3_J@VW=G&.O&,YJ[7,C7K\?$D^'WBMOL1TIKU'4'S-PE5,$YQCD]JQH
MO&>L6^KZ!:ZC'8+)J5T]M=64*EGLSM9D!E#E2V%&1@9SD8Q0!W]9NHZ_I6D3
MP0:A?16TMPP2%9,CS&/\*^I]AS6E7 _$?_D,>!_^P_%_Z U '>JP90PS@C(R
M,4M<9<ZYXCG\<W_AW3QID*16$=W%<3QNY7<[+AE##=]WH",9ZGI5;1_'5YJ^
MA>&\6]O%J^LS30$$,8HO)W^8^,@D?)PN?XASQ0!WE%9&BS:ZUQJ$&LV]L(X9
M0+2ZM_E%Q&1G)0LQ4@\=>>U:] &'?^,O#>EZLFE7VM65O?/@"&24 C/3/IGW
MQ6G?:A::;"LUW.L2,P1,\EV/15 Y8^PYKF?&VCV,O@S4])ALHI;K52\<$9&2
M]Q)DAR?]D_,3V5?05E&*6+XL>&='FE:6'3="EFC9OXY<K$6/OM!_,^M '<)J
MVGR:8VI+>P?8D5F><N J!?O;B>F""#GIBJFB>*="\2>=_8VJVUZ8?]8L3Y9?
M0D=<>]<KX<ABN_B#X[TB>,2V$-U97BQ-RHE>(,QQW^9%;ZBKZZ7'=_%%]<LX
M@D=AI[6ES*@QY\K,&"'UV*,GTW*.QP ="^NZ7'J'V%[V(7&\1E<\!R,A">@8
MCD*3D^E:#L$1F;.%&3@9KQS3";[]F_4=2N')N[J.ZOI9<_,9A,S!L^H*K^0K
MU70[J6^\/Z;=S_ZZ>UBE?_>9 3^IH I1>,?#TYD$6K6\GE.8Y-A)V,.JGC@C
MTK4LKZUU*SCN[*>.>WD!*21G*M@XX_$&O-_ 6H7UE_PFGV/1KB_(\1WK Q2Q
M("WR_+\S _IWKII=<DLH_#^F6<$,6I:SOE D4^7#A?-E<KD$\M@#(Y;J,4 =
M517"/XHUZVOO%MC,VG22:+81WD$JV[J)-RR,0Z[S_< X/O[5,WBW4A;>";D1
MVFS7C$MRFQLH7A,F4.[@9&,$'ZT =1;:M8WFIWVG03A[NQ\O[3'M(\O>-R\D
M8.1Z9J[7#R>(]:GO/&^GHUG;2Z/!$]I,L3.?GB9R6!89/  Z#Z]*RK7Q!XAT
M'X8^&M;:>QN;0PVAOGDMI#)% ZJ#)D2?,RDY/ SG.!B@#TVJ>I:K8Z/9M=ZC
M<I;6R_>EDX5?J>WXU4AU"ZNO$\UI UNVGV]LCRML)<RN3M4-NQ]T9/'\2^M8
M_P 4O^27^(?^O1OYB@#J+2\M[^UCNK602P2#<C@'##L1ZCWJ>N&OM?U;2(O!
MMEIT%G)'J86W<SE@5(A+ C'0<>_]:A3QSJ&D6_BN/7(K6XN=#D@$;VBM$D_G
MJ#&I#,Q4[C@G)H [^BN;:_\ $.EZ@TNJ1V5QHR63SSW-NAC:"1.=NUG8N",X
M(QTYK(M?%FOW,NAWEOIQNK'4707$"6$T;6B.,K)YK?*X7(#8 SU% '=T5YI/
MXR\5G1/%.I01:.@T"]FC97CD;SXXT5B!\PVG!/S<^F!C)N7FIZO>_$;PVEK?
M0PV-UIDUTL$EN7P?W><D.,G#8!X YX.: .RM-6L;Z_OK&VG$ES8LJ7*;2/++
M+N7DC!R.>,U=KCK+7M>U'4O%VG6\6GK>:4\2V>4<K(7B\P!_F'J!D8QZ&ET/
MQ3?:]X;\/W=LUJM]J#D7,;0MMBV9\T;=^1M(VY)/)''- '84A. 2>@K@;WQG
MK-S87>HZ!9?:UMKMX([+[#,S7*QR;'(F'R*<AB.#T&>3@=Y$_FPI(49-RAMK
M#!&>Q]Z ,1O&WAA)9HI-<LHWA?9*))0GEMZ-G[I^M7;S7M+T^>Q@N;V-)+^0
M1VJC+>:QZ8QG\^E><:1--_;/Q)M8='N-2:XO!&L,>P*Q,.-K%F&!SR?2F?V%
M?>&O"GPVTC4IA+=VVN1"0AMP7*3,%![A00/PH ];HK@?%WC'6?#EMK%\8["*
M.Q9&MK20&26\B^7>^5?]V,D@$KP5YSFKVH:_KQ\>1>'M/33DAGTM[Q)YU=F1
MA(J\@$;ASTR.O7CD ["HKBXAM(&GN)%CB3JS' %8/@K7KS7]$FEU&.!+VTO)
M[*<P B-FC<KN4$D@'C@FL_5;U[[XJ:)H1/\ HUK8RZI(G9WW"*//^[EC]<'L
M* .P,J"'SF.U NXEAMP.O.>E5-)UC3]=L?MNF7*W%MO:,2*" 64X(Y [BN5@
MN=8E^,%[9F_@-C#I<4R0FW/RJ\C!@#O^\=@^8@]ACCGE-#UW6O#7@&XUFT2P
M;3K;6)UN(95<RRH]V4)5@0$(W=PV<=NE 'L=%<AJOB>^?5M5TS2-J3Z=&FYI
M+":Y$DKKO"?NR-HQMY)).[H,<[OA_4+S5- LKW4-/DT^\ECS-:R=8V!P1].,
MCV(H M-?6J?:-T\:BV ,S$X$?&>3T''/T(]15&^\3Z+I=Q!!?ZC#;33C=%'-
ME6D&,G (YQGGTK)N/!+3#78QKNHQPZHZS1QJ5Q:2AMV]..[ '![#%<_XHCET
MOQS\-HI)+G4)K<WB-(=OFS$0 %CT&>] '<Q>(M&GTN?4X=3M9;*#/FS1RAE3
M'4''0^W6K6GW]MJFG6]_92B6UN8UEBD (W*1D'!YZ5Y[9Z%J4>N>.?$EQ9MI
MUCJ%EY4-J[*7E*1D&5@I(&><<YY.<5;\.:CJ%A\/O!BVOV6"TEL(A=WURP*V
MX$0V@+N4LS-@#!X]#0!Z!3)I8[>&2:9U2*-2[NQP% &237G$WQ UE? %_K<-
MM9/>6&J'3Y=Z.B2 3+$&"$Y4G<#@GC%;EGK>LIX[?P[JR:?)!<Z>U[ ULC@Q
M[7"-&^XG?]X'< O?B@#3B\8>'9K?39X]8M&BU*0Q6;;^)G!P5'OGCZD"M6VN
MX+R-G@D#A6*,.A5AU!!Y!]C6,GA'35T^VLC%&8H;K[6<1*,R;]_''RC<!P.P
M ]<Y5]>OI'Q9TFWCX@URQF25!T,L&&5_KM8K],>@H [2BL;Q7>ZKIOAB_O\
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M+2%-*$<<LMQ$TGF3.N[: &7"@8R>22>V.0#:TK5K'7-,AU'3;@7%G-GRY5!
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M[1>$W AV-_JP0"=V,=2.]2ZKJEIHNESZC?R-':P+ND949R!G'102>M '$0>
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M!BP.X[0"H '/'4FLF?X?ZA/X0\1:$VJ6P.LWTMV9A;M^Z$C!BNW=SC'!R.M
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MKAD>(MYI*%",Y&!@GUK+A\':WI6NZE-H6O16FE:I<&ZN+>6U\R2&5OOM$VX
M%O\ :! ]#0!$MQK#_&#[-)?1):QZ(MQ]G,.X(&FPX!W#D[!\WZ5!%XP\0:EI
MVG:WH]@]W;7,ZEK+[(P/V<L1O$I;&\#!Z8[=LG=E\+W*>-;77K*_CBA73UT^
M>"6$R,\:R;P5;<,'D@D@\>]9>A^"M=T!VTJT\1)_PC0E9X[9K;_2(D)R8EDW
M8"\GG&<'C'6@!;W6M1\1:=XJ_LR>WM[33&FL0)8BYGE2/,F3D;5RVT8YR"?:
MM3X=_P#)-_#?_8-@_P#0!6:/!FJZ?J.N_P!CZK;1:;K;///;W-NSM#,ZX=HV
M##[WH0<>_2M_PMH\_A_PQIVD7%TER]G L(E2(QA@HP."30!P4MYK_P -+S4F
MO-+;6O"5W=2W9N;49GM/,8LXD0_>7)//IU/:K6JWKR2_#Z+PWJD::/<2[(08
M2X=4@;:6Y!. ,;>.>O3%=';Z1XDL;*YLH-3T^XBFEF>-[BV;= KNS;<!L2 ;
ML#[O2J+^ #9:/X8LM&OT@DT&;S(WN83*LNY65]RAEY.XG@T 6;?6M5U[4=<M
M-(N;6W_LF1;8/- 7$T^P,V1N&U!D#CGJ<UGZ-X^F\26WA^WLX8[2_P!36X:X
M\P;Q;B [7 &1N)8C'/3).<8.E;^%]0T?Q!J>IZ-?6XCU0(]U!=1$A9E&WS4V
MD=1U7N1U%9UU\.6M=.T(^']3^QZKHS2-%<S1;UG\TYE$B@CACSQT[4 9_CN3
M6Q\.-6378[8/#J=NMO-!P)H?M$15V7)VMU!&>U=9H&KW/B*1]5L[FU.A/\MJ
M!&3+*02&<MNPHR.%QGCG'2LW6_"6KZ]X6ETV\UB!KVXGBFFG%L1&@C=75(TW
M9 RO4DDY/L!9T?PO>Z'XEO[ZQO8(]+OR)9].\HX6?^*1&W?+N[C'- &5\7?^
M13L?^PM:?^C!73>+?^1,UW_L'W'_ *+:F^*O#EOXK\/7&DW$SP>85>.:,9:*
M12&5AZX(Z=ZIS:3XAU73SIFK7^GBTE3R[J2U@<23H>&4!FPFX<$_-P3C'4 %
M+6-:UNR\4^'-%TYK%8-3MYR7GB9FC:)%.>&&1\W3CIU&:ST\7:]%X.\6W,K6
M,FJ>'YYHA+Y#"*=40.#LW94D-CJ>E=#JGAZ[O_&&AZW%=0QQ:6DZ>0T1)D\U
M0#\V>,;1C@UDMX(U!])\6V)U*V_XJ"623>(&_<;T"$8W?-P!Z<T 4]5O]9N_
M%O@,0ZA%#'>V]Q.\1@++YBP [C\P)X<@#C'O7HE<A=^$M0FF\+W=OJ=O#>:(
MDD3,UN725'C",0NX$'"@CDC/K6]KEI?W^BW5GIMXEI=31F-;AXR_EY&"P (Y
M].: /)_%.MV<6JVWCZWU"-[G3M0\@6JR99M/YC?"]R6+2 ^A'I7HWBSQ(VAZ
M!;W]FL<IN[F"WCF?F.,2N%\QL$94 YZC/'-7KC1UG\+2:*8[<1O:&UV;#Y84
MKMQC.<8]ZX35]/N_#'PZTSPQJGB"S)EN8K2*]N+7$/EJ2^R8,V-I5=G49X'J
M: -^VUCQ WCJ_P##PGL9(+>R2[2X>V8M\Y90K8<#(9<].1^=8FC^-?$<G@>W
M\8:E_9ILI;8@6D,3B0SM,(XSNR?ER>1C(]ZM^&I]7M-6%G!>^%[^.X5FE?3(
M&1XB%.UY,.P*Y 7!(/(QP#5W3O (C^&?_"%ZE>B>(1&-;F",QL/GWJV"3R&P
M>O:@!%\1:[IVL.U_:R7.B+927$UT+-K=K=T!;;AF.Y6 ..X/4U#:>)/$MU-H
M5[;V!N;+4&3[7 +1D^RQN,B19"<.%R,\<]0!6AI'A[Q UNUKXGUR'4[98FA5
M(+;R3*&4J6E.XY.TD8&!SGDXQ5\-^$_$6AK;Z9<>)$NM#LR/L\?V;;<%%.4C
M>3.-HP.@R0,<#B@#)D\4^+)="\6ZA#/I4;:!>3H%-L[">.*-7V_?^4D$\Y/7
MH,<Z*>)M=AUSPQ)=&Q;3=>#*+:.)A);GRC(I\PMA\XP?E%21^"]031/%>G'4
M;8G7YYYO,$#?N/-0(1C=\V /;FII_"6H3/X4;[?; Z$06_<-^_/EF/CYOEX.
M>_- &=<^+]?O],GU;P_9&Z$5V\45B;1B+B-)3&Y\W("L=K,.,#@')JR=9\3:
MAXQUC0K&?3K6.WLX+F&::V=V3>6^5E#@$_+UR /0TEGX+UW1]2O8=(\1);Z#
M>W#W#VSVV^:W9SEQ$^< $YQD'&>A[Z=KX<OK/QCJ>NQW=N4N[6*V2!HFRGE[
MMI+;N<[CG@4 <?>>)=9\0>%_ FJ17,-D^HZK%#<Q+$61G4OS]X';NCSM^G/%
M>EWBZA_94JV<L']H"+]V\L9,9DQW4-G!/OQ7%V_P^O[7P?H.CQ:M;_:]%OUO
M8+AK9BDF"YVLF_/_ "T/1NU=Y$KI"BR/YD@4!GQC<>YQVH \U;XA:DOASPKK
M$DMG&M]="UU2-K9B;<[BCL/G^55?:IW9^\#WQ4OQ(N[R\\ >,]SPFP@C6& +
M&0Q<%"Y+9P0"=O0<J:U7^'=C+'XHAEF9X-;+E(R.+8NHWE?<R .?]U?2IM7\
M&S:C\.G\*PWZI)-"L<UW*A<NV=SN1D99FR>O>@".'6M<L?'.G:/J$EC+::G9
MS30K!$RM;O'M^4L6.\$-UPO(Z"J%KXYU"'0M<N;Z.UEO+776TBT6)62-B6C1
M"V23U<L>>@P*VKKP[J%WXLT37'O+91IL$L+0B)OWGF!02#NXQM&!@UDM\.Y+
MOP_X@TJ^U)<ZIJ3ZE#/;Q%6MI25*XRQW8*#TSSTH UW_ .$BAN]0M[XVESI3
M6#2)=1IY;I-R#&4R<KCD'MTYKBO"FM:WH7@SP'-YED^EW\D&GO;>4WFCS VV
M3S-V.H^[MZ'J>M=GIVC^)393C6M:M;NY\AH(?(M3%&,\&1QN)9N.V .?6LI?
M FH)X7\,Z,NIVV=#O(;D2FW;]]Y6<+C=\N<\G)H ZS7KJZL= U"\LS#]HM[=
MY4\Y2R$JI." 0>WK7'/XMU]],\#7%N+ OKRQBY$D;?*[0F3*D-P,CIC\1UKL
M]8LYM1T6]L89$BEN8'A#NI8+N!&<9&>OK7+IX*U!+'PC;#4;8_\ "/%3N,#?
MO]L9C'\7R\'/?F@"F/&^IZ)#XLAUD6MY<Z+);K!);QF%9OM &Q64LVW#'!.3
MQ72VG_"2P:_'%=M9W>ER6Q:2>-/*>&8'[H7<=RD?B,=:Q+[X?MJ]UXK_ +0O
M8S:Z^D"[(HRKV[0KA&!)^;D ]!TK3T#2?$EJ$.NZY;WYMT*0""V,6\XQOE.X
M[FQV&!R3R<8 .)T37+_P[\,O[0L/(+#79H72:,L&62[*'&",$;L]Z["Z\37.
MG^/9]*NF@_LN/19-2+B,^8A20*1G.",$GI6:OP^NSX"N_#LFJ0^>]X;V"Y2
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M 9R!G(XZ5S'C!]2_X3SP7;6FHFW@GGN<Q^4&&Y;=R&///!(Q[YK+0:P/'/Q
M?2;VWM)HHK*0R2P>;N*V[$*!D  ]SS]* /3J*X.R\:7FKV/AJ*"%H[S5=.-_
M.T$8<QJNP$(&..6?J<X /!SD;GA.\UZYM+R/Q!9^3-!<M';S *OVB'^%RH8[
M6[$>U &JVJ6:PSRF;]W _ENP4D;\XVCCYCDXP,G/'7BJJ>)-)?71HANO+U)H
MS(EO+&\9=1U*E@ P^F>A]*QYO %G+8:O9KJ^LQQZC="[39=D&SD#E\P\?)EB
M2>M9'B[PB=?UK3[6VOIH-4T_36FL+YG)=)ED0!F/\0/1OK0!VM_K-EIMQ;07
M3RK)=/Y<(2"1][8)P"JD9PK''H":OUYSH_BQO$5WH%IJ, L]>T[56AU"S/\
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M6K28WLP*'YAG.W[W'^[SD '>45YUKWBW6M%::YDN+;S(M5CMA8Q1^:GV9W5
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MO-;N;OQH/#-C,+9H[#[=<7&P.V"^Q$4'@="22#Q@=\@ Z1W6-&=V"HHRS,<
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M)MEMR" KEPV[>><L>W2NBK+TGQ!8:W=:A;V9F,FGS""<2Q-'A\ X 8 ]#UH
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MB6DML("K*BJRCY]QR2'.>!VKJ%D5E0YQO^Z&X/3/2G4 <AX:\*:UHJ6UE?\
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MN:OXJT?0;ZSL]1GFBGO7$=LJVLL@D<_P@JI&?;-6M6UFRT/3FO\ 4))([92
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MX][+1)+JU1NGG-)L9A[[>/PKNM,L7T^Q6&6ZDNYR2TMQ* &D<]3@< =@!T
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MNHWB#D(8SA8S_P!MAG_MD:[:N?\ #'A&P\*RZJ]D2?[0NVN2"/\ 5@\B-?\
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MP6)XSC.?P%;%9/AJXU&YT2*35'CEN-S@31PF(2H&(5]A)*Y&#C-:U !1110
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M9_M&I2&. I$2F0I8Y;H. >.OM7)>)M<U[P[XL@LVU%7T_6HS;Z>[I$OV.ZW
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M["5I(XI6A?=&R%77&00P!!&<<BK]0P6L-M).\,81IY/-D(_B;:%S^2C\JFH
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MUK1[/5+4.+>[A2>/>,-M8 C(]<&N$TK_ %GQ-_Z^7_\ 25:Z/X??\DY\-_\
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M[@+ZX&?<8Y /0=0U)-/DLT:VNIOM5PL -O$7$9()W/C[J\<GW%7 ZER@8;@
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M$.Z!@BED^8\G((Q@GFN9*ZDOPF\;71UW4#+'>WR;CY>6"R;>3LR,@8."/;%
M'M (90RD$$9!'>EKCKJ;4;!=#M?[:D2UFA<RLL:/=RN%78L:",J5&22=O&!D
MUCZ-XUU2^\-Z!#/*JZGJ>IS:>UR8U&Q(FDR^W[N\J@&.F3G! Q0!W&NZU:>'
M=&N=5OA,;:W0O)Y,9=L?0?S/%7+>=+JVBN(\[)4#KGK@C-<'XQM=<M/ WC1-
M2OXKW3S8LUC(RA9U&P[UDVJJXST(&<'FELM0UK2?$_A.RGU);FQUBTE5K;R%
M18&BB5U*,/F.1D')/KQT !Z!5>]F@M+62\GC9U@4N=D9=@!Z #/Y5P$.O>+-
M>T2VU[0(+B1I+DLEI)]F%M) )"I4L6\P/M&<\?-VQ6BNJ7_B>;Q0EGJ#V-MI
M<KV42QQHQDE6,,[/N!^7+!0%QP"<\C !T^B:O;:_HMIJMEO^S748DC\Q<-@^
MHJ_7)?"__DF/AW_KR2NMH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.UW0[#Q)HUQI6IP^;:SKA@
M#@J0<A@>Q!P0:T:R/$7B*T\,V$=Y>Q7$D3S)"/(3=AG8*,Y( &2* *MAHFNV
MMNMG/XE:YM5&T2-:*+DK[R;MI/OLS^/-)+X7)\5Z?K<-Z(EL;5K2.V\K<&C8
M@G+;LY^48/\ .NBHH P4\.NOC>3Q(;W+/9"R^S^5P$#EP=V?O;B?;';O6*GP
MVM3X4G\/3ZK=O:"<W%DZA4>S?S#(&5@,E@S'D]N.*[BB@#DX?"6I2:-?6>J^
M))]1NKJU>T6XDMD011.,-M1< L>/F)/0>^9;OPBUYX 'A.342(OLJ6AN1#\Q
MC4 #C.-V .?TKI5D1V=5=2R'# 'E3C//X&G4 <K)X0N#X@L]9@UN:VN8[$6%
MP(X5(FC#;@1NSL;)Z\U=\(>&QX3\/0:.E]+=Q0%O+:5%4JI8G''UZG_ZU;M4
M[35+:]M6NH7_ -%SA)VP$D'3*GN,]#WZC(P: ,K7O#,FK:WI6KVNIRV%YIWF
MHK+&LBND@ 8$-P#\HP?YUD'X<1GP[J^D-K5VR7]_]OCD:-,P2>8),]/F^8#.
M>W0"NA'B*T/BS_A'/*N!>?8S>!RF(R@95X.>3EO3L:UZ .:NO"DUSK>E:P-8
MN$O+*&2"5Q$A\]'()&,87E1@CM^=8S_#1SI4NEQ^(KM+,:@+^VC\B,F%_-\P
M@DC+C.<9QUYS7?57-[#_ &@+($M.(_-<*.$0D@%CVR00/7!]#0!RMQX&N8_$
M4^L:-XCO-,DO41;]$ACE%P4& XW#"/CN!^%7F\*;?$NEZO!>^6NG6KVL<#1[
M]RMC<6;=DM\HY_/-;EE>1:A:1W5ON,$@W1N1C>O9A['J*KV6MV&H:IJ.G6TX
M>ZTYD6Y0?P%UW+^G\C0!S+_#FWN=%U?3;O497_M#46U-)X4\N2VN"00R')X&
M!C//7FK<'@R6[TB\L/$NMW.MFZMVMM[Q)"(XS@G:J#[V0IW'/W1T[]710!PZ
M> M0D31([WQ1<W":-<+-;$6L:NP"E0')SN.#C./PSS7<444 <;_P@LAT/Q'I
M;:KF/7;B6XG<6_,9D4*P7YNF%&,Y_&DU'P)<7%UIFI:;KT^F:Q96HLVNX8%=
M9X1R%>-B0>>>O4_3'8NVQ&<@G:,X49)^@K,\.^(+3Q+I9U"SCGCB$TD.V=0K
M;D8J> 3W!H R;[P;+>)H_P#Q-Y3-IMX+YII8@[W$V",M@@!<,1@ 8& ,8IWB
M/P=+J^LVFN:7K%QH^KVT1@^T11K(LL1.=CHW!&>1Z9^F.DN;B&SM9KFXD$<,
M*-)([=%4#))_"H=+U*UUG2K74K*3S+:ZB66)O52,C/H: ,'4O!IU#2M.@.KW
M(O[*^34!?.BLTDR@@EEP%QAB !@  >E//A26T\0S:WI6IFWN[N!(;T3P"5+C
M8,)(0"N' R,@XQVKIJ* ,[0]%MM TM+&U+LH=Y))'QNED=BS.V.Y))K/USPQ
M)JNNZ7K%IJDUA=V"RQ@K&LBR1R8W ANA^48/Z&NAHH Y#3/!5UHUO+'8Z_<!
MFU)]04S0HRC?NW(P&-P._DY'08Q6MH7A^+1;C4KH.KW6I7 N+AHX_+3<%"C:
MN3C@9.2222<ULT4 <E\0K6'5O#DNB7#:A'!?#$DEEI\ETP"LI_@!"\XZ]><5
ME2ZG=7-E'93WFN"V^591%X<G1Y$&,KNP<;AP2!GGBO0J* /.=6.G:Y9ZU;ZC
M;ZW/_:*"*)CH-SFU0?="_+U#?-GCYNN0 !%._P!J?P_)<W.O33:-(94E?P_<
M;IVVE,OQZ$],<\UZ765KGB"RT#2;C4KH3S0V[*DBVT9E<$D?PCZ@_2@#BU:!
M-0\27@.N;]=C2.1?[ N<0[4\L%>.?E/?O^50?9[--&\/6D+>($NM 8&TN#H-
MP58!"F'3;S\I[$5V">,-,EUF/2H$NI;F:S%Y 5A(29",X5C@%L<XK8LKVWU&
MSCNK2420R9PP!'(.""#R""""#R""#0!P\=W9C^U+J6'7)-4U&$027/\ 85R%
MCC (543;P!N8\DDDY)/ K-:SLO\ A&=!TF.3Q#'+HD\<UK=+H,Y)V*5 92A!
MX8^G:O4J* .;7Q78BW$,FGZ]*-FUC)H]P2_&#G]WCFN7TIO^$;#VN@W&N6^E
M,[/'977AZYG$&XY(C8!2%R<X.[%>F44 <1?G4-4\/O'X?OM8L=32Y64S76GL
MAN'P<*P=0 G R1T"@=\'MZ** .(U'X>&^_X2*%-<NH+'7,R3VZQ(VV3:%W!C
MSM^4?+QTZUH0>$[B'Q!IFKMJS32V-DUF%D@'[Q6(+$X(P<J,8' '?K73T4 <
M/)\.(+G1=2T^XU.4O=:FVK0W,481[:Y)SN7D@@>A[$\^EVS\(WR>)[/7]0U^
M6ZN[>T:U*I:I$DBLP8Y')'('0_ETKJZ* *NI6$6J:5>:?.SK%=0O Y0X8*RE
M3@^O-<G9^ +FWG\.SS>([J:30P\<&+>-0T3)LVD8ZX ^;GVQUKMJ* .7MO",
MUM_PD9&I!CKC%Y,V_P#JB4"?+\W/RCOWY]JU?#VDG0?#]CI/VC[0EG"L"2%-
MI*J,#(R><"M.B@# UOPRNJ:MIVLVEV;+5=/W+%-Y>]'C88:-UR-RGKP00>0:
MKW'@JUOM)UZVO;EY+O7$VW=TB!< +M0(O.%4= 2>IR>:Z>B@#E&\(7<M]X?O
M)]:::?1B[*SVRCS2Z;#D C V],=^2344W@"VOAXDBU&\:>WUYD>9$CV&%D4!
M"AR>FU3SGD?A7844 <OHWAC5M/B/]H^)[G598XS':M<6Z*L61C<P7!=L<9)]
M?4U>\*: ?"_ARTT479NHK52D<C1[6VY)P<'!Z^U;5% &5XC\/V?BC0;G2+XR
M+#.!AXFP\; @JRGL00#6;I/AK6+&WD-]XHN=1NUB,5M--;(H@!_BVK]]^!\S
M$_J<]/10!R<W@D?;=#O[+4/LE]I:,C3K#N-TK\NLF6Y#'+'ON.<@U)'X2FBU
M#Q'>#4E+ZXB+(#;\1;8_+&WYN?E]>_/M7444 <</ TBZ5X:L%U7Y- E26!C;
M\RE%**&^;IM)SC%7#X6NK;7M6U/3-7:U_M41_:4>W$A5D38&C;(VG _B##/:
MNEHH Y2\\$6[V&@6.GW/V.UT6Y2ZA0Q^87=0P^8DC.=S$]R3G-2R^$&/B'5]
M5M]5N+==5MDAN($12-R(R*X;J,!LX'<#GM7344 <TOAB9]5M-7U#4%N+ZQM9
M;>WGAM1&_P X&6?D[S\O   R3QSQ9\)VVJVF@I#J]]+>W"R/LN)HQ'(\>?E+
M*.AQVZXQGG-;E% '/^(/#,FL:MI&J6NIRV%[IC2>6ZQK(KI(H5U*MQG &#VK
M@_'7AZ+PM\/-?1M:FE_M/5(;M1,$4H[3Q%R,#YCQGT '2O7** .?BTA9-4M=
M?U348+IK.!UM7CC$44:OC?(<LV6( &<@ 9P.:XGX=Z/_ ,))\,K?3I]4CDTN
M2YG-Q;1QCS-OVAV\LONX5L GY<X8X/(KU:B@#D-4\$W$OB637="U^YT6ZN8T
MBO%BA26.=5&%.U^ P' //';KFU)X2SKVAZG'J#C^R8YD1)(]YF\T#S&=LCYC
MC.1WSUKI:* .*G^'5O>Z=KME?:A)(NK7@OO,BC\M[>8;=K(<GIM'7WYYJ>#P
M?J+Z_I&LZCXCFNKK38I8E"6L<:RA]N=PY_N\X_#'?KJ* .,_X5Y:W&A:[I-_
M?//#JUZ]^SQQ^6\$S$'*')X!5<9]\YS5S3O"=S]BN+;Q#K=QK@EMVM?WL*1*
ML3##<+U8C&6)SQQC)ST]% '(^'/!E]H;06]QXFOM1TNT_P"/2SFB1?+Q]W>X
M&Y]O8' &!QP,2P^$)))M&;4]2%Z-'D,ML_V?9*6VE1O?<<@ ] !D@9SCGJ:*
M ,#PI:ZO:6MZFJZC/?JUTS6TUQ"(G\H@<%1T ;=C/./P%+XG\-MX@73I(=0D
ML;O3[I;J"9$#C< 5(93P00QK>HH XF7X>O+#XDB;7;EUUY%6?S(4.T[ C,,8
MY(''89Z&K\OA.:;4O#M\VI+OT1'6-1;\2[TV'=\W'R^G?\JZ>B@#@9?AJZZ1
MJ^AV6OSVVB:B7?[']G1S SG+!'/\)/\ #C\:[:QMFL[""V:=YS$@3S7 #-@=
M3@ ?I5BB@#D[_P $M=Z[J^H0:S<VL.KVJV]Y;I&C;MJE5*LP)7ACD#K[53'P
M\>WM= DL]=N(=5T6'[-#>F!&$D.T*8WCX!7 &.<@\YKN** .(D^&]O>VWB&#
M4]5NKM=;>.63$:1^5(BJ%=<#.05&.V.#GJ9XO!FHR:QH>IZEXEGN[C21*L96
MUCC\T.H4[NO.!R>_;'?L** .)T_X?S:5>3PV/B*]A\/SS-,^DB-"H+'+(LA&
MY4)SE1ZGGFM"'PK/!J_B'44U)=^M)&CH;?B+8A12OS<\$YSW].E=-10!PZ_#
MKR-.T!++6);;4M"0Q6EZL .Z(C#)(A.&!'N*;=?#?[?%XA%YKUV\FM&!Y&2%
M$$3PA=K 8YY4<9Z<')YKNJ* .7L?"-S;^*XO$-SKMQ<W0LA9S(88T210Y88P
M/E&3TZ^_:MK6M+AUS1+[2KAW2&\@>!VC.& 8$$CWYJ]10!QMIX&NH=3T'4+G
MQ%=7$^DQ/ N+>-%DC8*-N,<?=&3R3VQ2KX B&C^(-)?5+EK#5Y)Y1%L4>0TI
MW,0<9;!Z9_6NQHH Y ^"KS^TM*U-/$5TM_96[VLDWV>,B:)BI("D84@J"#S[
MYJE_PK&W_P"$<.E?VS>B2&_;4+&[55#VLI9FR,#YN6.<]?:N\HH Y.X\'WFH
M>&]1TS4]>FO+O4(?L\MX]NB;(^?E2-<!>IY.2?P $TOA2:;5?#NH/J2[]$21
M(U%OQ+O0(Q;YN/E'&._KTKIJ* .)L?A]-I=]<Q6'B*]@T&YF::321&A7+'+*
MLA&Y4)SD#U/-67\%36^OZGJ.DZU-80ZJ ;VU\A9%9\8WH3]QB.O!!]*ZVB@#
M'\+:"/#'ANRT9;R6[2U38LLBJIQZ8';\S[UL444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'Q7
MW?\ "#-L(#?;K/!(R,_:$KMZQ/%/AU?%&DKITEW);1":.8M&H+$HP91SVR!0
M!SIUK5/#WC;4K&^U*74K$:(^JA)(D0Q.C[2J;0/E([')XZFFZ=>>+=0C\/:O
M9M.\%V8Y+^*X-N(/)D7),6TEP5R, GD=>:WI/"ZS^*AKUQ>&1S8'3WM_*'EO
M&6W-GODD>O3BL[0? )T&6.WB\0:E/HT$GF6VF2["D9!RH+XWLJGD+G' SF@#
M*T74/$-W-XAO[OQ!)]CT/5IT-NEK'^_A2)6V$XXZ\$<YSG/&)M.OO%NIV_A[
M6;$SO%=F*6^AG-N+?R)%R3%M)<,N1C)Y[UT6A>&%T635RUXUW'JET]W-')&H
M =@%8#'\.% P<UF:%X _L&9+>'7]2ET6&3S;?2Y"A2,YW ;\;RH/(7..!G-
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MJ[+&7.\ X3>50#GC)S@]#U4?A:1/%$&OG59I+F*R-EMDC4AU+!RQQCG<!TP
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M"FUE\-RC6;F1M!B:.#?$G[P,@C(; '&T #&/4DF@"OI=YJFH^)+[PW+K4_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>1(2<2;2/E8C!P,<D]*]/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9NLPQKHVJ2J@$CVCAF[D!6Q_,_G6E5/5;6:^TJ
MZM+>9(9)XFC$CH7"Y&,X!&>OK0!S/PPACF^%_AOS$#;+977/8@GFN,T+6-<\
M._#F/6K2>T^P6^K2I-:O"6>9'O&1COW#:1NX&#TY/.!Z1X3T&Y\,^%;/17O(
MKIK2/RXYA"4!'.,KN/\ .N=/P\OCX!F\+G6;?$EW]I^T_8SQ^^\[&WS/[W&<
M]* +FI^(=5O-5UK3=%$D<NF*B!EMA*))F3> V6&%P5''/)Y&.>AT.ZU"_P!
MM+G4[+[!J$D0\^WR&\M^AQR>.XKGM0\'ZRGB>;7M UZ/3I[V*./4(9;3SHIB
M@PKJ-P*L!QUKJ[&V-G910--).Z#YI9#\SL>2QQQR23@<#M0!Y_/XRUN/X?\
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M#!(7U.<CI7.:SI3^$? 5SI=YK<,:ZGJ?_'Z;3$4(EDWN)06(V8#+R1G('?-
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M@D&@W/GHQLR/, 5E"_?XX8\\\_E6BW@V:;5/%5S<:C&8-?M4MFC2W*M"%C9
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MRK%Y>1G/3)]>M<S??#G4KO2==TJ/Q!&EEJ-__:$>ZSW2))YBR;6;?\R@J,8
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M9US1;L)%']F8I/"X4Q':&SE@3WX(]*Z:QUNYU>:PFTN>*>T?31>2ADP9&?\
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MI+1B2'+;E(W]3MZ]L=.<AP^'9M=$T>STW48K:XTS4FU&-FMB\.7+[HQ&&!"
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M444 %%%% !1110 4444 %%%% $4EM!-)')+#&\D9RC,@)4^Q[5+110 4444
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MU7PXVO:9=:9-$B0ZC86&Q!DG>BJ'VMC"G(.!D@CT]&DBCE39(BNOHPR*4
M   = * .:\1^$I/$.D6$1U-[/5=/E6>UU"WBQY<@&,["3E2#@KGFJ]SX+GUG
MPY>Z;XBUJ:_NKH(!=0PK ("AW(8U!."&Y)))/T  ZZB@#E]+\.Z];VLJZOXF
M.ISB%H;=S9K$D>1@NRJV7;'?([^IK/'@&Y7PGH.@KK$6W1[J&Y28V9)D\IMR
M@CS./<_RKN** .7N/"!OO%-[JU[>12VUYIG]F36@MRN8\LQ._?URQ[=/SJMX
M=\':QH@@L[GQ3/?Z3:8^RVKVRHX ^X)) <N%XXXZ#MQ78T4 <,_P_N9/"FOZ
M$^LQ;=8NY;IYA9D&/S&W,H'F<\C@_P ZTY?"UT_B;3==CU417%M9&RN%6V!$
MT98-\N6.PY7_ &JZ:B@# \,Q:U%+J@U74&OH#=%K21[80,J'JN!U4= QY.#V
MQ52_\(W5QXINM8M-9>UCO;-;.Z@-NLA*J6(*,3\A^8]B*ZJB@#D-&\(ZIH>C
MZ3I\&NQ3Q6-O);2)<668YT;9M^4.""NP\DG.YJU_#'A^#PQH46EVS[D1Y)"0
MNU=SN7(5?X5!; '88Z]:V** .=@\-W4/C:\\1-J$3I<VJ6IMOLQ&$5BP.[?U
M^8]OPK+MO ,EIH-WX:AU4#P[<2.1;&W)FBC=MSQ+)NQM))Y*D@$\]".VHH Y
MV7PQ(?&-AKL-Y%%#9V;6:6@MR<HQ!/S;N#\HQQ68/A[%<Z/XBTO4K\7$&M7C
M7I:*'RG@D.W!4[FS@HI'XUVM% '.0>&[RXO]+O-<U&*^DTP,UOY5L80TC+M,
MCY=LMMS@# !)/IB5O"EF_C/_ (20NWFFU%NT&/D9@6Q(?5@KNOT8UO44 <UH
M7@^#P[X6O-$L+N5//,Q2XQEHM^0F.?X%V@<_P]J6U\+RGQ)9Z]J5W;SWUI:O
M;+);VODF0,5R7^9LXV\#@#)]>.DHH S]%M-0L=,2#4]3_M*[5F+7/DK%N!8D
M#:O P,#\*T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+N0' ]JFHH 8T,3O&[1(7CSL8J,KD8./3BGT44 %%%% !1110 4444 %%%%
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M9K;HH Q//\4?] W1_P#P82__ !FCS_%'_0-T?_P82_\ QFMNB@#$\_Q1_P!
MW1__  82_P#QFCS_ !1_T#='_P#!A+_\9K;HH Q//\4?] W1_P#P82__ !FC
MS_%'_0-T?_P82_\ QFMNB@#$\_Q1_P! W1__  82_P#QFCS_ !1_T#='_P#!
MA+_\9K;HH Q//\4?] W1_P#P82__ !FE\_Q1_P! W1__  82_P#QFMJB@#$\
M_P 4?] W1_\ P82__&:O:?)J;B3^TK:TA(QL^S7#2Y]<[D7';UJ[10 4444
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M1@0<'!Y'N* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8DFM?*70Y717C8@(9XPW\7WC@<]..E2?%#5)/"7PRO7T9$LW)2VB,*A!"'8
ML .G!./<YK3ET/5#\1X?$*"S^Q)IS6!C,K"0[I%<OC9C^'&,_C6KX@T*R\3:
M#>:/J"%K6Z38VTX*G.0P]P0"/I0 6.G6GA[P]%8V-H7M[6$*L407=)QR>2 2
M>223SDUQ%OXRAT_P1HNH>%=)+:7>ZFMK%'=L(R!),P.Q5SP&W 9(Q@=:Z+2[
M7Q7I6D)ILHTW4S GE17DEP\#R*!@%T$;_-CJ0>?:L&/X?ZI8> ?#OAVSNK.>
M;2[^.\DFF+1J^V4R;0 &_O8S[9QVH VI-6\3VAMX=2M]*LP[3-+J =GMX47
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M:-:W&D/?V>R*WDD60QM&'RS/C!W%3T' (ZG/ !VE%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW/./7%(TL:2*C2(KO]U2<$_2@!]%->6./.]U7 W')Q@>M+N79OW#;C.<\8H
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M6<$9D9P1SZ >I)X [DU=::-(O->150=68X _&@!]%-,B! Y=0IQ@YX.>E.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNQQ_RS7@>I/0#O7G7@_3QIWA7PG8ZG:RC4=2U.XOK&PE?9"!L8_OL@\!3N
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MK?\ 0L7W_@3;_P#QRC^V=6_Z%B^_\";?_P".4 ;=%8G]LZM_T*]]_P"!-O\
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M5B?VSJW_ $+%]_X$V_\ \<H_MG5O^A7OO_ FW_\ CE &W16)_;.K?]"Q??\
M@3;_ /QRC^V=6_Z%B^_\";?_ ..4 ;=%8G]LZM_T+%]_X$V__P <H_MG5O\
MH6+[_P ";?\ ^.4 ;=%8G]LZM_T+%]_X$V__ ,<H_MG5O^A8OO\ P)M__CE
M&W16)_;.K?\ 0KWW_@3;_P#QRC^V=6_Z%B^_\";?_P".4 ;=%8G]LZM_T+%]
M_P"!-O\ _'*O:?>7=V)#=:9/8E<;1+)&^_Z;&/3W]: +M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPRK"1&WS7CQJ>G.,@8XP*Z*3Q&T7C ^'C8L\AT]KZ.5)!\X5U0K@XP<MZXH
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M1::L@BGNY=Y!/VFYDFQCTWDX_"@"[1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!Z;16?I.DQ:1%<QQ7-W.)[A[@FYF,A4N<E5)Z*.PK0H **** "BBB@ HHHH
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M10!%<6ZW-L\#/(JN-I9'*MCV(Y%0:7IMOI&FP:?:>8+:!!'$LDA<JH& ,GG
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M=% &)_PD\'_0,UC_ ,%TO^%'_"3P?] S6/\ P72_X5MT4 8G_"3P?] S6/\
MP72_X4?\)/!_T#-8_P#!=+_A6W10!B?\)/!_T#-8_P#!=+_A1_PD\'_0-UC_
M ,%TO^%;=% &)_PD\'_0,UC_ ,%TO^%'_"3P?] S6/\ P72_X5MT4 8G_"3P
M?] S6/\ P72_X4?\)/!_T#=8_P#!=+_A6W10!B?\)/!_T#-8_P#!=+_A1_PD
M\'_0,UC_ ,%TO^%;=% &)_PD\'_0,UC_ ,%TO^%'_"3P?] S6/\ P72_X5MT
M4 8G_"3P?] W6/\ P72_X4?\)/!_T#-8_P#!=+_A6W10!B?\)/!_T#-8_P#!
M=+_A1_PD\'_0,UC_ ,%TO^%;=% &)_PD\'_0-UC_ ,%TO^%'_"3P?] S6/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#MP,DKZ]#7.6NB>)_#&B>"-5FLKG5)M&6XAO;.$B2=89ON[><,R *"!^''-
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MJ_\ X.;S_P".T?\ "%:/_P ]-7_\'-Y_\=KH:* .>_X0K1_^>FK_ /@YO/\
MX[1_PA6C_P#/35__  <WG_QVNAHH Y[_ (0K1_\ GIJ__@YO/_CM'_"%:/\
M\]-7_P#!S>?_ !VNAHH Y[_A"M'_ .>FK_\ @YO/_CM'_"%:/_STU?\ \'-Y
M_P#':Z&B@#GO^$*T?_GIJ_\ X.;S_P".UI:7H]II"2):-=$2$%OM%W+.>/0R
M,V/PJ_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1165J>NP:;>6UBL%Q>7]R&>*UM@I<HN-S$L555&0,DCD@#- &K16
M5I.O0:M=7EHMM=VUS9[//BN8]I4MDC!!(;@=02/?K6K0 45C:%XBM]>GU2&&
MVN('TZZ-I*)PH)<*&R,$\?,*N7FH26E[8VZ6%U<+=2,C30J"D "D[G)/ .,?
M6@"[1110 44QY8XVC5W56D;:@)P6."<#U. 3^!I] !13(Y8YD+Q.KJ&*Y4Y&
M02"/P((_"GT %%%% !1110 4444 %%%% !11535+]-*TNZOY(99H[:-I72$
MN5 R< D#I[T 6Z*HZ-J<6M:)8:K CI#>V\=PB/C<JNH8 X[\U>H ***9++'!
M$\LKJD: LS,<  =R: 'T52N;^2WU.QLUL;J9+KS-UQ&H,<&T9&\YR-W08!YJ
M[0 4444 %%%% !1110 4452BOY)-8N+ V-TD<,22"Z91Y4A8GY5.<Y&.>.]
M%VBBJ6DW\FIZ>EU)8W5BS,R^1=*%D&&(R0"1@XR/8B@"[1110 4444 %%%%
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M29HT9Q%& 6<@9VC/<]!0!+15>PN6O=/M[I[::V::-9#!, 'C)&=K =QT-6*
M"BH[B>*UMY;B=Q'#$A=W;HJ@9)/X54T75[/7]%M-6L'+VMU&)(R1@@'L1V(/
M!]Q0!?HHHH **** "BL?Q1XBM_"N@7&L75M<3P08WK;A2PR0 >2.,D5L4 %%
M9NO:[I_AO2)=4U.;RK6(J&;&3EF"CCZFM$$, 000>010 M%%% !1110 4444
M %%%% !113(I8YXDEB=7C<!E=3D,#T(- #Z*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KC/&/AG4-5U.SU?PYJR6'B'3XF5%E&Z*>)SRD@]
M"5Z__6([.L;4=!:\UB'5;?4[NSNH83 HBV%'4G)WJP.>0/0CUYH XZQ\77^H
MZ7XGM-3TY]$\5:98&25H6#I(JJ[1NA.05R3P<]>I[3MKNK?V;\.KL7\@?5'@
MCO1M7;,&MRY)&.#N';%=+:>%;6.;4KF^GEOKS4H1;W$TH5?W0! C4* %7YB?
M4D\DUD6_PZBBM]&AEU_5IDT:99++<8AY:JI54.$PPP>IR>."* .?TW2=7U+4
M/'+:5K]QI<T.K.\0AC1E>00QD>9N!RO3@8[YSQBS8^*]7U:+X>:C]J>W35W=
M+VV1%V2%8G.<D;ARN<9QTKICX.2.]U66TU6]MH-6?S+N"/8<L5"DHQ7<N0 #
MS],'FL6:*TU;Q+X7L]$MY8K;0+N=;A&@>-846%HU W 9!)&",Y&3V- $,E_X
MF\3VFLW&A3R6]W9ZA-:VG[Y!"IB?:1(I4EMV"3Z C&.^A:ZAJ/B77M;T@W[Z
M>^F6MLN+1@<SRQERY)&2HX '0X.<\8FF^'UO_;]WJ=AK.JZ;'?OYE[:6DP6*
M=N[<@E2>Y4@_2I-4\"6UWKD>L:;J=_HUX(%MIFL60+-$OW5964C(Z XXH P-
M5L]4;QIX!@U'697O&CO$N)+3"1M(D/+JI! )R0<^^,5Z+=1&>TEB$LD1="OF
M1D!E]P>QK"U#P=9WDFC2PWE[9SZ2SF"6%U+L'7:X8N&R6'4]<\YS718&,=O>
M@#R'POK-YH_PQ\(I#?3FXUN_CL_.EVMY :1R[+D<L0#C=GDY]JZQ=0U#0_B-
M8:&]W->:;JMI++&)\,]O+%@MAL9*L".#G!Z>E.@^'&F1>%QX?>^U"6TBF$UF
M[2*)+-E8LIC(4<@L>6R3T/'%;-CH"P:HNJWMY+?7Z0?9XY9$51&A(+;54 98
M@9/L.@XH C\67-Q::"\EMJ4.GN9HE:>12QVEP&5  <N1D*,'DBN4M-:U<WGC
M>P2\OH(]/LH;JQ:Y6-Y82T;D]0V02@.&Y&3T[==XE\.V_B;38[2:XN+9X+B.
MZ@N+<@/%*ARK#((/T(K,7P)"+[5;QM9U-Y]4M%M;IF:/YMH90X&S .&(P!MY
MSC., '-66J:[:V?@#6)]<N;G^V&@MKNV=$$3"2 ON&%W;@5SG/))Z#BM)-=O
M?#GB?Q!INLWUS=Q-:"^TK<$!=/NM$N ,N'*@9R2&%:I\#6YT[P_8_P!J7PBT
M*2.2U($>6**47?\ )S\I(XQ5*4Z=XU\5:<Z:==@:!=RR27%S;M$/, VJBEL;
M@6P^1T\M<]10!U.C6UY::/:0:A=M=WBQ+Y\S #>^/FP  ,9Z>U>>^-=>U;2M
M.\2ZC9ZK++<Z=+&UO':*/)M4PF4FW##,V6R 6(!4X%>H5Q6H?#:QOX==M3JN
MIQ6.LR&>>TC= BS'&7!*[OX1QG'M0!8;4+G7?&>JZ"E[-90:=9PR?N"%>627
M=\V2/NJ%' ZECG/%4X]0UF+5_#_A74M41[R:UGN+V]MD"&;RR%5%_ND[LL1S
M\O&,U<U+P'%>ZG::K:ZUJ=AJL$'V:2\@=-]Q'G.) 5*GGD8 QZ<##]8\"6&J
M6FFB&]OK*^TQV>UU""7,RLWW]Q8$-NZG/6@#.U&^UWPY:6>FW&I"]GU+6/LU
MK. JRQ6Y5G56)&TO\A7<1WSU%#V_B*TL?%$>HR^9I,EA(]FL\RR3Q-L(=20!
ME>A&<D5IW_@73]4\.-I-_=WUQ*TRW/V]I0+A9U^[(I PI &  , =JDL_")AT
MF]L[O6]2O[B[A-N]Y<,A=(R,;4&W:.O)P23US@8 .7T76+N/P_X#T&T\P?;=
M&6>1HY%1V6.*,!59NF=^3CG"U%KUUXRT'P;J$MSJGE31:E ME+F.21K>254V
M2_+U&3RN"?6NAO/AY8W6@Z/IRZCJ$%QHP"V&H0NJSQ *%QD+@@@ $8YQ4M[X
M%@U'P\VDW>L:E*TLT<\]XS(9I61@RCE2JJ"HP  /S.0"K?6^IZ1=V%K<>)KJ
MZAN[N61X?+474P\L;8HMBC"JV6+'&!C) Z\=K.I:GJ_PHU5KV^NUFL==^QAL
MHKO&MTB 2;>"0&[<$CO7HVL>%4U?4M*U)=3O;._TX.L=Q;^7EU< .K*RE>=H
M[<5F_P#"N=._L#6-'.H:BUOJ5V;PEI5+0R;P^4.WGYE!^;- ":K=ZEIGCWPA
MIT>J7,EE>"[%Q%(J?O"D6Y22%!ZGZ<#BLZUU75O$OA77=?LM4GL[FUN+E;*%
M OEHL)( =2/FW;<G/3=QC%='/X42YUC1=4FU6_DN=)$OEEO+Q*9!AR_R=QV7
M '85!_PA-O#)JJ66HW=I8ZJ[27=I%LVEV&'9"02A8=<'Z8- '-VWB#6/$6N>
M$3!J<^GVNLZ3+<SP11QGRW4)RA92?XCC=D>U;W@#4+^[L]:L]0O)+Q],U>>R
MBN)0 [QJ%*[L  GYL9QVJ\_A*T_M[2M4@N9[?^S+9K6VMH@GE"-@ 005)Z*O
M?M4WA_PY%X?DU)X;RYN/[0NWO)1-LPLC  [=JCC '!STH P_%5UK \=>&M*L
M-8FLK748[L3JD4;8\M%(9<K][YCUR,X.#BN7U#7/$NBZ-X[TE];N)KC1(H;J
MRU!HX_-:.52=C_+@XP>0 ?I6]XPS-\2_!BQ7C6SPK>EY4 81EHT"AL@C#8(Y
MQGMS6Q>^"+/4-'U>QN+VZ\W6&!O;M=@D< !0HRI"J , 8]>Y)H QK^]U?1)]
M'M)-=N+B7Q#>Q1;Y(HP+1!&6D$>!_%@ ;LXZ\GDV1=ZE8^/W\,-J-S+8ZAIK
M75M.VUIK61&"L Q'S*00?FSSQTK:U7PK:ZSHEII]W<W!ELY(YK:\0JLT4J?=
M<8&W/X8/I4]AH26NJ/JMU=27FHM +<32*JA(P=VU54 #)Y)Y)P.P H Y/PWK
M.JZGH$.C7>HSCQ#;ZF]G>S*%#!8VWLX&W&UH]H!QU<5=@U'6?^$\\3:;#>-<
M)!ID,]E!,%"1RMYG&0 2,J.N36_:^&]/L_%%_P"((D(O;V&.&4YXPF>1[D;0
M?]Q:IR^$()M:U;5&U"\$FIV?V.6,; J( P!7Y<@C<3DDT 8/A#Q =6U7^SKK
M4-4L-8BLF%YIM^BA_,)3]]$=NTKPW3CD?**S=)\7ZN? WAH7%\\FHZQK#V#W
MK(NY$$TF2!C;NVH%'&.>G%=K!X9 U.UU*\U"XO+RSMY+>VFD1%9 ^W<QVJ S
M':/;KQS6=#\/-,C\)Q>'GO+V6&"Y-W;7+,@FMYMY<.I"@9#,>H/7% %6>^U3
M2/'<?A\:C<2V.IZ?+/!)(%>6UFC(SAB.5((X8'!]N*YO3=:\1#P?X,\2SZ]<
MS3WU_;VUS;&.,121RR%6R N=W0YS@8X KT&#PYMO9-0NK^>YU%K8VL=RR(OD
MQDY.U0,9) ))ST';BLM/A[9Q^&M)T%-4U 6NEW*7,#_NMY9&W*&.S! /M0!D
MZOXDN=-\4W%CK=W?Z3'-=Q#3+Y5#6<L>$S$YP=KDAP2W(R,$ 5W][<K96%Q=
MLI98(FD*CJ0H)Q^E8-]X/CU*WO+*\U*ZFTZ\G$\UJZH0""&VJVW*J2H)')Y.
M",UTC*KJ58 J1@@]"* .)T/^W-<T/P]XC@UP1R7)CN;VW=08&@<9,2#'RLN0
M V<Y!SFJMGJ6J^*="\0ZM9ZI/97%G=W$%C'&%V)Y/ WJ0=VXC)ST!XQUK2T3
MX?VN@W"I:ZOJ;:3'+YT&ER2J8(GSN&#C<5!Y"DXSR<U8/@N"&YU5K#4;NRM=
M6<R7EM%L*L[##.A*DHS#KCZC!YH Y>V\2:SXBU/P1)!J4VGP:WI]S+<P11H0
MCQJG*%E)ZL<9R.G%9'B&]U.Y^%GCBRN]5NIVTG47M8IR5626+]V0LA4#/WR#
MC&:]%?PA9_VSHNH6]Q/;+H\#V]K;1!/*",H4@Y4D\*O?M5-_ %A-I7B#3KB^
MO9H-<F,]QN* I(0HRF%&/NKP<]* $U8W=MJ^G:?_ &Q=2PO;S,;:WQ]KGDRN
MUMP 58U!/)*C)4$FN6_X2?7KCX0:/KAU*6+4#?1V\\BQI^^7[48CNX.#M'5<
M<UUS^"@^KV6K#7=474(+8VDTX:/-S$6W;6&S"\]U"D?K51/AO8Q^%4\.IJNI
M"RCNOM*'=&64B3S H)0\!CGU/<XXH AO)-7O?B?<Z''KMW:Z>VCK=!84CWQN
M92AVL5.. .2">N,5DZ-XNUBZ\/\ ANQFG::_O[^[M);E=B.Z0&3ID;0S!5&<
M>N.<$=FOAE%\5/XA_M&[^UM9"R*8C\O8&+ XVYSN)/6L=OAIIC^&TT9M0U#]
MS=M>VMVKHD]O,S%BRLJ@=6/!'?Z4 9FI:QXH\):3J\E[-')#/<V\&DO/(LDL
M)E8*_F8 #*I)*YR3T)J74=/EL?BQX.+:A=72O;7PQ<$-A@B98$ 8SD<=!C@#
MFME_ ME?>'KW2=8O[[5&O%42W5Q(!*-IRFS: %VGD<=2<YIMOX)==7TC5+WQ
M#JE[=:6LB0M((@&5P 0V$YX7KU/K0!K^)I;FW\+ZK<6=R]M<PVDLL<J*K%65
M21PP(/3TKB'U?7)[#X<M#K$T+:M&BWA\M&\PFV+EN1G=GWQTR#7H.JV"ZKI5
MWI[S20I<Q-$TD>-P5A@XR",X/I6 O@>W6'P[$-4O@N@X^R\1_-A-@W_)S\O'
M&* (/!]YJ">)?%.AWNH3W\6FSP-;S7 7S-LL0<J2H (!SCCO57XD0RR7/A+R
M[RY@#Z[!$RQ, #E7.2"#D@J,9X]JZ#3/#<6E^(-6UA+VYEFU0QF:.0)L7RUV
MKMPH(X]2:=XC\.P>([6TCENKBUEL[N.\MY[?;N21,X.&!!&">"* .2DTZYO?
MBSJ=I#JEU9_\2*V#W$(3S6_>R=V4@>_'TQ5;1/%^KZAX9\(6TLK27^JS744\
MZ%8W=8"X."1@,VU<G'3=C!P1U]OX52V\23ZXFIWK7,UHEF5?8RA%)*G[N=V2
M3DGO64?AIIA\*VFA?VAJ ^PW#75G>JZK/;R%BQ*LJ@8RQX([^PH T?"\'B&U
MN]4@UB82V7F(^GF257G5"#N5R  0".#R<'FL/XK%Q;>$C$JM(/$UEM5FV@GY
M\ G!P/P-=5H>B'1X)/.U&[U&[EQYEU=L"[ 9PH"@  9/ '<GO5;Q-X5A\3G3
MOM%_=VRV%W'>PBWV<RIG:3N4Y')XH SK7POJ-U\0QXLU5[6'[/9&SM;6U=I.
M"Q)=W95YY(  _&N;\*74]K\,-.,&I)8!]8F25]A:22,W4FZ.( $F1N@P/7IU
MKU'8WD[/,;?MQOP,Y]<=*XY?AQ9Q:#9:7#JVHQM8WQO[6Z!C\R*4EB?X-I!W
MMP0>M &&=?UN/1?B#$E]>6\FC)YUD\ZQO-&#!YFUCA@1GUR<'KFK=M?ZU8>(
M/!4DVM7%W%K<+I=6\B((U*P>8K)@9!R.<DYS6J_P^M7_ +?W:OJA_MR%8KO<
M\9SA-A8?)P2OX#/ '&+;^#H9+CP_,VIWN_0P1;\1_/E-AW_)S\O'&* +?B[7
M&\-^$M4UE(A+):6[2(AZ%N@S[9(S7,ZQJ.K>&[3PWK":G/?)>7=O:W\$H4I(
M)N-Z #Y2IQ@#@CKGK7<7UE;:E87%C>1+-;7$;12QMT92,$5@V/@V&UATVUNM
M2N[ZSTN19+."X"?(R@A"S!06V@\9]B<D T 8FAC7=8\6:_!+XDO([;2M4B$<
M2PQ?O(S&K&-OE^[SCC![DGC&M\3%D/PVU]H[B:!DLY'W1-M)P.A/H>]:&C>&
MH]&U?5=1COKJ=]3E$TT<H3:K!0H*[5!'  Y)J[K.E6^N:+>Z5=[_ +/=PM#(
M4.& 88R#ZT <!K5I.NH_#J"._F\UYY<3R*K,@-LW08 X'3(/OGI5BRU'6+:#
MQYI;:S<S2:,%DL[R5(VE4/;B7:?EVD ^W0UN?\(4C2Z'+-K6HRS:.Q>%W\KY
MR4V?,-F,;>.,>O)YIX\&PBY\0S_VG>[]=14N>(\)A/+&SY./EXYS0!SL_B+5
MK7PAX1U:ZBU&[TV?3TDU2>P ,Z.T:%9"!SLR7+;?;MP>P\+7L6H^'+2[@U0:
MI#*&9+S !D7<<9  P0.",#!!XJI:>%6TZUTB&QUB\C_LNV:TCWK&PEC.P .-
MHR1L&",'KUS6EH>BVOA_2DT^SW&-7>1F?&6=V+,3@ <DG@  =J ,KQ?=*ZV.
MC>3/,M[+ON4@C+M]GCP7R!V8E$/LYKG?AS=+H_B'7O"!BF@MXI3J.F1SQE&^
MSR'YE /97R/QKLX-%\GQ#<ZPU_<RO/"L/D.$\N-%)("X7(Y8YY.>/052U/PC
M#J7BK3_$0U*]MKRQC:*-8/+V,C?>5LJ20?KQVQ0!R]YJ6M65[XNT.36+O[>L
M45WHLNV/<5D^14 VX.)<*2>S#D5I^%=<N/$UGX?FBO+A&CM&FU)3MR9 ?+\M
M^./G60\8_P!7[UT-[X<L+_Q%INN3H3>:>DB1$'@A\?>]<8X]"<TW2/#6G:(^
MJM:1D?VG=/<S@G^)@,@>@SDX]6- '#IK^KVU[X8F&JRWQOM4:SO)XE LY582
M$+$" ?EVC#*,'!R35W3#KFI^+_$EO+XDO(K/2+ZW>.-(8OGC,0=HV^7[O)'&
M#ZDU;@^&=I!I^EV(UW5S!I5T+FQ4O'^Y W?)]SYA\QY.2.Q'.=S2/#46D:UJ
MVJ)?74\FINCS1R[-@*J%7;A0?N@#DF@#S;Q->7GBCX'W_B6;4)XVN_WJVJ%?
M*2+SPHC(QR< $MG.[VXKV4=!7"2_"^S;1M0T*#6M3M]#O',@L(S&5A)8,0C%
M"P7(SC./K7;PQ-%;I$9GD95QYCXW-[G  S^% '%^+$M/$.K/H=[:7=SI]O:N
M9OL\#28GE4JG3H50LWU=#VI?A=K-SJ'@\:??!O[4T:1K"Y1P58E/N,0>>5V\
M^N:Z/1=%_L?[83?7-V]W<&XD>X"9#$ 8&U1Q@ #/0 5EQ^%UT7Q!K/BBTN[^
MXNKV(--8KY8CF,:X0 ;00W& <]^: .-@\0Z[J.@Z!<V^K7$/B"[U7[+J%C&J
M,88][!QY;*=FQ0#N(^I.:V FO:KX^UW18_$][:VMI;6D\1CAB+*S%\C[N-IV
M\]^G. 0>>T-;A=,AATCQ9XEBU0)N_LV?3=X24\E'+Q#Y=Q(+,WOFO1;#PT+/
MQ->>(&OKA[J]ACBG@PGE )G;M^7=QD]^] '*)J'BKQ/HUQJN@S-!>)?2I;(\
MR"W"1RE"DB;23E5))ZY/&!5JXU+7/$>H>(++399K:73F2" V\Z*%E,2R;WW
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MZ7,/+=2WD[WP[(6?:WRYW'J1U&1%%?:QI7A#0=8DUR[NKK7$T^T*3L@C@:0
MLZ_*<,1QDYY.2#TH ]/HKSK5KOQ-X.M=>U=[B&32EL/,MK>XNFN)(K@,%W E
M03'A@2"3@CC&:TK;3?$T/B"PN8M15=+EA>.]6:]\]G8KF.2(&/:K9SD#"X[4
M =G17C0U3Q GPIB\4GQ%?-J%I?E K;/+E7[68B)% ^;Y3ZC&!C'?J3=ZAH'Q
M%CLY-5O;^SN]*GNI8;@J0LD;+@H !MR&(QTH [RBO-]*D\5:YHV@>(["]AB>
M=H[F\$UXQ@D@89>,1[,*5S@$'/')-4YI-;O(/'S'Q)J47]CRL]GY7EJ01 )
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M/0D4 >HPS1W$$<\+K)%(H='4Y#*1D$4^L+P9;_9O!NCCS99-]G"^97W8S&O
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MNKC37@>W_?,N]4?.0"JCU.*@E\#VT^FZ192ZMJCKI5S'=02-)&79T&$W93&
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M;.\D;$L%V#=E,8"\8&/7KS4Y\%Z;+J&N75U+<W2ZW$D-Y;RE/+*HI5=N%!&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM<33/$[7UQ=%[@>6X= &(P ".@&.3ZU-)X1T^YBU07TD]Y+J=L+2YFE*JYB
M8!1L50,;F/ SD^PH Y+4XKVTN/ EC8ZQJ-M;WSM'.JS;MP^SENK9/;CG ZXJ
M\T5_H?CWPGI"ZWJ5Y:2VEYYHNI0QD*!2K,0!N(WGKZ"M;_A"+/.CL=2U-GTE
MB]L[S*QW;=N6RIS\O&.![9YJ_>^';:^\1Z?KDES<K<V".D*(R[,/@.""N3G
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MDWE((T*@DMM;!+, ./7IBN3UZ/4]#TCP?;-XBN[VX37K>TN+A6\LW",[$K(
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MH3%G<73?.J[CLR/X25VDCU- &UK6M6/A_2IM2U&;RK>+ ) )9B3@*H'))/
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M^=344 8(T"TT\QZA//?7TUE;O#;&;]Z\2-C<%"KEB=JC)R>.O)KF/AUX7#>
MM#MM6745-H1(^GW:%$296+ D%0Q .& R5SVXKT6B@#E]4\ Z-JFNMK)DO[.\
ME4)<-8W;P"Y4=!)M(SQQV-/UGP-H^LW-C=9NK"[LH_)@N-/G:"18O^>>5_A]
MNW:NEHH P;WPAIE[9:;9DW$4&G7"W5N(Y>?-4DAV)R6.22<DY)).:ED\-VLG
MB6/Q ;BZ%_' ;92'&SRB0Q7;C')&<]?>MFB@#"@\):9%<:Q+();@:Q_Q^QSL
M&23Y=HXQQ\O'%5_#W@;2?#<@:UFOYT12D$5Y=O-';J>HC4G"\<9ZXXS72T4
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MP01C. PZG&",9XK?T^Q@TS3K:PM@P@MHEBC#L6(51@9)Y/2@"S1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\J20.QY.!Z$FL[5/'ZC2?#>HZ-8W%W;:U>10+(-BE 22RD,P^<A6'H,'GID
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MTO-/N;N%YK4W2H%G5!EMI5C@@<D-@XJ33O$UOJ<EB8;*\6VOHC-;73JGER(
M#GAB5R"" P!_(T ;=%<U)XWTV&73VF@NX[#49Q;VNH%5\B1VSM'#;@&P<$J
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MY>-RID56R5(SD$]: /0**\U-Y-I7Q9T;2=!U&YO+"[M97U*UDNGN4MPH_=R
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M>-)# S NA<LH*YR1N'3@]LUR^GZ3J]K\.O!B/I%\;G2=:6XN[98CYJQ[Y?F
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M/>O._#FD7>G:_I-WH-OJFFV5T7?5](NXG^S6Y*$[HBPP&WX&$)R#V ->GT4
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MZYI>IV4$4D<<*-/:2Q[@/D<CY2&YYZC\P#NM UVQ\2Z):ZOILC/:W"DKN7#
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M <],=J]D)P">>/05PG@NPNH/%?BRXOM,N(8;Z_6>TDFBX=0FW/\ L].^#S0
M>$/%>I+X2\,P:Y:W-QX@U*"5UB551F2,_?<L0!E2GN2W3KB]-\0])A\-6VNM
M;7QMIKK[(R"(%X9?,\LAQG'#>A/MFCQ1)K \1Z1''I][>:&Z2BY2Q95<R\;
MY+*?+QNZ'!/7CBN*31-;A\ -I/\ 8%VEQ%X@%RL<84AHA<^82N#T"XQG&>U
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M^G7<=I/I]O'')Y>X,Z%RRC&>FX#/0]JY+2-#\0:-H'@?5!I%U+/H,MU'>Z>
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M_- ';4@()(!!(ZCTKDKKQT8-9O=(@\/:M=7UI%%-)'"L9RCDC<#OP<8^OH,
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MSF.@REBSJXD'G1X((/4=#_48-6?BDL2:?X?NGC9WAUZS(V*6;'F<@ =<XZ4
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M?:7*\>Z2.0@[D.2I(*@]>:V?$&DZYK?A^RU+3M"CL+O3M3M]0@TQV19)UCW
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M;61O_-2=9HGA7ACN7HRXY4CZ9K'_ .$7UNZ^$6E:1';K9ZYIBVTD44[JR-+
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M-^3@@YQG\:S/"]EXJ\.VP\+OX?@N+>WD9+763.FSR2Q(+I]XLH., <X'('-
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MR1O)EF7<TA9W;G"JP!;DDXX)-0:!J7B&PTRWTW6/#UU->VT8B-U:2PM#.%&
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M6XL]4L8X+JWBE0RVTD9)0\D!@0<'!.#ZCF@#0M?'6FW>CK>)#<+=&]_LXV+
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ME@RCE#@@C)_(\5R?BJ[TS6?AKX],.AI8RVEW(DX<(6DG54/FG;D _,!G)Z4
M>L@@@$'(/>HXYXIFD6*5',;;'"L#M;&<'T/(KD;3QG-;:[IFD:IH=U80:@NR
MQO'E1UE=5SM95.4)'(!Z_GC-N/%(LO#/C75-$T**SOM-N91.)74>;(L:DRMM
MR"<$<9YQU&: /1**Y6W\37,,6AZ?<6]O_:FHV[2Q++=;4<(J9.[826.\?*!Z
M\\5OZ9=S7VGQ7%Q:O:3-D/ [9*$$C&1UZ4 6Z*SM<U7^Q=)DO1:3W;*R(D,"
MY9V9@H^@R1D]AFL9/&3)=:]976F-]MT>W2Y>.VG6198V5B-K,%P1M.00/;-
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ML;**:YU!]N98?G(Z9.!M)YY]JFMO%-W-=:07T.Y6PU4$P7$;%VB^7<IF4+A
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M]7@^(\&K);)=V4^D)83S^:(S&ZRERQ7J003@#OZ#FNRHH \TL/#.OV/P]OO
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M&EQ$57$;*=AW\\MD>U;W_"#>$O\ H5]%_P# "+_XFC_A!O"7_0KZ+_X 1?\
MQ- &)!INJ0^)_&E\=.<P:G;01VA$T67:.-D.1NXR6&,]L]*S8/#NM6WA3P0H
ML ]WH,Z-<VHGC#.HC9"4;=M/WL\D5UO_  @WA+_H5]%_\ (O_B:/^$&\)?\
M0KZ+_P" $7_Q- &4^D7EYK>L>(YK1HIY=+&G6EGYJ&0KN9BSD-M!+,, ,<!?
M4X&,OAW6X?!7@F!+!7O]"O()+BV-Q&"ZJCHQ5L[?X@>2*Z[_ (0;PE_T*^B_
M^ $7_P 356/PQX#FOI+&+1/#CW<8R\"VL!D4>I7&10!N7=W=0:5)-!:K<7HC
MRMNDJ@,^.FYL#&>_IV[5S=EX.T>X\+B+5M'AEOYX&-X7$9EDE;)=MP.,EB2.
M>..E:7_"#>$O^A7T7_P B_\ B:B@\(>"KH.;?P]H,P1RCF.SA;:PZ@X'!]J
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MUF::6S:25"&#1*@!VDX.5_6O1ZBANK>X>5(9XI'A;9*J."4;&<-CH<$'!]:
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M79D\EU4^OE@-_O@GO6_XHT6]N]3\+MIMD'MM+O1<2@.J[8Q&R!5!/)^;Z<4
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M0?\ ASQ^&1WKFXO#>O0W_BZ6/2+.&VUC3HH+>*"X'[IUC=-N-H'\0)/0=LT
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MSAMW;D#I5FT\<B(>(4URP&GSZ&D<LZQ3^<LD;J60JV%Y.",$=:SI] UE]/\
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MY4D*\'W ->;:?X9\3I<^$KR;2+-+K3)I#?S/>[Y+EGB*&9FVY/)SC)/.. *
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M]*EOI]*MI=3M8[6^>,&:".3>J-W ;O5R@ HHHH **** "BBB@ HHHH ****
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M1M9F>!/M4^V*%UWY!<#G)0A>!G(Z5U.EW-Y=69DOK1;6<2.AC20R*5#$!@Q
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MUT^U>YO;F&VMT&7EF<(J_4GBN2M_'CR:MI$$EE ]KJAVJ]K<^;);,1E1*H7
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M<:6]O+;:;<7L6LQWWVZ2Z8/=QK-O52-GR!5XQD@8X'->J44 <GI&D:M;>/\
M6=8NK>%;2^M;>%&27+!H@V25QT.[CG/%5=,T+6]+G\60BWM9;74[J6[MI1.0
MY:2-4V%=N  5R6R?I7;44 >9)X.\1Z?X?\(76GK:'6_#L;0/;22GRKF)U"N
MX'!^4$9%;/B#2_$GB/P'J]C<6]I#J&H1>5%:QSEHX%]6D*@L>N<#'0#H2>TH
MH \YU)[VV^)GA,K9"69-)NEEA64 @ Q@[2>"<XZD<4NI>$==FM-8U*S,"ZEJ
MFHV]S<69F*I);1 *("X'5E&6(XY(Y')[.;0=-N-:@UB6%VOX%*12^<XVJ>H
M!Q@X&1CFM*@#SR+PUX@BU7Q/<BPTZ*#5M-BMX88;@_N71'0+]P#'S@D\8Q@
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M?7Y=9L2TA>)PY;]V^!D95F!Q[<UZ+J&I6.E6CW>H7D%I;I]Z6>0(H_$U9!#
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MFJ6]Z\"3_NX(XV#; Y7+L<=< 9)[ 9[FF"6-I6B$B&1 &9 >5!S@D>^#^1H
MY-M$U.?XAW6L/!''83Z.+ -YH+JX=GR5]/FQU[5@/X2\2R?"2'PH]K8B\@,$
M:.MR2C+'*KER2HQD+@#!^M>G44 <G_96J/\ $N#7_LL:V THV+YF&\.9%DSC
M&"!C'6L^/2?%WASQ+JK:);Z=?Z3JMQ]KQ=7#1/:3, ')PIWJ< X'/TZGO**
M.0N-"UJ'QUI6MVYMKN--,?3[IY7,;*2Z/Y@4 Y^Z?ER.O6JFK:%%J/Q)TV[L
M[H"*6U+:G"F")DAD5H"3V/F9'N%8=C7=5EZ)X;T;PY%-%H^G06:SOYDOE+R[
M>YZ_0=J *U[JFK6WC#3=/CLK:32KJ)]\_FGSHY%#-G;TV<*,^KC\=VFB-!(9
M B[R I;') Z#/XG\Z=0!RB:3J<7Q)N]>^S1M8R:8EFF)1O+K(SYQT .['6N:
ML?"7BBP\,Z'8?9K.X6RU&>>\L7N2L5U'(SLN6VG.TN#M(P2*]0HH \_TSP_X
MDTU?$@>PTJYCU'45NE@,Q*21L(UDC(*8&%5@">IQP!6EX,\+'PY?ZQ);0M8Z
M7>/&]MIIEWB!@#YC#!(7<2. 3]W\!UU% ",2%) R0.!ZUYE/X.U^;X=>)-!^
MS6RWFIW\US"?M'R*DDH?YCC.0!CI7IU% '!:GH/B.]\0:A<?9K*XM+S3EM[8
MW%P0=/DVL'VJ%.[=N!R"#P!G%9]GX3\3:3%X2U6V@LI=1TBQ_LZZLOM!"S0[
M5&5D*X# KG&,<XSQSZ'9ZG8:BTZV5Y!<FW?RY?)D#[&QG:<=#[59)"@DD #D
MDT <EX6TC6K+Q3XDU/4K:TA@U.6&2)8K@R,I2)4(/R@=NN>W3O7750L-;TK5
M)YH+#4;6YFA ,B12AF4'H2!V/K5FZN[>QMGN;NXBMX(QEY97"JH]R>!0!Y@W
MA#Q;)IEG#/:Z;/?V>MQZA+>O=-OO420L,_(=F%(&.< <"NCL-&UBU\5^*M4D
MM(6AU2"WCMPDPSNB1E.X$< EN.O KHVUO2D2R=M1M56^V_9,R@>?NY79_>SD
M=*OT <[X%TF]T'P7I>DZ@D:W-G"(G\M]RMCN#Q71444 %%%% !1110 4444
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M6382=NT9^49]!6'=^!_$MSX1\6:03IC3ZSJ37D,GG.JJI:,G<-AQ_J^.3UH
MZ:W\2ZI'XSBT+4M-MX$O+22YLY(K@NWR,H*2#: #\P/&1VYZUS&L^+M3_P"%
M;>+-2TVQL]-O+&_GM)#&Y;E656D!"C+DMP2!Z\XKI;S1M7NO'FCZX(;-;6SL
MYH)5-PV_=)M/RC9@@;>Y'6L-_ ^M77@GQ=HL[645QK%_/>6SI,SJN]E8*_R
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M'. >NWM7<JJH@51A5& /05P5AH7C#P[JVHVFCR:7/HM]=R744MTSB6S:0[G
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M%NQ8O"TD:E"K' .U@3VSS1?:#XB\6^%M1T_Q!)9:=-/$JP)8NTBQR*P<2,S
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M,MG@4 >A45GZ/<WEW:/)>"W)\PB*2V;,<L?!5QUZYZ=O?K2:[JL>B:'=ZC(
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M6+4K*?4;G3XKJ)[RV5'FA#?-&&SM)'O@US-IXFUK5-.T[6]+TN*ZTR\N1'Y
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M8<KR.!S@=>G&3DQ>!M>B^'.D^&]^FFYLKU+AI?/<(RK,9<#]WG)SC]:])HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM);JZE6*")2SR.<!17G=AXX\1RZ+X4UV[@TP6.L74-I-!$C^8IE) =6+8 !
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MTJ^B=F\LL75=\??!# C/3WH ])HKCK;Q'KEKXNU#1-3M[.Y*:9_:5K]B1U;
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M PR3@#.1C'0YX .ZHK(\*ZT?$7A72]8:(1/>6Z2M&#D*Q'('MG-:] !1110
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MK*>$Y"Y(+9Q@8SFM!?#NI1>+=;UI)+0QZA9QVT<19@4*;L,3CG.X\?K7544
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MXGTB*WCN3:WEK<QWEG<;=PBFC.5)'<<D$>]0IH=_>Z]9:YJHM/M6GV\L5I!
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M[&W=Z\9STK<3PY?1>.)/$$-_"D-S9Q6]U;F$LQ,;,04;<, [B#D'_  =X_\
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MCL!V '7K5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO.3Z 8(!WU%>?6GB7Q1J5IHNLZ=I\EQ:WTD;W%H8558[=^=ZR;LEE&,YX/.
M*EMO%\]WXIN-&DU"+3]2AO\ RTTZZAVBXM0W^LC<_>8KEN"?3'>@#O*CN)TM
M;:6XEW>7$A=MJEC@#)P!R?H*X>#Q?/=>*KC1I-0BT_4H;\)'I]U#M%S:AA\\
M;G[S%<G@^VWO76:[<W5GH-_=631+<P6[RQF9"Z94$\@$'MZT 3Z??0ZGIUM?
M6^_R+B-98]Z%&VD9&0>15FO.V\5^()-)\"7-O)8B371&MSYD+'#-"7R,-P,C
MICGU%!\;ZAX>M_&2ZV\-\^@^0\,L,7D^=YRY1",G&&XSZ&@#LK[7M/T[5M/T
MRYE=;O4&9+91$Q#E5+'YL8' [FI;/5;6^OKZSA\WSK%U2;?$RC+*&&TD8;@]
MJX77[?58O&O@-]0OH;C?>3&1$AV!)/(?[ASG;UX.3P.:GD\<7VDIXVGU)8)X
M]#EB2V2%#&'\Q%*AB2?XG )_2@#T"BN?@3Q/;:U;B::SO=.DMV-P=GE-#,,;
M0G7*'D<Y(QG/:N<L_%NL1:[X;M+VXMIGU.6:"]@@BW16TBHSA8Y1PQ&W# DG
MZ4 >AY&<9Z45YAI.O:CH</CW6M0OOML>GZ@ZK"8PFXB*,( <_*O('0^O)K<B
MU?Q+9:]:FZMI+C1I()6O9WMUA-HZKN!7#$LIY&#DC@YH Z'7->T_P[8"]U*5
MXH"ZQAEB9_F8@ ':#C)(&3@5<NKF*RM9;F<L(HE+.50N0![ $G\*\I\7ZCJG
MB'X4)K[W$45K>7-M*+(1 [(3<)L^;.=_W23TY(QWKU6]_P"/"X_ZY-_(T 0Z
M3JMIKFDVVIV$ADM+E-\3E2I9?7!Y%7:\9T+6O$OA;X6^'?$$<]C-HL$4*7-C
MY#>;Y3.$WB3=RV6!QM QZUUFH>(]=U%M<'A^)S+ID[6T"?9UD2XE5%9@[%AM
M!+;1C&,9R<X !U$^O:?;:]::)+*XO[M'DA3RFVLJC+'=C;QD<9SS5BZTRPO9
M$DN[&VN)$^XTL2N5^A(XKBKV>YNOB)X"N+RU-K=26%\\UN6#&)S'%E<CK@Y&
M:!XHUK5?!^I>*])EMU@M'G:WLY(LB>*%B&WMG(9MK$8P!D9!H [^BN'A\67U
MUX@\-R+*D>B>(+%I+?,7[R*XV!PC-G&"I8CCJM5- \7ZIJVC:G UW;G68-3%
ME 5MR$:-B#'*%)R5,>7Z]%.* /0Z*100@#-N(')QC-+0 4444 %%%% !1110
M 4444 %17%M!=PM#<P1S1-]Y)$#*?P-2T4 0VMI;64(AM+>*WB'(2) BC\!4
MU%% !1110 4444 %%%% !1110 4444 %1"UMQ=-=""(7#+L,H0;ROIGKCVJ6
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "LKQ)X>L?%.AW&DZBK>1-@AT.'C
M8'*LI[$&M6B@#GK#3O%$%NMI=ZY93QJ-OVI;(K.P]3\Y3=[XQ_LU#>>%)8_$
MMIX@T>\6WO(K7[%.EPAE2XASD;OF!# \[LGT-=/10!Q.J> 'U#PWJ6G1ZE'%
M>:I>K>WEVUL6#,K*RJJ[QA0$4#)/&>YK2G\.7L_C.P\0G4+<"UM'M3 +8_/O
M*ECNW\<J,<&NDHH \E\:^'[CP[\/?$/G:E#*=2UJ&^5E@\ORF>>+(Y8[@-N>
MW>NWE\-SZGJT&I:M>1O):VTL%JMK&8Q&90 \F2Q.[   [<]<\;MQ:6UV%%S;
MQ3!>0)$#8_.I$1(T5$5511@*HP * . L_A[JUM:>'+=_$4)&@S[K<I8!=\>Q
MDPV7.7P?O=/535Y?!5\MCXKMCJMN?^$@>1RWV0_N-\8C/_+3YN /3FNSHH \
M^\1KI<7@Y/ =[?Q7.M26,<5I#$I21W7Y8Y ,G;AE#$YX"D]*[;2]/CTK2[6P
MA+,D$83<W5B!RQ]23DGW-6##$9A,8T,H7:'VC<!Z9]*?0!S.L>&[^Y\5V7B#
M2M2AM+F&U>SF2>W,RO$S!N,,N&!'N*XGQ5X<N/#'@:2UDU9)VN_$4-U'*\(4
MQF2X#<\X;'7MWKURH;BSM;L*+FVAFV_=\Q V/IF@##;PR=2U@:GK<L%RT=I)
M:0P11E45),>8QR226  [8'KG-9=MX$N5\-P^%[S5([G0H)$*J8")WB1PZQ,V
M[& 0 2!D@8XZUVJJJ($10JJ,  8 %+0!S5MX;OK7Q7K6N1ZA;G^TH(H5A:V/
M[KRPP4YW_-]XYX%6/!WA^7PMX6LM%ENTN_LBE%F6+R]P))Y&X\\^M;M% 'GV
MI?#G4+[3O$>F1^($CL-8NS>@-9[I(Y"RG:7W?,@V# P#TYXYVHO#6H)XS7Q%
M)JD$CC3?L#1&U(S\^_?D/Q\W;'3OGFNGHH XG3X]+^'V@26'B+6;1X+ZZG="
M\!C#F0EV3&YL]2/TJ_X!\/KX=\*6]L%F5Y29F6=LN@/"(?=$")_P&NDDABE*
M&2-'V-N7<H.T^H]#3Z .:\6^%9?$)TZ\L-1;3M6TR8S6ET(Q(!N&&5E)&58<
M&J6L^#M4U[PC?:3?Z[&][?&,37(M,1HJ,&"I&'&.1U)).3[ =E10!S%[X8O;
M[Q78:W)J4*"VLY;5HH[<@L),;F#;_E(*C'!K#M/AUJUOIN@63>(XBFAW8FMF
M6P +)AAA\N<OAOO# ]0:]#HH X^/P;?(GBI?[5MS_;^3G[(?W&8Q'_?^;Y1[
M<US6OVXTZ3PQX8N/$>G6,FG6)=9M1LE:VN2H6-,!W \P ,>&XSTYX]5J*>V@
MNH_+N(8YDSG;(@8?D: //K+1Y_%?AW4?#][J.F7%C&(I+/4=&A\E89@Q; &X
MJ2I53\I_BP<5TOA_1]>LW$NOZ\NIR1IY<0BM1 HSC+, 3N8X]@.>.:WT18T"
M(H55& JC  IU '/^*O#MQXB72E@OHK7[!J$-]\\!DWM&<A>&7 .>:BM?#E_:
M^+=6UU=1MV.H6\4 A-LW[OR]VTYW\_>.>!72T4 8/@WP]+X5\+6>B2WB7?V4
M,JS+%Y>X%B>1N///K55/"U[;>)M<U6SU2*.'5HX_,MY+;>5D2/RP=VX?+CDC
M&<CJ!UZBB@#A$\ 7L?A3P[H:ZQ!_Q);R&Z68V9_>^6254CS..O)S4TG@S6;+
MQ%?:AH'B,:?::E()KRUDM!,!+@ R1DGY20.X(SZ\"NUHH AB@-O9);PN28XP
MB-*2QX& 3W/O7+Z/X(%IX+O?#&IWB7MK=&?+Q0F)@)69CU9N06X/L*ZZB@#D
MO#OAKQ!IGDP:MXG.I6=HNVV1;41.W&%,K9.[ /MS@G-);>$+J75=$U+5KZVN
M;W2$=8[J*V,<LY9"GSDL>,$D@=3SQT/744 <&WPX:Z\/:UI5YJH+ZAJ3ZI!<
M00&-K:8L&& 6.X CVX)JW%X5URY\1Z+K6JZW9S2Z=#-"T<%B4699 H).7.#\
MOT]O7L:* .&T/P/J^@N=-M?$KGPVLA>.R-L/.C4G)B$N?N9]LXX&.M6X_"%]
M'=>*9QJEN3KP Q]E/[C$?EC^/YOE^G-==10!P+_#[4+>S\/3:7KB6NLZ+:BR
M2Z-KNCN(, ;'C+>P.0>OX8O:QX*NM8T6V237)H]<MKH7L.I)$ $E VX$><;-
MO&W//4DG.>PHH Q]"TW5;-))M:U5=0O' 7=% (8T4=E7)Y.>23SQTQ5#4/#%
M_-XR77['5EM@]E]BGADM_-.P.6W1G<-K9/<,.G!KIZ* /.[;X:7ECH.@V]KK
MH75=!E=[*[-K\FQ^&C=-V2"."<CVJX_@"?4KWQ!-K6J17$6MV<5M/%;VQC"%
M =K(2[8P6S@YY'X5W%% '!_\(5X@N$T!+_Q':S?V+=+-#(M@0\RJC*-_[S&<
M'J,=^O;9T'PU<Z3JFNW5S>P746K7'GM$MN4\L[0F,ESD84=A71T4 </H'@C6
M- *:;%XF>3PY%)NALVMAYRIG(B\W/W,^V<<<5:U'P?=:RT$6J7UM<06^I?;K
M>46Q%Q$!)YBQA]Q'HN['W>,=ZZZB@#D=2\'W6M&*#4[ZVN+>#4?MUO*+8BXA
M D\P1J^XCT7=C[O&.]=%JUG+J.CWEE#,D,EQ"T0D=-X7<,9QD9Z^M7** .)3
MP/?1V'A.U&K6^/#S*RL;0_O]L9C&?WGR_*??FEO?A^-5NO%)U&_22TU^*%&B
MB@*- 8EPC!BQR<X/3J*[6B@#AQX/\0W-UH%QJ7B*UGDT:9I$=+ JTX*%/GS(
M?F(/48'L>TK^ A>OXJCU.]2>U\0;"\<4!1H2J!5(8L<XV@].H_"NSHH Y/1_
M#.NPVGV77/$K7\,4+0P&&V$#\J5WNVX[F )QT&>3DXQEV7P^U:VMO#<,GB*%
MAH,I^SF.P"[XRA3#9<_/@_>Z>JFO0** ../@032^);:YU#S-)UUVEDMEAQ)'
M(R*A(DR<@;00-HYQSZR:#X8UVTC2UUWQ'_:MC ACAB%J(F<%2N96W'?A2?3G
MDY-=;10!YP_PWU<>$9?"D7B.'^R$F1[1I+(M/$JRK($9MX# 8XX!Z=N*]",3
M26IAF<,S)M=E&,DC!('.*EHH XFP\"W,7ARQ\-7^I0W.C6;HP1+<I).J-O1'
M.XC&X#.!SCMS3KCP;K%IXFOM4\/>(AIUOJ3+)>VLMH)U\P #S(\D;6( SG(S
MZ]*[2B@#F;GPM<2^)M!U6+456+2()81%+"7>82*H8E]PY^4'IZU1M_!%WI^G
MZOHVGZI'%HNI22/Y3P%I;82_ZQ8VW 8.21D?*3WKM** .;U[P=9ZQX<L=&AD
M>RCL98'M9(C\T0C(&%/J4W+GWIT7A"RM_&:^(83Y>+-;;[,HPFY<A9/J$9D'
ML:Z*B@#/@MM237+JYFU!9-.DB18+00 &)QG<V_JV>..U:%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGO%=PTL:; Z[SL.W)P=NW(SUJ]0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117!KJ?B&]^(FL>'[
M;5XH+:TLXKF%GM%D.YR1AN1D#'L?>@#O**Y3X?\ BJY\6:!<7%];Q0WMG>2V
M4_DD^6[ICYDSS@Y'ZU6T7QI+J'Q U+0IX1'9M!YNF2_\]Q&YCF_\?''L,]Z
M.THKF/%/B:?3-3TC0M+CBDU?5I&6$S F.&-!N>1@""<#H,C)[U)?VGB.QM$G
ML-5^W2++&9X;FW3YH]XW^7L"D-MSC.[^M '1T5QD>KZL_P 5Y_#QOO\ B7)I
M0OU41+OW&79MW8^[^&?>JN@:IKFKZWXGM)]:6"#2;L0Q.+9,E"F[+$]Q[8H
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M_C);&<@@#.,'!JYJOBG4+)?#FBVT49\0ZR@SYRG9;JJ!I9&48)QSA<C)[\4
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M!RN/;:1SWP: .KHHKC/%6L:KIWC'POIUE>B*UU6>6*=3$K%0B;@5)'!//7-
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MCTH 997MMJ-C!>V<RS6UQ&LD4B]&4C(-3TU$6-%1%"HHPJJ, #T%.H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>3_Y'H^W>+O^@!I'_@WD_P#D>@#H:*Y[[=XN_P"@!I'_ (-Y/_D>C[=XN_Z
M&D?^#>3_ .1Z .AHKGOMWB[_ * &D?\ @WD_^1Z/MWB[_H :1_X-Y/\ Y'H
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M>3_Y'H^W>+O^@!I'_@WD_P#D>@#H:*Y[[=XN_P"@!I'_ (-Y/_D>C[=XN_Z
M&D?^#>3_ .1Z .AHKGOMWB[_ * &D?\ @WD_^1Z/MWB[_H :1_X-Y/\ Y'H
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M/O56QR V!D9[X&?05)0 445S[7WBT,=N@Z01G@G5Y!_[;T =!17/?;O%W_0
MTC_P;R?_ "/1]N\7?] #2/\ P;R?_(] '0T5SWV[Q=_T -(_\&\G_P CT?;O
M%W_0 TC_ ,&\G_R/0!T-%<]]N\7?] #2/_!O)_\ (]'V[Q=_T -(_P#!O)_\
MCT =#17/?;O%W_0 TC_P;R?_ "/1]N\7?] #2/\ P;R?_(] '0T5SWV[Q=_T
M -(_\&\G_P CT?;O%W_0 TC_ ,&\G_R/0!T-%<]]N\7?] #2/_!O)_\ (]'V
M[Q=_T -(_P#!O)_\CT =#17/?;O%W_0 TC_P;R?_ "/1]N\7?] #2/\ P;R?
M_(] '0T5SWV[Q=_T -(_\&\G_P CT?;O%W_0 TC_ ,&\G_R/0!T-%<]]N\7?
M] #2/_!O)_\ (]'V[Q=_T -(_P#!O)_\CT =#17/?;O%W_0 TC_P;R?_ "/1
M]N\7?] #2/\ P;R?_(] '0T5SWV[Q=_T -(_\&\G_P CT?;O%W_0 TC_ ,&\
MG_R/0!T-%<]]N\7?] #2/_!O)_\ (]'V[Q=_T -(_P#!O)_\CT =#17/?;O%
MW_0 TC_P;R?_ "/1]N\7?] #2/\ P;R?_(] '0T5SWV[Q=_T -(_\&\G_P C
MT?;O%W_0 TC_ ,&\G_R/0!T-%<]]N\7?] #2/_!O)_\ (]'V[Q=_T -(_P#!
MO)_\CT =#17/?;O%W_0 TC_P;R?_ "/1]N\7?] #2/\ P;R?_(] '0T5SWV[
MQ=_T -(_\&\G_P CT?;O%W_0 TC_ ,&\G_R/0!T-%<]]N\7?] #2/_!O)_\
M(]'V[Q=_T -(_P#!O)_\CT =#17/?;O%W_0 TC_P;R?_ "/1]N\7?] #2/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LC4_#6
MF:K?1WUPEQ'=QIY0GM;J6W<IG.TM&RDC))P?6M>B@""TM(+&W6"W39&.>26)
M)ZDD\DGN3R:GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,W5-!T[6I;634(#,;5R\:^8RKD\'<H(##V;(K2HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY['C'^]H7_?,W^-&/&/][0O^^9O\: .AHKGL>,?[VA?]\S?XT8\8_P![0O\
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MY['C'^]H7_?,W^-&/&/][0O^^9O\: .AHKGL>,?[VA?]\S?XT8\8_P![0O\
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M2P1JD>7="HR<X[\G-9FJ:5J=SHWA**+3Y#+87MM/<IYD8\M8T*MSNP>3QC-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR1A2L4CA2H8;MV,.IR 1S[&N;\0>$[_6+>(&TM8K^&V/V._LIV@DL[@LQ(!
M^:+E?K@_+SPZ]\*:A=>(X=4A6.UU"&X@SJ5O,4-Q;J%\Q)HP,,3AP.N,KR,8
MH ZVROQ>R7:"VN8?LTYA)GB*"3 !W)_>7G&?8U;JI9/?N]V+Z"")5G(MS%(6
M+Q8&&;(&&SGCGZU;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JEJ&K6&E",WUTD DSLW9YQU_F*NT4 8O_"7:!_T%(/U_P */^$NT#_H*0?K
M_A6U10!B_P#"7:!_T%(/U_PH_P"$NT#_ *"D'Z_X5M44 8O_  EV@?\ 04@_
M7_"C_A+M _Z"D'Z_X5M44 8O_"7:!_T%(/U_PH_X2[0/^@I!^O\ A6U10!B_
M\)=H'_04@_7_  H_X2[0/^@I!^O^%;5% &+_ ,)=H'_04@_7_"C_ (2[0/\
MH*0?K_A6U10!B_\ "7:!_P!!2#]?\*/^$NT#_H*0?K_A6U10!B_\)=H'_04@
M_7_"C_A+M _Z"D'Z_P"%;5% &+_PEV@?]!2#]?\ "C_A+M _Z"D'Z_X5M44
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M?K_A6U10!B_\)=H'_04@_7_"C_A+M _Z"D'Z_P"%;5% &+_PEV@?]!2#]?\
M"C_A+M _Z"D'Z_X5M44 8O\ PEV@?]!2#]?\*/\ A+M _P"@I!^O^%;5% #(
M9H[B".:)@\<BAT8=P1D&GT44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%4M0U6UTP1FY\_P#>9V^3;22]/78IQU[T 7:*Q/\ A*]*_P"G_P#\%MQ_
M\;H_X2O2O^G_ /\ !;<?_&Z -NBL3_A*]*_Z?_\ P6W'_P ;H_X2O2O^G_\
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M2O\ I_\ _!;<?_&Z/^$KTK_I_P#_  6W'_QN@#;HK$_X2O2O^G__ ,%MQ_\
M&Z/^$KTK_I__ /!;<?\ QN@#;HK$_P"$KTK_ *?_ /P6W'_QNC_A*]*_Z?\
M_P %MQ_\;H VZ*Q/^$KTK_I__P#!;<?_ !NC_A*]*_Z?_P#P6W'_ ,;H VZ*
MQ/\ A*]*_P"G_P#\%MQ_\;H_X2O2O^G_ /\ !;<?_&Z -NBL3_A*]*_Z?_\
MP6W'_P ;H_X2O2O^G_\ \%MQ_P#&Z -NBL3_ (2O2O\ I_\ _!;<?_&Z/^$K
MTK_I_P#_  6W'_QN@#;HK$_X2O2O^G__ ,%MQ_\ &Z/^$KTK_I__ /!;<?\
MQN@#;HK$_P"$KTK_ *?_ /P6W'_QNC_A*]*_Z?\ _P %MQ_\;H VZ*Q/^$KT
MK_I__P#!;<?_ !NC_A*]*_Z?_P#P6W'_ ,;H VZ*Q/\ A*]*_P"G_P#\%MQ_
M\;H_X2O2O^G_ /\ !;<?_&Z -NBL3_A*]*_Z?_\ P6W'_P ;H_X2O2O^G_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%8>NZ3JNL2K#:ZU<:5:(F2]HJ&61R>A+ @* !T&3GJ,<@&Y17*?#_
M %+5M0T2]BUF9;FYL-0GL1=J@3[2L;8#X' .<@X[BNKH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM76444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZU.N];*T"Y1?[TC,0J#ZG/MS4\?B>1-8L-*O]'O;.YO2XB<E)(CM0N?G4GG
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ME6BM;5A&H(! .<9[GOWSUJ_=^%=+U+PVN@:G$;ZQ5%0"<C< HPI!4#!'J.:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ$C'']T>26_0&O0?B%9VOBZ>R\)&>**VCFCN]2F9PHAB7.U!G^-^WH 2>HR
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M"<="?2N;N?B$EM\08/!ITJ9K^=/,CE$J^5LVLV2>HX4\8KM*\6U3_DZC1O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME!=P75E%>0RJ]O+&)4D!X*D9!^F* ,N^\+:9?#3&V26]QI8Q97$#;9(05VD
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MOI)Y;69/+E^8!G7T)Q^HYXK*L? .DZ;X?30[.?4(=.283)$MR<JP8.,-U W
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M&BN=TGQ%?7^I6EM=:,]K#=V9NX;A;@2*0"GR$8!#8<'\#714 %%%% !1110
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M3;],_P"O.P_]!2O1]7\%Z'KFA6^AWUM(VF6ZHL=M',\:@*,+G:03CWJ._P#
MNAZGX<M_#]Y%<RZ7 %$<!NI!@*,*"0<D#'&30!SW@.#4-.T>SU75[^.72/\
MA'K-H?W6Q;<(I9P>3N."ISWQTXK6\0>&].\6ZCJ>D:E%N@GTZ JP'S1MYDN&
M7T(_^MTJ:3X?:%-ID&F2G47L( JI;-J,YC 7&T%=^"!@<&MA=$M4UM]7#W/V
MMXQ$V;A]A0$D#9G;U)[=Z /'/ %UKWAOQOI_P\UU3,EC<275C==FA\B5<#U4
ME@1Z$,/IN?M"\?#6/_L(1?\ H+UZ7<Z38W>IV6I30*UY9%_(E_B4.I5A]"#T
M]A5#Q-X2TCQ?9QV>M0RSVR.)!$L[QKN&0"=I&>IH M^'_P#D7-+_ .O.+_T
M5HU6L+&'3;&&SMS(884"()'+D*!@#)Y-6: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBN.\7:&W]G^(=<;4=062/37
M^S107LL20LD;'?M1@"Q..N>@H [&BO'_ (4Z==^)O &GZK=:SJQU&'4?,,S:
MA,PD1) 2C*6VD%01R.]95QJ\-A\>M:T_6-=O;;08+,2B&34IHXU;RHVXPXYR
M6X'K0![K17(Z-HZQZ/?WD=[J#V.IVL5Q%#/?2R/;L4)(5R=P'*GKUS[5Y)X*
MU<7GP=\0:MK'B;4HM5MIIOLD[:K*L@81(44+OPV6.,8.<T ?1-%>8Z!>ZYKW
MP2%YKLMW!J)A<I<1NT,I4-A'RN#G'Y]>]9OPI\2W^EZMXE\(^)]1FGN]+D>X
MCN+J4NS0CACECG&-K#V8T >P45X9I%_K-U\?HK+4-1U$6UQ:F[-B;IUCB+1[
ME38#CY00#ZD$U./'&FV?Q$\0:1XZDOK-S=;=-N!-)'%%!T3&PC:3][?WR<D8
MH ]LHK*\-VTEKH-O%+J!U$Y=DNR^\RHSLR,2."=I'3CTJGXVU2]TOPM>-I<;
M2ZK/&\5G&O4R;2<C_=56;_@- '0T5Q'PH\5_\)=X!LKF:3?>VP^RW1)Y+J!A
MC]5*GZDUY_XIO_$_P_\ &=SXILKR^O\ PTEY]ENK"6Y>18@41C@,3C);Y3V(
MQT." >[T5R&C7&F^(?$']K6%Y<SV5UIL<D:K<R"/+.X)V;L!N,'C(Q7GOPN@
MNO$VL^-;+4=:UIEL[I8K1TU*=6@!:4?+\V#]U>N>E 'N-%>7?"3QGJNLW6N>
M&]=G%SJ&CS&-;K: 94#,IW8[@KU[Y]LE_P 6/&>IZ/<Z+X9T*86VIZU.L7VG
M&3"A8+D>Y+=>V#WP0 >G45RDG@:WAT66VT_4]5M]1,1"Z@U]*\ADQ]Y\MAN>
MHQCTQ7&>(_$>JWWQ&\._#RUO9K.$PI)J4]O(5EDPA<HKCE1A>HP3N]J /7J*
M\H^*-U>?#VPTOQ)H%S<1B.[6WNK.6=Y(;B-E8\JQ.&^7&X8/-5_B-;^(-9BT
MG7_!NIZA;7'V!M1-K%</MN$4Q$#9G:6 <\8^;ISQ0!Z_17F'A_QC9?$31-$O
M!-/;:A#?1PWUM!<O%@['/(4C*-C(SZ8[&L;7);IOVB=*T0:EJ2:9=6AEEM8[
MZ9$9O+E.<*PQRHZ>E 'M%%>1V_B/4_!_QFB\(W-_<7VBZI$LEK]JD,DMNS!L
M .?F8;D(P2>"/0YK>&;F\E_:'\0Z3+J.H2:=:6IFAM7O)6C1OW/.TMC^)N.G
M- 'LM%>&?%^SOO!O@33)[#7-8&HR7P2XN?[1GR^4=B -V ,@8 '0"O2&\-):
M+<WT-_J7DRZ>\<D$E_,X#\,KJ68E3P0<'T]Z .KHKPSX7>++O3?A#XA\4ZI=
MWFHW5G<R)']JN7DS\D6Q?F)P-S=1ZUU'PUL;CQ;X,7Q!XAO[VZO=3>1EV7,D
M2VZ!R@6-4("_=)R.>>M 'I=%>0^ /$^H:Q<>*_!>MWEQ=3Z2TJP7JR-',\:L
M4Y92#N!"G/7GVK#\(^+-<\ >)H-"\9:A<7NCZQ$DUGJ-Q*S>66 _B)) Y 89
MX.#T.2 >]45Y=XHN-6T+X9:]?:'+>RW0OY@\AN'EDB@$Y4["Q)7"C&1T&3VS
M3_"&O^&O%MUIEQX9U6ZL[JVD\R\TRXN7)E38P.58D,02#N'IS0!Z=17/^./$
MG_"(^#-2UP1B22VC'EHW0NS!5S[989]JYCX?:3-XE\#0:SKVHZA<ZEJ@>4RI
M=R1>0NXA1$%("8 !X'4T >CT5X_X \7:EKVB^*_#FM74L]_HHD2.\1S')(HW
MJ"2I!W KU[Y'UK&^%FKZ?J_@Y8_$.O:E/J]WJ9M+=!J\Z3%2J8( <<#+'..U
M 'O-%4-'L)=/T.TL+FYDNI8(5B>>1RSR8&-Q)Y)/K7COA*Z2[^)OC;3M:UV_
M33;.1Q;K+JLT2PC>1\IWC&!0![C17E7P;U;6M?TK7(=5NKJ^TN&Z\O3[V=F$
MDJ9;(W\$XPAS_M&N1^&&NVM];:I!XBUS4;F[EU.&SLH6U>=)"';:=H#@D#.2
M?:@#Z#HKR[Q]+K7@KX;6:VUS?7T4&H 7UP)V,[6AD=L&3J#C8A;MFKWA#5_#
MWBB_LM0\+:Q.D<"O]LTN:=\@%2 Q1B>0<<KP<]20* /0Z*\(^*]G?>#/#?AN
M.PUW6?M<MQY5U<'4IR9CM&>"^ ,YX&*](U/PXNFV.N7MMJ&I"&33G A>^F?R
MI$#$.A9B5)SS@]A0!U]%?._A[6/-^!^I:SJ'B;4HM;AEE^RS'5)1(S#;L79O
MPP)XQ@]3787^J:]>?L]/K&JRW5IK26GF"6)V@DXDPK':1R5P?QH ]8HKQBW\
M;W7A'X!:;KQFFN]6O<PQRW4K2DR%G^8[B> JDX]A77^$O"2S^&K*_P!9U#4K
MS5[R!9YKDWTJ%&<;MJ!6 4#..!0!W%%<C8>#KHI8KJVM:C="T^TCY+R2(S[Y
MBR-)L*Y*I@8Z<FO-OA79WWC+1/%,%_KFL_:8KCRK6X&I3@P9#8(P^#SCKF@#
MW>BO$_B#?S:;\8_"]G)K%Y9Z9<PJUX@OY(8F^=P2<, .@]*[SPQ86=_=#7]*
MU&^ETNZ@GMC!-?RS1N5EVK*F]CC(1NG8CWH ["BO$/AQ#<^(O&?CK3=0UC66
M@LKLQVFS4YU, \R4?+A_11USTK<^%7C'5M0UO7_"6NW)O+S1YG6*[( :5%<H
M=V.I!QSWS[4 >IT5YG\6_$EWX;G\.W$T-W)X>:Y<:F+5RC-\H\M2P(XR6.,@
M-MP:N:&=,\4VM_=>%/$<YLKG3Y;7R?M#EK.9L;756.Y#C/M\H(ZF@#T"BO$/
M'4,^A_$KP3H]AJNL)97DJ)<HVISL9AYB@[B7ST)Z8KH?'NKW'PO\):GJ&G7=
MS<2ZA<QQ6:WD[S_9G*'<07).,(2!GJ?2@#TZBN T_P +37/PZBGFU74VUV>R
M%R;_ .V2!UF9-PP V-H)QMQC KC--^,]\/@W<ZU<I')KEO<BP1RN%D=EW+(0
M/]D,2.Y7MF@#W*BN%\'^%!=>&+'4M:U#4KW5[Z!+B:Y-[*AC+C=M0*P"@9QP
M*YGXG0:MX8^$I<:U?MJ,%^VV]CN721XWE<J&*D9.TJ/3CB@#V"BO,M URU\6
M^'[/PMI.KN;U-/@EU&]%TYFA+*-VPYW-)G.3G:I(SD_+7H>G6$6F64=I"\\B
M(,;YYFE=O<LQ)- %JBO&M3N;P?M(:9I"ZCJ"Z;/:F:2T6\E$;-Y4ASM#8ZJ#
MCIQ7H5_:+)XYTIC-=*K6=R[1)<R+&S*T(4E <' =NW>@#HZ*\%U_4_$WP[\8
MR^)XKR^U#PN]X]K<6<MP\H@&1TW$X]5/J-IX//INBR:?KGB*[U.QO;BXLKC3
M;:6(+=2>7EWG#$)NPK?(H/&1CMS0!UM%>(?"LZGX@N/'ME/K.I-)$YM;.66\
ME?[-N\Y=RY;@C"\]>*/'4,^A_$KP3H]AJNL)97DJ)<HVISL9AYB@[B7ST],4
M >WT5D:-H?\ 8MQ?^7>W<]O<R+)''<W#S&$[<%5+DG!(SC/<UY]XL\3ZCK?Q
M8TSP!IUY-8V>WSM1GMW*2N-ADV*PY4;0.1S\WM0!ZQ17)ZQX,633"FA7M[IU
MVA!#)=R%90",HX)(.1D;NH]>N>'^*%Y=6/Q0\&6\.IWUK9WTZK=QQ7DD22+Y
MBCD!@!P3S0![)17C]KK%_:?'2VT7P[J=WJ.B26F_4(9+E[F.V?#\AV)*]$.,
M]6Q7:_$75K[2_!E^-)1Y-4GAD2W5#\RX0L[C_=56(]]H[T =717(_#;Q0/&/
M@.PU"1]UTJ?9[OGGS5X)_$8;_@5>9ZWJOB;X<^,'\2K>7^H^%IKR2UN+26X>
M46^&Z#<3@]U/L5/N >]45Q,,-MXFO=7N-)U:[6&_TB!K:>*ZDVQ-*TZET7.%
M;Y5[9!7MS7#^-(I]&^*W@W1;+5-7CL+O:MQ$=3G;S?GQR2^>GI0![=163HFB
M?V+)?JEY=W%O<3"6)+FX>8P_* 5#.2<9!.,]S6M0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B^+UDD\'ZQ
M!##---/930Q1Q1EV9V1@!@>YZ]*VJXS6_AQ:ZYK%QJ4GB/Q):-,03#9ZAY<2
MX4#Y5VG'3/U)H S?@MIM_HO@*/3-4L;FSO(KB1VCFB*\,<@@]#7-C2;S_A>^
ML:Y>Z%J$^A75I]G\W[&[J_[J-2"N,XRI'2NF_P"%1V7_ $-OB_\ \&O_ -C1
M_P *CLO^AM\7_P#@U_\ L: -33=4N6@O+&+2-2M]+TZQ2&&2XMR)+IR"/E4<
MX 4=ARWM7DOA;X67NL?"_4-)U'3;C3O$%O>O=V$LT13(V(-N_I@E2,9X.#VK
MT;_A4=E_T-OB_P#\&O\ ]C1_PJ.R_P"AM\7_ /@U_P#L: *^D:UXAU'X9W-I
MX@T/4X];BC\@J+9F-STPX(XSCKD]1[BF^(_ $FN?$_0?$UGYD5F\3)J0*E"Z
MJORJRGD[@=A!["K7_"H[+_H;?%__ (-?_L:/^%1V7_0V^+__  :__8T 8?\
M9>I_\-#_ /"0?V7?_P!D_9O)^U?9GV[O*QZ9QGC./TK:U.TL/%&G7]AXS\,W
MSO#=7"6=S%9M(SQ>8VQD:,$H<8X; . >0:=_PJ.R_P"AM\7_ /@U_P#L:/\
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M9V ;9(.!C)&6'(K?_P"%1V7_ $-OB_\ \&O_ -C1_P *CLO^AM\7_P#@U_\
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M=:\+:5=Z9<P7@GU&4VKVT7E#DC#  NW*_)G.3GUK;_X5'9?]#;XO_P#!K_\
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M,FO"]&\#/KOCGQQ'KNCWL.FZP7^QW4ELPPWF95P2/E/0\XST/I79?\*CLO\
MH;?%_P#X-?\ [&C_ (5'9?\ 0V^+_P#P:_\ V- %+X7S>)?#5K=^%_$NG7C6
M^GL18ZA'"TD<L8/W?E!/NOL<<8 KF_AAH=SHMCJ\7B+P]JD;OJ,-]:%;)G.8
MVW#! .#D =N":['_ (5'9?\ 0V^+_P#P:_\ V-'_  J.R_Z&WQ?_ .#7_P"Q
MH O/K^OSV=E?'P[>FVN-0DBGL6C7S8[41L [ G&=P#8SR&P,US4'@6Q_X6IH
MNO>%=.NM,M(%E?4B]N]O$V5PJHC@')R<X&T #OUU_P#A4=E_T-OB_P#\&O\
M]C1_PJ.R_P"AM\7_ /@U_P#L: ,;XXZ-JNOVFB6^D:9>7LEO=&:7R820JX Z
M]/PKT779O/\ "NH-##<2--:R)'$L+;V8J0!MQD<^M<G_ ,*CLO\ H;?%_P#X
M-?\ [&C_ (5'9?\ 0V^+_P#P:_\ V- 'G>B?"Z_U7X4FUET^XT[Q1IMW)=6;
MR1F-G&%.W?TYQQSP0.@KL=2U#Q%XF^#&H6&IZ%J,/B!X! T/V9OWS!A\ZD#
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M$:L 5/B"]!!'!&X5BM!J!OOB3>6.KW.GR6<XN(_LZIEW6V5AN+ Y7CH,=^:
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MM);)8V<;C#+"K%V9AV+.>G4!1GDD"UKWAR#Q!)ISW%W=0?V?=+>0B H 9%!
M)W*<C!/'O0!REI?:EI>M^,]);7G,-I80W=K=ZD5<6SNLFXL0!E05!QVI-'U+
M4(_'.F::EWJ)LK[1Y)G>[.3)*C(!,BMDIG<?E( _V:W;[P+IVI7FLW%W=7LH
MU>V6UN8MR!0BYV[<+D$9)SD^^:;;>!;:WU33M3?6-7N+VP@:W266=3O0XX8!
M0."HZ 9_BW4 <)/J?B"/X8:GXD_X2*_-_IFH3+$/D"2*MQLQ(H7Y@1QC@#C
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MH?LZS3[!Y<><E55%4#)P2>2<#F@#S7PQJMUHGPL\*_9[RX$^MZG'8--(^_R
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M$42[5W,6)]R3R2>I)Y)J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!&C1]I8\G!)QFI-?>2X\416*W]W(#8.XTZQD:&16+@"=Y0RX4#*@'J<X!QP
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MSCJIX&XC'3GG)YK6L_#MO9>([[7$N;I[J]1(YE=EV%4SM  4$8R>_?G-;%%
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MA2N>0>2I(SV[8J=O!EFRZ&IOK[&BX^R?,G&%V#=\G/R\?_7YKHZI:E=7MI'
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M>F[G_P"MQ75(I6-59RY P6;&6]SCBG44 <Q;^!-+MK:2PBFNQI#S^>=,+J8
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MTNWACNL<#S%4_-Q],]ZT1X:LU\1?VY'+<1W@M?L:[6&Q8<[@H7&.O.>OX<4
M>73SZK%\*=6UO^WM6:_T2]FBM)#=, 5CGV@2 <29'!WY_"NOO+N]U_QEK6AH
MQ6*QM8#&B:C+:-F0,3(#&I+8PHY.!CIS6FW@+26\.WV@M+>-I][,T\Z&499F
M;<WS8R 6YX_QI=9\":5K=[:7\UQJ%OJ-M%Y*WMG<F"9X_P"ZS+C(H Y:>'Q!
M;:IX$TS4?$4\MS-+=V][+92[4FV1.02,?>&,$GH1GKS6=JZ3+X2^)>BS7U]<
MVNF8>U,]T[R('@5RI<G++D]"2*]#E\(Z:]UI$Z-<0MI.XV@23A2PPQ;()8D$
MY+9ZD]233?\ A#=+9M;\XW$RZVNV^223A_EV C &TA>.* +OA^VCM- L8XVE
M93 C9EE:0Y*CNQ)Q[=*TZY*Y\&HLF@)97>I*=,G$@F>\8AD!7<K@GY\JNT#H
M 3]#UM '&7D]VGQ<T^T6^N1:3Z1/(UN)/W8=70!@O3.">3FN'N9M4B^&_B#7
MAKVK&_TK59UM6-TVT*DX4*RCAP1QAL@=@*]4G\.VMQXCAUUIKE;V&!K>,JXV
MK&Q!(VXYR0#D\\5G-X"TE_#]]H;37C6%].UQ<(91EG9MS?-C(RV#@>GUH IB
MY;Q'XXU[0[F[N;>'3[2W\B.VG>%F:4,6ERI!.,*!V'U-9OB"VN+-/ %K=ZD=
M2N(-;2*2[*A3*RQR@D@$\C&#SU%=!J_@;2]8U"UU&6XU"VU&WB\G[99W302R
M1]=CE<9%6;WPGIMXFE)F>%-+E$UJL4F K@$!CD'<<$]<YR<T <W9W%T^M_$.
MR:]O#!:) UL#<OF$M;[SL.<K\W/!JAH>NWNJKX$T6ZO;@+?Z2;Z[F$K+)<,J
M+A-X.[J2QP<G [9SUU[X*TN^UB\U)Y+V*2]A6&[BAN&2.X"@A2ZCJ0#CTQU!
MJO)\/M#?2=*L(S>0'2CFRNHKEA/#Q@@.<\$#!7I[4 <K8VKZ???%".UO+M'A
M6*2*8S%I4(M=P^<Y/'09["E>YU*YT_X8%=8OX3J$,:71CFYES:EB6SG)SW.?
M7K770>!]+MSK#I/?M+J\:QWDCW3,74)L[\ D9YQD9XQQ3AX+TY8M$C$]X%T4
M 6/[P?N\+M&>/F^7CG/% ',65QK6G/\ $'2=)O+J[FTY(I=.^V3&9T>2#>1N
M<DD;AD G%+IWVS4M?\*2Z3?ZLUB]F\NK;YY"H8*ICW;\@.7+ J.2,]@*UO$?
MAD6FD^);[3;6ZU"^U>%8KJW\X#S5 V97I@JA; !&<<UCZ)I,CWUI)H]YXV@>
M*6,R1ZM*XMQ&&&]663[V5R!MSR0<@<T >EUYIXSN[D)XNGLM3OI[BPL5DB2V
MF:"/3F6,O\Q#?O';[V-IXP#@&O2ZYB_\!Z+J%]JEU,;Q?[5B\J\ABN72*7"[
M Q4'&X#CT]J .?O)K_4?%W@V%M6OH(-2TN>6ZCMYO+5F5(SD8Z'YSSU'8BJV
MFV.L:SX1\7:/9:SJ*WNF:M/!IMR;M_- 5$=49\Y898KSG@^PKKK?P9IUK>Z5
M=Q3WOFZ7"T%L7GWX1@ P.0<YP.O3 QC%0/;6_@BVO;^RL-7U1M0O!-<0VJK*
MYD?@R;3C PH!QQTXH I>'=;3QC<:->6DMS#!:6?G7D2SN,3,=@B?GYMI24G=
MSPI[UVU87A71UTK3[F5K1+6ZU&ZEOKB)<':[G(4D<$A0H..,@D=:W: . L%N
MO&L7B<#5[S3[VSU.6QM7MYF46PCV[6*!@'W').[.0<=!4UE?/XA\<ZIHMU>S
MFTT[3[9XOLT[0?:'E!+2Y0@D#"@#.!DUH7O@#1;W7IM7W7UM-<@"[BM;MXHK
MK' \Q5/S<<>_>K]]X8L;O5H-5ADGL=0AA-NMQ:L%+19SL8$%67/(R..V* /.
M3K>LC0XH9M1NVGTOQ='I2W2RLK7,'F+Q)C 8X;!R.WKFNHDENF^*.JZ:M_=I
M:OH,=P(UF8A)#,ZEE!R%.% XK:O/!VCWGAUM$>*5+8R^?YD<I$HFW[_-W]=^
M[G-0VW@K3;757U5+C4&OWM/LCW#W3,S)DG)SP3SW&!@8 Q0!Y]IESJ<7@GP+
MXB;6]3EOKK4;6WG$ETQCDBDD*LK)T)[[CDY[] .AT'2X7^)WCDK/>1LJV95D
MNI."\3YX)P?8$$+VQ6XO@/2ET+3=&6:\6RTV=;BU02C*.IRISC)P<G!]?I5T
M^%K#^WKG6HY;N&]N8DBF,<Q"OM!"L4^Z6 ) R/PS0!Q'@S0=0\2_#NRU6;Q/
MKBZG=6,L:.MZZQH^\[7*CJ01USR"1Z8T/#&L3>)[/0;%IKJ"]T\N=71;APRR
M1?N_+<YR=[G>,YR$-;\%I;> O"7D:;8ZEJ%K:8\JT@ FFPS<A<XR 23R>F:=
MX8TL6\FIZQ)8?8KO5[@3R0L!O1%4(@;!(W8!8^A<B@"*W\476H7-Q9)X?UG3
MG$<FR]OH(U@4@'!)#DX_"N;\+:E-)KEOHFN#6-*UX64B.DMRTL%Z?ES-$Q)7
M<,$X ! <CMQZ+<V\=W:S6TN?+F1HVP<'!&#6/!X?L]-EMKZ>>]O7T^%H[7SC
MYK0JP ;:%7<Q( &3N/YF@#RQ)-<C^#NG^-X_$>JR:M: 3>7)<$PS+YQ4HZ=&
MR#U.3T P, =9++JOBW5?$]A;3&WEL)4MK8IJ,MNUN3$KB0HBD/EF/WC@A<8Z
MYC^''A;?\/\ 1[/6$U&/[,YDDTZ[0H@D60LI(90Q&<-C)7/:NAU?P'H^L:X-
M9,M_97S((YI;"[> SH.BOM/([=C[\"@#'TZ\OM2\66_AK6-1\QK31DN96LIF
MA%U,9"C/N4@X&WH,#+'C@8K^(8=3T'P]X<MO^$CO+RXAUVUMYK@-L:6-Y<[)
M,$EL*5!R>>_6NCUGP-HVLO82XNK&YT]/*MKFPG:"2./&-FX?P^W^)J6]\'Z9
M>Z98:>S7,=O97"W,6R4[C*IW!V8Y+'<23D\D\YH YW5=,@G^,VDEY+L>9I5Q
M(=EW*F")(P,888'J!P>XK/OO$6IZ!/\ $NZBNI[EM-2V:T2=RZPEX<G Z !F
MSCVKN)_#5K/XCM]=>YNA?6\)@C(<!0AP6&W&#DC.>M,A\*:;%?:Q=R>;.=84
M)>QS,&24!=@&,<87CC\<T 5;+16@U32M3M?$%VULT#)-!/,TJ7I9<JXW-A",
M%OE'(XX KIJYOP]X(TOPU(K6<VH3+$"MO%=7;RQVRGJ(U)POIGKCC-=)0!YC
M::1J'B37/&=A)XEUFW6SNXUM#!=&/RF:%6SQU4$_=X'7.3@C,TO5M9\21?#B
M6[U6^MGU2.\CO!;R^6)?+C8!N.YQG/;.1C K<T#1YK[Q?XRDF;5[&WO;F/81
M$T27$8B53AF7@YR,J0WOTKJ)O"6F2WFCW,?G6YT=2MC' P5(@5VD8QSE>.:
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MV1)('NY)+>]7*YFCD#?>XYZ-A^2<5@0Q/I_[.%K?V5W>VUSY,+[XKJ0=9@I
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M%QG;CH30!ZM5+5+B_MK5'TZP6]F,J*T33"+"%@&;)!Z#)QWQ7FGBW3M8\/\
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M8.8!)D^4.>2*V==TFXNOA^UE<:]/::K8VJE[ZVG>,B8*#E@AY#'^'G[W'.*
M.NN9)(;662*+S9%4E8]VW<?3/:LOPGKW_"4>%K#6OLWV;[7&7\G?OV<D8S@9
MZ>E8/@+4)-;T^_U2_>>+5PYMKRP:5]EFR #:$)Q\V-V[ONZ\5Q&A02Z9\._
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M:R)+O,R;02S#'RG.1BKM '/V7@O1K+1KW2S'<7,%[&8KE[JX>621,$!=['(
M!. ,8R>]:>E:7;Z-I\5E:F8Q1C ::5I'/&.68DG@ ?05=HH H:SI%KKNE3Z;
M?>8;6X79*D<A0NIZC(YQ5.[\*:7>Z99V$ZSLMBZO:3><PE@91A2K]>G'/7OF
MF>,/$O\ PB7AJZUDV$UZEN 62-U7&2!DDGID]@?I5K7=;@T*PCN)4:62>:.V
MMX5(!EE=MJJ">G/4]@": (6\+Z=)8:A:R^?)_:*;+R9I3YLR[=NTL.@P2,#
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MAZ':74PMM:N+F>?[;<R2+)*D:;8\[L@-DMMS@D>G%9'BW2-0\/> _$B'796
MN;>XM8+>61#:*\JJR9+$LA^;"G@<\5Z'K?A?2/$>E)INK6IN;>-@\9:1MZ,.
MC!P=P/OFJK>!M ?P^^AO:RM8R2"253<R;Y7!!!=]VYONCJ>P]* .=GC?PY\3
M$6PENY4N]%N+B>&:X>02RQNNUL,3@\D<8&#TI?#-G!X@\)^&_$SZQ<0WYDCN
M;FYCD_U[$E7@8'C9N.T*!Q@8KK3X;TUM;MM89)VO[:(PQ2FYD.$/48W8.<#.
M1SBJ&G^ O#FE:N^IV5@8IFD,PC$SF%9#U=8\[ WN!QVQ0!R5O::AXVT[7)X]
M5BL=0M=3GA2YW2>99>5)A  &  * $CH=QS7IEHS/9P,\BRLT:DR*,!CCJ!V!
MKG[WX?\ AJ_UU]9GT\_:Y<>=LF=$GQT\Q 0K_B.>^:UDT6Q37Y-;6-A?R6XM
M6?S&QY8;<!MSCJ>N,T :%07KP1V%Q)= -;K$QE!&04 .>._%3U%<V\=U:RV\
MPS%*A1QG&01@T >3ZEI&M_#'39M8\-WZZIX40>;<:/>-N,43'DPOZ<]#_P"/
M5TEO/Y_Q=\M))A:77AP7#0,YVEC.!NVYP&V\9K8'@G11;169CNFL(BI6R>[E
M:#Y3D H6P5&!\I^7VJQJOA;2M8U*UU&[BF%W;(8TE@N)(BR$Y*-L(W*2.AXH
M \N=YKOX>::DMU.S#Q>L22M(6=%%T0N"V>@QBNGMM+;P]\4+;3=.N[Y]-U73
MIY;NVFNY)?+=&4"569BRD[L=:Z&/P+X=BT>72DL"MG)<?:B@F<%9=VX.A!RA
M!Z;<8ITUO#X;>.[M=+U#4[BY=8)YUD\Z5(P"027;.T'LO<DXH \^TK6KRT^'
M_A^%[Z0+?Z_-9SW-Q*Y.SS9BJL^=W)15SGH36AXBBU7P-HOB/5+;5HTAN(83
M%90JQ%H3(D;RIN)QPY.,8R,UT&@>"[8^ %\/^(+2.X2>26::%C]TO*T@ (/!
M7<!D'J.#6II?@[0](TNYTZ"S,EO=)LN!<R-,TJX("EG).T G Z#)]: *L?AO
M38M6M[RWU"X2VNK5K9[03EH[O(W"0DG)8 'YLY(/6LKX/6D-O\-=+FB4AY5D
MWY<D'$K@8!.!^%;WA_P;H?AAF;2[:1&*[%,L[R^6F<[$WD[5X' ZX&>E6=$\
M.:7X=AEATNW:"*1RY0RNX7))PH8G:,DG P.30!S'Q9M(;GPE;-*I8QZE:;?F
M(QF90>GL3^=*K1WWQ*G\-70?^S;+24N(+9I&VRL\A#.><MMP ,YQD]ZZS6=&
ML-?TN73=2@\ZUE*EE#E2"I# AE((((!R#52X\*:3<R64QBFCN;)2D%S%.ZRJ
MK?>!<'+ ]3NSD\]: ,;X?W-[O\1:5<SRW%MI>J/;VDTS%V\LJK!"QY;;NQD\
M]*U_%FD:3X@T8:/K&X07DJQQ,C;624 LI4]C\IQ^7>M+3].M-+M?LUG%Y<>Y
MG;+%F9F.69F.2Q)Y))S46K:-8ZY:QVVH0F6*.595 =D(=<X(*D$$9R.>M '!
M:5=>*/!GBK2?#^NWB:YH^H2/%8W[KBX@=4)VR?WN,C/7KSVJIIEOJ7C#PHNO
MQ:S!I^HQ7<DLEV3(7M_+D.8F7<%V;1C;C&#GDG)] M?#>GVVHQ:@QN;FZA5D
MADNKAYC$&Z[=Q(!/0GJ1WJA_PK_PT-?DUI=/*W<L@FD59G$4D@.0[1@[2<\\
MCKSUH Q+&%/&E]XPL[^[G@N[.\-I:F*0JUI&(U*2H,\,6+'=WQCH*KC3;.?X
MN:+(TTEVS>'W<W)D(,Q62,*_! YZX''/2NFU3P)X=UC6?[6N[)OMC($E>*=X
MQ,HZ+(%(#CZYXXZ5=O?#6DZAJ5EJ%Q:G[39*4A>.1HP$.,H0I 9>!\IR.* /
M.+_6]1\/:-\2[RQN+B2:SO(EMVED:4PAXXP2-Q/"[RV.G%;?B"$^'=3\(W^A
MS3$7NHQ6%TAF9Q=0R(Q+ODG++MW;NO7G%=5:^%M(M)=3DCMF<ZH2;Q9IGD6;
MC'*L2.G' Z4W3?"NE:4]LUO'.XM%*VJSW#RK;@C!"!B<<<9Z@<=.* /-)]/-
MQX3^(EW)J&IM-I>I7;V3?;I?W+)#&RD'=D\\<YP.F,G/K.D3R76BV%Q*=TDM
MO&[GU)4$UECP7H:V6IV8@N/L^J2-)>(;N7]\S##$_-QD  XQP*V;*SAT^RAL
M[<.(84"1AW+D*.@R22?QH Y'XM_\DKU__KBO_HQ:T?&GARX\2:/:QV-S';:A
M8WD5]:22@E/-C/ 8#G!!(XK3UO0]/\1:9)INJ1/-:2X\R)97C#8.<$J02,@5
M8:R1K);437"H!C<LS;R/]\G=^.<T >:7L^LZK\0I+]H+:-_#NCW!E-I*TJ"X
ME7Y8]S*N3@!L8XX]:=8ZK<>'_P!G>UU/3W*W":>C^8!N*,[@._N1N9OJ*](L
M--L],M/LMG;I%#DL5')9CU9B>6)[DY)K&T'P^FDZ3<>&Y[=;C209/L^X!E,+
MDDQ.#W7<0.Q7'?- "6>A6%GK6GZK8:G<1Q2VYA,'G%TO,C<KL23E@ 3NZGUK
M)TF22+XS^([>//D3Z9:SRCMY@+*/QV_RK9T+P;H7A7S)M+LYE8(50/.\I1.N
MQ [':"0.!C.!GI4NAZ,]IJ.J:Q=J!?ZG(A=0<B*)%VQQY[D#)/NQ[ 4 4_B+
MK-[X?^'^L:GI^1=PP@1L!DIN8*6_X"&)_"L7Q!"?#NI^$=0T.:8_;-1BL;E#
M*SK=0R*Q+ODG<R[=V[KUYQ7>W%O#=VTMM<Q)+!*A22-QE64C!!'<8K*TWPKI
M6E/;-;QSL+12MJL]P\JVX(QA Q...,]0..G% ',>&M*M$^*_C%U1]T,=@Z?O
M7."R29SSS^/2N]G@CN;>2"4%HY%*L 2,@]>16;9^&],L-:N]8MTG6^O-HN)&
MN9&$@4$+E2VW@$XXXK6H \-M[.&']G.UDB#))-<0;FW$]+T 8!R!^5=9+YGA
MKXDWD>GR74L4WAZ:]D@FN'E$D\<JA6^8G!()'&*W_P#A7_AO^R9=+%E,MC),
M)C"MW,%#!MXQ\WR@,2VT8&><5HCPYIO]NQ:T4G.H10?9UE:YD/[O.2I7=@Y(
M!Y'6@#B-#TZ^UG1O#'B>WUV"WEW0S75P#(S70?AX7!;;RQP!CY2  !7IM<SI
MOP_\-:1J[:G8Z>89C(91&)G,2.>K+&3M!]P..V*Z:@#S+1;;4KKXE?$2+3K^
M"R=FL5,DEL967-OP5^=0".>H--U[PU9>$?"W@[1K!I'A@\1V1,DARSLTA+,?
MJ37;Z=X7TK2M7O=5M(IUO;TJ;F1KF1_-VC"Y#,1P#@<<5+K.@:=KZVJZC'+(
M+6=;B'9.\>V1?NM\I&2.V: //_&TOG6_C2ZLKBXNKFPM482F4Q)IKK'N"Q$9
M+.>&/ '(!;M5J]BDU/QWX3BGO;T0WVD3R7,45RZ+(0(^P/R_>/*X)KIKSP)X
M=U"\U"YN;)W?4(A'=J+B0)-A=H9D#;2P'1L9'4'-30>#]%MKW3[N&"=9]/B,
M-LWVJ4[$/48W8.<#.<YH Q_ANTD=IX@L#--);Z?K=S;6PED+E(@$8+N))(&X
M]:[6N0U7P!H]UH6I:=;VLI_M&X^TR^9>2X\[(/F'YL]AP.N ..HZNWB,%M%"
M7:0H@7>YR6P,9/O0!QM]YB_&'3(A<7'DSZ/<,\7GOLW!XP&"YP#@]1BN%N[>
M6/X9^)]:&HZDVH:7J]S]CE:]D/E;)P!QN^;CCYL\5ZY/X=TZYUZ+6Y(YO[0A
MB,,<JW$BA4/4;0=O.!V[50/@7P^VBWND-;3FPO9C/<0F[E/F.3DDG=GD\GGF
M@#HE.5!]17 ?V;:O\=))6C;?_8239$C#+BX(!Z], <=*[V&)8(4B0N508!=B
MQ_$GD_C6;>>&]+O]:M]8GMW-_!'Y22I,Z93.[:P4@, W(R#@\T >1W-IY/PX
M\6ZY#<W<5_8:Y=RVKQ7#HL3"X'\((!SR#D&NRNY9O$7CG6-"GD@$5K8P/!;R
MLZ[@^[?(NTC)!VKGM@8QDYW#X%\/MHU[I#6TYL;V8SW$1NYCYCDY))W9Y/)Y
MYHUGP+H&O2V<U_:RM<VB>7#<1W,D<H3^Z75@Q'U/<^M %GPI9WFG^&[2RO\
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M/ 0,?(RD$<<$=#WS3)O"ND7&E7NFS0226]\<W9,[^9.< ?,^=QX &,XP,=*
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M^<$YQ^'3MBF7>H77A)_B-#I<]QY%C;6EQ;++*TWD/*K!V!<D]@V/45VZ>!=
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M9^+,B7EI'9V'B>'=&D<WF*+N$<\[1C<A_$BK.K1R7'C+Q#;ZI;7%]:/ID/\
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MI*9+>G'6@!SEQ&QC56?!VAC@$^YP<?E6#X-\03^)_#RZE<VT=M*;B:$Q1N7
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M(4AMX4"1QH,!5'0"LJ7PCH<UW=7#69!NV#W,232+%.P[O&&V,?7(.>^:VZ*
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MG[W)QQDYXXZ5T%% &.GA;1DGU*8V?F-J:A;T2RO(LX P-RL2.!P..!Q5*T\
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M77@GP[?7UQ>W6G"6>YA$$[-*Y$R ;1O&[#$#HQ!(]:<G@[08TTQ([)D72_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !11G-&: "BC(-% !1110 44 @]**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,YHH **** "BBB
M@ HHHH ** <C(Z44 %%%% !11GG'>B@ HHHH **** "BC.** "BBB@ HHHH
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ME)*@D$$CH>U "T444 %%%% !7GNAW'_"<>,/$;Z@3)I.CW7]GVUD2?+>1?\
M622+T<YP #P!VSS7H5<!8Z9J7@KQ?K5W;Z=/J&AZU,+MC:X:6UG/W\H2"RMU
MR,D=,=Z .@30[/1=8.L03FTL(K.5)K;S"(4^9&\Q4^ZN K9QC/%5_P#A-K2,
M:9<75C>6NGZI(L=K>2A=A9QE P#;DW=LCZX-2:O;7GBOP]JFFK;RV%O=V<L"
MR7(PY=EP#M!.%'?/)]/7F9]+U;Q)X)T?PS>Z7<6=Y;S6RWDS[?*1(6!+HP/S
M;@O '(W<XQ0!NS^.HTO=:LK;0]4NKG2-AN(XUC&592X927 (V@<?>.>!P<,B
M^(5A,-&N$T[4!INKR1PV]^Z(L8E<95"N[?UXSMQGN:J:?::A;^+/'%[)IMT+
M>_2W^R.%!\XI"48 9XY]<5B)HVLQ_#SP1IQTB[-YIFI6<UW$ N8TB;+'.<'C
MI@\T =)>?$&&"]U>SMM!UB]N=*9/M,<$2'"LN[<"6Y&,8'4YX'!Q;@\;Z=?V
MVBRZ7%/>OK$<DMJB +A8P-Y<DX7!(&.3G\ZP=$U)[+XC^.]MA=W.Y[,IY"!L
MM]G'RGGY2?4X'J15/3-!U_PSIOAC1WL+B^TM4N'U"&PE52)W?>JL69<QC<PX
M.#CGCB@#H9?B'IL7AJWUPV5^8)+O[%)&L:EX9?,\LA@&_O?W<YJW9^+UNM7O
MM)?1]1M[^VMA=Q02B/=<Q$E=R8<@'(QAB#R*X)- UZ+P'+I']@7"3Q^(!=)'
M&R%3$+CS"5YZ!<8SC/I78+:WK_%I=5^P7 T\Z+]D^T%0%$OG;]N,YZ=\8H N
M6/C6SU#PC'XBM[&\,$DHA2W(03%S)Y87&[ .[C!.:EE\/>=XUM/$*//"\=J8
M95\\E9 <X39]W@G)/J![U@:9X?N+3XCZC;12(=##IK'DCJEW('C*_P"Z=K2>
MS8KOZ ,"T\4Q7TL#6MC<RV<UU):+=(4*JZ%@2PW;@N4(!QZ<#-;]>9V_A^\C
M\366KZ)8W^CW\U]G5[;/^AW$.3NDQDKN(P1CYLGD=37IE 'GV@W/_";^,/$C
M:CF72]'NOL%K9,?W;2+GS)'7HYS@#/ 'OS27]P?"'Q%T+3+0L-%U])H7M-QV
M03( 0\8_A#!L$# [XS5K3M(O/!_B_6[V&TFN]&UJ1;IC;C=);3\[\IU96SG*
MY(/&.]2/HUWXE\=:7KUY:R6FG:-'+]DCFP))YI  7*C[J@ 8!P2>P'4 Y?PG
MXMA\)>&=0>?2-3N-/@U>\$]W;QAH[=?.(!.6#, ,9V@X'Y5T%\8)?B[X:N[=
M@Z7&EW3!U8D.N8]I'X']:S[+2]8M_"'B3PPVD3_;-0NKP0S-M\CRYV;$A<'@
M -DKC=Q@"M :)=Z=XX\*""TN)M/TS2Y;*2Z &T,1&%SSG^ YP.,T 6]'\0>'
MK.U\5:I'9SZ='97KG4GGY+RK&I+ !CU&T #&?2K8\91IK.FZ5<:3?PW&I1>;
M;?ZM@5&-VXAN"H()'/!XS7+_ &"X@T#XA?VCH\C0ZA=2S6T4[A!<*T:(H!!R
M"67@<'D4[1;PQ:WHT^NZ'XE6XM(A8VMW>0PF&)I"J$L8V)W,0J[B,?3)- '1
M#QW9%[67[%=BPNM1.F179"[3-N*\KG<%+*1G'X8YJ/3?%.H7OCG7M'?2IQ:Z
M=%!L97C)RPD8L?FS\V%  SC'.,UQU[IWBC4[#3Y]1\/7MQK%CKL5S/-YL?EF
M%920+<%^!MVYX7IDDFNKTRUU/3OB/K][+I<[V>I6UJR7$;*40Q(X93SNSDC&
M <^U "^'O$7A^R\')J&G6-S:6<U])!#:-S+)<-,RE0-Q&6?)ZX ] *U(/%,3
M:S-HUU8W5KJ26_VF*!]C?:(\X)C8-@D'@@X(^G-<';>%]>/@?3C%ITL>IZ1K
MSZHMG*RK]HC\UVVALXR5?N>HQ74R64^M>-M+\1&QNK:UTJSG4+,FV2:27:-H
M7.<*%/)X)(QGF@"*T^)=A=Z?I6IKI.J1Z9J%P+87<B($BD9RBAANW8)'4 @9
MQG.17;UY'!H6MQ_"31-&;1[O^T;;48YI8!MRJ+<F0G.<'Y3ZUZVK;E#8(R,X
M(P10!RDOB:_7XE)X=3396M!IQN6E5X_F)E50_+ A5PPQU.>G I]UXYLK73IM
M6%E=S:-!,89;^(*47:VQG"[MS(&R"0.Q(!'-5[RRU*W^*MMJT6G37-C/I)L6
MFC=0(7\[?E\D'&WT!Y[5S^F:)K6F_#?4O DFF337.RXM;2[&/)EBE+%9&;/R
M[=YR#SQQG- 'I\<B2QI)&ZNC@,K*<@@]"*\[^)2VR>(O!SW$@A@FU$Q7+>:8
MU>/83AB",C('6NZTJP72M'L=.5RZVMO' '/5@JA<_I7)>.++4+WQ)X3FL].N
M+F&PU W%S)&!A$*E>Y&>O09Z4 8^@ZRNE>.O$YL;V>Y\(6.GBYE?S&GC@N!@
MLD3$G^'<2H/!]*ZZQ\717>J0:=)IMW;W-U9&^MED*'S4! *Y#?*PW#@\<]:O
M>(3JB^&-0.@HG]I_9V-JK@ ;\<=>,_7C/6N(TK3M4_X3CP_K \/:A#%]@FM[
MN>[FC:42,4.YSN)QP<?H * .FL/&UGJ'AG4-<6PO8H["26*:VD"";?&<,NT,
M1NST!//'K71PNTD*.\;1,R@F-R,J?0X)&?H:X.7P_<1_$V2.UD3^R-02/4K^
M#N)X6VH1Z;SL8^OE&NO%_='Q VGG39A:"V$PO]R^67W8\O'7..<T :%%%% '
ME5F=&B^*WB^UU5E6UCBLVMXG9MB%HR7*@<#)P373V&KZ)H?AJ35['[3-8WMZ
M%MXDRQ:1F6$*FX\ LN>2 -QZ5F:4FI:=\2?%.K2Z'J#V.H1VJ6\L:H=QC0AN
M"P(Y/%6-<O/$DVBSOH^BW5K"E_$)(%9%N9H"VZ=X\-A2=V!R#PQX)& #8MO%
M]BTNMQ7\<EA+HR))>><5*K&REE=2I.00#[Y'2DB\317.K6>DWFEWUJ=1@>2V
M>55*NJ@%E;:Q*-@@X/\ /BN'F\(ZIJMUXVLH='FTZVUJPMA:S32(0'C#Y$F&
M)W%B,]>,DG/!Z_P[KWB'4HX(M3\.7.FR6Z?Z;+,Z,DC!<8A"L2V3@Y(  XY)
MH Y+P/XJ@\,^";;[3IU_)8#4[B"6]0+Y<!>Y95W;F#,,D9*@@9]>*]8KR)]"
MUMO@]=:(-'N_[2DU$S+!\N2GVL39SNQ]T>O6O6T;?&K[67< <,,$?6@#SCQ\
M+&'X@^"C>S);V=P]V+MGE\M) L0*[SD X/3-2>"9KB;QWKITBXN+CPCY"&"2
M21I(OM.1N$#,3E,9S@XS5SQ997]U\0?"%];:;<W%GIKW+74J 8021!5X)R>>
MN!2:-IFI^"O$EQI]C837?A>^)N(!"5)T^4GYTVD@^6W48Z'/'>@"_JGCW3]*
MM9-0EMKB32H;C[--?1E"L;;]A.W=N*A_E) ^F1S5RX\50QW&H1VMC<7BZ>Z1
MW30,GR,RJPX+ D!6!)^N,D''&Z'IVKZ!+=>'KCP='J/^DRO9:MB(Q&.1RX,Q
M/S KN.0 2<8'J9?%'AZ[O=6OM1T:QO\ 3?$L#QI9W]J<0WJ!5XF&=NT?,#N
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MEC$9/!VM( ,X![XR<9(!+X6D:3XL>*R]G-:2?8[3?'*P;)S)\P()&#Q_@*]
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M6;6>1+!_*L]2(&VZA'W2P!R' X.1@XS0!U4T,<\313(KQL,,K#(-<'\'%W>
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M#*1D$>V*DK-\/:5_8?AO3-)\SS/L5K' 7_O%5 S^E:5 !1110 4444 %%%%
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M^*KH:* .>_X0?P[_ ,^#?^!$O_Q5'_"#^'?^?!O_  (E_P#BJYWQ[:P2>.?
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M.>0#C .:KVGBZ*YU'7K*2REMY=%17G\UTPZLI=67!Z$ \G% '1%U#*I8!FZ
MGDT!E+%006'49Y%<E<:QI]QXI\*)J&A7,>I7<<\EE-*4_P!&_=YD4X;.XK@=
M,<]>*QM%LK8^(_B3:^0GD-) 3'C@YM@3Q]3F@#T965U#*0P/0@YHW+N"[AN(
MR!GG%<I\,?\ DF7AW_KR2L:_E;3?C3)/9Z;+=W,WAW_50;5+M]H'+,Q ' ZD
M]@.>!0!Z+17*VGCFUO?#VGZI!8W1EOKS["EJ0-R3AF5@Y' 4;&);T]SBD/C9
M%TG7+LZ5=-<:)*8[RUC96; 4/N0Y 8;3GL>O% '5T5BQ>(4N+31;BWM7E75<
M-&$=?W:%"^YN>@ [=R!WK'U'XBZ;IL OY(6?2A<_9GNTE3*G?LW^7G<4W<9Z
M]P",&@#LJ*;(S+&S(F]@"0N<;CZ9KFM.\:0ZEX;OM8CTZYC:SG>V>T=D\TRH
MVTIP<;B2 !GG(]: .GIDT,=Q!)!,@>*12CJ>A!&"*Y[5?%\6GO=0Q6AN;BRA
M6:ZB$Z(4R-P0;C\SX&<=.G/(IEGXVLM673AH\1NY+ZS-['&SB(B,$*1SU;<<
M8Z<')'&0!+'P+I^GQK;1:AJ[Z>@VI8R7SM"J]EQ]XKVVDD8XZ5TX 4    <
M"N*U#Q?J:^(?"EG:Z3*L&K0RW$B/(BR?+%N\L@G (+ DY[8%6=:\>V6D0W]T
MML]S::=)Y=W)'*@92,;MB$Y?;GGIWQG!H ZVD5E;.U@<'!P>]8,OB.WO;O\
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MZ, 593D$>H- ' ZC;>(-'\8VGB;3M&FU&VN=-2QO;))8TFA96+*XRVTCYB"
M?>I_$]CK^I6'A[4!IGFW5EK$5[-8PS)O2(*ZX#,0K,-P)YQG.#@9KN&8*I9B
M  ,DGM2(ZR(KHP9& *LIR"/44 >=RVGB#0?&.IW\7AE=9T_6?*F*QS1B2TG6
M-4927QE3M!R.E37>FZ]H_C?3?$T.EB_AETTZ?>VEDZ!K<^89%9-Y4, 3M/3I
MG%>@44 <=X&L=4LK[Q+)J.FR6:7VJ/=P%Y$;<C(BX.TG!^4^WH36QJ]YJUGJ
MNGR66G27MB8Y1=K$Z*Z'*;& 8C=_%QGH3Z '9HH X'1_##?\+ U'Q#9:8^D6
M5QIYMI8G"J;J8ON\S8I(& ,9."23QW.)9>%_$B^ _#,(TMH=4\-7D<PMY)XR
M+M5+!PA!(&5;@L1SG@=3ZS10!P>J^&KGQAKKW\]O/IULFD7%C'Y^WS&DG&"<
M*3\J@=SR3QP,F3PA=^+(-.L-#U/0/LKV"+#-J'VA'BF1!@&-0=Q9@!U  R3[
M5W%% 'D-EX8\3:1J>I>)M-TJX753K,\GV-YX@E[92LIVD[\*RD%@3^M>LV\K
M3VZ2O!) S#)BDQN7V.TD?D34M% '$?V?J7AWXAZOKD.G3ZAINLP0"7[,5\R"
M6(%1E6(RI4]1DY[=ZV+!+V^UV36;FPELX8;4V]O!*RF63<P9V(4D*/E0 9SU
MSBM^B@#R:7PYX@?X2:GH8T6X_M&?4'FCA,L7*&Y$N=V_'W??K74RV.I2_%*P
MU<:;.-/329+5YB\?RR-(K@$;L]%/('6NPHH \XTK2-5L?#.LZ-J'A@W]O)J<
MTAC:6(K<P2S[LH"PP0I)^;;R!CGIJ^!]"O=!NM5MXWO5T%C$=.MKV3?)"<'S
M IR2$SMP"<\'ZGLJB%U;M<M;+/$9U&YH@XW >I'6@##\;Z)-KWA.\M;3B_BV
MW-D_=9XR'3![9(Q]":YN7P9JC>(=)U,&,/J$+0^(,'(==PE51Z@$&+_<85Z+
M10!R/B#3]1N?'_A._MK"6:SL/M7VF970!/,C"KP6!//7 JIIFG:K;>(?&]W+
MI5P(=1,36AWQGS=L(C(^]QR.^.*[FB@#F_ %A>Z5X%TC3M1M7MKNUMUBDC9E
M;D=P5)!%4WL=17XK_P!L#3IFTX:,;/SP\>#+YN_&-V[&.^.M=A10!Y78Z7XK
MTSPQ;VT>DW80ZY-/?6L-Q$DTUJ[NPV,'P.2N1N![=,UN>"]&O]-U_P 3BZT1
M+'3[Z>.:#;)&R%?*52NU>_!SQC/0GK7<44 <7X&\,W^@27EM>L&L[&22VTGG
M)%L["0Y/U*I_VS]ZQ_#=AXD\/1/X9D\,P7<44TGV36#)'Y?E,Q8&13\VY<]
M.<8XZUZ3'+'*"8W5P"5)4YP1U'UI] !7%1>%[ZV^(=W=1;1H-Z([^>//_+W&
M"@ 'H1L<G^]&*[6B@#SV^L]=T#QSJFHVOAT:[IFKB)R(Y(TDMID0)@[R 5(
M.>W\Y?$/A_\ MQ;2#6-"F9HK?S8+[2I%26RG+'**=RDC&WG&"1D@9X[VB@#S
MG^R/%,%SX%U*]M6U2]TV*XBOS'*BL&EC"JQ+$ XQ\Q&>Y --L;/Q#X;UW5[%
M/#$6L6-_?27MI>B:-!$93N9)=W( )/(!XZ ]*](IC2QK*D32()'!*H3RP'7
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M@J7 RK ]1@\<C-<]_P (%JZ:%K=AH\D]E:+/:W>C6=_,)?(FB;>PR"V(V(4
M9.,$_7J]'N_$FLP2+JV@Q:*HA9&4W*3-*Y&/EV=$')YY/'OD ?X"UG4-?\'Z
M?J>HPHDUS$)=ROD/G)Z8XQTQ6%?2W>I?%I]*O-,BNK!=%.(9905VO/M:3!'4
MA0,=>.O-;/P]L=4TGP;I^E:K8"TGLHA!_KED\S&?F&WH#QC//7('>%=/U,?%
M:36#ILO]FG25LA/YD?\ K!,7SMW;MN#Z9]J *\'BBST3PLU[I6DRR^&M,9K<
MS)-N<1QML9T4Y+HI!Y+ _*2 1C-C4?'+0:W'I6FZ)=:G-/IQU"V>*6-4F0%1
M@$GC[W4X[ 9S6)IGAW7M(\#:MX)73C<1R"X@L;_S4$7E3%CF0%MX9=YR IS@
M8K0L/#M_I/CK19+>REETJPT/^S/M)DC'S;D(.W=NQA.>.IH DT;7M4USQEKN
MCZAI,4=A;6UJ&ADE5RGF+(Q+#&&)X! .!M[US?P_\4OH'P]\+QS:3<-IT]P;
M-KT2*!&[S.%^3.XKG )X_&NIM-/U?3/B)KVI)IIN=/U*WMBDR3(I1HE<%=I(
M))W#';U(KFH/#'B&+X6Z#H9TB0ZA9:A%/,@GAP$2<R$@[\'(/YT >E:M.EMH
M]Y/):O=QI"S/ FW,BXY'S$#IZFN2M?&5CI7AKPH]AH-PMGJ_EPVL$!3$.Y"R
MIR1DX!]O4BNKU99IM$O$@@>2:2!U2(,H)8K@#)('?UK@(?#VO1>&O 5D=(E,
M^C744EX!-%\JI&R'!W\Y+ _2@#K?#_B9]9U/5=,NM.EL+_36C\V)Y%D#)(I*
M,&7CG!R.V*YSXAW%QI6MZ/K-]I$NK^&[:.5;RWC02>1(VW;,8SPP !'/3)/%
M:VB:;J-M\0_$NI7%A)'8W\5JD$QD0[C$KAL@,2,[ACCMVK2U"ZUFSUV*2VTU
M[[3&MR)EBE19$DW<%0Y (QG/([=: ,3PW?\ A.TT[5_%&B7T']C20I),D.0(
M#&'+?)_ 2&'RX'.3WJ>V\>VC>(M/TBZABB;48W>UDANDFP4&XI(%^XV/=@?6
ML'_A7\NJ3>+YX+/^Q+?6K-+>*V)7)E7)\YU0E5R2!@$GJ3@FMO0;CQ9J<"6&
MO:##IHCC*75XETD@N/E(_=JO*Y.#\W0<<]@"PGC)YHM-O[?2+F?2-0N1;0W,
M)W.-Q(65HP.(R1][.<$$@56T+Q)K&H^)/$UK<Z:K6^G3)#''%,I;'EA^^ 2V
M[U '3G&:I>#;?QAH>FVOA>ZTF'[/9'RH]8%RA1X >,1_>W[>,$8SR3V-_1M.
MU?2/&/BBX?33-8ZA+'<PW"3H"=L(0IM)SNW#O@8[]J (_#_BG1X/!.AW.EZ6
M;2+493!8:=&0#N+-G)Z ?*S$]N>IQF_'XO\ +U/4=)O=.EBU2SM?MBV\4BNM
MS#G&Z-FVYP1@A@,>]<?IO@_Q!9^#/"+K9;=8\/7;RO9M,F)XW+!PK E0=K#&
M2.0:Z*;1[[4O%%SXDDTZ: PZ2]C;6LCQ^;*[MN9CABH P ,MW/3C( RR^(GV
MJW\/WLFAW4&FZU*D$5T\J'9*X)4%.N#@C=Q^6">PO+5+ZTDMI6D6.0;7\MBI
M([C(Y&1QQSS7FZ>'->C\#>"=,_LB4W>DZA:SW2":+"I%G<0=^#G/ _E7H6J7
M5Y9Z;+<6&GM?W*X*VJRK&7Y&<,W (&3SZ4 <%X4@\/67Q4U>UT%Q8(FGHLVF
M^4\0FEWY,RJP PJX7(Z[C]3V^MZW;Z':PRS(\DMS.EM;PIC=+*YPJC/ [DD]
M ":RHM,N-9\6:9X@NM.DT[^S[::)(YGC:61I-O78S*%4*<<Y);H,<L\=:#?Z
MO::7>:4$>_TG4([Z*!VVK.%R&3/0$@G!/>@"S!XI9=>FT*^TYX=36V^U6\<4
MHD2YC!P=CMM^8'J& ZYY%5O"GC*X\5Q6=W!H-W;Z;<PO(MW+*F ROMV;0<\^
MN,<'KUJ,Z;>ZIXRLO$EQIMQ:QZ;92Q0V\CQF6620C/W6*@ +CEN2?0<R?#?2
M]0T3P)IVE:I:-;7=J'5U,B.#EV8$%2>Q% &EK-S/<2IHUC(T=S<)OFF3K;P]
M"P]&;E5]\GG:16)\)?\ DEVAY))\M^3_ -='K0U3P/I&K:G-J,\FHQW,RJKF
MVU":%3M&!\J,!7->&M,U;X<_#!)(M*DOM4C^>ZM9-0 1%#,2RLQ*J O.%ZF@
M#T:6*.>)HI8UDC8897&01[BOG[3K?2%^%%ZUE$J^)UOYUL&L5_TO>)L( 5^;
M;CUXQ7OPG9K-9U@D+,@81<!N1TY(&?QKDOAGI.J:'X9DL-6L'M9_M<TPS(CA
ME=RPY5CSS0!,?$NIZ?9I:SZ8UUJ-GI4=[?R-)Y4>[!#*C;2&;*MQP.G--N?'
MT*0^');32KRZ37DW6Q4HNT^67"MD]?T'7/%4]?TS7[_Q/?QOIB:CI,U@([(O
M<(D5M-\VYG0\ECE<, <8QQDUEZ?H/B*"P^'\<^B.'T0D782YB.U?),>?O#)R
M<X&>.^>* -2U\6>(+KQQIFES:']BBFTV6ZEMY;E6<,)43)(!& ,X /.[MBK&
MF^)M%LSXKOWTMM-_L^Z OG(4O</L7!PI.205 &><U+J>F:K'\2=-UNSL1=6?
M]G2V4S><J>26D5PQ!Y(PI' )K NO!^L:Q8>.;)[=K%M5NX[FQGDD1E)C";=P
M5B1EH_3H?PH ZZ#Q!>_VU'IM[H=S"TULUS#+$XE3Y3S&[8 1^1QDC_:KG;#Q
MKI6C^"(]8L?#UQ;6<FHO;-;0[,QR&8H68 \Y;/"[JV] U+Q3J C.LZ"FE^0A
M\[%RDIN'QC$84_*N><L0>@]37 ZKINJ:)\*/LM_8-#=#78YTC,J,'#W8=>5)
M Z@<T =Q8>-FD\3/H6JZ+=Z7<O;M<VAE=)!<1K][&PG##^[S18^-C<W^APW.
MERVL6N)(UDS29<;%WXD3 V$J,C!;T.*AU#2=4USQ39:U':-I[:797*6OVED9
MI+B90H)",PV*%[GDGIQ7.6.@>)FOO"&I7'AX+?Z?-)_:5Q->QM).S1,GF;@3
M\F3D#J,X"X% &W/\1I4L-;O8?#=])%HMR\-YNFC4JJ*K,PY.3AB=HSP.2,@5
M/J'BC4CXVT#3M/M(Y=/OK26[WF7:T@ 7'&.  ^?<^F.<D:#KA\-^/K(Z3*)]
M9N;F2S'G1899(EC7)W\<KD^U6CH^N0:UX.U.'2S*+'3Y;*[B:=%,+,L8#$Y(
M*Y0_=R?:@#I/%?B ^%] FU=K)[N" @S+&X5D4D#=SU SS[5"WB<Q^,;3P]):
M*INK1KJ&Y$P*.JD!E QDL,@^F.<]JV;^R@U+3KFQNDWV]S$T,B^JL,$?D:\S
M7P+XD7PUI5S]IB_X2?3+J.*VGX(%JF8L'GD%&:0]R3B@#>U_Q%9OH5O=:KH!
MN[1]52VB'F*RAQ+L67G!QN&1@'(]C4<MO"GQQMY%B0/+X>E\Q@HR^)XP,^O%
M3^--!N[CPMIFE:+8O<"UN[5PHD1=L<3J3DL1DX7\ZEET[4F^*5IK(TZ7^STT
ME[1I?,CXD:17^[NS@!<9QU_.@"I\,X8K>'Q5##&L<2>([P*B# 4?)P!VJE>2
M2:=\:+J;3M+-U=3>'E8QQ%8][?:"-S,>!P ,\GI6SX&TW4=,/B :A8O;?;-8
MN+V M(C;HWVX^ZQP>.133I^I)\4Y=:&G2MI_]CBS$PDCYD$I?[I;.,'&<=?S
MH DLO&\>H^'=,U.UTVY:?4+HV:VS?\L95+!O,8 X4;&^;![<<TP^.&_L/7;Y
M=)DDN=#G>*\M8Y@<A5#%HVQ\PVD'! /!_'F;#1/%FG>%].LTTJ5HTU>>>_LH
M[J)'N+>1W90'WXP"R[E)&<8Y&:WO!>B:EI>K^)5O=(M[2POKI9X!'*K(5,:+
ML"@<8P<Y ]LCF@#<BU\W,&B2VULDPU11(-LW^KCV;]_3D8P/JRCOD8-_\3-,
ML(HKXI%)I3W/V9ITNE,J_-L\SRNNS/?.<<XQ4_@;PQ?>'A=V][()+:TD>VTL
M9R5M2WF<GUR0OTB6LOPQ9^,/#=M_PB_]BV]Q902.MIK/VE JPEB1OC^\74'&
M!P>.1UH ['Q'K0\.^'[W5WM9;I+2)I7CB*AMH&2?F(_Q]C619^-'GUS2-/NM
M&N;2'5X7DL[AY$;>RH'92HY7Y3D$]?05=\:V-WJ?@K6-.L+<W%U=VDD$2!E7
MYF4@$EB!CFL&XTG6)=9\"W2Z5-Y>E)*+PF6+,9:'RQCY_FYYX[?E0!H77C81
M:5?:U:Z;)=Z/8RO'/<1R .0AQ(\:8^95(.26!.TX!XST<=['<Z:E]9@W44L0
MEA\HC,BD9&,D#D'N17 Z9H&NZ)X1UKP@FG-=13-<I87PEC$7ES;C^]!;<"I8
MYPISVKM=)TY= \.6.FP![@6-K' H& TFQ0.Y R<>M '+Z=XZD\0>'FU,>%;Y
M](FLII7D:2+YMA*F/:6&<C//3@CGK5S3O$^G6GAGPN-/T_R?[7CCCL+)6"K&
M#'O.YL<*JCD@$^W-4_">CZOI7PG&B7FFR)J45M/"(1+&=Y=G(PP;&/F'4CO6
M-=Z=JEGX1\$Z4ND-+K>GE&\F*[CCGC$415GC8Y0KDJ#NX(;&,D8 -+7O$,?B
M#PYXTT6ZT>6*?2[&87#2-')$',1>,J<[CD$,#M&,=C4GACQ5)9V7A'2+K2;B
M&WU"QCBMKQI%P\B0AB"@.5! ."?R%4HEO;C2/$VEOX8U&TUS6+*:3S+FY@D^
MU-L$0^=&"J%W(,8''3)S4\FBZTT7@$#29LZ.5-[^^B^3$!CX^?YN3GCM[\4
M:OA#Q!JVMZOXABOK..*"RU!K:/9-NV!8T..G.<DY]\=J37/$&K6?CW0M&M+.
M.2UNX9YG8S;6<H ,=. -X/N?3'*^%M,U72/$?B5+FQ LK[4#>PW8F4A@T:+M
MV_>R"O? ^M'B/3-5;QOX<UK3[$7<-I'=03KYRQE/,";6YZC*G.,GV- $]UXO
M9;?5;S3],>^LM*D>*ZD24*[,@!D$2D?/MSSDKR"!FMNPU.VU328-3L&-Q;7$
M(FA*\%P1D=<8/UQ7&:1I&M^&HO$6DPZ8]_:WUU/=6-RDL:JOFCE)0S!AM;N
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M$EN9;VV%M91$(9G,"D@<<=223P.22.M>BP&:2V4W4,<<C#YXT?>H]LD#/Y4
M/$B,<*ZD^QI'*R*T8DVL01\IY%>>_#:RM8/$GCEX;>*-AK+("J $+M!Q],D_
MG6VMM;VWCS6;Z&PCENDTJU8;%578F2YS\QQUP.<]A0!K:%H%CX<L6LM.$RV[
M2-+MDE+X9B2Q!//))-: N(&N6MA-&9U4.T08;@IX!(ZXX//M7#6/Q(FN]-T#
M59- EATO5[A+43FY4M'([%5^3&2N1@G(^A')THM6BD\<ZQ86VB1)JMOI\<HN
MY9%7[0A9@JDJ"0N0>N?I0!IZAX7TC5-;M-7O;9I;NT7;%F5PG#;AE =I(/(R
M/3T%;%>>^&_'-X? FE:UK,5JLNI7/DP.;@JA9W?AR5^10%P/O9XKM-,O+N[6
MY%Y9"UDAF\L!9?,61=JL'5L#CYL=.H- %ZBJNIW\6E:5>:C<!C#:0//($&6*
MJI8X'K@5BVOB.^NK/[7'IMM+;/9-=PSP7OF1OC'R%M@P<'/<<?7 !TE%<@/'
M2MH?AG5ETX^1KMQ#;A3-\T+2Y()XPP&#W%3W_BRX2+59])TA]3ATJ3RKD)*5
MD>0 ,R1*%.\J&&<E>>!0!TGVB$7(MO.C\\H7$6X;BH(!..N,D<^]25YO=3R0
M_&&"]T[2S-=7/AMF\IB(23YZ8\PGI@<=">V*Z[PKXA7Q-HBW_P!E>TE662">
MW9PQCDC8JPW#J,CK0!L&2,'!=<^F:=7D^O#P]8?&R:ZURUM#9#PV996FMO,4
M-]HQO(P><9&?PK6^&<%UI^GZ[?2K):^'I[MKG2H9SS%;XR6 _A0\$+V].: /
M0J*X=/B1:&[T?,%NUCJTRPPR0WBR31,XRAEB ^4'UW'&><5I:?XKDU:9FL+&
M*>T2^>RF=;G]["R,REGCV\#*\?-G!!QUP :6N^'].\264=IJ4<KPQRK,HCF>
M([AG'*D'N:N 6>E:>JYAM;.VC"C)")&@&![ "N(TGQ?K?E^,+Z_TZ&6#2;N5
M%BM[GYE6.)&VC<H!SDL3D<G&*9J7C.:Z\#WNL:GX.>;17T^*Z"RW,;"<.,E2
MIY '!S@Y&#@=* /0@00"#D'H116%+KI74+?2-,LXYKYK0731R2^5'#%G:N6"
ML<DY  7^$]._-ZOXRUM[#PQ/9Z0UB^I:HMI<07KM'(A!8[1\I^5MA^;T(XYX
M /0:*Y'6/&\>FR7UO#%8RW>GQ*]U#-?B$EBN_9'E27;&#R%'(YZXFM?&EOJX
MTJ+1[8W%UJ-H;T13OY0AA!"DR$!B#N.T  Y(/89H Z2*XAG:189HY#$VR0(P
M.QL9P<=#@CCWHFGAMT#SRQQ*3C<[!1G\:X3X7J5;Q<K6B6C#7I@8$(*H?+CS
M@@#([]!]!5/QE?2^&_&\>O:UHTFJ>&WLEM_-CC$IL'W$LQ0]F!7+>P'L0#TH
M,K9P0<>AI:\VN]3LO#_PRU_7_!,MG<6LSM=1;7*I;DHB-A<'D%<A#C&<< 5T
MQ\0W,$NF:6UG#)K%[$\JPK<GRTC0#+N^S(Y(& IY/H"0 ='2$@ DG '4FN3B
M\>6<5KK(U&UDM;_2)8X;BT1A(7:3'E&-N-P?( R![XJT=3O+S4;G0]6T$QQ2
M61G6X1C/;L,[3&S%% ?H<<Y'>@#?AGAN85F@E26)ONO&P93]"*>S!1EB /<U
MYS\-=7F3P%X8T[3[1+R<VNZX)FV+;)DX+':>3V'4]>@)'5^,H(KCP3KB3Q)(
MOV"<[6&1D1MS0!MAU()# @=2#0KJWW6!^AKE?AQ;01_#3P^B0QJLFGQ,X"@!
MB4&2?7-9%MK-MX)\&RWUOI'FQOK5U ZV^V/&Z]D12>YQD   ].U 'H51P7$%
MU&9+>:.5 Q4M&P89!P1D=P>*YW3_ !5<W'BBZT&^T>2SN4L_MMOBX63SHMVP
M@XP%8''&2.>M<M>>+9K;X9S:MX=T:VTW=J+6TD1D"F,M<>6SC:N"Q)_#.><8
M(!Z?145NT[VZ-<Q1Q3$?,D<A=1]&(&?R%2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %96O?VNMM;2:-%%+<1W*
M-)%++Y:O%@[AG!YQTXZXK5HH X>^T"Y\0^-=!UIM'?2VTMWDENI9(C+."I41
M+Y;-E<G)+$8[#DUFS^"-6U+2/&OA^XCAAM=7OI+ZUO1-GYF\LJI0#(PT?)].
MF:]*J&XN[:T$7VFXAA\V011^:X7>YZ*,]2>PH X^YTK6/%(\.Q:OIWV$Z9>Q
MWUU(9D=99(U8*(]I)P6.26"X Q@YJGH&F>+_  Q)>Z!::?:W.ER74LUGJ;W(
M7[.DC%BKQXRS*22,<'U%=V+RU-XUH+F$W*IYC0AQO"]-Q7KCWI;:\MKV,R6E
MQ#/&K%"T3A@&'49'<4 >;Z_X*U/6?&&KZM%;RVTZ6L!TJ^22/>EQ%O.2-WW6
MW;2#U!.0*[W0[G4[G28'UBQ6SOPH$T:2*Z%NY4@]/KS_ #K1HH XMM)U70O'
MVIZ_8V+:C8ZO;PI<PQ2HDL4D0*JP#E592I]0<UK6$&H76M2ZS?61M1';&WMK
M4R*\A!8,[,0=H)*H  3TR3S@;U% 'E<GA7Q!)\*M2\/C3,:A<7[3H#/'LV-<
MB;EMWH,?7\ZZ:33M3E^)MEK8L'6P32GM'=I$W*[2*_0-T&W!]_SKKJ* //=(
MT37=+\/:KI-QHEI?6\FI2RB-YU(NH)9MS#:1@$*3]X]0/K4OA_0-5\)VNOR:
M)I\ILY/+?3-'NKM?W;@'S,-E@BL2,#)^[VS7>T4 ,B:1H4:5 DA4%D#9"GN,
M]ZY'XF:-J?B'PB^EZ5:>?<23Q29:1450CJQR2>^.PKL:* (TE=K<2-!(C[<^
M42N[/IP<?K7*^!M-U/0_#]];7^GNDYO;BYC194;>LCEP <X!YP<UUU% 'EFF
M^"]>LO!OA(I;1KK/AVZ>4VS3+LN(W+!U5AD E6X)[@_6N@GT6^U+Q'=^));"
M2!X]*:PM;1Y(S([.VYF8ABH'W0/F/<^E=G10!SO@73KW1_!.E:9J-OY%U9P+
M#(N]6!([@@]#52_TG58_B59:[:6L5Q9OIK6,Q:8(8295?=C'S# (P._IUKK:
M* /-]-\,Z[I'@K5?!4=DL]O,+B&RU#S4$:PS%C^\4G?N7>W !!XY%=I#IDNF
M^%4TG2Y@DUM9"VM99!D*RIM1C^(!K4HH \MT_P -^)EO_"%_-HEM'=:;)*-0
MFDO0\EP[Q%#*6P21GG&2><8 %7_#VF>+_#'VKP[:V%K<:6US++9ZHUR%^SQR
M,6(>+!+,I8XQP?45Z'10!R5KI.K6/Q)U/5$M8I=.U&TMXS.9@IB:+?D;<9.=
MPQVKD4\+>*XO =IX732;<MIVHI,ERUVH6XC6X,@*CJO!YSSQP#GCUNB@#S3Q
M%X=\3ZO+XIMY=-M;Q+ZT\O3;B2Z 6U!BVM&JD9#%L_-@9R,D8 J_)H^N2ZSX
M'O)-, 728IA>!+A&V;X?+4#)&XCJ?TS7>5"MY:O=O:)<PM<QJ'>$."ZJ>A*]
M0* ..^+N?^%7ZQM +?N, ^OGQU:O=)U#Q!XFT74I[-K"+25FE7SG1VDF=-@
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M7LHY&#>5]GP4WE<C+-G.,@#'6N@TN^\57UL\FK:)#IYBA*^1#=),UQ(1C(/
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MX$X.!CGO7J-% $-I)<2VL<EU L$S#+1*^_9[9[FIJ** "BBB@ HHHH ****
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M#:M82:?-<,&G96<AT4D_(>F3@=\G)%<MHVN7GA6P\<7UAHL=U9V>O7,UP/M
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MI_+=V50\FP;2/E##J1D@].IFE\:1A+"'996][>6IO EY>"*-(LX4E]I)+9X
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MRO=.\.Z=9:C=_:[V"W2.>?)/F.  3D\GZGDUI4 %%%% !1110 4444 %%%%
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M<O;2)DLCE>CQL0-R$$$'% $[Z3HNF:M<>(IC]GNGC$<US+=.%V \ @MM !/
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M"0?EX SGU% '8T5Q>D^.;K7-"L[JTT65+Y[Y["\AD?*6+H"79V ^Z,#' R6
MXJI-\1IH_!WB#6HM.MKF;1;I[:5([K]W* %(=&VGC#CCV/- '?T5R<7BC5(_
M%=GH]_I4%O'J-K+/92)<EVW1[25D&W"G# _*6_&HM.\:W5UH&NW=UIL-OJ.D
MW#VS62W!?>XQL ;:/OY7:<<Y% '8T5' 9FMXS<(B3%075&W*#W ) R/P%24
M%%%% !1110 4444 %%%% !1110 4444 %%%% &5K/AK1_$!A;5+%)Y("3%*&
M9)(\]=KJ0PS[&I],T;3]&A:*PMA$'(+L6+.^.FYF))_$U>HH **** "BBB@
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MI+^6]_LM$FF<O*(I71)&/4LBL%8GOD<UOQQI#$D42*D: *JJ,!0.@ ["G44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->-?#ESX@TZQ?3YHX
MM2TV]BO[4RY\MG3/R-CD @D9%=+10!RZ:-?:GXKL?$.HVL=L=.M98K>W6;S&
M:23&]BV   %P/7))QTIO@K1M4T5=934H;=?MNJ7%]&89B^%D((4Y4<BNJHH
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MFK?\) (Q!:_V/]FR9=Y\[S]WW=O3;M[]<UH444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC=1NVRHS%FD89.U<<DGH*[[(SC(S2T 9FG:-8VDHO(K:5;EHA'NN)FE=$Z[
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MF&)I9GE\I#C*IO)V@X' QT'H*S5^'WA54:,:-#Y9G$^PNY57SN^4$X49YP,
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M49&<9&?2@ 5510J@!0,  < 4M%% !1110 4444 %%%% !1110 4444 %%%%
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MA%I9L'MX4RJ1L.0P /W@><]>3ZT 87@&>QU2*]U"XM5B\2K,8M5611YD,H&
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M#$A >.%P.*S;"#6=8UV*]UO2;>PATV27[&JW(G:9F^42\ ;!L+#').\YQ@9
M-O2M,MM&TJUTZS0);VT:QH/7 ZGW/4GU-<7::=IW_"[-5E>RM?,&DVTRN8ER
M)#*XW X^]P!GKTKT"LZYT'2KS58M4N+&%[^*,Q1W!&'5<YP#]22/3/% 'C3Z
M9:1_".ZUU8O^)I9ZR[VUSN.^$_;@IV'^$$$Y Z]Z[V6)(_CA;.N0TF@2EN2>
M1/&.E;O_  A_A_\ LI]+_LV/[ \GFM;;F\MGSG)7.,YY^O-6AH.F#58]4^S9
MOHXO)2=I&+A/[N2>G?'KS0!Y[X;,VB>(-"L=;TVWN#<-)_9GB"R(_P!+W1LV
M)P1N#%<MG)!(^M>J$X&3TK*L/#6D:6\#6=F(_LX(@4NS+#G@[%)(3/? %7[N
MUAOK66UN$WPRKM=<D;AW'% 'G.K:)JGC7P[KDT-E9/'JVUK&XDO'22..+_4,
M%$1&"VZ3[W_+0]*O61C^*'PE,5RJK?36[0R[A@P7:94GV^89^A]Z[6ST^UL+
M!+&UC,5M&NQ(U8_(O3 YR .V.E5=)\/:3H1F.EV26OGMOE$9.';^\1GD^_6@
M#R<:_#+-X8\;M90PV^F!-.UEO+QY<C_NSQV\IE4_20 5T^HVFGV^E:,EY;.M
M_K&K"[%FA6-)Y"&<1SD@C8BXSP22@P"37:MHNF-83V+64)M;B1I9HMORN[-N
M9C[EN:35]#TS7K9+;5+**ZBCD$J+(/NN.C ]0?I0!Y-=0A/!WQ0L7\I([:=I
M(H;<E8XF,*L=HSTW=??L*U=;L-.\/6/AL00FWM]>O[2'5K@R,?/58R55R3@!
MCP>F1D'BNW/@SPX5O%&C6JK>*J7 1-HD50 %..V ..G JY<Z!I5YHO\ 8UU8
MQ3Z=M"?9Y<LH Z8SSQV].U '(6&G6.F_&ZX2QMHK=9?#RNZ1*%4M]H(S@<=
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M'3%95UX8T.]LK2SN=+M9+:S8/;QM&,1GV_,Y]>]:P&!@=* /')[2%?!?Q4B
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M]Q(J.5P(@3GREY.0N<=3CIVK$\=06VBZ_H'C"2.,0VMQ]CU!V48$$PV!V/\
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MMVT*>?;;I[6 (OER1-O&P=6! ZY)SFC7K6_MT34X[>V\5Z8FDPPWL$WR7**
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M6:X>WBN87GC^_&L@++]1U%#WMI&Q62ZA4ABI#2 <@9(^H'/TH Y+QUX8DO\
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M1P7,,LD9PZI(&*_4#I0!S^HV6LZIJG]D2:?9Q^'4,,AN3.6DE"$-Y?EXXRP
M))^[GN>.GJ!KVU1E5KF%69_+ ,@!+_W?K[4MU<PVD!DGN(8%/ >9@%SVZD4
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M%M,NV2*50RL/<&J4?AK1(KBUN(M+M4FM$V6[I& 8E]%QT'TZUI1S13 F*1'
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MM/&.*M)=VSW+VR7$33H,M$'!91[CJ* "*TMX)YYXH426X8-*ZC!<@!02>^
M*R&\%^&'^T[M!TYOM,@EFS;K\[@YR>/7FM;[;:_:OLOVF'[3C/D^8-^/IUKF
M])\274GB[Q/INJ3V<5IIAM?L\@'EY$J,QW%F.3P!QCITH V[?0]+M-2EU&WL
M((KV8;9)T3#N.P)[@54O/!WAR_O;B\N]%LIKBX39-(T0S(,8^;U..,]:I^+]
M<U#1)- :R-N8;[5K>RG$B%FV2$Y*D$ 'CN#UKH9[NVM61;BXBA,AVH)'"[CZ
M#/6@ M;6WL;:.VM((H+>,;4BB0*JCT ' J:BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/US4QI&CW%X%#RJ
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M#.@S)<)+HNG.ES()9U:V0B1QT9N.3[F@#D_[+T_3?C!8P65G!!%=:)<"X2-
M!-B5,%Q_$>3R>>:E^$:6D?@> 1+"MP;BZ\S: '(%Q)C/?BNN&BZ4+Z*^&FVG
MVN)=D<_DKO1?0-C('M3[+2M/TV2XDL;&VMGN7\R=H8E0RM_>; Y/N: (/$-U
M;67AK5+J]:9;6*TE>8P'$@0*<[?]K'3WKS;3GMX/&G@/8UC!;2Z3<1QP1.&8
M0^7&4$C\!R>OW0,YZ]:]9DC26-HY$5XW!5E89# ]0167;^%O#]H+<6VB:="+
M9VD@V6R#RV888KQP3@<^U 'D%UHVF+\*O'-VME +BTU>\^S2A!N@VS#;L/\
M!^&*[>SO4N_BY>V.J[&\O287TZ.4##*Q/G,H/4D[0?9:ZD>&=!%I-:#1=.^S
M3/YDL/V9-DC?WF&,$^YI;WPWH>I16T5[I%C<):_ZA98%81>RY' ]J .7^%"V
MT7AS4X+7RQ#%K-XJ+&>%7S#M ]L8KHO%\23>#-;22-7'V&<@,,\A"1^M7[#2
M]/TM)%L+*WM5E<R2"&()O8G))QU/-6F574JP#*1@@C((H \CNX+&7P'\-((U
MAV2:CIOG+&0-Q-NV=V.YIFL))H.I_$:+0(!:[=)M9EBM5"!3B0.R@=&V@\CT
MKTI?"WA]+>"W70]-$,#F2&,6J;8W/\2C'!]Q5F+1],@OY;^'3[6.\E&V2=85
M$CCT+8R: .+TBQ\/:AKGA[7=-UU)94A>*V@M$B02Q,F2LBJ,[5QGG&&]S7H-
M9FF>'-$T:XFN-,TFRLYI_P#6O;P*A?OR0*TZ /-O!)&B?$?QEI%^PCNM0NUU
M"S+G'GQ,#G;Z[3P178>)-0GM]#U2+3"7U5;"::WC09(8*=I/U; 'K^!JWJ>B
MZ7K,:1ZGI]M=K&=R>?$&V'U!/0_2I+'3;+3(3#8VD-M&3DK$@7<?4XZF@#RS
M48X)_@_X8U;1 O\ :\4EDUI,G^L>X9U652>I)S)N!ZX.:U-,T+2;_P")'CN&
M[T^VFB,-BQCDC!7<T4FYL=-Q]>O)]37<6^@:/:7K7EMIEI%<LQ<R)"H.X]6Z
M=3W/>E&A:0+FYN1I=F)[H;9Y?(7=*/1CC+?C0!X]8V-I'\*? VKK!'_:(U*Q
M'VLC,N/.V[=_7;MXQTQ72:=X;T+5_B5XZMM2TZUN(=EDWE2*-H+1/N<#H&_V
MNHR>>37<'PSH)LXK,Z+IQM8G\R.'[,FQ&]0N, ^]<[I_A0R^.?$6I:KI%O)8
MWZ6Z6S.4<J(T*L&'8-QQR#CF@#D_"4R)I'@FPNF:>_$E\VF274F(1;J2H=Q_
M&=A&P#'!Z@5ESI:7'PEUR(O;S&U\2L(&BP!&IO$&8^25!!.,'H>M>T7VAZ3J
MD=O'?Z99W26Q#0K- KB,_P"R"./PJ&3PSH,L<\<FBZ>Z3R^?,K6R$22?WV&.
M6]S0!R<6EZ?IWQCBM;.RMX(+KP_*9XHXP%E(G0 L/XC@GD\\UEZ59?V=?WOP
MT:VS9M=B]MVV94Z>S&1U/KAQY7K\X]*]"GT:Q25M0M=+L6U.*$I!,\0## ^5
M=X&0O3I5/P_9:L]Q)J^OQ6D6HRQ+ L-JY=(HP23\Q )+$Y/; 4<XS0!O !5"
MJ  !@ =JXC6[EO\ A;/AVRO@#ITEC</:AQ\K70*_AN$><?[QKN*JZAIECJL"
MP:A9P742L'59D#!6'0C/0CUH \@\26"P:7\4K..%#H\,<$]O&5!2&Y:/=)L]
M#RI..A;WKU'P]HFEZ59B?3[*&"6ZBC:XD1?FF(7@L>YY/)Y.35E]#TF33CIT
MFF6CV1.XV[0J8R<YR5(P3GO5JWMH+2W2WMH8X88QM2.-0JJ/0 =* ,+QY=6%
MEX&UB;5/M)LOLY246S;9"&(7 /;)(&>E<IIHB7XN1VURVFA)O#FQ[:WYC \Y
M J,2?G."<' R#TKTBYMH+RVDMKJ&.>"52DD4BAE<'J"#P16?!X9T&U,!M]&T
M^(P(T<12V0>6K?> XX![^M 'CMGI>GV_P7T;5(K6%;^#5HS%<A1YB 7Q7"MU
M P3P..3ZUV?BAH_!/C2W\6Q6A>TU*(V%^D*98S#+0.,=V(*'ZK77?\(OH'V%
M;+^Q-.^R*^\0?94V!O7;C&?>J$EAK>HZX+:]MK"'0+2>.> Q.S2SE "BLN,*
M%?#=?X0/4T :/A[2_P"R-%AMW5/M+EIKID& \SDM(?IN)Q[8K+^(5SIUMX+O
M?[469[65XHBD,GEEV:10H+=%4G&XGMGK745!>V5KJ-G+:7MM%<VTHQ)#,@=6
M'N#P: /,XEB?XA^)[.\?3Y/M&A1&6"!<(7!DPI!)W,%[X'&.!7/_ /"/V"_!
M_P *ZUIEM&GB%);+[+=1_P"NDD,BH4+=2NW=\O0!?:O6+CP]IEI92R:9HMFE
MVEJUM 884C94.?D#<87))Q]:S/ OA6+0O#.E07VF6T6IV<(C>5 K9;&"ZD>H
M[\&@#G=,\,^']7\?>/K74].M9H%>U.R11MCWVX+.!T5B<G<.>O-9&D_:QX)^
M&0O9'=QK8$;R?>:("<1G_OC;CVQ78:9X4:;QKXEU/6-(MY+746@-NTA1R%2(
M(RL/0D XY'K757>C:9J#0->:=:7!MSF$RPJWEGU7(X_"@#@+M9K'Q]XWFTF)
M5OSX?CFB$:C+3?O=IQW.0*L^%_\ A%-7T#PAJ,4\;7ULJ^0(9<3-,R8E#@<M
MSN9L^A)KMX](TV'47U&/3[5+Z0;7N5A42,/0MC)J"R\.Z+INH3ZA8Z396UY/
MGS9XH%5WSR<D#/- 'D][>6,^D:#J&FO##9R>*XWC,[[[J1C.PD9FR-HZC;@G
M;MR1TKH;'1=$\0?$?QNNK6=K>P"*Q*^< RJ#"V6'8''\0Y'K79-X4\.L;@MH
M6FG[3()9\VJ?O'!R&;CDYYYJ:\\/Z/J%T+J\TNSGG"[/,DA4L5_NDXY'L>*
M/*;-+F+X=^ TN'D>-?$T"VS2G+-!YLGE'Z;<8]L5K2&PUOQ/XST37M4ALY69
M42.=(\FT,*[3&S^C;SQT)S7HM[I&FZD(1?:?:W0@8-$)H5?RR.A7(X/TJ#4?
M#>B:O<03ZEI%C=S0?ZIYX%<I[ D=/:@!WAZ&*V\.Z=!!=3W<,=NBQW$_WY5
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MT'8+Z.ZLA8M%][<<"53[8W[Q_LG/2MRWAMS\;KX>7$6&A0O]T9W>>_/UZ<T
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MIS;YG([ B)-JGO\ >R,C'.:Z+2KY+?1=/.HZW97L\V(Q=H5C2Y<G'R $C/;
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M&0;DDC8,K#U!'!I+BY@M(&GN9HX84Y:21@JK]2: '111P1)%$BQQH JH@P%
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M#3+.UGG.99((%1I/]X@9/XU>JG=:OIMC<1V]WJ-I;SR8V1RS*C-DX& 3D\T
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ME!./3D9^H]J]0MM*TZSN9+FUL+6">7_62Q0JK/\ 4@9--_L;2QYN--L_WO\
MK/W"_/SGGCGF@"AX,D,O@;P_(S;F;3;<EB<Y/EK6!XHN;>S^*/@^>ZFCAB^R
MWZ[Y&"C.V+C)[UVUO;06D(AMH8X8EZ)&H51^ I)K2VN6B:>WBE:)M\9D0,4;
MU&>A]Z /*WL[&ZM_BO+/!!+(AD =U!*@6JGC/3D?F/:FV>LQV.M^$GU?5Y--
ML;KPU"MK=MY?EF?@R*6D5@"5V'/&<5Z<-&TL"0#3;,"7_6?N%^?G//'/-++H
M^F7%DME-IUI):*<B!X%* ^NTC% &1X)T_2=-T.6#0[J:ZL&NI)$FD961BQRW
MEE0!LW9Z#&<UE>-;I[/QEX)FNCMT?[9,MPS?<6=HL0%OQ+8]\5V\<:0QK'&B
MI&@"JJC  '8"F7%M!=V[V]S#'-"XP\<BAE8>X/!H \H\7VVIQ>(/'$WA_P P
M(^@1FZ$/>YW-TQ_'Y(/3GE?45T=EJ7A3Q -'O]"DMI]5@LI%L(X)?FME:/D2
M(#PH(5?F'!(QUKLK2SM;" 06=M#;PCD1PH$4?@.*9::986#RO9V-M;/,=TK0
MQ*A<^K8')^M 'F_@W4O"VL^"_#EGJ,D<FL6%TC&S,I6Y6]5B&<J"&/)9B3Q@
MDGI5:6^L[/3_ (JVES<0Q7$DDS)"[ .X:U7:0O4YYKU&/3+"*^DOH[&V2\D&
M'N%B42,/0MC)I)M*TZXN7N9K"UDG>,Q/*\*EF0\%22,D>W2@#R^"WTO4==^%
M_F1VMRDNE7"OD*P<K!%@'UP<\'H:THM T)_C!>:<VE6!M%\/PXM3 GEC]\X^
MYC'3 Z=*[UM*TYY8Y6T^U:2( 1N85)0#I@XXQ3AIMB+S[8+*W%T?^6PB7?\
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MV,GAH2:<9&'$TH. X^D(3G_IJ: -:;Q/8^']!UK6=1U^WU*UM[F0QB%4'E<
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MQMG2V4)N5P"1R-F&'4CZU<\*SZII7B72M&OKBSUNQET^5M,U:W&V5(5,>5E
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M-EV62,71QDLJ@XYZ\5BR7?A;5QK>IZ4]K>SRZ<4N[R&3?&$ )1&.=N[DG'4
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M 'UG'O0![-16?H,GG>'=,D#[]UK$=V<Y^0<UH4 %%%% !1110 4444 %%%%
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M5JES*QNBR*D*YSY>Y>"%'&:N6FO:5?&Y6"^A+6JAYU8[&B4C(9@<$ @$YZ4
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M '@0/4CBK]]K.GZ:^R[NDC?RS*5Y)"#JY Y"CNQX% %A;2V28S);Q+*<Y<(
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M7./>M+3M:TW5GGCL;N.:6W8+-&.'C)Y&Y3R,]LCF@"Y%%'!$L44:QQJ,*B#
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M-#U/P/X8U":/[;<6EM&T?FW+RI#*%Y(0L55A[#(KT$@$8(!H  Z #Z4 >?\
MAQM.NOBQXW1C;32E;':IVL?EC.<?0A<^A K!TRYM_P#A4OB3P]K3)_;L37L<
M]L_^MGGD=WB95ZMN+)M(ZXXZ5Z\%4'( S]*:8HS*)3&ID P&(Y ^M 'G&O6>
MH>'M \)^)YDDGU+0XXH-16/YGFAD54E'^T0V&'T-+\1(/L'P9UG[<R)=W2K-
M,"PYE>16*CUQ]T>RBO2" PP0"#V-! /4 _6@#SNYURTTGXMI=ZO=Q0:9>Z.L
M6G7DK@0[Q(6D0.> Q&T^X ]JY)-02/PWJ]]:&66RL?&<EW>K:YWK;;OO@#G
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M%<6*2$!6A\U=[*#_  $ACZ8YZ&O;I(HY5VR(KKUPPR*<5!Z@'\* . ^T:?\
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MXP?>O1_"NH6FI>&-.GLKA)X1;QKYD9RI(49 /?'0^A!'4&M<*H.0 /PH "@
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M)C; ^IJK\/[NV/PU\/RBXB\N+38%D?>,(5C&03VQWKJ" 1@@'ZT;0!@ 8]*
M/"[*ZL(O@AX583VZ2+K,#D[E!#"Z))/N%_2MV;5=%LO%?BK2/%E_<6<>I2K-
M;,9&6*[MFA1-JD#DC:1CWXKU;8O]T?E2-%&Y4NBL4.5)&<'VH HZ#:V]EH%A
M:VD$T%M% B113$ET0#Y0V><@8Z]*T:** "BBB@ HHHH **** "BBB@ HHHH
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M#CG^+)Z#IGKCS#Q?K%K>>&O&-K'_ *!/;:LADT^& [I=LT6;B4X)PP&01M'
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M,N4&?7G/TYJAX4O_  KKMEX?TVX@U%_$&ER0YTZ66<&TFC 5G()VA0,GG@C
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MYP!U' ;W KKK^>T\0?$+PKJNBWD-Q!8P74E[<P.&1870!5<CC);D \_*3VH
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MK7-T^JM>07'A]"MV\6V-\3.6VD*!L [Y/IDFL"QGM(?@YX%4R1))%K%HSKD
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M@RL/8CK4U5[&6WGL+>6TG6>W:-3%*K[@ZXX(/?/K5B@ HHHH **** "BBB@
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M,S6D\+1".3SE&[:RJ?N]SGJ<5T,?BK19+^WLA>XEN=WV=GB=8Y]O41R$;7_
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M^'_PSCWJKV^HV+3+WC"HP<L.P!/)/3-;=K=V\?Q$\;R/*BQMIUJ Q/#%5DW
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M@@Y.0*Y;3KZXT77=8\2AOMNE6_B&Y%Q9!=S*DHC5;J(=6((*]_EW8QS7M]%
M$5M<P7EM'<6TJRPR#<CJ<@BI:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N.^*5_>Z1\/=4U33;R:TO+54:*2
M,CNZ@Y!R#P378UR_Q&T:[\0?#[6M,L4\RZF@S$F<;V5@V![G;B@#:BMBVC)
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M>)_-AU;5]8\.7US:ZQ^Z6XTBZA+PZJ/+3 "$9W;3L)7IMYQUKU-"S1J77:Q
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M=M):O&Z;F38%_=;0Y;+' P2>,5T]AXHT?4M&DU:VO,VD4ABD9XV1DD!VE"C
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MAL5S)E0JK\S'()/)R3TSBNS\(2(WQ \:N%91//:M$S(0)%6$*VT]#AL@XZ4
M26GC;3=?\+ZU=W4M_I5I"\\#7"P21R1(I*[PVT@..3@9*]QQ6]%K&G6.DZ83
M=SW"W,*_9B4:2>X 0'=M W$XY)QQGG%>?6$K0?#7QQI,UO<I>++J8V- XW&0
MOY84XPQ;<,8S4G]HR>'=3\'^(KJWN9M&_L3^S[B2&%I#:2GRVW,H!89*;3QQ
MB@#J-7\3>'M2\,"[.NW5E:-=)#Y]H'CF257'[MAM+*2<*00.#[U>U+QKX?TF
M_FL+N^*W<,0F:".&21RI.!@*IW'KP,]">QKD_&]Q;7WPZN9=/TR2WCNM1MYH
MD%L4DN )HV>4QX##.&.2,D 'O5F;4K&S^-;3W,\<<4GAU-DS?<_X^&/WN@R.
MGK0!TT'C#0;K1+76+?4$FLKN40P-&C,TDA. @0#=NX/&,C!IK>,M"CTF^U.6
M]:*VL)#%=>9"ZO"X&2&3;NZ$'IS7GT"3^'M->\;3GBL-4\42W<4[6AE>QA9<
M+*L94[68J<$C@/TYQ56X)70OB;:K;ZB7N\/;FX@DW3;H$ QD<DG/R]0.PQ0!
MZ99^,="O]433;>[=KF2$S1 P2!9E&-VQBNUR,C(4DU#X4\6P>*?[0:&VN8!;
M7<D"B:W=,A"%))(QNSGY<Y ZBN<O)XG\6_#J6/)CAAN1(RJ<1;H JAC_  Y8
M8Y[C%7OAU(UN_B+3IX+B*X36KR<[X65=CR90AB,'(.1@T =-K&O:=H$5O)J4
MSPI<2K!&RPO("['"K\H."3TS21>(--FUV;1$FD.HPQ"9XC;R !#P&W%=I!/'
M!J#Q=H8\2>%-1TH-MEFB/DOG&R5?F1OP8 UYZ_\ PD]PWA_QO%9RQZK=H-,G
MM&'$<4BX5V'H)@7_ -U@.U '9ZAKVB7SZ*QU>_M#+J 2W6*.2+[3(NY3&X*\
MIG.<X!V]>*JV%Q>/\4]=T]]0NFM1ID$L<1?Y8F9W!*C& >!V-4_&MM#IR>";
M*!7,5GK-NQP"Q2)8W4NQ'09(R3ZU-8S1I\8-;E<E8CI4""1@0A97<L W3(!!
M(H M?#*\N[[P3#-?7<UU/]JND,LS[F(6=U&3[  57\;ZI+H_B3PG.VI3VUE)
M>21W,:OA)%$3L-P'+'(&!].,TOPJ)7P2L3JZ2I>73,CJ58!IG93@\\@@T>.P
M8-<\(ZC)'(;.SU%GN)EC++"IB=0S8!P,D#/2@#:T?Q?H6N6U[/8WZ[;$D72S
MHT+0<9RZN 0, G)&.#4MGXGTJ]U5=,CFECO'B\Z.*XMY(3*G=DWJ-V.^.E>?
M^)="O_$5]XLU?0HF:*;28;2$C*B]E20R-M/<;0$W="3@'BMCPSJ/A_Q)J^GW
MMGI.J'4[-7\Q[\3@V.Y2&7=(=I8G PN>.>U '>R2)#$\LKJD:*69V. H'4D]
MA61:>*M'O=2@T^*XD6YN8C-;K+ \8G0=60L &QD'CMSTJMX]TR]UCP'K6GZ<
M";N>U98U!QO/7;^(!'XUEZ-XEL?%T-JEGI=S#JL,#I+)<V31G3F*8(#LH&2V
M!A3R.3TH VI/%^B0R(LEVRQ//]F6Y,+^09<XV^;C9G((Z]1CKQ3;WQGH5AJ-
MSITUW(U[;QB62WBMY)'VDX&T*I+=#TSC!S7GD,<EY\%Y/!<UI(OB&./[%]B9
M#N,@D^60''*='W]/>NBTXK:?%F]:>4LL>A00-<."%9TD<L-W3.""10!U$/B?
M2+G2['4;:Z-Q;7YQ:F&-G:4X)("@9X"G.1Q@YQ6;K>O:)=:%!<3ZO?:?;R7J
M0I+ DD4IE23:8R"N0"PVG('%<)H-G8W7P_T&SOKN_P!(O(;V[DMK^$%&M)/,
MD(W@C 1D;^+ .0.]3ZQ=:O=_#5(]65)[N/6XECN+> K]LB2=3Y^P#@$ DD<<
M9Z$4 >E:EK5C93?8Y99S<O$9!';0/-(J=-^%4X&>A(Y/ S7+_#OQ )/A_;:C
MJ>H3W32WEQ''+)NDDE_?.$  &2<#H!T'M5>WU,>'OBCKL^JI/]BUBWM6TZZC
MA:1#Y:D-%E0<$EBP'?/O7):=]KL_!_A_53INIRV>EZS>27MO#'+%*(I6E D3
M&"P4/D[3W(]: /3Y/''AZ'3;^_GOFAAT]Q'=K+!(LD+$9 9"N[D=#C![5);>
M,="O!=&"\9_LTB1.!!)EF<94(-OSY&<;<]*X3Q&=&U'X?^*M0T'3KPM?VJ0_
M:ITF\V\D' 55D^=MH[XQU Z&M;QH\L>F>%]=M;:ZO--T^X$EW#9%EE$31-'O
M4*0WR[N0/?MF@#JK/Q1H][!?S)>"(:<<7BW"-"UOQG+JX! (Y!Z'M7+WOB!K
MOXG^%;6SO-0CM[B&Z>:VEADA20",%&PRC=R6]<<=.*Q?$-K::[X0UC5/"6DW
ML[R/:RW$TRS"6^6*0,8U$OS-M4=>AZ#/-:-YK]EKWQ!\$W^G1WDMNB7HD?['
M*/*+1H &^7@YX/IWH ]$N;A;2UEN'61UC4L5BC+L<>BC))]A7.>'?&UAK7A2
M/7IQ):02'@2PNN=SE4521\['@83/)Q73L,H0.XKQ73$OU^&7A!XK&]9O#VI1
M3:E:FW<.%5G#;01\Y7(; S0!ZQI^OZ=J5]/8P2NMY H>2WGA>*0*>C;7 )7W
M'':J/CN6XM_ FN7-I=36MQ;V,TT<L+;6#*A(Y^HK(6)-=^)VEZWIC^9966G3
M17%R@.R0NR[(P>Y&&8CMQG&:V_&MM/>^!=?M;:)YIYM/G2.-!EG8QD  =R30
M!F^'/'&AWBZ5H[ZD6U.:T0KYL;@3,$!;;(1M<CO@D]:U+_Q;HNF2%;NZ>.-9
MA!)<>0YACD. %:0#:IR0.3P3SBN/GCB\3Z9X(LM-5I+G3KRUNKE_+*_94B0[
MU?(&UB<*%/)SG& :RM,DTVVBU+PEXGTC5KK4&O9WAA43O!?I)*TB,-IV#EN2
MV ,9/.: /8*Y2[^)'A2R6X:;5#MMIC!.4MY7\I@ 3NPIP/F'S=.V:ZB)=D*)
MM"[5 P#D"O,=$U'3;>Y^(=I>#>\VI2@0;"S7 ,*#8@Q\Y]AD\CUH [+4/&GA
M_3);:.YU%=]U ;B 1QO)YL8&<J5!SP1@#DY&*D'BW1WMH)X9IIUGMEND2"VD
MD<1'H[*JDJ#SC(&<''2N TC39]"UOX:Z??@FXL=/NH[A@I987=$VJS#@="H]
M<5NV=PWAWXF^(YM7+166K0VTME=,#Y?[I"K1%N@;)R!WR: .@G\8Z#;V.G7K
M7^^UU*18K2:&&21978X"Y53@D\8.#P?2KUSK%E;7C6<TDBS" SG$+D! <9W
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MM-MK2XM9-(O;CPOK%EI<?V92/,MYHMSD6[J<AF4CH#D;^,T >EVUQ%>6D-S
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MRKV(LOLWV<\('+@[]W7)/;I7044 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_X<\.3Z%?:
MQ<RW\=R-3NS=LJVYC\MBJK@'<<C"BN@HH **** "BBB@ HHHH *IZKI\>K:1
M>:=++-%'=0M"TD+;74,,$J>QYJY10!S%IX:U?[-]AU3Q&U]I^SRVA6R2)Y$Q
MC:[ G@C@[0IKIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC80-IR00>>.^!7H]% 'DB^%VTG2=$L7U._T?Q#INE((M2MT:2"0EF+0.,%7
M(&%ZG/'2EGNM3T[5M!\0^)=$O#:76C):7:6$;DV<X<N"R(<A2&QCG!&.U>M4
M4 >7:U;6R:;X9?2]#NK.V;Q)!>M$+9S)Y8#!II% )3)]><8S@Y 9K^EWNM>)
M/'%G8PSJ]]HD-O;RM$RQRR+YA*!R,=P.O>O5** .*\.^)4\1PV-N-#OK74K>
M(I<M=6;1BR;9AMKL,$DX "GIR<8KEO"BV8TBR\*ZWX7U&76[!UBVRQ2-;/L/
MRSB3.P+C!SUSP 3BO7J* .'\3V[WWQ/\%1P@DV@O+J8C^"/RU09^K,!74:1J
M\6L6\\T-O=0"&X> K<PF,L4."0#U4]C4EMIL5O?7%\Q,MW. K2MV09VHOHHR
M3]22:N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTE&4EC.0?7Z'V-7*\VT30M7\$>%HX9-1LK:?4-8:YOG3YA"DG_+. %3O?*J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@Y()[ UQNG6NHV_A7X@^'[749]9T6TL'33;F1O,8.T+EX0X^_M^4<=,XXZ
M]3;6=-%S:6IO[=9[U"]JF\9F&,Y0?Q<<\5QOAKQM:V9UF#Q-X@MDFCUNXL[4
MW+)$3&@3 P !QGK[UB?\)!I%[J7PR>VU"WF2$NDKHX*QL;4J%8] V>-IY]J=
MIS:,NB_$2RU-;9KB;5;O-NX!FE#*OE;5^\<M]W'?I0!W]]=P_P#"2:1;KKT=
MM*1*QTX;"UX-G!Y^8!<$Y'7O4]UXAT>QO%M+K4;>&9G$85W PYZ*3T!/8'DU
MP5M8W>FZW\*K/4,_;;>TNHY<G)#"U (S[8Q^%9=C>^'[K3M9\*>+KR\34?[0
MG,FG[F#7>^8R1M$ ,MG*XP>W84 >J:CKFEZ0<7]]#;D+O(=ONITW'T7W/%9M
M_P",](L?$.G:.]U&9KV)I@^[Y%0 8.>A+$C ].?3/)6NNZ5H7C+Q7I7BR5+9
M-16%[9[HDI<6_DA#&#W(.X8[EC4U]<:?I'COP1(8QIUA_9MU!;QRC;MXBV1X
M/.[ 'R]<\=: .O\ %7B6R\)^'[C5KXY6,8CC'61S]U1]3W[5:?7-,CM(KIKV
M'R9B5B8-GS",Y"@<D\'IZ5S?Q:4M\+]:P"=JQ,<#. )4)/X $U0N-9MT^*ND
M:K+=1/H=[I$MK97>[]S]H\T,P#=,LJC![[<"@#NK'4+/4[1+JQN8KFW?(62)
MPP)'!&1W![5R>H^(I)_B$?##ZNVCJ+-)[=D2,R7CLS A3(K+A0HX R23SQ2>
M"+9E\3^,;ZV(.D7=_&UJ5^X\@B F=?4%^,CJ5/I2>)X/"7BK4KGPYXC2W2XM
MT26WEDD\N0!@>8W]01R.>V10!O:/)J=I:ZB=?NX7%O<-Y=R$$2& (I#'G .2
MV3TR#T'%6K#6],U2::"RO89IH,&6-6^= >A*GG!['H:\C$NN6W@/683>W>M:
M3H^L6[07B_-+<6D;H\@!_CV$8STX/88K7U Z)XGT[6=3\)7]UJFMMHLUNMQ'
M(QV(>1&1@ .3G //!Z4 >@0>(]&N;K[+#J=L\VQI%42#YE7[Q4]& [D9Q6+;
M>-=(\0:!JT]KK,6FI"TL"W<I4&+'RB7#\?>Z ]>*H^&?$/A/Q-'X>:RCBGU6
MRAQ' JGS+#Y-LFX?PCC;SU.,5SEAJ%DGPM\=Z?+<1+=0S:IYL+-\R;F?;D=L
MY&/7MT- 'IL>I6EEI%E-=ZBDJR1H$N&P#<,5SE5'4D9. *:WB31$TEM5?5K-
M;!&*M<-,H16'523T;VZUP%I?K8^(_ FHW<R?V-+HAM89RP\N*Y94/+= 65=H
M_$5E^)HD32_BCJ,,L8TF[A@2%@P\N6X6/$A3L3DJ"1U(/<4 >J6GB/1;_4Y=
M-M-4M)[Z)-[P1R@NH]<>W?TK.\;Z_+X<T&.]C;RHVNX8)[DIN%M$[@-*1WP/
M7C)'7I7-WMSI\?C[X=BWFME4VEXJB-E VF)-H&.Q(.*Z#QY=RVV@11A0+.ZN
MX;:_F901#;.V)&.> ,<9/3=GM0 [1M4NIO%%WIT=X=2TZ.SBG%X0F8Y6)_=[
MD 5LIM8<9 //#"NFKSOPM81>$/%6I:9I=X)/"WV(WQC+[UL)=W*!N?E9=S8/
M/R_GVNC:UIWB#2X=3TJZ2ZLYL[)5!&<'!X.".1WH CE\1:/!>BSEU&W2<RB#
M:7X$A&0A/0,<C"]>:CO/%6@:?+<Q7>LV4,ELH:=&F7,>>F1V)].M>2^)=<TV
MZ\-ZV()X=.-OX@1IM/7F4L+A-\\Q;)4-C(QM X&3TKK]/O--G^,VJ3B:V;_B
M1VY5F(R!O<GKTX(S[8H ZV3Q-H<4-E+)JUFL=_C[(QE&)\]-G][KVJX=0LUU
M%=/-S&+QHS*(-WSE!QNQZ9[UY;X6T<>)?@?:6VG31C4;.>:XL9%(/E3QW$C1
M_3(P/HU=AX)O9O$-J_BBZM7MI+V-(HH)!@QQH#N'XR&0^X"T 5O'.JZMI>J>
M&X=-U!K9-2U%;.8>4CX4J3N7(X/'T]J;I_B'5;/XF/X2OIX]0MY-/^W0W*Q!
M)(<-M*R ?*0>H( ZBLWXHSV?]L>"K>YN5BSK4;,!-Y;!=K#.001R1S[U'H$E
MMX"\97NDZK)&;;6'-QIVKW#9>7UMY93R2O\ "2>0?7B@#NK_ ,0Z/I<PAOM1
MM[=\J")' "EON[CT7/;.,TZ_UW2]+9A?7T,&Q/,?>W")SAF/\(X/)QG!KS"+
M4=!^V^*?#GB^_N;::YU":5;<LP%Y;R$>48\#+' "X'/RBK'B!9-*EU*^T+5(
M(KBTTZ&/4M"U0AUN85C.W#9W!MI9<C@D<^X!VTWC+28?%R>'7N$6Y^S&X=F;
M 4EE55]R<D^V/>IH_&/AN6XC@CUW3WDE+A%6X4[M@RV.>PZ_0URJ:I!#\7-.
MNK_%B;WPVJ113'!,AG#&,>K 'D>V:?\ #,Z9+:>(KA#:.\6OWLGF#:2@+G#9
M[#;W]* .FT/4+:+PRE[/X@AU.W5I"=28HB.-Y&/E^7C[O'7%1ZCXTT+3]"U#
M5C?1RPV (FC3[ZOC(0KU!/;(]^E>6Z3J2:?\-/"&JY\[2M.UR674!%\WE(99
M@KL!V4LK?D:ZGQ1=:#K7@OQEJ/A](KJ6XTTBZO;<$K*50[5ST8JN<XZ9&: .
MTM_$6FS:1;ZB]W"L4P &&SE\9*CN2.>!Z5-#K>E7&E'5(=0MGL "3<"4;!@X
M.3VP>,5YQJ7B/3[36/"FLW.HR)X?DTZ2S^W6S9CAN#Y;#<P!&"%*Y[$$<8-5
M=9;2-+T[3-9T<W$WAYO$<=[J=T69TD)',H]4#[<D<;E]J .JTWQ'-?\ Q4N=
M,M]3^T::FD"X^S[%4Q3>:%YX#?=P<'^]GO5CQMXF;0;O0[-KQ=-M=2N6AGU%
MU#" !"P W J&8X + @#)Q638ZOI5]\;3+97UK<+-X>"+)#(K*["<G (X)Q70
M>*KW02]IHOB*&W>PU)9%W7/^K#KMP"3]TG<<'(Y QR: 'VC:KINISOJ&J"\T
M46GFQW$D2*ZL#\V]D 4C&", =^M+X>\8Z3XAT%M8AN8HK9"Y<RN%\M [*K-G
M[N0N>?6N1\&:<WAOQ]=:%H.J2ZAX:-CY[0O+YJV,Q<!45^VX9.WKCD^IYK3K
M_;\(_#!A?S8='UB*;6(4&YH85GD)WK[':V#V /2@#V6PUG3M3EFBL[R*66''
MFQ@X=,]"5/(!['O4:^(-(?4$L%U&W-T[,B1[Q\[+]Y5/0L.X'(KB]>CEUGQ_
MIU[X:N8Y)HM'O$N9X'!7#@>0I8<9WY8#V)JOX+UWPQJ_AKPUI%Q DNN:88D^
MP.A$UO/&-KR$=@/F8D\<^O% &SX8\0S1MXKDUW5%-MIVK-;QSSA(UCCV1D X
M '5NI]:[!9$N[8/!,0LB_+(F/S&1C]*\3AUC^R?$GB#7)98;S0+3Q _VZV4@
MM%N2)4N  ?G"L",<^HY&1[7:W=O?6L=S:3QSP2*&22-@RL/4$4 <E\.]7U36
M[#5;C5+TW#VVISV<8$2( D9 !.!G)Y]O:K]KJ4EGK6NOJFKA-.LO*V>>(XTC
M#)N)9L#OTY_.N=^']_::#-XET75;J&RO8]8N+E8[B0(9(9"&21<]5//3IBK=
M[=6]WX=\;:LDB'3[BV>."<G"2A;?:64]UW$J#WQQ0!TEKXIT&]U""PM=7LY;
MN>(310I*"SH5W @?[I!^G-4TUO3[*[U^_G\1175I:"-I;5 K?8<*01E?F)8@
MG!Y["N$%SI\&@?"<QS6T9$T&2K*,9MF#?FQ&?>M&UEAN/%OQ0@MY$DE>UMP$
M1@2Q%LP/ ]^* .OTCQ;I>J^'K+5Q<1QI=(A$>[<RNR[MF!R6 [#T-:UC?VFI
M6HN;*XCN("S*)(VR,J2"/J""#]*\NTZ>PUCP'X)CT_Q&FF:M:VT:VET-KQ"=
M8 KPR \$D$\=1C\#V7@34KW4]!F?4+2V@NH;R>&1[0DPW#*WS2IGLQ)_$&@"
M!_&5EJW_  D.GZ5?"*\TZ-E64 $LX0L2JL,$#@9[\TWP7XOL=1T'0;;4-8MI
M-<O+&.9X6=1([% Q.T=\<X]*PK'4;.R\0?$>TN;F*&X=Q,L;MAC']E7Y\?W<
M\9Z9P.XK%AN;"#P#\+62:VC9=3M-Q#*"/W;A\_B>?<\T >J7'B+1[2\-K<:C
M;QS"18F5GX5V^ZK'H&.1@'DYJFWB_2QXP_X1OSU^UK;^<Y)P 2P54'J3R?;
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M$TRS&)#*HP'*C<!]:S5\3Z(;"ZOFU*"*WM'*7+3'RS"V,[6#8*GD<$5BZO\
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M00"#P0:;)#%+%Y4D:/&>-C*"/RK-U#Q)H^E2R1WM\D30HKS?*6$*L<!G(!"
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M-1O;>SLM9M)[BX$C0I&^=X0D,1],'\C0!LQPQ1 ".)$  4;5 X';]32LBO\
M>4'((Y'8]JS+;Q)H]Y>16D%_&TTZEH 00)P.IC8C#@?[)-4KSQ[X4L!(;G7[
M%!'-Y#D2[L/@$CCTR,^F>: -Z&"*WC\N")(DZ[44*/R%/"JH("@9.3@=:IW6
MKV%G;Q3RW*F.89B\L&0R#&<J%R6XYX'2J9\6^'ELK.\.L68M[R016[F4?O')
MQM'N#P?3OB@#6BAB@39#$D:YSM10!G\*%AB65I5C02/]Y@HR?J:X;5?%(O\
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MBU-?[.LRUF&_UVU'# XYPN1G'(%>F:3IB:7;2)O$DTTAFGD5 @=R "0HX P
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MB"XD&]MY? B0*H+8)P  :S? 4^IZCIR:CKL30W=A$VFDR'[S1MB64'T8JO\
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MQ[9HVA4\^468#)+<[0>,$GMGS^2\AD_9RBL1Y@NK=;>&2)HV#"1;A2RX(Y(
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M5X1-!?1*AV1<\LXR4RI)Y'][-:4=\\'Q1T6]U"UEM&O?#ODK$(V8+.948Q9
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M[:YI21126<UJP:S>-=C2;BN%& 2#GG('6N8L;^?1M>UKQ('%[I-MXAN!<V0
M9D218U6ZB'5B""O?C.,<T >V12+-$LBA@K#(#J5/X@\BGU#:W4%[;1W-M*DL
M,@W(Z'((J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP)B37K)G 4MD"3G@=?I4=PEOJ/Q*AU^RDC:QL=(EANKQ#F-V=@4C##AB,,Q
MZ9'J*W_%7AV?Q'!I\45]':"SOH;W+0&3>T;;E'WEP,]:WESM&X@MCD@8&: /
M*-&NGTW]GVV*:4E]-;VZI-9S6Y?:?-^9GCZG:#OQWQ^-1NLNJ>-=533Y]1N'
MU+PNUO;7L]NZ*\I=^0=H5 ,CL!]2>?7** //?!OB/3]5TK1-'FT:X_MO34CB
MFM[BR919LB[&DWLNT< XP<G('KBEI,XL]&^(>GW$4\=PU_?7"AH6"LDB*$(;
M&#N/0 Y/I7I]% 'D-O?2Z!8_#S7[FWN)=*L])^PWQBB9VM)&CC&YD SU0J>.
M/QK:U_6[--$MM3T[1!'8W.KPL]\]@=T>1\UWY97=D$!0S#KS@C&?1** /'3%
M-='XH6EK;ZE<2WUC$]LTUO)NG_T;;D94<EN O'L,"MBX2#Q/9>"+72_WMQIU
MY;75S(J$?98XD.]7R/E9CA=IY/7&!7I5% 'D=]:7FK#XFVFF*SW=Q+!);H,C
MSPD2!@I[Y*E>.YK=\-:GX=\3:OIU[9Z9JCZI9J_F-??:,V&Y<,NZ0[22<#"Y
MSU[5W]% '*?$#4&TW0[2<62W$9U"!99FM_.^QKNR9PF#DK@8]"0>>AP_"%W#
M:^/_ !=-*U\8+B&RFCNKN%T$BK&P9B2H Y. ./88KT>B@#Q>"*:X_9O:SB@F
M>[@ :6W$9\Q0+K><KU^Z">G2MK7]8M[#QK8^(;^+5#X=OM-^RK=6RSH8)5D9
M@75,-M8'@D<X%>G44 >4ZY#I5OI?A=M,TZ6TLI/$T-[ME5][)AMT[JWS*"2.
M6]B<9KU4$$ @@@]"*6B@#S[7],U&P\>++ID4AM?$MM]BO7CX\B2/D2Y['RO,
M ]U6H?%<\7AOQQIVJ:A;WX\/R:<;'SK$R@6L@?<-PB.=I&!WY KT>B@#S.]T
MSP]<:38FS_M#P^D]]+=V.IJ75UE* &202<A7^88?&<#INK/U"ZUBX\':1=ZQ
M$LYT_P 3P/)>6MN0MQ;I)_Q\; .ASVX/4<&O7** ."N;N&7XNZ1=?.D/]C3*
M7D0J%9I$95;/W20"<'!KD+K$GP:\7VZ(QN)M5N'CA"'?(&N RD+C)RHR#Z#V
MKVRB@#S3Q#KMAH'Q$MM9%RZ"YT?R79[:66%U\TE-K1JQ# [L@C!!'?FK/AOQ
M'X7\)> ;-H-4EOK*.Z:"6XBMGRLKEI&+)C**,D\]!CKWW+WPYJO_  D%SJVD
M>(&LS=)&D]O<6JW$?R A=GS*5ZGC)&235^+08S9S0WES+=/<N'NW(5?/P -I
M '"8 &!U[DY.0#7KQFRMUO\ X*R>$!;LVNR/+!]A>,K)&[7#,LC CY5 (;=T
MXZYXKV:B@#SV.Z3P_P#%2\-^+AEO=)MHK:1('?SWC9PR@J#\W(.#ZYKE=-,D
M/PM\$32VMVB:?K\<UUFW?,<?F3?-C'*_,O(R.:]LHH CBF66W28!E5E#8=2I
M Z\@\CZ&O%]0/F_"KQ_;QH[37&M7+PQ!#NE5I4*E1U((!((]#Z5[910!PFIW
M,$OQ5\+30.KPBQNT,B<J"_E[ 3T!.#@5=^)%M?S>%!-I]M-=26=Y;W<EM Q$
MDT<<@9E4CG.!D8YXXYKKJ* /-!J>@ZKI^J:[H.A7VK7D&ERQ2&^6<[@>?L^)
M,[\G)(7(X]QG/TZ\6Z\;>$KV&2_G273;B#S?L3QQ12$1X1%"@*J\^N,<L<5Z
MW10!Y;X(UFVA\.6'A#5]&N)=?TZ7RS:RVC.A97)6<2%2H7G=NSGKC)(S-;S0
MC7/B;(Q 6>.+RF(XEQ;;#M_O8;Y>.YQ7IE% '-_#\_\ %O?#Z-D21:?#'(K#
M!5E0 J1V((KCM2\_3M>NM1\-7\AN)=45;[P]=)O2X;S%4S19&5X ?<,K\O/3
M%>JT4 >837J:3XL\?VMU%<"?4H(9;-4@=O/46^QBI QPPP<D8K*T?4I?#2>"
M->U"SO?[(30O[-N7%M(3:2_NVW,N-V#LVY [5[)10!YEXON;*[\,Z=<6&G&V
MMY]?M;E1]G,;3J)%9YF3 8#KDL,X /<5J6TT;_&FYD1@T3Z%'$)!]UG$S-M!
MZ$[2#CKBNYHH XGXBM>6/_"/ZW#:S7=II>I">\AA4NXC*,A<*.NW=FJ6O^(-
M/OO"6M:UHN@+J$3K"LL\]@P^T8<#)1E#2",'=Z=@>#CT.B@#RB&ZMF\?:G=2
M)J>I65UX:V^;+;.OVC;)(64?* HV\#@#)XR3RFFV>JQO<:#HFLMK.D7>D7*6
MTMRO^D:8Y4!(VDP#@DCY6P1L_P!FO6** /+/"E]H>M0:)IUWH^JG7]-:(R6M
MU]HV6DD8 ,NYCL X./7(&.:],O;.#4;"XLKE ]O<1-%(I_B5A@C\C4]% 'C/
MV#Q%%X6L]3F@G:^\%W/DVZ*.;V-&*RL/4-#L ]PU=!X]LIK?X.:K;RH7U"[0
M221QC<S3/('95 Y..0/9?:O1J* .#U:Z2W^*/A[4BDTEG/IEQ!'+#$TBF0O&
MP7*@XR >N.E<Z7C?P7\3HP"9+J^NV@7:<S!HD52@_B!((!%>O44 >:R7$<GB
MWX<2*V5BLKD2O@XC+0HJAC_"201@]QBLO?&W@KXG1@$R7-]>- NTYF#1*JE!
M_$"P(!%>O44 9OAZ19?#>F,IR/LL8/L0H!!]\UI444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+_4;;384DN6
M8>9((HT12S2.>BJ!R3P?P!/05;KF/'-II]]I-G;:C]MBC>\3R[RR+"2SD"L5
MERH. "-N3P-W- $?B'Q!HLWA/4Y[Z_U+3K2&06]Q/;QRQ3PO\K8&%R,Y7G&#
MGKS6I<^)-+L=<LM$N)I4OKP$VRM Y67:,G#XVY Z\UYQK9UVY^%/BJPOW?5)
M!.L-C>PVI62^3]V=Q11R1RNX<';[9KI/&FGQ^,[2#0[-F@NDC^W17[1.!;LH
M^0*>/F8G!'9=W<B@"[KWCNRTSP@^OV<%U<Q-(L,)^S2*"S,%#'(!VY/7OT'6
MM-/%6E/K5MI!:ZCO[F(S112VDJ;D'4Y90!CW]O6N&US5+KQ-\')RND7-MJ%J
M]L+BR2V<%?+F0L8UQ\R;5)&,\?2MOQPKW7AVS\6:7%(+W19/ML"RH8VEAZ2Q
MD, 0&3/!&<@4 =9::I:WM[>6D#2&6S<1S[HF558J& #$8/!!X)ZBJ7BK7D\,
M^&[S56C\UXE"Q19QYDC$*B_BQ'X5)X>LIK/2(S=J!>W+-<W7.<2.=Q7/<+D*
M/917.?%BWDD\$_:D!9+&]MKN4#_GFD@W'\ <_A0!9\2^(9?!?AFW>:9+O5[V
M=+:$SOMC:=^K'^Y&N"<#L/4YID7B+3M+\+:QK$>M'6;O3K=WNCYN!O"DA?+'
M$8)X'&<=SUI/'6G3RZAX9UV&%[B#2;_S;B.)2[")U*EP!R=I(.!SC-8^L>%V
M\6>)O$-W8'R[.\T#^SS.5*I-<%RRL/[P4!03[X[' !+-JVI>']"\+>(+J^GN
M)=1N+>+4HI')CQ..J+T38Q7&,9 .<GFNB359-*\:Q:%<RM);ZC;O<V3.<LCQ
MD>9'GJ1AE89Z?,.F .6O+>Y\4>'/"6@BUGBN[:ZMI=322,J+=8%^<$],LP 7
M'4'(X&:U?$=N][\5_!:P@DV4-]=3D?PHR+&,_5F_2@#N*\Y^)_BB&/P'K3:9
M>W\-Q;,(A=VBNJ+*& *&0#'<@\X!XSGBO16!*D X)'!]*\.EN+FW^"6J>#[S
M3]0&OV@>)X5M)'$V9MPD5P,$'/7/7\,@'K&I>*-+TF::WN))GFM[?[5.D$+2
M&*+GYVV@X'!]S@\<4DGBS1H[W2K3[2[2:LGF6)2!V29=N[(8#:/EYY/2N.UW
M49;[7-9L7T[4((YM)3[&UM8NLE\Q5\K)(%RH0D *2OWCGKBD32[C5?@QHLMK
M'+;:MHUI!=6AN(S&5FA09!#8.T@,OH<YZ4 =S<^(M-M+B\@GFD1[.-))B87V
M@.<( <88D\!1DY[5+8:O;:A<W%M$D\<]N$,L<T+1D!L[2,C!!VGD9Z5R<MM!
M?_#Z\OM>L+EO[9DBN+F"WW-+"KLBQXVC.8T"$X'56/>I? _]KV^JZG87.I/K
M&E0QQ&SU.:/;*<[LQ,V/WA7@Y_VN>>  =?>7265I)<R)*ZQC)6*-I&/T502?
MRKSSPEJD6J^']+\7ZEJ^J6DZ!GNXSYHM[CS&94C5&&UL':%\L9S@<DUZ'>S)
M;V4\LA(14).%)/X <FO(K*RU(_"/P?+;V=T\^AW]O=WMCY3"5HT=]P"$9)&0
MP'?% 'IUGK^GZE?SZ7')-!?QQ"1K>:)HI/+/ =0PY&>,C.#P:\VEU#4_^%)^
M)+P:M?B\M;R[6*Y%PWF@+,5 W=<8XKII8TU[XBZ'KFG%S9:;97/VFX,;*KF3
M:$CY R1AF([8&<9%<F\<[_!3Q59K:71NIKVZ\J#[._F.'F+*0N,D$<YH ]2G
MUFTL!:P3-))=3QEXX(8VDD<*!N; Z 9')XR0.I%49?&^@0Z)_;#WC_8A/]GD
M=;>1FBESMV.H7<AR0/F ZCUKGY)I=+^)%CKURDS:-?:,+);@1L1;RK)OPXQE
M0P/4]QBDTOPI_;5MXX^TQO#I^OW!^S)(A4@",+YVT\C+C(SUV@]Z .M7Q%IS
M>(1H/F3#43!]H$1MY /+SC=NQMQGCKUK)UO7]$NM/M6N-1U*RB.II;1R6\<L
M1DG23;Y9.WE2V5/8X//%<88/%<FG:#XP:RE.N6,B:<]FQ.)8F_=.[#WE(?/]
MU0:WO'5A_9_A+0K"!)[AH-3LW8QQ,[,$D#/(P4'W)/O0!T%[XTT2QU.ZTV26
MYDOK:(2O;PVDLCE2< J%4[NAZ9 [U8C\4Z--H5GK,5X'LKQE2V948M*[' 15
MQDMG(QCC!ST-<[:3*OQ>U2[9)1;-H\,:S&)MA99'9E#8P2 0<5Q]HHL_A3X:
MEN(+Z"]T_6S-&!:.YB;SIFR\> S(48].>1TH ]2T_P 3Z7J6J7&EP23"_MO]
M?!) ZF/(R,DC'(Y'//:M"_O$T[3Y[R1)9$A0N4A0NYQV '4UQ?@S4]$U'Q5K
M-]#?RR:MJ*1,\$EG+;!(HAM&T2 %CEB2?<<"NTOXVFTZYC09=XF51ZD@T >;
M:WXMEUCP5X;U^">[TWS=5L_.4;X4,;R#*EC@.N.I!QUKN-+\4Z5K%[>V=M+,
MEQ9JKS1W-N\+!&SAP' RIP>17F:2R/\ "SP?8FQOUN+'4;$7$;V<@9/+DS(<
M%<D*!R>G/6MG7+.YU?QYXBMK)95-[X6-G!.8V$9F+R';OQC.&!ZT =A!XMTB
M?4;2Q$TL<EZI:T>6!TCN !D[&(P>.?<<C(K;)P"?3TKS3PK>Z5K7]DVMQX;U
M--<L"AF2\CE$=HZC#.'8[><':!R<C@#)'IE &-I_BG2=4M-0NK2:9HM.D:*Z
MWV\B&-U&67#*"2!Z4^;Q'8100RJMU*TT/GI#%;2-+Y?]XIC*CZ@9Z=:Y34-%
MO[;X@W%M:0,VC^(X%>^8?=A>$@/G_KI&0GUY[57\1W \/_$234]6L=1N-&U"
MQB@2YLEE?[/+&SG:RQ\X(?(///XT =?!XJTB\L+&\LKEKN.^5FMA;QL[.%^\
M=N,C;T.<8.!U.*S-6\>6=C_8AMK:[G35+LVZN+63Y N[=E<;MWR$!<9[XXK!
MU'1]'ELM&BMH-0\,.#<W&GWL"LIMB2F1*I! \S.=K8^[C@\54NI]:DT7P9J>
MM6<KRV>MNUS+:VCY>/$JK,8E!9=V5/3^+WQ0!V46IZ4_C*Y5=0U W\6G*\EB
MRR")8M^1($*\N2<<9/&,5#;_ !%\,W4=C-#>3-;WLWD13_991&)-Q4*S[<(2
M1P&P>AZ&LZ*<?\+BGO'AGCMSH"1F5X6"AQ,SE-V,;@ISC-<A%',OP/T^R-I=
MB\35%=K?[,_F*!>F3.W&<;.<^E 'JM_XBT[3KF:VE>62>"#[3-'!$TABBY^9
M@HXZ' ZG!P#BI](UFPUVP6^TV<SVKG"R>6RAN <C<!D<]>E>?:YJ]MH/C_5+
MJ*2Z@&H:; LTATZ6ZC9LN$9?+Z8&<@]<]L&NL\"#1XO!UA9Z'=O<V5HGD"21
M"C[A][<K %3DYP1W% &QJ.IVFE6RSWDNQ6=8T55+-([<!549+$^@KBM&UX-\
M2/$QGOKR/3[33H)GAO"R+;G+EB%/ &T Y'4=ZG\?_:['6?"VO);3W.G:9>2-
M>QP1F1D62,H)-HY(7)Z<\UB7.IRS>+?%FIZ;H]SJ,<V@Q"WCFLI!%<,OF$H<
MJ,@@]/XN@H [FQ\6:5?WD=I$]PL\MM]KA26W=#-#Q\R9'/4<=>1Q5#PYXWM-
M<TN_U&>*>S@M;B6/,T#K\J-M&3C!8G^$9/.,9KD]+N#/X[\)ZBD.K3Q/IT\$
MDTME)'&DA\OY FT*BC!YQCCJQ%4DL]4?P%K.G6NFWLFH:?KLE\]L8GC$\:W0
MD"H^ &++R-I/3W&0#TVP\2:=J.JS:7&TT5_%$)C;W$+1.8R<!U# 97/&1T/!
MQ6M7#^'+_0M6U#^V-.T34DGM[9EFNKV&59(QU\E=^2QSDX7(&.N2*ZO2-3BU
MG2;;48(IXHKA-ZI<1F-P/=3TH NUQ'Q9OKW2?AYJ&J:;>3VEY;-%Y<D+X^]*
MBG(Z'@GK7;UP7QC22Y^&FI65M!-<74[0B*&&)G9MLR,> #T )H Z"]\2:-X>
MN[+2;R[G%U<([0*T<DK2[1DX8 [FZ<#GD "K6A^(-/\ $5I+<:?)(PAF:"9)
M8FC>*1<95E8 @\C\ZY?7;A+KXC>"KJ%)GMXTO3)*(7VQ[XU"[CCY<D$<U+X&
M)'B'QB6BE19M4\V)GB91(GE(NY21R,@CB@#I]:UJQ\/Z5-J>I2M%:0C,CK&S
MX'T4$U1L?&&C:AK$>EP3R_:98C-#YENZ),HQN,;D!7QD9P35'XEH\OPYUV"*
M*26::U:...)"[.QZ  <FLB_E$OC;P!/'%,T4-O="5Q"VV+?"JJ&./ER01SZ4
M =+=^,-%LO,>>XD6VBF^SRW8A<P129QM:0# P>">@/!(-;H((R.17DFEQW-G
M\*=7\%ZA9W$FN1I=6T<7DL?M32L[1RHV,%27!+9^7!SBO3-$LI=-T#3K">3S
M9K:UBA>3^\RJ 3^)% ":AK5IIL@BD$\TY0R>3;0M*^P=6PH.!_/MFLY?&_A]
MX=*FCO7EBU9_+LY(X)&61^?ER%PK<'@X/!]*YCQ'<#P_\1)=3U:QU&XT;4+&
M*!+FR65_L\L;.=K+'SA@^0>>?QJYJGAJ+4OAS+!H>F-I=Q!)_:&FPLI5TF1M
MZ,0?NEL'(/(#<\YH ZV76K""\NK6:9HWM;<7,SO&PC2,YPQ<C;_"W?L:IP^+
M-*FU(Z>SW,-V8#<1Q3VTD;2QCJR CYL>@Y]JYG5-.U?Q#\,-4NXK1HM8U6)+
MH6K'!55*E(O8E%Y']YFIWAS4]"US4;/4(-!U*&^LD<S2ZA%,ILLJ0RAGX9B<
M#"]LDXQ0!JV_Q%\,W4=C+#>3-!>S>1%/]EE$0DW%0K/MPI)' )!Z'H:EMO%T
M5SXXO?#JVETOV6"-S*;=\,SEN^,!0%^\< G..E>=0QS+\$=+LC:78NX]41V@
M^S/YB@7A<DKC.-O.:[&RD>T^+FIRR6UT8=0TVU%O,D#-&VQGW9<#:N,@\D=?
M<4 =O(XBB>0AB%!)"J6)QZ <GZ5SO_">>'SH<&M"ZG.GSS_9TF%I+_K-VW!&
MW(^;CD=:Z2O+;OPA?ZAJ7B?PD$>'0[UO[4AN0<!99 1Y8^DR^9QV&.] 'H-Q
MK5E!=M9RM.)A;FX(6"0XCZ9R!C.>W7VK@]>OHD^&.CWV@ZWJ<UM]NMECNY9V
M\V=&G"MO) )')'..*W_!LVH3^'6US7X&M]0GA2.6-@2R+$"O0>K^8X]G KAH
MXKA/@5X?LFM+L7<5Y;^9;_9W\Q-MP&;*XR %YH [6>XNH_C#8VHO+@VDNC32
MM;&0^7O$J -MZ9P3S78D9!'KZ&N(N9-_QBTNX6.4P?V-+$9A$VP.TB,JEL8!
M(!.*[<D $GH* /+;"34KR\\=;_$FHVBZ3<$6DAE#)"OE[_F# AAGU[5N^$/&
MYU'P9H%]K*,NJZG%(4MX(BS3;"07"CH"H#9Z?,/45C^$M)TW5/%_C,ZII,<Z
M3Z@DENUY9Y61 @!*EUP1D=O:MGQ1?-8^*-"M6LIX=/>&93?6=F998V^4"%2J
MDQAAU(&3M !&,T :<OCCP]#H=MK,E\5L;B;R$D,+\2;MI5ACY"&R#NQTK,N?
MB1IHU/2K.SMK^87=Y+;2N;&9=GEQEC@%<L?N\ '@DG%<*J3Q_#9]/?3M16>'
MQ)YK126TC,4%UO)Z'< O)(R/>NW\:.T7B/P9JP@N9K.WO93*]O \I0/ RJ2J
M@G!) Z4 ;%E?:9<>,]0BAU&^:_BM(_.LY-ZPQ)N.'52 -QY!()Z4^+QAHLU[
M96RW#C[<S+:3-"ZQ7!')".1@\<CU[9KE+VUN=3\?>*(+9)H7O?#RVL$SQLJ"
M;]YQNQC(W \&I_!GB"._TG1M$N= O(]8TU(X9X[FS98[8HNTR"0C;R =NTDG
M/IDT :MIXBT"P_X2/4SJU]+#:W -Z)UD9;5@@^5%VY"XY.,C)J>R\>^';_6;
M?2H+UQ<W2%[?S('1)L#)".1M8CN :XF^+?V)\5V:*5$F622)GB91(HM@I*DC
M!&01Q6A<Q1^)['P);::CM/87=M>SOY97[/%'&=RL2."QVJ%[]>@S0!UC^,M$
M2Y6(W$FQKS[")Q"YB^T9QY>_&,YX],\9S4=YXYT*RO;^R>:YDN[!5:X@AM)9
M'4-D@@!>1@$DC@<<\UYQJ]Y<ZCHQ:;2]1M[NT\0QRRV-K8R+##&+@'S/E7$K
M,,,3EB23@ 5UFD7"I\2?%EW+#<1P36-F$=X& 8HLF]0<8)&X9 H T=6\>6%E
M%X?ELHY[R#69T6*>&!W4(5+$\#); X7KUR.*ZM'$D:N P# $!@0?Q!Y%>-Z7
M%<V?@'X=SS65Z!INI#[8BVLC20@K*,E -V,LO;N*]DC?S(D?:R[@#M88(]C[
MT >>-XFB\/\ Q'\2)J5]?2VBV=K+#;(LD^PDR;RB*#@<#)QZ9/2NNM_$^CWF
MCVFJVEV+BTO#MMC"C,TK<_*J@9R,'(QQ@YQ@US<=PFC?%/6[R_CGBMKS3[9;
M>;R79)&0ON4%0?F^8?+U.>*Y0Z+J/AO3M'UNXTN]ET]-5O;JYL+7=YUM!<?Z
ML[5(/R@ D#IN(]: /4]'U[3]<6Y^Q2N9;67R;B&6-HY(GZX96 (XY!Z'M3M<
MUW3O#FE2ZGJDS0VD6-[B-GQG@<*">O%97A+^R;E[[4](TNXM8;LQ[[FYC=)+
MEE!&2'^;"@@ GKSV%4/BY_R2O7N,_N4_]&+0!JV'C70=2UXZ+;W;_;MADC62
M%T691U:-F #CW4GUZ4^?Q?HUM<P133R)'/<?98[DPOY#2Y(V>9C;G((ZXR",
MYK!U:&/Q-XO\*7&F*Y&F/-<7$_EE?)1H]HC.0,,S$?+U 4YKFO"XLETBV\):
M]X<U*XUNRD\H1R)*UM+M;Y9@^=@7&"3UZX!.!0!W4WC[P]!J,U@US.US!/';
MRQI:2L4=_NYPO /'S=.1S44GQ'\,QV<EX;NX-M#<&WFF6SE*P."%/F';\@R<
M9;%4O"SA?B+XWE:*5(YY;1HI7B95D"0!6VL1@X8$<5RDB2R?"KQU;+:W1N+G
M4[UH(?L[[Y0\F4*KC)!'.1Z4 >D6OBW1[S6UTB*>474D;20EX'2.=5^\8W("
MOC(^Z36(WBK2=&T/Q1K=G<ZGJ0L[ES/!*KGR90B_NT# ;$'!/89-5-4E$WCG
MP%/'',T,,-UYL@A?;'OA55W''RY((YK(^RW-[X7^)]M;VMPTUW<W$ENAA8&9
M3"B@ID?-DJ1Q0!TMUX^BM9/#D)L;UI-5<AV%E* @$98[1C+'(& ,\9/UV=3\
M5:5I"3R73W!CME#7+Q6[R"W!&07*@[>"#CJ!R>*X[4[PS'P#JZ6=^;.TN&2<
MBSE+INMR@)3;NQN.,X_I5/[1:Z/XF\0Z;XET;5KB#5;DW-G+;Q2RQSH\:J86
M5#C<-N.>,>V,@'H=UK^GP_9HTF>XENXC- EJAE9X\#YQMSA>1R>.0.IKG?AC
MJ$VI:-J\TEY<W2+K-U'!)<LQ<1*P"#YN1@8XXQ63;N_A+X@175]IL]MI%[H\
M%I;&WB:9+1XR3Y)V D?>X/0XI/"WB*#PSX?\1:AJ-AJB0MXANW4+8R;BDDA(
M?! ^48.?3'TH ]-K-U'6;.RN%LG:>2ZDB:00VT322!!P7PH.!G@$]3P,FM!'
M61%=#E6 (/J*X!KV7PW\5=6N]4M[IM/U:SMTL[J*!Y51XMP:([02"2Q8>M &
M9X?URSF^&-S=:WKFJQ6TFJ31I>Q/)YX43_NUW $J#@+SC@XXKL]7\;Z%HFH2
MV%[<3+=Q6YN6BCMI')C! RN%^;KVS@ DXP:\UF6XD^#6MV8L+X7,FLM)'";2
M0,ZF\63*C;R-H)XZ8KL6E63XS6MRL<K6YT)H1/Y+;!(9E8+NQ@':"<4 ;M_X
MOT?3K>2XFEG:WA17GEBMI'6!6 (+X'R\$$@\@$$@"K-WXATZU\I1))<R2P_:
M$CM8VF8Q?W\*#\OH>_;->>^=:Z-XE\1:3XET?5;J'4KMKFSEMHII8KF.1%4Q
M$(<9&,?-QCKQULI>/X'\;&ZO])NHM'U#2[:WA:T@>X6TDAW#R2$!./GX..?S
MP ;M[\0M-2?P[_9ZS7UKK,C[+B"!W4(J,3@ 9+94#;C(YSBJ]KJ,UK\4-<2:
MZO);&/2(+E;?YW"$NX.V,#.<*. ,U2UXM!J'@G5$T>XM+"VOIR\$%JS-"KQ.
MJ%D0$@DD9&."<'FKNG.S?&#5)C#.D4FDP1*[1,%+J[LR[L8) (XS0!NV_BW1
MKOPVOB"WN)9-,8X65;>3+?-MX7;N/S<=*VE;<H8 @$9Y&#7G6E:->V'CB]\.
M+&#X?6==;B(/"%BW[G'8><ID'^[7HU &5?\ B&PT^XEMY#/--#$)IH[:!Y6B
M0YPS!0<9P<#J<' .*JW7C3P_9V>FW<FH!K;4F"VDL<;.LA()QD @'@\'GBL#
M2YY/#?C_ ,3G5TF6VU1H;JRNA$SHX6/8T>0#AA@87J0>*YF+2+K1?#_@^"YM
M;A2/$AOS L+,;6!C*5W  [<;ESGH2?2@#U71]7M-=TV._L3*8'9E'FQ-&P*L
M5(*L 1R#5^@'(R** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)#%G"KCT48;)/?Z5)!XUT:XGLUC>;[/?7#VMK=&(^3-*NX%0WU5L$@ X.":
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MG+;&2%K=C'YC.2. Q)_B!R !WKN]0U&TT329K_4+GRK6VCW2S.,\#O@#DGT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YC_A#Y;?4[N[TSQ%JVGQWDQGGMX_)D0N<9*^9&Q7..QQ]*Z>B@"O96
M4-A:K!#N*@EF9V+,[$Y+$GJ235BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/DAC7:_W8YF<1'=[*Y/X"M"[36?#T]QJTFK-?:3;Z?+)/;W"*)6E0;@R%5
M(!!'Y"N6L-&TZUT?6M'N=/\ $MWIFK2R32VTFGA1$[G),97&T9 ('."!^-O0
MT;38O*U(>*]9BCB,,$=Y8 +&A&#G:!N8CC<V3@G&,G(!K:.OB#4K#P[KL6M(
M4ND2>_MI(U\IHY$W!8L+D%20 2>>^:QTU?Q7XCT-]9\/F9+D7D@MX9&@%JT<
M<Q0H^?GR54DG@@GC J#P_IZ>'WBMX_\ A+[C2+=_,M=.FL@4B.<C+ ;F"GD
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M[:&1B2]N%#&)^3G*9[G!P<\5V%C>0ZCI]M?6[;H+F)9HSZJP!'Z&N&G$^F_
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M737VAJWVBSE**5.S>&W!B"I4YX)..V>*K7FMV%UI/A2;Q!IE]Y]U?6WV8J5
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M)U2VN;<3$L>$X^8$^Q!!^E8^D:4NM7NI:MJ4&J6=U--Y4<?VF:WVP)D1CY&
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M0"(Y18Y=['/0C&.AY_.NH@BN8_BIJ&J-978L'TB*!)_);#2+([E0.O1AV]J
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M!;,;+@?)^[')!5=V=V"#QUQG/&R>'=;D^'_C?28="N()KC57O+6(LF)(R\3
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M.,#-3Z)XIMM8U;4=):WEM=1L-C30R%6#(XRKJRD@@_F#U% &]16'?>)H=/\
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MM4G<P9AR,[0<=Z[W4_$:65U<6EK9S7US;PB>:.)T78ISM&6(RQVM@#TYQD9
M-NC(.<'I6;H6MV/B70K75].=GM+I-R%A@CD@@CL000?I7G'AOQ*GA*T\6.-%
MU.\L[?7[MYY;5%9;>,!.3N8%L =%S@#G'% 'I6IZ-9:PD:7JS,(R2OE7$D77
MUV,,_C6:?!6A#K'>#_N(W'_QRDE\76LEQ;6^F6T^HRW%A_:*>2553!D '<Q'
M))X'YXKF/%^J6/B/PUX.URR#^3<:Y8/$7&U@#(,@C.,\>_2@#J/^$)T/_GE>
M_P#@QN/_ (Y1_P (3H?_ #RO?_!C<?\ QRHM7\:6^E2ZN%L+NZCT>%)KYXMH
M$:L"WR[B-Q"C)Q^>>*6^\:6MGJ^G:;%I]_=S:C;O<6K0(NV0* <9+#!^8=<
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M=KHRDAE8=B"#7*Z%+:Z5\1/B!=32"&UAAL9Y78G"@12,Q_F: -[_ (0G0_\
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MEP)-I4%[R608/LS$5KUR&@^(=$L_!V@/I-E/%;7X$6G6 (,AZG'+8& "Q)/
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M #.,9.,T ==6)HGAFTT.XN;E+N_O)YB?WM]<M,T:$[MB9^ZN>PZX&<X%4/\
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M!.3CI4<?A^]7Q/::QHMA?:-J,NH9U6$-_HEU!N.Z0C)7<PP1CYLGD=37I=%
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MY]T!-:P7"!K2$C&XGI(V1]U>[  G&2 ;FMZQ;:#H]QJ=V3Y,(&<8&26"@9/
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M@;N%]O2O+;/POXGA^'.CV$>E(FJ^'KX7,4,\Z&.] :0,H()V@I)P6P<]AUH
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M44;JQWL6"EC@\ GL/6@#;C\5W;W%K92>'KVVU"ZEF6*&X= NR( F1G4L #N
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MZ$3>5GK@C=[]*Q_#_AF]LO$^F:KINF7>A+,KMK=B95-K(Q0X**K$;M^"",<
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MEG*,H(;=MQR.]46TGQ'HS>$M>L-(>[GL-,&FZAIWG(LFPA/F1L[20R>O(Q^
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M0*\\%[YF9'>0OYA.,=<]#D?E6KK7B#5K3Q_HFBVMI$]I<P3SNQFVLY0*,=.
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M02*JE58\ C8I&?\ ZQZNXU&QM)XH+F\MX99CB*.2559SZ*">?PJPS!5+,0%
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M*0Q:Y)K::O!9RN-A6-/+$3L.-S(6)(.,G&>]:6JZ;XB\<>#]4T^_TR/09)H
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MM R3W)Q5'3-#UR'Q;X?U@>&UM8H;&:WO-][&\WF-L.]V!.\G:<'))[[:]*'
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M,VP;&-XPWF$=]NT>F1UK06&_T6RT33=*LDN[6+R[:XDDF"&&%4QO Q\QX'%
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M DX,EG(,LOU! QZ%L]J )6\9+'::9YT-K;WNHQO/#%<7GEQB)<?.SE<C.Y<
M*3S['%*T^)%G<:6)I+>.WNAJ?]ELDMP/($N"P82@<H0#@XY.!BI?%>DZ[#K^
MD^(_#=O!=W%G%):W%A+*(A/"Y4_*QX4@J#S_ /KEO[?6-8T6)-8T"TNXKFX
MN=+$R/Y4&QN0[;0TF_:>P'0'C) *7B[Q-K^F^&GN(-.@MKG^T8;-F:Y+ H[(
M-Z'9SG=CG&.3R1BM"[U:.+QKH&GW^APG4+BWN'AO%D5_)VJ"ZH2H;G*@\+7,
MR>!]9@\#W^EV(=D35(;S3;"ZN0S0PHZ,8B^2!DJQ R0,CGK6_?Z=K%[XX\,Z
MNVG!8+&"Y6YVSJ=AE"A0,D%L;>>/IF@"C-\1[U-)UK4X_#4SV^C7LEM>;KM%
M(5-NYE&#N/S9V\# ^]SBNAN?$RG7++1M/@6YO+JS:^'FR&-$A!502=K')9@
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M_AQ9WTV6V$LC7JH#'*"2PRO4#G;WP>>@.MXPU%-)\(ZI?S:='J,$%N[RVLC
M+(@'S Y!&,=L&@"?1M"TO27NKK3%D'V^3[1,YN9)1*Y ^?YF(Y '([8K5KC[
MKQ;<V.I>'=+L]$67^UK5Y(=MP(UC*1AMN-O"_,.?3. >E:'A7Q%-K\6HQ7EB
MME?:=>-:7$22^:A( 8,K8&00PZ@4 6=:\+Z-XBFLY=6L4NFLW9X-[, I.,Y
M.&!P.#D5KU@:SKM]8:@]K:::KQQ6;74EW=2F& 8; C#A2-QY/.,#GFK7AK7(
MO$OAO3]9AB:%+R$2B-CDIZC/?G- &K39(TEC:.1%=&!#*PR"/0BN.D\8ZO+J
MOB+3M/T"*6?1A$Q,U[L6570OP0A(; &!C'7)'>"'X@W,UGX>U4Z)Y>CZS-#;
M+,UT/.CDD^Z?+"X*[AC.X'OB@#N5544*H"J!@ #  I:XSQ%XXN?#]KJNH2Z1
MC3]-FCB9YYC$]SN"EFA!4A@-WKR01QBK.H>*M0@\8+X=LM&2XEDT]KV*:2Z$
M:'#JF&^4E1\W49/3CG( .JHK@G^(TT?A"/6SHC&=-1_LZZMA<#]U()?+)5L?
M,,X(X%:=IXNN$\27VCZUIT=@8+#^T8YDN?-#0!BK;OE&U@1T&1[T =21D$>O
MI6;I'A_3=">[;3XI8S>3M<3[[B23?(V,M\S'!.!T]*YJ+XA*]]HP^R6\MGJL
MBQ(;:[$LUNS#*&6,+A0>A(8[3ZU/HOB_6-<U.ZMX/#JK;66IR6%W.UZO[L*H
M.]1M^;D\CMD=>< '8U@ZOHGAOQ!K%DFJ16UUJ%B&F@A:8[D4D DH#\RY"]01
MTK/\?ZSJVCV>CG2U@S=:M:VTK22,IVM(/E&%/#8()[ G@]L:Y>_MOC#YEGIM
MO+J$OAL%X_/V1!OM'):3;DCMG:3TX'8 ]'HKD=-\:7.J^&M/U&UT69[RZO39
M2VX<LELZLRN[N%/R#8><=P.,UEZGX[OY?!OBN[T^WM8]1T1GA9A.9(C\@82(
M0O)P?ND#D=: /0JABO+6:ZGMHKF&2XM]OG1*X+1[AE=PZC(Y&>M5=$ENYM&M
M)+Z.-)VB4GRY3(",#DDJIR?I^-<Y'XJM;+5/&DTNBI;R:+#%-<30D-)=J8F=
M<X Z*,#).,F@#LZ*Q-%UFZU61'-O:/8RP":&\L[HS1N<X*_=&"/U]L4:[XCM
M]&N;*S+VXNKS>8OM,XBC54 W,S8/]Y0  22?3) !MT5P\7CO4+KP]J]]9Z"M
MU>:3,R36T5T=DR 9WPOL^<$9., \$=<9U="\5+KT,FH6\,/]C);I+]N$Q.YR
MNYU"E1PO0G/7C&00 #HZ*X9/B+&\^CRK:V\UAJDR0H;>Z\RX@WC*-)&%^53Q
MGYOESWIDOCS5C8^(KJU\.Q.-"N)([A9+[;O1$#DKA#EL$\' ]^U '>45QT?C
M:Z.IZ")M'$6E:Y\MK<&Y!E5C&9%WQA< $ XPQ/J!TJC+X_UN2VUR;3_"GVD:
M-=R07(:^52RHJL2GRG+8)^7V'))Q0!W]%>?R^,-2U3Q-X2&C1VSZ7JMI-=@2
MS-&[%47AL*<;=_3G)';%=KJ<MU!IEQ+9QQ27"(2BRR%%]\D*W;V_QH 1-6TV
M74&T^/4+1[U02ULLRF0 =25SFKE>0Z)J\FC?#+PQXAO]!MM0G@:-;:=;G,RF
M=MCN<H,$EN@)SGJ*[0>*-3BO+73+W1HK?5;V>5;6#[8'1H(U#&5F"Y7KC;@G
M..W( .JHKC)O'<MI;>(XKG2P-4T*#[3+;)<92:':6#HY4<8!!&W(/%1'QSJ<
M5UH(F\/K]FUN/%JR7@,BR^7O"NI4 *1GD,3QR.U '<45SOASQ'=:MJFL:5J.
MGQV>H:7)&)%AG\Z-TD7<C*Q53T!!!':NBH **Y&X\8W3Z;JNJZ7I:7NG:9+)
M'*QN-DDWE_ZPQKM(..0,D;B#TX)@N_'D\FHZ1:Z+I U!=7L9+RTE:Y$0;:JG
M:P(.W[PY_2@#M:P]5\(Z)K-^E_=VCB]5/+%Q;W$D$A7^Z6C921[&KRZ@UOH8
MU'58ELFCMO/NH]^\0X7<XW#[V.>1UQ6-:>)-5N)]'E;09/[.U0$K-%*7>V!7
M<AE7;A01Z,<'CF@#=T_3K32[;[/9PB*/.X\EF8^K,<ECTY))JK)X>TV7Q!'K
MKQ2G48HC"DHN)  A.2NW=MP2 >E8-QXWG_L&]\16&EK=Z+9R2*\@N-LTD<;%
M9)$3;@@%6P"PR >G%22^,[B;Q%9:5I6EI=I?::=0M;EKGRT9<J!N&TD#YNO)
MZ<4 ==17GK?$351X:U'6!X;3&D7$L&I1F^ VF-L-Y1V?/QSSM].:T[_QC?1^
M)8-$TS1/MDMSIQOH)7N1&I 95PW!*CYNO)Z<<\ '47=Y:V%L]S>7,-M @RTL
MSA%7ZD\"B2\M8;F"VEN84N+C=Y,3. TFT9;:.IP.3CI7EOB[Q(GBOX0>*OMF
MF_8M1TU_L]U:R,)/*D5EP5;'((/!^M=EJ>K0VOC;PYIDVDPS27B7!@OF8;X-
MD8+A1C(W @=10!T]%<)JGQ(ALK2?4+2WMKRRM[DP21)=C[4X5]C.D6TY 8'@
MD9 SQ6C+XODFU;5-/TNTM[JXTX1F2WDN3'-(KHK[D3:<J P^I!''&0#JJ*AO
M)+B*SFDM($GN%0F.)Y-@<^F[!Q^5<3_PL:3_ (1KP_KG]F0+!JMXMG*LEX5-
MK(S,OS?N^<%2#TQ].: .YEEC@A>::18XHU+.[G"J!R22>@I()X;F".>WE26&
M10Z21L&5U/(((X(-8&KZY-#!KX.E0WEEIUKOD#3X\YBA9HBI7 PF#U.=PXZX
MYZ[\2ZH$\ KHUC96UEJRJ[6_G% H^SEQ$"J$!!QR!S@# % '>Q7MK/<S6T-S
M#)/!M,L22 M'G.-P'(S@XSZ&IZ\RM+K4-,^(?CF72=)@NK@6]C*\;3^2G$<A
M/S;22Q[<<]R*[KP]K,7B+P[I^L01M''>0+,$8Y*Y'(SWP>* -.JL6IV$\TD,
M-[;22QD*Z)*I*DG&" >.>*J^)+*]U+PSJECIUQ]GO;BUDC@ESC:Y4@'(Z?7M
M7G.B:UH&IRZ1X8\1:,OA[Q'ILT#VT<L0"2-&RG]S(."&VD8SSGC=B@#UJBN0
MUKQPEA-JD-C'8W$NF >=%<7@A>1]@?9&-IW':1R<#)QZXL6OB_\ MB2RMM'L
M]]U<V*W[I=N8A!&QVJ&PK'<6## '\).>F0#IZA^V6OVW[%]IA^U^7YOD;QOV
M9QNV]<9XSTK@]8\6>(7LO"TL&DC3I=1U1;6YMKN5D=2N\[00I^1MF=V.01QS
M6S'K40^(,FF7>DVT%U'I'VMM0$@9O+\P*8\[0=H;)Y/8'% '4T5Q5QX]DM_#
M</BEM+!\/R.NZ43GSTA9MJRF/;C&<'&[(!SZBIY_%NIR>*+_ $'3=$BN)[>T
MCNHII;P1QR*Y(&<*2/N\8!S[=: .NILDB0QM)(ZI&@+,S' 4#J2:R/"FOIXH
M\,V6LI;M;_:5;="S;BC*Q5AGO@J>:YCXE2R:MX1\16L$C)96%E*]S(AQYLH0
ME8@?0<,W_ 1S\PH [QIXD@,[RHL(7<9"P"@>N?2B&>*YA6:"5)8G&5=&#*1[
M$5YWJ5R]UXA^'>@OS93PR7EQ&>DAAA!C!]0&.['J!Z5D>*+W5=-U/X@:3H?F
M!I=+AU"*.'K&Y.R4H!T)49X[C/6@#UB"]M+J22.WNH9GB.)%CD#%#Z$#I4KN
ML:%W8*HY+,< 5Y=JVMZ(=6\ WGABYM3++=I:>5;,N?LCH=RNHYPI"G!Z$5T7
MCVQN/$M@?"ME<M;RW<$D\TJG&Q$'R#/;=(4^JJ] '8T5S7@+Q _B7P=97MP"
MM]&#;WB'JDZ':X([9(S]"*Z6@!&940N[!549))P *J_VII__ #_VO_?Y?\:?
M?V4.I:=<V-RI:"YB:&11W5@01^1KSS6=&TN+XP>%+:/3;-(&L+O=$L"A3@+C
M(QCB@#T$ZG8*\"&]M@UPQ6$&5<R,.H7GD_2K5>;>+-*L]#\0^#FTO3HPS:M*
MZPQ!4&6A<D \  GD_4UL6OCKR;?Q#_;E@EE<Z&\8F2"?S4D$BAH]K%5Y.<<@
M8- '8T5R6G>,VN?%-OHL]M:N+J!I8;FPNOM"*R\E)/E&TXY!Z&K?BSQ-+X9B
MTV1-->]%[?16>$E"E2YP" >O0\<?44 =%3)IHK:"2>>5(H8U+O([!550,DDG
MH!7'6?C;41KU_H>JZ"+/48K,WMHJ78DCN8@<'Y]HVL#U&#_C4MO&NIZOX/N-
M=G\*1MH[Z7)=D27BMYA&=T10KT*[N>^.G- '>0S17$,<T,B212*'1T8%64\@
M@CJ*?7*VOB>,VGAVQT^PA6\U2R6YBM?,V16\*HI))"G@;E4 #GV&<4KKX@26
M6F>(VGTD?VIH"B2YM%N/DDC9=RR(Y7D$ _PY!&* .WHK%T#5=5U42S7VD+8V
MK)'):R?:1(TH9<G<H V$<>O6J%]XLF36=4TK3;2WNKW3X$F:VEN3'+/N4M^[
M7:<@# SZ\<=: .IHKE=:\9)8WU_8V0L);JQB625+N\$&YF&X(GRL2<8.3@#<
MO7G%&+X@W%[=Z!!8:%*YUFUFGB\^<1&-H\;E<;3@ GK^0- '<45YKKWCK5W^
M''B+4+6RAL=5TNZ>PN5,Y=8VRHWQL%&[AU(R!C\,'I;_ ,4OI]U;:;.NG0ZG
M+ UPRS7I2%$#;1\Y0$DD]-O9N>!D Z6BN!'Q)E?1=-ODT*5I+G5ETJ:(3CY)
M"<;D8@"12.0> <CI6A:^-7@O]=L]?L(]/?2K5;UGAN/.5X&#<YVJ0PVD8Q]*
M .NK+U+P]INKW]E>WD4KW%BY>W9+B1!&Q&"<*P!.#CGM5"UU_5Y-1TJ.XT%T
MLM1C9Q<0RF0VI"[@)AM 7(XR">>.>M8TWQ*@2&SO[>WMKK3;FY$/[F[W7*(6
M*B4Q!?N\9QG(!!]0 #O**S]<U&31]"OM2CMOM+6D#S>5OV;@H)(S@XX%<J/'
MNI(GAVYF\/ 66N(BP-'> R+,T>]5*E0-IP1G=GN0.E '=45R-EXQO&E\16FH
M:*R:AHT23_9[*4W'VA'5F4(=JG=\I&,=:?8^+;N;Q,- NM/MHKZ33C?1B.Z+
M!2" 8Y,H"I^8<X/?B@#JZ:[K&C.[!449+,< "N1T[QM/?>%-1U5]+2&_LKI[
M-M/-SEC,'"*A;9P6++C@CYA73W$?VC3)$NH8SOB/F1YWKG'(Y R/P% $EM=6
M][;I<6L\4\#C*21.&5A[$<&I:\@\(>,-0\+_  V\-W=WH1;01''#/?+<C?%N
M?:'\O'*9(&=V?;UZ[6O'26#ZJMA%97+Z7\LT4UX(I)7"!RD2[3N.UAUQD\>]
M '8T54TO4(M6TFTU&%)$BN85E5)%VLH89P1V(JW0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S7CS1+W7_"LMGI
MPB:[6>">-)7VJ_ERJY7.#C(4UTM% ''ZAI>M7WC/POK#V4*PZ?'<BZ"3@[3*
MJ@!<@;L;>3Q[5F1>&];'AOQQ8-91B;7+FYEM?WZX598EC&_T(VY.,UZ'10!P
MEQH.LRR>"&6R3_B3$-=@S+_SQ,?R>O7/..*BT?2?&7AJZO-&T^#3[K1I[F6>
MUOI9RKVBR,696CVGS""3C!&>Y';T"B@"AJ^EQZSH-]I,\C".[MGMW<=0&4J3
M]>:XP>&=<U7P9IWA+5[>%(K5X$N+V.8,LT,+*R[%^\&;8H.0 ,DY/2O0J* .
M4T/2=2L_'?B75+BV1;+4A;"!Q*"P\I"IW#MG/'7WJ]XSTZ[UCP=JVF6,:O<W
MEL\$>]]J@L,9)]!6[10!Q#Z'K$GB+P;??8D$.DVTT5U^^7.Z2-4&T=P"N>W!
M_"KOA/2=1TS5_$EQ>VZQQ:C?_:H"L@8[=BKA@.A^7/?K70V>HV6H^=]BO(+D
M0R>5*89 ^Q\ [3CH<$<>]6: ./U?2=>G\;1WT5O:7NEFR\J)+B<H+2?<290N
MT[B5P,CGC&0#5KX?Z1J6@>"=.TG58X([FT0Q?N9"X(!.#G Y/I^M;MUJ-C93
M00W5Y!!+<.(X4DD"M(Q[*#U/TJ:66."%YI76.-%+.[' 4#DDGL* ./L='U:U
M\3^+]1>R5H=52 6H$RY)CB*'=Z9)R.O%8Z^%->3P'X2T86<1N](OK:XN/WXV
M,D39.T]R<\9 [UZ+:W5O?6L5U:S1SV\RAXY8V#*ZGH01U%34 >7>(?"7BC6+
M/Q;9-:V-P^I'-E>S7!#Q0X7$ 3:=N"IY! ).3FM^+2]:/Q!L]>N+&%;>/2&L
MI%BG#$2-(K\9 RHVXSQSVQ7944 >72>$/$+^$KW3!90_:9]>.I*3<#:(C.)<
M$_WN,8QCWK<U'PY?:MXXN+Z>V\O2[K0I-+D;S5\Q6=]Q.WTQQUZ^U=9>ZA9Z
M;;FXOKJ&VA!QOE<*,XSW]@:?:7=M?VL=U9W$5Q;RC='+$X96'J".#0!QOA6V
M\;Z?;6>AZI;Z=]CL0L8U.*<EYXD^ZHB*\,0 "2?7'-7?!>DZEI,_B ZA;)$E
M_JLM]"4E#_(X4!6]#\ON.>M=710!S'CG1;_6=)L?[,2*2ZLM2MKY8I9-@D$;
M[BN[!QD>U5HM+UG_ (6,NOSV40MO['^Q,(YP2)?-\SC.,KVR<'/85V%% 'E]
MOX5\46GARTLUM;:41:S->75DUSM2Z@D9V"EL=BP)4C!QWJ<^#=>N=/\ '%E+
M#80)K:;K4QS%@K^4J!"-HPHVXS^E>DT4 9VA+?IHMJFI6\5O<I&J-%%+Y@7
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M(P544=22>E21R)-$DL3J\;J&5E.0P/0@T <O#HNIQ?#NYTZ<K<ZU>6D@N'W
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MN*UZ (;5)H[2)+B433J@$D@7:&;N0.PSVJ:BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\4>(H?#5A;7,YB1
M;BZ2V$LS;8HBV?F<]@,?F1R.M;=9/B&VN[NSA@MK*SO8&FQ=VMT0%EAVL"!E
M2,[MI&>..HH QM7\6:GHFAMJ5QIMK*HOHK93%<G;+'(4"RJ=OJYX]CR:NR^(
MKI/&TGAU+&)\Z8U_%,9RNXB0)L8;3CKG//TKEG^'E]%X-UC2]-,5L)M0BOM/
ML99F>.W",C&,MVW%6.!D#<.O)K7L](\13?$"W\1WUMI\%N=*:RD@CN6=HR9
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MD#+E-A*G: #R>G&: .DD\3ZU/XIU?0-/TBT>>RMXIXYI[LJCA]WWL(2#\O0
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M&:4R(W(4\$C(]JT='MO%^H6YLO%":;%;K$T4LEE*SM=DJ5S@J @YSW.0.@H
MIQ_$&6231KF/3TGT_4YDB"P.S3VZN,I(Z[<;>F[!^7/4TR7QOKKVGB6:UT*S
M)T&=TF$EZ0)$2,.=I"?>()X( '')IWA72O&NC6UKH%Y)IDFEV6V.+44=O/D@
M4_*GEXP&P I.>!ZGFD@\,ZW'9>-8FAL]^N22/:XN#A=T0C&_Y..F>,T 6(_&
MM^;[P[+/I,,6D:Z52WE^T[IT9HS(I=-NW! (X8GN?2H=5^($EM;7U[IME%>P
M6-RUN]NLC>?-L;8YC 4C@YP">=IZ<4R;PQKCZ9X)MEAL]^A2PO<DW!PX2(QG
M9\G.<YYQ2:?HGC'PYJNHV6D'2[C1;Z[DNH9KEW62S,AW.-@&' )) R/<B@"[
M)XMU>Y\47.A:9H]L\BV$=[#-<731J5=B!O 0E3P> #]16+?^-M7U7PSX2U33
M;>&U_M/5XK2YBDE.599'!0,!]TM$03Z'IS6_;Z)JMM\0;O7"D$MF^F1V2%IC
MYK.CLVXC;@ [L=:YZV\$^(+;P3H6GA+!M0TC6?[1"?:&$<R>9(^W=LRIQ)Z'
MI0!Z,]P+6Q:YO&2(11&28@DJF!EN<#('/:N/N?'5U9>'+'Q3<Z;&N@W31ER)
M29H(I" DK#&".5RH.1GJ<5U=S9?VEH\UC?!<7,#0SB(G'S+AL$_4UP\?A#6[
MKP+#X)U(6K641C@>_CE.9+9'# !,9#E5"]<#KD]* -.7Q3KD_B;6="TW1K.2
M>P@AFCEFO"J2*^[&<(2#\N  ".N2.,X/B'7(O%/@SP5KB6_D_:M=L'\MCN,9
M\W##/?D'FNCL=&U6R\=:[K7V>V:TO;6"&!1.0^8MWWAMP =W8G&*YZV\%>(+
M?P#X7T/R[%KO2=2ANIF^T,$=(Y"^%.S.3G'(H ZFQ\274OC74?#U]90VWD6R
MW5M,)RWVF(DJ3C:-NTC!Y/45HZ!J5QJ^C0ZA<6\<'GY>)4D+AH\_(V2!C<,'
M';-<QXXTB+7=0T);.]%OJBW36[^4P+?9WC/GH?3Y0"#V;;W(KN$18XUC10J*
M %4#  ':@#R_3KS7-.\4^.FT#1K>^:.^BD=);GR<CR$.U %.6/O@>YK9@^(3
M7<?A:_M]/0:1KK^0;F68AK:;#80J%(.64J#D<BK%KI&O:-XC\17=E;V=S%JT
ML<T,DDY3R76,)AUVG(XSP?;CK5/5O#&E:1\*9/#,MY@VUH9(9>!(9PV]75<Y
MR9", >N* .IL=2GO=9U*U$$8M+-DC$XD)9Y"H9EVXP,!EYR>OM5?4-=D3Q#;
MZ!I\44M_);M=RM*Q"0PA@H)QRQ+' ''0G/'-CPYITVEZ%;6]W();U@9;J4?Q
MS.=SGZ;B<>@P*PM:T+6;;QU:^*M#2VNF-D;"\L[B4Q;H]^]71@#R">01TH Y
M71=4GT7PA\0=1N=(M+EK?6KEY[)I?W3 1Q;L$J<CO@@9]JZG4_%FIV6KZ)I.
MGZ-;W$FJ6<LT#-<F-4:-%)5AM.%^8<C/TK(/A#Q'+X6\9Z;)%IRSZ[=RSP%;
MERL>]54ACL[;>W7/05K2Z#K4OBGPKJ?D6@@TNUF@N1]H.XF147*_)R!L[XSF
M@!MUXUO8TNK>.SLDU.PMXWN[>6X8@S,F_P I"JG/!'S'U'!YQ:L?&$FM-IMK
MIUBT5]=V)OI8[W*?9DW;,, ,EBV0!QPI.>@-&\T;Q3HWC'4-7\.KI]Y9:L(S
M=6MY*T1AE10@=6"G(*@9&,\4W5?#WB:T\1:=XFT>:RO=02S-E?VUPQACF0N7
M!0@';M8G&<\=SW *VN^)_$HTKP[(-,33+B[UN*RN89I3EL.2-C ?<;9UQG!Q
M@YS7?^9)':>9+'F58]S1Q'=EL<A<XS[=*Y'Q!H/B#5]'TF8O92:I9:K#J+0&
M1DAPF1Y:OM)Z'[Q')R<#.!T]U#>7&CS0I,EO?20,JRIDK'(5P&&>H!Y_"@#E
M[/QK>-KN@Z;J&GP6TNLQ22+;B8^?:%4WA95([J#SQ@C'/6J$_P 0-<71_$&I
M1:!:&+0KV6"Y#7QRZ1A22GR<M@D\X XZ\XK:=X2\40S^$9Y;728I-&>47)6Y
M=VN"\11IB=@RQ/S8.22?O#M8_P"$2UYO"WC33#%9";7+NXGMV^T-M19451O^
M3J-N>,]: .BE\2-=ZQ;:1I4,4MS+9"^E>=B$AB8X7(')9CGCC !.>@.+\+3*
M;'Q*9X4@F_X2&\WQ1MN56RN0#@9'O@4U/#GB'2?$FG^(--AL[AWTV/3]0LI;
M@H/D.5D1]ISWX(Z?IJ>"=%U;15UL:HEH/MVJ3WT7V>5GPLA'!RH]/U[4 &I^
M+)8/$%WH=A':/J%O:+<QV]U,8VNRV[Y8^#TV\GGD].]0W_BO6D\62>'=.T2W
MFN?[.%]'+-=E$P7V8?Y"1@@],YR.G)$/C'PO<^)UO;2ZTJRNHC&#IUV9O+FM
M)<<G(7(4-@\$D\@CI6;$NHZ=\6[6%%&HS1>%XHYW>38\A$Y!<9X))'()'7\"
M 7M-^(\=WHJ2W5B+/5AJ+Z7+9R2Y6.=%+,=X'*A03D#V]Z=%\0?LT>M#4K [
MM.,7DS6Q8Q7GFD*BH6 PVXA2#G&<YJC=^ M673#J&G7=K#XC&L/K"[]Q@+,I
M0PDXSMV8&<<G/3-7M5\/^(O&'A.^LM9DL],NY C6D=H[2K%(CAP[,0,Y*@8
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MGFM&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT]^-O5_#6O\ B7PU+'J%]:V6KK-%<V?V7<\-M)$VY22P!8DYR<#C'''/:44
M<WHZ>,)(99M;;28KE(62"&S:1HY)#T=RP! XX [$\GC&SI9U Z7;'5A;#4/+
M'V@6V[R]_?;NYQ]:MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSR#U':@#UNLXZO#<7FH:?8R12W]E$CR(S85"^[:&(R0?E)QZ$>M4? ]Q+=>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_"KP#+]@M TE[I9E?R5RVXKNW''.>^>M>H+X9T.,7832+)!>*%N0L*CS5 P
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M!.8EWQI_=4XX'7\S5>'PKH%OK;ZU#H]E'J3DEKI85#Y/4Y]3W/6@#5<L(V*
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MVEVAL_L-I+]F,2^5O/F*6V?=S@8SC/7U-<QH6J?8_"'P[6_O3;:4\]W%)<2
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M<P^=;SQ2Q<_/&X9>.O(J.&\M[Z&1K&[MYBN5W(PD56]\'],UY)J]GI'AV_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBHYYX;:%YIY4BB099Y&"JH]R>E
M"06\-K&8[>)(D+,Y5% &YB68_4DDGW-4;;P[HMEJDNIVNDV,%_+GS+F.!5D;
M/7+ 9Y[^M7+2]M;^'SK.YAN(LE=\,@=<CJ,BF6NI6%]+)%:7MM<21<2)%*KE
M/J >* (+?0-(M+K[3;Z9:13!RX>.%5(8]6X'4Y.3U-.;0M(>>[G;2[)IKQ0E
MS(8%W3*.SG'S#ZU*FI6$E\UBE[;-=J,M )5,@'NN<T2ZG807L=E+?6T=U)]R
M!Y5#M]%SDT 5?^$:T+RK>+^Q=/\ +MCN@3[,F(CZJ,?+^%4M=\-I<:7JAT2V
MT^SU>]B,9NG@&7SU#L!N((R,\XSFH(=:U'_A9UQH4LD#6 TE;V,+$0X8RE/F
M.3GH>F.M;RZG8/?M8I?6S7BC)MQ*ID _W<YH X6P\$QW-S;//X,T#1)()4E^
MUV4V^7*L#\@6-<9QC)/&>AKT2JIU.P6<0&^MA*9/*$9E7<7QG;C/7'..M)%J
MFGSWCV<-]:R729W0I,I=<=<J#D4 -O\ 2-.U7RC?V-O<F$EHS+&&*$]<$]/P
MHGT;2[K3UT^XTZTELD "V\D*M&,=,*1BJFE^)])UG4[^PL;R&6:RE$4@60'+
M;03CUQD GUR.U7K?4["\N);>VOK:>>+_ %D<4JLR?4 Y% $MM:V]G L%K!'#
M"@PL<:A54>P%%Q;07EM);7,,<T$JE)(Y%#*ZGJ"#P17)_$'Q5)X?\.74^EZA
M8)J4#Q9MY<.Y5I%4X7<"#ALY(-=C0!F)X=T2-[5TT>P5[1=MLRVR PCT3CY?
MPJ2WT32;3[3]GTRSA^U9^T>7 J^;GKNP/F_&HK*>:.[U5[S5+.:WCE!C1%"F
MV3:,K(<\G.3DXXJU%J5A/<BVAO;:2<QB41)*I;8>C8!SCD<T 0Z5H6DZ%')'
MI.F6EBDK;G%M"L>X^^!S6A156'4K"XNY+2"]MI;F/_60I*K.GU4'(H KR>']
M&FU W\FE6;79(+3&!2S$="3CDCL>U276C:7?7MO>W>G6EQ=VW^HGEA5GC_W6
M(R/PJ1]3L([U;)[ZV6[;[L#2J)#]%SFEGU"RM6=;B[MX62,RL)) I5 <%CD]
M,D<^] %/_A&=!-G%:'1-.-M%(98X?LJ;$<]6 Q@'WI\WAW1+B\>\GTBPEN7B
M,#S/;H7:,C!4DC.,<8]*M?;[/[+'=?:X/L\I CE\P;')X&#G!SVHMK^SO'F2
MUNX)WA;9*L4@8QMZ-CH?K0!53P]HL4UM-'I%@DMJNRW=;= T2^BG'RCZ4Z#0
MM(MH[F.#2K**.ZS]H5+=0)L]=X ^;\:FBU.PGO9+.&^MI+J/EX$E4NOU4'(H
MDU*PBO4LI+VV2[?[D#2J';Z+G)H CTO1=+T2V:WTK3K6RA9MS);Q*@8^IP.:
MBT[P[HNCW$]QINDV-G-/_K9((%1G[\D"HK3Q/I-[XAO=$@O(7O+-(S*HD'WG
MW_*/4@)D^F14NC2W TQY+_4[2]=99,W%NH1%4,<*>3RHX//:@!GA_0+3P]:7
M$-G!! MQ.9WCMXA'&K%57"J.G"CZG)[UK56M-1L=0C:2RO+>Y1#AFAE5PI]"
M0:8FK:;)+!$FH6C23Y,*"929,'!VC/.,'IZ4 16>@Z1I]R;FSTRSMYB6.^*%
M5.3][&!QGOZU):Z/IEC=S75IIUI;W,_^MEBA57D_WB!D_C5QW6-&=V"JHR6)
MP /6J9UC3!")CJ-GY1;:'\]=I/IG/6@"[6=+H&D37KWDFF6CW+LK/*85W.5Q
MM+'')&!C/3%6OMMJ9DA%S#YLB;T3S!N9?4#N/>N?/B6W\/\ AZPGU[6+*[N;
MBX%LL]N!&DSM)M&T9/W0?FYXVF@#8O\ 1-*U2:.:_P!.M;F6,%4>6(,P4]1D
M]CZ=*6ZT72KX6XN]-L[@6Q!@\V!6\K'3;D<?A7/?\)-<1?$5M-GO;(:+_8QO
MUD "[6\T)EG+$$8SZ=:ZN">&Y@2>"5)8G&Y)(V#*P]01UH J#0])%Y-=C2[,
M7,Z[99O(7?(/1FQDCZU'_P (YH@TI]+&CV T]SEK46Z"(GUVXQFHK_Q/I.FZ
MY9:/<WD*7EVK.J-(!M11]XYZ9. /7\#6/X>\432:EXC@UV_L8H['41:V[X$*
MD&-6 ^9CEN?6@#IM/TVQTFS2STZT@M+9/NQ01A%'X"K+HLB,CJ&5A@@C((J&
M[O;2P@,]Y=0VT(.#)-($7\SQ4D,T5Q"DT,B21.-RNC JP]01UH I0:#H]M83
M6$&E645G-GS;=+=5C?/7*@8-1VWAO0[/2Y-,M]'L(K"4[I+9;=1&YXY9<8/0
M=?2KEY?V>GPB:]NX+:(G&^:0(N?3)I9;VU@M/M<MS#';;0WG/( F#T.[IB@"
MJN@Z0MI/:#3+0V\^/.B,*E9,=-P(YQVSTJ:STNPT])%M+." 28#[$ W < 'U
MP*<NHV+V/VY;RW:SQG[0)5,>.F=V<4B:G826CW<=];-;)P\RRJ47ZMG ZC\Z
M *MAX:T/2A<#3]'L+47/$WDVZIY@]&P.1[59T_2]/TF P:=8VUG"3N,=O$L:
MY]< "ECU*PFM'NXKVV>VC^_,LJE%[\MG ZBH)=>TB'2I]4;4K4V-N"9;A959
M%QU&1W]NM &@Q*H2%+$#(4=3[5Q7@OPB-.M[YM9TFT^UR:C->1R_+)\KN77G
M^\N?P[&M4:U_;6@Z9J6DZI9VB7$L#N9PKY5L$Q?>&'(('UK8O-1L=.5&O;VW
MM@YPIGE5-Q]LGF@"._TC3=5\HW]C;W)A):,RQABA/7!/3\*9<Z%I%Y:0VEUI
M=E-;0?ZJ&2W5DC_W01@?A5N2ZMX1&99XD$K!(RS@;V/0#U)IEI?6=^KM9W<%
MPL;%',,@<*PZ@XZ'VH CO-)TW48(8+[3[6YAA8/%'-"KJC#H0"."*(](TV'4
M7U&/3[5+Z08>Y6%1(P]"V,FK3ND:,\C*J*,LS'  ]35>VU.PO())[6]MIX8\
M[Y(I595QUR0<"@""#0-(M;UKVWTRSBNF<N94A4-N/5LXZGN>]+_8.C_:+BX_
MLJR\^Y&V>3R%W2CT8XRWXUR^F^(M3\47EW+HFIZ?$MCJ;6S6DH#^?;H5#OD'
M<"225(XZ ]<U=^(OB'4_"OA&XUG3/LC20/&K1W,3.&#NJ<;67&-V>] '16.G
MV6F6JVMA:06MNI)$4$811^ XJ>2..:)XI45XW!5D89# ]01W%<;/XHU;0O&F
MC:#K2V5U;ZPL@MKJTB:$QR1@$JR,[Y!!&"#^%=2FJ:?)?&R2^M6NQG, F4R#
M'7Y<YH CT_1=+TD-_9^GVMKN4*?)B"_*.@X[>W2EL]%TK3KB6XLM-L[::4YD
MDA@5&<^I('-/EU33X)#'-?VL;AUC*O,H(9ONK@GJ<' [UE6?B>P\0Z;JAT74
M[59;<RPI.[!U5E&/,(SR@8]>AQUH Z"LZ70-&GGNIY=)L9)KM ES(]NA:91T
M#G'S#@<'TI\%Y':Z-;W.H:A:L!"AENPP2)R0,L,G !/(Y[U7U6[>XT![G2=7
ML;4L5,=[+B2$#<,]P#D9'7J: 'GPYH96V4Z/8%;7_CW'V9,0_P"YQ\OX47'A
MW1;O58M5N-)L9=0BQLNG@4R+CIAB,\=O2K5QJ%E:;_M-Y;P[$\QO-D"[4SC<
M<GID@9]Z7[?9_8OMOVN#[(5W>?Y@V8]=W3% %BJFH:78:K (-0LK>ZB5@RK-
M&' 8=",]#[TZ+4;&XLVO(;VWDM5SNF252@QURP.*2+4K":Y-M%>VTDX02&))
M5+!#T;&<XYZT ,&D::--?3O[/M?L,@(>W\I?+;/7*XP<U%;^'=$M'B>VTBPA
M>&(P1M';HI2,\E1@< Y/'O5.P\46.OV^JKHE[:2W%H\D*,[Y0NJ@[B <[ S8
M)'H<4OAW4[Z3PO#?>(GLX+E2XEEB8I"RARJNN[D!@ 1GUH L'PQH!TY]/.B:
M=]B=P[V_V5/+9O4KC&?>G'PWH;>=G1M/(GC6*7-LG[Q%&%5N.0!T%7;:\MKV
M+S;2XAGCSC?$X89^H^M-N[^SL$5[R[@MU8X4S2! 3Z#- %4^'M%)M2=(L#]D
M&+?_ $=/W/\ N<?+^%$GA[1I=875Y-)LFU)?NW;0*91Z?-C-5K_Q9HVG:EIE
MA/?VXFU'<T/[U<; A;>3G[O  /<FM"75-/@NTM)K^UCN7QLA>90[9Z84G)H
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M -NZT;2[Z6"6[TZTGDM_]2TL*L8O]TD<?A45WX>T:_U*'4;O2;*>^@QY5Q+
MK2)CIAB,\58CU.PEO6LH[ZV>[3[T"RJ77ZKG-.AU"RN)GAAN[>26/.]$D!9<
M<'(!XH 9<:7I]U>V][<6-M-=VV?(GDB5GBSUVL1D?A5?_A'=%_MC^V/[)L?[
M2_Y^_(7S>F/O8SG'%63J>GBS>\-];"U0X:8RKL4^[9Q3XKVUGLQ>17,,EJ5+
M"9) 4P.^[IB@"G>^'=$U*^COK[2;*YNXUVI/+ K.!Z9(S5NRL;33;5+6QM8;
M:W3A8H4"*OT XHL[^SU&$S6-W!=1 [2\$@=0?3(/6I998X(FEFD2.-!EG=@
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MQZXH K-X:T-D@0Z18[8(_*A @4>6G]U<#@>W2M&**.")(HHUCC10J(@P% Z
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M:R8[FMV@4QL<YR5Q@G-20Z986\K2P6-M%(T8B9TB524'120.@[#I0!Y=JO\
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M,5T)T;2S/-,=-L_-G!$K^0NZ0?[1QS^-3VEE::? (+*UAMH0<^7#&$7/K@4
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ML=<D6W#P0-#)!*P!7@NP9>?8CWKKUUS26N$MUU2R,[RF%(Q<)N:0 $H!G)8
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MO+?3K&XO;J01V]O&TLKGHJJ,D_D*CL=-L-.5Q86=O;+*0S^1&J;S@ $XZG
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MTFX7269[B0!4,+RDF.*/(4L6!8MSVX.> #I=:\7Z+H0T[[9?6ZG4)DCM\RJ
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M%,_L;2_)\G^S;/RL[MGD+C/KC'6KP((!!R#6!+XOTE/%?_"-B]@2_-N93O<
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M+#[+8L+BZ&<+GBW4@?\ ?6?QKTGPW(TW@[29(G5W:PA*LQR"?+'7\:OC3[(
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M',\>HV0M1:W,4=M;ON2U4P($B+$EF?H.2"2/NBJT\6GGX8_$R14MBW]KWH#
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MR*0%"[0%W@8SCU&>:]6TVTL+:V62QM[>-)44EH4 W@# )(Z\5(+&S6W2W%K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!J-Q=2S0+<, ;BU:(+$$S]\  C SR?>@#M/ ^H76K>!M$U"^E,UU<6<<DLA
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MOYRXG8G "<_,<GM7 PW>A:#K'AO2K1?[)A_LZ<VFH7Q)D\HRC]U&'XWMPPW
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M9>:MP+4IYHSYIZ*!W^O2D7QOX9>"ZF76;4I:L$F 8[E)!(PN,G(!(P#D ^E
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MR%!(4=V/% %_RTW;MBY]<4I (P0#WYJD^L:='I\%^;R)K6XV^1(AW^;N&5"
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M-NJ!B5YPIW*<=-V.^*E\1+I$OAJ^U[PO!=WMD^I65SJEP'DD%W%$^7"ASSM
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M-W^_G0R0+)$\?GJ.K1E@ XQSE<\<TV]\4Z+ITS17=\(]DBPR2>6QCC=L85Y
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MO1[C27L8[A^(X)_-#G<>B[E  )ZD8H WK[Q9IT7A6]URRF%U%;QR$"-&8B1
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M\2XXXXR0.N:WM&U'PSXNNK&XTRWU)]=M(Y,?:I;DG369"K;BYV]<+@9S^!(
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M7,2Z[JUV\S%I"ZK<S,%&2>2J#:6)[*3WH M67C&\?XFMI=R@71KZ&2+39?\
MGI/ Q$WYY(^D8QUKNZ\L\<>&)M'\$V>HV&M7,\^@/%=6"3+" Y3 *Y5 S%ES
MQDY/7->B:+J]KKND6VHV;9BG0-M/WD)&2K#L1T(H S=.U/3CJ^O30ZU<7QA:
M(3VJJ9%M#MQA JY.[&2.?PK \&W]YXPL['7UU:^M;A;F9I[7RF^SR0^8Z)&
MP"Y 53N7G.<^S_#-Y:Q_$7QW*\\21E[-@[, I"P[6(/?!X/H:D^$<T;_  ZT
M^$./-BDG\R,\,F9Y",CJ,@@T ;FI>,_#ND7,]M?:K!%<6Z"26(99E!.!PH))
M]ASP3VJ:/Q1HDVCVVK0ZC%+973B."2,%S*Y. JJ!N+9!^7&>#Z5RL]_8:?\
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M$*^H+ XQWS0![""& (((/((I:S?#TJ3>'-,DC<.IM8_F!SSM&?UK2H ****
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M1<$ ;<D[L9XX'7&10!V5%8&E7^F3>(=?-OK-Q<30>3]JMI6/DV?RG&S( &X
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MJLO[O"ENF3M;'KBO3Z* .(^'#K_Q5(Y&_7[J9 01N1MNUAZJ<'!Z&J^E7?\
MPCGQ \4KK;F"#4FAN;*ZD!V2JL>QHPW3<I'W>ISD"N_HH \9NM,N-%^$=G9W
M,,L<DVLI=0VFPEXH3="0 J.1A>2.V<&O8A/"T'GB5##C=O##;CUS4E% 'EWP
M[T;2-63Q*-2TZ&X=_$%U<1I<PYWQEE*.%8<KZ&MC7=22W\?VUA-;36L,FFGR
M[VUM2\MPWF<VX<*=B@#<0,'D'(QSW-% 'B&ERJOP]^'EM-!.DMGKD37"2P,I
MC53-ECD?=!9<MTYZUVWBB7['\1_".H213O:K#>PF2*%I '=8]J_*#C.#CZ5W
M-% 'E&HV-UK&J_%"QT[=]IO;.V2V["8K"P95/0\_*?0GFNB\->*=*\2G3!%I
M,PU.SC(G%Q9M&=/.S#C>RXR2 N%.2/8&NUHH \2U9U/PJ^(XP1OUJ>9 5(W(
MTL>UAGJIP<'H:[#5X[?Q%XU\)W6D8F_LQYY[B6,8$,9CVB-O1F8@;3SP>.*W
M_&/AV3Q7X8N]$2\6T6Z"J\IA\P@!@W W#GBMN$2K"@F='E ^9D7:"?8$G'YF
M@#Q7^TQ?:9X3NVL[RVDM=?1KG3K>PD2&Q'[T%0H7YF)()/)))QC.*Z&TFA&N
M_$J1OE6>.'RRRX\S%ML(7^]AN.,\\5Z910!Y%I\ILK;X5WT\-QY%G:RV]P4@
M=S%(UL%56502"6!'2O7 <@'&/8TM% 'E7A[S],US1AX>OY+S1[RX<W&C7B;I
M=+)1RSHQ&Y%!RN#P=W&=V:ZKQW:Z?>V6G0WUY=Z>_P!L#6VH6S;3:RA'PS'&
M-I&5.>/FKJZ* /(=1N-:N/!<4^K*MY_9_B2V<ZA:VY N[='3]_L7\02./EXJ
M_K^K+?:YKUD;.[M!-I*FU>WLG\[4<J_#/MRJH2!M^4_,<G'%>GT4 >16=SY&
MG?"S49;>[%M91-!<-]ED)1S:[ -H7/+< XP:OO?)I7C'QU!=PW*S:G;6\MDB
MP,WG!;<HV"!CAA@Y(Q7IU% 'D-A:VUWX0\&JVJ7WA[6+73"+:_:(I&I C#QR
M*X"LK?*0#UV\&N_\%W>I7WA.RN-6MH[>^??YBQ(45_G8!PIY&X8;_@5;]% '
MB5YJ?V_2-(G>RO+2>S\2Q2W&FVUBZQ6:"=LL=J_.S AB<G)8X YK7UUI[+6-
M2U;PS?3)J#W4:WF@7<>^._/R#?&I&5;;C++P-O.,&O5J* .<\>74EEX(U2XB
MTR/4W2,?Z+)%YJL"P!)7^(*"6Q_LURVB7<<OQ9AO(Y=1O(+K0?+2[FM717<3
M;B!\H"@#V ^I//IE% &#XBU2TL[BTL=3LC<:;?)*D[& RI'C;@R  @(<D$GC
M.*X/1/#L=EXJU>T\$W<G_"/WFER^<JR%[:&[8X3RF]<9) )P.O8#UJB@#R?P
MG=Z)JECHFC:AH^K'Q!I;P[[.Y-P8[:2+ \X,28PH )'/.< <UO\ P]>,ZIXP
MP,-+K<LR$J1YD92,!@>ZY#<BNYHH \\TO2+[3_&^I>'UMV_L*>Y36HY?X5))
MW0^W[Y5<#TSZT^^5[CXO7202&-Y/#;6R38.U93,2%STW '=CKCFO0** /,_!
M&NV4OA_1O#&H:+<'7M+,<3VL]FQ6%H_E\\2%=@&,L&!R2<#K6;93Z79SZUX7
M\5:=J\]W/?W$MO#']H>&_CDD+H5"'8#S@[L 8Y/7'KU% %7?%8:6IFV010Q
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M:?KL4[V,K,UO*89XI(VCDB<=596 (_K4M]JMMI\L$,OF///N,4,49=V"XW'
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M(K'O"/M)#-[ ^M9.CM8:;]AUA[O6!<WUNMJ+"9W<7,N YD5&R=V <L"%QG-
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MRWD-KX<U$ ^1IVO6EQ<'LL>XH6_ N*Z'Q23_ ,(IJR)'+*\EG*B)%&SLS%"
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M$::)O^$RTK4-+OX[2]U&63%XC8DADB11\[$[B<'N2.^*F^'UCJB&6/5V$O\
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MK;SS$=BHYVCCD]23CISC^.K62\\9>#F&FW5W:VEU*]TR6CRQHK1[06(!!Y-
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M+)#*@>-U.0RD9!'X5)5;3X?LVFVL'V>&W\N)4\F 8CCP -J^PZ"K- !1110
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M%7D#)YZ4 =G16+9>);6ZUM]%N+:YL=1$/GI!<A?WL><%D9&93@\$9R/2N?\
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M(O#&O^-3+9ZO?Q0Z@CL+:-IS#'Y*$LQ8\#)/&<]<# H ]2HKS[Q)J%MJFK^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M \\UG0;+4;?2H+O1;[1Y(HI9K2[T:-M]@Y;[A$0(RP()X*Y!YZ&JK6OB5(_
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M3N5E([@C- '$Z+JL-QXJTZ]UK3_$$5]'!]AMKB\TSR(07(R6968;V( SD#L
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M#RZY-<P6T4!$DT4A0*RAL>Y(Z@#I7H-% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO4'E<],UYG9:EKEHG@#5)M;N;K^V!%!=VTB((B'MRX88&X,",DY.<GH.*T?
MEK*OBOQD[W]W-Y>J!-LKA@W[E#SQVZ#& !VH [MY8XWC5W56D;:@)P6."<#U
MX!/X&LG2/$<&L:MJ^FQVUQ!-I<J13><% 8NNX%<$\8QUQUKFO%MM+/\ $WP6
MBW]W"LHO<K$X 4K%P0"",_,1DYX]*R7M;Z;Q)\29K/5KG3WMS;S(ULJ;F=;4
M$;BP/R\=!C/K0!ZI3)98X4WRNJ+N"Y8X&20 /Q) _&N$MM9O]8T_PK//J$B_
M;]+%Q-96(VW$\I1#N!Z)&N6R25&2H)/2N9N=1U+7_AUX0O;_ %"Y%TWB"&WE
M:,JGF!;ED4L ,$@(#Z9YQ0![)6?I^J?;-+%]=6D^G#<RM%=X5EPQ4$X)&#C(
M^HJTL++:" 7$NX)M\X[2^<?>Z8S^&/:O'[V^U+6OA#I%[?ZI=273:VD<DBE4
M\P"]*#< ,< # Z<#CB@#V:BH C6UB5\\NR(?WLY'7U;&*\YTW7-5B\0^#X_[
M3N;V+5/M$=[<%0+>X98BX:$$!@ 1P0 "#WH ]-H/ KR:>^\13>'/'-^/$MZD
MNAW]Q]DV1Q#(CB1PK_)@KSC  ZDG/&.BM]>NM?\ %=CHGGR6L(T=-2N3 =K2
MO(P55#=0HY)QR21SC.0#?\/^(H/$2:BT%M<6YL;V2RE2<*#O0*21M)&/F]:V
M*X3X8PR6\?BN&6=YW3Q#<J97 #/\L?)P ,_A4/C#4M1MG\1O;:K.9++3A<6E
MO8@ VK!'8R3EOE() PI)) .%[T =1JGB.#2M<TC2YK:X>35)&CBE0+Y:E5+$
M-SGH.PHTWQ'!J?B'5]&2VN(I]+$1E:4+M?S Q4K@GC"]\=:Y/5+R74=2^&=]
M/CSKF8S/@8&YK5B<?B:T/#O_ "57QK_UPT__ -%R4 =K17$^++K5T\;>%M-T
M_5YK*VU'[4DZI$C?<BW!AD9W<G&<C.#@XP<6#5=?TF7Q?X?N/$*$Z?%!<66J
MWR*6B27.5?:,,PP0O')/3M0!ZA17 Z3?ZA<>.-4T$7>I0V,FDQ7<#76WSHG,
MC(77.2 < [7'!'056T/6]5O="70+O49QXE@U0V5U. H;:I\PR@8P%:$<<8R1
M0!Z/17G]NNLZMXT\7:,?$5];VMI#:/;F%8P\9=)"0#MZ9'IDX'/7.':Z]X@D
M\$>$O%<NMW#7%U>6UO<6JQHL,L;R>6V1MSN/7.>#T H ]<HKS^ZO]=\277B2
MWTB>:VFTZX-I:-'.B*D@C5M\BE26!9L8Z8' SDTQ[GQ)<>--$TF[UE[3[5H\
MDMY':+&RK,C(K&-BN>23][..< 'D 'H$LL<$+S2NJ1HI9G8X"@=2:?7C.MWN
MI7_PLUR&\U2ZEETO7_L"SY"O-&MS&H\S P3AO;.!FNH\5ZQ=^&M1M_[1DU?_
M (1_[*0VI6@#M;S[C\\P SMV[<<$9SD'L =]15+1Y1/HEA*+M+S?;QM]I3[L
MWRCYQ]>OXU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HK,\0ZRGA[0+W5Y;::YBM(FE>.';NV@9
M)^8@58@O3<:3%?16\C^;"LJPH5W'(S@9(&>>Y% %NBLCPQK\/BCPY9ZU;PR0
MPW2LR1R8W !BO...U:] !1110 445R-SXWF^S)>:7X>U'5;*626&*:T*G<\9
M8'*DY5"58!O;IR,@'745"MR@6W$W[F6?A(G(W;MI8KQU( /3TJ:@ HJ.>>*V
MMY)YY%CBB4N[L<!5 R2?PJ2@ KF=,TM] \5ZM*B,;#6)$N0RC(BN NUPWH&
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MO[IF2!K=+8A/*56(+$?+NR2JY.>PJGKWA*#7M9TG57U"]M+G2W9[<VWECE@
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MWBM^B@"GI6F6NBZ3::99(4M;6)8HE)R=H&!D]S5RBB@ HHHH **** "BBB@
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MU(QFJ-_\OQUT@G@-H<X'N?-!KKM*T>WTG[2\;22W%W+YUS<2D%Y7P%!.
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MX]Q*ER#@$,R ^601D9.#TQ712>#-+N/!B>%;QI[K3HX5A0RL!(BIC9AE Y7
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M5+>-8U>7&X@# S@ =/:K- !1110 4444 %%%% !1110 4444 %%%% !1110
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MK*6)\QQNW.FWN20-IXKK]!N(KKP_IT\%[]NB>VC*W1SF;Y1\YSSD]: -"BN
MU.'4-2^*CZ*-<U*UT^71#<M%;2!"K><%^4XR#C'/7J,C-<O-JWB*V\(ZC9/K
MEX;G2?$<6GQ7N1OGA9X\"0XR2 _.",]Z /9Z*X"X^T:7XPT7PM_:^ISVVI-=
M7LTUQ<?O3L5=L*.H!5026P.>,9P<5';KJMQXA\4^$(]4O!%':17>G7AF8RVS
M2!AL+YRP#+D;LG&0<T >AU2LKNZN+R^AN-/DMHH) D,S2*PN%*@E@!R,$XY]
M*X[PIJ\WB72= MWGNHKVSWG50)VW"2+,91SG/S/\PSV4UDWGBK4_#NF?$2^-
MY-=R:;=11VGV@[A%YB(!P !@,^<8[4 =QJWB-=)U_1=*>RED_M25XDG#*$C*
MH7P1G).!Z8]ZW*\WU[25L/&O@.1;^]N6:[F60SW#2"1OL[G> 3A3UX7 YZ<"
MH;>3Q+XNT&XU;2;^*ROTOI5AE?4)5CA6*8KY<D 0H047G.3ELY'  !Z7,[10
MNZ1/*RC(C0@%CZ#) _,UE>%?$$?BGPU9:U%;O;QW2LRQ.064!BO./I6!IEY+
MXK\3>([6>]N;>#2VBMH([2X:+#,F]I25(W9)P <C"].32_"+CX6:$"<GRY.?
M^VCT =M17'^(KNZM?B#X.A@NIXX+R2Z2XB60[) L)9<KTX/.:YO5-2U2'2_B
M6L&JWL1TQE>T82[FB_<*Y +9(!8F@#U2LCQ1KP\,^'+W66M);I+6,R-'$RJ<
M>N2>GYGVKD89-0TSQCX,/]L7]RFL6TZWD,\NZ,E(1(I5>BD'N.2.I/6L+5[J
M7Q;\%]>\27%[=I/,MR8X(YV6.&-)&18R@.ULJN22"<MVP, 'KUO+]HMHI@-O
MF('QZ9&:DK@/MM]K'B.70(6*PV>E6TP1+^2T=FDW N&C4DA=JC&0 2<YXQFW
MJ>)[$>#--U+Q$YO);^2TNY;)QB5/+=EW94'>  .>,\XH ]1J%[F))Q;[@9VC
M:18@1N95(!(S[L!^-0:1IQTK2X;%KV[O3$"/M%Y)OE?))^9L#.,X^@%<:+")
M_CG,YENA_P 2*.? N9 N[[0PQC.-N /EZ=\<T =)X8\1)XFTZXNUM)+7R;N6
MU:.1@S;HVVDG''7W-7I+NZ36(+1-/D>TDB=WO!(H6-@1A"O4DY/(]*\>/VW3
M?AUXDU^RU6]MKG3]<NI88H9-L1_TD AU_C!!(P>/3OGO;V[O8OBUI-HM]<?8
MI],N)&MMP$>]60!L <GD]<T =C17FNAZW<P>)]/TSQ&VIV&K-<2M',9FDLM2
M0J^T)SM4@%6"X!&T=S7I5 &/XA\3:=X8@LYM1EV+=W<=I'_O.>I]@,DGVK8K
MSKQ58MXPGUNR;2;R\M(K5K&UF@:$*DY(=W^>122K+$.!P589Y-7_  AJ5SXQ
M^'(BGN)[/5XD>QNI(W*R0W,?RELCOG#8Z<XH [:BO&W\4WL?A[PSJ<MU?"?2
MKCR/$$2W+X"))Y+LXSUWD./4!NPQ76:I<R-HFKZHNMSV$5U>1P6SY:7$:NJ%
M8D!^_(P?:5[,I'K0!W%%>;V-]J0UWQCI@N-0M+>#3H;JV2>X$TL#,LF2&8MC
M.T'&3CMBLN'4=4T?X;Z3XE?7M1GU#5+:TLS]HD#0P-*R@S!2/OA2>23D]: /
M0+SQ&MGXNTS0&LI2U_%-*ESN78/+ )&,YS\P[#KWK<KSS4-,33OBUX1,=S=R
MJ]G? K<7#RX(6/)!8DC.1D#C@<5Z'0!CZ]XFT[PX=.&H2[/M]VEI#C^^V<$^
MP[GW%;%>:^*]/E\9?V];KI-[=PQP&QL+B%H0J3*P=W&^13Q(J*<#_EF?6M7P
M]XEU+7_A=)J=E&&UZ&TEA>%QR+N-2I!'NP!Q[B@#M:*\QTVXO]4U#P<^E:MJ
M;QW%LTFL_OBVS$8(+AP1&QDR-H R"<<#A^B1ZC>:GXGO+K7]7DCT75G:"W28
M*LBK$K>6XV\J<]!CUZF@#TNBO-M(3Q+K>D>'?$EGJ4$+RF*YO6DU"5X9HF'S
MQ^3LV(1G (.01R3UID3^(_&&E:E?:3?)9WT.HS0V\IU"1$@$4I4(\(0HV5&3
MNR?F[<  'IE%>>QI?ZK\1M2TNXUN^2R;2+>X\NTGV*KL[@[& R!P.>I]<<5S
M:ZAK2_"FU\4/K^I/J-C>B%/WN(Y46[\DB10,.2O4G)H ]FHK@KRXU3Q)XE\2
M:1:S&'^S5ABA,>H26S1M)'O\TA%._DXPQQ\G3DYHSCQ"OB7P7I>HZ_+YUU:W
MD=^UBX$<CQ*H##Y1AN3GC@YQ@@&@#T>XN(K6VEN)Y%CAB0O([' 50,DG\*D!
MR,BO%M?>ZF^&/CW3KO4+VZ32M1:*VEFN&,GEXC8*[9RX&\_>SV]*]ALK9+2T
MCAC>5U4=996D;G_:8DF@"Q17'76HRZK\27\-R3SP65MI8O"L$K1-,[2;<[E(
M;:H'0$<MST%<=K&N:]:^$?%EDNK7:W&B:K!!;7@8;Y(I'CPKMC)*JY!(()XS
M0![%63K&NQ:5<65FL$MU?WSLEM;1$ MM&YF)8@!0.I]Q@$FI-'TE])6Y#ZG?
MWYGF,N;R0.8\@ JF ,+QG';-8WC3PPGB5M/^R:K+I>NV1DN+"ZBY*_=5P5[J
M<J"/I[@@%ZU\1RSWM[8RZ-?07EI LYC8QD2ABP&Q@V#]T]<8J;POKT?B?PU8
MZU% T$=VA=8W;)49(Y/X5S'A3Q'K9\1W/AGQ986\>M0V?VB&^M?]5=0!MI./
MX3DCCZ\#OR'ATWND_#GP'J]KJMZCR7]M:O;B3$#0R2LK*4Z$\YW')S^5 'MM
M%>6>-M4O[73O%FH:?JM[/<Z>T;0M;2&*&PVJI,;C=ME8Y)(VM@, <<5HZQ'J
M.J_$BTTE=<U*RLKO1)9G2UE"%'$B ,IQP>>IR>H[T >A45YN@UOQ*?$-A8W\
MD=QID_V&UG;49(7C98D(E=$0B3<Q).[@@8 '4LU[5=9T<VMSKJWMUI7]FQI<
MWVB3,/LMR"V^5D4@LA&T@D$#:>.: /2Z*IZ3-'<:-8S0W0NHI($9+@?\M05&
M&_'K5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHJEJUS?6FESSZ;8"_NT \NV,PB\PY&?F/ XR?PH CL]$L['
M6]2U:'S/M6HB(3[FRO[M2JX';@FJ$'@_3('@56G-E;W)NH+%F'DQ2DD[@,9X
M)) )(!/ &!CH!G R,&B@#,U#0K;59D.H237%LCB1;1R!#N'0D  M@\X8D9YQ
MP*-2T6/4[ZPNI+NZB-C+YL4<3*$+[2N6!4YX8CVSZ\UIT4 8WB?PS9>+-)_L
MS4)+A+8NLA$#!6)4Y'."1@^F*U+:%K>VCA:>6<H,>9+C<WN< #/X51\0ZJ^A
M>'[_ %5+4W7V.!YVB#A-RJ"3R?858TJ]_M/1[*_\OR_M-O'-LSG;N4'&>_6@
M#/O_  W%?W5[,=0OH4O81!<0Q.FR10".C*2IP2,J0?R%1S>$-.-]8WUC)<:;
M=V=L+2*:T*@F =(V#JRLHP",C([&ET7Q&^K>(-=TE[$V[:3)$A<R!O-\Q-X.
M ..,=S6]0!2TO2K71[,VUHK -(TLCN=S22,<L['N23_D57U_P_9^([*&VO'G
MC\BX2YAE@?8\<B'*L#^?YUJU5DOHQ-<6T&)KN")96@#8.&+!<D],E&_*@#,A
M\*VUOK[:U%>WHNVM!9Y9U8>4"2!RI)(8DY))SUSTK-3X<Z3%I]A:17FHQ'3[
MI[JUG2<++$[DEP"%Y#;CD$'K6KX2\0#Q5X7LM:%L;8708B$OO*X<KUP,]*VJ
M .67X?Z(MGK=HQO9(-9R;E)+EF&X@ LN?XCM!R<GCTXK>TVP73;"*U2>XG"#
M'FW$A=V]R:MT4 8]UX<M[OQ)::Z]S=)=VD3Q1*C+L"MC<""O.<#OVXJ@O@/1
MVTS5M.N6N;JVU2Y:[G65QD3'!WH5 *G*KC'3%=/10!C6GAV*WNUO)[Z\O;V.
M V\-S<E"\*'!.T*H7)(&202<#)K,_P"%?:9_PB__  COVS4/[/\ /\_;YB;M
MWF>9][;G&_YO_K<5UE8/B[Q&_A;1/[2%B;M1-%$RB0)MWN$!S@]V':@"IJW@
M+3=5UF/6!?:G8ZB(A#-<6%UY#7"#H),#!_#'Z"NCM;6&RM(K6W0)#$H1%SG
M'N>OUJ:B@#&U+PU::AK%MJZ3W-EJ=O&85NK9E#-&3DHP965ESSR.#R,5#<^$
M-.N?#EWH9DN([:]9WNY$<>9.S\N68@\GVQQ@# XK?HH K6%F+"QAM%FEF6%
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MDUEXCD@MY1=.62/SXDV;B<E<,1CWKTC4O".E:E-ILQ%Q:RZ<ICMGLYV@98R
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MU!C(+84ACD;0,=!@52^%MA!;6FOO$9\KK=[" \[NNT2<<$D9_P!KJ?6MG0O
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M $$Z-=?:9+4W'VDL9V\SS-V_=O\ O9W'.<^W3BMZ&/R84CWN^T8W.<L?J>]
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M]BL]1<R7%G#=ND#.3DL$!P"<?3VZ5U-M;QVEM';Q;_+C4*N]V=L#U9B2?Q-
M')>/)[BTO?"<MM<W$#2Z[!;RB*9E62-ED)5E!P02HZCM6;<377_"7>.+1;^]
M2&+2H)X56X?]S(5E)9.?ESM'3'2NPU[0+'Q'8):7PE"QS)/%+#(8Y(I%/RNK
M#H1S^=9\7@;1X;J^ND-[]HOK<6UQ*;MRTB $<Y/)Y/)Y';% '#V+7MEHWPXU
ML:MJ4MYJ$]M;70FNG:.6.2%B04SMR"H.[&<\DDU>$Q\6^'?'%[>7-TDEG<7E
ME;Q13O&($B3 ^4$ ECDG.<@XZ#%=6?!.E'3])L=]V+?2)$ELE$Y_=LHPISWP
M"1SGK3+OP'HUUJ-_>J;RV;44*7D=M<O''<<8W,H."<'KW[YR: .1T"_N;R/P
MEX=7:;<^&8;ORVNGM_.?"K]Y 2=H&<=/FSV&&ZS9:[HVB:'97/B*XDG_ .$E
MM[=9+>X8LMO(P812$_?(!'+#D8KJ[WX=^'[W2M,L&BNHAI@Q97$5U(L\ QC"
MR9SC ''2K,_@K2+C3K&Q;[4(;*X6[B87#;VF4Y$C.3N9L^IH TM'TF/1;$VD
M5U>7*>8T@>\G:9QN.<;FYP.U5?%>CZ7K^@RZ3JS,EO=NL:NC;663.4*GL<@8
MK9484#).!U/>J.L:-9:[8BSOTD>$2)*!'(T;!E.5(92""" >#VH X'3[[Q3X
M+\1Z1HGB.>+7-'OI_L]CJ>W;<0R[3M60=\C(SUZG/:F6RZUXST34+^RU%;#4
M(=1GCCN?MTJBU$4I 1H0-A!0#(/7=D]L=M#X9M$U&WOKFXO+Z:US]F^U2[UA
M)&"5  !;'&XY/)YYK/G^'GA^?79]6\JZBEN6#W4$-RZ07+#O)&#AO<'@]\Y-
M &79R2>+]=\4Z;=:A<0/8+#;VPM9WC\K?"'\X!2-Q+$XSGA1ZG-&]TJ-_B/X
M,2YO[B]F&FW<<MTD[Q&9HQ&-V$;"Y.<@=>^:ZC5_ VC:SK2ZO+]LMK[RQ%)+
M973P&:,?POL(W#]:M7_A32=0N-,GDADB?3%9+;[/*T6U& !0[2,J0HX]J .(
MO->U'0+WXF7<%Q<7)TZ&UDM(YI#(L+-"2< ]!N.2/:K.MO<Z!IWA76]+O[R>
M:XO;6VNEEN'D6\CFX)*DD!LD$$ 8Z=.*Z^W\+Z;;ZEJM]MEEEU552\69]Z2A
M5V@;3P %XX[=:AT[PAIFFBSCC:YEM[%MUG;SS%X[<X(&T'DX!(&2< \8H X6
M:TN;Z/XB>;K.K@:;*TEF([V1/*86X<$$$$@'^$_+[5Z'X9O9K_PCH]]<L7GN
M+"&:1L?>9HP2?S-55\'Z:JZP!)=XUC/VW]\?WF5VG']WY>.,<5JZ7IT&D:7;
M:=:F3[/;1K%$)&W%448 SWP.* /'?%_B">YT(W5]X<UZ"^N-1M&+S686..-)
ME*1*=W)Z_5F/08 ZK1YGN?C-=W<T$\'VGP]#)!%<+M=%\T[E([$,1D>]=IJ^
MC66N6:VE_&SPK-', K%?G1@RG(]P*;J.BVNHW-O=N98;NV#"&X@;:ZJWWE]"
M#@<$'D ]0#0!Y=8^'-0\0OXHGTN:**XL?%GVZR\[(BDEB4!E;'.#DC([BMNS
M?4M=^,-M//:P6Z:+IKK<^1.95$LQ&V,MM7G:-V,=,>M=M;:-;6.EKIU@TMI"
MI)S$P+L226)9@22222>N>]/L]'L].T][.RC:WCD+,[HQ+LS=7+')+'^\<F@#
MA?$FG3>,H_$$(TF[NK=H386-Q$\(6.1&W.XW.ISYJJ#Q_P LAZUT/P_\02>)
M/!UG=W0*W\.;6]0]5GC.U\^F<9_&MC1](M]$TR/3[1IC!'G9YLA=AGGJ>3SD
M\UBIX&TJRL];CM?MY_M?>]VBW9!D=NK#)PK>XQ0!U-<]XSG6'0D5M2GL#-=0
MQ*;=2TLY+C]RF""&?E<@C&2>U7] TV32-!LM/EF:9[>((79RQ^F3R0.F3SQ3
M=>\/V'B33ELM020HDJ31O%(8WCD4Y5E8<@B@#@[:YU!+OX@Z>9[RTAM;&"YM
M8A=L[V[-%(3M?/RY**2 2 <XJO9?;+"T^'&KKJNHRW.I&"WNQ-=.T<J/;EL%
M,[<@@'.,]R2:[-? FBI<7]POVT3:A;BVNG-W(QE4 C)R3EL,1NZ@'C%/;P7I
M;6FCVV^[\K1V5[("<_NRHVK_ +V!QSGB@#CY)CXL\%^.-2O+FZ66VEO;6"**
M=T6!(4(4;0<$GJV<YW8Z8%=OX-_Y$;P__P!@VW_]%+5*[\ Z+=7NI7*F\M_[
M30K>PVUT\<4Y(QN90<;L'\>^>:W-+TRVT;3+;3K,2+;6\8CB621G(4# &6)-
M &1XSG6+3+.-M1N+,S7T,8CMES+=_-GR%((VE@#ELC !SQFN,^UZE%8?$JS^
MU7EJNG6Z7%HBW;.]NS6Q?"OU R < X!R!Q7H.O\ AZP\26<-M?K*!!.MQ#)#
M*8Y(I%SAE8<@\G\ZS?\ A M#WZHP6\!U2$07A-W(WFJ%VY.2?F(X+=>O/)H
MY:V6ZT[5?A_>IJ>HRR:I$8;U9KIWCE7[-O'R9V@@C@@ ^I-2#4+KPKKWB+0;
MBZN[F348UN=%:YNI')+D1&$$G(VR,IXYVMGM76MX0TUSHY,EWG1_^/+]\?W?
MR[>?[WR\<YXJA9K+XH\26>I7N@76GQZ.TPA>]50\DK?)E,$_)MR<G&25QTH
MZ33;+^SM-MK/SYIS#&$,L\A=W(ZLS$DDGK5JBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKFO&DT4>G6$,M[
M<P&>_AC6"V'SWASGR,Y&T, <G(& <T =+17DQEOHM,^)UD9I[1=/@$]K%!=N
M?LS&U\SY'X(&X [1QG(ITUC);S_#^[AU+4DGU-5M[QQ>/^]C-N6QC.%P1P5
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M^T/NAVVZ,H4YR #S@<5?FGN?^$A^&DGVNZ_TF&43IY[;)<6A8%ES@G))SC-
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M/A#1_.TF417 ;2%*V7^E2_N@1M/\7/''.>.*W::[I%&TDC*B*"S,QP !U)H
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M13B&&X6YR;F0M)*I!#.V[+G('WLC@>@J5?#6F)XCFU]8I5U&:(0RN)W"N@Z
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M^%8?#RK_ *(EK]F;8=A8%<,>.A.2>/6KVG6%OI6FVVGVJLMO;1+%&&8L0JC
MR3R:LT4 %8-UX/TF[UTZW)]M743#Y'GQ7LT9$>=VP!6  SSBMZJUQ?VUK=6E
MM-*JS7<C1P)W<JA<_D%/^30!D3^"M#N[34+:[@N+N._C2*X-S=RRL50DJ%+,
M2N"2>,<\T6?@O1+'58-4C@G>^B@-OY\UU)(SIG.'W,=^#TSG'&.@KH*Q];US
M^S+O3+"&-9+W4YVA@#DA5VHSLS8YP O0=21TZ@ I:1X"\.Z%J)O=/LY(FWM)
M'"9W:&)FZLD9.U2<GD#C/&*D'@G1!8:I8^5<FVU21I;Q#=R_O6888YW9&0 #
MC'2K^B7.JW-DYUBPCL[I)63;%,)$D4'AU/4 ^AY%:5 $%E:16%E#:0;_ "84
M"('<L0!T&3R?QJ>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KA_BD)%\-6<D-S<6\@U.T0/#*4X:50<@<-QV(
M(KN*XWXEZ;=:OX;M[&TL9[QVOK>1TBXQ&D@9CG(QP#[T 8ES8IX/^(]F-/OK
MN'3=2TV[EU!9KAYA$8@I$_SDD'YL53TLO;>(_ ,MH)EMM0BN%DN9I?WVH)Y!
M</,HXY(##))&>W2O1+70=-C,TY@DFDN8/)D>ZD>5S%_<RY) YY'<]:S;;X>^
M%[3[#Y6F'-BY>V+W$KF+(P5!9C\N"?E^[[4 <L9I/">OZ_X;&Z0ZTJW&CM,Q
M?YG(C>+)_A1B'P.BDU:OM%@A^)'A[25N+W[$=(N%DB^U2 2;#& 3SU.3DC!/
M?-;FG1ZCK^O6^J:OH7]F+IGG):K+*DKR.^%+@K]U=H(]]WL"=>?0--N=;@UF
M6&0W]NACBE$\@"J>HVAMN#@9XYQ0!Y7_ &3"_@/QV6N+T_V)?7HTT?:Y!]F"
M(LB[<'G!/?/''K6^+ZX\0>*;#1KV:U:-]!AO$ANHV99Y'8B1@ RY( 7'7&21
MBNJ7P;H:V.I60M9OL^I.TEXANYCYS,,,3\W<<''45%JG@3PYK-E8VE]8-(E@
M-MJXGD62(>@D#;L>V: .*U/1[O2;3PAID_B"[OGCU\6K312O&?**.PC/S')7
M@!CR/48I9M/@M9_B5HB>:VFQ:;#<QV\DK.$D:&0L1N)/)13]17>2^$=#EM].
MMS9,L6FR"6T2.>1!&_/S?*PRW)Y.3R?6I4\,Z3'J-_?BV9KG4(Q%=,\SLLJ
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MT!W*4)]& H ]2HKR/PS$ZRZAX'O[013SWL=^B-R5LG_>D$]3L*F'/8L,5?\
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M"1H6+;5'0 DDX%3Y&<9&?2ER/6@#!/@S0BDR):2Q13LSS10W4L<<Q8Y8NBL
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MD8,,NYY!ST+5T4!U/^UKP7 M/[."1_93&6\TMSOWYXQTQCWS5MF.QO+VLX'
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M7%KJMZNGLH^6%DDR@3.=J9XQZ'%;FB:LOBO3$\2VMDGGZ=IK1PQ&/E+LKF1
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M>(02$3./,C&<(^&^=>3PV1R:GDT'3)=3MM1>T7[7:KL@E#$&)>ZJ < 'N.]
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MD:SG,MP8UP&E8[G(]LDX]  .U9LEMJ^KZXEG?:/;6FBZ?<I<03BX$C7)0?(
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ML".#7I/*$;85.81QCC')XKLO$'A(6'V:7PS;64EZURUY<6%](QCU A-A)))
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M7?!<$P+1OJQ#*"1D>3)QQVKD]6:?PU;_ !1@\.PBT2WBLY8H;5=BP^9'B5T
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ML;2()&^ZI89/T%>?^%_"-KKO@WP?<ZI?7EU;V=I;7,-DQ181((QM)VJ&;&>
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MUY!XR\/:?IG@3QL8+^.Z\]8;IK:*,)#:R9QN0 G:6 R1GW[UJ^*++2_#&H:
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M\/0PVL,6C64<=HYDMU2( 1,>K+Z'WZTS4--.EQ7VJ^']&M)]:F"[@\GE&?!
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M)*Y;Y2,G!&>]6Y]?U/1-<T:SUH6<EOJS- DMM&R>1.%W!#N8[@P! /'(Z<\
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MSPN$A6-;@W!^62-^-[!B6W9ZCYCZUZ6NBZ4M^E^NFV@O(T\M+@0KYBKZ!L9
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MWXTU_#&@R+9J^BZ>RV1S:@VR8A_W./E[=/2@#R&Q%K/\+/!XE,$WD^)(H\D
MA8S=R#'?"D <=,"O;4BM9;/R4CA>V*[-@ *%>F,=,>U4CX<T1M/FT\Z18&SG
MD,LMN;=-DCDYW,N,$Y[U?%O"+86XB00!-@C"C:%QC&/3':@#PN/2=/3X"VFH
MI:Q+>P:B/)N5&)(O^)@5PK=5&">!ZDUV<]IIV@?%FV>TMH[.!] N'N!;IMW[
M)$() ZL,GGK77_\ "+Z!]@^P?V)IWV,/O^S_ &9/+W>NW&,^]3_V)I7VZ.^_
MLVT^UQ)L2?R5WJO3 ;&0/:@#RBRGLXKOX<7=F]O;6+SS&!7D#W'E-"Y+2R9
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M>/8-I)@D))'KGGZUC6FFV-EX2^%VIVUM%%?RW]G')<JO[QT>!]RENI' &.F
M!7JI\/Z,9KJ8Z59&6[&VX?R%W3#T<X^8?6F'PUH306\!T;3S#;-N@C-LFV)O
M51CY3]* ."TN30M=A\:Z9XIGABNEU.59_.D"2);J08&0GD*% (QWR>_.C:FU
M@^,,SOB*.3PS$Q\[AF G;);/4@8SFNMNO#FB7NJ0ZG=:3937\./+N)(%:1<=
M,,1GCMZ4^_T+2=4NK:ZO]-M+J>V.Z"2:%7:,^Q(XH \:@MK*[^%_AS*1,$\4
MA%9>"BM=OG!'(R/2NH\1>%= L_'?@JTMM(LX+>XN+TRQ1Q!5DS 200.HR.G3
MM7;MX6\/O;K;MHFG-"LAE"-;(1O/5L8^][]:L7.B:5>7-O<7.FVDT]MQ!))"
MK-%_NDC(_"@#SY8=+M/'NI>&[J:UTVS33H%TVWFB0QO"=_FA-_&=QYQR<#^[
M5?35LM)\4^#- .H2WNAQVET;&>Z8$3W"OA>< -M3<$]B,=J]%U;P_H^NK$NK
M:79WPB.8_M$*OM/MD<4_4-#TK5K%++4-.M;JUC(*0RQ*RH1TP#TQ[4 <7X0G
MTO1_%7CYS-:V=G%?PR.S.J1IF%=Q)/ ^8G\:]!CD26-9(W5T<!E93D$'H0:Q
MI_"FBFPO+:VT;2T^U*J2AK52CA<8W 8W 8&!GL.E:.F:?#I.E6FG6^?)M84A
MCW==J@ ?RH \>FO+";2O"6HZ:\,-C+XH5X3.^^ZDW2R"1W;(V@Y(VX/&W)[5
MKZW+=:+?ZAK#06FN^&I]2BFN=ORW5C,K1J"IZ.H*H0.#@^G-=Y_PB?AW$P_L
M+3<3RB:7_14^>0'(8\<G)//N:G_L#1_MC7G]F6GVAI!*TGE#+..C'U8=B>10
M!4\97=E9>#-8N-1-P+-;203?9CB3:1CY3V//6N+TITM?BEH2E["!9- =%AMF
MSM3?'Y:L^?G//!P/85Z9/!#<P207$22PR*4>.10RLIX((/45GVGAK0K![5[3
M1K"!K7=]G:.W13%N^]M('&>^* .7^+-K!<>$[5IHU+)J=IL?HR9F4'!ZCCTJ
MCKUOI7AKQEX?L8UM=(TB\^U2[EA00F\(C"E@?E#; P!]Z[[4-)T[5X5AU*PM
MKR)6W*EQ$L@!]0".M)?Z/INJZ?\ 8-0L+:ZM.,0S1!D&.F >F* //W\-V]OI
MLMIX<\01&Z?61=P)<HK6IN-C.T&$'"D M@=" 1S6/K=^MYX*U#[;HT>E:C8^
M(;0W\:,&B$A>+,B-V#*5)[\G/6O4SX>T8Z;!IW]E6?V*W8/#!Y"[(V&<,HQP
M>3R.>:D.BZ6VFRZ<VGVS64V?-@:,%),]2P[GW- '))+;-\=&$3Q&3_A'2'VD
M9S]H!P??!%<7/%#)\%;J25(V\O7V(9@#M!OP#SVXKUNU\-Z'9/$]KI%C"T,1
MAC9(%!1"22HXX!))/KFEC\.Z)%IT^GQZ18I93G,UNMN@CD/^TN,&@"Y$(H[3
M;9+$$0,$6/ 4$$\<=.:\BMQ#JOP%O]0NN-<@:>>:;&)X[Y)25YZAL[0!Z$#I
M7L%O;PVEO';VT,<,$:A4CC4*J@=  . *I'0-'.H-J!TRT^ULP=IO)7<6'1B>
MY'KUH XC5+-+CX@> CJ=I;M>365V;H-&IW2"*/.?7!SBNZUF\M-/T2^O+Y ]
MG! [SJ1D% #N!'<8S27.B:5>7T=]<Z;:37<0Q'/)"K.GT8C(JW/!%=0203QI
M+#(I5T<95@>H([B@#R;6= N/AND7B/P9J4ATF:YB6;1)'\R&<2.%S">H;Y@>
M/SP,5>F:QUGQAXPT37=2AM'=8TACN$C^:U,*\H7]'WDXZ$UW5OX:T.UNH[JW
MTFRBFC):-DA4;">I7C@^XIVI^'-$UJ>&;5-)LKV6#_5O<0*Y7Z$CI[4 <%I=
MW8:?XYT;2;^_:YTU=! TNXOB,3.)"';)P"Y0)@]=OUYBU[2M L=/\&VNEHDN
MGQ^)4C1Y&\Q<,LI958]4W'&.F17HNJZ%I.N6Z6^JZ;:WL,;;D2XB5PI]1GI3
MKK1M+O=.33[K3;2>RCV[+>2%6C7;TPI&!B@#BGCC@^,,TVEPP>;)X69X_+
MD83@+TZ] /I7.,L.H? */4XL_P!MPD3"X _?K?";!YZ[RQVX]#CI7K"Z-I:Z
MBNHKIUH+U4\L7 A7S O]W=C./:F+H&CIJ#7Z:9:+=L_F-,(5W%_[V?[WOUH
MX>TT6PO_ (MZG'J6GVLS/HEM+-$\89&E+N"Q4\$\8R>:U/A*Q/PSTI2Q(1KB
M-<G.%6>15'X  ?A73'1-*-]+?'3;3[9*NR2?R5\QU]"V,D>U2:?IEAI-O]GT
MZRM[.#);R[>(1KGUP!B@#S+QV/%,/AWQ=<7.AV,EM/;2QK=_VB=T=L =H6/R
M^O5B-W))YP !.%U >*_AWJVIVD=JGD7-FPCF\U$=X@8_FP.6"GC'7CFO3+FV
M@O+:2VNH8YX)5*R12*&5P>H(/!%,N+"TNK/[)<6T,MM@#RG0%>.G'M@8],4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1=HP3R,@L,C'O67/\0=26S\0W-MX:,B:%.Z7/F7JIN1$#EEPIRV#]WIQU[4
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M9A=[2<7(=MR('*N@7Y05S@Y/3D#MC^'=1L?#5[\0+^9%BM;;4U8I& ,DPQ@
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M @'445PMS\13%X4O-;BTAG?3;LVFIVKS[6MF#!6((4[U&0<C''/M732:K/\
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MO&NT@A#GDL"=IQVR >B1R)+&LD;JZ. RLIR"#T(-.K-\/?\ (M:5_P!></\
MZ *TJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHJO>7]GIT/G7MU!;1$A0\T@0$GH,GO0!8HHHH ****
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M+XDG2.!X-,>RM;1KF,R,SMN9F(8J!P .3W/' KH/^$2\-?\ 0O:3_P" 4?\
M\31_PB7AK_H7M)_\ H__ (F@#GO#=O<:3\,(-$N!;G4(+-K;RTN4*NV" 0V>
MG/?GKP>^0=#U6/P+X8BL;BQ@U_P\T;QQS7"F*XPA1TW \!E8\G']:[6/PKX7
ME0/'H.CNC<AELXB#^E/_ .$2\-?]"]I/_@%'_P#$T 84][K6M^%M7CU"WL+*
MYN;.2VM[&*^27YF4C>\F  ,D<#. #U)P,N32]0BTWP+-;BRDN]" CN;>2\5
MP\@Q%E89X!YZ9QVKL?\ A$O#7_0O:3_X!1__ !-'_")>&O\ H7M)_P# */\
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MA@ML74>XM&K@Y&[@$OQ]*Z3_ (1+PU_T+VD_^ 4?_P 31_PB7AK_ *%[2?\
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M3_X!1_\ Q- &=X?UG7+YQ)KUOINEI$FTQP7JSF=_[W0;%'/&23GMCGH#J%F
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MVPL.F5?&<=1^->B?\(EX:_Z%[2?_  "C_P#B:/\ A$O#7_0O:3_X!1__ !-
M''R6&HZ]XPFU'4+>RL;"[T*33)E^WH\B%WR2 HP3^./?M5CPK=>*["UL]#U1
M=)6VL0L9U2*]#&XB3A0(B,AB  22,<D<UU'_  B7AK_H7M)_\ H__B:/^$2\
M-?\ 0O:3_P" 4?\ \30!B^";>XTVYU];Q8$^WZK->V^VX1R4<* I /#?+[CG
MK71:+/J=SI4,NL6<-G?,6\R"&7S%7YCC#8&<C!_&H[?PUH-I<)<6VB:;#-&<
MI)':HK*?4$#(K4H **** .&\,Z9K?@N"]TF/2FU*P:[EN+.>">-&59&W;)%<
MC!!)Y7.?05/JN@:I=^"?$=KY43ZKK8E+11R?NXF:-8E&XXR J+DXY.>*ZB?4
M["VE,5Q?6T4@ZK)*JG\B:GCECFC$D3JZ-T93D'\: .*GT75Y=7\$72V&(]'2
M078,J9!:'RAMYYYY[<>_%49O!FJZI9^-;.919'5[M+JRGWJVQHPFW<!R/FC!
M[\&O1J* .3TFZ\;7EJZZKIEAITT$+ /#<^=]JEVD*0N/D3//))Z#IFLC3O"=
MY9^)$UO2=,&ARO:3+J%M',K074Q \LJBDCALG<0IZ<<FN\NKVTL5C:[N8;=9
M9%BC,KA0SMPJC/4GL*GH X'1/"<UIXPM-;L]+_L,/!(-5MX9E:"ZD(&THBDC
M@Y.XA3TX.37?5!->VEO<V]M-<PQSW)801.X#2D#)"@\G YXJ>@#SR[\)WNH>
M([+5X]+&F:S;ZAOFU*VF4)<V@<_(Z@Y9F3:,%>#_ !8XJMX:DU-I_'EI8Z=Y
M[3ZQ.D4IE541S$@^<$YVC@_*&)YX'?TPC(Q69I7A_3=$FO)K"&6-[R4S7!:X
MDDWN>K89CSP.GI0!Q(\(Z]X/N]$O_#,4&J"UTQ=,O+2>;R3,JL7$B,00#N9N
M#V-7=?T3Q3??V)XBM4LSKFF7$DO]GF7]TT,BA'B$F!EL '<1C)/;%=Y10!QN
MMV7B/Q!X&UJUN;&"WO;^V:W@LH[@.L.01N>0@9)SR ,  8SS4.N:-K%]:>$$
MM]/RVEWL%U=!ID&%1&0JO/)^;(Z#Z5W%% '(W.CW]S\2+?5VLS_9HTF2QD8R
M+N#NZOTST &,^OYUG>$=,\8^'K&#PQ+:V3Z=:.4AU<7'S&#=D+Y6W[^.,DX'
M7G'/?U76_LVOVL5NH#>*GF- ) 9 N0-Q7KC)'- 'F>O>$_%6JZ9XFLY+&RNK
MF[O1-9WTMUAOLXD1TA5=OR8"X/(!.3R372R:7JTOQ%TS6Y+)!:PZ;):S%)@=
MLCNK<9P2HVXS@'VKKZKQW]G+>RV<=U ]U$H:2%9 70'H2O44 <WX.TF_TN7Q
M%_:5JL4>H:K->0_O%8&-PH"M@\-\O(Z<]:I_#[0&TJ34V%SY]C;W,MGI8Q_J
MH Y9E![_ +PE/I$M=/K>A:;XBTUM.U:U6YM&97,99EY4Y!R"#UJW:VMO8VD5
MK:PI#;PJ$CC0855'0 4 35YWHUW?6WQ*\>?9-.:\W/9;=LJ)M?[,N-VXCY?<
M9/M7H,LT<$32S2)'&@RSNP  ]R:Q-&L_#J:E>ZII-S%-=7SJ+B6.^:82,J_*
M""Q&0H.,#H* .5M?!>IZ+'X+MK6%;I=(N)KF]E614#-*K[@@)R<,YZXX K8N
MM%U+2_B!)XDT^W^VVE]9K:WELLBI(C(<I(FXA2,$@@D>O/2NPHH Y;0O"BP:
M?KRZI'&SZ[=2SW,*G*HCJ$"9[D*.3ZDT>"-!U'P]H'DZK/\ :[Y!Y"NN,F"+
M*Q+D_P"S\W/=S74T4 >6)X)\0?\ "&6D$<4$.L:7K;:M;1R2@Q39D=MA8=/E
M<CIU'XUJ/HFO:YXS75+_ $J&QL9]%ETV=#>!Y$+N&)&U<'IZ]^O:N_HH X7P
MI;^-M-M;/P_J-G8?9+$+$-6CN,F:%,!5$6W(8@ $DX')Y-9"^&/%&E^%?$OA
M.UT^WO+*]%TUA>&Z$959@3L=2,[@2>1P<]17J-% &?H5O=6F@:?;7J1I<PVZ
M1R+$Y=054#@D#/3TK0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *R?$&NQ:#:6SF+SKB[N8[2UAW;?,E<X )Y
MP  23@\ \'I6M7,^-O#MUX@T^QDTZ6./4=,OHK^U\TD([IGY&(Y ()&: $7Q
M->P^)3X=OK*WBOY[5KFPE29C#/MX9"=N58<'H<CGVKS_ %+5=3U_X&#5M6B@
MDFDO(I(Y(W+,2;T C! V@#"CD\>E=_%HUYJOB[3_ !!J5LEF-.M988(!*)&,
MDFW>Q(XP N!W.23C%<J/!GB5?A?_ ,(G]GL&F@N4,,PN3B1%N/-W'Y?EXP,<
M_A0!U%IXKNX_%=QHFL:=#9 6#:A!-'<^:#$K!6#C:-K#(/&1[FJ$?Q"+S:-.
MEE#-8:I,D2_9YR\]N'&4>1 N O3=S\N>]6+_ ,/ZAJ7CN/4YK:-=-?1Y=.F_
M?#S TC!B0,8P ,=:J^%=/\;:1;6GA^^&FOIUCMCCU..5O-EA7[J>41@-@!2<
MX ]30!-I_B[Q!J^I:A:6/AVW*Z?J)L[B22_V@+L#!Q\F3UY&.!C&<G%.7XD7
M,'@M/$,VDV\1CU V-];R7I!M6$GEDD^7\V.I&.AS6OX2TC4]*U3Q%-?01)%J
M.H->0&.7>0I15VL,#!^7/&>M4I/ 2W7B/7GNI%;1-3B\P6H_AN7C,4DGM\@&
M/=SZ4 ;MQJUY_:-Y:06,$\5M:+,[FX*[G;=B/&TCHI.<]"..:Y[3?&]G%X3\
M,745E9Z8FL$QP1R2>7;V^ S;=P7&3C &!DFM3POHFHZ'X.6TO95O-6:/]](&
MP)&"A%Y]D5!GV)[UC:1X8U.R\#:)X>U32+'4K:WB>&^MVD!##JCQE@.0<]=O
M4\\"@#:NO%,NGV=DNH6MO;:C>W,L$43W'[K:A8^87VYVE5!'RYRP'O3_  QX
MGDUV[U2RN+189]/D5?-A<R03HPRK(Q ST(([&N43P'KVEZ)IDVC740U'2=0G
MN+&TNY6>-;:0%?LY?KPO?L>/>NXT)]<GBDN=<AMK25\!+2WE,HC SDER!DG/
M0#  'O0!GW^L+!X_TG2GTF"22XM9Y8;YG&] NW<@&W(!RO?MTK!G^(NKQZ'K
M.KKX=A-MHU]+;78-]\S+&0&,?R?,>2>=HQCD]MK5-'U*Y^(.B:S#!$UC8VUQ
M#*3+AR9-N"%QT&WU[U@2>$=>D\$^+]'-M;"YUF_N+BW/VCY524@C<<<$8[ T
M >AM*\EH9;94=V3=&)&*J21QD@$@?@:\>U35=3U_X$76J:O%;O*]TKQR1N6;
M/V[!&T@;0  HY/'I7K]@LJ:?;I.@CE6-5=0VX @8Z]Z\V;P9XE'PON/"0@L&
ME2YS!,+DXD3[3YVYAM^7CC'//I0!U-GXFU ^,'T#4=*BMFELFO;22.Y\S<JL
M%*N-HVM\P/!8>YK*L?&]K9^%[[59-+M=-$>L/82(L@$0D\T(TLCA1@9)).*T
M9])U6;XB:?KPM8Q9P:=):R S#?O=E;@8P0-N.O>L[1O#^N:;H.I6D^G6%U]L
MU>>[DMI90T<MO*Q)0DK]X9],$@<XS0!U>D7MY>K<&[MX(U20""6"4R).A56W
M@X&.21CGIUJ+Q+?36>D-':.$OKMUM;4G^&1^-WT4;G/LIK*\%>%V\-2ZL(8V
MM--NIUDM-/,OF"V^7#X/(&YN=H) P/H+-]I5QJWBJ!]1TZUGT:V@81"1P^9F
M(RY0C'"C:#G/S-0!A?#25]'FUGP5<S-+)H]QOM)';+26LOS(<]R"2#^ K2/B
M^_74/$M@VE6ZW6CP)<Q*UX0+J)E8A@=GR_=(/7!_.J6I^%+VP\>:/KWAG3;&
M"&&&2WU",.(1/$Q!4 *N,J1G)]A5_P 0>%)M5\5:5JMO,L,2Q/:ZDAZSVY(=
M4_[[7!]G:@"32?%DVM:1X>OK2S@9M6&^2/[0?W"!27.=GS%2 I&!\S#FJ5QX
MYN[*XTUKW2EMK?4-3_LZ*&:8K<@%RBRE"N"I(Z ]&!R>E6?"GA.7P]JVL2O,
M'LY+EVTZ(?\ +O')B20#TS)V]%%<N?!_BV32[.">WTR>^L];CU"2]>Z;?>JL
MA89^3Y,*0,<X P!0!T1\6ZW<>)]7T33_  _#.^FO;%Y'O0@:.7)+?=^\ /N^
MQYZ XGCC7;CQ#\-?$MW86%O-I<230+-+*0\FPE7D0;2,!@<9.3@].,]%H>D:
MK9>.O$.K74$ M-2CMEC9)<L#$K*<KC@'=QR>E<Q_PB'BC3_!>N^#;2VLKFPN
M!/\ 8;Q[DHR)(2VQTVG+ D\YQS0!Z-I/_('L?^O>/_T$5Q'Q(M]0UZWGLM(N
M6AN-&B74U*'_ %EPK9BC]_E60D>I0UVVG1W5MHMM%<11?:HH%5DBD+*6 Q@,
M0../2L31/#<<UO<77B'1]/EU2XN))9795G&"<(H8KG"H%7\/>@"WI7BBRU+P
M5#XG!(M&LS=2!>2FU277W(((_"L4^.-05?#<QT>!X?$ 'V?%T0824WJ'^3!R
MN>G0C'O5'0].U'P1HWB>/4(K"#0#)/=V6^4N(%<$F-T"_=SV&>I%9^C6NN^'
M+729]3\*6\UOIR*D<T>L&0P;\*QCB90,G. H/0[5X.* .BM/%VMZAX@U+3+3
MP_"R:;>Q6]U,]Z!B)U#%U&WD@'.W]3FJS_$=3%I^H6UI#=:;>7"PX@G+7,:,
M<+*8PN-O<C.0"/I6CX=T74K+Q+XGO+ZWB6TU6>.6$I+N8!8PA## QG&>":R_
M"^C^-/#UM%X;(TZ72+9BMOJGFGSE@SD+Y6W!<#@'.!UYQ@@%G6/'QLXM2GT^
MUMKQ-.F,,L#7)6>9EQO$:!3G&2!D\D'IP3,WC#4+GQ,NBZ;H\<C3:6NHP37%
MR8@59PH#C82N.>@8].G)%*TTCQAX<U[58=&BTV]TC4KM[Q)+J9HWM)).7RH!
MWKGD $?45?CT758?B*FMLB36::.+ R&0"1Y!)OW;<8 /3KU[4 9#_$?5$\)2
M^(F\/Q+:V$[0:BC7GSJR2;&\H!"' Z_,5].>M;^K>+!:ZG<Z98_8FN[:!)I/
MMESY2DOG:@PI))VDD]!D=<\<Q-X-U^;X;>(?#WV>U6]U&]FGB;[1\BK)+OY.
MW.0..E:5]I/BK2_%<GB#0;:RNH]1MHH;^PNK@QE)(\A71PI&,$@C'_U@ B^(
M5U=1^&'M= ESKAE3RYYO+>"2-6)4@KR,K][TYP>!575O&^M+X1\7%;&UL]:T
M/Y),3M)'M:,.KH=H).#T('(_"M+4M$UZ\UWPKJ$JVT[:;-//>%9-@_>(R!8P
M1R%W=3C('J:S[SPAK&HKX]B9+>%=?C06C&7=M*PB/#@#C)&>,T =IHDEW-H]
MK)>I&LS1*3Y<ID!&!R25!S^%<]/XRNY-(U/6M+TR.[TW3I98WS.5EF$1Q(T8
MVD<$-C)^;';BN@T-;]-'MDU*"""Y2-5:.&0R*N !]X@9Z9Z?GUKD-.\,ZYH6
MD:YX>LX;>XL;Z6>2RNGFV_9UFSN61<9.TDD8SGOB@"S=^.KN74])L]#TF._3
M5M/>]M)GN?*!VA3AAM.W[PYYYXQWKI9=4&G>'6U75XQ:>1;>?=1J^\1$+EE!
M_BQR/>N7M?"5[I/B;PN]C%')I>CZ=)8O(\N)&W!/F"X_V.>>]=/X@T>+Q!X>
MU#2)G*1WD#PEUZKN& ?PZT 8,_C*[TV#1]0U33(X-+U26.$21SEI+9I!F/S%
MV@8/0D'Y3Z]:I:?JNL:KXC\9:?J$-H]C9".%465CL4PEQA2N&)W<G(QCOBE_
MX1S6]9\.Z-X?UJ"WCCL)X'N;J*;<+A82"NQ<9!8A<YQCG&:LP:'K=AXI\4WD
M,%I-9:NL4D;&<JZNL/E[2NW'4 YST[$T <]X*\37^B>"_!,4^EQG2[_R; 7'
MVG]ZLC@[6\O;C82,?>S[5OZSX\-FFJ2:=;6MV-,D,4L+W)2:9E +B-0IR1G
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M*(YOFWH6).".%); YSQ0!'9?$"UOO#FAZBL,<%SJ^\1PW$VU(BF?,+/CD C
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MR>Y-3NZ1QL\C*J*,LS'  ]37%:WXIN[7PW;:G/I-E=6\^I1P1AY3CRVE"1S
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M#P3[57\/^$6TSQ?<ZY!96^E0W%IY5Q9VLI:.:;<#YF-H P 0#C)W'('?LJ*
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M*+YS>9N60N#C;C'..M;FE:/8:'8K9:;;+;6JDE8D)VKDY. 3QSSQ5Z@#S0>
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MI+L 87<" $[$\G)&. :H^&=!\9>'H(_#PN=-ET.W<K;WQ9_M*P9R$V8V[@.
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M7: /,;?P#X@MO ^B6D%Q8PZ]H=Z]W;.'9X)0SN2C':" 5?' [>];>I^'M?\
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M0HJI$X8*,*W]W%5/["U[2/'.H:[I$=E=6NL10B\MKB=HFAEC7:KHP1LKCJ,
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M21N/MD&JC>*M 31FUAM7LQIJN4-T91Y98'! /<Y':@#7HH!! (Z&B@ HHHH
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M[JD^HR^$/AO<W/E7-T^J6+IABN_-NY^9CGG/4_I7I>L6!U70]0TX/Y9NK:2
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M'>G>&=*\9V4=MINM:AI<VG68"+<6RR?:+E5X4.#\J]LD9SC'?- '->.M=O\
MQ)\)-=U:QCM1I,BO'$KAO-EC63890V<#D$A<'C'()P/5(?\ 41_[H_E7F+^
MO$UOX&U3P5:3Z7+I4N\65U-)(LL:,^_8Z!2#@D_,&_"O2[19DM(EN#&9@@#F
M/.W/MF@#R^ZU^R\-?%'QCJ.H6]Q+:QZ9:&400F3CD<]@/<\5I^!;:7P3\/\
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M$G 8,KA X7&?XLX![$8YJ[+KNL?8Y;BULH)XWU'[+%*,A8H58J\\F3R%*L,
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M]]*9M09/-O)6ZO,W+G\S@>P%5O&N@WGB#1(8-/E@2[MKR"[B^T$B-C&X;:Q
M) ..H!H YZ^;5$^+UM]DCM)+]O#C@M(S+$I^T+R<98CV]^HHN_'E]_PK.ZU^
M32K.2ZM+IK2ZMWD)C#K,(BR\989(.#CZ\5L)H>M'Q[!XAF^P-$FEM9.B2N&W
MF029 VG@8QU]^.E84_@779OA]K'A[?IRW-_J#W:2^<Y1%:82X/R9R,8_7VH
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MJRLJ[@P)/;H?SN:OX=U_4SX>FDN+&:YL-1%_<DN\:'"LOEQC:W #=2><9[T
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M][:*CSPC.4#@E2?K@U<KC1XQDLM=\71:E;01V>AVD-R)(<M)(K*['.<#/RX
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M$VW_ *$: -+3O%MS'XM'A?7K&.TOYHC/9SP2%X;M!]X#(!5AW4YZ=>F>G-S
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M&N-ZAR!W81@?0$^M<CXFL!!X2^)%BD2G2+._MWL!CY896\MI53^Z S=!TR:
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MD=K-:1/"DOWE0J, ^^*U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HKDK/QJES\1;OPRT&R%;;?;7!Z32
MH?WJ@]]H9?H5:NGEO+:&9(9;B&.5\;4=P&;/' [T 345634+*3S-EY;MY8+/
MME4[0.I//%-FU33K>!)Y[^UBAD.$D>955C[$G!H MT5$]S!&L;/-&JR$!"S
M!B>@'K4+:G8+9"]-];+:G@3F5?+)Z?>SCK0!;JM>Z?9ZC$D=Y;13JCATWKG8
MPZ,#V/N*Y_P3KU]KJ:Z;Z6VE-EJLMI"]NA56C54*GDGKN)ZUK>(=5;1=!N[Z
M.$SW"+MMX!UEE8[40?5B!^- $DVB:7<Z4^E3:?;2:>_WK9H@8SSNY7IUY^O-
M7@ H    X %8WA+Q!%XH\*Z=K,0"FYB!D0?P2#AU_!@16E)?V<5TEM)=P)</
M]V)I ';Z#KVH L45!/>VMK_Q\7,,7RE_WD@7Y1U//8>M,GU*PM1";B]MHA-_
MJC)*J^9_NY//X4 6J*@NKRUL8?.O+F&WBSC?-($7/IDTXW-NJ1.9X@LI C8N
M,.3T ]<T 2UQ$_A*_N+Z6\DTOPE)<2?>FDT]R[#W;=DUUG]JZ=]FEN?M]KY$
M3;))?.7:C>A.< U,]S!';&Y>>-8 NXRLX"[?7/3% '-V6F^)=.MQ;V*>&[6
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M989$DC;HR,"#^(I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6=KNJ#1]&N+P*'F "01DX\R5B%C3\6*C\:T:JW
MNF6&IHB7]C;7:QMN03Q+(%/J,C@T >8^+M"UOP_X:TK74DLY[CPW-]L9XD99
M)U8_Z1DDX^?<S'Z5N^.FAO/#&F>,=,"W#Z1+'J4+H,F2W(_>J#Z&,D_\!%=G
M=6%G>VAM;NT@GMB ##+&'0XZ<'BFV^F6%I8M8VUC;0VC AH(HE5"#U^4#'-
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M+$^C:<T<TGG2H;5"'?\ O,,<M[GFIAHVEK>1W@TVS%U&H1)Q N]%'  ;&0*
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MQI%&L<:*D: *JJ,!0.@ JM#I>GVTMU+!8VL4EV<W#I"JF8^KD#YOQH XWQ!
M@\=>";W1?+$LIFCE,& LEGY>XYQU4';CL"PQUIOQDQ_P@# MMS?6O/I^]6NQ
MT_1=+THL=.TVTM"PP?(A5,CKC@=/:G7^DZ;JJ*FHZ?:7BJ<JMQ"L@!]MP- &
M6GABPMM;_P"$BO9[J^O[>!HXI;A@?)0_>"*J@ GN<9/K7FD%_I_V?X?7EE/;
M6NGG4W:WBDEWW"QLDNYI9">I/48X)P2:]HBBC@B6*&-(XU&%1%P /8"LZ/PU
MH,*[8]$TY%\X7&%M4'[T9P_3[PR>>O- '%>%O#VB7OC?QD;C3+2;[-J4$D(>
M($1-Y*-N4?PDGDD=>]8VGPZ?)\'O&,+QVS3I)JC;"JEEVNY4XZC!QCTXKU:U
MTC3;&YEN;33[2WGF_P!;+%"J,_U(&3^-1G0M'9;I6TJQ(NVWW(-NG[YO5^/F
M/UH X"#5H-/\5>"DU>5(M-ET(BT>4@1B[Q'DDGC=Y>0/]X@=:@\9:;X?MOA[
M<_V,B/;IK<$JR;MZK*\\>_RV.<#DC X!W#UKT:YT'1[S34TVYTJRFL8\%+:2
MW4QKCIA<8%.FT72KFRBLI],LI;2''E0/ K(F.F%(P/PH X>XT;2-0^-MW!>V
M%K.DF@QRM%+&&61_/==Q4\,0,#)Z5SVA"STJSMM,9&>W_P"$KN5T+S9BL$:(
MIY8_Q*&W[1W;'(ZUV<OA62[^([ZM=Z79RZ4-,2RB5RK,CK(S;@N, 8;'!S73
M76BZ5>V,=C=Z99SV<1!CMY8%:-,=,*1@8H \;OC:W'@7XG02SV=RR7\DZ>6H
M"[O+BRZ+DX^8]<GGO75W&G6.G?$7P.;*UA@:ZL[U)VC4 S 1HWSGJW.3SGFN
MVD\/Z-*MPLFD6#BX*F<-;(?-*C"[N.<#@9Z4[^P](\ZWF_LNQ\VV&('^SINB
M'HIQ\OX4 <C\,OLD<'B")/)6X&NWXV# <*)?3KCD?F*UO&ME=7UKI::=J4%E
MJ<=\LME]I3=%-(L;GRW YP5W'(Y! (YK>M].L;2YN+FVLK>&XN2&GECB56E(
MZ%B!EOQHOM.L=3B2*_L[>ZC1PZK/&'"L.C#(X/)YH YWP)J,E_9ZHEUI2:;J
M-O?O'>Q0OOB>78A+H?1@5/KDG-<I8W=KJ.@?$F+5S"=1CN;M)HY\;E@6/$&,
M_P .!D>^3U->H6MG;6, @M+>*"($D)$@49/).!WJG>>'=$U"]%[>:187%V$V
M">6W1GVXQC<1G% 'F.DZM;V\_@.'4-3%EI\OAQ$MISY9C^TA8PRDN" VS@=^
M2._.DOAZWM=,M;?PGXA4W<6L37=G]M"R6TLIC;S(5V  ( S'Y<[2&[CCO;C0
M-'O--33;G2K&:Q3!2V>W4QKCIA<8%.ET329K."SETRS>VM\&&%H%*18Z;1C"
M_A0!Y7KUW%JGPVO)+K1HM.U"RUZ&*XB4AT6?SXB[QMZ,&S^)KI=9O(M-^*27
M%S+!<Q2Z*8OLC3QH\/[W.X"1E4J_0X.?DYXKKI="TB:R2SETJRDM8VW)"]NC
M(IZY"D8S[URNN>&M0NO$4UT_A_0->TUX8XK>"^/EO:!<Y"YC<$$G/&#T'84
M<E?>$[/0OAKX:M9HK&2Y_MRV9Y[8 _?GSM#CDX4A<_[-:^H)I7A[X@>(MMM]
MET[_ (147%S%9*(RVV60$J!CYMO -=3HO@S2K.QEBN]'TL+-/]H%I%"'@@;:
M%^3<!S\N2V%SZ"MG^Q=*^UM=_P!F67VED\MIO(7>5QC;NQG&.U 'F6GW%M'X
MU\!;9["*WDTJYBCMX9 QCBV1^6CN3\Y/T R#C/6J N8]/^'GC%[4*LL?B"Y^
MT+"!YHMA<IYN!Z;"?;!KUBV\.Z)9_9_LNCZ?!]F=G@\JV1?*9OO%<#Y2<#)'
M6IX=+T^WGN9X;&VCFNN;B1(5#3?[Y RWXT <!=Q:6TMSXC\.Z\^H:T-&G2VA
MM3"5= A9"ZHH/#;0,]R!6+?3Z-<_#/P#=P26[,FJZ>QD+#>)=P\XD]=V[<6]
M^:]5TS0])T42C2],L[$2G=)]F@6/>??:!FJX\*>'5GEG&@Z8)97$DC_9$R[
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MO;(GRKJ,K)L;:>588;(_H!5O68])U/6OARX6TN4:9XW8;6#8MB=I/<9(X]Z
M/09->T>&VAN9=6L4@G&Z*5KE L@]5.<'\*J:OXKT?1;[3;.\O8(YM0<K$&D
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MIESLQU8>W>MSPY?^#M=LO"EU9R037]G#MLX()?WD!,>V0.@/  '.X8SCN1D
MN>#O%37MA<_V[J-DEX-5N;* 96'S1&^T!5)R3^)/-=C7AM]9V9^$7C:^\B$W
M*:S=,DY4%U(N05PW4=>WJ?6O<5.44YSD4 <@GB:>S\?ZOIVJW]G!I5M80W,3
MN!$$+NR_,['G[OM]*ZDWMJMG]L:YA%KMW^>9!LV^N[ICWKA38:;?_&758M1M
MK:X T6W9$N$5Q_K) 2 ?8XS[^]<?8RGP]IFC2SW,UGX6'B2\^S7"A66* AA;
MM\P8;-^X@D8Y!]#0![)'K&F2Z>U_'J-H]DF=UPLZF,8ZY;.*?#J5A<WDMG!>
MVTMU" 984E5G0'H64'(_&O*/&&F^'QX'\<:AINI-JDEU%#-<2EXGA24' *;%
M"A\=<<\J3UK>OK.TT[XG^$/L$$$#S:??*WEJ%\P!8V&['7G)_.@#MSJVG#4!
MIYU"U%Z>EMYR^8>,_=SGI7+ZIXH-YXNE\,:=K%K83QV7G"X)20F<R%%BVMZ8
M)(^\<C!'?C_#CZ%X@\'Z9::SX@NXM8LKP/+8*T*7*WJN<[1LWDLQ)SGN<G@X
MZNW$1^-U^N$+?V!"<8&<^>_/ZB@#=\,OJALKG^V-6T^_NTFP_P!B38D!VKF,
M\DD@Y.3@X(K1M-5T[4#(+*_M;DQ?ZP0S*^SZX/%>07+M8>"O'YLH3]FA\2DW
M,4"\_9_W'F@ =BNX'VS7H-C+X2USQ!#J6G2VM_?26!@+V\N]5MBP;#J#M'S=
M 1GKZ' !I:3>&WT%;G5-:LKS:S[[Z/;%$?G( ZD#'"GGJ*N1:KITUD][%?VL
MEHF=TZS*8UQURV<"O)?#U[IUG\,_"$5Q%&SR:U*MF\DICAAE$TQ5G(Z@#.%[
MG'3J*]U-9W.@_%6"2[M+M^;A"@4*6^SKEU7)Q\V!G)^M 'KC>(-%21HVU?3U
M=2 RFY0$$C(R,]QS5IKVU2XBMVN85GE&Z.,R ,X]0.IKC+OP3IFL?#\0:=:6
MMM?SVD$\-W'&H?SXU#1NS=3R3R>S'UJ?P5J<OBUU\175J]N]O;_85B=<%)L@
MW!'MN5%_[9GUH [.N,\6^*WT^_T.VTK4[!I+C5X+.[MP5DE$;L0W\7R],<CO
MVK:\6RW\'@[6I=+#F_2RF:#9][?L.,>_I[UYOJ6HZ#<>"OAS/:7%IMBU:PP=
MZ[HR 1)GN#G[WOUH ]5NM6TZQGB@O-0M;>:4@1QS3*C/GT!/-+>:II^GLJWM
M_:VS.,J)IE0D>V37EZ7.BZG=^,]"\4:^VGO+>N7AE:%!+;%5\IT9T).% Q@\
M$9[U9UJVO].2]U'1+F+48(-(@AU72-6^666W5&*N''W7*L^01@G- '?SRSG7
M[%8]5M8[9H9"]DR@R3GC:RG.0!SG /6K$NJZ=!="UFO[6.X) $3S*'Z9Z$YZ
M5PK2VUU\3?!M_#;^0UWH]Q(5< 2 $1%5;W )'YUSMQ%::KH/BCPH^JZ8TUWK
MDDBWL]W&IC_>JS;D8[]Z;2@P,' Y H ]<FU33[<D3W]K$1$9B'F5<1@@%^3]
MW)'/3FE&I6+:>+\7ML;(KN%P)5\LCUW9QBN%FTG2S\9["$6-IY8\/R,$$2[<
MB= IQC' SBN>TR\TW3_#"6UQ"C(/&,\-B&E,<%O()69"^/X1@G;W..G4 'J%
MWXDT:ST2XUB34K5K"W!\R>.567(_A!!Y;MCKFJAUA=7TS2;[3-9LK2.>XA,H
MDVR>:I&6@!R,.<@9Y(]*\Z>YAEM/BU +VVNI7M?-'DX <_9/F95R>,\9R?<U
MI:[)87/ASX>7$#V\KQZSIT?F(02I*$E<C\./I0!Z1>ZII^G%!?7]K:E_N>?,
MJ;OID\U++>6MNT2S7,,9F.V(.X&\]<#/4_2N(\.S1S^./&]AK*QF=FB*),!A
M[+R\#&>J@[\]LL<UQFG:?O\ #OP[CU*)9E.LRQ6YG&6:UQ+Y:G/52NWCIC%
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MOJ=O=>'&N].\1V-@DC*(M1)CEC&&&1R=IR 5Z\9]JO7^LZ7I94:AJ-I:%E+
M3S*F0.IY/3WH FM+"ST^(Q65K!;1D[BL,80$^N!6%X^T._\ $O@R_P!&TW[.
M+B[55#W$A15 8-GA23T]*V;C5]-LS$+G4+6$S*6B\R95WJ 6)&3R  3GT%0V
M7B'1-1F2&QUC3[F61=Z1PW*.S+Z@ YQ0!+IVFVEDADATZTM)Y /-%N@ )^H
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M?[/.J73::.PM?,.S'^R?F(]B*ZV[T^ROT1+RSM[A4.5$T2N%/J,CBK  4
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MHGL;2Z96N+6"9E& 9(PV/SJ8@%2I ((P0: /*M%>"/X8_$$(T:Q+?:L!M(
M^; _E7=^#G5_!&@,K!@=.M^0?^F:UHC3+!8VC6QM@CD%E$2X)'3(Q4T%O!;1
M^7;PQQ)G.V-0HS]!0!Y;#9Z<^H?%,M!;-M0+DJOR@VH)^G(_,5'X?OGM]9^'
M4U_)_P 2Z?P\(+>1S\HNRB$@GH&**0/7D"O4/[,L/G_T&V_>??\ W2_-SGGC
MGFE?3K&2T-H]E;M;'DPM$I0_\!QB@#D?"%L\7CSQK-:_\@J6XMS&%^X;CR_W
MQ7MG)7=[_2J][#8S?&V%;^.W<'P\?*$X!!83G.W/?!/X$UWD,,5O"L,$211(
M,*B*%51[ 5%=V%GJ"*E[:07*J<JLT8< ^HR* /%R&\/Z0^H0M-;>%U\6-,KP
M(&6*W*%1(H((\L2\C@C@$=JV=?M_#=UX9\:ZOIFK-JUQ<Z2PNK@21O"&5"(Q
M\BA?,QGW ZXR,^J-%&\)A:-&B*[2A7*D>F/2H(],L(K06D=C;); Y$*Q*$SZ
M[<8H \[DAL[3Q'\,&MTAB+Q7 R@ W VN3]<G!^M8^EW&AZQX9OO#_B?7+J#5
M(=0E-QIJM$DTDWG%T:+*;V)RN""?3I7KG]F6&4/V&VS']P^4OR\YXXXYIS6%
MFUZMZUI ;M1M6<QC>!Z!L9H X]Y8Q\<;>,R+O_X1R0;21G_CX3_ UR6IB==*
M^*D>DINE6[A)B@X)C\N/S  /50_ZUZZVGV37'VAK2 S9SYAC&[/KG&:6&RM;
M>1I(+:&)V^\R1A2?J10!S&EZIX.\2:KIFH:7);7M\EHR1^0^3;P,!D2*#A1D
M 889R>.]</I>H:9I_P /XS=00RQMXJDC@9Y"D-O)]H9DDD*D?(N,XZ'@<9S7
MKMOI]E:+*MM9V\*RG,@CB50Y]3@<TG]F6'D20?8;;R9,;X_*7:V.F1C!H \F
M%Y93WWQ2BEU"UO&ETV*567:%DQ;."R@9X!P,Y/;)S73:5X2TC7_A38V2VUM%
M)>Z1;H;F.,;PX0,K%AR2K_-]<UVK:?9/NW6D#;U56S&#D#H#QT':L_5[;5X=
M.BB\,#2[><3 N+N)O+\OG=@(0=W3]: .>\#ZA?\ B9X]2U:V:&ZTJ)M/D5AC
M-T&Q,X]L+'@_[3"KOC.SEO+G1UT_6$TS68II);%ID#Q3,$(:-E[Y5CTY&#BM
M[2-.&EZ;':F4S29:264C!DD9BSMCMEB3CMTJ>ZLK6]C$=W;0W"#^&6,./R-
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M>T_>@I.^/E (/(^G:L>"]_L[XPZHNJR+%%>Z; --DE.%*H6\U%)XW;F#$=<
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M*@E1C)'<''; @@$'(- !7%>$O&DVN^*-:TNZA$*($N],/_/>T;Y=X]067/\
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M]J /3;>Y@N[:.XMIHYH)5#1R1L&5@>A!'!%<GIVNW_BW7M6MM+NOL.DZ5/\
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MQ(&LXCN!SGY!WK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXPQ&TYP>,'-<?_;\_BOQ'KNCZ7K[:9+8F!+&2*-7$CE/,=G5A\P_AQD=#WH
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M3$X9P/1:N^&GT^Z^*GCA2UM+*38[02K'Y8N<?1@,^A KO\#.<#/K1@ YP,T
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M>YA%  "@8&!QT%+M7^Z/RH X'Q@;OP]XBT[Q;H]M]K^UQ_V9=0QGB7?S;O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pacb-20231231xexx1028002.jpg
<TEXT>
begin 644 pacb-20231231xexx1028002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"!54!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J"\O;?3[8W%U((XP0N<$DDG   Y))(  Y)
M-3UQ?Q*CO$TG2]1MK6ZNH=.U*.ZNX+1F$K0[75BNT@DC<#@'M0!MV_BO1KA+
M\B[,3:> ;J.>)XI(@1D$HP#8/8@<]JAOO&&F6.FZI>&.]<Z;;BXG@^QRK)L.
M[:0&4<'8W/08.2*Y1CX1US2-6U*VT[4Y[.XMTMKN^<7 E8%UPJ>9EF*?>R!@
M8 &<G%:!-;?1O%VBC4/^$AL3HK_8]1$8\XNR2 6[LO$C#KZC=SUH [+3_%UA
M<:'I5[=&6&>_11';BVEWNY0.P1=NYE R=P!&!UK!\<^(TNO ,FL:'JT\(AOH
M87>/,3 ^>B.CA@&4C)R.*S%U^)-*\# 6L\-N8##+J1L&>6UD6%1L0%3M+DE=
MV"/E('J,-H)YOAWXNLXK'4'DC\1FY*26\A<Q?:(VW<C+?*"3C)XYH ]0TSQA
MH.NZE<:7I^H[KV)-YC,3(Q3IO3>H#K[C(KD]%U=/^%=:Y/X@U^_MHH]1N[<Z
M@DA\Z-5E(7:0#@X'85HW2V_B+X@^'-7TMUEM-+@NGNKQ?N8D0*D>[N<Y8C^'
M'.,BN3)W_!GQA;JCF>:^O/+BV'>^^4E"%ZG(Y'X^E 'J,^MV%@(89)9Y9##Y
MH$<#ROY8XWL$4D?CUY]*Y76?$(MO'?A6[35+@:1?V-S,T(SLDPJ%"$ W,QW\
M#DYQ@54\116]S?V5]IVO3:)K4&F(T%VPW6]S&2W[EU(PQ!7./O?-P#BHH+RZ
MN_%WP^NM1LELKE=-N?M,*H52W=TC"J?[F<' //:@#O=%UW3O$-B;S3+@S0K(
MT3[HV1D=?O*RL 5(]"*SO$WBN#PY=:3;26]Q+)J-TL"M' [JHP2Q^4')P#A1
MSWQ@&LKX>NO]H>+P,@2:Y+-'D$!T*1@,OJ"0>1Z4OQ#+07/A2^:*5K>UUJ.2
M=XXV?RU,<BY(4$XR0/QH IIXF72?B)KPU'4;U[!=/MIX;<Q.Y0L7W;8E7=T
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M: -*BBB@ HHHH **** "BBB@ HHHH **** ,'2= O;35)K_5-:FU27,BVJO
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M)-;W-HLZA@H7Y&W*5&%'!R,Y]:Z>B@"GIVGKI\,@,KSSS/YL\S@!I'P!D@
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M&GWZ6Q62]W0\ JH^8J2%W#K@^E)K3SVNF^"==^P7UWIVGP-!J$%LKB:(21(
M^T8;Y2O(]Z]2HH \F\5QZ??_  X\07.AZ)>1_P!H/;@.]O+Y]XRR*2=C O@+
MT)Z\]@"?1K[7+;3XK"1H;J9+VX2WC,$#/M+9PSC^%1CDGI6G10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5G:]I9UO1+K3//,"7*B.5PN28
MR1O7J/O+E<]LYYK1HH S]8L;R]T>:TTS46TRY8*(KI(ED,6""<*>#D C\:OJ
M"% )R0.3ZTM% !1110 4444 %>>^,[JQ\5:9'IOF:U:1QW"3LZ^'KR0ED;(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(%N+JWDA#R?*!N4C)P"3C.<=ZA\+Z,VB>']/L;B.V-U:VL=L\T(_U@10H.2
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M-L?]X^W!Y]CZ55MO$VBW5Q+;Q:C#YL<7GLKG9^[_ +XW8RG^T,CWH U::(T
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M6QC-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<A\0M4M=*TW2IKNW@:-M4@5;JX!,5DW)$S $=,8&2!DC-=?2
M$ C! (]Z /$+^2:_C^)EII<\^H7<PLKB,&/#7$2QH9,!5 (*AE&!R",9S7H6
MA^)/"_BW5+*_TE$N[Z*!@THB(:T1ARK$C@D@#;UZD< UUV!G.*145,[5 R<G
M ZF@#P];^T/[-VHZ>9E%W;1RPS0MPR2&X8A#_M8YQUQS77OJ,>G?%2SU&_N(
MUTF_T46]E=LX\H2B3>R;N@+#!]]H':O0L#TIK(KKM=0RGL1D4 >)>(H$@\%>
M.KL.BZ7J.LP262DC;*1)%YKIZ@L&Y'7:3TKL;BZLA\9]'$,\'S:)-&-CCG,B
M%5X]@2!7?8'I1@>E '&_%>-Y/A?KH1&8B%6(49. ZDG\ ":SM2\4:1-XUTD1
M7,-JMSITC0:N$W-,OF*/(AR"I8D!NC9X '.:]#I,#C@<=/:@#P:UO8'^%/@Z
MSCOUMKJ+Q&BL[J,PD7$IW$-Q\H()!Z9&>M=-9:G<7W@;Q+X1'EQ>++6VFCD6
M-\F]9D)$R$G+%P1GN">W%>IX'H*7% 'F7AS5?"'B>ZT2X@DO9]8T\%A;2RR@
MV!V[9-X/ 48QSP> *YBZN+$_!+Q?Y<MOO?5YV&UAEB;D%3[\#(]A7N015+$*
M 6ZD#K3L#TH 9%+'/$LL3K)&XRKJ<@CU!KR&S;2V\!^-M&NTA?4KC4K\1V)
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MP6^^V,\>V15/PC/<Z7K^EZ=8:Q%KOAZ6TE:%Y@/M.F(H!"NP_A/"X8 Y&.U
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M0&.69998+.%U9+U#'G<W!^50-P.0/K4-U\0O"5FCO/KUHJI.;=F4E@KC&02
M< ;EYZ<]:Y_59+6W\<?#R..W2PBB6["VQPOD(T&U%('"]ACUX&:SM(O=&BMO
MB-9Z@\!EGU6Y4P, 9)U,2!54=6.<@ 9Y/O0!Z+>:_IE@85FN=SS1&:-((VF9
MHQC+A4!.T9'/3D5!-XLT""TL+J75K58-0(%K(7XESZ>WJ>W>N T:9_#UYX8T
M+5E:PO$T%4:_2'S)I6WC-K&<$<8!(P2>,8ZUAZ5=6Q^&_P /;:4[7MO$$7G)
M*A78%:;).1T&1D]!D4 >K1>,M!N-.U*]MKTW$>FC-TL43ETXR/DQDY'0@8-3
M^&->B\2^'[/5(HWC^T0I(R,C#:64-@$@9Z]1Q7&.\=QX_P#&\-NRR23Z-"B*
MAR7<+*"!ZD9'YBM_X;7L%W\/=#2%F9K:QA@ERA&V14 9>1U!'- &GXHN[2S\
M.7DE[J[:1"4V_;48!HB>ZY!R?PJ:;6;#3XX$GN9)':'S!LB:1R@QEV"*<#GJ
M0!6%\464?#/7D8C=):LB+W9CT ]36'KQ@FOK"_TGQ+'HVM0Z6C123E6M;N$E
MOW; ]P5/(Y&[OV /1K6YAO;2&ZMI!)!/&LD;CHRL,@_D:I:GXATC1IH(=2U&
MWM9)\^4LKX+8!)/T !YZ5%X5N[B^\*:5=7=B+">2U1GM0"!$<= #R!['I7,_
M$2:VMM<\%37C(L":OEFD^ZO[I\$^@!P<]NM &]9^-O#5_IMYJ-OK%LUK9'%R
M[$IY1_V@P!&<'''..*?:>,O#M\+HV^K6[BUB2:=B2H1'^Z22._3'7/'6N#U^
M""XUCQQKEB\9TZ7PXUG),A&RXNB'P%(X8A=J\=R!UJ;64E;X6^$K[3H3/;Z=
M-I]U>Q0+N9H8@"XVCDE6P2.V#0!WUKXATR\FN((9W^T6\?FRV\D+I*$/1@C*
M&(]P#3+;Q/H]YHDFLV]Z)=.CSNN%C8J,'![9(!ZGM@US4[0>(/B7X;U71+F*
MYMK*TNOMMQ P9"CA1'&6'&=V6V]1@FJNFZ9>:?XUU/PPL#_V+<W":U')CY44
MG+Q?C,J'']TM0!U-O?6-SXQ>*'6Y7N5L 7TOC8B[\^:1C(;D+@GIVKF_B'XL
M2U\/EM(U:>"Z2^A@WPQ$QR$RJKQ^85*Y W9"L",'T--O9&E^,%]%:3HMTWAD
MPQ-NZ2^<Q ^H!!QZ<UQ]QKM@_P %;30Y-\6LZ?/:175B\;>=&Z7";F*XS@\G
M=T.['4XH ]5-_8?\)E)%_;K"XAT\M+INX>6B!P?.;C(;D#D].U11^//"TOV7
MR]9MV%U+Y,++N*L^XK@G&!D@@9QG'&:Q3>VO_"ZXY3,BI_PCI4LYVX/GAMIS
MT.WG!YQS7%M/;#X$7L:O&)SJQ<(/O'_30P..OW!GZ4 >PW^N:=ILWDW,Y$HB
M,QCCC:1EC'!<A02%]SQ3],U?3M:M3<Z9?07D .TR0.'7.,XR/J*\^U[Q#IOA
MGXCW&HMJ%O&+[28E;[6L@B;#OL:-T5L_Q;EXZ@@]<=-\/(=*M/ ^G66CZI'J
M=K;*8S<QGAGR688_AY;H>@Q0!T%Y>V^GVYN+J01QA@H."26)P  .222  .35
M:#7M-GM;JY6YV16C^7<&9&C,;8!P0P!!PR_F*RO'4&GW.A10ZC>SV"-=1^5>
MP-M:VE!)1\], C!SQSVZUP=_=^(9O#>H&[":Q'H^KVEQ+?Z:IC;4(%VLY 4_
M?3Y<[3@;?:@#TA/%FALEZSZ@D!L5#W*7*-"\2GHQ5P#@]CC!JDWQ#\)K$\IU
MJ'RXXHYW<(Y"I)]QB<<9X'L3@\US+7WA+6-,US7=$^TW,_\ 8TUM+?SRSD*I
M&5A_>G!8G)P.1CW&=KPUI6GZ_P#"33-*E5##<:1%;3;0,HWE@-]&#9/UH Z>
M75;."6UBED9'NL^2&B;YL#)SQQ@<\XK+T+4],_LW4[Z/Q =0M([R9I+B9UV6
M_0F,' &U>W7KUK'\ 2:GJ%DESKD31W6E1OI>Y_\ EHZ-B24'N&"1\^H;UKC-
M]Q)X.\1W6GQ->"S\7OJ$UM#RTUNLZOP.X(&??:: /6++Q!I>H74]K!<XN;=!
M)+#-&T3JAZ-M< [??I3+3Q-I%[J*6$%X#<RQF6)'C9/.0=6C+ !Q[J37(:QJ
M.F>./#6N3^%+?[7J$VE26_VU8&C;!Y$&Y@"2<M\HZ=\9%,\.:KX3\4ZCI-Q:
MVNHS:S8[F,-Q+<YT\E</NWG;VVXYSQ[D ':6_B'2[J[AMH;AFDGW>2?*<)+M
MY8HY&U@,=036I7E/A.>;3M8T&TT75$UCP]=[V2SN%!N=)_=L?O#G:,[,-TR
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M;*;4(URR0O(L ;[ID95(3/7DCCGI7.:UX@&B_$RP-WJLR:5+I,TI@'S(7#H
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M/P]=ZUJVAWD%Y# NEW7VG9)"7,AVE<9## PQ]:O:3XBTK7)[N'3;L3O:,JS
M(P"[AE<$@ @CN,BM)W2*-I)&"HH+,S'  '<T .HK,L?$&G:C=QVMO)-YLD)N
M(Q);R1AXP5!92R@$99>GJ*@3Q9HCW-M"+TC[5(8K>5HG6&9^?E20C8QX. #S
MCC- &U161JGB;2=',PO;EU^SH))S'"\@A4]&<HIV#@]<< GM5:YU'2Y_%.C1
MKK<RW,D,LD%G ^8KI"H.Y\ @[1R.1U[YH Z"BL0^+M#6[2V-Z=SW7V-9/)?R
MC/\ \\_,V[-V<C&>O'6LFTN[U?BY?Z>][/)9?V/%<) Q&R-S*RD@ #LHZY-
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MJY4J"6?@@[0,CD=>^:PM"U.6.^\<IJNKW(M+*[").[#-NAA5CMP,#!;CC\Z
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M .WHJEI$CRZ+822,7=[>-F9CDDE1DFKM !1110 4444 %%%% !1110 4444
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M-O:ZW%).Z1L_EJ8Y%W$ $XR0/QJ#3+VV_P"%LZY=.XCB;2K90\HV\AG++SW
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MXRN136\7:,EY:VSW$B"[F,%O.T+B&63GY%DQM).#CGG'&:YW6";OXHZ0]N9
MC:1=0_:%C;8CN4* MC )P3BL'PE)IT^DZ7X:UCP]JCZ]IK1QFWG$S0*T? G#
MD^6%QSG\ #D9 .TN?B'X:M5OF>\G86$GEW7EVDKF$X!)8!>% /WCQ[T:IXTM
M;#Q%HFE1P7$ZZDDDPGBMWD7RU3(V[0=Q)*],X'7&17*QG_0OB>##-FZ:4P P
MM^^!M@@V<?-\PQQFDB>2TO/AE?R6MVT%MITUM,8[=W:.5H(@JL ,@DJPY]*
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MSWMG:)=.K7VX6DK0NL=P5&3L<C:W'(YY[9KD]=TN;Q=XIEO]#D(B30;JS-T
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M=M+=?V1K%O?S0PKND:),AMJCDD!LX]JGUC6['Q%I1TK2'DN[B\9$.R%P(4W
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M(T$:J"N,C+*0"1CC/3FGWVGWFK^(/B18V2R1SW^G6\-M(R%4D=8I RACP>2
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MY"Y##KCKC![BN<U;5+.RTWP#J&G:MJ3:7)>JA>::1FGB\IR-Z]7.0,#&>P%
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M!V)! .@HJ&UN8;VS@NK=P\,\:R1L.ZL,@_D:FH **** "BBB@ HHHH ****
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MH641I'@*%!.-V#Q]YJ]CHH X#1KQM+\6^/M3GL-0:W+6\\6RT?,ZQP!6$>0
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M.@7;'4K:8$C$\JD;/HLBF3'8[?6NA\+#4SX2DU77K:2/5KJ >?"J%W4(FP*
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MP* .QD\5.WC[_A&187)B%C]H>=1][<X4$$'(4?-D^O3ISR_A+QA9^']%U/\
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M0K>&]MUN5\M@T2#>C#J RAEP<=1F@#I-7\9Z7HEOJEQ>I=K#II1;B2. N 6
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MLT#6[AYV5F9G$>-V "JCCGG'% &=X 0^*M(TKQ)>2:E#J222RR2K*5BN%9W
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M= T<J[64A0,$=JO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:S4VSYF#0"-=O']X?UZ5Z=10!YJMKJ-KJ7P^U!=)OIH[+3IK2Y2.+#PR-%&
M&!Q@91AGI7I)Z&EHH \Q\,Z1>:;K^DW&@0ZKI^G76]]5TB\B<6]J2A.8BPP#
MOP,*2"#V KTZBB@#SW2M2CT_XI^-O,M[N4-%8$&WMWEY$3\':#@G/&>.#S67
MI6EZYX9T[PYITVFWK6$\EW/?+IPW2P/(VZ.(LIRJ8."5(Y'7'7N].\-1:;XD
MU36TOKJ6;4A$)HI-GECRP0FW"@C )[FMN@#QAM+U:/X=ZQI0T'48[@^(#<11
M"'=OC^TK)E2"<@*.O0]B:[/QI#=RZAX4U2TL+J[AL]1\V=((B9%1HG4':<'J
M1GTKM** . N].O-3^(NJM]ENK>WO/#HL5N6B;8LQ=V(W#C@,.>GO1X)U;6X=
M(TSPW?>&KZWO]/2.VFNI8Q]E\N/"[TDS\Q*C@ =3SQS7?T4 >7WL%S%#\5+B
M:TN88+NS+V\LL+*L@2T*,02/45(EK+XJ\+^!["VL[J-K.:RO;B::!D2)(DR<
M,1ABQP!M)ZYZ5WNM:6FMZ+>:7+/+!%=PO#(\.W=L8$$#<".A]*?I.G+I.DVF
MG)/+/';1+"CR[=Q51@9V@#H/2@#RKQ##K^KZ/JD=WH6JRZA;ZQ')$D,>(!;K
M.I5HP" [%023@MDG.!Q750I?6WQ4GU%]*O#:7^DP1+*J!EB=9'+*Y!P" P]<
M]LUV]% 'D+>']:O_  CKZVEC<)?1>)I-6MK>>,Q?:8Q*'4 MQR ?Q SBNGO(
M)/$_BWPSJT%G>VUMI N+B=[FV>)PSQA!&H898]2<9'R]>17;T4 >/3Z9J<GP
M>UW2UTJ_-_<:E++%;_9GW.K7(D!Z8QMY_3K7K\<@EB610P##(#*5/X@\BG44
M <;\0;>YN4\."UM+FX-OKEK=2^3$S[(D)+,<#MD<=3VJ/3EGM_B5XEOY;*\6
MTGLK9(IOLSE9&CW[@..?O#Z]J[:B@#D?AA:76G_#O2;&]M9[:ZMT=)8IHRK*
M=['OUX(Y%3_$33;O5_A[K=A8PM-=36Q$<:]6((.![\5T]% ' :@]WJ/B_P #
MZBFE:C%;VOVHW!DMVS"'AV+NQG&6[=1U.*Q-0T'5]3@\;K9Z?*9YM3MK^SCN
M8BD=T(A&2N6&.2A&#[=J]:HH XWPM<6VJ7L=W!X*DT22*,B:>\LTA<$_P1D<
ML.I+<# 'KQV5%% 'GOAW3?.^)7C&]O\ 2)C:WSVC6<US:':_EQ%7P6''/KC/
M:M#XAVUS<VF@K:6EQ<&#6K6YD$$3/LBC;+,<#L/S[5V5% 'EOBQ-;U<^,--F
MT?4ITDLL:5]F3;#(#%RSG(W.&XVMG&!@=ZN6L5]+XL\$W;Z7?PQ6NF3PW#/
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M=VT= =H /Y4 >:>,K;7M;T?QCIUQHFIS77G?\2];=,6[0#9A^"-\AP<@[B.
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MJ : *WAS3Y-)\,:3ITQS+:6<,#GW5 I_E6G110 4444 %%%% !1110 4444
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M1,2 5*,P/((()'/MS659_$G3+VVT>\33M42PU69;>&\DA41I*Q(56^;/)'4
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M\Q&C\N9BH;8C;^3@C.< >M9/ACQG)JG@_3]8U"QGBFOF"P1)L/GLQ8A8\-V
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MJC(X9AM7Y1@YP!^ES6;;4Y_&O@J]DL9'6S^TM>R0(6CA,D6U1GN-W&1Z9.*
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MMM<QK+$X_B5AD&K-5M.B>#3K>*2""!U0;H8!A(S_ '5]ATJS0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$@#).
M!17"?%98E\-6%RZL6AU6S92H)/\ KES@#KQVH [NBN7T[QO;76OS:+?Z;?:3
M>+ ;F(7JH%FB'5E96(X[@\C\Z8?'E@EUI*SVEQ%9ZM((;.[8H5=V&4#*&W+N
M'3(^N* .KHKB)OB3;Q6&K7J:#JTD&DW3V]\P6,>4$"EGY?YA\W1<G R< C.[
M>>(X(9HK:SA:]N9+<7(C1T0",\*Q+D 9.0!WP>P)H VJ0.IZ,#VZUYMXK\:C
M5OALFJ:)#=>7=W,5M,<HCP?OD1XV!;J02O&1SG('-6X]/\,Z1X]T63_A&[FS
MU;5#,T#*ZB&%HXFWG:CE0Q3 X!SD<Y!H Z6Y\-P77BBTU]KR[6YM8FACB4IY
M>QL%@05SS@=_I6U7)^%/$VH:[K6OVUUILMO#8WIMHV+QD( B'#8;)8EB> 0,
MXS4OC_Q#>>&/"-UJ5C:F:92D8;<H$6]@@8@]<%AQZ]>* .GHK N/$S17\.FQ
MZ3=R:C):O=M;[HQLC5@O+;MN22, $^^*S[KXA:=;^$]/\3+8WTVEW94-*BH#
M;[FVYD!88 /!(R* .OH)P,FL[3-735)[Q8;:98+>4Q+<L5,<S#[VS!)(!X)(
M'(([5@_%*%)?AEK^\9V6C.O.,$=#0!UV1QR.>GO2UR%U>Z5%KG@^TOM.GFOI
ME<V%T,;(6$)+Y^;.2HQT/6I+OQW9V8N;AK&[;3[74%TZ>Z 4!)2RKG:3N*AF
M )Q] 1S0!U>1G&>:0D#J<5YK)?OHGQ8\02V>DWNHS2Z9;/Y%J!DG?)DDL0HZ
M#C.3V!J_J?B_PYKG@ZPU2ZTV[N[">_BA,)4(]O<"0!1(-P(PV.F?Q!H [S(S
MC/-0RVT%Q+%)(@=H6W)DY"MZXZ9]^U<9/$D?QOLY%4[I- F+8/7$T8%4+KQ7
M::/X(\6ZUX>T6>"YM=0G2Y2=E'^DX7?*?F((R1P.N.@SF@#TBBN:D\7?8]3T
M73;[2;^"752R13,8C&K*I8AB'."0,@=ZU;755N]7OK!+:8?8]@><[=C,R[MH
MP<Y ()R!U'K0!H4F1G&>?2EKF$O]+;XB75JNEW UJ/2PYN20%E@\PX5?F_OY
MZ@=.M '3%@" 2 3T'K2UYGX:M(?&6H:^^N:3.TMKK;BWNC(BO;>4(]D:LK;A
MCDG;\IW'GFNZUO6H-"L8[F>.64RSQV\442@L\CL%4<X Y/4G H TJ*YC_A-+
M>.#7S/I]XESH:A[NW38S%"F\,AW $;0>X/!XJ*R\>6]W?:+#)I6H6UOK,>ZS
MNI@@1WV;RA ;<.,X) !QQD<T =917/Z3XLM]4DUJ(V5U:2Z1(8[B.Y,8.=NX
M$88_*1R"<"M72[[^T]+MK[[--;"XC$@AG #J",C< 2 <=LT 6Z*BNKF*SM)K
MJ=BL4,;2.0,X4#)X'L*Y[3O&5O?:CI5I+875K_:]LUU8O+L(D10K$, 25;:P
M.#^>>* .FHK T_Q3'J<EF]K87$EE=SR017:LA4% ^2PSE0=A X],XHL/%,>I
M26CVMA<265U<26\=VK(5#('R6&<J"4(''IG&: -^BN7N_&]I;6%WJD=C=W&D
MV<S17%["%(7:=KLJYW,JG() [' .*O7'B. W<=GIL#ZC=/;"[V0.H58CPK%F
M('S$' [X/89H V20.IQ2UQ&H>)]!U?2_"^HW>DWTT%]J<*V?F)L-M<[F52XW
M \8?ID<>XJ]J_CBUTDZN_P!@N[BWT?RS?2QA0$W@-\H)!;"D$X]>,GB@#0UO
MPY!KMUIMQ/=W4+:=<"YA$!0#S " 3N4YX)&/>MFN1OO%5]%X]TO1;;3I)K.Y
MLI+HRHZ9?!0 @,1A1NY[G/ XY=JOC[3])M9=0EMIY-*@N/LT][&R%4;?L+;=
MVXJ'^4D#L< CF@#K* 0>AS7/ZAKL$]S?:7:V$^I/;0J]VL+* @<$JF6(RQ S
M@=L9(R,Y7PD.?A9H)R3F)^O7_6-0!VM%8ESXEBM?%=MX?DLKKS[FW>X@G^01
M2!,;E!W9W#(XQWSTJG8^-;:_T74M2CTV^4V%TUG);/Y?FM*K!2H ?&<L,9(S
MD4 =-D9QGGTI20 23@#O7*KJ.FM\0)X!H]T-=CTCS?.++B2#S.(U^?&=^>H'
M3KBN'\1:]=>*_@EJFJ:A8/;R+<$Q-O4J +O8%&TY)"C!) SS0!ZGK.EKK6E3
MZ>]W>6BRX_?V<QBE3!!^5ATZ?E3],TVWTBPCL[;S"B9)>5R[NQ.69F/)8DDD
MFLJQ\5QW7B9M"GTV]LIWMS=6SW 3;/&&"DC#$J02/E8 X/05HZ[J,ND:#?:C
M#:M=26T#RB$.%W;1GJ>@_P \T :!('4XHKR?7-4GU7PQ\/M;O[2:.[?5K%V(
M 8RAHF8E50G@G& <'CI79V'C.TN)M9AU"TN=*FTB-9[E+HH<1,I8."C,",*>
M,\8H Z6L?7O#EOX@-J+F]U&WC@9BT=I=-"LP88*R;?O+^7>J47C.V_M[3])O
M+*XLY-21VLWD9&60J,LC;6)5L'.#^>>*Z"ZN8;*TFNKB01P0HTDCGHJ@9)_(
M4 /CC2*-8XU5$0!551@ #H!3JY(^/+=3HS/I.H>5K0S8.OEDO\NX!@6&TE?F
M ]/?BEA\<I=:U=:7:Z%JTTMI>1VMRZHFV'> 1(3N^[@YXYQU H ZRBN4M?'=
MG<OI4GV&[CL=5N7M;2Z<+AI%W8W+G<H;8V#CZXJ&Y^($<,FMQ0:#JMS)HS#[
M6J+&,+LWE@2X!&WG ^8^E '8T5Q6I>-+D:WX3ATO3Y;JQUF.2X$BL@:1!"7"
M@,PP?F5B21TP,Y-=K0 45C>*/$<7A71)=6N;.ZN;:$CS?LP4L@) W$,PXR1G
M'2K$NKI%J%E9_9I6-S"\QD5DV1(NW)8[O5E'&>M &C17)OX^T^*;2WEMKA-/
MU29;>TO2R%6=N4RH;<H;'!(^N*NP>*8[J7-K87$]H+UK%KA&3"2*Q1BRYW!0
MPQG&>G&#F@#?I 00"#D'N*XW1/%=]JM_XFAN]'N!;:=<&!$C>)CM$:D@_,,L
MVXGT'3-0:;XPT/1?!_AJ?3M)OHM+U*5+6SBC4.8BQ. WS$]B>,T =U17.:9X
MPMKRZU>UO;*ZTNXTJ-9[A+HH?W3 D."C,",*<\\8JJ?'ENHT9VTK4##K0S8.
MGEDO\NX!@6&TE?F ]/0\4 =;6+JGAN#5M;TO59;R[BGTQG>W6(ILRZ[6R"I)
MRI(ZUM5GZQK%KHEFMQ<[V,DJ00Q1@%Y9'.%10<#)/J0!R3@"@#0HK @\4QMK
M4VBW5A<VVI+;_:88&*,+B/."8V#8)!X(.,?3FJOAGQM'XI%K-9Z-J<=E<QR.
MMW,BB-61]I0X8G/?T[9X. #J:*SM8UB#1H+=YE+O<W"6T$8(&^1N@R2 .A/X
M=S@54;Q-%;V=Q->V5S;2Q7:V:P.4+32,%*["&P0=W4D8P<XP: -:YM8;R$PW
M">9$3DH2<-[$=Q['BIJXN]^("6]MK\*:9-_:NDV9O#:O*FV6+!.]7!(*C'(Z
M^QJE/XUUFWTCP@_]D3M-JTT,4TA>$%\Q[SM&['S8/7&!GOB@#T'(SC//I17"
M6ZI%\:[B4H8C)X<220,W0^>0<\XZ #CTJ^_C[3XIM+>6VN$T_5)EM[2]+(59
MV!*94-N4-C@D?7% '645QDWQ#B2WUF:#0=5G&CS-'>!1$"BJH9G&7PPP>@R>
M.@JU%XYM9=2TF Z=?QV6K<65_(J".5MF\#;NWC(!P2HSVXYH ZFBN5U?QW8Z
M1;7=\UK<3Z=93>1=7,3)^[8,%8A2VY@I.#@=CC.#2S^-HQKESH]EH^HWUY#:
MI=((?+"31L2 59G  X/7'L#0!U-%<%J?Q DE\/\ AO5=%L)Y8=7U&&V;>45X
MOG(=,$_>.QE]!USTKNHG:2%'>-HF902C$$J?0X)'Y&@!]%<W>>,(;>+4KBUT
M^[OK72W,=Y-;[/D90"X4%@7*@\X^@R016'XU\0M<V?A4Z;!+>:;JNIV^YXV0
M+<1%7?R\,P/.U2<C&,@GM0!WX(894@@]Q2UE:%H>GZ);S_V?9M9+=R_:9+;?
ME8W8#( !*KTY"\9S7*?\)!>>(4\::;>Z7+%:V*O A\Q"%Q#ORQ#9R2<\9 XY
MZT >@ @C(.117G/@KQ9'I_ACP;IMUIM]'!?6D-M!?,$\IIA%G;C=OYVG!*X/
M;(YK=UCQS9:1;WMX;2XN;&PE\J[GA9/W9&-V%+!FVY&<#UQD@X .IHJ.">*Y
MMXYX7#Q2J'1QT92,@UY5,_AZT^*GB=-=NK>UL$L;:2-9K@Q*K,#N* $?,>.G
M- 'K-!Z=<5P?PYO-3LO!NH7GB":Z2Q@NIY+.6_W><+)>59]WS=-W7G'X5JQ>
M-;7^VM-TV[LKFT.IJQLY9&1E<J,E6"L2C8Y /TZ\4 7M"\-P:!/J,L%Y=S'4
M+EKN83E"/,8 $C:HQPH&/:MFN>T[Q4FJ+93VFG7,ME?,XM[E&0J=JL?F&[*Y
MVG&?QP>*P-,^(=ROA?6]>U71KL6]A=SQE8&B;:L;;-OW@21C)/3GC- '?D@#
M).!2UP?B'Q1IMWX<O)-<\,ZJVE)-;!3(JJLV]U,;C#@X#;<]QD9'45T=_P"(
M%MK^;3[.SGO[R" 7$T4)4>6AR%R6(^9MK8'L<XH V:*X6[\>3SWWA(Z3IEU+
M::R\K-OV))A(G/E[6(PP(!)) P."<UJ:OXTM=*@U"X6RN+J#3?\ C]>%HQY7
MRAF #,"Q52"<?3).10!TU (/0]*P7\3VEW-;6FF0R:C-=6@O L3!0L#?=9F8
MC&[H!U.#T )K!^$[!O#6I%89(5_MB\VQ2?>C'F<*>3R.G6@#O**X/XE7=SIO
M]C7\]A<7_AZWG=M5M[<9)4KA&9?XD4Y)!XZ9J;PY+HDJWGB+PG<+>V+VH06,
M$VU8Y%)/",0(B01D<= <4 =M4-W:PWUE/:7*>9!/&T4B9(W*PP1Q[&N0\-^-
MWN_!.G:WJMI-'/?.L<$<>PFXDD8[4C ;MTRV. 2>YK6M?%5JVLW.D:A!)I]]
M!;_:]L[*4DAS@NK D$ \$'!'TYH KV/@FVLHUMCK&LW-@B[5LKBZW1!1T4D*
M&*XXP6((X.173 CH,<<?2N;A\8P37.E*VFWR6>KDK9W14%6^7<I8 [D#+R,C
MZXKF_!FI0Z%;^)HX[::YED\37,-O:6Y4R/Q']W<0,*.22< "@#TFBF1LSQJS
MQM&Q&2C$$C\N*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5ROQ!TN^U7PW%'IULUS/!?6UR85959UCD5F W$#.
M >IKJJ* .'U30KCQAX@M[Y[>>PL[33KJV1IU"R227"A#\N<A5 /7&2>..:H^
M#X]:MK>PT74?!L-O>6.R.75/W1@D1,?.F/F+L!TQP3DXZ5Z-10!Y?_9&L-X0
M^(%E_9%T+C5KVZELD.S]ZLD:HISNP.5/7%+=:=K&D:WI>NKX:?6+.;2H;&\L
MP(S/;21DD,H8X(.X@X/OFO3R<#)I$=9$5T8,K#(8'((H X#Q;I^K:CX&BMK7
M03'=37L%P+*V*?N4257.YLA2V%[=S@9QFKVOVM]>>.O!^H6^G7,EI9-=-<R8
M4>5YD6Q<@G)Y],UV5% ''>%;'4M+\4>)XKG3I5MKW4/MD-WO3RV0QHNT#.[=
ME3QC'OTS8^(VE7VM> ]2L=.@,]VQB=(@P!?9*CD GC.%-=310!PVHRZ]?^)[
M(W.@WLVAS6)Q:K-&/+N=Y_X^!OP5V8X&X D\$XQG^%]+UB#X;Z7X5U#19X#-
MYEK>2.8W6*$LQ9L G.X':OH3DC Y])HH X[P+;ZMH<=WX<OK.=M/L)"FFW[;
M<2P=51@#G<O3.!D 5<^(%E=ZGX#UC3["VDN;NZMVBBB0@$L?<D "NEHH X35
M++4;GQ#X&NXM,NFAT\RM=GY?W.Z$QC///)[9XKGO$6E^)]9TC6H+S0;N[U&/
M5$EM)O.C\G[,LR,HA!;AMH.<@$\Y;H*];5U<95@PR1D'/(ZTM '$+%J6F_$.
M\UJ;2+N6TOM-@A4V^R0QRHSDHPW<?>'/W?>L34O"FK6W@F2WBL'GU#4->&K3
MV\#*1 #.)"NXD X4 <=3G%>I44 <=/:7S_%:QU5=/N#IZ:1);//A<+(TBN!C
M.>BGG%<Z_AS6KWP+X]TT:;-%=:EJ-S=6:2,H\U&V;<'. 3M/!QVKU&22.&,R
M2NJ(.K,< ?C2@@@$'(/0B@#C/%5G+KGP[FN98)-+OK)!?6IG*EX)8AN4G:2!
MG!'!/!]>*NVC:GH7@R34&TQ]0UF;_2KBTA<(7ED(RH9NR A1GL@J[J?AC3]6
MUBUU*\DNV:W7:+=;EE@DPVX%XP<-@\\^@SG%:EU%!/;21W(4P$?.&.%(]_;U
M'3% $6EWZ:II-GJ"1O&EU DRH_WE#*#@^_-<TMG?+\6YM5-A/_9YT5;07'R[
M3*)F<C&<]#UQUKKP % 4  #C%+0!QW@.TO[&;Q&M]I]Q:_:]8N+R R;2'B8*
M%/!.#P>#5WQLVMKH]N=$@GG/VR+[9';.$F:VS^\$9)&&Z=P<9P0>:Z2B@#RR
M/1=6@N?'GD>'+B"WU?3XEM%$D9)<0NA5L-]\LP)/(ZDMZVY-,U4V?P\0:5=%
MM*:,WH^7]SB QG^+GYCVSQ7I%% ' ^*/#]Q/XYT^6PE1(=8@:TU:(_\ +2",
MA]^/7!,1/I**Z/4-=GT_Q'I>F?V5/+:7VY#?(Z[(G )"E>IR%//;\\+HWABP
MT.[NKJ"2[GGN&8F2ZN&F**3N*)N/RKGG Z\9S@5JM;0O<I<-&&E0%48\[0>N
M/3- %?6#?C1+\Z4$.H_9Y/LHD^[YNT[,^V<5YSI^FZW)XE\':O)X=OTEMHKB
M+49[J>-I3(\:C<3N/R AL8_!1QGU.B@#S33O#U[!XET[5M&L+[1;F>Y+:U9E
MA]CECVMN<#)&\G;C;SSR!S18>'KV'Q+IVK:-I]]HMW/=%M9M"P^QS1X;=(!D
MC>3MQMY&>0.37I0=69E# E>" >E+0!YEI>CZUHW@;6?!CZ9-<RO]IAL;I2OD
MRQS%B&=L_*5+G<",\<9IT&CZUX#\0VEUI^EW&MZ9+I-MI\ZVS()HY( 0KX8@
M%2">_'\_2F=5!+,!@9.3V]:;YL8"$NN'.%.?O?3UH XCQ7:ZWJEEX9D.ER/<
M0:U!>W$,+*WD0H6X)) 9@",XSDYQQ6-XLTSQ'K<'B[3[C1;F]\V'&DR"5!;I
M'L'\);/F[MW)!/(&0*]1\Q Q4NNX $C/(![TZ@#@6L]93Q=X8UD:+</$FFRV
M<\8DCW6[L4*E_FQC"G.W=CW[YNAZ?K7A^6[\/S>$(M14W,LECJO[HQ&.1RX,
MV?F!7<> "3C ]3ZA10!P.G6VL^&/&NODZ1<ZCIVL21W-O<6I3]U($",CAF&T
M<#!Z8_31^&=AJ&E?#_2]/U.RDL[NW1E>.1E.<N2#\I/8CK@^U=;10!RGCG1]
M1OK;3-2T2-'UC2[U)K<.<!T;Y)%)[*58D_[M9>F>#+S2/&Y,#[]#N8HKRZ+]
M9+V+*Y(_VMRR$_WDKOZ* ./%E??\+=;5/L,_]G_V,+/[3\NWS?.+XQG.,=\8
MKD9=!\0#X0:EX7&A7)OENG\LB2/;,#=>;N4[NFW^]CGCGMZ]2%U#A"PW$$@9
MY(_R: ..N[6^N/B=HVJ)IUS]AATZ>"68A0$=V0@$9S_"<X%='KEI+?\ A_4K
M.  S7%K+$@)P-S(0/U-7Z* /+GT_7)_"/@6S;0;R.?2+^S>Z1FC)5(8RCOPW
M3)X'4^@JQK'AK4M=\0^,H1:S6]OJFE0VMM=28V&1-YY .0,L.WK7I-% '#^%
M;C5KN6UAU#P9'I-U;C_2KMA$48@8_=;3DY//. !GDG%=5K;0+H.H&ZCCDM_L
MTGF1ROL1UVG(+=@1QFKV1ZU4U/3+/6=,N-.OX1-:7"%)8R2-P/N.1^% 'E^A
MSRZ?;^'O[?\ #GB58=(0""22.%X+8E=FYMC;R%4D#() Y()YKJ?"]GJ-MXJ\
M77,]A-!%?7,<UK++MVR!8E0]"2.1WQQ6E8>$;6R=#)J.K7T<9#1PWEZTB*1R
M./XL=MV>F>M=!0!Y#_9OB>^@\-7NH>';V;6;#5UFOYY)XCN7$@_=?/@1C*\?
M*.G!.36W!I^J)>_$"5]*N@NIJOV/[O[[$ CXYX^;UQQS7H+NB %V"@D $G')
MZ"G4 >96^D:U96WPYNQHUS,^C6SVU[;H\8=&:W$8/+ %=PZ@]*[+3==N;SQ%
MJ6DW.DSVGV14>&X9U9+A#QN&.1R".>N/8BMNHHK:&&666.,"24Y=^I;'3)]N
MP[4 1ZA8V^IZ=<V%T@>WN8FBE4]U88/Z&N2\'^'=5A\,W-GKTN;L0MIL,J\G
M[-'N5'^K9+>XVYZ5VU% 'FO@^WUNPM+'P_J'@Z&.ZL=D+:M^Z,#Q)@"0?QER
MHZ8Z\G%))X>O3XGAUC1;"^T?56U/%^J,/LEY;"0@R.,E2Q3!&,-N/([CTNB@
M#A]$L]4TG7O%RS:5</;WMU]K@N$9"LBF)5V@;MV[<O< >_3//VFAZW!X$\":
M<^CW7VO2]3@GO(P4_=QIOW-G=@_>'3)KU<D*I)( '))[4*P90RD%2,@@\$4
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M7D]L-.P5VV<AC)3/.<A<] 1Q4>CI=W_P533H+5Y-072GTYK<%599D0Q%3N(
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MA%/S,> %#*,\G)'!JA+H=_=:CXJU[[!*DM]IRV%G:ED$CA5;+M\VT99@ ">
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MC7BK:W26SK$R.#OV;7!R"5S(!P,Y!XJK>P7NLZ 4U/PC&]G=3HDVE^9&95B
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M6;'"J.IP>2, DU!K/BB)O"'B&;6O#5S)'IS-#=6C8,<Z8!WH[;=R8(YQD>E
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MPQBU31(V:UOIX89C(_EO'F=$>-EP>3\RGV]<T >B6]W;7:%[:XBF53M+1N&
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M &3ZD@5+0!Y9!X8\3:7X<\%W]CIZ2:OX>C>"?3Y)T47$<BA7VN"5!^4$9_\
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MB-#'@[F')#MD !0>2170I(DJ*\;JZ,,AE.0139((IBAEC1S&V]-RYVMZCT-
M$E>72?#K43X?UO3UD0&SG>7PYM(S#EQ..>WSX3GH%/8UZ@[K&C.[!549+,<
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MZT^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBDL@)4J2,E3C(]N*Y1CK;V&HZ=J_AU=5@FN)Q!LN(BCPM(Q02AR"N%('RAN
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MVQ+MR,8..V:]1KB]?TG5;SXC>&=8MK!I+'2TN5G?S4#-YJ!1M!/.".<X]LT
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M+/T(4GD#'L?:@# \(7-]X=B\6ZA:Z7J$GA\WL8T>Q$3*Q+':Y12,K'N93TP
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MI;W8LJNA?LA(; &!C'7)'&;<'C2+4++P^VGVOF7NMP?:(8)9-HBC"AG9V /
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MEB%)] ".N:Y_4/%.OS:WX+CM=-6SCU3SY)[2\E:.4,D+'8^$.%&<YP22!P*
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MA@BTFVGF<#' ,I9CZ\"@#OJ*XF#X@"35-'A:TMI+756V(UK=B:6W8C*^:@7
M!Z$@D \<]:[:@!&940N[!549))P *K07]CJ$1-K>03HQ*;H9@><= 0>N*Y[X
MAZ;JNI^%PND01W4]O=0W+V4C86[C1MS1'M@X'!ZXQ6/X8U_PQXL\26UU#:MI
M7B33XWCN+&YA\N;81@KVW '!![>@S0!V&C:!IOA^*>+389(DGE:>0//)+EV.
M6;YV."3UQ6G7!W_Q*@M;3^TK:WMKO3UN?(=(KO-UM#[#(L(4Y (SC.=O/'2K
M4GC#69O$NKZ)IOAQ+F73C;,SO>K&KQR[LMRO! &<=^>> " =E4$EY:Q7<-I)
M<PI<SAC%"S@/(%^\5'4XR,XZ5S>F^,9KI/$B7NGQ6=SH<A62(7)?S%V;U?.P
M85ATX)X/%)-K;IXP\.6&H:%;I>7MM/(ESYHD:V*JI=%.T'G*@GC.* .LHKDI
M/%]]/I[:MI.B/J.F)=FVS%*?/D59/+>1$"D%0P/5AD GBF:UXY2PDU6.PCL;
MB33.)HI[P0R2OL#E(UVG<=I')P,G'K@ ["BJ>DZE%K&D6>I0I)''=0K*J2KM
M9<C.".Q'2KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8+?4VMWB6.X,CJ8X@I!&T#\<]1W'-=?110!RLVDZE_PLV+75ME:P32GLB?-
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MWEN)(2/<-G/MQWJ36=(U&[\?>'=6@MT:RTZ.Y29C( Q,JJ!M'?&WGIUKJJ*
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M>[B$B!A@KZ@^X((_"N<TS0=;\-:CK\>F16MW8ZK=/?0F68QM;SN/G##:=R9
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M"N=T3, >"2#R"#CFN?D\)^)'?QH3%I:KKUFD4*I.X$3"$Q;3\G09SGOCH,\
M&A9^,]4;5/#D=]I-O!9:[$?(D2Y+R1R"+S/G7;@ C(&"??TJQIOC"XF/B6'5
M+.WLKG0R2R+.7$D93>LF=HPK#/J>#5*7PWK;OX)80V?_ !(_^/K_ $@_-^Y,
M7R?)SUSSBDUS1;;6/B#H]S97BY,#KJ4<9#":"-U= WH1+@>X+CL: .QTV:[N
M--MIKZW2VNI(PTL*/O$;'^'.!G'TJU110 4444 %%%% !1110 4444 %%%%
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M"1)D 5TS6AU'21;:I#$QEC N(DY0GJ5YZCM[T 4_^$N\-?\ 0Q:3_P"!L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<SXZT/4?$7AX:?IOV42_:89BUS(R*!'(KX^56SG;BNFHH Y'Q7X?UN_OM(U
MW0;BT@UC3?,4PW)8P3QR ;T+ 9ZJ"#BL+Q]'K8\ &;5I+/[?)J-GLAMRQABQ
M,F!D\MSR3@>F..?2ZHZIHVG:U D&I6D=S"C!PDF2NX=#CU% &,^BZAJ/BBQU
MV_AM8FTRWFCM+>.=GW22[0S,VP8&%   /4GVK*TGP->'X6S>#]6FMXY'64+<
M6DC. 6D:16PRJ>"1QWQUKND01HJ+G"C R<_K3J .3T2V\;M$(M>NM*7[/&RI
M+9%RUR^TA6?< %'.2!G) Z 8.?;^"9[KQ)9:U?6=A872VTT&I/82L1?[TV_,
MNU> <MDY.0!SUKO** .%\+Z%XST."VT*YOM,ET6S(2&\7?\ :FA4_+&5QM!P
M-N[/ Z<\TU/"FN#3?&ML1IV[7I)7MR+A\1[XA'\W[OMC/&?3WKO** .&_P"$
M5UR*Z\'WMN^G?:-&M)+.Y221RC*Z(N]"%R2-F=IQG.,CK65J7@?Q1>:3KVG"
M?29#>ZDM[#=S/)YLB+*KK$X"_*%"X!!88XP.M=]JNNZ9HL7F:C=I H4N<@L0
M@QEB "0HR,D\#-7()XKJWCN()4EAE4/'(C95E(R"".H(H Y<:#K,7CY-?B>P
M:"?38[.Z5F<,C)(SY08((.[')&.O/2L4_#_4[[PWK^G7EQ:6US>:P^K64\$C
M2")RP90P*KTVX./6NXN-8TZUU2UTR>]A2^N]WD6Y;YW"@DD#T !YJ]0!RK:)
MJFL:UHVJ:S!90-I(DDCAMYVD$LSKMR24&U0,XZG)'ISS\W@;7YOAUK7AS.F"
MZO[V2X23[1(457F\S!_=YR,8KTJJFH:II^DV_P!HU&]M[.#./,N)1&OYDXH
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MC>:JCY0%(XV]SSGM73T4 <"?".O0Z;XSTR!].>VUR6YFMY'D=75IHPA#@*0
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MY^E &5;>)?$-MXM'A[6K33HI+VVDN-.N;5G>,E,;HW#8)(!!R,"JL'CS4)_
M_AOQ$+2V5M4O(;:: [B%$DFS*G/;&><UNV^B7=[XEMM>U=;>.:SMG@M;:WD:
M14,A&]RY5220J@#' SUSQR4/@'Q-%X4TOPZ+W2A;Z3?Q7%O-B0M,B2EQO&,*
M>V!G/J.X!LZ-?:S<_%#Q)9S7=NUE:06FR(1,"JN)3P=WWL]3CG X&*TO'/B"
M]\+^%I]7LK6"X>%XU9)7(X=U3(QU/S>HJ.T\/ZG9>/-1UJ*XM&LM1MX$G1E;
MS%>(,!M'3!W=2>/2I?'.A7OB;PK<:18O;QRSO$QDG8A5"2*_8'.=N/QH J0>
M)M4L_&3Z-K4%C%;2Z?)?PRV[L3&$8!E?/7A@<@#ITJA<^.-2MO!\'C/[);OH
MSE9)+4!O/2W9MHD#YVEL$,5VCN-W&3I7WAR_U#QK::Q.EG]B33I;&:'S6+MY
MA4DCY<8&W'OGM65;^"-67P8W@NYN;272 PB6\#L)S;[]VPQ[=N['R[MV,<X[
M4 6+'4M7N_BKJ%H+VV;3H=.@FBC$3?==VR<[OO':.<8QCCUT_B%S\./$G_8-
MG_\ 0#3%\.ZA:^/GUNSFM%L+BQBM)HI%;S$\MF(V8XP0V.>GO6AXKTNYUOPI
MJFE6C1+->VSVX>5B%7<",\ GC/2@#!.NW6ECP18QVEM);ZB$A>61COC(@+?*
M,8[=<]^E0R>*O$MS>^*;2QLM+CDT1D*M-)(PD4Q>9CC')'?@#W[6;SPSJ]R_
MA%U-B#HKAYP97_>'RS'A?D]#GGZ>].M?#>K6^I^+;L_8F&M!/(7SG_=E8O+^
M;Y.XYX^GO0!1B\<:PUMX6U>6PLDTG7)H;;RA(S3QO*A*MGA<9&,8SC'/8:">
M(-3N/$GBG2HK>RMY=.M(9;><AI"^\.1O'R]-O0>IYK//@W6?^$5\):2KV!ET
M.[M[B1S*^V40@C ^3@G/X>]:MGX=U"/QEKVK3M;"TU.VAMU5'8R)Y889(*@'
M.\]^,=Z ,/PUXJU"U\!^&Y[Z5+J_U@A(66!V()5I'=U7); 4\*!S@<#D6SX[
MOM+M-<EUG2IBE@8OL=REM+;QWID(54 DY5@Q /)ZYJE%X"U^/P9HVGQZG90:
MOH4RR:?<1HQC<*&4B0'G#*V" .,=ZTM4\*Z[XK\*7UAXAU"SM[V8(;?^SU<Q
M0.C!P_S\L20,], 8'<D HZL-67XI>!_[2:S<%+XJ;9&78WDC<IW$[ATP>._
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M>:&+9YF,[<Y)/ /<GO5JFQES&ID55?'(5MP'XX'\J=0 4444 %%%% !1110
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M6G7_ -DCGLK?4XF!O'922JMO4 @X7')SFE:ZUM_B_/8I?V_V.+1UN(X'MVP
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M!D*,N>S8)P?<U2\,>*M/\4ZU= 64VC>*[:T,,]G>Q9(0L"&[;T#=.1][W!H
M[RBO,/"OBO4[#X<Z7J.H7$%[>ZKJ+6EHIB*?OI+B0$NVXY48)P ,!<>]=!/X
MIO-!\56^D:Z;62VO;6:XMKNVB:/#0C=(C*6;^'Y@0?;'>@#KZH:;K6FZPUTN
MG7<=R;2;R)RF<(^ <9Z'@CI6!I^M>)=3L]#UBTLK.;3M2='FMN5EMH'&5D\P
MOAB!C*A>^!TS7.:!K,EKXI\7:3ICVS:S=ZPSPQ3Y*+&L46^1@"#@ ]!R2?3)
M !Z@S!$+-P%&36?INO:5K$LT6G7\%T\#%91$V[RV'9O0^QJ[")5A43NCR@?,
MR(54GV!)Q^9KA?AD,7GC;C_F9;K^24 =C#K&GSZE+IT5W&]Y$,R0 _,@.<$C
ML#@X/>KM<Q+-/;>)O$=Q:I&T\>F6CH)"0I(:X/..:Y^Q\;>(GTOPEK-Y;Z8+
M#6[B&UEAB5_-1I =KABV ,C[N"<=_0 [J'5K&XU:ZTN*X5KVU1))HL'**^=I
MSC'.#5VN037]6N?$_B?1D%G;_P!GV<,UK/Y;2$EP_P!\;AG&WH,?4USVB>+=
M0T7X9>'M7U6\@>._D1)KU[9V%L'#L7DP_P V6 7(V@;OPH ]0HK,T*\N;^P:
MXN)[*Y1I#Y%Q9?ZN6+ PP^9N>H//:IM8DNHM%O9;*6.&Y2%VCDDCWJI SDKD
M9_.@!NIZWINCM:KJ%W' UW,MO K9)DD8X"@#W(J_7CMQ/J5S\+O!-Y>3Q7=Q
M-JNG2I\AC))?.'8ELDGN /I75Q^,-0TG6?$%CXA2S>/3=.74XY;)&7,7S@H0
MS'+ IP1C/H* .WHKB[7Q+K[ZOI"MI_VJPO@1<>583Q-9$C*DN_RR+G@D!?7V
MK4\8>(O^$8TF"];:D+W4<,UR\;2);(V<R,JD$C( ZCEA0!T%1SSQ6T#SSR+'
M%&-S.QP *XK5?%>K:;X:76(9])OH7U"&"*:!6,<\$C(NX8<X8%F[GI6K_;MZ
M/B(WAUTMVLVTHWR.$(D#"4)M)R01R3T% &SI>J66M:;#J&G3K<6DP)CE4$!@
M"1QGW!JW7B_A?Q%XC\*_";0];CM-.GT&V0"ZBR_VGRS*074_=&"?NX/ Z]AV
M5WXRN&\3ZAH=K<Z?:WUN8S:VM[&P:]1E5BT;[U'4LH !Y7GKP =M17&:IXJU
M*2ZUFVT.-&FTLB/;)83W N)?+$FP-&0$&&49.>2>,#F:T\3ZAJ]_8Z7:VBZ=
MJ#Z>M_>+>1L_V8,VT1[05)8L&YR,!>AS0!UM%>;3^.]=M?"6OZI)%IS7.D:Q
M_9Q58G"2INB3=]_*G,A/?L/>NCN_$5U9>/(M&F%O_9\FF2WIDV,)$,;*I!.<
M$?,3T% '345P,'C+7+R+1=3LM-:ZL-0EC\VU2PG62WA<9$GG'Y&P,$@#OP>,
MF"X\7>*GMO%LMK!H\?\ 8$S_ .M61_.18A)MX888@GYNG3CO0!Z+17GE_K.L
M:EXO\$-8WD%M9ZG9SW?D20%]K")3\Q#KNXD('3'7GMU7BK6G\/>&[O58X3*8
M-F["%]BEPK.5')"@EB!U"]J -FFR2)#$TLCJB("S,QP !WKE(?$.JW>@:AJ6
MD/IFMJ$C-B]HWEHY)PX?<YQMX)&1QQUZ)H'BFXU#Q??Z'-/97D4-G%=PW=I&
MR*P9F4K@LP."O4'';J* .ATK5K#7=-CU#3;A;FSE+!)5!PVUBIZ^ZD54MO"G
MAVSU#[?:Z%IL-YG=Y\=JBN#ZY SFN&\$Z]_8GPS\/PQINN;_ %"ZMH?W32!?
MW\[LQ5/F8!5/ ZG'(ZCK/#FLZS>ZOJ5CJ=BP@@V/:WZ6DENDZL.5*2$D,I]\
M'VH Z6D)"J68@ <DGM7/7FNW,_BW_A'-,:WCN(K/[9<3SQF144MM10H9<DD$
MDYX '7/',:MXEU'6?A]XSM9/L]GJND17%O=[49TD3RF(>/Y@5W @C).,'@T
M=G8^)M'U+4CI]K>![KR1.L;(R>9$3@.A8 .O^TN13KWQ)HVG73VUWJ,$4L8#
M2!FXB!Z%ST0'_:Q5;PG;2KX;TJ6\:VFG6TC6*2* QE(RB_+RS$].2" >..*X
MR\OM=^'&N:Q>W6E2:OX8U*Z:\DN+4;I[1F #!U_B0!1CT Z]J .[F\2Z+ M@
MSZE!C4)1%:%6W><Q.!MQU'OTK5KR[Q#/ITOACP+-X<:.XL#K]L;3G:N,2X4\
M97!XZ9&.E;VG^)->&J^)=(O+.SO=0TVVCNK068:);@.K%4.]C@[EQG..>@H
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M0QLRS#Y >"P&#P,9S0!WD\\5M \\\BQQ1@LSL< "J^F:G9:UIL.H:?.MQ:3
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MEE91V660D@?A0!WU%<+;>+=>N)M#NX---U8ZBZ">&.PG1[1'&5<RM\CJ. V
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MA'0-$DOM/D;2+RWG20(ZATA;*@]>6[GH,=#6G>>$+C5/%&JWU\\']GZEI/\
M9DD,;MYBKECN!(Q_&1C\?:NPHH X[PSH7BW3%MM/U;6[*ZTRR 6&2"!TN)U7
MA1(Q.T <9P,G')ZYW]9M]1N(K;^SGMLI-NGBN<[)XMK H2 <<D'.#TZ&KT\\
M=M \TK;8T&YCC.!5;2=6L==TN#4M-G\^SG!,4@4KN )&<$ ]0: .*E^'#?\
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MQ6*RQR*H8DKR&RH/IR:ZRSTC3=.FEEL=.M+:68YD>"%4+GW('/XU<H \YNO
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M-_IXU+1K@2?ZE_)=/+,9&,[LX.<\>E6CX6N[CQC?ZI>26\MC>Z6NG21*6#D
ML2W3'.XC';UKK*9--';PO-*VV-!N8XS@4 <9X9\-^*]%CMM(N]<L[C0[(J('
M2!ENWC4_)&S9V@# !(!) QQFF1>$-531/%U@TUENU^>>5'#-B'S8PA!X^; &
M>V?:NLTC5K'7=+@U+39Q/9S@F.4*5W $@\$ ]0:+C5K*UU6RTR:4K=WJR- F
MQB&" %N0,# (ZD4 <S/X5U67_A$2);,'0B&D^9OWV(S'Q\O'!SW]/>J]AX2\
M3:'J-[::/K5E'H%[</<;)X&:XM2YRZQ$$+C))&[.,]#W[NB@#E[30-1L_&NI
MZZCVKPW5G%;1Q-(VY?++$$G!SG=SZ>]8=MX!U6U\&>'])COK+[=HNHK>QRLK
M&.4!G.TC@CB0],]/?CT2B@#+UG3+G5O#-[I@O3!<W-JT/VF)<;69<;@,\<]L
M_C7+V7A#Q!%J_AO49[[2E.DVLEJT$%NZJR,$'RDGJ=GI@9Z&N\K.L=<TW4]1
MO["SN1+<V!1;E K#RRP)7DC!R >E '&3> ]6G\!:YX<:ZLA+J=Y+<B<%\1B2
M3S",8Y(QCKSGVYTIO#6MVGC&3Q'I%S8I)?V\<&HVER'*,4^[(C#G(!Q@CD5V
M5% '-^"O#U]X:TFYL[Z[M[EI;R:Y4PQ% OF.6(.2<]?P]^M1Q>']3LO&^J:Y
M9W-JUMJ-O"DL$J,'#Q!@N&' !W<G!/'3O7444 >=1> M7B^'VE^&A=61EL;Q
M+DW&7VN%F,H&W'&2<=>V?:KT_ACQ+IWBB^U;PWJ>GPV^J;'O;2^A>18Y54+Y
MD94J22 .#C./R[>B@"&T@:VM(H7F>=T4!I9/O.>Y/U/8<5-110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S'CS
M7=2\.>'EU'3$MI)!<PPLDZD@AY%3@@C!^;J<_2NGKG?&?A^Z\3:$--M;F&V;
M[1%,9)4+_P"K<.!@$=2OK0!G3Z[KNF:A;:/J,MG)?7KSS12V=I+((K= G!3.
M2^Y\9SC'/M5:'Q?KMK9"VU/3EBO[C54TZPN'A:**='!82E"=PPJME<\D 9&>
M-+Q3X7U#69]*U72]233];TTMY4C1^9%(K@!XW7@E3@<]L56U;P;J>O\ A](]
M1UI5UN&ZCO+:[MX=L5O+'G:%C).5Y;.3DY]   "74-=USPU::W>ZO!;75A:Q
MQO97$/[MI7<[?+=<MC#%?F'8]":2RUCQ&?$UO9R6OVK3;F!R]U]ADM_LLJC(
M!#,=RMT&.0>].F\*ZEK_ (>U#3O%.IPSR7<'DJ+&$Q1P\@AP&)+-N"G)XX
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M4 <YXHN-9U#2_!.IWDMHL-WK=A,UK'$<P[CN4!]WS8!P>!D\C'2O468*I8]
M,FO//^$'\2S:+HNDW&NZ>\.CWL%Q;S_8W,DB19VAQO SC XZ]<^OH8!VX;!.
M.>.#0!QOPQNY-7\(#7[@YN=6NI[F0GL/,*(OT5$4#Z5Q_@;4M4MO@Y-'9>&Y
MM3RUVJ@2QA'!D?.5+;B.>@&3VKLO ]A/X<T6Y\,#8)]/GE-H9,XEMW<NC\=<
M;BI]"ON*K^&?"GB3PQX771+35],^5Y&2Y:S=F4NQ8G;O ."W'- %3P986.H?
M!*VTVVU'[?%]BDC%P 5*298X /(*-C'^Z#71>!-;F\1^!='U:XYGN+9?-/JX
M^5C^)!-9]GH4'@/X?2Z1IK2W=TR2+#NQON;B3...W/Y*,GH36UX5T-?#7A73
M-&5@YM+=8V<=&;JQ_$DF@#D)/%/BR;2_%UU;R:3$V@7,JJ&MY&$Z1Q+)M^^-
MI.3\W/7H,9JXGBG78]2\+75R+#^S-?(C%M'&WFVY:(R*?,+8;I@C:,>_6IHO
M!^I1Z;XMM#>VA.OR2R!A&W[CS(Q&1U^; &>W-.F\(:E);>$XA>6@.@NCL?+;
M]_MC,?'/R\'/?F@"CKOC'6=$DDGG%DFS5([86"J9':V=PBRLZM\C-G< P'I@
MFJFHZW%HOQ<U-0R&]O-*M;:RC<X$DQDEV@GC XR?8<9. 9KKX>:U-H^I:4FN
M6GV>?4QJ4$DEHS2EO-$FV1M_S 8QP >G( Q5O5? $VN:QJEWJ5S;2Q7NGQVB
MA(V1XI(RS)*K9X.YLX[>I[@&EJ6NZCHYTC3;J6";5-19P9;>TD9(U1-SD1AB
MS<D <CKD],'(F\7^(-+T75[G4]-<165U"L5^MHZK);NP#RF+.[,8SD9YX/2I
M]0\'Z]J6CZ0\NO0IXBT>3?;:BD!VR@KM99$)_B&,X/O[5J0Z7XF^P"6XUFU?
M53+&S;(&6W$:YS&$W$\Y.6)STXX H L^&=5?6+6>[34;'4;)I!]EN;08W+M&
M0XW'#!L^G;@4>(=0O["2P%LUK!:2RLMW>7##$"[25"J2-S,V%&,XST-0>&O"
M\>A:CK&H*D$#ZG+'(]M:@B*,JN,CIEF)))P.W'&2WQ)X>U'5-:T35=-OX()M
M,DE/E7,)DBD$B[2<!@=P&<'/<T <Q<>/M;3X?:SK4,=FU[I>J-8,9(7195$J
M(&V%LHV'!P2>16Y#K6OP>.?[!OY=/>.\T^2[M7A@<&!T=5*ME_W@^8'/RYQT
M%95Q\.]6F\->(-&_MFU9=5U(WXE:V(,9,B2$$!N>4 &,8!/7MNW>BWG_  F5
MGXFGN[2*WLK&2WEC(/1BK,^XG QM].E &7I?BW6;GPSJ:W8L4\26=^=/\A(7
M$7F,P$9P7W%65@V<CC/I7=1AQ&HD96< ;F5< GN0,G'YUPVE6>C^(?B')XGT
MB\6YM(K1$E>!PT,MQ\P0Y'5TC9@?0.M=W0!Q=OK_ (BUW1CKGA^&RE@^V-%#
M93 AIH4E,;L9-P"L=K,!C@8')JU'K>IZ[K&N6.C36MLNDND'F7$)D\V8KN((
M##"C('J3GICG/TSP7KFB7=Y8Z;KL,7AVZN'G\AK<FX@WG+I&^[ !)/)!(SZ\
MUH1^&;_2?$^IZOHMS;"+50C7-M<HQ"2J-HD0J>XZJ>N.HH P8_B#JNHZ3X7O
M;&TM(7U+43IUY!/N)BD4/NVL#TRGH>#5RSU?Q=>:_KOAT7>D+=6"0SQ7WV23
M:R2!B$,7F=<J?FW=.Q[2/X"EMK'P[::?>1!=)OS?RO-&2UQ*=^[H?ER78]\<
M#M6E9^']1L_&&M:ZMQ:LNH00PI"58&/R]VTDYYSN.>!0!ST7CO6KSPSX-U6V
MM[%7UJ\2TN8Y V%8A\E2#P,QGJ#UJY9ZOXMNO$>M^'/M>D"YLXH;B*^^R2;=
MD@;Y#%YG7*_>W].QJ"R\ :I9^'?#&DC4;1_[#OQ>>9Y3#SL;\+C/R_ZP\\]!
M6Y::!J%IXSU;7A<6K)?6T4"0E6!3R]V"3WSN.1B@# 7QWJUQX$\,Z_%!9QRZ
MC?P6EW&RL0-TOEL4YXZ$C.>M6K>?6I?BUJUJ-1@-M!IL,D4+VY(4,[\##CG*
MC+<YX&!BH(?A_J<'@G1O#PU&T+:;?I>>>86Q(%E,@7;GCDXSGM6XWAW4(_&\
MGB&TOK=([BRCMKBWDA+$E&9E*MD8!W8.0?\   Y)O''BI/ 3>*V&E>7:7CPW
M%JL+YF07'E?*V_Y"!CJ&SC/M71)KVLZ;XX@TG5Y+&6SO;&:ZB-O$R-;F,KE2
M2QWC#=<+R.@K.;P!J;_#J[\*G4;3=<7+3_:?);"AIO-(VY]>.O2MN\\.WU]X
MQTS7)9[40VEK+;26^QB9!)MW$'MC:.,4 8UOXO\ $%_::/J^FZ>]U9WTJ&6S
M%E(K16[]'$Q.UF48)&,')QTS4,_B?Q9,OB_[+)I,7]@R$H7MY'\Y1$)-I&\8
M)S][)^G>KOA[P=XAT )I$?B&*3PY"^Z&,VY^U+'G(B\S=C;VSC..!CM-'X1U
M)!XM'VRT/]OY*_NV_<9C$?//S<#/;F@#+OM8U?5O$_@&>SO(;6VU2TGN_L[P
M&0*X@4Y)# MQ(0.F.O/;T242-$XB=4D*G:S+N /8D9&?ID5Q@\%ZE%'X1DM]
M2MH[OP_ ]J6:!G2:-HUC) W AL*".2,UVU 'EGAGQ1JFE?#V+4KZYAOKN_U2
M2SME:(IF:2Y=,NP8C:.3@ 8 Q[UT\FO:EHWC32M$U1[>ZMM7CE^S7$,1C:.6
M-=S(P+$%2O(/7(QSUK+C^'%P_A.Y\/W&K((H[QKS39X;?$EO(93*K-EB&(+$
M8&.,^O&[#H-[?:[INKZW+:M/IL<BV\=JK!=\@"M(2W/W1@+VR>3Q@ U-:N+Z
MTT6\N-,M4NKZ.)F@ADD"*[=@6. !7,:1XHO[OQA-H(N[*\C;2_MT-W% R*'$
MFQE^\0Z\@@@^HS6YXMT*3Q+X5U#1HKLVCW4>T3!=VW!!P1W!Q@CT)K'M?#&N
MQ^+;;Q#<:I8-,FFFQE@BM61,;PXVDL2.1R3GCH!V ,"S\<>)Y/!^B^*+@:6+
M6XOEMKFUCA?<RM.8MRN6^4CCC!SC.><#J8]:U'6M>UG3M(FMK>/2MD3RSQ&3
MS9V7=MP&&% (![DD],<XL?@#4X_A_8^&!J-H6M;M;G[3Y+88+-YH&W/')QG/
M2M*/PMJ^F>++_6-&U&TB@U4(U[;7,+2!)57;YD9##J.H/_Z@"'X19_X57H6>
MOE2?^C'K0U37=0L?'OA_1T%N;#4HKEW)0^8K1*I&#G&#N';M4O@CP]<^%?"=
MEHMU>1736P8"2.(H,%BV.2<]>O'TINJ^'[R_\9:'K<5S D.EI.AA9"6D\U5!
MYS@8VCL: ,G1O&%QK.O/IZWEG;WMO>RQ76E3PE)EA4L%=&+?/D!&) (PQZ=^
MSNS,+24P.B2A249U+*#[@$9_,5R=QX/O-4OM)GU6:SEETN]%U#>Q1D3L@)*Q
M'/;D G)SCH"<CL64.I4]",&@#SV'QQJ\W@CPGKWEV0EU6^M[:ZC\IBH623:2
MGS<$8[YJR^N^*;WQ+XGT>QETJ :7%!+!-+ [D^8CMM90XR3M W9&,=#GBC#\
M/-=C\.:3H1UNR%KI%_%<VCBT8LZQN7 D^?D\XPN/K6]:>&]2M?$GB'5_M5H_
M]K0PQ+'Y;#RC&K*"3GG.XG'% &?IOCBYUK3_  I#:Q0P:CKMNUQ(S*62!(U!
M<@9!))("@GODYQ@XUCK%QX9\2_$74]0,5U-;_8 OE(4$A:,K&",G'+*#C/<@
M=JOV_P /-2T_2?#+6&JVR:QX?5XHIGA8PW$3\,CKG(^H/'\K#^ +O4Y_%!UG
M4K=X=>A@1TMH&0PO$N%926/0\X(YP.G2@"Y::OXE/B.&R-L+G3[FW<F[:PDM
MQ:S*,@,&;YE;MCD'O4/@36_$_B;3-/UJ_.EQV$Z3+)##&XDWK(RJP)) & 1@
M\\9SS@7=!TCQ7:!!K>NVM^+9"MN(;<Q&5L8#3'<<\$\  9YYP*L>"?#]UX6\
M,6^C75S#<FW:0K+&A3(9V?D$GH6QUH M>([Z_P!/T^*6P6V&;B-+B>Y<*EO"
M3\\AR1NP.@SU-<D/&VK#1?&<D7V2:XT >9!,\#HLT9A\P;DSG/49!P>#71>+
MO#]YKUOIK6%[%;7-A?1WB">,O%*5!&UP"#CG(/8@5B3>!M7F'BT/K%H__"0P
M+&W^BE?*;RO+)'S'C'0=>F3Z@#K7Q+X@AU[PO%?MI[V>O0/B.&)P]O(L/F [
MBV'!YXVC'OU+[#Q9JD'_  E5GK)LQJ.D,'MTMX&431.N8FP7.XLV5P",$8SS
M5B7PIJ4M[X3N/M=J/["5@XV-^_+1>6<<_+QSWYJE+!H?B_Q]I6J:5?QW0TZ&
M07KVT@:-P'4Q1OCN) 7 _P!@^HH [6P%X+"#^T&A:\V#SC"I5-W?:"2<?C5B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK \5^('T.WTZ*W6,WFI7T5C;F0$JC/G+D#&0%!.,C)P,B@#;GF
M2V@>:3=L12S;5+''L!R?PJKHVL66OZ3;ZIITIEL[@%HI"I7< 2,X/(Z5SZZY
MJ.E^.;;P[J4D=U;ZC:R3V=RL>QU>/&]& X(P001CTYZUP7AS6?$OA?X1:+XA
MMI;";2+-!]HL#"WFO$92K.)-V PSTVXQW- 'K,6O:?-X@FT-)G.H0P"X>,Q,
M (R=H(8C!Y]">AJ73-5M=7@EFM#(4BF>!O,B9#O0X/# 9&>]<HA+?&NY,9 )
M\-Q[21D?\?#XXJC'XZU6V^'NKZY=1VTM[::E+9*4C*Q*!,(@[#).!G<>>W7O
M0!WMYI]EJ**E[9V]RBG*K/$K@'VR*G1$BC6.-51%&%51@ >@%<C#JVN1?$1?
M#QN;:XL3IWV]I7MSY@._9LRK!1D\@E3T(]ZS+?Q=K,&L^';>]FM9)=2N9;:]
MM8(]T=JP5F54E'!8;0&!)//04 >@NZHC,QX49.!D_E572]2MM8TRWU&S+FWN
M$WH9(RC8]U8 BN*\*3:W+JOC21]3BFDM]0:.,2V^5&(4*\!AA1TQ^.<T:3XW
MO]0\/>#E;R%U;Q$7S)L/EQ*BL[L%SR<  #/4Y.<8(!Z#17#3>)M8T[7M:\/3
MR6TUU!I9U2PNVA.'0$JR2*&'(8=01P>G'.?8^*_$BV/@O5[V>QDM-<DAMIK6
M. AD:2,L'#[O5>F,8..>M 'I- (/0U1UEKA-$OGM)Q!<+ [1R[ VP@9S@\&N
M!\.>(=0T_P #>#K8W,<]_K?EQ0R2QG$2["[NW/SG XZ9)% 'I3HDD;1R*K(P
M(96&00>QIL%O#:P)!;PQPPH,+'&H55'L!TKE['7=0L_'C^&-2>.Y2>R^VV=T
MJ;&PK;7C<#@D9!!&.*G\9^(7\-V%G=MYD5E)="*\NXX3*;6,JQW[1VW!1D@@
M9Z&@#I20!DFBO,O%.J:G=^%-(NK/7+6>"XURVB6XM(P5GB,J[<\\8(^8#J1C
M@<5I:CJGBMO&W_"-Z??::F_1VO$N);1B5D$JIR-_(/X8SWQR =W17%:?KVM2
MZCXNTZXGM3+H\4#03) 0"SPF1MPW<C/';BH=%\7:AKMOX9LD:&"_U33#J-U,
ML>1&@VC"*3U+..N< '@T =V2 ,DX%%>:>,+CQ5!X2A74+JWMI_[;@MQ);)G[
M3;F90C,,_*3_ !*.N.H!Q701:OJL7Q"C\/3W$$MM)I#7GF+#M<2"54_O$8P<
MX_6@#JZ*\QN/&WB&/P1=:M$;%KNVUMM/(:%@KQB<1 CYOE/.<\_2MF?6->TW
M5+;1+VY@N;R],]RD]G:$>5;IL 78S'+;GZDD8'2@#M:0D#J:Y_PI?:[=V]['
MKUEY,D%RR6\^P)]IA_A<KD[3V(K&U235&^+ND6L6HB.T.F3RB$PY (>,$]1D
MGU[>G)H ZC2->T_71>'3YGD%G<-:S;HV0K(H!(PP!XW"M*O(K:^US2=,^(&K
M:1<V<*V&LW-RZ3P&0S;8HR4R&&T8'7DY/;'/5S^*+O4=473=-$L##3XKV66.
MW$S*9=VQ<$@8&TD^N1C% '949&<9YK%\*WVL:AX?@FU^P%CJ0+)+&OW6P<!A
MR< C!QGBN:M;S4(?BCXD>YU+=8V6G6\OD^3]V,^82%YZ\9)YS[8% '?T5P%I
MXD\47\.A:M8V#W%I?O&UU:F *L$$@R'20MEBN1G(^;G %/T35?%VN:OJ\*7V
ME0P:7JS6KYM')EC$:G &_P"4C=GJ<Y[8Y .\HKRD>,_%8^'L7BUY]-(@O&AG
MM%MV G3[28>&W?)@8QP>F23G Z:WUC7+'Q]#HFHSVEU;7MA)=0B" QF%T905
MR6.X$-U..1VH ["BN$\(>+Y_$=Y;QMJ$,=[&K?VGI,T'E3VSXX"YY*@\$\YR
M#D=*W?%WB!O#ND13Q(CW5U=0V=LLF=GF2,%!;'8<D^N,<4 ;U8>J^+='T621
M;VXD5871)Y$A=T@+_=\QE!"YR.OJ,]169/K>J:)XSTG1;^>.[M-8CE%O.(MC
MPS1KN(8 X*D=.X(Y)K.\ 0WS>(/&!N+R.9%U=ED7R,;V$,>"#N.!C''/2@#T
M D#J:S8]>TZ;Q#+H23.=0B@^TO&8F $>[:"&(P>>.">AKFOB1-J$,'AU;*^^
MS)/KEG#*OE[MX,@(SST!4''?UJC=0ZI)\7VALKRWANCX;0/<R0%P/](;)";A
MR3ZGCWH ]%HKSS2O'6H7OAW0UFB0ZMJ%Y<6CO!$64>07WNJ9Y)"# SP6SR!@
M[_AB^U^>^U2UUBS86T#H;*]:,1F=&&2&0$X93QG@'/2@#I**YOQ!KES9>(_#
M^BVY$(U5YP]T5W;!&F[:H/&YL\9SP#P:YB;Q=XG@\,>,+_SM.:30KB6WA<VC
M_O@@#;B?,QG#8( P"._2@#TNBN+DOO%=IIJ7MU>Z2+>ZFMR9-GE_8X64^8<L
MV)&SM"].3G':LMO&FLKX:\9SPR0/<Z#(3!-<6KIYL?EAQN3*D-R1G@=#B@#T
MBC(.>>E<+!K_ (AMO$_AJVOKBREM-=MY2(HH"K6\B1"0'=N^<'D'@4OPXEU.
MX'B&6_U#[5LUJZ@YBVL2C*H.0>!M4#&./6@#N:*YS6M=FA\2Z1X=LF2.YOTE
MFDG==WE11@9P.[$D 9X&"<&N?OO&&MZ9%XNTV1K1]2T2R^WVURT)V3PE"V&0
M,,,"I&0<'KCM0!Z'17/^%I->N[5+_5[JRD@NK:&6"&"$JT3%<L&8D[NH[#O5
M7Q'JNJ66I-##=06=I]B:6%Q'YTTTX)^01CG8%P20/XNHQ0!U5%><_P#"::[>
M:/X(OK1;")M=D6*X22-B%8QLV5.[IE>F,^XZU:LM8\4W$_BS18[FQGU;21#)
M:7'V8HDPDC+A&3?QRI&<]P: .\HKC=(\3W>O:/X9EL9XA=7^Y[P-#_JUC&)A
MMSP1(53O]X=:Z/6[B^M=$O;C3(89KZ.%F@CF?8A;'&X]A^7X4 7BBEE8J"R]
M"1R*6N&TGQ3?2^,)=&%Q'J<#:0;^*9(3%ND#A"J-]UT.1@C/U--\)>*[GQ,\
M8@U6U%XEN_V_3KBV,<UI/\N!LR&* [@>N>/FH [HHI<.5!8 @''(!Z_R%+7D
MB^-O&2?#VR\<2-I<EG&VZ[L$@8/)'YI0LKEOE(XP,'IDD]*Z._\ $NKZE<:U
M!H"N'TTK%%BV\U9YC&LF')8;5^=5XYZG/:@#N*"0.IKCK+Q#JVL:K;:,85TF
M^73$O;X,HE:-W8J(UYQU5B2<\8'?(Q?$-QXJ%OX.CU*ZMK.\GUE8+F.V3?'+
M@2,C\G./D4[<]3UXH ]+HJ%Y1:V;37$@(BC+2.%QT&2<5P-QXPUM/ ,7CF+R
M&M<"X?33'S]F+XX?.?,"\YZ=1CO0!VVHZM:Z8(A.9&EFW>5##&TDDF!DX502
M<#^GK1H^L6.O:5#J6FS>=:S ['VE3P2""" 0001@^E<3JQO;SXK^&Y;6_C2&
M73;J6$-!NVJ?*SGYADGCGC'O78^(&N(/#>I26,XMKB.VD>.4(&VD G.#QG_/
M- !JFOZ=HTMC'?3,C7UPEK;[8V8/(QP!D# _''0UIUX_<&_;X;_#J66X2XGD
MU33'C+J5QE#@,<DGGJ:Z+_A+]3T#4/%-MKDMO?)I5A'J$,EO"82RL'S&06;N
MHP<]^: .^JIJ>H6FEZ?->7[E+6)2TK^6SA5 R20 >,=3TKF+35/%(U_2U>S>
MZTVZ5A>L;<0_96QE60[B64G@@Y/?/:M;QI_R(GB'_L&7/_HIJ (-,\5>%]EE
M:6%W!;1W7_'FA@:!)L\_N]R@-G/:NCKQ$M+XL\->"/!+6[::9+.UOEOKEA^]
M2)!D0;2<OSGYBI [5Z1K>O7$/B&VT*R$BS26KW<LL<(E9$#*@"J2!R2>3G&,
M8YR #IJ"0.IKSR?Q?K^D>'8KKQ#8R6*)J36MQ?Q6^_;;;24G\L%MN3M4YSC)
MXZ"JOBC5-4N_#.B7-IKMK/!<Z]:Q+<6D8*SQ&5=F>>,$?,!U([#B@#TVJ4.J
MVL^KW.EH9/M5M&DL@,3!=KYQAL8/0]#7(ZCJGBMO&Q\-:??::F[1S>)<2VC$
MK()0G(W\Y_#&>^.9$\6:AIWB#Q/;ZL]O+9Z/ID5\OV>(HQRKE@<L<_<XZ4 =
MO1D'//2N5L+CQ3=?V)J"O8RV=['YE[!MV_9E9-R&-LY;!X.>O4;>W,:#X@U+
M1?#WBS6+^\%^\&MSVD:-%M+2>9'#&<@\+RHP!T'6@#U&LW6->T_0EM6U"9XQ
M=3I;0E8F8-(Q 4$@$#D]\5S8U_7]*U::;4;66XT&.QEN9[IK<0M;O&"Q &X[
ME(!QW![FN?\ %-UJ^K>$O"VLW-Q L-]JMA.UHL7$2/(K( ^<E@" 2>#S@"@#
MU:N?G\;>'[6*6::^9;:)BKW7V>3R-P."!+MV$YXP#UXZUO.H>-E)(# @D'!K
MQ\7NJ_#O0W\.>*]-.I^$&1K>+5K-<M%$V0!,GMGJ/PW&@#V+(]>M%<%J%U?W
M?Q4T)+/5$_L^;2Y[B-!%N0_-'\V<C)(/![#MR:5?$NM:QX:U?Q%H\MLD-E-.
MMM:RQ;A<)"2&WMG(+;6QC&.,YH [RLW4M>T_2;RPM;R9TFOYA!;@1,P=SVR!
M@< ]2.E<]IGBZ7Q5?65GI,@LDETJ/4II70.Z^82$C /'&ULGGMCKD87B_4-1
ML-'\'7_BE;>WNK;7%>Z:URR;%CF^8#D\J <<T >H5EZSXBTOP]%%+JMR;>.5
MQ&CF)V#.>BY4'DXZ5#X>N[_5+;^U)[B V5T!+9PQ*"R1$ J7<$AF/7C@9QDX
MS7-_%K_D7=(_[#=G_P"AT =E>ZK::=ICZC=O)%:QH7=S"Y**!DE@!D #KD<5
M/;7$=W;1W$6_RY!E=Z,AQ]& (K)\9?\ (C^(/^P;<?\ HMJR=;UC7;;QGH>B
M:?-91V^HVMPY>:!F:-HPO/##</FZ<=.M '3ZEJ%OI.FW.H71<6]O&9)"B%VP
M.N .34\4R30QRH3LD4,NX$'!&>AY%>=_\)=K\/@7Q9>/+92:IH%W/;B8P$1S
MJBJP;8&^4D-ZD<=ZEU:ZU>Y\=>"4BU%8H;NTN9VB\G<OF+&GS'D9.)"!Z4 >
MA45PEMXOGN_%-SHSW\-AJ4%_Y:Z==0[?M%J&'[R-R?F8KEN,^F.]=5K[W,7A
M[49+.X^SW"6[O'+L#;2%)S@\4 :(((R#FBO-?#VOZAI_@[P38?:8YK_6XXTB
MEDC.(46+>['GYVP,#IRWMBM_3M>O[;QW<>%M3>.X#V0O[.Z1-C% ^QD<#C<#
M@@C'!Z4 =717*^.=;U;0[?1Y-*-J3=ZI;V<BSQDY61L<$'C\CUJF^LZ]9ZK!
MX>N[J*XOY(9;R2ZLK/[L(<*BA&8C.2<DDXQC!SD ';5FP:]I]QKUQHD4KF_M
MX1/+&8F4!"< @D8/.>F>E<G#XL\0P66GZ=JEC';:U?ZF]C;2NF$DA4;S<; Q
MQ\HQMS][VJF@U*S^*6OL]['+/'X>C>"4P@8 E<@. <$Y!Z8XQWYH ]*HKSY?
M&.KOX5\$ZOFV$FLWEM;W<?E';B4$DISP1COFKYUG7M>AUV;P]):Q2:9=O9V\
M$Z;A<21A2^]L_*"25&,=,D\X !V5%<=>>(=4O-8O-(L5>VN+*UADF>*#[1B:
M0,0O)'R@+UZG/;'.WX9O=5U#P[9W.MZ?]@U-E(N+<$$*P)&1R>" #UXS0!K5
M#;VEM9HR6UO% K,798D"@L>I.._O7+6^LZMXCNM?31KFWM5TJY-G$)8=_G3J
M@9M_(PF6"\8/!.>U8</CS6=;M/!UUI:V=JNMR307$<\3.8I(U?)!##*AE)Q@
M$X'(S0!Z715/28]0BTN"/5;B"XOE7$LL$91&.>"%)..,5<H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO%?AJ/
MQ/ID,'VEK6[M;F.[M+E5W&&9#E6QW')!'H:W:* ,"VT"XFU^#6]7N()KNVMG
MM[=+>(HD>\@NW))).T#V'KG-8NG^ KF#PM;^%;S4H;C0X) 2%MRDTT8?>(W.
MX@#.,D#D<<=:[&_OH--L)[VY+B"!#)(4C9R%'4[5!)_ 5GIXFL)-(TK4XUN9
M+;4WB2W,<#,?W@RI8#[H]2>!0!5'AV[7QY+XD%]#L?3Q8BV,!R '+AMV[KDG
MC'2N5UC2I/"'@/4-/O-;BC&JZF2+S[)B.#SI-SB0%B-F-PR2.N.^:],IKHLB
M%'4,K#!5AD$4 ><>'C?0ZE'86NL^&M1M;M3'<#1[40S0IL;;)N1V  . ,^O%
M36?P\U>WL/#MJWB* KH5SOMREAC?'M9?FRYR^&ZC ]0:["VN=/M-8.C6UHT$
MOV?[43';E8BN[;]X#;NSVZXYK3H Y>P\+WVFZOKUU;:I%]FU67[0('MLM'*4
M"'+;N5^7.  ??US+?X>2VWACP_81ZJ@U/0)?,LKT6Y"D<AD=-W*L#@X([5W=
M(2 0"0">![T <S)X7N+NZU+4[N[@_M2\L/[/C=(3Y<$623@%LL2S9)R.@';G
M//@:^_L+PMI@U:W_ .)!<0S+(;0_OO+4J 1YGRY!.>M=O39)!%&SL&(49(52
MQ_ #DT ,N(%N;66!R0LJ%"1Z$8KB(?AY=+X6TC3)=:0WVBS)+IMW':[1'LR
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M52T<3/@D@#.!QDD#)P.: .<'@:^_L/Q5IK:M;G^WYYIFD%HW[GS$"$ >9\V
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M20^;OA.W&T[AM8;!R<CVJK;^"[S3;?6=,TS4XH=)U2224QR0%I+8R#$@C;<
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MM[>U,:X#,V5)<D?>[Y[]*ZZB@#SN#X>ZRFBZ%I4GB&W,&B7T5S:E;$@ND>[
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M2*4W&K17*2^3Y95GN4=N"QSCD_05VS^&I-3U.+4M5OHYY(+66WM1:Q&)8_-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW3;+>7[0FR5LXPISACGC H T**S[W7M(TV;R;W4[2WD 4E99E4J"< G)X!/
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M1P14M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>%];F5_$5IL=[AGW&\@V@1NI//RCY2.QYZL:] KF?[!U[SO._P"$@MO-_O\
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MU]@LPI46D&TG)'EC!I?L5H&5OLL.5^Z?+''TH \;FCT]OAI\3I ML6.K7HW
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MN+5P2H'50<#//;DFO6C:6S6YMVMXC">L90;3^'2GK#$CLZQ(K, I8* 2!T%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M! ,GGC''7BG^'=;T1-&U/PCXI@$VL+J,[/82Q%GO2TIDC=!CY@<K@]MN3@4
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MB'=*\4<@(:.)I&,8.>1\I'';IVK%\/:A9VDWQ!L;JXCBN?[2N+@Q.<$1-#&
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M:)QF260FT1EPPD!XR3@8.>>1P": .VOM2L]-2-KN=8O-?RXUY+2-C.U5'+'
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M_I<L*G2WDD5XKB+CS,#@*.6STP?7BO3?$>BP^(O#FH:1/@)=P-&&_NMCY6_
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MZ@C\*MTR...) D2*B#)"J,#GFGT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(RJP(8 @]B*6L+Q9XGM?"FCB^N4
MDD+RI#$B(6RS,%&2!P.?Z#DB@"#QCX>NO$.BP:=8R6]N([J&X+2 X'EN'"@#
MUQCVKH(4$<8'EHC'EE3IGO7#ZAXD-C\1M/,VJRQZ-/I,TY@D0*H=9$4$#:&)
M.3P<^U=3:>(=(O\ 1AJ]M?PR6!R/.!P,YVXP><YXQUSQ0!HB- Y<(H=NK <F
MC8A</M7>!@-CG%4--US3M6FN8;.XW3VQ"SPNC1R1Y&1N1@& /8XYJY<W,%G;
M27-S-'#!&NYY)&"JH]230!)@9S@52U:"_GTJXBTFZAM+]E_<SRQ>8JG(ZKD9
MXR*RX/'GA:ZO[.RAUNU>XO #;H&/SYZ#.,9/& >3D>M6[[Q1HNFSRPW=\L9@
M9%G?8Q2$O]T2.!M3.1C<1U'K0!)HFF2Z;:2&[N1=7UQ)YUS<!-@=\!>%R<*%
M50!D\#N<UID ]16=_;NF_P!N?V+]J']I>7YOV?8V[9_>Z8VYXSTSQUJO=>*]
M"LFE6ZU&* Q7"VS"0%3YK8P@R.3@@\=B#T- &QM7T'Y4CHDB%'564]01D&L)
M?&WAMY+J-=7@+VH#2ISG!Z%1CYP>Q7-7;7Q!I-[HRZQ;7\,FGO\ =F!X)SMQ
MCKNSQCKGB@#1VC &!@=!1M'H*QE\6Z";6]N'U**%+$@70N T3PY&1N1P&&1T
MXY[46?B[0-0U*+3K74X9;N:+S8XQGYU R<'&"0#R.H[B@#9  Z 48!(..17/
M^'?%UEXDO=4M[5)E^PW36X+Q.N_:J%CR./F8C'7 SWKH: $VKZ#\J-H]!63%
MXGT::\@M4ODWW#%(&*L(YF'54<C:YX/"D]*YW5_$(O\ QV/"XO;NS@&G-,TM
MLC+(9C($7YMIX R?0D\],4 =P !T I$C2/.Q%7)R<#&35;3+>ZM-,MK>]O3>
MW,<862Y,8C,I'\6T<#-<)XWN/$GASP^=3B\270N)M22)8EM[<Q1Q22X"C,18
MD*0,DGF@#T4@'J,TC1HY4NBL5.1D9P:Q(TN= DN[[5?$$ESI:P@[KQ(4,+@G
M)S&BY!! P>X]ZLV_B+2[HW:Q7#^99J&N(7A=)(U(R"4*AL$ \X[4 :E)@<\#
MGK61:>*=%OK>RGM+Y9X;Z1H[9XT8B5E^\!QVP?R/H:V* $VKZ#\J-H]!7'RZ
M]>:WX\N_#.F7+6=MIENDU_=1JK2,[\I$FX$ 8Y)P3V&.M1ZIK5]X/\2:+;WE
M[+?:1J\_V,/.JB2VG/W,,H&Y6Y!!&1USCB@#M"JE2I4%3U&.M5[RR6[L7M-Y
MBC<;28P,A?0>GU[5P6B^-[+1=1\2P^)M?&V#5F@MC<8RL?EQG&$4 *"W7 '/
M)K5\1ZG=P^+?!HLM1<6-_<RI+%'M,<RB%G4YQGT[XH ZZ&&.W@CAA0)%&H1%
M'10!@"G;5]!^58FEWEG<>)-:6WUQKR2(0B:RW*4LSANA ZM@D@D].U#>,O#L
M;0^;JL$2W&?(DERD<V#@['8!7_X"30!MX'H*01H'+A%#G@MCDUE77BC1;*Y>
M"XOE1HY5AD?8QCCD;&U'<#:K'(X)!Y'K51O%]BOC3_A&]LOGI:^>\AB?:"7"
MJ <8(^]D]!C&>N #HB >HS3$BCC9F2-%9CEBJ@$_6L/0M2TY[75[V+Q!_:%K
M%>2F6:5U\NUPJDQA@ -JCG//4\U;M/$6E7MVUI%=[;A8O.\J:-HF:/\ OJ'
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M17.N/I<DU[$L7EE=UPVX?NL$'(;(!Q1>^,?#VGW%U;W.K6ZSVBAIXE)9DSG
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MG4*,R%47/<$G  +#ID5*=>TS^S[:^6Z#P77_ ![F-6=IN,_(H!9C@$\#H,T
M:.!Z"C:N,8&/I6*WC#P\NGPWSZM;+;S3_9T9FP3+G!3:>0P/4$<=Z6V\6Z%>
MV37=IJ"7$0G:W_<HSLTBC+*J@;F('/ /'/2@#:ZT  =!BN5U?Q]HVG:!#JUO
M,;R*>Y2UC\I&.)"X4AN,J1GD'![=35J34K"Y\3Z7''KDD5PT$KKIH 'GJ0/G
M=2-PVXXZ=: -Y(TC!"(J@G)P,9-<[XM\.W6NQ::EE);0&TU&&_=I ?G,;9"\
M>OKV]#5V[\3Z-8S/%<WR1^7((I)"K&*-SC"O(!M4\C@D'D>M%]XIT/3;]K&\
MU.WBNUB,QA+98)D#.!ZDC ZG/% &IL5L,Z+OQC.,X]1FG;5P!@8'3BJ>E:O8
M:YIT=_IETES:R9"R)Z@X((/(((Z&IKV]M=.LY;R]GC@MXAN>20X"B@"; SG
MS2>6AD$A1=X& V.<?6LR#Q+I$XO,7JQ&R4/<K<*T+1*1D,RN 0#C@]#56U\;
M>&[R[LK6WU>WDFO1FW SB3C.,XP#CG!Y(H W6C1F5F12R]"1R*4 *H50 !P
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ML;O;);:E" Q4 ==W++E>>0.]>HT4 8NG>(+6:YT_2KA'M=6N-/6]-F4;]VO
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MD+QK< #),;, K\<_*3QSTKSS0M/NM6^!.K:7I8*ZC)]L'EXVNVZ9V .?[R8
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MTT\<(C/,: K@LAQUYJ/PUXMNK77O%NDZ]J$=Q9:$T3KJ3JJ'8ZYV/M 4L.G
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M"R1A$)' Z$ =\<5A:7>:8WA3X@Z9/LDN[G5]1CCM N9)V;A B]6.<<CI[8H
M])U#Q'I6F2B*XN&:4P&XV00O,PB'5R$!(7W/%0W'B[P_:1:?+/JMNL>HC=:O
MDD2C&[((Z# ZG%<+ \ND7VG>'M1BEMKJ'P]##]KMK8R37K@$-"L@4X53S@<_
M-G( YRM(N86\*_#&.171K6^7SA+&R[-L;@L<CH&(&>F: /1V\<:&VAZIJMM-
M-<1:8#]IBCMY!*A S@H5!&1SDC&.<X!J]X?UE-<\/VFIB*2,S0I(Z-$ZX8J&
M(7< 6'/!&0:X.X4W>N_%*"W4R2W6F0I J#/FL+>12%_O$$@''0D5V'@>]AO?
M!6CF'S,16<,3;XV3YEC4,.0,X/&?4&@"+P]XUL->CU:;9-:P6%S+$TES \2A
M8P S,S !3G=\I.0!R!S6A9^)-*OK]+&*X=;J2,RQ1SP21&5!U9-ZC<![9KRZ
MYM+^^\$>/-$L+>X;4QK=Q=_9_*8>;#YZ/@'&#O4' '7FNFU>YMO&.M^#KG1)
M?,DM+TW=PZC#6T/ED,DG]UF)5=IY//8&@#M[[4;73EB-R[ ROY<:(C.[M@G"
MJH)/ )X'0$U2/B;2!81WANF$4EP;9%,+B1I02"@3&XMD'C'8^E9'CJUL;Q-+
MCNM2N=)N5N&>SU* X%O*$(^?/&U@2"#@'IWKE?[?U*'1]);7+6U8C6I(/[;A
MM-RA%0A;E$P0&<DJ&Y7J>1B@#K]9\=Z5IOA/4]=MS-=+8LT3PI X=)A_ ZD
MIR1DL!@'Z4^]UC3+J]T'S-7O+">:X)@M1&\1NCM(*.K+G;U/..G6O.;F.6X\
M'_$VQMX+^:>6Y-Q'YT#AY$,<?S<@<G!..N!TKIO$FJ6FH:CX$N[=V,(U+S"[
M1LN$\IUW$$ A<D#)XH [&?Q'I=O=&WDGDW"=+8NL$C1K*Y 5"X7:"2RC!/<5
MR^KZ\-3\=R^&6N-4M;6/3?-\RSAF23SVE*!MRKG:H7@_<))SG%8VHO-IFNW>
MH>&]1,DLNJ*M]X=NTWB=_,53-#_$IP ^X97@D_=Q6W%=0_\ "[;H^8NTZ''
M&_A,@G8E,]-V"#CK0!M:!K^G3^&FN5U674(]/0Q7=X]LZ%G0?.2NT<^H XK7
M74+4Z9_:+3".T\KSC+*"@5,9W'=@@8YYK@;_ $F]L?'5UHMI"6T;Q./M5P0>
M('C*B?CTE0HN?5J[/Q,MFWA;5$U"&2:R:UD6>.+.]D*D,%QSG'3% #/^$GTK
M%P6DN$-O!]HD62TF5A'G&[!7)'T]*<?$VCB+2Y?MG[K52HLI/+?;,6&5 .,
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M(N[:BDDDC"G+'"D@X ..:H_$ZYN['P:]W97MQ:S1W5L-T#["P:9%()'.,$T
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M'MX2ZHRQXW.?X5^7K0!RO_"06EQ\0-7T/Q'JE[IEPKI_9*)<O;Q21%!\RE2
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MA=I4 !+ =@,C). "0.I K#U/XB:=#I>DWVFQSWD>H:C'8Y6!OW3;\.&&,A@
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MHWQ8OXY[C4)[5M%CG2SB$DY\PS."4C7/91G ^M;G@#1;OP]X#T?2K\YNK>W
ME&<[226VY]LX_"LR-G3XQWMVUO<BV_L..'S_ +._EF19G8J&Q@G!!H VH_&&
MBSZ-I^J07+30:C((K14C)>5^?E"]01M;.<8P<U%)XWT2'1+W5Y9;A+6PG:WN
MQ]G<O ZXR&4 GN.>G(YKS_0[N_TGP;X<MY=+OHH?[6NOM=P-/>2>T5GE9&1"
MA(W;@-P!P">YK>\$:>MQ)XSTJ^TZ_CM;W4)'_P!,C?\ >0O$B_?;[Q.#W)'?
M'% ':/K-HC:>I$Q-^<0 1,<_+N^; ^7@$Y.*HW'C'1[6X@2:69()[C[+'=F%
MO(:7)&S?C'4$9Z9&,YK$\ :?J\5H8-:1UDT=7TNTE;K,@;/FCV*"(#W1O6N9
M\+1VT6DVWA/7?"M_<:U9/Y0,D,C6LNUOEF\S[H7&"3UST!/% 'KKN$1G()"@
MDA02?P ZUY=XA\83>(OA7XDU&T&H:;/:/*L+IOB8!)-G+C@D\Y /&?:O4Z\:
MN(KQ?A/XNT,Z9J)O_MEUMC%G(?,WS[DV''SY!SE<@ <XR,@'HVF>+-*OM5CT
M>.2<7C0>=&9;=T2=!@,T;L ' )'(]<C(I9_&.CVMQ DTLR07%Q]ECNS"WD-+
MDC9OQCJ",],C&<U@:F7N/B)X.N(;>[,$=G=I+,+:3;$71 @8XPI)4]?2N>\+
M1VL6DVWA/7?"M_<:U9/Y0,D+M:R[6^6;S/N!<8)/7/0$\4 >NLP52S'  R2:
MX3P=>7'CZRN/$-Y=W<.FRW$D>GVEM.\ $2-MWNR$,S,0>"<#' KNG19(V1AE
M6!!'M7G'@65_ .FR^%-;@NHXK6XD:QO4MWDAN(78L/F4$*X).5./;- '56\<
MOAV75;W4]7EETA8XWA:Y<$P ;MRYQEOX2"<L<XR<5-;>)M.GU,::_P!HMKQX
MC/%#<0-&TL8ZE,CG'<=1W%<_X[AU/Q'X,NCI%E,YMYX+F*&13&]T(Y [*$8
M@<#&>21TQ@EFH[?%?BKPIJ&G17*1:;)-=7,LL#QF)6CV^6=P'S$D94= ISVR
M 7W^)'AN.RDO3/=FTBN#;SSBSEV0,&VGS#M^09..<5H6WB_2+K6AI2/<+<O$
MTT)DMI%2X1?O&-B,/C(Z9SG(S7G4UO=2?"7QK9KI]\;FZU*\>"#[))OD5Y=R
M%5VY((YS72ZJ[S^/O US%;7;00PW8FD%M)MBWQ(%#''RY((YH N2_%#PK#!]
MH:[N?LPG,$LXLY=D+!MO[P[?DYXYQ6MJ/BK2]-GE@=YIY8;;[7,MM$9#'#S\
MYQVX. .3@X%>=:1<0WGPZ\7:+';37%]=ZAJ,$$"PL?,=Y&"D'&, D9.?EQSB
MKMS'?65S/X=NK*^*PZ%#;VT]C;.3?R*C!@\RC*A3C"EE'S'.<@4 =I=>--"L
MVTH27;D:JGF6;1P2,LJ[-_! QG'1>IR..:A3QWH;:-J&J,]W'!ITGEWB26D@
ME@. <M'MW 8(.<8Q7$:3]H-O\+M^GZ@GV!'2Y+V<@\K_ $8QY;Y>!NX!.,]>
MG-=%X;MA<^-/',=U9S_9+V6W"&:!UCF00!'P2 &&<@XH Z=]>L4@TV8F8IJ+
MJEMMA8EB5+#( X^4$Y/85=NKE+.TEN9%D9(E+L(T+M@>BCD_05PG@/3-2M[^
M?3=1/F6OAMWLK"4MDRJX5U8^A2(HG_ FKT&@#G/^$XT,Z;I6H+-<-:ZK*L-G
M(MM(1(Y) 7I\I.#C..E6=6UO3H8M4L[J6[A%M:>=<2P0R$QQL& 964'GACQR
M-N:\^F\':O=:?X@\,0K);V.FW+ZAH\RG :5\21(/9'\P'_>7TKIX/MEQ\.]4
MU2_M)(]1U2SDGDMD1F="T6U(PH&<[0O'J30 V3QA9Z+8>$K6QCU"^M]56-8K
MF2-Y',7E%@6/5G( X^I/OGVOB--%^(/B[[;<:E<6R6UG-#;(DD[1@K(7*H =
MHZ9Z <>U4/+N;7PW\,[N2POBFFO$EXB6DC20G[,4^9 N[[W'2M?2I'C^(?C"
M[FM+R.">SM!&[6S[7*+)O52!AB-P'&: &>*M>@DN_!.LV&ISC3KR_&[RI&"3
M1F)V&4'4Y X(SGC&:Z;3/%FDZI!J,L<TEO\ V<V+Q+N%H'A&W<&97 (!7G/I
M7FVD0W4/A7X:P2V%^LMC?;KI#:2YA 21<M\O RPZ^M6=>T;4M=OOB58V$%PD
MM_;67V5WA9$G,:'>JL0 ?[O7O0!Z!;^*]+N-0M+)FG@EO4+VGVB!HQ< #)V$
MCKCG:<''.*Q/"]Y)!XN\<1W=],]I9W$#(;F8LL*& .V,GY5R2:I:L[>-!X26
MRM;J"YL]3AOKL30/&;58U;>C%@.22% '7.>@S6/JNDZGK*?$ZRL+:Y2>_P#(
M-JTD+QK.$B4,JL0 <E2O7O0!K>(/$2WGBOP7]AFU*"&ZO6X99(HKF+RF.<=#
MSM.#SR#BO1:\NU+75UZ]\$W-MI6JHUKJ :[B;3Y@;8^2ZD'Y><$]1D8KT?4[
M:2\TJ\M89?*EF@>-)/[C%2 ?PS0!E'QEHRFW=II5M+F;[/#>&%A \F<!0^,<
MD$ ]#V)JM%XJ2^\:ZAX:^R7:+;6T;&<1.-S.6Y##[J@+PQQDYQTKBFM;O5_@
MY%X*?3[F'78TAL6@>!@J%)%_>[\;=FU=VX'GH.>*Z.V,NE_%;5);BUO'@N],
MMEAN$MW=&,;/ORP& 1D'!.3VR2!0!F^ _&EG8^$=,BUB]O9KB>]GMS=RQR2H
MKF=U19)<$ G@ $],=!BNUU7Q)8:1Y_G"XE-M&)K@6\#2^2G/S-@<="<=<#.*
M\N6WNQ\$HK#^SM0^VC5!)]G^QR^8%^V^9G;MSC9SFM>\GBT7QQK9US1=3O=-
MUCR9[.YM())5R(EC:)U3D'Y>,CO0!UMYX\\/V;V:-=2RM>V[7-KY%M))YT8
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M%X!)+$@*H Y))(  Y)- #[6!K:V2%IY)B@P))/O$=LGN?>GRJ[Q,J.8V(P'
MSM]^:Q[/Q3IUUJ5YILWG65[:0BYEANU"'R3_ ,M 02I7(P2#QWQ5<^---2?3
MDD@OHXM2E6&RG>W(2=FY&.Z\9/S 9 XS0!LZ?I]OIEH+:V4A-S.S$Y9W8Y9F
M/<DDDGWJU6"OBW3GMM8F"7/_ !)V*WB>5\R87>2.?F&WGBG-XKTYDTS[,L]U
M/J5M]JMK>%!O:+ )8[B !\R]3U.!F@#<HKSOQSKEOK/PTBUS1[RY2-KNW"/&
M[Q'_ (^%C=6 (S_$"#7H$\ODP22^6\FQ2VR,99O8#UH DHKD/#7CFWU;PB-?
MU""6RA:1PH="=V961%7&2S<*,#J3Q6Q9>([.\U>32)(Y[345B$XM[E K/'G&
M]2"0PSP<'([@4 :]%<WXP\3OX9MM-:.SFN'O;^"T!1<A [@'//7&<#UKG[C6
M#IWQ9,C_ -I20S>'Q,MB@>5O,,^/ECR0IP.<8''- &_>>%[TZ[=:MI?B"[L'
MNP@N(3%'-&VP84J&&5./0X]JV=.T]=/BD!GEN)Y6WS3S8W2-@#)"@ < #  '
M%9]EXLTK4-"M=6MI)7ANY#%#%Y9$KR@D&/;UW JV>P ))P,U-H_B*QUJXOK2
M$30WM@ZI=6LZ;9(BPRI/4$$<@@D&@#6HK#U'Q9IFF:W'H\PNWOI8&GCBBMG?
M>JX!"D##'GH,X[XK+/Q*T(:5+J(CU$PV\C17BK9N6M"IPWFC'RX_/% '845S
M>HZCH[^+?#T$UQ>?;IEF>R$)<02KY>6+D?*V%Z Y()'K56X^(^A00ZC,$U&5
M-.F,-V8[*0^3@ EF!'"C/4]<'&<4 ==17-:AJ6C2^*O#D4EQ>?;9UFDL1#O$
M$J^7EBY'RMA>0#D@D>M03_$31(8-2F6+49ETV4Q7?E64A,. "68$#"@'J>N#
MC.* .LHKG8?&VCSZK86,9N<:@#]DNFMV6"<A=VU7(P3CGTXIZ^,-,;3]8O=E
MR$T>1H[U3%\T950S'&>0%.>,T ;]%<[/XUT>WN=+MV:Z:74X#<6JI;.WF(%#
M<8')P1P,GFJ?_"Q]%.G7=X+?4V-E(R7D"V3F2VVC):0?PC!SG/(SC.#@ ZZB
MHK6YAO;2&ZMI!)!,BR1N.C*1D'\C6"/&VD&>  SFVGO3I\5X(_W37&2-F<Y^
M\",XVY[T ='17-W/C?2H-0U+3TAU"YO-.5&G@@LW9L,"05&.1A>O3D<DFH8O
MB%H,Z:9-$]T]GJ+I%#>"V?R1(_W49\8#$\>QX.* .JHK'OO$=I9W-S;1P75Y
M-:QB6Y2UCWF%3G!/(R2 2%&6QVJ$>,-'=='DAG::WUA]EG/&F4=L$[2>JG /
M4=L=: -ZD;<48(0&QP2,@'Z5A2>+]+@DUJ.;[2CZ,B27B^0S%592RL-N<C"D
M\=.^*KV/CO1K^^TRVB%X@U./?:32VS+%*=F\H'/&X#\.",YH L^%O#K^&K.Z
MMC>_:EN+J6ZR8MA5I&+,.IXR>/ZUNUS'ASQ8^O:WK5D=/N8(["Z^SH\B8SA%
M8ECG@DMP/3%'B+Q6^B>(M!TI+"XG_M&60/)&F0%2-FP.>6R%_#- '3UGZUI]
MSJ>E2VEGJ<^FSN5*W,"J63!!Z,".<8_&N&LO$,>@>.O&YNCJ=W!"MG)'!$LE
MPT2F)F<@9.U<G/8>E=<_BO3##I3VS27;ZK&9;**!1NE0*&+?,0  ",Y(Z@=:
M +VE:;'I-@MK'++,VYGDFE(+RNQRS,0 ,DGL !T& *NUQFM?$"UM?",6MZ9;
M7%T)KI;0*8]IAD,@C;>#T(.1CN<=N:ZZ&?SK99S%+&",['7##ZB@"6BN3T/7
M="@TG4KZRGOI(3JDD+K<[RYN6=5\M%?D#<P ' '/3K6[IVJQZC)<Q"WN+>:V
M<)+'.@!!(##!!((P>H)% %^BL"_\8Z7I^N/HKI>RZ@ML;D0PVKN73<%^7CYC
MD]N!@Y(Q3['Q9I.H:#!J]O)*8)I# D9C(E,H8J8]G7=D'CV)Z<T ;E%8-MXP
MTF;^U%N))+*;2P&O(;I=K1*1E6XR&!'0@FGVOBFPN-9_LF5+BSO6M_M4<=U'
ML\R+."P.3C!Z@X(]* -NBN?3QCI9OM/MI!<PQZD2MC<RQ8BN#C.%/4$CD;@,
M]LU-#XFL[BY@CBANG@N+A[:*Z6,&)Y$W;AG.0 489( ..": -JBL6+Q-9SW$
M"10W3P3W#VT5TL8,32+N##.<@ HPR0 2.">*K-XVTA9T&9S;-??V<+L1YB^T
M9V[,YS][C=C;GO0!T=%<Q?>/='L-4O--:+49KRS\LS1064CD!R0&''*C'+#C
MD<\U<TKQ38:Q'J;6T=RITV5H;E98]C*ZC)7!/ICGISUH VZ*J6&H1:AI<.H0
MQS+#-$)45TPY4C(^7J"1VKF_#WCF#5=(U35=0MYM/M+.YFC+S)PJHVW!()RV
M1T'<X&: .OHK&MO$UE-K$6E3Q7-G>SQ&:WBNH]OGH.I4@D9&1E3AAW%2>(/$
M6G^&=-^WZDTJ6^]8]T<3/@L0!D@849(Y.!0!JT5S/_"=:2-4FTQH-16]2+SH
MH6LW#7*9QF,8RW/7ICKTYJS8>+M)U'1&U6*29(DG-L\4D1659@VWRRG7?D@8
M]Z -VBL*U\6Z7-<ZC:W#2V-SIT0GN8;M0A2(C(D!!(*\'D$X[TD?BVP.JQZ9
M-;WMO=S0-<6T<\.TW*+RVSG[PX^4X;GI0!O45S7@GQ0_BS1/[0>RFMMTTRJ'
M7 VK*ZJ,YY("C/O3)O%3?\)^/# L+HQ_83</.J]2TBHI!!R%'S9/KC'2@#J*
M*\O\*>,+/P_I.L?VK-J,\,.NW4#7+)).MNGF[$\R0YP.@ZDUWFHZ[;Z?*\"P
M7-W<1Q>?)#:Q[V2/) 8\@<X.!U.#@'!H U**I:1JUCKNDV^J:;.)[.X3?'(H
MQD=.AZ$$$$>HK&/CK25TC5=3:*]%OI4Y@O,P'=$R@%OEZD $<CCG/K0!TU%9
MG]N6_F6$?DW!:^C:6+;'NPJ@$EL'C@C\P.M<A<>+]-T#P)K&MZ)'J%ZL=]*A
M%SO)2=G"G(?E4#$<?A0!Z%17GNO:L;3XB^%+MCJ,4-Q:WOF6?SL79 @7$0)&
M[YCT'0\U!X[\1V^N_";7=1TNXOK6:S?R9%R\$L,JNH9' ([-TY'- 'I-%8=C
MXLTV_P!>;1D6ZBNO),\1GMVC2>,$ M&3]X D?GD9%0S^-=(MHA=2F<::9_LY
MU'R\VXDW;<%NN-WR[L;<]Z .BHKBIWEC^,UE$MQ/Y$NB32-"9F,>X2Q@,%)P
M#CN!63\3O$L,_@#5I-.?4%$,JPK?6I9(Q() K+N4@D?>4G!7/&<T >ET5SEQ
M?Z2/'=K:R2WPU5+"5TB42"%HMR[CC[K-G'3)_2J3?$OP^MF]Y_IYM(KDVT\_
MV-PENP8+F0D?*,G'//M0!V%%9E[KMK9ZBNG+'-<WS0-<?9X%!81 XW')  SP
M.<D] <&FZ!XBTWQ-IXOM+DFDMB<!Y+>2($C@XWJ,X((.,\B@#5HKF+_Q[H^G
MZI>::T>H37EH(VFB@LI'(5S@, !RH[L..1SDU/J?C+2M)26>Y%Q]A@F%O/>I
M%NAA?(7#'KP2 2 0#P2#F@#H**RKS7[:UNY+2&&YO;F*,2RQ6D>\QH<X+<@<
MX.!G)P< U0MO'&C7=EH]["UPUKJ\YM[24PD!I 6&".JYV,>10!TE%8H\2:=-
M>ZOIS"Y6?38T>Y58F)V.&VE=N2V0IZ<UC:=XM\.:)X3T&:.XOWT^^9;>SEFC
MDE=R2<;FYYX/!.<#@4 =G16!;>+;.\M8I(+/4&N)3)LLWMC'/B-MK,5;&!DC
MDD9R!UXJL?B#X?&F6-_Y\_DWEX+%/]'?,<^[:4?CY"#G@^G&: -'Q#H(U^S@
MB6^NK&>VG6Y@GMR,K(H(&0P(8<G@BF:?HEY%/%/JNLSZG+"2T(:&.)$8@KNP
M@R3@D<DCGI5%/'FER75Y9+:ZI]OM0KFS-DXFD1LX=5QRO!Y.,=#@D5=M/%>E
M7^A6>KVLLDL%XWEV\8C/F229(*!>NX;6SV&TDG S0!MT5R\WC_1+73=5O+K[
M7 VE,J7MNUNQEA+#*DA<C:1T;.WWJQ:^,M+N]972T2\2>6!KBW:6V9$N$7&[
MRR?O8R/KG(R* .@HKF?!WBI_%-M>SO8W%JL5W+"@D4 81MN"0?O<$D=JSO&N
MN36OB#PYHZP7;6U[=/\ :?(4YE18G8("#G[P!(]!Z$T =O17*6%YI_AB"[TZ
MT;5M1^SDW4T1_?O9H_(3)P<#!PF6;'MBI[KQWH%M;Z5<"YEGAU4XLY(('=9#
M@G&0/O<$;?O9XQ0!TE%4M(U2+6=+AOX(;F&.7.([F$Q2+@D'*GD<BKM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM!!!X)R>P-.T^ZU.VA\(6%WI&JPV"Z.L4TEK:MYXN%"+Y3L/FB3@G.5R0,G
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MHC*]O%+YN!M7).W>N<9Y)KUZB@#RUS>W&J_$2Y_LC4TBU'3($M"UH^92('7
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MHJ>6"Q(R%X#'.2!W)ZURFI^'+V3QW>VT,#'0_$-HK:DX) 1X2%(_[:(RJ>^
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M8>%]);4M2\X6RNJ$Q1E\%B%&>P&2.216M7$?%QBGPTU%@I8B:U.T=3_I$?%
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M'4E2NQB"",XP>QZ50L/%V@:)X8\,_8[/4%T_4@D%B@C,C)E25#').< \ DT
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M58 @X.#SZUQG@'Q=;:%X%T>*]M-1D@EO9K9[X(&BB=[EPH=F;<<Y'(! SR:
M/5**AN[N"PLI[RZE6*W@C:661NBJHR2?P%<[_P )S9+<Z3!+IVI1G5T+V+&)
M6$H #'A6)4[2&P0./<$  ZBJBZ?!'J3W\6Z.:50LVT_++C[I8>H]>N..F*Y^
MU\>65]JLVGVNE:O*\%Z+*XD6U^2!BH(=SGA.>OZ=*ED\<:=!)IKS6UY'I^I3
MK;VFH,J>3([9V=&W -C@E0#]"* .FHKE[GQWIMLT\C6UX]E;WXTZ:\54\N.8
MD+@@MNP&8 D+C--B\47LOQ#NO#_]ESBVM[-)C,'C^8NY&\_-D*-I&!SUXZ4
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MHDEL8ROD"V69&4QC<-S%0<G&[DY(&!73/::C_P ++EOFTR[%GJ.C1VOG(4Q
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M@]1DD8/-<)>>%=6U9O'EA::1=V4>L6=HUG+<.I#-&IRKMN)W,>._7DBO8**
M/-+^]UC7KOP=<_\ ",:K!-87XDO4DC55C/E,IVDL RY/!Z8]^*TM>\-ZA)XY
MM[S3T']GZO;?8]8YP L9W*WN67?'[!A7<TF1G&1GTH \^\66-WIWCBU\0'PZ
MVO:7-8BRN((8DEF@979U=5;J#N(.*CUVRNY['PS):>'9+-(M>AOI+2W@7=#
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MN/(SS7N['7=,UO2=?UOPY_;ZW.DPV>HQ6L,<LMO<(6;>JG@@[R#CC],^J44
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MPR76H72O)';Q$ A%QN=B2 %!('N3P#63)XQ2[\/ZW<6-G<C4=+$D=Q9R;!)
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MHY$5T8896&01[BO!=,?0U^'VM6XD8^)7O[R/3$M'8WAD5CY83;\VT'&>V,T
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M HHHH **** "N3\?:1JNHZ=IM]HD:3:CI-_'?1VSN%$X4,K)D\ D,<$UUE%
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M0UO2]7D2YC9)8TDMI0BHROO/W3M!R.GO7HM-$L;2-&'4R* 64'D ],C\#^5
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M^/KG^R;@Q:I;0QV3"2+]ZR0F,C[_ !R>^.*[XRQB58BZB1@2$SR0.IQ^(IU
M'FAT76QX:^']F-'N#/H]Q;/>J)(OW:QPLC$'?SR<C':J5_#>2ZUXIBMO#VK7
M>DZC.(;@Z9=6_ES[459,B0AE8G<C;2!QCJ":]8KFE\#:5%>SW%I<:I9I/(TL
MUO:ZA+%$[L<LVU6X)/7&* -30;VWO]$MIK6UEM80IB%O,FUX2A*%",D<%2."
M1Q3?$=C-J?AC5K"W ,]U9S0Q[C@;F0@9_$U>M[>&TMX[>WC6.*,;511P!4M
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M8 "D#.#["@#M['Q8TWBB70K_ $N?3Y?LAO())94821!@K9VD[2"1QD\5QWQ
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M3<S1H76!6VE\=@?7TKD=;TO7YM7\)ZPEA%=3Z?/<-=6\,RH(Q+&5&&;&X+D
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M6LLBS1D)([JV,9!(&W!..M<I?^&O%!\#>(_"UOH@D>>_DN+>[-U&$FC><2#
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M[*S9E12Q&P\KR O?)R1TK2\4>)CX:_LO_B7378O[Z*R!C=5V,YX//7H?;W%
M&_17'0^,=5EUK4-#'ALC5+:)+B*/[:OE21,2 Q?;\IRN,8//MDU+I_C5M5\/
M:/J5CI-P\^I7#6WD,WRV[J7#F1P#A04;G'/''/ !UE%<4_CZ;_A&=;U:'1C<
M3:+=26]W;17(((0!F>-MOS## \@'@^G.W_;S23:+':P17 U-#*62<XCB"ABX
M^7YA\RCMRR^O !M5'-/%;0O-/*D42#+.[!54>I)Z5EZ[XAMM$DL[=V@^U7C,
ML*SS"),*,LS.0< <#@$Y(X].$\6>);7Q9\,?&$$MI&EUIBE)%6031YZI)&^!
MD$9YP".: /4@0P!!!!Y!'>EKF;SQ/!ICV>F1-9F^:S6X*W=V+>-4^Z,MACDD
M'  /W3G'&:NE>/[76=,TZ2TLW_M"^N);9+.20 *\8)D)< C8!@[@#G<O'- '
M845Y]XJ\9:Y9>"M>NX=(-C?V$RVS/-(QC97*@2PML&_[PZ@8/7I@]S#)=?8O
M,N+9%N "3##+O!/8!B%Z\=0* )(+B"ZB$MO-'-&21OC8,,@X(R/0@BHK;4+*
M\DECM;NWG>$[9%BD#%#Z$ \?C7G-_KYF^">J:IH&E1:4ACNT,*2A##AW1G7:
MN"Q()QQUZ\5UVA:3!#!;ZO)I-M!J:V2VP:WDW%H0 0N2%'4=QQZT =#17G3?
M%"Z7P^=?'A6[;2H)WBO)A<INA"R%"RIU?&,G& ,]3@XV]3\;6UM//;Z?]BN9
MH+=+AQ<7HMPP<$JJ$J=S$#/0#D<\T =517#+\1UNU\.MINB75U_;L4S0!I%C
M*/&I+(V?<8)Z8R1GH9X?&>JRZVFB-X8EAU-M-%\8I+R/8OS[-I=<\9SSC/3C
MT .RJ-KB!;A+=IHQ.ZEDC+#<P'4@=2!D?G7!M\2[A?##:^?#DPL[29H-1#72
MAH&638VP8_>8//\ #U^N-F\U6T3X@Z=IKZ.CWLEC-+;Z@Y7*J"NY!P2 21GI
M^- '3T5Y@GC/Q./!/BW66L['S]/NKJ*/_26(C\K"X V?,!@GJ-Q[#-=)_P )
M4^GV.E6U\MFFIWD!E19;W9'L4+EVD*9!)91@*3D^@) !U=1_:(?M/V;SH_/V
M;_*W#=MSC..N,D<UQ]A\1;.]TB2X-HRWZ:C_ &8MHDH<2SD_+LDX!0C+;L=
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M.TGV!Q7GFG>'?$::OX0U*30[>&73EG34'>]#RS.\04RLV#NR1GJ3SCBO3Z*
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M<^8VTL HPH')ZDXZ9U;R'PSXP>SB>^@OFMW6\MTM;\@@HV!(!&PSAN,],UT
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MXJU110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M GB>2)I3&)X@P+Q[QRNX<9_#O7+2>"-6U/4/$<5Q9V.GZ=K.E16J"WFW&V9
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M]W-<$&V3R\&()M.,MDY! .<GIB@#JY?$3W&J)IFDVT=Q=FT6\D,\IB2.-CA
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MX?\ ".J:1:0P1ZOJ<=M/'-.0R,&?* A3\I,; MZ=N>-Y-8!^(/\ 94NB0+J
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M(CE$8F;<8TVD$*.3DCIP.] 'K]%<E=^-H9IS;Z2UH\BV<5WONY6C4B0$QJ,
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M;6B4$AAM.!\PY&3UX-8R^-_$$FFZZR:#9&]T*5UO%:^(CD54#CRSLR25/1@
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M(_.$NTG9G=QCIBO3Z* .3\1:!J-UX@T+Q)I@B-]IWF1S6LLFU9H9  RAL'#
MC(XP>]5+SP==:S_PE%[=F*VO-9T_^SX(PV\01A6 +'')+-DXZ #DUV]% 'GD
M.@^*[K4?!]Y=V>F6XT7S$FC6[9RX,/E[@=G'J%P>G)K*BLM6U2XUB_L-"TK5
M]'O[]Y0%U22W281D*"\>TJ3E.2?O=\C%>L5S[>!O"[7TEX=$M!-(V^3"81V]
M63[I/U% &1;6VJ:WXMT+Q5'90PV2:=)#)$\^9 TA4\8&&4;>N>0<U?\ !FBZ
MCHHUP:A' OV[59[Z+R92^$D(P#D#!&*W(M4TZ749-,AO+=[V%-\ENC@O&N<
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MPYK<:>-0T%KG6V9K7%P?ES$(_G^7CIGC-=LD\,DTD*2(TL6-Z \KGD9'O4E
M'FZ>%?%.CQ>&M4T<6$FIZ;IB:7>V<TS"*XB4+@H^W@AESR._YZ.M:/XJU.UT
MFXD&GW$D-[Y]YI9F9('CV;53?M);:</RN">W %=O10!YC=^"_$MQH/C33MFF
M[M<G\Z!EG<!"R("#\O 79U[YZ"M^\T75[KQ?X7U46]LMOID$\=P#.=V955?E
M&WD#;WQUKKZ* . MO"%]/XET?79K&UTW5K9R=1O+.;Y;U"A&TJ ,DMM)+#C'
M!/%=_3)98X(7EFD2.)!N9W8 */4D]*AL+^TU2RCO+"YBN;:3.R6)@RM@D'!'
M7D&@#S5/!WBXZ5IMO/%I4U[8:U'J$MX]R^^^"NQ!;Y/DPK 8^;I@8 K3\0^$
M-0\0W'FS6-I!JEO=K)8ZU;R[)(H@P)# #).-P"\@Y&2.:] HH *Y*VT;6=.\
M=ZYJUO%:36.IP6_+S,LB/$K+MV[2"#D<YX]#76TR6:*WA>::1(XD&YG=@ H]
M23TH \U@\%^((/ASX?\ #_E637FFW\5Q*WV@[&2.4R<'9G)SCI6B-'\6Z!XG
MU.ZT&/3;S3-7E6YDAO)FC:UGVA68%5.Y3M!QUX[=3V=A?VFJ64=Y87,5S;29
MV2Q,&5L$@X(Z\@U9H AM8Y8K2*.>;SIE0!Y-NW>W<X[<]JFHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X+XL
MZG=6?AS3].M)G@;6-3@TZ2:,X9(W)W8/8D#'T)KO:P?&'A>#Q=X?DTV69K>4
M.LUO<(,M#*IRK@=_3'H30!H?V+IO]C?V/]A@_L[RO)^S;!LV8QC%8L6HO8ZG
M:>$-(\I[BSTY)I9[G)5(Q\B# P2S$'N, 9YR!4]A-XN^SK;WUEI(G4;6O(KE
MRC?[0BV Y_V=V/>J5UX;U*Q\96_B32I(KIWLA8WT%S(8S*H;<LBL%(W YR,
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MR..W/6LY?'UY-%I6I6FF-=:;?SHABAAE,\,3_=F)V[2,8)';/4U?OM U2_\
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MMJ&J7$4\D\L[!D0JV?/DSG)(QTP!C XJ[>:[<V_Q!TS1#9VQM[JSGF6XW$R
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M _=R%7![4 :^FZM8:S:FZTV[BNH [1^;$VY=RG! />K4DB11O)(ZI&@+,S'
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MO=4MK>*ZTK5!IUQ+"':%063]]C[VT+)DCKQU&> #OJCGGBMH6FGD6.->K,<
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MK:WUK+=:8+A+AKE6 D$RJ&90O3!7A<].,]ZZ:QO;?4K"WOK.42VUQ&LL4@!
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MHQ(WE01 -@;MN6)+%B=H[#'&3U=% ' R^#M:;PEX3TA&L/.T2ZM9Y7,S[91
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MV'EF.,1@,=O.0,\=.G/6I/ V@WOACPK::+>RV\S6V_;-"3APSLW((XQNQU-
M&9=>(?%%SXPU;P_I-MI*-:VL-Q%/=-(PPY888+@DG;T'3DY/2JFE?$6?4M(T
MU);,6VLW%Y/97$2Q/.D+P F1@J?,P^[@9'WN3Q1 VH+\8M>-A':RG^RK4.D\
MC1_Q28((5ORQWZC'*W7P\NX=)L)M)U2.#Q!97TVH"[DB)BFEF)\U67.0A!QZ
M@ 4 0:IXX\2Z3X5\27\NDP^=I3(;>YFMYH(;N-^ZHWS!E/!&?QYJ[K?B'Q;H
M)L9+FST>2*^U:WLX4CDDW)')U#$\;@01N''?':GZWX8\1^(_!6IZ7J>H:?\
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MFX*?7&?ZU030-1U.]T>XUPV:)I+&6**U=G$LVTH'8L!M !;"\\GKQR 4-/\
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M(8W*'#*C!=K$'@@$G@^E;]VMPUK(+66.*?'RO+&74?50RY_,5Y+H&K:OX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4-W:PWUG/:7""2">-HI$/1E88(_(U-10!P(^&<3>%=(TJ;4))+JPN4EDO,8
M>5-OEO'[ PX3_@(K:\1^&9=4U+2-8TZX2VU329':$R*6CDC<;7C8#G!&,$="
M.E;::A:2:C-IZ3H;N&))9(0?F5&+!3^)5ORJS0!RLGA ZBVO76IS(+W5['[
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MZDD_I3--\3Z'J-W%:V5UF:X0S1J8'3S5 &6!90#P16PR*X =0P!! (SR.AH
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M*\-L?+N$90KK(F[/S =0>O2@#"M;K5M&\0_$V]2XMIKZSM+2>.22$[7"02,
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MJ;)%,T&U=HB? *[LGTSGO^% %^;Q=XGT:7Q1I.HOIUQJ&F::=4L[I+=ECFB
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M"S@NK>XEMG<@2;N"NX9)VCGC ['/&5%X^\0W7A_0[A(+"'4)M<&C7\3HQ42
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MAPV<%?F)Z?C5O7="O]7>]@,]E-IMY:K UI=VY<1N"W[P$,,\,.,#[HY%9O\
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M_;#^S(98FA6W;][Y@4,0=_RXVC'!K6URPEU70K_3H9DA>ZMW@\QT+A=RE2<
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MK*&4C!!&014-M96EDK+:VL,"L<L(HPH)_"IZ* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'GJ,&M>B@"O965MIUG%:6D0B@B&%4<^Y))Y))R23R2<U8HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK#\3Z^="MK%(D2
M2\U&]BL;97SM#N3\S8YP "<#KC'&<T ;E%<E_P )#JMAXPB\.:@+.9[ZT>XL
M+J*-HU+I]^-U+-T!!!!Z<8[USMCX\\2R^%=!\2W%OI:V5Y>I:W-O&LGF8>8Q
MAU8M@8XX(.>N1G  /3Z*XK5/%>I33ZU#H<:M-I;^2J/83SBYF$:N4W(0$'S*
MN3DYR<8Z]3I-Y-J&D6=Y<V<EG/-$KR6TOWHF(Y4_0T (-6L3K9T87 _M 6XN
MC#M.?*W;=V<8Z\8SFKM<P-<U)OB)<>'MEHEN-*%[%+M9GW&79AN0,<$X'KUK
M"C\=ZM)\-M,\3>19"YGO5MYHO+?85-P8<K\V0<#/.: /1*I6NK6-[J-]I]O<
M![JQ*"YCVD>677<O)&#D<\5REYKWBJX\9:IH&D1:0GV6UAN8I;KS""'9@0VT
M]<+QCI[TX>+M5BN_&L4EA#.^A1Q/;16X8M-NB,F&]3T' ]: .VJA?ZWINF7E
MG:7EVD5Q>R>5;QG),C>@Q_,US%GXXA_L+4/$+:GI^I:/:VGG;[.,QR+(,YC9
M6=B">,9QUY]:R?$SZU/J/@2YU%[+RYM7B=H88F#0N8G(7<6.X8)!.!R,]\
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MDMS:QW"F62]8*6D4!7!0+@+D@\G/057U'5M8O_&O@S['>06]IJ%G/=>1) 7
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M^4%>G'..>,5'XJ\5:YX?M]8N2-.BCL+=);9)4+O?X7=*557S&H^[D@X/).*
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MHR-QD.'5N1D '/UH Z^BL[7]9M_#WA^_UBZ#-#9PM*RKU; X ]R<#\:YN_\
M$^LZ"NA7^JI92Z?J=Q%;3);QLKVKRCY#N+$.H/!X4]QZ4 =K17#Z9KWBK5_$
MFK6$$6D16VEZC'#,TGF%I(60,=N#]\ ]2,>W>NHUZ6Z@T#4)K&9(;F.W=XY'
MCWA2 3]W(S^?Y]* -"BO/_#NJZ[;_#SPU=&:SE%U%";B]N!L6UB,>XN^9/G8
MG R".6SBK6C>)=>U[0]>.GI8/JFF7TEM"9(76*Y"JK+\I;*$A@.I'?H: .VH
MKD?!OB?4/%D27HC@@M(8A#=QO"RRK=C_ %B#+<*O'4'.:Z:_^V?8)_[/,(O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS(^[RKJ' R,@94Y&X'!P>#FNSJ"]O+?3[*:\NI/+@A4O(^"=H'? YH XW5O
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MDKMQQT'7UI-3\*7OB>]LSX@O8&TVTF$ZZ=:QD+-(OW3(['+*/[H 'KFNMHH
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MS$LT3X(W(P!!P>1P:L4 8/A^S\21L9_$>H64\JIY<<5A$T<9Y!+ON)RW Z8
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MW*27=Q9R02W4V<-)(#YDAQURS,V*Z6H;J[@LH?-N) BE@J\$EF/0 #DD^@H
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MW>\U2]U76=/U/PE/:3WSR%-421)$\L[4$BJ^WY=F5++GH>"<5Z]6>^@Z-)J
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M)O#VF7LMG.=4MYC=);QG;:3QH&*+(&*OC)4CJ" >,XKLM5L3J>CWM@)W@-S
M\(FC^]'N4C</<9S7&V/@C6X+KPM<3ZS8DZ#') J0V159(FC"9Y?[^ .>GMZ@
M$F@>,+C6]<%B+VTM[R"[ECO=*GA*3QQ+OV,A+?/G"$D C#'I7<UQTG@^\U&_
MT:YU:XLY9]*N?/CO8HBL\B@,!&23P.1DY.['09KL: //=3\8ZSI5W:M<_8E:
M764L7L$0R-';N^Q)&D5B%<C#8..#C'>IWUKQ=J7BKQ)H>E2Z1!_9J6TD$\\,
MC9\Q7;:P#=3@#=VQT.>*9^'>M#1ETM=>M3#;ZJ-2MI'LV:1F\WS,2G?\W)(X
MP3QS3M(&ICXI^,A8S6C.+;3UD^T*>6\M\,-OIS\O?(Y&.0"M9_$'7]4LO"SV
MMI80W.IW4]E>13!R(IHE?)4@_=RN<<GMGO5VTU_6GN_$_ACQ"+22[M=/-U;W
M5I&R)-"ZL.5)."",=?\ Z^=K6A'PY?\ @'3-/N$:X74KB1IIUXED:)V<D \;
MB2/;(ZXKJQX9N9;G6M3GG@_M/4K46:%5)CMX@&PH[L<LS$\9X&!B@#F=+US4
M-"^&_@![(6YCO)+"RG$J$L$D !*D$8/'<'K70S:UK&KWNOVN@O:Q/I)$*?:(
MR_VBX,8?:?F&U/F5<]<DGC'-*3P1J+>$_#6BKJ-J&T6YMY_.,+8F$/W1C=QG
MN<FI;CPEK=EXJO=9\.ZS;6<>IA/MUM=6QF4.HVB2/#+AL=CQZY[ %B_U?7HI
M+".X%GI:S6/F2N?](<W?'[E$!#, -Q) .0.U<GJ.O7WB;P_\.M96&WCOKK55
M;82PC#B*52>YQD9Q^&>]=5-X3U.+Q3;:O8:P@4:>+"=;N RN1OWF1"& #D]<
MC' X.,5F67P^U&Q\+Z!IRZO;R7>AWOVJW=K8B-Q\XV,-V<X<\@^G'J 36.O:
MY'KNL^%_$'V.:==--]:W=I&T:R1$E"K*6;!#>_2L[PGK\FF> O!.F6RG[3J%
MF2'$+2[$C7+$(O).2H'89)YQ@]0GARYDOM1U>ZG@;5;NS%E%M0^5;Q D[1SE
MB68DGC. ,#%89^'NH1>%_#UI9ZREMK.@9%G>K#E'4C:RNA/1AP>>U &]X6U+
M6[V34K?6;(QBVF M;L0F(7,9&0=A)*L#P>W3%=%7(WUIXHL_#%W.==M_[<D*
M;9([,F)0I^Y'$226.3R222>P QU%HUPUE UTJI<F-3*J'(#XY ]LYH X+QM*
M\'Q0^'\B023LIU#$<97<?W*]-Q _6HM/TGQ%INO>,O%MOI<<$U_%&MEITTZ#
MS&C7'F2%6VKGKUSC.2*W]=\,W^J^,- UR"\MHH]',Y6%XF8R^:@5LL",8QQP
M:O\ B[07\3>%K_1X[LVCW* +,%W8(8-@CN#C!'H30!B:1XGO[SQA<Z"MY:7D
M1TP7L%XENR*'\S81][#IT(*GU&36#;>(O&>M?#:Z\2B\TNRB_LZ[D*PV[M*L
MD;-M926P!A2.<XX/.<#HK7POKL?BV'Q%<:K8O.---C+!':,B??WC;ER0,]<Y
M]L=GZ'X-GT[X=3^$KN^CE$EO/;BYBB*X$I8YVDGD;_7M0!E?VWK6@^#_  ;(
MDUG.+ZZL;.4M P812!1Q\Y^88/)ZYZ#%:\NM:QJ][K]KH+VL3Z21"GVB,O\
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M(RH QG/&<DDYL:CX:UG6/".J:9J.K6[ZAJ4)A>:. K#"F",(FXD]3R3DD^@
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M+B>XV!FR PVKR!W/4Y]<6/Q_J^JZ;X3O-,M[.!M7NI+.YAN%9C#(@?<001D
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M5=0&A.^K0R7.G7XOYI983B9PK+M50WR+AL#KT&<G)(!T.CIJD>F1)K,UK-?
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M#N H V&U[3U\1)H)E<:B\#7"QF)@#&" 3NQM/)'0T[6];L?#VDSZGJ4CQ6D
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M_P!EZM;1-;L[PB:.>$G.QUR.AY!!_P#K=1'#%#N\J-$WL6;:H&2>I/O3BP!
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M"_92/)*QB,?Q_-P/;FM+P]K.EZQ:W7]DHR0V=T]I(A@,6V1<;AM(!'7TK7H
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M3M6E>=XI;<N]O(XP[1D,!@]0".#Z]*["B@#DIO!7EWWA=]-NXK6T\/JZQ0/
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M;S^%[BXN-1U&?4@NL7=F+**Z@@V+;1@EAM0L23N.3D\X'3%02^"(-2U.\O\
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M,_.Z*<@D#V/&3VKE-1\6W(\!W>OZ)XC74(TU"!()##&&6-VB1HY%V## LYZ
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M%;S3M+Y;#'Y2, K[DQ6T=[)\9KQ'U2Z\J/1X9A  A09E8%!E<X.T'/WO?H
M=XS*B,[L%51DDG  I:XCXL&Y3P+-);7L]L1<VROY6W]XK3(I4Y!XY[8]\C(J
MRVIWMSXS'A6'4IX_LVG_ &RXO/+C,TA9]JJ 4V   DG;_=Z<Y .NIK2*IVEA
MNP6"]R!UP/Q'YUR_@W7;_4;C6])U1EEO='O/LYN$3:)XV4,C$#@-@\@<5FW,
M=Y)\:[>(:I=I NAO,L*B,H/W\890"IX; R>O'! H Z?0O$%EXB@NYK$3!;6Z
MDM)!-&4/F)C=P>>_?%:M>-0WNMZ/X5\;:WI>I);?V?KUY-Y!MU<3X==RN6Y
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M7C,JX5QLX92.F!DCD=JZ"ZU75+O7]0T&PN-0W:=:PL]S;I;&1Y)-Q!8287:
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M"L"5.& /0XSS^!%+7EGARZURP\'^*-1M+F^U2\AU>YC6$I&[LJS*K.H"C+A
M<+]W(  [5U7@W7K?Q +RYLM;;4;5=BB*>)8Y[9_FWK(H5?;&1V/I0!U-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6)XM\/?\)5X;NM%:[-K'=;1)(L>]@ P;CD=P*VZ* .?U#0=0OI+G.J0
M^1=6:VL]O+9^9&2"V74;Q@D/C!R.!6II&F0:+H]EI=KO-O:0)!&7.6*J !D^
MO%7** //I?AE(- U/PY:>()K?0KUF:.T-LKM;[FW%5<G[F<\8S[]<Z&I^![J
M?6+;6=)\176F:JEN+6XG$$<JW,8.1O0@+N&3@BNO\Q/,,>]=X&XKGG'KBG4
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M2:8&-MMM_*RY7;YC_,=S;<CC:.2<=,9FF> )=(N[BWLO$%W%X?GF:=M*$2$
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M?)@C<"HYZ_+],56M/&6M2_#_ ,.:[=QW<MO*\B:K<:?"K2H$+H'V8/REE!;
MX[5UMKX8EM/$UWKB:G(\]S:):E)(@0%3)5N,$MDDGL<]!571O!EQH&E:98Z?
MK4H&GF;898%82K(VXJX!&<'D$$'I^(!R^O7DFK:%X-N[/Q-/>0W/B&.,7-N(
MU$B%Y&3<NS&] JC!&,@Y&<5I^*]5UC34UXP:U)YEAIJSV<-K$CR!E1F:2YW)
MM4$J, $9 ; S6E-\/[-]&@LX+V:VN(M4_M9;F)%XN"Q)(0@KM^8@#TQU[LNO
M "W-[K,JZYJ$<&LVRP7L($9\QEC\L/N*Y'R]0,9_2@#/NM;UV]U[P7!;:F+2
M#6K"::X18$;:RQ(V5+=\N<9XX&0>AI1^,=7TC0-=M[F\%[?VFN+I5G=3QJN1
M)LVM(% !*AR> ,X%=':^"6MKWP[='5YY7T.!X(1)$O[Q74*V[&.RC&.F.<U!
M-\.[.]L-=L[Z^FFCU>Z%X[(H1H)@%VM&1TQM'7- &??65U9_%OPKYVIW%XKV
M-[M\]4!1@(\D;57@\<=L<5G7?B;Q##\/_&^H+JI^W:3JEQ!;S>1'Q&FP!=N,
M?Q'GFNG@\&WAUS2-7U#Q'>7=UIL<L2?N(D60.%!W +_L\_IBH)?A^LWA_7]'
M?5IO)UN[>ZN'$*[D9\;@O8#Y1USWH C2_P!:TSQ]H=E=:LUY::Q:7#O T"(L
M#Q!&!0@;L'<1AB:P[[Q5K\OAG4=2MK]X-:M]8^Q1Z6(HVRAE"*FTKN)*'?NS
M^G%=C<>&9)]>T;6)=0=IM)BDCCC6$ 2B0 -GGKA1C&,&O/M)NVGEEGM?&6HZ
M;J<\\LKZ7/I"3SPLSD^7\T>]@.!P<8''% 'L$"21V\:2RF615 :0J%W'N<#@
M5Y?I<%U_9_Q*DFU2\N!'<7,>R;80W^C)@G"@C X ! P.E>E::UVVEVC:@J+>
MF%#<*GW1)M&X#KQG-<^W@H+/X@-OJUS%!K6YI8-B%8W9 C.#C).T< G /.#0
M!RVB7NLZ+I_P[D&JM+9:E##9RV)A01JIM]RLK8W[@5YRQ!]!4WB+Q)K6DQ7M
M]%JOGRV^KQ0^1:Q*UM';M(B".1F4'S"&R0K$@D=!70'P239>&[7^U) N@NCV
MY\E<R%$*#?S_ '3VQ5&Y^&D<^FZEIJZ]?Q6-W>_;HX0D9\F4R"0\E<L-PX!/
M?O0 VUANG^-&I ZI>>4FE02B'Y"F#(X*8*\+QGC!]ZZCQ+<7EIX;U">PNK.T
MNHX28[B];$,9_O,?053'A8)XKBU^/4[M)OLB6EQ'A"+A48LI8[<@Y)SMQGVJ
MWXFT"#Q1X>N]'N9I88[@+^]B.&1E8,I&?=10!SN@ZY?O\09]&:ZO+G3GTE+V
M)KV%8Y-_FE"0 JG:1V8=1QQ5_P"(VI:CHW@'5M3TN[^RW=M%YB2>6K]P,88$
M=Z6R\(2V_BB#Q!<:Y>W5XEG]CE#1QJLJ[MPX51MP?3\_70\4Z OB?P[=Z-)<
MO;PW2A))$4%MN<X&>!TH Y_[;K>F^/M'T^YUA[JTUBSN':(P1H+>2,(08R!G
M'S$88M6'<>*=?C^$VL:TNIN-1L=0EACF\F+YD6X$8#+MQ]T]@*[.?PS)<^(=
M'UF746,VF121(BP@+()  Q;G.?E&,=*Q;SX:)=Z5J^D#7;V+2]0N6N1;)&G[
MIVD#MAL9(R#@'@9[T 2WMWK=S\39-!@UF2UL)-&^U@101EXW\X)E2P/./4$<
MGCH1S$OB#Q3'\.=2\0-KS&[T2\F@VK:QA;L1S;"9>">5X^3;CWKO$\,R)XL7
MQ#_:<DEPMA]@V21+ADW;]QQCYMWI@8[5F/\ #Y)/"6J^'7U68V^I7#W$LODK
MO4N^]@O;&?;CG\ #-U*UOM1^+\D-AJ3Z=(_AQ"T\<2R.!]H;A=V0.>Y!_J*N
MF^,]<6S31;Z0W&K)KLFD->6\<:&5$C,OF!6(0.1A<'@9S@]*ZV?PO.VOV^NV
MNJ-!J"60L92T"O'+&&W#Y<@ALGJ#^%5M0^'^F7_A[^S/M%U%<"[-^NH1N!.+
MHDGS<XQGG&,8QP,8& #$U:]\9:-X>\57;W,D5M;6OVG3;BY6!YU8*2Z,$RI&
M>AQGUS74^&;;5EMC>ZGK#7RW<,,D<'D)&MN=OS!2.6!R.O3'O5"3P7<7GAW4
M-,U/Q!>7UQ?PFWEO)8D4I%_=1% 5<YY/)/?H,='IMH]AIMM:/,9C!&L?F%=I
M8 8!('?% '/ZCK-S=>/;7PM;7+VB_P!G/J$\T:J7<>8(U1=P(')8DXSP.E8+
MZKJE[I7CKP]?WTK7&C0EH[V-$5IH9(6=5<;=N0 02 .V,5U6L>&4U+6;#6K6
MZ>RU2R5HTF5 ZR1M]Z-U/WE[CD$'H:9_PBL?]F:Q +M_MFL;OMEX8P6.4V *
M.@"J  .<=\DF@"+X?6\D'@'0#)=S7 ?3K9E$@0",>4ORKM4<#WR?>LC6(;J7
MXPZ&B:I>0Q-IEPXB3854AXP<!E/7N>O'!%=7H.E-H>AV6E?:3<1V<*012,@5
MBBJ%&<<$X'7BJ>J^&5U+Q%INM17]Q:7-E')"1$%(EC?!*G<#CE1R.: //E?5
M[/2OB+JNEZN]B^GZK<7*HD*/YK)#&Q5]X/RD#'&#[GI73R>([_5]9MM*M5O(
MMVDQ:A*UD81)NE)  ,IQM&T] 221TQS9'@;_ (E?B.P.JR&/7I9);AO)7,9=
M0C!.>FT#&<U'J'@$W#Z5>6.MW>G:OIUL+1;Z"-3YL(_A=&RK>OUR?H ;'A1M
M>.A(GB18_P"T8W9"\97]XF?E8A> Q&,@<9K!\7>'M=?Q%#XE\)W]NFL6UJ+>
M>QNN8KJ#<S*#W4[MV#W]1@UUFEZ<-,LE@-Q-<RDEY;B<@O*YZL< #VP    !
MP*HWFA74FO-K%CJTUK.ULELT+1K)"X5G8%EX.?G/(8?C0!P]UXHB\1_#KQQ'
M<:5+I6MVEE(NHVDISAC"0K ]U(7@^WT)O:?>ZSI&O>"[:356N;'5[5XY;5H4
M5(3' '4H0-W;!R3G/:MJ;P1%<Z7KL$^H2O>ZZ@CO;SRU!V!=BJB]% 4G&<GD
MDDU))X1>2]\.W3:D^_0U980(1B7<GEG=S_=],<\^U ',ZCXDUK3[BPG&J_:I
M)-?2RGCMHE:T2!Y"@CWE0QD P3@G#9!XXJ\DWB35O'GB+2+?Q"UG:6*V<T.V
MTC<@/O+)R.00N">O3'?+Q\,T32XM,C\0:@EG;:@M_9QA(SY#B0R8R5R_).,^
MO0UNZ;X:;3O%&I:W_:$DKW\<44L+QC $8(0@]<_,<^N>U '+)K7BOQ#H9UGP
M\+@7'VMQ!;R&W%J\22E"KDGS,E5)SQ\W3BI-:\4W>G^)KO3M4O[K1%FDB&E7
M1A1K28%5+([E3ARV\')&!@CWT(/A[]BU2\>PU_4;32+V9I[G2XPAC=V^\%8C
M<BMW"D?45=U7P@=8@U*PNM19]+U&17EMFA4F, *-L;Y^4':#R#@DXQ0!T]>9
M/XDUJSO/#\CZK]L>\UDV-X+>)39A&,FU8W*ABRA1R">0P)Z"O3-HV;<<8Q7"
M0?#-;?2],TU/$6H_9M*O5N[%=D68L%OE)V_-]X\G/TH 983>)-6\;>(]/7Q"
MUM::5=VC1JMI&Q='C#M&<C@')&>O3GC!JV>M>+/$.B:=X@T1;C=/.)3;2FW%
MJUOO(*9SY@8*/O?W@> .!U>D>&VTKQ#J^K_;WF;5#&TL31@!3&NQ=IZ].N<Y
M]JR-.^'HTJ]FCLM>U"+0IIFF?2 $,>2<E0Y&Y4)ZJ",Y/K0!VM>+:3>ZSH7P
MRAUZQU5HHK75Y%:R$*%)D>]*,')!;/S'!4C'IWKV=PQ1@C!6(."1D _2N+/P
M[0^#'\,'5YOLKW/VDR^2OF;O-\W'IC?[=.* &W^KZQK&MZ_I>E/?0/I@CBB>
MU%O@RO&) S^:<E?F48 [-R>,4=2DU237?APVM111:G]IN!<K"V4WBW<$CV/7
M\:U]3\#RW/B Z[I>OWND:A/$D-ZUM&C)<A> 2C@@,!P#S@5;O/"*7%]H5S%?
M2Q?V.[R1!E#F5W4JQ=CR202>W))H YR]U*^\5>%O&5[#J,MI;V37=E;P1(A#
M"),,S[E).XYX!&!COS74^"/^1!\._P#8,MO_ $4M94O@'9<ZW_9NM75C8ZSO
M>[LUB1U\UUPSH6&5SW'?VXQT>A:4NA:%9:4ES-<QVD*PI),%W%5  ^Z .@H
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MWU2YA^(*:)>FTU(:Q(UO)L1@7$,9"D,",'I6GH7B*Y\2V/AHV5[-%-+&\^I
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MYTF18K@R1;5).?NGOT/I^5>:Q6EY<?M%RVDVLWY\G20ZR*R@C[A*@;<!2>2
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MMM$%\L(RA2#D$GA1W[5T5% '*P>"EM3J+P:S?QS7U\M^TBB/*2C ^7Y<;2%
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M;>)O#U[HMX\J6]W'L=XFPPY!!'X@5<-];"_6P\Y?M;1&81 _-L! +>PR0/\
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M1P7<6HZ?&)9A*B["IVX((8YR'4UT= %73;(:;IEK8K*\JV\2Q*[XW,%& 3@
M9XKG]*\"V>B^)]7US3[^]A?57\VXM]R&(R?-AN5W=78XSC)]ACJJ0D*"20 .
M230!YPGP:T=/"%QX9&JZF;"XO!>N28M^_ &,[.G [=JU->^'-GK5[I&IQZG?
M6&KZ7&(H;ZW*AV0=F!&#U/;^(]JET7XBZ5X@U.UM=.L]1EM[IYDAOA /(8Q#
M+9(.5'/&0,UT\][;6UQ:V\TRI-=.8X$)Y=@I8@?15)H ;I]D-/LU@^T37#]7
MGG8%Y&/4G  _   =  *YO_A ;1?&>I>*$U*]6^O[4VDB 1F-8R% VC;G(V*>
M2:N6/C+3K_QI?^%$ANH]2L8?/E,B+Y90[<$$,<YWJ>@KHJ /.&^#>CMX+3PH
M=5U/^SDN_M8.8]^_&,9V=.<]*U=>^'=KK6M:;KD.JWVG:S8QB);VVV;I$YX9
M2"#U/;N>#7944 <=KGPZL-=FT6XFU35(KK29&EBN8IE$DC,06+$J1DE1T P.
M ,8Q!8?#'3-,LO$=G:ZEJ(@U[>+A7=7*;LAMI*Y)(8C+9_/FNXK$\5>*++P?
MH<FL:C#<26D;*KF!59EW' ."1QD@<>M '-'X3:8=-\.V(U741%H$QGLS^[R6
M+A_F^3G!'M6M#X&MH/'=UXNCU&\%_<P?9VC(3RPF% P-N>-H/6NCLKN._L+:
M\A#"*XB65-PP<, 1G\ZGH \X3X-Z0GA*\\-C5=3-C=W@O9"3%OW@ <'9TX';
MM65XUT[78_%ND6^EZ\=+AM-+,?VO4+99+:1MP&!E2HDP!G('&,=37KE8OB3Q
M1IWA:VM9;]I&>[N$MK>&( O+(QX R0![DD"@##^'MWXJF&J0>([JWOX()(Q9
MW\,'E"<%27P, $#Y1D#&<\G%:>J^$+:_\26OB*UN9;'5K>%K<3QJK"2-L_*R
ML.<$Y!X_&KOA[7HO$6G/>16=[:;)GA:*\B\MPRG![D$>X-:U '%-\,=&'@*7
MPA!<7<%C/();B92IEF?<&W$E2,Y5>@Z#%=/H^FKH^C6>F1S231VD*0H\F-Q5
M0 ,X &< =JO44 <Y:^%I]-N+^;3=<O(1?7$EQ+%(B2HCN<DH",K^9'&<5FZC
M\+_#VH^#E\-N+A(4G-RMTKCSO/.<R$XP2<G/&,=,8&.UKFO$7C?3?#FHP:;+
M#=7>HSV\MREK:(&?RXU9F;D@?PD =210 Q?!-M=>&[O1M;U&^UA+J(12373*
M&"CE=NT  @X.>22!DG IOA3P2OA>R6R.MZGJ-I$AC@@NG79$A[ *!GCCDG'8
M"L^?XJZ+$S)!8:M=316T5U<00VV9+=)"H4,I(.[Y@2!GBMOPGXML?&.G7%[8
M6]W#'!<O;,MU%Y;%EQD@9/'/U]10!AV'PMT[3?">I>&K?5=3&FWI;Y&:,F)6
M(+!3LYS@<MG';&3FQ_PKC35TC0;-+NZ%SH4@>PO"$,B<\JPQAE.!D8[=:ZN^
MNX]/T^YO95=H[>)I76-=S$*"2 .YXZ50\,>(;7Q5X>M=:LHKB*WN0Q1+A-KC
M#%3D D=1V- &/!\/=.ATG7[3[5<M<Z^SF_O/E\QMV1M48PH 8@#'&:SS\)]-
M-CX<M!JNHA/#\QFLS^[R6+A_G^3GD#TKOZ* $()4@'!QUKD])\!6VD>,M0\3
MQ:I>RWM^NVX201^65XP  H(QM'>NE^VVQU V F4W0B\XQ \A,X#'T&<C\#Z5
M8H X_4OAY87NL:KJ-K>7-C)J]J;34$A"E9D(QN&X':^.,CUZ9YKH])TJST/2
M;73-/B$5I;1B.-,YP!ZGN>Y-7:* .*U#X:Z;>3:V(+VZL[77&1M1MX0I$C*<
MDJ2"5+9.>N<]JEUSX=Z9K7]@HMS<V4&ANKV<-MLV@KMQG<I)^Z*["B@! "%
M)R<<GUKB](^&FGZ'HNLZ/8ZGJ*6&J>;F$LA$/F *VWY<DX  W9Q]<D['BWQ7
M8^#=%.K:E#<R6HD6-C;JK%2>F02/TK9MYUN;:*=,[)4#KGK@C- ' GX1Z6=$
MT+2AJVI"WT2X:XM2/*W;R^_YODY .?SJ_JOP[M;WQ>OB>PU;4-)U-HQ%<26A
M3$Z@ ?,&4C. !^ XR*[.B@"*VMTM+:.",N51< NQ9C[DGDD]S4M%% !1110
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M)J>[[7:SM&89,DG[H08QN.,'H<4GACX;Z=X3NI#IVJ:M]A,OG)I\EP# C^N
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M'/H/K7::K\,='U;0M%TV2[OXI=%"K8WT,BK/&%P ,A<'[J]NPJQK/P_L-?\
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M!"G^$G=U'/!K(36K^'QYXV\'_;;Q]-ATHWEL[7#M+;MY:$@2$EL$OGD\8XH
M[_5O%NFZ5X<O]='FWEG8NR3?9MI8%6VMC<0#@\'GM5[0]7M]?T.RU:U21+>\
MA6:-90 P!&1D D9_&O#?#5FJ?LT:O>^=<,\L,RF-IF,8Q+U"YP#[BI-$O]4T
M'4/A:+75[YK?5;;RKFUDES#M^4 !.@P&Z]>.M 'OU%>,'7/$OBWQ!XWL]*>^
M6^TNXCM]-6"Y6**#:[9:12PW[]IZAN..*F\0ZAXCD^+/A+1UU6ZTXZCII:^A
M@EW(LFR3>5!RN1C@X(R <&@#V&BO&_'=IKO@#P]H&KP>(M7U&&PO@NH^;<,#
M<0L^X;@#V^YG_:'IQ1@\2ZO9_$2[L)KZ_DT[Q'8M)H8:XD(B9WPC#G@8!;U
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M<>,;><9Y'6@#W&JUGJ%K?FX^RS+*+>9H)2O177&5^HS^=>4^#]7U*\\;>-]
MGNM3CT^&W66WANKEGFMRRC(#[F(Z]-W'M7,>"-6NO"_P$U?Q-93W#7ZSO"@>
M5FC1G=%W[#\NX;LYQS0!]#5SGC/QG8^!M(CU/4K6\GMGE$1-LJ,58@D9#,/0
M]*X[3;[Q/I=LGB"".\GT/^P#<3_;[Q9FDN5C,BR(-[$!N 0,#GH,5YUXH>]U
MCX"6/B34=5OKJ_OM2)F62<M$ 'D4!8_NIC;_  @=30!],(P=%8=",TM1P?\
M'O'_ +@_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/E7OGCG/-5?#OPWT?PO=R/IUWJ8LVE\Y=/DNBUO&_9@N,DC QDGH#U KL**
M*&M:/9Z_HUUI6H1F2TNHS'(H;!QZ@]B#@UA-\/-%D\+6V@3R7LUO:.DEM/)-
MF:!DX0H<8&!QC&/4&NLHH P]'\*V&CZMJ&KB2>ZU2_VBXN[@KO95 "J H"J
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M=[:6_P!I:9BIC9/EQC!SGYQU'K0!<T/PMI^A7NH7\+37&H:C()+J[G(+R8X
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M[#O78TV1_+B>3:S;5)VJ,DX[#WH IZ5I<6DV?D)/<7#D[I)[F3S))&QC+'Z
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M!B/.,@D<]NQ!]ZHV?PRT+3]-US3[6:_BMM98FY3S]VT'J%R#C/3)R?>NRHH
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M5@3R>>O)]3745S-IXUM+KQ]>>$/L=Q'>VUM]I,Q*F-D^7&,'.?G';L: &R>
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MU/K4E1P3"XMXIE!"R(' /4 C-24 %%%% !1110 4444 %%%% !1110 4444
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MDE#1"X+%MP&,@ L3MSM]0: .EKQ#X@ZKJ5NWC-HM;N+J>S2VEM18321#3!N
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M&!@*O3T^M8DGP@\+R:;-IA.HC39+C[2MDMVPBC?OM';\<^V* .STS_D%6?\
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MCM'\I;]X@8DJ3N&X=^#DYH ]3HK@O'-PZ^*O#=J=29XIVE5M%B!#WIV\,6#
M!5ZDL<#&>3Q7G_AS6=5NO@5XO>?4+LSZ==RQVTWGMYD2@(0 ^<X!)_.@#WVJ
M6KWS:7H]YJ"P^=]FA:8QAMI8*,D ^N :\,L+S4-/USX67L>JZC+-JT!6]\^Z
M>191\H *DXX#'MZ$Y/-:4%U<>+/$GQ,;4[J["Z/ ]O8P1W#QK$H$H+!00"3L
M!.<YW8Z4 >H^#O%$'C'PQ:ZY;6\EO%<%P(Y""PVL5[?2MVO._@;_ ,DETG_?
MG_\ 1SUSGQ"O+C^UO%L4>K37KV^EK/!:V[-%_994 [V<,!N8G( !8Y&< 9H
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M9-<U/6/#7Q#\0W-[=0ZAIEZL5CY<S)]D5'P%4 XYZ'CGO3M>D;Q)XN^%E_J
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MJHR<'UP#47A?7X?%/AJRUN"%X8KM"ZQR$%EPQ'./I5/X@?\ ).?$O_8,N/\
MT6U>)2R77AKX3^!O$FCW=XFIM>" H+ARDJ$R'88\[<?*. .Y[T ?2%%>0>*[
M^?P)\7-)UJ[O+QO#VK1O#-"T[O'!-C&X+G S\I_%L5Z5X<L)-.T6&.8R^?*6
MGE665I"C.=Q0$D\+G:/8"@#5HKPOXA:A=H/&SP:Q/?7%F+:2%K9VB&E?.!MW
M!L%V] #T))'2I?&FK:I<:+\,+M=3O+>YU*2W6ZEMYFC,FY8R<@<'DD\CO0![
M?17C_@Z&:;XD>//"S7]^=,$:&)6NY&>)F RRN26!^;KGL/2JGP^O;Z\%_P"
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MZ!)%9B"V""#D=\@'-:-% ')7GPX\/:AI.GZ9=1WDEM8.)( UW(6#   ELY.
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M&0G=D8&.>*Z&N+U_Q^VF^)9O#VE:/+JNIP61O9(EE\OY=P 5?E.YN<XX&.]
M%ZP\!Z+I^B2Z4AOIK>153=/>2/(B*055&SE "!PN*OZ7X;L-)U&[U&,S3WUV
MJ)+<W$F]RBC"KGL!^O?-1:[XGM?#?A.77]3AEABBB5V@X,@=L )UQG) ZXJ$
M^(-4M9M/74-$18KZ9(EFM;OSEB+<CS,JN/0%=PSQD9!H 77?!.A>(]6L-3U*
MU>2[L<B%TF>/@\X.TC(_^O5.V^&WAJST?5-)MK6>*QU.3S+F%+E]I]E&?E'
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M<O/ \[L,\?=R?EQ@=/0>E;6B:+9^']+BTZQ\[R(@%7SI6D;   &6).   !T
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MRW;NL ;KY8)PI/J!GWKBOB%X!ATCX67'A_PIIU[/Y]Y',MO'OF((/S')S@8
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M]OK?5-+BMHX2AM[B&X\Q)U8'/! 92N,'([\5JT %%%% !1110 4444 %%%%
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M-]M^Z/>0QS.D5RR'*ET!P3G\^^:Z)$2*-8XU5$4!551@ #H * /G>*63Q3X
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MPUI6CZ!_85G;LNF['3R'E9P%;.X98DX.3W[T 7K&_L]3M%NK"[@NK=\A98)
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MK&TF1]XL@S_.O)KZTNTT?Q%X+M#+)K=G?&\TV0RMO:W8>:I+9RP^5HCVR5%
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MSE60C.,$'GCF@#W"BO.M7CGN?%/BJVU&WNKR)]/A.E_9D:0P,5<,!M_U<A<
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M:-S\MU<,57YAT;:-S8/<Y["L-+L^&M*\7I9S&UMCXGAMY9V9CY$+B$.<Y!
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M!2-@&&022<9Y*@<]*[CPIH<^@7FK6SZJES!+(EQ#9I&RK9A@057+-\I*Y X
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M=KAM#J$+RFTF6X@VS.FR0=&^4CD9/YU7F\*:1<3W,LL$K"ZD66XB-S)Y4K*
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MA1],!%F(IGC6$$8.%4@=..G2M"Q-VUA;M?I$EX8U,ZPL2@?'S!2>2,YQFK%
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M4;*R\]<XYZXXK>U_^U6:QUE=,M_$-DNDQ?;=.9PL\.[<3/%GC)P01P?D&*[
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M&ROY8</D;BW._J1SSFM6V\ >%K1+9(M'BVVTOG0AW=_+;! QN)X&3A>@STH
MXRVT\^-M.\0/=:M:6.H6>ISHURUN3<6 CD/E[7\P;5V*.@ .6SDY-7(M&L]7
M^*.HVFH-+>6TFAV\LD;R.J2,9'!)3/ X'R]!Z9%=5>^!O#&HZXNM7>CV\NH
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M<#TJ*/PKHT46HQ):N$U$DW@\^3]\3P2WS=2.#[<=* .*0W)\+_#5F#7&G&&
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ML7=[26UC:%I!ABA48S[XZUI4R&&*V@C@@C2.&-0B(@PJJ!@ #L,4^@ HHHH
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MWG!W_L[:7VE=HV^;[[LYV]JK7FL76BZ?87FKK;>2PCBO9("=L$K87>,]8]Q
MYY ()R,XX?3[2$>&?B?  WEI?794;SD$6Z$<YSUK1U)8W_9[828V_P#".(1G
MU$ (_7% 'HE)N!)&1D=JRM!N)/\ A$=,N;YBLOV"*2=FZAO+!8G]:\PM!;0S
M^ M2TY1';W.HR*EW.X:[NHW20LTK  8)Q\O/;)!XH ]D) ZD4$@ DD #N:\?
MD\/Z7?1?$W[5;"86TKR0"1BPB?[,&#KD\-GOUK0TK43J_B7P;I>LL)K27PVE
M]&DW*W%T0@)(/#%4W$>FXF@#K?"VOWNM7VOVU[!;Q'3;\VL?DDG<NQ6R2>I^
M;T%:&J:N+.]LM.@59+^^+>4C'A449>1O]D9 ]RP'&<CE_AU:6]CJ_C.UM8UB
M@CUD[(TX"@Q1G '8>W:G1L[?':59<[4\.@P@].;CYB/?(7]* .Y&<#)!/?%9
M>N:N="MTU"=5.G(P6Z<?>A4D 2>Z@GD=AD]L'C==:W\$_$2'7A:J;/6K9[64
M(HS]K3+QX]Y!E?<@5L:MH\&D_"S6K)TB4G3;F2Y:-0JM*T;,[ ?4G'H,#M0!
MUX((R.129&[&1GTK"\$RSR^ O#\MT3YS:=;LY;J3Y:\GWKS8M:FV\':QI0Q;
MW/B,+'?W# WETKM+OWD 83MM.3@+G&,4 >A^'_$%[J?B'Q'IM[#;Q+I=Q%%$
M8B3N#QA\DGOR.@%=(2 ,DX%>7VGAC1?$_C+QY%K-N)X%N+;:6D($>;9?G&#@
M,/[W45E^%-0O]0D\ Z9X@9I[.YL;N1/M RMS(C8B+@_>Q%AAGN<]0* /9 <C
M(Z45YG9^'HM0\0>-_"FP+H3PP201@?+:3R(V[RQ_#T#X'0GWJ;P3.OB.STBP
MOK2);GPYNCO4V#"W*9B3'U4._P!2AH ]%R,XR,^E+7C^E6,?B_PE)JEYK%G8
M:I:7LDMS=I:$WEK*DIPF_?TQA0NW&T@ 5ZZLT3RO$LB&1 "Z!AE<],CMF@!]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M($&%S]!5VB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!549+$X % "T4@(8 @@@\@BDDDCAC:25U1%Y+,< ?C0 ZBBB@ HHHH ****
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M%EQX;.HZ5+IO]F7B7]TTDL;!I$1@$CV,206;.3C@>O% &OXW@BN/ NO":))
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M9(C!QZL.#G^1ZCP3INJ:1X>^QZI<3S,D\OV?[3())4@W'RU=AD%@.N"?3M0
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MLBX&QMISP6';-<]\0];77/ASXD>TTP7>G6ZR0?:6<9\Q#@O&I'*JV06R#P<
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MD@X !^Z<XXS5C^)UO<:/HU_;:/=S?VC?_P!GM&)$S%-\WRYS\WW20>F,$D4
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M%>=:QX]OKGP-;:QH]G'%+-J*6,ZRS?ZH^<(VVD AL]CQ@'..U;^H^+187?\
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M>(R1UW9 ()':HM6\<OI,%[?2Z3(--LK]+&6623RY'+%5WQH5PZ N.=PS@^E
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MKKI]JRD( 03G)'N<#\J .C_X07P@#@^'M+SZ?9U_PI?^$#\)?]"YIG_@,O\
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M#=MSC..N,]ZCL+E[S3K6ZD@>WDFB21H7^]&2 2I]QG%<^-5M/^%BW&GC1/\
MB91Z3YZWN4WRQ>9@1CVW9/)'(H ZBBN @^)<LVA6.NOX>N(M+GN_LL\S7";H
M293$&"C[PSC/3&>,XK?A\22-XVF\-SV(A9;3[7#<&;(FCW;3@;>H/49XXZT
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MERP1BBAF X!.,GZT +17G&F^/-7MO!VN^(M4TM)TL;RX3R[:Y'RB-]FWYE'
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MB4J,Y.&4@\X).>WK>^'FDZIHGAEK'5K6.WG%U/*H28295Y&<=!_M?_JKK**
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M;:LZ[2KQ[NQ(;@U2UW1O$'CCP=J-E?6L6C7$@C:T@,XF*R(X<,[*,8) &!G
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M/J!WET*R\9>&9+KP_:Z9:W>EM<RRV6IM=!?LZ2.7(DCQN<J6/3@],CJ/0Z*
M./L-.U2S\?Z_JSZ?*]G=VEO# ZR1[G:/?GC<,9W<?TKEM-\)>*=&\.>$+VSL
M(I-7T#SX9["2X55N8I3\VUP2 1A2,X[_ (^LT4 </K^E>)_$?AV*[2&VT_5[
M.\AO;*R>42(#'GY9' Y+!F'' XYZFKD-WXKU/2+N6]\/6MG((=B:?)=)/]I8
MD;MS ;57 ([YW'.,#/644 <1X1\+2:#XDO;G3K2XTK1+BV7.FS3*ZBXW9+H%
M9@HV\'GDGIQ5_P =^'[S7]&M#IKQC4-.OH=0M5E.$D>,GY6/8$$C/KBNHHH
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M<12M"VR54<,4;&<-CH<=C0!PME8>+/"_B36%T[2;;4],U>Y^VI(UX(OLLS*
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M\*Y+5/ 6H7WPZTK3([PIKUG<0WOVS=R+@MF5L]^'?'T% &E;M;6^@^(O$_\
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M<!I"#&"P+8!.<=2,C)Z\4 ;&G_$>WFTN\?4K#^SM4L[Y=/FLI9U*B5ONGS,
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M,4-XDE[9/-Y0N80#E-WID@D'@XP?0@%!O'[1Z'XEO3IBRW.@2,D\4%T&20!
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M6?+FC61,^A&14M4-$AFMM"L+>YC\N>&W2.1-P.&50#R.HXJ_0 4444 %%%%
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M656C,G&$)W8P ,8ZY;IF[;^-(]2@T!-.M@][K5J;N.*9]JPQ!069R 2<%@H
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MZ$9I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF "*F&&!@_+GC-'B_1]3U74?#LUA#"Z:=J*WDWF2["5",N%X.3\V>W2NJHH
MXOQ!H_B*S\7P^)O#:6ETTEH+.]L;J4Q!U5BR.K@'# L1R.E9?C#^UXKCP5+=
MK;S:BVMAS#&Y6-?W4GR*Q&3@=R.3SP.!W]]J-GIEN+B^NHK:$NL8>5PHW,<
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MTB3P_K&C1V4U_9Z6FEW]C/,529%P0R.!P0V3R.AKN-)74OL7F:L8!=R-O:*
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MRB@FE60B2(I&\; )C!SNSG<,>]=M4%U>6UC 9[J>.&($#<[8&3T'U]J ./\
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MO25 ^,/B/  SIEF3[_-)7;5RMCHFK6WC[5=;D6S-K=V<-O'ME;>&CW')7;@
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M+'LR"H/(QG'&?44 <M!?ZMI7BWXB76D6-K.UO);3R"XF,:D+:J2J[026//7
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MX9-5N/+=+B3,EG)Y;$X&W!X!&<CKTJK+XO\ $]U?^(++2?#]E--H\JJWFWK
M3*4#@+A/OD'H< >IJYK?A_6[^\\,3I+:3OIEX;JZDDD:/>2K*510K<#=QD]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;1)NSM)P0Q3 X/WN*T5\1Z@WB^\T-ELHT.GB^T^=MV)EW;6#<\;3C..S ^U
M&W>Z'INH7]M?75L)+JU)-O(78&(G@E<'C(X/K6A7$^'O&5[XA\+:5J-O':+?
MWMX;9[?#%8MI;>"<YR%0MGOP.,YJI<>,O$KQ^*6M-,TQ?[!D.[S9W(E01B3
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MN/2IY=8TZ"2P26\B1[\[;56.#,=N[Y?PYK@M4UN;7?A9XX>YLK>UDM'OK0I
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M8[YJK-X^U&2Q@U?2]*FO[![GRS;0V4[3-#O*^:K@;#TW;<=/XLT =_17'?\
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M#([;0"Q"@9]R15F%G>"-I5VR%067T..17.^.=<N/#WAPZA#96UVHN(8W2=B
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M**5R2!R2RCIQ5R]\2:IH.JZ-!K,%HUKJTPM4DM]P-O<$91&R3O!P1N&WD=*
M.MHKS>?QYXC&A>(M6BTK31%H5_-!.C7#DRI&%)V':/FP2<G Z#'>MG4O&(BU
MZVTB"XLK.>YL5N[9K\$+<LQ(\I2" && 3U/S# - '7T5#9O-+9027,8CG:-6
MD0?PL1R/P-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %<[XZT2^\2^#]0T6P:W26\01^9.[*J#(.>%.>GM7144
M 5-+BN+?2[6"Z6)9XHE1O*<LN0,<$@']*\\E\"^*'T>2P-WI,CQZPNI)=2&3
MS+D"7>!+Q\I ^48W< #C&:].HH Y;2M"U6T\=:KK=R;)K:^MH(,1R-O!CW?-
MM*XP=QXW<8ZFH--\.:SI=YXG$4EA+9ZK<27<.YG60.\:H5;@@ ;<Y&2?05V%
M% 'G \":[:>&_"QL+RQBU[PZ&2)G+M;W$;+M=6X##( ['&/Q&OK&A>(M>\%:
MMIU[<:>-1U&'R0D3.+>!?8D%F/)).!G@<8Y["B@#SC5$U&U^(W@R..&U>ZBT
MV[22-IF"$ 1 X;;GW^[[>]3ZKX'U6^L=8NX;JTCU;5+ZWN9H69C;O%#A5@8@
M;BI .3CDDC&*[&;1-,N-4BU.:RA>^A&([AE^=!Z ]A5^@#A(_"_B(:[KNI/)
MI6W5-.CMO)0R#RW0. ,X^[\^=V.<8VCK4?\ PA^MCPYX.TT'3S)H-S!-*YG?
M$HB0IA?DX)W9YZ8[UV.IZSINCBW.H7D5O]HE6&$.>9'8X"@=3R15Z@#F-%T'
M4])\6Z[?>;:/INIS)< ?-YRN(PA7'3'&<Y/ICO6OK,6H3:?MTS[,9_,0LER2
M(Y$S\ZD@'&5R,X-:%% '*^$_"@\.ZEK-W%#;V5OJ#QNEA:N6BB95(9QD  MG
MD 8^45TUQ!'=6TMO,NZ*5"CCU!&#3I)$BC:21U1%!9F8X  [DU5TO5K#6[!+
M_3;E+FU=F594^ZQ5BIQ^(- '%6_@G6!X*/@JZN+2320PB6^$C"<VV_=L,>W&
M_'RYW8[X[5L^*/"(UZYT6:WG%J;&5DE(_P"6EJZ%9(A_O?+SVQGK6U9ZUINH
M:A>V%G>13W5EM%S&ASY1;. >V?E/%7J .7T?PB-)\8:OK"3#[)>8DAMAP(I6
M $S?\"\N/_Q[UK/C\*ZRL7C-3]@SKQ8P8G?]WF(1?-\GMGCZ>]=Q10!E^&["
MYTKPUIFG7?E&>TM8[=FB8LK;%"Y&0#SC/2J?C;0+CQ/X0O\ 2+6:.&XG"-&\
MN=@9'5P#CG!VX_&M&QUK3=2O+RTLKR*>>R95N$C.?++9(!/3/!I]]JMCILMG
M%>7*0O>3"WMPV?WDA!(4?@#0!S,^A^)I?%MAKGGZ4X6Q:VE@D\PK;.7W&2+C
MYB1A3G;D#J,X%?PYX4UW2?".E^&[N;3Y;2*1UNWA=U:2$LS!1E>2Q(#=.,@=
M<CNJ* .5\)^']3\,W>HV*O:MH#SM-I\2R,9+8-RR8*XVYR0,\9QS755%)=00
MSPP23(DLY(B0M@N0,G [X'-2T <A8>'M7L]9\67S"Q9=8,;0*)GRA2(1X;Y.
M^,\9]/>LFV\&>(;'1?"%O#-ILLFA%EGMII'\BX!7:LF0N0R\D CJ>M>BT4 >
M<2> -;N?#/BC2)[_ $\-JFI_VA;RI&^ V^-\,">!F/'&>N<]JZ(:+J&J>(-,
MUC5X[6!M,27[/;VTS2AI9%VL[,47@+D 8_B)SVKI:* . C\&ZT/!WBO1W;3Q
M/K5W=3Q.)G*QB;LWR9ROMU]JNWWAO6+JY\(S*+$?V,^^X!F?YSY9CPOR>^><
M>GO726^LZ;=ZK=:9;WD4M[:JK3PH<F,'.,^AX/%7J .4T_2+W0?%GB#6)[NQ
M31]0:.X=Y&*R1%(@A!SA0O .[/MCO5+PUHMFWCK7-:T^[$VFLRF.-"#$+IU7
MSG4CJ2JQ\^K./6NME&GZO!>6,H@NX5)@N86 =02H)5A]&!Q[BI+.RM=.LXK2
MRMHK:VB&V.*% JJ/8#B@">N8\1:#J=]XG\/ZUIDMHKZ;]HCD2YW89)54;AMZ
MD;<X.,^HKIZ* .(C\+:RA\9D_8/^)[GR,3O^[_="+YOD]L\?3WJO8>$_$>G7
M_ARXCGTR5--TE=.DBF:1EC<8'GQ@*,L0,$';QQFN_HH \VM? 6O6O@C1](^U
MZ:][I&JK?P'YQ'*JRN^&."02'[ XQWKT6 2B",3E#-M&\H"%SWQGM4E% ',^
M+M#U'6Y=":Q-J%T_4XKZ3SY&4L$##:,*>N[K[4RUT35;?QYJFO%;-K>ZLXK:
M./SV#@QEB"?DQ@[OPQWKJ:* /-+#P/XDTW0_#=K'/IDTFD7D\\MO++)Y%P)"
MQ5B=F0R%\C@C//%;?AS2[KPK+KL^N:CIBVFI:BUU&X)C^:157:=QP/N\#)SG
MK7853U+2M/UBT^RZG96]Y;[@_E3QAUW#H<&@#EOAUH,.E6-]<V\[S6<]S(FG
M[ND=HKL45?5=S.0>ZE?:NUIJ(L:*B*%11A548 'H*=0!P&L^#_$%]J'BL076
MG/:ZW9_9XI;C>9;8>65,8 &-A)+9SP23@U/;^&->36_"E_.VG,NCV<MM.$D<
M%]ZHN5!4]-@ZD9SVKN** .7DT+4V^(O_  D"&U%G_99L ID;S-QDW[\;<8XQ
MC/O[5F6O@N[N?$6E:WJ5MIUK?VT,D=]<6,C$W^Y-F'4HO&3NY)(( 'K7=T4
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M2[Q(S9D..&P<?Q9P.1BO3Z* .$A\-^*M#\1ZG<:#>:4^FZM,+F>.]63=;SD
M.Z!?O X!P2.PSW-^Z\.:HGC+2=;LKJWE2"P>PN?M6[>5+*V]=HP6RO(.!S76
M44 <!-X"NM5M/&-CJDMO';Z].LT+P2,[0LJJ%R"HS@H#P?;WK0;0-9UMM"7Q
M!]A5=)N%O&:VE9S<S(I5#@J-@RQ8C+<X'O77T4 >?'P9K;>%?%VDEM/$NN7E
MQ<1.)WVQ+* ,-\G)&WMUSVJYJ_AC4=8TS^R]1T[2+^Q-C'$J33.K03KN!=&\
MLG!!3G@C'O7:T4 4-#T^32=!T_3IKE[J2UMXX6G?K(54 L?KBK]%% !1110
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M21YVX5B2V<MDGKGIQBIAI/BO4= U*WUJ]TMKRXM)+6&.S61(5WC!D<MDLWH
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MC?>7]S[5;I+M^FX'%:%% $5O;06ENEO;0QPPH,)'&H55'H .!4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP13_  X\1++&KA=/G=0PSA@A(/U!K:L](TW3[B>XLK"VMYK@YFDBB56D/JQ
MY_&J/C"QN]4\'ZOIMC#YMS>6DEO&"P4 NI&23V&: //[[P_86,?P]U?1;9(=
M6FO;:.6:+[]Q \1,V\]6&T9R<X%5YOLD'P_^*4$GDQA=3O2L;8&"8DVX'J3T
MKT7PUH%II>EV#-ID%M?16RPN5"DJ<#=M(Z D9XQGO5BX\+Z#=WUQ>W&CV,MU
M<QF*:9X%+2(1@@G'/''TXH X&XTC2]5\<^#H[NT@N(KC0IA*K*")0%BP&_O
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MW9)HU(+-Y@9B.FXCO[GUH Z_5_$NE:+]@%W=Q*U_,L-NN\?/G^+_ '0.2?\
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M=188PJJH;[20-H]>17-7$C:7X*\?-91%+6+Q(?M$=NN"+?,/F@ =MNX'V)H
M]AM=0LKXR"TO+>X,9P_E2!]I]#@\54TBXGCTB)]4U*RNIS(R&XMP$C8[R%4
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M#5O">E>)Y[SQ-X:U5]#U^UFF@FNH) $9XF*E9TZ$?+G/H03F@#4OO$FMVO\
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M-;VW-R#@PB5=XXS]W.>E3R2)#&TDKJD:C+,QP /4FO+]+EOM"U;08KE+76=
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M\%KX<TZWMKBXN+>*!$BFN3F21 ,*S<#J,=A6G0 4444 %%%% !1110 4444
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MX)\41ZSX7T274K^T_M>^MO.,&]4=^3DJF<XXH W)=#TF;4/M\NF6;WG!^T-
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MSNBC2/!R5"#KG''UJ[I&G#2M+AM/,\UUW/++C'F2,2SOCMEB3^-.75],>_\
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M:-'),I/[_<QD8?."S'CD^E:7B'7[2;Q=X$OY+A/^$?N_/E29C^[\\QCR=QZ
MX+8SW)]*[Z>SM;JW^SW%M#-!Q^[D0,O'3@\5 VC:6]@U@VFV;6;'+6Y@4QD^
MI7&* /+KUM+FU7XM1(UI('TV&7:"IRRVTF6 ]0<9/8U)=:9IW]G_  O;[);Y
MFEB5SL&9%:U)8'U!.,YZUZ:NBZ4D4D2Z99+'(%5T$"@,%&%!&.0 ./2D.B:2
MRQ*VEV16'_5@VZ83OQQQ0!PME:V:>,?B/:""$6QL[-VAVC9DPR9..G8?E6#%
M:V=SX'^%7GPPR%[VWC.Y0=RF*3*GU&<9'2O6CH^EF260Z;9EY@1*WD+EP>NX
MXY_&FG0](,<<9TJQ*1G*+]G3"GV&.* .'T^TLX_'/Q!LQ! MLUC9NT(0!,^7
M)D[>G8?I6;H-I>7G@'P*^C:K;V6M6]H\MI'=)NAN %"NC8Y!PW4<CFO3#H^F
M&664Z;9F28$2MY"Y<'KDXY_&FMH>D/;I;OI5BT*$LD9MT*J3U(&,#H* /,+W
M54O=!\)7-WI\6EO;^+/*NHPX,2RAIO,96_NER3]>.U:UOI>BZM\7=76>RLKN
MWET6VE"/&KH^9'^;!X)QCG_&N^?3;&6R6RDLK9[5<;8&B4H,=,+C'%":9I\=
MX;Q+&V6Z/681*'_[ZQF@#QOQ+JFFS^%]:>PFMK**/Q&C/!))NN))EN(P\AR?
MW:\<*!T Y&<5UBWD"?%S4WAGMQ+<:#;FT+.,2L99-NWUY(Z5VKZ-I<C7#2:;
M9NUSCSRT"DRXY&[CYL8'6IFLK5[J*Z:VA:XB4K'*8P70'J >H% 'D*-%J7[/
MLBMN_MB!B&'2=-0$W'N)"Y'O\U;5OHUAJ'Q;NK?5K&SN9'\.P//')$K*\GFL
M&8J>"??TKO\ ^R=-&H'4!I]I]M/6X\E?,]/O8S3AIE@MZ;T6-L+H_P#+<1+O
M_P"^L9H =>;4T^?HJB)O8 8KQK3[2SM_AI\-[R*"%+EM8LLS!0'.68,"W7IQ
M]![5[5-#%<0M#-&DL3C#(ZA@P]P:IG0M(,*0G2K$Q(Q9$^SIA2>I QP: /(_
M&^IZ?<^&/'B64MO9LE\J7$<SE[BYF3R_F4$_(@ &, YVD\5U?C&XAT;4]"\=
MVI$UO;G[%?O -^^VE( ;CKMDVGCU-=F^CZ9++/+)IUH\DZ>7,[0*3(G]UCCD
M>QJRUO"\ @:&-H0 !&5!48Z<>V!0!YSXM>;0M"T"^U"26VMY=72YU:6)5;RB
MZOM+9!!5',8R0?N+WQ6YX8M-"/B35-4TG69=3N;R*+[7(DD3P@KPF?+4#?C/
MOCKU&>KFABN(7AGC26)QM='4,K#T(/6HK*PL]-MA;V%I!:P Y$4$810?H!B@
M#B_B##;3^(/!45XD;V[ZJRNLH!5LPO@'/!R>W>N8\2Z;-INK>.9O#%N8K3^Q
MH1=QVJ[5-QO)8*!QN\G)./[P]:]<N[.UO[=K>\MH;F!OO1S1AU/U!XI;6TMK
M*W6WM+>*"%?NQQ(%4?0#B@#SVV;P_KE_INM:'XAFU#5X;*=+*&)H!L1HSQ*B
M("%!"X#=&(]:RO#,GAOQ#X;\+K=>(+HZII\\++8*T*7"72\."NP.5)W%B3R,
MDGO7J-EI6G:<\KV.GVMJ\QS*T$*H7/JV!S^-$6DZ=#J$E_%I]K'>R##W"PJ)
M&'NV,F@#R@:7IC>&OBJQL[8M%<W00^6O[O%NK#'I\W/'<>U>G^&I#+X5T>1F
M+,]E"Q8G.24'-2C1-)"RJ-+L@LO^L MTP_UXYJW!;PVL"PV\,<,2_=2-0JCZ
M 4 >8V6F:;+K7Q-5[.V94V  QJ0H-J"V/3)Y/TK.CMK2W\#_  NO(H8DN7U*
MP#3!0';=$P8%NIS@#\!7JHT;2P9B--L\SC$O[A?WG.?FXYY]:0Z'I#11Q'2[
M(QQG**;=,*?88XH \A\9:II]QX4\9BRFM[,1ZPHFBFDWW$\Z21 N,GY$ 7@
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MFLH8MEO)<G+M&"=IS@<8QCCIBK=UH^EWRP+=Z;9W"P?ZD30*XC_W<CC\*NT
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M$OX>>.R2:U@<Q1_:6." R_<'S(7QV/0]*U;.ZM;GXKZA%>7^G7?VGP^BLL(
MC9A*YV@$G<0.>>WH*]'33K&.Q:R2SMUM&!!@$2B,@]1MQCFHUT?3%5573K,!
M(O)4"!>(\YV#C[N>W2@#QS3K.S@^%7P^O8X(4N3K%D3.% <DRD'YNO3CZ"NU
M\/SVT'Q8\90RRQ)-,M@8D8@,^(GSM'?WQ75G0M(,*0G2K$Q(Q94^SIM4GJ0,
M<&K(LK1;H70M81<A/+$PC&\)_=SUQ[4 9/C&VM[SPI?6MU?M813!(_M0 /E,
M74*2#P1NQG/;-8_A*_U<>)]4TKQ!9VAU6*U@D.HV61'<P[I FY3]U@=_'?G'
M %=C/;PW4#0W$,<T3?>210RGZ@U%9Z?9:?&T=E9V]LC')6&,("?H!0!9K@/A
M$ZOX9U0JP8?VS>=#_MUWLD:2QM'(BNC##*PR"/<57M--L-/W?8K*VMMWWO)B
M5,_7 H \;\1ZKIUQX9U66QGMK.)/$B.\$LFZXDF6X0/(23\B\<*!P .1G%=%
MX_M3>:A!K7AQ6GU*PM2]^;64*9[%^L6X9R[ %DQTVD]2N>_?1M+D:X9]-LV:
MYP9RT"DRX.1NX^;!]:D&G6*O.XL[<-<#;,1$N9!Z-QS^- %?0;_3=3T&QO-'
M:,Z?)"I@$8 "KC 7';'3';&*XNVA;0/C;J5U>_)::_91+:SM]TS1 *8L]F(&
MX#O7?6EC:6$1BL[6"WC)R4AC" GUP*6ZM+:]MVM[NWBGA;[T<J!U/U!XH X/
MXDVQ\0ZAX:\.61\R\&J17]QMY\BWC#;G;TR6 &>IZ54TS3=!O_%/Q".N6UG+
M$D\7F-<*I,<1MTR03]T<=1Z>U>AV6FV&FQM'865M:HQRRP1*@)]2 *9<:1IE
MW=QW=SIUI-<Q_<FD@5G7Z,1D4 >56$-[9^%?A;!J7F+<KJ:_++PP3RY=@(/<
M*5&*Z/3884^*OB](F6W,FF6K-(@ (8^9EOKT-=M=:;8WKH]W96]P\?W&EB5R
MOTR.*J7^C12V][)IZ6]EJ<\+HE\L"ET<C 8]S@X/6@#RW0H-.\1^'?!FD/>Z
M0_\ 9=XL\DINHG-S&H<!5CSOS)N4L& QSU-1^-]1TZX\.>/XK.2WLV2X6.XC
MF?=/<S(L>&12?D0 #& <[2>,5TUOX'N[RR73]6\/>%(D\L1M?VR-),1C&Y5:
M,;7[AMYP>>:[B32=-FFFFET^UDEG3RYI'A4M(G]UB1DCV- '$_;['_A;^G7+
MW4'DS^'G6.4N-LC_ &A.%/<_2N8U);FV\)_%!-'B*NFJ#=' ,$1;(O-P!T^3
M?^M>PM86;26\C6D!>V&(&,8S%QCY3CY>/2FVVFV-G))):V5M \GWVBB52WU(
M'- '$>)5M[_6O =]H+1-*UY\C0XP;$Q$R=/X,!!Z9([URLFF::?AY\3I/L=M
MOBU2^$;;!E-JH5 ],'GCO7K]GI&FZ<\CV6GVELTGWS!"J%_K@<TP:'I BDC&
ME6(CD.746Z88^I&.: .$U==5%TNKZ%>V5U=QZ+#_ &AI-^/DN;?YR&5_X6SY
M@YX/&:ZW0-=TRZTK1(HW2TGO;%)[>QE<>:(PH[=3C(YJ[)H.CS>7YNDV+^6N
MQ-UNAV+UP..!R:M-:6S74=TUO$;B)2D<I0;T4]0#U .!Q[4 35P'Q@=4\&6Q
M9@H_M2TZG_IH#7?U5N]-L=0V_;;*VN=OW?.B5\?3(H Y'QGY?_"<>!0^S+7\
M_7O^X?\ J17<=*I2:-I<QC,NFV;F(;8RT"G8/0<<5;:-'C,;(I0C:5(X(],4
M >5^"-!L_$=IXTM;RYNC:2>)+Q9K>&<HLJ_)PV.<'H<$9%;.HW&D:9XZL=*M
MEM-.N+?1F"W%RV(H[8R >7''D ME.O8 <'.*[*TTO3[!V>SL;6V9AAFAA5"?
MK@4^>PL[FXAN+BT@EF@.89)(PS1GU4GD?A0!XCIJZ???#+X=I*8)FCU^&!\D
M$JI>;Y#Z C''IBNRUZWTK0OB-X+$<-I86?EZBQ"JL2;BD9/H,GDUVK:'I#QI
M&VEV31HQ95-NA"DG)(&."35B:RM;GR?/MH9?)8/%OC#>6PZ%<]#[B@#RZ^2Y
M@UOXJ#14V7O]GVKQB 8;>89,D8_B_7-;V@7_ (-UZ+PO=V,EO/?6MN4LX8)?
MGMU:/;('0'@ #!W#&<8Y(SV,6FV,%T]U#96\=Q)]^5(E#M]2!DTVUTK3K&::
M:TL+6WEG.97AA5&D/^T0.?QH \;U*VM?^%6_$N-88=D.NW)C4*,(1Y7(';O7
M3ZOHNGV_C;P1=Z%;00W1>4S/;J!YEKY669R/O#)7!/=O4UM^,?"9U7P;JFD:
M%9Z?;7-^@1G8>4OW@<DJI)Z>E;VF:9:V$0>/3[.TN)%'G?9D !/^\%!/XB@#
MQ]]8TN?1O!MW8W-K9V \2+)':/+NGC4O+O>5V.1DDY&,#<!DUO6>F:7<^+OB
M27L[611!;$9C4A=UL2Q'IGJ3WKT,:-I2[\:;9CS)1,^(%^:0='/'+>_6E_L;
M2]\S_P!FV>Z88E/D+F3O\W'/XT >5Z9=0Q6OPDNKR:-(EMIE>65@%'^BD $F
MO8 0Z@CE2/S%5!I&FBWCMQI]IY,3^9''Y*[4?^\!C /O5ME5U*LH92,$$9!%
M 'D=I=Z7:?#CQY<:C;-=60UR^CEBADV%PTP &X<J,D9/IGK6AI=Y;R_&()/J
M&GW)G\/",K;8\LGSQA!R=Q )Z]CT KT"+1M+@CECATVSC292LBI H#@]00!R
M*6+2=-@\ORM/M(_*C,4>R%1L0]5'' /I0!Y XBC_ &?_ !4D>U8UN[Q5"\ #
M[0< ?I76>)(=4773J7AZ]LI[Z#2T%WI-\/W=S;EG(*M_"V0X]#QFNP&B:2+=
MK<:79"!F#-&+=-I(Z$C&,T3:'I%QY?G:58R>6NQ-]NAV+Z#(X')XH @\+WL.
MH^%-)O+:V>U@FM(GC@<Y,:[1A<]\#OWK6H    & .@%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XF\3Z=X5
MTL7VH2JH>18HD+8+NQ  ^G.2>PK9KB?BNRQ^!GE<A8X[ZS=V/15$Z9)]J .G
MFUO2H+2*ZEU&U6";/E2>:,28Z[3W_"K-K=V]]:QW-I/%<6\@W)+$X96'J".#
M7"PZK$OQ>6>YN(VL+[1Q'IEQN'ENRR$R*K="Q^4\=0!5GX>6KP7'BB2'_D%3
MZO*]D!]TC \PI_LE]W3C(- '2W?B'1;"2>.[U:R@DMT\R99)U4QKD %@3P"2
M!S49\4^'U-D#K>G@WV/LO^DI^^R<#;SSSQQWXKF$6S;XYW&Y8#(OA^,\XR&\
M]\GZX/Y&N(D6PB^ >OR1"W4KJ4NUEP""+L;<'V'3VH ]EO\ 7-*TIPE_J-K:
MMMWXFE"D+G&XYZ#/?I6%K>KZA:^//"5E:W:C3M2-T)XA&IW[(2ZG=UQG!X]*
MYGQ1J^F2:QXPLHYK>PNO[(1999&W2WX,<A18E)V[5R02 22W;&:Q;VXN=1TW
MX81:%J=O%J1TV>.&9R&59!9@$'WSE<]C[C% 'L%OJVFW1N/L^H6LOV8E9_+F
M5O*(ZAL'C'O3;#6M+U266*PU"VN9(<&1(I0Q4'H2!V/8]Z\WU+Q!!J?PHN'T
MNUDMKC3;F(:KIT9#S0^7,IG!SG=G#'<<[AG.>:WM G\,:YXI@UO2M:FU;45L
MS$TB.NV*$G(60*JX.[H#SUXX- '87E_::?&KW=S% KMM4R,!N.,X'J< G\*@
M.N:4+"*^_M&U-I,VR*82J5D;)&%.>3P>!Z&N>\9VDUUJNC?V9K4>F:Y$)WLO
M/0/#<#""2-QUY!4\<C!-<O!XGMI4\*R:EI]CI6HO>WZI>R2M]E@D7<)73Y@&
M\PL=NXX&3UQR =OK7C31-&\-/KK7T$]KG9"8I PE?. H(]^OISGI4LVI6]WJ
M^CFS\1VD<4AE/V1#'(;X;3]TYR-I!.5],&O)I[NW?X5^.H8[H3O%XA:5R<!@
MAN8CO( & 0">@'!]*[7Q#?6%W\1/ %U;7,$J22WH25'!##R".#W&: .Q;6]*
M2]%F^HVJW)<1B(RC<7_N@?WO;K7)WOB=M:\6:EX=TOQ#!ILMK:QF"9#%(9;A
MV;*E6!R%"C*C!^8\CBL87%WHNK1SZ?=VVL^'KS7FBELI1BYL;EICN,;#[RA]
MS8/.WVR:U],O((_BSXN.\.R:=9DQH<L=OF$@#UY'YB@#I].URPF:WL)-6L;C
M4MFUUAD \QU&'VKDG@YR.<=ZFN]<TFPN5MKO4K2"9BH"23*IRW"]3QGMZUX_
M:ZWI,L7P_NK6\L[6RCU!MEC%)O\ L:-'( LCL2Q<GCG /. <9K:T?5_#S6GB
MGPUXO>(7LFJSO+:3DB2[1G!A,8'+_*$ "\C:/:@#N!XOT@^+7\."[A^VI")'
M#2 88MA4'JQY.!TX]:O/KNDQWZV+ZE:+=,_EB$S*&+]=N,_>QVZUQOVN.T^+
M]W&\D=M<7/A^!+:.5AEG\V3Y1ZXR,XKFX98;_P" 5SI<^?[;@+P26[']^+[S
MB5XZ[RQ#9]Z /4KWQ)H>FR31WVL6%L\*AI5EN%4H"< D$\9)J6RUO2M1:=;'
M4[.Z:#_7"&=7,?\ O8/'XUPMK9VES\7WM=3CM+FX_P"$9A69)%5@\GG/O.#U
M_P #3_$"7_A;QHUSI$#&+Q-$+,[%RL%ZHQ'*1_=V;L_]<Z ._L[VUU"V6YLK
MF&Y@;.V6%PZG'!P1Q54Z]I"WXL3J=H+HR>4(3,NXOC.S&?O8YQUJS864.FZ?
M;6-LNV"WB6*,'^ZHP*\6U/7-*NM"L9[6YMM/@A\41RO8;]TL1%R=\LS,25R<
MM@8 # 9- 'KEUXFT*RFEBNM9L(9(G2.1)+A 49L[01G@G!P/8TJ>)="DN8[:
M/6;!YY9C!'&MPA9I  2@&>2 1Q[BN/T:WTK4?BUXK$L-I<;K*Q95=%;/#DG!
M_P" '\J@\&QZ2&\<W<EG!<O;:W<RA416D 6)<;>X/+@8[DT =U;:]I%Y>"TM
MM3M)K@AB(TF4LP4X; SS@]<=*@F\6>';==TVNZ;&OG?9\M=(!YF 2G7J 1QV
MR*\LT_6=+EU+X;W5O?64-FC3*EG ^Y;-6MV"QNY)8OG"\XR1P*L>5I[>#OBN
M^RV+_;+P;L+GB%"H_P"^LX]Z /6KO4+.P5&N[F*'S#A-[ %SC. ._'/%16^M
M:5>6TES;:G9S01+ODDCG5E1?4D'@<&O.[S5[+2-<\%:Q<:I:(&T>2)H[N<1(
M5*QDNKM\N[.!CN,^E9UU%!HW@$ZE8ZC;7MJ?$"ZAJ3Z4ZSK!"TI<JIP=P0E&
MY'J<4 >HP>(-&N8+F>'5;-XK4XG<3KB+TW<_+^-,B\3:#/>16D6LV#W,T0GC
MB6X4L\9&X,!GICGZ<UQ%P?"^IV_B'6M-U9]5N9-$EAN;@2(T2( 2BN%4 /UQ
MGG .>U95Q%IQ\&?"L,EMAKRS# A?F!@;?GUR<9]Z /4M,UK2]:CEDTO4;6]2
M)MDC6\RR!6]#@\4VVU_1[RYDMK;5+.:>-/,:-)E)"?WL9Z>_2O-=?6XD\1?$
M>VTC_C]ET6V*QPGYW(60-@#G=M./7D5JZ)?^$O%.J:#J5IK$]_J%K&Y@M@T:
MM:HR8<2JJKA> .>,XQUH Z\>*O#S26T:ZYIQ>Z<QVZBY0F5@=I"\\\\<=^*@
M_P"$OT@^+6\."[A%ZD(E<-(!ABP"H/5CR<#IQZUY0PL(_@1J<\8MUD&KLPD7
M .1>C!S_ +OZ5W(O;6U^-=P)[B.,W.A0) &;!E/GOPOJ>>U '6PZWI5Q>"SA
MU&UDN6+!8EE!9MOWL#OCOZ53\6^(H/"WAB_U:5HO,@A=H8Y'"^;(%)51ZYQV
MYKAO"]Q>:1J7AJR@N[;7?#E[YATRXQMNK+$;':^.&4+E2>H)Y["NH^)TB1_#
M/Q$7=5!LI%&3C)(P!0 FBZA. FLW7BJUN](FMT5XW6(>5<G'"NF.""1M.3G'
M-;R:YI,FG2:@FIV9LHR5DG\Y=B$=0QS@$>AKA]5OOLOB?P!?W$B_V*898C-G
M]VEP\0$98].1N4'W/K69K]NOV_XE7MNR?V9)HFV8Y&QKL1/T[;@NW/U% 'IE
MCK6EZG/+!8:C:W,L*JTB0RJS(&&5) /&1TK.D\7:3_PE3>&UO85OQ;^:VYQ\
MK%@%0#^)CR<#T'K2>#+2PB\*:1<6D%NK2V$ :6)1EP$!Y(Z\D_F:PWO+:R^-
MTJW,\<)N-!A2$.V#(WVA^%]3S0 _P;XQBFTOR_$.M68U"74KFU@65DB:4)*4
M4*O&>@%=7J.LZ9I"!M1O[:U4@D&:0+P.IY[#/6O&;DV0^"/BFY0P>;_;$S>8
M,9R+L%3GZ=/:NFO]9L-.^(VN6OB#6'TRUO[2W:QF<QB&:)58.F]U(!#,QQD9
MW4 >EQRQS1)+%(KQNH974Y# ]"#Z5DS>+?#EOL\[7M-CWRF!=UT@S(,97KU&
M1D=LBF^$K'3].\*V-GI8N/[/C1A;_:"2S(6)!YYP0<CV(KSK3K309_"WQ(CO
MH;0N-5OE8,J[QP/+QWSNSMQWZ<T >IW^L:;I>W[??V]MN4LHED"DJ.I^@R,G
MM3)=>T>![5)M5LHVNP&M@UPH,P/0IS\W7M7F^G7L6G7NDZ1JDD6GZU'X:A2X
MO+EMTDJDX\F-2=I8,#DX8GI@]HM!TYM?^!VASZ3(DFL:.BW5H5.2L\9)\L_[
MRY4C_:% 'J%SK.EV<\D-UJ-I!+''YKI+,JE4Z;B">![U7B\3:%/>1V<6LV#W
M,D(G2);A2S1E=VX#/3;S].:Y(W<>O?#[Q'XHN(#"FI:;(((Y@,QP)$VT'ZNT
MC?1AZ5B7,.G'PW\*@R6V&N;8$$+R#;MN_-L9]Z /3],UK2]:ADFTO4;6]CB;
M8[V\JN%;T)!XIEMK^CWMQ);VVJ6<TT2>8Z),I(3^]UZ>_2O,M>%P^N?$VVTG
MYKM]+LV$4)^9\*^\ #J=O'XBMK1+[PEXHUG0]4LM9GU"_MHI/*@#(IMHV3#B
M5%487@#YN,XQ0!UJ^*O#SRVL2:YIS27;%+=1<H3*02I"\\\@CCOQ4"^+](?Q
M9)X<6[A^VQ0B1P9 /F8X"#U;J2!TX]:\H06$7P%DN(_LZ2#6-PD7 .1?<'/^
M[^E=S#>6UK\:K])YXXWNM&ME@5FP93YLF=H[_A0!W%Q<0VL#SW$T<,*#+R2,
M%51ZDGI56VUK2[V&XEMM0M98[;_7LLH/E<9^;^[QSSVKE?B3/+9Q>';V3/\
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M_C$.FS^)EFTU&.T"V-RA7:#T4X9A['-=G>/ /C;I6&C$CZ).#@C)_>IC] :
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MT=S:SQSP2#<DL3!E8>H(X(J6F111P0I%$@2-%"JJC  '  I] !1110 4444
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M42V-I<1QQS6L$B1G**\8(4^P/2J=OXDT6Z>X2+5+4M;QB64-(%V(>CG/\/\
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M[$XS6B"& (((/((H @^P694*;2#:.0/+''Z4LME:32I++:PR2("JN\8)4'J
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M3^(='U#QM\/9K34;>>%8;M&E1P45C F%+= W^SU&1QR*]01$C0(B*J 8"J,
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MV\+2+(88RZ?=8J,CZ&I* .8\2W/A+5X[OP]KVH6@81AY;:2Y\IPIZ,.033O
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M(]A70:AK>D:1\0-8_P"$DO+FVT[5;>W?3[N*:00RJJ%7CRAQG)) _P!H^HR
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MQ7/G6Y>6:Y"G<,N/LZA<>OS9 ]\T >O*P90RD%2,@CO2UD>%)DG\(:-(DBR
MV4/S YYV ']:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBN5^(^H7^D> ]5U/3+V2TN[2+S(W1$;G<."&!&*
M .JHQ7F^K:WK?AO4/"#1ZO-J:ZQ<QVUQ97,46_:R@F5#&BD;>^<CD=*[K4-8
MLM+VBZD?>REQ'%"\KE1U;:@)P,C)QCD4 7J*RD\1Z3-86E[;W@N(+P$VYMT:
M4R8ZX503QWXX[UEZKX[TO3TT=X1/<+J=U]GB>.WD(7!(<G"YR-K#;U)[8!H
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M+GC/6JWBVZU/P5HC>(;;4+J_M[1T-[:76QO-B+!69"%!5QG/]W@\4 =J%4=
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MA<6BJT\2*SLF<XX4$D\'@=,<UK6-]:ZG807UE.D]K.@DBE0Y#*>AH G(##!
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MZ@$8.*R/&&IQW%QX[TOR9+*Y&G?NTM[8M)J/[@X=GVG*+G;@8Q@Y/.*]:HH
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MQM):@8$1VCY0.V/3M6K110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS0R-&Z[I-VPJ01D88$9.!Q7/7.I0Z;\68M3NXKJ.TO\ 0T@MG%M(Q>03,Q3
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M5?*)7_6@6P0[?[WS?+QGGZT =PWBC1UU/3].^UEKG4(_-M%6%V69,9)5@-N
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M4D#AX5(W!BH&2",G(R.#Z57LO'6@:A>:=;6]S,3J,>^TD:VD6*4[=VT.1MW
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M7QGH=UI>HZ@;I[>#36*W@NH7A> XS\R, W((QQSGBI8/%&FSW5U:?Z5'=VT
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M))/-B !W(54AN".!GUH Z.BH+.[AOK&"\@+&&>-98RRE2589'!Y'!Z&N#O\
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MK<71@EMW5VA)P'48^89XP.0>,52T[X@>&]5,9M+UVB>&6<3/!(D82,X?+D
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MG[C,6_<X[#SE\P?[IKT8D $GH*R- T231[>0W6HSZE?3;?/O)U56<*,* %
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MRY0HA< J#@'O7HU% !7E*F:U\/?$K2Y;*]%U<W5[-"!:N5D22%53:P&&)/&
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MR[0$ 4>@'IDGFKHNE:CJ'P#GTFSMIHM359B+>:-HF8BX:0+@X/S+Q^->LT4
M>=Z-J.B:_/#>P>&M3^WV<$IF_M"*53:Y0AHU9\AF8X7"]LD],57\(V]WI7B'
M2[31;V\O?#L\$C26=_"?-THA054.P! )^78>< D9QFO3** ,[Q P7PYJ1PS9
MM9 %52Q)*D  #DFO-;\2K\&?"MI]ENVNHI+ 20+;N9$\MT+Y4#(P :];HH ;
M'(LL:R(<JPR#3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW&<&N/BL[Z/X&Z!IS:9J/VZ&[M_,MOL<ID0)<!V)7;G&WG- 'J-]KUI97YL
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MYM1!<P7%N$:2.>/;@-G:01D$?*>A->>M:PW%]X^34]'U*XT^^N[3"QVLH:1
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M=8$A6=3YB[1B8L/F)^8Y). * ._U'Q[HFF:E=Z=+]NDN[1$>6*&RE=@K' 8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***H7^L6UA=6]HRRS7EP&:*WA7<[*N-
MS=@ ,CDD#) ZD4 7Z*I:9JMKJUO)+:NQ\J5H94=2K1R+U5@>AZ?4$$<$5=H
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M4G /./F'7% &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%XY@OCXDT:[\-SK
M_P )-#%,8[:3_53VOR^8)#GY1NV $?Q$>Y'>UCZAH7VG6[36K2Y^S:A;1/;[
MF3>DD3$$JRY!ZJ""",'U'% &-\.+ZUU#0KN=(YX=3>]D;58KA=KI=8&X8'&T
M *%Q_"!WS78USS^&94TO5(K+59K/4M2F$\U_%&NX.-H^53P!M0+CGCG)/-=
MH(4 DD@=3WH 6BBB@ HHHH *\JU'5-0T7XI^*=0T[2_[2D@T6WD:W$WELP#-
M]WY3D^WY5ZK7GEK+%9^-K[Q&4UR26Z@6VD@&B3; B'C:<9SUYY'/2@"W\-M)
MBMO"ESJ=IJ<5U-KES)J+SQ1XC1Y.JJI/\.,8/.0:RK'QEK1^%FB:S<SJUU>Z
M@MM>7OE*!;Q-<,ADVXVC"@ 9&.03FK&D/;>'M1U&728M?AL;V0SFPDT69XH9
M".63 ! )Y(Z>F*Y_4+FU\.^!+#01/XAMK.&[\Q]2?2' A7<TOSJRE7!?Y<8
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MK<I,8!O8K)Y@!YQC<?3I6Q;>&3:^+KS7XM1F4WL4275LJ+LD:,$*V3E@,,>
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MEOF%UK3JU]=B(9(4 *J+G"@!0!G/?J3FNGM8I(;6**:42R(H5G"[=V.^,G%
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MW3 &,Y_&@#J;"Y-YIUK=%0IFB20@=L@'^M6*JZ=:M8Z;;6CR^:8(EC\S;MW
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MJ6WBZRNO[<"6MZ&T9PEPIB&YCMW?(,\\'OBM'1-6@U[0[+5K5)$@O(5FC60
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M&F2ZG>Z9JMMI\<9D-P]N#\H&<E 2Z_\  E&.^*YOXG.S>(/ MI-_R#YM:0S
M_=9UP8P?J2>/:O0YH8[B"2&9 \4BE'1AD,",$&@!P(8 CD'D4M<?!J-SKOC'
M7-!M[Z>PM=&@MUS;[=\DDJLVXE@>% 4 =R3G/%<NWB_Q%<>';$_;E@U&T\3I
MHMY*L"E+E1*%+;3TR",[2._3L >L45Y_%_;W_"?7_AIO$MXUI)IL=^LY@A\Z
M)C(R%4.S: < \J3Z>M8Z>*/$DO@GP_=)JBK?/KZZ7/,T"$3H)V3+#''"C.W'
M?I0!ZQ17GD.H>(M \<7&AW>LKJ5K>Z9+>VD]Y$D?V:5" 0Q0 >7R#[?SCTK7
MM53Q3X8LFU.XO;?5+&<W,TD2K#)+&B-YD'RJVW+'&1M((QGK0!Z/17D-SK?B
MA?!7BC7!XBF$^B:I<Q01BWB"RI'(%VR?+R,?W=O7)SVZK5-4U+1_&^AW%QJ$
MO]@:JIM3 43;#=$9CRVW=A@&&,]?RH [2J1U$C6QIOV*[P;<S_:_+_<#YMNS
M=G[_ 'QCI5+PU/=7UI<ZC/=236]W.[V:,J@1P X0@@ D,!OYSPP':LIM1U/_
M (6LVC_;W_L^31&NDA\M/W<OG*FX'&3QV.1R: .OHKQ]=?\ $\?P[/BF3Q!*
M]Q9:DT1@%O$(YX_M7E$/\N<X/&TKC'KS7K=RDCVLJQ3&&0J=LB@$J?7!X_.@
M"6BO)](\0^(K?X;6OC.^UM[J2:V6'[(UO&L8EDG"+*2,'(SR,@'VKIH$\76N
MNEX3+/ILEHX:/4)(=ZW &4*>6!\IZ$'IU% '945YWX4\23:Q?_8+C5M0LM9A
ML7%YIE_ BN)LIB:/Y<,@PXX)&&!Q7/#Q!XO@^&&F^/&U\SO#MDN; VT8CGC,
MNQLD#(;G.00 !C'<@'LM%<%=:KKGB"[\16VC2W=O+ITPMK4PF$+YOEJ^Z0/D
MD%FQ@<8'KTGL=6U?5_$,7A^^N/[/N;;2H[N]-F5)DF=BN%+ X0;2?7+ 9X.0
M#M'D2, R.J@D*"QQDG@"G5YAXAL]=BD\#VVK:X[WW]K&*:6S541_DD*N5*XW
M[0O;')P*[GQ%JW_".>%=1U5E:<V5J\H#<&0JO&<>IH UJQM6\10Z9<M:16=U
M?WJ6YNFMK0*7$0.-WS,H.3P #DX.!Q7*ZKK&L^']!T#Q&=3DO$N9K:._MGC0
M1NDV!F/ RI4D8Y.1USUIUM93GXVWY_M.[ &CP2[<1X*^?)^[^Y]W_P >]Z .
MYL+V/4=.MKV))4CN(UD594*. 1G!4\@^U6*P_%=U=6FDQ/:ZA!8;KJ))9I%+
M.8RPW+$N&S(1PHP>37()XAUH6?C^W2]NHFT:!+BQDN8HS*@: R;6&,$97C(S
M@\\T >ET5YO::IKUG?\ @>[N-:ENHM;C$5U:M#&L8)@\P,I W!LCG)(.>@'%
M3V_B#4M#UCQ/I.L:A/>3Q0K=Z42D:-+$_P BHNU0"XE(7)SG<O% 'H-%5-,@
MNK72[:&^NVN[M(P)IV55\Q\<G"@ #/M5N@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&\4^'T\4^'[G1IKJ6VM[
ME=LK1*"Q&0<#.0.GI6S5'5]7M-$T]KV\9A&&6-%1=SR.Q"JBCNQ)  H ET^U
M>RT^"U><SF% @D90"P P,XXS7'-\,X/[,;34U[4H[)+\7]K$!&1;R>9YG!*Y
M8;B<!LCGH:WH?$R-JMKIMWI6HV-U=!C")T1E8*N3\Z.R@^Q.>>F.:?X>\10>
M(EU(PVUQ;G3[U[*59PH)=%4DC:2,?-ZT 0Z?X9^P>*+W71J$\LEW!'!)$ZKM
MVQYVG(&<\G)[YJ*V\(K97VMW%KJ=W''JKM,]N0A2.5E"LXXR3A1P3CVKI**
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MDTZ]&<LIS]!@8P!@ "K=KX;BM?%5WX@%]=/<74"6\D3;/+V*25QA<YR3W[T
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MM#U&Y%KLCB&Y8T1@K_)RO; QU).>WH&H>&XM1\2Z7KCWMU'/IJR+#$FSRR)
M ^[*DG( [BLX> [7^R->TTZI?F'6YI)[HGRMP:0 -M^3@$ #O0!T>G7#7FF6
MERX ::%)"!T!*@_UJS5;3[,:?IUO9B:2801K&)),;F &!G  S^%6: "BBB@
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M^$O@RXTW5KRVENKNQBD^8.I5W (P1D#V!&>];_B&VU+P<FF:T=?U6^TRWO\
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MPU"YO(/M+KMN@1-;D 9B<'G*^_8CD]:PM+L#)\7?$Y%]>H5L;1E*S9"[O-X
M.1@=0,8S]: /0:*\K\,/K-W\/CXFO/%]S!<QP7D>^Z"&W0B5U61UVY)7''X#
M&.#I:-?WZ_$"+24N-3CL;K1&N?\ 3'W.95D51*H<L4R&/RD#_=% 'H5%>-6^
MIZ]'\-;#Q3)XAOY;V#4_*,;%1'+&;LQ%7 'S9!_# P!6[XKUVZT?7;]=9DU*
MQTJ98UT_5K-F,%LVT;EF5>F6[L#P1C&,T =GJNMII][:Z?# ;G4+M9'@@#A,
MJ@!8ECT'*CZD>Y$^C:B^K:3!>R6-U8R29W6UTFV2,@D$$?AD'N"#7%ZS8)<_
M&#06%W=*LNFW3@QS$ 8:/[OH#W]:@$_B;Q;IVJWNBW:6E[;ZC-;VKM>LD<0B
MDV[9(@A#;@,G=D_-Q@<4 >DT5YQ-'K6M?$"]T9O$=]9VQT>"[ LF3$<C2,#L
M8K]WY>XR?7'%=9XLN)K/PK?2PZI'ILJH MY*F_R\L!D*.K'.  .I'% &W17!
M:)J>HQ>/M4TJ(7WV3^R8KRWMK^7>XD+NN0Q8E0V!P3QZ#I6'::KK6J:3X6DL
M]8OTUVZOO)UB",J3#'\_FDQN&6/85 !VC.0.<T >LT5YW+/K_BJ3Q)%I5U]F
MN-/NVL[-Q>M$(G1%.YT"$.&8G.[(QP .20OKUYX]TS2;S7)H4N- :>Z2Q9?+
M\X21JQC8KD DGDY(!.,=@#T">>*VA:::18XT&69C@"I*\7U6YOM1^&=Q%?:C
M=SRZ=XC%BLQDVO*B72JI?&-Q /Y@'K73>+-3NO#NI*=0&KMX=^QA1?V,K,]I
M/N;=),HY9<;,$@@8/!S0!Z%1532I4GTBRFCN5ND>!&6X4Y$H*CYA]>OXU;H
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M=M=FUFROKS3[VYB6&Z>V,9%P%^Z65U8;AT!&#CBH;GP1ILUIH]K!/=VD&DW
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M.)]6.FP*99HT$DY!^6%6SMR?4X.!Z DXXRNF7=W>13M=Z?)9-'.\:*\BOYB
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MSABV%^7D9)^]DCL17;5AS^(U@\96GAUK*7=<VLERMR679A"H( SG/S#KC\:
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MX4:*%$:5Y648+OC<WN< #\A3Z* ,6V\,VUMXCU#6Q=73SW\20S1.4\O8N=H
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MTW\__6JY?>$8=0&HQ7&IZ@UIJ047=MF/8^$5#CY,KN"C."/;%=%2,2JDA2Q
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MUU"D_P F9 %D*@@X+ #)Z^F*DOO!NGZCH.GZ3/<7H73I(Y;2X24+-$T8PI#
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M#C:JXVX/8C P?:LW3/!-GIEA<VHU/5KMIX3;B>\NO.DBB/5$R,*#QVR<#T&
M#C;2]U/2OA]HOB.37=0N+S5(;*TD%S./(A\QU#2@;3M?:2-W/7)!K6U)]?\
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MR.??&16,^M:RWP<M+\ZO=B]M]3%JUPK@/,@N_*^<XR?E],9[UZ+_ ,(W;_\
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M!I5L!J;V/FWL,9$*%I;@%N88\$$,P&-PZ#)XZC=M[>&TMHK>WC6*&) D<:#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY=GF?,%.X#)Z9(XSTK>U2RCM+MM%T^^OI8]/T58H;"WF: 6H&0LTDJL,DA0
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M(!(R5!"GN*MW_ANTU'7;'6)9[I;NP5UMC'( L8< /\N,'( ZYK9HH *Y>^\
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MY0OS?*H8D@#C/- &;ID+Z1\6I],M[N\DL[K1?MDD=Q<O,/.$VS>-Q.W(.,#
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MVZ<*)9GE*CLH+$D*.P' H GU:".ZT>\@E#&-X7#!6*DC'J.:\IT*\?2_A[X
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M>?-+:HS  Q/W )'!_(]:V;G2K;6?B_JEK>&8VYT*#='',T>_]])U*D'\,XH
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M6GS+/:Q"[F'E.IRI!W9X/3TK9O+*"_T^XL;E/,M[B)H94)/S(PP1GKT-6**
M,%?!VCJ((V2ZEMK=E>*UENY9(4*\K\C,0<<8!X&!@<59'AS3!KD^LB.<:A/#
MY$DHN9!F,<A<;L#!)(P.#6K10!S/_"O_  V-.L[%+*9(;*=KBV*7DRO"[9W%
M7#[AG)R,X.:'^'_AA[34+4Z<5M]1<274:7$BB0C'HW&<#.,9P,YQ7344 9&K
M>&=(US1!H^IVOVJS&"JRR,64CHP?.X'WSFJ]OX+T*UT=M+BMI1;M*DS/]ID\
MUI%(*L9-V_((&.>,5OT4 8D_A/2+O3]0LKF"69-155NG>=S)*%^Z-^<@#L!Q
MR?4UL11I#$D2#"(H51G. *?10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!=>8#&2WS94^P&#DCC.S=6EYHGC;5KN\\'3:[IVL&*>"6"&*66WD$:HT;[R
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MH R_B#I2Z'X:TN*TN[Q5?7+= WVF3>(Y'^:,ONR5Y/4^GI6CK&H3:K\1=/\
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M: .QM[>*U@2&%=L:# &2?U/6O,Y)=,A^+^LVFJWQ@LO[-@EBBDNWC02%B"0
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MNBO;&WUGQO:[XPR:3 99&R0&DD.(U/J%"NV#T+*: )?^$)T+_GC>?^#"X_\
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MP<IG+D?>!/7.?6@#KO\ A"="_P">-Y_X,+C_ .+H_P"$)T+_ )XWG_@PN/\
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M?S?M4^LVXFG,K[G$DA+#KP#G&/2M#QO)%\/?#&IZQH2&*\O!#:11LQ:-)"Q
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M9B3M   ZX)Z5FW+WM_IFHZ9X@\*SZE"]Q.(!&T+I-%O;R\[G!1@N.3TP#G/
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MU/":OIPD1&W ?+.FY@NX=&&>?UH R-=BTJ+XV6JZC:)+:RZ&\CQ_9S*&D\[
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MSR.,T 9_Q$L;?0M?T#QMY"&WL[H0:DNWY3%)\JRL.Y1B,'KR/2NBUZQM-?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[N"T:,RLHC:7H0<'('T%:&K>)I++6;'0+&W2\UJ[B,Q0N4BAB7@R.<$@9X
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M5#]AM?[0^W^0GVLQ>3YV/FV9SMSZ9YH XGXP\> C_P!?UK_Z-6CX@?\ (U>
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M-S@YY&WTKT">&.Y@>&4$QN-K ,1D?4<U!I^F6>E6"6-C#Y%K&,)$K'"#T'/
M]A0!S_PZUZ;7_!UL]YD:E9LUE?(3RLT9VMGW/#?C69IO_)<];_[ UO\ ^C#7
M5:7X=TG1;BYN-.LDMY;EB\[(S?O6)SN;)Y/N>>32Q>'M*@UB35X[0+J$B[7N
M-[;W7^Z3GD=..G% &G1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;2+-[*W.8;=HAY<9ZY"] >3^=6KS2-.U'3CI]]907-IQ^YF0.O'3KW]ZNT4
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M1H^BW%_,OFM!'D(@P97Z*JCU9B ![B@">RL;73;..SL;>*WMHAA(HE"JO.>
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M(/<8Z5)?>+]7\/WGA[^UX+*YL=9GCM1+:J\;P2N,KE6+;E]3D8]* .YHHHH
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M5^(&^YNX=DEC_P >]PT><P=]IYZ5+XUCMK'X1>(])ANWNFL;8QR2NVYMS-N
M9N[X()^H/>NM;PCX;:>2=M TPRR'+R&T3<Q]SCFI?^$:T+^SVT_^QM/^Q,YD
M:W^S)Y98]RN,9X'/M0!0N-<L?#O@6#4=0E1(8[),*3S(VP811W)/ %8OPOL_
M^$3^'FAZ;K4\5G?73.T=O/($8L[%@B@\EL$9 Y!S74VOAK0K&:.:TT73H)8_
MN/%:HK+]"!Q3-;\/VFNR6!NH('^R7"SI(\8:1"K!@$/\.2HR?3CW !KT444
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M-5@$.H65O=1*VY5FC#A3ZC/0^]16>A:5I]P;FUT^WBN&7:9A&-Y'INZX]LT
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MOA3P[/<M<S:%ILD[##2O:H6(]SC-2P>']&M;::VM])LHH)V#RQ1P*JR$="P
MYZ#K0!YS=:%??#/5=*NO#.IS3:%J&H16LNC7#^8J^8?O0L>1CDX_$DBMKXRD
M#X<763C_ $JU_P#1R5U=IX<T6PNDNK32K.&= 0CQP@% >NW^[GVJ;4='TS6(
MEBU/3[6]C4Y5+B%9 #ZX(H @\2G'A76"?^?*;_T UY!:6CZ?X.\$:YK$DVI^
M%H;>(7EG)C9:.?N3X4#>JG@AMV,YKVF;3;&XL38S6<$EH1M,#Q@ICTV],4R#
M1M,M=.?3[?3K6*R=2K6R0J(V!Z@J!C!H XOXJ2QRZ!X?ECD5XWUVR974Y# L
M2"#W%5[@C0OCNE_J#".SUC2OLEK.YPHF1PQCSV) R/7-=DWA3PZ]K%:OH6FM
M;Q-NCB-JA1#Z@8P#5R[TO3[^P-C>65O<6A 'D2Q!DXZ<'B@"6>ZAMY(8Y'Q)
M,VR-!R6/? ] .2>U</\ $X@3^"LG_F9K3^3UU^G:)I>D;CI]A;VQ8;2T<8!(
M],]<>U%_HFE:K)%)J.FVEV\1S&T\*N4/J,CB@#!^*'_),?$7_7F]0V&D6=CH
M>AZU<:I>QPV$"7#K+=.\; PE<;2<?QY&/2NHO=+T_4K06E]8V]S;#'[F:(.G
M'3@\513PCX;C,930-+4QD,F+1/E(Z$<<8H YEVW?'RV/0GPRQP>H_P!(%5/&
MQ7Q%\0/"6BZ:1-<:9?#4KYTY%M&F,!SV+'@#K7:W/AC0;V\-Y=:+I\]T>LTM
MLC.?^!$9JY9:=8Z;"8;"SM[6(G)2")44GUP!0!9HHHH X#7/".D>,=7O-1TG
M4)](\2Z;+]G>]M'PV0H*B1<_,I!'IQQG Q6I\/-;U37?"WG:P(FO;>YFM7GA
M&([CRV*^8OL<=N,@].E:]UX:T2]F>>YTJSDFD/SR-$-S?4]2/8U?BM;>WM5M
M88(X[=%V+$B!55?0 < 4 <-\,B#>>-L'_F9;K^25!X'A?1?B)XSTN]^2>^NE
MU&U+?\MH6SG;Z[3@'TKMK#1-*TJ6633]-M+224YD:"%4+GU.!S4E_I=AJBQK
M?6<%QY9W1F1 2A]5/4'Z4 </XLMVUOXI^#[2S^=]*,U]>NO_ "Q0A0@/H6((
M ]LU#\'R-*TG5/#%XPCU73M0F,L3\,Z,<K*/53GK7?V.FV.F1-'8VD-LCMN<
M1(%W-ZG'4^YJOJ7A_1]7FCFU'3+6YFB&(Y9(@74>@;J!0!#KUW#)H>M6Z.&D
MALI#)CHF4. 3ZXYQZ8]17DOA&34_ OAO1_%H\S4M O;"&/48]NZ:Q"Y >/N8
MQDDKVR37LO\ 9&F_V<=._L^U^Q$$&W\I?+.>N5QBHTT'1XM,?3(]*LEL'^]:
MK HB/U7&* +-C?VFIV,-[8W$=Q:S*'CEC;*L*L51TW1=+T:-X],TZTLD<Y9;
M:%8P3[@ 5>H YSQ_;37GP]\06\"-)*]A-M11DL=I.![U)X4U*SD\!:/?BYB%
MJNGQ,TI<!5 0;LGMC!SZ8K?K&'A'PZ+DW T2P$A?S"1 N"_7=C&,^_6@# 1&
MB^'6A>8I1GO-/?:PP1NNXF (['!KGO&VG7?@-M7UW1X'ET'5H9(]5LHQ_J)6
M4J+A!V!) 8?C]/3K[3+#4T1+^RM[I8VW(L\8<*WJ,]#4[V\,ELUM)$C0,A1H
MV4%2N,8(],4 >>^/R!;> ,G_ )F&R_\ 06K=^)7'PT\1_P#7A+_*MF]T'2-2
M,)O]+L[HP8\HSP*_EXZ;<CBI;S3+#4;/['>V5O<VW \F:,.G'3@\4 5?#'/A
M/1O^O&#_ - %:M06EG:V%LEM9V\5O @PL<2!54>P' J>@ K@;C2KWQC;Z[.B
MV+Z?J<9L8&F+;EAC++O7 QRY9P>XV^E=W-#'<0O#-&LD;@JR,,AAZ$5#8Z=8
MZ9:BUL+."UMP<B*",(H_ <4 <M\,M9GU+PFMC?L/[4T>5M.O%SD[XS@-[Y7!
MSW.:YBVTR2#Q[K?@B2W9](U2Y36NGRB$Y\U/H95C&/1FKTFQT'2-,N9;FPTN
MRM9YO]9)! J,_?D@9-7/L\/VG[3Y2>?L\OS,?-MSG&?3- 'F?PVBO?M;>'KY
M)"GA.>:!)'_Y:ES^Y8?2(N/HXKJ-=:[U3Q!8Z7I_V=A8[;^Z$Y.W.2L*G'^T
M&?ZQCUKHX[>&&6:2.)$>9@\K*,%V "@GUX 'X5!#I.G6U_-?P6%M%>3?ZVX2
M)1(_^\P&3^- '!>%FN?"WQ*U;0+_ ,B.#7%.J68A)V"4<3(,\Y. V/05FW6F
M:KJWQ"^(5OHFK3:?J'V.Q\IH]N';RV^5B1D ],J01G->E76@Z/?7T=]=Z793
MW<>/+GE@5G3'3#$9%+;Z#I%I?O?VVEV<-Y)]^XC@59&^K 9- '/_  YO=(N/
M"$=OIEBNG26C-#>V))+P3C[X8DY.3SD]16;\(+F"T^#ND7-S-'#!&L[/)(P5
M5 FDY)/2NQD\/Z-+=SW<FE637-P-LTQ@7?(,8PQQD\>M5H?"'AJWVB'P]I48
M4[@%LXQ@^O3K0!RGPOMY;K4/%7B41/%8ZSJ'F60=2IDB3($F#V;/Z5Z+0
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M[6UCN 98O,DN2^[.P$@;5 &>I)/;%;.@S:O)!=IK*V_VB&Y:-&MT*H\>U2K
M$D\YYY.#D=J +)T;2VDAD;3;,R0#$+&!<QC_ &3CC\*M2PQ3J%EC210RN R@
M@,""#]00"/I3Z\^\6:YXM\-Z.NI&[TO]]J"6\=N;)SLC>0JI+>;RVW!/ YH
M[J\LK34+9K:]M8;F!OO131AU/U!XJO9Z'I.G3F>RTRSMYB-IDB@56QZ9 SBL
M/4Y_%&DZ5K-Y+>Z=.EM8M<6TBV;)AT#%E=?,.0<+@@CO2Z1K&K:A\-[?79)[
M9;^>P%X-L!\M24W!=N[)'XT =55&]T72]2???:;:7+8 W30JYXSCDCW/YUE^
M!=7O]?\ !NFZOJ+0&XO(A*5@C**N>PR2?UJAI/C4ZA\0=2\/2P>7;)!YEA.?
M^7@QN4FQ_NOQC_9)H Z0:/IBZ<-/&G6@LATMO(7R_P#OG&*$T?3([%K%-.M%
MLV^];K HC/\ P'&*JW\6O3:F%T^[LK6R6$%FFMFF9Y"3P,.N  !ZYS7+>"M<
M\6>*/"NE:^USIFVXN"L]JMFZGRUF,;%7,AP<+NY!]* .M_X1W0_)CA_L;3O*
MC;>B?94VJWJ!C@U;N[&SO[;[->6L%Q!P?*FC#KQTX/%6*R=1CUV;48DTVZL[
M6T6(F1Y[8S,[D\!0'7  SG.>HH >WAS0WABA?1M.:*+_ %:&U0A/H,<58NM+
MT^^@C@O+"UN(8B#''-"KJA P" 1@<5Q7@_7/%OB;P]:ZQ]JTL WIBFMELW!,
M23;'*OYO#;02.#SQ5_P[KNL:CXZ\3:->36K6FD&W$1C@*O)YL9?YB6(XQV'-
M &[-X9T"XE,LVAZ;+(>KO:1L3^)%36VBZ59P2P6NF64$,V/-CB@55?'3( Y_
M&N;TG7-9O?B%K^@S7%H+/3H()(F2W(D8RJ3R=V.,>G-4=%\9ZLV@^,-6U-;>
MX70KRZMHH;:$QF40J""26;DY_"@#KK;P]HMG>"\MM(L(;D9Q-';HKC/7! SS
M6E7&6.I>(;W1M*UBQU/3=1M[N6W^T1Q6Q 2-W4/Y;!R<J"<[L]#TQBNSH I7
M>CZ7J$R37NFV=S+']QYH%=E^A(XHN]&TO4&C:]TVSN6B&(S- KE/ID<5=KCC
MXU*?$J/PV\&VQF@=(;D_QW2!7>,?2-U/UR* -^Y\.Z'>2B6ZT;3YY  H>6U1
MC@=!DBEM] T:T29+;2;"%)@%E6.V10X]&P.?QK#^(FMZQX:\,/K6D_9V6UD0
MW230F0^46 9EPPY&<_3-5/$OB?4]%\0^%EBN[%M&U><6TDC0DNKE<H5.[&&/
M'3CWH ZVRTO3]-C:.QL;6UC?[RP0J@;Z@"JW_"-:#]G^S_V)IOD[MWE_9(]N
M?7&,9J&XN]0;Q;:V%K/ +1;9KB[5H2SCY@L8#;AC=\_8_<-9GC_Q?+X0TJWN
MK>U-U(9E>9%&2ELK+YK_ (!E'U84 ;,'AG0;:>.>#1--BFC(9)([2-64CN"!
MP:L:CI.G:O$L6I6%K>1H=RK<1+(%/J,C@U+YGVJS$MI.@$J!HI=NY2#R#C(R
M*\RL?&_BJ3X8MXTDDTF7R&D:6R^S/'N1)"AVR>8<-@9&5/I0!Z58Z98:9;FW
ML+*WM822QC@B5%)/4X ZT6FF6%@TC6=E;6S2'+F&)4+GU.!S7)>,_%NH:7\-
ME\5Z.(4<Q6\PANHB^5E9!@X88(W_ *58U_4?%?AO2)=75M.U>WM4,MU;);O;
MRF,<LR-O89 R<$=NM '5/:V\C2-)!$S2H$D+("749(!]0,GCW-9R>%O#T3AX
M]!TM&!R"MG&"#^56=(U2UUO1[35+)R]M=1++&2,'!&<'T/8U=H AN+2VN[=K
M>YMXIH&&#'*@92/H>*S?^$2\-XQ_PC^E8_Z\H_\ "L;QGXU/A;4='B$'F6TU
MPO\ :$W:V@8[%8^F7(_!6KHM;UBS\/Z)>:M?N4M;6(R.1R3CH![DX ]S0 L^
MB:3=7*7-QIEE-.F LLENC,N.F"1D4^ZTO3[Z:*:\L;:XEAYB>:%79/\ =)''
M0=*Q=(?Q)J^F0ZE<7=MISW""6*S6W\T1*1E1(Q8%FQC.W;Z>]9GB3Q!XCT'X
M;W^MS)91:M9-)OC,3-%(HFVJ1\P(!3!Z]Z .QMK*TLC,;6UA@,\AFE,487S'
M/5FQU)QU-3UP>I>*=<\.:GX;746L;^RUFX2T/D6[0RPR./E89=@R^O3%6O$^
MNZSIWC+PUI%A/:);ZNUPCM-;EVC\N,.",.,YH [*J-MHVEV5RUS::;9P3O\
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M=6M;K3XK2PMFFMX9;5I&EV1[CN82# +9'3M0!M+X<T-+9K9=&TY;=F#-$+5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY,EJH5RP#% =V1D9 -03>(;C4/'U[X9BU./2VM+:*:(&-6DNR^22N[C:N "
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M!"\'D/%&T6 /+*@K@=.*X;P_=^(M=\#:9K"Z^L6HWT DCB>VC\II,$[>F<$
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MT-[9S3R2_9(@P9,8 XQ@YI/%FI^)?#FAZ:_]JH]U/J\5FTHMTVO#(QP=N.&
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M]82^O48Q?/9744*J2FS.'4Y!8,#G& 01C% &^$01B,*H0#;MQQCTQ2@!5"@
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M<X)('7O0!W=%-3=Y:[\;\#=CUIU !1110 4444 %%%% !1110 4444 %%%%
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MFJ0WMFU[;X\B."Z#O,[H4"!=QR26'_ZLUW+1H^-Z*V/49IH@B!!$2 CH0HH
MY?6[^Q\37L_@^UN;>4R1$ZEM=6,,)X* ?WVZ?[(R>NW.#X#UU/#NL7?P]U:^
MB>?3\'39W< SVQY5#_MKTQZ=.F:]($4:MN5%#>H'-(88BVXQH6ZYVB@#R[PS
M8Z3X@\=^/[6YN'ECDNH%,4%X\8D7RL,"$8;AD$'/N*L?%2'3-*\*>'].B\FS
MM8]8LUCBC;R]B!CDC&",#N*])6*-#E8T4^H4"E:.-SET5C[C- 'FEI]F\!>/
MII-2D672]>_X\M6N7\R2WD YMWE8D[#C*Y/MSUJ'5[C1+GXY6PU&[M/LX\/$
M9><*N_S\@9R.<9./2O43&A4*44J.@(XIOD0_\\H_^^10!R-KK'A[P_8ZX-%D
MCO(K6)]1N4MY?-6,E0-N<GEMC$#V/M7'>(M)T?1Y;7Q5\/\ 4X[?5+FYB3^S
MK.4-#?AG 93$.A ))Z8P> >1[ (HU4J(U /4 =::MK;I<-<+!$)F&&D"#<1[
MGK0!Q7B6S\(^,-2O-!U\0PWUCM:WG,HBF564-NC;V.<CD< D<BG_  QGU1]'
MU&UO]0?4[6SOY+>PU"3EKF%0.<_Q8.1N[X/I7936UO<(4G@BE0G)5T# GUYJ
M155%"J % P !P* *>LV']JZ'J&G;]GVNVD@W?W=ZE<_K7(?#;4X-+\&6VAZO
M+%8ZGI"M;W4$[A"H#':XSU0K@AAQU]*[RH9K2VN61I[>*4H<J70-M^F: /-]
M(MQ<Z_XV\9R,(-,O+9;:SDD^42I''AI.?X2P^4]QS7*Z'IOV3X>^$O%]JKZI
M!I49.H:;)(9D";CF6-&)"2)UX XS7N[*KC#*"/0BD6-$!"HJ@]0!B@"KI>JV
M&M6$5]IMW%=6TJAEDB;(_'T/L>:@\1S16_AK5))I$C06DN6<X ^0UHJB(,(J
MJ/88I657&&4,/0C- 'EOA[4+*+X)^&VDNX%"RV*L3(!@BZCR/PP:'TJ_T_QY
MJ7AVRA9M"\3@7[RH?E@VD"Y7_MH"HSVWBO3_ "(<8\I,?[HIX      X% 'G
M/@^]LA\5?'X2Y@VYL=N'&,+"0<?0\'TK-^&NB:'XE\*ZA'?9O(AJ]R[6_P!K
MD\IAYF5+1AMI'0\CFO51!".D2?\ ?(IRQHARB*N?08H \X\;ZAI^G?$SP!]H
MN[:VB@>]W[Y%18P80%SGH">!780^*M%N]2BL+'4K2\G9&E=;>=7\J-1R[8/
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M5\6?$SPV=/=9K+03-<WMRARBR, $B#="W&2.PZUZ!+#%<1F.:-)(SU5U!!_
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MFO;:9;B"(C!^R2J&BSZD#(/H:M^+[VWNY++PN+Z&"YU23$@8@D0J-S?*>N[
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M*B>15"AW &X@#IDY.*M444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXEP)(RQR50$\].: .WQ17$>'M1U6Y^)?BG2[G59YK#38[5K>%HXA@RH6;)"
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M]#U*TUJXCO;F:TCFE\F$[Q+@-P4P.O&!0!Z,RAE*L 0>H/>A55%"HH51T &
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MGEMQ=VR "8(<"5 P(YZ=QD&L+P]X[O=/^#4?B[6[J34;Z4NL<11(P\GFM&B
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M2^NXUWP+&PEC96./F4X/ ]".:QM;U76?"WCW2YM1U>>7PMJ)-OAHH@+:Y/W
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M='X+I$=V!G#@$ ,.>,BO8Z* .,\'^*H)-'?3-92WTO5]+!@N[8@1QG;TDCZ
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M&TD!N&0XR",C!KA;.V6Q^ WB7S83!+>2W(@$B%7F4OB/;GEACI[5[<0#U%%
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M)\TJ"^[ONW$DYYR3FK'B75K/2[:S74+<36-[<?99]T1D55,;MEA@_+E0#G@
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MT%M-:?V;!'')<0"2/S QW $@C(!H [O0HI$6[<:M+J-NTQ$3R[2T97Y73*J
M0&4_K7/?$B^U'3H?#[Z=J5Q9M>:S;6,QBVG=%(6W<,#@\#FMGPU<Z5BYT_0[
M?986K%]Z1E(_,D9G94&!D#.>./F ]<<W\6#%+:>&H''F;=>M)I8PI8B)2VYB
M!T4=S0!-9ZSJVE_%1/"TM_)J=A<Z<;Q6F1!+:L&(P2B@%3CN,Y(Y]7?$'Q9J
M'AV6QFT^/?:V,L=UJY R5MF;RP /4DLW_;.NFM--T31DN-1M;:UMQ,H>:Y4#
M=(H'&6ZD>G-<UIFCKXKT;4M1GU:]@@UDN)[9$APD6-B(V^,LIV $C/#,Q[T
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M!V-%16UQ%=VL5S X>&9!)&X_B4C(/Y5+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445ROQ#UB]T+PE+?V0F54F
MB6YF@0/)# 7 D=0>,A<]>G7M0!U5%<AHJQ:E<:;JOA[Q%<7^CL7%S"]SYP)*
M':VYOG4@XRN>X.!BJG@RYO;GQIXPMKF_NKBWT^ZBBM8I925C5DW$>_)[YZ4
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MHXHK6UNY-VV<L0,$ '!W D9_AXK3C\.:B^DJTVO:@-:,>XW22XB63'00_<*
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MC:F->\'^'I--O;F&;57@\N6.4[U7&^7)/4A%D'/?%=DBA$5020HQDG)_/O0
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M""O"*".Z-V-=?10!YKX4+>$_B!KV@.UW-IE\RZA;W3PG8D[<2HS*H4$D!AC
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M?,I&V/<68Y[YRW.:[/P]KJ:UX<M=3EADM9&B#3PS1LC1/CYE((SP<\]ZV**
M. ^%19--UV.6*:&236KJ=%FB9"T;,"K ,!D&H]*99/C+X@D>.7[-/IT$*2F)
MA&[*3N4-C!(SZUZ'10!YWX"'_"":1/X7UHM;I9W$C6=VZGRKF%V+ AN@<$D%
M>OUJQH^GRZA\1-2\:W,4MM81V*Z?9"9"CRJ&WO*5/(&>!GDCG'2N\HH X"#P
MW:>,?AO86,K2VMY;J)+:XV%);6=22K '!'N.X_ T>%M5U30?">MZIXJLYOMT
M%^?M"6D)<S82) Z*.H; ;TY/3%=_45Q"+B!X3))&'&"T;;6QWP>WID<^F#0
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M3IT>D:-8Z9"Q:*SMXX$)ZD(H4']*N444 %%%% !1110 4444 %%%% !1110
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MD&@#O/#Z!-#MF2]FO8909H9YF+.T;DN@)/7"L!^%<Q\5KJ[L/"<=Y87MU:7
MO8(O,@F9,J[A6! X/!KI/#MS'<Z4HMK*>TLH#Y%JD\31NT: *&*, 5&0<9[
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M[>7[6SM#)&C [7SDC<N<$D9S7'7FLZKI/P_\*:UINLWMQK]]]F)L9IS,+W>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[M/?)[ 'KAD02+&74.P+!<\D#&3C\1^8JIJNH_V79BY%E=W>9$C\JTCWO\S
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M-?UAKGQO8I>W2KIEG#=6,MU"GFIOC=B",<C* @,,C)S0!Z-17F-EK/B&VMO
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M6TFM9X=^H02QJ$;>@*F':N5PQQR3D=<FL"TUGQ7XBT*Q\0:&)_,FN/,^SRM
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M>][8+<+$DS0L+B%HF#+U&UN>#Q]0:EUC4(-#T;4-4=!M@A:9@HYD*KP/<G
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M4JY7!PF2Q.!Q@=N" >DT5D>&+U-1\/6UW'JB:I'*79+Q0!YB[SMR   0, C
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M** "BBB@ HHHH **** "BBB@ HK-U_68?#VAWFK7$$\T%K&99$@ +;0,DC)
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M9"K+-&=F ZC'(V#!!%79?$=O#XLMO#SVUP+BXMWN4FPOEE4(!&<YS\P[5L4
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MM<6Y7='(H(!PP((PQ&"* .*_M[6H]*^(4,=[>6[Z+"+BR>X6-YHP;?S=K'#
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MU$"J70L#R#D9&1ZCI70OX(L%FT!K.YN;.+0@WV2&'85.Y=K;MRDG()[]\]:
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M0,J\>U1C/0CIW KE8?$.NZCH.@7-OJUQ#X@O-5^RZA8QJC&&/>P<>6RG9L4
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M Z*"V <#<2!Z9YI(_ 5G!9WVF07UW%HM]*TLVGKMV#<<NBMC<J-W4'N<$9H
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MY*IXW_ZY:?\ ^BY*TKGPC%=7&@SOJ5X)-%),! C_ 'A*["7^7GY3CC%6-/\
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M7^RR;PTA@/W!)M &X<C(ZUT%9^CZ2-(LS";NYO)W;?-<W+ R2M@#)P  ,
M  8K0H \OT6*^MG^(EU!K%\L]M=R&-V*/R+=&!(93TZ8Z8[5/82:\/ =EK]Q
MXM:.6^L;3>+B%=D18J6,852QD920!SECTZ =$W@N 7FN3PZG?PQZP"9X$*%%
M<H$+KE2<E1T)([XZ8;<>!K2X\'V/AUM0O533VA>TNE*"6)HB-A^[M.,=Q0!A
M66LZLVJ>,M.2\OH(K*QANK)KE8VEB9D<GJ#D$H#AN1D]*I6.JZ];:5X UN?7
M+FY;5YK>UN[5XT$3+)"S;AA=VX%0<YY] .*Z=/ L2ZCJ5^=:U-[C4;1;6Y9F
MCPV P#X"8!PQ  &WOC-!\"6YTG0-.&J7PAT.:.:U.(]S-&I5=_R<@ D<8H Q
M9_$ES:>+7TS6[N_TF>744&GSE ;.[@W+B+=@@.1D'.#D]<<5);6<@^-.J.=0
MN\+I$$NT%,$>=)\GW?N_K[UNW'@^.]CDM;S4;FXT][W[;]FD5/E?S/,"A@,A
M-W..O;..*L0^&4A\77'B,:A=&XGMUMFA(3RQ&K%@!\N<Y)YSWH Y+3]1\6>(
M]!TOQ%I$I22>83R133H+9H-Q#1[=I(('\6<Y![<58TU=>UGQGXEL3XFO+>UT
MN]MC"L<,661H@[(WR_=Y(]?4FM#3_AU::7?RFSU?5(M)EF,[:0)1]GW$Y('&
MX(3R5!P>^1Q6MI?AI-*UO5]5CO[J6;5&1YDD";%9%VJ5PH/  ')- '$Z1JNO
M1^'=:\3WNO75RFBW6H*+/RHU2Y2+<$#D*"""!R,#CIUK9L%\5/J&B:E#<M)8
M3(#J*W,T92164%7B"K\I!/ S@CKD\ULZ+X2M-'TS4=.:YGOK74)I9IDN0G)E
MSO'RJ.#D\52\/>!(O#\L2+K>JWFGVQS:6-S*K10^G0 MCL"<#TR : .)\1W]
MYXL^".K>)GU">(72R/%;)M\M(5EV!",<DA<ENN3Q@<5[!#_J(_\ ='\JXB;X
M8V;:5J>C6^LZE;:+?NTC6$?EE(F8Y;8Q4L%SSMSC/Y5JIHVHP^+;&[AU;49+
M.&T,-Q!,R^3)UVMM '[S)!R. %QWH Z6N:\27-Q'J^DVR:@T-O-YWF6EL#]I
MN6 &W8<?*JY)8D@?=R>:Z6L#6/"T>JZYI^L1:C>6%[9H\(>V*'S(WP65@ZL.
MH'/6@#D-/\1^([CX?07XAO;^6VU66WO1;*GVIK9'=<J!P7&$!V]1G!SS5G_A
M)+F[\(MJOA^[OM;M5U$"YCB0+>0VX4;X@I .]6Q[E3USS6SI_@6+2;006&LZ
ME%LU![^,LR/M+!PR$%?F4^8V<_-TYXJPGA".#?/;:C<P7TM__:$UQ&J?O)/+
M,>TJ1C9M.,=>^<\T <EK'BB63X7:SKGA[Q'<RM!=((WDC42P M&K0R!ER",M
MSUY!R>_1:YJ\\/CG3]*O+MK#1Y[&647"N(_-N P CWGIA,M@8S[@8I]_X!L=
M2T35M.GO+E&U:X6XO9X0BL[+MP "I"CY%[9ZY))K!\62*OBZ!;[5]<T=;>Q$
M<%_;6WFQ7+.V74@1LJD;%[ G/H!D SIM:\50_#%]:DUNZ%V=2CAAD>WB"RP&
MX$:M@(#AE(.<Y/4$ UMRZOJ?AKQMJ-K<ZG<ZE9?V%+JGE3J@*21O@A-JC"D'
MH<].M/M_#E[XGT"YT[5-=U.YTXSQ36UU+:I;SOL(;!4I]T,%P2H)Y[8)WI?"
MT$_B=-=GO+B28636+0,J>4\3$,V1MSDD>M '/:;)XLOU\.ZS:W!:&Y\N34$G
MF3R9(9%!)C4#*LI(V\\]R:Q]8O[OQ;\*?%&O'4+B",I=I;VT>T(L,99-K CD
ML%))/3(QC%=1H/P_M] G1(-:U6;2X)/,M],FF#0Q-G(YQN(!Y )P#SR:AG^&
M]L;?6;*TUC4;/2]6\QY[&+RS&KN,,R%E+*#UP#C\.* .GT/_ ) &F_\ 7K%_
MZ"*OURR:!?VGB#0WL]7U)K.QMC!<0RNODRIM8*6  S)NV\CH%]^>IH XSQM>
MZM:ZUX8M],U-[-+^^-M,HB1P5\MVSR,Y&/7'J#6=IUWK.E^*O$'A?4=3FU2U
M_LO^T+2XN$42Q@ED9&*@ \C(XJ7XB$2:[X/C6Z:W>/4_-:5 "8E\MP&.00%R
M0.>.:Z.+PW&LFI74MW-)J&H1""2ZVJ"D8!VHBXP -S'G.23G/% '$>&M9NK;
MP=X T6TWA]2LW9VC=5<K$@)52W )+#GK@'&#R+=[J_BCPQIEQ;W]PC&_U2WL
MM+N)7626!)FPQDP #MPQ4G.>,YK6G^'.G3>%]+T4:A?QOI+!K"_C=5G@(&."
M% (QP1CFK%QX$LM1\.W&E:K?W]_+<,KO?2R 3*Z'*%"  NTYP ,<G.<G(!CR
MV$EC\9-##7US<QOI-UA9V#%2&CR0<#KQQT&.,5D2>(]=O/#L%U!J<]OXE;63
M:3:=&$)2/S2NP1LI Q'A]Y'N3CBNMA\'RVVL66NW6MZGJ-]86\D**RPJ)5;!
M*D! .=HYX.>]<3HK2M:@67BGQ/8ZI(SROI;Z;YIBE=BQ3+Q<C<<;BV#UR.P!
MTUS?:QK&M:YHUC<W2OI44,230RQQL97CW^8X*\CD#  '#<=,)9:OKE[X@T;P
MMJUPEM?#2WO]1ELV'[XK((E56Q\H)RQQ@\ #'-7+WP,VHZG;ZZFKWVD:R]LD
M-])ISJ$N,#H58$<'.#V%6-1\#V=U<Z7>V-]>:=J.FJT<-W"P=W1N663>"'R<
MGGG))H S/AW!);:QXSAEN)+AEU@CS9 -S#RH\9P ,XP,^U=Y6#X?\+Q^'[W4
M[I-1O+J349A/,+C9C?M"Y&U1C@?3T K>H XJPOKWQ9K'B6WBU*XT^/3+D65L
M+?:"'"!C(V0=W)P >,+TR:YNV\5^(-<TGP7<KJ#V%Q?ZA+8WRPQ(4<QB0%UW
M D'*9 Z9Z@XKN)/"B1:]>ZOIFHW.GSWZ*MXD2HR2E1A7PP.UP.,C@]P:@F\#
M6!BT*&TNKJSAT67SK:.+8=SX()<LI)SN;/3DDT ;>D65QIVEPVEWJ$VH31YW
M7,RJKODDC(4 < @?A5VBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K%\3^(XO#&FQWT]I<7$3SQP'R2OR%V"@M
MDCC)'3-;5<1\5PQ\#,$(#?;K/!(R ?M"=J .WHKA;7^T+3XDW6@2:S?W-G>:
M.;S,KKOAE$H3,951M&#TQC(K/T;5M3ET>X\+WFHW+>)+?5!9R7._#M$3Y@F
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M'<97R\)C(ZYS\P["N.@\27&G^,/$=C/<W=S:SVWF:.))<*\BMY4D2$<Y\TJ
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M&L0+;W=O*4\MD4$*!A01@,><]Z@\/>![7P\\>-5U:_@@4K:V]]<"2.W!&/E
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M@8).,G\JXJ+X8Z7#IUG8)JNL"UL;Q;RRC^T+BW8$G:OR\CYC][)'8CFNVHH
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MH#\F, $C  SWS5T^#["36-5U&YGN;G^U+9;6ZMY2GE-& 0  %!'WCW[UT-%
M'*>'_ EMX>9!%K&L74$"E;2"[N!)':Y!&4&WD@$@;LX%:7AOPY;^&-/DLK6[
MNKB%YGG_ -(*$JSL6;&U5X))-;-(3@$@9]J ,S7]!M/$>E-I]XTR1F1)5DA;
M:Z.C!E8$@C(('4$57CTB'2YIM;NY[S4[Z"V9%D=%+K&/F*QHBJ,L0.V20!T
M%7])N[F_TN"YO+"2PN) 2]M(ZNT?)')7@^OXU=H Y#P];VNO>)IO&"Z9<V9:
MS2S@-W"8I7&XLS%3T'*J#UX;MBNOJEJMY=6-B9[/3Y;^;>B^1&ZH2"P!.6..
M 2?PJC+XC6+QE;>'&LI@\]H]TMR6780I4$ 9SGYNX'XT 44\!Z?%!?6,-W>Q
M:3?2M+/IRLGE$L<N =N]5;NH8#KC&36-<VKS_&97MKFYLXH]"$ FAB!C+^<3
MY9+*5SC!QUXKT*B@#F+WP%HNH>''T:?[1M:Y-X;M9-LXN"23,& X?)/;&.,8
MXIH\#6\F@7VE7FL:M>&^B\F>[N)E>8Q\_("5VJ.3T&>>M=310!SFI>#K74])
MTNQEU"_CETN5)K6\B=%F5E!49^7:>"005YJ&+P%IB-KIDNM0G76X1%=I+/D'
MY-A8<<,1]0.P XKJ:* .7E\#VT^G:19RZMJCC2KF.Z@D:2,NSH-J;LIC '&
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MK<QV[2*)I%9T3/+*I )_#<OYB@"EH6CP>']$M-*MI9Y8+6,11M.P9MH& "0
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M?=3>*O$WB:UEO;NV@TN5+2WCMIFB*L4W-*VT_,23@ Y7"].37)^#-4NT\'>
M-"MBJKJ-O=229N&@+^4<A ZJ6&=^>,'Y>O6N]G\%V+^()-;M[W4+*\N(UCN_
MLLP1;H*, N,=0.-R[2/6J)^&>@GPO8:");]8]/D\VTNEN2+B!_57QQUZ8Q[4
M <YXEC\5>'? VNO-KA1H[N"2P,-RTTL44DJH4D=E#,.3@YSUYXKT/1])DTI;
MH2:I?7YGF,N;N0-Y>0 53 &%XSCMFLBY\":?>>')=%N;[4YHIY%DN+B6X#SS
M%2"NYR#@ J, 8''N:Z:)&CB5&D:1E&"[XRWN< #\A0!A^-=:F\/>#=4U6WV^
M?;PY0L,A6)"AC[#.?PK+M-(U^'Q%8W0U"-=)FA>*\@DU.6=IF*Y1XLHNQL@Y
MVD#'0<5U=]8VVI6$]C>0K-;7$9CEC;HRD8(KGM!\"V/A[BVU/5KA8T*6J7=U
MYJV@(Q^[4C .. 2#QQT)R <QI%SJ$/CF;PEJ.M7<MNER]Y:7AN'$ER@1<VI/
M3*;MS8.2,<<G&C=SZMXFU[Q-I=E.8&TTQP6Y34)+9HF>(.)2J(=^2V,,<83I
MR<[5YX(T^]TO3+&2ZO5.G7'VJ"Y1U$WF9)W%MO))8Y]>^:BU;P%IVJZTFL+?
MZI8:AY0AGGL+GR3<(.@DP,'ZC!_(4 9>GWVJ7WBBP\+ZUJ"F:WT;[7=26$S1
M?:9O-,1(9=K +M)(&.6]J@U9=7\/Q>%+:37[B]N&UY+2:8$J9(&#L(Y%R02
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ML[2%E()Q@ #IP>.:Y)O$'B"Y\/:;%)JUS%>67BQ=&EN8@H^U1K)MW,,<\8!
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M]?-=.LA%RX*Q'&"(P -JGKCFL^^\%:;J&A:AI4\UT4U&3S+V<.OFW#<?>.W
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M^U*6.65)I[B2X#SS,I!4L[ \ JN ,#B@#6T?27TF.Y5]3OK\SS&;=>2!C'D
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M6N3Y;QAB@#K_ !8ZCTP,=\ZOB/5)F\<>'/#OG2P6M\EQ/,T3F-I?+4;4##!
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M=2I4<^G'3 &=_P )5<G3O"6LM<7RKI[K!X@B^UR!$R_D;I!GDB0,WN <YXH
M]8U2YN[33+BXL;$WUU&F8[82B,RGTW'@?C5E"S1JS+L8@$KG.#Z5YWXKEO%^
M'/B?7K34KZWDFW36C1W#?NXTPJ[.?E#8+\8^^/2I?%.H:EIEU9W\]GJ-_H0L
M +D:;<LD]M(3GS2JL"ZX'X;2: /0:*\YM]7DUK6M,T2QO#?67]A17B3-?2VK
MW19BA<L@+$@+TR.7.<D#'4>$;/5M.T4V6LZC'?W4$S*)5<NPC."JNQ )8 CG
M'(P: -'5[\Z5H]Y?K;O<?9H6E,2, 6"C)Y/%9^GZ]>:II&@:E::2TD.IQQRS
M_OU'V1'CWY.?O\X''KFN1%P_BW0O&]Y=7=W$UC<7=C;107#QK"L2<$JI 8L2
M2=V>"!TJM9W%W:Z'\*OL][<117"6\,T,<A5)%^S%OF Z\@=: /5**\SU'5[K
M2O$\D?B'^TK>SGU.-K#5K2X=K8('7$$J!L)G!4D@YR3VI+72=0\2>)/&>G2^
M)-9MHK2YA%J;>Z,9B9H0V>.P)^[P/7/& #TVBO)_"GBK5/$I\'Z9JD\L7VO3
M[FYN9(G,;7+Q/Y:C<N"!@%SC&>.W!MFY\10WOC+PWI=U)<M9"UN-/>YN"'"R
MG+P&4G.2%8*Q.1NZ]* /3:*\HE\:):>'=>NK0ZGIVI0/:07%AJDK,;+S)-AE
M5F+ J0Q((R,J#CG%=3IND:U8>*XKPWR1:7/ 8I;*34);HO*.5=#(HVG .0."
M.: .NHKD/$VJS?\ "9^&?#PFE@M=1-S+.\3E&D\I 5C##D9)R<$'Y<=":IZ6
MUU#XZUWPM-=7EQI9LH;Z!GN9/,MRS%602YWX)7(YXY'2@#5TWQ5<ZM-I]Q8Z
M.\^C7TDD:7L<P+1["P#/&0,(Q4X(8GD9 SBM^2[A2X^S!@USY1E6$$;BH(&?
M3J0.:XOX06D<'PUTB9&F+S1-N#S.ZC#O]U22%_ #-1V^GPGXWZA)ON0PT:";
M N9 -WG..F[&W 'R]/;F@#I/"OB(>)]';4/LC6A6XEMS$[AB#&Y4G(X[5>>Z
MO5UJ*T73V:Q:!I'O?-4!'! ";.IR"3GIQ7CD:W6F_##4?$%GJ=_!=V.M3-#'
M%.4B(-YM8.@X<$,?O9]L5WTUQ=Q_&&TM1>W!LY=%FE-L9#Y8<2H VWIG!/-
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MRYMN< !S@]OF% 'H5%87AGS+N.]U=IIWBO[AI+:-Y69$A'RH5!. &P7X_O\
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M4GC'8>];]<%KC%O&WP[9B2Q:Z))/)/V8UGP_V_XRTO5+S3;X65_!J4\$$_\
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MF<)(\3;&;/S;0V.<XS],=Q?R2S>.$\+1,6M(M+%VD4]]*C2LTK*Q+C+-M &
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M<$$.9"=Q8%5P<\8'88IMCX-TFPUB'5T-Y+J$4!MQ<3W<CNZ$Y(8D_-SC@\#
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MVN;6ZNHQ%=-:SM&+A1P-P'<#(### =Z2Y\):3<RZ4XBDA&D_\>202F-8N-O
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MX<V,Z7,!68J1*OW7..I&3UXYKA=5TG[1XMU6XU/1_$T,LTB+;W.BW3B.:)4
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M#/W<]*W:\+L](\CX*+XFM-1O[;5M/>XFM7CN7$:[;E_D\O.TAN<Y!))ZXXH
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MK:SC3[24300B\F&QPVX'.[/!Y SUKI** ,@^&=,;7X]<*7']HI#Y"R_:I/\
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M)),@[C'G;R0"1C!QR#5N;P_IT^OP:Y)'*=0@C,4<@G<!4/4;0=N#@=NU:E%
M'*7'PY\,W(OXWM)UM[]_,N;6.[E2%WR"6\L,%!.!R!6O#X>TZWUB'58XI!=P
MVGV-':9V BW;L$$X)SW//O6I10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(%7 E'*;02R_-@C:.O2@#TZFR1K+&T;C*L,$50@U&XDUJ?3I-.N$CB@247A
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M=?SH ]7MI7GMTDDMY;=VZQ2E2R_7:2/R)J6H+.X>ZM(YWMY;<N,^5-@.H[9
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M;GYF&23P![<D<9JP>+;:;5M(TYK*\BEU6S:[@9U3:%55+*WS9##<!TQ[T =
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M/]CW1[HXU.W<[;MH!) &"2<^QP 0?\(1H?\ <O\ _P &=S_\<I#X)T,=4O\
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MNQV>$@G>A#;2.#GD$>E %S_A"-#_ +E__P"#.Y_^.4?\(1H?]R__ /!G<_\
MQRI?#_B3_A(-SQZ5J%K;F"*>*XN8U5)E<9^4@D\=\@=CT(JGXV\1WOAVVTHV
M5D]PU[J5O:,RL@V*SC( 8C)89 [#.21CD G_ .$(T/\ N7__ (,[G_XY5:^^
M'?AZ_M6@E34 "0RN-2N"R,#E6&7(R" 1Q3-0\=I8:O)I(T'5[C44LA>BWACC
M8LF[:0"'QD'.?IQG(R7WCZRL;>_NWL+UK'3KB.VO+@*H\IVV_P );+!=ZY('
M?C.* *VG?"[1K)F-SJ6O:ED@J+S4Y"$(.00$*\_7-:G_  A.A?W;_P#\&=S_
M /'*M7^N11ZF=(MK2:^O?(\^6*%E7RXR2 69B "Q! '7@] ,UYOH-_I%I\)+
MZ;6M+N[K3&U></;KPZ?Z3\F[YAC#;<X)_&@#O_\ A"-#_N7_ /X,[G_XY1_P
MA&A_W+__ ,&=S_\ '*;J'B^*R\2G0(]*U"ZOS9F[C6%4VR*&"X#,P Y/5L#C
MKDC,=OXZTN?PO'KC17,0>Y^QBU=1YWVC?Y?E8SC.[WQCG- $W_"$:'_<O_\
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MK=RQP,@81L6"X#,-Q.QN!^?(SK6TXN;6&=5*K*BN >H!&: ,/_A"-#_N7_\
MX,[G_P".4?\ "$:'_<O_ /P9W/\ \<INK>,+?3+C4X8["[NSI5JMW>F':!'&
M0Q&-S#<V$8X'IUSQ4=YXWL;6]T:UBLK^Z;6(&GLV@C4APJ!\<L"#@KUP!GD@
M T 3?\(1H?\ <O\ _P &=S_\<I/^$)T/^Y?_ /@SN?\ XY45CXXTZXT74]1O
M(+G3SI<YM[NWG53(D@QA1L)#;MRXP3DFL"_N9;GXO>$FFTRZLI&M+TDS.K!Q
ML3 ^5B 5YR/]H<F@#I/^$)T/.-E_G_L)W/\ \<I?^$(T/^Y?_P#@SN?_ (Y4
M4^J6EEJ&L:]?R;++38ULT;&3N.'?:!U+,T:8]4Q4Z>*HH];M=)U"PNK"YO(W
MDM/-*,LVT99 58X<#G!_ F@!O_"$:'_<O_\ P9W/_P <H_X0C0_[E_\ ^#.Y
M_P#CE5='\<Q:Y?BVM-$U;RUNYK.>X>)/+@DC'.\ACU(P,9[>M;VKZE'H^D7>
MI2PS316L32ND(!<JHR< D#H/6@#+_P"$(T/^Y?\ _@SN?_CE'_"$:'_<O_\
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M9AC/. ,DX/H:N:OXXLM(MKN]:TN;C3[*;R;JZA*$1L" V%+!F"DX.!QSUP<
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M1>'6\1:1<V%M:MY:QM-;R0J4!VN0-K#KSU_7T+1XY8]+A$]G#9R-EC;0XVQ
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MHE:,YV9[9!//K1J5UJ'B/2WTJ+0[ZS^U@1W$UV8U2&,GY\;7)9L9 P,9ZD4
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MYH]T\;1HK,K E00R CGD>G2MN[@NM8\/NFH^#T-E=3(DNF%XS,(@#F0D,%#
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M;2LZ$.$B5#PK$CD=QTJC=^'IO^%G@VLJ#3-0A2]U*W[^; P$3#TW$KGU\HT
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M!,TJN+F-BP#@#[O*'@UL30QW,$D$R!XI%*.IZ,I&"* .?;Q="FMZ)IALI?\
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M 445F:WJ_P#8]K!(MK-=2W%Q';11QC^-S@%C_"HZD]O>@#29E1"[L%51DDG
M H5E=0RD,I&00<@BO//%FM0:_P"!O&^FW=BL5YI-LZRH6$J;C%O1T; [>H!!
M%6=)\:/8/X?TS4M$O+.SU"*.WL[]W1DDEV#"LH)*;L<9Y/H.< '<++&[NBR(
MS1G#@,"5.,\^G%-^TP>4DOGQ^7(0$?>,,3T /?-<=!=:5JQ\:VB:(+:>'$=Z
M90A-RQARK$ D8VXQS^58VD:CI]A\+_ JZEI)U"*XELH8C\NV"9B CG)SQD]
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MY+D6QG2Z0RK\VWS/*Z[,]\YQSBF:3:6P^+WBB,01;)]-M&E78,.2T@)([Y%
M'<QR1RKNC=77)&5.1D'!'YTZN(^$B+'\.K.-%"HMS=A0.@ N)*[>@ HKD+CQ
MY%#HC^(4T^2;0(Y3&]VD@+[0^PRB/',8(ZYSCG;BEU+QO+;:_)HVG:#>:E=?
M8!?PF*6-4FC+;>"3QWZX/3 .<T ==14$ER(;%KJ6-U"1F1T W,,#)&!U/TKG
M+'QFUQJ6C6EUI<EK_;5M)<61,H9L(H8K(N!L;:P/!8=1F@#JJ*\UA\;^(?\
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M/]#U+6-*T^XT=8Y-0TK48=0A@D?:LY3(*$]LACS74+!$DSS+&@E< .X'+ =
M34E '"6T&O7WQ%L=?ET":SLTTJ2TD6:XB+JYD5^BL0?N\<]^<5AS^&/$4OPR
MUO15T:7[?>:J]U%&9X<&,W"RY)WX' (QZ_G7J]% '&^,-.UR:[T+Q%H=DMQ>
MZ8\GF:=/*J&:*50'4-DJ&&T$<X_D:?B#2_$WBCPTETEA!IFJ65Y!?6-C+,LF
M6B))$CKP-V2,#(&!D\G'=S316T+S3RI%$@+.[L%51ZDGH*<K!E#*05(R".]
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M-='10!YI:Z!K5KJOBZ:#P[';VFK:;%';1Q7$65=4D4J1D#=EP2<XZ\GO:O\
MPWJ^H?!%/#BV?E:K'IT%OY,DJ89X]F<,"1@[3C)[\XKOV=%^\RCZFE!##(((
M]10!Q6M6FM:KKOA'41HLL:V5S+/=)]HB)B5HV0#[PR><G&1[FJ>DVGBSPKJ^
ML:=9Z-%J.FW]]+>VEZ;I8UMS*<LLBGYB >?E!S_+OH;B&X5F@FCE56*DHP8
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M86MA9SPW3&6+,;2*@'&_)P4.<>O&:[>HX;B"Y5F@FCE".48HP;##@@X[CTH
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MAN]-32T@6">Y55M;D'YI&49WY&,$9(QVR:R].\,>)+7POX)T^;25,VBWZSW
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MX6\_T::,1SC]P?D;/0 YZ]N:Z[PSXDDUXZE;W5@;&^TZZ-M<0>:)5SM#*RL
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M*[*-I& 6Z$\@$\< @'<45#:2RSVD4LT0BD=06C5]X7\<#-34 %%%% !1110
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M@-'Y_FG.5X)Z <^YKU*H+R]M-/MFN;VZAMH%(!EFD"*"3@<GCK0!S8TK4?\
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M=%+"-V/4F,':?Q% &MI-_P#VII%I?^2T'VB)9/+<@E<CID<'ZC@U<I  H
M X %+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-R@#@/A(BIH.MA5"C^W;SH,?QBM":]DT>[\9:I;VL<\ULD4QC9_+\P) #C<
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MOM&?+D&"K1MCD @]15/6/#>N>,/"=]9:U+:V%Y-Y;6L=J[2I \;;@S,0"Q)
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ML[E9-OS%2S$8.&XSMJY:^%;W3/%^C7=C';G2M-T@Z:H>8B4\H0<;<?P8Z]Z
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MQ)]FNK..SDLY)9([B-93Y]F5#8$BXZDJ >F,C&[K3?#-MXVA6VL=>DTO[-:
M*;NU=VEN@HPN5( 3L6.3GH ,Y&?:^#KZX\2:/KEU966GZI:[O[1N[.8XOE*%
M=I7:,Y)#$MTQ@9Z@ =+\1)6MK/4[*P6\TVXN!$8X=[7"Q%BHFP%VD=]N>AZ]
MJ[VN \-Z#XQ\.0CP[%/ILFA0NPM[]G?[3'"23LV8VEAG .<#KSTKOZ .)U55
M'QB\.L ,G3+S)]?FCI)_'%[97>E?;M.AMH]2U+[ EI)*5N44LRI,5Q@J2H.!
MT##DU?U#1=3N/B'I.MPI;&QL[2:WDW2D2$R%3D+MQQM]>]<JO@OQ;_9.G6LP
MTF:[L=:CU&2\>XDWWP5V.7^3Y"%8#^+I@8 Y .C/BS45U7Q)IKZ?:)<Z5;)=
M6X>X(6ZB8,=V=ORX*E3UP:DT;Q9/KFB^';ZTMK=I-5RTL?FM^X15)<YV\E6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME<LH./E.X9/0XSZB@#UU6#J&4@J1D$=Q6)I5EX;BU_5I]+@LEU;>HU!XE'F
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M<>YA)&4W))SR0W(P.XQF@#L:*K6#W<FGV[WT<<=VT8,J1DE48]0">N.F:LT
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M$\C!Y0T9C[*1GDMGU]*AMO#'BK0];U)=!U331HNHW+W;I>1.TUK(YR_EX(#
MGD!B /SR =O;S?:+:*;RWC\Q ^R089<C.".QKF/B5K-WX?\ AUK6I6+%+J*$
M+&Z]4+L$W#W&[/X5U$4?E0I'N9]BA=SG)..Y/<U5U;2[36](N]+OH_,M;J)H
MI%S@X([>A[@T 4O"6EVVD^$M+LK9 (UMD+-WD8J"S'U))))]ZSY[J#PO<Z1X
M8T>&))]2GN)(1(/W<" F61MHQD L %!'7J,4S0M.\5Z!IT.D&33-2M+91%;W
M<TTD,PC'"AT",&(&!D,,XI=<\*WUY>Z)K-G>QMK.DRR.&G!6*=)!B2,XR4&,
M;3SC'?K0!3G\9:G83>(]+NK6TDU72;+^T('4M'%<PX)SCYBI!!!&3]:K?\)E
MXCBC\+7DMAIKVNO+'$L22.KQRO%YBL6.1MX.1@D#N:T+SPI?:@VOZE.;1-4U
M/3O[.A19&,4$6&ZMM!8EG)/RCH![U7F\)ZP^E^#K56L=^@RPR2DROB7RXC'A
M?DXR#GGITYZT -'C#6[1/%MK>VFGRW^A6R7<;0LZ12QLC. 0<D,-A'OQTJL/
M&_B*R'AO4]4TW3QHNLO! 3!(YF@DE4%6;/R[2>PZ>II^OZ%J%DOCS6YFMC:Z
MCH[1HB.Q=/*BD )RH'.[UXQWIVBZ'?\ B#PIX0BU$6D=A8QVMYF&1F>=HXP8
MP05 09()Y;.,=Z ':[XUU70S+<W-O90Q)J*6R6+DF>:!G5//#!L*"6R 5[8S
MDU<N?$/B&;QKJ'AW3[734\FQCNHKBX=V'S,R_,!C/W>@^N>QQ;[P%XCN=(UG
M35U#3&2[U,:A#<2I(97Q*KA)". %"X!&> !@5T-KH6KP>.+K7Y6L9(YM.CL]
MBNZ'<C,V[&TX!+$8R<#UH Q6\>ZLW@31_%*VEG%;R7 @U,.&;[.OFF)I5P1E
M01G!['KQ771ZA=7'B>6QA\AK*WMDDF?:2WF.3M4'..BY/'=?6N;TC3+#PKX"
M_P"$=\5W^FI#*+E23/M$R.S.P 8 Y ?'&?6M3P#HLVB>$+*&[EEFO)466>28
M8<G:%4-[JBHO_ : .FKFM5UV[L?'6@:.+6V:VU&.Y;SF8F1#&@. ,8 .X>O2
MNEKFM8T+4+_QKX?UF!K86VEK<*Z.[!Y/-55XPI QMS[Y[4 <Y/XW\3_V+XFU
M*#3]*5-!O9HI$>21O-CC56(7&,-@DY/'08[UK:EXU6'6;#34N;+3VO;%;NVE
MU!&*3NQ(\H,&4!AP3U/S# JF/!VLGP[XOTQI+#?KUS/-&XE?$(E0)@_)S@+G
MWSVJW?\ AK4M1TI-*O[+2-0T\V$=NT$\CCRYEW R(VPGD%?0C'6@">[\0:G:
M>)_">F7-C:J-5CF,[[B7AD2'>54=,9XSD\5C>)-=U#Q#X$\77.F"T73K:"[M
M )D9GG"(5D<,& 49W ##9V]L\7X_!^I6M_X,>*[AN(O#\$D4LD[L))R\7EY
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M?(K(D<X./*="Y9@1SN&/I6!)X O=0T;Q3IU]=00?VOJ'V^VGMV9FMY!LVY!
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MV$2)U8#@'/W /QH -5\2W7]M7ND:6$6XLX(Y9))+*:X4N^[:F(\;>%R6)[C
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MX0),R*9%'16QR/SJ6J6C6#:5HEAISW#W+6MO'"9G^](54#<?<XS5V@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKF?'6OZCX:\/KJ.G06TT@N8862?/(>14XQCGYN] &]>V%IJ5J]K?6L-S;O]
MZ*9 ZM]0>#3K:TM[.U2UMH(X;=%VI%&H55'H .@KDY_$&N:;?6VE:F;#[?>R
M32P26=K/.L=M&$^\@^8ON<#@@8Y]C1E\<:QIF@W5WK.G&U%OJ*6QOS:2K";=
MND_E$[P!T(SP2#GM0!V=AH^FZ6TS:?86UJ9F+RF")4WMZM@<GWJ[7!ZSXOU?
M3/"3ZU:/I.I1M?0PV\T!81RPR%%R &/S!F8?>QQTIW_"6:WH?C"'2O$T.G"R
MOK6:YM+BR#YC,*[G1]Q^;"\[@!]/0 [JBO/[OQKJ]GX+M?&CP6C:3)Y<TUDL
M;>=';NP 82;L%@""1M ZC/&3;?7_ !)?>,-7T+3!I426UI#<P7$Z2/PY;[R@
MC/W>Q&/?I0!VM4M3U:QT>"*:_G$,<LR0(Q4G,CG"C@'J:XB+XCNWA+PUK-Z+
M?3H]49X[F[DC:2&W==PP<$8#,O!)P.]7]9\3:SI7AW2+[&F7+W>IQ6LDD6XQ
MM#)-M1XP&/)3:>2<$]Z .EMM;TV\U:[TJWNTEO;15:>)<YC#9QD].QXI^IZM
M8Z-;)<:A.((GE2%6*DY=SM4< ]2:X28:VWQ5\1+H1L$N3IEH3)>AV0?-)@;5
MP3GUSQ[T?\+ U:7P?::G]@M(;^/5TTO4(7+,J/YH1BF",]<C)X]Z .Y&MZ:V
MNG1%NT.I" W!MQDD1@@;CV')%.T[5K'5A=&QG$WV6X>UFPI&R5<;EY'.,CD<
M5RUQG_A=EI@#/_"/38S_ -=TK!U_Q3KM]\,O&5VLMK97>FWT]CO@C8[HUVJ<
M$MPQW'YNWIGF@#U2BN.U77-<\/ZIX>2\ET^72[^X^RW-PELZ-%(P)C 'F$ ,
M1MR>A^N*V],O[R^U;5%)@.GVTH@A*QD.SA07R=Q! )V\ <@^E &M17#^(;K6
M5^)GAJQM+^"*TF@NI?*>W+C<BJ,MAQGASCICGKVE'B;6-6T[6]3T-;+R-,N)
M8(H;B-F:Z,0^?Y@P"9.0O!Z GK@ '67MG:W]I);7MO%/;.,/',H96'N#P:H>
M'[[1+RQEBT%[<VEG,UJR6Z;4C=0"5 P!QD=.*?X>UJ#Q'X>L-8ME9(KR%90C
M=5SU!^AR/PKSC1[SQ/I]GXTO= ATR2.UUZ\FDBN]Y>;"H2J[2 IP."<Y)Z#J
M0#UJBN(A\='6OL,6E V[W&FQZ@[O92W7EB0D*FV/'.5;))'08!SQN>%-4U/5
M]!CN=8TU]/O@[1RQ%64-@X#J&YVD8//(Z4 :%YI>GZC+;RWMC;7,EL^^!IHE
M<Q-ZJ2.#]*MUR4NO:WJQU[_A'([-FTF8VJ1W*%C=3JBNR@AU"#Y@H)SSD]!S
M(OB#4-0\0+H-I';V=[#8)>7K3J9A$SG"Q *RY.0Q+9Q@#CG@ ZFBO-KSXA:O
M!X6U.Z6RLAJNDZFFGWD;%C&^Z15#ISG!#@X)XYZUIR:[XIA\:'P\XT@F[L6O
M+:<1R8@VN%97&[]Y]X8(V9]J .VI&940NS!549))X KS>;Q[KMOX,O-1:TL)
M-1T_6#I=P%WB.0B54W(,Y&=PZGBM2U\2>(-/\=V>@:_;Z<;?5(99;&:RW@H\
M8RT;[C\WRG.X ?3T -Q?%FAOH-UKB:@C:;:LZS7"HQ"E3AN,9.#Z"M='62-7
M0Y5@"#ZBO*M)UJ]\._"WQ+J^GQ6\L]IJM]($N 2A'G'/ P3^8KL-6UG5;>ZM
M4A-E9VDMH93>7*F3?/D;84C#JQ.,MQGICK0!T]%>=+X^UBZ\+^$-7M+&R#ZW
M>):3QR,^%8[\E2.@^0]<]>AJ=O$?B$#Q?I5S-I\>H:39I=6UW;V[;"KH[8*,
MY^8%",YQR#CL0#OJ*YSP$][+X%T2:^N(YY);&!U98RIP8U/S$L=S>IXSZ52D
M\1:O!XJUO1;B33H!#8"_TZ9X7VNF2'\SY_X2 #C'7/'2@#L*I6FK6-]?WUE;
M7 DN;%U2Y0*1Y99=P&2,'(.>*Y;PYXMU'Q#X=T*[B^R1ZA>SO'=PM ^(!'N\
MP;=^000!D]V7CFJ]UXFUN:T\>01M9VEQHD8-M,D3/D&'S,D$C+8P >@]#TH
MZZ_UO3=+NK.UO;M(I[V40V\9R3(Y[#'\^E:%>3ZDVHGPE\-I9I8+FY?4K)HC
MM:,8-L^ Y)8D^K#KZ5U_AK7=5NO$FNZ%JXLWGTX02QSVD;(KQRJQ *LS$$%2
M,YYH ZFL_6=:TW0-.>^U:ZCMK52 SN">3P!@9)JGK^I:A875@EM]DM[.4O\
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MVC#$1F2XC.T@XSC'7C/M7<C0[R^\266N:G]F633H)8K2"!V9=\F [LQ4'HH
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M4':!F"^:1_OLBD_[HJG!X1O6O/%[75Q;K#X@0(OE9+08B\KG(&[CGMZ5V%%
M'!MX/UV31_"UG/>Z>[Z'=0S[E1T$BQ1F,+WY());]*V-+T&^LO&VM:Y+);FW
MU&*")8D+;H_*# $G&#G<?I[UTE% ',Z_H&J7WB71M9TV]M8S8K+&\%W$SH1(
M -Z[2,.,8]P2,BN?E^'VL/X&UOPV=3LW_M"]>XCF,3+Y:M+YAW#)R<C&!@#U
M->C44 <QJ&@ZE?\ C#0-<WVB1Z;%.DD6YB7,H4$@XXQM'U]JV=7AU"?3RFF3
MQ078DC=6F4E" X+*<<X*@C\:O5G:WKNG>'-+DU+5;C[/:1XW2;&;&>!PH)H
MY1_AW'<VGBE,6VG'7K983!9Y:*-U#?O#D+EB6YP!T[DYJ6+POXCN=>\-:MJ.
MHZ:'TB.>-XH('*N'15R"6SD[2<]!QP>:ZJXU:SM-4LM-FD9;J]$A@01L0P0
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M"Z^T"SML^3!\@4A<@9)())P.N,<52U'PKJ\_BK4=2M-2M5M=1L%LY%N(6>2
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M(\]HEI>6UX[ 3!/N2!P"0XZ'(((/:L^^\!74FA_9+:ZM_MEQK"ZO>3R*P5I
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M!1T73?['T*PTP3O/]DMXX/-?[S[5 R?KBKU%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^.M>U+P[HUM>Z:E
MM([WL%NZ3@\K(X7@@\'GJ<_2NHKAOBQO_P"$1MA'(L<AU2S".PR%/G+@D9&:
M (SXKUSP]XM_LSQ+]AFL;NRGO+6XLHF0QF$;GC8,QS\O(/'Z\+:>)O$EU)H5
M];V!N;+4'3[5 MFZ?98W&1(LI.'"Y&>.>H K8D\,OJVM+J6MM!)Y-I+:06\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\TZRU!56]
ML[>Y5#E1-$K@'VR*LT4 (B+&BHBA548"@8 'I2T44 %%%% !1110 4444 %%
M%% !52#2]/MKEKF"PM8KA_O2QPJK'ZD#-6Z* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"J=,T]KT7IL;8W
M8Z3F)=__ 'UC-6J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQC''-=(/#.MK>_;!=^&!=;M_GC0&W[O7=]HSF@>&=;%[]M%WX9^U;M_G_V
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MA9C<%QR. 1D=*JZ=J=BWCKP/(NHV!A?3+B&."V<%(5*Q;(MQ)+MVYQG'09H
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M;3;Z"6>TU"UGBA.)'BF5E0]?F(/'XTRVUS2;V;R;75+*>7RO/V13JS>7G&_
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M[7KS3/A]?:YH5[ )(D22.8*)592P'R\X[]>:Z&[U73].""^O[6U+C*^?*J9
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M)J.G.L92)"6\L!AAD88&2Q(// KLK#6--U19FL;ZWN! VV7RY 3&>N&';\:
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M@#EM+\*%K^&^U/2="M)(-VU-.ASOW*5.]RJDK@GY<=<'/%="=(TTQB,Z=:;
M20ODK@$]3C'L*BDU_2(KX64FIVJW)D$0B,H!\PC(3_>QSCK7,1^*_P"RO'7B
M*UUW6;:WTJUM[5[?S]D2HTF_(W=6/RCOVH [<*%4*  H&  . *K1:980+&L5
ME;1B-S(@2)1M8]6''!]ZS=8U&WDT^PFMO$5KIZ7%Q$8I\QR"Y4L/W:[C@[@<
M9'/-9_\ :NHQ_%;^R'NP=,;16NQ#Y:C;()E3.[J>,]\<T =#%I>GV]T;J&QM
M8[@C!E2%0Y_$#-$6EZ?!=&ZAL;6.X.094A4.?Q S7-W'BNP\.^&-5UJ^U^'5
MH(KF7RC"$&TG[MN"N<D=,GGG)Z5MP^)-#GNH+6+5[![BX&88EN$+2#D':,Y/
M0]/2@"V^GV4EZEZ]G;M=H,+.8E,BCT#8R*D-M URMR88S.J[!*5&X+Z9ZXID
M5_9SWDUG%=0R7, !EA5P7C!Z;AU&:R=3\7Z1I7B*PT2YNHDNKM7?YW"B-5'4
MD]R< #ZT ;-Q;07<#07,,<T+?>CD4,I^H-1MIUB^_=9V[;U5&S$IW*O0'CD#
MM4%YKVDZ?/Y%YJ5K;R_+E990I&[[N<],]L]:T* *9TG3B$!T^UPGW/W*_+SG
MCCBEGTK3KFX-Q/86LLY0QF22%68H1@KDC.,=JA?7](COQ8OJ=JMT9!"(C*,^
M81D)_O8YQUIVH:UI>DX_M#4+:URN[][(%^7^]ST'OTH MQ00P[O*B2/=C.Q0
M,X  _0 ?A4,VFV%S=1W4]E;2W$7^KEDB5G3Z$C(I+K4["QMX[BZO((HI"!&S
M. ')&1M]>.>*JKXGT%K(WHUK3S:B01&;[0FP.0#MSG&<,./>@"[)86<TZSRV
MD#S+C$C1@L,=.>M6*J'4[ :B=/-[;B]$?FFW,H\S9_>V]<<]:R=/UJPLM,O;
MZ_\ %%E>6@O) MRS1QI".HAR#@E1QGJ: -=-,L(P EC;*!+YV%B4?O/[_3[W
MOUI9-/LI;R.\DL[=[J,829HP74>@;&15:/Q!H\L=U)'JEFZ6DGDW#+,I$3_W
M6YX/;%3Z?J=AJUNT^GWD-U$KE&:)PP5AU4XZ$>AH ==:?97S1-=V=O<&)MT9
MEC#[#ZC(X-/NK.UOH#!>6T-Q">3',@=3^!XIE[J-GIT:O>744"N=J^8P&X]<
M =SCTJN^OZ/%I::F^JV2V#_=N3.OEL?0-G!/M0!<2V@BMA;1P1I %VB)4 4+
MZ8Z8J&'2]/MUC6"QM8EC5E0)"JA0WW@,#@'OZTECJNGZFUPMA>V]T;:0Q3"&
M0/Y;CJIQT-<I%XI;3/'7B*UUO6+>#2;2VM9(//V1+&TF_(W=23M'4]J .K&D
M::(S&-.M-A()7R5P3ZXQ[U*+*U#PN+:$- "(B(QF,'J%]/PICZG81V"7[WEN
M+-PK).9!L8-]W!Z'.1CUJI+JD&HZ+>W&D:A [Q(X$L9$GEN!G!'J/0T :%Q;
M07<?EW,$<R9SMD0,,_0TGV2V^RFU^SQ?9R"IBV#80>HQTQ7/>#]>:[^'ND:U
MK5Y&LL]LDDT\FU%+-^0&3Q@53\-^(KC5O'OB.Q74H[O3K6"V>W6-5'E,_F;P
M2.2?E'7TH N>+O#4FJ^!]0\/Z+!96INH_+4-^ZCC!.2<*I_+%;&E:;!86RLM
MC:6URZCSS;*,,P_VMH)_$5A^-?$S>'WT:W^U1V,6I7GV>6_E4,MN-A;OQN8@
M $\#))SBK=G%KT.L-;RZBEWILEHSPW!@42)+N4?,5PK#!R, =\YQ0!K/IMA)
M?+?/96S7:C"SF)3(![-C-.-A9M=?:6M(#<9SYIC&_P#/K7'>!/&4%]X9TH:]
MK5H=9O99U2-W2-Y=LSHNU!CLH ]<>M=1?:]I&F3&*^U*UMI  S++*%V@G )S
MT!/ )H MO:6TDS3/;Q-*R>679 6*?W<^GM4']D:9Y?E_V=:;,[MOD+C/KC%1
MWVOZ/IDIBOM4L[:01F4I+.JD(.K8)Z>],N/$FB6EK#=7&K6<=O/&)8Y&F4*R
M'HP.?N\CGI0!)=Z1!+;S_9(X+2]:)DANE@4M$Q7"L/7'''M7'6_@O4KK3QIF
MKZ7X7:+RO*>^B@9YW&,%MK+PYZYW'!YP>E=I=:QIMBD;W5];Q+*I="\@ 91C
M+#V&1STY%68+B&YMH[B"5)()$#I(ARK*1D$'N,4 !AC:#R70/&5VE7&X$>^>
MM-M[2VM$*6UO%"I.2(T"@G\*ICQ!HQLI[T:M9?9;>0Q33>>NR-QU5CG /(X/
MK1<>(-&M75+C5K*)FB,X#SJ#Y8&=_7[OOTH LVFGV5@9#9V=O;F4[I##$J;S
MZG Y-<WXQ\*RZOIBPZ-:Z=!<O>P74\LF8R_EN'Y*H2Q.,<]*Z"SUC3=0TS^T
MK._MI['!;[1'*#& .N6Z#&.:Y9?%#WGQ.T_3+#58;C39M/FFD@C525=2FTEN
MN"&..WUH ZUK*VGGANKBTMVNHEPDA0,T>>H5B,X_*FMI6G-#%"UA:F*(8C0P
MKA!Z 8XJ$:]I!U)=.&I6OVQB56'S1N9AU '<CN.M1'Q1H(N4MO[:L//><6ZQ
MBX7<9?[@&?O<CCW% %Z/3[**X-Q':6Z3'.9%C 8YZ\XS2-IUD]ZEZ]G;M=H-
MJSF)3(H] V,BL[Q/XFT_PII!O[^15!=8XDS@N[' 'L.>3V%85[XI:U\?:<AU
MBV&@3Z9/<N3L$89'10WF>GS'OB@#K3IM@97E-E;&23(=S$N6SUR<<TW^R--\
ML1_V?:>6#N"^2N,^N,4EMK&FWFEC4[:_MI; J6^TI*#'@<$[NG%&GZOIVJ^=
M]@O8+DPMME$3AC&?1AU'XT /GTRPNC";BQMIC!S#YD2MY?\ NY''X4Z2PLY;
M@7$EI \PQB1HP6&.G/6N5^(6LZKH=IH\VEW:PM=ZI!8R!XE==LA(+#/.1@=\
M5##XBUC3OB'%X3U&:"[BOK%KJUNXX=CQ,I(*NN2".,@C'I0!UT>FV$22)'96
MR)*-LBK$H#CT/'--GTC3+E8UGTZTE6,!8Q) K! .@&1P*YOP1XAGNO!SZGKV
MH1%X[RXA:XD"Q+A9F11Q@=@/>M^/7]'DL9[U=4M/LUNQ2:4S*%B8=F)/RGV-
M &B  , 8 JJVF6#F<O96S&?'G$Q*?,QTW<<X]ZK6OB/1;W4!I]KJUE->&,2B
M".92^PC(.W.<8(/XUI,P52S$!0,DGM0!6.FV#3-,UE;&5P0SF)<G(P<G%']F
M6'V62U^PVWV>3[\7E+L;ZC&#4-GKNDZA<-;V>I6L\RIYA2.4$[/[P'=??I44
M7B?09[J*UAUFPDGFE:&.-+A27=0"R@ \D C/UH NVUA9V?\ QZVD$'RA/W48
M7Y1T''8>E23P0W,+PSQ)+$XPR2*&5AZ$'K27%S!9V[W%S-'#"@RTDC!57ZDU
M5M]<TJZM;BZ@U&U>"V)$\@E&(L#)W_W>.>: )1IE@MHEH+&V%M&<I"(EV*?9
M<8'4TY[&TDN5N7M8&G7&)3&"PQTYZU#8ZSINI-,ME?03O#@RJC@E >02.H![
M'O4*ZS8:DLMMINJVS79A,B>6RN0O3>%[KDCGI0!;73[)+UKU+.W6[<;6G$8$
MC#T+8S3?[*T[Y_\ 0+7]Y]_]ROS<YYXYYKE/ ?C*VU7POH0U?6+1M<OX#)Y+
M.B22?,W1!CL.P[5V4T\5M"\T\J11(,N\C!54>I)Z4 0C3+ "$"QML0-OB_=+
M^[;U7C@_2D;2].= CV%JRAB^#"I&X]3TZGO5:T\2:'?3&&TU>QGE6#[25CG5
MB(O[_7[OO[U+8:WI>J32PV&H6US+" 9$BD#,H/0D>A['H: (M2T:.YL+M;#R
M;'4)87CBO8X%+Q,5(##Z?6N5@\&7U[:"PU?1_"\<.P1M=6D+-,0!C*AE&QO1
MMS8//-==!KNDW-^+&#4K62Z(8B)906;;][ [X[XZ=Z237M(AU!+"34K5+MW\
MM86E 8OC.W']['..M %B?3K*ZN8KBXL[>6>$YBEDB5F3_=)&1^%6:PTU&WBU
M[4I)?$5L]O;VZ&2Q/EC[(03EV;.1N]#TQ5Q-=TA],&I)JEFU@3M%R)U,9.<8
MW9QUXH G&GV0OC?"TMQ=E=IG\L>81Z;L9Q27.FV%[+%+=V5M/)$<QO+$K%/H
M2.*@OM>TC3'5+_4K2V9@"!+*%X)P"<] 3QDU+?ZG9:=&IN[R&W,N1&9&'S$#
M/ [XZT 23V-G<RK+/:P2R+PKR1AB/H321Z?90R/)%9VZ/("'98E!8'J"<<US
M?P]UJ\UW1M1N+R]2],6J7-O%.BJ%:)&PI&W@C'.?>F>*?%MOIOB+1M"&IP61
MO6E-S<>8F^!$CW+][(!9BO)!X!QZ@ Z0Z3II6-3I]H5B&V,>2N$'7 XXJ2\L
M+/4(A%>VD%S&#N"31AP#ZX-8&DZ_9:;:?8=9\5:;>WR7'D>;OCB9BY/EHR@X
MWX'8#ITK6FU[2+>]%G-J5I'<%Q&(VE .\\A?J>PZF@"U+96DT"02VL,D*8VQ
MM&"JXX&!T%0RZ/IDYC\[3;.3R@!'O@4[ .@&1Q4=WK^CV$\L%WJEG!-#$9I(
MY)U5DCR!N()X&6 S[BJ[>+O#BP6<[:[IPBO3BV<W*8E.<?+SSSQ]: -FBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K \::&_B+PE?Z?"=MV4\VU<=4F0[HR#V^8#\":WZ* /'VUS59+[0OB#
M;6,FV_A&D26>S#,6&48]P/M&5S_=P>];/BVRM-.N_ .FSO%(J:J-YEQ^\;RG
MRY![ECGZFO1/*CV!-B[%((7' QR*22W@F8-+#&Y'0LH.* /.+66T7Q?\38S)
M"(_LEJ[*2,9^SN"3^F:Q=.UB'1M%^%^J7\@71(K22&>?K'!.T2K&S^G\:Y[9
M->O_ &.VRQ^SPY;[QV#GZT&TMV@:!K>(PM]Z,H-I^HZ4 >7^.Y_#TWPX\0W>
MC>0;>\OK:2>ZC?,=S+YT>XJ<X;  R1QU[@ULRM:0?&G2HX##'NT&9 J$#($J
M%1@=NN*[@VMN8DB,$1C3A4V#"_0=J06MNKAQ;Q!QT8(,B@#B_BX8!X#D\\Q@
M&]M,;\?\]TSU]L_A4-TE@/C9I("VP9="FV#"\8E3;C\-V/;-=[+#%, )8DD
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M[Q7GD:2X)8*"\A)?:,YZ\ ' KLWM+:5R\EO$['JS(":E95="CJ&5A@@C((H
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M.0<?Z[*D'ZKQ[CUKW-X8I)$D>)&>/.QBH)7/7![5&;.U*A3;0E5S@;!@9Y-
M'G$QB/C7XB00%#))HT!\M",LPCE'0=\$#\JZ;X=7UK>_#_01:W$<WDZ?;Q2>
M6V[8XC7*G'0CN.HKHUMH$D,B0QJYZL% /YT^.*.% D2*B#HJC H XCQ9!>'Q
M/#=Z#K=M9:[;6))M+Y08+N N20><J0R\L.F16]X/OQJ?@[2+Q;'["LMJA6VS
MD1@#  ]L#CVQ6I<6=K=X^TVT,V.1YD8;'YU/0!X=K^MZ7=>';YK:XM]/2'Q(
MDDMANW3!Q<KOFE+$E03R , 9 R>E=99R:0_Q7\13:@UGY<VE6CPM<[</'^\W
MD;NW3/X9KOS:6Q,A-O$3(07R@^8CIGUQ1/:6UT4-Q;Q2F,Y0R(&VGU&>E 'C
M#V:Z5\-M(68""T?Q3'-IZ2_*4MC<Y3 /0;<M]#79O/#_ ,+QB0RQ[CX<<;=P
M_P"?A3_*NVE@AGQYL228Z;U!Q2?9;??O\B+?_>V#- 'B]VT4OPC^(BV[(ZKK
MEVV(SG"^<ASQVQS79^-"EUHMAXQT-X[NXT24W2/"P83V^-L\8(X.5R?JM=JE
MM;QJRI!$JN,, @ 8>]86LZ1K.I7L=E!>65OX?D@\N[@\AC.W/*HP(559?EZ<
M<X[8 )O"Z/-I\FK3(R3ZI)]J*L,%(R (E([$1A<CU+5S_B>\MM/^*7A&XO)T
M@A-K?1AY#@%B(\*/4GL.IKO    !@"FO%'(5+HK%#N4D9VGU% 'F&AW5HOA_
MQUI7B%XTO!?7<ES',0#)"Z_NW4'JI4 +C^Z!78>!;;4+3P)H=OJN_P"VQV<:
MRA_O*<< ^X& ?I6W):6TT\<\MO$\T?W)&0%E^A[5-0!X=KFMZ7=>'IY+:XM]
M/CA\2I)+8;MTJL+D;YIBQ)4$\@# &0,GI71VOB'1;#QGXNT_Q1=06\.I)#+:
MR73;8[FU,(78I/7!W<=<L?>O2#:6Q,A-O$3(07^0?,1T)]<4LMK;SO&\T$4C
M1G<C.@)0^HSTH \W35M,\/?$/2A?[=+T5M!$.EF[.R.)A)\R$M]UB@CZG/ '
M6N>OWCN/AI\1)K<;H3XB:;*J?N![=BWTP":]IGMX+E56>&.4*=RB10P!'0\]
MZY[PKH%]H\NO?;_LLD>IZC+>J(G9MH<*-A!49^[U]^E &!+K>E7_ ,8=$DM=
M0MIXGTFYC62.0,C,7C.T,."<#H.:Y+49;1O@_P"/PLD)4:[=;<,.\Z$8KVR*
MTMH0HBMXHPJ[%"(!A?0>WM2?8K3:5^RPX)SCRQ0!P/C::RT"]\,:LG^AZ(MV
MWVNZLXU(C+0E(I&X((&2,XX!^E;7A&+09-2UC4]#O9;\WK1&ZNQ('BDD4$ +
MM 7<!C./49YKIS!"T!A,2&(C!0J-I'IBEAABMXEBAC2*-1A410H'T H X>_N
MVT_XRV$FHN(["YT=[>RE<X07'FAG7)X#% OU"UQ7B:W2'P;\1[E&0:/<ZE U
MGR-K2;HO.9/J^1D=U/I7M<]M!=1&*XACFC/5)%# _@:&MH'C6-H8S&OW5*C
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M_P"F:AIUJLDT,$#7+6R*96A6=7E7./0$D'CCFM6ZDT7Q)#J&K>%]8N=5U_\
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MUP0N!CG)'&* /3].US2=79UT[4K2Z>,9D2&969.WS*#E>?6JMQ>6X\5VMO\
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MB* _?&T  #.,55L=;L])/@G4=4O9[;19?#L=DMY"Q"0W("%E<C[N0H'U7V.
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M->TO4[J6UL[Z*6XB4.\0.'"GHV#R5/KTIU_K>E:7/%#?ZC:VTLP)C2:55+
MDD ]@ 23T&*Y+PY>^$_$?B.UUG1KZZU+4(K9HVF,CD01-SM<' !)Z*>>I[&F
M_$)[./Q)X(DOC$(!JC[FEQM'[EL9S[XH Z2U\7^'+W2Y]3M];L7LK=MLT_G*
M%C/HQ/3^M/MO%.@WGVK[/J]G(+1%DN")1B)6&5+>F:\Y\16]L-3^(6JV3Q+I
MTOA\V\\BD!);O:^ #T+!=H/NP[U8UORX/A[X-U6RBC?3[.ZT^?46@4']PB\D
MXZA6(8CMC- 'H]AK.G:G+-#9W<<LT&/-BZ.F>A*GD ]CCFHD\0Z/)J"6*:C
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M2,,%@.2/K3BH88(!^M9<.KV6L17EM87SQW4"XD7R]DT)(RI*2+D9[9&#7/\
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MC&5QD9STS3;KQ7H-E<)!<:M:QS20^>L9?YC'Q\V/?(QZYXH UA&B@ (HP<C
MZ4H55Z*!]!7+ZOX^T73_  A+XBMK@7MMN\J+R58[I,[0K<97GKG&/RJY=^,O
M#MAM%WJUO S1--LD)5@B\$E<9'XCGM0!M1Q1Q B-%0$Y.T8R?6N=\2:!?:QK
M>@WMN]LL6F7#3NDI;,NY"A7@<<-G//TJ]I7BC1=;N6M]-OX[F98EF94#9",,
MJQR. 0<CUJ[8ZC:ZE')):2^8D<C1.=I&'4X9>1U!X/O0!.L4:1B-$54'10,
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M[A0,$].!D=*L^,I8+/Q_X)O[UDBLH7O%DN)>(XW:)0F6/ )/3-=W00",$9%
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MS;^<%?)=D&/F( ZG(XZDG@4ZS\7^'[_0GUJVU.&33T?RVEP05?(&PJ1NW9(
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MR")3T9RBG8.#RV!P?2LZY\:V$/BG3M$C2>8W=LUT)XH'D39\H7:5!# [LY'
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M4NS9.XTS!570E3YCJ5R&' &2#STJ>X\5:+:3&.>]"*LWV=IC&_DI)G&QI<;
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M]WCV( P]5R&YZ=:E\4ZK%9>-=%MKB,VB2VTVW4TMS++NRO[B,[3M+8R>#G
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M#<<@8H WZ*P[/Q=HVH7EY9VMQ-)<VD7GO%]FD#/'G&^,%?WBYXRN?UK*TOQ
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M/!J2\\8VUKXSM/#WV>Y8S6CW+3);2.N R!0"H.1\QRW08&3S0!-X.\.S^%M
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MCM-Q%'!)(R!@2#A5.1A221P.,XR* .DHK''BG17L-/O8;T3PZB<6?D(TC3D
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M#ZPO+N\FO)I);C,\S%F<"=P.?H!5V_\ %\%CXSLO#IMKIGGMWG>5;:1U !4
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M.*W33=<GTDQR[I7A@20RIC!7YP0/K5^QLX-.L8+.V4K#!&(T!.3@#')[GWH
MY?XHVES??#?6+>TMY;B9EC811(79@)4)P!R> 35'5HHO%GBWPU>:+)O33A<3
M37J*0(@\118\G^(L02O4!3G'&>]HH \@\)RZ5/H^F^%];T75I-?TYTC-I,;A
MH-T9PLX;/EA,?-G\ #QGUV21(8FDD8*BC+,>@%.HH \DT33K[4/V?I=,T^"0
M:DB2G[.RF-R1.S[<'!!9>GUK1TZ[T;Q:%GTC3M576X+6=!-J!N =/=XRNW=(
M=I8M@87/'/:O2J* /$KO7;>?X3Z3H3V=Y;:GIMQ86UW!+;.@B9)HU)+$;3N(
MR,$DY^M==]M31/BQK#WD-SMU+3[86AC@=Q*R&0,H(& 1N'7'!STKH?%OAV7Q
M/I":?'>K:*+B*<N8?,),;AP,;ACD#-;B!@BAR"^/F*C )]ASB@#Q6R9U^#W@
MV![>Y2:'5[9Y(W@<,%6<LS8(Y4*0=PX]Z[+3Y8F^,FJRC)2328(HY=IVLRN[
M,H;H2 0<5W5% 'D-E-IUE=:WX8\4Z7K%Q=3ZA/-;11?:'AOXI)"ZX"G8#S@[
ML 8Y/7&MI=[_ ,(K\1==CUBWG@MM3@M#I\T<3RQD11[&A!4$Y!)('?.>]>D4
M4 <1\)BR^ +6&2">&2.>XRLT+1\-,[ C(&1@CI2:Y(UC\5M!O98+AK>33KFV
M5XH6<>87C(4[0<9 /)P.*[BB@#RO2)3I?@[Q1X8UB&5M4::\\J(QEFOEF+,C
M1\?/G=@XZ8YQ7>>$].N=(\(:/IMX^^YM;.**4YS\RJ 1GOCI6Q10!PWA>1#\
M3?&KX($YL_*<J0) D15MIZ'!X..E<KX?;31I)\'^)-(U:YUNWG=!:N;AK>Z_
M>%DE!!\M5Y!).,8)KV.B@#SG2=4T[3OB7X]%_(D8?[$1O4GS +<94<?,>?NC
MDYZ5C:'#=>%=*\':5J-E-:)(MW(;R.T,TUKO?<ENI"ML+*P!XS\N!ZCO]'\.
M7&F>)];UF2_CF&JF)GA6W*>7Y:;%PV\YXZ\=?2N@H \26*<?"_5X%LK\/:>(
MOM$B202%Q']K#9Y&6PO)QGWKKI;V"[^+FBW:++Y)TB>,/)"RA7:1"H.1\I(!
M(!P<?6N_HH \_GG:+XKZQ/%;-<D>'EC2/:=LTJR.WE XQG!''O7-6%^+K5/A
M_J(M[[]S)-'<016$D4%F[0,HA1 N,!N,\],D@5[+10!Y'-9ZA=:+\1=#M+:Y
M&IW&HR7<"&)U66,K$1A\;?FVLH&<UN^&M2\/^)=7T^]M-*U4ZI9JYD;4/M&;
M#<I#+ND.TDG PN<CGM7?T4 8/C.&PN/"MY!J<=P]G(T22&VSYB9D4!UP"<J<
M-T_AK@IK_7--\/\ B6"40^++&VAMS:WLMJ)&D5G.Y) O$IC'S\>O.,\>MT4
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MN+:&5C"Z!@8Y$3YANSD9'?ZX .X'BC2)=.L+ZWNOM,6H?\>8@4N\W!)VJ.>
M#G.,8YQ7.^!-2EU#Q-XQ4W5[+;P7L*0QW9;=%^Z!90K?=&[/3BLB:'_A&/$O
MAC68]#N+/P^EK<VK6\$+.;)I'#J[HN2-V!G&<$D&M?P5,TWC3QE/]EO(H;FY
MMY())K:2-9%$"J<%@.<]NO- !XQU1M'\=^$)Y+ZZBLY6NUG@C9BDNV$E?W:_
M>;)X&"<D5KV7CKP]?:1J&IK?&&#3CMO%N(GCD@/8,C#=D]N.>@YK-\8![;QE
MX/U62&9K&SFNA<S1Q,XBWP[5+;02 3QGH*P=9AOHI_&'BG3M(-W!<P6EM#!+
M;%_M&QOGF\HC+!0WRYZ[,],$@'=6_BC3;BZN[0_:8;JTA6XE@EMW$GEMG# 8
M^89!'&2",&L^T^(?AR].FM!=3M#J,@BM[@VL@B:0DA4+E=H8X.%)S7-Z3<+'
M\3I=1$.L3V=QH*HMY=6LHWNLS,W!4;.,?+A<]AR,XMI!<Q?"+P7:/8WHNK75
M+5YH?LLF^-4F+,2NW( '.: .LTO53IOCSQP]_?W#:?96]E,JRNSK"&20ML7M
MDCH!SQ7:6=TE[:I<1I,B.,@31-&WXJP!'XBO)-:M-5?Q[XEUW2XKB1K'[#=0
MVLL#^3?B..02("5P77<"I&<-C\/5-(U2+6=,AOH8;B$2*"8KF)HY(SW5E89R
M/RH K:AXDT_3I[B%S/-);1B6X6V@:4PH<X+;0<< G'7'.*KWGC70+*'39I+X
MO%J?_'I)%$\BR\$X!4$9P.G4],5@:-/)X9\9^*8M7BN!!J-PE[9W*PO(LJ[
MICRH/S+M "]2#Q7-V6BWF@Z1X"M+JTN=\.KRW<L20M(+6)Q*5#%00N-Z@^AS
MZ4 >J:1JMKK>EPZC9^;Y$V[;YL31L,$J<JP!'(-7J** "BBB@ HHHH ****
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MN-V<9YRRC'?/&: -"BO/?^$PT[0O 5GJ6B)J.H6MS?&WBDN=[NK-.58L6^;
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M>8_W49\8#$\8['@XJ]JWBFPTA;MI8[F:.R4/=O;PF06ZD9RV/;G R0,'&"*
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MTC,Q'  4$UB^+;>]F\-^&=7L]+N+]-,N(Y[G3_**RO&8FC;"'!++NR!7H5%
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MXFC,;N47CS/F. ><8SSP-77KB_\ %O@+Q$EEHM[:^?8O'!'=Q>5/.^T\;,Y
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M-9W_  LC2/[+N[X66JL+&1X[V%;0F2UV<L9!G &#G@G(SCH:P]-T*]T/Q!X
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MY+C<6' X'7T&*R8=)U5/@[I.DMI5\-1AU%)9+?R&W*HNC*3Z?=YZ^W6O7Z*
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MB%N Q;;C8><\@ &M[XH6EWJ7P\U;3K"TGNKRZC5(HH4+$G>I.3T' /6NPHH
MS]'B@738)(K7[.[1J) T/EOD#G(QFO+M1M_$6J:=:3:AH&J2ZK9:_%<3; OD
MK"L^1Y"[L'Y<9;&>NX]*]AHH XO08;M/B7XDO9K"ZAMKRVM$AE>([&:-7WC/
M3C<.>A[9JEHUMJ.FIXWLKC2KS_2[ZYNX)E0,DJ21HJA<');(/&..Y%>@T4 >
M36^GZ[HNB> ]:@TB[NI-%M7L]0T]$Q.%=%4LBG&XJ4'3KGZD;OB^35/$?PVU
MQ(=%O();N'RK2TDC!G<\99PI(7Z$\ <]<#O** /.M0OA:_$[PM.]O=%3H]RK
M*D#,Z?-'R4 W=>. >OIS52ZT_7[!/$&OZ;87(_M;5;9GMXD'VA;2-0CR(IZ2
M-@D \@$'@].UN?#4-SXJM/$+7UXMS:PM!'"IC\K8Q!8$%-W) [UMT >66UA?
MV^L>-I(]!U.*VU32X5M6D'F,[+'*I#'<6+$N.N2.^*D:QU >'OAS;_V;>^;I
MD]LUZH@;,(2!HV)XY^8CIG/6O3Z* .,\,VU_IWC7Q5'<:=<+!>W:7,-U@>4R
M>4JXSG.[*XQBM;Q?:VU]X?DM+W2I=3M)I$2>"($N$W#+KCG*_>XYXXYK=HH
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M"7<2^6+ XX Z^@Q62^DZK)\&-?T@:7>_VC<75P8K<PG<X><NI],;>?:O7:*
M(K:02VL3A77<H.UU*L/J#R*EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMIKUA=7]S=3&WN;U"G[@-(%B,@!Y8AD!QW#'FM3QL^M1^'6;0H99KCSXO.2
MJ)3#N'F>66XW[<X_3G% !'XOMS-K-M/87D5WI,23SP81B\; D,A#8/W3U(Z5
M1LOB%97C:'(=+U*"SUG:EK>31H(_,92P0C=NS@'G&">A/6L*RTS4;7Q+XFNH
M?#M]!9ZCI,20EW1W+J) 0_S$ER6'<\<DBH_[*U5?!WP_LO[*NS<Z5>VLEZ@4
M?NECC96/7GDCIG- '0>*M>AN]!\16=I8W=ZEE;R1W4UNRJL3[-VT$L"S*"I(
M'3..3Q5_P(Q'PZ\.,%+$:7;G ZG]VOK7)VEIK>@Q^,-$DT6\O8M4N+J]L;NV
MVE&\Y>4?+ J5/Y]NV>P\$V]W9>"-$L[ZTDM;JVLHH)(I"I(94 /W21VH X76
M_$-YXI^%_C*6]TZ>U%J]S%$?,3:IB(4+E6R3D$GC'/!/%=;H_BR ZCI>ASZ=
M?6KW5IYEI<3(HCN-BKO"@,6! (/S <5RDNCZW'X%\:Z%_8MTUQ=WEY):NI0I
M,)7RFWYL]"<YQC'K6U>6E_/XM\#WB:==?9[""X6[<ICR2\2HH///(/3- &E'
MX\L)'L919W@L+Z_;3H+PA=C3!F7E=VX*61@#CMVI-'\3W^H^.M>T:73)H[73
MQ JR;XR 75V+M\V<,-H  .,<XR:XNYL?$^I6.C7.I>'K^?6;#7HKF[E\R/88
MED; @!? 7:5[+TR23S76Z/::E8?$GQ%<S:9,;/5([1XKI64QIY<;*RMSG.<8
MP/RH S_BT(XM,T&=I&AW:W:PRR+(8\Q,6W*2"/EQUJGIU^+'XKO9Z#?RW/A]
M=-:;4HQ.T\-M*"=I4DG:Q 'R@].<5K?$JQO]2L]#AT_3[B[>VUBVO)1$!A8T
M)+')(Y]JZRZ-P-(N7TV)!=F%V@21=H\S:=NX=N<9H P]/\;V=_>:/";&\@CU
MF)Y;":0)ME"+N((#$J2O(R.GH>*@M/'L>H7EQ;6&@:S</;7KV4Y6) L;JH;+
M$O@ YQG\\9&>6LK'79]8\%ZO<^'M2-Y9O,NISW$D9<R/"5ROS<1ALD 8 '0$
MUT_@6TO;.[\3_;+&XMEN]8FN[=I5 $D3*@!X/!^4\'F@#&3QA;:U\)KS6O$^
MB7DFG2>9YT4#(=\?G. %*N&^7:H).W/7FNSN=<AM;N#3;6UFN[U[?SQ;Q%04
MB!QN8L0 ">!SDG/H2/.TT775^"&H^%VT2[&HQK+!&N4(F+3,X*D-]W:1R<>V
M:V=1&M:'XUMO$UGHUWJ6GWFFI975O;[?/@=&+*VUB 1\Q!Y]_J 6M2\4^']8
MT#0M0O=,OYK:[U2&*!&38T%R)-JE_F'1@>F0<=ZNWWCJ"UUC4=)MM%U:^OK&
M-)7BMX5.]6SRI+ 8^7O@G(P#6?XO@UG5]%T-_P"RIOM":S;7DEM$58P0QOD[
MFS@MCJ!GDX&<9J"SU#[%\7/$C&TNID?3K/F"(N5/[S ('(SSST&.2* -FT\>
MZ5J6E:1>Z?'<7+ZM*T-M;A0KAT#%P^2 NT*<\_3-17/Q"TZT\+ZCKDMC?>7I
MUTUG=P*BF2*56"D?>P1EEY!/!KG+71O$/A_3=)B73[J:SO=2NKS5;6PD42Q"
M0DQ(&W#Y02-VTCIUQUS;KP_K@\!>--&A\/7,4U]JS7%G&AC*LC-$0!AN,!#G
M.!T S0!Z!;>+HI_$+Z+)I>H6URULUU:F=4472*0#M^;*G)'#[3SSBH? OB6]
M\3Z3->WFGR6Q%U/&A+(5PLC*%&#DD <D@ GI56^M[RY^)NA:G'871LH;"XAE
MF*8"/(4*@CK_  G/I3OAY9ZCI.DW>EZAITUNT-]<R+,[*4F5Y6=2F"21@\Y
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MQVEY#:)!.P&US&KA_<<L.HYH VM3UZ+3]4L],CM9[J^NTDDCBBV@!$QN8LQ
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M0R.L)2(]"Y<C!)X YY![ FK/AGQ)9>*M%34[$2(A=HI(I0 \;J<,IP2,CV-
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M( "T(0'!8$Y()X' KK-#\.VN@-?-:SW#_;KE[N83,&S*V-S# &,X''3VK7H
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M:"5!]CB(^^YZ.1@$A?7 )QD]!10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11534M5T_1K,W
MFIWL%G; A3+/($4$]!DT 6Z*IZ;JNGZS9B\TR\@O+8L5$L#AU)'49%7* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N1^)QF3X<ZW/!=
M7%M+#;-(CP2F-LCW'./:NNKF/B):W.H> =8L+*VEN;JZMVBBBB7)9C^@'N:
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M!.@G5@ZN3Z=1U'?O@ ]GK.U36;?2Y+2!TDFNKR0QV]O" 7D(!9L9(   )))
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MIG(RHP&+*6'(W*,^U8LNCZC)XU\76[65P+37-/@AAO5V^7&5CD1MW.0<L,
MY_6JG@^.\2'3M(U#P(EKJ=CY:3:D\$7V<A,?O$<'<78#@ <$Y)XH G^(?B""
M_P# ?B5+.TOKB&UBDA>[MV"HDJCD?>#,%. < C.>N#CM=&_Y >G_ /7M'_Z"
M*\O2PUW2_A[XE\&RZ'?W5T1=?8[J! T5PDI9@2V>&RQRO7TS7I^B"9="L%N+
M>2WF6W17BD*EE(4 @[21^M '._$FZU&R\.6]U96]U<6D5Y$^I16;$3/:C.\*
M1@]=N<$<9Y S4/A:7P_K%]!KOA746ELTMI(I[".=MH=BI4F)CA&^5AGC.>]=
M!KM]J.G_ -GRZ?I\U\ANMMU'#MWB'RWRPW$#A@G&<GH*Y*W\/07/Q.T[Q#H>
MF7&FPQPSKJDLD#6ZW18 (NQ@"S!LL6QC@<DXH T/#WCDWNBZOJ^L6<MA:65W
M-%N8HP 1@@0;6+,Y/M@DX!/%:\/BFW_MRVTB^LKO3[N[C:2U%R$*S[>652C,
M-P')!QQZUP,GAC7KWP9XBT.+3IH;Z/6)=0M9)6417(\\2HH.>X]0 #C-=)?6
MMQXNU[PS>+87EE%IDSW=R;F(QLC%"HB7/WB2<DKE<+UY% &C<>.-.MTAN3:W
MDFFS78LUOXT4Q>86*=-V[;N!7<%QGVYK!TG4(-#\<>/KB7SY(XVL2D2L7=V:
M(G8@8\DD\+ZFH_!4WB+PYI47A"X\/W<EQ9R-'!J8V_97A+$B1FW9R ?N@9.!
MTR<9>JZ!K;^-O$GB72[:[CO;66VN-.$D;>5>A(3'+$1VSG )P1U!QDT >K6L
MSW%NDLEM+;LPR8I2NY?KM)'ZUS?Q)W)\.]<GCDDBF@M'EBDC<HR,!D$$<BM[
M2[Y]1TZ&YEL[BSE=1OMYUP\;=P>Q^HXJIXITA]?\*:KI,;JDEY:R0HS= Q4@
M$^V<4 -\-VT3>$-+C<,XDLXFD+L6+DH"22>23ZUSND^(K'PKX0T%KR.^F.HS
MK;B1%:9C(['&XDY/0],GC %6M!UV^L?#5CI]UX?U7^UK:W2!X%@_=NZJ%R)L
M^7M.,Y+=.U9VOZ)?VOA[P;816TMW-8:I:7%VUNA955,F1OID\#J?2@#H=,\6
MVVIWFJ6#:=J%K>Z>B226T\:[Y$<':R;6((.".H([XKF8_%EIH_@?PQ/X6TFZ
M.FZC?Q6L*R2*6C1I3N!WN26;# <X&>2,8K3LXKF#XG:UJ;V-W]BETV"&.80L
M0[HSEE Z]&'UKE[+0]9MOA5X2MFTF[:]TC58+FZM H\S8DK,=H)PW# \&@#O
M+SQ7%:&]5=-OKB6PMUN+N*'RB\(8$A2"XW-A2?ES]370#D5YKXKTB;5;Z[U*
MRT_5]*\1P0+]@O+,$BX^7(BEQE" V0=V!CH3@UU5KK]W'K]IH=_IEPLLMF)3
M?(!Y#R@?.@[\=?\ (H Z"O+[F+3W^,&K6>I7\MO8#2(YU3[?) BR%R&8888.
M!VKU"N"MK"XD^,&HZC/IEPVFRZ9':QW$D!*-*K[B/4<'J1CCK0!G^ _%MW;>
M$VFU>6\OXI=8>PT>9AF6\C)_=DLQ /1OF)' KI9/'6G0:1K5_/9WT;:-(8[R
MV\M6D3"ALC#%2"I!SG\J/&LNKP6FF?V7:W,]J;U%OULL>>(,'.SD8YV@D<@9
MQCK7%RZ/JJ:5\0[.+P_?0C5$4V0^5]Y,*IC(8_-G))Z#G)SU -W7/B)<6^DB
MYT[0-4 >XM8H[BXC2.-UF8#<F6^8XXZ<$C/%:UQJ.E2>-]$@O-.O8M8>VG>U
M=R-D:87S%;:Y4G[OK]169XJL-0U#X=:8MI87$MS:S64\EKMQ+B-U+@ XR1@_
M7'%3:A'>WGQ%\+:D-,NX[:"UNDG=DR(FD"; Q&1GY3G&0.YH T+SQQIUG#]K
M-K>2Z:+L6;W\2*T2R;MAXW;BH;Y20I&?6F1ZGHR>.=51+&]_M>WT^-II=K%9
M(=S;0B[N3G=S@?6L#PA+XB\,V3^$I?#]W/+!<2_9-27:;5XG<N'D;<""-QRH
M!)Q6K!:W:_%75+]K.X6RDTF*V2X,9V-(KNQ&?HPYZ4 01?%319+33;]K#5HM
M+OW$:ZA);@01N20 YW9'(Z@$#IG.<:>J^.-/TE]5+6E[<0Z3Y?V^:%4VP[P&
M'#,"V%()V@\'UXK@=!LY_%/P+TKPS;V5R)[M8T:9XB(HXQ-N,F_[IX' !W9Q
MQUK0\76?B#6;;Q?IEQHM_=%XL:48F46WE[!R?F&Z3=GJ">F,#)H [*_\965C
MKL&CK9:A=7=Q:M=0BWA!6100, D@9^8=< =R*QM9^(>SP+<:[I6G71FCN_L,
ML,X17M9?,$9WC=@D%A@#/49P,X9;PW\GCWP]J,NEWL-M#H\MO,SQY\N1F0JI
MVD]E/3..AK#NM#UBY\!^+[6+2[HW5QK[:A;PLFUIH?/C<%<\9VJW!YX]Z /5
MK>5Y[=))+>2W=NL4I4LOUVDC\B:EJ"SG>ZM(YY+>6W9QGRI<;U';."1GVS4]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1169K>M0:':P2S12S/<7$=K!%$ 2\CG"C)P .Y)/04 :=%<Y!XRT\P
MZVU_'+8OHK!;Q)<-@,H92I4G<&!&!USQBGQ>(([S64T._P!*O+62ZMFGB,H5
MD= <,I*D[6&1P?7K0!T (/0YHKS;X:ZPNG_#SP[916MQ>W5PUQB* J6C0329
MD<LPPO;/<D 9K?N/&P36-4TFUT+5+N^T^*.5XXQ& ZON(*L7 _A[X)SP#S0!
MU5%<Y;^,]-O='T>_LTFG?6/^/.V  D<A2S9R< * <G...,Y&8CXVMHX=9633
MKT7^D1B6YL5"&0QD9#H=VUU(![YXQC/% '44$X&37,?\)M:>;X=46%V8M>4-
M:S Q[%)3?M<[^#M],YZ5C_$:]CU/X?\ BZV-K,@L(BOG,R[7?:K?+@YX##.0
M.N.U '?T5@MKD=C%96,%N]U?/:";R4=4VH !N9F( R>!W//8$BK9>/-*U'1K
M2^M8[AY[NY:SBLMJB;SUSN0\X&T DG.,#/I0!U&1G&>:*\X\/WL=M\3/&=Y>
M6\E@D%A:RSB5@P  D)<$$Y&.?Z5MGQW;J^C;])U#R]:7=8LHC._Y=V&&X;25
M^8#T]^* .LHKEM8\<V6D6UY>FTN;BPL9O)N[F$IB,@@-A2P9@I.#@>N,X-3W
M7BZWC>^%C9SZ@+"!)[C[.R9"NI9=H8@M\HS_ "R>* .BKGV\%Z&S%C%>9)R?
M^)A<?_%UT%8^N>(8- ETQ;FVN)$U"\CLD>+:0DCGY=V2#C@],T 5O^$)T/\
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MM+DQHS1Q%07!W$$'>N,'GGL,T 2?\(3H?_/*]_\ !C<?_'*/^$)T/_GE>_\
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MPK2I&8(C.QPJC)-<OI_CFTO[G1D-C=PV^M"3[#/)MP^U2WS '*Y4$C/XX/%
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M<8\R/&Y?<9!'YBI** ,GPWH%OX8T*WT>TGN)K:W!6(W!4LH)SC*J,]:UJ**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT^:YB&G:M;3,UM&H" Q3*#A26# LP.=W48% 'H\[O%;R21Q-*ZH66-2 7('
M!/'-1:=<SW>G6US<VCV<\L:O);R,&:(D<J2.#BJ^O&9?#VHM!<26\RVTC)+'
MC<I"D@C(([5P::OK@\">#]5-OJ&JVC6:RZI'9SE;I\QKMD&"&< DY /.1Z4
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M" %&,#CBMVB@#F+3P'HUGIVHZ6GVA])OR[2:>[@PH7.3L&-R<\@ X!YIFD>
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M #\.*M>(?$?]@7.CQ-923KJ5_'9"17"B)GS@GN> >WXUH)=7C:U+:-I[+9+
MLB7OFJ0[DD%-G48 !STYH RI?!UD\NF745W>6]_IT/V>&]B9/,:+^XX*E67@
M=5Z\CFG77@W2KSP[?:+.)VAOY/.N9M^)9)=P;>6QC(*KCC   Q@8KH** (+*
MU%E:1VXFFFV#F29]SL>I)/\ D>E3T44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<MXVU>;34T2TBG:W35-4BLI
M9U.&1&#,0I[%MH7/4;CCG%=369K^@:=XFTB73-4@\VW<AN&*LC#D,I'((]:
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MO$D,Y:1YU.1([MDL?KQ[<# !R=UJM_X1UOQE%;7MY>P6FBIJ4$=Y.TWER_O
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MSV[SNPA>/;B1"3E,A@IP1SSUJ+X8Z?! ?$LR-<%TUZ]B >XD==H8=5+$%O\
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MWMH;G!D&]LD[!G:3DC</:@#U6_N7L]/N+F.'SGBC+B,,%W8&<9/2J/AC6O\
MA(_#.G:SY'V?[9"LWE;]VS/;.!G\JS9=#72[^^NX-5N1;7&GO'_9TLK2*9%Y
M\X%B2#@X..#D$\UQ?PQU!-7L=$T>_DN[%M/TV*:TMTG:,7J,/FE)4C<%/R[.
MW4YS@ 'KE%8/C8O'X&UV:*6:&:&PGECDAD9&1UC8@@J0>"*Y>:\NQ=?#647M
MT&O $N0)VVS#[*6^<9PQW<Y/- 'HU4KJYOHM1L8;:P$]K,SBYN#,%^S@+E3M
M(R^3QQTZUY9/:W-SX?\ B)<R:QJ_F:3>7+V16^D7RBD".O0Y(SV.1Z#)S6]=
M7][-XG^'5P;RX47\,S7,2RD1RG[-N!*#@D$F@#O(KNWGN+B"*57EMV"RJ/X"
M0& /X$'\:FKRW0-*F63XAC2;J2VU#[?)%:RRW,A17:%,%LD@G<?O$$BM?P9J
M\=SX@NM/O+'4M(UF*T5IM.NIVFB=0V/.B<DAADX)[\>E '=T45YC%'K'C2PU
MN:SU!;*_MM3GMX;@7DJFT\J3"@Q*-I!4 G/7<<]L 'IU%>>ZE>R>&?&VCZS?
MZC,^D:I:-;3G[0YMXKD+O615)P ZA@!CL*34+J_TX^&M.DEEC?7+R:6X%Q=R
M+M^1G2 /R5 )5<+C.S'<T >AT5Y3XJT[6O#_ ((\7R'6Y8X_+CN;&WM[N1I+
M3)VL/,.&*,0<#H.16N89M&^)GA^.#4+Z6/5;*Z-VEQ<M(CM&(RK!2=J'YC]T
M 8[4 =IJD][:Z9<3Z=9"]O$3,5L91$)#Z;CP*IZQKBZ3'I\;0A[S4+A;:"$O
M@%RI8Y;!P %8YP>GO61\3Y)[?X<:W<VMU<6T\,!D26WE,; @CN.U9'C2PAN]
M=\#22O<;I;\1MLN9$X\B0Y&UA@Y[CGMF@#L]%OM1OK:<ZII9T^XAG:+8)A*D
MJC&)$; .TY[@'@\5I54O+<?V3- LDR 0E0ZR,'&!UW9SGWSFO)].N+O2?A/I
M_BY]8U&74+BU@MI9+B[9HD22=5:3:<@,%)^;KSSF@#V.BN'&B:UI^K3WUKJ]
MO96MQ8R0BVENY+A3.%+),#)T(QSCJ!S69X<O!<:JVA:]9ZII>L#3I$E@>[DD
M@O5RF9HY WWA@YZ'#\DXH ]%M+NWOK<7%K*LL+%E#KT)!(./Q!J#4+F^MWLQ
M96 NUEN%CN"9A'Y,1!S)R/FQQ\HY.:\?L89;+X'^&KNQO[ZUN);JU5GBNGQA
MI]I&TG&,'IC%=3XDTQ_#DWAA;+5=59;KQ'$)1/>O(&5U8E#D\KE 0#GOZT >
MB5"]W;QWD5HTJBXF1I(X^[*N Q_#<OYUP]FLGC2\\76L^HW=G=65Z;*T^SS,
MAM5$:E90JD9+,6.3U QTJJ-.@F^+NC227<]TY\/N[7"3NGFLLL8#85L 'KM'
M!ST- 'I%174LD-K++%%YLB*2L>X+N/ID]*\QLEUKQAX8?6K35(M/U".\E?[4
MUY+BW$<I!C>$#9MV  @]<[CS6OILQ\6:]XLAO;BXC739EL[:&"=X_*'EAC+\
MI&69B<$] H [Y .C\*:]_P )/X7L-:%O]G%Y'Y@BW[MO)&,X&>GI6S7&_"C_
M ));X?\ ^O;_ -F-8>H:G=:1XF<>(8KY+&XU1&L=9L[AFA10Z@6\R _(,@H<
M@@DYZ\T >D1W=O+=S6L<JM/ JM*@ZH&SMS]<&IJ\HMW'A_6?B=K%FD[W-AY<
M\*-/(REC:ALLI;#<G/.<#IBK&KS7>D>#O#?B?3;^[GOGEL_M&^=G6]68J&4H
M3MY+9& -N.,"@#T^L%?$;GQVWAIK$JHT\WRW/F@[AY@3;MQQR3SFN<T^.7QL
MGBE)=4N[*]L]3ELK5[>9E^R+&%V,%! )8Y8D]<XZ"L7Q5KL^@_$"+480UV@\
M-JLUVB;O*B:Y4-.4!&X ?-@?RH ];HK.T.SM;/2;=;.\N+R%XU=;B>Y:=I01
MG=N)/7KQQZ5S>FO-)\3O$NGO=736GV"UD6$W#[49C)N*\_+G Z8Z4 =K2.6"
M,57<P' SC)KQNQO=2N_ 'P]N6UC45N+K6%MYYEN6+2H6FX;.=WW5ZYZ5TNB0
M26?C#Q?H4=]?M8I:6UQ");N21X7=9-Q5V)89V@]: .NM-3E72+2ZUFW33;J=
MDC>W\X2[)';:JA@,-DD=*TJ\7V-JWP^^&EW?W%U-<RZO;*\K7$@9MWF9)(/7
M@?-U'8UM>+KJ[T34=0DU*#49O#S01PQ:CI]T[2Z8P7!,B!@2"2&+<DC@YXH
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M*2"".1R*\O>'4]-\$>#_ !=:ZUJDVI.;%)X9;IGBN8Y=JE"G3/S=>O4G)YH
M]DHKR3QA?W,&C>)-6TW4;VZN+'4H@MX)FACM,/&IMT0$B3&3NR #N.22,5I^
M-[R_TS5+^[O[:_N?#\EJL7VS3+AA+IC@'<[1J02#N5MW8#GB@#T)KNW6^2R,
MJ_:9(VE6/N44J"?S9?SJ:O.H+6RO?C3%>0RS/'+X>2Y21+B10_[\;3@-]TC'
MR]#Z5VNEZ2FEM>LEW>7'VNY>Y87,QD\LMCY$_NH,<#M0!H4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<@F15!P&) YK0A\+:?!K?]KQ/=+>BU%F)#.S?N@<XP<Y.[G)YSWK;HH YD>
M]#&@MHNRY^QFY^UK_I#[XYMV_>KYR#NYZTFK^ M#UFYL[J9;N"\M(_*CNK:[
MDBF*=U9P<L"<GDYY//)KIZ* .?U'P7HNI6NG0-!+;MIK;K.>VF:.6$GKAP<G
M/?.<]ZFT?PMINAZA?7UG]I-S?%3</-<O)O*J%!PQ(S@=>O-;5% &5J/AZQU3
M5].U.X,_VK3V9K8I*5"%AAC@<'(XYJHO@W2UAUB(-=[-8+&]'GM^\)&T_P"[
M\O'&.*Z"B@"KINGPZ5IMO86Q?R+>,11!V+$*!@#)Y.!6-)X'T21-739<I%JS
M.UW&ERX1BX <A<X4M@9(YKHZ* ,%O".FO/I$S/=&32 19GSS\@*[3G^]\O'.
M>*J-\//#QUZ;5D@N(Y+B3S;BWCN76">3^\\8.UC]>#W%=310!F^(=Q\-ZFB1
MR2N]K(B)$A=F8J0  .>IKF_!'AJ%/"7AT:BE]Y]A!&PM+LL%@G"8)"D9."3C
M.0/X<5VU% '*7?PZ\.WJZHDT-UY.IR^?<0+=R+'YI()D" X#$@'-79O"6GRF
MY'G7R1W<2PW,8N6*S(%VX;.3DC.6!#'/)K>HH QIO"NDRZQ9:H(9(KFS@^SQ
M>3,T:F($$(RJ0&4$ X/%0^'/#PT2[U:>-YQ%?7)G$,LYEVL<[FR>F2>@Z!1W
MS6_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF34AIEPLUQILD6'EC,;1MA&'+KNR :22+2]6\.ZE./ UQ;V-R(89X'LA#=7
M,@W$(GS80'<.Y(..F2 ;]]XPLM*L-2N]1L[^U73XTDF5H0YVMG!&PL"/E/.<
M#O4%GX^T>[UZUTDQ7UO+>H7LYKBV,<5S@9(C8]3C\#VSD9X?5;+5=-\">-K-
M[W4+W0DTX&QFU*-EG1B&WQY8!F4#;@D=\#H:Z&[M9/%,_@Y;:TNHETVYCOKF
M:>W>,1JD9 0%@ Q9B/NY& 3Z9 -S4/&NF::@N;B.Z&FBX^ROJ"H# DF[9@G.
M[&[Y=P7;GC-2ZKXLL=*%^3!=72:=&);Y[9%86ZD;OFR1D[?FPN2!@XY&>$T"
MS?2[>;PMJ_@5]1O8[B06^H-9)):W",Y9'DD/W<9Y')XXR>*U+*[U3PCXM\06
MESH&I:E8ZM="\L[BQA$B[F14:.3) 3&T8).,4 :S>-#-XRTS2+*QGN+*[TYK
MY;E N'4L@4KD@[0&.<\\C /-:/C/Q!)X7\):CK$-H]S);1%E1<8![%LD?*#U
MQS6'>0ZE:_$C0M4ETR>6)])EM)3:)O2&4NC88\87 /)]*U?B%I]UJOP^URQL
M86FNIK5A'&O5SUP/?B@"T/$<45M8+-:W7VZ]!\FS"KYLFT99OO;0H'<D#D#J
M0*GT;7[+7/M26_F17-G+Y-U;3+MDA?&0".1@CD$$@]C7'W(U"/Q3X;\5KIFH
M'3TLI+&Z@,!,T ;:RR>4,L1N7!P,@#.*UO#>ES'QGXD\1M%+!;:@+>&!)4*.
MXB0@N5/(R6P,@'Y<]Q0!!X_UJZL)] L(+:Z>&^U.**X,.W]Y'AV,8.X')*C/
M8C(SSBK/AR?3=+U34M#LH=32X"#4#:7#AEC1^ L1W8494_+G@Y[57\=QW$VI
M^%/L]G=W"VVKQW,[00.XCC".I8D#U8<=:AN6N]*^*<NIG2[^ZM+_ $F*WBDM
MH"X65)&)5SP$X8'+8'O0 [4_B%$- T35=)L;JYAU34H[)2RJI3][L<$$_>.U
M@/?DD5OV_B2WN-;FT?[+=QZA%:+>&&15&Z,DJ,$,1G((P3VKS:RTO6(?AEX;
M231;\7&F:^EY/ (LR&(7$CEE7J>'':NEN9;RP^)\.LOH^I2VE]HR6J&"#S#'
M*LK/MDP<)PPY)QUYH TG^(6AQZ%9:PXO%M;N[^QH?LY)63>4.[' &0>_..,U
M<MO%EO=Q)Y6G:F+MWD2.REM_*F<1XW/AR $^9?F) Y Z\5YS;V&JQ?#W1K.7
M1=16YM_$:W4D8MV8^4+EI"V ,XVD=<9[9KI/&,%S9>+=*\1G09M;TO[))9W-
MM#;B66'<RNLBQGD],'T% '6Z#X@L?$=A)=6+2#RIGMYHI5VR0RJ<,C#L1_6L
MO4O'FF:;JUWI9L]4NKVUB2:2&ULWD8HS8W*.X'<]/?/%7O#,< T^6>VT--'A
MN)3(MN8%BD;@#?(J\!B0>.N ,\\#%LHKA?BYJETUG=+:RZ9# EP8'$;2([LP
MW8QT8<]* -+5?&>G:1#<74\-W)86LHANKR*,-' V0"&YW'!(R5! Z'D&I;SQ
M59VK7GE6]U>1V2*]S);*K"(,NX9!8$_+@\ \&N&T^V?1=3U?0]8\#S:PUS?3
M7%E>QV<<L,T<KEPLLC<(020<]OPS+XFT:X_M"_O]#@U/2_$=K'%' ]E;NUIJ
M*B-=J.,%-H)*98C: #T' !T__"6SGQ]<>'_[,NO(MK);AIE56W;G(#  YVC:
M1TR3VZ933?'^E:Q(BV=GJTD3M-&TRV+E(VBSN5B.0QQP.O3IFJ2QZA8_%-]0
MN--NI+>[T:& SV\9>-)$D=G!/; ;([GMD\4[X=)/I_A>]CO;*\MY$O[J;9+;
M.K,CRLRE1C)R#VH L^'->T*V\(:.^D_;);6\9X[""0EYYB&8G[Q[88Y8@ =<
M53U[XB0V7A/5]2T^RN9+S3YQ:3V\JJ#;RL0 7^;!7Y@?E)SGZD<CHMAKN@^&
M? VL+HM_<-HINH-0T](2)PDQ^^BG&[& >.N?KCI_&)U+Q1\-]9-GHMW"TIA>
M"VFCVW$NR1&9BF>.%P >>/<4 =5-KR1>3$+"\DO98VE%D@3S0BG!8Y8*!DC&
M6YSQWJI;>--'O-%M]3MI)9%N)_LL5N(\3-."08]IZ,,'.>  3G'-<KK[7,'B
M^Q\3S^%KW5=(NM/^QRVZV@EN+9UD9U?RCSA@Q![CO@\4S5K&\L[GPSXETOPS
M);V5A>SRSZ9:P*L_ES1B/S3&O!<<G R<$#UP 7_#%Y)<_%7Q.C)?0JEG:DV]
MU(6\MB7SM^9E (P?E./UKK]0U>&PN;6T\J6XN[K>88(=NYE0 L<L0,#([]Q7
M*: ]U=?$W6=2_LO4(;&ZT^V2*>XMS$"4+Y&&P0?F'&,^U6_&^EV6KW&F07EO
MJD;()9+?4]-60RV<@V <H"0&!/4$?+0 W6?'#V8T'['I=Y(-3OC;-O15:/86
MW+@M]X[#CMC)ST!V+KQ)!!<3VT%E>7ES;1+-<PVR*S0*P) ;+ %B ?E7)XZ<
MC/$7%MXD.A>$;W5;6ZO[G3]9,D[0V_[YH,2JDK1CH2"I(ZC//.:U-)^V^'/&
MWB*XO["^>QU@PW=M/!;M.4=8PCQ.(PVTC P>A'>@#HH_%>DW.EZ?J%E.;N/4
M3MLXX!EYFP20 <8P%.<X P<XKC_'_B&VUKX;^('LI+RTO=-N(X)XBYCDB?S$
M!#;6PP*MZD'-9=OX>USPE:>&M=CTRXO/L=Y>S7NG6P#RQ17)XV 'YBF!D#N3
MVYK:\;SZAXD^&^KK:Z'J$3W30K;6[VY^T2;9%+,RC.T8'&[!^7W% ':)K$4N
MM2Z9#;W$LD*JTTR!?*CST4MG[V.=N,X(/0BF:[K]KX>MH+F]CF,$LZ0;XU#;
M6=@JY&<X)/;-<SX3;4/#VM77AZXMKZZTJ5C=V&HM;N2OF,2T4S$9W DG<>H/
M)!JY\2;&\OO"#?8;66ZFM[NVN3!"NYW6.568*.YP"<>U &N_B.SC\0S:(\5R
M+R*S^VX$>X/%NVY7;DDYXQC-8UK\2=$O+;3;N.'419:A.+>.Z:V(B20L556;
M/&2.V<9&<5GVMU=W7Q336O[&U2+3FT(P":6V*D-YV[!7J#@'C&[VY&>=M].U
M*/X.Z#IC:5J O[?4HI);?[*^]%6Y,A)XZ;>?_KT =X-1TG_A.[V&**_DUF'3
M SH-PC:'><;0Q"EBV1D>F,U3\->.AJWA:'6+ZPN+<W%TT%O'\I\UC,Z(BG=R
MP"@$G ZGI38(YW^,,U^+.[%F^AQVRW#6[A#()F<KDC&=I'\NM<[HFF_\6W@\
M.Z_X>U1T@OI$G,<3;X\RR.LL17YFVY4Y'KWZ4 >D:;J:ZE]J7[-<6TEM-Y,D
M<Z@'=M5N""01AAR#45]KD%G?II\4$]Y?-$9_LUN%W+&#C<2Q50,\#)R><9P<
M8G@6WUBS34[2_O+N^T^*=1IUU?1E+B2/8-P?(!.&X#$9.#VQ56:"\T+XGW.L
MS6MU<:5J=A'!YMO"TS6\L;$A6506VL&)R!C/6@#0G^(&@V_A]-;:2X-J;C[*
MX6!M\,NX*4D'\!!/.<>V:U]'UB/68)Y8[.^M1#,T)6\MVA9L '<H/53G@UYG
MJWA_48?"VMW$>GWCS:MXACU"*UB@9G2%9(SN8 ?*2$+8//('7BO6T<21JZA@
M& (W*5/X@\B@#$O_ !79V37^RVN[N/3_ /C]DM8PRP?+NP<D%B%()"AB 16;
MJGC80:SX9M=-LY;^UUCS)5N(-I#QK$S +EASG:><< ]ZSM!%YX6U+Q38:AIU
M[<Q7VH2ZC936]N\J3+*!F,E00K*1CYL#!STK)LO#>J>%;3X=++97-[_937*W
M@M5\PQM-&V!_NAFVYZ#% %C2?$D/AK7?&\EU'JEY!;7L<A6)7G,$7DJS,2QX
M49/&?7 XKN9?$%H([0VB2WTMY#]HMX;<+N>+ ._YB !\R]2.H%<3#;WFSXCE
MM.OU.H9-J#:R?OO]'$?R\<_,,?KTYK.%G?:./">LW?AJZU:QCT2/3;VT6T\R
M>UE7:0XC89(R"#CMSZ9 .P;XBZ FE6FHLUWY5Q>BP*_9V+0S[MI20?PD'\^V
M:W-'U9-9LFNDM+VU"R-&8[R Q/E3C.#V/8UP>OVC2Z)HDNG>&9[",^(+:^:U
MM[/$@B1AODE5 0&..G7&.^0/2U(90PS@C/(P: .=U#QMI>G0ZC<NEU+9Z9*(
M;VYAC#) ^ 2",[C@,N=H.,^QQ%>^/=)LKFTMFMM3DN+RWDN((8[)]\BIU !
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M,0R'((VDY]N2-+5-3TM]?\,Q:IINH0ZA-/*;($C;$XC;=O*.5.5!P/FZC@4
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M34M% !1110 4444 0RVD,UQ#/(FZ2$DQY)PI(QG'3."1GK@GUJ:BB@ HHHH
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MD<, <C/3G].M>@T4 >:^#TN1#IVDW_@,6FJ6/EI-J$EM%]GPF!YB2 [BQ X
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M#CH2.HSTJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCB\M9%RRN 5//RX/UXQQ0!U]_P"*TTR'0GN],O8GU>XBME0A/W$CC.V3YNH
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MW:HPI!Z>U ':T5GZ+87.F:9':W>I3ZC,K,3<SJH=@6) ... <?A6A0 4444
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M8 )P"0-Q./KS6%XQ\-Q:'X \7FVNKRZGU??.T4@5BTS #"!%!Z*..>E>CT4
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M6BPAD*,"&W$D$ C"JQ.?2@#OJ*** "BBB@"*YN%M;:6X=9&6-2Q6*,NQQZ*
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M20^:N"ZY<H/O!1\V/]FN5TJ^@3XGW-\9M0N+6XT% MY<V[JKE97)_A"J,8[
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MWUG:^?*GVXE;29X76*X(&<(Y&#D<CGGMFM+4]4L]&TZ6_OYQ#;18W.03R2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7O9VM+K9J7BQ-1@ME@=G2#S4)8H!E<A2V".A'>O9$97174Y5AD'VI:* /,-
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MO<XM)"\;FU"#* ;L%@1G&._3FKMY8W>J^,/'-I:I-#+?Z+%;6\SQLJ&4+("
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MW@D9"%E0 LA]0"",_4&O&%:\F^ ^CW<][)<S7%[:2#SL?*QN@3R!DY)R2<T
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M@K5KW4-_VS6M/FEM5B41Q[VW*$(&[C.,DG/)XKT77=-@UG0-0TRYE,4%W;O
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MU!&<,IY!YY%3UPD'BC4KVW\,:?$)VO=1TD:A=36RQ"0 +&/E$A"#+29Z' '
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ML[:<Q+'YGG^7LW*"!\I<YY&<=NM;FE2^*8O%/DW5O<S:'+;DF:[^SK+#,#T
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M&1SS5AM;LDUI-()G^VO&9546TA4H" 3OV[>I Z]ZY+PE_P E7^(0_P!K3_\
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M< ^_M0!K4444 !&1@UP4?PYGB\'6_AI=>=K6VN(Y8&>U4E%23S%7AADYZGN
M, 5WM9,OB*RB\3V_A]DG^VSP/<(WED1[5(!^8]3R.F: *,WA5KKQ:VN75Y%*
MDFFMILMK]G(5XV;<3G=D'/Z?G5#P]X(U#06ALV\47=WH=JX:UL)($#( <JK2
MCYF53C XZ =.*[.B@#*\2:1)K_AZ^TE+H6RWD+022&/>0C @X&1S@UCWO@>/
M4?".G:-/?LEWI@B-CJ,$6R2%XP K $G)(&".ASVKK:* ./UGP9J&IW>G:M;>
M(&L->LHVA^VPVH*31'DH\3,0>1GKP?PQH1Z#J=O%:/#KKO>1R/)<S7%N&6Y+
M*!@HI4*!A<8/&!UYSJZEJ5KI&GRWU[)Y<$6-QQDDD@  =R20 /4U5TK78]4O
M;ZR-E>V=S9E/,CNHP 0P)5E9258'!Z'C'.* .?E^'D!T,65K??9;H:L-86>.
M >6LX;.!'GA,#&,_C6E;^&;F'QD/$,FJ"9_L"V#1-;@;E#E]VX-PVXGMC';O
M71T4 <Q_PAR3:[K]]>72W%KK5LEK/:^3MVHBLHPV[KASGCZ8J'PWX/U'0UM[
M6[\2W.HZ;9<6=K) B% !A0[CE]HZ=!P#V&.MHH XO_A7=O+I.NZ1=:E/+INJ
M7,ETD2HJ-;R.X?<'ZDA@".GOFK.F^$;\V4]IXD\03ZY"\#VR(]NL(",-K%MN
M2SXXW$]SZFNKHH X!?AWJ1TC3-)E\42266E7<-S9YLU\U5B.41FW8;' !P.G
M(-=CJ^FG5M#O=--Q)";F!X?.3[R;AC</?O5ZB@#EM1\*ZAKEA'I>LZQ%=:8)
M(WF1+/RY9]C!@'?>5 )4$[5&>V*GD\+%O&$VO1W[I'=6J6UU:&)6$H0L5^8]
M/O$$8Y]JZ*B@#B[;P ;?0&\--JAE\.^;N6U>#]\(]^_RO-W8*9X^[G'&>]2:
MAX*N_P#A*)]=T'7Y=(FO(TCOHA;),DX085@&^ZP'&>?IUSV%% '+7G@Q;O6=
M'O6O%>WTV": V\\/F&X690)"[;ADG&>G4GK5GPGX<N/"^G-IIU,WEBCL;6-X
ML- A.1&&W'*CH,\^]=!32ZAPA8;R"0N>2!C)_4?G0!A>(?#(UJ]TS4[:\:RU
M73'=K:X$8D7#C:Z.A(W*1[@^A%20:-?SZC;7NL:C#=&T)>WAMK8PQJY4KO;+
MN6.UF Y &3QG!&W10!S,'A:YM];\0ZFFI1[]9CC1D:V.(?+0HI'S\\$Y]_3I
M5!/ 4T>@>&])75UV:%=1W,4AM>92@(4,-_3#'./;I7:T4 <Q+X2E_P"$DU;5
MK;5I;==4M4AN(%B!^9%94<-U& W0=QUI]MX7E;7].UG5+V&ZO+"WD@BDBMO)
M9P^ 3(=QW<#@# !)./3H@ZLS*K LO# 'D?6G4 <]XB\-3:UJ.CZE9ZDUA>Z7
M*[Q-Y(E1U==K J2.W0YXK#N/AO+/H?B'23K\Q@UJ[^U2-);(6C8["V,$9)*#
MT &>.]=[7/MXOL1?P01VU[-;S7;62WD40>%9@2"I(.X<@C=MVY!YH 9=>&;B
M\\4Z;K<]_$396\EN8!;';(),;N2_'W1CK^-<])\,KH>%[OPO;^))(]#DD#V\
M+6BO+ /,$FSS"WS+D''&??'!]$HH CCC98%CDD,C;<,Y !;WXXKAT^',\?@^
MV\-C7F:UM;B.:!GM5)54D\Q5X89.>I[@# %=Y10!S5QX3-[XJEUF[NXY8IM,
M;3)K3R"%>-FW,=V[()/Z?G5+P[X*U'0C!9R^*+N]T:T8&UL9($5D ^XKRCYF
M"\8''0=ABNRHH S->TJ36=-%K#?2V4JS13)/$H9E*.&'!XYQ@Y[&LZ?PU>:K
MJ6FW.MZC!<PZ;/\ :8(;>T,.Z8 A6<EVS@$X QSUSTKI*R=(\166M7^IV=JE
MPLNFS+#/YL93YBNX8SSC!'84 8R^"K@6GBBW.JQD:^SM*?LO^IW1^6=OS\_*
M._?\J9:^![NRU33;^UUZ2&6UTQ-,F"VRD2Q(<JR[B=C>IY!]*[*B@#@K3X<S
MV>@:%I,>NEX]&OQ>P-): EBI;:APPX^<Y[GVZ5I^)/"%QJ^KV6MZ5K,ND:Q:
MQF#[0D(E26(G)1T8X(SR.>/RQU5% '/IH.I6Z6<D&N,]W&SM=2W%N'6Z+ #E
M%*A0-HQCI@=><V/#?AZW\-V$]M RL;BYDNI=B;$#N<D*N3M4< #)Z=:V** .
M4U/P?/K-O+8ZCJ4<^G/>B[1&MOWT6'#[$DW<#(QG;G!(],,O/!ES+KNLW]GK
M3VEOK$*1WEN+=7)9$V!E<GY?EP",'V(ZCKJ* .,A\!RVFG^&H[;6'^V^'U9+
M>::W#(ZLFPJR @_=Z8;/UJGXA32]%T[Q#%?:E%+XAUO3YMJE=AF"1E4CB7)Z
M%N%R6)8GGMW],<QJ4+E02<+N]?:@#B)/ US?^'O"\D&I3:1KVCV<<4=U$@D
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M]%B\1^';_1IY7BCO(6B,B#)7/0_G6._A*^FU+P]?W&M":?1S(06M !,738>
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MENM1GC$0D$/EQ1(,D*J;B<9))RQ)]>!C7HH X4_#R9O \WA<ZPODRW1N3/\
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M?"[Q3K46HR6UKY=W%!:I&A5H8]R'>2I;<V&/!&,CT.?1-"_Y%[3?^O6+_P!
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MH:/X&U;4M,N5M[NU@,J.8P_3V/'\ZR8M3UW3O&OARUN]5%Y::U:SF2W-NB+
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MK#Y2$#"87K@YY///M6%J'@*&]\/SZ6E_)$]W>B_NKKR@SRS!U8''0#*J,8Z
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M;E)X*Y SCGG-=U_PBLMGKVH:KH^I&R;4@OVR%H1*C.HP)$Y&U\=>H/<5!?\
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M>$6YMW7+"/'SAER,9.3@YKJ?%UU=V'@_6+VQN#;W5K9RSQR! V&1"PX(([4
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M9L_%>C_V?>/-"4E6>"X@;;)!*O*NI]1_6MJL;Q'XC@\-6MM<7-K<31W%S';
MPA<(SL%!;)'&3VS0!E7'@5=2\.7VEZSK>H:A->(J-=OL1HPK!EV*H"CY@">"
M3CD\#$MIX.DM_$<&O3:[?W-_'9FSD,BQA95W;AE548P>>,9[GKGJ:* .+_X5
MQ82>%9] N;Z[EB>[:]AN!M26"8L7WH0,<$G''<UHV?A0C2[VTUC5KS5Y+RW:
MUDFG"(5B8$%55  ,YY/)) R>!CHZ* .+MOA^T;:$]SXBU&X?17S:DI$N$V;
MI 7!^7@DY)]14MWX M;]?$J7>H7+QZ^$^T*H5?+**%0H<=@HZYSBNOHH Y:S
M\&/!XAL=<N==U"ZO;:U:U<NL:K,A8-@A5&.5!XY/<XXJLOP]@C\*:CX<35[W
M^S[QI-J$(3 CN795.WG)8\MGVQ7944 <XWA0OKFC:L^I3&;2X'@C3RUVR*X
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MEC.%10 JCD\X).>3TQ9U;PE_:UGI"G5+FWO=*E$MO=Q(FXD*5.Y2"IRI]/\
M"NDHH XN;X=02VOB"V.M:@8]<P;G>(R0=H5F'R]3M'L.P%:,OA0SZOH6I2:E
M-YNC)(D2B-0L@=0K;OP Z8KHZ* .-T_X?1:7?SBSUK48M&GF-P^D@IY.\G)
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M8JZDKPV.<?=#=N*W=3^']E=:G:ZEIFI:AHUY!;K:&2PD4>;"OW58,"#CL?\
MZU6IO!MK+J&B7D=_?1/HYD: !D;S&D!#M(64EBP)R<CDDT 8LLNJ^%/%_AV'
M4=<N[[2;Z)[-WG"*%N@-R,Q"C[RAEQGJ,U!XIU+6+'X<WFO6FJW4,TUU%+ ,
M(=L$DRHJ\KD91MWJ"<9XKK_$?AVP\4:0VFZBK& RQR@H<,&1@PP>W3'T)IGB
M;PY;^)]"?2+BYN+:V=D9C;;0QV,&4?,I &5':@#*>_N-=\::QH*WL]E!IMI
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MSZDXKT&L32O#46E:]JVK1WUU-+JC(\\<NS8"B[5VX4$<#'4UMT >?.FN:O\
M$+7]'B\27MG:6UM:W$(BBB)0L7RN2O*G;SGGIS@$&LE_XI\4:-<ZKH,Y@O$O
MI8[97G40*D<I0I(FTDY522>N3P0*Z^T\-16GBJ^\0+?733WD20RPML\L*F=N
M,+NXR>_>LG_A7=G%K5Y>V>K:I9V=]*9KS3H)@L$SG[QZ97=WVD9H S])MIYO
MB[KKM?W2XTVTD"+(&0;C)\HR/NCJ/S.<UB7GB#Q!%\+?$FI)K5P-0L-7FMX[
MC9'EHUG6,*1MP."?NX.:[]O"]O\ \)4VOP7MW;S26Z6\T$3*(Y50DH2"N002
M>A /?(SG*D^'5E+X:U+07U743:ZC=M=S/F+?O9PY .S !8 ]* *VI3:MHNM:
M9HW]KW=_)K5Q-+N<QQ-$D<8)CC(7@$G/<@ @'/-9/B.?QAX?\#^)[F;5&A%N
M\<NFRATEG6-F 9)"4P0#G!'/OQ78^(_"5IXFTVUM[N[NXKJTD$UM?6[B.:*0
M<;@0,<]QC%4[OP)!J'AF\T:_UC4[EKW:+F\D=#,ZJ<JH^7:J@]@.Y[DF@#,U
M#^VK+X@:1ID?B&\-MK%I<M,K1QGR6BV$&+Y?E^\1SNX]3S6;;>*=6TK1M:LI
M;Z2[GMO$,>E6UW/MWK'(8^6.-I90[8)&,XR,5V=QX82Z\0:7K4NHWAN=-CDC
MB4",(X< /N&S.3M'0CI5!_A]I=Q8:Y97MS=W4&LS_:9UD* QR\89"J@@C:N,
MYZ?6@"FUOXJL;O59?MSPZ4^GN\7G3)-/#<KDY3*8*$=0<X/3%8=CJNO6^C>
M=<FUVZN'U6XM[6ZMG1!$R21L<X"[MP*@YSZ\ <5UNF^#396-S!<Z_JVH2RP-
M;)<74B,\,;=0HVXR<#)().!4?_"!VO\ 8^A:8-4OQ!HD\<]J?W6XM&"%W?)R
M "1VH S?!]K*OQ"\:L]]=RB*[MP$D<$$- IYXZ#)P!C%=]6'9^&8+'Q/J&N0
M7MVKW^QI[;<OE,Z)L#_=W9V]LX[XSC&Y0!YS:ZMJOB3P;K7B.SU2>SN[::Y^
MQ0IM\M%A) 5U(^;=MR2>1NXQBJRZUK7B;6_"Z6VKW6F6VM:++=2Q0HA,3@)R
MA*D]6[YXZ8/(Z;_A"+6)M4BM-0O+73]5=I+NSB*;"S##E"5W)N'7!^F#5I_"
M=J?$.F:O#=7%N=.MVM;>VB""(1G&5(*Y_A'?C% &Q9PR6UC;P37#W,L<:H\[
M@!I"!@L0.,GKQ7+^+KZ_T77?#VII>S)I$EX+._@&W;^\!$;DXR 'P#SW%=?6
M=K^BVOB+0KS2+W=]GNDV,4.&4YR&'N" 1]* .#TWQ)J'V_Q1I$FH74MR[HVB
MRR[06BD<Q*RX'*K(#DG.5P:U)[S4]2\1ZGX?M;B[V:9:09EBG2*5Y) Q\QB5
MYQM&  !G.0>,;[^%=*;6M)U58-D^E0/;VP7H$8 8/K@ X^IJAKW@BWUC7(=;
MM=4U#2=32+R'N+%U'FQYSM<,"#@]#C^0H YS6!K2Z=X 3Q"]O)JJ:]&EP]N<
MHY"3 'H.2,9XZYJV;%V^.+G[?=K_ ,2)9<!EQC[2?D^[]W]?>MZ^\&VE[#H\
M0OKV(:5<B[B*LK-)+\V6<LI+$[F)Z=:F_P"$9C_X2\^)/[0N_M1M19^3^[\K
MRM^_&-N<Y[YH XN]U[5K.;2;N+59KR2?Q EE<30J!9F%Y&7RE#8RRC'S*#\P
M(+=JT+=-<UCQ_P")M,7Q)>VUI8&RFA6.*+(WAF9/N_=.#[].>,&RGPQL8]-@
MTZ/6M62TM+Y;ZSB$D>+9PY?"_)\PR3][=CM[[FF^&(M,\1ZEK4=_>23:@D23
M12E"F(P0F/EW9 )ZDYSS0!Q]IJ'BOQ-X>MO$&B3B*X>Y:1$FN%%N85D*F-DV
MD_='WNN[N!P/3*XVV^'5E9:I<SVFJZI;Z;=3&>?2HY@+=W)RW&-P4]U! /3I
MQ794 >?^*[6>]^*'ABWM[V6R9["^!GA52ZC]UG;N! /N0:RD\4Z[H#:YH%W?
MM?W%IJ=E:6NH2JJOY=S@_-QM+*,\D8R1D8XKNM7\-QZIJVGZM%>W%G?V"R)%
M+$%8%'QN5E8$$':/0^]5KKP1I%_H>HZ9?":X_M*3SKJY=@)7D&-K @  KM4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%&A3R]KXW @J2<X'?M6S10!RZ>![---URP_M'4##K4DDMV2T6=SJ%;;\G&5
M%0ZC\/=.U"'2F34=3M+[2X?(M]0M9ECG\O&-C$+M8?A_,UUU% '-77@JRNK7
M2X&OM07^SKM;U)/-5GEG&1OD9E)8_,>.!SC' Q.OA.S&M:IJDEU=ROJ=NMM<
MQ.R>68U!  PH(P&/?O6]10!S-AX+ATNQTZVL]9U5/[/!2"1I48^60%$9!3:5
M  QQGC.<\U5U?P<W_"//8Z1?ZE:WDMZUZUU;SK&SSMDEI<  ID@E5'.T 5V%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Y
MI^K/KGBG5+>&1EL-'=(6V''G7!7<V2/X5!48[ECGH*Z.N&^'\$EAK7C6QG!$
MW]MO=C/>.5%9#]."/PH HP7K^-O$'B+33J&M:<;2>&*QEM4F@\K$8=B_ 7))
M(P_48QZUTWAC6I;^;5=)O7#ZAI%SY$SX \U&4/')@< LI&<<9!QQBL?P7*#X
MP\9,4D1;B^CDA9XV42J(54E21AAE3TH\*0/)\2O'6HJ#]F>2SME;LTD<.7_+
M>!0!W-%%% !1110!%<SK:VTL[I(ZQJ6*Q(78X[!1R37F.N>,9==^&]CX@LI[
MW32U_;[MH>(&)IPN"Q&&&WKM.,UZDPRI'J*\4A:7_A2>CZ4]C?+>V=[;)/"U
MI(&!6XW-@8Y 49)''(H ]3TSQ1I.KZE=:=:S2B[MD$CQS0/$2A. Z[P-RY'4
M9%,C\7:-)?V=I]HD5KTD6DKP.L5P0,X1R-K<<CGD=,URNLP2ZE\2KZ.T+K]J
M\+2VD5QL;8)FDRHW8QG!SCTJEX3NM*U2VT;2K[P]JO\ ;VFO%YD-VLQBMGCP
M#,'8E , E<<G('3F@#J?B)XAG\,^"M0OK3S!=[ D+K"SA&9@NXD @8W9&>"1
MBF:5<Z9IWB9($U;6/,U6(FWL+])RNZ+EW4RKE3@C(R!WQS5?XL!Y?AQJEO#%
M+-/-Y0CBBC+LQ$J$X !/0$U7\67D=MXR\&Z\R3/ID)O(I9XH7D\MI(U"9"@G
MDJ1TZT :.M^/=,TWPUK6JVJSW4FELT,L(MW4K-@$!L@87D$MTQ6E!XHTV2\T
MZQD>>&\U!':WCEM98]^Q<O@LH P.>:\VO(+S4?"OQ.@@TZ^$UU<M- CVSJ9%
M\N/[O')^4_+U]16YKFIQ?V]X&\1&"\&EV[7,4LIM)-R&2$*A*;=P!8$9Q^E
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M-6BMT9+<V^TEC(I "OG  X))SCC-(I+:+\4$\F;==R3FW7R6S,#;A!LX^;+
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MM!&<'=@#')J?Q)8FTNKV\T.ZN-(URTLXHC8F,SVNI(L>5BVD?.PR4RO(].:
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MHKQ(?*^V1#&V8KV)Y''!QD<'- %K_A,-$_LG4-4^U2_9-.F>"[?[-)F%T +
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MD\ ?.3U)YQBK=[XC\4>&=+UB;4X#+$UQ!#I$]WY0D9I2%(E6([<(3G(QD>]
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M':7W,%+9!&,@>I*7VLZ[K-YX@MM#-Y#+IDHMK<P+;E'E\M7S+YISMRP7Y0.
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ME@7>Z@#<>.W!!YQP: .=_P"%=VUQH&MZ1?WTDT6J7SW_ )L:>6\$S$-E#D\
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M!'MV$C)!(VC/K[5U%% ',W?A:ZO=1T&^GUAI+C29'E#-;K^^9U*MD @ ;3@
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M)MHP& <$*V.,X/TZY["B@"&TM8[*TBMHBQ2-0H+MN8^Y/<GJ34U%% !1110
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MM/N)5A>9XG=5*2!05!&3@CD\5J+\,+2/PMI>D1:QJ$=UI4K36.H)L66%F)+
M #!4Y.0<_6KE_P"!GU7PQ=:1J&N7ES/>-&;F]=$$C!&#*JJ %501T [GN<T
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M>FHVDLN-\0W^6T;, -PSR">>V34'Q=20_#35'CN9H2ABSY38W@R*I4^V#TH
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M7Y9YC$N/M![A6]NU-M/#U_X/T2]N9]:MK:_UC6EN[UXHV(VN_P T,"X)9R.
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M::)0Q96QR"#T.0"/PJO\.FUS6M'L==U+Q!<W&'NH7M?)C5),3,JL<+D,-O;
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M+79+^]:[M(&MT7]V$96P6W )G)('0CIQ0!3\<:[<:+8:7%:R>3-J>J6^GB?
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MHHW\2>+])U&_TB^2SOX-1FAMI&OY$2 12E0CPA"K949.[)^;L,  'H.I7O\
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M'G^T!U&QXU:,*C!N?EP#G&*S/!FEZGXBT22^O?$^L^;%=WMLBQSA5($C*K,
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M>2ZD_L^4*JS>:%+1MMZ<=3SCO@D4V"VU+4?$/C?3)O$6K+!8);&V:*81NA:
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M2;2KX2+;R%2&A?8Z,K!E93V((%4;#P=8V'B!-<%YJ,]\+86SO/<EA*H)(+#
M&>3P,#VSS7150OM4BM;:^>%#<SV<7FR01L V""0,G@9 - %?4O#\.HZG;ZDM
MY>6EY;Q-%'+;2 ?*Q!8%6!5ONCJ#TJ.T\+6$,E_-=O-J-SJ$0@N9KO:2\0!
MCPH50OS'@ 9SSFI_#FL+XA\.:?K"P&!;R!9A$6W%,C.,X&:U* .5T#P#IWAV
M53:ZAJTT,(86MO<W9DBM<@C,:D8R 2!G.,GU-:?AWP[;>&K*6TM+BYEADF><
MB=E8AW)9L$ =2<UKT4 9EEH&GV&N:EK%O#MO-1$8N']=@P,>G'7UP*JP^%+"
M/5M8U"22>X;5XUBO(9BIC=%4JHP%&  Q'7G/.:W:I6%U>7,UZMWI[6B0SF.!
MS*K^>F =^!]WDD8//% &+X>\"Z=X;EC-M?:I<0P9^RVUW=&2*V!!'R+]"0"<
MD G'4U!8_#K1].U66[M+K4HK22;[0VF+=$6ADSG=Y?UYQG'M7744 9NO:+!X
MAT:XTJZFGBMKE"DODE0S*>HR0<?A4^EZ>NE:;;V$<TLT5O&L<;2D%MJC !(
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MM/N69@UNTJR%0&(!W+P<@ ^V:NT 86C^%+#1M!N-%BEN9[&?S-R3N"1YA)<
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M<ES<K<Z>LBP(C*$PX ?(*DG( []N,5L5D>*-</AKPW?:Q]CDNUM(S(T2.%)
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ME_=R, AL9]ZVLZYXQ3Q$-/O/LEY9ZE+9VTRZC+%]F\L@*3$JE7!^\=Q.0V.
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M9SCM3;GX=:+<-JJI-J%M:ZKN:[M+>Y*0N[##/M[,>^.#W!H WM#_ .0!IO\
MUZQ?^@"N(6YU#^V?B1;?VI>[+2W@DM3YO,!,#.=G9>?2N^L+*'3;""RM_,\F
M!!&GF2,[8'3+,236/_PB%C]KUJY%S>"7646.\(D7YE5=HV_+\N%)''KZ\T <
M/92ZC9:=\.=9_MG4I[C4WM[:[2:Y9HI4DMV8Y3IN!4'=U/<FO2]8@2YT:]AD
M,@1X'!,<C(W3LRD$?@:R#X*TXV.C6?VF]$.C.DED!(N49!M7)V_-@$CG-=&Z
M+(C(X!5A@@]Q0!XM':+%\&/!K12SK)/J&G$LTK2;3YHY4,2%^@&/:NPTI+G3
M_B9JFA+J>H3V4^D17H%Q<-*T4IE="4+9V@@ X'&>U7D^'FC1:-:Z3'/J"V=K
M<)<0H;DL49#E "<X53G _/-:0\-VR^(9-=%U=_;Y+46A?<N/+!+ ;=N.&).?
M7VXH X31;[Q%=?"O1KVU:YU6Y2_G:\A-V8Y[J%99@51\@[AA#@$9"XZ<5UW@
M?5;'5])NI[&XOW5;ITDM]0+>?:OA<Q-N)/'4<]Z?9>"M/T[2;+3K*[OX(K*X
M:YMW68%T=MV[DCY@=[<-D<UJZ7I%MI*W'D;WENIC/<32$%Y9" -QP .@ P !
M@4 9GC&YF_LN/2[6&:>YU*3[/Y<#*'\KK*P+$ ?(" 21RRURF@3OX;^*=WI\
MFFW&FZ;XBB^TVL4QCP+F( 2!?+=@-RX;D]1TKNWT6*3Q!%K)N;G[1%"T"1[Q
MY81B"PVX[E5.>O YQQ577_"MCXBNM/N+R:Z233Y?.MC!)LV2?WLXR?IT]J .
M9U:Z?0?'-_!?W^H'3-8TUY;15NI,Q7$1^=(AGAF#*1CN,#CBJW@V^OM6TS3M
M!U"ZNQK&F7LRZHXNI-S"+H=V<D.7B..A&['2NZU#0[#59M.EOHO.DT^X%S S
M=1(%*@G'US]0/2EM-$L++6-0U6W@"7FH",7$G]_8,+^AH \WU[4[VVM9=4L-
M5OKMX]?CC-VLS1VZQF94-NL>XB0*#@MM )R<Y%:<^GWFM?$O7-)DU[5[:R2P
MMKA$M+DQE'+O]TXX'R\COWK6F^&N@S6UW;%]06VN+K[6(4NW"0R[PY9%S@9(
M]\9.,5JV?ABSLO$$NM13W9NI8%MW#R[E,:_=&",\9)SG/J30!PES<2>+/A_X
MUU:ZO+M)(#?6\$,5PZ)"D2$!2@.&+8);<#G=CH!7>^$_^1.T/_L'P?\ HM:S
M+KX?:/<7.JRQS7]K%JJL+VVMKDI%,S#!<KV8]\<'N#70:9IUOI&F6VGVOF?9
M[>,1QB21G8*!@#))- '/>(IGO]?L],33+C4;6T7[7>10F( LV5B5O,=01P[8
MZ@HOK61\++J;3XM6\'WL4T$^C7!-M'.RES:R9:/)4D$CD'!(' KL=.T6+3+Z
M^NX[FYEDO9!),)G##< %&..   ,#BJ;^%+(^*_\ A)EGNUU(0BW^64!&B!SL
M*XP1GUY]Z .#O+O7K[0=42*[U&/Q7'K)BA@@E<)Y7F@ !1\GE^4<EB.#R3FM
M34--O+_XEG0#X@UF"Q?0/-;R+K8^\3!=P('!P!SCGZ$@X^F:2\HD6>'QWI>J
M33232VME.XM1([ECL<DQ[<GJ3SWKO=.\,>5JEEKM]>7$NLQV*6<TBL!&Z\,P
MV[>A?+9Z_AQ0!RL:ZUXLC\0V]A?/;W5A?/96L_\ :4L30&-5VLT:+M?<<L=V
M<YQP!5B.\U37_$%[HDT\<KV6FVKEK;49;0222*Q>5#&I+#( &>!Z<ULZC\/]
M&U#7I=9$FH6ES< +=+97;PI= < 2!3SQQVJ36_ NCZW?6E^6O+"]M8_)CN=.
MN&MY/*_N$K_#[4 <M<1>(+.]\"Z=J/B*:6ZEN;FVO);.7:DP6-R"PQRPP <]
MQGK19:;<W.L>-=#?7=:%EIWDRVF+Z3S8VDAWG][G>0".%)QSR#783>$--EGT
MB5'N83I+,]J$DSAF!#,V02Q()R23G)/4YIT7A6TAU#5[Z.ZO%N-655NFWKR%
M7:N!M^7"\<?SYH XO2/$FJ:S9>"M.FEWR:CI4EU.S73VS7$B; !O12W1F8@8
MSCKC@Q^(+?Q'H'A&>.?7Y1(NL6YM?(NFDDB@DE5?+D=@&<#G!/7OFNHN?AUH
M5UX?T_1W-XL>FMNL;B.<I/;?[KCG\\]O058G\#Z7<Z&FDRSW[PB=;F25[@O+
M-*I!5G=LDD;1[< =!0!CVEO-9_$Z\T)M2U&XT^]T3[7(D]V[%91-L+(008\@
M]%P/3%.^#]K'#\--)F5IB\T;%M\SNHQ(_P!U22%_ #/>NC7PY;#Q*FOFXNFO
MEM?LF2R[3%G=@J!C[W.>OX<4>'O#6G^&+-K/3C<"W+%DCEF9Q&"2=J ]!EC^
M= '/7$SW'QQLK24GR;30);F$'IYCSJC'_OE0*E,UW_PN"6P^WW7V.70#,(/,
M^1)//"[E'3..]:>LZ/(?$&F>(K.,O<V2R6\\0X,UN^,@>ZL%8#OR.XJP?#MK
M+XC_ .$A6XNTOFM?L@(8!1$3NV[2O7=SD\_AQ0!Y='<:K%\+H?$QU[59-0L]
M4V)ONFV.GVWRRKKT<%3_ !9QP!@5V4<LOBGQ3XJTB6_N[0::L,%LMM.\10R1
M;_..TC<<G !X^3W-7O\ A -)_P"$9;P]Y]]_9K3^>8_.&=^_S/O8S]_YOK3]
M5\":7JVKQ:L]QJ-KJ"Q"&6XLKIH&N$'\,FS&?PQ^@H Q-8BF@\2_#J"YOQ?W
M$5S<1RW6T+YKK;N&; ) .0>*K17E[_9/Q(C^WWO_ !+Y93:,;E]T.+<.-K9R
M!NYQFNON_"NGW5WI%P&G@.DY^QI"P"QY7:>"#GY>.:J7W@32;^_U2Z>6^C&J
M1[+N"*X*Q2G9L#E?[P'X<#(- &!I6L76L:SX6T"ZN[A89/#R:G<.DS(]S(=B
M %P0V!EF(!Y.,\5D6T4^F>&OB@;._O(IK6[FEBG$Q,H*VZ,OSGDXX&<YXZUV
MMQX"T::VTF.)[VVGTE/+L[N"Y831IC!7<<Y4@=#QZ8HC\!Z1'9:Q:K+?E-8)
M^V%KIF,F5VGKD#(&,]?>@#GKV34+C7OA];KJ^H0Q:A9S_:EBFQYFVW5@3[Y)
MYZ\Y&#@U5AOM?T_PQX^LM)O+FZNM*NF6QDNI3++&AC1R-S9+;06(SGM79_\
M"(V7VS1KHW-X9='C:.S)D7Y59=K9^7YLJ .?3UYK%\2>%UL= UQK"UO]2?5Y
MD:^A24!RN5#O&/E^8(.%! .!P: (K%;F]\<:7)H]_JCZ*+ RW@EGD9!*"/+!
MWY^<@MN48X&36M\2O^2:>(_^O"7^58>@:9,VJ6MQI=_XS58Y 9TUJ1_)\O\
MB4K*,L2. 5Z'G/KW>I:=:ZOIESIU]%YMK<QF*5,D;E(P1D<B@#SN[M=1\-ZC
MX0U*TUK4KE-3NHK"\L[B<M$R/&QWHG1"NW^''\\NBU&\\.ZIXE\-7-[>7-W=
M[+C1I+BY=F9)2(P@).1Y<AY(YVG)Z5V5AX8M+*>TFEN;N]DLT*6ANY WD C!
MVX R<<;FRV,C/)K)T\?\)5XELM:NM!O=/72%F2!M0B5)'D?"DJ 3\@4'D]2P
MQT- '46-K]BL8+7SIIO*0(99G+NY'<D\DFK%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117%?%*2Y@\(+/:7
MMS:3K>VR!X)2A(:9%(..HP3P>* .UJKJ5_;Z5IEWJ-VQ6WM87FE8#)"J"3^@
MKA]1@DT7Q-H_AVVO+J:WU5KJ[?[=?R9>1%CQ&KC+!<%FVCJ1Z<53U[0[[3_A
MQXPM-2U,W4:037-I"ES(SVR%&Q&SD@NN0<!LC\A0!V&D:SJM_?1+<Z*(+"XM
M%N8;N.Y$@!./W;J5!5L'/&1UYK>KSB6XDL9/!N@6TCB#4[:6:03WDJ^8\<4>
M$W\L!\Q.T8!V^F0<WQ1I^M^'_!6LJ^O3 K?VTMG'!=2,]M'),J&-G;ET^]@'
MWH ]9HKSW5()-#\1Z-H%M>W<T.L375S+]MOI/G=$3$:N,E5.2VT=2/3BLGQ3
MI^M>'O FO!]=F!6[MYK.."ZD,EK'),J&,N>64_-@'WH ]8HKSR9I_#?Q(:.U
MNKZYAN=$N+N:"XN7E#S1NN&4$X4D$C"@#VJ3PY:-KWACPWXF_MZZAO7:.YNY
M5E+)/NX> H3M"[CM&!P0,<T =_17E\$>L>--+U>ZL]16QU"WU*>&*Y%Y*IM/
M*DPJF(#:04 R#UW$GMCTNV9GM87=T=F1273[K''4>U #Y&=8G:--[A257.-Q
M[#/:JVF3WESIEO-J%F+*[= 9;<2B01MW&X<'ZTFK(9-'O%$DD1,+X>)RC*<=
M01R*\M2YU"Y\"_#:X_M6_CGO+ZWAN)$N&S*K(Y.[.0QRHY.: /7J*X?PHLFG
M>/\ Q1HT=U=S6,4-I<0QW-P\QC=P^_#.2<':#C-=Q0!!+=V\-U!;22JL\^[R
MD[MM&2?H./S%9'AOQ&^OW&LPR6/V5]-OC9D>;OWX56W< 8^]TYKG=;TZWG^,
M?A]W,X9]-NBQ2XD3[K1XZ$8')R.A[YKG9]/,^D_$R_6]OK>>QOI[BW-M<O$$
MD2W1@QVD;N@&&R/:@#V*BO.EU:^U[Q!I>CS-&R2Z#%?F-KEX/.D=MK'*#)VX
M''0;L]ACI_"%AJ.EZ*UAJFIKJ,]O,ZK+N+,J'#*CL>68 CD]1B@#=.<' R>V
M:Y?2_&]K>>+[WPM>VS6.J6RB2-&D#I<(1G*$=P""00#^1KJ:\]UOPFGBB^U\
MV\YL]7LKV&?3[U?O0RBWC_-3C!'^% '6MJMPOB1-)^Q*4>W-P+CSN-H8*1MQ
MG.6'MCO6K7FWA;Q;/K6OS"_LGM]<TK39HK^S _Y:!T(*^JL!D?UZG-DO[VY^
M#:>-H-2N5UM(_MWG"=O+)$GS1&/.W9C*[<=L]>: /5#=VXOA9>:OVDQF41]]
M@(&?S/\ G%0Z=<7]Q]J^W6 M/+N'C@Q,)/.B&-LG ^7//RGD8KAM.LXKGXQW
M=S(MQ%+)H5M<,@N)!M<RN,$9Y P!CIQTK)CU^^TCPIXB8ZA<X_X2MM/^U32E
MWMK=I(U)#-G&%) ]"<T >N45Q.O6TOA&TUO7=-U*X8)I,K1Z;-(TJ&6/YO.!
M8D]" 0.#QGFH--TK4WO=!UVUU:**T9!]IW7DLXODD4;>& 4-DY!'KCIQ0!WM
M%%<AXRU6>WUKPOHZRR06NJ7S1W,L;%&*I&6$88<C<V!QS@$=Z .OKF+7Q3>Z
ME/#/I>C_ &S2FOGLY+A;@+)'L8HTFPK@H&4CALXYQ67:BXT_XF77AR.>YDT>
M]TG[;Y33N3;R"38=CYW*K YP#U'&*;\);*&#PBTZ-,7:]NT(>=V7 G?&%)(!
M]P,GO0!WM8NK^(X=-U&TTJ""2]U6[4O%:Q$#"#K(['A4'3/4G@ FMJO-M,D:
MV^/^NQWORM=Z5"; M_%&N-ZK_P "R<>U '6/KFH6>H6%KJ&C[%O)O*6XM;CS
M8XSM9AORJL,[<# (R>HK=KC?&&M:KI?B/PS8V4T"V^J7A@F$L.]E 7=N4Y&#
MQWS67I&E2:MX^\507.KZL+?3KVSEMXH[QU528@Y!YY4DGY>G)H ]&HKR1[^Y
MA_X1?4K#4;R\2ZU\6\NIR3,BWD<C2918<D>6,  G'W 0.<U;;3Y-4\2?$"TN
M-5U46]FEN]M''>R)Y3- 7R""#@-SMSM]0<# !Z3/=V]M+;QS2JCW$GE1*>KM
MM+8'X*Q_"IZ\A4'7I/A5?ZA+<275S%()I5G="Q^S,2?E(P2>I')^E>N@!5 &
M<#CDYH ;--%;023S2+'%&I=W8X"J!DDT0RI/#'-&=T<BAE.,9!&17*_$^".X
M^&?B 2;L)9R.-KE>0,C.#R/8\5DFX,7B'PCX9$MS'87EE+=2YN'+3NB+A-Y.
M[:,EBH..!VX(!Z'17%>&+B\LO'?B/P\9YKC3;>.WNK8S.9&@,@;='N.21E<@
M'I7:T %07=W;V-L]S=2K%"F 6;U)P!^)('XUR+7;:W\2]1T&\DF2RL=.BFB@
MCE:/S6D8[G)4@G&% [ DGK7#ZQ)=WW@[4M/U&XN+I='\40V=K<O,V]XO-CP&
M(/S,H?&X\_C0!Z?)XCDC\<P>&VL<)-8O>+=>:.=K*NW;C_:ZYK>KSS5-*AN/
MBOI-@9KM(/[#N QCN'$C+YL?!DSO_$$'CKBL6RU[4-/\,1Z=]ME>,^*I='6X
MN+A@ZP!G*J9>6&=H7=UP>".* /7:*\UUO2=8T31?%EU_:[V]K)I4MS:V<%Y*
M[P31H271VP0IR,J.,X]:Z3P;I M-*MM3>_O[JXOK*W:47-PSH&"=54\+G/./
M04 =-117E/C>[G&G^,+[3M1O;BYL A26.9H8].944^6N#\[G.X\8PV">,4 >
MK45YSJ]M/K'Q#TG3Y-4U&"TO=%FDGBMKIHP6#1@$8/RGGJ/IT)!ATG0GO_'?
MB72I];UHVFG)ISP*+]]P;8Q))SR#@Y'0Y/&0, 'IE%>27U_<Q1Z1JFGZC>7B
MS>)(X'U%IFC2:-YF1H4BR0T:CY<D 97(SG-::::^L>._&NGW6J:H+.&WM)(H
MHKV1!&S)(25*D$#(S@'![@X& #TBBO++#6=7O/ _@*]NI[B6TN9534WB+&60
M;&"9V_,1N +8[#GC--NKO5_#FC>,]<BN+\6,4J1Z7]JED(C1M@D=4?/RJS,5
M)'0<9% 'JM%<5::#J4/B*ROH]32WTVX@>">V6^FG^TDJ61T9ONN,$Y')&:X:
M(WR_"#3/$G]LZJ=6M[\*DS7CD%3>&,AESM?(/\0)[=.* /;J*\[E:;PU\1Y8
M;2ZOKBWGT*>\E@N+EY0\T<BX8!B=I()&%P/:J^BVNL:WHWAKQ+;:O%;RLT,]
MW.;R61;E&XDB,9 1?F. !]TC H ],J"6[MX+FWMY)56:X+").[;1D_D/Z>M>
M33VEQ=:#\1+B36-7\S2KRX>R*WTB^4R0(Z]#DC/8Y'H,\UHRP)JOC[P->W3S
M&>ZT>>25HYW3)"1'C:1@98\#KWS0!Z?17F,FIW.E>*5M_$45]'%<ZMG3]8M;
MAGMY%,GR6\J X3 ^3!&,C/7)KTZ@ HKDOB%K-SH^A60MI6@^VZC;64MPAP88
MY'P[ ]C@$9[9S5'4$GT'XB>'[&PGNCI^LPW,-U;O.[A&C0.LJEB2K<X)!YR.
M] '=T5YW\---EOM)MM;O-6U2XNH+J\A5);MFC9/.=0&4\,1C()Y_  #T2@ H
MKCK^]_M'XEQ>'+J:1+--)-ZL22-'Y\AE*')4@D*!T_VLGH,95Y)=:)?^%?"D
MFM75Y;7M]<)<7;N5E")&9(X"X.>=RC.<D#WH ]&HKS6_DO=*\5^(= MKR\&F
MRZ VI0GSW+VDRL4PCDY ;&<9QD''>LZR^UV.D_#?6EU349;S4)K:VNO-NG9)
M8Y(&)!3.W(*@YQG/))/- 'JD5W;S74]M'*K30;?-4?P;AD9_#FIZ\OT;3(8]
M6^(TD,UY#)%<91X[N4$$VZMG[W)SW/2HM,LQ#\,].UV[\2ZO!>:A86D+R>>T
MI<LZD+&F1B1A\FX$'YB3SDT >JT5Y5)KFJ>'=2\<-!%+$EGI$5[;6<TYG$4A
M$@SSD#[H) )''6NFTW1HI?[!UFWUZ\"26^+A6G9UO_,08)R?E(/S J!CD# H
M ZBWN[>[\[[/*LGDR&*0KV<=1^&:;?7$UI://#;-<F/YFB0X=E[[?4^@XSZU
MY=X7TR]C\ :Y_84C+J']L7$<4<MVZ+(JW/,8)/RLR@KN'//7O74>!M7M=2N]
M5A6WU'3[^ Q"ZTR^=G-N2&PT9)(*-[<<$]Z .JL;VVU*Q@O;.99K:=!)'(O1
ME/0U8KA?A=+)_9.O6A)\BRUZ]M[<=A&'W8'XLU=U0 45P&C;_&=SXL6]N[NW
MFL]2DL+407#Q&V1$7;( I'S%B6R<YZ=!BN<T[5=5\36_PXN+[4+VWEU+[7#>
M"WG:,3!(W ; X!.,Y'(W<8XP >Q453TO3TTG3+>PCGN)T@7:LES*9)&'^TQZ
MU6\3ZI)H?A75M5AC$DMG:2SHAZ%E4D9]N* *WB7Q&_AZ32 +'[0FH:C#8E_-
M"^49#@-C!ST/'%;U>3ZW81OH'@#5FO+FXNKC6-/DFF>=F68O\Q)7.T<],#@<
M# J]LU7QH_B:&VO!:W=GJ$EI;2K>2QM:; NQA&HP03ECG[V2.@  !Z&UW;K?
M1V1E47,D;2K'W**5!/X%U_.IZ\UL;!9OB]8S7-R]Q<MX:2:2>"=U2603*-P
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M<5JH>2/S=C8R!QP<]?:LV7QM)IE_H]OK>E&TAU>18;:YAG$R"5AE4?A2I/;
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MIU^CR6DZE)461DW*>H)4@XH \V\6Z.ND?"K4-7M=0U,7US!9O)(;Z3!;<BG
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MMYLC2^3OA4DKN)X!8MCIQ77V_A[3EU#3=1L]5NE@GMF@>(3LRWP9-P=B3DL
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MF2Z_'KCI/_:,<7DI*+F0 1YR5V[MN">>E &MTKR%KJ2-?"FJZ==7-S'=>(!
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M+;4D!0LY[^8-H/S<\GGD5CVL[O\ "/P'=/,QN3JUHGFESO(,Y##/4@@<CVH
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M8^(;JY\<ZGH$UK#'#:6D5Q'*DA9I [,.1@8^[TY^M=%7%:=_R637?^P1:_\
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M?IEQ)9SQWEO;"-4N)VD\@[0&" LRKTQ\O;CI23>!/#$_B Z[)H\!U$L':7+
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M=N><8Z\UJ49S0!S]AX'\-:9K,FK66DPPWKN9"ZLVT,>"RIG:I//( /-5=?\
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M,W.F2J8 UX!'+"23EFQ\KA1N*_[2_CUUG.US96]P\+0O+&KM$_5"1G:?<=*
M*VMK*^A7\<$+S2O;NB1IC+$J0!R0._K7-^!?"T.G^%=#34;">+4+&%089YVD
M2.4+AG5=Q0'D\@9Y/J:[/('>B@#G=4\">&-9UA=6U#2(9KX  R[F7>!T#J"
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M_9D^,M@RKN8:!<$+ZGSH^*X744LM>^ %WXAO(XI]8E?S;BY8?O$E^T %,]5
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M<J !M=R6V_\  00O_ :H7]KJVKZI_8D^D11Z!#)#,;Z2Z$C7 0A]GED9!WJ
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M1Z39Z'\5M"LM.B:*WBT.X1(C*S !7C 'S$UV$WAS2)[JQN7LD$M@NVT*,RB
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M,$D.E6$%I'*YD=8EQN8G))I^IZ1I^LVZ0:A;).D;B2,DD-&XZ,K#!4CU!!H
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MA\*-/LK?P[=W$%I;QSG4;R,R)& Q43MA<CG P.*[F>V@N45+B&.558.HD4,
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M2-(L=!TR+3=-@\BSAW>7'N9MN6+'DDGJ35ZBB@ HHHH **** "BBB@ HHHH
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MA;&?[WJ15#4[:W\+VFG:/'J?VC1K[Q&J7RA=D-NKJ7^SCDA8RVW*YQ@D'J:
M.VM_$-Y+\19= *VK6 TL7L<L>2Y;S=F"<XQP>U=-D9QGFN LK&RL/CA<K9V\
M,'F^'E=UB4*"WVC&<#O@#\JF\;1Q+XQ\#W!1 _\ :3Q^9@9P87PN?KVH [C(
M]12"1&;:KJ21NP#V]:\EOX+.6Y^+L:)$8TLH7VIC <6KG/'?<,_6I+?2[+3-
M3^&=_9VZPWETGE7$Z_?F0VI.UVZL 0, ],<8H [WQ;K%QH7A?4M2LQ;O=6MM
M)<)'.3A@BECP.3TJ[IE\;K1+*^N6CC::WCE<]%!903C/N:\JS9^(?A=XYU#5
M(8IM6CEOEF,H!>!H\^4@SRH50N![GU-:$%TEWXHT31[Z>R2VD\/02V<=[ )8
MY9"2)-H+ ;MH3U.,^IH ]2+* "2 #TYH5E==RL&![@YKR'5?#NGZ=IG@_38K
M]]0@B\2+;K,>-D;)(6B4@_=!&.O&,=J].T_2;+0-(-CH]G';P1AWB@3.W<26
M/YDT 7_,3S/+WKOQG;GG'KBAI(TSN=5QC.3C&>E>1^';*R\3>$M$UJXUNVMM
M1M;E)IIX;8"[^T[L-&[%LG<3C;CD$8&,5+'X?TF_U'XE17=C#/'%(KQI(-PC
M8VH;<H/1LD\CF@#U?>N_9N&\C.W/.*&D1/O.J\@<G'7I7C\=C;6_ASX9:Y'$
M!JUS?644UZ23-(CP/N5G/)4X''05<TWPEH.O:_X]M=5MDD@CO$V;W.(=T"DN
MO/#9SS_]>@#L?$FO7^CZYX=M+>*W:VU*]-M,T@8NOR,WRX./X>^:Z-I$0J&=
M5+'"@G&3[5Y!ID]]<^&?A7-J3N]RU_R\GWF3RI0A.?5=IK;T"VL_%%YXXMO$
M$$<MU#J4EL!,!NAM0B^44S]T'YF!&.<F@#T7(!QD4$@9R1QUKQR&VOY_AGX4
M\<7EO]JUG1 +B5G3+W%IEE;.>I\O#@GN,]ZU?$=M9:S\//%_B;R(V^WVCFUD
MV8;R(E(C;/7YB&<>S+Z4 >FB1&;:'4MC. ><>M".LB[D8,OJ#D5Y9?:#I<7B
M?P \=HB/?QSQ7CJ2&N4^S;MLAZN,@<'/ITK/OY3X9LOB1;Z0GV2RM;NR816Z
MX6&.1(_.*JN,?*6/&/PH ]C21)"P1U;:<'!S@T>8A8+O7+9P,]<=:X6P\/:1
M)X@M-5M]4L72[LG@^R:?;K'%=18R&<!CD+QAO<#O7#:7I=E;_"[P/K44"KJ:
MZK:J+OK(%:=E*!NH4@GY>G/2@#V>#5[*YUB[TJ&8/=6<<<DZ@YV!]VT'W^0G
M'H1ZUD>,->O] 31GLXK=TO-4M[*;S@Q*I(^"5P1SC/6L30+#3T^+GBZ8VEJL
MJ16+QN8U#*SK)N(..">Y[U;^)7_'EX<_[&&P_P#1E '9M)&C*KNJECA03C/T
MI<C.,C->3>-A87UMX^EMD26>TLT6YGO6#"%UB+(D"X!7J"6)^\> :NZZ+;2I
M/"/C>=8V2)$L]3F90289D"AV/^R^/P8T >F9'J*1I(T(#.H)Y )ZUY%H5J;7
M4]7\&W6G101Z[/'J<$0BX2UDR98V]"NS:/0R#&.*N>,+>?2KW6]2.FV>M>'O
M*CBOK=,)=:<$C!S%D8*A6#XXP3]: /4SG''6J.DMJ(TJ ZP]F;_D3&SW"+.X
M@;=W/3'7OFIR(-0L@&0203QY*L/O*1W%>*V5K#<?"'X?F0'<-;MT#JQ5@&N'
M!P1R* /;U=7SM8'!P<'H:IWNKV6GWMA9W$P6XOY6BMX\\L0A<G'H O7W'K7'
MZ#I]IHWQ;UFQTVWCM+2;2;>X>&%=J&3S)%W8'?'?O1XWL+&Z\>>"#=6EO,)+
MJYC?S8U;<H@<A3D<C/./6@#8T;Q#>WGB_P 2Z3>I:QV^E_9C"\>06$JLQW$G
M'8#@"NE9E12S,%4<DDX KS!=%TO6O&WQ CO[2&Z@2ULC&CC<@_</A@.F1V/4
M=NM9FD:M+-IWP[L]2NX([.[TR3:]Y'YD<EPHC"!@6 SMW8R>I]<4 >Q*P90R
MD%3R"#UJD#J0UQ@S6?\ 97V8%5^;S_.W<D_P[-N/?-8W@[1;;04U2TM-1%U$
MUVTQAC0+%:LX!,: $X'0[<\9]ZRTM+?_ (7;>H84*3^'8VE5AD.?M##D?0 ?
MA0!W61ZBD:1$^\ZCZFO$81;+\#/#9D\H2QZO&L>[&Y3]L.0/3C/X5TO_  C6
MCZW\6/$=MJ-DEQ VGVDIB8G:7W/\W!Z\=?<^M '>VAU+^TK\7;69L\I]C$.[
MS0NWYO,SQ][ICM5Q)$D&4=6_W3FO,;>PBDUOXG6$-V-.6?[,@N!TB9[?[Q]L
MMS]36=>ZUJN@Z;XF@GT*WTWQ-;Z-YL=UIV#;W$*MM\Q1C*LI8G!_E0!W7B7Q
M%>:1K&@6MJMK)#J&H+:7&\DNF49L@ X'W>];-H=2_M*_%VUF;/*?8Q#N\T+M
M^;S,\?>SC':O.M8L-%B;X<7VF0P8?48@EP@&Z1&A<DLW5B2 23SDGUJIJ4]U
MHLGQ8GT<-%<0K:NACZIFW!=AZ$ LV?6@#UP2(S,JNI*_> /3ZUD)J[:UX?NK
MSP[/:R3 RQ6\MQDPF1&*$G;R5RIY':L>PTCPG=7>B:KI[1 S6KP01P$;+J)D
MRPE7'S@8[]">>37"V6G:</@!KKK:VZSE;YBRH%<[)Y-N2.3CC'I0![,CLELC
MW#QA@H+LIPN<<XSVJ3<H3?N&W&<YXQ7G:3BZ^(GA[2=117TXZ 9[6.4922YW
M*&X/!98QQZ!CZUR?BBS-MX2^)>F1IG1[&YMWL%_AAD=4>5$] "PX' W&@#V\
M.I8J&!9>H!Y%*2!U->?S:79:+\7=".G6Z6[7VGW8NF3K.5,94N>K-DGDY-:/
MQ)T8ZEX5>_M[>.74=)D74+7<H.3&0S)]&4$8^E '7Y&<9%<WK6OWVG>,/#>E
MPQVS6>J23I*[;C(I2)G&WG'4#KFN$_MN&Q\91>+K"PB?3?$=LUE;$1X:6Z50
MT98]MY+Q^^P$UJZWH%E8>(?A[HWE*UNDMTD@4;!*?L[%B0/[QSD=\D=* /2E
M=77<C!E]0<BD21),['5MIP<'.#Z5XW>3GPUI?Q"MM+7[)86NIV9,<"D+#%(L
M7G%5&, J6Z8_"NIL_#NDMKT6IP:G9.MY8/ ;.P@6.&YB'(=@&.=N0 WN!WH
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MH[WEQ=OIT#W%S$89Y'7<98R,;6SU7V/%5K;P=X;LS:M;:)91-:%C RQ -&6
M!(/7/ Y]A6O-<06RJT\T<08[5+L%R?3FI%974,I#*1D$'(- &-_PB7A_^SIM
M._LFV^Q32>9+;[?W;MG.XKT)SS3[_P +:'JDEK)?:9;W$EJ-L+R+ED'IGJ1[
M'BM*>Y@M8]]Q-'$A.-TC!1GTYK,\4^((?#/AB_UF1!*+6$R)'NQYC=AGW)%
M$3>#/#+Z?]@.AV'V7SO/\L0@#S.?F^O)Y_"K$/AG0K<WGDZ191_;8Q%<A85
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M2&*>6&2;[4"<PL,E%P>)#D8ZB@!!X2\/ 7(71K)?M4:Q3[8@/,10%"'_ &<
M#'2GGPSHK?8LZ="?L/\ QZ=?W'^Y_=].*T9KF"W*">>.(N=J[W"[CZ#/6JMV
M=0&K:?\ 9[BT2R/F"YCE4F60[?D\LYP,').0>* *5YX.\.:A>W%Y=Z-:2W%R
MGES2-'S(,8^;U.._6G:AX0\.ZIIMOIU[HME+9VW^HA,("Q?[N.GX5J/=6\9
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MJ05M<3PTCW<FHMNAB@=AD^6<%I"5^8Y7 ')[5N>%O"0AO=?GUO1X"U]JLE[
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M=1MY.W;DCI7M58Q\(^&V^T9T'33]HD$LV;5/WC@Y#-QR<\T <39:%HVI^/\
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MM/U*T6TO;*"XMT(9(Y$#!2.A'H1V(J2SL;73X/(L[>."+)8K&H )/4GU)]:
M."\#3R:[:Z;INHVR"X\,EX+H%/E-RN8XROK\FYS[LIKF]0N)M#\+?$R32E,!
M354!^SC:8XV6(2,N.AVECGMUKV2&V@MWF>&%(WG?S)2JX+M@+D^IPH'X"JMM
MHFE6;7+6VFVD+76?M!CA5?.SUWX'S?C0!P^L6VC0^/?AW<:;':)$WVI(7@
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M!Y*MM9,/'(JJ&V@ Y!Z8K*TV'3I/A9XZ@>.V:9)]6;854LNTL0<=1@[<>G%
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MURP..*?::A9:@C/97<%RJG#&&0. ?0X- $D$$-M;QV\$210QJ$2-% 55 P
M.@Q5/3]"TC29IIM-TNRLY9SF5[>!8R_U('-0>)]?M_#/AR^U:X:/_1X7>.-W
M"^:X4D(,]SBLS1-1OG"ZO=Z_IUSHTMJIEX5#!<'!(#@XV8)X;+ XY- '555G
MTS3[F\CO+BQMI;J)2D<TD2LZ*>H#$9 /I1#J5A<61O8;VVDM%SF=)5*#'7Y@
M<46VI6%[*\5I>VT\B*KND4JL55AE20#P".1ZT 5O^$;T+[(UI_8NG?9F;>T/
MV5-A;U*XQGWIU]X?T75$@2_TFQNDM_\ 4K/;HXC_ -W(X_"KD]S;VWE^?/%%
MYCB-/,<+N8\!1GJ3Z56AUK2KB">>#4[*6&W;;-(DZLL9]&(. ?K0!= "J%4
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MV&JWJ07*8#NNZ)GV[@< C !&,^]=?9:C8ZE$TMA>6]U&K%&>"57 8=02#UH
MA_L/2?-N9?[+LO,NE*W#_9TS*#U#''S#ZT^RTG3M,W?8+"VM=P"MY,2ID#H.
M!T&>E%IJVFW\\L%GJ%K<RQ?ZR.&979/J >*LRB1HF$3JCD?*S+N /TR,T 4;
M+0-'TZ:XFL=*L;:6Y_U[PVZ(9/\ >('/XU-8Z7I^EJZZ?86MHLAW.+>%8PQ]
M3@#-><V'C3Q7/\/;[Q8SZ/)]ADF\RT^RR)O2)RIP_FG#$ D?*?2O0-+UBWU+
MP[9:TW^C6]S;)<_OF \M64-R>G&: %LM!T?3;R:\L=*LK6YG_P!;-!;JCOWY
M(&32MH>D-]JW:79'[8=USFW0^<?5^/F_&I+;5-/O+1[NUO[6>VCSOFBF5D7'
M7+ X&*I7OBG0K'2;O4Y=5M&M+1-TKQS*^.N!P>IQ@#O0!:ET72I].33Y=-LW
MLD(*6[0*8U(Z$+C I6T;2VT_^SVTVS:RSG[.8%,>>N=N,5#9>(-+O=/M;Q;^
MU5+E04!G7KMW%>O) ZU$;X7FJZ7-8:Y8FQE24M;KM=KKCY2C ]%(.< T 6?[
M"TCS;>7^RK'S+88@?[.F8AZ*<?+^%7ZJ2ZKIT%ZEE-?VL=W(0$@>90[9Z84G
M)K/M?%>CWGB2]T*"]@:]M$C,BB0<LV_Y .[ )D@=,B@#2N=.L;RXM[BZL[>>
M:V;=!)+$K-$?521E3]*AFT/2;B_%_/IEG)>#'[]X%+\=/FQGCMZ4^/5M-FOW
ML(M0M9+Q 2UNLRF1<=<KG-87CKQ*-!\,:G-9:E8P:K!;--%#.0S-@$X";@><
M''7Z&@#J:*JZ;,]SI5G/*<R2P(['&,DJ":M4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-\3[PV.FZ'+/QI7]L
MVPU)C]T0Y)^?_8W!,UW-1S017,#P3Q)+$XVO'(H96'H0>M 'FNJW<#?%FYET
MJXMFOY?"TRPM&ZDO+YH*#W/<>U5/#+^&?$.A^$WD\07+:CI\T)BL$:%9HYP-
MLBLH0.5^\6R>0"2>]>F6>CZ7I[(UEIMG;%%V*88%3:N<X&!P,\XI8=)TVWOY
M;^#3[2*\EXDN$A59'^K 9- 'E,ER\'A7XEV]BX_M$:M<2"&,CS3#LAWD#KC;
MNYKH=*3PIXAU[1=6LM?DU*Z2VDBBMXS!@0,OS+,B("%' PW1B!WKNH[.UBNI
M;J.VA2XF $DJH [@=,GJ<5!;:-I=D)Q:Z;9P?:/]=Y4"KYO^]@<_C0!Y;X7T
M31I?@E?WKZ=927,=MJ06=HE9D&^48#'D<!>GI3KC3=._L#X6O]DM]TT]LDC;
M!F16MFW GN#@9!ZUZBFCZ9%:R6L>G6B6\AR\2P*$;ZC&#36T/262)&TNR*Q?
MZM3;IA/IQQ0!Q.G6MFGC[Q[9B"!;9[&S=X=@V$[),DCIV'Z5S,-K:7/PW^%W
MGQ12%M5M8B6 )*E9<K]#@9%>O'1]+,LLITVS,DP(E?R%RX/7<<<_C3#H6D&*
M.(Z58^7&2R+]G3"D]P,<4 >::S#/9:Y\1X-#B\FX;1;:1([<;26VR D ?Q;>
MF.>E:VB/X5U_4_#>K6'B":[O;:-UM+6%H%:-&3#K(B("%  Z\ XQR1GNXM,L
M(;MKN*RMH[EOO3)$H<_5L9IMII.FV$\T]GI]I;33',LD,*HTA_VB!S^- %IT
M61&1U#(PPRD9!'I7BTVFZE_86H^$=/B/VWPK>MJ5E,R;LQ#][;H#_>;<Z_1"
M.]>UTQ8HUE>58U$C@!F Y8#ID]\9- 'G6K7B:Y\+?%'B?RVC74M+D$"N,,L"
MQMM!^K-(WT85 ;2SLO$_PSDM8(87EAN%=D4 R VV3D]^>>>]>CR6%G-9K9RV
MD#VJ@*L+1@H .@"XQQ4/]C:5NA;^S+/,'$1\A?W?.?EXXY]* /*-+DT/7O"M
MYI'B/Q!=6NJ0:C*US8HT*3FX$Q9#%E-[$_*!@GTZ<5O:;I6F7/Q-\<+<6=M(
M!9V1(>-3RR2[CCU/&37=MI.FOJ*ZBVGVC7RC"W)A4R@>@;&:0Z/IAFEF.G6A
MEF!$KF!=SYZ[CCG\: .<^%<AD^%WAYF8L1:A<DYX!(Q^F*S?B@%>_P#!,9E,
M9?Q!" RMAA\K#(_,5W=K9VMC#Y-I;0V\6<[(4"+GUP*CNM*TZ^D62\L+6XD4
M85IH5<CZ$B@#G=3T'1/#^F>(-?NHKN\N);&07<[REIGA522B'@(/]W'//:N/
ML+ZR/C?P*1>Z<+=]+N(8[>"0,(HRD6R-G)RY[<@9QTKUORT\OR]B^7C;MQQC
MTQZ53BT;2H%A6'3;.-82QB"0*!&6X;;@<9[XZT <%\/]%TF73?$%R-/M)+FW
MUO4%AD\I6:(;B %/\(P>@]?>N;FDL+C]FRSVO;R36\5J6P06C;[0H_ XR/SK
MV:TTZQL-_P!BLK>VW\MY,2IN^N!S41T72FMS;MIEF8"YD,9@7:7/5L8QGWH
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MUF1(9KDJWF(4D)"D  Q[N@Z'W!%>DP>&]+70[+2;JRMKVVM(U2-;F%7 P,9
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M3;"0>9^&.OMGM4.N1"?XD^#;W261I'BN1<O$00]IL!&['5=Y7;[FNZ95=2K
M,I&"",@BJMCI6G:8KK86%K:!_OB"%8]WUP.: .2\#>6?$_C?;LRNK#IV_<I_
M@:V?'*[_ (?^(QMR?[,N<#'_ $R:M2VTK3K*9I;6PM8)6^\\4*J3]2!5IE#*
M58 J1@@]Z /*M2>PU'1?AK$KV]Q";ZW255(92?LS94_F,CWJKK*S65[\4H=(
MB*.MI8R>5;@*<&-O,( [E :]1_L/2#'#&=*L?+A_U2_9TPG.?E&..?2I8=-L
M;>Z>ZALK:.XD^_*D2AV^I R: .*T8^%]<\0Z%K6G>(9K^]AMY$@AA:$;(67Y
MA*B("%! P#T8CUKOZIV6DZ;IKRO8Z?:VKS',K00JA<^K8'/XU9EBCGB:*6-9
M(V&&5QD$>XH \&T?1[J\^&D>K6OG:C:V.JW,U]HYE)BO(1*21M!Y8## =#CD
M'BNU\7^(]/GT'PKK=E>E/#K:C&UQ<6ZJ1"FQPA92" %?;D$<$#N!7>V>FV.G
MAA965M;!OO>3$J9^N!3(](TR&":&+3K2.*<8EC6!0L@_VACG\: . N]*\.7E
MOXANK'Q3,\VHK:K<WT;PR0Q2B11"2$55R3C(_N]<9%4M4O=5D\.>.M+U^PM/
M[7M]&\QKZRSY5S%ME"$J>5<8;C^@%>F1:/ID&GG3X=.LX[(G)MT@41GG/W0,
M=13[;3;&R@>"ULK:"%_OQQ1*JMQCD <\4 >:ZNFE:E<_#=@+2X0W B=AM8'_
M $8G:3W&2./>M/5--T[2_BEX)AL+.VM$^S:@ D$:H,;4.,#W+'\379'0](*0
MH=*L2L Q$OV=,1C.?EXXY]*EETVQGNTNIK*WDN8\;)GB4NN/0D9% 'F7AS4/
M#NI^$M1T?Q3+&=5BU29[RU>4I<2SB8M&4 (9LC8JX],=*N^>UOX^\?1VLB1Z
ME-IMH;)"0'>0138VCOSCI7?MI6G-J(U%K"U-\HVBY,*^:!Z;L9J0V=J;P7AM
MH3=!-@FV#>%]-W7'M0!Y?X:?PQXATCPE,?$%R^HZ?)$8+"-H5FCF VR(RA Y
M7[V[)Y SFLU=1M+SX/>-(-5E@&M+->&^BF8!_.W'R^#S@*$"_P"[@=*]=@TG
M3;:^EOH-/M(KN;_63QPJLC_5@,FF3Z'I%U=/=7&EV4UPZ&-YI+=&=E(QM)(R
M1CM0 W0)HI_#NFRPR))&UM'AD.0?E'>M&FHB1HJ(JJBC 51@ 4Z@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/
M''B-_"_AW[>GEJ7N(K?SIE)C@#N%,C@8)"@DXR,\"NCK%\3ZAI5AI:+K:0MI
MMW,MK-Y^/+ ?(!;/&,X'MG/:@"M;MKD.IZ:ZZG;ZEI%SN,LP@ =?D+*0RG:4
M)'IGIR<U-H7B[1_$5WJ%OI]Y!*]E<- 0L@)DVJA9U'7:"VW/3(KA[+1&\#>.
M]$L_"^IRS:/JSR?:-(>7S5@0*6\Z,]57.!SU) R<\9UU<7+>#?B;IVF3?\39
MM6N91;HW[TPE8=[!1S@KN&: /6+36M*O[EK:SU*SN)U7<8XIU9@N<9P#TSWH
MN-:TJTO$L[G4K2&Y<A5ADF57)/08)SD]O6N(\0RVFLR> ;WP\\;3?VC%)"82
M,K9^6WG XZ+M"@^^!UK,T#5?#MWX>UOPYXL>)M475)VNK*5RLURYEWQ&, AF
MR-@7;_=':@#J['6[X?$/7M-O;R+^S;2Q@N8@4""/<7W%FZGA>I./:NEM;RUU
M&U$]C=PW$+<++ X=?P(R*\E\4S:A%\1-?N;*,75M;:?9RZE8J<27%L#)O52#
MU ()'\0&.AP?5-'U+3]6TBUOM+FCEL9HP86CX 7TQVQTQVQB@#G/!VM:MJVO
M>);6_N8I(-+OOLL CA"%EV[LL<G)Y'3%::7EZGB^]M9KV-=.M[**YVM& 07>
M13E_[H$8/3OUKG/!TT6E^/?&FFWLB07%Q>1WL"R,%\V)D W+GJ 00<=#6W93
M6NI^)]:NXGBN+%+*"U:48:,R*TS.N>AVATSZ9QV- &G%XCT.:YMK>+6-/>>Z
M!:WC6Y0M* 2"5&?F'!Z>AJ$WR0:_>O/K]I]D@M%9[ A T!!),K-G.",#!&.*
M\GT^&S@^#G@>Z1(4E_MFT;S0 &W>>03GUQQ]!7;V A3XUZNL817;1(&8+C)/
MFODGWZ?I0!N:'XQT77M$.K6]];I;!V#%Y5!0;V52P_AW8R ?6M6SU"SU&)I;
M*[@N8T8HS0R!P&'4$COR.*\G\+FTU+X3^'-/@UU--U2"\_<2@*XBN \Q5)%/
M9@&&#U.*[7P/J.H7G]LVVK6-K;ZG:7OEW4UF28;E_+3#KGD';M!';% &_=ZQ
MIFGR^7>:C:V[X!VS3*AP3@'D]">/K3)-=TB$1F75;)!*&:,M<(-P4$L1SR
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M[X#TC5+Z59+RY@WR.$ !;)[#%9?A7QC&T6IQ>(]:L8[F/6;FRMO-=(/,6,@
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MPSY\HG<)&)*\\8.<]J].\86UC/X0O;6\O&T^U=4C^TQX'DDNH5N>,!L9]LT
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MQ96^],;&\I<KCICCBD&F:>L<D8L;8)(-KJ(EPP]",<U7;Q%HJ1V<C:M9!+[
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MEO>7FBVXM(Y#AG?=)T'?!/..E=ZUI;/,DS6\1E3[KE!N7Z'M4AC0R"0HI<#
M;'('UH \@\+7GAO7/#F@:1J=_>MKFFSQ#^RBX2:.ZCX+8"@XZL3G&"<FIHSI
MS6?Q8<FV+%I5+97./LPX_P"^L_C7JPMH%N&N%AC$S#:T@4;B/0GK1]EM^?W$
M7/7Y!S0!Y;%J-K:ZC\++ZZNHX[?^RYT,SO\ +O-O%A<^I(( ZDUZ;J6GV^K:
M5=Z==+NM[J%H9!ZJPP?YU-Y$055\I,(=RC:.#ZBI* /%#<:TGAS3=:FBD^U>
M!YS;7)"<W2AO+FVGT\D(V>A+'TKH?'L/D?!G7;B]58[J]3[3*K]0[NI5/<JH
M5/\ @->D&-"K*44J^=PQP<^M#QI*N)$5QUPPS0!P&KZA:6GQ1\+W5Q<Q1V\V
MEW4<4C,-LCEHB%4]R>P')KGB]A)X6^+,A>W:1KJZ&[*DD"!=O/\ O9Q[UZ_Y
M,7R?NT^0Y3Y1\OT]*;]EMP"/(BP>OR"@#/\ #,JS^%=(E602!K*$[@<Y^0=Z
M\JOVN+OP?\28]+/VB4:X9)8H3EGA A\P #L55A[X(KVE$6-0J*%4= !@4U(8
MHB3'$B$]2J@4 <#KL]KK_B7P/>Z!<13S)<O.TD+ [;0QG?NQT!.Q<'N:Q_"F
MLZ!<>%7\,^)5277;;4)?/T^7/G7$_G-(CH.K9R#NZ =>*]4AMK>W+F""*(N=
MSE$"[CZG'6E^SP?:/M'DQ^=MV^9M&['IGKB@#QKQOJVGW.C_ !!LX)(=/N48
M+-;?>N+UUC3$N&SMCQ@#:/X<DC-=+>:C9W7Q*\#2PW44BR:?>%6#CYLK'@CU
MS@X]<5Z UO"S.S0QEG7:Q*C++Z'U%!@A+!C$A88P=HR* .;^)$B1_#;Q&7=5
M!T^91DXR2I %<ZVMZ9!KWAF!Y[:QN)-$W1ZI,^<H2@,,0)VER0#D@X X!S7I
M#QI(NUT5E]&&:;]GA^3]S'^[.4^4?*?;TH \?T"S.K_ V+^S7$FJZ-=37MN,
M?,DT5Q(X4CL67(QZ,/6K3W^JKXBL?%&GP2QP>+(/L$<93FW8+FWE?UX\UCZ*
M0.U>L)&D:[415&2<*,<GK0(T 0!% 3[HQ]WC''IQ0!Q7Q)M;>P^$6L64*8AB
MLU@A0<]U5!]<XK6L=0T>VU?3M(O)[;_A(_[/4A67]Z8Q][#8Z94G&>V<5?U+
M25U:>U6Z8-9V\JS^3C_62*<KN_V5.&QW('I@R3:7#<:M;ZA+AGM@?) 4#:Q!
M!8GJ>&8 =/F/7C !>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *AGN[>V*":9$,A(4$\G R?R')]!4U<;X1OGUSQ1XJU*4Y6
MSO?[*MU/_+-(E!?'^\[9/^ZOH* .ETS5]/UJV:YTV[BNH%D:(R1'*[EZC/>K
M"7,,EQ+;K(IFB +IW /0X]#SS['T->1Z1X@UCPQX0U[6+.ULI=/L]=NVN$F9
MO,D4W&T[,<*1GJ<Y]!WZ[Q_?-H?]A:_#\KV^HQ6\Q'\=O,=CJ?QVL/=10!V=
M%%% !1110 45#=&5;65H&190I*EU++GW (_G7#Q>.M0F\&^%M?%K:AM6O;>U
MGA.XA!*^W*G/;'<&@#OJHW^L:=I<UK#>WD,$MW*L-O&[?-*Y.  .IKEI/$OB
M6Z\1>)-(TZSTM&TJ*"6*6=Y&#AU9L,!CD[0.,8YZUDZYK?\ PDGA?X?ZR8?)
M:[URQE:/.0K$/D ^F<T >FT5Q>J^+M1:768]#MA-)I;^5Y;64\WVF4(KE%:/
MA.& R<\]@.3'/XYE.HZ?I\GV?1;J]T]+N)-5C8>9*Q(,&<KM9<#/4G<,"@#N
M**XW4?%\]CK5CHUS/8:9>W-@MPCWJL8IIB2#"K!@ 00.Y/S# -=79/<26%O)
M=1K'<M$IE13PKD<@?0YH GH)P,FN'?QAJEYX9U'Q/I-O:3:;923;+>0-YES%
M"Q5W#@X0G:V!M/0<\\5EU[4M7^(7A\Z=>P+I-YH[WT44D+$D%H^6PP^;!X].
M>N: .STW6-.UE+A]-O(;I+>8P2M$VX+( "5S]"*O5Y)8:QK6@:;X\U72[>QD
MAL=<N;B=;EFS(H2,LJ[>AP,Y.?I77WOBR2;48].TP;)C8I>O*]G+<A!(2$7;
M'@Y.UB22,8'!SP =917GK^.?$*Z9X=E?0([6\U+4#83P79>,JV&(905!V$+G
M)Y&<8-7HM?\ $EAXBT72M=BTJ,:G'.!-:"1E$R9*I\Q'5/F^H(]Z .TJG_:E
MC_;']D?:4_M#R/M/D?Q>5NV[OIGBN1TCQIJ&I:3KF18_VII^H_8(H45MCL6"
MHQ^;.UMV<CH 3SBM*/7KU?B$^@3VML8ETC[:L\6?,=O,";<'H.IQSVYH ZBB
MN+\+^,I?$<-O?1W6G/;>6[7ULBLMQ8L!D*X+<X(()VCIP.>*L7C?5[F+1]3L
M]*EN].U"9 ]O'83B6"%_NR^;C8P P2 !UX)QF@#OJ*RO$VIW&B^&-3U2UABF
MEL[:2X$<KE58(I8\@'TKDO\ A-?$5C-X<OM5TW3UT;6GAMPUO(YF@EE7*%L_
M*5)[#IZGN >A45PNF>*/$FI:IJJ?8])@L=)U(V]W(\LA8PA Q*8'+#.>0!V]
MZ9<^-]3M_!T'C/[);/HSE99+0*WGI;LVT2!]VTM@ABNWU&[C) .]JGJ.J6.D
M6Z3W]REO%)*D*L_0NQPH_$UA1>([U/'L>AW(M187=B;NQG56#2E2 R')QD A
MNG(/:J&K^*M5L/#EAJOV6QN(KS4HH$W!EQ \H6.0#)RQ&&ZC&1UH [:21(8V
MDE=4C0%F9C@ #N3573-4L=:L$O\ 3;J.YM)"P26,Y5BK%3@_4$5D-KE[J7B3
M4M&T<VL;:9%&US-<HS@R2 LL8567'RC);)Z@8-<=X#\0/I'P\\/6@B'V[4+R
M]C0+$\RQA9I6=MJ#<P&,8&.HY R: /5*HR:SIT6KPZ2]Y"-0F1GCM]V7*CDG
M'8?6N1'CK4=/L-7;5M)D\VUN(8+&86\EO%?M*<(%$@)4ACANN.HS4%^NJ+\7
M/"8U&2TD'V*]*/;QLF#MCW*06;..,'(SD\#% '=:A?VNEZ?/?WTRP6L"&261
MNBJ.IJ:*6.>%)HG#QR*&5AT(/(-8OC+5KG0O"&IZI:VT%S):P-*8IV(5@!SG
M Y^G'UK)U#Q1K,.O>'-,L[*Q<:Q:2R^9+(PV,B*QX Z?./4G&..M '9T5S?@
M_7[[6HM5M]3AMX[[3+][.5K;=Y<F%5@RALD9##@D]*S=>O=97XF>'M.M;RWC
MLIK:YF,3PLV60*,L0PSPYQTQSU[ '4:=K.FZNURNGWL-U]EE\F8Q-N"/@';G
MIGFKU>46NIZUH\_Q"U'28+%ULM0:YE%T6^=5@1BJA>AP#R3Z<'MU,_C!KF>P
MM-/3RI[K3DU!G>TEN1&C\(NR/!))W<Y &WOF@#KJR;SQ3X?T^[-I>ZYIMM<J
M,F*:Z1' ]<$YJ'PGK&H:WHOVC5-,ETZ\CF>&2-XV0/M/#H& .UA@C/N.U<KJ
METMG\=+*5H9I1_PCT@*PQEV_UX[#F@#M+KQ!H]EHYU>XU.U33@,_:?-!0_0C
MK^%:".LD:R(<JP!!]0:\:N-"U'2?AI\0[N[M&L+34I9;FSL&(S"A[D D*6XX
M'3%=]>:MJ5E]@MX!9VEF;'S&O[SYD\WY0L04,I+').?;&#0!U-%>>+\0=3N?
M"OA/6+33+4MK5['9RQR3,-C$N#MXZ?(>3TST-;?A[7]4NO$VLZ%J\-F+BQ2&
M>.6TW;7CD#<$-SD%3SW]!0!U%%86N:\^GZKI&CVBQMJ&JR2+$TN2D:1IN=R
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M[=T<<@$4A&1\Q7CMSTJU'X]\GPOX5O[PV>FIK$?SW,L;&WMSLW!2-PQGH"6
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M-9AND'JHZG\*UZ "BBB@ HHJE!JUC<ZK=Z9#<!KVT5'GBVG*!\E3G&#G!Z4
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M>1&(/,2%0'J> <_2LJ3P[KX\4:;K%O<Z?LAT[[%+!/O<0MNR98L8R2, @[>
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MQ+H$Y4G!(#9XZ[30!*_C*;5;F2WT5A$8[*"Z,DMA-<@F92R(1&1MX ))/\7
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M</\ 8S:033>5"B!F+H.78$@<8'.>,8K%?2=9\3^#M6\*_P#$AMPIAV76FES
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MD<<WAZW?,$9M\7(0'(B,F[&WMG&2.!CMTVD:]I^NF]&GRO)]BN#;3[XFC*R
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MRZQ?Z3JUA=I:ZKI,KO;R21[XW5UVNC@$'!&.0<BN@BE6:%)4.4=0RGV/-/H
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M^'EP&/87QD<L<C@?3U-=)10!@>+_  _-XCTF"WM;I+:YMKR&\ADDC+IOC<,
MP!!P?8U3;PQJ-IXH_P"$BT^]MS>7-JMMJ$,T96*?:<JZX)*D<C!SD>_-=710
M!Q%[HNK^'/#<YT"_@&L7>H->W#26V\74CY)C5<_*#A1G)PJDD]37;U2U35;7
M1[9+B[,OEO*D(\N)I#N=@HX4$XR>M6W=8U+-G !. ,G ]AUH Y>'PSJ&D>(M
M5U+1+NV6#52LEQ;W,;$1S 8\Q"I&<C&5.,D=15'_ (0*6SA\,6^F7D20Z)<-
M<L9XRS7#N&#DX("Y+L>_Z5T^BZY8>(; WVFRM+;B5XMS1LAW*<,,, >HK1H
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M70]9DL;ZWU6VFFLI+>$PF.6, M&<LV5P1\W6N?\ %_A^X\.>!KZ*74X)7O\
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M=E.3$WESH[H%=1N^0D/G!W8Q75ZEX9G?Q7;^)=*NX[:^6V-I<1S1EX[B+.X
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M[SX"QVR2*AYW<MELY(/TKKGUF[U7Q?J/A_3[A;1=-MHI9YS&'9I)=Q10#QM
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MQ:6D5N)))/+4*9)#EG/<D^IZU-0 4444 %%%% !1110 4444 %%%% !1110
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M@9)KM:* .7\.>&M7THVZ:KXDEU6&T7;:H;982.-H,C DNP4D=AR203@C/C\
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M5U!<),;(?/Y.-B[0XP..3DD^W2NTHH YRW\.7EMXMU'7TU&$O>6T=OY)M3A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5CZ[X@AT9[2U2%KK4;Z0QVEHA :0@98D_PHHY+=O<X%-UW4==L7@&C
M:!'JBN#YA>^6W\L\8ZJ<YY_*N.-A)K'QAC.LQSVK'PZK0P073+M8R_O5$B%2
M2"0"1C(Q0!Z):?:_(!O?)$Q.=L.=J^V3U^N!]*GKSKPSJ?B:QT[6K*ULY->.
MGZQ):6SW5X(G, 4-\TC [RI.WUY]J[C2;F_N].CFU/3UL+MB=]NLXF"\G'S
M#.1@].] %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE?Z39:D\
M$EU#NEMV+0RH[))&2,':RD$9'!P>:NT4 06EG;V%LMM:PI%"N2%4=R<D^Y))
M)/<FIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pacb-20231231xexx1028003.jpg
<TEXT>
begin 644 pacb-20231231xexx1028003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"!54!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$[R-/*K.D,,3RR,HQEMJ G R.>F2!WJ#PY:36^DK-=ILO;QVNKE3U5WYV?\
M 5VH/917,W<TFA?%E]3U(E-*O]+2VANV'[N&5'+%&/1=P.03@'&* -Z;QGX>
M@T2/6)-3C%A))Y2RA6/SYV[2N,J<\$$#'>I=/\3Z/K.HW.F6-ZQO(8_,93$Z
M$H3@.A90'7/\0R*\QUO39H?"'BJ[$4@M]6U^&YLX/+.YT66+?(%QG#;6;IT
M/>NMFN(3\9;.X$BF#^P9(S,/N;C,C!=W3.T$X]* *_A+Q7#I7A"YO_$6IW+H
MFK7-L+B5'E/$I5 =H..P'05VTVJVD%[:6<CR">[#&%/)<Y"C)R0,+C(ZXKA/
M!>DVNO\ @+7=&O4817=_>AE92&"O(Q1P#^# ^U:'@#^UM0A:^UZ/%YIZ-I2-
MG(D,;XEE!_VRJ#ZQT ;/C&\TZR\-7+ZGJUUI5LVU3=VC$2H=PQM(!//3IWK*
M\8>(S8Z_X?T4?;4AOKB3[4]O!,7,:Q,P5&09R6"YVG( [ TWXM R?#35H8T:
M2641+'&BEF<^:AP .3P"?PJ#Q7>0-XY\#SK(&ACGN9))%&516@*J6(X )( S
M0!TVCZ5)8:4]I)JE]>(\C/%+<L?-C1N0FX\G'JW/K7EUKK_B*#X47OBT^)+D
MW]E<R@1W"1-#,J2[ A&P'D=P0<U[))+'#$TLDBI&HR68X %>9?"S0])O_"@.
MHZ9#+=PW\\NRZA^9<R$HVUAZ'@XH ZY?&.G0:=;3:@98;I[%+ZXMXX))6MXR
M,DN$4X .1SZ'T-37GC'0+#^S_M&I1C^T(S):%59_-7;NR, ]AQZ\ <FN4\2Z
M@7\5:UIDMI<6Q?2E%O+:6C-+J!(?*&0*<*A(XR/O$DXK%TRXC:S^%7F1RJ+1
M66?S(67RR+8H"<C@;^ >F1Q0!V-E\0]+U/Q)8Z981W<T%U9-=BX%G* ?WBHH
M'RYQRV6(P, 9J]HNJ:0S:]=P:Y/=0P73&Z-TY$=H0@)1"0,*!SW')YK(U&4V
M'QBTZ[FAG,%QHTEK%)'"S@R^<C;<@'''.3@8KEKVTOM2T+XB0Z7"TUT^K1W4
M,(!'VB-/*+!?[P.QAQUZ=Z /2K7Q1I%W?O8I<21W2P?:?*G@DB9HLXWJ'4;A
MGTK*TKQ/X=TOPU;WK>(+B[L;B[DBBN[PLSO(9"-GW0< _*.,  <XIVA^*-&\
M37<5]8V$OG00L+BZNK1HC:J>3'O91DY'(4D<$D],^=/(D/P=MA-&X\OQ"KR1
M-&=VTWA8?+C)RI!''.: /4])\9:!KE_=6-AJ"O<VJ>9+&\;QG9_?&X#<O^T,
MCIZTZR\7:)J%W:VUO=L7O$>2U9X)$2X5>6,;,H#8'/!Z<]*Y?6$75O'EEKFC
MP+J$>F:5=BY:+E+AG \N#=T)R&..V>>HKG=/U!+K6/A]J(BO2L1GCGABL9(X
M+-VMRHA10O0'C//3).* .]F^(GA:"&XF?4R8[:<V\[I;RL(G&,[\+\J\@;CQ
MGOQ4E]XPMK/Q?8:!]GN7:YMWN&F2VD=0 5 "E0<_>Y/0=^M<(61_ OQ,B"DR
MW.H7C0)L.Z8-&H0H/X@2#@CTK6^T"U\:>#=0>*=[:31I;8210LX\T^60AP#@
M\'KCH?2@#NM;N;6TT2]FO;R2SMA"_F7,9(>(8/S+@'D=1QVJE8ZSIMIHNDA+
MVZO5N;57MY&B>6>>,*O[Q@JYZ,I)('+#N0*?XN8+X-UH'JUC,J@#)8E"  .Y
M).,5P?V6TN_#'@P?VQ=:'JUMI0%MJ*C]W&P2)7AE#?*<G'RMCE#0!Z987]MJ
M=C%>6CEX)02C%2I.#CH0".G>L"^^(GA73C="XU4 VDGESB."1S&<9R=JG@ C
M)Z#(YJSX+N]2OO"=G<:O;1P7S%_,$2%%?#L!(%/(W##?\"KE=%U/2['QC\0(
MM19!YES#^[9,F9?LZ@HH_C/^R,GGIS0!U=YXS\/6!L1/J<?^GQ&6UV*SB5 N
M[*[0<\=!U.0!R:?%XMT:XL[6YM[B6X6ZA-Q$D%M))(8P<;BBJ6 SQR!SQ7G.
MC:7<: _PPL-21EGM!=O<!AN\CS(VV!ST7E@O/<5TBW#>'_BKJUYJS&+3M5LK
M=;2[?_51M%N#1%NBD[BPSU^M '03>,M @TJSU1M0#6-Y((H)HHGD5G)P%.U3
MM.>,'!SQ6A/JUG;7L=G-(ZS20O.H\IR-BXW$L!@8R."<\CUKA-'\'OJW@OQ7
M87"O;PZQJ=S=V =2IA4D&)\'E?F7?CT(K;\$W-_J.D?V]KL!M+V2%;=TDXV"
M+(=CZ;I-Y_W=OI0!9T#6-'MO"$>HQ:W<W^G>9(%O;LLTDC&4KM'R@GYOE4 9
M. !FL:PU]KGXM7ELM]>_8(M$$[VMQ&\2Q2>;C<$90?NXYYZGFN.L/MEI\.O"
MM^MK<2V^DZ[)<ZA;I$QD2(RRX?9C) #ANG?/:NJL=7L]0^+_ /:-KYSV+^'P
M@N?L\@CR)RW+%< 8SR>.".M &MI?B?P[I/A:VOW\07%W83W+Q17EYN=W<R$;
M?N@X#?*.,  <UK:7XHT?6=0N;"QNF>ZME#R1O"\9*'@.NX#<I(^\N17E49_X
MLY9VS1R>>-<#M"8SO"_;"^2N,XV<Y]*[)GAF^,P<'=!)X>,/F+G:7,^[:&'&
M[;SCKCF@#;E\;>'X$ADEORL,\C10S^1)Y4K@D%5?;M8\'H><'&<&MR2>**V:
MXDD5(40NSL<!5 R2?08KQ/1-9\/'0O#NC:GK#V=II%^MW$+BQGCE.QF,22,5
MV+C<-S D'&..M>P:Z;<^'=2-S ]S;?9)?-AC^]*FPY48[D<?C0 RR\0:??W0
MMH7G65H3<*)K:2(-&"!N!90"/F'YU7A\6Z+-?V]D+MEENE9[9I(71)PHR3&[
M*%?CG@GCGI7 6ECK!BU'P]H^L'6]*NM%N4M+BX4"?3Y" J1/)Q][/0X8;.@Q
MS;\+ZCH.N+H]M/I.J_V[IQ1I;>\-QLLG489]SG8!P< <G(&!S@ ZA/B%X8EN
M%@BU%Y96EDA"Q6TKG?&,L.%ZX!^N#C.*OV_BC1[O08];M[EY=.E8+',D$AW$
MMM&%V[C\W'2N?^&K)Y/B4 %6DUZ\F 92I=&8;7&>H(Z&JGAS2+[3O%.H>&VM
MV&AV=W_:MK)_"5DR5A ]%E#O_P !7UH Z2ROM.N/&&H10:M=2WD5K'YU@Q/D
MPKDX< C 8]#SVJ6'Q;HD]]:VB7A\R\+"U=H76.<KU"2$;6_ \]LUR&H6\VH>
M/_%UI9N4GNO#Z6T$O(4S?O. W3(W*3Z5/X-\1Z?JNE:)H\VBW UO34CBF@N+
M)E%FR+L:3S&7:. <8.3D#UP =1=^+-%L+A8KF[:-3.+?SS"YA67.-AE"[ <\
M<GKQUJ2[\2:793RQ332YAD2*5H[>1TC=L;59E4@$[EZG^(>HKS+17TM=-N?!
M_B;2M6NM7CN90EJ3<-!>@RETD4J?+5>023C!!-7O$(GT_6M5U/PU?RIJ1N8T
MN]!N4\R'43A%W1@C(.W&67(^7G&#0!ZJ2 "2< 5B1>+=$FN;6!;MA]L8I:RO
M"ZQ3MZ)(5VL3VP>>V:E\3V-WJ?A35[&Q?9=W-G+%"V<8=D('/;D]:\^O&'B?
MX;Z#H%G%)#KD$UG&]NR%9+-X67>[#^%0%;![Y &<T >@IXETJ0ZFJW$A?2\?
M;$\B3=%D;A\NW)XYXSQ65J'CS3K6Z\.QVL=S=0ZT2\4\5M(Z^4(V?(PN2QP/
MEQD DG%<[+>II/C/QY;W4-R)M2MX)+)4@=O/"VY1L$#'##!R1BLVPD:TT+X7
M7T]K>)!8[HKD_99"T;&V9!E0N<%N 0,&@#TFX\2Z7;3M%)+-E)4@=DMI&1)'
MV[59@N%)W+P3QD9QFJ]G>:=/XSU""#5KJ6]BM8Q-8%CY,*[CAP,8W'H>3TKA
M]9,]CK-_JOAJ^F2_DO8UO/#]W'OCO3E5WQ@\J=N"67(&WG&#5V_BN+WXA>*X
M+!RES<>'UM[:7HOG9DX#=,C<I]J )?''BN)[71CI&IWD1EUBV@\R")UAN%,H
M#J)-NUA@'HW.#UP:ZW5/$^DZ-YQO9Y%6!0T[16\DJPJ>A<HI"COSCCGI7EUS
MK=O=_#?POI2V=Y'J6F7VGQ7=G]DD+PF)U#$@+T."1ZY^M:+WNGZ1XI\1Z;XH
MM-7-OJUQ]ILY(!<M%=1O$B&(I'_$-N,$=.O&* /5(9H[B&.:&19(I%#HZ'(9
M2,@@]Q3ZI:/;1V>BV5M#:?8XHH55+;=N\H <+GVZ5=H **** "BBB@ HHHH
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M&PR8V@YXSG /!.>*;KVO6-M;W]EYUUY\-N9)FLXG=K=2#AF*@[>A..N!G&*
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MKV:9+$WDUU EOYQ#2%$ $F$ &&SP3TZ<FL^#Q'XF@BT/0]8@CL]:U.]F@6X
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M<@D*"3M!)_ #DUY[J?C:^\(ZKX@T[4V_M!+/2QJME,55'==_EF.3: OW\8(
MX-=%:6WB6+5M.F?4K>[TZ6%OMT<D:H8Y, H8=JYVYR"&)XQSF@"_H.O67B/3
M/[0T\RFW,KQ RQE&RC%3P>1R#UJY>WD-A9RW5QO$,2EG*1LY '4X4$G\J\M^
M'FL27EM_PCFG7OV.[BO;N[N9&0$M";B1=L8888D]2.%]R<5Z;J2D:+=J6+$6
M[C)ZGY3Z4 0Z+KVG^(-*34],EDFLY 2DA@=-X!(X# $]#3],UFRU@7!LVF86
M\K0R&2WDBPZG! WJ,X/I7-_";GX6>'_^O8_^A-67KNKZGH/@#7]5TF>**Y@U
M6;!DBWY#7 0XYP#SUP>G2@#T>J.GZK#J,-S*D5Q EO/) YN8C'DH<%AGJOH>
MAKFH-2URP^(<&C7NH0W=K?Z?+<QJ+<)]GD1U& 0<LI#=SGCK7)^(=;UK4_A-
MXMGN=2*7%EJ<UEOMXU0/$LJQ[<<D @G/.?>@#U^BN&\3>(Y_#&HV%OJFHWMK
MI4L+[M62V1P)]PVI)A"%7'0X&?7@UU>DRS3:'92RW,%U</;HSSPD>7*VT99<
M?PD\C':@"]17G%GXIUF'6_#$%SJ$=V=3FF@OHX80;:-PC,!#*%!;:5P>6[]#
M5:?7?%DVE^-;N+6;:!M!N9C"$LE/F*D*R;#DG .3SR>>HQB@#U"LO1?$%CKX
MOC8F;_0KIK2;S8FC(D4*2,-@X^8=JP+?Q+=ZYKVE:-:S&R:;2%U6ZFC56<!R
M%5$W @<EB20> !WS5?X9QSQ2>+X[F83S+X@G#2[0N_\ =Q<D#@'Z4 =O+,D2
M.S$G:NXJBEFQ[ <G\*HZ!KMEXDT:'5=.,AM9BX0R(48[7*'@\CE37+:2M])\
M7O$2OJEPT$-G:,D)5-H5C(=H^7( /.>ISR37)^'-3UO0/ACHFL6E_$MG'J;0
MR61@!\U)+QT8ESR"-V1C XYS0![/17#ZAK>N:MJ&O6>A+=1R:6RP0M"MNRR3
M&-9/WGFL#M^8#Y0.A.>PZC29+Z[T&U?6+5;2^D@'VJ%'#*CX^;!!/'XT 9<_
MCK0[>TEO9);K[!$6!O5M)6@)!P<.%P1D8STSQFK[^(;"/Q+#H#>=]NF@:X4>
M4P38I /S'@]1TS7FAGUSX;:,^D:W8_V[X)*-"E]:C]];0MQB1?X@ >H_/H*W
M=8>74?B?X=ETN\CB%QHUR\=SY>_"%HR&4'@G&,9X]CTH ]#HKSW3/$>NW'A7
M4?/U"R6[T[6GTZ>_F41@PI( 9 N"OF;6P%Z$XX/2HX?%.LFW\<P17;.^BVZ7
M%G/>6FR0AH6?:Z +W7@X'!Y!H ]&HKSJ+7O$=AX>TC5;W4(KR36Q96]O;1VJ
M)Y$LB[G;<6 8E0< X&[T'%6VO_&VGG72NG3WMK'8F?3Y+GR!,9QUB*Q-AAW!
MP.F,\B@#NJ*Y'P;XC@\0W%U)::W)>PQQHLEK=0K%<VTN6W!U"KP1C''4'DU5
M\6>*I-#\0):7]]/I&FS6JFUU%;=9(3<%F!25BIV@ (1TSEN: .XK*U[Q!8^'
M+2*YU#SA'+,D"F.)G^9F"C)' Y/4D5AP:QJ:^/=-TB2]26UNM&:[DV*I'FJR
M+N1@.AW$]ZY+7]7U'5_AYJQO)DFFL_$R6<3E N4CN4"[L=_7% 'KU4M+U.+5
MK>6:*&YB6.9X2MQ"8V)4X) /4'L:Y*/4_$FB>/=/T;5-1M]1LM9@G:VD6U$1
MMI8E#$8!.Y"#W.??UI:?XTU8>%_.NF2XU&XUZ3286CC50 )& (4D#.U6QD]<
M9- 'H]%>?7WB/Q+X6MM>U'4[*:YT>VLQ/:3730++Y^X+Y3"(X*DD'=@8&>M;
M\5EXFBU6V)U:&XT^6W=;LO$JO#+@;6A 7E<YX<GH.30!T*LK E2#@XX/>C<N
M[;D;L9QGG%</\*?M<O@Q+J[U">Z>6ZNL^:%X(N),G( ))Z\_ABJMK<W-I\3?
M%MU<ZG<O:6.GVT_D[4("8E8J/ER ,$^ISR30!Z'17F][XIURS^'MIXZ%TLD;
M+'=7&F^6OE^0[ ;5;&X.H8'))!(/'.!TGCJ:X7X>ZY=65W+:RQZ?+,DL6-W"
M%L<@XSC&>OI@T 7M0\1:?IFH:98SM*9M2D\NV*1%D8X+<MT' ]<UK5Y9JD%W
M'8_#=$N_,G:\C,<DT8PF;9N,+C('YGUJY_PF&K: GC&VU&X349='DM?LLS1+
M$6^T !58+@85CUXR.] 'H]9&N>)M*\.?9?[3EFB^U3+!!Y=M++OD;.U!L4_,
M<' K)TZ7Q7%XI@CGM[F?19H&\^6[^SH]O*.1M$3993TP02..:S/BNSK:^$VC
M3>X\3615,XW'+8&>U '4Z?XFTG4]2ETVWN76_B02/:W$$D$NP_Q!74$CW'%:
M]>:Z&)/%?Q3N-9O473KGP_$UDNG;MTK[\D2LV -A!.T#/KFKM[KGB+66UX>'
MDN5FTVX:UMEC6W,<LJ(K$2^8P8 EL?+C YR<X !WM(64,%)&X\@9Y->>ZUXO
MO]+O;.#7II?#T=S81M'=+$DUNMX=V^.5\, !\N,$9!;GI2G^TI_BSI4;:Q+L
M.@O/LC5&CW>;$&Q\O(; .>OH10!Z%5+2]3BU:T-S##<PJ)7BVW$)C;*L5)P>
MQQP:X[PQ>^*]>O\ 5'DUJTBM]-UFXM#$+$'SHU5<#.[*X)!ZD]<GI572O&FJ
MR>$].DNIH7U/4=;DTM)O*"I&!(XW;>^%0X!/4C.: /2*165U#*0RD9!!R"*X
MCQ%%XFL/#OBMY-7W6<>GO/8W*JBW*.L;%U;"!<9 P0,C/KS5:PU:_P!.T?PC
MHMO+=7%QJ5CYQEC6'S(XHXH\JF[:N<NO+9XSP>P!Z#64WB"Q7Q,GA\^=]O>V
M:Y ,3!-@(!PQX)RPZ9KD9?$GBC1-->WU:V5;J\U:'3]*NI_+RZRG[\B1L1E
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M9B6; &<]!@#KGH** .-\.^![[0!#8_\ "275UH=J^^UL'@0,F#E5:7[S*IY
MXZ#MQ56Y^&YNK75%?5@EU=ZD-3@NXK;;):3?*,I\_(VKC!]3UKO** (;1+B*
MUC2ZG2>=1AY4CV!CZ[<G'YU-110 4444 %%%% !1110 4444 %%%% !1110
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M+E$A3RP5 ^0\=22/6K>H>"IM3T..PN];N)KG[5%=SWDD*[I'C(*@*,*J@@<
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MM)AM(BJ@ )\KMD#)RX<#)/ ![UC^-]0TO4+.Y\&S"2?5=2M?W$"0.1RV!(7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7:>9!&K\R#&[CWQSCKCFHM*\7Z=J_B+4]'MF/FV#)&S,I&]R"S8XZ 8Y[\T
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MDNO6(1)C S"4$!QC(R/3<N3T&:U+W5++3UC-S.%,N?+107>3 R=JKDG YX%
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MIW+E_P!RH7'K\V<>^:TM*U%=/\;^']2U"X1=*O?#D=K:W3./*6<,&="W0,P
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MDI+16H9HR+A@I!*J03U )XSUK7\.:G9)XY\;L^IFY6>QLY8[B10HD58Y 6!
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M+JEG&0Z26S*VG93#@L5PN<!< Y/T!( +6D_$/1=0T.?5[B26SLXKB2(R302
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M8E7M_$L?G),A7:!<2EB<CH 1D]L\UUYEBG^*'B6*!T=YM"BC4(<[W!DR!ZD
MCCWH U!K5WXP^'_]H:'>76F7D\:21O':>:ZDD$* X ;(XW9P,YS@5N_VHFG6
M=E%JDNZ_DA#.EO$\A9E WL%4$[02.<8&1ZUA_"^\@N?AWHL,18R6MK'#,"A7
M8ZC!7D=1CFJOC6"&37;":U\0G0=;@MI&MKF7:8)D++NBD#<'D*?7J1G% '9V
M5[;ZC90WEI*);>9 \<@Z,IZ&N7BOK]?B[-IK7TTE@=$%TMNP4*DAFVDC !/
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M3:A8D_-M![]C7-BYEAT"_P!2M(GNK73?&LM_=0P#<QMMY^<*.H!(8=OESVH
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MJ1C(SUH VJ* 00"#D'H110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:EFVK,C,<#T )_"J&I:C:7_Q.\'WD+,8!:7OSNA3;O"!,Y QNP<9Z]J]!HH
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M*% 55P?7&.2<51G@EU'X:?$>VM(WFGEU>ZGCC526DCW(P91W!"G!'7%>S44
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MQ10!E>&+"YTOPII&GWC[[JVLXH96SG+*@!Y[\BM6BB@ HHHH **** "BBB@
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M%RT[&"/SIA!;O*8H^?F;:#@<'\CZ&O*Y$E/P1U*S6VN?M;:JSK!Y#^80;P2
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M0N(PJ-O8D#A03UH ZZP\5Z/JRZBMO/.KV 'VF.6VDBDC# E6V,H8@@'! YK
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M94#M@\8[5HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5POP\OY+_4O%N;B\EBBU7RXENV<O$/+3*8;D '/%=U0 4444 %%%% !1110
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MF:\>CN+V^@\'WTVD:NEW::N#>VL=A)%#:#;( B1@ $9(^<9]V&<5[,    ,
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M(@_O!C R#CY OKDT >KT5!97!NK&WN"NTRQ*^/3(S4] !1110 4444 %%%%
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M898(EP"1V+,6;'8;<\Y%=/161X@\16GARVMI[R*XD2XN8[9?)3=AG8*-Q)
MR: ->BBL>\\16UMJ4FG06UW?7<4:RS1VL8;R5;.TL20 3@X&<G'2@"/Q9X>_
MX2G0)=(-V;6.5XW>18][?(X< 9..JBHIO#,ESXLMM>GO49H;-[-K<6_R.CD%
MB<L><@?AZU?TO7;#6-.DO[:1UMXW>-VGC,10H<-D, 1@@@Y]*TJ .-MO *6^
MAGPXVI/+X=\W>MH\69 F_?Y7FYY3/^SNQQNKLNE%5=2OXM+TRYOYDE>*WC,C
MK$NYB ,G H YB7P-<0>(K[4]&\0WFEV^I.)+ZTBB1Q(^,%T9@?+8CJ0#_*M"
M;POO\4:5K,-V(DTVV>VBMO*W HVW.6SG/RC']:U-(U.'6M&L=4ME=8+R!)XU
MD #!64,,X)YP?6KM ' 1_#.2'2++2T\1W@M-/U!;ZR7R(R8B'+X8D9?ECR?7
MH:W8?#4]OXJOM>CU(&6ZM$M?+>#(54)*MD,,G+'/K[5-8>*;+4?$-[H<,%T+
MZQ"-<J\>%C##*G=G!R/3-6I=:AAUR'2#;W)N)HFF1E0%"BE0QW9XP748Z\T
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MT53#)%MV%/;Y1D'.?:@"KIFK:C=>,=6T(W^H?8FTJ.[MYKB)(YXV+LA*_*,
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M%();<<D^Q&,=2ES)XCU3QW_88U^;3HYM!2\<6T<;B*8R[3L)7E>.^3C.,9X
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M%1@R28W-]< #]*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M678S7DLEW';H5GO796;9%@Y10<$G(P%Y(K&O?$.O)\-/%-U'J=W;W>E:R]I
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MWN;>788FC4$!0 H/1F[\YJGX>\"6?AV6(0ZIJMS9VY)M+*ZN \-OG/W0 "<
MD#<3CZ\T <Y87GBKQ1X<LO$>D745O<27!FQ->$0>2)"&B:,(0,*,;OO9&<]J
M]-KC[7X<Z;8ZK/<VFHZK!87$QGETI+C%J[DY/RXS@GJN<'ITXKL* .$^,O\
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MM&-\C;F/U-2TV-2D:JSLY Y9L9/Y "G4 %%%% !1110 4444 %%%% !1110
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MQ UY=M>I:_8\$IL,>X,00%ZE@#G^G%;-%17%S!:JC3RK&'D6-<]V8X 'N2:
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MXR,&NKHH CM[>*TMHK>!!'#$@1$'15 P!4E%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&_%?_DEOB'_KV_\
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MW<'&.F.U0W_@'1K[7IM8$E_:SW(5;N.TNWACN@.!YBJ?FXX[4 9TUQ>K\2]
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M/[H8D*/88%=??7=[KGC75]"0D0V-G \:)J,MHY,F_=(#&I+8PHY.!Z'-7O\
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M+L3[L>3^-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=XN)40D%A'LVX.TG&_..V>* +]MX)T>TFTB6'[6'TA&CLRUR[; P"MG)^;(
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MK0R7LK&($;=@RW"8.-O0]\U;T?Q%/J?BG7]&FLD@_LKR-LBR[_-$JLV<8&,
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M1K2WOIVGNHXE625CDL?<X&3[X&>M7J** "BBB@ HHHH **** "BBB@ HHHH
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MW@BL2%SWQ]* .'MKB:"Y\%:A8W-U/%>ZD\,FI3RE9+]'21LM&,C9P-N3D8&
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MJJBQ2RNQ4+C;AB=PQ@8.:JZMX&T'6[.SM[^WGE:R)-M<&ZD\^//7$F[=^9H
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MX1*_F?OE(4Q[   IX(  R#7HESX>M%U+^W+>&276(+5H+=Y+J0*5ZA&&<8)
MR<'UKSK2O":FQCMH_#OB?3-7"?/+%J9CM4E/)=2)2-F[G 4G':@#UV-!'&J
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M80H0X^;D@_WL@ <8R<M\/ZOJ/B6;PQI>L3V^;G01=B.]A,B74N_:25#+N8(
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M8[3D@<D8S7%6^DV5A\:S%9PBWBF\..6CB)10?M"C*@?=./3'KUKG=-U>;3O
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M>E7^A+HMW;&;3U"A8WE<L-I!7#YW @@8.<UJTV21(HWDD=4C0%F9C@*!U)-
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M ,6;PEH5QH<&C2:>GV""198HT=E*.#D.&!#;LY.<Y.3ZU6U?P)X:UV6TEO\
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MEEI,>)(P-3N''VAF\\(T<>!D1 94 GD \8P:]=LK*#3[.*TME9((E"HI<MM
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M< P /3U- 'G?A?3]%UKPMX6\2-?21ZBK12S7D+@27,[?*\4AP2RER1M[8&,
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MJ5C'<36A)A=B04SU'!&0>X/!JG_P@_AH6LMJNDPI!+<?:GCC9E!ESD-P>QY
MZ#MB@#D;E%\*?$'6SHT+*&\,R7[0;V837"2$*QR22Q'&>IK)U*RTZ[^&O@_7
M $GU">_T^:>]/,DDCR+Y@9NI&[(P>!M'H*]270--76%U<0,;]8?($[3.3Y?7
M;R<$9YQZ\]:RO^%>>$]KI_8L/E-,)_*WOY:N#G<J9VK^ &: .DFD2&"261MB
M(I9F] !R:\@LA'!>^ ]1T\,L%W>R)]MG<&ZO8WCD8M-@ 8) (!)/3H>*]@$:
M"/RPB^7C;MQQCTQ7.1?#_P *010QQZ);!()O/B4Y(1N>F3PO)^7ISTH Y#5=
M/O=3;QQ92VLU]JDDRC2KF$9$&8E,:!QQ$48[CDC(;/.:DUCP[ OC#P+I-X\T
MB26=['=J+B3;*1$A/4YP2S>G!QTXID_A#[9K>H3ZWX%-_=7%T[KJ%EJ"PQM'
MG";E\Q&4A0H/#9.3WKL-,\(6-O#IDMZCSWVGAQ;RM<R.8%8D[%8G) 7"Y/+!
M1F@#DX=*M=3\4ZYX19[)+73K.VAL+:]A>=EA,?,D9,@.X,2"W)X7G@4R$2+K
M_A_PM?:S;:E:C3)C#/J%L9([R99=I!7> S*@X))[GOFNUUWP;X>\2W$%QK&E
MPW4\ Q'(2RL!Z94@D>QXYJ36/">@:_IUOI^IZ7;SVMMCR$P4\K P-I7!7@#I
M0!Q<OAO4],T.'3=)U.SUB6SU22==-O%,<4D9C)^S DM]S>&7)(!QGI72> ;^
MRO\ 0[G[)I\^FR0WLL5S8S8S;S<%E4C@K\P(QQ@UHCPMHJV%E916*PP63%[8
M02-&8F((+!E(.3DY.><GUJ_8Z?:Z; 8;2(1HSF1CDLSL>2S,<EB?4G- '$:M
MINGS_&C1Y)[.V=FTFX=F>-22RR1[22>XYQZ5DZ=%!XG\!^)]5U/Y=9M[J]_T
MC.);)XB3&J-U0* IP,9R<]37HNH:!I6J7UI>WUE%/<V9)@D;.4SC(]QP.#QQ
M5>?PKHES>W%W)8CS+G'VE5D=4GQT\Q 0K_\  @: #PE>7NH>#]&O=1!%[/91
M239&,L5!)QVSUQ6S0!@8'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKC/B/J3:=I^CAYHX+&XU6&"\EF0M&
ML95R-X!'R%P@/(&.#P: .R5E895@1Z@TM<-9^%-(MM3UD7=[9RV6HVBR7.GP
MP"*WC"\>=C<=I(SSD9QGM6)\/+>&RU]='U>-FNK"V9M"EN(@K2V3.3O_ .NG
M0-G! QP,MD ]3+*&"DC)Z#/6@LJXR0,G R:\BL;*#QCX;U6XU'5K.PU*SU&9
MKFZ%M_I=DT<Q*8<OP-@4#Y<8R.N:U[&/3O%/B;QEH_B'9)/"(XH5E #16S0@
M[X\_=)8LQ8=#MST% 'H]4M6U6ST32[C4;^416T"[F8]_0#U). !ZFN&AM[.#
MXE>%!:RO/#)HEQ&MQ*<O<*OEA69L#<<<Y]ZY+4[>RE^%WCO;# \4'B60PX4$
M1_O81\OIP2..Q- 'N3,JKN8@ =R:6O.]4^R_\+$LO#A73+?3CI;26=M<VH>!
MYC*1(%0,J[PN/4X+>IKHO!>DQ:%HLFF0:FU_#!<R!&*X6$'!\I>3\JDD=3CI
MVH Z$LH8*6 )Z#/6@D#J0*\;\=&SNM!\<ZA8 236EQ&DM[=,#)#-&(\1VX !
M51D')/WBV :W[_2[#5/B_8QW<*SPSZ!*TT;,2DA$T8PR]"/8\<#TH ]%!! (
M((/>EKR/2O"R>(OAOKNC6Z()M.UB\72]XR(#'*2B#/\ "?ND>AKI/"6HVWC6
M]M/$/V-8EL+46RHT>#'<M@S+S_<"JH/^TU ';D@ DG '<T!@5W C;USFN4\:
M/927?A^QN%EGN;B^W6UIO"0S,B,3YQ(/R*/FP 3D+@5YW?Q*/AK\2;1S%MM=
M3E:&.#*QQG;$2$&>!DGCU)H ]O# D@$9':N<\=^(+SPQX0O]7L(K::XM4#^7
M.3M(+ 9P.3U]17.3:9::)\3O"LNG0"*6_L;Q;ME)W7&Q8V7>3]X@GJ:Y._6R
MU_\ 9_U37;Z**;69&DEN9W4>;',)\;,]5 7"A?[OUH ]R4Y4'U% 92Q4,"1U
M&>E0SS1V]A)/,Y2*.(N[C^%0,DUY'IR6]MJOP\OK!%@MKJ6<)-*X:ZN8FA9B
M\S  9)P2.<''.>* .WT_Q)JEYK7BS3GMK,/HYA%OAFP^^+S/G/XCH*T/!NM3
M^(_!^EZQ=1QQSW< E=(@=JDD\#))KG]#_P"1[^(O^]9_^DHJ[\+?^28>'O\
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MDVBP_%35-.EMK.U@N="ADEL[,D1AO-=1GIEMO&<#C ^H!Z0&4G (S]:6O)_
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MT1<A9 &C ! /O^8% 'HA95QE@,\#)ZT$A02Q  ZDUY;!IMIKVM^*?#-U+I\
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MC<,XR,^F:\^UW3[?2?&/A"X\/P16YO)I+6YCM@%2>V\LL2P'7;@$'MGWJO\
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M@@Y!% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)GD@=3C\12R2)%&TDCJB*,LS'  ]S0 ZBF&6,2K$9%$C LJ9Y('4@?B/SI]
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M*R*L5RT4D;A2OWHV]">_>N>T+P -(^(M[JRM?FQ%I"MM)+J$DA>3YPX<%B6
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M'@0Z>90R36MKJ/FIY)AE8D.XW;PRACD!3G P>X /28I8YX4FB</'(H9&4Y#
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M-BTEI;B1)Y(V9Y638%78S?*,DDG'0<<G#9?"MXOQ$?4K=D&C7T4<]]&3RUS
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MP =NRJZE64,K#!!&017F_@;5;'PWX-U&64+'$-=NK>")2%!9IBJJ,X 'N>
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M:#;:/=W=S/9-=PNKHJ. RC&2>/O<DXZ< Y%<EXH\/^*-<M?%EE/HRWKW2_\
M$JN9+J,1PQ;1^[5"<K)D-EL '/+8 K=AT_6G\?:3K$VD21VT.D26LI6>-MDC
M.K ?>!. N"0.IXR.: +EAXZM+O0%U"2SGANS?-IOV$LK/]J#%2@;."."<],
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M2/R-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%9FMZK)I-K \-E->37%Q';1QQ@X#.<;G8 [4'4G!Q0!IU')
M/#%)'')+&CRG;&K, 7.,X [\#-<Q;^.;2.#Q$^J0BT;07 NO*E\Y&#(&78<
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M#*GY21R"#6!?^.9-.#74^D21Z<NIC33++*4E9BP3S%C*X9-QZ[LD<XH O_\
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MGVA2\1,IC!"8^89 SR.O&>M;-EXKNY?$\^A7VBR6MS]C-[;;;A)/.C#!2#C
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M(QUR.E:ND^)[B\\47>@:AI3V%U%;+>0GSUE$L)8KDX'RL",$<_6@#?FN(;9
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M""%#',C9>/<6')!P=V 2!TYQ5+0/"CI\(CX9\1Q+:E8)DF?S%94R[.L@(/\
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MX@%^=?E^;)=0,XZ^QJSKFHW6F:>LUEI\M]</-'"D29 &]@N]B <*N<DX/ H
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M8;F DJ)87#J2#@C(XX((K#'B275=4GTS1K6&9[>UBN+EKMS&J>:"8X\ $[B
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M3G 8#IG!Z^E2W%O#=V\EO<1)-!*I22.10RLIX((/45QGA9%3XG>.PBA038'
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MDMO!M[I&N>#_ .STAET[0[.:UE>27;)(9%0;@N".JY//>N\HH ;(66-BB[W
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M[60E@&7"X/"D@Y!Y'O23>*O$MUX@U_1M(T2PEN-+$#K)/>,J2+(K-CA,[C@
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M=/OI;&X6%RT;.F/F4D X(8=:RK;P?>:7XC\-3:>+9M,T;3Y+(^;,PE?<$&[
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MA4^:"8TP@)!(&23TR.#SC/M?">NVWA_6O#8-D+34KFY<7PE;>D4[$L/+V_?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.H7FK>&=-U'4((X+JZMUG>*/.$W#('//0C/O0!JT444 %%%% !1110 4444
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M<MHGAR#PK\1&M=!W0Z1>V#SW=BK$QP3*Z!'4'[N\%QCOL/IQU5YH&E:AH_\
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M:Q/<6Z3VU@MI#:02&1]A.XRSN0"TCG)Z8Z\G&:SO'>N17?Q(T/PK?7*P:/'
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MV%HZO;V]M'%&ZG(<!0-WX]?QK2H **** "BBB@ HHHH **** "BBB@ HHHH
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M%_<!'1?]GH:Y*V\*ZKKGB30-4UVRL].M="CD^SV-K)O1I2<*PX&%550COGL
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M>&0["0I"'#@'[R\_7CBM+X9^.9/'OAJ749[(6D\%PUO(J,61B #E2?\ >Z4
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M0W 5_P!VDA W $]LYQ5;6?$>EZ#:0W%]=(OVAUCMXU(+SNQ 54'?.1[#J>*
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MQ3=*U>TUC1X-5M686DZ>9&\@VY3LWL".>>Q[58%Y:M;BX%S"83P) XVG\>E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDL=O&;/22H6!F8#(SDEN2QWDDGDDYJOJ=GJMEXW^*,NAH;2V334>2XC& KB
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M'Q&CU[PC>$>?ITD>65AOC9HPRR+]-Q4_0CO78PPQ6\*0PQI'%&H5$10%4#H
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M8&YL?WBI0Y]!@=\^CZ_.A^,TERES:ZC/8Z24M--EN$B,%R_W3B0@'<I.2N2
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MI_M+(;5,&7GYR,?>Y//O4\V@:/<74EU-I=G)/(5,DC0*6?;C;DXYQ@8STQ0
M:#;6EIH5E%8VYMK7R@\<)&#&&^;;CMC-:-%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117G'QDUV?3/#=AIL%
MT;,:O?1V<UWNV^3"?OG=VX_3- '>Q:E83N$AO;:1V9E"I*I)(ZC@]1WIIU?3
M!G.HV@PXC/[]>&/1>O4^E>-Z%J.B'XH>(-:A2*+2_#6D"VM(AQN 0EG ]-JL
M,_[2]R!7+KX734?A7H]K%912^)?$VJ&YB8)\T,6X[G']U H!./[U 'TA+?V<
M$PAFNX(Y2"P1Y &( R3@GT!-<_XV\5#P]X#O_$.GSVLQA0&!F_>1R,6"@?*P
MSR>QKSJ;^R-2^)?B_7M7AAN=+\-Z:EEB901+*0<Y'\39#KCU(]JYM=*N-/\
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MAA18T7T4# 'Y5X5X9U33;6W^(?C]8K5;@3RIIX"*&C"@JK#^[O+J">^#UYH
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M<P);?:6GC6#;N\TN NWUSTQ7C?C!;W0?$&G^+=-G75[2WC30-8LY!N+ L <
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MGG&>O>NKJAH=G;:?H&GV5F0UM!;1QQ,!C<H4 '\15^@ HHHH **** "BBB@
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M]XDO=+DN,NS7%E(#!LW'!W=.E2Z[K:)X:O+K2=5TM+G8RV\US<*(1*!T8YH
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M,\I^ZB_[*L W'&"S'N:DDCAU;Q-\0+#2]9TR?4]9E73XGO;CRG@09$J!""S
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M)-=$5N-4\07SQ*$4?NDD<C9GL,)(<?[OM7T:EC:1W$UPEK LTP"RR",!G &
M&/4C'K4?]D:;]B6R_L^T^R*VY8/)78#G.0N,9S0!Y%/;@^*? G@SS@OA^QT_
M^T+AONQW3Q!N3GAEW(&]"&SZ5CW>H7=IX-^(?BZ1'CM_$=PMIIL3K@RQ_,@D
M /JC$C_=/M7O%UI]E?&/[79V]QY9RGFQ*^P^V1Q4DUK;W**D\$4J*0RK(@8
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M.3U%>NW%E:W;1-<VT,S0MOC,D88HWJ,]#[TY;:W2:298(EED #N$ 9L>I[T
M?/'A[6I/#_P@\7>*='18+W4M0(C$*X6UC9]J]. 1N? [94]QGOO!?AK2[C4]
M#U'^U;6\DTJR/V6WLW,BJ\H_>32R=W<D\$#OUQFO1A8V@LS9BU@%J008?+&P
M@]1MZ4MI96EA (+.UAMH0<B.&,(N?H* . ^-^NC1OAK>PHX6XU%EM(QGD@G+
M_AM##\15O0OACH<&A:'!J<,U\^GPHR0SW#O DI&681YV\L3U!ZUV5QIUC>2"
M2YLK>=P,!I8E8@>F2*FBBC@B6**-8XU&%5!@#Z"@#PS3O$A2]^)GCBV827D
M-E8@#/EI'A0Q'8$E&P>NUO0XR=/DTS4]2^'&@K.LR9.L:A=.=QN+AOF*YZN=
MZE#U]/X3CZ#33K&.&>&.RMUBN"6F18E"R$]2PQSGOFDCTVPBEAECLK9)($\N
M)UB4&-/[JG' ]A0!X1J,\.I:Y\2?&=PJ/8:? =+MXRN5FD&$&?5=X4D=\CMD
M'L/AQKN@^%?"OA+PU-=-_:&J0M-'MC8JS,2Q!;IU.W_@->DBPLQ;R6XM(!!*
M29(Q&-KD]R,8-*UE:O-!,UM"TL (A<Q@M&",':>W'I0!/1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTNT@D@E@N,D*I7)..58#I0![C17!^(_B3#IAUN/3+>.Z;1H@;J660K'YS<)
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MB+*I)'R\@;AU(QF@#T*BO/=,^)H%]XLM_$%C%IZ^']KR203&575LX RJ_,>
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MW;@ 8'F9ZG.0#S6OI_C#5-3.B7EOH$YTS5I6V/U:& *2LTAZ+NXPO.0>N>*
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MLDA #$X.U H5B<<9]ZO>&1<>)/C;KFJWB0D:#9IIT9B)*>8Q)8C/.1\X/UH
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MN=\8)+!3M^9BS%N< <#MD^KT4 <-:^#-1B^*]QXG>>S&FK8I9VD*@^9&HQD
M8VJ,@\Y/!(QW&1X"\!:[X3DN;2YAT6=&O'N(]5.Y[D*V 0%*X!('7=@9Z-7J
M%% !7(PVOBW3_$VM7T<6G7NF7KHUO;M=/%)"50+G.P@AL9([5TM_J-CI5HUW
MJ%Y;VENO#2W$@C4?B>*KC7M(+:>O]I6N[45W68,H!N!C.4_O<$=/6@#S2'X2
M:BO@?Q7IYO;2#5=?N%N"D.[[/"%DWK&#C)')!..XXXYZGPUH6NZ7X=>V:RT7
M3[U+/R4-GN;SI53:KR.5! SV 8^_8]G10!ROP[\)MX+\&VFD3/%)=*SR7$L1
M)5W9B<C(!Z8'3M5/PMX"_L77M<U6\NA-]OU*2]AMD'R19)VL?5L$^PSW/-=7
M;ZKI]U?W-A;WMO+>6NWSX$D!>+/(W#J,U;H \FL/ACKK>#_%^EZA?V27VN73
MW"SPEF#$LK+O) ('!&!GAS]*ZG0=(\3?\(BNBZP^G6ABL#9H]D[R,QV; YW!
M=N.N!G)[CI7851FUK2[?5(=+EU&U34)^8K4RKYKC!.0N<XP#S[4 <1\.?!NM
M^%--M=.OK31(_LK./M]MNDGG1F+;>4&T<XSD\#H.M>BT44 >>7O@W7=2^+>G
M>*[O^SCINGPF&"W%PYD&0WSD>7C.6/&>PYIGA3P'J_AK4_%5O'<V@T;6)'EM
MO+D;S;9F#?P[<'[P'WOX17HU% 'F_P ./!6M^$]/M].OK31%^S.__$PM]TEQ
M,C,6VX*#;UQG)X[=Z?X5\)^*?"VN:\D$NES:9JE\]XMU([F:,L>04QAC_P "
M'KWQ7=ZAJ=AI-O\ :-1OK:S@SCS;B58USZ98@57L/$6AZK/Y&G:SI]Y+C=Y=
MO=)(V/7"D\4 <#J^E:IX8\8>*?B!>7%FUDFFB.T7),@"J/DP1@;G YR>O3GC
M(\'^ ]1UKX7:1H]\T5MIU_.-2U&59"TUTK$.B 8 7("9.3C;QG/'K.JZ/IVN
M69L]4M([JV)#&*7E21TR.]3V5G;Z?9Q6EI$(K>%=D<:]%4= /:@#AK+P1JL/
MQ,UC7WN+2+3[BQ2RL_*R988PH!4+C ^89SD_3GBI\.? ^N>$;./3[RUT/$$S
MLNI0[GN)$8Y*X*C;GIG<>.QZUZ752WU73[J_N;"WO;>6\M=OGP)("\6>1N'4
M9H \\_X5WK3)XZOGNK'^U_$&Z&UE#,5AM^@1CMR"5P#@'[HJ&_\ AOK<OA[P
M5I$,^G20:+<I/>1.S(DA4#&W"DMSO)SC.[MV]4JI8:KI^JK,VGWMO=""4PRF
M&0/L<=5..A]J +*!A&H=@S #+ 8R?7%<9K_@Z]U[XBZ!K5Q);-I&D1.Z6[,V
M]KANC8QC PASG.5Z5VM% 'CDWPFUZ;P)J^F-?:?_ &SK.JB\OI]S['B#;@@.
MW/#?-T[FM[5O ^O3^._#FN:?>V"0:;9/:R+(C?NR0P+1H..C8&3QM&<UZ+10
M!Y+X;T23P7X)U[0M>U333JVH0W5V(8IBTDVY2I;YL$] , >O)SQT7PN\-7^@
M>#=,CU@ 7\<!C6+_ )X1LY?;_O$D;O\ =4?PYK<UN'PS97MIK>N)IL-S"PAM
MKR[VJR$\A59N_4_G[UN4 (V[:=H!;' )P,UY"WPJUT_#?5]&%]8?VYK.H?:[
MZYW/L=-^[:&VY[9Z=2:]?HH \_U/P/J#^*_">MVS6MPFBP20/:NQB7E"%*<-
MP"1UYPHZFLG5_A?JL_@WQ!;VM];2^(=?N4FOKB0LD80/N\I, D*.G3G]!ZM1
M0!YMJ?@/79?%?A'5=/N]/CBT>V>WDCE5BL0*E08U_B(4@#)'*@GTK0^&?A#5
M?".G:E'JT]K-<7EZ]RSPLSERV.69@/3ICN>>>.YHH S?$.EMK?AO4]*2;R&O
M+62 2XSM+*1G]:Y[P%HWB?0M L=&U;^RX[>Q0Q++:.\CS#G&0R@+UZ\Y]J[.
MB@#S#X?> M=\(I)974&B2HMR\R:H-SW)5L9 4J,$XZ[N,]&K=\->$+S3?'/B
M;Q+J4MO++J;I':B)F)BA08 ;(')PO3/2NKO+VUT^U>ZO;F&VMXQEY9G"(OU)
MX%)8WUKJ5G%>6-Q'<6THS'+$VY6&<9!'6@#SVV\!:[_;/CJ]GN[-6UZ)X;6=
M68O&FQE0$8&W&5R03]VL6P^&/BN./P5#=7>E?9]"DD=XD+[58G<K@8^=L\G[
MHXQZD^R44 >=Z7X.\16'BSQCKINK SZJNVP?<Q90JD('^7Y0/DSC.=OYXLGP
MDU-/A]H'ANWN=/WV^HB]U-G+[;@Y/ (&3P0,''05Z]10 V)62)%=][A0&;&-
MQ]<=J=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5S?CSQ.W@[P?>:W'#%.\!0+%(Y4.68+C@'US^%=)7E?Q7:
M77/$?A'P?;*DKW=Z;VXB=]H,40)PQ . 1O['I0!?L/'VM1^-]'\/:YI-G:C4
M=-^V&2&=F,)"L6#Y& /D([]N>U13_%"YO?[/GT#38[JWOM2%E:I(Q$MU&N?-
MF4#[B*1C)S[@8YT9_ <^K:CKVL:K=1KJ>HV#Z=:"'+)90LI'!(!9B26)P.I
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MMF+I ,8,C,0,L1P!@ 8'4\T 4-3^);&P\2:AHUM#+8:!A);F<G;<S9YCCQT
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MG97-RN[ (VX"YP!SDX/.#TJQI'@W6;'Q]XF\1S7UH5U)%CM2JLSQJJX"MD8
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M9[FN(U+P5J][\0_#^O"\LC9:79M#L9&#+*VX,Z(!C&T@#)XP.N.>\H \SO\
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M.;JUB8"XU.5+*+)Q]XY;\-JL/QJ+P?XHFMO%9\$)ID=OIND:5')]I>3#@ (
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M];\*Z?J>IV'V"\N8]\EOD_)R<=>1D8.#TS6S38U9(D5W,C!0"Y !8^O'%.H
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MJ;2-4TG0]/A2XUG59"L*.3LBC7EY7QS@#/'&?6N>TWXBZC=:/XSU.:VLEM=
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M\[8SG"C';.#6);_$C4]7U#0?['TV%[;5;LJL$H8SK9J<-<L0<1C/0$'/KVH
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M#U[UKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQM:\.:GI:3>0]Y:RVXEQG874KG]:T:S]6UW2]"2W?5+Z&U6YF6"(R'&]ST%
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M,X>*V7E]I[$C//L?6K&J^,M.\-ZFGA?2DMK=-.LO/NII!F*TB  1 H(+R-D
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MC@<7>?"&1O __".V&HPVZ2ZP=2G1HV:((>/)49!V@!?KCMG@ N6'B.;1]/\
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M;V<\[.L:QQLY=AD* ,Y(]*Y+2O!E[8?$G6?%,NHQ217\<<:1"([T15 V[B<
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MAMC1"Q('.WGJ03D#%%OX\\22^(O"NEO9:>DFNH;N2':Y>TM@"P!.[YF*CK@
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MV.Q.X[B3@=>G',^E?#G5;/QMI7B"[UR&X^Q:<EF5%O@@CKL&<*"..YY;H3D
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M4&AR&(;=L5<_*G4 9/!/6K]AX&W:[I6IZI+"T6C6PM],L8,F.'Y0#(S'!9B
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MG@ [CPEJ&IZKX6T^_P!8MX8+Z>,O(D&=F,G:5R2<%<'\:VJ0      = *6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I&944LS!5 R23@ 4M9NOZ>FL:#?Z0;CR&O[:6W5P>1N4C('?&<T 9/\
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MLLDY5D M5;!8 L<N1D]>,=#D4 >I5A^)]7\/:39P'Q&T MY90D2S0&4-)V
M4_-UQ^-.\5^);/PCX:O-:O06CMU^6-3@R.3A5'U)_#K7FFIRZQXI^(?@G1-8
M-L#"G]M7=M!&0(",[$8DG." .W)/8@4 >HPZ_H[:_)X=AO(O[3@@$SVJ@@I'
MP >F.XX]Q6I7DFF^-;V;3_'7BQ[72!_9+O9V-VEH0UQL).';?N(),> "!SFK
M^G^._$-CH@\2^);2SA\/KI:S&2'(FENF90$52>%.2!US@'// !Z917FNF>.]
M;N]<MI;B*R318M/DO=6>-&86/REDC\W.&DQC<,#OQ6AI?B/Q3K^GZ1K6FZ9;
MC3[^\ ,$C /#9Y(,KL3RQP"%4<9'6@#NJ*\;T7QGJ?\ ;/BSQ?K>HP2:%HC/
MI\$,,!42MN'^K^?AB0@RV<Y'W16R/'NN6VK>#([VUM0/$9<O9HK;[:/"E#OS
MR<-\V0!P<8Q0!Z717EMGXT\9Z[K>OV6A6>F7,>G:DEJLCJR!8E;$A.6^9O3&
M!A6/7 -G1O'.K:WXPUC00UI97VGZ@J)93PG,UF& >17W#Y]I+#C&".#UH [2
M?Q+I%MXAMM!EO NJ7*EXK?RV)90"2<@8QA3SGM5C5]7L-!TJ?4]3N5MK.  R
M2L"0N2 .!DGD@<5XOJ7B2X'Q)\:^*+..&8^'M/%E;FX)\M&Y+$XY)+AE XSN
MZX!K;U_QEK<W@7P@DMEI<VI^)98X9;6YMC)$4?!WA2W;*$@Y^][4 >J6MU!>
MV<-W;2++;SQK)%(O1E89!'U!J:O-;[Q9XA_X3W5?#>A#28]/TG31<2230/\
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M:0E"@ 8*H(.U%RHS\O ]>E 'I! (((R#5*WT?3+2?S[;3K2&7G]Y% JMSUY
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M;\84*X('/'6N2@^*_B^X\(:)JB6.F&[U;51:1(8W 9<XPB[LG!'+$_Q  <'
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M<)*8]X)7(P1D9'S'\A6?I?P^O]/\;:IXDDU\S37UHL&3;@.K!0"<YP%W -M
M[ 9P.>\HH \NM_A)=1_#*3P<VO*HFN!+-.EMPRA]Y&-V=Q.WG/11QW/2>./
M\/B_P7_PCT%S]A6,QM ZIN5=G !&1D8X_*NMHH Y:3PQJ6K>%[[2-=U6&0W5
MJUM_H-MY,<8(^]M+,2V?<#L *C\(^&M=T#1+;2K[78+BWLXC#;?9[3RVQC"E
MR6.<=@ .G)-=;10!Y;;_  @D'PSNO"-SK09Y9_M"W$=O@!]V<L"Q+$C /(X
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MC ?=GM\O;JN<U@R_""2;P5JNAOKW^F:IJ7V^[O1:_P"LYSLV[NF>>O6O4:*
M/'VBGUKXWV5A97$$R>%]-+$SC*F:3@\+TP&7@=-F*VM5^%,.H^#=7TH:DW]J
MZM<K=W>H/%_K) VX#8#P@Y 7/'O72ZSJGAGPAY%]J$4%F]Q+Y,4L5H69Y#_#
ME%)R>?KS70T <!I/P\O[#QW'XFN=>^U.M@MHRFV"DD8)VX.%7C& ,X)&<DFJ
M!^$LI\ :MX=.N_Z9JM]]LNK[[-]\[@VW;NZ<>O6O3J* /)?%UO9>-- M_!6@
M:DEQJ>FZC%'<[HROV<1AMSD8'RCH,<9P,YK>\9:'K4FF:/IWAK5KRTOEOEFF
ME0$"9<YD>1AP!R6V]#T Z8[B."&)Y'CB1'D.795 +'U/K4E $5S"+FUF@+%1
M(A0LO49&,BO)K3X,W]OHVAZ<_B1)8M*U$WD:-9_(5SNQC=RQ/<DC' [Y]>HH
M X)_ >J6GQ"N_%.DZS;1M>VZ07$=Y:&8C:%&Y"'7!PH]N3UJQJ?@:[U#QSH?
MB'^V#LTRV>'RY80[LS9W.""%!(;^[@8''IU6J:I9Z-IL^HW\IAM(%WRR!&;:
MOKA032:7J=IK.EVVI6,C26ER@DB<H5W*>AP0#0!YEJ/P>OKRT\4VL7B3R[?6
M[X7@C-MG8V_<0QSENI ' [_3=N_AY=77B7PSJG]LJ(M%MWA$/V?[Q8$93G"\
M8 SG&T=37>44 <%IG@'5-+O_ !5?6^OJEUK5P98I1;\P<G;N^;YMH)  Q[]L
M:>D^#DL_&U[XKG>!;ZZM%M7CMD*HV""9&R3ECA1[ =^M=510!RWCCP>/&%CI
MT:W(@FL+Z.\CWIN1RN<JPR."#UK#U(:5X/U37O$>HZC%<^)[FP>2WAQM\N%<
M*D<:\]7V@D\L>PZ5Z+44EK;S31S2P1/+']QV0%D^A[4 <A\*O#<_A?P!8VEX
MA2^N"UU<JW4.YS@^X4*#[BG>+/!%SXB\4>']<M-6-A+I329'DB3<KXSMSP#P
M>2#U'ISV5% 'EUO\)KVV\(>)=$37QYFLW)G\[[.?E!=20V6);(7'48W-US6A
M>_#>ZN[GPBZZRJ1: I&S[-PYVJJE!NPNT*,9W8ZG/.?0:AN[J&QM)KJX8K#"
MA>1@I;"@9)P.: &WUFE]IUS92,RI/$T3,IY 8$$CWYKC_ O@O6/"&EPZ1+K5
MM/IMM(SQB"S\N:3+%L.Y8C&2> ,^^.*Z?0]=T[Q)I46J:5.9[*4L(Y3&R;MI
M*G 8 XR#6C0!\]>+_!,V@_9/"O\ ;AN8O$NOB=;<1A#&A(W,[9)8C*@=!P3C
M.,>GZ[X!DUCQOHFNQ:JUI;:9;- MM'$"W.02K9^7(.,XR,#'/(ZR?3+"ZF\Z
MXL;::4<;Y(E9OS(JU0!YII/PLNM*\(^)M%36U\W67D82I;;1&'P,$9R> 1U&
M,FB_^&LXT;PI VMQ1P^')!<2;[4E)-BK@A=W&-I/).2Q/M7I=% 'E5U:6_Q'
M\9^&-=\/ZF9=+TZWG%U=J"KY8!?+&0"'(W9Z;1SW7/J<<:0Q)%$BI&BA551@
M*!T %-A@BMXA%!$D4:]$10H'X"I* /)=0^#E]=V'B:RB\2>7;:S?B]6,VV=A
MW[CO.<MZ#H._7IU^J>![36K/0+/4I1/;:5.+AH_+"K,RJ0JX[*">G/  )/)K
MJZ* .3TSP)9V/C;6?$TD[S2ZA)$Z6_2.(H@7<1_$V=Q![9]>:Y34O@_?7EOX
MKMX?$?E6^NW@NQ$;?.QM^\ACG+#D@#@=#7J]% '$R> &N==\*W]UJ2RV_A^)
MPEM]GVB20C 8'=\H7"X&"?E')ZT_Q+X&N=<\;:'XCM=7:Q?3HY(G00ARRL"#
MM).%.&(R0>Q[5V=9'B'Q-I/A:Q2]UBY:WMW<1JPB=\L>@^4'DX- '*^%?A]J
MWA/1Y;2SU^(SRZC]L=S:G:Z]T8;LDD #.>/0GKM>%?!]OX:U'6]0C,:S:O<+
M/)#"NV.+ . H[DDL2>.O08K1'B72#XE_X1W[6/[5^S_:?LY1L^7G&<XQGVSF
MM:@#E/$7@]]7\6Z#XCMKJ..YTDR 0S(62177'8@@@\^]9EQ\-$?PGKVF0:HR
MZKKLGF7VI20[BYW9*A 1A<9 &>,GK7?44 4](TV'1]'LM,MQB&T@2%.,9"@#
M/Z5S/BSP1<^(O%'A_7+35C82Z4TF1Y(DW*^,[<G /!Y(/4>G/67=W!864]Y=
M2".WMXVEE<]%51DG\A5;1=:T_P 0Z1;ZKI=P)[*X!,<FTKG!(/! (Y!% '!:
M?\++VP\*^)=&3Q !)K<[R&?[,245R-P;+98E01U&-QZU8U7X>V]L/"]Z=7-I
MIWA:U<L@M]Q?"#=(#GY6^7/0\UZ)2$!@00"#P0: /+I-.M_B%\0M&\3:-?"3
M1+73WBN)T!!D+EAY(R 0<$[NX![$BO454(H50 H&  . *YNX\:>&='U0Z$]P
M\-[%&7%I#93,0@&=P"H1MZ\CBM;1];TSQ!IZW^DWL-Y:L2HDB.0".H/<'V-
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MUY9K/Q*OM0EUNU\+K&\UA(+2U41^;+>7)/S;5S\L:#.6/7CD=_4ZX/PG\/\
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M6]H^E&PA%I%!Q-<W;'&,?PJ>2.N%QWR*W?$_@>X\6>'(M(U'6I#NNH[BYD6
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M.[/ !VY'?/7UU(/$%U'XMLO >ERQ;M.LEEU/4!$%\J, !$C0Y 8Y7KD 'OV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYVYSC'-,/B'118S7W]KV'V2"0Q2S_:4\N-Q_"S9P#R.#ZUXMJ'B9H/B-X_\
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M\Z1HY VU"#A_=>#@]#@UX1-8ZCX3\$>%-+\1,]K8:UK9N]7W9"QQDH1$_H"
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M,IADF:Y0*L@ZH23][VZUY-K5Y%8>.?!_AN74+;3]"TW3%N;:6_4K!-.H*J[
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ME=SINL:;K&G#4-.O8+FS.[$\;@KP<'GVQ0!:$4:R-((U$C !F Y..F331;0
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M_:V-UJ5M%=W9 MX&D&^3)P,+U(]Z=IFN:5K1N!IFH6UY]FD\N;R) ^QO0XH
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O./C5>7'_  A46B60)O-:O(K*,#T+9)^G '_ J]'HH ^?SI-O
M:^/-:NHHC-8>#M#$1/E_\?,WEGAO;[RD=,*%Z509I-#^ NB6:M/;PZWJBC4K
MD(P_=N23CC)RJJ/?:PYKZ/I"H88(!'7F@#R#P?/;:W\;M8NUM6@ATC3XM/L8
M#&5*(1G<1CY>A&#S\X%4_AWIL&L/XJ\-SVBR6<'B26YE+I\L:HPVJO\ M,4
MX_AW=.,^I>(M-UF_BM/[#UA-+FCN5DG=K83":, @H02/;OVJUH^CVFB6;V]J
MF#+*\\\A W2RN<N[8[DG\. .!0!<GF6WMY)G#%8U+G:,G &>!7SI8P2:Y\.-
M5@M[=+GQ/XPU5I/)'+P1+*"6?^XJE6Y./O"OH^D"JK$A0">I ZT >&W-R]G\
M6$T74]:CTV#1M'CM]*FN8BX=V1%:2,9 ,G+ =>G0XKUCPEH6G^'/#=IIVF13
MI;J"^;@?O79CDL_N>N.,=,#&*VBBE@Q4%AT..12T >0_%)O-U(:[H&IBW\2>
M&74&U<_\?$<H4[57^+.[&._(]*H^(M5=/BCX=L=3GM]"TZUT[[;;)=1EX?M;
MYR<;E!923C)X(]Z]K**2"5!(.0<4%%8@LH)'()'2@#PKQ7I6F6">#_"MK]KD
MMM6U9]2OY[B,B6Z*XR2N!R^3A<=EXJQ>ZFVH_&'Q!;:OK"Z2UK:+::8LD)=]
MD@'F-",X\P]CAC@XP<5[:5!() R.A]*-BE@Q4;AP#CF@#Q6Y;2?"?Q)\):->
M[]/\-:?ISSV7VKA6NF+99STWC/X$\8S1\1+;1A)X8T#3[5K2PUW67U"]8HX,
MVW&[AN26W<#V&!TKVHJK8W*#@Y&1TH*@D$@$CH?2@#Q.^U1K_P",FN6VK:PN
MD?9+);;2UEA+OMD WM",@>8>0#AC@XP<5'?BP\._$/PEX=6TNTT32M.>_M;5
MHV9Y[H[\%L#[P/.3@*<]!7N!52P8J-PX!QR*,#(.!D=Z /,/@>WV[PWJFNS#
M-[J^HRW4[!2 ,D@*#WQAC_P(5+\:II9_"^G:#"Q3^V-1AMI93PL<>[))/0<A
M>OO7I0 4 *  .PH90RE6 (/4&@#RW0=*CUGXNC7-*@6+0-$TX:;;SH,)<2<Y
M"'^)5#$9Z9 K&^%^FP:QI^M:!/:+):V7B26Z=G3A A0HJGU++SC^$,#C<*]1
M\0:;K5^+#^Q-:32S!.'GW6PE$T>,;,$C'X5<T?1[/0[ 6EG'M4NTLCD#=)(Q
MRSMCN2?Z#B@"Q>W265C<7;AF2")I&"C)(49X_*OGW3-4>S^!.OZHA:75_$E^
MZ,44GYI6*E,^NU7..VX>M?1-(%"@!0 !T H \+C\.P:=\3O OAIXFE.CV(N[
MB9(\F64_*O/]U2H/H!GN3F/3+B/Q/XM\:VVO:NUE>W%S_9ZV:0EKEK12?W</
M. &XW$*?7C.:]YI-B[RVT;B,9QS0!7T^QMM,TVVL;.$0VUO$L448_A4# %>0
M:TB^&/VAH/$6N'R=(O+3RK>]D'[J*3RPNUFZ+T/7^]]:]HI&574JZAE/4$9%
M &!<^)8;S1M2N?#[#49+>TEECEM_GB:0*2J!APS$]AG'?&1GQ>STRZ\1?"[1
M_#NGNUWK/B&_:^U:YSN\A%<Y>0]C\J  ]2#BOH< *    .@%"JJYVJ!DY.!U
M- 'A>NS+>_$/Q3K\H,FG^%=*%I C#(FG8'"GU&\L#ZX /!Q7.VOAM;/2_AUH
M=W!+))J5T=4NL1$D(,%8Q[E3S[XSP!CZ7J.;S?)?R-GFX.S?G;GWQVH \<;6
M].N?C!XGU^^:*:+P]8I96<!PSRS,22$7J6W;UX_O"N:;2+OPIX=\#^&M=26&
MSU;5'OM2B1&?.TILA(4$G(QE?7Z5ZYX \&W/A"RU&.^NX+ZZO;U[Q[E(RC%G
M R""3Z>O<UUY )!(!QR/:@#PSP]XB6.^^)?C>6)H[V/-K;IMSY8C 1 3TRS>
M7Q_LFN>E\,QV'A7X?:!=P22SZQ>?;[MA$698AAO*7W(?GU(&> ,?2@4#. !D
MYXJ.XCDEMI4AE\F5D(27:&V,1P<'KCTH \K\9W!TWXY^$+Q+=IGEL;B$1H.9
M#M?:OL-S#D\#J:]%\/:+!X?T:*PMXXD 9Y9!$NU/,=BS;1V7).!V&!6=X>\,
MW=D]O?Z_J*:OK,$)@CN_($6R,G)  [GC)[X'3G/2T >4:O<)K'[0NDV4P8PZ
M)8-.B;<[I9.,_0 J<_[!KAKN0WOA;X@^.YXFE.I7?V"PC9,X3(0/^"-@>X]<
M8^C\#=NP,],TM '/^!M.BTCP/HUA$K*L-JJG<I4LW5FP>Q))_&N)\;W$>J?&
M?P=HL^1;6*-J+*%)\R3)" #N0R ^P)/:O5J3:-V[ SC&: /!+R8ZAJWQ'\;S
M1F6VL(CIEE&4W*SKA=WNH;:_U.>U5=5#Z%\)? VB[Y+32M2NU.JW3HP7:S!R
MK=#M.X^F1'QQ7T-2,JNNUE# ]B,T <CX/TC2_P"TM1\0VUX=1N[T)$;Q(O+@
M$:CY8X1S\@P.<G)[D@XH_&75FTOX9:DD6?/OBEE$HZL7/S#_ +Y#5WM<?>>#
MKW7-:M+G7]3BN[#3[][VSM8[?9S@"-7.>=GS?4GG XH X'XB6,6E>&OA_P""
M)5D%M-<Q"Z,4;.66)5#@!022Q<G [BI?#6L/>?%#QOXFO[=P^C636L%NJD^6
MB99@3TSE,<=2QQQ7M! )!(!(Z>U 4#. !GK[T ?.4=\VE_LZZC>(S2:AK]\?
MM$H4D!I'Y&>_R(?H7]:V].5+WXM^$]",,B:;X?TL2VT;1,&D<J%\Q@1\N?E;
MGH!S@G%>Y;%VA=HVCH,<"C W;L#/3- 'D/@[0;'QSXJ\:ZWK-G'=Z?-J M((
MY1\K^4NT-^"D8(_O&L+0I(/%6N^,+77M5:TOKN\^Q'3XH2UTUHA^6*+G"J>C
M84],DC.:]\I BABP4;CU..: .6T#Q3HTOB2]\%Z?:7-O-HUO&,/'B,Q@* %.
M<\97J.>V:=\1M6O-#^'FMZCI^[[5%;XC9>J;B%+#_=!)_"MFSTBVL]0N]0^:
M6]NMJR3R8W;%SM08  49/YY.35X@$$$9!Z@T ?/FCR6&H>)_AKH,$4GV&PL_
M[29VB8-<7#\E@",X$BYR>V3T -;=OQ\2K#6/#URFHZ+XK)74M/<[FA9%Y<CM
MCKGUR.XKVC:H.0!D#&<=J BJ<A0"1C(% 'B\6/\ A95AK/AZY74-&\5,8]3T
MYSN:%D7ER.P'7/U'\0IOAK5M,O/%GQ!\2:R9%MI+A-*W $>5#N6(DG^'.4/K
M\K'M7M010<A0#C&0* JC.%')ST[T >'^'KG4O!&B>,-/>9-3T_0;5I=)U!/F
MV&521'D?521VY[$5B7T,%M\'/!?AF*1E77-0C>[G"G!4D.W/<C>@X[H1U%?1
M010NT* I[8XI=J\<#CIQTH \?U>WC\2_&:V@>.1-)\,Z49IH@O5W7_5_]\E>
M/]DUSGA];+_A1GBW5[_[3:G6+EY9)+:#.S+A40#@%0<Y[8;'M7T)7/\ B+P[
M/K%_I5Y#=HHT^1W:TN(R\%QN7'SJ".5ZJ><'/% ' >#=)TWQ3KOA[5+;7-,N
M+3PW8+;PV5DS,S.5VM(X=5*@^F.W7K7JFJ7RZ9I%[J#J76U@>8J.I"J6Q^E<
MYH7@2STCQ?=^)4BM+:XGM1:BVLH?+B W;F8_WF) YP.!T/6NNH ^=+.\ELO@
M#>/;EIM7\3:@8W90>7E?!7/?Y$.?0O6Y:Z#;67Q@\*>'Q$TJ:%I@FDE6(YFF
M(" Y_NKA2,GC:1UZ^W!0H    Z 4M '@>@RP^+=:\7V^OZL]KJ%Y??9'T^.$
MM=-:H<K%$2?E0GAL*>F21G->[6=I!864%G:Q"*W@C6**->BJHP!^ %2A%#%@
MHW'J<<FEH \6NQ'X4_:(N-=U]A;Z7J-GY=G>R\1(^Q%VENBGY&'/]X>M>B:G
MXF6Y\-:Q>>'3]OEMK*62&: ;XFE"DJJD<.<]AGT/)%=(R*ZE74,IZ@C(H
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M&9H=-ECUJT*:G(8K/YN9F#;< =?O<<]ZO:CKVEZ5/'#?7L4,LBEU0Y)V#JY
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M3VEU*)QY0VA7:,@;2I&,;BO(STQ0![+:^(M$OM-FU*UU>QFL821+<QW"M&A
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MMCKQL '3%8W@Z*#Q=_PD%KXEO+I=3U#5,WNFPV[">2-,>7&7Z+$#G/3I]X4
M>]0S1W$$<T+K)%(H='4Y# C((KS?XF>(M;T_Q+X5T/P]J<EI=ZI<E)@L4<@$
M0*@MAU)!Y/\ WR:](1(K:!8T58X8U"J!P%4#]!BO&;=+/QM\?[V>[._3M+L?
M(M#O*B5^,["",X+R<@]A0!I:5XXU2U^(GBG0;S47U#1M*LFN3>M%&LENRJI*
MDJH4\EAR.J^QK6^''B&_?X<P^(?%NJAGO)GD22953:A;8B *!DDKD #)W5F?
M%6SL?"GPPO;#0M.AM&U2YCM7:"/&=QRS.1R<A2,GUK*U>=-.^(G@K1I+.\?1
M]+TPW%I L#$S3JK(I( X("JV6QMSSC)H ]0@\6:#<B_,6IP'^SU#7F<C[.#G
M[^1\IX/!Y&#FH(O'/AB9=.,>M6I_M*0QV8W$&9@VWY1Z;AC/3->+:7J=Q#\&
M/%FM);S-J_B*_=3LB;'[QBI4<<X7S#Q_>%:J>&4TOXA^ O#36TTL>DVGVVXF
M2(GS)CP.>@"LH/L,]SR >Z45SO@_QA:^,K"[N[2RO+5;:Y:V9;J/86*XY')]
M?P-=%0!%=2I#:32RRF*-(V9I!CY !DGGTKP2U\=>+O\ A5FI^,Y_$DL<B7XA
MT^WDMK?;,FY00V(P2<%N01]PUZ'\7]<_LGX=ZG!;L6OKV/[-%$G+D.<.<#G
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M@J%O,D!(0#W#)^ 8D\4 6O$OBJ^/Q!\*:9I^KBTL);9M1U,X3R_(4;E)9EW
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M75]"G[U8B5WC<.=O 4>@QZ4 >E1>*=#GU:'2XM2@>\GW^4BDD2%/OA6Z$KW
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!QWC+P;>^*]4T2<:G!;V>EW:W?V9[8R>>ZD8W'>,#&1T[FNQHH
MH **** "BBB@ HHHH HZQ;7]YI,\&EZ@-/O7 \JZ,(E\LY!/RG@Y&1^-9OAW
MPM#H=]JNIRS_ &K4]4F$MS<%-HP!A$49.%4>Y/\ 3H** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'8'ZFO8M,L(M*TJSTZ 8AM8$@3_=50!_*B'3=/AO)+V&RMDNI>7G2)0[].K
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MQ+*YA18VC+0Y^1BK$E2?3/I4/B'Q7-:>)]*\+Z3'%)JM^#-)),"4MK=<[G8
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M/6 A6;=DE^<DD8';&!QU)V](\ :E8?$%O%%YK:71:Q2U9?L^ULC!.WG"+D=
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M8XR3SCIC-=VH"J%'0#%>4ZG\)-3O!XOCM_$*10:_<)<",P$E2'W89LY*@%@
M/8]L4 1ZG\3/$.G_  MT7Q&]MIJ:MJMR(HK8Q.4V,6VG[^>B@_\  A6SHOCC
M6+WXD:GH-];64&FZ?IZW,TH+>9&QVD;R3@$J22HSCU.*GF^'DMWJ7A"6ZU*.
M2S\/*2+=;?:)9, *1S\H7:N <GCKSFH[/X<3PW7C.>?62Y\1B1!M@P85965<
MG/S;0V !C^6 #CO&OC75?%/P^EDT](+>QUS45TO3HF1C/.F[#2$YP 2NW&.
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M-NOE._F.2 %&T'GD5R'P<T:[M/ D%YJ<D5Q-J<IU'+1'S-S_ ,3,2=Q(VD$
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M'&@PJ(H 4>@ KS"Q^(6O>)+S1)-"M;?R;Z])DM60N\-DI(:65P<(S8^5<?\
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MUA\L$DDDGDDGH,YZ <=2=K0/$&F^)]*34])G:>S=F5)3&R;BIP<!@#C.:TZ
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M*+6/Q(\=OK=Z+P1&V!$;;]YW'=ENI ' [X)Z>KU%=7,5G:RW,Y*Q1(7<A2Q
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M!QR0,GUK6H \R7X33-\-K7P=)KH6!+E99Y([7 D0,SE<;LY)(^;)^Z.*W9/
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MQS@KMV[ PVJ.HY)SC)/.0#A]5\=W\?PRU+Q7I6MPRVS00BT::V4S1SEBLD;
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M//!))/\ $N.AKTO4+%[S1;K3XKEX7FMVA6<C>R$J1NZ\D=:Q='\%66D_#_\
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M>0;EMK=>-VWNS$8'8=3GI6GX8T)?#F@6FG&8W$T42)+.PP9&50H..P 4 #T
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MC%7:BM;:.SM(;6$$10QK&@)S@ 8'\JEH **** "BBB@ HHHH **** "BBB@
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MVLDAE_W=JG-=%7BHN+[Q#^T!J6H:?8K?Q^';3[-$C3"-1*P(.20>[2#IV]J
M/4]!\3Z-XFCN&TJ\$YMI/*N(V1HY(FYX9& (Z'J.Q]*UE4*H50 HX  Z5XQ:
M6.J?#-+R^N)+6]\7>+M16*""/=Y$+%B2QZ$A=_/3L/4UO:-XJUB7QKXHL;C4
MTGT7P_9#S;DP(':<KN).,#Y<2# ]!G/4@'H\D,4P DC1P.FY0<55U#4++1-*
MNKZZ816EI$TTNU<[5 ))P/H:\N\-^*/'.K>$[3Q-=WUA!I44%U/>R- -[;5;
M9L7H5!"]\D[@>@KG[37_ !3HOPNC\12:F+G7/$^H(D$4]NK<'<@'IM*J"!C
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M5F41P6R\;F;!Y"@CO\QS@UG7OB?QQ8^$_%6MV\+W%M!+&-+:XM@DIA!Q+*4
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M,4YA6/#Q3N01\W<%=W'; ]<G-^)GBW4?"$.C7<*2)I4MWY>HW4,8>2%.,8#
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MD$C1H77HQ49'XUYQ\*YUN-)@T[2M1*:?HL:VEU!Y*YEN<;I&!(R$W,1ZD@]
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MO-=EJGPXM;[Q;INN6FHSZ>ME8_8/LUNBA6B^;"@G[H^8C@9QT(ZUVA95*@D
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M-ZP\4Z9J7B74] MWE-_IJHUP&C(7##(P>_45M4 5;"TDL[;9-=S7<S'<\TN
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M7D\FC6QMU#1*-ZX*@*?X %..,GOG/->C44 <./AM;_9?%J-J=P;CQ(Q,TX0
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M89&2=K#&0?F%>@^&_%.F>*K:[GTMY6CM;E[63S(RGSKC.,]N16U@>E '(R^
MX+B#Q!-/?2/JVMV[6TU\$ \F,KM"1KGY5 [9R3R3Z9-U\*(;CPMH&CQZW=0S
M:-<I<0W2Q*>5[!#P.<'OSG.<UZ&K*Z!T8,K#((.01064,%+ %N@)ZT <+IGP
MU72[[Q+=PZY=F36T*DLB[HB59=Q;JY&XGL,]B0,13?"FQ?PSX=T*+4[F&#1;
MH70=8U)F?);+ Y&<D^O7H:Z/P_XLTSQ-=:G;Z=]H+:;-]GN&EB* 2<@J,\DC
M'/U%;M #8T$<:1@L0H !9B2<>I/)IU%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7*_$75=:T3P/J&HZ!#YE]
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MB*%51@ = *R]2TBYO-2AO(-0\E8X)(&MY(1)%*'*DEAD$D;1CGUZYH XF_\
MB&=(\*6^JV>H+J\FN7:Q:.MPJQ^6"JAO-V@?<??G\!GO534/$WB72='\7:U>
MW<KZ+;62PZ?)<6ZPO+<L I=% #>7N;C=G(Q@GK6M=?";3#H?A^PT[4+JQGT*
M=KBTNE578NS!F+*1@Y8 ^V,=*T/$O@(>*?#/]D:AK=Z[M/'/+<%4^?;G"[
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MU! !Z>G.WWB?QOHVC>#[/4;O9KVK7[":$11;F@!!V'Y=H?!49 &,\]*ZZ;P
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M34VF@M[HW=S-.!L0J"T:E1@#)+\9R=PYY%>GKX*M7DUN\N;J675-7MVMI;P
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M+4X&XDYQU-9G@SQ]/<Z#>ZOK>J7:7.APS#6-.FB16:7/[MDPH('#+MSUQ]2
M>MT5Y9H>N^,O%-YX=O[5Y;:UN)3=WZ" "VAM3]R(.R[I)&')*GC/05S%S\0?
M%#:)XXUNVUAET^RO!::=*]O&>=^,)A0&)#*23G '0DY ![RS*BEF8*JC)).
M!6!J7C#3M,\2:5H,L=S)>ZGDV_E(&3:.2Q.>  ,UYSXUEU_5H/ GA.?5KB*]
MUF-?[52%$7<BJID)X_WN/NG!R*NZ-;S^)/C-K=VMVY3P_IR:;!<E%R)V!W/M
MQMSGS 1C% 'K-%>2>#/$OBGQ3X3T*X&KHNI)K317@^SI_I%NAW.#@84!2!D
M<[1U-=OX[\6P^"O"=UK,D7G2)B."'./,D;A1].I/L#0!TE%>7KXB\2Z=X\\'
M:+=7OVFYU.TEGU6V\I0D/&5V8&5"D,.2<XYYJGX7U?QIXQO-4N-,UR./3;76
M_+5YX$)>V1N43:N,D$DD\_=Y&30!ZVS!$+'. ,G S6-X6\3V'B_15U735N%M
MVD>/$\>QLJ<'CTK.^).OS>&? .J:K:W)M[J)%6!U56/F,P4<,"#UYXZ9KC/$
M?B+Q3I6G> ]'M]2G.NZLZF^"0Q$LN%+CE?EP6(!&!@'- 'KU%><^ M?U_6_'
M/BV&^U".YTO3I4MH5CA"*DO.\*>I ((Y)SP>*C^,NHZE!HFE:5I&H3VM]J]\
MEDJPX!=&X.3C( XZ$=: .I\1^,M,\,PZ?+=K<3KJ$ZV]M]E0/O=N@ZCK70UX
MMKEO(_Q.\(^%K68W,7AVQ:[>6= %1L81G"@#"!4/&,YQG)S4WASXE:KIWPNU
M3Q9KLYU%I-0>'3$,2Q&4<!1\HX&0Q[G"GK0!['2,RHI9F"JHR23@ 5P/AJX\
M7W_BR":ZNI3H\5C_ *89+=8HY;ICG; "H?8HP-Q)SCJ:K?'#4+JP^'<L=G>3
M03WEPEHJ1!<S!\Y0Y!(!4'I@^^,@@'2Z5XUTS6KZUM[&&]E@N_.^SW@A_<2>
M5@,0V<XR< D '!QFNCKR34I-9\)7G@+P1H^LS"2=B+MO)B_X]TP6_@XXWX/7
M@Y)/-3Z7XYU'69_'FL)J1B\/Z3&8K$QQ(3YBH2S@E3DY48!R/G'% 'J0D1G9
M ZEUQN4'D9Z9IU> 6^I^)?#/PCM=;BUJZ?Q%XFU"-HA)'&_S/D#[RDD%%7V'
M&,<Y[G3O$VJZC\6D\-V>H^;IND:<&U)O*4F>XZ8W8R/O X&.010!Z-17D/A;
M6_&/BQ]0U"SU^*'2;36B&DN($R]HAY12JXR5R23ZK@CFFIXQ\5^.-/>Z\+-/
M:&>_$-D%MP8XX$/SS3NRD9/("*0?8]: /5UOH&U)]/WXN4A6;:>Z$D9'K@KS
MZ9'K5FO.M2U*1_CUH6GV[9\K2)VNMO97/ /_  )%/XBM_P"(.H:AI/@35M2T
MN[^RWEK 98Y/+5QQU!# B@#IJQ_$_B6Q\):%+J^HK.UM$RJP@CWMEC@<<>M>
M?:+\2-0U#7O!NGSLL-KJ&DO<75W( !+,L1+$>BJ5;/3G/8<U9->\81S>!-!E
MUESJFJ7$LMZXMXU+VJON4E2ORL4STQC!SS0!Z\EQ$\<+[PHF \L/\I;C.,'O
M@$X]C6+H_B[3]<U_5=&M(KH7&EE5N7DC 0,V< '/)X)Z5P&E7=YJ_P 6_$NL
MW6M7)T;PPK)'&538"RDR+C;VVL,_>X'-<3I>M^)=/\%1ZUI-RMGJOBG7SM+0
MAWFW$C W<!%(ZX));' '(!]*5B6OBG3[OQ??>&8TN!?V<"W$K-%B,JV,8;N?
MF'Z^AK:SA<L1P.37C6E^.-;?X=>,_%MSJTK0QW+P:.S0Q HJMA#@)ALEU!R/
MX3TH ]FHKP_3O%_C9O$?@O2I=0$DUY8M>WT4D"#*,&*M(0/E P>%Q@ =2<58
MTCQYKY^$OBGQ5?ZH6=;N2/2YA!&I RJIA2""-QZ')X//>@#VBL"'Q=I\_C.;
MPK'%='4(8/M$C;!Y:IQ@[L]]P[5Y_::WXQTWQAX$TV]UIKU]4M'FU"U-M&H0
M;=V<@9R,D=0/DZ<XK.\/^*K?2;7QU\3+N,SBZOA9V"9P9%3Y4 /8'*Y_W#0!
M[A17FFE:IXLGUF#4;^\FAT6UTV2?5':V6.(S%2P2 ,NXA./F)(.#SVK@HO'_
M (ZF\'Z)>+JC_;M9U@Q6P^RQEY(1A2% 4#:&QSC)+=0!R ?1%%>6Z!XTU8^+
M_&]WJ]\CZ#H<*CRHH@!'*!EE4]6(VLO)Y..!T$6C>(?&7BV;0+_3VEM8+FZ^
MTW<8@'V>"S!P(R[+F25QS\IXR.%H ]7I"0H))  Y)->&7?C_ ,3-;^/M5M=7
M*:9I<WV6QE>WC8*^[;A< ;B25Y.<*>1DBK?C*[\0ZIX=\">&YM6N(=2U\(FH
MB%54M'M4R%L#(P&Z# .#D&@#TS4O%FFZ7KFC:3,)WGU<L+9XH]R?* <ENPY[
M9_*MVO--$UK5;CXJ:KI']L22:%H6GQB??%$N9V4<DJ@QQN..@(/:N%/Q \:S
M_#R[UR'5G66]U86FFE[:/>ZYX50% [-EL')  QS0!]"T5YUXD\0ZS8>-M!T:
MYOTTW1WLGNK[4 JCSG0'=&K,"%Z*3CG#<5:^%NJ^(M>T&XU77IIO*EN&2RCE
M@6-FA&-KG &2<D?\!SWH [NBHYYH[:"2>9PD4:EW8]%4#)->*:M\0?$M_P"$
MXM?TN^^Q3ZSJ@L-&LA$C_N@2ID;<I)8L/H.,=: /;ZP=#\6Z?X@UC5M,LXKD
M3:5((KEY(PJ;R3P#GD_*:Y;5/&%TWBR]T6'4&MM.\/Z?]KU>^54\R5]N5C7(
M(7/WC@<]!COP5EJVL^%/@S%KEG=R1>(O$NK&976)'9RY(^ZRG@A21CNPH ^A
M*IZMJ4&C:1>:G="0P6L+32"-=S;5&3@=S7C\GC;Q7:>+_$=H^I(UEHVC>9-N
M@4K#-M5@21]YSR,9P6)XP*??^+_%EI\'/#EY_:;#Q+K-VD,$@AC)=9&8KE2N
M/N[>0!U% 'K6B:O;:_HMGJUF)5M[N(2QB5-K 'U%7^E>8:_XAU^'XI:#X7TC
M47:)+(W%^'B0J< @,QVY49 ) (SD <FL?1O'6OGX4^*_%%_JQD,5U)'I<X@C
M4XRJI\N"""S#@Y/!Y[T >F>%O%.G^+])?4M-6X6!9G@(N(MC;EZ\>G/^36TS
M*BEF8*JC)). !7D>O>*/%'A;P=X.U349;B:TF(?7+B"-!*N\ H -N% +$< 9
MV@9&:J^-IM4UA_"/A>U\2W%U'KT\LL\L*1KYMGNWJ3A1_P LSC' .TY!H ]F
M5@RAE(((R".]+7D]]XVUK5[S7M)\.M=2-I,?V*&6"!6EN[P@KN8[=D<:$$G@
M9[''%+>ZWXPC\;>'O"T&KQMJ)T@SZ@?)0Q&8@J'/RYP#EL @' '&: .\\1^*
M=/\ "ZZ>VH+<,+ZZ2TB\B+?AVZ9]!^OM6W7E5CJGBQ/B1X=\*7>N?:7MM/:\
MUEHH8]DC98* =@8<E >F<U@7?C_Q,UKX^U6UU<IIFES?9;&5[>-@K[]N%P!N
M))7DYPO49(H ]THKR[5O$/BNQT/P+:2W0M9=6,:ZIJ;1K^Y^56*\C:K,"PR1
MU7BK_P /=;UWQ!K>OW$]Y-+X?MKDPZ:\D*C[0,G+!P 6 P,'ON]J /0J*XOQ
M=XFO8/$NB>$]'D$6HZHS237)4,;:W3)9@#QN."!D$<=*Y71_&NL3>'?'OB"?
M5WDTO39)+;27$4>=R X;.WYMQ:/KD<F@#UZ@G )ZUX?8>+/&\K?#ZTEU7_2]
M9G:>ZC:V3?);A@Q9N,*NPD *!]TG/.!N:[X]O)[WQ9-97QL=)\-6YC,B*I:Y
MO6R%7+ X56&,#J>^.* .V\,^+=/\6)?OIT=RL=E<&VD>9 H,@'(7DYQD?G6]
M7%?";16T3X;:3'*#]HND-Y,3U+2'<,^^TJ/PKDM>\;Z_%X^\4P:?J132-$TP
MRR;X49$G*@CG )/) 4G[WJ 10![%17AFD>,_&UX/A[9RZB!=:M.\UT#;IOFM
MU?=N;C@%,@8 )VDYZ5OZ[X^OI;KQ;=6-Z++2O#4!B#A%8W=Z<A4.X'Y PVD#
M!)/6@#U2BO&=>\5>+-/\ >"XTU6;_A)-<N$\QH[>(LT;\X"[< J'C'&.^:U=
M!\7:R?'WB\ZKJ,<F@Z'9JTL<<0"Q2X#$!OO,0%D!)ZD=!P* /4:*\3O?&OBN
M_P!(\.W=GJ?V'4/$VI>7:V:0QNMM9@XW?,I);H2QXPW &*UO$GC#6++Q;XDM
MKJ^;2]-TK3!-8QQHGF7TSK\I!8'< V5P.,XSWH ]$U_6[3PWH5WK%\LK6UJF
M^00IN8C(' _&K.G7T.IZ9:W]N'$-S"DT8==K;6 (R.QP:\AU/Q+XUB\(^$+>
M;4Y;7Q'K]\(V3[+$/+@/!RI4X(RC=B-Q':M76/%6N'XNR:)IFHF/2]/TTW5\
MLD2-'&^T_,Q #8"LK;=W)XX'( /4J*\8TSQMXRB^!]YXH=OMVI2W3_9Y6@4>
M5!N"ERJ@ X(;],\"MC1-:\07WQ(BT6QUJ74-'L[&.34;SR8V1[CJ55PH W C
M@=,'T- 'I]8/BCQ=IGA+1#JVH&62U$OE$VZASOR1CJ.X(K!^+^N7N@^ +BXT
MV]FM+^::.W@:$#<[,>5!(./EW'(YXZUQ/B;2[BSN/A_\/Q+)J$JS_;[E7 &X
M)D@$J/ND^9DG)[\F@#V^*3S84DV,F]0VU^JY['WI]>2>&?'^IVVF^./$.O7X
MOM)TN[^SV?EPK$&92057'."6C R3U^M7O#^J^,O$&M>'[P3216#Q/<ZHIMPE
MNJN!Y4,99=SL.K,"1GOVH ],<E49@I8@9"C&3[<UPL?Q:\.O97U\8=26RL)A
M!=W'V7<D+DXP<$GKW /;UKH?%^M#PYX0U;5R0&M;9WCSW?&$'XL0*\A\(^ _
M$.M?!^VT6%["QL]8F%[=WDDKR3NA(*@1[ !D(ASO_G0!ZGJ/CK1].N]"M_W]
MR=<8"Q>W0,K@[?F))&  P)]JZ6O&K"UL+?XKI '8:-X&T0*9'.<2,F2Q]]A/
MXK5;4?'7BJ_\.Z/J>GZC]@O_ !'J@MM.LQ#&XAM0Q4N=RDEL[<D\8;@"@#VZ
MBO+M9\4:X?B\N@Z9J133K'33=7PDB1HT;!^9B &P 4; (R>. <C5^$6M:YXA
M\%MJNN71N7N+N4VSF)4/D@A0,* /O!J .ZDD2*-I)'5$499F. ![FG5Y3X^.
MHZ_\3_#GA.SU>YMK1HC?WD<2H54(248Y4[LLN,-E>G%5K[X@:GJWASQ?XBL+
MUK#2=(S:Z>Z(A:YG! WN6!XRRX48X;F@#U^BLGPO?7FJ>%-)O]0C$=Y<VD4L
MR@8 9E!/';KTK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *H:UHUCXAT>YTK4H!-:7*;9$)Q[@@]B" 0?45?HH
M Y+1?!5QH]C#I?\ PDNJ7.DP#9':R"('8.B&0*'*_0CCCIQ4E[X'M+CQ/-K]
MI>W%C>7%B;"8PA>8\@@KD?*PP #R..E=310!Q^H?#70;WP]I6@QB:UTS3KE+
ME8(6'[YES_K"02<Y.>_-22_#_39M6\1ZG)=WC7.NVOV29MRCR8]NW$?R\< =
M<]*ZRB@#Q#Q1X?L[+4?!?P_T^ZN&L8;S[5=W$V'"%1\BL<!1GYOEXZCN<GTR
M/P9I[3ZO=WLDMW?:M ;:XN'P"D)&/+C X1>_<D\DFK%SXHM+;QA9^&GMKQKN
M[MVN$F6+,*JN<AFSP>/3N/45MT ><6?P<TNTCT%1K&J.='E>2%C(N2&.=HX^
M4 YZ<\GGIC=C\!:<FJ^(M2-U>-<Z[;BVF<LO[F,+MQ'QQQCKGH*ZJB@#S"?3
MK'0?#MY\,]*MM6N;JZTR4074T.Z',FY<,ZC"@$DG@#ZL>>R\(^&H?"?ANTTJ
M.5IWBC42SMUD8 #/L   !V %;M% '+^+=".I7_A[5(T+R:5J*S,H[QL-C'\,
MJWT4UQ6A1S>+/C%XFU>&^DM$LK5+"RD\H$NASO>/<,'# D'D?,.N:]=HH XV
M^^&FA7GA2T\-J;F#3X+I;J3RW!>X<9)\QF!W9)R?H.F*T/&?@ZQ\;:$NEWLT
M\ CF6>*: @-&Z@@'D8Z$C\:Z*B@#G6\+W$VEFVN?$&I379>)_MA\M77RW#@*
MH4( 2HSP21P2>,4[KX>:5J$?B WSR27&NQI'=31@)M" !-@YP00#SG)]N*ZZ
MB@#F= \(RZ)I45A)KVHWB6\'V>U,FQ! NW:,!5&X@="V[';%9#_"?1'\$V/A
M5;N^2SM;O[9YJLGF2OEC\V5P1\V.G85WM% '*7/@2RN?&.G^)/MUZD]E:?9$
MB5P59<DY+$%LG<<D')_/.1:6.E?#35W;&MZA)K]]++F*#SEA<X)W;!GG@ G/
M0XQ\Q/H5% '%?#?P2?!^BR?:G,E]=2O-(,Y6$,<[%_(9/<CT K7\7>%+'QCH
M?]F7SRQJLJS1R18W(Z]#R"#U(P?6MZB@#!L_"EI;:M?ZS)-+-J][$(6O&P#%
M&!PD8Z*N>>Y)ZDT[PEX6L?!OAZ'1M/>62&)G<R3$%W9F)))  ]NG0"MRB@#G
M/&G@^U\;:/#IMY=7%M%%<I<;H-N6*@C!# @CGTZ@4@\%V!\867B62YNY;NRM
M#:PQR."@!)W/TSN.X\Y[UTE,BECGB66&1)(VY5T8$'Z$4 <[X2\%6'@]+X6=
MS=W!O+A[AVN'!PS8SC 'H.3SQ2>(_!5KXDU[1=6GO;N"72FD:)(2N&W@9SD'
M!XZCGTP<&MS4[^/2M*N]0F262*UA>9TB7<[!020H[GBH-!UF#Q#H5GJUM%/%
M#=1^8B3IM<#W% &,G@/3DU3Q'J+75X]SKL MYG+KF&,(4Q'QQQCKG[HK-N/A
M1HMQX$M_"AO+X06THGAN=Z^8CC/(XQCYFXQWSUYKO** ,S2-*FTZ,M=ZI=ZE
M<E0IFN-JX [!4 4?7&3W)XK@=6!^)'B_PL;&WN5T73)7O[Q[B%H_WBMMCC(8
M?>RI./[K9[C/J-% '*:MX"T[6?&MIXFNKJ[\ZVMOLWV9' C=<L?FXS@[B",X
M/0\9!R[/X4:99^#-6\-)J>H-#J4ADDF9EWJ=RG@ 8YV@$GD_ECOF)520I8@9
MP.IK!\)>+K'QEIUQ?Z=!=16\-PUONN%5=[* 25P3QSC/UH R-2^&FGZI9^';
M:74]10:'('A>.159\!0,X&%QL7&T#'/<YJ?1OAYI^AZWK6J6=[>+)JBA3'N7
M;#A2HV\9.,G&<_UKK&EC21(WD17DR$4L 6P,G [\4^@# \.>$--\,^$T\.6O
MFRV8617:8C?)O)+9( ]<?0"L?P_X*3P1I9@M]6UB_P!.MG,MOIP5/O%L@950
MS<GNP7N?6NWHH X_PAX5N;#5M4\3:T4;7-58;T0[EM81]R)3WP ,GN1[9/0:
M[H]OX@T2ZTF[9Q;W2;)=AP2N1D ^_2M"D=UC1G=@JJ,EB< "@#G+WP-H>H:U
MH^I3VW_((A:&UMUXB4' &1WP!@#IS3+[P39W_CJU\527EVMQ;VWV98%*B-ER
M3SQD=3G!&?ID%VD^-K#6[VTBL+/4);2[,P@OQ#^X?RL;CG.0"3@$@9(.*Z6@
M#AK/X8V%GI'B#34U743%K<LDDS;D#)YA&X#Y><@8RV< G&,G,]W\-M(NU\,H
M;F]BB\/ILMDB=1YG"C+G&<_*.1@\FNRIDDL<(4RR(@9@BEF RQX 'N: ([RU
M6]L+BT9WC2:)HBT9PR@C&1[\UPZ?"72?^$)M?"TNHZ@]E!<"=F#(#)AF;81M
MQMRY/KTYX%;UIXPLKWQK>^%HK:[%[9P">:5E7R@IV[>0V<G<#C'K70T <L_@
M33I?$FKZX]S=FZU.Q^P$!E"P1;0#Y?&0>,\YYKS;QAX:L=(LO"GP\TZZN7LY
M=06>]N)B&\J,$D!L#:N2[$#'49/6O<JYKQCXWTWP/8P7NJV]V]O-*(5>W56^
M<@D @L#T![4 20^$;0:E?ZK=7$UQJ=Y;_93<G"F"+'W(A_",G/<D]37/CX1Z
M,W@ >$I;Z^DMUD$L=P64.C!F88 &,?,W4$G/7@8WK'QKI=UKZZ#<I=:=JSQ^
M;%:WL81I4YY1@2K=#P#G@^AKHZ .8G\'O?>'+W2=2U[4KQ[N#[.]TQC1EC.,
MA550O/<D$GUJ"#X=Z3;ZGX<O5FNB/#]L;>T@)78<K@NW&2QX/!'('%=7++'!
M$TLTB1QKU=V  _$T^@#B['X8Z+9:5KVGFXOIXM:DDDN#+*,H7Y.W '.0#DYZ
M?6KOAKPA)X>TZ"R;7=1O8;6,Q6J2[%6%<8'"J-Q Z;B<=@*Z>H+VZ2QL;B[D
M61T@B:5EC7<Q"C) '<\=* .(;X2Z(W@9/"@O+\6@N_M;S!T\V1\_Q';@CH.G
M85I7O@*RO?%6DZ^;^]CFTVW:W2-7!#ALY)8C()W')!!^E:_AS7K?Q-H%IK%I
M#<0P7*EECN$V.,$CD9/IZ]*U: .+M/AO8VDGB9TU/4-VOM(TQW*/*W@@[?EZ
M@,0,YP.G?+9_AAH\^D^&]-6ZOHH-!E$UOY;J#(V<Y?Y>N><C'4UVU4]6U*'1
MM(O-3N$=H+2%II!'C=M49.,D#H#WH \EUJRU75==U/6[+Q%<>&-4L=UE;Z?.
MAD%S%&<JP!^\'ZX4-T[FMB_\/>(/'/A'PH-7^TZ?K,-PEW=21$1K& 3G<N<[
MRN, ="3G KN?#>O6_B?P_::S:03PV]T"T:7"@/M#$ D D<XR.>AK5H KW]G%
MJ.GW-C/GR;F)H9-IP=K @X_ UY_:?!O2[2'0HQK&JL='F>6%C(O.X@[1\OR@
M')R.>3STQZ13(I8YTWQ2)(F2-R,",@X(_ @B@#@]2^$VDZEJ6OWAU'481K,2
MI-#'(/+5E& V,?-[ Y R?;%U?AQIF?#/FWM]*GA\[K9'9=LC * 6&WMM7&,=
M/<UV5% '#R_"_29M)\26+WM^6\07(N+N?>N]2&W!5^7&T'/!!X)J74/AOIM\
M/#:B_OXET%BT&UU)DX7[Q(X(VC&,8[8XQV=8DOBBTB\90>&#;7ANYK4W2S"+
M]R%!(P6SUX],=.>: *47@73HM>US6/M-VUUJ]J+1R67$$87;B/C(Z \YY%9$
MWPFTB3P%#X274-06TBG6;SMREV(8G:1MVXRQ.,=>>:[^B@#F+_P:M_#?V[ZI
M=_9;^T6TN(75'&T;OF7(^5R7;GITXX%5A\.M,C\3:3K-O=7<']EV*V$%M&PV
M>6N<<D;@<$@D$$_GGL** .+TKX=P:+K.IW=AK>I066I3FXN;%"@5G)).'V[U
M')^Z0?>M6R\(V-CXRU#Q.LT\E[>P);E'(V11KCA !D9V@G)-;]% '+0>![2W
M\;:GXH2_O/M5_$D;1978FU0H(XSV!P3C/.#QC*;X2Z(W@:/PH+R_%H+O[6\P
M=/-D?)^\=N".W3L*['4-4MM-L;VZD;S!9PF>:.,J75 "<X)'8'KZ55\,>(;;
MQ5X?MM:LX+B&VN=QC6X4*Y 8KG )X...: ///$VEW>L>*&ACUZZ\+RZ)&$L;
MF8ETO1(H+/R0IY^4@$GU Z5U_P .[OQ%>^%$D\3*#>K-(D<OE>69H@<*Y7 Q
MGGL.,''-=710!R>M^ ;#7/%]EXCEO+V"YMK9K5HX'"K+&2QPW&<?,V<=:R8/
MA'I4/@:7PHVJZDUG-,)9'#H&.&W;<;<8SR3C)P.<  >A5S.J>.-.TZ_O;*&U
MOM1N+!$DO$L8?,, =@%!Y&6.<X&3@$G% #;KP+IMUXQT_P 2-/=)/86HM8;>
M-P(MH)(SQGOC@\C@\9SS]]\&]'OHM>B.J:E'%K%T+IXUD79$^[<2HQR3R,GH
M#7I%% %>PLTT^PAM$DDD6)=H>0Y9O<XX_   =@!7&S_"W2I]'\0:>^H:@/[=
MNQ=7DX9/,)#;@@^7 7/;'>NZHH Y1_ &E-XJTS7Q-=I+IMFMG!;HX$6Q<XSQ
MGOV.#WXSG"OO@UH]]!KD!U34HX=6NQ=O&KKLB?=N)48Y)Y&3G _'/I%9^MZW
MI_A[29]4U.X$%K",LQ&22>  !R23P!0!CGP+I[^(M%UJ6[O)9M'A>*WCD=2A
M+ AG88^]SVP!@8 Q5.U^&FD6MKXD@^U7THUYI6N#)(/W9DZ[< =.V<]/<YW=
M&UX:Q/=P'3=0LI+7R]PNX@H;>NX;2"0<#@\\'BM>@#SJU^$^G:;<:)?)J>JW
M$^BPO'$K2+F4$$;,X^48) QCKG.>:XZZA\3"*]\6Z%XBN++6[R42S>&YH#*^
MX':(P&&>!WV@8[@#->[4QY8XWC1Y$5Y"5168 L<$X'KP"?PH Y2_\%IXAUK0
M/$.IW-Q;7^G0%7M[=AY99UPXR02.I&0<],$$9H7X>Z:'\4R&[O6F\1J4N9"R
M[HEPRA8_EX #8YST%7="\867B#7=8TFUMKM)M)=8[F255";R3@*0QS]TUT-
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M[*%"EQM[!1@+COZU8M? FD6WB75]=+74USJJA)XY)<Q@!=GR@ 'H2.2>O&*
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M D-LL$6415VJ<Y(_$]3]:YVR\#V-M=:+<7%W=WSZ+&T=B;DH2@90I)*J"Q
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M;]LM[>5!',1]5++WY!!Y."* -3P?;:W9^%-/@\170NM66,FXD&.I)(''!(!
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MP[&K4C^7$[E6;:"<*,D_05Y9K>NZQ+\8H=%TS5)X=-TW33<W^X@QHV#AG[G
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MD>:_0GV !/UQZUS>A:AJLGQ9DT1==N;K3=&TX2:@TC K+=,,'/H,'(4< J:
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M%I'VB]21UPV 0BM@#H&0X]!0!ZO17AVI^.]:U/X;ZUXS2\GL/,O4M=#MH3C
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MQ$\-^%--UJ=9DTMIKR0@,K-@H)'&.2""V,X)P.,T >HSSPVT+2SRI%&N,N[
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M$4*,DDX'J3R?K3ZY_P &>*H?&?AY-:MK.>UMI9'2)9R-SA3C=QP.01^%=!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Q'Q:UZ?P]\/+Z[L[B6"^D>.&V>)L-O9AT_X"&/X5V]87BKPCI?C&PM[
M/51/Y5O<+<IY,IC.]00.1[$T <%9ZQK$_P 1/"WA"#5;J0:78&YUJ7>6\^3:
M!M9CUP^!_P "([5B7_BG6YM5^(FL6VLWMOH^E1FTMB),JLW"X0'C)<#G!PK'
M&,@CT^P\!Z%IOBF;Q#;13+>20I#L\T^6H4  A?7 '7///7FJO_"L_#G_  B=
MUX;,5R;"[N?M4Q\\^8\F0<EO^ B@#DAXB\06?A+P/X:%_*WB#7P#->R?-)!!
M]]VY_C"L ,_W3WK+T?6[/3O$GCOQX7GO+#1X4TRQ,TS2%VR-P#MDX+[>>>'K
MT?4_AYX?U6ZTBXN(9U?2MP@\N=EW!NH<]6SWYR<G.<FH+;X8^&K;0=5T80W$
MEGJ<C2S"28DJQ(;Y/[O*J??:,YQ0!SWA]/%^O:AX=UBYO;NVM5C>\U*1V,4,
MN]04@CA[A1U<CG)(8UG^ 3XD\7V9UT^);RUTR+67N DA+>= IXBR2-J #GU+
M'/W17?Z7X,T_2]*;3Q=ZC=(;<VR/=7)D:*,C;A.R\=P,\#TJ>S\)Z7I_A ^%
M[5)8M-,#P$*_S[7SN^;U.X\T >>^#=9U6;Q=?^'_ !1?W]KK5A<27WF"=O(N
MK7! 4+G:%!*L,#H/8US/AW7KK0/!NO\ Q!-S>7>I:O?&PTR.ZE+JZY_=EO4K
M\_MP1WKV3_A#]-DNIKN[DN;NZEL3I_GS.-Z0'.5!4#DY^\<GWK)D^%GAN7PC
M;^&G%X;*WF6:*3SSYJL"Q&&Q@#YVX _B)Z\T <[I-QJ[_%O3_#Z:]>W4&EZ;
M]JU<M,2DURW&,= /F0A1@#'3K7'W/BWQ#-X3\:>(X=;U"&Q?4!::61+DGY^%
MCST^5LDCGY0 >M>NV'P\T+3=9O\ 5+87:W-[$(I,W#$+A-FX9YW8S\QR<DGO
M4<GPS\-R>%K#PX8+A=/L;G[5"%G97\S+')8<G[Q_R* .?U#7-8CU'PEX'.H2
M17T]DEUK%_NQ(L2+\P#=BS*P+=1^-<]X2@U76-'\>^*?#]Q(=2U&X:UTJ2=]
MTABB' 4MU)7@9[KSTS7H^H_#[P_J>OV6LSP3+<VEO]E18YF1&CYP& ZXR?KW
MS4>D_#O1]#TJRL-.GOX%L[C[3#*)\N'PXP<C&W$C_+C'S'- &7\+=:7Q)I;Z
ME]IOTN8(ULKRQNIGD$4Z9+.-Y)^8$?3!'K70>.]3&C>!-:U#[1+ T-JQCDB;
M:P<\* >V6('XU>T;0K'0TN_LBL9;RX:YN9G(+2R-U8X 'IP !4?B;PY8>+-!
MN-&U+S?LLY4MY3[6RK!A@_4"@#P_5=/N](^#.AZ(L]W<:MXMO(I)D=]S'<=Y
M(SW_ -6#GKWKJ_#NK:A9_$SQ#'/JLS:!X?TI5FMT/[F)]H8*@Q_"JL,GDE3Z
MX'='P3HS:GH^H.D[SZ0KBUWRE@"PPS$'J>GTP/2H[7P%H%I<ZY<);RN^M&3[
M9YDS,#O!#!1_#G)]Z /*]2\5>(=8\,:/?P:M<V>L>)]5$-C;6\I5;:T#%?NC
M@G."7///89%;TEE)XE^/9M?[1OS8>'K..9D$YVK<,  !]5;GN<'FNBM/A)X8
MLQI.P7S'2V=H2UTQ+;^H;_9]A@<GU-;6E^#-)TCQ%J6N6HN/M>H.))@\I*!@
M",JOT)ZYQDXQ0!T%>/:=_P 57^T;?WA^>T\.6?D1GMYI&"/KEY/^^:]?D0R1
MLBR-&2,!UQD>XR"*X_3/AIHND3:A+9W>JQMJ+;KPK>L#,<DY+#!!^9N01UH
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M';JP#2E<$NPR0 <YQWQSZ5/\/=%GN]6FWWD<>L.KZA DV%N-N< G&X+R<A6
M[=*DU[P'HNOKI7F+/92:4<V4MC)Y30CC@<8Q\H[=J *G@[3M?AUK6M1U.XO$
MTZX:-+"QNY_-D157#2-R0I<\[1TST%;/BW6E\.^$=5U<D!K6V=TSW?&%'XL0
M*O:=IL&F6YBA:5V8[GEFD,DDA]68\G^0Z# JIXD\.6'BO19=(U,2FTE96=8G
M*%MIR!GTR!^5 'AN@1Z]H^G?#S1K'4;FRN-6NVOKB&(@&2'(=GD[G*\ 9QA>
M>3QV>I>*]9\3>)_$6CZ%%=FWTF(VT:VK&-I[M@1N>7C8B$'@$$D=^E=I=^"M
M$O?$=AKLT$AN["#[/ JR$1A.< J.#U-5(OAYHUOXAO\ 6+:?4;=]0?S+NW@N
MF2&9N>6 YZD]\<GUH X:[L=0U#Q]X#\):I?'4)]'MCJFHSD[M\@^YDGKA@!D
M\D-D]:RO$OC:[U[P9XGU[[;<0VDUS_9&BV<$A3S,X\R1@/O%E)Z\#&!SS7K$
M7@K1H?%TWB5(YOMTL*0%/,_=!5QMPG3C:/;(!QGFL)/@[X4BL4M(TODB2]%Z
MF+ILHXSA5]%Y[<G YX% '4>%=&7P]X4TO2% S:6R1N1W?'S'\6R?QKF?%WB3
M4)/'.A>"M(E-O+?*;J^NE'S1VZYRJ'LS;6&>W&.M=U#$D$*0Q+MC10JKZ =*
MQ-3\):?J>OP:YYES;:E#;M:B>W<*6B;.5.0>Y)!&",]: /,X?&6HVVA?$N^%
M]<MI6GS_ &?2YGE9V28Y0A7.21N*'!)X/O573[_Q:-8^'6D3ZY?B\NPU]?0O
M)DM#G?\ O">3D;U Z  #&<FO3;_P!X=O_"\/ALV;0Z5#(L@A@<KN(R?F/5LD
MY.>2:L7'@[1KKQ9!XEFAD;4((! G[TB,*"6'R]#@G^1ZB@#B=$B;Q7\:/%&J
M":2.#1[1=+MI4QN21LERN01D$./^!50\":EK_BGPEHBOKUX-2M=;?SW#9\^W
MC(9Q)_LX<*.V64?3J$TNS^'^J+)H^@:OJC:S>227$D+B06S-@DX8@ $XY)[<
MG@"K_@#P5#X-T>6,MYE]=RM/<OG(#$YV+[#]3S[  ZVO#]?\?7]]H'BKQ+!J
M4]I:6=T-+T6&!ROFS9&^5L??)!R > ,\9YKW"N ;X.^%#92VH2^2*2]%Z MR
M1L?^ZO8+TSW.%YX& # \7:GXC\'Z1X2O[V>]OM*M$$>NB&=EF,KJ,,S*0< D
MD#(&< ]17IF@1B/0K39?2WT;J98[F9B7D1R67)/^R0/PK-N_!6FWB7T+SWBV
MM_&D5S;"4%)%4  <@D9 Y(()SUZ8Z""&*V@C@A18XHU"(BC 50, "@#S/XN$
MZU?>%O!L9)_M74!+< =?(BY;/YY_X#39O%MQK/B7Q4@N9;/P[X8M7640.8GG
MN,-U9<$!=K  $9.,YZ5V6I>#=)U;Q18^(;L3M>V<+0QJLI$;*<Y#+W^\?J#@
MY%59?A]H4UUJ<CI/]GU2=+B]LQ)B*>13D$C&[D\D9P>XH \OO_%'BJX^%7@R
MW^WWL?B'6KTQ1RPOLED@#$;B?7!CY]#FNH\*:CKU]\6/$T)U6:[T_2[-(#;L
M^(1<-@@*/;:XR<D]S7;W?A32KWQ#I>MS1/\ :M+C:.T16Q'&&&#\O3./Y"N<
MUGPG#X<TS6[_ ,/:7+>7VKSDWH>5W*QR-^]9$!!) ). 03QSQB@#A;?5/&NI
M^'-+:VO-5?Q/J&K.;CRMP@M+92RD$8,87H02#GU.*]TMXC!;11-+),40*9),
M;GP.IP ,GV KR;PYX3UGPUXLT>+PUK>N7.@G=]NM=4A=(X8PO&W>J\D] HR,
M<\5Z[0!YIKWBU[OQQJ>E_;);/1/#U@;S4I()#&\TI&4C##D  @\'DC%<[:WW
MC:7X(1:Y!?W-WJMQ=&^F3S")#:!L%(\<J,!6^7!PQQ7=ZG\,?#FK:MJVI7*7
M0GU2$0W CG*IP -P7INP.^?I5ZQ\%:?I<>GII]W?VQL+=K>)UF#ED;;G=O!#
M?<3''&T8Q0!%X"U&UUSP_P#VW97=W-:W[^9'#=2M(UL0H5H\L23\ZL<^_IBJ
M'Q;UV?P_\/;RYL[B:"_EDC@M6A;:WF,PZ?\  0Q_"NHT31;#P[I$&EZ9#Y-K
M #M7.222223W)))JEXG\):9XNMK.#4S<!;2Y6YB,$I0[U! R?Q^M ' >,M3U
M[P9:^%+R]N+V^T.TC$&M-!<,LIF90-[,I#8R20,XSP>HKTS0HO)T2T47TM\I
M3>ES*<M(K'<I)^A%9=YX)TR]2_@DFO!9WXC6YM%E'ENJ*% Y!*\*,D$$^O2N
MABBC@A2*)%2-%"JJC 4#@ 4 >;?%O5]3AG\,Z'H=W=P:CJE_M/V64HQA &_)
M'3[P.>V#6?X?\3:E;^-O'>J:CJUS=Z+HEL(VAX$?G 981KVP59>YY&2:]#NO
M"^FWGBJR\1SI(VH64+0P'?\ (@;.3M]?F/-4++X?>';&VUFWCM9'CUAI&NQ+
M,S9\S[P7GY<\=.>!SP* .+T2Y\8>,X= U=+J[L8Y;S[;=R*YBMXK52=MNB?\
MM2PY+$$#U[5=T2]USXDZ!K.KZ?J\FEJ]R;;2@A8+%&A7=(X4@L[<\'('''6N
ML\.>"M.\,V\,%M<ZA<Q6X(MTO+DR+"#_ '%X ZD9QG!(SR:K:%\.]$\.7$S:
M?)?I:R3&<6+73&W1_4)WZ#KGH/04 <G>^*==\3:_XAT;15NY(M(B^QQ_9CY3
M3WC J7>7@(B$$[003COTJIXGU/Q%X(;PM/KE_=ZCH<-O]EU6>TG='6X;^-F4
MAB ",9ZX/<BNWA^'FC6VOW^KVT^HV[:A)YEW;0W3)#,W)RRCGDD\9QR>QJS?
M>"M,U%=0AN9;IK+4)(Y+JSWCRG*!0H QE1A%'RD9Q0!PWC36-6\'W7AJ]NKV
M^U#PO'%]GU">WG9)?-8<2N5()X((&<?F*N7>OW#>*--\)1ZS/]@T_3CJ>L:E
MYA666,?=7>.5SE22.<' (KK;_P %Z;J0U&*YFNVL]1>-[JT$@\J38%50!C*C
M"*#M(SBJNI_#CP]JNNW&L7$5PMS<69LY%BF*(4Q@':.X&,=@5!QD T >9Q>*
MM=A^">L^)KC5K[[9J-_Y6F,TAW11[PH _*3/KBM[Q)I?BS1/ FM:Y+XKU!9E
ML(/(MT.# 4(#98Y)8@\L,$G/;%=9'\-?#L>AZ9HYCN9+33KE;J(23DEG7.-W
MJ.3P,#DU!XNEU#Q"=4\&PZ+>I%=VBA=5*@VZ[C\V3D<@=ADD]@.: &^&)=2U
MK5]'UL:K</9MH<7VRTX\KSY KJ0/[V"Q/<#9V-=1KMY%IWA_4;V>5XHK>VDE
M=XR R@*3D$]_2FZ!H=IX<T.TTFR#>1;1A SG+/@8R3Z__J'%.UO1[7Q!HEWI
M-[YGV:ZC,<GEMM;!]#0!X=X>U75_"GP[L-1MKB>X\3^,+X1PM=.9%CRVT2$'
MJ<;>O]X=A@]MHVHZE%\9I_#]KJ%W>:;9Z0C7YN)#(/M!.0XS]UB&'RC Z\<5
MT3_#_1&TO2+%1<H=(E2:SN!+F6-T  Y8$$84#!&.!Q6MI&@Z?HGVEK.(^?=R
MF:YG<[I)G/=C_(# '8"@#0ED2*)Y)&"HBEF8]@.IKPW3O%6K0?!_Q3XMNM5O
MB]Y=M'I0>8DPIOVIMSZ$MGUV<U[;?6<.HZ?<V-P&,-S$T,FTX.U@0<'MP:Y5
M/AAX<7PY8Z"T=U)8V=PMP@><DNREB Q[K\S?*,#DGJ: /.[#5?%L'C3PMI$V
MM7@>WTEK[5$F?<D096^:7NQ!(."<#*J,8)+]*\5ZU:_ W7_$NH:M>RW%W=R#
M39))/WB LJ+@C&,,&.!QP>*]1?P3HTNJZUJ<D<SW6L6WV2Z8RG_5;=NU?[O
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M;>?EZ#ISP,DX%3>'_!6G^'+2.VMKO4;B.!"EN+JY,@@!&/D' !P2,XR!QG%
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M10 4444 %%%% !117#?%W7)M!^'E[<6D\T-]-)'!:O!(4?S&8=".?NACCVH
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MAKJ*6Z=F<(Y+*I+$GY00O)[5XC=:KJU]\/O%WBQ/$6LPI-J@@T>&.\?&P2
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M.2P.=PS6WK&LZG>?&*^AM-4O+72=#THSWYCF)B5RA);83M+;6& 1@%<D'!!
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M3-'N(8*V\  DN.0>IJ^WA[3[;XF>#_!FG!CIOAVVDU.X+G):1F^4L?7=M/\
MP+B@#V<9P,\&BO ]<\<ZGJW@[6_$UOJ5U;2W=^-,T"VMYF3"AAOD(!^9F!/)
MSM.,8XK>\2S:VGC7P-X2TW5+UKN&W%QJ,OVE\3*F,-)@_,"R/GUSB@#UZBO+
M/A;K-S=3>*]9U37IY]*;4OLUD]]. H"9Y7HJ[MR\  <5ZG0!7OK@V=C/<A5;
MR8RY#-M! &3SVKSJ#XRV;>&8/$MSH-_!HTMU]E,X=&96]2N02O49'I6E\8M<
M_L+X9:JZ/MFNU%G'[F3AO_'-Q_"L&P^%-WJG@SP[H.M:HD6DV2K<2V-K;%))
M96RQ#R%ST+,.%'7MQ@ ]6AECN((YHF#QR*'1AT((R#3Z\)UOQM<W7AWQ3X@M
M]0GL[*PN!I&AVUM*8PTHQND('WC@@@'@#/&:U=8FUVUUKX>^%[?5K[^U'@:>
M_D:X=MY50<R#/S*'#G!ZA<4 >MW=W;V%I+=W<R0V\2EY)'. H'<UDWFOSVOB
MS3M%31KV:"\A>1]01?W,!4'"L?4X_4=:\I\1>'+R?QAX1\$7GB'4]3+RS:A?
M2R3,N8@Y9,@'@_*P!['&,=*OZ;XHN++Q-X^\1O>WMQHVA1"TM;22Y=XWF  8
M@$D9W*.>P>@#V.L2VU^>X\87NA-HU[%!;6ZS+J+K^YE)Q\JGU&?_ !T^G/-Z
M!INN:OHGASQ%=^(IH9Y674+Y%SY<D3)E857=M50",G!)QG.:X2R\3ZC%\*O&
M/BN75-0)OKUH=)5[J0M"F_:FPDY&"S9]=G.: />J*\5C_MOP_P"//!>GR:_J
MES(NF276LQW%PSQJ@4DL5_WMP!.3P*RM6\7ZWK7@Z/7+?4[NUU3Q!JHLM&M;
M>=D$%NK%"=H."Q/!8Y.2,8H ]_HKR7Q!=ZK/\6?#_AS2=5O$@T_3_M.H2&X;
M80 0K2#.&((4\_>W 'U'/:9XBU)/@WXP\17FM:E*MU>.FFO)<$2HI8(I!&,<
MDY P/E/ H ]UM[NWN_-^SS)+Y,ABD*'(5QU7ZC-35RGPY\._\(QX'TZR=YC.
M\2SW ED+;97 9P,]!DG\<GO7DX\<ZA9^$/&?B-=4OI#J%^UAHD33N_E("<N@
M)XX<<^H H ^@Z*\=\:3Z[:6?@+PK::E?MK5[(IO)8[IT>1%4>;N8'IDDY[!3
M1X>\37]CXE^(.O7VK7=]I.CH(8X9'PC3*/G$:CA1N&![.,D]: /1O%_B6'PA
MX9N]<N('GBMMNZ-&"D[F"C&?<BM'2[R34-)L[V6W-O)<0I*T+-DQE@#M)]1G
M%>$ZHU]XKM?!>EZI?3W&I>([P:C>0+*WE0V8^946/.T#:,@XSD')KI;SQ%KW
MC/6O%&G:$ERMMIH.GV@MY?(4W!RK322 @A4P<*.O'![ 'KE%>/78U[_A8'AG
MPE:^(+Y[BTT<RW]TLK%78@H'9<X)'49SDE<YJ#Q/<:YX N?#DVJ:IJ&L>'+>
M%K349XKAXY5G=BPD?:V>%90H)/3L2#0![%=W=O8VYGNIDAB!"[G.!DG 'U)(
M 'O4U>,:SI7]N_%3PQX9;5M0N;72M.%]>3?:F!9UX1^O#[MIW=?FZUE:WXXU
M/5O!VL^)K?4KNVFO;]=,T"VMYF3:@8;Y" ?F9@3R<[3C&* /?**\A\2S:VOC
MCP/X2TS5+UKJ&V%QJ,OVE]LRIC#2X/S LC9]=V*H>&O&>H:/X8\=^+KO4KO4
M[.*^\C34NI-P)!*@@# 5273(4 ?*?2@#TGQOXOB\%:"NJ36<MV'F6!(HG"LS
M-G'7Z5T4;.T2-(FQRH++G.T^F>]>&R6EUKGC7P+H6HW]S>WRJ=;U?S)2T:MC
M=&H3.U0.5P .&'K6K!J>II\4[SP_KUY?)%JEPEWHM[;7+B(PH=QAV@A<% 5/
M'4YYR#0!ZQ>7#6EC<7*023M%&T@AB&7D(&=J^YZ"N>C\;6MMX%7Q3K5E=:3%
ML+/:W"_O0=Q4*!QDM@8Z=1TK'^,6LW>D^!O+TVXG@U.]NXK6T>WE9'#ELG!!
M_N@C\17+>/\ 1O[5\7> /"#WUY.=HENR;ACO2(?ZP\_?.)/FZT >GZ+K-_J4
M]Q%>:'<:>(XHI8WD<,LF\$[<]F7 !'(!/6J7@SQBGC*#4;B&PDMH+.[:T#O(
M&\UE'S$8[<C\ZE\8:NOA7P%J>H+(^ZTM"L3R,68R$;4R3R3N(YKQS0K76M('
MPVT"TU&[LIKV5K^ZMHGV PYWDRXY8L-PP3@!0,9S0!]"T5Y+?>)-=\8>(O$^
MEZ''=?9M+4V-NMO+Y(>Z;*M+)(""$3!PH.3QP>W;)<R^#/AY]IU:\DU&?3+$
MO/.S$M.RKGJ>>3P"?QH Z2BO"]1\0>)9/"'A;5AJ-S_PDFOZLDEO;PR,L4=O
MSA!&#M*X*$D@GYN3Q6M<?VWXN^)_BO2=*UZ^TZSL[..W,L<C,D4C ,2JY #9
M&W/' ?&"<T >O4AR <#)]*Y[Q'::O'X&N=/T:_;^V?LGE6UQ(P#R2!>3D_Q$
M!N>QY[5YYHGC,)\-==\1O/?V^IZ;9_8+FRN9Y'5+H?*L@WDD%BRY],'ZD [[
MP7XQ3QG:W]U!826T%K=-:J[R!O-90"Q&.W(KIZ^?-"M=9TB7X;>'K74;NREN
MF;4+NUB?8IASYA,F.6+#<,'@  8SG/47OB/7O&>N^*--T-+H6VF V%L()?)#
M7+95II9 00J8.%'7C@]@#UNBL*T63PYX'3^UK^2]DL+$M<W3.=TFU"6;=U['
MGK7F/@^778? MAXYUKQ%J+6E@MS=R632,WVP$,JAF)X&=H ((XR/O9H ]KHK
MR/0AXM\6Q^'=;GOKJQA>X_M&]G$YB@\CJEM'&#\P*\LS#OU/2FZ#J.JCXDZA
MX9\1W=_%>RWO]HZ9=17#B&>W4Y\G8#MV[5/;KNSR.0#T-=?N#XR;0?[&O1;K
M:_:/[1*_N"<XV9]?QS[=ZJ>-O&$?@S2[:\>QEO7N;E;6*&-PI9V!(Z_0UYII
M7CB]TOP[XX\:O>7-W;&_-GH]M<3N\:X; 8 GI\ZDX_ND4X6,^I_$OPAHFH:A
M<WMUIEL=7U=Y92R"; *@+]U0K%0  ."* /;AG R,'N*6O%H-7\4?$S2=3N]'
MFN[*&>\%M831S&"*T@1@7F<J0TCMTV\@>W4V/$FI:KI?Q%73M6U"_P#[#UJW
M2QTV_M+AT^R7( 4DA" 6+Y)SV([ B@#V&BN7\?>*?^$*\%7NKQQB6>)5C@1^
M0TC'"Y]AU/TKB&O=?L/&?@+2QJ=W<ZM=Q276LJTI,9C8 XV?=4*0X7 '0=S0
M!Z_3)IHK>%YII$CBC4L[N<*H'))/85X0WCB\L;+X@^)O[3O'MQ<-INCPF=G5
M'Z-(JDX&-R-GMG'<"K'BVRU#4=#^'OA"^U*^FU#5) ^H$W#9:, -('&?FQN.
M,]-E 'M\,T=Q!'-$VZ.10ZMZ@C(-8^L:_/I6M:/I\6C7M['J$K1R7,"Y2V
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MK1_"\6GFXEU&-I3,)MHA10225P<]..>:U_$&N6?AO0;S6+\L+6TCWOL&6/.
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M%O"]_HEE'IWVV?5[H6L2B;9M.1ECP>!GF@#9T71K+0-*@TZP1UMX5"KO<NQ
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MW/V]C,Q,@((P#GY0-QZ5T5% &=HFAZ?X=TJ'3=,A,5M$,*"Y8GC')/)X 'T
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M7)+47,-MMWQ^;L8[F"C;P<G)'I6 GQ0@M+?1+O7=(N-,L=953:W7FK)&I89
MDZ%,@@]"/R. #9T?P-HVBZ:UA";V>W,30HMS=O)Y4; @J@)PG!(X ->?^*?!
M,-M<>%?"6C:9J9T*"^%UJ%R$DD"@$E5W8/\ >?@<#.>I->RTR::*WA>::1(X
MHU+.[G"J!R23V% &7:>&M-M9[ZY:)KB[OUV75Q.VYY$Q@+Z*N.R@#\:YVV^$
MGA*T@T^&*UN0MC<&XA/VI]VX]B<YP.P&.I]3GM+:XBN[6*Y@??#,@D1L$94C
M(//M4M &%%X.T2'5M4U-+5OM6IP"WN6\QL&,+M"J,_*, =,=*S9/AEX8?PG'
MX:%I,NG)*)@%G;?N!)^\3G')XZ<FNOHH @BLX(;,6B(?)VE2"Q).>I)/))R2
M2>237')\)/",>AQ:0EG.+:.Z6Z#"X<.77=CYLYP-S<#'7/7FNXHH Q/^$3T?
M_A(K/71;$7UG;?9;=MYVQQ\\!>F>3SUJE;?#SPU::9JVGQ6+?9]59VN@TS,2
M6Z[23\O0=/0>E=110!Q]C\,?"^G7NF7=O:SB73HC%"6N'(8'^_S\WI@\8P,8
M %30?#S0;76[[4X%O(FOI/-NK:.Z=8)GR22R X;DG@\<GBNJHH R+7PUI=GX
MDO/$$,##4;N)899"Y(V+C  Z <#I5:]\&Z5J!ODNC<RVU_,D]W:M*3%*Z;=N
M1V'R+P",X&<UL1WUK+?3V4<Z/<P*CRQJ<E V=N?3.T_E5B@# 3P;HR>*[CQ(
M(9#J%Q&L<F96\LA0 /DZ<8'Y9Z\UB1?"'PA!9PVL5I<I'#>"\C*W3AE<9P <
MY &>V#[UW5<MXG\8-X=UW0-)CT\W<VL7!A0B;9Y8!7<Q&#D -G\* +UOX2T:
MU\0S:Y#;%;Z6U%F6WG:L0QA57HOW1TK,C^&GA>'PG<^&H[%UTZY8-(#,Q?(;
M<,,3D8/..G)]3G7\4:\GACPU?:U)#YR6D?F-'OV%N0, X//-9,7B_4IK7PO/
M'X9NY4UH!IVBDW+8H0"&<[>>#[=#WX( ZQ^'7AS3=7AU.UMIDN8K46JDSN1M
M!R"03\S9P<G/(!ZC-7+#P?I5A/ILJB><Z7&T5@+B4O\ 9U8 ':3R> !EB<#@
M8K4DU*W$]S:PL)[RWA$SV\9^?!SM^F2IQGTJEX8UB[U[08-0OM(N=)N)"P:T
MN?OIAB >@/.,\@4 4/&OA_3M8TZ"^O=/O;Z;2I/M=M!92E)'<=A@CT'?/'%8
MWAWP]=7WQ$OO%][9O9VL5G'8:7;2KM=4 !=BO\/S;@!Z$^U>@44 9/B+PYIO
MBK26TO5HGEM&=79$D*;BIR,D=LU!=>$-$O/$MIX@GM"VH6D(@A;S&"*@)(&T
M'!P2>H_D*W:YCQWXP7P3H*:HUB;TO.L"0++L9F;. .#GH: &1?#W08-=OM6@
M6\BDOW\R[@BNW2&=N3ET!PW)/!XY/'-=!?:=::EIL^G7<"RVD\1BDB/ *D8(
MXZ5/$SM"C2H$D*@LH;(4]QGO6/X>UR]UF;5$O-$N],6SNF@B:X/%R@Z2+P.#
M^(]S0!'I/@[2-'FLYHHY)YK&W%K:27#[S!%_=3L..">I'!)JSHWAO3-!NM2N
M;"%DFU*X-S=.SEB[G/KT')X'%:U<UJ_BY;/Q!'X?TVR;4=6-NUU)"L@188EZ
M%FP>6. !COS@<T :NJ:1;ZM]D,TD\;VDXN(7AD*%7"LN?<89A@\'/(K(O/ '
MA_4-(NM,N[:26"\NOMETWFE6GE_O,1CVX&!QTK=TVYFO-,M;FYM'LYY8E>2W
MD8%HF(R5)'7'2K5 &'<^$-%N_$]MXAGM2VHVT(@B;S&"A 21\N<'!)/(_D*H
MP_#S0;;7+[5(%O(GOY/-NK>.[=8)GR3ET!PW)/!XY/'-=510!2U72K36=(N=
M+O$8VES&8I$1BI*GJ,CI4!\/:6WAD>'6M0VEBV%KY))_U8&,9ZYQWZ]ZU*@O
M+RVT^SFN[N=(+>%"\DLAPJJ.I)H P-(\":/HVFM80/?2P>4T,8N+MY/)1@01
M&"<)P3R!FK-KX2TRVN[:Y;S[B6UMFM;9KB0N88FQE5/4D@ ;CD^]%_KUY:^(
M](TVWT2[NK2^5VEOTXCML#(W#'?W(]L]*W: .,3X6^%H_"DWAL6DQT^602'=
M.Q<,#D8;L 2>!QR?4U<TWX?^'M)US^V+2UD6Z$"P8:9F7:.Y!/+=\G///7FN
MGHH Y70_AYH/AZ9SIZWBV[2^<MF]T[6Z/_>$><9X&,YQ@>E68_!NE*UL)/M$
M\-M>-?0P32ET2X)8^8,\YRS$#. 3D"NAJCK.HKH^B7VIN@=+2!YV4MMR%!)Y
M[<"@"+Q!X?TWQ/HT^E:K!YUI-@LH8J00<@@CH0:33O#]AIM_<:@B--J%PJI+
M=S-ND95Z+GH![  9YZU7\(>('\5>%[/6WL39"[#,D+2;R%#$ DX'4#/XUN4
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M5V(JMF25F!R2,=LCI7K6O:C#I'A[4=1N"1#:VTDK88J2%4G (Y!^E96@> ]
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M]0-QJ=V8]-#73[X8]^Q ASD8PYXZ[><UZQJ?@/PYK&NMK5]I_FWS6YMF?S&
M*'(Z XR,\'J./05#'\.?"\>B66C_ -G,UE9W"W,4;3R']X,X).[+=3P>.>E
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MV @A%<MN5>!PI J67PAH]PFH"ZADN)-0MOLEQ-+*S2-",X0-G(')/'4\G)H
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M:P*$C0$G 'N>3^- 'GOB'Q3]L^(5YI$]W);:%X?L#?ZEY3E&N)" 4C)'.W#
MX'4\'-<1+J.L/\"D%W?75WJWBK4A! )YF=D1GP%&>BD(>!_?KUW4OAYX9U;6
M+[5KS3O,O;ZW-M/)YK#<FW;G . =N!GKQ2CX?^'$L-,M([)T72Y!+9R"9]\3
M\?-N)Y.% YSP!Z4 >=VMP_@CXC7]MI]]?W6BZ)X=$M_!+.SH)%7Y H/"$@)@
M#U-4-3UOQ'<^!?#VKC4+C_A*/$&K(]G%#(RI#""0$5 <;,;2<@YW<YQ7L5GX
M7T:RT^^LH[)7BORQO#*Q=[@L,,78DD\$]^.V*BTGP?HNC26DMM;,TEG#]GM7
MGD:0P1_W4W'Y?KU(X)H \\U#Q,8/B[K^I2WMW_8_AS3 9+9)V,<MRRY "9VY
MVEATXV9]37.W^HZN_P  X[F_U&^N-8\0:B!;@W3Y4.V @&?N%%)V]/F'%>L2
M_#KPO/=:Q=2:;NGU=2MVYE?)!Z[>?E_"G3_#[PW/I6EZ:UE(MMI<JS6NRXD5
MD=1@$L#D]!W[#TH TO#6A6_AKP]9:3:O(\5O&%W22,^3CG&2<#/0#@=J\@\,
M74$$GC[XCO/<NMK+-;:<9+EV#*H. <GY@2T> <@'I7N4<,<4*PQHJ1(H5448
M  X %<K!\-/"MOX<N- 33Y#IMPX>2(W,F3AMP&[=D#.#@<4 >/:59:OINC_#
MW1X-2N[*[U6];4)XX9=F800[228ZDKC )P G3)-=O?\ B'7/%OC'Q%HVCPSO
M9Z/#]F2.*80B2Z<$;Y7R#L3#?*N<D9P>W>77A#0KS6M/U>>P5[W3XO*MGWL
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M;%1P",<Y^HZ\9KRFTN[YO$/@#P5#J-VK6D7]H:M,)V'F/RQC8YRPW[E(/&6
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M[58Y/L_UV8KH5L=:T&:/Q;J]S<*FD:3-++#+<AI=1G*Y8LJDJL8) 4#IQP*
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MP0@2R2/N.X\D9[@9P/85MT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/@/PW=Z_+K<NGG[?.H69TGD19@,##HK!6' X(.>]=&JJB!$4*JC  & !2T4
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MHT]B9K&X*F99)Y&>7:05W.6W'! ZFI+CPEH-WJ6G:C/IL3W6FQ^7:.2V(E]
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M 0N,X7;WS@?]]>QK<H S]*T/2]$25=-L8;<S-OE=%^>1O5F/+'W)-8$WPO\
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MW;V$5K;6MXUI"T<QD\[;U;)4<<C''K0!K0>%]%MM?N]=BT^,:G=J%FN"22P
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MYO"NOZO?F Q*=0GN))QYMX[KN$:*IPD*KV[\_*,DUZ(?#.C/:7]M+8I-'J
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M]S@I:LL?)'SM\J<C_:85Y+KMK>6OPN\$^%K6XF?6=9NU>5Q.P?YOF<,0>V]
M<] *]OUK1--\1:7+IFK6JW-G*07B8D9(.1R"".14"^%]$6]TZ\73H1<:<ACM
M'&?W*D$' SCG)YZT >=>#(Y+KXU>(I5U">6UTRTCLMKRG:\IP6"IG 5=K# Z
M8!/))/K3H)(V1LX8$':Q!_ CD5FZ=X=T?2=0O;^PT^&"[OG,ES,H^:1B<DD_
M7G K4H ^:CKWB+2OAGK\EO/<BTA\1,KW4TC,\D>5 16)SC*_,??'.3CK_'SM
MIOACQ=XBM+N[V:Y):6M@OFM@LO!D0#D C=CUVYZ$5ZE+X<T>;24TJ73X'L$D
M$HMV&5W!M^2._P W)SU[U)JNAZ9K<=M'J5G'<I;3+<0J^<)(O1L#TR: /(_&
MNAR>#/ %WJ#:C?RZKJ-M:Z9!;F8[(6!Z)CN%!Y[D$_Q&HM:T"RU+QSX"\'R2
M&>'3;'[3?R"=MK[>!T. 2ZGD<_./:O7=<\.Z3XDMH;?5[)+J*"83QJS$;7&0
M#P1ZFH_^$5T/^W8M;_LV$:C%"L"3#(VH.0-N=O'&..,"@#R_P[JENOB+XB>+
M9)6.GZ?&]G:0F4E6$:CS-H)[D1\C^_[UQR6&IKX'\&V%UJ=W%?:]JGVO/VEA
ML@&-TKG//R[",\ #CDFO=X? GABWTV_TZ+2(5M-0D\RZC#-^\;(/)SD#(' X
MJU<>%-"NKC39Y]+MY)=,799%ESY(P  !T[#KZ4 <#K_V^[^)VJ-*CZO96.DY
ML]-@;>J7+\#S4S@,1N(9N,8YX%=-\-?#^J^'O!UM!KMQ/-JLF6G\VY>;9R=J
MC+$#"X!VX'UZUP^J_#:\UZSO-2U/2[Z/QD[.4U"PN8HH&8<1$#<"$"A<Y7?P
M>3Q7K6BVUW9:'86M_<_:KR&WCCGG_P">CA0&;\3DT <!\;;R>7PK8^'+(%KS
M7+Z*U1 <$J"&/Z[!^-97AM/+^-.I_P#$QE%AH6EI;2 RGRO,*[MJKT"JH;@?
M\\\G)R:]2O-#TS4-3L=2N[-)KRQ+&VE;.8BW4@=.<#\J@A\+:%;WNHWD6F6Z
MW.I K>28YE!&"#['OCK0!Y)X/LM1\1_#OQ1>V.I/::KXAO)/[/5YR&$2%F6-
M23D A9E^@/I77?":^AU?2KJ^DT]M/U6U*Z;?6RC;&)(LG<J]B=XS[K[5TEIX
M)\.V&GVEC::<+>"TE,T BE=620@@MN#;LX)'7H36KI^F6>E0/#90+$DDC2R'
M)+.['+,S'EB?4G- '+?%+Q5=^$?!,U[IR@W]Q*EK;,1D([Y^;'L <>^*Y2*U
MO+#XK^%=&L+J:6:PTZ2?7+HN6,V\?\M2>IW#(!Z;AC@5ZCJ^C:?KVGO8:I:I
M<VSD,48D8(.001R"/44VUT33;..Z6"U53=_\?$A8M)-QCYG)+'C@9/':@#R7
MX?:!+XWCU'7Y]2U"VLFUTW=M'%,<2K&V55LY.P#(&,<EO05[22 "2< =2:IZ
M3I%AH6FQ:=IEJEM9PY\N),X7))/7W)-6IH4N()(95W1R*489QD$8- 'S7>WU
MQ>^$_''C(S31#6=12SL/*<J\P5L*,CG:%SQ_$5YX&#W6I:MJ=IJ7@SX?V4]Q
M,6L$N-0F@F EG1%(V*Y(P&:-LD'..GOWTG@GPW+H5MHDFD6[:9:R^=#;G.U'
MR3GKG^)OSI=7\&>'M=N;.YU#3(Y)[-=EO(CM$T:_W04(X]NE 'DWBW2;WP_X
M,EL6O VJ>(]?15M;"9@EJ"?]6AX[8!.!]X<<5ZKX9\*_\(]=:C>/J-U=W&H&
M-I5E;*1%%(Q&.R\G ] !VJ[+X9T6:337?3H"=,8O9@# A8XR0!QG@5JT >:?
M&FZDG\-Z;X:MGVW.NZA%:_2,,&8_0'9GV-5GU4:E\29?#WG"W\+>&=-6YN(P
MWR7#;%*!SW158''0E><\5WVK^&=&UZZL;G5+".ZFL7+V[.3\A.,\ X(.!P<C
MBH[WPGH>H:A/?76GH]Q<1+#.0[*LR Y"R*#AP/\ :!]* /&=%\2Z_8^ -)LU
MN9K-O$VO-#93.?FM+-F4'9GIR3M] <CM78>-GC^'&D:QXCTN]E-S):PV-M9,
M04C<L<2MW9OO'+9)P1DYX[G6_"^B>(].CT_5M.BN;6)@T:'*^60,#:5((XXX
MJ*Y\'>'KO07T.?2XGTYV#O$2V688PQ;.XG@<YS0!Y?IMLC?%70-$CU"65=(L
M3>ZO<-,<7-R> 6.?F(9E^G3M6W\(V76M2\5>+I&!?5+\I;@GYA;QY"'Z<X_X
M!79V?@KPW8:F=1M='MHKHP"WWJ#@1A=H &<#CC(&:M:%X<TCPS8?8M&L8[2W
M+%BJDG)/J22: *'CW7/^$<\":SJ@;;)%;,L1_P"FC?*G_CS"O&=/T:ZTZ?X9
M^'FNYK:X=SJ5S$DQ18H]V_YNQ9OF&3TP%'?/O.LZ)IOB#3S8:K:)=6I8.8G)
MP2.G0U'/X<T>ZURVUJ?3H)-2MH_*AN&&61<DX';J3],T >5:AXBAM_BYXFUZ
M621[+PYIHCC@60XEN60GA<XSCS 3V"Y[5DRW]_IO[/@N)[RXGUK7KT>6?.8N
MKR,"H'.1^[7('^U7KTG@7PQ+/JL[Z/;M-JJE;V0[MTH/49S\N2 ?EQSS4H\'
M>'A::9:?V5!]GTR02V<?.(G'1NO)XZG- 'C<,5]IGQ"$+:C<K;>%_#^[4'2<
M[58QG*J.FXAASUW MV IVCZ[JWASX+Z9';7\G]L^(]3,,4TDA=K82$?-DG@[
M0"/^NF:]E/A/0B=6)TV$G5AB^)R3..>O/N>F*@N_ _AF^T2TT:XT:V?3K1Q)
M!  55&&>>#D]3G/7O0!YYX;-BWQ;U$VEW(NB^'-.$3,TI*S7#*=TAY^9BH?)
M[[<UPCOJ=S\,M0U8W-W'/XEUI8=.A6=LLN\XSSDJ,.H'3)R<X7'O\'@KPW:S
M:E-!I,$<FI1F*Z*Y'F(1@J.?E&.RXITW@SPY<Z;I^G3:1;26>GOOM86!*Q'V
MYY_'- &GID(MM)LX%G-PL<"()BV[S % W9[YZYJU0    , =!10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y
MY\:K\VGPZGMH@QNK^YAM8-OWMQ;)Q[[58?C0!Z'17C/BRTN/AQHJ76EWMR=<
MUUK;3 \CAH[4*#S&#@# PHS]?6M6'P7+!JFK7KZK'I=W<Z6-*LHDG+R@OG;-
M.W5I&?/3/U)' !ZC17@V@^(Y_"W@OQ!=WFDI:^)O"]NNG.Z*-DXF=?+D;^\0
M5SGN#G^+BQ)9Z@FL_#K3K:>6?Q#/)_:NJWA.9!"=I<.W]PC<@'3Y0* /<:*^
M?9?%$5AK7Q'\7Q/F6/.F:<B-T;(5Y,=AN$;9[EL=ZLZY926OPQ\!^&%8W&HZ
MK?1M+ND))Y+2J3GL753Z8- 'O-%>0>([)O">LZ3X>LM6OO,\6:GYFH7DLN'"
M($#)&1C9N+<8Z=!VJ?QW.GPZTC5]7T"[9;[59K?3X8,KY-DP0G<% Z[03ENY
M':@#UBBO+[/P;+:ZW-J=WJJZ=.NE_P!G6W[[?<222MM%Q.W=S(P  )'3GC%5
M?A-%)%J=YHNM:<MOKWAY# UQ$/EN8I3N5V/\3?+P3V;US0!ZU17EOQ-,NJ^.
MO!7A^T)%Q)<R7<CC^!4 *DCH1D$X/7;BLS4X)?#OBS1OA]HUS?S6^H23:K?O
M+<@33J2V(A(<84F,[L<D?CD ]EHKP7Q;H,VC>$9-'2[MWU?Q3KZ+Y-F?W-IS
MRL?3IPI.!G=TK2L[.UT'XL:W>Z9YHT;0]!V:@7E9U>0+D(22>=H'';;VH ]H
MHKPOP9H@TWX;6?CO4Y[QKC3EN=1@M5DQ'*S!E!<=<GY1G/W5'J:N^']$U'Q7
MI_AKQ!KE_'#FZ_M2:Z>4>=,RY*0Q*.(XE4$D9R<'CO0![/17B^DP2Z?\4;C1
M]=A6^M=8NCK.DZJ@RZ^7B386_NA5"[>@XQ][BEIT>J?%CP_J>HWEQ%:V=[?K
M!%//(-ME;HRD+$G_ #U<X!8X[8/:@#W6FR2)%&TDCJD: LS,<  =237B&HNM
MY\5?$6IB:5-*\+Z1Y4TJ2D.\FPY 8<AR-Z%NN!P0<&L&6![;]GO3=,9S/J6O
M:F@AC,A)C9VR._= IY_YZ9H ^A-,U.TUC3HK^QE\VUER8Y,8#@$C(]CC(/<5
M9=TCC:21E1%!+,QP /4FO&;F[TG3_%]IX3$J1>&/#VE_VC=1!LB]EPNP$9^<
M?,K!>A/X5R<FX_ V:23,VJ>)M75;>(R$M&"V$&,],(V,_P!X>U 'MNK>)-0F
M\,P:MX1TU-:::<(J&41*T>XJS@GJ,C@^ASTKIZ\5N-'TN/XG^"_"^G>6ECHU
MI]NN9$;B1B0(\G/)+A"/]_WJ(VCS?$+XB>$XVN)1JEK!]G3S&/ENR [B?X44
MN2?88Y) (![?17C$=SJWB3Q3K?ARS9)K#P[9)8PI=R[8FF*[3<3#DOMVMA<$
M9P>#S7=^"'T71=,M/!]GK<6H7^G6RR2C?ERK'=NQ_=^<8&3@%?:@#K*Y7XA>
M+I/!'A676HX(;AHY$C$$CE=Y8XX(!Y R?PKJJ\>^+W_%2^,_!_@E&)2YN?M=
MTJGD1C(S_P!\B6@#L?[<\6'1M.U!-'TYWNO(,EJ+EQ)$LA4$_<P=N[GIT-=A
M7/:;HJ^'KS5]5NM3NKJ*5$*FZDWF"*-22!P,#)8UX);ZU/#\,]2FLBPU?Q;J
M_E1"-^8(=Y"K[9(D4#T)]* /IRJ6JZO8Z)8/>ZA.L,*D*">K,> JCNQ/  KR
MKQ)9"]\?^!/"VFW#%+&Q:YDN8VR?+"A4?/<@H6!.>2*S-5\':./B3X3\'(\U
MS9V$4VH7DEU,69@\A*(3P/OX'J=PZT >BZKXOO+/XD:-X4M+."5;V!KF>9I#
MNAC7=_#C')7 YKL*^?=1N_MNL_$7Q69&BTW3;7^R+5HW*EF&%"*1R%WA2<'H
M<=":OKJ>I>'O /@+PC874RWFMN1<7$4@$D49<,\:,2 K_O-O7C:>] 'N=%>(
M^*])/A/P?XSUJ:6WCO=4\BSAT^TD++;#A5R>"9"N6)Q^><UU.AZ)HWP^M[/Q
M!KNL26T\MC#IQ2YE_<QXY"J,=?EY/?#-W- 'HM<'JOCC5+?XEVW@[3=/L[EY
MK4W+7$DS((1AN& 4_P!T=/[PKNP00"#D'H:\3\"V-UXU\>^,_%5OJEQ8QM-_
M9]M/ B,QC& <;P0#M2,Y'K0!WG@'QVOC6/4XI+'['>Z9<>1<1K+YB$\@%6P,
MCY3VKL:\:U_2].\%R>'O FB3RV<&MW33:G?238EDA0 N"_&"PR.,8Q[FL_P_
MJ-BC_$7Q9"JQZ=:P26.G6WW5"HOS;4[ L8S]7]Z /=:Q+K7_ +3I>L2>'XTU
M.^T_=$(5?:C3!0WE[NF1D9^N.M>3:9X:M]#^$]KXNU6YO#<VNE3M#:F4B,F<
M?*6'4DL^<YZ$#^$5BW>@6NF_#3P=X<@"1:IXAO(Y;R<-ADCQN;/IM61,^P-
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M%XQPV<@8)&/2K4VM6$.M6VCF=6O[A&D6!>65%'+MZ#.!D]2?K5_<,D9&1U%
M#)X8KF"2"9%DBD4HZ,,AE(P0:P!X"\*#3K73_P"PK+[):S>?#%LX$G]X^I^N
M>@]*Z(LJ]6 XSR>U!(&<D<<F@"DFC:;'K+:NMG$-1:'R#<;?G\O(.W/ID"HG
M\.Z/)KRZX^GP-JBQB(7)7+!1T'I^/6M/K7&:5XOOM3^)FL^'%@M1IVEP(SW(
M+;S*^TJG7'0M^5 &R/"/A\:-<:.-(M?[/N9/-FM]GRN^0=Q]\@<^U&J>$/#V
MLV-I97^DVTMM9_\ 'M&%VB'_ '=N,#@=/05LDA1DD >IH) !)( '4F@#*F\+
MZ'/IMOITNEVS6=O*)HH2GRK(,X;'KR>?>JOB[PM;>,-,BTJ_2(V7G+-(Q!,@
MVG(">A(R"W8$C'.1IZI/>0Z/=SZ9!'=7J0LUO"[[5D?'R@GL":BT.[U"YT.Q
MGUFVBL]1EC!F@CD#*K^@.3G\S]30!<FM8;BU:VD4^2R[2JL5X],CFJ&B^&]'
M\.QR1Z/8164<AW.D.0K'UQG&>!S6J#D9%% &7JGAS1M;N[.ZU/3K>[GLG+V[
MRKGRR<=/R'7TJK%X*\-0:?>V$>C6BVM])YEU'LXE;.X;O7!YQT%4_B'XJF\&
M>$;C6X$@EDA=%6&8']X68# (/! )/?I52[\<2Z!\/[;Q'KUO$+R[CC,%A;9#
M-(XRL8)SD^IQQ@\''(!TU_HNFZIH[Z1>V<4VGNBH;=A\NU<$#CIC _*J<OA#
MP].=.,ND6K?V;G[("G$6<9P._0'GOS3M$F\0R7%PNM6ME%$(XFA>V<DER#O4
M@D_=. &XSZ"N7N/&NN3?$^Y\':7;:?*(+7[3)<3;QY? (5@"?[R\_P"UTH Z
M2^\&>&]3U@:M>Z-:SWX 4S.G+ =-PZ-^.:CUW0K032Z_8Z)#>>((+8Q6C_*K
M \[1EB  ">O7'2L[X<^.U\>:+<W;V7V2XM)S!,BR;T)P"&5L#@YKL00P!!!!
MY!% 'GOPV\!QZ+X1LH-=TT_VI'</<S":42H92QVR !BN0N!NQGBNMOO#&B:G
MJ\&JWVF6UQ?6Z&.*>1,LJG/'ZGZ9-:F]/[R]^_IUKGKWQ'-?>&=3O_"D4.IW
M=J[0PJ[A8I74C=AL@$#)YR,E2,]Z 'Q>!_#$.CII":):#3TF$X@V97S!T8^I
MY[U?DT'29=;CUJ33[=]3CC\I+ID!=5YX!_$_G4]C-<OI=M-J$26]TT*-/&K[
MEC<@;E![@'(S6;XJOM>L-*BF\.Z;;ZA>-<(CQ3S"-1&?O-DD<]/SSSC% %G2
M_#NCZ)<7=QINGP6TUW(99W1>78G)/_UAQ1?^'='U34[/4K[3K>XO++)MY9%R
M8^_'XC(].U:)=5^\P'&>3VI20 22 !SDT 8L'@_P];0:C##I%LD>I,6O %_U
MQ)R=WMR>.G-23^%M!N8=.AGTFTDCTW'V-'C!$& !\H_ ?D*UZ0.IQA@<].>M
M &->>$/#VH:G<:E=Z1:S7EQ ;:69TRS1D;2/RXSUQQ4=QX)\-76A0Z)-HUJV
MFP-OB@VX"-Z@CG/)YSFKSZU8)KD6C"=7U"2)I_)3DI&,#<WH,D 9ZY^M:% &
M,_A309-%.COI5LVG,P=K<K\K,.A;U/ Y/I5S4-)L=4MXH+VW66.*198QDC8Z
M_=88Z$9X]*YJX\77Q^*5EX4LX+66U:R-[=3Y8O&O( &#CEMOX&NQW+NVY&[&
M<9YQ0!CW/A30KS2[G3;K38IK6ZD$LZR$L97&,,S$[B>!R3T&*+CPGX?NYM.E
MN-(M)'T[_CT+1_ZKOP/J >>_-;#,J+N8@#U)H+*I + $] 3UH P8O!'AB#2[
MK3(]%M%LKN02SP[.)&!R"?7!Z#M5R;P[HUSJ-EJ$VFVTEW8KLMI6C!:(>B^G
MMZ5I@Y&1TI"ZC.6 P,GGH* ,&Z\$>&;VXU"XN=%M))M14)=R%.90"",GMRH/
M&.0*G_X171!Y/EV"0^3!]FC,#-'MBSDI\I'!)R1W[UL4QYHHX6F>1%B4%F<L
M H ZDGTH ;;6T%E:Q6MK#'#!$H2..-0JHHZ  =!6/%X+\-P65]9Q:/:K;W[[
M[J,+Q*<YY]LCITK0TG5K/6].CU"PD\VUD9A')C <*Q7(]B0<'N.:N,RJ,LP&
M3CDT 9<_AK1+J73I9]+M9'TT;;,O&#Y P -OIT'Y57O/!GAO4+^\O[O1[6:[
MO8?(N)F7YG3 &,]N !D<\"MPL%!+$ #J31D8SD8]: ,.3P7X;EMM.MWT:T,.
MFDFTCV?+$3UP.^<#.<YK5OK&UU*QFLKR!)K:92DD3CAE]#4X93C# Y&1SVI-
MZ[BNX9'49Z4 94_A;0;J'3H9])M)8M-Q]C1XP1#@ ?*/P'Y"HM3\&^'=9U1-
M3U#2+:XO478)G!R5]#CAA]<UMEE7&X@9.!D]302 0"1D]!ZT (B+&BHBA44
M*JC  ]!65:^%M#LKO[3;Z;"DGG-<*,$JDK<,ZJ>%8^H -:%U>VMC9RWEU<10
MVT2EWED8!5 [DTW3K^'5--MK^VW&"YC66(NNTE6&0<=LC!H B31].CUF36$L
MXAJ,D0A>YQ\YCR#MSZ9 JQ>6EO?V<UG=1++;SH8Y8VZ.I&"#[$5-2!E)(!!(
MZ@'I0!F0^'-)MQ+LLU)E@^S,79G/D_\ /,%B2%Y^Z,"H9?"/AZ?2;32I='LW
MT^TD\R"W:,%(VY.0/Q/YUL[ESC<,YQC-0WTES%I]S)9PK-=)$S0Q.VT.X!V@
MGL"<#- &7J_A#P_KUU;76IZ5;W%Q;+MAD((95],@CCVZ<UKP00VMO'!;Q)%#
M&H5(XU"JH'0 #H*X^]\;77ASX?V^N>)M/C@U:7]VNGVTH;S)2Q"(IR>HP3UQ
MSUQ6WHDWB&2XN%UJULHHA'$T+VSDDL0=ZD$G[IP >,^@H C3P9X<CBU"--'M
M534)/-NP%_UK;MV3^(SCI6A9:38Z=+--;0;9I]HEE=F=W"C"@LQ)('89XS7%
MW'C77)OB?<^#M+M=/E$%K]IDN)MX\O(!"L 3_>7G_:Z5?^'/CM?'FBW-VUE]
MDN+2<P3(LF]"< AE; X.: ,B+PQJNK_%^[U_6-,GBTN&Q^R:?(MTJLISEF.Q
M]PSEQ]&YKM)_#6BW.AC19=,MFTP8Q:[ (^#D<#WY^M:@(8 @@@\@BDWI_>7O
MW].M %>^TVRU/3I=/O;6*>SE38\,BY4CTQ4>GZ-I^E%VL[98Y) JO*26=PHP
MH+,22 . ">*RKWQ'-?>&=3O_  G%#J=W:NT,*NX6*5U(W8;(! R><@$J1FMJ
MQFN'TRVFOXDM[IH4:>-7W+&Y W*#W .1F@ @T^TMKRZNX;>-+FZ*M/*%^:0J
MH5<GV P*HP>%M"MKS4;N+2K9;C4@5O'V9,P/4'/8]QWJ+Q3?:]8:=;R^'=-M
M]0NGN8TDCGF$86(YW,"2.>GY]#TK:+JN=S 8&>3VH Y^W\!>%;46 AT*S06#
MM);?)]QFQEO<\#DYZ"K4?A308KS4KM-+MUN-24I>2!>9E(P0?8]\=:UR0H))
M  ZDTM &++X1\/3Z99Z;-H]G)8V3^9;P-&"D;<\@?B:X?7/A\/$NI:I-XGT6
M?4)_-*Z;=Z?<1P^3;_P(0S*=P).2P8<\>E>HAU.,,#GISUJ@VM6 UV/11.KZ
M@T+3F%.2D8(&YO0$D 9Z_@: ,[P-HVI>'_!NG:7J][]LOH$(DEW%NK$A03R0
MH(&?:K2>%M#CU*^U%-,MQ>7Z[+F;;\T@QC!]./2J7CSQ,_A#P=?:W%'%));[
M0D<I(#EF"@<?7]*U=&N;NZT*PNM2CCAO)H$>:-,A4=@"5&3G@G% %27PAX>F
MT>UTB71[-].M9/-@MFC!1&R3D#_@1_,TFK^$/#^O7-M<:GI5O<3VPVPR$%60
M>F01Q[=*T-3U.RT?3IK_ %&YCMK6%=TDLAP /ZGV[U-;W"7%I%<@,B21B0!Q
M@@$9Y]#0 MO;PVEO';V\20PQJ%2.-0JJ!V '2L9O!?AM]<?6FT:T.HN0S3%/
MO,.C$="??&:W-RX!W#!Z'/6@$$9!!'M0!E7OAC1=1OWO;O3XI;B2(0RL<CS8
MP<A7 .'&>S9J:]T/2]1ELI+RQ@F>QD$MJ67_ %+#&"OH1@5>+J&VEANQG&><
M4K,J#+, /4F@#,_X1S1O[3N]3&FVXOKR/RI[@)AW3&,$]>@ _ 4MCX=TG39H
M9;2S2-X(S% 2S-Y*'&50$G8#@<+CH/2M(D $DX [FN1^(OB^Y\'>&8]2L((+
MJYFN8[>&&4G$C-G&,?0F@#1T[P5X:TG4GU"PT:U@NG<N75>C'J0.BGD] *L+
MX9T1(M2B73+?9JC%KT;?]>3G);UZG\ZTH/-^SQFXV>=L'F;/N[L<XSVS3U97
M&58$>H.: ,2?P=X=N=.LM.ET>T:SL9!);0A,+&P[@#_)[U)-X6T2XGN)9=/C
M8W)3SUW,$EV !0Z9VL %& 1CBK&KZU8:':I<7\ZQB218HDZM+(QPJ*.Y)-7V
M95&6('..30 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7G_ ,9M5DT[X=7=K;9-WJDB6$*CJQ<_,/Q4,/QK
MT"J=]I6GZE);27UE!<O:RB: RQAO+<=&7/0^] 'C.E:+%:_&7PSHYN"7T#20
MUP1(=ID9=JQJ.F,,K<#)^8FH[ 7_ ,5-*U^_O;JVMK*XOA9127+Y^Q6ZE3B*
M/H97R 6)'MZ5[0FC:9'J\NK)I]LNHRH(WNA$/,91T!;KC@?D*IV?A#PYI^JR
M:I::+8PWSL7:=(0&W'J1Z$Y/(]: /,/^$=MO%?Q=UG25>>/3=*T>'3IIHGQ(
MVX9QN_O$<$]PI'>F6WVW6_%&M>&K!X!I7AFQCL+6*_FQ$KE=IN)!C]X5"G Q
M@<=,YKV"TTK3["YNKFTLH()[M]]Q)&@5I6YY8CJ>3^=4;CPAX<N]9_M>YT6Q
MEU#@FX>$%B1T)]2,#GV% 'DTFA:?;^//A_X1@N!<VNBVS:A/<OC,A9\QCZ&3
M&%]'%9>HS1WNK_$OQBQ\O3[6(Z9!Y3%#-+\J8R.<%PC''7('0D'W=M"TE];7
M6FTZV;4UC\M;HQ@R!?0'\34(\+Z"-)GTH:/9#3YY/-EMA"NQWR#N(Q@G@<^P
MH QOA=IPTKX:Z':>9YCB NYSG:[L69?^ EB/PKDI]?\ [5^('BJ^UA@=!\)V
MN([1_N23LI^=@>&/#!<],C'->L0016T$<$$210QJ%2.-0JJ!T  Z"L^;PYHU
MQJ$E]-IML]S+L,KL@/F%/N%AT8KV)Y':@#P2]L=6'P<\)^%;I"=3US4LV\4O
M!A@SGZJ/F4^P8UUGA"RMYOCIK$D-PS1Z181V.2Y_>2D G"YX50&&!P,#\?5[
MC2=/N]0MK^XLH);RUS]GG>,%XL]=I[9IMIHVF6%]=7MII]M!=W;;KB:.(*\I
M_P!HCDT <?\ %SQ)>:!X2AATZ?[->:I=QV,=SG'DALEGSV.!C/;.>U<MX5M-
M)OOC4R:9L73?#VG+;0L",3W#@YD_VF*[\MU.W->L:MHFF:]:+:ZM86][;JXD
M6.= P##H<'ZG\Z99^']'T[4KC4;/3;6"]N %EGCC =@,8&?3@<>U '%?&R[(
M\"+I,"*]YJUY#9VZD9(8MG(_ 8_X%7/66B6.B?&."320\>F^'="VZI-N)#'8
MP56)/7;M;'HOM72>*_#6K>)/B-X<N9].,GA_2R[R-YR!GE8<,%SG"D(<]>N!
MZ]O;Z1IUK9S6<-E"EO.6,R;,B4M]XO\ WB>Y.<T ?-=OJ;Q_"VZBLMBZKXOU
MC8WEL ((M_RKQTY5@!_=;MQGO_$>G0ZG\2_!/AC3FQ#ING/<-/&?F6+;L1MW
MJ-N5/8L#7HO_  AGAG[#:67]A6'V6TD\Z"(P#:C]VQZ_6M%-*T^/59-42R@7
M4)(_*>Y"#S&3@[2W7' X]J /(Y;9],\;Z5\.=%$DFE6-M)J,\-U<[/M<C,S*
MCOC)0$@D '.#D'%97B+08-,T/0/!ZZC#<OX@UJ2_U&:'Y84C0CS @[(/_9#T
MZ#V75O"GA_7;R&[U71[.\N(1M22:(,0.N/<<G@\<TFK^'["[2*]CTFPN-3L(
MF_LXW$8VQOCY1QT&0.G3M0!YWK\EKHOQYTV0JRV]]HDD<L49.93E\*!_>.U
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M-I_VJ[*R':KMPL:CI]_!)ZG>3TP![&OA70$TVUTX:/9?8[60300&%2L;C/S
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M[>"YN5!Y$8^7/Y>8?PI?B%I=CXD^+W@S0'M(I!#&]U=97.85)*H?]DE&&/\
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M7 R3DGZDDDGN: /)_%FGZ;XJ^.FB:5=P02VVF6+7%YY@&'+G;&ASU^8H0/\
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M8&%'H ".1FMNQ\ V,NH:Q=W4EFTG]E?V=%8VS&188CEM\CD O(S?-D@8]^M
M'I7G1'9B1/G^Y\P^;Z>M(\\4<B1O*BN_"*S %OH.]>&^ HSJ'PY\.ZW-;3.?
M"R7MV)3E?-QOVQ+ZCH2>VT#N<9EXFHZU\,=,9G:\\5^+=3$R2?QQ1QN<%3_
MB  \=-YH ]4\;>+-2T'7?#6DZ5':2W&KW1A<3HQ,<:[=SC##H#WKM%=7^ZP/
MT-?/_CO6]6'C_7-:TI(KD>%-,CMO-EY"2S$*SA<8+8=^#Q\O?&#M>)=;LHM/
M\'>'/"HAL=.UZ8-<2PR>5OC&TM'Y@&=S%L%N3D8]10![''/%*SK'*CLAPP5@
M2I]#Z4Z1MD3L650 3N;H/<UQW@KPQ!I.KZYJYN+5[V^DCCD@LAB"U2-<)&O
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M3FN-4:8:M*\4X\RYG4$[7'4JGW=HP!C%<--J%YX@^%NK:[>HUYKWB>_6QTZ
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MO>GXT 5CX?T8Z.=(_LJR_LT\&T$"B+KG[N,=>:;;>'=$L]+DTNWTBQBL)/\
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M!A410JJ/0 =*BL].L=.\[[%9V]MY\AEE\F()YCGJS8')/J:#J%DHF+7EN!
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M..< '0:KX<T37'A;5=)LKUH?]6;B!7*>PR.GM6E'%'#$D42*D: *J*,!0.@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N0^*&NCP]\.=9O ^V:2 V\//.^3Y1CW )/X5U]4[[2=-U0(-0T^TN]
MGW?M$*R;?ID&@#YZM]#7PQ<_#>TUDM<Z!J:;[FRG<F$7+\ARO3CS8QSQ\I]Z
M[?Q1J]UJ/Q;L?#"O9PZ=IUE]M$%W*8H;B;^#=@'<$R&"\<J>:]+ET/2)[2*T
MFTNQDMH3F*%[="B?[JD8'X4R\\/:+J$L$M[I%A<R6ZA86FMD<Q@= I(X'TH
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MV@D,)>&-C VZ+*@^6<$97T."1QV)H \7\;"Y\.&*"T8Z7)XRUE6NW,OE^1"
MBE2XSM9MQ9B.F6'.*=XJTRP\.^#_ !AKYN+.>]O+6/2XK:S&8+6,X18U/\3
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M2+(.,$\X!.<9Q0!XY>1'5/&GCZ'3K^PU'5-0A72[03W*1FU!4K,FQCN(''*
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M?FDSZ@%S]=F*O_$/PSX?TS5O#7AFT@6)-5U0W]_-,Y=BB* _S-D_,,G ZD4
M>A7OB#4M0N?#3:!=:4D5Y(LM[;W<P\_R2H;" 'E@-V<9Y [9KII]0LK6=(+B
M\MXII,;(Y)55FR<# )YYXKR*UN[2X^-7B#4;:WB*^'-)-M9VT28+2;68X Z
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M5WWAKR6\-V$\%E]B2YB%T;;_ )Y-+^\9?^^F- %ZZO;2QC$EW=0VZ$X#2R!
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MDD ]JO-1LM/56O;RWME;A3-*J _3)K-\1>+-'\,6<<^HW<:O,P2" .-\S$X
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M.*56,FYMNX<XVCJ6Z#'X5';ZCJUSX[FMH;S29=#BM 6CCEW7*3;NX!X'7_\
M77FUMHN@+\;+/18K:WCTSPWIF%BE&\R3/EN<\MA7W<]-I-86E^(;BR^'7COQ
MIIK;-2U74-J-&.;>$OM5L]C\[X^@- 'T -2L6NFM1>VYN$!+1"5=XQUR,YK
MTC6K]]:UR;4M2T4Z'"Z+9203@NG'S"0YP#TK MX_".F^'+#6[*ZCO)O#VERW
M$0AG+*2\?S.X!QO<Y^]R<GTX\UCC6+X&:7HMO(CZGXIU=!*0.A9P<Y]@L8..
MF[% 'T-;ZKIUW.(+;4+6:8QB41QS*S%#T; /0Y'/3FBXU;3;29XKG4+2&1%#
MNDDRJ54G )!/ SWKQVZL;?2/B+J6O>'[&---\*:$\,K1KA9KD(Q"$C[Q 8;C
MU&WGM7*K=V&M:)X*T6XNEN;C6-4;5-8NW.2S+G,>>[;#C;ZA<#F@#Z/;4;%+
MN.T>\MUN9?\ 5PF50[\9X7.3QS4,FN:3%ITVH/J5F+*$D27'G+L4CJ"V<9]J
M\?U62#5_BOXJU^<*VF>%]*,#J!CSG*LQ3/N=ZGU''0US7EP:?^SS8:?%Y+7N
MOZJH+%1MB=CG(/081%4XZ;B.QH ^@?#^NV?B31XM4T]BUK,S!"W4@,0#CMG&
M<'G!&<5R'Q!\8:UH/B7PUHVA-:/<:O.8G2XA+^6H91OX8?WC_P!\FNQT*PL=
M,T.RM--1%M(X5$91=H88'S?4]<UXWJ5M<>//C-XA;3[N6)M!TIX+*:"4JRW!
M! ((/]YW!_W: .T\*^-]5U#XCZ[X0U&.TN!IT8ECOK6-HP?N?*REFY^?L?X3
M7;R:G80WL=E+?6R7<GW(&E4._P!%SDUXSX(\2Q:3\!]6UW3K6(:Y:^9'=RA,
MR23%OEDD)Y; <'GT-6O"FEZ5<:5X?US5M:MIUTRW?5Y8;=S-++.R[GFG?J-N
M-H7'48R>E 'K(U?3#=FT&HVGVD-L,/GKO#>FW.<\]*S;?QEH5WKUUI%M?P2S
M6</FW,BR+LBR<!2<]>N<=,<]:\X\,V\_A3QQ>Z%J!34M D27Q!87@^9H>N23
M[@D>_!'4URFFSV=E\$?%&O\ D6_]IZ[=O&B(@S&DC[1&,#CA7;'T]J /H1=8
MTQUW)J5FP,7G B=2-F<;NOW<\9Z9K)\(7^L7'AU[SQ%=:5)+YTA6;3Y-T/E
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M !1110 56NM/LKXJ;NSM[@K]WS8E?'TR*LU%<NL5K-(\ODJJ%C)Q\@ Z\^E
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M(]#5.QT;2]+=WT_3;.T9_OM;P+&6^N ,TZ?5]-M3;"XU"UB-T56W#S*OFD]
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MN5N;C3[2:=<;99(59ACI@D9KG['6KN;Q?JTKZYH<OARVMH\)%.IF@E)ZR'H
M</U/IZ&MN/Q!HTJVC1ZM8NMXY2V*W"$3,#@A.?F(/'% %JXL;2[>%[FU@F>!
MM\321AC&WJN>A]Q45SI.FWEW%=76GVD]S%_JYI859T^A(R*N52O-7TW3I%CO
MM0M+9V4NJS3*A*CJ<$]/>@"[5>&PL[:>>:"T@BEG.Z9XXPK2'U8CK^-0-K>D
MI-;0MJ=D);H*;>,SKNF#="HSEL^U6(+VTN9IH8+J&66 [9DCD#-&?1@.G0]:
M &6>FV&G[OL5E;6V_P"]Y,2IN[\X'N:H>*=,U'5_#]Q9:7J!L;MRI64$C(#
ME21RH8 C(Y&:O1:KIT]V;2&_MI+D;LQ)*I<;>O .>,C/IFN&\->-KF^\4>*I
M-6U.RM] TRZ6RMI) L0:7)W98GDC&.O.: &CX8V<GBG1=:M]*TW1'T^;SI3I
M\SL9\#A"-B #/4\DCCO7H,5K;P2RRQ011R2G,CH@!<^Y[U+U&14=Q<06EO)<
M7,T<,,8W/)(P55'J2>!0!7ETG39Y+B2;3[61[E D[/"I,JCH&)'S#V-2"PLP
M8"+2 &W&(2(Q^['HO''X57CU[1YA+Y>JV+^4@>3;<(=BGH3SP#ZFK$5_9S16
M\L5U!)'<\0.L@(EX+?*?XN 3QV!H <MG;))-(EO"KS_ZU@@!DXQ\Q[\>M):6
M=K86ZV]G;0VT"](X8PBC\!Q44>K:=+8R7T=_:O:1%A).LRF-"IPV6S@8[U'%
MKND3^;Y6JV+^4@DDVW"'8AZ,>>![F@"2XTG3;N8S7.GVDTIZO)"K,?Q(JVJJ
MB!%4*H&  , "J5KK6E7TD,=IJ5G</-&TL2Q3JQ=%.TLH!Y /&1WKC/B+XVGT
MJRL;/PSJ-E)K-WJ,=B(OEE*%LYR >,''7UH [-=$TE$B1-,LE2&0RQ*+= $<
M]67C@^XYJREK;QW$EPD$2S2X\R14 9\=,GJ:IMKFDP7(LYM6LA=*RQF-YT#[
MST&W/4]A6C0!76PLTO9+U;2!;J10CSB,!V4= 6ZD4V'3+"WLGLH;&VCM7SN@
M2)0C9ZY4#!S5JB@"I!I>GVMD]E;V%K%:."&@CA58V!ZY4#!S7$ZSX'O]5\?Z
M!J#6NDCPYI$;I'9%V!+.""VSR]O'RX7/\/6JGQ%\3^)_"6D:IKL=[96]HD\=
MOI]H]MO>4G&YF;<,#AR !T JV=3\7Z1H#ZYK&H61M4T:2[EC6TVM#<A5*I][
MY@<L.W(]Z .[BL[6"U^RPVT,=O@CRD0!,'J,#BH(]'TR$VQBTZT0VH(MRL"C
MR0>NSCY<^U<YX"\1W&J>&-(DU[4+3^VM1A:Z2V4JC&(DE2J9R1MP<UT>H:QI
MFDJK:CJ-I9JWW3<3+'GG'<^I% $JV-FJSJMI %N,F8",?O,]=WKU/6F2Z7I\
M]O#;S6-M)#"P:*-X5*QD="H(P"/:HIM=TBVGE@GU6RBEBC,TD;W"!D08RQ!/
M Y'/O4MSJFGV=FMY<WUM#:L-RS22JJ$8SD,3@\<T 6F574JP#*1@@C((JI;Z
M3IMI,)K;3[2&4='CA56'X@5S'C?XB:9X4\.)?6UQ:WEY=A180K,I$I;HY(/W
M!U)Z=L\U?TR[O],$EUXAU[39;&:*)K>0;8OGVDR8/0J>"O).!R: -F/2]/A\
MWRK"UC\Y2LFV%1O!Z@\<CZTEMI&F65K):VNG6D%O+GS(HH%5'SUR ,&FS:WI
M5M:0W<^IV<5M/CRIGG4))GIM).#^%2P:A970N#;W<$HMW,<YCD#>4X&2K8Z$
M9Z&@!+?3+"S$@M;&V@$@PXBB5=P]\#GJ::FDZ;%:):1Z?:);1MO2%85"*WJ%
MQ@&BQU;3=4:9=/U"UNS"0LH@F5]A/0'!XJY0!!=V5K?P>1>6T-S%D-Y<T8=<
MCH<&H[W2]/U%8UOK&UNEB.8Q/"KA#ZC(XK,\:ZP_A_P9JNK13"*6UMVDC9E#
M OT52#V+$#\:\SN/B1XLT+PSX2UW46L;MM:EVR6"VY1_+)^5HV#==I7J#RPH
M ]BGT^RNF@-Q:6\Q@;="9(PWEGU7(X/TJ.XTG3;N[CN[G3[2:YB_U<TD*LZ?
M1B,BDN]8TNPF$-YJ-I;RE#)LFG5#M'5L$].#S36UO25DMXVU.R#W*;X%,ZYE
M7&<J,_,,#.1VH L2V5K/<PW,MM#)<0Y\J5XP6CSUVGJ,^U%I96EA!Y%G:PVT
M62WEPQA%R>IP*P-7\?\ AO2(K)GU6TG>^D2.V2&=6W[FV[LYP$'.6/'![\4V
MUU+4KWQ[-#:ZMH\^B0VG[RUBD#7,<V[JP'0?7\J -N[T?3+\L;S3K.Y+XW&:
M!7W8Z9R*?;Z986MDUE;V-M#:,"&@CB54(/4%0,<TU=7TUKMK5=0M3<+NW1"9
M=PVC)XSG@=?2N=TC7K@ZOKMYJ.OZ#+H$<D:6;07"[H3CYA(V< ].,_E0!T9T
MK3CIXT\V%J;(# MC"OECG/W<8ZU/!!#;0K#;Q1Q1+]U(U"J/H!5.TUW2+^Z%
MK9ZI97%PT0F$44ZLYC."&P#G:<CGWHNM>T>QFEAN]5L;>2)0TB37"(4!Z$@G
M@&@"6STK3M/>5[*PM;9I3F1H850N?? YI1IM@MK]E%E;"WW!O*$2[,YSG&,9
MS3'U?3([^.P?4;1;R492W,RB1AC/"YR> 3]*@D\2Z'%I4VJ-J]C]@A8I)<+.
MI16'5<@]?;K0!J45E>'/$%GXGT2'5K YMIF8)DC. Q ) Z9 !P>1GFM6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KD_B=/>6_PT\0/81O)<&T9,(,D(Q"N?P4L?PKK** /-_AWJVCZ+\*=&AL+
MNWN;MK;*VL<@,DEP^6*;>N=Q(/H!D\"L7XF:?)=67@OP!!*KW%]=*]Q(1G*Q
MKEW(]RS-^!KUBWTRPM)GFMK&VAE?[[QQ*K-]2!S4YAB:596C0R*,*Y49'T-
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M=V3VP/:O7H+*UM7D>WMH87D.7:.,*6/J<=:46ELLTLPMXA+, )'"#+@=B>]
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MX[*UBM?LT=M"EO\ \\EC 3\NE/,$),9,49,7^K^4?)QCCTH =&%6-0J[5
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MGD^^T<84M]<=:D@MX;6%8;>*.*)?NI&H51] * )**** /&?BI<0^)?B1X/\
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MT.]TZU\4?&BQT>.+_B5:)HH$J$%2!)@;/491E!![;J]673K%5C5;*W"QOYB
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MM7J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWBM-8L9WN6=(%BG5C*4&6"X/S8'7'2H/&&KC0/!VL:INPUM:2/'_ +^,*/\
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M/\!WL^J^#K#5KRR6TOK^,3W**NW>^-N_';<%4_C0!T,LL<$3RS2+'&@+,[G
M4#J23TJE;:[I-XMPUOJ=I*ML TY69?W:D9!;G@$<@]"*X#XGO<:CXM\&^')G
M,6C7MV\UZ6.$F\H!A&Q]#@\=\CTKGKB\NH9/B%\0R'AT^:R_L_3"PP)\;8Q*
M!W7< 0>^30!Z[:>(]$U"6WBL]6LKB2Y#F!8IU8RA#ABN#R 0<D>E:=<#\./
M^G:1X<T#4KFS0ZS%9#$Q)S$L@!* =._YEC_$:V?B#KG_  CG@+6=35]LL=LR
M1'TD?Y%_5A0!S?@3QS+J1UK4=>UJUCTQ]4:QTD3>7#Y@4]0>"Q.Y?RKT&]O[
M/3H/.O;J&WBS@/*X4$^@SWKYZ?PW!IR_#3PQ>1[KB>0ZC=GR\L%'SB)>_.6!
M]3CMC&_<ZHVL_%CQ1;:KK<&DM96ZV.G+<+N=4D'[QX5R,R,,8/)PPX- 'K*^
M)M">.RD76+!EOCMM"+A?WYSC"<_-SQQ5RPU&RU2U%UI]W!=6Y8J)89 ZY!P1
MD>AKQ^]T"QG^(G@WP7IL4B:7H^G2WDZN3OVR<'=Z,3UZ8+Y%>M:/HNG>'].7
M3]*M$M;169UB3. 6))Z^YH LW5W;6-NUQ=W$4$*XS)*X51Z<FHX-3L;JUEN8
M;N%X(BRRR!QB,KU#>A'?->:>)==MH/C?H]IX@NH[/1[.P:YM#<,$B>Y)(W$G
MC(&<9Z$<<FL_QCIUBNK>%/#^F0O::!KNJ2WVHNY<"Y==K88OSA@#@=#\N.E
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MM/< =3TH Y'4?A=!K>F:?8W]II4$UJ\9DU.T1A<3!>O49!;N2S=2>3S7I%8
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MDM'HK6=K?(0T$D\&]$.1NX'J,C/O3[37M*O[I;:TOX)I65G0(V1(JG#%3T8
MD XS@GFF2^)-%AU.+39-3MEO)9#$D7F#)<#.S_>P1QUY% '.V7A#5M(O+[5]
M/O[-M8U.^6>^>>)BA@4$+"F#D8&/F[^W;6\'^%8/"6C/:),US<W$SW-W<LNT
MS2N<LV.PZ #VJW'XET6:Z6VCU*!Y6F-NH5LAI1U0'H6'<#D=ZU: (X[>&%G:
M*&-&<Y8JH!8^_K0((1.9A$@E(P9-HW$>F:H7_B+1M,F:*]U*V@=-N\.X'E[C
MA2Y_A!/ )QFN5^(WQ$MO"<-MIMG=6@UJ^E2./SV^2V1C@S2?[(]^OT!H [I8
MHUD:18U#OC<P')QTR:<0&&& (/8UE:+9:I9O=F_U<ZC#(R-;%H51HUV -DJ
M#ELGIQFN,^)/B76],\3>%M$\/ZBUO=:K<&.9?)CD"Q J"_S*2#R?;Y3Q0!Z.
ML<:'*HJGU Q0\4<A4NBL4.Y=PS@^HKS?POXOU>;XK:[X1N;I=2T^Q@$J7AB5
M'C;"91R@"GEB.@Y7ZUV4'BO0+FZM[6'5[.2>Y9D@1903*5Z[/[P&#R..#Z4
M:JPQ('"Q( YW-A1\Q]3ZTK(CQF-D5D(P5(R"/3%8W_"8>'/,>,:W8EDN%M6Q
M,#B9LX3/][@\>U9=K\2_#-]KU[IEMJEJT5E;F>XNVF58E.X#"D_>QU)' X'.
M> #JS!$1&#$A$9R@VCY?IZ4/!#)(DCQ(SI]QF4$K]#VKE_!^I747A%M3\0>(
M]/U&-II'2_A BB$6[ &< <$'GWQSU-S5O$NF)H&I3PZY9V$L2M")[H[1!,RY
M3<K8/<'&.10!K7\4[VTKV20?;@A6&28<*3W) )QWQWQ7,?#OP9)X-\/"PO6M
MKF\\^29KN,'<Y<\DY&1P .O:IM'\2VFDZ'I%MXE\2Z;-JMQ )/.#",3*<D.%
MXPNW'. .,\5LZ;K^D:QITFH:=J5M<V<999)XY 40J,G)[8'/TH T&BC:19&1
M2Z9VL1RN>N#35@A2/RTB14SG:% &?I69:>*="OKJ*UM=5M9;B5#+'&L@W,@&
M=P']W'.>A%5V\;^%ULI[TZ_I_P!E@E$,DPG!0.>=N>A..PH WMJ[@VT;@, X
MYIJ11QL[)&JLYRQ P6/J?6N8\3?$'0/#$]I:75["][=R1I% ) ,*Q \QST5
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M+*9;1XX+SRG6VN&C#^2Y7 ;!ZX...^*@G\0:3;"U,E_#_I<9EMPIW&5 ,EE
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MBECGA2:&19(I%#(Z'(8'D$$=13Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O,OC=?_ /%)V.@1S+%+K=_%:[F.
M J!@S,3Z [<_6O3:XO6?!^H:Q\0M%\0RWEJ;'2E<16;1L2Q<$,Y;.,],#'\(
MH XV\LB?&]YXFT"T7^R_"FARVUJ\:?)<7 1_D3'W@H;!QW&*XNUN[75?#O@3
M0G$TRZGJDFI:I<O&Q:XE5CN0<9<[6VY'&<#UQ],@     #H!2!%&W"@;>G'2
M@#R>STJ#QK\9O$\VH6ZW&E:;:1:?Y<@^60GYBI]0&#'ZA:I:+=V,'Q7\5ZF(
M-MMX:TM;&RMD4G9&B%F('8?(P!_VQZU[/2!0"2 ,GK[T ?-T5S>6/P%>_B:?
M=K>K^9JUS$IRD3LP;G_@"@]OGQZUZ'XKU/PS;>"=6\4Z!#'/<VFE?V?;7D"M
MLCC<A553]W@MDXY'0XKT[:NS9M&W&,8XQ1M79LVC;C&,<4 ?/U[;V7_"*_#7
MP3YB);WDZWMZTA"JRK\S<GJ"7< ]]HQVJYJS7]M=>._B%I$#0VBV":;ILB+M
M\T9C1YE_V5VY#="![5Z%'X.OY/B>WBV]N[6:W6S-G!:^6V8ESG=NZ$YW=OXO
M:NS(!!! (/&* /GW1WT_4/%OPWT*WBD^P:=8_P!HEVB8-<3OU8 C.!(N<G_:
M/3!JSI6M7;6GQ/\ &-@LCZHTK6UL%0EH(H\*&/H=K X_Z9GT->\[5!S@9QC.
M.U 4+G  R<G% 'D7PYT?0]8L?#-S_:@U*7383<+;V\1"07,@W223L2=TF[@9
M(]0.]>K:A>)I^FW5[(K,EO"\K!1R0H)./RJ=55%VJH4>@&*6@#YSL=1EL_@+
MK%[&'EU;Q-J+HS*I^9I'(*@]_E1C_P #K:M_#]MI_P 6/!OAPQ-*-$TX7,TR
MQG,TQ^4'/]U2JGVP>_7W$ * %  '0"EH *\-\.^(8X9?B9XV<L;M9'M[92IR
MBQC;&#Z;BR<?[)]*]RI H7. !DY.* /FV?PTEAX6^'V@7D$DL^KWGV^[81EF
M6(8;RQ[D/SZD#/ &.IU75GN_C5JUMJNL)I*V5BL.EF:$N?WBKO>(9 ,AR0#S
MZ8.*]JI"BE@Q4%AT..10!D>%M$T_P[X;LM,TR&6&UB3*B;_6$DY);_:).3_3
MI7FWQSU**_AT+PE%=1H^HZA']I;>/W48( +^@RX//]VO8:* .;A\+>&]$;^V
MHM.62>TMSY<\CO.Z1JI.$+D[1CTQ7B,&KWMG\#M?UZW,@O\ 7]48W=P@/[I'
M8@C/_ 2/;S!7TE3=B[=NT;?3'% 'BFASZ9>_&:P@@B>'2_#FC*EF'B92VY?]
M8P(^4;&)R?0=SBN3NA+/\-O%7C"XA9[KQ'JGV>T1TR(DW$;OKMWH#V_&OIC:
M 20!D]32T <3X;\1Z3I.IZ3X"@MKT74&F)(DKP;8RBKC)R<@G&>1U.#SQ7;4
MF!NW8&>F:6@ ) !). *\2FET[QQ^T,D-RUM<Z9H]B4C23:T<\F.0 >&(,G_D
M.O;:* .!\861\$?"S7SX7MO(E^>95@7'E^8X#LH'3:I.,=-OM7(6F@'5[CX?
M^']&_>6&BK'JFI7D9R@E.'"[AU=FW''4!@:]MI%544*JA0.P&* /(/ ^@6/C
M?7?&.O:U9QW=C<ZGY%O%,N0PB&%?\%( (]6KV"BB@#YKU>=M1TKQ]XRD1I6U
M*]72--C*YW 87=[_ +OI[C/4#&]I'AZ+3_BSX2\/R1/(="TL3S2",GS)WXZ]
M J\$?[IZD\^[44 >!6M[?W>D>/KV:*2Y\4:O?/HUK9#F2.+&, ?PH%<DGI\H
M)-7Y?#DS>+_ /@B5S+%H^G27=\ZYVDL-I /U&!W 8&O;0JABP4;CU..32T >
M)>*Q8Z#\3_#FA*]GH?A^VADU"#SHB;=[MB_) 902IP0,C!QV(%>E>"]"T_1-
M'E:R>YG>]G>ZN+JY7;)<2,>7(P, ]A@<?7)Z)D5B"R@X.1D=*6@#RKXS7"7M
MSX3\-2[A;ZEJ0DN"%)S''C*@#J3OX'J!6?J@3Q!\8M4U&XB=]+\*Z2=\(7(E
MD968I^(+ COMQWKV0@$@D D=#Z4M '@&A7H\/_L[:[JQ!6]U:24LVS:"\K",
M!?7"_-QQR?0UH>)-'N=*\'?#OPA*6M]+N[B-=5?.U<_*Y1CVW,S]>ZBN_P!7
M\'7OB/4XEUS4XKC1[:^6]@LX[?8QVKA4=L\J"23QSGMBNO95==K*&'H1F@#Q
MUIKI?$_C#XA)&T.EV&EM8:8<8%PRX^9?5-XP#T.1CI3O#.A6'@[X06OBB\LH
MWUFTL)+FVF9<O$TH.Q!]2_(]6->PT4 ?-5EX1>6S^'WA=MWVS4IFU>]D*9,4
M6-RCGH2N[.>I ST&-KPY?R64'Q-\6:=:RI=1E[>T_=G]TD8VAB3U/W6/4_(<
M]>?>Z",C!H ^<M+FL=1NOAGH$<<K6JDZK=RO&VZXN.6(&1EOG!7=T]\"M_2-
M>1/%?Q,\8,&:YL(GM+6,*3L6(8R?0,RH?^^O0U[:%4$$* 0,#CH*-JX(VC!Z
M\=: /G5+2>#X0>$-'ADDBLM<U5!JMWRJE9&!P6],$ GU0BNL>23_ (3K7/'4
M4/EZ%X?TAK&P8#"W3J"2$]5#$KD<$XQ7KQ167:5!7I@CBEH ^9)O#_V;X=>$
M]/O4D>\\3:I]JGE\LLT<)()"@#.Y@4;CDX ["OIB)56)%5-BA0 G]T>E/HH
M\DU34MGQNO;S7'9-/T'2O/TZ _\ +:1PH+(O\3$LR\<Y KD]0TC6M*^%:Z/>
M1M#K7C+7!(UN0<PJ[*>1VY5<_P"]@]*^ABJE@Q4$CH<=*6@#QC1-*M$^/$-A
M% YB\/Z4D22>7S)*Z??8]AL8@=AM4#M7LDLBQ1/(V=J*6.!DX%/HH ^>M%UW
M[+\(_&OB<%FU37+R10%!)02$HJY]5!D;'88]15@^&HM+\7_#GPK/ SRV</\
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M &.1CM SV)!88[CGUKU;49I[?3+N>VB,MQ'"[Q1@9WL%) _$U8"JN=H R<G
MZFEH ^=;&RO?$/PIMM%LF:\\0^*-2:XU*4_,8(TEY>4_P@;%P#CJ0*[%[8:O
M\>M*TY"9+3PQI6]BW/[UQ@9]\,A_X#7I.L6VH3Z7/%H]W%8WSD%)Y(1(HY&<
MKWR,CVS6=X;\*QZ%?:MJ<T_VG4]5G\ZYF"[0 .$C49.%4<=<G]  = S!5+,0
M% R2>U>*6IL?'/[0-]+/<;K'2;+R+4Q3M&9'_BVLI!X+R<@]A7ME% 'DWQ4L
M[/P5\-;J#P_9I8+J5W';WEQ"I+[&R69FY9LXV\G^+WK.T*ZTV]^-.^.![?3?
M#FC+!9(T1#!2F[S&!'RC8S=?5>YQ7M) 88(!'H: H!) &3U/K0!X]\,M!L=5
M\,WWC#7[!;B6YU*?4[=9%R8BK9W+[DKCZ**Y&UU=K7X%^)M:R6U+Q%J#+*X!
MP@D<J5)_W5D..V\>HKZ0INQ=NW:-H[8XH \5U2ZL_#_BKX=Z1J<AMO#-E9F5
M9IE*Q2W*JRJS?0A6&?[]/^*,>D?V'I^FZ5 UM'XIUI'O+C8X\U01N?!YZE2,
M#G!('->T,JMC<H.#D9'>FR!BA**I< E-W3/:@#QV[U/2;OXTR7-\T4.F^%M)
M!CADQGSGP<*O=@& P.ZCO7*7NG:AX=\#Z59ZQ%-8VWBCQ +C48U4YAMR5Q$0
M.<D9; YXQZUZ]X(\&WGAJ^UR]U&[MKVYU6[-T\L<90J>?EP2>!DX^M=B0#C(
M!P<C- 'B.A:];_\ ">^//%<MLT1TBR^R6MN8R-B(.0?[I+(H _VB.QKDYO#_
M -F^'/A33[U9'O/$VJ"YGE\LLT<)()"@#.Y@4;CDX ["OIH*!G  SR<=Z6@#
MR8S0ZO\ M"V]O*ACAT+3 ((=N?WL@&3@=@K\GH-HKTG6]0LM(T:ZOK\E;1%
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M>&_"NEO;VTBCY;A]C;A'_>55.,CC*]Z .XC\;>&IIDBCUFU:1[L62 -]Z?\
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M>$CSD'@<#)8 YKH;+0K?Q%\9=5CGLE.B:)ID-A'"\?[M\_,%P>" <_\ ?(H
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M,'^W:EJQOKTJ-PA5>2">G 8'W*F@#V_3]:TW5;B\@L+R*XELI/*N%C.3&_\
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MHSDM@G'45TWQ-U:71_AUK-Q;J[7$D!MX@@);=)\F1CT!)_"O,&\+_P!EZ_\
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M6N[QHU1IF50HX'   X'UZDDG5HH **** "BBB@ HHHH **** "BBB@ HHHH
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M-;QVK7T=LT<C0%AN"9 8@#N!CGK\O'J%% 'E/ANW\.VNE67B$+?:FNDZ<L$
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MXA>-;7Q#<:A:SW3BRMX;>U=I9K,%ODC?!"JPVECCOG(Y->YT4 >07V@1ZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5#6-:TW0-.DO\ 5;R*UM8Q
M\TDA_0#J3["K]<E\3QGX8^(O^O)Z .KCD66))$.5<!@?4&J5KK-C?7<MM:3&
M=HF*2/'&S1JPZJ7 V[AW&<BN3^(.JWVF?#>---D,5[?&WL8I0<>69"%+9[<9
MY[$YJ33=3NO"WB+1/"-U8V::?>V\BZ?+:%AL>)=S(X;KE>=W&3VH [>BBB@
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MP" 2!TZU;T*[\2?\)%>6>HVLLFD^0LMM>S)''(),X:-E1CGCD' [@YH Z<D
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M,D<<F_.&C948Y]0<#O0!T]'05SGC#7;C0[73!;*JM?ZE!8M.XRL"N3ER/7C
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MOC/1?!^K7MU;013V=[%';3SQ+_I4$DBH"55R$<;N3@@^E 'I5-=U123G@$X
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ME1LC8#+8(90<YXP3T%>A5C:]K^F>'[2/4;Y793*MNKPPF0AF8+@D<*,X')%
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MJYX50 H7/3OGFM;0-)UBR+3ZYK8U.ZV>6ACMA!&B\$G:"<L<#))[< <YW**
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M+^>!(+Y6M!+#<!?NML+ JPR<<GC\<]-J6J6VEQ1-.6+SRB&&)!EI9#G"J/7
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MW52'6,E59=W7&#QQ6]J_@4ZII]@4UJ\@UJPF:XAU4*ID\QAA]R<*5(P-O P
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M.ULAADY8D\ 'MBL:,:)X!\)67A+5KM[\7,4T-K MJQ>Z!R6CPN1D[\=NOUH
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M)N(EFGN#_JXBP#E 007QPH(.21UZ5QDVOZM>:5\0+#^T;M/[)M5FM+IX%BN
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M69KOFXFM]0EG+=3+YDG7WR!0!Z;KWB&P\.6275^9MDD@C1((6E=FP3PJ@D\
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MLF?8@X.#@YQCFO')-?L)_A=\1;;1[@&5M2N)TCC1E_T9Y(UR.  -N1BNZ\=
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M!8FZ@! .3@98Y/ Z5TU% ')^'?!MUH;0Q7/B34-3LK08L[:X5 (N,#<RC<Y
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M+0Q2&,1I&K$%MJCNVU<DD]!C%9L_@BVF@OM/6ZDCT>_N3=7-D$'S,2&95?\
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M.-5G\W2[DW8EE17>XE(()<\<$,1@ 8[8  '4T4 %%%% !1110 4444 %%%%
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M&I3+HFJ6\UNL>U L%RHW*=VW/*AL GJ/PK6T#PXF@7&J3)>SW!U&[:\E655
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-C$LIZ(T@&Q6Y'!(/(J.VO+&;QE>00ZU+-=16B"33008XAN/[SIPQSCKVZ4
M;E%>?>//%<<>G6']D:K<12MJL%N6AB/E3 RA702%=I(&>%;/!]#76:IXDTG1
MC)]NNC&(E#S,L3R+"IZ%RH(0>[8Z4 :M%-CDCFB26)U>-U#*ZG(8'H0>XIU
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M>?O%?,W >I&1GTS53PMI=[I_B&]\*R0.-'TN[.HVLA^ZT<N3'%_P&3S#_P
M6ND_X1O4O^AQUW_OBT_^,4G_  C>I?\ 0XZ[_P!\6G_QB@#A_MVC:;K_ (FT
M#Q?%J2MJ%[)/:B-K@QWL$BJ BK&<%AC:1CT]*T[)+.U^+.DVPA2WCA\,_9HX
M7??Y+^:A$6XYRVT'ODBNE_X1O4O^AQUW_OBT_P#C%+_PC>I?]#CKO_?%I_\
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M\1W&HCXF^'=)M]6O+:RU"WN7GCA*\M&H*D%E..O-=Q;Q^5;11[ FQ NT'(7
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M+D9YP00>00000>17#P+>ZA\3?$FDMKFI6UE:V=O- L4_^J9P=Q^8'/3.#D4
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MDQJ!5;:9K>18G8]$WE=H8_W2<U<O_&6B:;)=K<W$GEV<B17<R0LT=NSXVAV
MP/O#Z9&<4 ;]%85_XOT;3M8;29YISJ MS<BWBMI)&=,@?(%4[SD]%ST/H:R]
M6^(6G6OA2VUS3DGO(KJY2VCVP/\ NW,@1MXQE2#GCJ3P* .QHJ."9;B!)D61
M5<9 D0HP^JD C\:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *X[XIJ\WPWUJU@AEFN)X-D44,;.SMN'  !-=C1
M0!Y<=-;PE>Z;XPT'3I)+*ZMXK76+&WMSY@& %F1 ,[E/##'(_$U)KFH1:9X[
M77+^RU*YT+4M/B@2YM(YLV\L;N=KHF& (?N.O;K7IM% 'FFHZ/HTUAH\=O;Z
MCX9;?<7%A>VZLK6['9GS000!)G.UL?=P<'BJEW-K<FA>#]2UFTEEELM=9KB6
MUM'R\6)568Q*"R[LJ>G\7O7JU% '"Z+(7^+.NW!M[B..?3K5(Y)(&52RERR[
ML8R-PR,_RKG]3TN_UJ3XGV5A#,)[T6QM2\;(L^R%0P5B #DJ5_&O6J* .2\/
M>*+7Q//9/'HEY#>P(?M+7=FT7V0E?F178<DG PO;DXQBN%M;74U^&4-I;Z7?
MRWNBZRUW=6?E/&TT8N7<K&W&XE6##:3T'?&?9Z* /+-1M;+QAX9UR;PQH]]'
MJ$VF/;?:[V.2.1LD-Y"F3ELX;.. <<\TS4M>BUN'P.]MINII+9ZI$;N V$N;
M;$3JP/R]B>V>.:]6HH SM=U"?2]&GO;:UDNI8BA$$2%GD&X A0.^"<>]><^(
M='TJ^\1Z1K7A"&XM?$9O8S<>3!)"&@)_>_:%( 7CUP2>.:]7HH \VEL[R;Q;
M\0-,CANH9]8LH5LKCR6\HXMF0MYF-HPV!USZ50N8YO$GPMTGPO%9W-OKD36E
MO)"\+*;5H73?(3C 7:C$'/.0!DFO6** /-+#53X7\3>)M(US2K^YAU6]-Y9R
MP6;3I<HZ*IB. 0"-N,-@8]JH>+]'U#6O&=A;V0>PG30V0%82UL)1+&X@D(&T
MHP4@CT_(^M44 87A/Q ?$6B0W4UC<6%VHVW%K/$R&-QP<9 W+Z$=JP/$,4VC
M_$W1_$LT$TFF-82V%Q-#&TGD,6#JS!02%/3.,#OBN\HH YAK^'Q#K^D'3A++
M;6$SW,UR8F6/)B>-45B!N8^83QG 7G&1GF(2V?B9FWN +K)M\P/^^_T8)\G'
MS?-QQFO3J* /*U\P6/PN4VUSNM/+^TC[._[G%L4._CY?F..:N1E;/Q%\0K?4
M-*OKF"\C2=8X[=RMQ"+4*P5P,9)!7 .<GI7I%% 'GO@V'4--\2#3K34[C5_#
MOV)GBEO(B)K)]R@0ER 6R,G:>1M&<=[OCX20ZEX3U#[/<2VUIJH><P0M*44Q
M.H)503C) Z=Z[6B@#@M*G"?$OQ3=RP7$4$MA:!'>!@&*!]R@XP2-PR!FN:\.
MWEUI?A+P+9W.G7EO"!<1W5VE@\EQ:.,[44;2R;\X+ =!QC.1[%10!XI+9WC_
M  T\:6,6F:EYRZ\UTL<L#EWB^TQOD$Y+G:I)P3TYZU[':7D=Y9)=QK*D3C<O
MFQM&V/4JP!'KR,U8HH \;FBGD^$7C2T6SNS<W.I7;0P_9GWR!Y=R%5QD@CG-
M=-JTOG_$'P/<113O#%!=B600OMCWQH%#'&%R01S7?44 >*2WMSJ&F>&[J?2M
M3M[NS\0QRW=A;V$B062!Y.%55PY.02WS')/3.*ZOQ?8ZII_BG3M8T-=LVL1G
M2;P9P4R"T<V.YCP^?:O0*PK'P]/#KL^IWVL75^OF.]I;2HBI:AN#MVC+'' )
MZ GU)(!KV=I#864%G;($@@C6*-1_"JC 'Y"O.M+F73(?'.FWUE<O=7VI7,UM
M;?9W/VJ.2-578<8()!!YX[X%>ET4 >/1Z?<>!K_0)-<M+^[TP:)%I\T]CYC_
M &:=&9OF$9R5(; /L*]&\+6]E!I#/I^EOIUK/*TR12*5=\XR[*>5+$9P><8S
M@Y VZ* /'?&D]WJ>F>.=-?3+^&Z7_CVM[.S<)=($7]^\BC#G@C!;@*!@FNE\
M41WWD^&O%6C6,T][92B%K=T,;R03@1D,",C#;&YZ8).*[VB@#S?0O#NIZ1XR
MNM&?S)]&G>+67N6Z-< ;73ZF54EQVQCO63XSN+O4K3QSIKZ;?PW C_T6"SLW
M"W:B,?OI)5'SGJ-I; "@8)KUZB@#SJ"X^T?$CPU=BUNUA&C2Q%Y+9U".S(5#
M$CY20IX.#2Z5?R>&_'?BBVU>UO"NJ3QW-C<Q6SRI,HC"&/*@X9<=#7HE% 'A
MVCI>:5X/\":M=:3JDMAIT5S;:A!%%*DT0D(*R!1@LHV\D<8-;6OVL=SH,&O>
M&]!O!;6^L6FH72M$ZW%]'$3N(1_F.,J1GD[3Q@ GU>B@#SR#58=6^*^DZC96
M]])9-H\T/GM92HH<R(P!+*,< \GC/%:'Q*CE&CZ1>I!--%8:S:7=P(8R[+$C
M_,P4<G&>U=G10!YM%J NOB)K>H)9WZV4^@QI%.]G(JN0\AQ]W()SP#@GL.1G
M'ACFC^&_P\MVM+H3VFJV;W$7V=]T*H6WLPQD 9')]:]AHH \OTZ^ET&]\:Z1
MJMI>F?4;N>]L9H[9Y4N(I(PJJ&4$ KM (.,5C6)N-&TKP3K-_I6J2Z9;Z2VG
MWJ0Q2I+:N=C!R@PQ4E,9''Z5[310!Y3XCAL9/"45QI&B7=O#=:W:W1!MY#+.
M%D4O,R$%@, \MR<9[BO5497174Y5AD'VI:* /,(&ELD^(]A-9WHFNIIYX2ML
MY21'MU52K 8)+#& 2<]N#4+"0:'\+T^S7.^SDM_M*_9WS %MRC;^/EPQQS7J
MM% 'D=@UGI]UK/AKQ+H&JWMQ/?SS6OE1RR07T<LA=>0=BD%N=V ,<FO58]EI
M8QAU6)(HP"J9(7 Z#N14]% 'F7PNT/3;CP]*VI:+']NCU&XF4WEGMD +DHPW
MKGH>#6OK6[_A;'AB013-%%9W:22K$Q1&?9M!8# )VGK7;44 >*WEY<ZAI>D7
M$^E:E;W=EXDAFN;"VL)$AM(Q.Q) 5<2$C#%OF)+'&,UU.F2[/'7CJYE@N(X9
M[6S$3O V)"D3A@IQAB"P! S7H-% ')_#))(?AQH<$T4L,\-L(Y(Y4*,C#J""
M,UB:5<)I%_XWM-0LKEI;V_>:VMQ;NWVJ-H44;#C#9((//'? KT>B@#S*\\+:
MAHGPHT6163^W/#42WL9W<$J"98L_W2A9?P%=KX:MIH=)%U=QF.]OG-W<(>J,
M^,(?]Q0J?\!J+5?#T^K:O#/+K%U'IBQA9M-1$\N<AMP+,1NQT! /(&.A.=V@
M#S;7[@>'_B)<ZAJ]AJ5QH^I6<,45U9+*_D2QE_D98^<'?D'!Y_&H]=M+>UTC
MP='INC3V-K'X@ANOLR0L6BB_>9D< '9G<"0>F[GG->FT4 >5/-;:+XJ\1:=X
MCTC5;JVU6Y^TV<]K%-+'<(\:H8F5#C(VXY'0\\8J<73^"/&L5[>:1=0Z+?:3
M!:Q?9(6N!921%B(B$!.,/U'4UZ=10!YUXD+)_P (=J<>CW%K8VVK-(\$%JS/
M#&T<@5FC0$@DD$C'!;!YJYH#EOBKXEG:WN(X[BSLUBDDA959D#[U#8P2-PR
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MP7,#12(&&5;:P!P0#CZ5YU;V]W'X*^&]NVG:@)['4+=[J/['+NA58Y%8L-O
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MAM[E3@[?F"C(YP>V,T/ FE:C::E<Z7?'S+'PY(]IITI;<9%D"NI;T9(V5/\
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M<7L16<2LKCR-Q ,F.#D]-V/6FQ7TVHZC\/)H-)U816!>.Z:2QD3RF^SE,$$
MX#'&[[OO0!VNH>,]'TP2RW,DPM()Q;3W:Q$PPRD@;6;ZD D9 /!(KFTUP:)\
M2_$RW$FHW4"V-K+%:PB2X*DF3<409VC@9Z#IZBJOA?4+W0+6]\):EX?O[N\2
M]G>UE%L7M[I))#(KM)]U<%N<],=SQ6KIK20?%+Q'=S6MX+9["V1)OLLFQV3>
M6"G;@XW#I0!UNE:I9ZUI5MJ=A,)K2YC$D3@$9!]CT/M6#XK\06D>C:W:PM>O
M-:6K&>:R#9MF*%ERRD$'H<#) Y(P:K_"N"XM/AOI%I=VUQ;7,".DD5Q$T;*=
M['HP!Z$5S]E/>:"/&VB:CIVH23ZA=75[8SP6KRQW"2IA5W*"%9< '<1VH Z/
MPKKL5KX$\+?:Y)KB^O=/A,<:Y>69A$I8\^G4L2!R.>16K:^*]'NM.O;[[5Y,
M=@YCNTG4H\##^%E/.>F,9SGC->?Z';ZCH\_@;6[FPOOL-OHO]EWD9MW,EK)A
M"'*8W;25VDXXXS1K_AO5]5/C#7=)M93]JFL);2VD4QFZ^S$,QVG!YZ#(YV^A
M!H [Q/%VG-?SV$D=W#>PVOVS[/+"0\D.<;U'?GJ.H]*0>,M'.G:/J EF-IJ\
ML<-I*(6PSO\ =![KGGK572M>7Q4DCVNBWUH?LSI+-J%J861B/]6N[EN>21P,
M>IKS^UEO&\">"M+&C:M]KTC5[3[:ALI!Y0C9MQ''SC'.5R,=<9&0#T2Y\=:/
M;W>J6BI?SW.F!#<PPV4C.H8$@@8Y&!G/3D<\TV+Q]H$\FF>5-</;ZDR1VUV+
M9_(:1QE4+XP&/3'8\'!K)TEI(?'?CBZEL[U+>XAM/)D-I)MEV1,&"G;\Q!('
M%<W#:WL?PI\%6;:;J/VJTU*T>>$6<I>)8Y=SDC;D #O^5 'HVK>*M.T=;IYU
MN98K,!KN2"$R+;@C.7Q[$$@9(!!(P14%QXWT2WU&*P66XGN9[3[9"EO;22>=
M'Q@H0,/G=VS@ DXQ7&[H]%\4:_8:]X9U'4[75+HW5G<VUJTZ2JZ*IB<#A2-N
M/FXQUP*U+>VDL_B9HS+I<UK:0:"]LP@MW:"%S(C",.!MX"G\J +FK_$.RM_!
MRZ]IEO<7(DN5M0AA*F&0R!")%/(()Z=2<>N:W)_$EI"QC^SWDDR0?:984@)>
M*,D@,R]>2K8 R3@\5YG/8ZA+\/?$J1Z9?F4>)6O4A-K(KR0_:4?<BD M\H)X
M]*W/%5O'JFJ_VGI\FMZ+K,-@KVE]%:R,EPI9\0R1[2#@@':<-\XXX(H ]#M;
MB.[M(;F(DQS(LB9&#@C(J6L_0GOI?#^G/J<"6]^UM&;B%/NI)M&X#Z&M"@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHKB/BC*;7P[8W:W$\'E:I:;C'*R J95#!@#AACL<T =O17,V'CG3-0U.
M[TQ+748-0@A-PMM<VK123Q#C=&&QN'MP?:IK/QCIM]X5'B*WCN7L6;:H\L"1
MCOV<+G.=W&.OM0 ^#PXT/C*X\1F]+//:K:-!Y0"A%8L,'.<Y)Y_2MVD4ED#%
M2I(SM/4>U<]<^--+M'MGF2Y6QN;C[+%?[!Y!ER0!G.X D$!L;3ZT =%17#Z)
M-]F^)WC$374OV6*TLY<33,R19$I8C<<*.,X&!6Q%XOT]]4L+&:&[MCJ*LUC-
M/&%2XP,D#DE3CG#!2: .@HKG+GQMI5J899!<?89;O[$M^J P^=DKMSG=C<"-
MV-N>]5+'QFUSXH\0:=-IMY';:4(@9%BWDED9RQ"DG!&W  )]<9X .FO[9[S3
M[BV27RFFC*;]N[:",$XJEX;T7_A'?#UGHZW#7$=I&(HY&0*Q4=,X[^]9.G?$
M/0]2M#>QB]BL!:-=F]FMF6'8&VE=_0MD_='/;KQ5^'Q39MJUOIEU;W=C=74;
M2VJW,8'GJHRVW:3\P')4X;VH W**XZ3XEZ%'975[Y.I-:VETUK=3"S?;;LI
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M^8@  $9+$ $@=2!3]"\06/B&TFGLC(&MYVM[B&5-LD,J_>1AZC\J -2BO/\
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MB@ KD?B-8WE]X9A^Q6LMR]O?VMP\<*[G*)*K,0.I.!T'-==10!QQM'\0>/\
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M?,,F-N%'/7.1CK6IXGBU>\'BW1I=)U29/[.$>F&TB(BN/W)!:1P1N<-QL8]
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MNJW9>WM8H#<2F1"&C0+N.5ZY [5F:;XLM-0U6WTUK2\M+BYM/MEO]H5,2Q9
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M\LM8ECNK2ZM8_, 8($,;\_)C P3QCN*T?A?:7NG_  [TFRU"QGL[F!&5XIP
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M6XAO9[L ,LCJG4%L(@(;   ]!0!T7ASQLVIZ;JVHZG83V-O9WLMNI8HV-C!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGV@6DJ%)2HV@E9$8 X &1BMC3]/ATZ QQ-)(SMODEE<L\C8 W,?7  ]   ,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-@R-]W;G@=JQ?$XM=;MW\#26VHWES,L3274L#!%3>&:7S0 H88) &.< #'0
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M644$*!A0PX8]^] '(6>NZM!JWA)O[4GOEU&ZEM[VX50+2X^1V'E X("E1A@
M".YK8TG4-0GUSQW87E]+<P6)B6W$BJ/+5X-Y'R@=S]>*=;?#:TM[;2+?^W-8
MD32)O,LMTD8\M-I7R^$&1@XR?F'8BM6V\)16M_KM['J5Z9=9"^?D1X0JFP%/
MDXPO'.: .(T/4+[3O!7PS^QW<D27<\-K<1C!62,QNV#D<<J.16O<ZKJR:UX^
MM(M4GCCT^P@N;,[48PNT<C-C*G()4=<^V*U'\ VG_"+Z5HD6I7T?]DS)/8W8
M\LRQ,F0/X=K#!(P1SFE3P);K<ZS<G6-3:;5[9;:Z=FC.X*I7<!LP#AFZ8 SP
M* .<@U/7-,\(:%K4VN7-W<ZVEA:B*18U2!Y,%G4[?O$9'S9&XYQC@=-H=KXC
MM/$US]KFWZ)-;AHHKBX$LT4X;G:0HRA4]R<'IQ4LW@K3;OP5'X5O9;FYLHHD
MBBE=E65 F-A#* -PP.<?7-3>'_#3:(3)<ZQJ.K7&SRTFOI QC3@[5  '.!DG
M).!SQ0!S_BZUEG^)?@M%O[N!9?MH*Q. %*PYR 01GDC)SQZ5)IMYJ/C >)I+
M;4[BPDT_4)=/LEAVX1HE7YW!!W[F)X/&,8P<FM_7/#,&N7^EWYO+NTNM-D=H
M9;9E!(==KJ=RD8(_$=B*K'P?##JFHWNFZC>:?_:0!O(H=A5W QYB[E)5R."1
MUZXSS0 _P+X@F\4^"=*UFYB$4]S$3(JC W*Q4D>Q*Y'UKE+;4/%?B;P_#K^B
M3B&Y:Z=XTFN%%OY*RE3&Z;2?NJ<MUW=P.!Z'IVGVNDZ;;:?8PK#:VT8BBC'\
M*@8%<M!\.K*SU6ZGM-5U2WTZ[F,]QI4<P%O(YY;C&X*>X! /3IQ0!FYUK5?%
M_C#2_P#A(KZVM;*"UDMO)2(-&71VP#M^[D>F3@<^N-K=[>>(_A5X1U:\NYEN
M9[VQ\WRMJJ[&507(QUXR,<<]*[V'PK'!K>LZK%J5X)]5CCCF7$95 @*KM&SC
M )ZYK/;X>VA\*Z9X>75=16TTZ9)H7'E;R4;<@)V8(!]J &"^N+[QS+X6^WW4
M=M8Z<MS)(K!99W=R!E@. H';&2>>G/+:GXG\10>$]?@&J2)J&BZS#9)=B-/]
M(ADDC"[QC[P5^=NWH*[V_P#"T5WK5IK4%[<6FJV\)MS<Q!#YT1.=CJ1@C/(Q
M@@U4U#P)8:AH$^DM>7D2W-T+RYN(RGFSS!@VYB5('*KP !@ =* *$\FHZ9XG
MTKPW+KMY<KJLES=O<2JBR(D:+^Y0JH !+$YQD $#'6FZI>ZWX8L8K*;5!>2:
MCK$=K9RL%66""0$A68C!;Y&4,0>HSG%;7B3PC:^);>Q,UY=VU_82>;:W]LP2
M6-L8/;&".HQ@U#=^!M.U+PY-I&I75[>/,ZS/>R2@3B5?NNI  4KC@ 8Z\<G(
M F@6OB*S\0WRWTP?1I85>VCGG$LT4H.& (490@YY)P?K2:_/<-XCL[-=0F$#
MVLC"QL>+F23<H$A;HL:C/)(!) YZ5=T#PZVBAI+G5M0U6Z*[!/?2!BB?W5
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MHI(VI/J7F'RB?-<,'7&S!0[SQ^1%:VCZ';Z1)?3H[2W5_/Y]S,P WMM"C
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ME!ZX!Q^'% '3Z+_R M/_ .O:/_T$5>JMI]FNG:=;V2S2S+!&(UDE(+, ,#.
M!^E6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(!) _ $_A4E>6NTVM>+_ (=7]Q=7*2WVDSSRB*4HH;RHFR .!DL<^O'I7J5
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MP''+$+S5I+#6)[6[$,@2ZN+6-W7Y2,9?[G3!(!]: /39IXK:%I9I%CC7JS'
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M1';M#?*H+,%) +9X)[\UO.Q5&8*7(&0JXR?89XK'\+>(4\3Z.VH):R6H%Q+
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M"ON&WG( 'X<8H X?^UM0MYO"][;:K>WPO-:-K<7QD*VUU&_F?*D)8@!=H 8
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M$T^Z6\B82AG><9(D=F!+'D]>.?I5JU\.VUIXDN]=6YN6N[N)(959EV%5SM
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M9)A/&L+*%+CH6!4YQD\=._4"H_$OAVS\5:)-I&H/,+28J9%B8*6VD,.2#CD
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ME#.\PS^\=F!+'YCUXY^E68O#4$'B"]UN.]NUO+R%89#E"H5<[<#;QC)_/G-
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M[Y7&1WZ#I@5=T>>^M_'VE6"RZC'97NC2NZW=RSO*Z,@$NUF;RV.X]\\\@8H
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MO+AA\U8FD .0N3O(8#H5.#WT]*TC6-.\5_:WODBTNXMS&U@]]+=%I@<B1&D
M*\<$#@]: .MHKE/$;^=XETNR6]NI&:":0Z7:N8S+]T"5Y R[47)&.<EA@$BN
M'35-8N?AGX>N7U>^CO!KZ6;S).2SQ_:F3#$_?X '/7'.: /8ZPO$OB,^'3I1
M^PO<K?ZA#8EA(%$1D;:&/<]^!^8KD;G4;KP?XL\31P7=[>VL'A[^U5@N[AYL
M3*\@.TL?E!"C('%4-;L_/\,>!-8EO[NXN[G6--FGD>X8I*9&#'Y,[0 3Q@#
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ME4]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+Y]M:/.S0PODG*J3V)) .0#T K4U33+/6=+N=-U"$36ERACEC)(W ^XY'UH
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MBK(ZG*LK#!5@>A% '&744NG^/;K0(9+B31M1T:6YDMVF<B"1&"[D.<JK @$
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M-;F18Y2%VAB@.TL!T./?KS4[>#M)_P")>\(NH+C3XC#;W$5RXD"'JK$D[@<
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M%T1M6^&?PYN[^>XGN9-:ME>5IWW-ND?))SG/ YZCL:]E^RQ_9!:_O/*";/\
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MO[1KNU%I;,_G( #A>F6P1QV[XH ZNBJ<5^9]'CU"*TN29(!,MLR!)>1G:0Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB8@2.2HX(4G'?./>F_\ "%Z3_P ]M8_\'5Y_\=H_X0O2?^>VL?\ @ZO/_CM
M',^//" M_#-M>Z"FI3:MI=Q#/I\/GS3C<I&5VEB "N1VJSXCM;/Q1_94]YI^
MN:=<K \MOJ%G#*)[*7C,;!020?H0=O7D5N_\(7I/_/;6/_!U>?\ QVC_ (0O
M2?\ GMK'_@ZO/_CM ')3:3=ZQHF@Q^*H-4AUB&"62/5],B<2V[[\*&$8."Z;
M21C&01Q27D'B&XT+P/\ VM:W-SJ-KJZ7-Y)#;$E85\U0[A1@,59"1UR3Q77?
M\(7I/_/;6/\ P=7G_P =H_X0O2?^>VL?^#J\_P#CM '&ZU<26/C'Q.EKIFMM
M!J,$,%U+860NU9A&1N&&'EN$8#!!Z XY%3R"VN9/ 9T33]1_L[2[ETE62UD#
MVRK$T6) 1D-DC^?2M"Y^%6G/>O/9>(?$^G1R/YDD%KJKA'8]6);<V3CDYK8A
M\"Z+!'L235QDDL1K%V-Q/4G$G4GF@#F7LV?7O'KWN@WM[I^H&R5(OL[C[1&J
M+')L/'*\D<CID>M6O#,&J>&Y]9%N^KZIX?M[-9K.&\B87(E&XM#'O 9A@+C/
M&2 .];__  A>D_\ /;6/_!U>?_':N:;X=L=*N3<6TE^SE2F+C4)YUP?]F1V&
M>.N,T 7K*X:\L+>Y:"6W::-9##,,/&2,[6'8CH:GHHH X/38;I?C%J]^UC>+
M93Z=#;Q7#6[A&D5B2,X]^O2K-_%<?\+9TN]%I=-:1:7/!).L#%%=G1E&0/13
M79T4 >/2:)K$WA[4[BWT::XGM/%<VK)8W,)3[9;L6&%W#!)5B<=<CITKM_"L
MEK?W,E_:>$WT1/*\MI+JS2">0Y!V@+SM&.2>I(QT-=510!Q'C70M1/B#0/%F
MCVQN[O1WD6:T5@&G@D7:VTGC<.2 <9S6Y;^(?[114L=.U%9VQD7EG) L7J6+
M@ X]%)S^HVZ* .#T5;WPKXI\31WMC>W%GJ5T+^SN;:W:8,2@5HFV@[2-HQG
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MC:7=QVEV+'^R[BVDN?*($;R%2H.>>@/T[T :,WCC3[=M.EFM;M-.U&=;>UU
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M[7=8U.79>HR6P <'"].: -:^UZ.TU,Z=#:7-Y>+;_:7B@* K'N*@_.RYR00
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MQ3*I*TJN%)!/8'D9'O0!0M/%\>M^ ]=U'Q!HUZNG1M=131PE&)B1F4J"KYR
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MY87^EZYI6N3>%YM;TZ?28;&YMD@1[BUEC)(8(^,@[B#@]LYZ9O\ BRPOKSP
MEM8^'VMIY[Z"=+"VC7,2)*CDN5.W=A<G!ZG'.,T 2QZ?X9TCQUHTG]BW]EJF
MI-*UM$' @@=(VWDJCE S)UQG/'0YK5\,>)[W7-<UZTGTR>WAL+S[.C,T9"X1
M3\V&)R2V> 0!CG-5O$,-U=^.?!U];V5U):VDERUQ*(B!$'B*+D'GD_EU-+X5
MM-0TWQ9XIAN=.G6"\OQ=PW?R^4R&)%P.<[LJ>,4 =!J6M0:==VEEY4MQ>W>[
MR+:';N8*,LQ+$ *,CDGN!R36;'XNAO-,U>2SL[HZAIA*7-C($66)L9!.6VE2
M.00QR.F3Q5#Q#8:A9>/=%\3VUM-=V<5M+8WD4*[I(E<AED5>K#< "!SCL:@M
MM)N1JOB_Q&;6X5=3MXK>UM_+/FR".,KN*]1EFP <$ 9.,T 0_#W3(-6T70O$
MMW9W4.K+:[I+LR*/MGF+EBX5CN&>0' QQ@5IVGB.[U+QUK/AZ72[A;.TMX/W
MJR(/O[\N2'# $*  ,G@Y S5CX?V]Q9>!-&L;RVFMKJUM4AFBE7!5@,'V/X50
MM8+_ $SXG:W>OIMS+9:A9VWEW,0!1#%OW!N<Y^88 !S0!SWP_P#%MOH?@+0H
M;RSU%X)[N6V:^" Q1R/<2!0Q+;CG(Y (&>3FNXU7Q1#I@OC%87E\-/C$EW]E
M"?N1MW8.YER=OS8&3C'J,^?1:-JZ?![3-'.DWO\ :,.I+-);^7RJ"[,I.>GW
M3Z^U:-S:76B>-=7N;KPA+K^FZN\=Q;3P01R202"-4:-Q(1M7Y0<YP/SP >AZ
M;J-KJ^F6VHV,HEM;F-98G QE2,CZ5:JIID+P:;;QR6\%LX3F" 82/OM'TZ9X
MSUXJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^.? D\NE75IYEW*T<DS*<KY+G:P5CM;D'!_/@BO1[B>.UMI;B8[8HD+N0,X
M&3Q0!)6!JWA.UU35DU6._P!1T^_6$0&>RGV%XP20K*P*D DGIGFJ^G>-+>^O
M](MI+"ZMEUFW>YL))-I$BJH8A@"2K;6!P?Y\58L/%,>I2VK6MA<265U<26T=
MVK(5#('R6&<@$H0./3.,T :.FZ5#IB/MEGN)I,>9<7$F^1\= 3T &3@  <GC
MDU=!!S@].M8-CXICU&6V:UL+B6RN;F2V2Z5D*JR;\EAG(!*$#CN,@9K.TG7M
M M7\6:@EE-IWV&Y+:G)-R9'6,'< &/&W&,8SZ4 =A17+_P#":QQZGI-A/I%^
MDNK1F6TQY; J "V[YOE*@@D<\=,U0F^)5M%I^JWR:%JTEOI5V]M?,%C'D[ N
MYN7^8?-T7)P,G&1D [>BL.Y\2PIJ!L;*UEOKE;1;UHX613Y3$A2NXC))4\>W
M)&1G5L[D7EC;W2HR+-&L@5NJY&<'WYH GHK N_%"1SZC%8Z==:B=-Q]K-N4&
MQBN[8NYAN<*0<#U'.>*YOQGXI%]X3T2[T9)KJPU6_M(VEB95WQM*-T1#,""V
M"I'3J"10!Z$&##*D$>HI:Q]"T/3])-U<V.GMI[WSK+/;;AM5P,9"J2JD]]O6
MN=B\07FO:GXOT>\TN6.SL46%6\Q"!F(ON;#9RV1P,XP,]Z .Z!!&0<BL74/#
M<&H^(M-UN2]NX[C3A(L$<93R\2 !\@J2<@#OQVKCO GBR/3/!_@ZPNM-OEM[
MZ&*TBOR$\HS%20N-V_G!&[;C/?O72:QXVM-)@O[H6=Q=6FG/LO)H63]V0 6P
MK,"VT$$X^G)!  .GHJ*UN8;RTANK>0203(LD;CHRD9!_(UP/AJ8>._$7B*^U
M,>?I>F7S:=9V3\Q;D WR.O1V)(QGH.E 'H=%<\-'L?#VI3ZVEP;33HK)UFMR
MY\F+!#;T3HG ;.,9P*B'C.WBETHWVGW=G::JZQVES+LVEV&45P"2A8=,CV.#
MQ0!TU%<?/X^1'UN.WT'5;F71W ND01#"[-^X$O@C;T ^8^E/B\?6<L^C,--O
MTT[6&2.TU!U18VD92RJ5W;QD C)7&1QD<T =;7+VW@>UL9I/L.L:S:6DDC2&
MRAN_W0+$EMN064$DGY6'6J=W\1889-7CMO#^LW<FDR[+M88T^1=H;<,OR,'@
M#D^E:$?C.QODTG^RH9K^35+=[JW5,(!&N-Q8L< Y8#')S^= &_;V\5I;QV\"
M!(HU"JH["I:Y!_B)IJ^'-+UM;*_>VU"[6S"K&I>&0R&,AP&SPP/W<YQ[BK-I
MXP^TZAJ>G/HNHP:A8P+<K:OY1>XB8D!D(<KG*D8)% '345S5GXSM+_PG9^(;
M:RNY(;N5(HK<>7YI9I/+ QNP#NZ\\8/I72#D D8]J %J&VM8;2+RX$"*26/)
M)8GJ23R2?4U-7 ?$F]GTNZT34+RPN+_PU!)+_:<, W8)4"-W7^)%.[(/'3VH
M [^BN+\.2Z&D.I>(_#5U]MTR:VC M+>7(B:,N6"HQ C)##Y>.G2K@\<V+:1X
M?U06=X;77)XK> X3,;29V[QNZ<'IF@#J,C.,\TA(&,D#/2O+M.UAO#?C/QVU
MIHNHZDJW-M(\=FJDHOV=68Y9ADY)^49)]*W;_P 2^'=7M_">HO93WMOJ%]&=
M/G7 6&?#8+_,#D .,8(R* .UHKFM8\9VNDPZC.EG<7EOIG_'[)"R#R\*&8 ,
MP+%5()QZXY.14Y\56MP\46DP2ZG-):+>A82JA87^X26(P6P<#KP>E &]17!W
MOCZ>=_"DNDZ7=26NLSN'\P)'( B.3'M8C#97DYQ@<$YKNB["+?Y;%MN=F1G/
MIUQG\: '45P_A[QU)<Z#J^L:W9R6=M:7DT((9''R/Y:QC:<LQ/M@D\&MF+Q1
M&FO6FCZC8W%A<WL;26AE*,DVT99,J3AP.<'MT)H WZ"0.IQ5#6]0ETG0[[4(
M;5KJ2VA:40APN[ SU/0?YYKS76]5GU;PK\/M<U"TFCNGU6PD9E 8R[HRS%50
MG@GH#@\#B@#UFBN:L/&=I<3ZS!J%G<Z5-I,:SW*790_N6!(<%&8$84Y&>,41
M>,[;^W=/TJ\LKFSDU)':SDD9&60J,E&VL2K8.<'\\\4 =+15'6=4CT31KS4Y
M8)IHK6)II$A +[5&21D@= >]85EXZ@NK-;R32=1MK:6*![665$ NFE^ZB?-U
MSUS@8YSCF@#JZ*Y/_A/M-MY]6MM1@FL[G3+87<D;,CB2$\!D920>>,'&"?QJ
MQJ'B>ZLM-U6X_L6X,UE9_:T4RQ[)5^;@,#VV\_48SF@"SKGABTURZM+QKJ^L
MKVT#+#=64_ENJMC<IR"I!VC@@]*L:9H\.F,9'N[J\N679]HNY=[[>N!@ */7
M &<#/2N:M?'CV7ACPU>ZMI=^T^K>1 KQ+&P>5XPV<!\@'#8&,\<XJ1]>T^_\
M0>%QJGAW4;74IYKD637(4?9V5&WYVN<Y4<<$<@T =I17,:EXVM;"VOKV.PO+
MNPL)_L]U<6X4['R VU<[FVDC=@<<XS@XAB\4:A-\1+G0AIDILX+%)Q(KQY;>
MY&\@L" -I  YZY'2@#K 0>AS2UQFA^(_#]CH6MZG;6-Q800ZK-%<Q2#=)+=%
ME5L ,1EF(  ./I6I'XIC378M&O["YLKVYA>:U60HRW 7[RJRL1O'&0?J": -
M^BN&'Q-LSI/]K?V+JJZ;'=FUN;AEC MV$GEY8;\L-V/NYQ]>*VM1\4QV=SJ5
MO;6%Q?2:; L]TD#(&4,"0%#$%CA2?Y9/% &_117-7OC*WMK?4KRWT^[O;'3)
M&CN[B#9\A49?:I8%MO?'H0,D$4 =+17+W7CBRAU/2[*ULKV^;5+9KFSDME0I
M*J@' )88/S#DX SR:O\ AOQ'#XDLKF9+6>TGM+E[2YMY]N^*5,9&5)!&"#D'
MO0!LT5RGBSQ+?Z+K'A^QL]/DN$U&[,<CJZ X",VQ0Q')QU.!CW--F\=JFM7V
MD0:!J]S>6/D&9(DC.%ESA@=^"!CZ\], D '6T5RC^.[-'BE-C=_8)-2_LL7>
M% \[=LSMSNV;AMSC\,<TMSXV$>LZKI%IH6IWE[IT<<KI$(P'5]Q!5BX&,+T.
M"<\ \T =517-VOC.PU"PT6XL(Y)Y-8C:6UA8JAVJ,ON).,C(&!GGVR:P_'GB
M.]_X0,7%II][;M<W<=K*&:-7B'VA8V4_-_$-P!7(P>HH [\,&&00?I2UQ]I_
M9?A_4[DZ7HLL&IZA"MQ<6*31HJ*A*JQ&[RU+<CY>3CGH2(U^)>E2:7I-_!9:
MA-'J5V;)42-=T4XSF-QNZ_*>F1[T =I1D9QGGTJAH^H2ZIIL=W/I]UI\C%@;
M>Z"B1<,1S@D8.,CGH:X*TU!M"^(_CB6TTJ\OW\BRE,-MMR $D+$EV 'TSD]@
M>: /3**Y^'Q?I]WI>E7EDDD[:K%YMK!E48J "Q8DX 7(!YZD 9S65+\2],@T
M2[U&2QO@UC>BQN[=51G@D+!03AL%3N&"N<^E ':TA( R3@>IKG8_%N[$4VD7
M]K>23O%;VUQL1IE10QD!W8"88<DYSQC-8FM>-- U/P3KLNJ:5>7%M82_9M2L
M 5WH01@Y#@%2<$$'^M '?45S>H>+8=-U^VT*/2K^YNKBU:X@$*IM<+@%02PP
M>>K8'O5SPWXB@\2Z=+=16\]M+!<26MQ;S@;XI4.&4X)![<@]Z -BBLO4=;CL
M=2L]-CA:XOKM))8HE=5RD>W<<L1_>7CKSZ D5CXGA^S66+.X6]O!(8[.0HLB
MA#ARY+;0 2 >3RPQF@#=HKSW6/B.Q\,S7FDV$WVR#4H]-NHI60-;.753W(;(
M/RD''.3C%=];R/- DDD#P.PR8W*EE]CM)'Y&@!Y8*,L0![TM><W\A\0?$Z]T
M+5-&EN],32D"PR-$57?*P:;[V1D* "/F&.@K4A\7:;HOAR*[@L[Z7P]9L+7^
MT-XDPJ-Y9?!;>R!A@MC/&<$<T =E17*:GXYAL-;ETBWT;4]0NULA?1K:JC":
M/=MRIW?7KCIQG(JA9^(KWQ!K/BC1[S29H;.SBCC 9T^7=$7R^&SELJ,#.,<X
MYH [H$$9!R**\Q\!>+(]*\%^#[*ZTV^%M>I':1W^%\KSFR57&[?S@C=MQGO7
MIU !1D9QGFN7\=^(KWPWH45U8VC3RS74-N6W*!&'<+G!/)YP.V>M8%_=/:?%
MVPO4TN[DNIM!F_T2,H7+":/ )W;!P.I8#\<"@#T8D 9)P/>EK@]:\7:%JWPX
MOM5U31[VXTY)3;WMB=HDCD20*5;##HP'()KHKWQ"EKJ<NFVME->75O:K=RQ0
ML@81DL%VAB-Q)1N/;DC(R ;5%0VMP+NS@N55E$L:R!6ZC(S@U-0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWC
M"P@U/28;*\T9M5L9K@+<QQGYXDVL1(O(.0P7H<X)QFNAHH \JN_#/B+_ (0/
M5-/B:]U"*WU*"YTN*\<?:7@C>-V4D^X?:&YP!TR!5^XT[5O$'CB:]DT:\LM.
MO?#TNG&69X]\3O)D%E#'' / )/3.*]&HH X3P9>>*+73-.\.ZCX>DMIM/1+>
M74#*C6\D28 9,'<690!C QG)]*J>&1XG\++=^&1H,MU$+J:2PU-94\@12.7S
M+D[@5+'@ D]O6O1J* /-YK+5O#WC+6)3X6.O:;JTJ7,,T/E>9!+L5&1]Y&%.
MT$'H/>I?$OAT:M) MYI%W;7UM9*]EJ>CMM:"<E]T0((.T?+C(VG)R5KT.B@#
MS75?#UYJ]CIJ:_I]]_;5KIL;1:SI3!98[KYMZ94CCA3R-O)Y%26.E^)-'\3Z
M-XCU*!]0DFT9-.U06V&>&56WB0+QN!)(.WOSC%>BJZL6"L"5.#@]#Z4M 'E/
MB#PKJUUX:\875MITSWVO7MO)!9JR;DCB,8!8DX!(5FQGN!UKJO%VFVNOVUA;
M:EHEU=63EI&F@^6>RD &QQ@Y[L/ESVXQFNLHH YWP3::Q8^'A;:S<SW$J3RB
MWDN2#,8-Q\OS".K[>OZ\UEZ]#K=SXN>VETJXO]$DL=MNL4J+$MQD[C,"P)&-
MN.& [ FNVHH \FTK1M>A\.^ +6?0[N.72+S?=C=&=B"-UW<-W+=!S@5-KWA3
M5]?N_B!:Q6DMNFK068LIY"H21X020<'(!.!R.]>IT4 ><7L^OZ]JOA"]D\+Z
MA;2:?=M)>J[Q (3$R$J=_P RY.<\9'3)KO-5^W#1[TZ8$-_Y#_9A)]WS=IVY
M]LXJW10!Y7I^FZY+XA\&:O-X=OQ<6J7$>I3W,\32-(\07=]X_NPV< 8P#PO3
M-FQ\/7L/B73]7T;3[[1;R:[)UFU+#['/%AMTF,D;R=N-O(SR!R:]+HH \TL_
M#U[%XFL-7T;3[[1KV:\)UBVW#['/%\VZ3&2-Y^7&WD9Y'4TOV&YMK'XARZEI
M#M:Z@[2V\<\BHMRODJ@7(.5)88'0\C%>E51UC2++7M+FTW48C+:S8W*'*D$$
M,"""""" 01Z4 >>Z+=26NIZ%+KV@^)%EL(Q96MU<QP-#"TFV/<QC;))^5=Q!
MP#[DTAT;66\&>/K'^R+H7.JWUU+9H=G[U)$55.=V!RIZXKM-/\+6UA*DDVHZ
MI?\ E$-&M]=M*J$=#C@$CL3DCK6XK*Z!T8,K#((.010!YOKGA_\ MBWLA<:/
MJEIJ%IIL7V'4[!@LT4_S!HF(;IPIY^7YCR*[G0TU&/0-/35W1]26WC%TR=#)
MM&XC''7-:%)O4.$W#<1D+GDCU_44 </HUIJ?A3Q#XD1]-N;ZQU.[.H6DUOM8
M^8R@/$^2-O*C!/&.XK&F\):IHWP^\+Z);V4E[=6>J07MR("NV,"8RN 6(SC=
M@>N*]15U8G:P.TX.#T/I0SJN-S 9.!D]30 B-O16VLN1G##!%<+;V.K:?XI\
M9N=)N)K;4UBEM[B-TVMM@"%<%L[MP],8YSZ]Y10!Y8FBZRG@;P'IYTBZ-UI6
MHVLUY&"G[M(PP8YW8/48QFI[6RU?P[XBUFTD\(C6K/4;V2]L[U#$/+,G+1R[
M^5"G/(SQT!Z5Z62%!)( '))H!#*&4@@\@CO0!':QO%:0QR>7O2-5;RUVKD#G
M [#TKA=*TS4O WB;6F@TVXU#0M7N3>JUIM:2UG;[X9"064X!!7.,8Q7>JZ,S
M*K E3A@#T/7FG4 <QKUA>^+_  QJNF+ ]A%=VCQ1-<8#M(>A(!.U1CG/)R>!
MCG#N=.U;Q1X=\/Z->Z5<6-S9W5M+?2R%?+00\DHP)W;B !CH#SC%>AD@ DG
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MR,QXSD##=<=JP=/T+6[/X9WW@.73)9+H)-9VUX-OD212,2LI;/R[0W*XS\O
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MR_#_ ,:Z6-&G%YJFI7,]K&9H?F21@5)._ Z<@_K0!VVJ>*(+*\:QM8X[F\2
M7#QM<)$H1B0OS-_$VUL#VY(XS@S^,/#^O:9X5U1M+GN[>_U...T=PH^RW(W
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M!D]16]10!3T[3+;2X#%;"0[CN>265I))#TRSL22<<<GVJY110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%'N+$#DLQ.2Q)Y)))))Y-4;WPQHFHZHFIWFEVT]ZD?EB61,DKG.#V.#R,]*
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M&M(Y;//V=PF63.,\GKT&,],<58L/#6D:6\#6=F(_LX(@4NS+"#P=BDD)D=<
M4 >?^'?.T77]"LM;TVWN1<O)_9OB&R(_TK=&S;9Q]X,5).<D$CZFH+2&ZC\
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M.35H:-IPU>/519Q"^BM_LR3 8*Q9SM'MF@"]1139(UEC:-MVUA@[6*G\QR*
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MUVSWRA;J02,&F & &.><#@>@XH \NM+>WU;3/A1<:C;PW<LN8I'GC#EU%N^
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M2UM(UB@CUCY(TX"@Q(< =A[=JE\4W1D^('A31[Q0=*NQ<N\;C*33(@V*PZ'
M+$ ]3@]JZ32_#VCZ+-<2Z;IUO:RW!!F>-,,Y]S4VIZ38:S;+;ZA:I/&CB1-W
M!1QT92.5(]00: /+-?@DTO\ X61I5DNS1AHRW2P+Q'!.Z.&"#HNX+N(']:M7
MOA^TT6]\#:QHJ20ZM=WD%O=,LC,;F!HBTF\$\A0N<]ORKTB'1M.@LI[1;2-H
M+G/GK+^\,V1@[RV2_''.>*ATWP[I6DNCV5H(VC0QQEG9_*0]53<3L7@<+@<"
M@#C-.A2?4?B9'("5,ZYP2/\ EU7N*S[47#?#[X<L/W]IOM_M-D"-UROE'&%/
MW]I&\KZ+GM7H4?AO2(FOVCM K:A_Q]D2-F;_ 'N>>./IQTKF?%7A3?:Z186/
MARTU70[1G,FG-,(W5B,(T9;C !?Y<CJ/2@#*FTBVT*P\<:YJ(N]+TBZ4+:+;
M';-$A15D*+T0O)R <'N<9I^D626GQ3BL7LK*TMKGPZWFV4&&1@)D5?,X 9L,
M1G'<C)K4\.^"-.@:Z9O#R:7875LUO/ISW)G$^2#N=02@VX(&"3\QZ8%;UEX/
M\/:?<VMS::1:Q3VB%(90F60'&>3UZ#DT >66FG6"?LYZI+';0Q3F.[9GC4(S
M;+B0+DCD@#C!KK6F6_\ B5I>BZG&DNG#0?M-M#*H:.2?S K'!X+*@&/0$GO7
M3#P?X>%G>6BZ3;K;WK^9<QJ"%E.<_,!U&23CIFI[KP]I5[;VD-Q:!A9G-LX=
MEDA.,?(X.Y>..#0!Y'XCMI+;P=\0M+0O_96G7]O_ &?ACB$N8VDC7_94MP.@
MW5UQTVST/XNZ:-/C^SB^TJY-VP8DS,CH59R?O,,GD\UUMQX:T:ZTDZ5/8126
M#-O> YVNV<Y;GYCGG)SSSUIS>'],?48-0>V+WENGEQ3-(Q9%/502>A[^O>@#
MS_POYVB>(="TW6],MYI9ED&FZ_8D8O08RQ$P/S!BOS9R<GIWKI?B=J5[I/P]
MU2\L7DCE41JTD7WHXVD5788Z$*3SVZ]JV=/\-Z1I;P-9V8C^SJ5@4NS+"#U"
M*20F?]D"M*:&*XA>&:-)(I%*NCKE6!X((/44 <!KMC;Z-XI\'7GAR&*!KN[-
MK.EL JW%L8V8E@/O;=NX$],^]+X2TG38?B9XU>+3[1'MYK/R66%08MUN-VWC
MC.3G'7-=;IOAW2=(='LK01F-#'%EV?RD/54W$[%X'"X' IUGH.F:?J-Q?VMM
MY5W<D&>4.V92!@;LGYL#IGI0!E_$3_DF_B3_ +!T_P#Z :RM%\(PZUHGA.]U
M6_N;J#3[:WN;:TPBQB41C:S8&6*]N<?6NPU+3+/5[)[*_A$]M)P\3,0KCT(!
MY'L:=8V%MIMG':6<?E6\0"QQ[B0@'  R> /2@#R'Q.UK+H6L:QI@WM#X@B_X
MF%RP-P)1-&C1Q8 *QJ,@9/(W<8.:W+WPYI6O?%S5;+4H#<6DNB02O$96"L_G
M.,\'M@8KJY_ _ABZ>]>?1+-VOGWW!*??;(.[V.0"2.N.:NP>'M)M=4&I0621
M7@B$(E0D$1CHF,XVCL.E '&^#]&TK_A+O&\?V&V3%]'&A1 K*K0*6 (Y&>2<
M=>:YOP[J2V_@7X;6E_)MTF^N98[PN?ED;$AB1SW!?!P>N.:]6/A[2/[3N=3%
MA$M]<H(YKA05=U QU'MQGKBH3X2T!M .A-I=NVE$Y%JP)13G/R@_=YYXQS0!
MRWB;0=(TOPAXXCT^653-9/=R6B/B*W?RFVE%4#;N*[B.YP:S+W3;74/$7PVM
M[D.T5SIMPLR"1E$BK;QD*<'IR<^H)!XKO;?PKH5IH<FBV^FPQ:;)GS+=,@29
MZ[N<MGISFN<UWPQ+<>+O"9M=)F?2-*2Y21TN%3RMZ*$V9</P5[=!C% '*M:V
M'AQ_'.A&:]@\/+-8BV@M9,,DTV"T*%N K';D'@*U:^G6HA\>^*-.D@M;6";1
MH)9+2S8B-7S(,\8RV .<#C'%=S+X;T:?2)]*GT^&6RN&+S1R MYK9!W,3R6R
M!R3G@5!%X.\/03B>'2;:.;R#;^8BD-Y9SD9'/.3D]3DT >7:;IMI9^"?AOK4
M$974WU*SA:ZW$N8WW!DS_=([=*ZWPGIVGP_$WQO(EG:I+'<6AB81*&4O;@MM
M..,G)..O-=-_PB6A?8;2Q_L]/LMG();:$.VV%QT91G@CMCIDXZU:30M*CUE]
M86QA&HN@C:YV_.0!@9/KCC/7'% '+_%A$_X0AIRJ[X;VT*R$<IF= 2#VX.*9
M/%;O\;$APG[WP])YRJ<%OWZ $X]J[+4=.L]6T^:PU"WCN+2==LD4@RK"LVU\
M'^'[*>&>VTJ".>&(Q1RC.]%/7#9SGWZ^] 'D=GI=G;_"'1-<CC/]J6VK+Y-T
M7)>,&]*E5)/ ()R.ASDUW.E_9/$?Q \6V.M017!L!!#:V\ZAA'"T>XNH/=F/
M+#GA1V%=%_PA^@#2DTL:;&+!)/-6VW-Y8;.<A<XSGGZ\U)?>%-#U._@OKW38
MIKN%/+69B=Q3^ZQS\P]FR* /*?#=]]G\&_#W3II[>+3;R:\25KN,R0O(KOY2
M.-RYR2V 3C('I5WQGX<@T/P!XOBCU)90\MO<K:6\1BBLV:100@W'&[J5SQZ<
MUZ*?!GALZ"=#.BV?]F%MQM_+XW?WL]=WOG-">#O#L>@_V&FDVZZ86WM; $([
M=<MS\QX'7/0>E %K2- TS0C=-IUMY+7<GG3L79C(^ -QR3R<<^O6N1N-.T]_
MCE'+-9VK/_8)FWO$I/F+<* ^2/O 8 /45WL,200I%'G8@P,L6./J>:HWFA:5
MJ&HVVH7=C#->6H(AF9?F3//!^HS['F@#Q[4-*LYOA[X]U62+=?66N7LMK/N.
MZ!UE4AD_NGU(Y/>NUU) ?BQX1N.?,FT^\WG)P<+'CCIW/YUT7_"(Z%]@NK#^
MST^R7<AEN(2[;97/5F&>2>^>N!Z58_X1[2OMUI?&US=6:>7;RF1BT:]P#GH>
MX[]Z //M/,VA^)-*&LZ;;WUI=ZC(VFZ_9D>87E#XCG4C/1B,@X^5?3CU-F5%
M+,0J@9))P *RK3PUI%E-');V83RI&EC0NS)&YSEE0G:K')Y SR?6K][96^HV
M<MI=Q^9;RKMD0D@,.X..U 'FVLZ%K7B_PIJUU;V-GYFI2+>6%P]XZ31+'@P8
M3RB <#.-W61N16D_E?%'X2"5%47MQ;%DXYANDZCV^<$?0^]=M;V-O:6"64"-
M';HFQ$#M\J^@.<C';TJIH_A_2M CECTJRCM(Y6WND9.UF]<9QGWH \K_ .$D
MMGU7P[X^^QQ1:?'$FFZHPCYCED7KCMY;!5SU^<CM727]A8V=KX>LKNV8ZGJ6
MH/>?8594AFF*N[+,2#E$!XX)RJX!KM/[%TPZ>UA]AA^R-*9VAV_*7,GF;L>N
M_FFZOH.EZ]##%JEC%=)#()8MXY1AW!'(H \@OX@/AE\1[1S&$M-4E,,<!*QQ
M?+$2$&>%RQXZ<GBNC\0Z=IOA_4?#MI!#Y%CKNI(-4E:1B+AEC)17R<?,V,_W
ML<YR:[!O!?AMHKR+^QK58[PJ;A$3:LNT  $#MP..G&:MWN@:5J6C_P!DWUE'
M<V. !#-E@,=,$\@CL>U '):/I]GIOQGU>.RMXK=)-%@D9(E"KN\UP2 .!T%=
MEK&I)I&D7-^Z%_)3*QCK(YX5![LQ 'N:J:?X4T+2KX7UEID$5X(A")\%I-O/
M&XY/?KUJWJ6DV.KQ1Q7\ GCC<2(I8@!P<AN#U!Y![4 >8>*=+U[P_H>C^(WL
M;(W>@7)O+J:WNW>2=)3_ *0-IB4 '<3][@#O73>,9S>IX6N[5UN]-FU".26U
M0@FZC:-BI53]\+]_;Z+GM767VFVFI:?)87D7G6LB['C9CAU]#SR/KUKC/%'A
M)3:Z38V'ANTU30[5I&ETYIQ&ZL0 C1EN  "^5R.H- &9/X8-KI/C_4Y+1K6R
MNK:1K" L4,:K#EVV@_*&D&X#KQG S5"YLK#PY\/_  YJ]NJVSZD--M]4O)2[
MJ8-H/SC</ESA3C'RG'3BNE\/>!]/@>Y?^P?[(L;FW:";3_MC2B?)!RX5BHP
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MK'!+>:5=^?L&#<,IC*ESU9LD\G)YZUB^';33_$WA'1-7N=;@M]2M;E)II8H
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M\09&D$"N"0"..,G&5![5Z'X3T6ST75=;%GJ2W NI(YY+6&,)#;N00=@!."V
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M[YZ"@#TL$,H(((/(([TM<5\*"1\/K2+<2D-Q=0Q@G.U%G<*/H  *L_$V^O\
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MW6@Z3>_9/M.GV\GV,@VP*#$)'0I_=Q[5')X:T26:\FDTNU>2]4)=,T8)F4=
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M< %CR0.PSQ5J:[MK=XTFN(HWD.$5W +'VSUI\DL<6WS)$3<<+N8#)QGC\ :
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M/EF8]2X_B/UK2EN8(1F6>.,;2V7<#Y1U/TILM[:P",S7,,8E.(]\@&_Z9ZT
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M/+$/V9HP8]@& NWIC':@#S[35B_X6]-:W9TW9/X>19+:W&8_]=A5;/WS@\'
MR".*YC3+"'2_@ WB'2K-%UJ.TGB6\C7]ZD37!5\-U&$R1Z8SZUZ[!X9T&V,)
M@T73XC#$T,12V0;$;[RCC@')S]:LV.D:;IEHUI86%K:VS9W0P1*B'/7@#% '
M :W%HB>)OAQ=:6MJL!GE6WDBP,Q&!L#/<9Q^)]ZW/B?>7%AX"OKB'S!&LD(N
M3%G<(#*HDQC_ &<@^Q-:EMX/\-6;H]MH&FQ,DGFH4M4&UO4<<'D_G6S)&DL;
M1R(KQN"K*PR&!Z@B@#A]471ECO-;\,212ZX=$FCM$LG!1HU&Y"47CAL $^N/
MISFHQV\_PA\+ZMH@7^UXI;)K29/]8\[NJRJ3U).7W ]<'->F:5H&D:$DJ:3I
MEI8K*VZ06\*IN/O@<T6V@:/9WC7EMIEI#<,Q<R)"H.X]6]B>Y[T <#;:#I%]
MX[^(4=UIUM-&(+1@CQ@J&:%\MCIN]^O)]361IZ07>B?">:]2*4LQC=YE!RH@
M?"DGM[5ZK_8&C^?<S_V59>==#;<2>0NZ8>C''S?C3&\-Z$^GQ:>^C6#644@D
MCMS;(8T<?Q!<8!]Z /+?&ESIUYX?\?3:<8%$1CCN)KE][/*J+L6%<C8HX(;)
MR=V!WKI-2%O-\3/ EV@B>6:TOE>5<$OB-.">^"6_6NNG\-:%=7=Q=W&CV$MS
M<1^5-*]NA>1,8VL<9(QQ3_[ T;S[6?\ LJR\VT4);/Y"[H5]$./E'TH \DDT
M+29/ WQ,F:PMFDM=2O3;L4'[DK'&PV?W>?3'0>E;K:DD_C?3[+5]0CMHKC08
M7LVN41DE<LWG %^-Q&SWP*[H>&="6"X@&C:>(;EMT\?V9-LK>K#'S'ZT7OAG
M0M1L(+"]T>QN+2#_ %,,D"E(_P#=&./PH \Y2+3] U3P3H<6HR7GAQ[Z[_?3
ME3$TZKF*/(&"H=FVC^\H]*WO"T5I;?%?QM';+%'OBL794P,MLDR<#OZ_6NNN
M]$TJ_P!+73+O3K2:P4 +;/"IC4#IA<8&.V*;8:!H^ES&;3]+L[64J$+PP*K;
M1T&0.GM0!ROCFVAO/&'@BWN(Q)#)?7 =&Z,/(?@^H]1T/2N5U-VT&U^)D.E1
M?9[6WN;*0PVR8$<;I'YQ51P,KN)KUB[T?3;^Y@N;S3[6XG@YAEEB5FC_ -TD
M9'X4EOHNEVMQ<7%OIUI%/<C$\B0J&E'^T0/F_&@#D-.TCP[J'B.PU:UUF"]>
M>R>W^S6T<0BG@QG]XJC[JG&,]"0.]<;H^G6NG? .'Q!8V2C5$LVCDNXUS,(#
M<8E /7 0'Z8KUK3_  SH6E1W$>GZ/8VJ7/\ KEA@51(/0X'(]JLV.E:=IEH;
M2PL+:UMCG,,$2HASUX Q0!Q^E:9X?O?$FEZS8ZW%=226;P);VB1+'- 1G]XJ
MC.U3C&<8) [XKB)K.U/P1NE\F,"#7F$) P8_]."_*>W!(XKU_3?#>B:-Y_\
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M)!<21QA5G(MF+9P.0S#)!ZYYZUI7WA.]N=>U";4O"7A_7DN9]]O=SRB*2*+
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MMCI]_P##&\M+:*&ZN%*33(N'E5K0DAFZMR!UZ5L_#R"R@UCQ>$BMXYQKLR(
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MX<ND;* /+W9&!QD$=JFU>&72M<^(<.@0BWF_L.WE2.V4+\^)064#^+;TQ[4
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M&Y"MZ2>.V ?UKJK34]'N/&7C32O$ES;1_:(XEA^TRA%DLFBQA&)Z;BY..YH
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MUU[4$@<Q F$!B J_W1@]!QS7-RKI\_[-EF0+9YX(K5B1M+1L;A1GU!^\/SH
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M]J$=[=Q6^F#7+FVTIII JM#YF$1">HW!P/TH [^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&ZM;>^MI+:[
MMXKBWD&'BE0.K#T(/!J:B@"C<Z-I=[;0VUUIMI/!!CRHI(%98\<#:",#CTJU
M!!#;0)!;Q)%"@VI'&H55'H .E244 5I].L;FZBNKBRMY;B$$12R1*SH#U"DC
M(S[56'A[1!;26PT?3Q!(P=XOLR;68=R,8)K2HH SKW0-'U*"""^TFQNH8/\
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M;9Y>FQ95+?EF@"U1110 4444 %%%% !1110 4444 %%4DUG3)-2.G)J-HU\
M2;83*9,#K\N<\4ZZU33[&:.&[OK:WEE_U:2S*A?Z GF@"W134=)%W(RLN2,J
M<\@X/ZTZ@ HHJ&[O+:PMGN;RXBMX$&7EF<(JCW)X% $U%-1UD171@R, 58'(
M(]:=0 45%/<P6L?F7$\<*9QND<*,_4TD5W;3P-/#<121+G,B."HQUY% $U%4
M[#5M-U3S?[/O[6[\EMLGD3*^P^AP>*N4 %%%% !1110 4444 %%0?;;3[?\
M8/M,/VSRO.^S[QYGEYQNV]<9XSZU/0 4444 %%%5S?V:WZV)NH!>,AD6#S!Y
MA4=6V]<<CF@"Q1110 45'-/%;0M-/*D42#+.[!5 ]R:AM=3L+Y ]G?6UPI;:
M&AE5P3C..#UP"?PH M4444 %%%% !1110 4444 %%%% !14=Q<0VEM+<7,J0
MP1*7DDD8*J*!DDD] *@;5-/0VH:^M@;O'V;,J_OLC(V<_-QSQ0!;HJO%?V<]
MY-:174$ES  984D!>,'.-PZC.#U]*L4 %%5[6_L[[S39W4%P(9#%)Y4@?8X
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M^?450^6S[PKI@_,,GG.,?3D [ZXUA8/'&CZ2^DV[RW%C-+#?,XWH%V[D VY
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M4BZJ;2^0Q7S,N!A1CHWS;B >,<]0 :8^(,Y\ 6_BG^R8\/=_9I;?[2?E_?\
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M8F]^WV[F2)@,[H^5!WC&0.X]*I6OC>9]?TNPFLH'@U)6"RV=P9C;.!D+*-H
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MKB6[M4MKRSO)K*YCC<NGF1M@E20"0>#R* -:;4+."^MK&:ZACN[D,8(6<!Y
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MA_Q-=ZEK]_I-Y98$$2S0WL".(9E/!7YAPX/;)R.:H?$=01X4) R/$EE@_BU
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MRW\7OX=TK1[2YF;36OH99KHH#B14PPV\=3TSDD=!G !O_P#"/Z+_ - ?3_\
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M[<+RW-GMW?:!*OEX]=V<8H YVUT'4K3Q]>ZTD-I]@DTZ*SA03L'!1F8$C9@
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M@5((W G@\9Z&NBHH \T_X5]J=IX5M=.L?L'GG7%U>>/S62&("0/Y4>%)(
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MDNE-8LOG,9 QD5\@;,$<8ZUU-4I-7TZ+58=+>]@%_,I>.VWCS&4#).WKCWH
MQ_&NCZKK.F6<>E-;LT%[%//:W+E(KJ)<YB8@'@D@]"..16!+X2\22R>-"1I0
M77[-(HE69P(G$)BP?DZ#.<]\=!GCT2B@#AY?#.MO+X*<1V/_ !(_^/G_ $AO
MG_<F+Y/DYZYYQZ4S6='M-;^(6D7=C>H2('&I1Q,&66&.17C5B.A$N/J-X[&N
M[K%BL_#G@VQN[N.&PTFUD<RW$N%C5F]2>_L/RH VJ*9#+'<0QS1,'CD4.C#H
M01D&GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->:;=23L) RA6E\P!LYP1D\A".,5O>'+7QDKPIXDO-+:*V& ]B'WW)Q@&3<
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M#D8.,$#/KZ8UO\/_ !#:^&;!+?4K"'7-+U&:^LY0KF%Q(SEHY.^"'(XZ8[T
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M78ZP^7@G!^4>O)/HM.MHO$GA?0/"FE6PTJ4VYAL[U"\C/+&-J;HN!R!ECD8
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M5A@NW<X[9/;M7(3^%=;&O>*[BRO[:WMM<MT"3#?Y]O*L)C! '&,X;.<\8QW
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M@!G,(9.,<<=>O/3BNG.NWNI:]J>EZ,MJ#I:QBXEN0S!Y77<(U"D8PN"6YQN
MP>:YE? VO+\-+;PQOTTW,5Z+@S>>^PK]H,^/]7G/.W]?:M6'P]K^C>,=2U?2
M&T^6SU@1O=V]S*ZF"9%V[T*J=X(Z@[<^HH 9\(<_\*MT7*[3B;(]/WSU-K7B
M77X/&(\.Z3IMA+)+IKWD,UQ.RC<KJN& 7@<]LYR.G-7/ 6@W_AGPA9Z1J,MM
M+-;E_FM]VTAG9N^/[U-GT/4W^(]MX@3[)]ABT][)E:5A(=SJ^X#;CC;C&>]
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M0QNRRCY <AB!@\#DY.  =_17)S^);^[U_6-*TN.WADTRRBN6:[C8^:\@8JH
M8;0 N">>3TXYR[+QUJMUI7A+4Y+.SBAUV\6W:$%V:-61F#!CCGY2,8]#F@#N
M[FY@L[:2XN94AAC7<\CMA5'J34>GZA::KI\-_8SK/:SKNCE7HP]17/6NNW=[
MXB\4Z)<1P>5IUO"\4D:D,PE1R0P)/3;VK"\&:C?V'PP\(BSBMUAEA"W-Y<L/
M*M8PK'<PW*3D@*.1UH ]'JG=ZI86-[96EU<)'<7KM';(V<R,!N('X"O-M?\
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M2)?,8&,I'Y>6^7OG/'3ISUK*3P+K^GZ5X:GTC4;&#7-$MC9DRAVM[J$@95\
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M3_-TN:2>=4+J'+H4VIP>@.<GJ>PK>N-;TVTUBSTF>[1+^]#FW@P27"J68\#
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MT 16L+6]K%"\SS.B!6E?[SD#DGW-2T44 %%%% !1110 4444 %%%% !1110
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MPBD_T<HRA@XW?O.&'39GVJ+5? 5S?>&M7L8KNW74-7ODO+JX9#L4HR%45>I
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MV<#3,J]6P. /<GBN7\-^%/$^@I#H[:_;3>'K9@8/W#"[\L'*Q%]VT+VS@G'
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M?Q$8_6JEIX4U31;C6X='N[4:?JT[W.VX5M]I*XPY4#AU)Y"DKCUH J#QU=W
M\(ZM;I;1Z#KCB"8RQL98)64[%W!@,%@5SC@^N:UKW5];%IK-SIMO:7*V\ZP6
MJO\ NQP5$KNQ?!5"6X&"=A%,U#P39S_#W_A$[1S#'%;+';3-]Z.1,%)#CON
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MD"2^8!M[9)QU[>_%R;PMXCT[Q/?:IX<U>QM[;5"KWMK>V[2K'*%"F2/:R\D
M<'CC\@#J]*NYK_2;2[N;22SGFA5Y+>3[T3$<J?H>*N5#:P&VM(H&FDF9%"M+
M(<LY[D^YJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5D*W)0'!;(7,8)7J>F1WZ>]\0:G-JU_H]A*%N=/MXC+.EBTHDFD!(&T-\JX
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M;6KS5/%FH:%IDT5LNFV\4ES/)%YC&27)1 ,@8"KDGOD 8ZT :VC:UI^OZ?\
M;M,G,UMYCQA]C+\RDJPPP!Z@U6G\5Z-;:I)IDMVXOHT\QH!!(SA,XW8"_=SW
MZ5S_ ,)O-_X0IO/V>=_:-YOV A=WGOG&>V:HW$UU!\>9FM+/[4Y\-H"GF!,#
M[0><F@#N=.UBPU5IULY_,> @2HR,C(2,C(8 \U>KGK>36K[3=1N(K2VT[5][
M10BX'FH53E-Q4C(.XG(Z;O:LKP5XFUCQ05:X2WM38!K;5(&B.\78)!5/GX4#
M!R<YW#'0X .VK.LM=T[4-6O]+M9R]Y8!#<Q[&&S?G;R1@YVGIFN;M-=\1:_H
MB:]H*6<D#7C1Q64RX,D"2F-F,F>&.TL.,#@<UF(NKO\ $KQF-'N+2VG%E8L9
M;B$RC(67 "AEZ^N>,=#G@ ](HKAM/\6:IJ_A;PUJZBTLH-00M?7+D'R6"G:L
M:$Y8LXP!S@=C67/X\UQ?A]?ZU"EF;VPU4Z>_F0.JRJ)UB#!2<HV&!(.<$'B@
M#TVBN1L=:UNW^(#:!JDME/!<:<U] UO"T9A*R!"ARQW## [N/H*PCXXUVX\*
M:1XBL_L:_P!I:F+(V4L#,85:5HQR&!+C;DCH>>!B@#TNBN)O_$FL75UK%EHX
M47.EA8LBR>99YS&)-IPPVK\RCUZG/'/1Z;?WMSX<@O[VP:TOFM_,EM"<E' Y
M7/UH +OQ!IEE>FRDG>2["AV@MX7GD13T+*@)4'U.*ET[6=.U8S"PNXYV@(69
M4/,;'^%AU!]CR*XSX-$W?P_BUB=_-O\ 5+F>YNY3U=_,91^ "@ =JV_$^HVW
MA.RN]9M[=&OKZ6"U52<+)*6V(6QZ!N?90* .FI'19$9'4,K#!4C((KD;K7=5
MT+Q9I&DZA+;W5KK"RQPSI"8V@G1=V&&XY1AT[@CDFN;G\:>*T\$ZKXD$FE#^
MR;Z:&2W%N_\ I"1R[" =_P G'/\ %SZ4 >BV.BZ5IDCR6&F6=H[_ 'VMX%C+
M?4@<U>KC3K>O6'C?2]+OI;&6TU>WN)(4AA96MGB"M@L6.\$-UPO(Z#I7/S^,
MO%B^#M<\0++I0.C7\\+P?9G(N$BD"D [_DXR?XLGTH ]2JE8:M9ZG+>Q6LC,
M]E.;><-&R[7 !(&0,\$<CBN:&NZY9>-=%T^^DLI;'6H)WCCAA97MFC56P7+'
M>"&QG"\]A5.'QCK*:%XMO)K:&YN-'U(VL2VT#?ZH",ERNXEB [,0",XQQ0!W
MU0W=U%8V4]W<,5A@C:60A2Q"J,G@<G@=!7&+XON'\+:KKFE7MKKEI!'&UNUK
M"?,4DD2>8@.25!#8^4D<>]/@\47-YX7UK6M(U?3=3MK:T\^UE$1!#JKLZ2J&
M!!X7'W>O0XY .OLKR'4+&WO;9BT%Q&LL;%2I*L,@X/(X/0T6UC:6;3-:VL$#
M3.9)3%&%,C'^)L=3[FN1M?%EY?1^$]/B,,>HZSIXO9YBA*Q((U9MJYY)9@!D
MX')YZ&C?>,M:TV#Q;I\HLWU30[07UO.8F\NXA*EAE V0P*D'G'?':@#T.BN$
MM?$?B"#Q!X6BU"2PELM=A?\ =0PLKP.L7F [RQW9Y!^48]ZW?%?B!O#]A9F%
M$>[U"^AL+829V"20XW-CG  8X[XQQG- &]17(2:[JNE>,['P_?2V]Q'JMM+)
M972PE2DL8RZ.H;#+@@@@@]O>J_@76?%'B73['6+^73$L9#<1S00PN'9DE9%9
M26( ^7&#GIG// !V]06EC:6$1BLK6"VC+%RD,80%CU.!WK$U[4=2M=5MK>*:
MWL[&2!V-RZ^;*\P(VQ)$#EN-S' /3''6N7C\=Z[=^#?".LV\-@L^K:C'8W,3
MH^WEW4E3GY?N=P>OM0!Z517%6&K^)9==\0^'I;G3I;^UMH;JRN5MF2/]YN&Q
MTWDX!7J&Z&F:/XKU+6O"VCRQ/;1:U=7GV6ZB: E8'C+><"N[(VJIP2>I7UH
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MS?9TQDG&!^(J[I/B;4+WQA-H"WUM=12:5]MAO4MBJK() A YQ(G(((/8C)H
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MUN+N/8)57=L(((.._('%9LWA?5+O7_#^L76L6\DVE+,'5;(J)C*H5L?/\H
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M^<X;"J&^0+R /FX)JF?AV;70],M=*U".UO-.U)]1AD:WW0AG+;HQ&&&$PY
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MRP7Y<="<GH #N:*I:1-?7.CV<VIVJVE^\2FX@5PPCDQ\P!!((S[U=H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MP?%OAV3Q1HRZ<MZMHOGQ3,YA\PDHX<#[PQRHS6]10!S<WA5[KQ=_;ES>121M
MIS:=):_9R \;-N8[M_!R/3I^=9_A[P1J6@F&R/BBZNM"M7#6UB]N@= #E5:7
M[S*#CC Z =.*[2B@#G- \+OH[:V+F\CO(=6NY+N2/R-FUG4*RYW'*X45F^'_
M  -J.@M%8CQ/=7&@V[A[>P>! Z '*HTWWF4''&!TQTX/:T4 </>^ +JX7Q):
MVVNM;:=KIDEE@^RAF25T",0^[E3@';@'W%78?"%S#K6A:B=6$ATFT>T5'MN9
M58*"20PP?E&./SKJZR;WQ#96'B#3-%F6?[7J7F>05B.SY$+MENG0=.3R* .;
MF^'"W>DZS8W6J,7O]2.J0SPP;'M;CC!7+'(&T<'U//I;@\(:G+XCT[6]5UY+
MJ>TMI+9HXK)8DE5R"<Y9L'Y>?TQ716NI+=:E?60MKJ-K,H&EEB*QR[EW?NV_
MBQT/H:NT <3H7@._T&1;&#Q-=/X=CD,D6FM NY!G=Y?G?>*9[8''&<9SK:%X
M<GT;6=:U"2_2X75)UG:,0;/+8*%&#N.1@#MUKH** ,#PE#K,&G72:SJ+Z@_V
MIC;W$EL(':+"]4'3#;P,]1BI]2TN_NK]IK>_MUMI+?R)K2ZM?.C?DG=]]>>2
M,="/PQL44 <5_P *_P#L5KX;71M5:TN="66.*6: 3+*DH&\,N5QR 1@\5$WP
MUAN=*U^PO=7N9TU:[%Z)%14>"8!<.".IR@]!U&*[JD9@B%CG &3@9/Y"@#F;
M'PWK*6%Q'JOB-M1NWMVMX96M%B2-6ZL44_,QP.2>W &3FC_P@EP/#_AO25U>
M,)H5S%<12&T.93&"%##?P,,<X_2NAT#7[/Q'827EB)A%'/);L)H]C;D.&XZC
MGUK4H 1MVPA2 V."1D9^E<EI/A#4-&TK[)::XJS#49+\2FT^4[RQ:-EW\J2Q
M[@C'KS7744 <I;>#Y[&:]O;'4HK74+V]2[F:.UQ"=J;-GE[NA&23NR2<\<8K
MW?P]MK[2/$-K+=+%<ZW+'-++;0[$C>/:4*H2>Z@G)Y)/2NSHH Y!/!M_/XAM
M=:U+7WGN(K*2SD6&V6)75R"=O)*]!ZG/<#BL^T^'-[;V.@VC>)I631+CS+4K
M9HO[O:R[6Y.6PWWNG'W37?T4 <BG@RY6#Q1%_:L9_M\L7/V4_N=T8C./GY^4
M=^_Y54G^']V@T2[TO7FL-7TNS6P^UK:ATN( !\KQEO49R#US[8[FB@#D-8\#
MMJNEV0&M74&M65P;J'50BEQ*1ALIPNPC V^@'OG9T/2[[3X9'U357U.^EP'G
M,*PJ%&<*J+P!R3U).>O0#6HH R_$>B0>(_#M_H]PQ2.[B*;P,E&ZJP]P0#^%
M9LG@G3WU30+X/('T>-XQDY\\$ _.>Y#@/_O<UTU% &!J?AV;4/%FC:XM\D0T
MQ9E6 P;O,$H ;+;AC@#''YU5M/"=S:W/B2<:G&S:V=Q!M3^Y(0(,?/S\H]N?
MRKJ:* ,KPUHS^'O#ECI#7(N19PK"DHCV%E48&1D\U4;PY<?\)NWB1+^,$V'V
M$6YMR0%W[]V[=US[=/SKH*175\[6!VG!P>A]* .&B^'(7P_'I[ZJ?M5MJ+:E
M9WD<&UH)BY8Y4L0RY8C'''YUN6_AQI-7DU;5;F.ZOFM#9H883$D<9.6PI9CN
M8XR<]  .^=ZB@#"\(^'IO"^@P:3)J37L5LOEP,81'M09P#C.3SR?8<"H]5\,
M/=>)+/Q%IUZMGJ<$#6KEXO-CGA)W;'4,IX;D$$8/K70T4 <=J'P]L]3T:_MK
MB\E74;R\6_;4(5VM'.@ 1D7)PJ@  9/&><G-3IX0N-0T:]L/$^L2:NUW;FV+
MK MNL:'DE57/S9 .23]T8 []510!R_ASPSJVDF!-4\23:K!:+MM8VMUBVC&T
M%V!)=@I(SP.22"<$8LGPTNV\/3Z GB)X],^V"ZM8Q:+OB_?>:59MWSC.<<#&
M><]*]"HH YVT\-W-MXSN/$+ZDLOGV:6C0&WP=J$L&W;NN6.>,>U="0&4@C(/
M!I:* //8?AK>1:%IVC?\)(_V+3+V.ZL@+-0RA'+JKG=\Q&<9X'J#QC=M?"]W
M:>(-<U9-3C9]5ABB*/:\1^6I53D.,_>.>GX5TM9-UXALK/Q'8:%*L_VR^21X
M2(CLP@RV6Z=QP,]10!SL?P_GB\->'=&36$V:)>1W4<IM.93&3M5AOX'S'./;
MI4UYX*U!/$UUK.@^(YM)-^$^WP"U29)648#J&/R-CC/-=E10!SEYX;NY5EMX
M-2B-A-9+:26U[;&<,06S)G>OS'=SG.<"H(_"$]GIT>EV.HQ'3%TZ.P:UO;7S
MPP3=\_#KR0V",8X%;NI:DNF1V[O;75QYUPD %M$9"A8XW-CHH[GM55?$=BWB
M:7P^%N/ML5I]L;,)"&/=MX/\1SZ9Z&@"QHFDP:%H=CI-LSM!9P)"C2'+$*,9
M/O7(:E\-Y[^Q\1Z<GB"6'3]:N#=M%]F5FCE.TGYR<LORCY>#QU]>IT'Q!9>(
M[2>YL5F$<%S);.)H]C;T.&X//7UI+?Q#97/B6ZT&-9Q>6T"W$A>(JFUB0,$]
M>0>G'O0!0B\,7D?BZ+Q"^K)+,FG&P,;VN-P+ARV0PYW#ICIQUYK'/PVWZ ;!
MM89+R+4VU2SO8K<*T$S,6/REB&7YB,<<5WM% '*Z?X5U&'Q>GB/4-;6YN/L
MLGBBM!$C#>7R,LQ'.._KSC@:?BC0(O$_AJ^T::9X4ND"B5!DHP(93CO@@<5K
MT4 <C#X1U-O$>FZ[?>(/M%Y9VTEN52S6.-PY4]-Q(^[SR2>Q'2J;_#R=_ ]Y
MX8;64\JZNC<M.+3YE)E\T@#?C[P_+\ZZ3Q'XALO"^CR:IJ"SFWC95;R8BYRQ
M 'L.2.216M0!SDOAFX?QA!XBBU3R9?L2V=S"L *RJKEP02<KR2#UX[@\UGQ^
M!IT\.>(]';5D9=<N)YY)1:X,1FX< ;^?;T]Z[.B@"II=I)I^E6EG+,LS01+%
MYBIL#;1@'&3CIZUS^N>$)_$%KJ.G7VI12Z7>S++Y3VN98 -N1&^[ ^[D$J<%
MC75T4 <O<>$[K_A*[O6M/UAK.._MXX+R#[.'+^7NVLCD_*<,1T-8T?PRDMO#
MV@VEGK\T&JZ&7-GJ*VZG"O\ ?1H\X93[G/O7H-% '(:MX,O-9\,RZ7>:XTMU
M<3133WCVPY\MU951 P"KE1QD]3W.:O'PY</XTM_$;W\>Z*Q:R,"VY 968.3N
MW\'*CMT]>M=#10!G:_ICZWX?O]*6<6_VR!X&E*;]JLI4D#(YP:P[GP=<W%IX
M:@_M2-3H4L<J-]E)\XHA09&_CY2?Q_*NMILCB.-G(8A020JEC^ ')H Y;5?!
M\^MVT]AJ.I13Z=)>"Z1&M?WT.'#[4DW\<C&=N<$CTQ9MO#,]CXMU;7+74RB:
MDL1EM6@##S(TV*V[.=N,$CCD=>U7O#^O6?B71X]4L!*+:1Y$7S4VME'*'([<
MJ:U* .$C^'D\7@_3_#RZRACLKX7JS&TY8B4RA2-_3<3^'YUHW^D3Z=XBO/&#
MW33F'2FM39V]J2[JI,F4.XY<G( QCM[UU*.LB*Z,&5AD,#D$>M+0!XOH%Q/;
M64%SHGCC1=1U,Q[A8-ID;74SGDH[*PDR3P7('J:](T^'6D\7ZE+/J#W&D21+
MY5N]N$%O(,#"/U<'YB3T&0!WJPFO:>/%C>'UBE74#:&\+>250QA@OWCU.6[9
M[UL4 8/BSP[+XFTR"RCOEM!%<Q7.\P^828V#*/O# R.:K>)_"4VO3:;J%EJT
MFEZUIQ;R+R*(.I# !U:,G#*<#@GBNGJAJ6K6^FM;Q.LDMS=.8[>WBQOE8*6(
M&2 ,*"<D@?F* .,\7PRZ/X3BMM4U^X^T7][$ESJK6R^3$H^;#Q@%5B(7;M/!
M+<G!-)X2GO8]3CM]-\3:+KEA)O\ /^P:>D0MSM.URT;E2=P5=IP2#D=#6Y%X
MWT^ZLA);V.HSW/ERR/8" +.BQMM<E6('#''!.>V<&MS2[VVU'2[:]LU9;:XC
M$D8:,H<$9Y4\@T <YI'A#4-$T6"QL]<020W\EX)6M/E</O+1LN_D9<]QC J"
M[^'D%WH>MV7VP6]SJUW'>236\ 6..1"A7;&2>,H"<G))/3MVM(74.$+ ,02!
MGD@=?YB@#FO^$7O7\4Z9KLVKI++96TENR&UQYH<@L<AOEY48X.!USUK.U+P!
M/?3^)%BUZ6"RUZ/]_!]F5V1_+V9#D_=P!\N/H17;U%=7"6EK+<2*[)&I8B-"
M[$#T Y- ',/X-N3?:!?)K<BW>E6\EM))]G4^?&X7( Z(1M&#S[YH'@B*XO/$
MSZC=K=6OB!46>!8=AC")L&UMQ[<].O/M6YH>LVOB'1+35K+S/LUTF^/S%PV,
MXY'X5H4 <K:^$;EK?2+35]56_M-)E2:W46WEO(Z B,R-N(;;G/ 7) )]*B7P
M7<K:^*(/[5C(U]G:0_93^YW1B,X^?GY1W[_E77T4 <C#I.N:7>>&K.SU=GLK
M*#[/=P"S 2:-4P'+DDJPPH !Y)STS70:QI5KKNC7FE7JEK:[B:*3:<'!&,CW
M'6KU96A^(;+Q +\V2SK]ANVM)1-&4/F*%)P#SCYAUQ0!YYKNF7_AZ7P5::MX
MD_M%8=<@2#S(4A*QB.0 L<DL1P-W'7IDUTE[X%NI[GQ$+37&MK#78V\^W^S!
MV60Q^665R?ND $C&?0BNPE2!F02K&68X7<!D]\#\C4E '&6W@:[L=1TB^L_$
M$L<UCIHTR4M;(_FQ @@J,X1L@<X;H,BJL?PYFB\&6_AM==9H;>\%U'*]J"0!
M*90N P_B/)SSV KL#J2C6UTO[-=;VMS<?:!$?) #;=N_IO[X].:NT <_)X<N
M)?&EKXB:_C!@LFLS;BW.&5F#,=V[@Y48XZ>O6F:)X;O-&U+6[T:E#,VJ3_:"
MIM2HC<*%&/GY& ./UKHZ* ."7X:A?!FF:&NL21WFE7!N;#48H KQ/N9N5)(8
M?,01QD8JYJ'@J]UCPW=6&J>(9I]1G>)UO$MU1(S&X= (@<$9Y.22<]>!C;T;
MQ#9:[/J,-HLX;3[C[--YT13Y]H;@'G&".H%3ZEJ\&FO;PLDDUU=,RV]M%C?*
M54LV,D 8 )R2!T[D4 8EEX1NX?%4FNW>MO<R3V*V=Q"MLL:O@L01U*CYCQR<
M]\<5G'X=W)^'_P#PB+:\6ME:,1S-:#*1I('48##)R "2>0.@KJ]%UBWUW3$O
MK:.XB1F9&CN(C'(C*2K @]P0:T* .:NO"\__  DT7B+3M0CM=1:V%K=A[<R0
MW" Y!*[P0P/0[NG'-4K[P$MUH3:?#J/E33ZB-3NKEH-QFF#A^!N&U?E48YX
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MEA(K</D_-]231JNAZU;Z+:PZ9KM[_:GVM9YK@P(WVIL8*N,!43 '3LN!DGD
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MF>&#88E?S8PZKN0G:Q'4_-P,$=*T9_ ]Q%XDO=5T;Q#>:5'J)5K^VBB2196
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MCE="_P"\ 8'^Z" >,YXZ8 /8J*R];DN[+PU>R6EY;Q7<-LQCNKXA8U8#[\A
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M(H8T4O)-(>B(HY8GVH YH_#N(^']>T=M:O7BUJY>XN'=(\J7QNVX48)VCV]
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M$$KP=WS'D,/QJFW@>PN-%URQO;B:XGUO)O;H@*[':%7: , * ,#GISFNHHH
MY*W\%3#6=&U:]\07UW=Z6DL:,8XT617"C!4+@<+R>I)Z\ 4D7@6.&RU#2QJE
MP=&OYY)Y[4HNX^8VYT$@YV,2<C&<'&:ZZB@#@K.>U\1>/M$U31B9-.T_3[J&
M5O*:/RG9HU5"K $'Y6.,=!]*LV7P\33=0N!9:[J,&BW,S3RZ2NPQ%F.64,1N
M5">J@C.3S7:44 <A<^!3_P )'=ZOI6NZAI0U#:;^WM@A6<@8W#<IV-CJ1S5Z
MY\)02>(--U>TO;FSDLK4V9CBVE9825.P[@2.5'(Y]ZZ&FNZQHSNP5%&68G
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MW=F7+!H+N+RY$*DJ01]1U'!% &%;^"3;WWAZZ_MBYD?1('@A\R-/WBNH5MV
M.RC&,8QWJ:\\'[O%,GB#3-5N=-N[F)8;Q8D1TN%7[I(8'# < ^G:NFHH P_"
MGAN/PIHHTR*]N+J,2O(&F"@J78L0, <9)ZYJ;1]'ETRZU&XEOGNWOI_.<O&J
ME"%"A1C^$!1@?7GFK=KJ,-[<W$5N&D2W8QR2C&SS!U0'N1W[ \9R"!;H YB/
MPL=/\8:AXJ@O[@RW4*QSV:1KLE5!\OON[ Y[UP.B7$SP!]/\9ZI::I*7E?2Y
MM)2::*1V+&,EHP[ $XW$@=\@=/9:* .<T_PY<IXF'B6[O2+V:QCM)[9$'E
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MX2GDGO=,,;18G*[PI.>J@<@\@_2FZ)X*32XC%?:SJ6L0K$T,,5_(K+&A&",
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MVJHPH4KM&""#GO6QIVAQV6HW&ISSR7>HW$:0O/(H7;&I)"* , 98GU)/7I@
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M6=I%8V<5K &$<2[1N8L3[DGDD]23U-3T %%%% !1110 4444 %%%% !1110
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MV]>^T^W=H)MOEQML!++@9R<\Y)SUH ZFJ.L:M:Z'I-QJ5ZQ6W@7+;1DDDX
M]22 /<US5I>S^)_%_B72WO+JTM])\B&%;:0QL7="YD)'7L #\O!R#FN-U[4[
M_P 0_!J\FU2>3[;8:DEE+)%\B7!2[C3>5''3!^N: /3],U>YO=1O+*[TB[LG
MMPCK+)AHIE;/W7'&1CD=N/6M:H;:#[):K#YTLNW/[R9MS'G/)KS.'6]3MK[P
MI<1ZI<WWV_4GM;R[!Q:7*LLA B0G("[1AE !QU;- 'J58MWXCBL_%>FZ!):3
M^;?Q2RQ3Y7R\1@%AUSGD=N]5/'>O3^'O#1N+1E2ZN+B&TBE89$32.%WD'K@$
MGGN!6!J>E_8OBOX27[;>3QRV=^I$\Q<JP2/+ ]03D<# &. * /1*Q9?$<47C
M"W\.M:3B:>U>Z2X.WRRJD @<YSENX%>?W&O:PGP?UK55U2Y%_9:C-%#<;AN"
M+<A #Q@_*<<BNCU-=_QBT122 ='NQD'!^_'0!V]%>:V>K:EIH\2^&;W4+F?6
M5G3^S)Y7^:2&<[8F&,?<;=NP/X37>S*UCHTH6["O# V+FZ.0"%^^Y].YH NT
M5YGI>K:A%XI\)6POK^YMM5L[@7<\Y(CNG2-6$L2D[HQDG& H((P#UJI<ZYJZ
M?#'QE?+J=T+S3-3NXK6??\R)'(%53ZC'KF@#U-YXTF6$N/-=69$SRP&,D?3(
M_,5D^'/$47B.+47BM)[8V-])92)/MW;T R?E)&.?7M7+2VK7'QETUVO+L9T%
MY=JRD*")HP0!TP>_K7.$:C:>%/'VL6&KW=E-I^N7D\*0;0K,NP_/D$L".,<"
M@#V:BN*BUB?7_&S:&\\UM:V^E17CK!(8WEDD;'WAR%4#H",EN<XKE=3\1^(8
M?"6OVPU69+W1=:ALH[P(N;B%Y(]HDX^\%?!*[<\4 >I:E?3V(M3!83WGG7"0
MN(2O[I6ZR-DCY1WQS5VO/O$D.K>&TT,P^(]2N1>>(K:.43^7S%(>8\A 0N5Z
M#'4BG>-+B^M+I=.TG4[V77M7EVV5NDNV*UC"@-*P ^ZN">>I.* ._HKA'FU.
M3Q&OA1;V>Y^QZ7'<2SFZ-O+<2.[*7W*I.!MZ# ^;G.!52'4?$=E=>&/"FM:A
M$U]?S7)N+RU?YV@A3>JYVC#MN4$@9P"1R<T =9IOB.+4O$FKZ(+2>&;3%A9W
MD*[9!(&(*X)XPO?!YZ5K/-%')'&\BJ\I*HI/+$ DX_ &N%\)VALOBAXSA^T3
M3)Y%@4,S[V4%9/EW'DXYY.31XCLS/\6O"P^UW<:R6=X2L<I4#:(^@[9R<^O'
MI0!WU%>>>'XM8U?Q/X@%SXEU!;?2=7011*(PLB>6K%'^7E><<8[GDXQ0M=:U
M.WU'PE,FJ75\-0OI+:\NP<6MT"CL/*0G("E1AE !QU;- 'J5%>5S2:W>0^/B
M?$FHQ?V/*SV?E>6I!$ D ;"\KGL,9YSGM<U+Q+J4.E^'M:U"VU";1;G2TFO)
M=+)$EO.ZJPD=5(8H!NZ9 YR#Q0!W&KZQ;Z-;PR3AF>XG2V@B7&9)'.%49X]2
M3V -,T;59]36Z6YTN[T^:VF,3+. 5DX!#QL.&4@]?7(K@?%"1:EI'P_NH=8N
M+Q)=5M(_M4;[1-^[DS)C'#$C\.E:T]QJ>L^(=:T&SN)D72H((XW6\,,GF2(6
M\UB%.[L,'C@Y!SP =W17F=T_BI=7\$Z5J.O&&ZO4O(=0:PV%':.,D.I* AOK
MP#T'%=P()])\,/"VJ&2>VMF_T^]QU"GYY,8&!U/L* -2BO-M(U;4(/%WA6U6
M]O[BUU.PG-S-<G]W=21JC"6-"=T8R3QA001@=ZS]2UW7)]"UN2#4+FW\56^K
MFWM+&)AS$9%"*(B"K*8V+;R#W.<#% 'K-%<-/=:EJGB?4?#T-U.Z:;90,91=
M"WEDDDW_ +PE$P<;1P %R3D'C&7<2^+;2Z\$Z=J>NA+ZYN+BVOFL@C1RA8W9
M6^9 =V ./NYYP: /3&8*I9B  ,DGM38I4GA26)P\;J&5AT(/(->4:I-?CPU\
M2M%N-5OKF+2XA);322?O0KV_F%"P RN?T..E>B>&+?[-X9TY/.FES;1MF5]Q
M&4' ]J -:L[5M8@TG[)&ZM+<WDWV>VA4@&1]I;J>@ 4DGV[G KAK75-3\1^!
M-8\46VIW-I?P273VD:-^[B6%F"QNG1MP7DL"?FXQ@56U:=_$>H?#;5I);FV?
M4&,K1Q2$",M;,QV^G7&?2@#T'1=5EU6SEEN--N]/FAF:%X;E0"2O\2D<,ISP
MPZU3U7Q3;:7/HJ"WFN(=7N4MX+B(J8P6!8$\YP0"> :;XSA)\!:VBSSQM'I\
MS"2.0J^5C)ZCGMS7"WUH\?A'X:QQ7<P>74;)A)(=YCS;-]T'C [#I]: /6J*
M\PG\1:GX4E\=PF_N-0CTNVMKFT:\(9HVE5@02 ,J& ./3-;UE8>);?Q)IUVE
M]&VE21NE]%<7IF,K%<H\0V *<YR 0N#P* .DU;5['0]-EU#4;A8+:+&YB"22
M3@  <DD\ #DUDWOBUM-TF?5+[0=6@LH8S*SE(F8*!G)17+#\N.^.:YOXF,W_
M  DW@))S_P 2]M94RY^[YH \K/X[J]%EC2:)XY5#1NI5E89!!Z@T .!R,CI1
M7%VM])XC\:>(-%-W<6UGI$-LD2VLIC9WE0N9"PY( "@#IUR#QCESXF\0W7AW
M3 ^J2PWUIXI71KF:.- MTBR;=Q&.,C&0" >: /7**\]@MM4/Q"U+PVWB/5#8
M2:;%?;RR><CF1D(1]ORJ< X Z],#.<2/7_$$_@?PO.FM3I>2>(%TV:;RT/G1
MB9T!<8SG"C.",\YZT >NT5YNESK7AKQO>Z-)K\UW87>D2W\-SJ6TFSE0@$L5
M"CR^0<<?XII.JZC#XN\,V:7VH36NIZ=.UQ-<GY;B1%0B:-&YC&6/&%&".* /
M2:*\;N=2\0)X!\2:]_PD=^;O1]5N$MUP@1UCF"@2 +\P(XP,#VKKM8OKS0O'
M>BWUQ?7!T/4U:S>%G_=P71&8V^C ,N#QG!H [:BL3PPT]UITNI33S2)?3-/;
MI(V1' 3^[ ],KAO^!8["L/3KJZ\7:KXGA_M"ZL5TV[^PVJVS[#&P0$RL/X\L
MW ;*X7IU- '4:QJ]KHFG->W1;9O2-$099W=@JJ/<D@5GZ=XF^TZS-I.H:9=Z
M;=JV(&F ,5R-NX^7(.&(')7J,'T./.]4U2\\5_#+PSJNH2RQ7AUBVMYA"VU'
M9;G87 ]?ER/0FNF^*!?2/ <6H02RR7.F7UK<0R2-N<MYJJ<GOD.P^AH [TG
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M2MH-4F\^2")XU2*3(.^/Y,J<@=^>]:5CH$5IK#ZM/=3WE^UN+433! 5B#%L
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M;L!)"_0XR"""."""#6Q10!S\GA.UGM-5CGO+N2YU2'[/<W9V"0Q@$!%^7:H
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M.64EB=QSSWJQI/B-=4\1:WH_V*:"32C"'>1E(D\Q2P(P3Q@=^>>@K;H YO\
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MO.001@G@@BJ]OX:1-6&JW>H7=[?QPM!;S3","W5L;MBJH7)P,D@],=.*W**
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M5S&H(51L4 8W$].IYS0!S.LPWUKK?@C3;+6=1MK:^,\<ZK-N+ 0%NK9.?3G
MX('%6HTO]&^(?AS1_P"VM1O+1]-N3(+J0,9&0IAF( R?F/)K7/@NT,^CSMJ6
MIO-I)9K=WF5B2R[26RO.5XQP/;/-7;GPY;77B:SUY[FY6ZM(GBB167R]C8W
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M1RS$#U)ZU/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME5AA1RH'.2<@$B@#K**\JTG5?$E]\-/#6IQI<ZM)')*=0MX;DQ7%Q$C2("K
M@L5.TD9^;'O79>"=3L=5\._:+"[O+B(7$JLM[N\^!MY)B?<2<KD#DG@"@#>N
M;F&SM9KJYD6*"%#)([=%4#))_"L>_P#$GV#Q9HVA&Q=AJ:3,ESY@"KY:[B,=
M3U'IUK$^+\"3?"_62YD!C1'79(R\[U'.",CGH<BJGB334_X3WP-917-W$A34
M 9!.SRX,2$@.Q+#TSG([8XH ]#HKR9/$&H:!H?B2R6_N)DM?$$-A!<W<[.\$
M,IBW9D;)X#-ACDC(ZXQ76Z1I.M:=XK:YDODCTJXMMAL)+^6Z;S@<^8C2*"HV
M\$#CO0!UE8OB?Q1IWA/38;[4G*0RW,=NN/5VQGZ 98^P-;5<%XCM?^$JU'5;
M&72;R^T^"U>Q1X&A 6>0!G;YY%R5'E@$=#O% '>UA>(_$?\ PC\ND(;%[A=1
MOXK'>L@41%SP3W/0\ ?B*Y7PSXPO+?X3:A>WD1;6?#\$UK=PN<GS85XSCJ"-
MI)^M9^NV.[1O .J2:A>7-S<:Q823/)<,T<I<%B0F=J\]-H&!Q0!ZO17FL=G=
MZKXH\=V%QK>K);VBVSVRPW;1F)FA+94K@@9[=#W!P*S+>]U0>%? ?B5]8U&2
M_O;ZSMKE6G/DR1R95@8Q\I/?=C.>] 'J$5U>OK%Q:R:>8[*.)'CO/-4B5B3N
M79U&,#D]<U=KA[22\E^)7B73VU&\^S?V;;RQ)YO$+,S@E!T'0<]:Y'3+G5(_
M O@CQ&^N:I+?W&HVT$XDN6,<D4DI5E9.C<<[CD^_0  ]9CNKUM9FM7T\I9)"
MKI>>:I#N204V=1@ '/3FKM<-'<Z@OQ,\06<>HR^4-&BG@2>3,4,C.XW!>@'R
MC-9WAC4&N=8CT+7X]9TW6OL$D<L$UY(\%[RF9HI V 1@],$!SZ4 >BVUU!>0
M^=;RK)'N9-R],JQ4_J"*EKQ+3UN=/^ VB7VG:C?6ES)<6ZLT=RY!#7.PC!.
M,$Y P#WS79W^FC2=4TVP77=9O/M4]Q<'3VN"TL_R*.)0R^7$A^;&<$MCT% '
M:W-U!9VSW%S*L<*#+.W05+7BFHRW6J?"B?\ M&YN99K+Q"+:-C<N6V+=JH#-
MD%\ X!;G@'K7:?:#>_$23PN]Q=QV%EI2W2HMU(LDSO(5+-(&WD*!@#/5CZ#
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M#$TS+C.9IGE;G_:<D_K6)XPG\N'3(1J-Q;&:^1?L]J#YMX &)B5@R[,X!+9
M 4Y.#0!TE86H^(_[/\6:+H;6+N-4$Q6Y\P!4\M-Q&.I[>G6O/Y/%6K:#X<\9
M_OYEDL]4BMK4W$QG-JLPCSEFSD+O) .0#QR*V-7TF+3OB?X(,-U>R;TOE;S[
MEY>1 /F&\G!YYQP>/2@#T6BO&Y_[2D\"^-=2;7M7%WI&J7GV-UNV78(RNT$#
M[PP,8.1Z $FNA9KS3O'/@Z5-4OY1K,5PM[#-.6B;;!YBE8_NH01_"!QUS0!V
MUC=7MQ<WT=UIYM8H9=EO*95?[0FT'?@?=Y)&#Z5=KRR6\U)/#_Q,(U:_\S3Y
M96M9?..Z+;;JX"GL,^F*L6QOM-\1^!+A=6U&?^UH)([V*>X9XY,6_F*0GW5(
M(Z@9/<F@#OK*ZO;BZOH[K3S:Q0RA+>4RJ_VA-H._ ^[R2,'TJXS*BEF8*JC)
M). !7F]C-KMQ;^/;33]0FFO8+]8K+[3/C:#'&=BM_!G) QC!(-9UWJEIK'@_
MQK:RIK.GZA;Z2SSZ7?7,A,+*DA$B/N.Y&) ..#M&1S0!ZM;SQ75M%<0.'AE0
M.C#HRD9!_*I*\MO8+FSTKX?06.J:C:QWMQ#%.$NG;<IMRQ'S$_W1@=!V%:-W
MI[6.HC18=;UC43!IKLML;MTDC+2,1/+.&!/]U5P3\N0#S0!WD]U!:B,SRJGF
M2+&F?XF/0"JXNKTZVUH=/(L1;B07OFK@R;L>7LZ].<].U>5&277_  ]\+]0U
M&XN9;JXO$261;AXRW[J3)^4CYOE'S=>O/-=9$;@?%JZTMKZ\>P;05E$#7#81
MS,4+#!R#A1SU]Z .VHKS30[N]6WU7P;>:A>R:O#J8B2Z>Y?S6M9/WJRALY!$
M:NO'&Y0#UJ>5M3\3ZMXGTNTG>%]-=+6V9=2F@>#,2L)2J*=^6)Y8\A<8ZY /
M1**S]#%ZFB6::C=0W5ZD02>>'[DCC@D?B*T* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_6-%L]=M([:]\[RXY
M5F4PRM&P=>5(92",'G@]JT** ,6#PU;KJ=OJ%Y>7FH7%J&%L;IU*P[A@E0JJ
M"V.-QR<9YY-1P^#M'BNM6E\J62/52S75M)*S0LS*%9@G0$@#)_+%;U% &#IW
MA.QT\V(,]W=1Z?G[%'=2[UM^-OR\ DA20"Q) )P>:IM\/M$.N7.J1F]A^UR>
M;=6<-TZ6UP_]Z2,'#'U'0]P<FNJHH P)_"&FW6IZE?SO<22ZC;?9+A&8%&BY
MPNTC QD_US5[1-&@T#2H=-M9KB2V@4+$)Y-Y11T4$\X'OTK1HH CN+>&[MI;
M>XC66&5"DD;C(92,$$>A%<[;^";.UL5TZ+4]5&EJ-JV)N?D"?W-V/,VXXQNQ
MCCI7352M;B_EU&^AN;!8+2(H+:X$P8W *Y8E<93!XYZ]: *FK>&K'6!IPF::
M)-.G2XMD@8(J2*"%.,<X!(QTYZ4Q/#%K'K-_JR7-VMW?Q+#,P<8V+G: ,8&,
MGGWK;HH YD>!-''AJRT$-=BTL9TGM&6<B2%U)*E6'/&3USUJ:X\(V5P+R,W=
M^MM?1K%=6XGRDRA F#N!8$J,$@@GN:Z"B@!L4:0Q)%$@2-%"JJC  '0"L74O
M"FG:GKMOK,CW<-[#";<O;7#1>;$3NV/M/(SSVK<HH YC3_ NF:39VEMIMSJ%
MJMI+)) R7!8IO)W+A@1MY/RXQWZ\ULZ5I-KH]O+%;!B9IGGFD<Y:61CEF;W/
MM@#@# J74;LV&F75XL#SM!"\@A3[TA )VCW/2N7G\9ZC;>(-/T2;PZZWM]%)
M-$OVQ" $QNR<<'F@#H]9TBSU_1[K2M0C,EI<ILD4,0<>Q'0YP:S1X0L1J&E7
MS75^]SI@<6\DD^\_.,.6)!W9  YZ8XQ5&3QG=V^I:-976AR6[ZA>R6;[[A3Y
M152X(P#N! !'3K774 <X/!&CO;:S;7*374&L/YEY'.^0[X W# &TC QC&,"I
M/#OA&P\-Y-O<ZA=R;/+1[ZZ:8Q1_W$SPJ\#IUP,]!6_4<\\5K;RW$\BQ0Q(7
MD=S@*H&22?0"@![J61E#%21C<.H]ZS]&T>#0[-K6WFN)8VE>4F=][;G8LQSC
M)RQ)YK-TWQ'?ZW9+J6E:-YFFR#=#+<7'DR3KV9$VG@]MQ7/M6EH>K#6]*2^%
MK/:EI)8S!. '0I(R$-@D9RO8F@#/LO!NF6.J:IJ"-<2/JHQ>Q2N&BFX(Y3&!
MP<<8K/B^&NB16MI9_:=5:SLKE;FTMVOGV0,N<!<<X&>.<CL1SGL:* ,*'PK9
MV]_JU[%<WBSZJJK=-Y@.0J[5QD<87CC^?-5O^$%TO^Q=,T@3W@L],G2>U42C
M*.ARG.,G!SP?7G-=-10!B+X9M4UN]UA+F[6\O(%MY6#C&Q<[0!C QD\^]4E\
M!Z2F@Z=HJS7JV.G3K<6R"491U.Y><9.#DX/K]*ZBB@#"?PI8RZQ>ZI)-=-<W
MMK]CGRXVM%S@ 8XQDG(YYJ2S\-VMK>6EU+<75Y-9Q-#:M=.&,*MC=@@ DD*!
MELGCKR<[-% ')#X=:(N@_P!B))?KI_G+,L0N6.PJV]57/W0&.<#\<UHZKX5L
M-8OM.OKB:\CO; ,L5Q;SF)V5@ RL5QD' ]/;%;E% '+#X?:"NB:CI 2Z^R7]
MQ]I<?:7)CDW[P4.?EPPS_/-6[GPE83W-C>1S7=OJ%DC1Q7L<N961N65RP(<$
M\X8'!Z8K1U2XO[6U633K!;V8RHK1-,(L(6 9LD=ADX[XK-?Q'(GCI/#9L?E>
MP>]6Y\T<[75=NW'^UUSVH 9>^"])O]"DT>7[0MK-/]IG*2X>:7<&W,W4G< >
M,= .@Q701H4C5"[.5&"S8R?<XK#\+^(G\11:HTEE]D>PU&6Q*>;OW&,+ELX'
M7/2MZ@#+\0:!:>)=*;3;]YA:NZNZQ/M+%6#+SUX(!_"HI/#=M+X@MM;>YNC?
M6T!MXVWKMV'!8%<8.2 ?Y8K9HH Y27X>Z--8W5J\M[BXO_[3,@GVO'<_\]$8
M#Y3[=/:E;0M/\)RZEXDM+35K^]DAC6:"&9II)]G (5FPS8)Z]!G%:'BW7G\,
M>&+[64L_M?V2/S&B\S9D?7!_E6M;R^?;12XQO0-CTR,T 8'AG3@;W5/$,NG-
M8W6K/&3%*H$JQ1H%3?@D!C\QQG@$ \BNCHHH YC6? FD:SK:ZPTM_97_ )8B
MDGT^[>W:9!T5RO4?K[\"KK^&K9;B.:SNKNP*6RV@6V<!3$I) *L",C<>>OO6
MU7/6?B2:[\5ZSH7]G['TZ"*9)/.!\[S-V!C'R_=]3UH )?!.BR)HZQ13VPTA
M6CM/L\[1D(P 920<D$ 9[^]4;GX;Z#=0:C;NU^MM?W'VJ2!+MUC27<&+HO0$
MD _RQ6GX0\0GQ5X9MM8-I]E,[RKY/F;]NR1DZX&?NY_&MR@#!F\*63ZHFIVU
MU?6EZ+=;5YH9\F6($D!]X8$@D_-][GK27W@[2;[08-%*306,,JS*D,F"SAMX
M9F.23N^8DGD\G-;]% &._ARUD\16^NO/<M?6\!MT.\!?+)!8%<8Y(!S_ "J"
MT\(V5H+!#<WEQ#I[%[.*XD#B!MI4,#C)(#$#<2!GCM6_10!RS> M)?0-0T1Y
MKQK'4)VN+E#*,N[-N8YQD9.#@>GUKIH8_)A2,R/)M &]\9/UQ3Z* ,C7?#MI
MXA^QB\EN5%G<)=0B%]N)4^ZQXYQGIT]J:/#=K_PDL>OFXNFOTMOLN2XVF+.X
MJ5 QRW.>M;-8)\1R+X[C\--8X1[![U;KS>NUU3;MQ_M=<]J %G\*6,FKW6IV
MT]W97%ZBQW?V64*+@ 8!8$'# <;EPWO23>$=,DGT>2(2VRZ.#]BC@8*D>5VG
MC'/R\<TOC'Q#)X5\+7NMI9?;/LJAFB\WR\C.,YP?7TK<5MR*WJ,T 8<7A6SA
MOM7O8[F[$^K*JW3;Q\VU=JX&/EPO''\^:NZ)H]MH&CV^EV;2FUMEV1"1MQ5>
MPSW_ !K0HH S=>T*R\1Z6VGWXD\HNDBM$Y1T=6#*RD=""*JMX6LFUC3M4,]Y
M]IT^-XH"9MPVOC?NR#N+8&2>?I5G7M:@T#2FOIU+_O(X8XU."\CL$49[<D<]
MAFLB3Q5J5GJ"Z;J&BI!>7-TMO8,EUOAN049V;=M#+M"'.5ZD8SG@ E7P1IBZ
M5J^F^?>&VU:9YKQ3*,N[\.0<<9 ' _#%3R>$[*6XT>=[F\,FD BT/F#Y<KM.
M>/F^7CG^?-7-$O=0OK.1]4TLZ?<QS-$8Q,)5<#HZL ,J?< ^U:5 ')GX=Z$-
M<N-4B-] +J3SKFSANW2VN'_O/&#AL]QT/<5UE027EO#=06LDJK/.&,2=V"C+
M'Z#(_,5/0!CZCX:T_5-9LM6F-PEW9JT:-#,T8=&()1L?>7(!Q55_!>EM/J!B
MDNH+;4G+WUG#+MAN&(PQ(QE2PX.TC/?-=%4%I>6]] 9K:598Q(\>Y>FY&*,/
MP92/PH ECC2*-8XT5$0!551@ #H *S-=\/6/B&.T6\,Z/:7"W,$L$IC=' (R
M"/8D?C6K10!BIX8LX_$#:W'/=)>FT%D#Y@*B('(7!!Z$YR><U0_X0'2/^$7_
M .$<\Z]_LSS?.\OSOFW;_,^]C/W_ )NM=310!COX;M9/$-MKDEQ=/>V\!MT)
M<!2AP6!4#!R0#_A69I?P[T/1]3-W9-?1P>;YZZ?]K?[*DF<[Q%G&<\C/ .,8
MP*ZNB@ K&N/#=K<^)+?7FN+I;VWB:&+:XV*C8++MQ@Y('7FM**\MY[BXMXI5
M>6W*K*H_@)&0#[X(/XT7EY;Z?937EU*L5O"ADD=NBJ!DF@#%E\&Z:]WJ$T,M
MW;1:D<WUM!+MCN"1@DC&5)'!*E2>]3S>%[";6M-U16GBFTV-H;5(F"QQHP 9
M=N.00 /P&,5'?>(Y++QEI.@&QW)J$4TBW/F_=\L D;<?[0YS6]0 5D7GAVTO
MO$%CK<DURMW8JZ0;' 15?&\$8YS@=?3C%:]% ',ZUX%TG6]:CUAI;^RU 1^4
M\^GW3P-*G]URO4?K[U+<>"](FU.RU"(75K/:6WV1?LMPT0>'.1&V#DC//KFN
MAHH YC3_  +IFDV5I;:;<ZA:K:2R20,EP6*;R=RX8$;>3\N,=^O-33^"]&N=
M*-C+%*2;LWWVD2;9A<YSYH8=&SZ<8XQCBNAHH QH_#=JJWCRW%S/=WD(@FNY
M&7S3&,X48 51R>@'))Z\U3_X0?3/[*TC31/>"VTF9)[-1*,HZ9V$G'.,G@YZ
M\YK8-Q?C6UMA8*=/-N9#>><,B7=@1[,9Z9.[/M5V@# D\)6,WG137%Y+9S7/
MVN2SDD!B:0.'STW ;@#M! )'(Y.=^BB@#&O_  U9WNLQ:Q'-<6>I1Q&#[3;,
M SQDYV,&!5AGD9&1VJ&]\'Z3?>&I?#[K-'I\Q+3+')AY26W,68Y));DG.36_
M10!%;0&VMTA,LDNP8#R$%C]< 5FZ_P"&['Q$EI]K:XBELYQ/;SVTICDC?!'!
M'8@D$5KU!/>6]M-;PS2JDES(8X5/5V"EB!_P%6/X4 <^G@'0%35XY()YX=6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN:[;0;V'Q'K-QKUG<S2::L$<%L%E;RY&(WN^W.TX#(N<9!5A4)A'@C3+/1]
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MY4Y'/!&:8WARQ?Q!#KK-<'4(H#;*_G''ED@E=O0Y(!Z4 8/PYZ^+?^QDO/\
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MR#REE."2/E//4)@\<4C>*X9-)TZWTV74[-=0\0QV%]%>.RSV65!:$,22,[0
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MQB,$X'!)''- '.:21XH\2^*M/OI[N.+3)8K2VBBN7C:)3'N\S*D$LQ)(8YX
M]\\O;:IK.L:#X*>]U.]CN)-:DT^XF@F:,7,:>:-Q X).P<^HR*]*NO"^GW&K
MOJL;W-K?2Q"&>6UF,9F0= ^."1V;J.QJ.Z\'Z/<Q:7#Y,L,6E.)+-()601N
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MVS@?*>!P/;-;%Q\./#MU!?V\T5V;6]F^T26PNY!$LA8.S(H.%)(Y(YY.,9H
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MD>6 -H)QR@('.:];KD4^&OAM+6.U6&\6"&Z%W;QB]E"V\@8M^[&[Y!DGIZT
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M&: /9Z*X;PG#_9GQ!\5:1;S7#6$<-I<1Q33O+L=P^\@N2>=H)YKMW021LA+
M,""58J?P(Y'X4 .HKR/PWHJ7OP^U#6[J_P!3FOK4:DD+/>R$ !Y ,C/)&,@G
MG/?@8MM=7']@?"ZZ^U3^?<S6L<[^:V95-NS$/S\V2 >: .QT?Q%/J7BK7]%F
MLT@&E"W*RK+O\T2JS9Q@;<!1QSWKH*\NO=3NM&\0?%'4K(9NK73[.6+C.&$,
MF#CVZ_A6KINB7)U+0M?L]:@BM63;,J-))_:"NOR[MS$%@?F#8SU[4 =Y17'^
M)M1)\;>&="N)&CL+\7,DBABHG>-5V1DCM\Q)'? ^E8WB/S/".G0:?9ZM=/;:
MGK]O#-ND.;&WE.61&ZJIVD#G@/QCB@#TFBN#NX)-$^)>C:?ISS)INL6=RMW;
M+*VV-H@I65><HQW;21C/'?FN*2&=/@S9^(AJ6HG5K34"(;@W;DJ#?&,@@G#9
M4G.X'/T % 'N-%<!'8KI7Q6@L+:YO?LVHZ1-)<I)=R/OD61 '!+95L,1D8KB
MH["Y/P7C\61ZSJ@UO3VFF@G:\=EPMPPV%,X8,.N02<]<<4 >J+XBG/CYO#3V
M:+%_9IODN1+DM^\";2N..I/4]JT]-FU"=+@ZC9Q6S+<.D(CF\S?$#\KG@8)'
M;M7(Q,\WQE@:52COX8)=0<%2;A<BL/3+H)X2UJWN]5U!-WBF6TAV2&2:<"90
ML 9FS\P&W)(P,Y/6@#U>BO++=KN.\^(VGL9;*"VL(+BW@M[I\6[M#*2488VD
ME%) XSZU!902:?9_#35XKV]:\O\ [/;W327+LLL;VQ8J4)V\$ CCKSR>: /6
MJ*\XTJ!/&NCZ_<7>IW%EJ-MJD\*W$4I5K%8G&P*,X V@%O7<<^SI?/\ %OBG
MQ+H[740%E% ELLC2*R+)$&\Y0I'S;F(SVV@<4 >BT5E^'(;JV\/V5M>ZBNI7
M4*>5)=A<>:5)&2,GGC!]\UB>,-3:#Q!X6TB69H;#4[N1+EU8KOVQEDCW#H&;
M''?&.A- &SXGUB;P_P"&=0U>&U6Z:S@><Q-+Y>X*,GG!]/2KNG71OM+M+ME"
M&>%)2H.<;E!Q^M<3XFT>'1?!'C>*#4)Y8I["6=+.1LK:@QL,)W"L5)QTX.*K
M"\FO=<\.^'FDA6VDT(7*Q3E@D\GRJ1\I&XJN3CIR3C@$ 'I%%>;FPFT:PT[0
M]0UZXU"5M7?[/909W31^67%O([-G8@.XDGH ,'@5@7T]]'\.OB'"US<6[:=J
M$@ME@NY/W V1ML5N"4RQXQCGI0![/17 :GI%AI*Z:@U#5)+G5+V)WM#<-)]M
M9(V)0[F 1/XFQ@?*!CH*YB]GOH_ 'Q$@:XGMCIUZYMEM[N3]P#'&VQ6X.W+'
MY<8YZ4 >S45YVULVB_$3PJUK=7CG5+.[%XLMP[B8QHC*=I.U2"3]T <XZ5%X
M8AC\6>"M.\27.K7%IJ8NFN;BYBD.4VR,&@*G@)M^7;CT/)/(!Z317F:VU]XV
ME\46ZZA':WEGJ$EK!)OD$EF$"^6Z!6 &>6S_ !9()P !Z#I9D;2;,S7274I@
M0O<(NU93M&7 [ ]?QH MT5QVNW_G_$+0_#]W(4L+FTN+CR]Q47$J%0$..H"E
MFQT/&>E8^M^9X8ATK1+?5KN:SU'Q D$SO(=UM$XWBW5QR < #G.&^E 'I-%<
M#+!+I?Q+AT>QDG32M4TN66>WCF8""2-@!(A!RF=P!QC)YZUR&EI/#\/? WB+
M^T+]]3DU*VA>5[IR&CDF*NA7.T@@]<9]Z /;:*\O\17MQHNNWUYKEG/<:'-=
MQ-!J]E,2^G[=@\J1 <A-RG)'!W'()-3M!>>--2\66'VV.WN;*Z^S6Q+R"2T7
MRU*2H%8<EBS9[XQT % 'I-5[Z^MM.LY+N[E6*",#<S>YP!]22!^->=BQFO?B
M!H=A?:O=WD4WA^1KEX+AXH[EU>-=X4-\N[J=N,^XSGG-2A%Q\+]5M;B6:>/2
M_$YM+4RRLS)&MTB@$DY. Q )Z4 >WT5%;V\=K;I!""(T&%!8L?S/-2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4[@#D$=*Z&B@"&TM8K*UCMH PCC&!O<NQ]RQ)))ZDDY-3444 %%%% !1110
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M+JV,99Y&EED^4A5W.20 2>,@#)/<UC^!/"L-CX3T)-1L;B*^L8ES!<3LZ13
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M9KI ESY4\D:W"@8 D56 ?CCD'CCI4NI>&]*U8V7VRV9A8R++;+',\:Q.OW6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(RI,4>EPS)$2=BR%R"P7H#P.: /0Z*S]<UFV\/Z/<:G>"1H8=H*Q+N9BS!5
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M@\@BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8M/EN5GCCD1&42Q;%;YB!@'KW]C0!=NO%85M3.GZ;<:A'I;;+MH74$.%#,B
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M;WP_!_9UY$FNQR26LDAC.%1-^6VL<97!&,]><5R6J1WK^)?%'V+0=6N=.O\
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MLLEK!JUC;0V=T[H5,D08\@,6 R1VZ9H Z&W\;6K>(K+1KRU>VFOXGDM'\U)
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M=@1C!W'Y3G. ,CGFN8O9FM/C)!>66F-<7=QX<<F*,JA<^>F-['   XR?I[4
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M;M+0SB4*L+N<*7X^[[U+?^(H=,N=0^UQA+*PM!=3W(?.T'=A=N.6^4\>X]:
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M !1110 4444 %8>L>$].UG4(M1D>\M;^*/RENK*Y>%S'G.PE3AAGG!!K<HH
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M+<!C'Y\6W:+KSL[M^/N\>N?SKT+2] LM(8R0M=3SE=IGO+J2XDV^@9V) X'
MP.*U* //_&/AV7Q'<3R-H-TE]# K:7JEG<1Q30RD'*,=X. WU')[];%GI6NP
M>/\ 3M4O+1[F*'0?L-Q=QO&!)<%T<D*6!P=I[=37<44 <GX!TS4=)TS4H=2L
MGM9)M3N;F,-(C;DD<LOW6/.#S2>-?#^HZG-I&IZ'*L.JV-QL$C?\\)1LE^N
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MCM)*]2.AKK[.6>:QMY;JW^SW#QJTL&\/Y;$<KN'!P>,]ZGHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<."O&&SQTQ76-I\$GQR$I:X#'0!,=MQ(H+"X  P&QMX^[T/<4 >@45Y7I?\
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M6MY<'^U+:606L;LR1HX+ME1D8'X^E=%9:):07<FH.TUU=S0B$S7)RPBZ[ ,
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M.BER<[1Z# Z^IK'^(&E22:!H.FVL&H720:K:R.84=W2%&^9BRC(('?K7>T4
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M/1+&/6Y-859_MLD8B9S<2%2@R0-A;:!DD].] '#>%9[CP[\2]7T2[M39VFN
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M+M;Z?@6;">020  #"R;MP& .,]AZ4 2>#]+N]%TRYTZ[U;^T3#=/Y1PV8(V
M98B6)+;0>"3T(KA?'$[/I/C+4=.N;BYN;!TQ=M*8A8.BH?*AQDL>=S=!\V"3
MC%>GZ7I=GHUA'8V$/E0)D@;BQ)/))8Y))/4DYK&O? /AO4+C4IKFP9_[2'^E
MQBXD6.1L8W[ VT-_M 9]Z ,I;P:]\29]%U EK2STJ*YBMB2%F>1B&D(_BV@
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M<7*21K*PC<"!R,IG:2#WQFM;1?#4&D^(=:U6!&B_M)D:2/SF?>Z[LR'/"DY
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M8M5B$%QLU4DWH^UR_O<C!_BXXXXQQQ0!RNG:M-KWBCPWHVIR,]K)X=34W0G
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M"".-S/=1DJ,?*MT0!] * /<5.5!]12UYU=VJ^'_B;I#Z=Y[/?Z9>-<J\S/\
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M-W**Q S@D X_(U0\*:S)XB\*:9K$L*PR7D"S-&IR%SV!J]J7_(+N_P#K@_\
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M=K#&X>^!0!='AS2_LE[;&"1DOAMNG>>1I)1C&&<MNQCC&<8)]:4>'=)'A_\
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MD\YR&0=%VYVX'88XK3HH YS2_ ?AC1=6?4].TF*WNF8L"KL50G@E4)VJ2..
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M%YX8T:_T>#2;BPC-C ZO#$A*>6RG*LI4@@Y[@]S5NZU.TL[VQLYY0MQ?2-'
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MWA4)'&O10.U3U4TNZ>^TFRNY%57G@25@O0%E!./SJW0 4444 %%%% !1110
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MQ]LCE=F(:6(12;"W/.5"D^N3GK0![2K*PRK CU!H5U<95@P]0<UY39Z2J_\
M"P/#^E7$&EVZW]H+1"O[E'D2([-H_A=L*0.S&M_P1>L=<UBPU#08M(UN**![
ME;5@UO<)\X25"!QGY@0>>!Z&@#MRRKG<P&!DY/:C>H*C<,MTYZUYV=$TW4?C
M!K-O>V<=Q;R:/;R20RC<CL97&2IX/0=>E<<-,LXO@E#K(BSJ>GWX2TNW8M)
MJWVQ51CRJ[>,#B@#W1G52 S %C@9/6E9E12S,%4=23@"O+?&26&H/XZ\B-)[
MFSTM5N9;U@RVQ$3NBP+C(8Y!+9 SMQD@BI-.U$:IXP\)Z5JS+-9OX=6\A2;Y
MEGNSM!)!^\RIDC/3<30!U?A37[[6KS7X+V*VC.G:@;6/R-Q#+L5@23U/S>U=
M$KJX)5@P!P<'/->+/<)X>T;QDMELM;!?$\,=R44E8K=O*W\ CY<$@@$<$CBN
MYT30;.P\7?VI::I:;KRQVFRL+<1PRJK B8@,W(W!=WH<4 76\07L?Q&3P_)%
M;"P?2WO1*,^9N61$P>P'S'].:Z0$$ @@@]#7GVM:58ZS\8;2SU&W6XMCX?E+
M0N3M?_2$X8?Q#V/&0#VK#L/!JZQX:\7^';49M+#4W_L5Y3N$$BJK%%)_@#Y4
MCW:@#UZJ5WJUG9:C86$TP%U?.Z01YY;:A=CCT '7U(]:Y+PCJ,'C6\L]?:S6
M+^S;7[-L:/!BNFQYRC/]P*H'^^U1>,-.T^Z^)G@DW=G;3"3[:LGFQ*VX+#D
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M#T&M6EH]IKCK##<6C,##,P!561LY!SC(/X5V?VF 7 MS-'YQ&?+W#=CUQUH
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MK-*@(^0,<*#[G!./3ZU=%Q"T[0":,S*,F,,-P'KB@"B?#^EG4EU$V@^VK#Y
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M$W%BV/8$DG Z#)S@"K](K*RAE((/<&EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?XK)'_P (E;S2*G[G4[-M
M[#[@\] 3GM7<57OK&TU.RELKZVBN;69=LD4JAE8>X- '$2Q65Q\;)X&2"3S/
M#96=, [O]('##Z$=>U<%#X>L&^ NE:[90!?$-NT;65VAS-YOVC8J ]<')&WI
MDYQFO8XO#FBZ6([FPT.T6XMHC%!Y,**ZKDG:I.,9))//.:POA[X030_"NF6V
MJ:7!'J=GNW."K@ODX=<'K@XS@'MTH K:$L.M^./&=CKMO%/-$8(HH9E# 6K1
M_P (/8MN)QWQGH*XZSM7O?#?@'^T@;C;K\EM!/(3ODM0)@@+=2"%'U %>OW^
M@Z3J=RES>Z?;SSHAC61T&[8>JY[J?3I3KK0]*OOLWVK3K6;[*0;??$I\DCIM
M_N_A0!R7A"SM=,^(_C.PL+>*ULUCL)5MX4"1JS)(&(4<#.T9^E6_BO\ \DM\
M0_\ 7K_[,*Z2#1]-M=0FU"WL+>*\GXEG2,!Y/3<W4_C3M1TNPU>U-MJ-G!=V
MYY,4\8=3^!XH YW3_"5I?/H>KZC>WE_)80*]I%,4$43E1\P5%7)]"Q.*X/5I
M[*?1K/4],,<=N_BJ-DGN'WW4LOG[7(/&Q0,@*=QVXSBO8[6TM[&V2VM84A@C
M&$CC7"J/0#M66_@_PW*UTTF@Z:QNW$EP6MD/FL#G+<<\C/UH XZV\.Z)K7Q5
M\3QWMA;W5NUE93A&&5+DR'?@?Q<#GKR?4TWPOINEE/'T4EG:9.J7$2J8USL\
MF,[1[=\5WT&B:5;:B^HP:=:Q7LB[7N$B =AZ%NI%-.@:.UW=W9TNS-S>)Y=S
M+Y*[IE]&.,D<#KZ"@#RW1]1BL] ^%UOJ3JNCW$+B8R_ZLSB,>2'SQU+$ ]P#
MVK6\9Z/H-K\/O&RZ:%E$BM=3(&WQQ3E1]P=%;@$@<_,/45W,GAO1)=&_L=])
MLFTWJ+7R5\L'U"XP/PI5\.Z*FC#1UTJS&FC_ )=/)7R_7E<8- '":II.G:C\
M1?"$5[:Q2QW&D7 E1QQ,%$9 8?Q <\'BL86VFZ"/%^CO'/\ V =:LH;&VAEV
M1_:'".\18@A8]VW<,<#/&:[#5O"[W?CG0;F/24;2-/M9H#AT78S[=I1<Y 7:
M>F#SQFNFET#2)]);2IM-M9+!SEK=H@48YSDCN<\YZYYH \Y@BC/B7XAV5W]B
M99-,MW>"!<1^9Y<O8DY8 #GCH#@52M-,L;#PW\+=4M;:.+4)KNTBDNE'[QT>
MW?<I;J5X QT &!7IJ>%M C+%-%L%+0?9FVVZC,6<[.GW?:G'PSH306L!TBR,
M5HVZW3R%VPGU08^4_2@#D_",&FV7CCQO,\5I T5[%M<JJE%-NK-@]APQ/T)K
MO+>Y@O+>.XMIHYX)!N22)@RL/4$<$51N= TJ>XN[PZ5927MU 8)I9(ANE0C&
MQFQDKCCZ4N@Z-;^']&ATVU5%AB+L%1=J@NY<A5[+EC@=AB@#DKVTL#\;;22X
MM[;G0I)-TB+]\3H V3W [UR%_I.GW7@'XCW\]K%)=VVLWS03.,M"RE""A_A.
M>XQGO7L-WH^F7]Y;7EY86UQ<VI)@FEB#-$3_ '2>E5AX7T$6MQ:C1[$6]R_F
M3Q>0NV5O5AC!/N: .*FOH[[X@?V;J]Y;0I+HT$EDMW"LB2Y+^=MW'&X_)D=2
M!75^"M-M='\,0:=8ZC+J%I;NZ13R$'@,?E!'55.0/I5G4?"V@ZM9V]GJ&CV5
MS;V_^ICEA!$?^[Z#Z5IP016T$<$$210QJ%2-%"JH'0 #H* /.V_XDOQY>ZOV
M\NVUC2A;V<S\*948$Q9]2!G'?(KT*:ZA@DBCD?#S-LC4<ECU.![#D^E1:CIE
MAJ]HUIJ5G!=V[')BGC#KGL<'O[U'IVB:9I))L;*&!F&TNJ_,1Z9/./:@#S"P
M2WUOX/\ B.^U55&MP2WLMU,W$L%S&S-'ANJE0(P .W%6K/3EU+X@>&6URSBD
MO;GPP7ODD08DE#19WKT."3P?3VKT&7P[HTVH/?R:9:M=.59Y#&,N5^Z6]2.Q
M/(J631M,FU)=2DL+9[Y%V+<M&#(%] W7'M0!X\^A:4?AKX_8V,);3M2OTLB5
MS]E52&41?W.3GY<5ORZ5IVL?%'1EU*UBN5N?#;/,D@RLS"2/&\=&]<'/0>@K
MNAX8T%;6YM1H]B+>Y??/%Y"[96]6&,$^YKG;OPJTWQ#T^]&D(='M-->S0JZ+
MY;LZL&4 Y  !&1@\],4 <A9P6&C6FKZ-(DTFD#Q3#;Z5;";9$9CM<Q,Q!_=!
M@<C!Z$=:G>*)C\5[.Y-G(HM(Y?*A7;&LGV5R2JDGY@5&3URN>*].N/#^CW6D
MC2KC3+273P<BV>%2@.<YQZYYS48\+: /.QHNGCSX5@EQ;J-\8Z(>.5]NG% '
MG<&F6.G7'PPO[2VCAO+@+'/.H^>56M"2&;JPX& >F.*LW<1\&>+=5TC3[5$@
M\4IYE@4B!6*[X24$?W=K"7'3"M7>GPWHA%H#I-F19_\ 'L/)7]Q_N<?+^%9V
MFVFN:CK*WVO6EE:QV+2K9Q6\QE+EN/,8D#:0F0!_MMG'% &WIVGVVDZ;;:?9
MQ+%;6T:QQH!T &*\I\<26-YI7Q FLQ'YEND<=U/>-N82K&"B0KP4 R#N)^\3
M@'K7L%9-SX7T&\OKB]N=&L9KJXC,4TSP*6D0C&"<<\<?2@#B;G3]/U7XF^'&
MNK>&Y6XT2<S[@&$I5H\!QT;!SP<_I7.M=C1_"=_8IB#11XV:RNE7Y4ALS("R
M_P"RA. 1Z,1WKUN/PYHL-Q;W$6DV236T?E02+"H:)/[JG' ]A1'X<T6&UN[6
M/2;);>\):YB$"[9B>I88PQ]S0!R36EC:?&W3GM88(FET&;=Y0"[@)4V\#VS^
M ]JW?'MSI]IX%U:75&N5LC#Y<OV5PDAW,% !/ R2!D\8)JU8^$_#VF30S66B
MV,$T *Q2) NY >N#C(K3N[.VO[26TO(([BWE4K)%*H97'H0>M 'GVC9M/C$\
M+_8;<R>'T+06APBD3@*">-S '@X'!'%<],?^+ ^*?^OR\_\ 2DUZE:^%]!LI
M8);71K&&2WC:*%XX%4QHW4 @<9R?S- \+Z"-.ET\:-8"RE??);^0OENWJ5Q@
MF@#3B_U*?[HK@= BMM?\4^-['7K>*>:.X2!8IU!VVAC&S;GH"=YX[FN^AABM
MX4AAC6.)!A448 'H*HWV@:3J=TMS>Z=;SSJAC\QT!8H?X2>Z^QXH \CTN%[[
M1?AM)K")=.=2FA6:X4,TL 67R]Q/4$!2/7@UTEMH^E:S\2/%\5[9V]W;+I]C
MY<<BAXP"DO('3..AZC)QUKN[_1M+U6TBM=0T^UNK>)E>.*:)75".A (P,4P:
M!HZW5Q=+IEH+BY7;/*(@&D7T8]2/K0!Y-HFK,GAWX;0ZC>I!I]Q;3H9KA \?
MGJ (@V3C[N\#/?Z5/XO\/:7IG@'Q$MI?B\#:E:W&U%58[25YXPPCV_=)!R0#
MQD>M>FOX8T*31O['?1[$Z;G<+7R%\L'U"XP#[BC_ (1?03I$>DG1[$Z=&<I:
MF!3&#USMQC.><T 3:5H>F:&DZ:990VJW$GFRB(8WO@#<??@5RNOV\*_%WP?,
M(D$LEK?J[@<L B8!]<9/YUW$<:0QK'&H5%&%4= *J3Z/IMUJ$.H7%A;RWD Q
M%</&"\?KM;J/PH \>FT'2I/ 7Q)N&L(&EM-5OC;,4&8"JQL#'_<.?3&<#T%=
M))!9S_$WPU<WL-N[2:#++))*BG<X:+#$GN!GGM7:#PQH(MKFV&CV(@NGWW$?
MD+ME;U88^8^YJ23P_H\IL3)I=FYL#FT+0J?(_P!SCY>@Z>@]* /,+&WT[Q5X
M;U>/6=;BL=1MM2F>[81(+JWD28F,HQ.[[H55P.G K5MO#>CZO\5/$D&HZ?#<
MQFQLI2DB8!DR_P Y _BXZ]>3ZFNVF\+Z#<:TFLS:/92:DA!6Z:%3(".ASCJ.
MQ[58BT;3(-3DU.+3[9+^48DN5C D8>A;J10!Y;9V^G>*M!UR#6]:AL=0MM3F
M:Z;RT%S;LDI,;(Y.X (%"D#IP*M^*EO-*N=;U>2UMM>T)Q"-2MWPEW9,D:?-
M&3P0 0^WC!)QW-=_<>%]!NM9CUB?1[*74HR"MR\*EP1T.<=1V/:I)O#VCW%Y
M+>3:;;/<2E6E<H,RE<;=_P#>Q@8SG&* .&\NW3XG^([NVM;<W8T2WGMM\:AC
M*6DP1G^(G:/6J/ANST?7_#OA75SKT<=[:3PR'R(D6X>X/RR12')9MQ)W9Z]>
ME>F2Z1IL^J0ZI+86SZA"A2*Y:(&1%/8-U Y/YGUJM;>%]!L]8DU>VT>RAU&3
M.^Y2%0Y)ZG..I[GO0!YHDEIKGPR\?W6J1PRZM'+?"X$H!>$QAO)49Y  "[??
M/<FO3/#!#>$]&(((-C!R/]P5'>>$O#VH7TU[>:+8SW4T9CEE>%2SJ1C!/?CB
MM.UM+:QMH[:TMXK>WC&$BB0(JCT ' H \XL?#.AZS\3?&]KJ6GV]Q"8K%_)D
M'R[FCDR^/[W^UU&3@\FN<T"_GLM*\$V.J7XCTB2>_B@N+I \;%'Q;[L\?=W[
M<^V.@KN++PN]QX^\1:IJFDH]E?Q6\=O([J2!&K*X8 YVMD<<@XYKJK_1=,U/
M3?[-OM/MKBR  %O)$"@QTP.V.V.E 'E7B_P]I>F> O$:VE^+P-J-K<%455CM
M)7FC#"/;]TD')&>X]:Z77_"PTZZL)/"4.F6]^DLUXVGW*$17ORJCDD=' *X/
M^T<]374?\(OH)TB/23HUB=.C.5M3 IC!ZYVXQG/.:GNM$TR]%N+FRAD-MGR&
M*_-%G@[3U7@#I0!YC;ZS!>77@FT;2VTS2)-4OH;VRD(:..\7<4CR.&7S"Y4=
M,@<<59UG3TM_$_C:QMH$_LB?P]]KN80H\M+KYPK = Q5<G'7 ->BRZ)I4^EC
M3)=.MGL1R+=H@4!SG./7/.>N>:1-#TM+":Q%A;_99_\ 71% 1+QCYL_>X '-
M 'F%KIECI]A\+-2M+:.*^G>WCEN5'[R1&M6RK-U(X& >!C JY.UUH>MK<7MG
M::QH%WKFZ&_A^6ZL;AIMNUP?OJ'^3(YQQZ"N_/AK0VCM(SI%D4LSFV7R5Q"?
M]CCY?PIT7A[1X;PW46FVR3&4SEE0#,IZOCINY/S=?>@"[%=6\\LT4,\4DD+!
M941P3&2,@,!T..>:EJK:Z;8V5S=7-K:0PSW;B2XD1 #*P& 6/?BK5 &#KR))
MK?AR.159'O)596&0P^S39!%>>ZI9WO@"_AT*&.2?PMJVHVQL2.383_:$9HC_
M +# $CW_ !)]4NM)T^^NH;FZLH)IX#F*21 6C/\ LGMU[5/<6T%U$([B))4#
M*X5UR-RD,I^H(!'TH \\O);?5/B-X@T75[RU@!LX!9Q7<*N)(&5O,*;CC._.
M<<G _N\4KO2[+3C\.(K6\?4%M]3:WBO9@"\D827 R.J\#&." #7H.K^&]$U\
MPG5]*L[XPG,9N(@Y7Z9[>U2W6B:5>O;/=:=:S-:X-N7B!\G'3;_=_"@#B-"M
M+"'Q[X^86]LDJ/;>4=BAANMLMM^O)..O-<OINFV5IX ^&VJP6T::@VJV4;70
M'[THQ963=UVXXV]*]=FT#2+B_EOYM,M)+N:+R9)VA4NZ?W2<9(]JB_X1?03:
M6]I_8UC]FMW\R"'R%V1-_>48P#[B@#SX0V'B>^\9Z3KNJ6MI<I>.C+/&GF1V
MX1?*=&8\ #D8X!R>_,@\/:3JGQ+TZTOH1J$$OA;,KW*X:X(E0!Y!QEL<\]#C
MN!7>W_A;0=5OX+[4-'LKJ[@QY<TT*LRXZ<D=JL-HNF/JJZHVGVQU!5VK=&,>
M8%]-W7'M0!9CMX8K9;9(U$"((UCQP% QC'IBO&EM[*#X/^.3%#;QS_;-13Y5
M ;8LO3UP,CCW%>U5DR>%] E^V>9HU@WVU@]UFW4^>WJ_'S?C0!QCZ;9:3\1?
M!$MA;1V\MY9WB7,B##3@1QL-YZL<\Y.:Q=#M]/\ %/@Z"YU/7([/5;2^,UR8
MXD%W%=+(?ER?F)/"@8Y! 'I7J7_"/Z/]HM;C^S+3SK0;;:3RANA'HA_A_"HO
M^$7T'^V_[:_L>R_M/K]J\E?,STSG'7WZT :U<5<6EYXFU/5YXK>RN--\F32H
MQ<2LN1G]^1A3U;"?]LJ[1U5T9& *L,$'N*JZ?I=AI,!@TZS@M(2Q8QP1A%R>
MIP* /-O#6MZKIWPO\1:.6WZ_X8AGM1MY+*J$PR =QMQCUVU6U*#1I/"GPXU"
MR6!G;5[ K<#!=BP)DW-U)+#+9[CGFO3+7P_H]EJ$NH6NEVD-Y-GS+B.%5=_J
MP&3^-4D\$^%HW9D\/::"TOG'_1EQO]<8QWH XVTT#2+_ ,9?$6&ZT^VFA5;5
MEC= 55FMB2P'0-G/S=>3ZUBVMA:1> _AQK"0(-3?4]/C>\(S,R,2I0OUV[>,
M9QBO6%\/:,DMU*FEVBR78VW+B%09AZ,?XOQJ,^%]!:SM[0Z/8FVMW\R&'R%V
M1-ZJ,8!]Q0!REE8VC_%7Q9"UO$8I]*M6F0J,.29,DCOT%<=I>F6-M\-/A]JT
M5M&FH_VM9)]JQ^]VM*5*[NNT@D;>GM7L/]@:1]KGN_[-M?M,Z>7--Y0WR+_=
M8]2/:HO^$6T#[%!9?V-8?98'\R&'R%V1M_>5<8!]Q0!R(@MH/BCXK(D^R))H
M4,DL\0PRG=("_'< 9_"J_AF.YTSQ)IV@^(M(L)I7TZ6"PU6R \JZ@7RRRR(1
MPW"'N.3CK7=_V#I'VR:\_LVU^TSQF*6;RAO=",;2>I&.U+8:'I>F2![&P@@9
M4\M2B8V)UVK_ '5X' P.* /&(K#3G_9]TF400+<_:;=FD10)!F[VYR.<XW#/
MUKN=4TG0-'\3:#INFZ=%#?7,]S=PP[MEL6$85Y)%P=S!2-H&.2>1R:Z4^$O#
MAMI;8Z%IQ@EE\Z2+[,FUW_O$8P3[U8U#0-'U6*VCU#3+2[2V.Z%9X5<1GVST
MH \;G6VE^$>O1.;:9;7Q(RQ%%&Q$-XGW!D[5()[]#WKM@]N_Q<ATFX@@&G1Z
M.SZ?#L'E>;YI$I4=-X  ]0,^IKK/^$<T3[->VW]DV7D7SE[N/R%VSL><N,<G
MZTL_A[1[FTM;673;4PVG_'L@C \GC'R8^[QZ4 >/Z_8B'P/XYL@@.EV.MVXT
MX]H"TL)D6,_P@%B,#IDBO8M*T/3-$6==,LHK47$GFRB,8WO@#<??BDG\/Z/=
M::NFW&EV<MBARMN\*F,'.<[<8SGFKT420Q+%&H1%&%4#@"@#@-8TG3[[XRZ8
MEU9PS)+HTYE1U!67;+'C>.C >ASV]*Y-;DZ7X3FLHQY6BQ^-7M+I!PD5GYN2
MA]$W8!'3!([U[!+HVF3ZDNI2V%L]\B[%N&C!D5?0-U ]JCA\/:-;6MU:PZ59
MQV]V2UQ$L*A9B>I88PQ/O0!R>H:<EK\6-&33[>-;;4-.N5U2!$'EO&FWRV9>
MA.YBH/ID55^$>@:2O@W2=7%E$=00W,2W!&75//<;0?3CI[GU-=Q9:'I>GQ21
M6EC!$LBA'VKRRCHI/7 R<#H,U)INDZ=H]L;?3;&WLX"=WEP1A%SZX'% &!X[
MGL$L](M[V.262XU2!+6$2B..28$LHE)!^3Y22,$G Q7"SQ0MI_Q9LYVLY5CB
M$RQPIMC63[+DE5).&# 9/J,\=*]9U/2=/UJS-IJ=E!>6Y8-Y4\8=<CH<'O53
M_A%O#_\ I'_$ET__ $B-89@+=?WB*,*IXY  ''3@4 <#'I=CINO?#6[L[:*&
MYNHY([B91\\RFUSAVZMR!C.<8XIT\!\(^*-8\.6-LL=OXH'GZ>R1C;%.<).#
M[*I$N.F 17H!\.Z*6M&.E69-D,6I\E?W _V/[OX5FZ3::YJ&KKJ/B"TLK7['
MYD=I#;3&7=N(!D8D#!VC '^TV>PH W;&RM]-L(+*TB6*W@C$<:*,!5 P*L44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %,DECA3?+(J+D#+' R>!3ZX/XM6]M+X5LY+A$_=ZI:8D/!0&502&ZK
MQW% ';07=M<O*D%Q%*\3;9%C<,4/H<=#34OK22[>T2Z@:Y09:%9 74>Z]17F
MVLZ(N@_$2UE\)V<5K<2Z)>&ZAM4"JVT#R6*CC)D.,]3BH?#D/AWQ!H?A*_\
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M9M=0"Y89$)D&\CUV]:XB6*V3XRZ?-8QP;I?#\^&C  ?$L87D=1VKFK?R=4^
M5]=76?[:@::6:3&)TOUE)'/4/NV@>Q Z4 >O37EM;EA/<0Q%4\QM[A<+TW'/
M;WJ2.6.:)98G5XW&5=3D$>H->:V>DVU[\6HUU:QMI;E_#,,MTCQ@JTWG$%B.
MA/;)K6^% ">!EA3B*&^NXHU[*HG? 'L* .NN;ZTLMGVJZ@@\PX3S9 NX^@SU
MJ22>*';YLJ)O.U=S ;CZ"N%\/F+4_&WC>PUJ*.68/"B13 $&S,?RA<_PD[B<
M=SS7&V%C]K\.?#P:I&+@?VS+!!),,O):XEV*3U*E0O'0C% 'MD$\-S"LT$J2
MQ-]UXV#*?H14E5=.TVRTBQ2RTZUBM;6,DI#"H55R23@#W)-6J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N5\?Z
M)?>(="@L+&WBF87D$\@F<*NR-PQ'0YR!BNJK-UY[B/1+EK34K;39PHV7=R@:
M./D9)!('3(Z]Z )M/TRQT]&:SL(+1I /,$<:J3CH"1UQ4-OX?T:SU.74K;2;
M&&^FSYES';JLCYZY8#)S5F:_L[5MES>6\3B,R$22!3L'5L$]!ZUFZQXLT;1=
M"&L3WUN]K(0L#1RJ1,Q. %(X//Y $]J +MKHNE6/G_9-,L[?[1GSO*@5/,SU
MW8'/XT6.BZ5ILF^QTZTMFV[<PPJF%SG P.!GG%+-J^F6]FEY/J-I%:OPL[SJ
MJ-]&)P>E2O?V:1PR/=P*D^/*8R "3(R-ISSQZ4 5X]"TB&_:_BTRS2[9B[3K
M H<L1@MG&<X[]:4Z)I)NYKLZ99?:9UVRS>0N^0>C'&2/K2KK6E- LZZG9F%D
M:19!.NTHIPS YZ ]3VIXU33VL!?K?6QLVY%P)E\L]OO9Q0 ZQTZRTRW%OI]G
M;VD )/EP1+&N?7 &*JS>'-#N)[J>;1M/DFNUV7$CVR%IEXX<D?,.!U]*L?VI
MIYAGF%_:^5;N4F?SEVQ,.H8YX/(X-9VK^+=%T?P[+KDU_;R6:C$;Q2JPE?LJ
MD'!)/^>* +5_X>T75([>/4-(L;I+;_4K/;HXC_W01QT'2I[S2]/U".&.]L;:
MY2%P\2S0JX1AT*@C@CU%,EUK2H+6.ZFU.SCMY"0DKSJ$;'7!)P>E4]9\5:1H
M<5@]Y>PK]OGCAMQY@^?<1\P/]T Y)Z?F* +;:'I+7,]RVEV1N+A=LTIMTW2#
MT8XR1]:C/AO0C;16QT73C;POOBB^RIM1O51C /N*19YI?$$)BU6T:R>S+BS5
M09';<,2AL_<P<=,<CFK)U33UOQ8F_M1>'I;F9?,/?[N<T <1>^%-0GUR_FO_
M  MX<UZ&YFWV]U=OY<D$> %C(,3\#'53SDG'-=;X=T:/0='CL(EB1 [R>7""
M(X]S%MJ ]%&<#^E6[C4]/LS(+F^MH#$GF2"655V+G&XY/ SWJ>&:*XA2:"1)
M8G4,CHP96!Z$$=10!2N="TB\O1>W.F6<UT !YTD"L^!R.2,\=O2I)M)TVXOH
M[Z?3[66[BXCG>%6D3Z,1D47&K:=9^=]JU"U@\@*TOFS*OEANA;)XS@XS2G5=
M.$]O ;^U$URNZ",S+NE'JHSEA]* $LM*T[37E>QL+6U>8[I6@A5"Y]3@<GZT
MV_T;2]5>)]0TZUNGBSY;30JY3/7!(XI]UJNG64Z07=_:V\TF-D<LRHS9.!@$
M\\T^\O;6P@\Z\NH+:/.!),X1<^F210 26%G-8&PEM('LRGEFW:,&,K_=V],>
MU5(/#FAVVF-ID.CV$=@S;FMEMT$;'U*XP36-X(\07>M6NNS:A=6TJ66JSVT4
MT*[(S$BH0>I]2<Y-=%9:E8ZE&\EA>V]TB-M9H)5<*?0D'K0!#_8.C[[9_P"R
M;'?:C%NWV=,PC_8X^7\*B/AC0&-P3HFFG[1()9LVJ?O'!R&;CD@\Y-/U5[E)
MM.%OJ5M9J;I1*DZ!C<)@_NTR1AB<<\]*EN-7TRS$QN=1M(!"5$OFSJNPMG;N
MR>,X.,]<4  T?3!?/?#3K07DB[7N! OF,OH6QDBBQTC3-++G3].M+0R'+_9X
M5CW'U.!S5Q65U#*0RD9!!R"*K7&IV%I.L%S?6T,SXVQR2JK'/ P": "_TRPU
M2%8=0LX+J-6#JLT8<*PZ$9Z'WIITG33I_P#9YT^U-EC'V<PKY?\ WSC%27%_
M9VEM]IN;N"&#./-DD"K^9XI\%S;W5LMQ;SQ2P,-RRQN&4CU!'% #;.QM-/MQ
M;V5K#;0+TCAC"*/P'%0S:/IEQ>F]GTZTENFC,)G>%2Y0_P .XC./:GV>IZ?J
M)D%E?6UR8^'$$JOM^N#Q7+_$3Q6_A[PM?SZ7J5A'JMNJ,()L.Y!8 X7<#G!S
MG!Z=* -[_A&M!^R1VG]BZ=]FC?>D/V5-BMZA<8!]Z=?>'M%U.X@N+_2+&ZFM
M\"&2:W5VCQTP2.*T7=8T9W8*JC)8G  ]:X6R\2ZAXGO=1;0]7T^W_L[4C;BV
MF"NMQ @3S')'S#)9MI'' SG.0 =RZ))&T<BJR,"K*PR"#V(JO8Z;8Z7!Y&GV
M5O:0DY\NWB6-<^N *2SU33]1+BQO[6Z,>-X@F5]N>F<'BL.X\26_AOP[>ZGK
M>LV=VD=Q(L30 )G)^2'&3EQT/YGIF@#8M=#TBRO)+RTTNR@NI,[YHK=%=L]<
ML!DU5B\)>&X)"\6@:8CF43$K:(/G&<-TZ\GGW-9%]XFN(?'6B6<-]9OHM[:7
M4SNH!P8MO/F;L8^8] ,8KJK6[MK^V2YL[B&X@?[LL+AU;Z$<&@"H- T96N6&
MDV(:Z&+@BW3]\/\ ;X^;\::?#FAM!! VC:>88&W0QFU3;&?51C /TJRVIV"7
M#V[7MLL\:EGC,JAE &22,Y QS35U?37M6NEU&T-NIVM*)EV ^A.<9H C.A:.
M9YYSI5B9KA=LTGV=-TH]&.,D?6F'PWH1MX;<Z+IQ@@;?%']E3;&WJHQ@'W%1
M_:V@UJ[FGUBR&GQVBO\ 9B%5XCDYD9L_=(QVQQ7+Z[X[^T>"X]>\-WMLR_;8
MH7#KO;RVG$><9^7(Y&0>* .P&B:2+F>Y&EV0GN$*32^0NZ12,$,<9(QV-.L=
M&TS3'+6&GVMLQ79F&)4^7KC@=/:I+?4+*\FGAM;RWGE@;;,D4JLT9]& /!^M
M23W-O;!#<3QQ"1Q&GF.%W,3@*,]23VH SSX8T!K=K=M#TTPM(9FC-HFTN>K$
M8QGWZU/>:+I6HI;I>Z;9W*VQW0":!7$1]5R..@Z4IUG2Q8F^.I68M Q4S^>O
MEA@<$;LXS3SJ5BMBM\;VV%HP!6<RKY9!Z?-G% $1T/2#;75L=+LC;W;F2YB^
MSKMF8G)9QC#'W-%SH>E7EM;V]SIMI+#;X\B-X5(BP,?*,?+QQQ4J:G820).E
M];-#(XC2195*LQ. H.>23VI;/4;'4/-^Q7MO<^4VR3R95?8WH<'@T 0SZ)I-
MU91V5QI=E-:1?ZN"2W5D3Z*1@5=CC2*-8XT5$4855& !Z 56@U33KF\DLX+^
MUENHN9(8YE9T[<J#D4/JFGQWRV+WUJMXWW;<S*)#WX7.: )W@A>>.=XD:6($
M(Y4$KGK@]LX%$=O#"TICB1#,^^0JH&]L 9/J< #\*RK'Q3I&HZ_?:-;7L,EW
M9A!(HD'+-N)4#N5"Y..F?K2Z[XFTOP\UDFH7444EY<)!"C. 6)."W/8#DG_$
M4 3+X>T1+>XMTT?3UAN#NGC%L@64^K#&"?K2OX?T9TMD?2+!EM?^/<&V0B'_
M './E_"I;G5M-LH8IKK4+2"*49C>6955Q[$GGK5M65U#*05(R"#P10 CHLB,
MCJ&1AAE89!'H:I:?H>DZ4[/IVFVEHS#!,$*H<9SC@=,]JHQ>*-.U#6]1T*PU
M"V&HVB)G<0X#MO\ EV@@L5"9(!XR*SO ?BH:YX2T:ZU6]M%U6_B>3R0RHSX=
MA\J9R0 /TH W9?#^C3ZLFJRZ592:C'C9=- IE7'3#8S3M:AGN=#OK>VC$D\T
M#QHI;:,LI R>PYJ2[U33]/DCCO;^UMGE.(UFF5"Y]@3S5ILE3M(!QP2,T <Q
MX+\,0:'X=TJ&ZTRTAU.TME@DFC56)8* S!L9YQSW]:U[OP_HVH:A#J%YI5E<
M7D&/*N)8%9TQTPQ&1BN)L_%/BV]A\5SP2:,W]A7<L"0M:2*9U1=W+^;\I(..
MA&:FC\<WNJP^"-2T\1V]CKEPT5Q!)'N=2$<D!\XQE/3GVZ4 =I_9&F'4O[1_
MLZT^W8Q]I\E?-QZ;L9I@T'2!>F\&EV8N3)YIE$"[B_\ >)QRWOUJ6;5=.M[Q
M+.:_M8[IR D+S*'8GIA2<G-+<:E86C.MS>VT+1Q^:XDE52J9QN.3P,D#/O0!
M#>:%I.HW*W-[IEG<SJNP22PJS;>N,D=/:I+G2=-O+F&YNM/M)YX/]3++"K-'
M_NDC(_"K$$\-U D]O+'-#(-R21L&5AZ@CK4-[J=AIP0WU];6H?A3/*J;OID\
MT 5SX>T4BZ']D6&+L;;G_1D_?#T?CYOQI8- T:U>-[?2;&)HH3 ACMT4K&3D
MH,#A<D\=.:MRW=M (S-<0QB5@L9=P-Y/0#/4TEM>6M[;"YM;F&>W;.)8G#*<
M<'D<4 4O^$;T(6)L?[%T[[&6WFW^RIY9;UVXQGWK-U'3=9U#4AI0@TV'PUMC
M+LK-YSA3DQ;,;0IP 3G[I/<\9VL^.K>Z\(>(M1\-ZA:/=:4LN"^) _EJ"Q"A
MAQDX#<C([UTFDZO:WUO;0F]MWOS;1S30+(N]=R@Y*CD#F@#3JFVD::^H?V@^
MGVC7NW;]I,*F3'INQG%5]/FF6XU1[O5;2YACGS&D:A3:IM&5<Y.3U.3C@U;L
M]1L=0#FRO;>Y"8W>3*K[<],X/'0_E0!5'AS0Q9W%F-&T\6MR=T\(MDV2GKEA
MC!/UJ6VT72K.836NF6<$HA$ >*!581CHF0/N^W2KDDB11M)(P5$!9F)P !U-
M<IX'\8MXJ&JQ7%L;6ZLKG"PL,,;=QOA<CL2I_2@#=L=!TC3)FFL-+L[65LY>
M&!4//)Z#O4D.DZ;;7TM]!I]K%=S?ZV=(561_JP&3^-*=4T]9I86O[42P@M(A
MF7<@'4D9X%(-7TTVOVH:A:&WW;/-\Y=F[TSG&?:@"*P\/Z-I=Y-=Z?I5E:W,
M_P#K98(%1G[\D#)YJS>V%GJ5L;:_M(+J G)BGC#J3]#Q4<NK:=!>)9S:A:QW
M+D!(7F4.V>F%)R<TMUJFGV)<7=_:VY1/,82S*FU<@;CD\#) S[T ,DT72YM.
M&G2:;:/8C&+<PKY8QTPN,<4#1=+&GO8?V;:?8W.7MS"I1CW)7&":J^(=:ATS
M2;AH]1L;:],#26PN6!#D#C"[@6].#3/!^I7.L^#=&U.\96N;JSBFE*K@%F4$
MX':@#5M;2VL;9+:TMXK>!!A(HD"*H]@.!5:?0])NK_[=<:7937GEF+SY(%:3
M81@KN(SC!/'O69XW\0W'AKPO<WUC;?:K_!6VM\9WL 6/X!%=C[+6KH^J6^MZ
M-9ZI:-NM[N%9D]@PS@^XZ4 1)X>T2-K5DT>P5K0;;<BV0&$>B<?+^%5-0TV?
M2K.>X\*Z1I*ZE-(ID\U?)61<_,69!DGZUI-JNG+=&U:_M1<CK"9EW],],YZ4
MEQJVFVA87.H6D)10S>9,JX!. 3D]">!0!#HFG2Z=8L+EXY+RXE:XN9(QA6D;
ML,\X  49YPHJS?Z=8ZK:-::C9V]W;,03%<1B1"1TX/%-GU73K6[BM;B_M8;F
M7'EPR3*KOGI@$Y-+>ZGI^FA#?WUM:ASA#/*J;C[9/- #+?2-,M)WGMM/M(9I
M(UB>2.%59D48520.0!T%,TS0M(T4S'2]+L[(S',AMH%CWGWP.:LRWMI \:37
M4,;2 LBO( 6 &21GJ .:K'7M'%DEZ=6L1:.^Q)_M*;&;T#9P3[4 -/AW1#;S
MVYT?3S#<2>;-&;9-LK_WF&,$^YJ2YT72KRUAM;G3;26" @PQO"I6,CH5&./P
MJ>[OK2PMS<7EU!;P#K)-($7\SQ3?[1L3;PW'VRW\F=E6*3S5VR$G "G."2>F
M* (9M$TFXL$L)],LI;-.4MW@5HU^BD8%']BZ5]KCO!IEE]JC79'-Y"[U7T#8
MR!1_;>E&UNKD:E:-!:9^T2+,I6''7<0>/QJ+0-?L/$FDPZCI\R20RKN # LH
M/3<.QQV- ":!H-IX?LYK>TA@A6:8S/';Q".-6( PJCH,*/J<GO4M]H.D:G=P
M7=_I=E=7,'^JEF@5V3OP2,BM"B@#._X1_1CI1TK^R;'^SVZVOV=?+/\ P'&*
M?%HNEP:4=*BTVT33BI4VJPJ(B#U!7&*O44 9MWX>T6_TZ+3[O2+&>RAQY5O)
M;JT<>.FU2,#\*=/H6CW,-O#/I5C+%;8\A)+=&$6.FT$?+^%:%% %.72--GO8
MKV;3[22[A&(IWA4NG^ZQ&1^%0KX>T14N$71]/"7/^O46R8E_WN/F_&M*B@#-
M_P"$?T7_ $;_ (E%A_HO%O\ Z,G[G_<X^7\*4>']% N0-(L +K_CX_T9/WW^
M_P ?-^-:-% &8WAW0V^R;M'T\_8SFVS;)^X/^QQ\OX4X^']&;3Y+ Z38&RED
M,LEN;=/+=R<[BN,$YYS6C10!2_L;2_MT=]_9MG]KC4(D_D+YBJ.  V,@>U,.
MA:0=1.H'3+/[86#&?R%WEAT.<9R/6M"B@"DVCZ6]\U\VG6C7C+L:X,"F0KZ%
ML9Q[4^PTRPTN)HM/L;:TC8[F2WB6,$^I  YJU10!0OM$TK4YHYK_ $VTNI8U
M*H\T*NP4]1DCI[4MWHVEW[0M>:;9W#0?ZDS0*YC_ -W(X_"KU% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5PWQ@BAD^%NM-+&C&-(V0L =K>8O(]#7<U!=V-IJ$/DWMK!<Q9SLFC#KGUP
M: .&U/3["Z^-&D^?:P2E]&G=@Z [R)(]I/KCG&:Y"\2"#X7^*8D5$M[7Q4RH
MHP%B07<1P/0<FO81HVEB=)QIMGYT:A4D\A=R@= #C@4)HNE16\]O'IEDD$_^
MNC6!0LG^\,8/XT <+J6LV,/Q-6*^UD:?87.E!=/N%,7DNXE?SDW.K*&/R9 Q
MG:/:L?4-!T"RM/!%GITC7VG_ -OE(IK@HV]&20LJE0 8]W&.A]Q7J5WHVEW]
MI':7FFV=Q;18\N&:!71,=,*1@4L^D:9="$7&G6DPA $0D@5O+'HN1Q^% ' W
MWA_0;?XMZ'9+I=A%;/I5RP@6%51W$B-RN,-CYCS]>U<IKNDVUCX-^($5O#&N
MCQ:Q;FR &%BDWQ>=Y?\ = 8E>.F"*]'U7PS=:G\0-/U:>RL+C2[:RDMG2=]S
M%F96#!"I'&WU[UT<FD:9-9QV<NG6CVL?W(&@4HOT7&!0!P?BY-,\+^(/#,JB
M/1]'GNIOM5S;Q1JBW!C"PL^Y2O3>,D<=<BL?Q;IVB6GP_P#&-UI.IRZ@+JXM
MI[F4O&T*R^:F[9L4*&Q@M]17J\VGV5Q8FQGL[>6S*A3;O$K1X]-I&,4D6F:?
M#I_]GQ6-M'9;2OV98E$>#U&W&,4 <;J6K:/)X]MH;6>SANAI,C&]GEW0K 90
M&1$R%9RR')SP!WZ5Q6DW-J_PQ^'3//"P@U^%)69A^[&Z; ;TXQU]J]D.D:8S
M6K-IUH6M.+8F!<P_[G'R_A0='TPV1LCIUF;0MO,!@7RRV<YVXQG/.: .+D$/
M_"Y(Y]/6 RS>&9'1TQB0^>NTDCJ.G/I7-QF+4OV?9B^[^V(&8OVG34!-Q[B0
MN1[X:O6O[+T_[:+W[#;?:P,"?R5W@=/O8S3?['TS^T#J']G6GVT\FY\A?,Z8
M^]C- '"6.F6UQ\7YEU"TM9;C_A'H))E,:D&7S7#-CH3VSZ5I?"; ^'EG&I^2
M.YND0 \*HN) !^5=4VDZ:]T]TVGVAN7!5IC"N]@1@@G&2,5)9Z?9:?&8[*TM
M[:-CDK#&$!/K@"@#A=+TO3;GXM>+4GLK:1396;,KQJ02PD#$CU([^_O7'6=G
M9Q? _P -Z@D$0NTU.V*W&T;P1=;1\W7A>/I7LQT?3#<2W!TZT\Z8$22>0NYP
M>N3C)_&HSH&C&W6W.D6'D*VX1?9DVAO7&,9H \Q\:ZAI]Q9?$.&V>WM9DMTC
MO#<ONDN)!#E!&A("*!CGG)SP.M:>F:U!)\2M&6^NHS:R>'U.G2,X*//O FVG
MIOP #WP#ZUWSZ-I<D[SOIMFTKQ>0TC0*6:/&-A..5QQCI1=:+I5[:0VEWIEG
M<6T./*AE@5D3'3:I&!^% 'C:ZA:V'ASQ!);3A--A\9F2]-J%?R[8E/FVX(*[
MMO8@XQ7H/A^UT&;Q?<ZSIFO2ZI>W-DJ7!BEA:'8&&PMY:CY^H!/. WI73Q:;
M8P1310V5O''.2942)0)">NX <Y]Z2PTO3]*@,&G6-M9PEMQCMXEC4GUPH'-
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M_2O8H=&TNV\GR--LXO)1DBV0*OEJWW@N!P#W ZT1:/I<%M-;1:;9QP3\2Q)
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M=BNDZ:EVMVFGVJW**%680J'  Q@'&<8IUYIMAJ(07UE;700Y3SXE?:?;(XH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMXY2!'(PQ@CE<@'C/5J?+XKUV?Q#K^C:=HMI)-I<4,J2S7A5)%D#'G"$AOE
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M*EF2(X(R ,=\DXQWH Z^BH+*Z2^L+:\C!"3Q+*H/4!@"/YU/0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4453O]
M5T_2EB:_O8+832".+S9 I=R<!5!ZGGH* +E%%% !1156VU*RO+JZM;:ZBEGM
M&"7$:-EHB1D!AVR* +5%%1SW$-K \]Q*D42#+.[  #W)H DKE/%=OXHO;J"W
MTFRTNXTT#=<)=W3QF9NRD*C?(.I&?FZ'C(.]INKZ=K$<KZ?>0W(B<QR^6V3&
MPZJPZ@^QJ[0!S<-QXQ329I[C3](DU#SE$5I%=.L?E<9)D*9W=>-N.!4EEI%S
M<^)U\0ZC!#;W$=F;.&"*0R$*SAV+-@<Y50 !QSR<\=!56#4K*ZOKJR@NHI+J
MTV?:(5;+1;AE=P[9'(H AT=]6DLF;68;6&Z\UPJVKLR^7N.TY/?&,UH444 %
M%%% !7G $7AKQ;J6L:#JFC75EJK+)>V$U^L3I,./,C;D<]U..>_:O1ZHG1=*
M)).F61)_Z8+_ (4 <Y?:T^J:/J$::_I.EW,MK)%;".^20I(PX=FXQ@] N>YR
M> .8TV&>'6/"E])>>&+5-+@G@N8XM2WEO,5 9<[1N8E2<'UY8YX])_L32?\
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MQQ74-]:+;7MJ\GEL&0Y21#@@\$@@X]?:I]"\*I::9K46I+%++K=S-<7D:$E
M)!M\L$@$@* ,X&3DX%=-10!S'@KP]>^&_#PM;ZY%[>K^[$F<9BC^6)<_[H!/
MNS5R\?@+7AX,LK19+*'6=,U=M4M#YK/#(3([;'.T$##D=.U>GU4U#5+'28//
MO[J*WCYP7/7 R<#O@<T <<?#VO:QXP_M;5+*QM;*?1I=,GACNVDD7>X8D'8
M>GMUZ]J?X5TWQMI5O::'J+Z8^FV.U$U&)V\Z:%/NIY9& Q  )STSC)YKL[6[
MM[ZUBNK2>.>WE4-'+$P97![@CK4,VJZ?;ZE;Z;+>P)?7()AMS(/,< $DA>N
M >: //AX0\3Z;X9\1^%;*&PNM-OQ<M974MRT;PB4$F-DVG)!)P<]_P *[[1;
M>ZLM!L;6[6(7,%ND;B)RR$JH'!(!QQZ59NKJ"QM)KNZE2&WA0R22.<*B@9))
M] *=;W$-W;17-O(LL,J"2.1#D,I&00?0B@#SF;P9K\W@3Q5HABL5NM7O[BYA
M;[0Q1%E<-ACLSD8[ U>O=$\5:9XF7Q!H$5A.;RTBMM0L+J=D&Z/.QT<*>@8C
MD?SX[RF3316T+S3R)%$@+.[L JCU)/2@#CM5T+Q!?:IX7OG^QSR:;<R7-V?-
M9!\Z,NR,;3D*&ZG&<>])K6B^)-/\8MXB\-"RNEN[9+:^LKR5HPVPDI(K@'!&
MX@@C^?':T4 <9X@T'7]6L_#V39S75EJL6H71\QD0*F[]W'\I)X8 $XSC)QFI
M;+1M7M/&?B36#;VS6^HV]O% HG.X&)7'S#;@ [^Q/2NNHH YSP'HU]X=\%Z;
MH^HB'[3:1F-FA<NK<D@@D ]_2N3UWP9XHU33_%E@!ILYU.X$MK?33MYBQ!D*
MP;=ORA=IY!QSG&237I]4[K5=/L;JVM;J]@AN+IMD$3R /*?11U- '.P:/K9^
M(D'B"X@LUM?[)^PR+'.Q97,@DR 5&5&,=03UP.E48M%\7>'O$>JMH2Z9>:3J
MMR;LB\E='M)F #GY0=ZG&<<?AU/>4PS1+.D#2()G4NL98;F48!('H-PS]10
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M8S@_2@#.M/%>LVGBU=!U_2K:)[NVDN;"6QG:19-GWHSN5?F (.>E1V7C2_\
M^$@T#3=1M;6&76(Y6:U20^=9,J>8%D'?(!'1<'UJU<^']3UK5TU>]>&PN;6R
MGMK%+>0RF*24 -*6*KTV@ 8]3GG PM.\'>)X)/"4DO\ 8T;Z(\HF\N21C/OC
M*-*25&7).2IZG/S<T ;6C^+I]<U"2.R-DPM[Z2UN[-F(N;=$9E$A'?) .,
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M3GDGJ3V%/;PEKO\ 8/@NP T\R:#/!+.QN'Q((XS'\O[OONSSZ5-)X*OKJ_\
M%UI<2VO]D:^ WF*S&>-O*$>-N-N 0&SGMC'.0 30>+=5_M[3K*72Q-;WZ/\
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M=-LE63$=VSD;) >2JXR2#DC:>M+XN\.ZM?:KI&O>'Y[9-5TPR*(KO<(IXI
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M$=A-<OIQO ;>4@1.K!6B?[W/S#YO_':@M?!VKVGPRNO#\6K;=:G@,9OP2,L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M29&<9&>N* %HI"0.I%+0 45SVM:GKUD]_-96%DUC:6WG>9<3.K2, Q95 4C
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MHH **** "BBB@ HHHH **** "L[5=473XTBB"RWL^5MX"V-Q'4D]E'!)_F2
M=&L/6/!WAWQ!=+=:OI%K>SHNQ7F7<0O7 _.@##N["\TOPP-*T" :M=37)DU1
MHKE(9&\PL\C9)^4L?E'<*>.@-8WAB_U=OBWJ<<_AO["C:=;1RH+N-A;HOF;#
M\OW@3Q@=*]!T?0M*\/VC6FD6$%E;LYD:.%=H+$ 9^N /RJ>/3[.+49M02WC6
M\FC6.28#YF5<[03Z#)_.@":*:*=-\4B2*"5RC C(."/SI]4M,TFPT:U:UTVU
MCMH&D:4I&, LQR3^)J[0 4444 %<MJCWVI>*H(+"VM;F#24\V9;BX:)?/D4J
M@R$?)5"Q((_Y:*>U=37(6>E^(=-NKJXLM-T&)[E]\S?:Y\R-TW-\G)P ,T 8
M_P .6FT/5==\$7\<<1M9#>V,<<I=?LTQ)*JQ"DA6)&<#DUR5SHNGGX5>,+XV
MX-W8:K>M9S%B7MRDPVE#_">.HZ]Z[Z3P_K<VLC6'T?P^=25=@NOM=P) O]T'
M9P/;I4(\+:H-.N=/_L/P[]CN9#+/!]KN-DKGDEALY)[^N!Z4 5;G3;32/B;X
M0N+"$0SZC;7BWD@)W7.V-&7>3RQ!YR:QM$L8O%O@^WUF[U>SLM4M+PS7-U':
MG[7!.LAS&6+YP?NA<8*D #I75-H6NO=V5V^E:"UQ9 K;2->W!:('@A3LXR.#
MZCBJW_"(WW_"0?V]_P (WX6_M3=O^T^;+NW?WL>7C=[XS0!D#P]I6I^*_B/!
M?6JW$,<=LZ1R,656-N3N )QNSR#U&3C&:@T/4WU&;X<Z7JS^;8W6D/<%9CE;
MFX1%"AL_>VC+8/<@]0*Z8:!KBW%].NDZ );\!;MQ>7 ,P P WR<X''TXZ5!/
MX4U*YTFWTJ;0/#3V5LP>"(W,_P"Y(Z%#LROX$4 <MJ&FV5K8?%NUMH5BABCC
ME2./Y0C?9MW '3G/'2K]YH6FP>(?A_+%;^7+?QRPWDB.P>XC^S;MKL#EAD#@
M]N.E;">$+Z..\1/#GA=1>J%N<3S RJ   QV9(XZ=^IYJP_A[6W>Q=M(T M8#
M%HQO;C,';Y?DXXX^G'2@#D;Z9O"MK\2+;1E^R65I<6+I% I"P)*B><R@8Q\I
M8\8_"NJL/#>F_P#"066K6^IV*PWEH\'V73;;RHKR/&X,V';.WLWOC/-3PZ'K
MMO=7MS'H_AWSKX;;IFNIV\\8QAP4PW''/;BJND>$=0T 7/\ 9/A[PS9FY&V5
MH;B=68>F=F0/8<4 <1I>F6EO\+O!6N1Q8U1-5ME6Z+$R!6N&5D![*03E>ASG
MK7:Z!IVG)\7/%TYL[598X;&2.3RE#*SK)N8''!/<]Z?_ ,(IJ8TR#31H7AT6
M-O)YL-N+NXV1OG.X#9@'//U)]:LR:%K<VJ?VG)HGAI[[R?(\]YYBY3!&"?+Y
MX)&>O)H ["">&YA6:"5)8F^Z\;!E/T(J._N(;73KJXN%WP11.\BXSE0"2,=^
M*Y#P]H?B3PSIK6&G6.@16QF>58UN9@J;CT'R?3ZG)[UI3KXNN;>2":RT!XI4
M*.IN9L,I&"/]70!PVLZ#>_#G39O%7@K5-VB+MN+C1KAM\$B,1DPMU4G(_P 3
MTKH;=(&^,UP3 L:7/AM))(V4#<3.P.X=SC -+'X5U2)HO+T+PZL<3AX[<7=Q
MY*,#D,(MFP$'G(%3:GX?UG6;RVO-1T/PU<W%L"(I'N)L@'J#\G(]CD4 <KX>
MLKW4/AUIBZ-+8O<0:S=RQ6=WS!=JLDW[LX] =P[ J#VR(-3FL=4\,Z8(],N-
M&N8/%=M;W=F)<""4LI<(RX!4@J0??BNK3PKJ<=ND$6@^&XE2<W*F*YG1A*<Y
M<,$!W?,><]ZR/%?AOQ5>Z38:?::!I$\$>I17LRPW;$N5;+;S( 6W=SR: (-5
MTUO!GC346\*0M MQX>NKJ>UC)9/.C_U<F#_$2<>^#[U>T/1M/U.V\,>([;6+
M.%EVJ'L[8K+=EUP\4K;R7.<DY&003Q@UNV&G^);!I);?3=#6:8+YDDM[/)(P
M'0%F0D@9.!G R<5GZ;X0OM'U2;4].\-^%K6]E!#3133 C/7'R?+GVQ0!Q5WH
MNGGX;^.K\P9N]/UF]:SF+$M;E)5VE#GY3QU')[UU/BZ'4$OKG5UTVS\0:;_9
MT<5_I[D+<6R_,QDA)&.0Q)'!)08/'%__ (1;5/L%U8?V'X=^R7<AEN(?M=QM
ME<]68;.2>^>N!Z4^7PWK,TA=])T+<T(@<B^N1YD8SA&POS+R>#D<T 4FDM+K
MXB>!-0LO,\F[TJZ=#)PQ3RXBF1T!PQ_.LBQBM_$'PI\0:SJ:JNO6\E[++='B
M:UGB9C&JMU4*H0 #M]3752:-KTNHVNH/I/A[[7:+LMY1=3@Q+T(7"8 /<=ZB
ME\.:Q-?37CZ+X=,T[*TV+J<),R]"Z!-KD=B030!@V=@-;\>>'&URV\RXN_"Y
MDO87)VO)OBR&7H1DGCI^5;_PP06^B:O8Q9%M9:W>V]O'G(CC63A1[#-2RZ/X
MAFU9=5DTO0#?I'Y2SB\N RI_=!"<#VIVF:5XBT99UT_2_#]NL\AEE"W<^'<]
M6.4ZGN>IH Z35Y[FVT6_N+./S+J*WD>%,9W.%)4?GBO*+V.*3X*Z7XHTS!\0
MQK;W$=Z@_?2W+2*DBLW5@Q9E*GCH.U>A>9XR_P"?30?_  )F_P#C=9%OX<UB
MUNS<P:+X=C<RF?:+J?RQ*>KA-FT-_M 9H RX?#6E:W\4_%%OJ=KY\(M+&;RC
M(P429D.[@]1CCZGUKTRN-AT?Q!;ZO-JL6EZ M_.-LLXNY]SCL#\G('8=NU:/
MF>,O^?30?_ F;_XW0!>\1_\ (L:M_P!><W_H!KG_  #)-#\(M&EMDWSII@:-
M>NY@IP/SJU>VWBK4+22UNK'09()05=/M<X# ]0<)R/:H],T_Q+H]DEGI^FZ!
M;VR?<B6ZGVK[ %.!]* .4\.Z;:>(?#?AGQ%_;5G;WD$T,DMU;VI%S+.?EDAD
M?>2VYB01CTP *M^$O"^CZGXC\52WMH9FLM=+VVZ5OW3>4AR,'OGGZ#TJ_:^$
M+ZQUU];M?#?A:+4G))N%EE!R>I'[O )YR1SR:MV6BZ_ITUW-9Z7H,,EV2UPZ
M7EQF5O[Q.SD^_6@#SIM(LH_@A)JZPXU*RU)S:W6XF2#_ $[;\C?P\$YQU[UV
MW]E66B_%[3(].@%NM_I5S]KV$YG*NF&<]6;D_,>>>M2_\(IJ?]DMI7]A>'/[
M/9_,:V^US^66SG.W9CKS]>:LMHFOOJ,&H/I>A->0)Y<4YO;@NB]P#LZ'OZT
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M\,:L;.SM#HOA[[/9.)+6+[9<;86'1D&SY2.Q'2MGS/&0'_'IH/\ X$S?_&Z
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MK]MJ=[INC":)?*-S'=SO*L?=1N7!'L3@GFN@TO2;#1+%;+3;6.UME9G$<8P
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M* "BBB@ HHHH **** "BBB@ HHHH *Y[QOKEWX9\)7^M6<<$KV:"0Q3 X<9
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MY8YO]7,?^ #$N..^.M:?@:Y36K*PDU&TCCF\,P26EQ^ZX6Z4E&*\=0B;N/\
MGJ/2@#T-9XFF:)94,JC+(&&1]12F:-6VM(@;(&"PSD]!7C=L]G'_ ,*_U#3_
M "X;.;4Y/)EG</=S1NDA=Y7&!R>JX/;)SQ6WX:\,:)J7C7Q@;S3H)Q:ZI!+
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MLEAA"L1U(R.@SV%:#7EJMTMJUS"+AAE8BXWD>H'6B2]M(;A;>6ZA29AE8VD
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MOPWW9/,88Z-MR<^O-=!IFG>&M5UO0M8LM;CN7^SR00VUM'$JS0LG*RJHSM7
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M5K;WMM);74$<\$@VO%*@96'H0>#5"7PUH4]O:V\NBZ>\%JVZWC:V0K$?51C
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MX/)$,;^7L&T-]DW9QZYR<^M10V-E967PJN[:WAAN97A5YD4!W#6AW GJ<\4
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M CTJQ0"$0 +;H/W>2=G3[N2>.G)K0HH K6FGV5A;FWL[.WMH"23'#$J*<]>
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M7BZ?:"Z10JS"%=Z@#  ;&<8JY10!1@T32K74)=0M],LXKV;/F7,<"K(^>N6
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M!+++%!%'),P:5T0 N<8RQ[G''- $M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-0
MU33])@$^I7]K9PD[1)<3+&I/IEB.:MUEZCHFD7MRU_JEI;W/EPF,?:D5TB3D
ML0&X&>,GN%'I0!HPS17$*302)+$X#(Z,&5AZ@CK52VUG2KVY-M::G9SSKDF*
M*=688Z\ YKC/"FA:I9_#G4[/1Y%M'O;FYETM;DL!;02.?+Z<CY?F ]6Y[U'X
M&,.D^(Y]!U/PKI.CZXMKYL5WIL0$5Y & 8JQ&X$-MRK$GO0!Z+1110 4444
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M/$$./,#X"<]@2PY[50?Q)K%KXPLO#TUA8S-=VC72W"7#QA I ==NULD9&#D
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M,<_V:=K>;8<[)%^\I]QD4 6Z*** "N#>\T:_O?$-MJVK:#_9VIQK%A-25I
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MLI+NS"&XA6-=T>\97/'<#-6_[,L/^?*V_P"_2_X4 <'XJN[+4M0T'7])\0Z
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M5UM% '&^'O"&H:'X(OM'74S_ &C+'+!;WG4PH 4@Q_NJ%/U)K+T_PGXF@O\
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M)*XA@2.17^]M)9C@Y. .GID]S5*YU?3K/4+73[B]@CO+LD00,XWR8!)P.N,
M\T 8<NBZK-\0[#7S':+9P:?):2+Y[&3<[*V0-F"!MQU&<USZ>"?$*?"W4?!^
M[32[^;';3><X#(\K/N?Y/E(W8VC/UKTFB@#D)]"UF?QGX?UCRK);>PM);>=?
MM#%B9 O*_)@@;>Y&<]JK76A>*='\7ZAJOAM]-N++5O+>ZMKYW0PRJH3>A4'(
M*@9'M76ZEJ=EH^GRW^HW,=M:18\R60X5<D 9_$@5;'(R* (+.*>&SBCN9_/G
M"_O) NT,W? [#/0=A4]%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDLUT_189H1'+,X=Q(BH,80@;=H[\^U=5/$)[>6$G D0KGTR,4 >075[J=_\
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M'!)+' @1"Q")\Q&74 9'7KQS5/CZ]LM$N+G6--;3W@U%+(WDUO*EN8VZ3[6
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MHH **** "BBB@ HHHH **** "H;NTM[ZTEM;N".>WE4I)%*H97!Z@@]:FHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHJG?ZK8Z8$^V7*1&3.Q3RS8ZX Y.._I0!<HJ*UN
MK>]M8[JUGCGMY5#1RQL&5AZ@CK4M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQNO[Y9/ND;5R /FR<8[T =38>)[V\\?ZKH3:9.MK900,)=T9Y<N=Y^;.TA0
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MHBFN[9XXW/0,1QGVSU]J *R^,K-9],6[LKVSM]48)97,ZH(Y7(RJG#%D9AR
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M5>Z??V5S>0O-:><B$7 0995V,2& .<$"L;_A:^B_V9:ZJVG:NFES2F&2]:V
MBMV#E/WAW9 R.H!QD9P>*7PK/+?W5KYW@0:+>6X/VJYFMXE0-M(Q"RG<V3WP
M !GGIGEO#\-QKWP4?PY:6-PUU>2W$"2/$?)53<N3(7^[A>>,[LKP.10!W&I>
M/+/3]9N])CTK5[Z\MH$N#':6P<O&S;=R_,,@8/\ 3-3:KXUL=)M;J^DL[V;3
M[.7RKJ[A5"D+9 ;(+!FVD@':#CGT.,[2["YM/BA=3_9+K[!_8\%G'<M&=C21
MNQ(S]".>E85A87F@ZQJVE7W@DZRMU?375CJ$<,31E96+[9F;E-I)YYXZ#ID
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M")[:6,L2LDC$[@0#RH!)Q0!UT_CFV34=8T^WTC5KN[TH1M/'#"OS*X+ J68
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MR,;L*6!;;D9P/4<D$  Z>BN6F\<6_P#;?]D6.EZA?7+V*W\!@"!)HV; (9F
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ME&5SN"ED8 X_ 4VY\=I'J&M6%MH6J7=UI"QO.D:Q@%64MN!+@8P.GWCG@<'
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MJ:U:1F"J68@*!DD]!0!YHNEZX(/!&NII%RLVA1-:W5@[IYKQO$J,Z8;!(*Y
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MO<=* -&+Q/'<:5HE];6KS#5V00HDBY4,A?)/3 523CT[UO5P7@CP_-I>N:M
M9EDTK3+B2'2T'_+(2[99%]]I(4'M\PKO: ,O6=972/L4:VTMQ<7MP+:"-.!N
M(+99OX5 4DG]#6%<?$"WM?#NM:M-IMQNT6Y:VO;=74L"-IW(<X8$,I['KQ5C
MQFFMN=).F6D]Y8BZSJ-M;3+%+)%M. &9E&-V"1D9''3-<@WA#7+CPSX\TB/1
MXK(:G,;BQ"S)L;Y$P@ Z'*$'.!D\9ZT =[=^)([3Q)IVBO9S-)J$$LT$JLNW
M]V 64Y.0?F&.U>>ZYK=[XI^%/C&;5-.6(6TMS'%\ZNL9C8*%'?(P3GW-;OE:
M]JOC7PKK$GAZXM+6TM[J*X$T\1>,NL8!(#$$9'&"3P<@<9RYO#_B%? GC#P^
MNBRR37EY=26LJSQ;9EEDW*1ELC SG=CMC/. #J=+\5_\3C3-#NM+N[3[9:&2
MSN)2FV?RPNX;02RG!!&X#CT/%)=>.K>WTF;7(["XGT."9HI;R-E)PK;&D5.K
M(&!!/7@D CFJ=[IVJW/B_P &WZ:5<"VT^"X2[<R1?NC)&JKQOR>5.<9K)TWP
M_KNF?#O4O K::\SE)[6SOPZ>2\,I8AW^;<I7><K@]!C.: .AU+QR+37#I%CH
ME]J-RVG_ &^$V[1[9H]P7Y26]SUQT&,Y%-L]:T\^*]=*:#=0ZM:Z?#-<.VPO
M.F&*(NUCSP1SCFJFG:%?Z5\0].EBL)Y-*M- 73!=EX\;Q(K E=V[&%ZXZU+%
M:ZO9?$'Q#K*:-<3VTVG0Q6Q66(>=)&7.WELKG< "10!<E\8RV_B+3=#FT6Y%
M[? N$2:-_*C'WI'PW"CI[G@9JKJ'Q'TS3H5OGBWZ5]I^S/=),FY3NV;_ "\[
MBF[C/7O@C!JGX3LM:TZ2;4]4T2[E\0:I.AO+AGA\JWBW >6F)"=B+GH,D\U3
M\-6/B;P]"WAA_#<%U#%*XM-9,L?E^2S%@9$/S;EST YQC(ZT =%K>MQWT&M:
M;:::VI)90E;S#J%#,F[RUS]Y]N#C@#(YSQ4?PP_Y)CX=_P"O)*RK&PUWPYKW
MB:UCT>;4=/UBX:\MKJ"6,>5(Z!620,P( P,$9X[=JW/A]87^E> ](T[4K1K6
M[M8!%)&SJW3OE210!TQ.!DUR-QX]M;?1TUXV,[: 9?+-^K [5W;/-V=?+SWZ
MXYQBNJN(5N;:6!B0LB%"1U (Q7FEKX>UX?#.;P'<:<QN ILX]0#IY#0E\B7[
MVX$*?NXSD>AR "_XFO[JX^(OAW3#IWVRP:WNIO*,B%)V"H V"<?*&;KZ\5E:
M?I%J?'.H^%GT RZ);::B16LDRNL2RRR%W7<V1NXP!R HZ8K?O=*U"'Q_X;N;
M73;B;3=-L9[:2X$D?!<(%X+!C]SGCO4MC9:G%\4-6U232YUT^XL(;>*XWQX9
MD9B>-VX#YO3M0!5\+ZSX=T3PSJDNGZ7<:=;66IO926[D/+/<C8G'S'<S,5'W
MO<FME/%:V^HWUGJUA/I_V2R^W-<,=\)A!(;YQT88Y7\LUQC>$_$-WX:\0Q0V
M1M-2_P"$B;6=/$\B%)0'5E!*L<9VGKCG%=#<1Z[XU\,ZGINH:.VA)<V4D&)Y
MDE9I6& 1LSA!SUY.>@QR 3Q^/+7^VM.TZXM'B.IHYLW6:-RS*-VQP#\C$=.H
M[9I= \;/XANXTM= U%+7[1/;37,AC"P/'GA@&).2,9&1DCGKBIX8NO$LRVUI
MJWA6*PFM5 N;T31NLVT?\L@.<L<=<  GG-6?A]I^HZ9I.H6^I6$MI))J5S<1
MAW1MR22%E/RL>QYS0!UU9%]KJP:Q'H]G;F[U%X#<F+>$6.(';N9CTR>  #G!
M[#-:]<9?Z9J6E_$=?$MI:27UC=V LKJ*%E\R%E<LC@,1N4Y(('(ZT 0ZQXS:
M]^'OB'4=*MYX=0T^*X@N(9&59+25$)+'G! X(()SD5=\'Z'8"ST[6SI0L]1%
M@EN9%<9EC(5LL%."<]SSU]:QKKPQJ8\+>-IH["1]1\1-+Y-HLB QJ8O+3<2V
MW/5C@GKCG%=GX?2>+P_I\-S;26\\5O'&\;E20P4 \J2.OO0!HL2J$A2Q R%'
M?VKR/7-;O?%/PI\8S:IIRQ"VEN8XOG5UC,;!0H[Y&"<^YKUVO*YO#_B%? GC
M#P^NBRR37EY=26LJSQ;9EEDW*1ELC SG=C'&,\X .ITOQ7_Q.-,T.ZTN[M/M
MEHTEG<2E-L_EJN\;02RG# _,!QZ'BJ][\1],L8X+UXM^E2W(MOM23(64EMH<
MQYSLR.O7OC'-17FGZK<>,/!E^FE7 MM/@N4NW,D7[HR1JJ\;\GE3G&:S/"UA
MXF\/6J^%YO#<%Q%;NR6VLF6/RS"6)#.A^;< <;0.2.H'- 'I=<=\3/$5YX;\
M(-+IK!+^\N([*VD(R(WD/WL>P!Q[XKL:YOQUX6/B_P +3:;%.+>[5UGM9B,A
M)4.5)]NH/UH DM_!>AP6"V[6:RS[,/?.<W+MCE_-^^&[Y!X[5':WHT"'2?"\
M ?4-3CL@0"X4>5&%3S'8],G X!))] 2#3==UN6U2&_\ #%Y#J"KMD*2Q&W+?
MW@^_.WO]W</0UFWVE:OIWCZP\416YU"*33CIU]#;D*T?S^8LB!B,C)((SG'/
M- #[OXC6-GX9U35WTZ\,NE3_ &>]LQL\R%\@ DEL%3D$,,Y!Z=<6)O&DEOXA
M31YM U!9[F%YK$YC/VG81N'WODQD'YL<>AXKF/$/A'5[[PWXTN;;3I&U'Q!/
M!Y-F)(P8XX@B@N2VT$X8G!/4"NAU.SU.[^(?AK5(M+N/L5I;7,=Q(7C'EM*$
MVC&_)QM.<9_&@".7XC6UMX6U/6KG2;V-]+NS9WEJ&C9HI,J <[L%3O7D9Z]*
MMVGC9'\50:#J&CWVFR7D;R6$UQLVW(098?*25;'.UN<=<'BN$\4V&I6'@'X@
M2WNG2VZ7NIQW5L7="'0O"H^ZQP<J>M=KJ&FWWB+Q3H6H&PELH=($TY:Y*Y>5
MTV*@"L<@9))Z<#&>< $EMXZAGETB233;F&QU>X>VM)W(#;UW8WIU4-L..O;(
M%5[GX@-&VNK;^'=1N'T5\70WQ+A=F\L"6P?EY &3["N731?%5U#X:O+[P[-+
MK%AJHFO[F6ZB+2KAQF,[N(QN'R_+CC"GDUM0Z5K*S>/G;2+@#51FR_>1?O?W
M C_O\<C/..* -M_&EL-1\/VZ64[6VNQ[[6[+*(Q\F_:W.0Q7H,<UK6>J&\U;
M4+);9U2R9$:<L"K.RAMH'7(!!/U%<=J.A7#_  :LK6[1K#5-'L8)H7<JQAN(
M$&""I(()4CCLU=!9IJ>A^#WN%T_^T-9=6NI[:.01^;.YW,H8\ #.!GLH% '1
M44R)G>%&DC,;LH+(3G:?3(I] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !117*?$72+/6/!E]#=1(7 412[1OB)=
M1N4]C0!U=%>?^%=9N3+=^!O%PCFU:UB)AFD7*:C;]I!GJPQ\P]1GUQ=\/ZK:
MZ+X1\):=:VJO?:C9Q>1 A"!B(59W=L< #J<$Y(X.: .NN;>.[M9K:7=Y<R-&
MVUBIP1@X(Y!]Q5#0?#^G^'+#['IZ2;"=SR32M)(YQC+,Q).  !Z 5@WOC>:'
M3?$<2:<L>MZ+;&XDM99LQNFTLLB.!\RX![ Y&#CK4=EXOOK+1?"TFJ:?N_M<
MP6YN1.,+(\8(9AMXW<X [\=Z .VIC31))'&\B*\F0BE@"V!DX'?BN>M/%@N-
M:U[3)[1+:71XDED>2?Y9%92RL,#A< Y/8]C5.XUNVF\1>$8M2\/NM_?B:2UF
MD9&^R$1%F7/7<5 !XQSU.* .O) !)( '4FDCD26-9(W5XW 964Y!![@UYW_;
M&H^(;#QU9:II]O\ 8[/S;=%\P.%"P!AP1R23G/;IVS1X/\52:;X>\$Z==:3/
M'9W]E!;07ID7!E$(8 IU"G:<'],<T >C45SEOXI>^NK@6%BMS;6U_P#8)V6<
M>;&X8*S&/'W03ZY(YQCFLS2?%>IRZWXL_M"Q LM(<*%@D\QPHB\SA<?,S9_D
M.<9(!VU%<O8^+I)M:L=+O=+>VFO[%KVV"S!R57&4<$+M?YAZCKS60WQ-9=#G
MUH^'KQ=.M+QK6\E::,&';)Y98+GYL$\@<>YYP =_4)N[81&4W$0C#;"^\8#9
MQC/KGCZUDWFMF;5KC1+"QCOKF&W66Z667RXXU?(52<-EFPV!C&!R1QGSOPWJ
M.GZ7\';:74=":\LFU21#;-L A8W;!-V3V8CH#^5 'L%9.O>'[3Q':PVU[).L
M4,R3J(7V_.IRI)QV(S6;?>+I[?Q7+X=M=$N;J\6R^V1MYJ(CKOV=2>!G/)Y]
MC45MX^LY_"MGK+6DT<UW>#3X[-F&X7)D,>PMTQD$Y]!T[4 =8H*HJEBQ QN/
M4^]+7.:?XIDNO%=UX=GTN6*[MHEGDF25'A\ML[2"=K'D$?=X/MS5W5=8FLM1
ML-.M;%[FZO1(RLS%(HU0 DNX5L9R !@YH UJ*XF3XC6\?A.#7AI5TZO>_898
MD=28I/,\LY.?F&>F <\=*OV?BRZN-?O=$GT2:UOXK,7MM').C">+<5ZKD*V[
MC'/7K0!T]%<KI_C1=2\'KKT.GL)'N/LPLFE D$GF^5L/& V[MZ=ZKZ=K>J:I
MX]UW0[S3[<Z=:6UN"OF[AB02$L05YS@#'8#WH Z^*6.9-\4BR(21N4Y&0<']
M11YT1F,(D3S0NXIN&X#IG'I7E'@'Q0_ASX=^'5ETB=M-DNWM'O%D4")GN'52
M$ZLN2 3QCWKL8]4LC\0;^R31'&J0Z8DIN\INGB+D*B\]-P/WB* .IHK@K7XE
MFYT;2]:;0+N+2[VZ%K)</,F86,IC4[>K#(&2.F>,XK;O?%)34]5L-/L3>3Z5
M;I<78,OEXWAF5$X.YB%)YP.1SSP =%163X;UV/Q+H5MJ\%K/;P7*AXEF*%F4
MC@_*Q ^AYXKG-#\8WC/XKO=<AAM=.TF\DC+K+N\M$C0XQCYB<D_4XH [FBN8
M?Q<]E>:3'JVF/96VK.(;6?S0^V5AE8Y1@;6(SC!89&,TWXB:YJ'ASP/J.IZ;
M$CW$:A0[OCR]Q"[@,<D$C H Z9I8TD2-I%5WSL4G!;')P.]/KSGQ')-!\2O!
ME\=+!U"2WU!&BA=2SX1-H+G P,D\],G\=FR\>6LFAZA?ZA:26,^GWOV">V:1
M6/G$J%"MP"#O7DX YSP,T =;17+:-XUMM3\3S>'Y8X$O4MA=1/;7(GBECW;3
M\P PP/52/<9K3U'6OLNJ6VDVD N=1N(GF6)I-B)&I +NV"0,LH& 22?0$@ U
MJ*Y>+QI&VEP37&F7=M?SWQT^*RE&UGF!.2K'@QX!;?Z#IGBGQ^+3'JU_H][I
MTD6J6MK]LC@AE5UN8<XW1NVWD'@A@,>] '2T5PUE\1C=VN@7\FA74&F:S,EO
M'<M,AV2OG8-G4J2,;N/Q&"7Z=XIUB7Q5XJMI]-$EKI(A5(X9U+8,9DS\V 2V
MX9Y &._< [:BN(L?B#<7F@C7/^$9U$::]HL\,J.CM)(SA!&$!W=6SN(Q@$],
M$Z=OXJD;5]4TBYTUEU"PM4N_+MYUD66-L@;68+@@J000/J: .DHK@[;XB7][
MX<_M^V\)WKZ:+(W?F_:(P6VG#*%ZD@9/09P<=L] GB+SK;0YK:W2?^UL% DW
M$:%"Y?..0 ,?4@=Z -F6:*")I9I$CC7JSL !^)I]<SX^U*PTKP=>W6J:0=4L
M5V":V^7:<N "=QZ!L= 3[4:EXLELO%4?AZWT:YNKF6S:ZB=9$5&"LJXR3P.>
M2<=. <B@#IJ*Q?"_B)/$NE27?V62TG@N);6XMY&#&*6-MK#(X/UK(LM;U/4O
MB#KFA7-A VFVMM!P90V1)YA+$$<YP!M[8]Z .NCECF3?%(LB9(W*<C(.#^H(
MI]>2> _%#^&_AWH(DTB=],>]EM9+M9%41,]S(JD)U902 3QCMFNPUSQO;:5-
MJ,-O';W$NG('N8Y+M86.5W;(P0=S;<'!P.1SG@ '5T50TC5+/Q#H=KJ5IE[2
M\A$B!UYVD="/7L:\7LK3PZF@?$%9[:$:I'K=ZFG_ &>/_2E8!?*6+;\P ;L.
M.N>,T >Z-+&CHCR*K2'"*3@L<9X]>!3Z\KAM]077OA=/KD8_MDQ727,C >83
M]G)PQ]?7WS73:AXY_L])[N72IAIMOJ*Z=),[[)"Y8+O6,CYDW,!G=DX) H Z
MZL;0/"^F>&TF&GI,7F.7DGG>5R,DA=S$D*,GCW/<UG7?B^Y3Q/>>'[+0;FZO
M+>U2Y4F:.-)%9BH.2>!D'KS[8YK4\,Z_!XG\.VFL6\4D*7 ;,4GWD96*LI^C
M*10!K45S%UXN?R=5NM-TQ[^TTF1HKIUF".SH 7$2D?.5!YR5Y! S5:[\?PBY
MT.'2]+N=276K>2>SDC=$5]B!MIR<@\C.< <]2,4 =A3))8X5#22*@+!06.,D
MG 'U)K-?4KY?##:F=-,-Z+8S&RFE V-C.TN,C\17FNKZE=:W\/\ P7K>J6:-
M=MJ^GS))'AV;<X)VC'RYZ8^E 'K],BFBGC$D,B21GHR,"#VZBN>TOQ5->ZWJ
M6CW>CSVE]:0)<QQ><C^?$Q(!!!P#E2""?QK*T#Q9I%OX,T.YTW2XM.@U*[DM
M;2T>01HC[Y"=S $#.QCP#R0.<T =S5#6=)M=<TF?3KQIEMY@-QAE:-A@@C#
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MQ G*85<$':#R<DUZS10!QUI8:LGQ(O=;GTN1;272HK8,DT;?O%=G(&6!Q\V
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M[B,BNVN6=+:1HXFE<*<1H0"Q]!D@?F:S/#_A?2/#%O)!I5L8EE;+L\K2,W7
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M&L;Z;S/*14VM$S G"MN? !. 1SDFNUT"[\0W^ZXUK3(=*55VK:I<B=G;NQ8
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M+0>='C$D0C&[YN,$9/7CUH U8O&LK:QHL$VCR0Z=K0(L[MIU+EMF\!XP/E!
M.#N)]0*L6'BN75+B7[!8Q3VL-^]C.5N?WT)5RA9H]O R./FS@@^N,>XT/69(
M_ H73FSHSJUX/.CXQ"8SM^;GDY^GOQ4%SX3O;[Q)9ZS!I1TK6(=0W3ZA;SH(
MKJT#GY74'+,R8'*\'OB@#J_%GB ^%O#-[K7V)[Q;5-[1(X3CUR?\#5"V\6W+
M>*+'1[[1WLX]1MY)K.<SJY?9M+*R@?*<,".3^%2^/M+O=;\#ZKI6G0B6ZNX?
M*C!<*!DCDD]JH7VE:I=^,?"FI+I[K:Z?;W$=R6E3*F5%48&[G!7GZ\9H @NO
MB996\5M?)%;SZ7/<BWWQ7@-PH+%1(8=OW,C/WLX(..U:5]XLN5BU6?2-(?4X
M=*D\FX"2E9))  76) IWE0PZE>>!6+X7T_QGX<M4\+BPLYM-MW9+76#<@%("
MQ(#18)9P#@=!TS[OL=.\6>%_$6LPZ7IMIJ6E:K>-?13RW7E&UD<#>'7!++D9
M&W^O !KZCXRAM[IK.TCM3>1VR7,D5_=BUVA\[4Y5CO.TY&,#C)Y%5=/^(-IJ
M]MH;6-NB7&KQ32117LWDA3$0KID*V6RW  Y )^M6^TWQ5H'BZ36]%M(-:M]0
MM88+ZWDG6W<2QY"RJ2",$,<BK.NZ+=:[9V=GX@T&#5;:2.1YQ;R*KVLI(*>6
MS%20%)!8$$X!QSB@"[+XKDAGTBQELHK;4]269DM[JY\M5,94%0X4[F.X$ #D
M9/;F1_$.H#^S(%T21;R]$QD664K#;B/KOD"GKD;>.>?2N=7PI>R^%])T/Q'I
M1U^VCBF\Z0SI]H@;>##M=BN2$)4L".@ZU#;>'/%=C;^&[>Z1=:L;5)UNK6XN
M@""S9A9R1B38ORG@\\@'B@#0?XD(OA*UUV/2)I1+?_8)88YE/EOYOEDAOXAG
MI@<^U69O&.KZ??:9!JWAL6,.H7QLDF:^5PIQE&.U3]_D >HP<<$\R/"7B:/P
M@^DG3(&F37OMZ&*Y7:T8G\T]<8XP .OKBNV\::=:ZQX*U*"]D-JHMS.LI^]
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M@D3RS;LV=S+G>'"DC:!@D#YN];!T"\@^(6G7L%FS:3:Z0^GF3S5R"74@XSG
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M,WW7A_FXA@N Z2+Y?F JY [9R,9!'>K?C:RUJ]TVR71XQ.([V.2\M?.\HW,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN0".3@9./4CEO%OBB3Q#X#T/5-&C0V6H:C:)(LTIC<'SU!C8!3QN4@G/;H:
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MI;$/Y@W;Q*TF=O\ =PV/7/:NADU&QAOX;&6\@2\G!,4#2 2. "20O4@ &K-
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MC(PJKD?WBQ[UT5G?V>H1&6RNX+F,':7AD#@'TR.]2O+'&4#NJEVVH&.-QQG
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M[\$:E8^!=$T'38XKJXM-0BOKB1I/+0E9?-<+GGDD@>W6O1Z;))'#$\LKJD:
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M90DB-M^92&! (4]?QN3>'=6M/%&E^)K&."2X33_[.O[-IL!XPVY6C?&-P;U
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M-%,S21ND8D^<$8P1GH3CU-4KOQ5JG]B>.IK.RLK*^T8OMD!,@DQ"'WG@9;&
M,]..N* /0:*X2+Q7/H^C>%[;4[JRMY=3@ 6]N"QB7;&A"L21\[9[D#@]>AZ_
M2I[RXT^.2_ACAN2SADB;<F Q ()Z@@ _C0!<H) !). .]%% &2WBGP\CLK:]
MI:LIPP-Y&"#[\UH6MW;7ULES:7$5Q ^=DL+AU;!P<$<'D&O,M!U:72/&/Q"E
MATB]ORMW')BV5#R(<X.Y@>?8&NFDU?\ L'5?#6E6=C;K9ZQ+,6"DJ87*M,Q
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MUMI]Q/;Q)++'&75)'**Q S@D X_(T /N;F"RM9KJYE2*"%#))(YPJ*!DDGT
MHMKF&\M8KFVE66"9!)'(AR'4C((/H17!V/C#Q%J/@R7Q)+H>FG36TI[M8FNF
MWLZY)4C81M*@X_#.,\::^*W^S>$K2"VACO->AWID'RH%6$2-P.3V &1]>* .
MEO\ 4;+2[-[S4+N&UMH_O2S.$4?B:FBE2>%)HF#QR*&5AT(/(->:Z]XBO];\
M%>/;&]L+:'^RK>>V:6*=F\UO+W!@A7Y05(/WB0?SK3TGQ'JMCJ7AG2;VPM4L
M]5LV%K)',S2(\<0?]X,8Y'H3@]S0!W5%<7X"U/6M3N/$3ZG+;R)!J\]LOE[A
MMV!% 4'^' ^N23WJU\2=2U'2/A]K%_I<D<5S% 3YC@DJ#P2N/XN>* .JHKF&
MUZ]BU'2]!5;5M6N[=[EW^8QPPI@;B."Q)8 #([G/',OASQ)+JFJ:OHU_;I;Z
MGI4B+,(V)CD1UW)(N>1D9R.Q'4T ;5]?6NF6,U[>SQV]M"N^260X51ZDU-'(
MDL:R1L&1P&5E.00>A%87C75I="\'ZGJ<=C!>_9H2[P3OM5E[YX.?IW]:H:AX
MHU.U\0:#I-IIMK(-5M994D><KL:-%)!&W@?,.1D^PH ZZBO/5\:>)9-'U^5-
M)TW[7H,TJW>ZY<1S*B!QY?RYR5/\6 #CKDXMW'C75)]5T.RTK2;:4:SIS7L$
MD]R5V85#AP%. -XZ9)]!UH [>BN L_B-/%IVJ0ZQIL<.N:=?16!M8928YY)B
M/**L1D*V<\C( )]JUSXDO=,\6:?H6L0VY&IQ2-9W-MN ,D8W/&RG/.TY#9Y]
M!0!U%%<AX9\7S>)8K6]MFL7LY-_VJ%&(GL2 2%D!/)R,$X&.V0<U1'CZ]F@T
MS4[/2WN]-OIT0Q0P3&>*)C\LQ.W:1T)7L#U- '>T45QDOC#4;G0]4U_2;*WN
M-.T^65/*=R)+E8B1(RL.%Y#;00<X[9H [.J=AJNGZJ)SI][!=""0Q2M#('".
M "5)'?!%<6_B74M5\<>&AI4UO_9%_IDM[&D@8,WW.6QW ;@?7/MCV&L:OH$/
MC_4],L;2>&RUB:YG^T3%"R+%&65 H/S8!.3@=.O. #UBBN5N_%PDN[:RT]46
MXFL4OF>:*2141SA!M09))#=QC'?I60WC_6!I&AW)\.^3<ZAJ7]G307$CQE'^
M8AER@RA"YW=L]#0!Z#15#1Y-4ETU&UFWMH+[<P=+60O'C<=I!(!Y&#7/:SXF
MUZW\8?\ ".Z3I=E/+)ISWD,L]RR@E75<, O Y[9SD=.: .PHKA[_ ,:ZBMOJ
M3Z=8PSW&EGRYK?9+(;B8(KO'&RK@8W;02#D]@.3HV_B>XUB^@T_2[4071L8[
MVY-ZC#[,),[(R@P2YPV1D8QWSB@#IZ*\]_X3_4E\-S:I+IUJLMMK7]E30K*Q
M!Q(L9=6QZDG!'2N@/B"[7QY)X=^SPM&=,-_%+O*G(D";&X/'?(_*@#8L-2LM
M4MVN+"ZBN85=HR\3;@&4X8?4$5:KSD>/+VT^'TOB&'1+-7CU%[62VCF( _?^
M5N!VC<23GG;ZUKS>)M7T^YAT_5+.R@O[R:4VOD/).BP(JDNX"ABV6"X& <YR
M* .OHKSR\^(&L6'A?5M1FT("XTV\CMV+^9%%<1NZJLD>Y<GEN5)&,=:T)?$W
MB&#Q<N@2:7IYDO+1[FSD6Y;:FQ@&$ORYZ,#\HZ\>X .SHKA['Q[*=!N9]0LX
MDU*WU9M(,4+LT<DP(PP.-VW:=W0G@\&@^,]7MY-;AETD3_8+$WUO=JDL$$P7
M[T9+*=KCTYR/2@#N**X2R\::PTWA6>^TRTBT_7T15,4[-+'(T7F D8QM.",9
M)'!]JJZ7XGUJUE\<:CJ"PW4&DW#A((=P;"0JP5>O'/)]23CM0!Z+16!X>UJ?
M62)X[C3[W3I(0\5W9,<;\\H02<$#'?//08JWXCUVV\->'[S6+M6:&V3=L7J[
M$@*H]R2!^- &I17*7?B74M#UC1[76;:U^S:M)]GCEMV;]Q.1E8VS]X'! 88Y
M'2L2?Q[XA&B>(M4BT;3Q%H5]-!.K73$R)&%)V';][!)R0!T&#S0!Z-145M.M
MU:PW"9V2HKKGK@C-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<YXZT6_\1^#M0T;3OLRS7D?E[[B1E5!D'/"D
MGI71U5O]3L-*M_M&HWMO9P X\RXE6-?S)Q0!RFK^$]3N[?1=5TZ2TL_$NE*L
M:N79H9XL /$YV@E3U'&0>GK3-5T+Q3%XE@\3:$VF+>36HM+^PN9G,+JK%D9)
M H.X;CU7I74:?KVCZM(T>G:M8WDBC<5M[A)"!ZX!/%:% '+7VDZQ?6=K;ZE;
MZ7JUO*LO]H6LQ*)N)79Y65;A<,.<$YSUK#7P'JMAX<T"TL+BU>XTG53?1P7$
MS^6L1\P"%7VEOE5P 2.<=!7HM-ED2&)Y9&"1HI9F/0 =30!R^F:'J]MX]U'6
M[G[$;6[LX;?]W*^\-'N.[:5Q@ECQNXQWK,N/ U[JMSXUBU%[:*S\0+$(6AD9
MWB,<80%@5 Z@-P?;WKM-/U"TU73X+^QG6>UG0/%*G1E/>C4-0M-*T^>_OIT@
MM8%+RROT4>M '/\ ANV\8H+>'Q%<:9Y5JNWS+)G9[HXVAGW !1W(&<G'0#!P
M(O .M_\ "'3Z$;ZSMYK34&O]+NXMS'S/.,JF12 !]XJ0-W7/;!]&CD2:))(V
M#(X#*PZ$'H:=0!QDF@^(_%'AW4=,\53:=:BYM6MU332[KN./WC%\="!A1ZG)
MZ8S9?#OC+4+3PU!?#1A)HM_%.\Z7$A^TJB,N=NP;201QD\GMCGT6B@ KEXH/
M$]M;7UI+::7J,,UQ.T#37+IMC=V*I(OEMD ''';C'<].2%!)( '))JKINJ6&
ML6:WFFWD%Y;,2HE@D#J2.",B@#AX_ %_I'AWPG9:3<6L]SH5X;AQ<LT:2AP^
M\ @,1@OQQT%:5GX?UG0?$^K:EIHL[NUU<1RSPS2M"8;A5VEEPK95AU!Y'O78
MT4 ><2_#W4]*L-!N] O;8ZWI4T\SFY#+#=>><RJ<9*C.-O7&!]:O^(_#WB;Q
M)X+O-.N9--74+N2)MBRN(($217P#M+,3M.3@=1Z<]Q10!Q^@>'=6\.>(KS["
M+)?#MZ1.;,S-NM9S]\Q?)C8>NW(YY&.E=A1574M2LM'TZ;4-0N$M[2$;I)7Z
M*,X_F10!RF@:'KWA!;[3].MK'4-,ENI+FU,MTT$D.\[BC (P(!S@CGVJQJ7A
MK4KSP;KVGB6U?5-960S.69(D9XQ& ."2%15'3G&>,X'6*P90RD$$9!'>JNH:
MI8Z4D#WUS' L\Z6\1<_?D8X51[F@#EIO#>M2ZGX-N@M@%T17%P/M#Y<M%Y?R
M?N^?7G'I[U%%X0U66#QO;W+V<:>( _D/'*SF/,/EC<"H],\&NYHH XQ-#UR7
M0=+TO5=/T6_M(K8V]Y:-(Q5L*@C=69.3\KGD+C<,$XR9?#^@ZWX8T'2M*L);
M.6&.[=KE;B21O)MF9F$<3=6*Y4 MC..@KKJJ7.J6-G?V=C<7,<=U>EUMHF/,
MI4;FQ]!S0!;H.<''6BB@#D?"WA_5](\3^(]1OELOL^K7"31B&=V:/:NW!!0
MYX/6IO%NAZGJ%]H6J:0+5[O2KII?(NI&C25'1D8;E5B#SD<&NHJIJ>J6.C6#
MWVHW,=M:H5#2R' !8A1^9(% '#3>#_$<Z^-_,DTPMXA@2*+$DBB(B#RSGY3P
M.?KCMG TM;\,:IJWPZMM$1[2+4K=;8J3(QA9H71L;MN<';Z<9KLJ* .1;1-<
MF\<Z9K\Z:>(K>PEMI42=]VYV5OERG(&T#)(SUP.E8C> M<ET34HA=V=IJ?\
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M!3TJ">VTFSM[D1B>*%8W$;%ER!C@D ]O2KE%% !1110 4444 %%%% !1110
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MCDW@ ;,@G./;WKIM/O=;?Q?J%I=?8)-*6%7@-ON\R%_ERLA/!)RQ&.@ SU%
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M[TIE52XTN^VY..?-M>]4KOP[J=CXTF\2Z*UI,UY;);WEI=2-&&V'Y'5U5L$
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MYX/3- 'HU%4='_M7^S(O[:-F;_+>8;(,(B-QVXW<_=QGWS5Z@ HHHH ****
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M/A?P_!8ZK;0:YH,LK6USL9H9DD)+HZ]0""!QGIGOQVFB6VL10/-KEW;37LN
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M=1NY9Q."^U \OF$;<<D=.O?/;D=M23XSYMXK1YQX;C$L4DK*I_TA^C!2>O\
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M/WR6##;N(8+P<<$YS@2WO@^\U>\TZ35)K.1M/U 7D%['&PN @<LL/TY"DYY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5A:ZGB2ZF6WT*YLK%%CWO=74)FW,2<(JAACIDD
M^HP.N-VN>\2^*].T$PV4VI6-I?W0/D_:YE1$7O(V2,@>G5CQZD &;H'C9V\&
M:EK'B2.*TFTBXFM;TPY,;O$<$IGGDD #UXK9T*?5M1MX]0U'99K*-\=@BY:-
M2.!(YZMC!(  '3GJ>"\70Z1>_#![70+Q-3L+"^@FU"6W?S/-7S \S,R\%N=[
M8Z>W%:T^DVMC\4/#=UX<BA@BNK2Y;4EM0%26 */*=@O!.\C#=3SZ4 >@T54T
M_4['5K8W&GW<-S"':,O$P8!E."/J#5N@ HHHH *Y-?$%]KWBG4-%T62*"VTO
M:M[>R1^83*PR(HUR!D#JQSCICO765YIX,/\ PBWQ \4Z)JA$+:M?-J6GS/PM
MPK_>13W9>!CKWZ4 =A;C7K77H8+B>"[TMX)"9A#LE24%=H;!VD$;^0!TJ])K
M&F17RV,FHVB7C$*MNTZB0DC( 7.<XKC+^6?_ (77IUE#?7?V=M*EN)+9;J3R
MO,#X4L@;'0^F*YRR>*_^ NKVNH_\AF!KE;E&_P!:+[S69/?<6*8^H H ]8&J
M:>VH&P6^M3>@9-N)E\P#&?NYSTI1J>GM'<2+?6QCMCMG82KB(^C'/R_C7 ^(
MA=^&9?#'C*ZC>2YMH4T[6!$NYGCE YXZ[9<'_@5)XM>;P]I'AN]U"62WM?[5
M%QJT\*J_E/(KX8Y!!19&4 D'&U>X% '=1:WI,]C+?0ZG926D1(DG2=3&A'4%
MLX%-&OZ,6D4:M8EHW2-Q]H3*L_W5//!/8=Z\W\2V?AV?PKXWU33-4.K3W6G!
MKJ8/$\(=5(CQL4*),>G.,9ZC,OC+1]&M_ 6B7$-A9QO/>Z:'F2-0T@WKU;J>
M">_<T >D6FK:=?R7$=GJ%K<O;-MG6&97,1]&P>#P>M4=*U".VT6.?4M?L;W=
M,Z"\39%&Q+D*@P2,C[O7)(]:YR"UM+?XTSVL$$,<4OAQ2\2( K8N"!D#@\<?
M2N)6&TD^".G[DB*IKVU#@?*#?'('IQ^E 'M%IJNG:A-/#97]K<RV[;9DAF5V
MB/HP!X/!ZU&=;TE;@V[:G9"=208S.NX$=>,YXKD([:VM/C0UO:I';+)X;RRP
MJ%Z7& <#T!KD]"33-=\+^%="?5M'?^S-3%RT[W<9:XC5WP!$3O#/N&0P&,GJ
M>* /5_$%U<V?AW4+VREC2>WMY)HRZ;U)520",CCCUJEX)U._UOPAIFK:C)"U
MQ>VZSE88]BIN&< $D_K5GQ04C\'ZSG"HMA/[ #RS7/\ @#6]*LOAAH,MUJ5I
M"D.GQ^87F4;<+SGF@#JK[5],TPJ-0U&TM"P)7SYECR!U(R?>G/JFGQ74-K)?
MVJ7$X#11-,H>0'H5&<G\*\[UO6M,O-;UU(VAT^Z?0X_/EO&R\\;ARD<49. 1
MN.3SR0,=ZI!U7X4>#O%-FZSW/AV*WFE,9W-Y/EA)T]CL.3_NT >G0ZUI5PL[
M0:G9RK;C,Q2=6$?^]@\?C3X]4T^::WABOK9Y;B,RP(LRDRH.K*,\@9'(KS*'
M^T+7Q9=V?DNEKXTA^T1!4V_9RI"R9]&,!5B3_&,5Z!++X>@\1V%I*;%-9%NW
MV-&"B81?Q!.X''0>A]#0!G^/]2U[1?"=YJV@?9GN+-/-DAGB+AXQ][&&&"!D
M_A5JYUO_ (H=M;M+I)"UF+B"7RLB0E<J-F>I) QGJ:W)(TEC:.10Z."K*PR"
M#U!KRSP;9WMIK5QX#N(I&T_0[TWT4S<J]NWSV\>>Y#DM_P!LL4 >A6UW)IFB
MP3>(;^SCN-H\^7B*(.1R!N)_GS4PU?3&M(+L:C:&VN&"0S"9=DC$X 4YP23Q
MQ7&>+=5CTCXAZ%+JFHR:=I<UE/##=@)L2X+(<,74JN4! /'<9P37/:_I7AZW
M\,VK:7<&^M+CQ3;2M/*R-&SO(OF"(J -O8[>,@CM0!ZE#KFDW$=S)!JEE*EJ
M=MPR7"$0GT<@_+^-/.K::%MF.H6FVZ(%N?.7$Q/0)S\WX5Q(MH+?XMZM:VD,
M<2R^&HRT42A0S"9U!P.^,"N2M]7TW_A6?PYA-];^;!J]B95\P9B"NP8M_=Q[
MT >Q7NL:7ITT<5]J-I:R28V)/.J%LG P">>:F>]M8[V.S>YA6ZE4O' 9 '=1
MU(7J0,CFO+1?:-=ZIXST'Q3KS:<US=,QBE:%%GM6C41E&="3@#HIX/(YKM=.
M?P[:WFB6+R1?VPE@!9B\V_:_)"C.3US\O/T/H: &^-O$K>&=,LI5>&$WM]%9
M_:;@$QVX?),C#(R %/<#)&3BI[0Z];Z[;0SW=M?:5-;R/YZP;)%D!3:"02I4
M@L1@#IWI?%=SHB6%M8>((H)-/U*X%HPN" @8HS+DGIRF >.2*XW1M(O/ OQ!
MTS0=%U2>\T'48)Y'T^X?S#8! "KJW4(6(49]>YY !Z&VL:6FHKI[:E:"];A;
M8SKYAXS]W.>G-+;ZKIUW--#;:A:S2P?ZU(YE9H_]X \?C7DOAZ?0M>\(6>EZ
M]KMU%K-E>[IM-5H4N/MBR$Y0;-Y)8YSGN<GK71:\UUX5^( O]/A+)XEM_L9P
MN52]C!\IV]BA8'V3- ';MK&EK8_;FU&T%IG;YYG7R\^F[.,T#6-,:SAO!J-H
M;6=@L4PG79(2< *V<$D\<5PGB"XMO"_C#PQ!>:A+IVC+836L%W\FU+C*??9U
M(!9%;YC@\GGDUB^(]*\/6_A(/IETU]:7'B6WF>XD=&C,CR+YGE%0 %]=O&01
MV- 'J/\ ;^C?9?M7]K6'V?S#%YOVE-F\=5SG&1Z=:P?&'B&[L=+T6_T6^MFM
M[O4[:WDD51*)(Y) IVMG [\X/X51UR31-$\9:)9VUM8:9>2175Q'>2_NX8P0
M@D^0%0\C8'4\ $\]#PT$]E-\,K2V>XAEAA\5J)@Q "QF[;EAT4$9/84 >TV6
MKZ9J1F%AJ-I=&!MLOD3*_EGT;!X/UKC_ !-K>L:+\,K[5['7;._O+>4XNX[=
M2A4S;=H 8@%0<9YY7D4QM&LXOBY92:1:P11#2I4U184 C969?)# <9.&QWPO
MI7(NT2?LWZH$*"-;J8#!X ^V\4 >M7DLJZ_IZ+J]M;Q;)3)8NBF2YX&&4DY
M7!)P#G-4--\=>'-4;4/*U>R5+*X,#.]PBA\!<L,G[NYMN>A(K(U]85^+G@R1
M5C$LEM?AF &6 2/&?7O^M5?!L.G:HOC?0[UHI#<ZW>"2V+#>8V5!NQUQSU]:
M .Y;5-.2W@G:_M5AG(6&0S*%D)Z!3G!_"K=><>"FO[VZM_#NJ1N7\*R-'+,R
MX%PVW;;,/7]TS,??::[RSU.QU&2ZCL[N&=[64P3K&P)CD'53Z'F@!FKC4FTY
METEX([QGC"O.A=$4N-Y*@C.%W8&1SBN/M]6\4W'CV_\ #7]J:<J6UC'="?\
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M6+#0-)N-3U*X2"U@0L[L>OL/4GH!WKQV[U72+GX%Z0#=6_VR"[M3<)*X$J7
MG7S2P/(;ER2>Q)KTOQXRS?#?Q$\3"17TNX*E3D,/+/(H R]1\7S37WA&XTN^
MM3IVIW)BND7;(1^Z9\%\X&,#(QGWKK[#4]/U2W:XT^^MKN%6*&2WE610PZC(
M)&:\WU6?3]4B^&R++;W4!NT1P&#J2+8\'UZCCWK/UL36L_Q3BTN(@HEA*T,
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M,GE"$S+N+XSMQG[V.<=:CN?$NA64TL-UK-A#)$Z)(DEP@*,^=H(SP3@X'L:
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MCU*T:\.[$ F4N=OWL#/.._I4)\4: )EB.MZ=YC2M"J_:4R9% )7KU ()'N*
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M7X=S(/[<T[,80N/M*97>,IGGOV]:LV6MZ5J5W<VECJ5I<W%L<3Q0S*[1G_:
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MX@$$T(UC1O*F8M*G]B_+(3U+#SN2?>MO^VM*^P17W]I6?V.5@L=QYZ^6Y)P
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MS(9(H?,&]T'5E'4CW% $1T72FGEG;3+,S3$&20P+N<@Y!)QS@@'\*NLH92K
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M;]TL1%R=\LS,25R<M@8 # 9-=;HUOI6H_%KQ6)8;2XW65BRJZ*V>').#_P
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M[);>2L/V>+RE(*IL&T$<\"@#RUM6TA?$OBW2/%&MR:;'?NLL(E,:1W5JT*H
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MACM_!'CRY\R-=(O=:@DL@2-LA$D7FNGJ"P;D?W2:]IM8K5(M]I'"L<F&W1
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MY"QN)-S(S-]UR@3@\\ =: .B^'NMW6N6VORW.HB_CM]9FM[:8*H'DJL94#:
M#U//O4=YXBEN_B%/X8?5VT?RK2.:VV)&9+QF+;MID5AA< 8 R23SQ5;X8W=G
M<2^+UM9HG!\07$H"$<HRQX;Z$@\]ZE\36WA'Q;J-WX?\1+!%=V81[>9I!%*
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MH[>!3B6WGB91)E>J[5#DD]OK6YX<&G7?Q7\;HXM9I<6&U6VL?EC.<?0A<^A
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M58^C?9RW_ UK6US5+&T\?KI;!--E;20(KM(MTURN\X@B&".",D $G(QC&:]
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MO,;2\A_X5;\/49F1[?6+/S1(I7:$9MYY'W1D9/0>M=C'=6__  NVX831[?\
MA'TCW;N-PG9BN?7:0<>G- %72M7G\7WNL2Q:S?:9)IVJ-' 4A81>1$$W"0,
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MV!3D$L< 8)-7I;_1])\4>)M&\7KJ,::G<^?:/&]P8KR%XD0Q@1'EAMVX(R:
M/5HY$EC22-U>-P&5E.0P/0@U@>(/%UIH&L:1ILT4[RZC*R@QP.X151F)^4')
MR ,#GG/05IZ-;0V6B6-M;VK6D,4")';NY8Q*!PI))R0..IKE/'4R67BCP9J$
MX=;2"_F6654+!"\#JN< ]3Q0!7M/%D6C^-O%R:WJ\QT^V2S>V21-QB#H[/M5
M%SCIDXXXR:ZZ;Q!I<-M93F[$B7PW6HA1I6G&W=E%4$L,<Y XKB]-O+/_ (3S
MQ]-)+&J/:6@5G(&<1.&'/H2 1V/!K#\/ZS!8^'OA_;W""VS9S1G4O(\R2W<
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MI+SS[>2-XPY2,;<H5#$Y/ YR<8% '?56U&S_ +0TRZLO/EM_M$+Q>="V'CW
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M1M%F,W0C W$8/R]=IX)YH ]1HK'TWQ1H^K:I<:;979>[@C$K1M$Z;D)P'4L
M'7/&Y<BFCQ9HIO[:S-VRO=N8[>1H76*9Q_"DA78QX. #SVH VJ*;(GF1LFYE
MW#&Y3@CZ5YKX>\7:IHWBNXT7Q)<//IM[>S0Z3J,H4'>CE3!(5 &3C*G'.>_8
M ],HKG[!IE\6ZPDU].]M##!)'%(PV1EO,W'IG^$=3Q4UOXLT6YN[6W2[8->9
M^RO)#(D=Q@9_=NRA7XY&"<CD<4 ;5%<W-X^\-07TED^I9N8[A+9HT@D<B1_N
MCA3UXYZ<CGFN7UWQK)KOPX\3ZAI<FH:=/8F98I!"\38C(7EF7 ).> 0P[XYH
M ],HK TCQ7I%_>0:3'>E]0-N)0K1.!(  &*.1M?!/.TFI9O%FBV]W#;S7;(9
MI_LT<QA?R6ESC8)=NS=D$8SU!'6@#:HKF[CQ[X9M;Z6REU,"XBG2WD00R-M=
M_N@D+C'3GH,CGFHV^(GA58O..J9B$YMWD$$A6-\[?G.W"#)QEL ^O% '4445
MP%U-J5Q\8#H2:S?0:<VB_;O*B*<2^<4ZE2<8[4 =_17!W.MZOX2\;:1I>I7S
M:EHVM,T-O/-&BS6TXY"L4 #*V<#C/Y<[&F:OHZ7?B&[CUNXN$MY5-VD[$QVA
M"#Y8_E'! S@9R30!TE%8-YXOTRSL-3NF2]9M.MQ<3P_8Y5DV'=M(#*,@[&YZ
M#!SBJEGX[T?^P](OM3G:REU%(]D<D$B@R,@8A<KRO)PW0XZT =317)Q^)- U
MS5_#\MIKEVDD[W'V:UC5XTNBJL'$BLN?EVDC..?6M+4/%NB:4\HO+PQI#(L4
MTPA=HH7;&%>0 JA^9>I'4>HH VJ*YN#Q?;W'C6Z\.+;70:V@21I3;2;69R0,
M'& N%^\>"3P>*Z-F"J68@*!DD]!0 M%8L'BS1;BZM+=+M@UYG[*\D,B1W&!G
M]V[*%;CD8)R.1FN;U+6?[:\>W/AEKC5;2VCTX.LEI%/$XG>1EW[E7[JA>"?D
M.3G.. #OJ*H1M_8VA!]0O'N/L=ONGNG4!GV+EG('&3@FN8\(RZCXRT2/Q#J-
M[=6L-XS/:65K)Y:PQ!B%+,.78XR<G'/ H [:BN>M;F?PY;W\GB#5&N('O52R
ME>,>8R,B*L85!\S;]PX&3UQ1=ZY::MH.MC3+V:&ZLHG67]V8I8'";AE77(R,
M$''(Z4 =#17 Z5JUM+X%\%RZQKM[:W=V;1DDB=B]W,0/W;G!RK$\YQ]:EUW7
MQ<^/+3PT[ZE#9M8S3S-:0SH[2;D5,.@SM 9B2#MSC)XQ0!W-%<Q;:]IGAS3!
M9ZGK-Q>M8D0W-_) S*C'D>:Z+L4X*YR1V)ZU:U7QCH&BW2VU_J"QSM UPJ+&
M[ED'4C:#GJ..M &[17,CX@^&&#^7J32LD"7!CBMY7?RW&5(4+D\<D <=\4W5
M]=T.]T;2+W^WI[6UO;J!K2>S)!G8L-L9^4G:QX(('OB@#J**QM2\5Z-I,MS%
M=W3AK2-9;GRH))1 C9PSE5(4'!//89Z5KQR)-$DL;J\;@,K*<@@]"* '44A(
M ))P!U)K%L_%VB7]W:6UO>,SW@=K5FAD5+@)][8Y4*V!SP>G/2@#;HKF)_B'
MX6MXKJ5]3)2UF,%PR6\K^4PQG=A3A>1\QX]ZV+W6;"Q^SK+,S27()@C@C:5Y
M !DE54$D $9.,#(]: +]%<3\-]4GU6#Q))+?7-Y'%K<\,#W&0RQA(\+M(&W&
M3Q@<YKH]8\0Z5H M3JEXEL+J98(2X)#.QP!D#CZGB@#3HK(TGQ/I&MW%Y!8W
M3--9[?/CEA>)D!R0V' RIP<$<4R#Q9HMQ=6ENEVP-X2+61X72.<CG$;E0K<<
MC!.1R,T ;5%%8MYXMT2P>47-XR1PRB&:<0NT,3G VO(%V*<D Y(QGF@#:HKF
M[OQ=;VWC2U\.?9[HO-:/<-,EM(RCYD50" 01\QRW08&3S7-^&_&=GHR>(U\0
MZQ<2"#79X(Y)4>7RH@$"[BBD(N2>3@9S[T =3K&A:CJ^J1;M:,6BF,+<Z<ML
MI,Y#9YD/(4C (QR,^M;-U;_:K9X#+)$KC#-&<-CN >WU'/IBJM_K5CII59WE
M>1D,BQV\#S.4'5MJ G'(YQWK/D\<>&X[33[HZK$8-1R+5U5F$A&<C@<$8/!Q
MR,=: -V&&.W@C@A14BC4(B*,!0!@ 4^J.D:O8Z[I<.I:=,9;6;=L<QLA.&*G
MY6 (Y!'(J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^(+74-5L]*U2],6F3Q7<MS]H#I&5):!3(?F8\\+D#KGD9](HH \[\'?;]/\
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M0X/!QTKN:* "O$/,(^ O]C/;W*W]M=QQRP-;N"&%[O(&1\V%&XXS@=:]OHH
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M:KW#7EA$)KB(6LI(0]"OR_-GG&W/0TOAWQ%9^)]-:]LH[F)4E,3Q74)BD1@
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MR0V,*H"C#'&3G%<[X \;65OX.T6'6=0NYKRZN9H#=2QR2+YAGD"*\N"JL1C
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M%N[#.]%4 @?=Y;+=!QSUJQ>>,-%L?.>>XD%M!-Y$UT(7:&*3.-K.!@8) )Z
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MIYM)0/=VHMV$R97<ORD<@@<'IUYX-3^%M<_X2+PW8:F89(9+BWCD=&B9 &9
MQV[@-R\\$9!K@M.AFF\1>.XK>UU21=2TJ#[+-=02#SB(I03E@-OS, %XZ\#
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M82&*\3R&,MNPZ[TQD#ISTP<]*TGUJV3^SLI.?[0.(=L9/\);YL=!@$Y/\\4
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MS?7%@\-[%?PVQNEM9("))HLXW(.AYXQG([XI/!GB0^*_#=MJK6TMN9P7"NA
MP6. #_%@ 9([T =!17#^+M=>'Q?X=T,PWIL[LW#W(@C<&4)%E5!7DC+9./09
MXJY9ZIIOA73[JP%UJNHQ:>3)<RNK7#6J-\X5FQD[5/3YF"X)[4 =917/7WC;
M0M/DTU)+B67^TT:2S:W@>19@%+?*5!!)'0#DDCCFLVS\>P:IXJL](MM/U 6]
MSIS79EDMG1@3(J+P>0!ELD\=,4 =G17F'A?QC9^'[#7O[8NM0GB@UZZA-PR2
M3BWC#A4\Q^=J]!R:]/SQF@ HKCK'Q-X>TS3/$.L)>:E):VU^XO3/%*YAE"KE
M40C*H,CL ,FM*Q\9:1?ZS!I<1N4GN86FMGEMW2.X5<%O+8C#8R#Q0!OT53U7
M5;+1-,GU'4)A#:P@%WP3U(   Y))( 'J:H0>*M.EGO[>1;J"YL(EFG@D@8N(
MVSA@%SN'!Z9QCF@#;HKE;/XA:!?/I?DR77DZFPCMKEK5UA:0@D)O(QN.#Q^'
M6NEN;F&SM9KFXD6*"%#)([' 50,DGZ"@"6BL&P\7:9?WMM:H+F*6[MC=VOFP
ME?M$0QED_,?*<'GI7.CXEY\)Z_KATF]']G3S11Q&$\[#M^=N@YR3Z#U/4 ]
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M-C]XDX "]1R?2N9EM;UO@=JFG#3-1^W27\C);?8I?,8&[\P$+MSC;SFO9J*
M.$UA9;SXG:#/!;WHMQIUU$UR+639&TFS9EMN >#U]*Y_PE';II=AX7UCP;=O
MK5@RP^9+;%K5MAPLXE/RXQSZYX%>MT4 >9PK.)?B438WX%YS;9LY?W_^CA/D
M^7YOFXXJO:1W=D_PRO9-,U%H[+3I;6Y5+1R\,K01J RXRN64C)X]3CFO5**
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M6=4^RWHBT:>2"\CV)O0HH9B/FP0 PZ&@#I**QY/$=J&M(K:"XO+J[M_M4=M
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MH!@D Z6WMXK6WC@@C6.*-=JJO0"I*RKW7[73]?TS1YXIQ/J7F"WD504)12[
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M4UGXCM-6U1M$FM+VSNI;,7:),54R0D[2RM&YP02!C(/- &_17DW@7QU8Z!X
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M>>">*OGQ]8(\7FZ9J\,$UU!:Q7$ML$CE:;[A4ELE?4@<?B* .LHK'7Q)9?\
M"07FC2K+!<6EJ+QWE"B,Q$D;@P/J#UQTJJGC*P_M+3;2XM;VU34\_8;B=%$<
MY W8&&+*2.0&"Y^O% '145YM\2_$,-[\//$'V&#4)(;<-";ZV8+&LJM@CA@S
M 'Y20I7/T..WNKYM,\.27RVTETUO;>9Y,;*&?"YP"Q _6@"W=6D-[#Y-PA>+
M()3) ;V('4>QX-3UR>A>,?M7A#2-6U.TFAN=06)885"$W$CKN C ;IU^]MP
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MW& 4Y !))XQ71QVEQ;_%J.Z%I=&QCT'[']I\EBGF"8/MSCKM&<].W7BNVHH
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MX$;2*@0-D<<J?IWK(\/Z/>6'B#2KS0+?5--M;IW;5](NHW%M!E"2\988#;\
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M]ASP0P7KTY^M;&@WD%^6O(O!$^C200,)I;BR1)"Q&-D6WYF&>^ , >O'<44
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MJEFL>H2%VE\N="=C[G8LWRG:<9Q0!LGQY9KI6N7[:7J8&B3&*\AV1>8,*&+
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MDUK3XM!.MO<*-.%O]J,W4>7MW9_*N=T;P[!JVE7-[K-MJ,-[J$DDEW;F[FB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !6/XB\.V_B6RAM+JYN88HIDG'V<J"70AESN4]",UL4
M4 (BE452Q8@8+'&3[\<4M%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5#6='L]>TF?3;]&>VFQN".48$$,I!'(
M((!_"K]% &#I_A:*SEC>XU75=1$3!HTO;G>JL.0< #<1U!;.#SUK>HHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX7^(L#'^BG^8KL*RO$>@P>)M$N-)N[BXAMKA=LOV<J&9<YQEE..G:@"K* ?
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MF*%-P7:"-J@CY0!UH X=-:U*VN_"US%JEU??;M6:UN[P'%I<HPD(6.,G@+M
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M'^GOX>U;1'U'46M-4N'N;DEH]Q9SN;!V< G_ .MBND%FC:=]BF=YXVB,3LY
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M7)+%E(;"@  9QECG/&.(CFOM)^#7B&XL=2NX+JUUJ=1.C .^;H*<G'<$],4
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MVEQ>1;WMO*JR^5C&QOEVLOU']:8OP_TI-*UC3A=:B8=8E:6[+7&YF+ !L9!
MR .<9XZUT3WL?GW%M"1+=PQ+*T ;!PQ8+DGIDHWY5F^$?$/_  E7A>RUH6IM
M1<[SY)?>5VNR]<#^[F@"GJW@73=7BTUI+O4+>]TU=EM?VLXBG5<8*E@,$$>W
M\S3]2\#:-JOA^+2+D7)2&43QW0G;[0DW_/02'G=R>3_A7244 <Y!X-M(-*:S
M_M'5)9FECF:^FNB]P60Y3YB,8']W&.3QR<Z.FZ);Z;>7EZ)9;B]O-@GN)MNY
M@@(5<*  !D]!W-:5% &=KVAV7B/1+G2=05VM;A0'V-M8$$,"#V((!_"LJW\$
M6-OK$6KC4-4?4([4VAN)+HL73.X;@1@D'G&,=\9JQJWB-]+\3:%I'V$R)JLD
ML8N/- $92-G^[C)SCVZUM7#RQVTKP1>=*J$I'NV[VQP,]LGC- '+K\/],C\-
MV&@I>7ZV-C.MQ !(FY65MRY.WD!LFK$_@JPEUZ;68+S4+.ZN8UCO!:S!%N@H
MP"XQU XRN#[UMZ?-=7&G6TU[:?9+J2-6EM_,$GE,1RNX<'![U9H RO#GA^S\
M+Z';Z18/.UM "$,\A=O7KV^@P*9XD\,:;XJTU;+4EE CD6:&:%RDD,@Z.C#H
M:UV944LQ"J!DDG  J.UN8;RTANK=Q)!,BR1N.C*1D'\C0!@P^#;2+1IM.;4=
M4G-PRFXNKBX\V:95Z(S,"-G^R !R?4YGF\+VDGBA/$,=S=07RV_V8^4RA'CS
MG# J<\GOT[5N44 <FWP_TQ_#E_H3WE^UC?SM<3@R)N9V;<V#MX!;!K1?PS;R
M>(++6Y+R\>\LX&@CRR;2C8W9 7G.!^7&*VZAGNX+9X$FE5&GD\J('J[8+8'X
M*3^% '/IX'TV-+RV6YO?[-O9VN+C3S(IAD=CN;DKOP3R5#8/3&"15ZY\-VMU
MXCL=;:>Y2YLHWBA1"HC"MC<"-O.<#OVXQ6DEW ]Y+9K*IN(D222,=55BP4GZ
ME&_*IJ .:'@C38SJGDW.H0KJ-Q]JD6.X($<NY7+H.Q+(I[^V,UHV&AP66I3Z
MD\\]U?S1) UQ/MW>6I)"@*J@#+,>F3GV%:E8OBS7G\,>&+[65LS=_9(S(T0D
M"9'U(/\ (T :.HV2:EIUQ92221QW$9C=HR VTC!QD'M63_PA^E2>#QX6NEEN
M],6%8569AN5%QM 8 <C P>O%;=O+Y]M%-C;YB!L9Z9&:DH Y_0O"5MH,<GE:
MEJEW.T?E)<7USYSQ)_=3(P!P.W.!G.!4-KX$T>W\+7/AN4W%WI=P6+0W#@D%
MFWDA@ 0=QS['I7344 <QIG@>STNQN+8:GJ]TTT)MUFO+KSGAB/5$R,*#@=L\
M#G@58C\'Z4/!_P#PBUPLMWI8B$(2=@6"#[H! '3 (/7BM^LS7=:@T+3TN9E+
MM+/%;0Q@XWRR,$49[#)Y/8 T 9FD^";/2;.>!=3U:Z>6$VZ37EUYSPQGJL>1
MA1P.V>!Z"F_\()IXT?2-+%Y?BVTB=+BT =,JZ9V9.WD#)X/KSFM32+_4[N>]
M@U/2?L+6\@6.1)Q+'.I&=RG"D8Z$$#\:U* .5O/A_I-UKT^KQW6I6<MT%%Y#
M9W31176!@&11U..."/UI^N>!=+UK4K74EGO]-O[>+R%N=-N/(=HO[AP""M=/
M10!S>H^"-)U"WTU%>[M+C3&+VEY;3$3QEOOY9L[MW\6[.>]6-%\*V6AZKJ.I
M07%[-=:@4-PUQ.7#%%"@XX'0?T&!Q3;;Q&\_C:\\./8F/[/9I=K<&4'S SE<
M;0..5/>MZ@"IJ=A'JNF7-A+))'%<QM%(T1 ;:PP0"0<9&:Q3X*L3:Z';_;;[
MR]%96L_G3*E5VKN^7YL*<<_SKI:* .2N/AWH\VNW.JQ7.I6GVQM]Y:VMVT<%
MTW<R(.N>^",\YZFM2'PW:P^*)/$"7-S]JDMQ;-'N7R_*!)"XV]B2<YS6S10!
MR=U\/-(N->N-6BN=2LVNR#>6UI=M%#=$=Y%'7(ZX(SSZFM*3PU:R>)(==6YN
M8[J&V-I&B%!&L9()&W;Z@'\/2MJB@#DV^'^F/X:O= >\OVL+V=KB8>8FXLS;
MVPVW(!;!J?5=&DUS5]'@G\QK'2K@7DDLH ,\ZJ1&!@#(&XL2!C(4#/..EHH
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MEKZ5D"ACOA:' 0* -N.V,YSDGMW\+6$FI:7J$DMTUSI:,EJQE/RJP 8$?Q9
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M\=[C3W"G<\JJ06SN#%O3@\<5V\OA/2Y-0TJ]59HI-*1DLUBE*K&K !ACOD
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M<\&-(9@3K"QYCG=,*8I"<;2,'@<]?>NITCP]9:)<W\]HTY>_F-Q<>9(6#2$
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M@2(.[A %#.<D_4U)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?#%_':-F\ELY%B9.,R%#@CTYQ7-?"":"7X7:*D. 84>*5.A20.VX$=CGG\:
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M ! )."0 .*C\-6D?B#PIX;\3-K=S#?L\=S=7"2DB=F)#P,I.-FX[0 .,#'-
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MDCFM[F2%BC8W(Q0C*G X-;-8^NZX-(;3K=(Q)=ZC="UMU8X4-M9BS>P"GZG
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M.:B7P7HJVFJVHBN?)U9F>]4W<O[TL,,?O<9''&.*Z"B@#S;Q+X=BCUC389M
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M?W0Z+@MC@DG/7/-:Z%S&ID 5R!N .0#]:@U"_MM+L9;V\E6*"(99C^0'U)P
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M[?56F5IS*=T9CC+XVXP<X'.?7B@"_HFA6'A[3DL-.25+=.%$DSRE0.  6)(
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MZM>X-W''/(D=QCC]X@8*W'!R.1P<U/J/AS2]6NK*YO()&EL6WVQ2>2,1-TR
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MR2("2KX1.2.['/)ZGC.<53TX-IFH>(/ LKR-/>72S6$KN6<VLP)8AB<YB"2
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MX^[>1"6,G]\@+NW')')K%.B65[HGQ*:Z$\QLKRXDMB\[DQ.MNC*PR>H/?\*
M/8:*\I^RI:7/PYUN-YCJ6HO''>7#2LS3J]LS,&R>1D @=NU06/A;3M>M?':W
M\]V3::K/]ED:ZD_T=A"A#CGJ#ZYX&/6@#UVBO*]"N#XBA\,Q:HC:CJSZ#Y\M
MI>$"W6-F"BX?(),AQ@8'=ON]:Q[0S:A\-_AU+<7=TTSZW#;M(L[@E-\HQU]%
M7!ZC'% 'ME%><Z3H=@OCKQ;X=2-DTJYL;69H [$+(WF!G7)X8X!R.X!JIX88
MZA;67@>_B5KS1+QC?$K_ *R&+#12?]M-\><]0)* /4:*Y[QQ<6EKX+U.2]O+
MJSMS&(VFM,"4%F"@)GC))"_CU'6N9T>U:W^*-[IIM(=/M;G04F>SM)2%#><5
M#$J%^?'!(_,]: /1ZBN7FCM97MT2295)19'*J3[D X_(UXCIEE%!\,/!NOH\
MYU5=4MT%RTS%MC7#*R=<;2"<COWKL]*%MXI\5>,;?6(UF?3YDM;:"3_EA$8]
MP=/[K,Q)W#G@<\"@#H_!NNR^)_"&FZU/"D,EW&9#&A)"_,1CGZ5EOXLUJ3QE
MJ'AVRT6QEDL[5+KS9=0:,2*QP!@1'!R/7%-^$W_)+/#_ /U[G_T)JRHX+R?X
MUZ\EG>+:R?V/;Y<Q"3^(] 2.: .I\(>*K;Q=H\E[!!+;2P3O:W-O+@M#*F-R
MY'!ZCGWK?KSN\\-Z/X5T?2-$CFO+F:]U;SS$SKG4)RI9O..,"/@$X'\(&">O
M.W*2Q^"_B99LWD)9W#O!#;2L$A)A1BJ8Q\N3TP!GM0!ZWJ.I6NE6OVF\E$<9
M=(P3W9F"J![DD4V=]2&KVJ016S:<4<W$CN1*K<; HQ@CKG)KS+Q=X5T:R\*:
M7?):F2ZN]1TTSRSR-(7.]5)PQ(7()!P!D5O:C;0V7Q7\*QVH,4+6-XOE(Q\L
M;0F,+T'4]!0!WE4D?4CK,J/%;#3! ICD#GS3+D[@1C&W&.<UY[X<MM.\7>##
MK6JWDMMJ]O?RRW-Y"P6>V>.4XB!(.U=@5=O<'U-:4-NK_%S7;<R3^5+HD+LO
MG.,$R.#M.<KP!TQ0!WM%>#)HZQ_!/2?%MI<7?_"16?ER6]S]H<EB9]GE[<X*
MG.,8Y/7.3G:\;F"ZTGQMJ%CON+FR*![R>3:;*5$4B.WP-PZY)R!EOXN: /7Z
MJ:EJ5KI-A+>WLHB@C RQ[DG  ]R2 /K7!ZA80:I\4]'BNVFDAN=#F>:+SG".
M0\8P0#C'/('7OFN5U"T@;X5Z[9R1B6#3/$QM[,2_/Y,8NHP%4GG&&(^AH ]Q
MHJ"WAMK.*.UMDBAC4'9$@  &><#ZFIZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *I:EI-EJ\4,=[$SB&431%)&1D< @,&4@@
MX)[]ZNT4 8UQX5T6[TNXTVXL_-M;F3S;A7E<F9N.7;.YN@ZD]!Z"N5\5>&VO
MO$,$E[X4DUS2X;18;9K:\$=Q"^XE]Y=T+ C;CYN,'UKT.B@#B]'\#Z<VEW5G
M>Z=/!IL[QR1Z9-?23>4RY.XG<<$G'R@D#:#G)-=#_P (_IO]L1:L89#?Q1>2
MD[3R$A/[O+8(SR?4\UIT4 <]8^!?#&FZV^LV>CV\-^[%S(N<!CU8+G:IY/(
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M3\C"?W" <,OL<BJL?@;PW#:6UK#IBQ06UQ]JA2.5U"2Y)WC#=1DX],\5T-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***0$'."#@X.* %HI,C=MR,XSBEH **** "BD!!S@@X.#[4M !1110
M4444 %%%% !12 A@"""#R".]+0 4444 %%%% !1110 44A8+]X@9..3WI: "
MBBB@ HHI 0PR"",XXH 6BBB@ HHHH ***0$-G!!P<<4 +1110 4444 %%)N&
M[;D;L9QGG%+0 4444 %%%% !1110 444A(526( '4F@!:*** "BDR"Q&1D=1
M0"&&001ZB@!:*3(! R,GH*6@ HHHH **** "BD!##(((]J-R[MN1NQG&><4
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MECS/']H63 (;@X4]<9X]:WK5=9N?B7'X@DT"\@L&T4VO[R2+S%?SMX#*'ZD
M]">HSC/  Z+XG6DFAZ?KIT74TTF[G\A[DJG[EC(8URH;<W(&=H(&<<GBMG3?
M%0O?$LVA76EWEA=BV^UP^>4(FBW;2PV,<$$C@\\UPT?AW7U^#FGZ"=%N/[3A
MO4D>'S(N%%UYI.[?C[OOUKJI++49/BK9ZN-.G&GKI#VK3EDPLC2*X!&[/13S
MCK0!V%%9^BWUYJ.EQW-_IDFFW#,P:VDD5RH#$ Y7CD '\:T* /-OB?H%C8^
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M;.]CJMK+=[F*I(P5 0NUB-N-X)SSQQ5G6/'UAI%M=WIMI;C3[*?R+J>)TRC
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M[-<7%N Q#A@K;4SN<*QP2/0XS@U@>$(/$.GVECX?U#PG D]CLA.KAHS#)$F
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M-Y,\=W;WPTY[+Y6D:X)^55(.T@]0V<8!)Q@U)+XFBGBUVQU#1KU9-/MQ)/
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M1 UPYB4C^()G&?>KO_"#>&O^@3%_WTW^-);^*3>W$ILK$W%K#?FPFD28;XY
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MT?\ "#>&O^@3%_WTW^-4[CQI<#6]8TBQ\/7MW>:;'%*P\V-%D5PQ!#%N!\O
MZDGH,$UMZ!K5MXBT"QUBT#K!=Q"55<89<]0?<'(H H?\(-X:_P"@3%_WTW^-
M36OA#0+*ZCN;?38XYHF#(X9N#^=4M:\8G26UAX]+GN(-'A2:\D+^7E6!;$>1
MAR%&3R!VSFB^\:);:SI>FVVE7EW)J=J]S;/&457"@''+<?>&2<#Z]* .HHK$
M\,>(U\1V5W(;.6SN;.[DL[FWD8,4D3&<,.",$'/O2ZQXC@TR^BT]/)DOI8FF
M"33K"BH"!DL<]2<  '//8$T ;5%<,WQ+M6\(MXCM],N9K6WN&MKY%==UJZL
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M.ULJ P/53CVS3++XA"Z7P_<2Z)>6^GZVR1073R(0LK*652H.[!P1NQU'I@T
M=H3@9-1B>$K&PEC(E_U9W#Y^,\>O'-<?XHUM=4T#Q+9V>F?VA;6,$L-V[.H'
MF>7N*H"/F9003TYX!)X&7HNH:=:^&OAO;7VDM=2W%O;K:7/R[;>7[/G/7.<
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M2SL2TMS</,P&2=JEB<+DDX'XYJG;^+)9/$W]AW&CW-I--:O<V;S2)B=4(!!
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MA,PC)C+,H"9'S-E3Z <9/- &[14-I/\ :K."X,;1F6-7V-U7(S@U-0 4444
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M $GCWP.]EGB@"F65(P[!%WL!ECP /<^E'GPFX-OYJ><%WF/<-VW.,XZXSWH
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M,*1GW_';\567B/Q-\/M4M4T'[->79B6"Q$\19 LBLS.^0O..@)Q@>IQZ#10
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M9'>IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR&=#('8YXP6R N,@#'4YIL&F:VWC?0-5GTHQV]MIDEI<,MPC;'<H1W!(&WG
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M6;0PIP8))-LI;VQ*N!W W?WJV-2TGQ(GP\-MI\BMKTS)/=[)?*,K,X:5$?\
MAXRH/8 <T 7K?Q9*VK:MI-SIN+_3K9+KR[>X$BRHV<89@N""IR"/SK-T[XB-
M=:"/$%YH5S9Z*UF+A+HS(Y>0N%$03ALDG@\ _D:IZ?H>LV7B[4-3B\/06MC=
MZ2ENL,-RFY)%9S@C@%CN&3G'^T3Q42^#=8OO@S:>&G1;+5[-(C'YCJR-)$X=
M>5)^4XQ[>E "ZH]W+\6?!,M[I4-I*T5[B6.82%AY(^1CM&"/3D<\&O2*X"6W
M\3ZSXM\*:O<>'Q8IIWVD7:R7D;8,D87*[<Y&>G?U []_0!S\_B.>;4-2LM'T
M];^730HN=T_E#>R[A&GRG<VW!.<#D<]<<IXR\5'7/AS8ZGHL>ZSU"[MXI?-D
M\MUS.JM$RX/4AE;GIGJ#6OI^EZMX9\6:]=6VGR:CINKR)=)Y,L:O!,%VLK!V
M7*G ((SCIBL>]\%ZK8?#O3]#LK47E\-1COKDQR*B*?/\U@"Q&?[HXYQDXH [
MG2])M;.XNM173X;._O@GVOR7+!RF0O. "<'K@5ITV-B\:LT;1DCE&QD?D2*=
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4R2:*$ RR(@/3<P&:?7%_%J*.7X6Z_YB*VVWW+N&<$,.10!V,<T4P)
MBD1\==K T^O'YH;+5_$OA6W\(6@MM5TR2&;5+B. VXCM2OS(^0"^_L.?PSFN
M^UGQ5#IVJ'2X&L3>K;BX<7MX+= I)51NVL225;@#@#GMD Z*BN*L/B);:E8:
M+)%:I;76J22Q+#>S^4B/%]Y=X4[B<C;@<@YXZ5#XB\2>(;8^&DAT^WM7O]4^
MRW$4ERV?E+D ,$^ZP3.['0@8YS0!W=0QW5O-/-!%/$\T! EC5P6C)&1N';(Y
MYKDKGQEK \17^AV'ADW=Y9P0SG_3E175R0<$KQC!QGK[46OBK3++4?&%Q=Z4
MFGG23$UY<)M9[D&/<I.!R0N  2>N* .SHKG8M=UD:K:V5QX?*)=V[RQ3QSF1
M(G4 A)CLPA.>"-W.0,U@>&/&MZ/!3:WKR6P,M]+;P^7<$;G-PT:H=R@*HP/F
MR> 21VH ]!K,UVQT?5;%=.UI;>2"X=52.9]I9QR-IR#N],<US]K\0;1=3U.S
MU)+:%+*R-_\ :K.Y^TPO$#AANVKAP?X<<Y!K#\4WE[J.J>!+ZZTB&VCFU>)X
MY?/WRH#&Y".-HP2#G@D9&/0T =MI?A?2](F6:W6ZEE3(1[N\EN#'V^7S&;;Q
MQQBM.XO+:S56N;B& ,<*97"Y/H,U-7F7BG4)O"?CJYUW6]&DU/P[=VL4"W44
M8E.GE2VX%#T5B02?8=<8H ],5E;.U@<<'!Z4M>9:IJEMX>^&%_JW@B:SFL;F
MZ#QNCE1 )71&"  \AB>#C;GVP>NF\07*:M;:)%9V\FKR6S74L7VDB*&(-M!+
M[,DDD #;V/IR ;]-DD2*-I)'5$499F. !ZDUR5OX^M6T^]-S9R0ZI9WR:=)8
M!PQ:=R!&%;C*MD$,0. >.*35M1O;ZP\0:/JVA^5''IKSQW*.9K>4%6^7<R+A
MP1G&.G- '603Q7,$<\$J2PR*&22-@RLIZ$$=14E<+X%U>=_"?AC3M.M([H1Z
M7;F[F:8HMN?+4JO"G<Q!SM[#!.,C/=4 1?:K?S/+\^+?G&W>,Y],4KW$,3A)
M)HT8]F8 UP#6MO\ \-!(_D1[_P#A&R^[:,[OM&,_7'&:Z#7[6WF\2^&))8(W
M=+N;:S*"1_H\G^ H Z.H9;JW@FAAEGBCEG)6)'<!I"!DA1WP.>*XFX^(&I+:
M^(9[;PT95T*9UN?,O53<BH')7"G+8/W>G'7M5Z^\0V4NO>$5.D)<KJOF26EY
M*5W6W[DN<#!.2O'!'6@#KJ*X'3O%VJPWOC.\U6V@-AHLAPEO,S,JI"'PJE &
M)SDDD8Z=!FNDT?6+O4Y8V:UM39RVXFAN[2Z,\;G."N=BX/?W_.@#:IID02+&
M742,"0N>2!U./Q'YTDLB0Q/+(<(BEF/H!7&>$=9DN/ ]SXQN;:>YNKT2W?D0
MKOD\I6811(/90./[S,>YH [:L?3O"^C:5J][JMG9A+Z]8O-,SLQ))!.,DA02
M 2!CH/05GZ?XMFF\3QZ%J&GQVUS+I_VY/)N#+M 8 HX*J58;AZYYIWA[Q5-X
MBAT^^M+*!]-O%8^=%=;W@(&0LB;1M;L1DX/'ID Z:F3316\+S3R)%$@RSNP5
M5'J2>E/KSOQGKDFN^!/%AL-,@NM/M(+FV:>6;:QD1"'>-=I!"'N2"2IQV) /
M0HY$FB26)U>-P&5E.0P/0@]Q3JXNS\40Z9I&B:7$]E]M;2H;@B\NQ;QJFT*/
MFVL220< #^$YQQG)O?'VI:GI/AR\TFRCM_MVL)874<\Y#*ZDL55@I!1MOW_0
M].> #TJBN1U;QL-/FOK6"+3Y+S3X5>YAGU 0Y<KN\N/*$N<8Y(4?,OOBJ_Q"
MEN)M!BTO0I[IM:M99[<2S+$5:-061L@XP2 3^6: .XHKC(?&.LSZX^B#PR(]
M333H[TQRWR[%+,5*EE4\ @C(!SQP!R*(^)5T?"]OXC/AYTTY9A!?%[M=\#>;
MY3;%"GS &[DK0!TD.@^'K7Q;-JB10C7+J/>Q>8ERH 0LJ$X'& 2 /3O6[7,3
M:O OQ%ATIM&C:[_LR2XBORR[R@=08QQD DYY(''2L-OB7>KX>GUYO#C+IUI>
MM:WC&\7?&!+Y99%"_/@G)''L30!Z'17,:SXPCL-0N]/M!827=I"LLJ7EZ+8$
MMDJBG:V6(&>@ R.>>(;#QU!K%IHO]F63O>ZK$\RV]P_E^0D9P[.<$C#848!R
M3Z9( .GBNK>>66*&>*22%MLJHX)0^C =#]:DDD2*-I)'5$499F. !ZDUP/P\
M$B^)?&PELXK20:C'NAB;<@/DKR#@9!Z]!UKJ?%<,4_A'6(YHTD0V4Q*N,CA#
MB@#4AFBN8(YX)4EAD4.DB,&5E/(((ZBGUYAX;\8WN@^%?"$>H:#)'HUU:VEH
MNHBY5BDC1J%+1@<(3WS]0.E=7I?BF6\UW7-)O;&*RFTM4DW-<[A-&P)$@^48
M7@@]<'B@#I**H:)?SZIHUI?W%H+5[B,2B'S-Y53R,G YQCC'%8'CK6M6T?\
ML%-,CMRM]JT%K*TDK(V"2VT84X!VD$]AV.> #J!=6[736HN(C<JN]H0XWA?4
MCKCWJ:O-GDOK+XO:@^GZ5!/?2Z! [Q"<1Q[_ #GR6DVY/3 .W)XX';9L_B!9
MWGAG2-4,,=M<:G*\,=O<W 14DC+"3=)CA1L;G'/''- '845S?ACQ8OB&]U2Q
M>WCBNM.D17:";SH95<95DDP,]"",<$8KI* $+*&52P!;H">M+7EWCR]U&'4X
M_%ME)(;'PQ=I'-"G2='&+@^^U60#T*O7=ZQXAL]'T,:JQ,\4GEK;I$03.\A
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M))G8ZM@X.TYQQG^1!_&@#EH]$NM7\7P^(+ZU:R2UL'M(('=6D+2$%V.TE0
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M8E[=92@B5I(R(U 3!7L>G'8]*]"L-/B@FGOWL;6WU&["BZ> [O,VY"Y8J"V
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MQ=9F:.XV,V0_RC8&5L<9(Q0!UMIXEGC\6#PYJMI'!=36QN;2:&0O'.H.&7D
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M%RD<A;.-GR<8_O'/:@#H9O%^M2ZWXATG3M"MY9](CAD#S7NQ)5=6;LA(;"X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR_DY8@D\X XZGI./'][J%[H,&BZ3#<)K5A)=V\D]R4V%0N5<!3@ MU&<XZ4
M=G?7]GIEH]W?W4-K;IRTLT@11]2:FCD2:))8V#(ZAE8="#T->8ZSXGN-?^'7
MCC3M5T]++5M)MI(KF%)/,C(9"R.A(!P1SSS6]_PD5YHUUX4L)+2#^S=3B2#[
M8TA!CE$>Y4*XQ\V, YZT =E167INI7%]JFIPF&(6EI*(8Y58EI'VAFXQC W
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M^E>"-1TJ."W@UF\19XI7;=N"LVS('W<H><9/' YKT=-_EKY@4/@;@IR,]\4
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MS.0F65LJ=@SDKZ#&<Y:N^HH \S/@CQ"?AC-X9VZ=]L>]-P)/M+^7M-QYV/\
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M3RRLK6PE^\K)M.X*22,'GH<=:ZW1=*AT+0K'2K7+16<"0H6ZMM&,GW/6K]%
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M_P"$<T=[>219+FXN9;NY=!A3+(Q9MOL,@#Z50M]$UC3_ !YK&LVJV4UCJ5O
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M1V& !SUXQA1^$]9O_#>E^&]:DL7L;&6$R74,C%[F.$@HI0J A.U=QW'H<=>
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MB^;Y/;/'T]ZJ-X/\2Z:OA_4]$NM-75].TU-,NH+EG-O<PKC!#!=RD$9''?\
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M&]2 1GFG0>!_$EKI-A!'-I<DEKK$NH/;22R>1<)(S,%8[,@J6R.",@'M5A_
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MTFRCT?6WBMXY()V:6":1<IO!&-I/H3CU]:6MZ!K6G:;\0-8OIM/-OJFD$^7
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M D%0#R W7V]ZO:#I_C(6\=KKVH::J6T91)[$.9+AMI57?< %QG) SD@<@#!
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M\8CA1@V%BCVHF3CG/?N2:]%K@W\"WMT/%NFW-S;#2M=F:X21-QGC<HJX(X7
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M615;E(SGRRV< GIG@\5>KRJUU/5M"U[XFZFT=G<7ME!:3X&Z.-U2!V!QDD'
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M!*H0-DAQG[Q ].>N>))O$VL3-XXM84LK2YT6)&MY@C2;MT)DRP)&3C 'I[T
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MVNK"VE3R1(\P,I4..3A00V0>2.G7FO4;5;E;=1=R123\[FBC**>>, DD<>]
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M$J%)(Y%#*ZD8((/4&O-_AK>66B^(M=\&6E_'=V<+#4-.D282YBD^^F0>JO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@=6^H/!H X/28M>LM5%C=IH.[4HFA-WIMQ,]S$%1BKGS,DHIX^\ "P]:BL/
M_B2WM_"R27VDJVA3L<QPR'SE9&0NV2,N=V2/7)S7<Z9HFE:+&Z:7IEG8HYRR
MVT"QAOKM S5^@#FM#T*_T[Q9XBU:X:V,&JR0NB1NQ:/RXQ'@Y4 Y S[>]'B7
MPW<ZEJ^C:YID\46IZ5(YC6?/ES1R#:Z,1DC(P0<'!'0UTM% '&WWA*]U%?$-
M_,UJNJ:MI_\ 9T:AV,=O%M8?>V@L27+'@= /<]!X>L;G3/#NG:?=F(S6MO'
MS1,2K;%"Y&0",XSBM*B@#D-2\-:S-XPN=5L[VS^RW5@+-EN8V9[?!))C ('S
M9&02.0.N,5BVG@#7=.TOPO<6FH6']M: CP*&1Q!/ X"LC'E@>,A@.O;O7I-%
M 'GTW@WQ!=/XPEFNM,#>(;2.W"(),0E8C'G<>N-Q[<X_AZ5=N/"^K3/X18-9
M Z&0TH,K_O3Y1C^7Y>.#GGZ>]=I10!QT?AK5H]:\6WX:R*ZW#%'"OF-F(I&8
M\M\O.<YXZ8QSUJG'X-UB/1_!UD);$MX?FCDD;S' F"1E !\O&0V:[VB@#D8?
M#FJP^(O%&IAK(IK%O#%$AD8&,QHR@M\O.=V>.F,<]:BTOPUK&F>%]&T61-+O
MK:TMFM;RWG9O+N%^7:P^0X(P>"".?Q'9T4 >>K\/;VR\/Z/::;=6T<^FZPVI
M10R[VA1&+_N5/WL /P>Y'09XVM.T'5+;QU?:[<26CV]U9Q6I5"P<&,L=V",<
MECQGCU-=110!YI>> O$=QH^JZ8NI::R7&J#489Y8W,LF)5<)(>VT+@$9X '%
M=$OA[5H/')U^*[LVAN+".UND:-@VY&9LIS@ [B.2<>]=310!S7A#0+W0HM8C
MOFMI!?ZE/?+Y+,=HE.2AR!T]>_H*9X1\'Q^&;&^LWG^T0S3.L"G_ )8VQ9F2
M+\"[_P#?5=110!PGAOPOXKT".+0QK-C+X>MW_<2F)_M@BSD19SM'INY..F.,
M=5K]E/J?A[4=/MC&)KJVD@5I6(5=RE<G /3.<5HT4 <9>>#;W4/A]IFA/>QV
MFIZ8MNUK>0Y=5EA "O@@<''(]^])/H/BW6_#6I66LZO8VUY<6K6\!TU)%C4G
M&7<L<DG&,#& 6ZYX[2B@#AK+PKX@C\2Z/J\]SI,(L[![&2WMH7"JI*D;,G_9
M[XQZ&EM_!EW=Z_I&L:M%IT=_91/'=75FS;KX-&4VN"HP.=W);D8&*[BB@#@+
M7P/JMMX/G\&&[MGT5V:..[+-]H2W9MQC*;=I;!*AMPZ@[>,5K0>';ZT\=2ZY
M +067]EII\4'F,&&QRX/W2,<XQ^//2NIHH X?0_"^NZ+X=MM*;^R[N-;FX>Y
MAE9O+GCE9GV\H<$%AV(('O4^B>%]4\,Z(]GHDMC T^IFZ>"0.\,$#$;HH^AZ
M#(. ,D\"NQHH *1MP4[0"V. 3@$_6EHH Y3P=X=U+P_=Z])>O:2)J>HRWZ^2
M[$QE\#8<J,XQU_2H[?PYJMOK_BK40;)DUF*)(4\U@8S'&4&[Y><YSQTZ<]:Z
M^B@#S>'P)X@TO3O#MSH^HV$.M:/:FQ?S@[6]W <'#8 93D \=Z[C1[?4H;,M
MJUS#/>RMO?R%*Q1\ !4!)...IY))/'0:%% ')ZQX6O/^$IA\4:!<P0:F(/LU
MS!<J?)NHLY 8KRK ]& /IBMBUBU>ZD1]3%I;1IG,%K*TOF'&/F=E7CGH%ZXY
M['4HH X"S\#ZK8^$KSP;%=6K:),9(X;EF;SX8)&):/9MVL1E@&W#J#CC%:%U
MX8U.S\7V>LZ%+8QPIIHTR6&Z#G9&K[E9-O4CD8)'UKKZ* /-XO .N0^%+/1_
MMMA*]OK U+>0ZY43&7;T.22<9P,>]= N@:@_C^;7Y6M5M9=+73S&LC%QAV?=
M]W'5L8_'VKJ** /-T\":_'X#TWPV;S37.GW4,D4N'4,D4F\9X/)X![#'?-=#
MXTGT6?PQ>Z3K=U;Q/>6K[;<2@RNPZ>6IP68-MQ@=<5T]59],L+J]M[VXL;:6
MZM\^1/)$K/%GKM8C(_"@"EX7TJ;1O#EG9W<QGO0GF74S')DF;YG;/^\3CVQ4
M>KZ?J%_J^E-&+4Z=:S>?/'([!Y'"D+@!2,*3NYZD#IBMNB@#D_&_AB_U]-(F
MTB6UMK_3;U;N*XFW<8!!3"CD-GGD=*AN/#FN6OC'_A)=(FL!+>6J6^HV=RS[
M&*'Y71PN<C.,$8(KLJ* /-!\.=8_L)H_[4LTU6VUJ35[&9(6\L.S$E'!.2I#
M8XZ>IK3'A36M3\52:MK,NFK;7&COIEQ;6WF,2&<L2&;'YX[XQQD]Q10!Q/AG
M0/%^CQ6NDW^L:?<:/9;5AFBB=;J5%^XCG.T#@ D9) QWS58^"]8;PQXMTEI;
M$2:[=SW"2"1\0B50I!^7DC;^.>U=_10!PQ\*:Y8>(;#7])GL/M8L$L+^UN&?
MRI54Y5T8+D,/<8Q5-O &L3^$_$6ESZC8_:=1U1M2MWCB<(C^8L@#9.<$H!QT
MSU->BT4 <;;^'_$3^-+;Q)>W&F!X].>S>VA#[<EP_#'GJH^8CO\ =XR<O_A!
M-9_X5F?"GGV'GFZ\[[1O?;C[1YV,;<YS\OZ^U>C44 <Q/H>I3^/-.\0'[(MO
M;64EJ\0D8L2[*Q(^7'!7'O[5+XS\-2^)M'ABM+S['J%G=1WME<%=RI,F<;AW
M!!(/UKHJ* .0N/#.K^)O#>HZ;XKO+,-=P>2L>G(XCC.0?,^<Y9MP4]@,8[DT
M#PYJ^JQZ'!X@ELGCTFX2Z\RV9BUU+&I",05&P9.X@%LD#H*Z^B@#@AX.U@^'
MO%^FM)8[]?N9YHW$CXA$J*F#\O. N??/:K=[X:U._P!*CTJ^L](U#3SI\=NT
M%Q(X\N9=P,BG8>H*^A&.#7944 <1'X+U.PO/"MQ8ZE#*^CV3V,[W2,3(K*@W
MK@]04Z$]^M3V_A6_.K>+Y[F:V6WUZ-(T\MF9H=L7E<@@ Y'/7CISUKL** .
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MY#B6V:93N3"C#+D\'.1GH>E>B44 9^A6-QIF@6%A=2Q2S6UND+/$I56VJ!D
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M=.:ZBQBU6/4-0>^N;>6S>139QQQE6C7;\P<YY.?\^@!H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 57O=/LM2@\B^M+>ZASGRYXPZY^A&*L44 06EE:V%NMO9VT-M"O2.&,(H
M_ <5/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9'B/6_^$>TDZBUL
M)XDD5909TBVH3RP+D D>F>: ->BN.\"^+;KQ'$\%U#&TMO&#-<HZH&<L<*(B
M=ZC;CE@,\X]:[&@ HHHH **** "BBN.\=>+KKPY$D%K#&LMQ&3#<NZN%<,,J
M8@=[ KGE0<<9XYH [&BLGPYK?_"0Z2-16V$$3R,(AYZ2[D!X8E"0"?3/%:U
M!1110 4444 %%%>>>(/B)<:/XC^P_9(UCMI'66,W$1-P&3]T=^X"'Y^OF8R.
MF: /0Z*BMI7FM899(Q&[HK,@8-M)&<9'!^HJ6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J]W8VE^D:7EK#<+'(LJ+*@
M8*XZ,,]"/6K%% &3HGAO3= MXX[2'=*D?E?:90&F=-Q;:SXR0"3@5K444 %%
M%% !1110 5DZWX;TW7H)$NX=LSQB+[3$ LRIN#;5?&0"0,BM:B@"O:6-I8(Z
M6=K#;I)(TKK$@4,YZL<=2?6K%%% !1110 4444 %8EWX3T:]U"*\DLXPRO*\
ML:HH2X,B;&,JX^?CUK;HH 9%%'!"D,,:QQ1J%1$& H'  '84^BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJU
M_-=06$TME:B[N44F. RB,2'TW$''UQ0!8<E48JI8@9"@]?:L#PGXBF\1VNHR
MW%DMI)9ZA-9&-9/,SY9 )S@=3GM5G0K_ %J^2<ZSHD>ELA7R@EXMQYF<YZ*,
M8X_.N=^'Z-+I_BR-&VLWB"_4'T)84 2-X\;^Q)O$R6D;>'8;DP&7>?-:,2>6
MTX&,;0V?EZE03GM7: A@"""#R"*\:MLP?LS3V;QD7,<,MD\./F$WV@IMQZ[B
M/SKO(KWQ1IKV6G0>&HKNTBBAC>].I*A^ZH<["I/!SWYQ0!U5%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% ",H92IS@C'!P?S%4-+T/3M%\_P#L^W,
MN)#+*!(S!W/5CDGYCW/4UH44 9A\/Z4;\WILT\XRB8\G890,"39G;OQ_%C/O
M6G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pacb-20231231xexx1028004.jpg
<TEXT>
begin 644 pacb-20231231xexx1028004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"!54!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M66/[0ACWI\W(W8R* ,KP[XNU_4/!?B_5+_Q==6UWI4C"S8B':Y )5"I3YMQ
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M$]Z]2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_9C0%C^ IMMXJTBZU"#3Q<2PWUQGRK:YMY(97 4L2%=02  >>G:@#9HHHH
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MAS4/#.DSV>HZ_=:U+)<-,L]R#N13CY1DGT)Z]2>!71T %%%% !1110 4444
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MUX?M_$J>'9+N<:O(,I;"SF)88)R"$P1@$YSCBM^**."%(8D5(XU"HBC 4#@
M"O&=4_Y.HT;_ *\&_P#14M 'HS>._#<?B=/#<NH&'5G.$MYK>2/<2,C#,H4Y
M[<\]JTYM:LK?6+?2I#/]KN$9XU6VD92JXW'>%VC&Y<Y/<5YW\0?A\GC:ZU::
MR80ZY8B&2SG!VDG:3L)[ XX/8\^M0_#+QU<^*]:M-.U>)XM=TJRNH;Q77;O_
M 'D #>Q^4@CU'O0!WVJ^+M&T?4H=,GN'EU*8;H[.UA>:8CU*H"0/<X%.M?%6
ME7>H'3DDN$OUA:=K66VD24(" 6VE<D98#(SGMTKROX$SR:MXD\9ZQJ.6U62>
M-7+_ 'D4ER5'H,J!C_9%>S/8VTFHPW[1 W,,3Q))W".5+#\T7\J .=T[XC>&
MM7:Z73KB^NVM6VSB#3+ES&>>"!'P>#^56)?'7AZ'PTOB*2\F&E%F0W M)CM(
M8H=RA=R_,".0*\7^&=]K%C?^+3I=HDL<FMVL=S+YVUH8S.X8A<?-P2#R,=>:
M]G\2:?8MX<FL?(B:WFOH//B/(8R7*%\CWW$_C0!=L/$FDZKH US3[HW6GE2P
MDAB=VXX/R ;LCTQFJW_"9Z*?L(22]D:^A-Q;I%I\[L\8Q\VT(2!\PY..M>0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBN6NOB!H=IXB?0)/MS:HB>8;:.SD
MD8KC.1M!R,>E '4T5SEKXY\/W_AZZURQO3=6-H&-RT43%X0HR=R$!A@#TJI;
M?$C0;W1&UFU34I].4,6N(M/E90%^\>%Z#O0!UU%<SK_CW0?#-A97^J33Q6EZ
M%,$JP,X;(R!P.#CGFI%\;Z&NM6VCW4\]E?W7_'O%>6TD/F^RLPVD^V<T =%1
M7-Z]XZT3PWJMGIFIO<QW5ZP6V5+=W$I) PI4'G) _&K-KXIL+K68M),-_!=R
MQM)&MQ9R1JZKC.&88.,CC/>@#;HKGU\9:5<:C=V.G_:=1GLSBY^QPF18C_=+
M=-W!^4$GCI5K2/$NE:]ITE[I5Q]JCB8I(B*1)&XZJR-@JWL10!K45QUC\3O#
M>I6=Y=V;W\UO9'%S(EA*PB[G< N>Q_*MB#Q3I%WX<;7[*Z^V::J-(TMNI8A5
MY;*]<C'(QGVH V:*P?"_C+0_&-O<S:+=-,MM((Y5>-D921D<, ?7\C56[^('
MAZS\5IX9>XF?5W("V\4#MDD;OO8QTYZ\4 =1145Q<PVEK+=7#B.&%#)([=%4
M#))_"H["^M]3TZVO[202VUS$LL3C^)6&0?R- %FBN8L/B!X=U#Q1+X;2ZDBU
M>/.;:XA:,D@9P"1@G'/'4<UK+K-NVN-I BN1=+$)B3"?+V$D [^G4$8ZT :-
M%<]=^--(M]:?1K<W%_J<8W2VUC"93"/5R/E7Z$YJ2W\6Z7<RWD$0NC<V40FN
M;=K9TDC4YQ\K 9Z'IG..* -VBN1TOXD:!K>G3:AI::E>6D+E))(-/E<*P )&
M N<X(/XUT>EZE:ZQI=MJ5DY>UN8Q+$Q4J2IZ<'D4 8'C?PE>^,+*VLX-?N=*
M@BD$K_9H\M(P.5^;(( /./7!["J?A_X>?V;I^KV>M:]J&OIJ<(@=KUR3'& V
M54ECC.[/X"M3Q)XVT7PG-:QZQ)/";MMD#) SAVXXRH//(ZTMAXVT*_UXZ$MQ
M+;ZJ%WBTNK>2%V7&<KN #<9/'H: ,G2/AU#8:CH=S>Z@;U-!@>#3H_)V% W&
MYSN.]@  ,!1QG&:R=3^%>LZEK=[JJ^/]7M);M@72U4Q*%'W5 #] #Q^/J:]!
MU75+/1=+N=2OYA#:6R&25SV JTCK(BNC!D895@<@CUH Y:]\$02WV@:E8W(M
MM3T2(P0321>8LD9385==RD\$D8(P:N^$?"MGX0T=K&UD::2:9[BXG< &65NK
M8'0<  =@/QJ+_A-M(-M/>H+N33;=F22_CMV>$%3AL$<D @@L 5&#S3-?\>Z#
MX8L;*]U6:>&VO #!*L#.&R,X^4'!QZT 9OC3X>OXQUO2-2;5_L;:3)YMNB6V
M_+;E;YB6YY0=A6L=!U>YUNPOK_74DMK.1I?L=O9^4DKE"H+$NQ.-V0.F0*D7
MQ=IW]J66G30:C;SWKE(#/92(CL%+$;B,9P"<9[53F^(.A0^(Y/#S?;FU6-=[
M6T=G([;<;LC ((P<\4 9NL>#[S0M5U/Q7X,$8U:YC_TG3IAF"\(.<]05?J<Y
MP3UZDUD?#V.TU;Q#-XDUZ"_3Q?,IA>WN;.2*.T0#&V+(Q@@?>+$G/N<]YH?B
M?1O$:S_V7>K-);MLGA96CEB;T=& 9>AZCM4NNZY9^'=*FU/4/-6TA&97CC+[
M!ZD#G% '-W_P_D7QTWB_0M5&G:C-%Y-U'-;>?#.N .1N4@_*O0]A[YZ'3M*G
MLWNKN>\%SJ5RJJ\YBVHJKG:JH#PH+,<%B<L>?3%_X69X972[75)KBZ@TVZ;;
M#>2V<HB8Y(P6VX'0]<=*TO$/B_1_"^EQZGJ<TBV,A4+/%&9%RW(^[GKZ]* ,
M7P5\/F\&ZQK%_'JWVO\ M602SQM;[-K L1M(8X&7/4&CQ5\/G\4>*M&UUM6%
ML^DR+);Q+;;@2&#?,=PSRHZ8K2'CG2=EA(\.HQPW\D<=O,]C*(V:0@)EMN!G
M(ZU=O/$EE:ZJVEQQW%W?)$)I8;6+>8D)P"QX S@X&<G' H UE#! &(+XY(&!
MGZ5Q%G\/9K3XCW7C3^V%>[NH_*D@^RX3;M5>/GSG"#GZUL-XVT46"WB/=2H]
MY]A5([20R&?;N*;-NX$ '.1Q@U2@^(^@W.KW6DP+J,NH6B%Y[9+"4NBC')&W
M_:'YT ==7#W7P]EN?B1;^-/[75;JWC\I+?[+E-FUEY._.<,>?TJWJ/Q)\-Z5
MING:C>3W,=IJ(_T:3[,YWGTP!D'V.*N1^-M#;7(-%GGFL]1N!NA@N[>2$RC_
M &2P"GZ T 6['3+VUUN_OY;Z*6*[V8@%OM,>T$##;CGKSD?E5:+PCIUOXXD\
M56Z^5>3V;6MPJCB7+(RN?]H;,>X(]*AUCQUHF@Z[9Z-J#W*7UX0MM&MNSB4D
M[1@@8ZU>UWQ/I'ANRBN=6NA;B9@D,6TO)*Q_A5%R6/(Z4 8+_#\:?XLN?$GA
MO4_[+O+P8O()(/.MYSG.XIN4AL\Y#>OJ<]!9Z=J,<LEU>:H+BZ,9C14A,<$8
MR#D1[B23@<EC[8R<TCXSTV$VJWUOJ%@UW,D-N+JT=?,=R JY (!YZ$@]>.*I
MZA\2?#NEV<][>-?16<-RUJUP;*7RS(K%2 VW!Y4C(]* ,SPK\.+[P?<:K/IV
MOQ.VIR"687%AN"L"Q!7$@Q]X]<]JUD\*:DNC3VCZ^9KNXOEO9KN6U!)*LA50
MH8  >6H^GYU;LO&.FW]W%:P0W_G36QNH5DLY$$L8*Y*D@ _>7C.>:HZ3\2-
MUV"XFTI=1O$MVVRF&PE8H?3&W.: -?Q!X=LO%'AZ?1]7198ITPS(NTH_9USG
M!!Y'7\:M65C+8:);6$$Z^9;P)"LKQY!VJ!DJ"/3IFL>Z\>:%9>%HO$LTMPNE
M2''G?9WRAW;/F7&X?-QTJ.+XB>&W6P>:[FM(M0 -I-=VTD44V1D8=EV].Q-
M%/X?_#__ (0&*^@AU0WD-W()6#P;&5L8X(8\?A3-9^'TFK_$#3O%QU<17&GH
M(X8!:[D*@L?F._)/SGD8[5W%8<GBO3Q>W=M;Q7=V;)MEW):V[2+"V,[3CDL
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M_+BNMO+I+*SEN9%D9(E+L(UW-@=<#O6-X9\9Z/XOLYKS1'GN+>%BC2&%D&\
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M&>UDC62,;<E6(P?O+Q[UNT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3<S6&MV!!M[^U ##'."IR&7.>#ZGGDY .DN[.WOH5BN8A(BR)* >S(P93^!
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M>"O#<Y13*FE0(KXY"F-"1^.T?E69KWP^BUWP)8>$GU*2&RM888C*L0,DGE*
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M2ZAIMX2SVUS$N 2-K8QV(X(/H/Q */P82"T^$6DRP1ERXFDD$8RS-YK _C@
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M6K7:6MI'U=^Y[  <DGT% &C17+#QQ"FE-JUUH>M6FF*GF&ZEMU/R8SN,:N9
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MSTZ<^X]: .@HJAHNK1:YI%KJ=O#-%;W4:RQ"8 ,R, 0V 3C(/?FK] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR;-A@;:"GE=V&<@[B?7VKB(-8OO#W@OQ_J^G21K<VGB"ZD42)N5N8P01QZT
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M-1LV+6UU$LT3%<$JPR#@].#7&7NKZAXET?Q;)I]U':VNFM<6,:-$'\Z2./\
M>%R>BY.T;<'C.3G%5?"NMW!T7P5X:L9%AGN-$CO)YRH8QPHB* H/&YF;J<@
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M&N[W67$<;&(%H_E>1V/(WG"G&2.2.O2K>I:_XPTC0O%%S+;H(M/M_M.GWMU
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M.XW0)W-SG)/7%=FOB35=%\6ZIINM7-O>6D.CMJR/!;^48PCE63&X[AT()YH
M[BBN$LM;\5W,VA7\%B]S97Q0WL)B1%MXW7(>-]V6VY&<@[NH Z5VMW=0V-G/
M=W+B.""-I)'/1549)_(4 1Q:C9S:E<:='<(UW;(DDT0ZHKYVD_7:?\FK5>,Q
MZG!H?C30O%37#>9K;-9ZO&P8>5YAW09R,?)A4)]![UWOB;6-1T37_#\BS1KH
M][=_8[L&/+H[*?*(;/ + *>.XH ZFBO/K#Q?J+WGBS3[BZCEN]/=1IVV#8)@
MY*)U^\?-!C)&!D5<U_5M;TQYXFU"WA$.G>= \4/FRW-P,[LQ#)6,87)'][[U
M ':TC,%4L<X R<#->>2^+=?O8? TEB]C!_PD$1,ZR0L_EOY!DR#NY /\/4XQ
MN&:T;#5-:O->;PU+J, N]/LDGO[V"W \R21FV*BL2%&U<D\YR,8H Z'1==L/
M$%I+=:=(\D,4[P,7C9"'0X888 \'VK2KA?A6)ET#5A<LCSC6[T2,B[5+>8<D
M#G S5FVUG5_$DGB Z-=0VHTJ[>R@22$.)ID4%C)SD+EMH"X/!.><  ZB^O[;
M3;1KF[E$<0*KG!)+,0JJ .222  .235'3?$FGZH+X0?:!-82>7<P/;N)(R1D
M?+C)!'((SFO/=>UZY\7>"_!FN6\@LUN]9LU> Q[MLHE*DYSR RGCOQ7JMNDD
M<"+-()90/GD"[=Q]<=J .=@^('A>XM$NUU3;:._EK<RP2QP[LXQYC*%SGCK7
M2@@@$'(/0BO M)U*:;X3V?A?[&(4UR]N;--2NF'V>)C,QP=N6W'&%! !/?BO
M4K^]D\*:7X<T"S,D]S<%;*.4H&;;'$69]I(!;"<#/5L\XP0#K**X*;7_ !;I
M6FZ_+=:7-<PVAB>QN1"OFRQL0)<QJW+1C<1C ;':L_6_$4^J_#?Q+J>B^)(K
MNUCM-T-Q%$%FC.UMZ..-K=,' (!Z9YH ]-!! (.0:I3:K;6^KVNF/YOVBZ1Y
M(]L3%,)C.6 P.HZUQE[JGB+2Y_!^F6=]9.NJ;XI'FM3E-L)<'AN0,=.,XZC-
M7(M5\0Z=XP\.Z'J5Y97*7EG<R7$D-L8RSQ[<$98X&&'&.U ':4F1G&>?2N)L
M-9\1^(]"@\0:'):>7+=LL=C,N%>W60HQ9^H<A2PQP.F#U-.QU"^LOB#XVN[S
M46DLM-M+64P^4.(_+E?:O/&#DY[T >AU1UC6++0=*GU/4)'CM8%W2.D;.5'K
MA037)66M^*[J;0=0M[%[BROV0WL!B1%MXW7(>-]V6VY&<@[NH Z5D>(]7U#Q
M3\+_ !/K%K=1P6 CN88(#$&\R*,E&9CU#$AB,8 XSGF@#TZWG2ZMHKB(DQRH
M'4D8X(R*DJCHG_(!T[_KUB_]!%7J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "D.<'! /;-+574=1M-)L9+V^G6&
MWCQN<@GDG   Y))(  Y).!0!A>&?"]WH&KZW?3:C#<KJMS]I:-;8QF-L8P#O
M.1@#M3K;PU>VOBK6M;CU&W/]I010B%K4_NO+#!3G?\WWCG@?A5RV\4:;<ZE!
MIQ^U07DX9HH;FUDB+J!DD;E ('?TR,]:V P)(!!(.#CM0!PD/P]O(/"?A[0D
MUF'&BWL5VLQLS^]\MBRJ1YG'4Y.?RJ_X@\(7?B.TU+3;^_MI=-O9$=%>U)EM
M<*H/EMNQDE20<<%CUZ5UM% %6^T^UU+3)].O(A-:SQ&*2-OXE(P1_P#7KG]%
M\/\ B#0+*/2[37+6XTZ ;+<WEFSSQ1CHA99%#X' .!^-:UKX@L+S7[S1(3-]
MMLXDEF#Q,JA6) P2/FZ'D9%:E ',:QX1-_-I&H6FH/#J^E2O)#=3)Y@D#C$B
M.H(^5AZ$8P,=,4K>$$O?[;GU.X66\U>S^Q220Q[%BAVL J DGJ[$DGDXZ8J]
M9^*-)O\ 7+G1;>:9M0M0K3Q-:RKY8(R"6*A>1TYYJQ+K5C!K$.DNT_VR9&DC
M06TA4JI )WA=N 67//&10!RMOX'UGS/#<EYXA@D;0G/E"*QVB1/+\OYLN3NP
M>3G'MWJ4>![W^Q_%6GG5X"-?FEE9_L9_<^8@0@#S/FX QTYKM:I2ZG#%K%OI
MC17!FGB>59%B8Q@*0""_0'G@4 <\_@Z]^W>'+Z#5XXKG2+5[21OLN5FC8*"0
M"WR-\@P?F'L>E6="T*;PW=Z]J-YJ4$T%_<->N!;F/R2% /.\Y&%'85T@8$D
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MXC;4H&9M.%B8/LI'1R^[=O\ 4GC'3\ZZ2B@#@G^'EY)X#U'PNVLP;;VY><W
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MOLD\P*5\SCG@G/2N]K NO&>B6>L2Z3++>&_BB\YX8M/N)"(\XW_*A&W/&>E
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MMIC17!FN(GE5UB8Q@+C(9^@// H YN3PAJL]UX;NI];MWFT9V?BQ(67='Y>
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M+OPQ<'5(@VA*P4"U/[[='Y9S\_'R_K^5$G@^>^ETO^U-2BNX],O!=V[BUV3
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M6YC*.P48!WGC"C_&EU[PU+J^M:-JMMJ+65SIC2[2(A('250K#!/!X&#SCT-
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M\Z.D;;<@]&Q@^E7H=8UZQ\9>';2^OH+FSUNVG8P);A/L[QHK@JV<MD$@Y^H
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MKK9N(!;F/:-GEX!WGC:!0!CZEXCUO0_#>B^*+B[2YMKI[?[=9B)0D:38 ,3
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MNX(;9);N_5HHK?'^OE=<<^V.2>R@^E<3<:0=!\6?"_P_YIDM;2*[!8]'E2W
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M.02,=3D=>.A !WC.J+N=@HZ9)Q5.74DBUBWTTVUTSSQ/*)UB)B0+CAGZ G/
M[XKRS4-7U?6_ &ASW>IS1W:>(HK*XDMT1!/LN=H8J5./N@X'&>H(XKL;G4=5
MM/B)H^BG4#)87.GSRN&A0.70H Q8#'\1X  ]J .M>-)!AT5@.S#-*JJBA5
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MQN+RA!M222*0JK$?5 V.F?I71IIUNLUU,R^9)= +*TG.4&<)_NC<W'N3U)H
ML@A@"""#R"*6N*^%E[-=>"UMIW9VTZZGL5=CDLD;D+^2X'X5E>)_$^MZ-;ZG
M?1ZDLDMIJ44:6EM"LD"V[/&NV9RN5D(8G ;(RO&* /2J*X>ZO?$%Y\1[[0+?
M6%M+(:7'=HR6J,\;&1EX+9!/R]3D=>.XS=(\:ZK?^'/"]K+/&NKZO>SVDETL
M8 5(&??(%Z;B$&!C&6SC Q0!VEMXALKKQ'=Z%&LXO+2%9Y-\15-K$@8)Z\@]
M./>M5G52H9@"QPH)ZG&<#\ ?RK@=#M[BV^,6MI<7LEWG2+8H\J*K!?,?@[0
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M8"^TJ[2YM]Q0LH(*L.JLIP5(]" :\\U/4[[1_BUX@O[#2SJ4L&@12&W678S
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MCD&@#V"J-]J]CIMW86MW<+'-?S&&W4_QN%+8_)?S('>K<*-%"B/*\K* #(X
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M#\A4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6/XET:[UW2C86NJR:<'8>9)%$LA=?[N&XP>_J..A-;%-DD2*-
MI)'5$499F. ![F@#GM%\/:M87OG:EXFNM4A6,HEL]M%"BDXY.P#/ (P>.:KP
M>!K>*SM-*:[9]$L[H74%D8^00Q=49\_,BL<@8!X )('/5T4 <EJ/A36[S79M
M4M?%US9%T\N.%+*%UB3KA2X)Y."3WP/08MS>%3<Z9IL=SJ<\^IZ?/]IAU"11
MO\SG.5&!M(8J5&..F, UT5% &1I&A)IM]?ZC--]HU'4&0W$VS8-J#"(JY.%
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MYY64*6/T' 'M4]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<,>%+"X++]YB6X#9QM(%=OH&A6WA[3GM+8EO,GDN)6( W22,68@#@#)P .@
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MMYDUS/C?*^ ,X   P     !5#_A&W7Q=<>(DOW$\UF+/RC$"BH&+ ^N<D]Z
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M_9PPA=/OY"L6('<@$5U]>%0:OJ>E^%/&"PV\*:9=>)KVUO-0),C6:2$*9/*
M&X#(YW=^E 'MUE>VVHV,%[9S)/;3H)(I$.0RD9!%3UP]XZ>!_!.@:1HTID6:
MYM]/@N"RDD.22X)^7) .,\9(X(XIK1>-K%]<-FPFMY+ OI\5U.CS1W0XP"
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MH">@Y)..>![YRKW4M<T(:'H%YJRW%WJ>IO +Y(U#QVZJ7 /&/,(PN<=\]>:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4.?4 A2.N1GH171.&9&56*,1@,!G'O3J* ,#POX5B\+)?)!?W5RE[=27D@N
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M\CBNRHH YJ[\'QW\4]I>:C<SZ=->"\:U=4^5A)YFU6QD+N&<=>O(KI3THHH
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MU&664S:I;0!(KE8=K!?+5 IQG8Q'WN<9QFDUY5/C2\>_U'Q5H[);PV]O<Z=
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ML2-*VYBH&!D\=JMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8 3(8C P/:@#OJ*\UTD>)M>T3P_XELM1MX))6CN;QI=0D:&6%OOQ>3LV*1G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_9$DSG<(_8\X)QG'' JTO@RS6/7(Q?7VW6R3=_,G.5V';\G'R\?_7YKI**
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M9 7J2 ?PXQ4?A'1;C0M*FM9[N]N4:X:2'[=/YTL:$#Y6<<'D,W'3=CG%;]%
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M 5"C"[0 "< #N3U.:I/X&T]]#TC2/MM^+729HY[7#IN#1_<R=G('Z]\UT]%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<00V<KN V2" %Y&!DL..1SR*N_\ "3Z2VF:?J$5UYT.HE5LQ&I+3EAD!5Z]
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MD#..^.]/M+"[\-^,_"BW<%U<QP^'SIS7$$#R*9PT?#$#Y00I.6P/>LIXKA_
M'Q&MA8WOGWFI7CVT?V63=,KJ@4J-O()!Y'I0!Z;?ZW:6#K&5GN)VC,HAMHC*
M^P?Q8'0>GKVS66_C[PVMGIEV+YW@U-BMJ\<$C!V&<KPO#<$;3SGC%<?=W!T3
MQ1::MJFEZE=:/J&DV]N)K6&5GMIHRQVNB_, =Y[=?QJ?5+6WMI?!AT_0KFQL
MX]7:Z:!+9R8HRCC?( #L))!P>1GGD&@#T#2-5MM;TN'4;,3""7=M$T31N,,5
M.58 CD&KU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6R+E8W5@",C[PP>*[+4=:MK6[&G".XN;R2$RF"U&76/.-Y.0%YX'.2<XS@T
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MJJO=RQ0%A;!E#?..N0I!( ) () H Z"BJDVI6\6DMJ:%KBV$7G P+O+IC.5
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MC,_V?4)WM[2[,?[J>1=V5!SD?=;!( ..":KZ5XQ_M+Q'KVG/I]Y%#IC)'O\
M)+%B4+DD+D\@C QG\\4 =717*^'M<T*S\%:?>V-W>3:=-(8K5KDO)/,YD8!1
MGYB2<XST [ 5>@\5Z=+-?V\JW-O>6$8FN+62$F41GHZA<[U]US0!N45RMG\0
M]"OFTHQ?;!!JC".VN7M76%I""0A?&-QP>/PZUJ^);JQL_#6HS:E)<Q60MW$\
MEL',B)M.2-@R,#OVH U:*YC_ (2W1-(AT.Q>2]8ZA;!K/,$DC2*L>[EL'<^,
M<9))/O6CH/B*Q\10W+V8GCDM9C!<07$1CDB< '!4^Q!H UJ*Y>3Q4S>/F\,"
MPNO+6Q^T/.J=2SA000<A1ALGU^E<OX1\8V>A:'?C5I]0GCCUJY@>Z9))E@7S
MMB>9(<X'0<G/3UH ]0HK*U+7K;3I)(1!<W<\47GRQ6L>]HX^<,>1UP<#J<'
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MBBB@ HHHH **** "N.^*=O<7GPXU:TL[6XNKF=42.*WA:1F.]3T4'L#78T4
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M+-=_$/PE<PVE]]GBLKN.6<6D@6)I%0)N)7"G*GKTQS7>44 >2V%EJ$/PDO?
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MO000S333Z?/%%%%$SN[M&P4!0,]2*WZ* /-1'<G5_AM)]@O]EG;2K=-]CEQ
M3;A '^7Y?FXY_E6MX.CG3Q=XQEEM+J&*YO8Y8))K=XUD41*I*E@ >0:[2B@#
MB;I;FQ^+Z7[6%Y+9W.BK:I/# SHLBSLQ#$<+\ISSUZ#)XKD;FROY?A#XKL$T
MO4C>7.J3R00?8I0\BO<!U8#;TVC.>U>R44 >9:E(=&\=WNI:EX>O]4TC5[:
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MR!5=W1E4\<'"GZ5@1V=]_P *\\>6?]F:A]IO[^_>UB-I)NE67[A QT/Z=\4
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M* &4A0"#CZ4 -OM<@M+]=/B@GO+XPF<V]N%W+'G&XEF50">!SDX.,X-9<WQ
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M>66L:;_8"ZM8:5>QRG4M*O87$5DQ0X,+..#O(&%)!!)Z5%X1M6M-/LO#.J^
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M.: (/&.O6FN_##Q+<6$]S!<644L<L>YH98)4'*M@_P!2"#WKL],).DV9)R3
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MBYN=+72=_DEHMNYYMIG^_P!@N ?OCG &:[G3K&/3--MK&*2:6.WC6-7F<N[
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M@RDEL?:),9SSGZUTE_K<5G?II\-M/>WSQ&?[/;[-RQ@XW$NRJ 3P.<GG'0X
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MN\@(++NR. >.OMCFJ_@^&Z@MM.T/4? :PZI8>7')J3V\1MF5,#S5DSN+D#(
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M/5YDT>9H[W9'&/+55#,_+@$8/09/'0"MJ?Q-9I<Z9:VJO=7.I0M/;QQX'[H
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M1[Q;R!1(#_=/. >W7'O7E7B77[OQ7\%_$=]?Z?+;-%+*(CYBE1LGV!1M;)(
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MUG<6#S8"3F%4RO7C)3'..H- %[6KV6Z^)W@:672KRS=C>,OG.A#C[.WRD*Q
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M  #%+AB5=2<@C8P.,\B@#JJP=6\)V6JZHFJ+=W]C?K$(#<65P8R\8)(5ARI
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M,VC;3<JK1*-I3?N!+X/R] .3Z"NETW4X-6T:UU2S#O!=0+/$" &*LN0/8\T
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M658XC*8H\;R ,X&2!G\: +=%<)#\3[5H-'OI]$U*VTC5&CCCU"0)Y:2/]U6
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M;;C=V8-P0?7@FN3'B^+5?A#-KOBC09KNPFRTL,3H593,0H^\#A2$&>O?!YH
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M(CLK9.XG(*DC&"*K3V&L?\+.O-5MK!Q;-H?V.&Y=DV>>)&<9&[=CD<XKM**
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MR,Q212_!'SD$5)KFD7&OV%C:Z_X;2]MIO-DFCM9D$EB_R^7L<LI)QNR5[^U
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MBMTBRY! 8QQG[X4G!R1R#C-3KK.F77CVTMX=*\R^ETE[FVU%BH5H2R_(,98
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M=+#Y$VTH5*E1@, 2"#SCGIF@#L=!\.Z9X:L/L>EP-'&3N9GD:1V.,<LQ)/'
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M!=AN!S@ G/3BG^(-/\1Z;XSA\3>'[&'4XYK,65Y823B%L*Y9)$8\9&Y@0?\
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M(1O\X&%)P"/3OZ5Z=10!P7B'1_$_B[PL[RVMMI>I6]S!=V5FTXE >)MW[QU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSZ)]LD&\C[3*%0!6(Y( +,1WR,]*Q=>N-0T_2_B-HT-]>BSTRWANK&5;AQ)
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MFY;5]/U I>3^>XDDMD(D6;=G.'!C3K_$:]-DB66!HF+A67:2CE6 ]B.1]10
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MXM4MWD:V;?!-'*T<L3>JNI!&<#/TK;J"\N[?3[*>\NI5BMX(VDDD8\*H&2:
M,>?P7H=SX?70Y;:4V <2L@N) TC@A@S.&W,<@')/858_X1O3O[=&M8N/[0%M
M]E$OVE_]5G.W&<=><XSFM6.198DD7[KJ&'T-5+6747U*^CN;:&.R0I]DE24L
M\N5^?<N/EP>!R<T 0Z)H&G^'K:6VTZ.6.*65IF5YGD^=CEC\Q.,GFDO?#^GZ
MAK-AJUPDQO+#?]F=9W4)N&&^4'!R.#D5J44 8D/A/2X9(R!</%%<F[C@EN'>
M-)BQ;>%)]22!T!Y !JSX@6]?P[J*:;;17-ZUNZPPS-M1V(( )]/R^HZUI44
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MU"WE%Y; K'<V\[PR!3U7<A!(Z\>Y]:V;*SM]/LXK2TB6*WA7:B+V']?K4]%
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M%O!:V[,0(U>/>TH _B). W4!1@CFG_")=GPOTA<DX,XR3DG]_)6U>^#]$O\
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M2_VCY MS,UQ(<Q@YV[2V,9YZ=>: .6^)MC;73^$FGB#G_A(+:/))^ZV[(_'
MHL!!KGQ \1Z)J46^STNUM([*V=CMVNC%Y .[9PN[J,<8R:ZW6=#T[7[-+34[
M<S1)*LR;9&1D=3E65E(((]0:KW/A;2+F[M[O[/)#=6\/D1S6T[POY7]PLA!9
M>^#GGGK0!C?#:\O[C0+ZUOYY;G^S]3N;&WN)3N>6*-\*2>YZC/\ LUS7C9TN
M+7QK=64LUW<V%NA,\DOEKISI'N"P$9)<\,W0<@9.,5Z=965MIUG%:6<*PV\0
MPB+T'<_4D\D]R:QKWP-X<U&]O[NZTX22ZA'Y=T/.D"2@#:"4#;=P'1L9'8T
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MG;.7)R =JJ3GH37=R>'=*TZZU=[*XFM_MUCE[&!_+B79QYBA<%6.0"<\X^M
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MNV@^^%)QZ$>M &9;>"/#EG<6UQ;Z6B3VL;10S>8Y=5./XB<G&!@GD8XQ2_\
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MYJ[/YWD/Y!02X^4R E<^^*\VM/B5K'_"!0>-+O1;1M+,A6XBM[AO.B02F,L
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M@"+0H"OD9Z[<=,]_7O0!Q]AX=T32_C"MG;:;:16]OX>B>%2@)5A<,H8$\[L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZX)'ZUR.MV6N7'C2W?\ LQ=3T(V>Q(FN%2.&YWY+R*>6&W ! ;'.!SFNQHH
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MF8J6/3KTXZUZ(!@ $Y]Z6B@#B=+TW5_"WB7Q#)!ILNHZ=JMP+V%X)8U:*4J
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MZ_G7745'%<03/(D4T<CQ-MD56!*'&<'T- 'G$WPZNKNV\3:7-(BZ;)+)<:,
M>89I0KLWMMD7Y?9F]:OZQH.M7GPHO],:W%SKVI0%KA4=%'G/@GDD#:HPHYZ*
M*[F6:*WC,DTB1H.K.P 'XFE61' *.K @$8.>#T- '&7FF:K<^,?!^HIIDPMM
M.M[A+IFEBS&9$11QOYP5.<?K6)+X/UW4?#_BZS%O]AO+S6?[4TZ261&5BOEE
M0VUCC)C/TR*]0HH YC2]1\3ZE:R/JGA\:;Y<+ P+=1S//(1CY2#M5>O4@GCT
M.>3@\,Z_#\/?"&D'29#>Z7J-M/<H)XL!(W+$@[\'(/ _E7J=1P7$-S'YEO-'
M*F2NZ-@PR#@C(]#Q0 \'(!QCV-<7IVEZM%\5M5UJ73)4TZYL8K:.8RQGYD.2
M2H;..?3M7:$A1DD #N:19$?[KJWT.: .9\:6^MW$6E_V3;/=VJ7@;4+2*=8G
MFAVG@,Q QNP2,C(&.F:Y";PMXA&A^.M.AT**)=78-9+!<Q[1F)5QCC &#GI[
M ]:]561&.%=2?0&G4 <7XJTC5=5\%:9'9V!:_L[JTN6M'E16;RG4LH;.W. >
M^*==V&KW?Q!\/ZNVENEK;6=Q%<,)HSY;2;<#&03C;S@?3-=;'<032RQ131O)
M"0LB*P)0D9 ([<<\U+0!YWX4L?%_ABT/A9=)AFL89G^R:Q]I0*L+,6^:/[Q<
M9/&,'CD#FM.+3=1C^(VLZM)8NNGSZ9';1SF1#ET9V/RAMV/FXX[5V-17$ N;
M>2!G=%==I*-M8#V/:@#R;PWIE_XJ^"NB^'1I\D4%RL0EO'D3RUB64.2H#;BQ
M"X VCD]<<FYXI\/>)]:A\6V,ND)?&Z3&E73W2+'#'L'[M4)RKYSEL#.>6  K
MT'0]$L_#NDPZ7IXD6T@&(DDD+[!Z GG%:- '#P:=K3>.]&U>;27CMH-)DM9B
ML\;;)&9& ^\"<!><#J>,CFL2?PKK]QX(\3V*Z84O;K76U*UB>>/][&9TD R&
M(5L*>O&<<UZ?/<0VL#SW$T<,*#+22,%51[D]*D!R,CI0!#:2SS6L<ES;_9Y6
M&6BWABGL2.,XZXX]SUJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K,UO6H=%M[=GC:6>ZN$MK:%3@R2MT&>P
M !)/8 ]>E:=<KX[T+4M8TVPN=%>(:II=]'?6\<QPDI4$%">V0QY_EUH ;>^+
MM0TVTUZ6]T!T?2+<71=9F,%Q'M+'RY"@RPP05(_&K$OBSRM2\-6QL<QZZC&.
M02\Q%8C)@KCG@8SFJMS:^(?%/A76;/4K"#29+RQEM8+;[0)R'92-[NHP!D@
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M_EK<1AD7C^[M8$^\:TSPUX,N[7P3?Z'K-T99KF&2P69>2MJH:.(?]\DM]6-
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M7S$)S$K@Y4'(SNX^G.* )M+\5R:S+')8V,4UB;R2TDD2YS+ 4+#<\>WY02G
MW9PRGZ+X_P!8O] \#ZKJ>FI$US! 64R,0$[;A@')&>!Q]:Y\>%+VX\3:;K=O
MI3:/JT=WG4+N"=!#>6XSD,BMEF;Y>JC!SR<"NF\;:/<^(/!6KZ39E/M-U;,D
M6\X!;J 3VH C_P"$BN8)-+TQ[2&36+V)I5A6Y/EK&@&YW?9D<D# 4\GTR1-H
M'B1-9O=3TV>V-IJ>F2*ES;E]ZX8;D=&P-RL.G /!R!6!<:/KW]O:!XIBT]/M
M5K;/97NG+<*6,+8(*.<+N##."0".]:^@:)/#XEUSQ%=Q>1-J7DQQVY8,T<<2
MX&XC(W$DG )  '- %G5=<N[/5/L%EIGGNMHUV\\\IA@50=H3?M;YSUQQ@#-8
MS?$2-]$\-ZK:Z1<SQ:Y.D"*)$!C=@QQR>3\I]![BI-:T[7;CQK!<K8P:CHWV
M/RXXIIPB6]QO),C*0=WRX (!(P<8R<\YIOA;Q):^$_!FFSZ8GG:-J2W$_EW*
M',:^8,C..3OZ>@Z]J .GL_'"(_B"/7+'^S)-$C2>?$PF5XG4LK*0!S\I&,=?
M6GR^+YK"XT<ZMI?V2SU:18+>=9_,,<K#*)*NT;2>F06&>/>L75/!U_KVL^,H
MKB!K:RUFQ@M[>XWJ=KQ!N64'.,L/P!Z59FT;6O$FF^']-UC3Q9MIUW!<WEP)
MD=)C"#@1 '=\S8)W!<#/4T 58]6U37D\<V.J65F;*RWP(HE+[0(0P^4I\Q).
M2<C!XYQFH_!_BFXTKPUX)L;K2'2PU"U@M(KWSUSYOE;@#'C.T[3@Y_"KL6B:
MY8ZCXS1+".>UU9C-;S+.H8L81'L*GI@C.2<8]3Q5/_A'=<'AGP)8#36,^B75
MO+=CSH\;8XV0[3NY)W9'3\* -/6OB):Z7%J%S;P6UU;Z?,8;A/MBI.Q4@/Y<
M>#NVDXY*Y(..V5O/'5Y_;CZ3I'AZ?49SIR:A ?M*1++&S;1RWW>_7GIQU(IZ
M?8^,/#&M:K9:=I=GJ6DZA>R7EO=2W8B-HTIW.KK@E@&)(V\^_/&C;Z5JL?Q-
M.KRVS26)TA+$W.] 6D60N6V Y"G/Y]L4 =#JFK6VBZ+<ZKJ!,5O;1&64#DC
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M)("&B8,<E02<$9/]$\)Q>-M-M++P]J.G60MK$)$-72Y!\Z%,  18R&*@ DD
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M <D<CW]0#L**XJX\>R6OAVV\3S:6!X?G=<S"<^='$[;5E:/;C:<@D!L@$'U
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M=(5!P!WVD^@-:EEX^BD\/3WU_9I:7L&I-I;VYN 4^T!L<2$#Y<'<3C@ \'N
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MMIVMV\RH\48()\S&&.!N 7# \<CFNY@U&RNKNXM+>[@FN+;;Y\4<@9HLYQN
MZ9P>OI1=ZC96#0K>7<%NT\@BB$L@4R.3@*N>I)(X% ')W?AJ^U+QMK5S<0^7
MIFHZ,-,\U9 7!RY+;?3#\>XZ5@R>'/&4W@K2_#4NG6#R:5=6Q2\^V;4GBA<%
M3MVDJ=J@'/X9KU.B@#@AIOB[P]XHU.ZT6RL-1TW5Y%N)(I[HPM:S[%5CG:=R
M':#P,\=N]R31]8_X3W1]7DC6X@M-/EMKB965"TCE6RJ?W1M]<\]Z[&B@#S&?
MP;KMUX-\4Z;]GACN[_66U*U#3 JRF5) C$=&PA'<<CFO0XDFO-,\O4(4BDF0
MK+%')O"@Y&-V!GCOBIKBY@M(C+<S1PQCJ\C!0/Q-0VVJ:?>N4M+ZVG<#)6*9
M6/Z&@#@K7PEKL?@";P)/%$T&#;1ZF)1M^S%\Y*?>\P*2,8QD#YJU[[1-07QU
MH&H6=D&TW3+.:V8^:H<[P@&T'J!LYR1UKL:* ,#QI8:OJ7A:ZM=#F6.^8H0&
MD,?F(&!=-XY7<H(S[US]CH.NVOBVZU9-(L+:RN-(6T6V@N>8G5G8*/E .=PR
M> .>O?OZKV=_::C"TUE=0W$2NT9>)PP#*<$9'<&@#SN+PIKT7@7PCH_V*,W>
MCZA;7%Q^_78R1,2=I[DYXR!W_'8TO1]9\,:[KTEC9I?6&K7'VZ(&81M!.R@.
MKYZH2 <KDCT-=D[I%&TDC*B*"S,QP !U)-1VEW;7]I%=VD\<]O*H>.6)@RN#
MW!'6@#S^/P-J6A:;X-CTH6][-HEQ++<+)*8A(95<.RG!P SDXQTK1LM'UBV\
M3^+=2DLE:+5(+>.WV3+DM'&R'<"> 2V1UX'X5VM% 'E]GX2\4Z+HOA6^TR&U
M?5]%MGL[FSEFQ'=0OM)VN.A!4$9'\N=7Q+I7B?Q%X3$,ME:QW\EY!.+5+C,<
M"1R*^#(0"S'!Z#'0=LGNZ* &HQ:-69"C$9*DC(]N*X'1]'\7>&;[4M*TZVL+
MG2+N[DNK:]FN"KV@D.YE:/:=^"21@C/<C/'<WM[:Z=9RW=[<16UM$,R2RN%5
M1[D\"IE8,H92"",@CO0!QUOHFJ^'_&NK:O8V_P#:%CJ\<)FC\U4EAFC78&^;
M *L.O.0>U95SX&U.R\-:>;%;>YU2WUX:W/#YFQ)79F+1JQ'& X )'.W/&<5Z
M/10!Y\="\23:YXFU*:PM%35=+CM8HDNLLD@#@ DK@CY^3QCL&[L;PWK?]@>!
M;(62&70I[>2[_?KAA'$8SL]2<Y&<5W=GJ-EJ*RM97<%RL,ABD,,@<(X )4XZ
M'!''O5F@#AHM!URQU7Q@8K6WFM-7/FP2"?:^XPB/85(P,$9SGIV)K9\(:?<:
M5X*TO2M4ACCGM;9+61=X='P N0>X/H:Z"L[6M"TSQ%IYL-7M$NK4NLGEN2!N
M'0\$&@#F?AWH)TF'4'^U&XLX[B2TTW/_ "SMDD8[<]_G9AGN$7VK3\>Z5?:[
MX*U/2=.A62ZO(O*3>X15R1R3_A706]O#:6T5M;1)#!$H2.-%PJJ.  !T%24
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MP>,CWJG<^.KFR\.V/BBYTV-=!NFC+L)29H(I" DK+C!'*Y4'(SU-2ZAX:O\
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M4ALAL=1CK['-TSPA>?\ "5Z5X@EL+72]0AC==4ELYLQWY9, ;0!GYOFRP!&
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M22_GE1;A9BYMF6-FRN4!Y48SD=2*27Q5?7=OK-WHNGP7=OI,SP2"28H]Q)&
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M]\EV[1[I V0<)GJN ,>ISVJA#\0]6F\,:/XF.CVL>EW4\=O<HUP3,K-)Y19
M%Q@-ZG)'I0!W8U&R.J'3!=1?;A#]H-ON&_R\[=V/3/&:M5S URX/Q#N=#&FV
MN]-*%W%<^:=\@,FT(QV_*,@G^+UKG;?XB:W)X7L/$DVC64>G27OV6Y07+-(H
M,YB#(-N" <=<9YX'< ])HKD-8\77,5YJMII,$4T^F*OF++'(WG2% _EKL!V_
M*5Y.>6QCC-;FEZE<:QX<M]1BM'L[FX@#BWNU*F)\?=88SP?SH GU'5=/TB%9
MM1O8+6-V"*TT@7<QZ 9ZGV%7*\7O=3U76?@2FIZHT4\L][#(K1YW$_;1D<\
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M%]>ZE??#;P/?W_EW-S+JVG3*5;YI"6S\Q/ ))^E=;!XRNK#5->LO$-K;6_\
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M%F,H4';\F"!M[D9SVK.\-^'?&'AV%/#\=[ILF@0N1;WA+_:HX2<^7MQM+#.
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MY!^3)(Z>_M6EXB\,:EXDL+O3]0L=(NK6:!1 997#VDVW!=3Y?(S@C[IX/KP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU?[HSS@8% '.?"BRL#\-_&,LEK;?:A/>1*[1KO">2IV@]<>W2M7X,^%-%NO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\L9QP202.<8K/UCXJZ?IFGZCJ=O83WNFV-T+(W$;@>=.>JQ@_> [MQSTSUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LG6]5NM-:QBLM->_GNY_)""41B,!&8NQ/8;?U%
M:U% 'G^E_$B[UCQ+J^@6?ATO?Z6"9E-XH5L'&%)7GD]\5V>CZ@=5T:SU!K=[
M9KB%9##(?FC)&=I]QTKR/X<_\EW\=_\  O\ T8*Z+QM()/'.E6!OVNEFLI@-
M#52H<X;]^[Y 4#'!()^4[023@ ]'HKQKX=07GC3X(7%K?:K<QW4<LR6UZ9V5
MX2H!4ELYV@GGVXJY\%M4_MNQN/[3D<ZWI(6R>-V88CY(D()Y=B6!8\_*/7D
M]1O[B6UL)[B&)9GB0N(V?9NP,XS@US'P_P#'2^/M*N-2M].:TMH9C!^\F#,S
M@*QX QC##G/X5TNI?\@N[_ZXO_Z":\.^$F1\!_%C*S*R/=NK*Q!5A;H001T(
M(!H ][KD/$OCI=$\0VWA^QTV34=6GM);M8%D\L;$5B #@Y9BA &/J17C-I=7
MUIX3^&NNIJ>H-J%UJCPS2274C!H_/*[-I.,8'ISDUV.M:;:M^TSH:E7Q)IAG
M;]ZWWQYN#UX'RC@<>W)H ]:TVZEOM,M;N>TELY9HE=[>7&^(D9*G'<5:KP"3
M5M0UG0OB1KM[<W$>H:9=B*Q9964V:HY "8/RY[^O>K/B36-7U:Y^%%V+ZXLK
MO5=HNG@<IOYB^;;T/WF(R,<T >[45XC\6-%;P3\-472]6U5I9=9$OGS7;-(H
M=&R@88.WY0<'//-3?V:(?CPV@+?:C_9M[I7G74)O9/WS#/);=D<@=".XZ$B@
M#VBBO!/!FK7LGP-\1?:?$LVF?9-1>"*_DW2/%'B,[%P=V3N8#'/S5I^$KZ[7
MXSRZ<B7%GI][HRSO:&0@%L+B0J"0CGD\$D9ZYH ]537;.X?58K(M=SZ;\LT4
M/)W[=P0?[6,?B:A\*ZW<^(O#]OJ=WI-SI4TI8&UN?OK@D9Y .#C/05X_\,=+
MM#H7CVYVRB:WNKE(F$SC:-C8XS@GW//O67;^)-97X0>$+87UU_Q-=7:VN[HR
MMYAC\T_)OSD9^O1<4 ?1M%>2:??7%E\6O%?A:W:3^Q3I0N5M]QVP2;$Y3^Z#
MN/ [X->:B]U"#X/Z)XD75=1;54U[R4F>[D(5-K';MSCJHZC/;IQ0!]2T444
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MZBO%[J\U+_A56MLU_>0W&G^(&M87BNW)2/[2B;-QP74!B!N'3'%=99V[:/\
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MXY.<<9ZB@#VJL#Q!XBET/4M#MA9":+4[U;0RF7:8B59L[<'/"GN*X'5KZ_\
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M^ZUZ9M=FT72K6*ZO+>W6XN#-.8DC#$A%R%8ECM8XQP!GTH \I.GR'3=-T_\
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MT6Q6YDWPR\_,K;LC[QX'')XKI:JO?P"__L])$:],!G$1./E! R?0$G'X'TH
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M<[S%G:6SSTZ\]:N2>$]+EDG\P7#P3W NI;9IV,3RA@P)4G@9 .!@''(-;E%
M&')X3TN:2?S!</!<7 N9K9IV,3R A@2I/ R <# ..0:?%X7TV'4=3U",7*W.
MIJJW3BY?YPHPN!G"X!(&,5LT4 <W_P (+H7]BV&D"*Y%C83+/;1BZD'ENIRI
MSNR<'D FF:IX \/:OK(U:YMIUO2@CED@N9(O/4=!)M(W#Z_2NGHH R&\,Z8=
M<AUA8Y8[V&W^RQM',RJD7!VA =N,@'IVJG_P@V@G1K_26MYVL[Z<W,ZM<R$F
M4L&WALY4[@#P>U='10!#:VL5E:QV\._RT& 7<NQ]RS$DD]R3DU-110 4444
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M.X=D#D+NVJ!G@8) KOKJU2\@\EWF1">?)E:-C[;E((_ TEE8VNFVB6ME!'!
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MX6TJ^N;R:>.<F]4+=1K<R+', NT!D#;2,#!XY'!S6N$18Q&%4(!M"@<8],4
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MR/FSU'I7JNH>'-+U*XM+F:!H[FS!6WGMY&A>-2,%0R$':?3I4-WX2T2]T?\
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MLZ3R++$",$"0'<01P020>],NO"6B7NBRZ/<6C/8S2>;,GGR!I7R#N=@VYCD
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MN-&-G,=/N)3-+ ;N8AW+;B2=^?O<]>M.NO!/A^]U":^N;%I)YX!;SDW$F)D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\\ <X'(J@;/P]_PCGA/2AXZT#/A^[>Y\PR']_F3>!C^'N.]>Y?\ ".Z)_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %4]5N+JUTFZFL;?[3>+&?(A[/)_"">PSC)[#)JY2
M$A5+,0 .23VH \O;QIXQ7XB6?@T+H4EW):?:;J>."8I;\,=O^L!;HO/'WA7=
M:'=ZF=$%QXB2TMKQ9)%D$.5C"JY56!8YP0 ?QKS7X1_\5+XX\8^-7^9)KC['
M:M_TS&#_ .@K%4%SJ-]XQ\?>++62\L;6UT>+[';+?2X2 N"LEP$QAW&"!D@
M,.: /8_M5OLC?SXMDI C;>,/GICUI#=VRQ"0W$0C)VABXP3G&,^N>*\6NO#=
MF?B!X)\':<TCVVD:9+<S7)^63;(2,D]5.>1_=+@]JCU_PQIT/Q!\(>#M' @L
MM'CFU2YGD.]HE+[AECZ%>,\?,,YH ]N-U;J)29X@(?\ 6$N/D^OI1-=6]O&L
MDT\44;$ ,[A0?Q-?+,L'F_#K6=4'[I?$^N+!8PM(0 JN6WL2><?,O/J2<G!'
MI'CVWN-)L]$\1>&[F.\'A.!8KJRF'#0/&HW8/<IU[X/M0!["CI(H9&5E/=3D
M4V2XAB=4DFC1F!*JS $@=<5G:(EE8^&;5[.U:VM/(\]+?',8;YRN/;)&*^>-
M1U]/$G@:[N[BXCEU[Q/JZ6JY<'[#;*WR)_L#@^FX$GG!H ^EVN8$5&:>-5D(
M"$N &)Z8]:<DT<C.J2(S(=KA6!*GT/I7C.N:?:ZU\6O"^B:>R16'AW2_M4UP
MHPR)@! #ZC$9'INS7/>'=?/ASX7>,_%FE_NKO4]0VVR EO(0L51CG^(;GZ^@
MSUH ]4^(GC&\\,Z;9#1/L5QJEW?1V4=O."_S.#@D*P(Z#\Z[&:>.TM)+BZE2
M.*%"\LC?*J@#))]!7AFCVVDWWQ-\'Z-:RPSV^AV#7D]T&#&[N9,9;=_$=^&S
M_O>E>B?%J"]N?A;KT6GJ[3F%253J4#J7_P#'0U $'AWQAJ_CN6YNO#\-M8Z'
M!(8H[V]B:62Z8==D89=JCU)/TZXZ#P_=:W+_ &DFNQVD;6USY4,ENC*LL>Q6
M\S#$XSN(QG@J>36!\+K[2;7X4:++%=6Z6\-O^_8N $DR2X/H=Q-97BV_N-?^
M)_ASPL[O#HHM3JMZC IYX4MM1P?X05&5/KSTH ]*AN(+B+S89HY(_P"^C C\
MQ2+=VSJC+<1$2,40AQ\S#J!ZGBO!)-2FMO _Q(\4/'MTW7+H6^F1.O$G+)YJ
MJ?4$'/JGM26_AR'3O&WPX\-74@6ZT^W^WW1W'",6RL:C_KHISW.[/3  ![[<
M7$-M'NFGBAW<*9& !/\ 6O.-!\;>*O$/P\U+7[*UTG[:;MHM.CE+1121JR@L
MQ9^OWN,CI7!Z_P"+X+^'Q_K-](DUW$S:+I=FQ!-O$3L>4+VSP=WJ,5?U33-/
M6]^&/@S= T=JOVZ[DX(.WD@'N&=9!@=210!Z^?$=G:ZCIFCWTT0UB]3)MH6W
M;,(69CZ+D8!/4D5%H=]KMWKNMQ:C!8+ID$JK826TNZ1UP=WF#)P>G8?CUKRS
M39]&E\?_ !!\8W5G9O%I,;0VL;Q*=\D:_O' Q][<JC=_TTQGFL?3)+[1_A+X
M;T72K@V]]XIU4)=W,/!B60C@$="4V?AF@#Z%BN8)GD2*:.1XSAU1@2I]_2FF
M\M560M<P@18\PEQ\F>F?2O)K4PVGQ3U?5K"(0>'?#&B&QN&0825U!<Q_[1&3
MGT*^]><2:/M^%FE)>-'%>>*-:\V)<[$ACS@R$=.RXST5CC&30!]13W-O;!3/
M/%$&.%,CA<GT&:D1UD4,C!E/0@Y%>/?$9KG1M2T_QAHCQW]IH,:Z?J.G3#.(
MI IS@]RLB@GK]WK@BO5M)L[;3](L[.SA,-M#"J11D8*J!P#[T 7**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$ZW:RZ)ITBWD@EN0ULA\YP<AFX^8Y[FK#:-I;W]O?OIUHUY;)Y<$YA7?$O\
M=5L9 Z\#UJ]10!FIX>T6-+Y$TFQ5;\DW8%NH\_/7?Q\W4]?6G/H.D/IT.G-I
M=F;*!@T5OY*[(R.057& 1ZBM"B@"I_9>G_V>VG_8;;[$P(:W\I?+8'J"N,'-
M,?1=*DCM(WTVS9+(@VJM I$!' V#'R_A5ZB@#/?0=(ENWNI-+LVN)'5WE:%2
MSLOW23CDC QGI6A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?< MW'Q+EMO#>K:D=&$D^EW:6TR17.8I [*JR1R;?F4[AQ@$8-:$OBW6(/%
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M(L+IQP0P4MC/) -==IECJ,_Q!F\1_8_+TV\TN&W0O(!(K!F?+)V'S8ZYR.E
M%?5OB)'8V]]=V=M:W<%C<&":$7@6YD*MM<QQ[3NVG/4C.T^Q-K4O'$4,MW#I
MJV4TUI DTB7=W]G+EUWJB#:26VX/. -PZ\XSM.TOQCX:U;4K#2[73KW1[Z[D
MN[>YGN#&]F9&W.K( =X!)( (SW([/N-)\5^'_%][JNA6]IJUGJL</VJ"YN/L
M[Q31H$$@8*005 R .HH F3Q_-=7/AR*RT25QKD$TD7G3")HFC7+*P(/<@9],
MX!X!@7QUK<FG:VZ>&X3>Z)*ZWL1O\1E50.#&^S+$J>A5?KVJW?:-K=QXN\*Z
MG+'%.FFI<_;)$<+\TR@ (IY(7'?G&.IJK;Z!K,8\;EK),ZTS-:#SEXS"(\/Z
M<C/&>* -*7QM:/#I0M3;+/J-D+Y!>W A1(B%QDX.6)8  #L>>.<H?$J5M%L;
MY=#D:6;5UTF>)9QA)"P&Z-B )%(.0> <]JJ1^&O%.B1>&M6TBWM9]0T_2TTN
M^L)I]BSQKM(9),$ AAGD=#6EX@TGQ)K>F:,TUK;?:X-8M]0E@CG^2&*,@^6'
M(!=CUS@#)/8"@"S#XLU1]0US2;C2+:VU.PM%O+<?:S)%-&VX LP0%2"IR,'Z
M]Z@\,:[XCO/AWIFK?V9#J-_<)$^Q;O875C\SDLH"X!)VC/3K4W]AZE-X^U35
M'MUCL;O2DL4<R LKJSMDJ.WS8Z]JB\.6?BGP_P" K#35TVPEU"R$5NJ&Z.QX
MP<,^[:,<<@<_TH [6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L?7?"NA^)U@&M:;#>BWW&+S
M<_)NQG&#WP/RK8HH X[_ (53X%_Z%JR_)O\ &C_A5/@7_H6K+\F_QKL:* ..
M_P"%4^!?^A:LOR;_ !H_X53X%_Z%JR_)O\:[&B@#C6^%'@1E*GPU9X(QQN']
M:9'\(_ 41)7PW;'/]YW;^;5VM% ''?\ "J? O_0M67Y-_C1_PJGP+_T+5E^3
M?XUV-% ''?\ "J? O_0M67Y-_C35^$W@12Q'AJS^8Y.2Q_+GBNSHH X[_A5/
M@7_H6K+\F_QH_P"%4^!?^A:LOR;_ !KL:* .._X53X%_Z%JR_)O\:/\ A5/@
M7_H6K+\F_P :[&B@#CO^%4^!?^A:LOR;_&C_ (53X%_Z%JR_)O\ &NQHH X[
M_A5/@7_H6K+\F_QH_P"%4^!?^A:LOR;_ !KL:* .*3X1^ HV9E\-VI+==SNP
M_ %N*D_X53X%_P"A:LOR;_&NQHH X[_A5/@7_H6K+\F_QH_X53X%_P"A:LOR
M;_&NQHH X[_A5/@7_H6K+\F_QH_X53X%_P"A:LOR;_&NQHH X[_A5/@7_H6K
M+\F_QH_X53X%_P"A:LOR;_&NQHH X[_A5/@7_H6K+\F_QH_X53X%_P"A:LOR
M;_&NQHH X[_A5/@7_H6K+\F_QH_X53X%_P"A:LOR;_&NQHH X[_A5/@7_H6K
M+\F_QIJ_";P(@('AJSY.>2Q_F:[.B@"MI^GVFDZ?#86$"06L"[8XDZ*/059H
MHH **** "BBB@ K,U'0--U6^L[V\AD>XLV+V[K/(GEL1@D!6 SCCZ5IT4 %%
M%% !1110 4444 %%%% !1110 4444 9EIH&FV&K7>J6\,B7MYM%Q(9Y&\S:,
M+D%B.!P..*-1T#3=5O;.\O(9))[-B]NZSR)Y;'@D!6 SCCZ5IT4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4C*KH4=0RL,$$9!%+10!SMIX$\,V,_FVVDQQ@
M-N$0=S$#G.1&3L'/M71444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+\QQAB!GC!Z4 7:*** "BBB@ HHJM9ZA;:AYYM95E$$S0.5Z!U^\/P)Q]0:
M+-%%% !115:QU"VU&&26TE66-)7A++TW(Q5A^!!'X4 6:*I7,NHKJ=C';6T$
MEB_F?:Y7D*O'@?)M7'S9/!Y&*NT %%%<O:^)M1U8ZA-HNEV]U:6-S):DRW9C
MDFDC.'VKL( SP-S#/L.: .HHJEH]^VJZ'8:BT#0-=VT<YA8Y,990VT_3.*NT
M %%,EEC@B>65U2-%+.[' 4#DDGTK.FO[RZTW3[W18(+F.Y>)V,TACQ W)<<'
M+ $8% &I1110 445CZUKHTN]TS3X84FO=2F:*!9)-B#:A=BS8/0#@ $DD>Y
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M.9)2QD$A8<C V_=Z<_6I]?U_^QYM.LX(%N+_ %*<P6T3R>6F0I9F9L'  !Z
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MUL[LDC QD\8XH Q-.\GQ/XX\6Z=K$?FQZ?\ 9X;6W<D".-XRQD7T8L3\PY&
M :Y**XU+4/#7A(7U_>M)%XG.G"Y6=E:X@0R@,V#@GY0-W7Y<YS7J=YX:TN^U
M%-1DAFCO5B\G[1;W$D+M'UVL48%AGGG.*;=>%=%N[?3X)+/;#ITBRVD<4KQK
M$Z]& 4CD9/)]30!SGA.V32OB)XITFT:5;%8+2X2%Y6<)(X<,1N)/.T9^E3?$
M"SM=;?1/#[AXKZ^NFDM;U&*M:&)"[2*1_%C@#WR>E=';:!IMIK5SJ\,,BWUR
MJI-*9Y&WJO0%2V.,G''&:FU'2K+54A6\A+F&02Q.KLCQN!C*LI!!P2.#T)%
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M-3)X1T)/#T^@_P!GJVFSY\Z)W9C(>.6<G<3P.<YX'I0!S6IA)O'UMX6!M(K
M:6US!;7,;/'-(92'X##+* ",YQN)]ZRWCN]!N_"_A&]UIK^QO-3N$GFPR%42
M/S([8DL20691R>0-O3(KL=3\"^'-8T^TLK[3O-BLR6MW\Z19(R>I$@;?SWR>
M>]377@_0+W08=$GTV,V$#!XHU9E:-P<[U<'<&R2=V<G)YYH YSPYI]KIOQ;\
M2PVD0BB;3[1Q&OW5):3(4=AQG [DUM>,/#^D>*;:UTC4I98+EW,UE<0/LEBD
M0?>0^N#T],^E6]-\)Z-I.IOJ5I:O]NDB$3W$L\DKNHZ9+L<GGJ>:LZIH>G:R
MUNU] 9'MF+P.LC(T;$8W*RD$''<4 <3X?NO$6E>*AX,\530ZQ;75G)+9ZBJ;
M9&12 R2CZ$<_3DYXYK0[G^Q/A#X8-KNMDU/5H[.^N(V*LL!N) >1]W@;<CIN
MKUG3] T_3;R2]ACEDNY$$;7%Q.\TFP'.T,Y)"YYP,#/-5(/!?AVWTN\TR/2X
MOL5XQ::!V9E.26X!)VC)) 7 !Y'- ',ZR9_"OC[2QH4)%MJ&GWC7-DF?+WPH
M&20*. Q9@I(ZYI?#%A8:YX5\,>)FU2>+4-T4]S=Q.-US(WRO"_JA<[0O;  Q
M78Z?H5AIDQG@29Y_+$7G7$\DSA <[0SDD#/.!U[UGZ=X$\-:3K#ZI8Z6D-TS
MF3B1S&KGJRQD[5/N * /.X]26W\7^(-.U)'@T*_U[RKF]C;!67RHC'&QZHK$
M??'ICC.:]BAABMX5AAC6.-!A548 K#?P3X?EM=2M9;%Y(-3<27B/<RL)F!!R
M<MP>!T]*V;.SAL+2.UM_,$42[4$DC2$#TW,23^= '$>"?W?Q#\?PMQ)]KMI-
MIZ[6AX/Z5O>6ESXWOHB6VKI<2R%'*E=TDF.0<@_*>E6-0\,:5J6HKJ,L4T-\
ML?E?:;6XD@D9.NUBC#</8YJS8Z-8Z;;306L;H)B6ED,SM+(V,9:0DL3CC)/&
M* /'+"V,'PK\-^(1=7C:I#JD:I.]RYPK7;(RXS@@@G.1SWKN1"'^,UY:O),]
MM-X>5WA>5F3)G93@$X7( Z8K8'@?P\-$AT864@TZ&7SHX!=2X5]V[(^;/WN?
MKS5Z/P_IL>N_VTL,O]H^0+?SC<2',8.=N"V,9YZ=>: /-/">DW#_  BLAH:V
MJ7\E[(?(G<HEVL=S(3"2.@*J1^&#QFNN\!:E:WJZO FF7.DW\%TIO-.F(*P.
M8U \LC@H0N1C'4G'-:$7@CP]!;R00V#11R7'VG$=Q(I63).4(;*<DG"X&3TK
M3L-*L],,[6T;"2X</-+)(TCR$  99B2<  #TH X_Q8T'AWQKHOB*Y?;IEVLF
MG7X<DQH67=')MZ9RI0GT8"L+PRTV_4?!=]#)%=3WT=Y&'D+2+92?O<%NN4VM
M%GL6%>GZCIMGJUI]EO[=)X/,238_3<C!E/X$"E_LVS_M;^U/LZ?;O(^S^=_%
MY>[=M^F>: .2LU,'QGOH$DE\DZ%%((FE9D5O.9?E!.%X4<#%<A+_ ,D*\8?]
M?M]_Z4&O4QX?TT:[)K0AD&HR0^0TPGDYCSG;C=C&3GIUYJF/!6@#1+K1OL<G
M]GW4AEG@-S*0[$Y))W9Y/)]: -JV_P"/6'_<7^52U';P);6\<$6[RXU"KO<L
M<?4DD_C4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7.^,?$%WX<TZSNK6V@G$U[!;2>:Y&P2.%R !R>?4?C715
MQ'Q43S/"MHFYEW:K9#*G!'[Y>A]: .WHKR[4M-/@[QY#)X928"]TF]GO+0RO
M(K/$JF.0AB?F+-MSW_.ET#2(M8TCPMXG@UVT@G1X7FN8+4^==LV%>&5_,.XE
MC@Y'!' % 'J%%<5\6US\+]<D#R(\<(93'(5.=P'.#R.>AXK*U30XO#OQ \*Z
MAHTEPMQJ4TL&H*TS.+F,1ER[@GJI&<C'4>U 'I54H7U(ZO=+-%:C31&AMW1V
M,K/SO##& .F,5Y1OA$/@_6-*+M#=>(1&NISN/M5XDC2[@^ /W?& "2<!>!BM
M>ZO;C1?&'Q!OK'?)/;Z+!<Q([%QO"RG@$],@<"@#J_%GB"[\/_V.UM;031WV
MIP64K2.08Q(V,@ <GKW'XUT#[MC; "^#M#' S[UY'JFGZ;)X1\ :Q"J2WD^K
M:=)+>9S),SG+EVZM\W8]".V*]5U&%+C3;F)RP5HF!V.5/3U'(H 9I;:@^F6[
M:K';QWY3]\ELQ:,-_LD\XJY7BUO$;GX;?#-WFN%>35;6)V29E+*WF$]#UR!S
MU':NM\+6<&C_ !+\3:98*8;(VEI<^0&)42-Y@9AGH3@9]<4 ;^O^(&TJ]TK3
M;:&.74-4F>*W$TFR-0BEF9B 3P!P ,DD=.M-MM5ULZI<:==Z9:I(EMY\$\=R
MQBF.[&WE,J1WZ]14'C#0-%\4QVFC:H\L5TY>XLIX7V2Q.F,LC>OS X]CZ5A>
M%;[Q+H?C%O"'B"\CU:%K)KNRU()MEV*P4I*/7D<_J<\ '2^"M?F\4>#].UJ>
M%();M&<QQDD+AB,<_2MZO"M&T^WL_ACX$UR$2+J2ZI;1"?S&R(WG960#. I!
MY'?KUK6\<FWNM)\;ZA8;KBXLF17O;AP&LY45"([? W#KDG(&6/WN: /7Z*\T
MU?2;37?B=I5I?F>6VN]!F,\0G=5?YXQT!XZYXQR*@M]*B\3ZEXI\/S7-I#)I
M[I:VJ7$#2S6L'DIY<D;&0$'=N;=U)ZD\"@#U*BO+M9M]3M$L[]88/%^G6^E1
MPW<+'9< 9;_28@<@EP#G!R=@P:[[P]=6EYX9TRZL7D:SDM(VA:488IM&-WOC
MK0!IT5XWOA$7@_6-++M#=>(!&-2G<?:KQ)#+NWX ^3C !). O Q5UM"L-4\1
M_$>"]66>&!+=XD>=R$8VV[<.>N3D>G;% 'J]<[X?\07>JZ_XATVZMH(1I<\4
M2&)RV\/&'R20/4<8_.N*T75I=7NOA_I.K2&6TN]%-VZRG(NYU10 ^?O8!9L'
MO@]A6UX%LK?3_&GCFUM(UB@2]MRL:]%S IP!V&2<#MTH [VBN \4:?!>?%+P
MM!,TQAN+2]$T8F95<*L> 0#T^8YQUSSD5RK:A-X?\)^(K&SEEM].A\5+9,RN
M1]EM7,1<*>JCYB/;=0![3533]2M-4ADFLY1+'',\)=>FY#M8#Z$$?A7%ZK81
MZ+\1O#46D6\<%IJD=U!J%K$H$4L:1AE<J.,@G&[J0V*7X2V%E:^%YY+>VABE
M.H7<99$ )59W ''8<4 =C</J0U6R6VBM6T\B3[4\CL)%.!LV #!R<YS5VN'\
M01A/BQX.=7D'FP7P=?,.T[8UQQG /S'GWKC)]&M)_!?Q&NY?/>?3]5O)+1VG
M<F%DCC967GKG'/7 Q0![715+3)Y)]$LYW.^5[='8_P!YBH->?>%;73/%/@C3
M/$.H7DD&K17?VBYO86"SK,LA!A)()VG(4)W!&!0!Z=17C?C62"7P_P"+]6TT
MM-/9:C&IU&X<"2VF1H@8H,#(5<\DD<LW!ZUM>.(KVVU34=3DTN'7=$^QK#=P
M1N%NM/P&+219X.0P)Q@Y4<\4 =./$%W_ ,+$_P"$<>V@6U.EM?).')=B)53!
M&  .3Z]JZ.O-7MM.\1?%+3]X:?3[CPMYJH25$B&="-P'48(.#6K\+F9?"<]K
MO=HK/4KNVA#L6*QI*P5<GG '% ':T5P5B+?Q'\0_%>F:W;QW$5A':I9V\PRJ
MQNA9G4>I;@L.1@#-<>/MM[X7\-PWUW=R"V\7#3X+CSV#36ZNZ@DYY/RXW=?E
MZT >VT50T?1;#0-/%AIL)AM@[.$,C/@L23RQ)ZGI7E5Z\#6NAZWI1:2.;Q1&
MBZI.X^TW :=D=!@<18RH!/(4?*.* /9**P?&VHWFE>!]:U#3L_:[>SDDB8#.
MTA?O?AU_"LG3=(T,#0/$.F7,B3FV98O)D'_$PWQYQ,<$N1M+9)R#DF@#M**\
M<0KJGP2E\5M*4\11)+=F_7B:.=)#\F>H7C9LZ8XQ6Q%IT>L?%,0ZK#(RW'AF
M*:YM6E;9YAF(8%<].!QTX% 'I=<[;^(+N3X@7?AV6V@2WBT]+R.97+,VZ0I@
MC  ^Z?7ZUY9/IT,7P;U35 \[7VD7\R:?.TS%K94NL*$YXXX]_P !CK]0T6PU
M[XOWEGJ4336Q\/Q%HA(R*W[]^NTC/T/'?L* .YU5M233V;2(K62\W)M6Z=E3
M;N&[) )SMSCWJ[7B-Y%<6_PKUZT:YN9;;2_$(M=/E>9B3 +B)=I.?F W.O.>
MGM75W^DVFI?&5K6\$LMK+X?,DD!F?8Y\\#D9QC&..G H ]#J"\O+?3[*>\NY
M5BMX$,DDC' 50,DFO*-$FMO^$*TO2KJ:ZEV^()[6SM%D&+A8Y)-L4C-G]T ,
MGK]T  \"JM[;@^#OB?I]Q#;^3:2F2"WC^:*!C K?(".,-SP!SS@4 >KW%SJ$
M\6G3Z7%;/#-*C7!N&92L!!)*X!RW3@\=:T:\TU^RM;*U\ &SC$ .KVRLD)*H
M=T3,<J."20#G&:M:+!:^+=>\96NNPK--:7HM8(WZV\'E@HT?]TL=S;ASG'H*
M /0:*\5TV2]UO3/AM/JUS<R7$UY<V[RB9U,T2I*%8X/4JH^;J<]:Z_P/;1:7
MXQ\9Z19J8M/MKBUDA@#$K&9(0SXSTR>: .[J&[N8K*SGNYB1%!&TCD=E49/Z
M"N.U>Y%[\5=,T'445]+;2IKJ*&09CGN!(JX8'AMJ9(!Z;LUB0VFR'XC:#)&)
MM&L$66RCE&Y87>W+NBYZ!3@@=MU '6:%K&NZN=+U V-I_8VHV8N0RN1-;%@&
M16!X?(/48P<_BY_$-[>^)-1T71[>T>738XFN7NIF3+2 LJJ%4GH,ECTST/-,
M^'EE:VGP_P! :VMXHFFTVVDE**!O8Q+DGU-97B/P?;>(]=N=6T#5Y]'\3:>5
M@DN8>5D!17594_B7##G^>,4 3:QXSU;3/!L^M-I$$-S!>BUEMY9RP4&41A@0
MHW9W CIP:[:O'-;UW5-=^$6N0ZU!%#J>G:M!87,EO_JY62XA^=?KN'Y=N@WA
M;6?AWXK.ML[VMI<Z#-<W9\QFW.DJXD.<Y8 GGK0!Z+17D&FJEKK7P_O+%&CM
M[UYU^U2R W-[&T+/OFP,<G# $L1QT/%7?#FA6EQJ7BZ_>*XN;K2]:EEL5:XD
M.QUA0CC=SG.,'/:@#U*BO*_#VEIK_AWPUXGCUVTM[N.2&6>[AM3Y\\A^62"1
MO,^;<QQC''& !Q2O)-HOB6)];TV*]T^[U@FRUVT8&6&1I2%AF!YV@_)D<  <
M9% 'J=%<[XZN+2W\&Z@;Z[N[6!U6(R69 E)9PH52>,L2%Y[$\BN8TJU:#XE:
MOIK6T%A:W&AQ3/9V<I"!O-==V0%^;'!( [=>M 'I-5[Z::WL)YK>-))HXRR)
M(Y56('0D X_*O%M+L8;?X=^ M>C:;^U#JEK$;EI6+&-Y65DZXVD'D=^O6NKT
MT6OBG5_&R:Q$DT]A<FTMX9.3;PB,%73^Z6;<VX<\#G@4 =9X0UJ7Q'X2TS6)
MXDBEO(!*T:$[5SV&:VJY'X7?\DP\._\ 7FO]:P=*M-.\9Z?XI_MFY:#4+359
MXC<JX2:QCC8>68V/W!M7.1P26]Z /3**\M\5+9:FWBTV^^^N+/2$,LEXP5+$
M^4[H81C=YC<,3QC"\\8J2[&LW>D>&]7MK&U\0K%H\9O=+N' D?S%4^=&3D%_
ME8<\]<=: .KU7Q!=Z?XT\/Z*MM UKJ@N-TQ<[U,4>[ 7&.<CG)[\5T=>4%M,
MUW5?AE]C^T_V;+;WJ*DK%9-JP!2K$'.<@@\\\^M;GP_2+3+_ ,7:;"?*T^RU
M3]Q&S?+"K1(Q ST&23CWH [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J
M:GI=CK-B]EJ-K'<VSD$QN.,@Y!'H0>A'(JW10!0T_1K'3'>2VB?S9%"O--*\
MLC*.BEW); R<#..36;I_@;PSI.LOJ]AH]O!?.Q8R)G"D]2JYVJ3SR .M=#10
M!ROQ(TV_UGP#JNEZ9:/=7EU&(XXU=5YW Y)8@8XK4TO1;"T:&\CLY8KA8O+4
M7$S2M"IQE%RS!1P.%XX'H*UJ* .:7X?>$UB$0T2V\L3BX5?FPD@.<J,_*,GH
M, ^E:<&@:9;:M<:I%;;;RX01S2>8QWJ.BD$XP.PQQ6E10!S"?#SPG&JHNC1>
M4LXN$B,CF-) <Y5"VU>O0 "NBFMXI[9[9U/E.NPJC%>/0$8(J6B@#"'@W05L
M;&Q6Q(MK"436L0GD A<=&7YN",G'ID^M7(-"TZVUB?5HH&6^G0)+,97)=1T!
M!.,#MZ5HT4 9^IZ'INL/!)?VJS26Y)@DW%6B)QDJP(*G@<CFH[3P[IEDUP\,
M,IFN4"2SR7$DDK*.B^8S%@!D\ ]ZU** ,$>#- &E6VEBP(L;64300">0+&X.
M01\W&#R/0YIMUX'\-7MS>W%SI,,LMZFRY+%OWG&,D9QNQ_%U]ZZ"B@#'A\*Z
M+;7]K?067EW-I%Y,#I*XV)W4#.,'J?4\FH-9\$>&O$&HQ:AJND07-W$-JRG*
MDKZ-@C</8Y%;]% &5=^'-+O+LW4MNZS& 6[-#/)%NB!)"$(P!'S'@^M:,$$5
MM;QV\$:10QJ$2-!A54#  '88J2B@#FE^'WA18A$-$MO+6<7*K\Q"29)RHS\H
MR3P, ^E74\+Z/'-J$R6KK)J*A;MEGD'F@# !^;L.!Z#CI6Q10!@W'@OP]=:3
M::9-IRM:6;!K5?,<- 1TV.#N7\#5G2_#6C:+=W-WIUA'!<76WSI026?  &22
M?3\3R>:U:* ,ZYT+3KO5[;59X&:^M05AE\UP8P>H !QSW]>]00^%M%@@U"!;
M%6AU%B]W'*[2+,QZE@Q.2>.?85L44 9NFZ!INE2"2T@?S%C\I7EF>5D3KL4N
M257@<# X'I1IN@:5H]Q=3Z?91V\MW(99F3/S,3DGVR>>,5I44 9UUH6G7NK6
MNJ7$#/>V@802^:X,8;AL ''/?U[U4'A#0Q9W]H+-OL^H.9+N/SY,3,>I;YN2
M>_K6Y10!#:6L-C:16MNI6&)0B*6+8 Z#))-8T/@GPU!K[ZY%I%NFHN_F-*,X
MW_W]N=N[_:QFM^B@#GKKP+X8OIK^6YT>"1[\YN<EL.?[V,X#?[0P?>IY/">B
M2.[?8V021+!(L4\B+)&!@*RJP##D\$'J?4UM44 9?_".Z7_:RZHML4O5@^SK
M*DKKMB_N  X"YYQCKS4FDZ)I^APRPZ= 8(Y9#*Z^8S N>2WS$\GOZUH44 9=
M_P"'M+U*_CO[BW87D<9B6XAF>&383G:60@E<\X/%,N_#&C7MK96TUBOD6+K)
M:QQNT:Q.OW64*1R.QZ\UKT4 (!@ #/'J<USC> /"K+*IT6W*RSBX9<M@29W9
M49^7GJ!@'O7244 ,\J/R?)\M?*V[=F/EQTQCTK$T7P7X<\.W<MUI.E06L\F0
M64D[03DA020H/HN!6]10!C+X4T1;N6Y6Q"M-,+B6(2.(GE!SO,6=A;(!SC.0
M#4[:!IK:RVL>0XU!H?(,XF<'R\YV\'&,\X]>>M:5% &#_P (9H!TB?238$Z?
M<2>;+;F>0J[$Y)(W=SR?4\U/=>&=)O+J"[EMY!=0Q>2EQ%<21R^7UVEU8,PS
MS@DUKT4 95YX:T>_TB/2;BQ0Z?&05MT)1!@Y'"D9P>?KS2_\(]IG]K#5?)D^
MWB#[.)_/DW>7UVYW=,\_7GK6I10!SS^!O#<FG_8'TQ6MA<?:E0ROE9N?G4[L
MJQR<D'GO4T'A#P];-?F'2;9/[0B\FZ 7B5-NW!'3D#G'7O6W10!A_P#"':#]
MEL;86&V&QD$MLJRN/+<=&!#9+ <9/..*FO?#.DW]^U]/:L+IX_*DEAF>(RI_
M=?81O'LV:UJ* ,NY\.:3=S6$LMH VG_\>GENR"'C'RA2 ../IQ3[/0M.T_4K
MO4;6!DN[S'VB0RNQDP,+D$XX' ]!6C10!GZIHFG:SY!OK?S'MW\R"5':.2)N
MF5=2&7CT/--_L'3/[+GTW[-BUN-QG42-NE+?>+MG<Q/<D\UI44 5--TVTTBQ
MBLK&,Q6T2A8XR[,$4< #).![53N?#&DW-_/?M;R17D^!+<6UQ)!)(   "R,"
M0 !QTK7HH QI_"FAW&C+I$FGH=/5_,\A790S9W;FP<L=W.3GGGK4K^'-*DU1
M-2DMFDO$A-N)7F=CY9ZH03@@]P>IY-:E% '-P> /"MLELD6BVX6VE\Z')9MC
M<],G[O)^7ISTK2TW0=-TBXNKBQ@:*6[?S)V,KMYC_P!XY)Y]ZTJ* .>L_ WA
MG3]<?6K31[>&_=BYE7. QZL%SM!Y/(&>35J+PQH\%QYR6K9^T&Z$;3.T8F)+
M%PA;:&R2<XZ\UKT4 4]4TNQUK39M.U*V2YM)QB2)QPW.1^H!S6;!X+\/6UTE
MU#ID<=RD!MQ,KMOV'MNSDGD\]?>MZB@#!_X0W0!I=KI@L2+*TE$UO")Y L3@
MY!7YN"#R/2G7O@_0=1U3^TKK3U>\,?E/*)'4R)_=< @./][-;E% %+2='T_0
MM.BT_2[6.UM(ONQIT'Y\D^YK-O/!/AK4-<&M76D6\NH#&93D;\="R@[6(P.H
M/05OT4 8E[X0\/ZCJ<VHWFEP374\7DS.V<2+C ##."0.A(R.U)#X0T.V2V2V
MLVMOLT/D1&WN)(F6/.=N58$C/K6Y10!D'POHWVC3YUL@DFG*4LS'(R" $8(4
M @#(X/KWJ)_!^@RVVI6\ECOBU/F\5II#YQ]3\W7@<CGBMRB@!D4200I#$H6-
M%"JH[ < 4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)0D<C(X..E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6#XD\'Z-XM6V75X9I!;%C'Y5P\6-V,YVD9Z#K6]10!P7_"G/!G
M_/E>?^#"?_XNC_A3G@S_ )\KS_P83_\ Q==[10!P7_"G/!G_ #Y7G_@PG_\
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M"68Y8A0?ER23\I%=-10!'!!%;01P01K'%&H5$48"@= *DHHH **** "BBB@
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M+,MM-L(8&,!E..&^;.>3^=166DZAJOC+Q-H,WB?7$L[*ULO)>.Y"2AF1\MN
M'<9..IZ]*ZV+PC8PZSI^J1W5Z)["W-M"&FW+Y9QE3N!)S@<DYXXQ7.:=IUS=
M?%'Q3<"35K"&>WM8XIXX"L<VU6#@,Z%202.1SR<'K0!C>'?%6L:E'X2T'4[N
M7S+NZOX+J\C8QO<+;9"@,.1N.,D<G:>>36G/<Z_8^)/$OAC2KV27?I27VG27
M4I=K>5F,?E^8V202,C<3CZ5U-SX-T:XTG3]/CADMDTZ02V<T#D2P./X@QSDG
M)SG.<G.:>WA6RDMK])I[J6XOPBW%X9 LS!/N@%0 H'. H'))ZG- '"_\)H-/
MT7Q)=11ZKI^M6-@C2:5J<KS")MQ7SD9B=Z989(X.T<<UT5II>O6WB#3M1@U*
M&/37A=+J&?4I;H7!*YC= R *01D[< CMQ6ROA:PDFN9K]I=1FN;7[%(]UMY@
MR24PJJ,$G).,GUX%4M!\!Z7X>;%O=ZG<1(K);PW=VTL=LI&"(U/ X.,\G&1G
MDT <]X4UFX3Q!IVD>(?[4L->$4FX2SM+::EA<EXCG:"/O;0!@'&.F-OQ/JTZ
M>+O#'AY)I(+?5'N'GDB<H["*/<$##D9)!)&#A<=ZT+#PI:64VG2275Y>?V:K
M+9BY=6\G*[200H+';QEB>#5G7/#]CK\5L+KS8YK683VUQ VV2%QW4_H000>X
MH YO3)+N#Q_K'A2:ZO)],>PBO[=WN'\VW)<HR"7._!*Y&3QR.E,^#UI'#\-]
M+G5YR\JR;@\SLHQ*_P!U2<+^ &:ZBTT*&S:[G2YN'OKL*)KURIE(484#"[0!
MDX 4#DGJ<TWPYX>M?#&D1:5837#VD.?*29@Q3)+'!P">2>N: .6T'3XA\7_%
MDOF76Y+>R< W,FW+++D%=V"/0'@=@*X_1/MFE?"WPUKEIJE]'-'JBQ>0DNV%
MHWNV1E9!PV02<G)'8BO5)/"]DWB*;78IKN"]FA6&7RIL(^W.UF7H2NXXSQ[5
MGK\/]*3PU;>'UNK\:?;3BXB3S%W!P^\?-MR1NR?_ *U &1<2ZMXJU?Q1I]G<
M&WDT^5;:V9-1EMVA)B5Q(512'RS'[QQA<8ZD]GH@O5T2S34KB"YODB"7$T'W
M'<<,1T[BL75? .EZIK8U@7>I65^T:Q3S6%VT!N4'02;>OU&#^0KH5LXX=/6R
MMBUM$D8CC,6,Q@# QD&@#SOQ5IT_C*'7XX])O;E5B-EIMS"\(6.6-MSN-TBL
M/WJJIP.D7'6MC1-1N?'?PQ6:&ZFLM5DMVADDB<QO#=)E3G';<,X]#72:-I$6
MB:5%IUO-/)#$"$:9@S@'WP,\Y.3DU1\/^%++PW=:A/97-VWV^=KFXCED#(TK
M')<  ;2?; ]N!0!YZ/%EP]KX.UO[1?+#;%8->A^TOLC+-Y(:09ZB56/N <YX
MKIM0GD.B2ZD=9NK./4M3B$"(SR-+#N"K%",_*90I;(Q@/V XVW\&Z))I>M:<
M;7%OK,KS7>#RSN "0>W3(]#S4NM^%].UW2K73YQ-!':2QS6KVTGEO Z<*5/;
M R/QH XRUO\ 5 WQ"L/M5_:I86T4]HLEQYLMN7@9B-Y+=U!QDXR<&JIN]1T7
MP+X?U@Z[J4U[KL>G6,CSS!X[?S "TJJ1P^W(R3R<$Y-=@O@32X[C5)TN=1$N
MJ0+!=L;HMO 4KGYL_-@D9[9XQ5B7P=I5SX13PQ=K+<Z='$L48D?YT5,;,, #
ME<#!Z\4 <Y+IL>G?&/0O*GNI$DTJZ^6XN'FVD-'R"Y)&>,C../K6IXHU:=/%
MOA?P\DLD%OJDEP\\D3E'98H]P0,.5R2"2,'"X[U8L_!-C;:O8ZK-J&JWE[91
M-#%)<W1.5;&0P  /0?7OFM'7/#]CK\5N+KS(YK683VUQ"VV2&0?Q*?T(((/<
M4 <WILEW;_$#5_"DMU>3Z7)I\6H0,]PYEMR7*,@DSOP2N1D\<CI4?P?M(X?A
MQIDZO.7E$NX/,[*,2O\ =4G"_@!FNIM-"ALWNYUN;A[Z["K->R%3*0H(4#"[
M0!DX 4#DGJ:;X<\/6OA?2(]+L9KA[2+/EI,P8IDEC@X!.23US0!Q&NMJJ?&H
MOHRVKWR^%W:..Y!V.1<<+D$8R<<U/\/9;.#PMK?B5'FN-9NI))M4BE4(T5Q&
MIS#M'W0O;J2#FNI;PM:MXL7Q(;J\_M!8/LP^==GD[MVS;MZ9YSU]Z=%X6L+;
MQ'<ZY:O<6US=JJW4<3CRI]O +(01G'&1@T <EI$/B/5],\-^(K74X83*8I[U
MY-1E>*XB<?/&(2FQ&R<+CH1C)ZTR/6;FP\516'B(ZG9S7&IM]@U"*=WLKN,N
M=D+*#M1MN%P1R5SGDYW](^'>BZ'J'VBRFU%;593-'IS7;&UBDSG<L?3(/(SD
M \CH*NIX1LMT:S75Y<6L5X;V.UF=6C67<7!!V[L!CD#=@>E '$:-8FUL_B1<
MVM[?P7%O>W'E2+=.Q!$",#AB03GN1G' -%S;:G:_!^?Q(OB366U";0H9CFX^
M1'$8;<HQD$YP2#DXSUKLW\%Z:USK$T<][#_:P/VF..?Y,E0C,%((#%1C/Y8J
M63PE8S>$!X8>XNSIP@%O]]=_E 8";L=, #/7WH QDU*75/&6G^';BYGBMET1
M;]A%,T;SR,X3EU(;"@$X!Y+<]*Q/%6BS6FG^$K._UJZU*:+Q)!#Y_FO&XC;<
MRJVUN7 V_.?F[\9KJ]6\#:9K$>FM+<W\%[IR[+:_M9_*G5<8*E@,$$>W\S4]
MYX.TN]T6UTQVND2UN%NXIUG;SA,I)\PN<DL<G)/K0!S\\FHZ]XB\0Z%:321I
MI<4$,!&IS6\B%XM_FDJI+G)Q\Q(^3IR<LL;_ %:Y\3Z+X2UG4EDEATJ2\O;B
MRE:/[5(LOE*NX888^8L!CGV&*V=5\ :3JFIV^II<ZE87\,(@:YL;QHI)HQT5
MVY+?7K[U/J7@G2=0.FR1M<V-UIH*VMU9R[)44]5).=P/?<#GGU- &-\.[;['
MK'C.W$LLH36" \SEVQY4> 6/)QTR>>.:/$WA74+WQ!)XA\(ZRMAKT$:P7,,H
MW07*@;E60=C@\,,_AUKHM#\+V'A^ZU"YM);N2:_E\V=IYV?+8 S@\=A_^JBX
M\-0R:M<:I;:A?V5Y<*J2O!(I5E484;'5EXYYQGD\T >:^)M>E\3?"3Q2NIZ<
M^F:SILZ17T$,K!&D!0!@0?F4KC@YZ#KP:ZZXN6;X@:?X2%Q=Q6"Z7)J#L+J3
MS)W\T(JF3=OP 6. ?3L,5JOX,T>7P]J&C3)-+!J+-)=RO(3+,YQ\Y;UX&,<#
M  &*6X\(6%Q_9TOVF^2_T\L;>_$VZ<;AA@Q8$,#W!!'H!0!PUWXIU;0)/$>A
MM>RO#::I8VUM?S'>\$-S@MEC]XH,X+9/(SFNPN-&FTRYU*XCUFY>QGTYT&GW
M$C3$2KG,JN[$@8(!4<=ZN3>$-'N]&U#2[R!KJ+46\R\DF;+S/QAB1C!&U<8P
M!@8 J#3/!EGIEC<6RZCJER\T)@^T7=T9I(XS_ A884?09.!Z# !Q?PRU%=;T
M[1M(N9[NP;2]-AEBM4E:,WJ.H_>Y4_,@/RX['KUQ78?$=2WPU\1A1D_V?,?R
M4FFQ^ -*ABT58;F^B?1@RV4R2*'12 "I.WYEP.A_'-=-+!'<6[V\Z++%(A1U
M< AP1@@CWH S?"S*_A'164@J;" @CN/+6N$U&>^M_!G@E[#4;FS^TZK:PN8&
M #QR,QYXY'3CIZ@UU=KX*MK*Q&G6VKZO'I:C:MDMPNQ4_N!]OF!>V _2KFK>
M%['5[?3;=WFMX=.GCN+:.V*J$>/[AQ@\#TZ4 <_H:7=IX_\ $&@?VKJ$]FUC
M;W49N)S(\+LSJVQFS@':#CH.V*X\O/K?PO\  5[J-Y=SW4NMVZR2FX=6?,[#
M)P1D@ 8/4=L5Z>GAJWCU^ZUM+R\6]N8%MW;<FT(N2N!MX())S[U13P#I$?A6
MU\.K+>"SM)UN+9Q-B6%U;<"K =B3USUH Y[QA?WFA7]W]O75QX?:T2&#4M/N
M9&;3Y #N>90VYNJG<<] .]>C6\T=Q;130R"2*1 Z.IR&!&016'/X2M9Q=I]O
MU%(+V$0W,(F#+*H7;R6!8$C@L""?7@89'X<,'B^UU.TFNX+6"S^S-;^?^X91
M]Q5C[$=2Q] !G)P 87Q:W_V+H/E[0_\ ;]GMW=,[CC-:#>%[J3QA_P );J^H
M6R265D]O:10QD1P@Y+2.S'YCR>. !6KXB\,6?B>*UBOI[I([6=+F-8'"XD7.
MUB<$G&>G3VK4FM([FQDL[G,\4L9BDWX&]2,'.,=1Z4 >::9J.H0>(O!/E:AJ
M%S;ZDMPES=7$K".^Q"9!(D3,=@W#(X7@],5;\+Z9>Z[JGB WWB'63%IVN2Q0
MQ177EAD\M/D; SM^;@#&",C!)K9M?ASH]J-*Q=:I(=*<FT,EXQ,:E2NP8_AP
M<<<XXSBM;1/#EMH5QJ$]M<74C7\YN9Q,RD&0@ L, 8X &!QQ0!YAI23Z;^SU
M>ZCI]_?6UVB7+B1+ER05N) ,9)VY[E<$^M=D=1DU3QQ;^';BYGBMH]&6^*PS
M-$\[L^S)92&PH'0'DMST%6U^'^D)X>OM"2:^73KQF+P_:,A%9BQ1,@[5+$GC
MGWJ36/ ^FZR=/FFNK^WOM/79!?VL_E3A#U4L!@@_3^9H Y[Q#'JV@>'M MSX
MCNKNXCUVVMY9E(1I(GE&(Y,$DX4@9SSWZT^2RO\ 6_B-XBT>7Q!JUM8QV5M,
MB6LXC9&8O]T@<#CZGC)QP>CO?!NFWNEV.G-+=QPV=PMTC++EWF5MP=V8$L=V
M3SU)YKGK73[FY^*^MW DU6SB>PMX8[J.W*QRLI?>-SH4)&5Y'X'K0!F:!K&I
MWVBZ58ZKJ]U-=6VJW=BT5L"L^IK"& (<,NT+P6;(!V\GGFC>ZQK2?"WQ9,-3
MO8+K2]:DMK>03EI$C$L8"&0_,V Y&<Y]Z[ZX\"Z--#I*0&ZLWTIG:VFMIRD@
MW_ZS<W.[=U)/)-5I/AQHDFEZIIHFU!;34[G[3<I]I+9?(/!;)&2JDGJ<<G%
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MI=6L[)/"3U(?DDGOG.3R>:UM'TBWT6Q^S027$Q+;Y)[F4RRRMP-S,>2< #V
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M2[O;FWLI_M%M!.ZLL4G.&!VACC<< D@>G Q7_P"$%T[^R=7TPW=\;;5YWGO
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MME%16]NEK;I#&9"B=#)(TC?BS$D_B:EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@$$$9!Z@TM4M6GO[;2YYM
M,LDO;U0/*MWF$0<Y&?F(..,G\* ,^/P=H46AV&C)8J+&QG2YMX_[LBOO!_,G
M/U-6-;\/V>OBS%ZTX%G<)=0^5)LQ*OW6/KCGCI6J,X&>#10!D#P[9KXC?7A+
M<"_>W%J7\SY?+!R%VXQU).>M.T+P_9>';::WL6F\J:9IV$LA?YV.6()]3S5Z
MSO;>_@,]K*LL0D>/<O3<C%6'X,I'X5/0!BW?ABRN=9?5XI[NTOI(1!-);3%?
M-C&2 P.1QDX( (SUJ'4_!6@ZKX?AT2>RVV5NPD@\IRKQ.,D.K YW9))/?)SG
M-=!10!EZ'H-IH%HT-L]S,[G=)/=SM-+(1P-SL2>!T'050UOP3I&NZK!JLS7E
MKJ$4?E?:;&Z>!WCSG8Q4C(K9U*:\@TVYEL+5;J[2,F&!I/+$C=@6[?6IX6D>
M"-I4$<I4%T#;@IQR,]_K0!CWOA32KV'3E$3VTFFG-E/;N4D@XP0#W!'!!R#W
MIESX1TN[T>_TV<3O'J+;KV4RGS)S@#YF], # P !@8%;U'2@#$?PM8RZCI5_
M)-=-<:6C):L9?NAAM;(Q\V0 .?2F6GA+3[4V2F6ZG@L9/.M8)Y=Z0O@C<.,G
M 8X!) SP!Q6O9WEOJ%G%=VDJRV\J[HY%Z,/45/0!S\7@W1T@U>WEBEN(-7<R
M7L<\A99&( S_ +)P!TQC ]*JVOP_TBVN-,G:XU.XDTPL;0S7TC>4"-N!R.,<
M>XX.:MZCXBEL/&.BZ$;)6BU-)W%SYO*&)0Q&W'?<.<^M;] '*CX>: NNSZK&
MEW$UQ+YUQ:Q73K;SR==SQ@X8YYYX/I6I:>';.R\07NMQ/<?;+U42?=)E6"9"
MC;T&,G&/6IKO54@U.VTR%!->SJ9=F[ CB4@,['L,D #N3Z D.@N-1?4;^*:P
MCCM(@GV6<3AC/E<ME<?)@\=\]: ,-OAYH!UV?542[B:YD\VYMHKITM[A_P"\
M\8.&]P>#W!JU=^#=+NM??6E:\M;V:,1W#6ERT0N%'0. ><= >#[T]M<O-/T.
MVU+6]/2S&/\ 35CG$HM<G ;.!N4=2>PYY -;H((!!R#0!E^'] L/#.C0:5IJ
MRK:PYV"65I",G)Y)XY[# JO'X2TB/4M3O?)D8ZD,74#RL89"5V$^7G;DKP3C
M^9J#Q+XK31/"VJ:U8P)?_P!G%EEC\W8-RXW#=@\C/\ZWX)/.MXY<8WJ&QZ9%
M '.:#X#T?PY*7L'OB$5EMXY[MY4M0>OE*Q(4^^,_F:M:=X3T[2]#NM'M9+I;
M.Y+EU:8LP+DE\,>1G)_/C%;M% '.-X)TIM,TG3O,NQ;:3*DUFHF.8V080YZG
M )X.:M)X:LX]<N]92>Z6^NH1!*XEXV#.T 8P,9//6H=2\12Z?XPT30_L2O%J
MBSD7/FX*&)-Q&W'.<CG/K6_0!S"> M&BT73M(C:[6RTVX6YM4$YS'(I+*<]3
M@DG!R.?I4]WX-TG4+^_O+P3SR7]I]BN5>4[7AYPN!TP23D8.>];,=[;RWTUD
MDJM<0(DDB#JJONVY^NUORJ>@#F+3P'HUG>Z;>A[^6YTY&C@EFO)'.PX^5LGE
M1M&!TJ6/P/H*6NJVC6TDMIJ;O)<6\LSM&"YW,44G"9;GCG('H*G\6:^WA?PY
M=ZU]D^U16B[Y8Q)L;;D#C@@]?:LU/''V75-(L=9TN6P_M?BSN%E66-GP"$8C
M!5CD8XP?6@"WH?@G2-!@EAB-W=K)$8/].N6GV1'K&H8X53W ZX&<X%48OAKH
M,5K:V@DU)K2SN5N;6W-])L@=22-F#D $^N1V/6NPHH SM;T.P\0Z-/I.HQ-)
M:3 !@'(8$$$$$<@@@'/M64G@31A?&^<WTUT]FUE)+->2.98SG[V3R>3C/3MT
M%;B7T5P;R.T9)I[5O+DCW8P^T,%)[<,OYTFF37EQIEO-J%HMI>.@,T"2^8(V
M[@,.M %*R\.6EG>6UT\UU=36D30VS7,F\PHV-P!QDD[5Y;)XZ]:EUK0+#7H8
M%O$<26THGMYXG*20R#HRL.GTZ'N*GU6>^MM+N)M-LTO+Q%S%;O*(A(?3<0<5
M;4L4!88;'(!S@T 9EMH-M:I>,DMPUU> "XNV?,K@# &<8  S@  #)/4DTN@:
M#9^&])BTO3S,+.$$11ROOV DD@$\]3WK3HH QIO#.GS>(&UP&XBOFA$#M%.R
MJX4DJ67.UBI)QD&J \ Z,/#BZ &O/[-6;SQ%YYSOW[\[NOW_ )NO6NHJ""]M
M[F>Y@AE5Y+9Q',H_@8J& /OA@?QH Y_5O 6C:QJ\>K2M?6]^(Q%+/9W3P-.@
M_AD*$9'Y5T=O;PVMM%;P1K'#$@1$48"J!@ 5)10!QTGPR\/26-WIX^WQZ;<R
MB9K&.\=84?<&)50?ER1TZ>F*MW7@/0[N_O;N1;P-?6XM[N-;N0).H7:I<9^8
MA>,FNFHH YMO VBM::1;XNQ_9.1:RK=R"0*5VLI8')!  QZ  8%17WP]T&_U
MV75RMW;W$X NDM;IX8[D#@"15(#<?GWKH-0ENH-.N9;&V6YNTC9H8&DV"1\<
M*6[9/>I;=I7MHGGB$4S(#)&&W!&QR,]\'O0 X(@C$84! -H4#C'I7+)\/-"C
MT6+2$^VK8Q3K/'']J<[&5MR $GA5)) ''KFNKHH PKCPGIMWJ\VIW7GS7$]D
M;"4/)\CP'DH5'')).>M4;7X>:':/I;JU_(^ED_9&EO9&**5V[.OW,<;>A[YK
MJZ* ,C3?#>G:3JE_J%FLZ2WTIFF0S,8_,.-S!"< G R?:EO_  ]9ZCK6G:M.
M\XNM.W_9BDF%7>,-D=\CCFM:B@#!3PGIZR('ENIK=+LWJ6TLNZ-9BQ?<.,\,
M20N=H/:K^M:/9:_H]SI6HQ&2TN5VR*&*GKD$$="" ?PI_P!O2>&^^P;+FXM&
M:(Q;]H\T(&"%NWWEY[9J2PENIM/MY;VW6VNGC5IH5DWB-R.5#=\'O0!DCPEI
MXU'3=0,UZ]UIRNMO))<,YP_W]V<[BV!G/IQBHQX)T5K+5[.XAEN;;5Y#->1S
MR%@[G'S#^Z>!TQC KHJ* ,'P[X2T[PT&-I+>W$A7RUDO+IYFC3^XFX_*O3@=
M<#/04[Q)X2TKQ3';?V@DR3VKF2VN;:4Q30L>NUAR,UN57U"^@TS3KJ_NF*V]
MM$\TK 9PJ@D_H* ,.X\#:-<Z99V3"[5K2X^U172W3_:/-Q@N9,[B2.#GMCT%
M0O\ #W07BU6+;>"/50HNU^UN?,P .Y/)P,GJ?6K6CZUJ^HW=JT^C)%IMW9BY
MBNH[D.4)P1&ZD @X.<C(X/UK9AO;>XN;BWAE5Y;9E691_ 2 P!]\$'\: ,S4
M_"]AK'A]-$O7N9+)=F0)2&;805RPY."!^5.F\.6=QKMEK,LMRU[91M%"_F8
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M.=.$CB.1U9R2 >2!T!'%=6?A_P"&W\-GP_)8O+IVX,B2W$CM&1]W8Q8E<9.
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MCN)^8YY/4\9Z5C37DT:^&]5TZ^N[I+GQ$L#ZI),4-U&\D@,:Q@D&, ;1G'W
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MK>HT1G=D;8B;25)QN^8\]3GF@#H_%>LS^'O"^H:Q;VL=T]G"TQB>4Q@@#)Y
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ML^&#(IR=N!C(Z]. 9_%&G:3K&A2Z7K2[K*\=(#S@AV8;"#V.[&/>N(LSXF\
M>(='TC4;\:[X=U&Y^R6L\Z_Z5:R%3M#'^)< C/IGIT(!ZA7/S>(;B'QY:>'F
MLX_(N+*2Z6Y$I+91E7;MQQ][KDUPI=U\ _$L>=*#9ZE>_9CYAS#MA0KL.<J
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M<KPM(H[-L(W#V-7I/#.DR:M9:F;9UNK&/RK9HYY$6), %0@8+C '&.PK7HH
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M.[0Q.<G<D9.U3DDC XSQBMVBJ4#ZD=6NTGAMETY40VTB.3(S<[PPQ@ <8P:
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MDTBXB'1  V !U'H>>M5SX*\.MH$FA/ID<FF2.9#;R.S ,3DL"3E3DDY!'4T
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MJMIJ<UNQO+-2MO(LKKY0(P0 #C!'!XY[T 3VVEVMGH\6EP"1;6*$0H/-;<%
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MYWX(^4D*#R."1WK(U'PS;:9;^)+F+4H%2^T:5SI]C 8(=R+Q, '.&YQVS^%
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MB2 -IZ[,J+P?(8CZ(VY7]!AJ /3Z3(QG(Q7FFJ^&]/T[QIX!TJ-&-NL%[#(
MY42A81RP![DDGUR<]:R[?PUI$MI\0].>S5K+3YG>SMRQ\NV9K=7+(N<*=W.1
MT[4 >P$@#)Z45Y18:E-J=WX*TW4[FU,-[X?6>,7\)FCN;G$><C<H+A<D9S]X
M]S4&O>'H-'\/Z7IZ:I)=I%XJM@@CW1+:K(ZDPIAC\JYR.<C/M0!ZZSJJLS,
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MA;1;W<V\6A8QXW';C=SG;C/OFN*M-)T^R^--U!:6L5O%/X=#21PC8I/V@@G
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M%Y18PIO8I"6Z^6A)5,Y/W0.M9]K!K&M:]'<:SI$%C::9/(]IBY$S7#D%%DX
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MBO+FVS=0J42XBD:*0*>J[D(.T^F<4V]\.:/J&D)I-S81/IR  6HRL>!R!M&
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ML$8;)8J@Z*"<X7V'% %'Q9<W*:1_9]@P&H:D_P!DMR6V[202[YP<;4#MG!Y
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MO2YM!TJXNK2ZEL(&GLQMMGVX,(QC"?W>..*C7PWHR->LNG0AKX8NB!S/_O\
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MJ_O'5[9MRENI' &.@  %2P1:9XGM/%6G:_K4-C=PZG-]H$BQK-%&KYA=&;D
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MM9^A7=O?^'M-O+1)$MI[6*2)9!\P4J" ??%:% !1110 4444 %%%% !1110
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M5Q=2VL%Y;RW$7^LB256=/J <BD;4]/1D5KZV5GD,2 RJ"SCJHYY/MUH K?\
M".Z)_H?_ !*+'_0ABU_T=?W _P!CCY?PI+CPWHEWJ\6K7&DV4NHQ8V7+P*9%
MQT^;&>.WI5N]O;:Q@,ES=V]JI^57G<*N[MU(S],US_@C7[O6M O+W59K?S(+
MZY@,D2[(]D;E0>2<# SR30!M2Z5IW]H?VK_9MO)J*)M6<1+YN/[H8_XXKE_
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MMUJ-E8M&MW>6]NTAP@EE5"Q]LGF@"2*V@ADFDBB1'G</*RK@NVT+D^IPH'T
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M]E_NEL9(]JGGU&RMKF*VN+RWBGF_U<4DJJS_ $!.34TLL<$32RR+'&HRS.<
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M#MVZU)XU\0'0?#6I7-G>V46I06LEQ##<88OM4G 7<">G7^= '1JH50J@!0,
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MM9CF6"*W14?_ 'E P?QH \GLK"RM/ WPPU""WACO'U2R1KA5'F,&1PRENI!
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MXY%T>[$LWAEIL8B#',D>,9#$89<\[3C@DBE9VM-7^* T[RTU41QFS5,"3?\
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M #@"N.TSPDS^,O$>J:QI5C/;:B\+6QDVRL@2,(0P*\9(!X)H X;PW?SZ78>
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MIJLZMJUG?+-)#YNRY^W!SDD AB22<YXP>>!QZ0VE:<VH#4&L+4WH&!<F%?,
M]-V,U''H>DPZJ^J1Z79)J#C#W2P*)6^K8S0!YE$=&UY/&&B^)M=-A<#4IO/A
MD,*.800870NI; 0+C!XQ[\^HVL$<FD06\OF31- J-]I&7<;<'>/4]_QJ*YT+
M2+W4(=0NM+LI[V''E7$L"M(F.F&(R*T* /$9K+4%\.7?ABQ@#ZAX.OFU"VE=
M,[H4_>0*#_>=79?^V9]16]XEO[K4_AAX@\5Z5%*LVH6\8A*C$JV:L WYAIGS
MZ,/2O3%@A26258D623 =PHRV.F3WQ1#!#;VZ6\,21P1H$2-% 55 P !V&.U
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M8890P 1#[K&$4^X- &C>ZC8Z;$);Z\M[6,G >>54!/U)I9+ZSBLQ>274"6I
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MTO"L>9;^/;'%)S]X<D ?C7"_#C1=&F^'ANY-.LI)DEOE\UXE9E7SI!@$C@8
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M&J64,-S_ *B22X15E_W23\W4=*EFU.PMIT@GOK:*9T,B1R2JK,HZL 3R!ZT
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MX#<?Z\Q0*OF_[V!S^-<M\1O%G]@^%-2ETO6+.WU:W52L;E'?)(XVD]<'/(/
MZ5OF=F\3P1#6H%7[(Q?2]J&1SN7$N<[@!G&,8YH N0Z5IUO;R6\-A:QP2_ZR
M-(5"O]0!@T#2]/6Q>Q6PM1:/]Z 0KY;?5<8-,;6]*34%L&U*T%XS;5@,R[RV
M,XVYSG'.*SM/\8Z+J6MZEI5O?6YFL-JR$RJ-S8)8 =PH R?<^E &Q:65II\
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MDWEV]I;:G9S7,:EVBCG5F"@X)P#TSWH ?%I6G07TM]#86L=Y*,27"0J)'^K
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MEQ1)''DG:B@#GKQ0!Y2VH:E!XI@\0:?%*EMXPM_LD"^7@P2(/W$S^N4\QOH
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M4RJS1L&##R7R PZC.!]:[Z.UMXH6AC@B2)L[D5 %.>N13&T^R81AK.W(C&U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %(0&!! (/!!I:* (DM;>*$0QP1)$.B*@"_E1]F@./W,?'3Y1Q4M
M% &+XGT>36/#.IZ;9K;QSWUM);^9)P%#J06X!)Z]*GT'3?[,TBU@EAMUNHX$
MBEDA'$A50,YP#V[UIT4 ,6&)&+)&BL>I"@&FQVT$,CO%#'&\AR[*@!8^_K4M
M% '/:5I.L_VJ]_KVH6MT83(EE';0&-8T8CYFR3E\ #C&!GKFMYH8F<.T:%A_
M$5&:?10!%]F@ (\F/!Z_**)+:WEA\F2")XO[C("OY5+10 QH8G #1(P48&5!
MQ0L,2OO6- W]X*,T^B@!J(D:[4557KA1@4UH(69F:)"SKM8E1DCT/M4E% '*
MZOH6N2:^VHZ;=:;/;R6Z0&RU&!F6+:2=T;*>,Y&01SM'/ QH:-H$=@;BXN8[
M-KNYV^;]FMQ%$ H. %R23R<DG)]@ !M44 ,>&*2$PO&C1$8*%001Z8I4CCCB
M$:(JQ@8"@8 'IBG44 11VMO%#Y,<$219SL5 %_*C[- 0 88\#I\HXJ6B@!BP
MQ*Y=8T#'JP49IJ6T$1D,<$:&4YDVH!O/OZU+10!%]F@QCR8\>FP4_P M RL$
M4,HPIQT'H*=10!1TS3(=,CF$6#)<2F:9@H4,^ O '  "J![#G)R:MF&(OO,:
M;_[VT9I]% $:011MN2)%/JJ@4KQ1R;?,16VG<NX9P?44^B@",V\)!!AC()+'
M*CKZU%=6S&UF^QB"*[,;"&1X]P1\84D#&0#CC-6:* ,3P_I>HV@EO=;O(+O5
M9U2.22WB,<:(F=JJ"2>K,23U+=@ *LC25EUQ=5NF$DT,;0VJ <0JQ&X^[-@9
M/8# [DZ5% #4C2,L415+G<V!C)]33J** "BBB@ HHHH **** "BBB@ HHHH
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M9AIM_;W30;?-6)P2FX97([ CD'O3K+6M*U&[N+2RU*TN;FV.)XH9E=XCG'S
M'(Z=Z +U%%% !1110 4444 %%4;O6M*L+ZVLKS4K2WN[DA8()9E5Y23@!03D
M\\<5>H ***J:EJ=CH]C)?:E=PVEK'C?+,X51DX')]S0!;HIL<B31)+$ZO&X#
M*RG(8'H0:=0 4444 %%%% !115+^U]-_MC^R/MUO_:/E>=]E\P>9LSC=MZXH
M NT53U+5M.T:W%QJ=_;64!.T27$JQKGTR3BK,4L=Q"DT,BR12*'1T.0P/((/
M<4 /HHHH **,C.,\T4 %%%9=MXDT2]U+^SK;5;2:\PQ$*2@LVTX;'K@]<=*
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M02HWFW*[E5F#AL)]X$#:?>M*7X>ZBGC;PKK%O>6[VN@V2V969F\R<!&4MP"
M?FSCGI5"?X5:A%H?B'PWIUY:)I&M7J77G2%O-MAN5F0(!A_N@ [A0!;U;XB:
MH/%?A;3=%M[&6S\06@N(WN5<-&"I()(.#Q@XQ[9[U2TWXHZP_@WQ?J%YIUK/
MJ7A^Y:#;;!ECE^;:&()) &"3ST':M2_^'EV?&/A34].FMH]/\/VRVRPRLWF2
M* 5ZA< @?G[5'X9\"Z_X=C\3/'>:<;C5[U;N,D.R)^\+,C@@9!4D<4 ;/@7Q
M3+XKMIKQ+VPO;+RHBDEM$T3I(=WF)(C.Q4C"XYP<]ZH^//&>J>#M;T ^59MH
MFH7*VUS/(C%X&)'.0P&",GIQM/6G^"_ 2^&/$>MZPD5K91ZB(U2PLY&>*+;U
M;+*O4DX &!6GX^\))XU\(W6C&18I79)(96&1&ZG.?RR/QH Y.P^)6JS^*_$>
M@7,5BDUG"TFF.L+@79WA%ZOW)4<=<DYXJ6ZU,P_'?1M+N],TR>[DTMI!J"1.
MLL8Q)E1ER,94]LX8CZ[-W\/+&;QIX<UV':D>CVK6YB/60 ?NO^^26/UQ4.H>
M#=3NOBUI_C".:T%K:6AM?(9V#N"'^;.W YDZ>W7F@#R[2O\ DGOQ8_Z_Y/\
MT,U[%\-O^2:>'/\ KPB_]!KD;/X8ZW;>&O%^E-=Z>SZ_.9DD#/B'+$D$;>?T
MKO?".D7.@>$],TB[>)YK.!82\1)5MO /(% '!^+?B5KWAZVU>].G6UG'87RP
M6]K>Q-OOX<X,L;AQQS_=(&1R3P-#Q'X]UC3_ !1X5TS3+6Q>'7H]P-R'W1'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %5;[3+#4XT2_LK>Z1#N03Q*X4^HR.#5JB@"K9:;8Z:KK8V5O;!SEA#&$
MW'WQUJ#4- T?5KF&YU'2K*[G@_U4D\"NT?.?E)''/I6C10 @    P!TI:**
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M]=O6@"Q14+7ELDQB>XA60#)0N <8ST^E)%>6L]M]IAN89+?!/FHX*X'7D<4
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MSP9<Z<EQ\7I[B\DM]/-RY:XM"-ZH6GY0CC//%96B:A"WQ!^'$MI-$EN+-X4
ME5IO* <#SBN!N/\ =QQTR3S7:0:/X\MC>&#P;X(B^VJ5NMF\><#U#_WAR>M,
MCT'QO"+,1^"? R"R8O;;0P\ICU*\<'@<^U &)/X6U;4;;XBZ1#;KJ][J6HQ"
M&]21-D>&#['9B"I12. #Z"K&N"X\-_$7P!HES<65O86^GLJ22P?Z,UV596?8
M"HR3MQSP7SWK!U3X2>,-6UF]U*\T+1FN;V=IW>&_DC5"?0?7GOR:Z:V\,?$/
M_A&;'0M5T#POK,%F"(Y-0F>1^IQSVP#CCL* .]\ Z$?#>@3:6-734HXKN0QO
M'%L6$-AO+ W-P"3W[X[5YSX3C?PS^T3XAMM5/EG5XY9+*5^!*&=7"J>_ (^J
MXKIK1_BCI]I%:6?A[PG;V\2[8XHII%51Z #@56U6S^(VN0+#JOA7P=>1H=R"
M>21]I]1GH?<4 >ERWMO#=06KS(+B?=Y49/S-@9)QZ#U]QZBOFU9;F7X(^*-3
MORPUX>(59YCQ*DP,7 /4$9;'IS7H^G6?Q&TC>=/\,>$;=G #NDTNY@.@+=34
M,FD^/YM0^WR>$?!CW1D$ID+R9+C@.?5AV/44 9&MVO\ :?QJ\ QZS;1R33Z1
MF[BD089_+E)##O\ -VK+\(:3_;/PY\=Z%%?IIZ2:P(K=FR(U8N@5#CHK$*OX
MUU]QIWQ"N]4CU.X\)>#);^( 1W+NYD0#IANHZFH(="\<6]K<6L/@KP/';W)4
MSQ+N"RD'(W#H<'GF@#EY]?\ $$?@3QU97VEBP\3V$-K%>7-J HGB+8WD+P&V
M%OF'48Z8KL?!>DP7EUH'B*UURP,$FBBR.GVUMM\U%7/SG>>48X)Q[<9HL[/X
MC:?!/!:^%_"$4=P<SJ)9/WO&/F_O<<<]N*KZ9HGCO1DN$TSP=X*M%N1MF$+.
MOF#T..WMTH \CCL;5/@$^IK!&+Y-?")<;?WBJ(P<!NH'? KU#QC:6<WQV\%F
MZM[=XI[20S>:BE9"$?&[/7''7VJ;_A&O&7V+[%_P@O@3[)YGF^1M;9OQC=MQ
MC..,U;O--^(.HK:+>^$?!=R+3_CW$S._E=/NYZ=!^0H [W3_ !-H=_K=WH5C
M?127]E&K36Z _(IQC!Q@]1T/&16Q69IND6MO.VJ2:=9P:Q=0H+R:!!EV &1N
MZD ^OH*TZ .!^(Q']N>!O^P]'_Z U3_%50_A&!&) ;4[,'!(/^O7H1TKI[_0
MM)U6>&?4--M;J6 [HGFB#F,^JD]#]*??Z/INJP1P:A8V]U#&P9$GC#JI'0@'
MO0!Y[>VBZ#\1=:C\/VD5M+)X5>X6&WC"B2=96",0.K<XSUJ/P[9:)K6F>$]:
MAUV);FV>,QK;1HLTDC#$D4AY9L\EL^A;WKT1-$TN/4EU)-/MA?+'Y8N!&/,"
M?W=W7'M4%GX8T'3M5EU2RT>RM[Z;.^XB@57.>O('?OZT <U\7(()?! DE5<Q
MWUH5?H4S.@)![<$UFZCHVG>%_B;HUWH\ LH)].O6U5+8$!HHU4K(P'5M[?>Z
MDUT/Q#T:^\0>%SIEA:+<R27,$C*[JJ[4D5R#GKD BMVPTJPLE:2VL([=Y4"R
M9 +;1T4GG@9/&<#G% 'E6GO:P:G\-[JS\BVLI6N#"'<-</"T#,6F<8!)."1C
M@]S6QX-\+Z%?ZYXK>[TNVF-IKSM;AT!$1\J,_*.@SGGUP,]!790>#_#5JL:P
M:#IL:Q3?:$"VR#;)V8<=1FKECHNF:9//-8:?;6TMP=TSPQA3(?5B.I^M 'C]
MO8Z<?V==5/V:V^T;+MR0B[\K<2!2>_'0>E=+?WL;>/M+TS4;N"VM9=%5[/[5
M$KQR3;R) -W&[;L]\9]:[/\ X1?0#;W=O_8UAY-Y)YMS']G7;,WJPQ\QY/6E
MU#PUH>JZ?#87^DV=S:0?ZJ*6(,L?^[Z?A0!PB^'9;#2M,L_"VLVU]<:?>7$]
MM;:@N;>=<8>-"O387.TC."6'8XZGP%?V]]X;;R=+;2W@NYXKBS+!A%,)&,@4
MC@KN8XQ6K+H&D36]K ^FVWE6@Q;*L87R.,?)C[O''&*N6MI;V-NMO:P1PPKG
M"1K@#)R3^))- 'CGBZ>RG\+^*+_3C&@AUV-9+BZ?=<-<I+$I$73RU4#CDDC=
MP!S730W>FZG\2/$VE:ZT#J;*!;!)R-K6[(WFE,]]YP2.>!Z5U<_A/P[<SWDT
M^AZ?)+>C%R[6ZDRC(/S''/(!_ 4NH^%M U=;9=1T:QNEM0! )8%81CT'' XZ
M=* /.O$L4]A>>!(?"+"YF@@U!+!KJ0MY@6# .X]<@?*>G3M4FO?\(_JGP-UN
M\TRT1287DN!,@\]+D-\_F'&?,#$_GQQBO29]$TNZO+>[GT^VDN;88@E:(%HA
M_LGM^%5F\*>'G6Z5M$L"MVV^X!MUQ,V<Y?CYCGGF@#D)M,LM(^)/@V73K6*W
MEO+*]6Y=!AI\)&PWGJQSSDY-8=HL&K_ S5=3O@%UV W4\\^,3Q7D<C%1NZJ1
MA% ]"!TKU'_A']'^TVMR=,M3/:#;;R&(;H1Z*>WX4C>'=&;4&OVTRU-T[AWD
M\L99AT8^K#L3R* .#U<GPWKGASQ9J5FK/?V/]F:LJ1 LTK('CX[DNK)_P("J
MGA'3WMI[CX?:A9P8MKU=28)'^[-LW[T*">N)ODYZJ#Z5ZK<6L%VBI<0I*J.L
MBAUSAE(*D>X(!H%K MV]V(4%PZ+&TN/F*@D@9] 6)_&@#SN^FN[;QQXYFTX$
MWL7A^%K<*,GS )BN!]<5!X?L=#UBT\)ZY;:[$MQ;E/*2UC19969<212=6;N6
MSZ%CZUZ%%HVFPZG)J<5A;I?2C;)<K&!(X]"W4BJ]CX8T'3-3FU*QT>RMKV;/
MF3Q0*KMGKR!W[^M 'D\LEIKGP)\2:AJ4<,FL^;<->M(!YD4ZRD(OJ,+L 'IQ
M767LPM_'NBW$QCO;1]$>,6GF)NA8NF9<.0"&'R<'/'IFNHNO!_AR]O+B\N=#
ML);BX&V:1X%)D'OQSZ9KFO$'A6>XUU9&\*Z-K6D);)#:V\C+"]H026P"I!#9
M'0C&WIUR <Y+I;>"_!&B1WGV>TM;O6P=0D15D2.!C(8DD(X95/E@\XXQR*[3
MPYH^G:?XHU*]LM66YEOH(WGMK=46%<<+)A>C,,CWP?2IO#_A&QT_3+ZTFTJR
MM[2^8-)IL1,L" #'\0 )/4X ' ],G9TG0]+T&T-KI.GVUE 6W,D$84$^IQU-
M ''ZY:6#?&'09+FWMB&TRZ=FE1>2K1X))[@9^E<Q=Z1IU_X9^*-U=VD,\]O?
M7;P22+N,3+ C IG[IR!R.3@>E>LWND:;J5Q:W%]86US-:/OMY)H@S1-ZJ3T/
M _(56'AC0EANH1I%D(KL[KA/)7$Q]7&/F_&@#CDN+/4M=TN&3RY=2'AU9;B2
M_;=;Q0.1N8)U9R5P3E0 .3VKEM-2VOOA[\+WNDAN'_M:&%S( QV;9@$.>W X
M]A7K;>&-!>6RE?1[%I+%=MJQ@4F$=0%XX _2FGPMX?.E#2SHNG_8!)YOV;[.
MOE[\YW;<8S[T 79H+6YTQX#%%):/%M"8!0IC@8Z8Q7C=G:VT_P *_AJT\$,G
M_$YM8R9$!^4R29'/8\<5[3);PRVQMWB1H"NPQD?*5],>E9Y\,Z$=(_LDZ/8G
M3MV[[+Y"^4#G.=N,=: +P@M9;(6ZQ0O:E-@C"@H5QC&.F,=J\G\+V%Y>?"CP
MFFDW=I#J%O>3S6UO>*6AN2KS@QMCG[I+ ]BN?<>M_9X?LWV;RD$&W9Y8&%"X
MQC'IBLU?"^@I9164>D64=M#)YL420A5C?GYEQ]UN3R.>: ,KP%?QWVE7Z_V1
M_9-W;W\D5Y:*P9%FPK,4(X*G<#]2:RO#UI81?%7QHYM[9)56Q:)MBA@S1/N*
M^Y[XZUW-I96UA!Y%I D,62VU!C))R2?4D]3WJM-H6DW.H-J$VFVDEZT7DFX:
M%3(4_N[L9Q0!XWI>FV-O\+/ VKQ6T2ZBNK6H%UC]X%-PRE=W7;@GY>GM70-'
M8^)-<\::+KFI6UK.)_+"7$2%UM3$NQXV8\ '<W'1CGO7>_\ "*^'_L,-C_8M
MA]DA?S(H/(78C?W@N, ^]&H^%M!U>Z@NM1T>QN[BW $4DT"LR@=!DCI[4 <9
M)9VT'CWX>-%,]TS:=>1F[F7]Y.BQ1[6?U."3^)H\ ^'-&GU3Q)=R:? T]CXC
MN3:MM_U'RI]WTZ_H/08[RXT;3+K4(+^XL+>6\@&(9WC!>/\ W3U'X46&BZ9I
M4D\FGV%M:O.V^5H8PID;U;'4^YH Y/QUJ"VGB?PK;WEU':Z9<2SB269 T0G"
M+Y0;/'=\9[X/:JJ^%?#*:)XFL;N^%[I]W()IXHT79;3,,8A"]')VG:.<E>.>
M>YU+2[#6+)[+4K."[MGY:*= ZD]C@]ZK1>&]$@TZ#3XM*LTL[>02Q0+"H1'!
MR& _O9YSUH XSX=Q@W&H:5XBMT/B6T@B@E,J+^]LPN(RF."O)W=?FSGC '&6
M_AS2I?@*-8BMU36;225K.[0GSHY%NG"(AZ@$D#:.,MG&3FO:9](TW^T?[7.F
M02ZDB;5G$:^;C^Z&../QQ7,_#_P@NC>&[2#5]*@34K>>64OE7#,TC,KC'\05
M@,D9&..* ,B/PYI>L_%35;;6-.M[@2:+:RS1,ORM+YC@MCUXQGK6?;6^F^*=
M/\3V.N:S!8WEOJ<WV@O&BSP(DF871V.0 @7!'O7J":+I<>JMJB:?;+J#KM:Y
M$8\PCT+=<>U5[KPQH-]J\6K76CV4VH18*7,D"EQCISCMV]* . \417VGMK&K
M"WM_$&BM:Q1ZK:3CR[NU"1!M\9(Q]UMY7C!)QWIWBPW44VM:[!:6FN:%-:QK
MJ=C+^[N;1%CW;HF/&-K[\'OTYS7H-QX>T>[O)+N?3;:2>7;YKL@S)M^Z'_O
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M[8@Z1<.S2(O++)'@DGN!W[5RUWI&GWO@_P")]Y=6D4UQ;ZG>-!)(NXQ,L,;
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MU-)A>2QQ$;FC@+[D;<0%)YQCIWKF8[&SBM_BKIR6T"V40\U+<( B,;0,2%Z
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MUU_"/B#2+GPSH8C$6F-=Q,EK832J'_=DJRH/X@,=0.F* .G9E12S$!0,DD\
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MMX6GD2&",*))5F782!U/)&?>@#=\<>*)M#L8&TR\L3=?;+>&>"3YW$<DBJ2
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MI=$L)'8L[VT;,Q/))4<U=H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY/Q%XZ,OPYG\2>&KRV+))$,2()"$>4)R,C:2#GD'Z5VO]HV)O?L7VRW^U_\
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M3E\S=?VH\IQ')F9?D<G 4\\$^E.MM0LKR6>*UO+>>2!MLR12JQC/HP!X/UH
MJ?\ "-:#]E2U_L33?LR/YBP_94V*W]X#& ?>FWVA6SQW5SIUK96NKO;M%!?&
MV4O&2N%).,D XXJ_->VMO-%#/<PQ2RG$:/(%9SZ 'K2)?V<DDT:7<#20?ZU1
M("8_]X9X_&@#SNV\!-=V:V&H>#?#-G((Q&^J6TF^7(&/,0>4K;^^2_!YYKO#
MH.D&\-X=,LS=%P[3&!=[,.C$XR2.QI\6KZ9/=1VL6HVDEQ+&)8XDG4NZ$9#
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M(TV744U&33[1[Y!A+EH5,BCT#8R*DDL;.6[2[DM8'N40HLS1@NJGJ W4 ^E
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MN-+2.S\.R& 2)<[OM4N2-H^4;>0H[_>K6?QW%#HF@7$]@XU;7%0VFFI)N;+
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M,_9E0 _OOEVH3GH&/0^AQFS^.EB\/Q^(QIQ_L-YHXUG>7;*T;N(Q*L>W[I+
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ML_\ A!OAS_:HTO\ L31S?F,R_9P@W[!CYL>G(_.K?_"L?!'_ $+&F_\ ?D4
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M@%) SM[9K1;PYJ5SK&I^(9I84U-[![+3858E+93D[F;'+,V"2!P!@9ZUUM%
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MS D#G(Z]*O7GBK^S;K4X[RR/EP3P6UF89 [W<LJ@B,*<;6!(ZG&""2!4>O\
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M?J!?XCZYIT9S%%86DK@?PREI0?Q*A/\ OD5%I_AK3/#CC5+B...'3XF@T^%
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M^8\#IU-=+'HFHSZ3?SZC9Z9/K=P7"$R,T2+R(U#%,@*#R .3D]ZQX/ VHO\
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M53(Q)()..,9Y%&;P+JD.E^$/L\6EW,^@HT<EE<,P@F5XPC'?M)W#&<E>YXH
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MPWH-F7^5"Q&!P0 2<XM1>%->MM2\67T5U9-<ZI;)#:3NS!@RQD L,?*H=F(
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M?;+I_-8.V\E%4_+C^^VWOM!R.E4AX'NK*Q\':9I[6HL=&E,]SYA;,DHC(5P
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MP))$,:.7&U7*JP) ^\ &Z=Z@US6H-#LHYI4>6:>9+>V@3&Z:5CA5&>!W)/8
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M- '7T5S/A7Q)=^)+6QOT@M6T^[M6F\V&4DPR@J/)8$=1ELGCE3P*M7GB _\
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M-PCCV[C'Q@$&0!=JG&-WM@@':T51T^[N9-+%SJ<$=G,-YE02;E0!C@[B!Q@
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M.>PR0 .I)QQR1QD&LW%M?^-?&-U#;RG28AIT"B0JCB$&1\'!(+.X&.>1C/%
M'I,<B2H'C=70]&4Y!IU<1_;)\*6GA;2K31;: :B3OM(9"# =ID<*,<_,<9)'
M+#-7H_$^HQ/!87^F06^KW,DS1VZW(:..VC./.D<#A>1QC)) XYP =317'VOC
M9FL&EELQ--/J!L=-$!(6_P  'S%S]U!\^6Y&$)&<@58U3Q!JNCZ;KEU=V,"I
MI]D+J.X+$12-ABT8[G;M'.!DMC H ZBBN-TK7=2T_1M&LM46.YU_48VN#&)"
MJ1I]]V<D?*J[@H !_A ]15OO'MY9>&[_ %5;&VN$AU!+*TE$K)'=ABB[TX)(
M#,P]#L)!H [RBN'D\<WZ:QK=@=*@4V%FEVC/<$;58,Q\WY?EPJ@X&[[P'?(O
MVOB]Y]&T"1K(#5=9MUGCM#)A8UV!G=VQPB@CMG) Q0!U-%<)?^/+RQ\-ZOJR
M6-K<QV=W':VLPF,<5YNV+E"0> [%<]#M)S6I8>)KZ[\8RZ*^GQ1P+IPO4E\T
M[QE]BAUV_+NPQ R2 .>>  =/17)> M4U;7M/O=8U%H3;W5U(+-8BV%A1B@P#
MZE2V>IW=@!4__"3SZA)J_P#8\$,EOI1:*6YN'(2291EHTP.@X!8]#P >: .F
MHKC;7QS)J%UX3%GIP^SZ]$\Q:27#Q*L>YL #G!VC)Q]X8K7T+Q!_;M_K4<4"
MK::?=_8TG#Y\UU4&3C'&UFV]^AH V3(BNJ,ZAWSM4GDXZXIU<K]L34OB')9/
MI=K+)H]D+B*],A+Q/,2NS&WY<JA)//&*Q;7XC:A>:)I>IP:1;M'?:FEB!]I/
M(:0H"GR_,=H+G. !CJ<X /1*H6FMZ;?F[%M>12?8WV7!!P(FQG!)]N:SI_$3
MS:AJ%GIL<+KIJ;KRYG8B.-]NX1C'5MO)/101U)Q7%:;<O%X!L)[W2H+R7Q?J
MF^>VGD( 6=B5Z Y"Q*#V^[0!ZKUHKD;OQ/?6OB>[\/:7I,%T]KIRW$2K/LRY
M)"HV5P@PI.>>JCO4C^+74302I:VMQ8VT<FIRS2YBMI77(B7',C>PQP1U) H
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M6T92;:PD,Y8[ER>" NT\#@GKZ9FLZ!JUQXSTO7M-GL]MO:S6LL=T&.P.5.]
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M5BMQ*I'[E2",-CDGGC'!IZ^(;NZUJ'0;6"'^T8K5+G4)6RT5KN^ZN <LS$'
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MTR;5*[/,^?9R3]W.WCL!67-XHUZYUSQ#I.C:?97<^G+$(3)(R*79=Q#GV!7
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M)/EC=(%'<F20*/4J*T)O$.MV^N^'].FL[17U9I7DB!8M:Q1IN;+9P[$E1D
M$]^M9:^ M6'@A-);5+5M0CU!=0$AA/E22"<RG>,[CDGGTP,#C)U;7PQJ@\=)
MXCO=2@E'V 6IB2(C8=Y9@@). <+DG).#TR, $%GK$D^I^+-5&DVMQ-HR&TMY
MH$(FN-L?FO%N.> S*,#ODT_3O&._P\WB.]GLY-$%BMS]HME8-YA)!BVDGD$
M>I)Q@8I-!\-:[H6F1QIJ5I-<-J$MY<_NV59U<R$@GDAB73GH-@X/.:MW\.Q=
M>%-=TJ.YCM)=4OOMZK&NZ&"0%&"@'&Y24R>!]X\4 :-GXCU2ZU_3['[+;,LR
M/)>PQ$LU@H7*"23.TL3@;<#N02!D]56)96>N1:9(DL^FP70A9(([6!A"LF.&
M;)R1GL,=^O&-2R6Y2QMUO9(Y+H1J)GB4JC/CYBH/09S0!/1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39
M(HYHFCE17C8896&01Z$4ZB@"M9:?9:;#Y-A9V]K%G.R")47/T JS110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 51GT32KFY-S<:992SG&99+=68XZ<D9J]10  8&!THHHH
M **** "BBB@ HHHH *BN;6WO8&@NH(IX6^]'*@93]0:EHH K6>G6.GJRV5G;
MVP;[PAB5,_7 JS110 4444 %%%% $-U:6U] 8+NWBN(3R8Y4#J?P-,M-/LM/
M1DLK2WME8Y80QA ?K@59HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M32=1LQ,(F\NX9A)'&V#@M@]!]: -&BJB726VF17%]>6X C4R7&X)&QP.1D\
MGIS4HO+4VGVL7,)MMN[S@XV8]=W3% $U%01WMK-<O;Q7,+SQ@,\2R LH/0D=
M14DLT<$32S2)'&@RSNP  ]230 ^BJB:II\D2RI?VK1LVT.)E()],YZ\BIA<P
M-<-;B>,S*,F,.-P'KCK0!+157^TK#S8HOMMMYDQ(C3S5RY!P<#/.""#BG7%_
M9V@<W-W!"(U#.9) NT$X!.>@S0!8HKEO&NO7^BZ3I][I<ML4GO[:"0NA?='(
MX7*D$ '!ZX-=#=W]G8*C7EW!;ASM4S2!-Q]!D\T 6**BDN8(F19)HT9\E S
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M6FKJ%DPN"MY;G[-_K\2K^Z_WN?E_&@"S161I'B;2=:T?^U;6\A^Q[F'F/(
M Y4,?0'&1GUK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KB?BZ<?"G7_P#K@O\ Z,6NVKF/&6GZ[J-O;0Z-I_AZ
M]CRQG36D=E'3;M"@^^<^U 'F\^I6UE^S#:02.IGO+06UO".6D=I2,*.Y')_"
MJPM;?P9X)^'ECK<ES!K*7S3VL)G$,$;,^XF<D'"J'7('/+#C)KJ;/0O'VGS"
M:R\/_#RVE7H\,4R,/Q"U/?:?\2=3$0O])\!W0A;?'YXN'V-ZC*\'WH X7PA)
M'=:#\7K<S07&3<S1K$/D8[9OG1<G X7')[<U):W7AZU_9OL6U*2X4LPWKI\B
MI-))Y\A0,2#@?*>2.W'-=M!I_P 2;6YN+FWTGP'%/<\SRQBX5I?]XA<M^-0+
MH/CY-/DT]?#_ ,/%LI'WO;B*81LWJ5VX)]Z ,+P1J7VK]H#6Y7O;*7[3I"$F
MTDW1.X\GA3GYR!D9[X)P.E=G\8SCX3:]G_GG'_Z-2LZ+2_B-!>)>1:-X!CNH
MXQ$DR+.'5/[H;;D#VI]]8_$K5(1#J&E>!+N('(2X%Q(N?H5- %?P#X)TC6?!
M_A/5]5-Q?RV=JCVL,TG[F%O4(  3P/O9Z5B?V)IVO_M'^(+'4[=;BU.D*SPM
M]USB$#/KC.1Z$ ]0*Z6RL_B9IL'D6.F>!;6'.?+@^T(N?H%Q4*:3\1(]1;44
MT3P M\QRURJ3B4_5MN: ,?5+"TTO]H;P18V4*PVUOI,D44:_PJ$G '/-5X-*
MO/#'Q:UKPU96[?V5XJM_/1D&!!R?-.>V%,F!ZLE=!+I/Q$GU!=0FT3P!)>IC
M;<NDYD7'3#%<\5::/XIM<I<-9>"3/&K(DA:YW*K8) .. =JY^@H P_&U_H^G
M_$6WM(+G[/J/]B2V["YE"6<4!#$ )P7<XP%! X!YQBO/TU&[A_9STWR6:6VB
MUC%]&K9Q#N9@K#LI;;^.*]5FT[XDW%_%?SZ3X#EO(5VQW#BX:1!Z!BN0*9!I
M'Q$MK"6Q@T3P!%9S$F6WC2=8WSURH7!S0!HVOAWP=XC?7;O3[M+IO$-H@NEB
MF#JJA<*X4?=;OSSD'T-<S\)/[0G@/AC5K<Y\*WLH,A'#,<B,#UP&E/TV5H6^
MD?$S2M-EM=%TWP-IBL=W^AI,G/K@KM)/3FKFEV7Q,L]0GGDMO" 6]N5FNF1[
MC><*J<<8R%48S0!U>@^*]%\2RW\6DW@N'L)O(N $9=K<^H&1P>1QQ6S56STV
MPT]IVLK*WMFN)#+,88E0R.>K-@<GW-6J . \=D#QQX!R0/\ B8S?^BC4_P 3
MT272M!CDY1]?L5(SC(,E=5=Z+I5_<1W%YIEG<SQ_<DF@5V7Z$C(I][I>GZDL
M:WUA:W2Q'=&)X5<(?49'% '%Z;IUC9_%S6;"VL[>*TN-$MWEMTC54=A+(N2H
MX/'%<_X6L;F[^%?A--*U&VLM3@OIY;);E-T,[J\X,; <XVECD<C&17J/]BZ5
M]J>Z_LRR^T.FQY?(7>R],$XR1[5%_P (YH?V1+0:/IXMD?S$A%L@17_O 8P#
M[]: ,CP)J+ZAIVHK<:4FF7UO?R0WD$3[HS-A69T/HVX'ZDU@6VA:+J7Q=\3P
M7^G6EPC:?:R>5+&&5F/F!GVG@MT&[J,^]>AVMI;64 @M8(H(020D2!0"3D\#
MWKD8O"TEU\0M7U;4]+LY]/NK:&"$RE792F[)*D<!MW8]N: //K72H?\ A$_"
M4%Q&)K-/%QM[%Y.2UINE"J&ZE3CIT(Q79"VL]'^+>E:6EG!::2VE3R6$2(%C
M-T9092!TW;/T)]:[6YT;2[U($NM-LYU@QY*RP*PCQTVY''X4^^TNPU.!(+^R
MM[J)&#*DT0<*1T(!Z'WH \[T[PQ'K;?$+PZ54:)-=*MGQE(9VB#2%/3;(5.!
MWS[UJ>"-0F\5P6=WJ-OLGTB)K.X1T_Y?,[)2/HJC&.TI':NVMK6WL[=+>U@C
M@A3[L<2!5'T I8K>&%76*&-!(Q=PJ@;F/4GU)H \IT;38KGPKXIT^UOHM,?_
M (2N86LGE@QK*LL;1H5Z%2P Q[T[4;J>_P#!OC^PU[1K2VUBSL3+<R6YWP7#
M&%O+E3/(;"]#R,"O1AX=T06TUN-'T\03L'EC%LFV1AW88P3[FGC1-*%E)9_V
M99_993NDA,"E'/J1C!/ ZT <':73)XU\$V][C^SY-#8VF[[IN]J9_P"!"/./
M]XXZUS_B>P6+1_BE;QQ(=(B\B:W0J"D5R8PTNST.2I..YKUV;1=*N+".PFTV
MSDLXB#';M I1".A"XP,>U#Z-I<FGC3WTVS:R!S]G:!3'G.<[<8ZT <1<:?9:
M9\2O!+6-M#;O<V5ZLS1J 9@$C8;CU;DDY/<UT7C2REU#2+:WMM2CL+TWD3VD
MDR;XWF0EU1QW!V_GC'-:G]AZ3Y]O/_9=EYUN,02?9TW1#T4XX_"I[VPL]2@\
MB^M(+J'<&\N>,.N1T.#WH \B\1ZA/=_#[Q9;ZII$&GZM9:C:27S6[;X96+PX
ME0GD90#(/([]:Z6\GT^Z^,^GQ^9;3!]#GC=<JP;,L9"GUR.<>E=HFDZ='8RV
M*6%L+2;/F0")=CYZ[AC!S[U!!H6DZ:L4EAHUE%);(5@$,"(4!.2%./ER>M '
MC-OX?TB?X!-?Q6D0U>":4VES&/WR3"Z81HC=1G(&T<?-G&3766&A:7J/Q6UN
M#5M/L[B1M)M)9(I(U96D)<,^WH3VW=1GWK9\ ^$!H7AZU@U73+$:G;RRR?:(
MPKD[I&8$-@'(#8_"A/"TMW\1-3U?4M,M)].N+2*WA,I5V5D+9)4C@'=CK]:
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MPWKTU]J\^BLKK:/$4\M2")#Y:C#X+!3G. <=*],BT^R@L!816ENEF%*?9UC
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MSAU?[?#Y$UAM N82X$P;;PRB/<Q/;;[UW%EI6G:;$\5C86MK'(<ND$*H&^H
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M=!T=)H)ETJQ66W4)"XMTW1*.@4XX'TIT&BZ5:QW$=OIEG$ESGSUC@51+GKN
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MCZ38M8$Y^RFW3RL^NW&,T >6^)]"T.R\'7W]G7K7\<FNVTYD)0I#*\J;UB*
M!>#R!Z_6NDMM.L;#XS-:V=I;V\$_ATM+#%&%5R+@ $@<$X)&:ZYM T9["&P?
M2;%K.'F*W:W0QI_NKC J1='TQ+Y;U=.M%NU78LX@42!?0-C./:@#S[X?1^'9
M_@W90:T=/^Q>6WVP7#*JC]^VW>3T^8#&>XKTU0H4!<;<<8Z8K/.@:,;.YLSI
M-C]EN7\R>'[.FR5LYW,,8)R <FM$  8 P* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *BGNK>U4-<3Q1 \ R.%S^=2UQ?Q:17
M^%GB ,H;%N",CH0RT =?!=6]R";>>*4#J8W#8_*I:\GN=/\ MGBKP5<>&--G
MMKBVP=2NTM'@C^S;1E'8J Y/.!SCKQ727WCFZTZ6VEN]($%G<:J--C6:8I.P
M+[!,$*X*9]#T(.>U ':4C,J(SNP55&22< "N.N?%^LMXGU30],\.I=3V"02[
MWO1&KQR$Y/*\$ <#OSR,#-7P[X@UV^;Q=)?V5I/%8W\L"1)<MP$BC^0 I@@Y
M)+$CDGY: .WM;JWO;6.YM)XI[>5=T<L3AE<>H(X(HNKJWLK62YNYXH+>)=TD
MLKA50>I)X KDM&\5V\OASPR-/TN&"YUB+-I8HX2*%%7<Q+!>%48Z+R2!CN&:
MSXGO+;PCXANM7\,"0:<622WEDS!=Q8!WJS+RN#R"O7B@#M%97171@RL,@@Y!
M%+7'W_BZ]LM9TG1['0UN)-0LWG@/VD1HI0+E3\IPHW#GVX!J#3O'EY>:;JRR
M^'YUUS2[J.UGTZ&3S 3(0$<.%^X0=Q.. #Q0!V]%<C;^,YI+OQ'8M8P2WFBP
MI.1;W6Y)E96.,E<JPVD$$'M5.Q\?7\\7AF]NM#2WTW76CACE%WODCE="ZY3;
M@J<$9W9[D#I0!W50W=Y;6%L]S>7$-O @R\LSA%4>Y/ KD_"NM:WJ?BOQ-;7T
M5J+6RND@C\N=B8QY8884I\V=V2<CTP<4OQ5BCE^&&O\ F(K;;4LNX9P01R/>
M@#L%8,H92"",@CO2UR-AXGOH?$>EZ)J&E);0ZA:/+9SK<[W)B"EED7: IPP/
M#-_A1N/B3#'!:ZC;6UO=:;-<B$B&YW7*H6*B7R@OW<C.,YP0?8 '>45QJ>+]
M9N_$VJZ-8>'4F;39[=)I6O0@\N4;MXRO4#G;['GH#5N_B3##;0ZC;6UO=Z:]
MSY++%<[KD)N*^:(@O*Y&<9SMYXZ4 =K#>VES//!!=0RS0$":-) S1D] P'3H
M>M3UY?97>K:7X\\=_P!@:'%J$@ELW:-KD0+_ ,>X.!P<L?H!ZGUUXOB+]IL/
M#6IVVF Z9K,XM7GFN"C6DV2NUEV'/S*5!R.?3- '<T5F6NISW6OW]@MM']EL
MTCW7(E))D89V;-O&%VDG/\:_@NMZE<Z79126FGRWT\L\<"1QY 7>P&]R =J+
MU)P: -*BN+7QU+]D\5'[!;2W7AU/-E6*[S',AC,GRMLR&^4@@C@CK5N3Q?(E
MQX57^SU,6OKP_G_- WE&3&-OS# QG(^E '2SSPVL#SW$J11(,M)(P55'J2>E
M+#-%<P1SP2)+#(H=)$8%64C(((Z@BO,QJNKZYX7^(<>K6]FT%H]Y;QA)F;R]
MENF%52@R.2V[(.2>*N^&O$]]IUCX,TR\TI([#4K**"WNA<[I!(L ;YH]N &
M.,,3Z@=* /0J*Y"X\973Z5J>LZ9I:7FFZ;+)'(3<;)9A%Q(T:[2"!@XR1NP>
MG&8;SQW<R:GI-GHFD+J"ZM8/>VDK7(B#!0IPPVG;]X<^O&* .N^V6OV[[#]I
MA^U^7YWD;QYFS.-VWKC/&>F:GKD;+79)O&XTZ\\/P6VI?V*MXUPLJR. 7 ,.
MX+T#9[X. <5%=^,-9L]8TC2'T*SDU#4?G-O#J+,UO$/O2/F$ *.G7D\"@#LZ
M*X;5OB(EE;WMY96MM>6UE<FWEA%UMN9-K;',<>TYP<\$C.T].,W;CQD\NIZA
MI^DVMO<W=E;QW'V::X,4LX==X\M=IR ,#Z\<=: .LIDLL<,32RNL<:#+.QP
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M_P!F6Q/D/N63YW^;D Y[<^G>@#T&H)+VTANX;66ZA2YGSY4+2 /)@$G:.IP
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MMEBN#B-A!Y6TY4<#KGVX'/'I-5[:_L[R:YAMKJ&:6V?RYTC<$QMC.& Z'!H
MXR70-9DN?!$@LX\:*#]K!F'.83%\GKSSSCBLH>%/%&F^%/$?A*TM+.[L+P7+
M6-VUSY;(LN3L==IR02>0<'/:O4** *.BP7-KH=C;7B1+<PP)'((G+KD #@D
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M:B:A$[^?-$GW4,9& 2  3GIG&3S0!1TC5;7P]K7Q$U.X4^1;7D+E$ RQ,"
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MF,( _P G'W<\9JNW@>_OOA58^&;J>"VU.QCA\B>)S)&)8B"K<@'!Q@\<9[T
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M9OLG(BF *@2)P>"'!VY]>:VK?Q'JL7C6WT/5+&UBAOK62XM7@F9W4QE0RR9
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MZ'8K9:9;BWM5)*Q*Q*KDY. 2<9))X]:X'1EU*]\2^/([V'3;J$2PK-#.C.C
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MUY!K(EUVZOO$=[HFD+;^;I\,<MU-<!BJM)DI&%!!R0I).> 1P<\8_P )"Y\
M0F1!'(;R[W(IR%/GOD ]Z .X)"J68@ #))[55T[5;#5X9)M.O(+N*.0Q-)"X
M=0PZC(XXS7*S:EK;?%V+2XYK8:>ND-<"(ALG,R*Q/JWR\=@"?6N5TKQ!JOAC
MPYXKU>SL+2>QLO$%Y)<B64K(Z>: 1& ,9 .<D_A0!Z_17+ZGXHE&K7&EZ8(O
MM%M;I/))-#+(F7W;$Q&,C(4DD],C /.-'POK,^O^';34KK3KC3KB4$2VMPI5
MHV!(/4 XXR#CH10!?O=0L]-@\^^NX+6'(7S)I BY/09/>HK36-,U!@MGJ%K<
M,<_+%,K'CKP#[C\ZXCPU,?$/Q8\4W=[\ZZ((;.PC;D0[U)D<#^\Q7KUQQ78:
MAIVG1ZA%X@N%6*>QAD#3XY\HC+*?;@'\/>@#4HKA;KQS?67A:S\73V,']ASF
M-Y(E)\^&"1@$E)Z,>5)7 QGJ<59?Q+KUUXKU?0=.T_3]]G;0SPSSW#[7#[OO
M +G/R]![G/8@'8T5YQ#\0]8E\+:3XG.DVD>F7%Q';W49G8S*6E\HLF!C ;L3
MDCTK2N?$_B2X\4:SH.D:3IS36$,,T<US=,$97W=0%R&^7  XZDMT! .UHKB-
M)\;WNN^']-O;73%M99KB6WU![ALQ6#1!MQ;D;@2 !R/O<FJ4_P 1KV/P)K&O
M06%I<3Z5?M92!9R(Y<.JB1.#D$.IP3Z\T >B45R</B+68_&2Z#?V5E"+NRDN
MK.2*5G*E& *R9 _O Y'TYZU6TWQE?WGA?5+NXM+:'6;&\:R-B&8KYVX*B[NI
M#[EPV.C=\4 =6^I6,6HQ:=)>6Z7LJ&2.W:0"1U'4A>I'O5JL>Y\/VU_K&F:M
M=PVQO+$$K*D(W[BI7 <\A/F8[?7!SQSD67BZ?5-:O;&Q:Q,UE?\ V6XL96*W
M B# &8<\C!W 8QCOGB@#K)9HX(FEFD2.-1EG=@ ![DUG6OB70KV=8+36]-N)
MF.%CBND=C] #6I7@VEVAUKX)3:)8:3<WNJ37LWV4I;L$B?[02'\T@*N![Y[4
M >\T5Q>HZYK6@:>\,RVH&GZ;'(][>L=M[.%.8TP00?DSGG[PXJ*X\<:E*?")
MTW2K>1?$,#2+YUP5,3>3Y@!PO0<9/7 .!TH [FBN,/BK5C(^F-;V<.L6MLDU
MWM2:>$.^[:B[!GD+DD],C ;G%1/'FL3CPL$\/?9YM:::.2"\E:*2"2-&.""G
MW3MSNZX_AS0!WU%><ZEXPUX>%?&49BL[76="4@RQ%GC9&B$BLN<'=@]^,^O2
MNS\.M=OX?L6O6C:5H$.8\\C:.N>] &G17,G7]0U35-7L="BM&;2BL<CW);$L
MQ7=Y8V_= !7+'/)Z<5B_\+&NKW2_#=]I>E1.-7NVLI(IYRK6\RAMRG"\@%#\
MWI_">E 'H%%4=(?4Y-+B;6(+:&_^;S4MI"\8^8X() /(P:O4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<UXTT7
M4];T^Q32Y+;?;7T5S+;73,L5S&N<QN5!.,D'H1E1Q72U%<7$%I;R7%S-'#!&
MI9Y)&"JH'<D\ 4 <#-X/\1S-XT+2Z5CQ#:I%& \B^4WD^4<_*>!USWQT6KLO
MAG6I+GP9*!IX&A@_:!]H?YR8C%\G[OWSSCT]ZZ.S\1:-J%PMO::G:S3MTB64
M;SP3G;UQ@'GVK3H \T_X0KQ+8>&O$/A;3Y-,FTF_%PUG//*Z2P>;DE&4(0PR
M3ALCKG!Z5WVCVUQ9Z-96MV8C/#"D;F+.TD#'&>>U)_;.FG6?['%["=1\HS&V
M#9<("!N([#D=:O4 </8>%];T*'7=+TQK*;3=2GEN+>2>5E>T:4?.I4*0Z@\C
MD'L?6LF;2G\.>//!.E:3''.MEI-U"!/(4WJ/+!.0#@D\],?2O1-1U&STG3Y[
M^_G6"T@7?+*_114#Z1I5YJ$&L/;127<:?N;G)W*I]#V!_6@#D=1\ 7FJ66LW
MIO8K37KZ^@OH)8LO';O  L2\@%A@')P.6/''.E#9>,-0T:^CUIM(2YDM7MX8
M;.23RF9A@R.S*2,=@ >IR3QC67Q1H;Z9?ZDFIV[V5@[1W4Z-N6-E )&1UQD=
M/6M2*5)HDEC8-&ZAE8="#T- '#W'A/79/AEIGAZ&>R2_L5MT=3(Y@NDB(RCG
M:&"L!R,'TY%/L_"VMGQ)K6H7DFFQ6NJZ=':M';[V:%D#@ 9 !'SYW<=,;1UK
MN** /.I?!WB2?X=:7X<=M*^TV,EMAQ-($9(64@YV9RVWICCU-:__  C^JZ7X
MTO?$.EK:31ZI;Q1WUK-,T>V2,81T8(<C!((('K[5UU% 'GMUX#U%-(L8;.2S
M>[.OKK=\\LC(K/OWE$PK'&,*"<=,]ZV[70]3C^(EYK\HM!93Z?':!5F8R H[
M-G&P#!W8Z]JZ>B@#F_&/ANXU^WTZXL)XX-3TR\2\M6ESY;,N04?'(5@2,CD4
MD&B7MWXIC\1:E%;17%K9M:VMM%,9 "[!G9G*CT   X&3WP.EJ"]OK73;.6\O
M;B*WMHEW22RL%51[DT <]X)T/4] L;^WU(69-Q?SW:-;2L^!(^[:=R+TR>:=
MXMT+4=5NM"O=+:U^T:9??:#'<LRI(I1D(RH)!^;/2N@M+N"_LH+RUD$MO<1K
M+%(.C*PR#^(-34 <E8:%K5GXPU[676PDCU"V@AC59G4AH@PR1L. =W8G&.]<
M_:> _$>E>&_#!TZ\T^/7M $L2AV=K>YBD^\K':&'08X."/R]-JG::I8W]U>6
MMK<I+/92".X1>L;$9 /X&@"#1(]8%N\VMR6OVN0C]S:;C%$H[ MRQ/))P.PQ
MQDXGBOP_J^L>(O#E_8BR$&E737$@GF=6DRNW  0@=3WKKJ* (+I9GL9EA6,S
M-&0JNY"Y([D G'X5Y]9^"_$>G^'?"5E')ID\FB2,;BUEFD$%R"I"OG9D,I.0
M"I&><UZ110!YE>>!/$ESX9\6:1]HTIFUJ_-W%)ND0+N,9.1M.,;, <YSU&,'
MH[O1-6NO'.B:X4LDMK*UF@F3SW+DR;>5^3! V]R,Y[5U5% &?HYU<VDG]M"R
M%SYS[/L>[9Y6?DSNYW8Z]JT*** .0T7P_J]C\0-?UZY6Q^QZI' BI'.[21^4
MI7)!0 YSZ\>]3^+-%U?4]0T.\TQ[26.PN&EGLKQV2*?*X5LJK?,AY&1U^E=1
M5/4]4L=&L)+[4;E+:UC*AI7Z L0H_4@4 >?7G@/Q)<^%_%NC_:-*9M:OS=Q2
M[I$";O+)R-IQCR\ <YSU&,'I?%FAZIKVF:0]I]CCU#3]1@O_ "I9&\IRF<KO
M"Y_BZ[?PKJ*IZIJECHNG2ZAJ5REM:18WROT7) 'ZD"@#GW\/ZK/X]MM;N!8M
M9KI3V$RK(X<LSJY8+MQCC&-W>L_PMX<\6^'K:+P^;[3I-"MI#Y%V-_VKR=V1
M&5QM![;L\#H,UWE% '$7&AZE9:OXSUF?[)]CU*P1(@DK&1?*C<98%0.=W8\8
M[UE>&]$U#Q+\-O"FG7D=K%IL<5I<2R)*S/*D8#H@7: I)"Y.3T.,YX]&N[6"
M^M9+:YC$D$J[70]&'<'VK.:Z\/\ A+3X;>:[L=*LQ\L233K$@]EW']!0!Q.K
M^!O$]_I?B?3EN-*D&IWPNX+N9I/-V"1&6%@%PJKMP"">/X1G(Z&WT36D\?2^
M(9ET]H7TI++8DSAMZNSYP4Z9;'7MGVK?T_6=+U;?_9NI6=YY?W_LTZR;?KM)
MQ5V@#S:'P+KL/@K3M,$FG?VAIVLKJ<7[YS%*!,TFQCLROWL9 /2O18/.\B/[
M04\[:-_EYVY[XSSBI*K7]_:Z783WU[,L%K ADED;HJCJ: .<T+P_JEEX@\2W
ME\+,6VKRI(@@F9GC"QB/!!0#G /6N<M_!/BM/#/A[1'DT@)H>HP7$<HDD)N(
MXV8@D;?D."!CYLGN,<^F0RQSPQS1.'CD4,C#H01D&JVI:I8Z1:K<ZA<I;PM(
MD0=^A9CA1^)- &'HFAZI8>-?$.KW(L_LFJ+;B,12L70Q(5Y!0#G.>O'O6*W@
M[7DT#Q?HT4FFM!K-Q=3VTCR.K+Y_7> I V\],YSVQSZ%10!Q<WAO69=6\'7F
MVP"Z(DBW"_:'RY>+R_D_=]NO./3WJIHWAKQ?X>EN-&T^^TQO#TD\DD$\H?[5
M:H[%F15 VL02<$GW(/2N_HH Y?1]#U.Q\<Z_K$XM/L6I);I&$F8R)Y2LO(*
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M/;M4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&-FXQV!7W.*C6Y\6?\+$T*PU+4--5VTZXFDBMK>0Q$B1%R,N"25(QG@<\'-
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MW9VXR/N[?Q]-[4O&&K31ZO+H-L)WTVX:W2V:PGE-TZ8W@2)A4Y) SGID]<
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M18- &8L,2>9O!QCJ<8_'/:NDD+B-C&%9\?*&. 3[G!IU4M*U:RUJQ%[82F6
MN\88HR?,K%6X8 ]0: .7TGP-)'\.+CPAJUQ%)'*)E$]OD$>9(T@.#W5F_'%3
MZ)I'C"*%8-<URRN([:-D@DM87229MI4-*2<<9SA1UP<\<[J:[IKZ^^AK<YU)
M(/M+0[&XCW!=V<8ZD#K4FEZM9:U9F[L)6DA$CQ%BC)\R,5888 ]0: .;M/"5
MU+XHTK7]16PBU"QADBFN+/<&O2RA?G! P!R<9;G'(QSS'@C1;_Q)\)+31I9+
M:/2[J682S*S>;Y0N'+(%QC)P1NSP#TR*]5EBCFB:*5%DC8896&01Z$5!8Z;8
M:7 8-/LK:TA)SY=O$L:Y]< "@#D[SPKX@T[Q5=ZSX6U*P@AU!(UO+2^@9T#(
MNU9$VD'.T 8X!Q^1JWA'6DUK3M?T+5H!J]O;&SNOM\;-%=1%M_(4Y4AB2,?3
MH*[:B@#D-:\+:MJNE:63J=N^JV.I1ZB9)(F$+,H(V!0<JN&XY)XR>235A/#^
MHCQ[!XADGMGB33#I[H RLQ+ARXZ@<KC;D\=ZZ>B@#FF\)1_\)[_PDB3E8WM@
MDUL!Q),F520^N$=U_+TJAJ'ACQ#9^+;O7?#&IV,*ZBD:WUK?PLZ%D&U9$VD'
M.W QP#C\NTHH KV-O):V44,UP]Q*H^>9Q@NQY)QV&3P.PXKA=7\":U?Q^++2
M'5;,6FNGS%DFA9IHR$"B/.<;!CC@XR>.<UV-EKNFZCJE_IMI<^9=V&S[3'L8
M>7OR5Y(P<[3TK1H XA_"FN6?B.T\0Z9?V)OFLELM0@FC=89E4Y5DP258=.<Y
M'I5_PEX:O-#M=8@U*ZM;M-0U">[VQ0E0!(>5.2<_3MZFNHJE?:M9:;<64%U*
MR27LWD0 (S;GP6QD#C@'DX% &1X.\+'PEHDEB+DW3^8_EO(?NQ D11Y]%7 ^
MI-4-$\,Z[HFBR6D-U8O,^I2WC!@WER1R%BT3<9'WN#ST!QV/9T4 >>2_#-9=
M+U6.UN(M)NKJ_BU&S2S&Z*SFC4 %00,[B"3P.N,<<ZT>C^*K[0]0@UO4=.DN
MY[1[6)+2-XX5WC!D?))9O0# '([Y'6T4 <U8Z-K.F^$='TNVN+,W6GQQ0N7#
M>5<1HFP@\9&1]<'UZ51T_P ):AH=IKT^@OI^G7VIS1S0VX1GMK<J &.,+DL-
MQ) ')'''/9T4 (N=HW$$XYQ22%Q&QC56?'RAFP"?<X/\J=10!RW@;PY?^%],
MN[*]GMI_.O);I9(=PQYAR5(/IZY_"H]1\,ZO-XPN-7LM0M5MKJP%E(EQ"SO!
M@DYCP0.<\@]P#SC%=;10!YY8^!M;L])\)6;7MA*V@3^:2%=1*H0H%[X.&)W>
MO;UWM6\/7]UXQTK7K"[MXC;6\MK/'-&6W(Y4Y7!'S KWXYK8.K60UL:/YK?;
MC;_:A'L;'E[MN=V,=>V<U=H X>7P)+J1\7P:G/#]E\0%&7R22\!1 JGD8/W0
MW;IBM#P]IGBNV$*Z_JUC=):(5B^RQ/&UP<8#2DDCIV QDY["MLZM9#6QHYE;
M[<;<W0CV-CR]VW.[&.O;.:NT >2^+- OO#WPGU^VN9[=Y+G58[M'C!PIENXV
MVD'&<'WY]J[2;P_>ZOKMEJFJ200/I\$T=JEJ[,1)*H5I2S 8PHP%P<9/)K<O
M],L-4A$.H6-M=Q Y"7$2R*#ZX(-6(XTBC6.-%1%&%51@ >@% 'G-GX"\16^G
M^&[9]5TS.AW9E1EMGS,I5E+/\W+G=GTSDDFM-/"6J+!XOC,UF3KY<QG<W[C=
M$(^>/FX&>WI[UNZAXIT72M02POKY8+J12T<31MEP.I7CD#VJYINJZ?K%K]JT
MV]@NX-Q4O"X8!AU!QT/L: .47P?JT4GA&YM[ZSCN=#M'LY=\;.LJ,B)N7D$-
M\@.#QSUKMFW!#M +8X!. 3]:6B@#A[#P5>CPGXCT*_NK?&L374XF@#?NC,<X
MVGK@GKGFF0^%/$DVJ^&-0OM1TP2:*LJ&.&%RLBM&(\Y)SDC)]!Z&NNO]6LM,
MDLX[N4HU[.+: !&;=(02!P#C@'DX%7: .;\):#?:"^L_:Y;>1=0U&6_7RBV4
M\S'R'(YQCK^E<XGP_P!:C^'T?A3^T;%X[>XC>";RG4[$F\T;ADY8\#C &.]=
MU-JUE;ZO:Z7)*PO+J-Y(4V,0RIC<=V,#J.IJ[0!REUX9N[_QI_;-R;;[')I+
MZ;-;AV+$.X9F!P/3&/Q]JI^&O#/BK1([;2+G7;2XT*S(\AU@9;MHU.5C9L[0
MHP 2 20,<9KMZ* .;\+:#?Z)>ZY+=R6TD>I7[7JB(MF,LJKM.1SPHYX^E3>,
MM"N?$GABYTRTNUMIY&C=6D4LC;7#;7 ZJ<8/UK>HH X^R\+ZP/&$VN7]]8M%
M=::MG/!! R[2K,1L);I\W4_D*Q8/ /B-/#^@Z-)JVFB'1+^&XMY%@<F5(RQ&
M\9Z\@8&/K7I5% ')P>&]5LO%6O:K;7=H]MJT<1>&2-@ZR1Q^6,,"0%/!Z$\8
M]ZRH_ NJQ>#?#6A+=61DT:]ANC,2V)1$Q8+C'!.<9YQCOGCT&B@#DK3PWJFA
MZ]K%[HTUFUKJSBXE@N2P\B?&&=2H.X'@E3CD=15*+P'/IC^$X],G@-OH3RR.
M9\A[AY%8.>!A>69N_7':NZHH YO4M!OKSQQH^N126XM]/@FA:)BV]_-VY(.,
M#&T<=_:LO2O#/B+3;O5]2>XTVXUC4B0;Q]^(4'W(T7'"KUQGD\FNXHH X=_"
MWB72O$M_J'AO5["*SU1UEN[:^@:3RY0H4R1[6&20!D$XX_*YK7AJ_P!4M9]-
MG%CJ>FS6:0[+\MOCF&[,P(4Y)RO V\KP175NZQHSL<*HR3Z"J.CZUI^OV)O=
M,N//M_,>+?L9?F4X88(!ZB@!=%T[^Q]#L-,\]Y_LEO'!YK_>?:H&3]<5S\?A
MC5+3Q#XCOK6\M&M=85&\J1&#I(L7E_>!QMX#=,]O>NNHH X%?!&JIX5\*Z.+
MFS+Z'>07+2DMB819PH&/ESNZ\XQWJ5?"OB;2/$.HW/A[6+"'3-4G-S<6]Y;M
M(T$K !WBP0#G&<-QFNYJIJ>IV>CZ=/J%_,(;6!2\DA4G:!U. ": )X(O(MXH
M?,>3RT"[Y#EFP,9)[FN33PMJ6A>(]0U;PY<6GV?4W$MYI]WN5#+WD1U!*D]P
M0<UU5I=0WUE!=V[;X)XUEC;!&589!P?8U))(L4;R.<*@+$XSP* ,+4- F\0Z
M-?V&N3(([RW:#R;4G9$#_$"?O-D Y( &.G7.;%X6U6_L-%TW7;FTFMM*GBG\
MZ$-ONFB'[O<I&$YP3@MDCM73:9J5IK&F6^HV,ADM;A \3E"I(/L0"/QJW0!Q
ML'A;5(9/%KF6S)UT[HQN;]R?+$?/'S<#/;T]Z@D\':JV@^$=.6>SW:!/!,[D
MMB?RD*  8^7(.>^/>M]_%>BQZG!I[W9$UQ,UO$WE/Y3RKUC$F-FX8(QG.01U
M%;5 'G'AP:N_BGQW'IK68$FH(HDF9@86\A/FP =_^[E>G7GB[;>!;W1-1T"7
M0KZV%MIE@]BT5[$S_>8,94"D?.2.>G'%==::1IFGSRSV6G6EM--_K)(8%1G^
MI Y_&KE 'G%O\/\ 6;?PQIFC?VC8RBPU@:BDAC9=RK,TH4]>26Z\ 8Z'K6ZV
MESZ=XUO?%=]=64&GG35M9 TA'EJC,^\L0!CYB,<>N:ZJHYH(KF"2">))89%*
MO&ZAE8'J"#U% '%^&]+TZ\\<ZSXDTNZ%QI\JHJ>4X:%KDJ/-D0C@G8(U)'?>
M/6NTN(FGMI85D:)I$*B1.JDC&1[BJ\LEAH6D2R^7':V%G"SLL,?RQHHR<*H]
M.P%36MS%>V<%U Q:&>-9(V*D95AD'!Y'![T >?67@/Q#;V7AF!]5TP'0KDNC
M);/^^0JREF^;ESNSZ9R236BGA'55LO&$!FL\Z^TC(=S?N-T0CYX^; &>U=M1
M0!P2^"]9L+W0=7TN]LEU/3].72[J.8,8;F!<$8(Y4@C/0]<?76\)^'M2T.]U
MRXOKRUG&I7INPD$3+L)55QDL>/E''ZUT]% '.>*?#][K%UHM[IUS!!=:9>?:
M%%PA9'4HR,#@@YPV1]*@LO#^J6?BK7=9,MI*-2MX(43+*5,08!CP>NXG Z>]
M=54<\\=M \\S;8XU+,<9P/PH \\A^'NL6'AOPY'IVJVUOKF@>8D$[1LT,\;_
M 'D=>H!XZ9QCWX[31+;58;=Y=:O(+B]E(W+:HR0Q@=%0,2?4DGDY] !4VDZM
M9:YI<&I:=-Y]G."T4FTKN )&<$ ]15V@#F_%7A4Z]-IVHV5W]AUG2Y3+9W13
M>O(PR.N1E6'!Y!JU;1>(+I4CU)["V0$>8UD[NTGL-P&S/_ CCH0>:VJ1F"(6
M8X51DF@#D[3PUJFA:YK-UHL]HUIJTOVF2&YW V\Y&&==H.\' )4[>1UJI'X$
METW_ (1*#3)H?LN@O)(WG$AYV=65CP,+RS-WY.*ZC1]:T_7K-KO3;CSX%E>(
MOL9?F4X88(!X-:% ')VOAS4[77O%&I>9:,-92)8X]S#RC'&4&3CG.<]L=/>N
M3N=&U'P[=_#71UEM9;NRGN(E<E@D@$#=>,J2,CO@\\]*]8JG=:1IE]<Q7-WI
MUI<7$/\ JI98%=D^A(R/PH Y+6? UYKEEXAGEOHK75-6ABMT:++QP11MN"$G
M!8,2VXX'#8QQS-:>&]?B\80^(I[S3"XTS[#);0PNBC#[QM))P,]R.G;O79T4
M >=Q> M6B^'^E>&1=V1EL;Q+DW'S[7"R^:!MQQDG'7MFI_&-MI/BV_TK2;?4
M8O[8M;S]\EK,&DAA*$3J^.55D.W) Y*UWM5X;"SM[J>Z@M((KB?'G3)&%>3'
M3<0,G\: )U4(H50 H& !V%<[X@T6]UB6XMY+?3K[2KBV6)K6\W#9*"W[P$*>
MS#C@_*,$5T?2L[2=<T[7%NVTZX\\6EPUM,=C+MD !*\@9^\.E ">'])_L+P[
MIVD_:'N/L=ND/G/U?:,9]OI6E110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5QOQ8_Y)9X@_P"O;_V85V58'C30
M;GQ1X5O=$M[F*V^UH$::1"^T9!X (R>/6@#E;[1=5\3:UX+N8--EL;;2&6YG
MO9Y(\NNU?W:!&).['.<#'Y5/JGC'6=)NK=KG[$K2:Q'9/8(ID9+=WV)(TBL0
MKD88 @<'&,\UV^F03VNF6UO<O&\L4:HS1@A6P,9P>E<&_P /-;_L8Z6NNVAA
MAU4:E;R/:,TC-YOF8E;?\W4CC!/'(Z4 7I-:\5WWC/6M"TV328H[&.VGCEGA
MD)*R%MRG#=<+U[8Z<Y%>X\8:]?:7-JWA^R-VL5V\45C]CD/VB-)3&Q\[(56.
MUF'&!T.36YIGAZ_L?&>IZY->6\L5];PP-$L15E\O=ALYQSN.1BLJQ\&:_HVH
MWMMI'B&*#0+RX>X:WDMMTUN7.76)\X ))P2#C/0]P!YUKQ/J'C#6M"L)=-MD
MM;6"X@FFMW=E\S=\K*'&3\O7(QZ&L&\\3:SXA\-^ M4@N8;)M3U.**YA$)=6
M<"0Y^\#MW1YVY].>*Z^T\/7]GXQU778[FV:.]MHK=(&1LIY>[:2V><[CGBL6
MV^'VHVG@_P /:1%JEM]LT._6\AG:W8QR@%_E9=P(XD/0]J .[,GD6IDN)%_=
MIND<+@<#DXR<#\37!3^,]9'@1?&]O':O8#]^VGF,[S;;]N1)N^_M^;ICM[UW
MRQ%K813D2DIMD.W ?C!X]ZXBU\!WMMX6G\(_VC$^@.[*CE#]H2!FW&+.<'J0
M'[ ]* $NO$/B;4/%]QHNARZ4D3:5%J-M/<PR'AY"N& ;G(7J,8SWKM+RV^V:
M;<6LDA3SH6C9TX*Y&"1^=85OX;NK?QV^OI<6ZVC:>E@MLL9#*JN7#;LX_B(Q
MCI6YJ-LU[IEW:*X1IX7C#'L64C/ZT >4PZU?^"](@\)^/=+WZ&J+:VNMV:[H
MMHP$\Q?X&&!SZCH>M=PFNZ@WQ$E\/[K9K-M)^W12",[U<R[,$[L,,<]!574_
M#6NZWX<;P[J>I6,UI,BQ7%XL#+-(@(SA"2H8X^]D@'G%37WA?4$\5V6N:+>V
MMN8[#^SIHKF%I!Y0<.I7##Y@?7B@#C]9UW4?$'@G1KVYCMC>1^*8;=1&&CC8
MQW!1<Y+$9P,]:Z"/Q)XDT?Q3-HFLP65^;BPEO=/DL8VB+M']Z%E9FYY&#G^?
M$4'P\OXO"RZ6=8A:X@U;^U;:5K8X#"4R!7 8;@2>2-OTK:?PY>WNH3ZO>W<4
M>I"QDL[/[.IV6V_EGR>68D+Z8 QZF@"EX1\4S^)]LMKJEA<*+5C<V_D-'-:W
M.5PK(6SM^^.G\/4YJAIOCO4)_!NEWEQ%:G5]3U1]-@5%81*PE==Q&<D!4)QG
MD\9&:U[;PM<'Q3;>(KO["FH6]I);L]I&R?:BVWYI,] -O"\]>O%8Z?#B['@^
MTTDZK%'J.GZBVI6-['"<)*79\,A/*_.1U]* %MHM1B^-3I=7,$[_ /".,89%
MA*8_TA>&&XYY],<'\3/I'BK7=3\$IJGEZ>MU_:,EM<3,?+AMX$F9&EPS<X49
MQNY/Y5<L_#>O?\)E%XDO]1T]I5TTV+6\%LX4Y??D,7)'('.#Z8[UF1_#_58?
M#%IIT6K6HNK/5SJD3M QBD)=GV.F[)&6X(/84 $?C353IOC3RFM)Y] C$]O/
M);NBS(8?- 9,@YX(R" 1@TV\UOQS;>#9/$D1T>6,6<%VMJMM(SA"N9>=X!(!
MW#Z$>YLR>"-7EE\62/K%H_\ PD-JD+_Z*5\IA$8B1\Q^4 \#KTR?7;BN[#PE
MX7TZU\0:G901Q1I:>=*PCCD(7 ^\>,A2<9H 6#69M2UC38M-N+>6QDLOMEQ)
MY1)*M@1;3NXW?.>0>$-2^)]=_L'3H)43?/=745I "I8;W;&2!R<#)P.N,<9S
M67\/- AT/P\[0^=Y=W.\T"S9W1VY8^2G/( 3!QV+&M+Q;X;7Q3H36 NI+.X2
M5+BVNHQEH9D.58#OSV]Z ,/^W_$]O/K,;VB2VL%@UW:7\UH\*^8OWH70MD\<
M@C''K6<OBWQ1'I?A#5Y/[+D@UQH+=[41.K))+$6#^9N/&5^[MX'&3UK>M]#\
M37.D7T.M:S9W%W-:O;0_9[8QQ*&&"[C<2S=.F .<=:I/X*U)O#_A33%O[4'0
M;B"?S#$W[_RD* 8S\N0?>@"-/$WB"RO?%.F7DFGW-WI=BE];3QP/&C*RN2C)
MO)X*=0W>L_\ X3+Q58Z5X8\1:A'IDFCZI]EBN8((W$L)F48D#%L$;C]W' (&
M3UK3UO0+NUNO%?B"2Z@,%YH[6_DA"&01HY!W9P<[CVJMX8T*\U[P)X/AU&>V
M_LZUM[2["Q*=\Q2-3&C9X4 XSC.[;VS0 R'5H-!\;?$75KD%H;.SLIF5>K;8
MI#@>YZ5<O_%&M:'IVAZWJ'V2:POYH8;J"*)E:V\W[K*VX[@I(!R.>HQTJT?!
MCW>M>*+C4)X9;#7K>.W>!$*O&J(R@ALX).XGIP<5';^#]1GTG2=&UB_M[K3]
M,FBD5XXBLER(O]6'!.!@A2<9W8[9H =9^)K^T\4:_I6O36<45G:B^LY8H67S
M+?G>S98Y*D8(&.Q[U%=>(?$.G-X12]6Q$FK70AO$6%E:+,;/A?G.",8.<U!K
ML.A^,O%FC06-_'/>:7<RF^%O(#LA P\4F.S.(Q@]<-Z&MOQ)X?N]:U/0KJWN
M8(4TN\^U%9$+&0[2NW((QPQYYH P9O$/BJYU3Q=8V<NE0_V*(WADDMW?S T7
MF;2-XY/3=GC'W>>+47C.ZOK?P8D,,=O+XBB,KRL"RP[8?,*J,C+$G SZ$X-6
M(?"VHPZIXJO1>6I_MQ$5%\MOW&R/RQGGYN.>W-<OJ]C)I-GX3\)2:WI5O<V,
M#2K)J%N?L\XC4(G5@1(-Q( /8GL* .L\(ZWJ^K:CKEKJ/V0QZ9>-:))!$RF4
M@*P8Y8C.&P0.]6=;UZ:V\0Z1H%D8UO-1$LK2R*6$448!)VY&6)( YQU/.,&A
MX+N=16>ZT^X?0KBUB42+/HZ,B*[$Y5P2P+'[W!SZCD9N^(O#4NJ:MI.M:?<I
M;:II;OY1D0M'+&XP\;@$'D8P>Q[4 85[XRUG34\5Z=,MF^IZ+9?;[><Q,([B
M$J3\R!LA@5*GG!Z^U;_A:YU^^M4O]7DL#;75K#+;Q6T;!XV9<L&))!ZC&,=Z
MH7W@ZYU&U\0S37-NNIZU:"R,@0F.WA"LH"C.6.68D\9..!BNAT2RGTW0[&QN
M)(Y);:!(2\:E0VT 9P>G2@#G/$.M^(8/&>GZ#I+:<B7UG/,DMQ$[&-X]O)PP
MR/FZ<?7M56;Q+K]PFIVMAY)U'2D2&3R[&6:.XN?*5V4$$;$RP49Y[_79O_#]
M[=^.-+U^.Z@2"Q@E@,#1DLXDVY.[.!C:,<&LZ\\)Z[:>*KW6?#6MVUG'J03[
M;:W=L9DWJNT2)AAAL <=#W]@#-EU+Q!?^.O"2RR+IPN=.GN);":$OY4JA V2
M&&X_,0#Q@=CFI-=\8ZSHCRSS_8D\O5([86"J9':V=U196=6^1FSN 8#TP36Q
M?^%;V37="U6RU15FTZ&6WF:YA\PS+)MW,,$ -E<^G/3 Q6'=?#S69M'U+2DU
MRU%M/J?]HP/):,TN[S1)MD;?\P&,< 'IR ,4 ;QUS4_^%D/X>_T7[&VD->Q-
MY;;Q)YJIACNP1U/ '6N53QOXI'@I/%,W]E""WU V]Q;)"^Z9/M'DY5B_R$9'
M&&SC.>U=6/#NHKXYC\1&\MG":8; Q&(J6.\/OSGCD8QCIWK%;X?ZDWP^N/"Y
MU*TW2W9N?M/D-@9G\[&W=Z\9STH V3KFICXD/X>_T7[&VD->Q-Y;;Q)YJIAC
MNP1R3P!UKE%\;^*5\%+XIE_LH06VH&WN+9(7W3)]H\G*L7^0C(ZALXSGM76G
MP_J!\=)XD^TVNU=,-A]GV-G)</NW9]1C&.E8C?#_ %)OA]<>%SJ5INFNS<_:
M?(; S/YV-N[UXSGI0!L76N:A=>,KOP]8O!:-;:>MV)IHR_F,S%0 ,CY!MY[G
M/;',O@37;_Q-X1L]9U"*"*2Z!98X490J@E>Y.<D$Y]"*Y'Q#+)JOCB[BBUG0
M+>XL+2.![75[<D$OEW:,[U)4@H#U'&/KV?A"\OKS2'6]&GMY$ODPS::&%O-&
M%7!0'. "2O!(RIQ0!S7BF9[?XO\ @^2.VEN&%G>_NXBNX_*O]X@?K4.DZ3XC
MT6[\:>)X--AMY]4EB>STZ>= $"#:TLA#;02"6(#=B,UT&J>&M0OO'6D>(8KN
MV2+38I8A;M&Q:02#!.[/&,#L:N^,- F\3>&;G2X+P6LLC1NDC)O7*.&PRY&5
M.,$>] &-I?BG4+SQ)JVC17-I=K!I\=Y:W8@9%8LS*01NPZY7(93[9-<U=>(O
M&6K?"BZ\2F]TRSMYM*DEV00.9EDSC*L6P 5SV)''7K750>%M<3Q5/K\VJV3R
MW&FK9RPI:LJ!E9F!4[R0OS<YR3[9X2Q\$SQ?"^3P;=7T;$VCVJW4<1'!S@E2
M>V?7GVH BO=:UG0K7PC%YME/'J-[#9SMY#*P5HV8;?G.#\N,G/7M4[ZWKFM#
M7F\._8U;2KAK2**X0M]IF159@3N&Q?F"CW&>G%-O_"NLZC9^'$N-2LC/I-Y'
M=NRV[*LA1"@4#<2!AB<DGGMCBHSX1UW3/$NHW_A[6[:TL=5D$UW;W-J93'+C
M!DB(8#) '#9&?7I0!:GU_5X/&VAZ/+#:Q0:A8S3RI@L\<J!<KNS@KEO3M7-G
MQ9XVN?#VN:Q9IHVW1;ZYBD@:*3-RD+8;:=WR' )[Y/ICGJ;CPS=/XNT35XKR
M/[/IEK);>7*I:24.%!8MGK\H[<\UROA+3M2UC0_%^FP75M%9WFN:A"\NTF2)
M6<AMHZ$D'@G&">AZ4 ;5YXJU*YL[6_LGM;+3[K2EO;:29/.EFF8;A$(U8-A5
MP20._48-5#XUUN[T[P5>64%@G]O$).DJN=C>4SY4@],CIC/N.M7G\%7EKKS7
M.DZE!;V$FF1Z:T$UN9'AC3.TQ'< ,@\Y!&1GFJECX$U6STWPG:OJEI*= E\P
M'[.R^:-A0+]XXX).>>>PH KWGB/Q$-%\=Z?/>6B:CH5OYT-[;VY4.CPF0#87
M.&&",Y/8XKK/" NAX1TDW<\<SM:0E62,IA=BX!RQR??CZ5DOX-NKB_\ %\MQ
M>PB#Q%;+;[8XSN@VQ&,').&X;/:MSPYI]]I6@VEAJ%U#<S6\2Q!X8C&NU5"C
M@DG/&2<]^U '+V]]J<?Q4UT7&I1?V?9Z;!-Y1MS\D9:0D ANORY+$'/' Q45
MSXSUF#P+#XW2.U?3SMGDT_RSY@MF;&1)NQO (8\8ZCWK<E\+W)\:W.M1WD/V
M.]LDM;NVDA+,P0L1M;<  0Q!R#_AE6W@.]B\*MX0EU&*70=^%<H1<"#?N\HG
M./\ 9W^G;/- ';K)Y]LLL# B1-R,1QR.#7G6F>,O$;>'KSQ+J7]F#3--DO$N
M8(8G$LOE%E382Q"Y( P<]SGG ]'V[(ML2J-JX4= /2N2T;P4UMX2U7P[JMS%
M<V]_+<.7@0H5$S%B.2>03P: (X-=\11:[IRS6GVK3+F-_MDBV4D'V-@N58,Q
M^=3R.F>_M1IVM^)-;TG2=>TN&SDL[VX4O9R J\=J21O\S=RX&&QC')';)E\.
M^'O$M@L%GK7B"#4-/M%VPK';&.68 87S6W$$ =@.2!D^M3P[X-UWP\HT>'7X
MG\-Q2EX83;G[2J%MWE>9NQMR>N,XX&.P!8BU_6->CUZ?0GM(ETNZDLX8YXB_
MVB6-07W$,-JDG:,<\9YZ5E)X[U;6F\'2:)'910>((KC<+E&9H9(XR3R&&X!@
M>,#..HSQL6OA;4M%U+6I-%OK:.SU>9KEXKB-F-O.PP[I@_,#@':<<CK4*>!7
MT^]\)G2[F&*S\/I*JQS(6>?S$V,200 >2>AY- $FGZSK>H:S-X?-S8QWVFVD
M4NH74<#,C2R9V*BEA@87))/< 8ZU6^$_F_\ "'3^?L\[^T[SS-F=N[SFSC/;
M-7+SPOJ=OXSE\1Z%J%M ][ D%];74+.DFS[CKM8$, <8Z$5:\&>';OPSI-Q9
M7=]%=F6[FN5:.$Q[?,<L0<L<]?:@#.\1>+WTKQ-_8\E]:Z69;19;*XO82T-S
M,2P*%]P"XPO&<G=[<V8M=U4>/;?0)_LOD3:.UZ2(SO24.J$9W8*_,>P^M2^(
M?#]]K:ZA9R/87.F7EN(A!=Q,Q@DY!D4CKU'''*YR*I/X-U"PU70[_1=2@673
M]._LR7[;"TOFQ?*0WRLOS97/7!S0!3L/'.H2Z0//CM#J,^O2Z-;LJ,L8VLP\
MQEW$\*K' /)P,C.:G\1MKZ>%O&5OJBVTM@NE3-:7<0V,Y,3[U9,GH>AXR#5/
M_A6MX_AZZL'UL+>C5WU>PNX[?#02EB1N&<.,$YP!U-:\WA_Q!J?AO5++5]6L
MY;V^M'M%,%NR0PJP(+;2Q+,<YR2!P  .<@&/HFMZWI4O@FSN6L9-,U:T$"Q1
MQ,)862 .K%RV&S@Y&T8]^M=YJ$D\.G7,MJ8Q.D;,GF@E<@9Y (/ZURS^$=1=
M_"3?;;4?V /F_=M^_P#W?E\<_+QSWYKJ[V*6>QGA@9%EDC*JS@D D8R<4 >?
MCQKKTGA/P9JL,=@9M;NX;:X1T8 %PQRI!.!\F.0>M;&AZQKMQXBU_P /W]Q8
MO<V4<$]O=0VS*A64-PT9<G@J?XN<U1B\":E#X;\+:2NHVI.@WD=UYAA;]]L#
M +C/RY#GGGI6Q9^']0M/&.KZ\+FV9;^WBA6$HP*>7NP2V><[CG@4 <5X0URZ
MT#X56-_<-;7<EQ?R6]E$T)4B>2ZD7<S;CD9);@ X&,]ZZRXU[5=%\7:5HVH2
M6US;ZO'*MM<1PF,Q3QKN*L-QRI'3H1C'/6J%K\.Y3\/1X6OM10R0S-<6M[;Q
M%6BE\UI5;:2>A;'7D>G6MA- O[[6--U769K22XTR.06T=NC!&E=0K2-DY' (
M"CID\GC !@Z%XA\8ZSI%QJV_1HX+66\ADB,$A+F(L$8?/P,C!!]SGG K1>,?
M%(T'PGKKC2Y(=9F@M9;01.I#2@X<2;C@ C[NT\=S70>'_"^H:+X9U+2GO+::
M2ZFGECE6)E"&5BQ!&3G!;UYJ@? ^HCPKX9T9=0M=VB7<%QYIB;$WE=!C/RYS
MR<F@"QI^O:_#XEUS0KU;+4+JVL$OK,V\9MP^XNOEMN9L?,H^;/?FJVF>+-4?
MQ1I&D7-Q97!U&QFEE:"$[;:XC"ED5PQ611N((!R".O-6=3\&WVJ:[K5^VHQV
M\6IZ5_9H$2-OB^\0X;//+'CCZU#9>#=;BU7PU?W.KV.[1[>2U,4%F55XV51Q
ME^&^3KT]!Z@&3X>UCQ!:> _%&M/?6MW<V=U?2*)K=AN,3'KA^F%   &/4UO0
M^*;R^N?#NDVYACO]2T[^T+B9D++$@5<[5R,DLV!D\ 'K4,'@K4K;P]XCT6/5
M+9K75)+IH"UN0T/GDEMQW?-C)QC'O[2-X,O(F\.:A:7L":OHUM]D+-&?*NH2
MH4JPSE>@8$9P?6@#,U'QOK6FZ;XNM72R;5_#\27"2F)O*N(74LIV[LAA@@\X
MR*T+?Q#KUMXL\/V6HM826>MV\S(D$3*]N\:*_+EB'!!/\*T[4_!%QJ>E^) ]
MW FIZ]&D,TPC)CAC5=JJHSDXR3DD9)[<"K,_AC4;C7/#&HF[M5_L6.5'01M^
M^\Q A(.?EP!GO0!MZY<W]GH=Y<:7:QW5]'$3##+($1F]V)  []1TKFM(\3W]
MYXONM!2[L[R/^S%O8+Q+=D7?YA0K][#KT(*GU&36UXNT&3Q-X5O]'BNS:27*
MJ%F"[@"&#8([@XP1Z$UDVOAC78_%T7B*XU2Q>;^S?L,L$5JR)P^\;27) SUS
MGVQV .?L?&_B>7PGX?\ $]R-,%K>7L=K<VL<+[BKS&/>KEOE(X^7!SC.><#J
M(]:U'7-:UJQTB:VMXM**PM)-$9/.G*[B.&&$ *@]R2>F.<>+X?ZE%X"TOPT-
M2M2UA=I<_:#"V'"R^8!MW<<G&<UHQ>%=7TOQ5J.K:-J5I%;:ML>]MKF!I DJ
MC;OC(8=1U!H B^$G_)*] _ZX-_Z&U00WNII\5]92?4HO[/M-,AF\IK<_(A9]
MP!#?>^7)8@YXX&*W/!/AZY\*^$K'1;F[BNGM5*B2.(H,$DXY)SUZ\?2H9?#%
MR?&T^N17D(M+NR2TN[:2$LS!&8C:VX 9W$'(/^ !AW'C/68_ L7C>*.U?3SB
M=]/\L^9]F+XR)-V-X&&Z8ZCWKOX9DN((YHSF.10ZGU!&17#VW@.]@\*R>$'U
M&*302Y5'*'[0("^XQ9S@]UW^G:NX">7#LB51M7"+T ]/PH \M\!ZS/)%>Z#H
M\]JNI#5KRYN3<(76*#SV&0H92S$\#!P.IQQGI=0\1:C-J^I:3ICA+C3X(R\O
MV&2</*ZE@N%(VK@#N2=W;'.1!\-]1M;>">UU2U@UFVU*6\@O4@;'ERL6DA==
MWS*<^OOQ6EJ/A37H_$K>(- UBTLKN[@2'4+>XMVEAFV9"N &!# ''6@!EOXO
MU6Z72=/N=/DTS5[FRDNKN/[.TYA".$PJJ?XB<@D\ =R:H77C#Q98Z+82W.F6
ML5W)KD6FGSHWC6YA=P%E09)3(XP<X/Y5IZSX-U2:XTK5M(USR-=L$>-[BYAW
MQW2.=SJZ@C W<C'3IZ$9/CFSU*UT#0!>ZC%/J4WB*Q8S>45B1M^ %3.=HP.,
MY/)SS0!JZ5X@U^S\=GPUX@%C.EU:-=V5U9QM&!M8!HV5F/(SD'/\^-/QEXA?
MPUI,%]@I;M<I%<W/E&46T9!S(5')&0![;L\XP9+70IY?$XU_4GA-S%:FUMX8
M<E8U9@SL2>2S$+V& .^<U=U>VU&X2U;3KB&)XI]\L<Z%DGCV,I0X/'+ YYP5
MZ&@#E-4\5ZI8^&8M8L[[2M0@DU*&"*:&,E)8)&1<\/\ *X+-GKTZ"K]YXHN=
M-\<7FFW?D'2X-%?5"RQD2J5DVD9W8(P">@K.F^' ;PWJ]A:7$%C<7VH)J,20
MQDP6\B%"%"\9!V<GC[QX&,5;3PAJ=YXI;6=7U&SF2?2FTVYM8;9E4JS[CM);
M([<G.<G@<4 3:=J7B?4+?0M6ABL9;'4 LEU; %6MHG7<K*Y;YV' (QSGC%<A
M:ZCKFC:;X_U;29+%$L-:N;F1+F)I#,%CC)089=G Z\YST&.>H\,^%?$.AQ6V
ME7/B"&YT2R(^S*ML5N&13E$=]V-J\=!DXQP.*B'@G4CH/BO36O[7.OW$TWF"
M)OW'F($(QGYL!1Z4 =E97(O;"WNE7:)XED"GMN /]:GJGI5K+8Z19VD[H\D$
M*Q,Z @-M&,@'ITJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4E.!]<4 >B45Q5GJ_BIM7T>3[&]UI]X"+T&!8A;97*NC;B67/!!R>_'2NUH
MJ7>EZ??NCWEC:W+)]PS0JY7Z9'%6@ JA5   P .U+10 4444 %%%% !1110
MC*&4JP!4C!!'!%5[33K'3]_V*RM[;><OY,2IN/O@<U9HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7>G6.H;/MME;W.PY7SHE
M?;],CBK-% "*H50J@!0, #M2T44 %%%% !1110 4444 %%%% !1110 4444
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MTFTN9-/DT]XI;"YB&YK>2,80X/48R".^:JR>#[_6O#]_IOBG6?M[W</DJUM
M(%A (8,%R<ON53D\?*  .<]?10!S/AW0_$-B\9UWQ&-42W7; ([40ECC&^0Y
M.XXR,<#DDY.,3>-/#L_BOPQ<Z+#>QV8N"F^5H3*0%8-P-R]UKH** .:UKPY?
MZQJ.@WIU&VB?2K@W#*+9B)6*E<#Y_E&&/KS4/_"&M/K_ (BO;V\BGLM<M4M9
M;58"K(B*RC#[CDD.>WI75T4 <?X;\+:_HXM[/4/$QO\ 2[/ MHA:B.5@/N"2
M3)W!>.@&<#)QQ70:3;:E;1W(U/4$O7>Y=X66 1>7$3\L?'4CU[UH44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3)B1"Y$@C(4_.1D+[T^L/Q7
M<QQZ*;)IECDU*5+&/+8)\U@K%?<*6;\* .,\!?$+5]5\87WAOQ)#;PW!MTN[
M!XHS'YL3#=R"3\VUE.!TPP[5V>AW6HW,VIW-[=P/91W4D-L$BV$*AVL6.3DA
M@X[<#/>N"^,&B7FGSZ'XVT*'.HZ1.D3H@_UD3-@*<=LG;]'--\8V]XVK>!?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5U=7DB6,JP"D #&<C.>F!U !4\->(]4TO3? ]C=6%L-,U.SAMHI4F)F1U@#
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MC,#YR *0S8&W!QQQD9- &2/B)>S>$/#NNVND0R'5=02PDB-P1Y;&5HR5^7#
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M(63:$!D+;/F)+>@X'6M#_A+M9T_Q;IFF:UI%M;V&KETL[B"X,CQR*N[9*,
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MW*<\X&<_@36_#'B+4H]&UF.[L?\ A(=+NFN$B.X6Q1UV/$#@L!M'WL=<\#.
M 0^'_M@^+_B(7RP"4:9:@/!D+(NZ3!P>0>HQD].M=EK$]S;:->3V7E?:8H6>
M/SLE,@9YQR:YW1M%UY/'5]X@U&/3X8+NQBMS#!.\C(R,QZE%!'S=>/IQD]3>
M6_VNRN+?=M\V-DW8Z9&,T <)X=\5ZA!X)\,/>B*ZU36?+CMOG(W$H7=Y#C@
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MD?\ <8CD?@:GK/T+3Y]*T#3]/N;IKN>VMTBDG;K(RJ 6_&M"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U70-
M'UT1#5M+L[\0Y\L7,*R;,XSC(XS@?E6C10!S?_"OO!O_ $*NC?\ @%'_ (4?
M\*^\&_\ 0JZ-_P" 4?\ A7244 <W_P *^\&_]"KHW_@%'_A1_P *^\&_]"KH
MW_@%'_A7244 <W_PK[P;_P!"KHW_ (!1_P"%'_"OO!O_ $*NC?\ @%'_ (5T
ME% '-_\ "OO!O_0JZ-_X!1_X4?\ "OO!O_0JZ-_X!1_X5TE% '-_\*^\&_\
M0JZ-_P" 4?\ A1_PK[P;_P!"KHW_ (!1_P"%=)10!S?_  K[P;_T*NC?^ 4?
M^%'_  K[P;_T*NC?^ 4?^%=)10!S?_"OO!O_ $*NC?\ @%'_ (4?\*^\&_\
M0JZ-_P" 4?\ A7244 <W_P *^\&_]"KHW_@%'_A1_P *^\&_]"KHW_@%'_A7
M244 <W_PK[P;_P!"KHW_ (!1_P"%'_"OO!O_ $*NC?\ @%'_ (5TE% '-_\
M"OO!O_0JZ-_X!1_X4?\ "OO!O_0JZ-_X!1_X5TE% '-_\*^\&_\ 0JZ-_P"
M4?\ A1_PK[P;_P!"KHW_ (!1_P"%=)10!S?_  K[P;_T*NC?^ 4?^%'_  K[
MP;_T*NC?^ 4?^%=)10!S?_"OO!O_ $*NC?\ @%'_ (4?\*^\&_\ 0JZ-_P"
M4?\ A7244 <W_P *^\&_]"KHW_@%'_A1_P *^\&_]"KHW_@%'_A7244 <W_P
MK[P;_P!"KHW_ (!1_P"%'_"OO!O_ $*NC?\ @%'_ (5TE% &-IWA'PWI%XMY
MIN@Z;:7*@A9H+9$8 \'D#-;-%% !1110 4444 %%%% !1110!GPZ'IMOJTNJ
MQ6JK?S+MDGW'<Z]@>>0.P[5H444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***Y_7=%UC69REKK]SI%M&@\O[(B%Y).>7+ _*./E&,\Y/2@#H**YCX?
MZMJ>L^$8+G5RDEXDLT#SQKM6?RY&02 =L[:Z>@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Q==TO6=1> Z5XBDTE4!$BI:13>83C!^<<8YZ>M87
MB+Q;::(+;0;W4;O[6\"_:K^&RD<J,8) C4@2-R0.B]?0'MZ* .3LG'B'PU#%
MX2U&YT2UM91#'*U@/G15QM"2C(&2.2 <J:W])M;VRTZ.#4-1;4;E2=URT*Q%
MLDD?*O P./PJ[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 44@((R#D>U (.<'IUH 6BDR,XR,]:6@ HJEJ9U,1V_\
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M4Y^E '2444@(.<$''6@!:*3(]:"0.I ^M "T44 @C(.: "BDR,XS1D9 SR:
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MLZ7,+6"T(\J[4)O5G4#+8(&&)_B]2*Z"U\+Z%8W-S<6VDVD4MS$(9F6(?O$
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MA=X(\Z:1WC\1Q0*Z2L"(_M<B@ @\ !0!Z8&.E>K3^$= NC8FXTN"8V*[+8R
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MY[=)[;8K3-B(M;@EQS][))!/3G'4UW'ACPY:^&=-EL[.&."*6=IO(B)\N+(
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MNORB 1#:D8\V'/EC)VC+'@'^+WH ]T$B,[(KJ67[R@\CZT@FB:5HED0R*,E
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M,4 /4!5"CH!@5C2>$M EOI;QM*MA/,<RLB[1*?5P.&_'-;+,J(7=@JJ,DDX
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MFIV<EG?VL-S;2C#PS('5N_(/%5[30=(L+B.XL]+LK>:.'R$DB@566/.=@('
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MY-6[2RMK"#R;2"."+);;&H )/4GU)]: .8\87%D-=\,6<L9DOYKN1[-9)-D
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M#KL5DDVR(N".C8YZ],>U8/B^;2AH/CZUTU;6R2WBBM[A9VR\KI$OEK$F0$0
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MF[L[-[.W>V41VS')B"_+MSW QP>XQ7-7SW2?%+7S8#=>KX80P+ZR>;)M_7%
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M*GJ<_>)SFNEN+F"T@:>YFCAA7[TDC!5'U)KAOAFUFEQXP@M&A"#Q!<,J1$8
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M)!=( LC+F)I-I8'"D8&1C/O766VL:7>6DMW:ZE9SVT1*R313JR(1U!8' Q0
MCZ+I4KW3R:99NUWC[06@4F;'3?Q\V/>B+1=*@M9;6+3;-+>;_6Q+ H5_]X8P
M?QI8-7TRZ:5;?4;24Q1K+((YE;8C#*L<'@$<@]Q1;:QIEY%-+:ZC:3QP_P"M
M>*=6$??YB#Q^- #9=#TB;3?[-ETNR>PSG[,UNIBS_NXQ3K/1],TYF:RTZTMF
M90C&&%4)4# ' Z =J/[8TP6\-Q_:-GY$[;8I?/7;(<XPIS@G/'%/O-3L-.V_
M;;ZVMMP)'G2JF0.IY/N* (M/T32=)>9]-TRSLWF.96MX%C+GWP!FKS*KJ590
MRL,$$9!%<EXLU^\T^?PX^F7EL;:]U>&RN0$#DJP8G#9P/N^F>>HKI+'4[#4T
MD>POK:[6-MCM!*L@5O0X/!]J &6&C:7I1;^SM.M+3>,-]GA6/(]\"BUTC3+*
MX>XM-.M+>:3EY(H%1F^I R:HZUXKTC0+_3K*_O(8;B^D*1J\@7"A22YST7C&
M?4@5CZ=XJDA\8>)[36=3LH=,L4M&MI'VQ*OFJY.6)Y)P._;@4 =G65'X9T&&
M^-[%HFG)=EM_G+:H'W>N<9S[T:K/(5TU[76+6R62ZC),JJXN8S_RS3)'+9&"
M,_2K-QJ^FV=P+>YU"T@G;&(Y)E5CGIP3GF@!;G2]/O+J"ZNK&UGN+<YAFEA5
MGB/^R2,C\*@_X1[1/*CB_L?3_+B<R1I]F3",3DL!C@D]ZTJHPZSI=S=2VL&I
M6<MQ$"TD23JSH!P20#D4 ']C:7]HFN/[-L_.G4I+)Y"[I%/4,<9(/O3;;0M(
MLS;FUTJQ@-MN$!BMT7RMWWMN!\N>^.M"Z]H[V[7"ZM8-"CA&D%RA4,>@)SC/
MM4M[JFGZ;$LM_?6UK&WW6GE5 ?H2: *LOAG09KF>YET33I)[C'G2M:H6DP01
MN.,GD \^@J>31=*FNQ=RZ99O<B(PB9H%+^61@KNQG;@GCI6!KVO7MCXP\*6U
MO=VXTO4FN//^0$L$A9U(?. . >!VZUT5KJNG7UDU[:7]K<6BYW3Q3*Z#'7+
MXXH H7'AC39KS2YEL[.%--.ZW6.W4,GHJM_"O<@=2!VR#M53M-6TV_25[/4+
M2X2'_6-#,KA.,\X/'%,CUS2)KBWMXM4LGFN%+01K<(6E SDJ,Y(X/3TH CA\
M-Z%;C$.C:=&/.^T82U0?O<$;^!][!//7DT_^PM(!N#_95CFY&)S]G3][_O<?
M-^-2W>J:?8.J7E_:V[L,JLTRH2,X[GUXITNHV,%H;J:\MX[8'!F>50@/USB@
M"O/X?T:YTY=/GTFPELD.Y;9[=#&I]0N, U+;:3IUD)1:Z?:P"8 2"*%5W@#
M!P.>!CZ5-:7EK?VR7-G<PW%N_*2PN'5OH1P:FH SK3P_HMA;3VUGI%A;P7!S
M-%#;(BR?[P P?QJS9V-GIT'D6-I!:PYSY<$81<^N!Q5BB@"O>V%GJ-O]GOK2
M"ZAW!O+GC#KD=#@\9J'^QM*^TR7/]FV?VB1=LDOD+N<>A.,D5>HH H#0](&G
M2:<-+LA8R<O;"W3RV^JXP:GLK"STVT2UL+6"UMT^[%!&$1?H!Q5BB@"M>:?9
M:C&D=]:6]RB.)$6>,.%8=& (X(]::FEZ?'?M?QV-JEXXPUPL*B1A[MC-6Z*
M*%MH>DV5[/>VNEV4%U<9\Z>*!5>3/7<P&3^--'A_11!- -(T\0S-NEC^S)MD
M/7+#')^M:-% &==>']&OK*&SN](L)[6$YBAEMD9(_P#=4C _"I+C1M+NC ;C
M3;.8VX A\R!6\L#IMR./PJ[10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<SXVLVOK#3H;?55TS4/MZ/8S
M.@=&F57(1P>H(##ZXQS735!=V5K?P^3>6T-Q%G.R:,.N?7!H \_M+"X\:^%O
M$NAZMI]M8:S!=[9+BU8M"UR(T:.9">1T3(Z]<]35_P &W\WC #6-4LC$]G;G
M3W@E3C[1D?:#CNN511]&K>U6UU>ST^W@\*PZ1;LLP\Q+N-EC$9SNVB/'S9P?
M3K5O3-+CT_2(["1A<<,9G=1^^=B6=B/]IB3CWH \9BLK ?L_Z?<K! )5U&,K
M*  P/VXKPW7[N1]*[G[-:V/QIL(K2&&W5] E#)$H4$"9-O ].:ZW^Q-)\@0_
MV79>4&W;/LZ;<^N,=:D72]/6X2X6QM1.@ 600KN4 8 !QD<4 >*VNCZ9>? &
MV>"U@;6VF*VDL2CS_M7V@A &'.['Y#VKM_#L['XC>+K'6MAN)(+9K<2@;9+4
M1D-MSU4.6S[M791:3IL-\]]%I]K'=O\ >G2%1(WU;&32WNEZ?J1C-]86MT8S
ME//A5]I]LCB@#Q^**>U^&&@QS.?LH\3P?82YY^S?:3Y?7M@9'MCM7M=5KG3[
M*]1$NK2WG5/N"6,,%^F1Q5A5"*%4 *!@ #@"@!:\O\/:7!K7COXAVLMW=1Q-
M<VZ2);3F/>IAP02.1T(XP>M>H$9&#TJI;Z5IUI,9K:PM893U>.%5;\P* .?U
MJUMM'\-V?A?1!%8R7Y^PVB+_ ,LT(+2.!G)*H'.<\MCG)KE_%<%[X-\1>'O%
MUS<V/V.W9=*O%MK9H0MM)]TG,C9", <#%>E3Z?974Z3W%G;RS1_<DDB5F7OP
M2.*6ZL+.^55O+2"X53E1-&' /MF@#SV_=/#GQIAUV_D6/2M8TL645VQQ''.K
MA@K-T&X#C/4FO0)=0MHYX8/,#S3'Y(T(+$=V_P!T=S_4@4YK&S>R^QM:P-:X
MV^08P4QZ;>F*CL-)TW2T9-/T^TM$?[RV\*QAOK@"@#SK0K+3]0^)OQ %W>7$
M.);0 P7\MOQY'/W'7.,=^E3?"EVMM1\4:18NMUH%E>C[%?!1F5V!,BEP/WA4
MX&XY/OTKNCX?T5F+'2+ D\DFV3_"KT44<,:QQ1K'&HPJH, ?A0 ^N0\<W]C9
MW/AV*ZCC^T2ZD#:33R%(8) C?.^"-W!("Y&21R.M=?4%W96M_#Y-Y;0W$60V
MR:,.N1T.#0!XI>3V=QX-^*$+W=K=N+IKA"NW!)BC&]1S@9XS^IKJ[JUL['X@
M> #9PPPM+:7JL8U"^8/*1AG'7G)KO)-*TZ7S?,L+5_.*F3="IWD# )XYP.!2
M#2--$D4@T^TWPX$;>2N4QZ''% 'C$NIV=Y\ -=@U&:$:VLLYOX9F E%SYY()
M!YSC;CV&.U>V64T5Q8P30R))&\8*NC9!&.Q%02Z)I-Q<R7,VF64D\J[9)7MT
M+./0DC)'%70 JA5   P .U 'DFMZ)HVI:%<?$/PEJW]AZJD#7$TD$@\J5P,M
M',G0MGCIR>2#6A=2OK7C#X;SZO:1I<W&GW<T]LZ\+(8HF(VGT/8],>U=XV@Z
M.]S'<MI-@T\6/+E-LA9,=,'&1BIY=.L9[E+F:SMY+A,;97B4LN.F"1F@#R47
M>EZ9HOC&&\M4DLSXI2..(2F**-V\DAG8?=0,,GZ5;MKFTN/&7CB&YO[*\:XT
MB GRPHCD94ESM7)SMP.YQ7I0T;2Q%-$--LQ',,2IY"XD'^T,<_C3CI6G$$'3
M[4@QB$CR5Y0'(7I]T'MTH \H-I::;\$="UBTLT5E@L3J%Q;PJTS6PD1I020=
MPXY!R,9R,5MSP^$]6FU36(O$UQ>RS:)-!=3VTL16*VP3N<(HPPR=N>>#V!QZ
M#!9VMK 8+>VAAA.<QQQA5.>O XJ*VTG3;*VEMK33[2""7/F110JJOG@Y &#0
M!QOA>YUBQ\6PZ+KJ65_*--:2RUBS&TRP!T!65.@.2""..N.]7/%^HV-IXH\,
M0S"&*^DDN'M;NZD*PP8CPY*@@.Q#8 )'<Y]>HL]-L-/W_8K*VMM_WO)B5-WU
MP.:?=6-I?*BW=K!<"-@Z"6,/M8=",]#[T >(PZM%:>$]0E^TK<V%MXS:741'
M@_Z+YN=Q4?P%MIQT-=7XQO-*N/#WBC6/"DR76LRZ8%GNK&;>%B!X!VG ;:7(
MP,X7Z5Z&ME:(LZK:PJMP2TP$8 D)&"6]?QIMGI]EIUO]GL;2WM8,D^7!&$7)
MZG &* /.=8U30-3U7X>G0[FTEA2_'E) P)BC,#X4@?=Z#@^GM5">^L[/0?BK
M9W%Q#%<R7%RR0NP#L'MEVD+U.<'\JZ[7/"<LNJZ!/H=CIEM;V%^;RX7/DF0E
M&3@*A!/S9R?2NDETG3;BYDN9M/M))Y(S$\KPJ69#P5)(R1[=* /.2]I-JWPJ
MN8FA=FBD02J020+0\9^O;UJSX5TC3;CQ3XW9;"SEN;?4XWM]\2MY3B%2K+G[
MIW9Y']*[Z32]/E>)Y+&U=H0!&S0J2@'0#CC\*=;Z;8VDSS6UE;PROPSQQ*I;
MZD#F@#R;PU-X?\0>$M#M-4UZ[75["Z1FTX-"ERMZK'.%V;SEBQ)ST))/!JS9
M:G9R^'OB19ZS- FJ?:KSS8KA@&:'R\08SU7: %_^O7IRZ7IZ:@VH)86JWK##
M7(A42$>A;&:;<:1IEW="ZN=.M)K@(4$LD"LX4\$9(SCD\4 97@*:*?X?>'FB
MD211IUNI*MG!$:@CZ@UYU=WUG;> _B?93W$,=T^J7K+ S .P9$*D+U(."<^Q
M]*]DBBC@B6**-8XT&%1!@ >@%59=(TR>XFN)=.M))YD\N61X%+2)_=8XR1[&
M@#SZ.#3=0^(_A*7R[6X630I6W85@Y4QX)]<<X],5SL]R-.\+:J% 71X?'#)?
MH@^2.T\Q2P('1=VW(]_>O96TO3VG2=K&U,R !9#"NY0.@!QD41:7I\$<L<-A
M:QQS#$JI"H#CT8 <_C0!Y_JE]9R_%NTFTRZM'NYO#UPD+I(IWOO4QC.>>Y%9
MGAB7PWXA\->&(KS7KK^U=.GA9=/5H4N$NTX<%=@<@G<6)/(R2>]>HVFCZ98%
M#9Z=:6Q0%4,,"IM!Y(&!P#3H]+T^&_>_CL+5+R08>X6%1(P]VQDT <+X'TC2
M9_$OC"1["TDEMM;W0EHE)B(B0@K_ '3G/(J]\4V2/PO9RR$+''JUDSNW 5?.
M7))["NNMM.L;.1Y+6RMX)'^\T42J6^I YJ6XMX+N!X+F&.:%QAHY%#*P]P>M
M '!W"V&I_&;3F(@N8?[ F>/.'4G[0@R.Q[UR$-Z-)\(Q3>;)!H]GXPN%NG@4
M,((=[[#M((VJY0]#VKV0Z5IQG$YL+4S !1)Y*[@ ,8SCICBB+2]/@AEAAL;6
M.*88D1(5"O\ 4 <_C0!S?AJWT&3Q-J6K:3K,FJ75W!&+N6.6)X1MX3/EJ!OQ
MGWQU[9R_B,J2>*? L33-$7U1@&1MK#]V>GXD?G7=V5A9Z;;BWL;2"UA!R(X(
MPBY]<#BF7.EZ?>2B6ZL+6>0='EA5B/Q(H SK+PUIFC3ZCJ42R27]XG^D7=Q*
M7D95' R> H]!@5YSX<U&PM? GPXAG6(7<KR&TN;B0K!;NJ/EG (W'!(5<C)/
M45Z_)#%+"89(D>)AM*,H*D>F*JG1M+:U%J=-LS;A_,$1@78&_O8QC/O0!XIJ
M$UE<?#/XDQ-=6UU(FKR3HPV]_)^=1V!)."/S-=S>VEG8?%GPJMG##!YNG7B,
M(E"[U'ED XZ\Y/YUV<FE:=,)1+I]JXE8/)NA4[V P">.3CC- TG3EFCF&GVH
MEB $;B%=R8Z8..* .1^+D4#^ 9GF1"R7=KL9ARN;B,'![<9JO>:9IJ?&;28E
MLK95.B3'8(U .V5-O'MDXKN[JRM+Y EW:PW" Y"RQAP#^-1?V5IWGK/_ &?:
M^<@"K)Y*[@ ,  X]* /)K.]TS3= U2&Y@C>$>-I(;16E,<-O)Y@9&<CHBD$X
MZ'@<9R-GPN+#5O&_CS3+R\M;Z.]2T5UCPJR@PLK[5R>!P,Y/09.:[[^Q=*\B
M6#^S++R9<>9'Y"[7QTR,8-0ZE974&GW,OA^VTV+5FC5(GN8R(R%/"L4^; &<
M8Z4 <5X-^W7-U;^%M1C=O^$6F(DF9>)QMQ:D>OR,S'T*+ZUL_%,$_"_Q#C_G
MT/\ ,5N:'IUU96\TVH2PRZC=R>=<O"I$8. H5 >=H50.>O)[UILJNI5@"I&"
M"."* /.-5T?3U\4>![C0;:WBOEF9Y9+50-UIY1WEB.JDE0">[>]8.B3:'KWA
M$:3XAUZZ@U>UOW:XT]&A2X^U"4L#&"F]BQ(P03UQFO6[+2]/TT.+"QM;4.<O
MY$*IN/O@<T'2]/.H#4#86IO0-HN?)7S,>F[&: *7BN&TN?">JV]_=/:VDML\
M<LZ=8U88+?AG->>:C>>*K>R\0Z-=0VUWK2Z$\UGJVG@J9X0V-K)_#)RQ&..N
M*]8EBCGB:*:-9(V&&1QD$>X-0V>G6.G*RV5E;VP?EA!$J;OK@4 ><ZT;74_"
MO@*[T H+I;ZT^Q&+JL>W$J\?PA VX>W-0ZG/?1:U\57THL;]-/LS%Y?WP?(?
MD>^.GOBO2K;2M.L[F2YM;"U@GESYDL4*JSY]2!DTZ+3K*"Y>YAL[>.X?.Z5(
ME#-GKD@9- 'EFK:IX?GT#X;W%C=68BBU2U"8=08U\M@P/I@X!]\9KO?' W_#
M[Q&%&XG2[G&._P"Z:M"+0](AD,D6E6,<AD$Q9+= 2_(W9Q][D\]>35X@,I5@
M"",$'O0!Y5J,MAJ6C?#6)9+>YA-];QR*&#*3]F;*G\QD>]-OK>T34?BQ;"&%
M85TR"7R@HVAS;2_-CL>!S7I1T72C'%&=,LMD7^K7R%PG.>!CCFAM&TMWD=]-
MLV:7_6,8%)?OSQS0!YAJ]G::7\,?"NIVME ELTFF-J\T<8W26HPS;V'++N()
MSZFNDU.$R?%OPU=Z8RG?877]HM&<AH,+Y6['^V3CZ'TKLXK.U@MC;16T,=N0
M08D0!<'KQTJ.RTVPTV-H["RMK5&.66")4!/N * /%%U&Q@^!VGV4EU EU!JR
MB2$N-\>V^).1U& 1U]1ZUU>I:K8Z9\1-7DFOK"YCO](A00W%W'%Y?+[0-Y 9
M&R2=N2...17>?V-I?F32?V;9[YW$DS>0N9&!R&8XY(/.37+ZGX<UJ;Q#>W9L
M/#VLV=R4\I-3#));*JXV*0CAESENQRQH Y>^T*ST?P3\/M(,]G>H-=M5FE@P
M8YV*R;N1]X?P\]0!FND\/106OQ9\5P6Z1Q(UE9.T<8"@M^\&<#OC%;>D>$]-
ML+)HYM.TYGDF,YCBME6*)B%&(U.<#"C/J<GC.*UH].L8;IKJ*SMTN&^]*L2A
MS]3C- ''^.IH;7Q7X(N+F2.*%-1E#22,%49@?&2:HV-KI^H_$;QTUQ#!<*+&
MRV^8H8!6BDSU]1BO0;BTMKQ%2YMXIT5@ZK*@8!AT(SWJ$Z3IIEED.GVADER)
M&\E<OGKDXYH \CMO*D^&WPNGDV-*NKV2+(V-P'SC /X#CVK6\2S7VB7FOZQ8
M26NL:*UU$=6TJ8;9X9 L:AHF'4X$9"GTXKT0Z)I1B2(Z99&-"61?LZX4GJ0,
M<4YM(TQ[P7C:=:-= @B8P*7!'0[L9H H>,/MQ\%ZW_9F_P"W?89O(\O[V_8<
M;??T]ZX_0)O"OB*3POJ%IKT]S?6:XM+*)H5DARF'5T5 P0 <YXX&,Y&?2ZIP
M:3IUK///;Z?:PS7'^NDCA56D_P!X@9/XT >8W1LM!\:#7E3_ (I"_O@MP=P\
MJ._&5%QMQ]S=\I.<;QN[*:USK6GZ?\4]=M?$-S!;PW>G6XT^2Z<)&T(W>:JL
M>,ECDCO@>E=N=)TUK5;5M/M#;*VX0F%=@/KC&,T7.D:9>10Q76G6D\<!S$DL
M"L(_]T$<?A0!YW?6.BKKOPWL=/MQ_9(FO!;Q2DN&00-M/S$DJ3@C/8BLZ^N=
M*TN'XDQWMH)M.&H6FZVCD,2[G2(9++]U=V"Q] >O2O6)].L;F9)I[*WEECX1
MY(E9E^A(XJ,:1IBB8#3K0"<%9<0+^\!ZAN.1]: //+"[M;CXK:I%=ZAI]Y]I
MT&(,(0HC=A+)\H&3NP.>23]*P-.M;.#X4_#Z\CAA2X.LV1,P4!R3*0<MUZ<?
M05[&-)TU0H73[4!8O) $*\1YSLZ?=SVZ4TZ)I)B6(Z99&-"65/LZ8!/4@8Z\
M4 >=:M>6EGXN\;6$]]ITS:K901+'=7<</D-Y3*$8.02F&#Y4'&X\9J*X^R>$
M+KP+;7.JK;Z.EE+;_P!I6ZQ^4;K;& [%E91N4. QYY//6MZZ\,:R=9OII=,\
M-ZS:7,V^)]05DEMTP (P/+<%1CC!7J3WKH-+\-6%CH1TJ:TLY;=Y&ED@%N!
M&9MQ"QG("@G@4 8_AV3PQX=L]5OK36O,L;J^\R:ZFFC\@SO@$(5 7KC..,^X
M..RJJ=-L#9)9&RMC:)C9 8EV+@Y&%Q@8/-6J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J"[OK2PB\V\NH+>,G&^:0(,_4U/7'_%0 _"[Q#D9_T0_S% &W
M_P )-H'_ $'--_\  N/_ !K5!!&1R*\7^'=UI^K^ O#7A.\TB66*_MKKS;B:
MV_=;59^$<]7R0>.F*ZB]\=W9\1ZWH>B6UM)_8-@;FYEN2W[UP 1$H7&..K'/
M/:@#T"BO+M;^+OV/P!HGBW3M/2:'4+D6TMO*YW1/ALX(ZX*'MSD'BM#6/'NM
M>%]$U?5?$6@PVL2310Z7''=!FN"X/#D?=QC)X]<9QD@'?R2)#$\LKJD:*69V
M. H'4D]A4=K=VU]:QW5G<17%O(,I+"X=&'J".#7G-WX[2_M_%>A7<>G:A)8Z
M2][OMI"8+F'9^\C."2I&=N0>X.!TK,T+QY!HO@/P3::-HL-K+KMR]K;0&5GB
MMP)MK.S'YFY8'&1G)YXH ]?HKSNP\>ZO<ZKXMTZ2RL!)X>A:0R*[CSS@LORX
M.T$*<_,2#CK6%;_%_66T7PWKEQHME'INK7QLW5+AFE4ABNX#& .#USG':@#V
M&FR2)$F^1U1<@98X&2<#]:=7F?QD&J:GX3OM-T>0J]I NH797.3&K_*H]SM=
M_P#MECO0!Z917'^$_&L>N?#2/Q,R&::"T=[F*/[QEC4[U ]\9'LPK,\*?$:?
MQ#H\NKK'97%K#8S7-Q#:,PFMY4P1"RMUR-V'& <=* /0Z*\_\&?$1O$VG_VI
M(^GFQCM)9[P0,PELW4@A'4_>!7>0XP#MZ50TGXM)?S:!<2Q6:V>MW;VL=O'-
MNN+8[ML;2#."&(Z8&,CDT >GU$MS ]U):K/&UQ&JN\0<%E5LA21U .TX/L?2
MO,/ 'B#Q'KGQ(\8)>O9FWL9XK5HU9L1(IF \OCDDY))Q_0=7X.(OFUKQ"Y&W
M4;UQ"Q_Y]X?W2?@2KO\ \#H Z<2(93$'7S H8IGD YP<>G!_*G5X=>>)=3T'
MXS:1X@U"4C0_$-O]E@!X$<0;$9/ODI(?02$=J]*\6^+1X=NM&TZWB274=8NQ
M;6XD)"(,C<[8Y(&1P.N>HH Z>BO.[WXBZCX>\+ZQJ/B'0GM[JRO?L=JJDI'?
M$GY'0MDA<9)Z\#N>*NOXRU?0YM?/B32-ECIEJMU%J%JK"*XR!F,;B?F#''7M
MD@4 =O17F]E\2KN*;PG+J]E;1VGB;<+?R&;=;-E=BN3P^[>O("X]*;_PLG41
M?^-K3^S[7=X;@,Z/O;$X&3@C^'@>_- 'I5%>6ZQ\5+_3?AAHOC"/3+>1[^80
MR6S2, N=^"&_X!Z=ZUM(\;ZM<?$74/".I:;9PS1V8N[=X)F8?P_(Y(Z_-U [
M=#0!WE5[N_L]/C$E[=P6R$X#32! 3]37FOPGU_Q!XCU'Q'>:E):O$NH-"X4L
M#'M4!50=-OU.>2:V_C  ?A1K^1G]RG_HQ: .GM]=T>[F6&VU6QFE;HD=PC$_
M@#6A7S7JNI:;K?PH\*>$-/MWF\3S")K96A,6P9;+"1P 0<$<$\_2O6]8\62^
M#K'POHE[/!-K&H*EO)<W#[8DV*OFRL>,\G@9&2>HH [FBO*K_P"+<]KX.U?5
MX+.TN+K2-1^PSHLA\J8%L+)&PS@'K@Y[\UHP_$'5++Q?H.DZWIMI#:Z[;B2T
MEMYF9HGQG8^0 >H''3/>@#T2BO,+GXIW4FG^)-:TVPMY=)T&Z2W=9&82W/S!
M792.% R",@Y]JM:_\3)M-U;PI%IFG)?VGB&,/#ERDBYVX'ISO'7IS0!Z+5>:
M_L[>[@M9[N"*YN,^3"\@5Y<<G:#R<>U>0_$/Q5XVL?!UBM_86>E7%]JGV218
M9S(6BZK@CH&P0>^.PS6IXDOU@^)W@JVUG1K"YU";S/)NHII!]G.><#HW&#R.
M#F@#U*BO*[WXF:^FI^+[&STG3W/AZ(SM-+,ZAT )^Z 3NQ[@>]6[GXI.?#?A
M&[M-.7[?XDG6WB21SY<!W!68D<D D8'&: /2:KW=_9Z?&)+V[@MD)P&FD" G
MZDUR/ACQAJ6L>-==\.W=K9H-(VAYXF<&7=RI"D$#CJ"WYTSXQ 'X3Z_D9_=1
M_P#HU* .QM+ZTOXC+9W4%S&#@O#('&?J*L5Y'IOBJX\$_ '0]:M;6&Y,44:M
M%(2H(9R,@CODULZ5\0-5E^(&F^&]4TRTACU/3A?6[P3,[("&.U\@#/R-TZ<<
MF@#MKO6=+L+F.VO-2L[>>3 2*:=49LG P"<G)J[7A7ARW34_B5X^;Q/;V5U9
M6IBGN@Y9@@B#%2GJ!COVKHHOBS<1^'](\4WNGP1:%J>H-9*BL?.@7+ 2,>C?
M<;*@#'J: /4Z*\ZU7Q_K5K\0[KPCINBV][<"S^TVSF8Q@G&</G@#KSWXZ9X9
MJGC[Q'H^L^%M'NM#L_[0UJ,^;$;@@02#@C<-P(Y!XSWZT >D45Y+'\4/$<MA
MXM5='TW[;X:D;[1(9W\J1 6'RC&XL=C=2!TKH5\>W5WX;\,ZE8Z/,[ZVZ([A
M&DBL\_>9\<E0<^G )R,4 =S4%W>6NGVLEU>W,-M;QC+RS.$11TY)X%>=:5\2
M-0UCPYXRE@MK'^T?#QE"RH[&"=5#D..IZ(>,\\<URR:U?S_L]2:MX@L[/5K.
M60R/')+(DDI:Z8$LRXVD,01CL,4 >YHZ21K)&RLC %64Y!![BG5Y['XV\B^\
M(^%M'L[>&\U/3TN?WFYHK2$1$@8!!8_(0.1TJF_Q6F_X0/7M:CT^$:EH5V+6
M[M6<E'/F!-RMU .<\CL1[T >G45YIIGQ(U:;Q;X9TO4=*M(;77[ 74#PS,[Q
M$H6^;( P<=!TSUXKTN@ JA<ZYI-E,8;K5+*"4=4EN$5A^!-7Z\X\53BU^,/A
M:;[)-='[!=CRX5#,?N^I% '>V>IV&H[_ +#?6UULQO\ (E5]N>F<'CH:M5Q\
MGB'3]*T;4O$\NDRVMRTJV9@=0DLS+(4B![#)<\\\'/:IYO$M_I/B/3-)U>UM
M@NJ*ZVMQ;R-M691N,;@CN.C#KCH* .IHK@]+\<:Q>P7NI7.CVEMI.FW-W#?S
M"[+.@A!^9%VC<,COCKTXS4]MXUOGU?2(GTU9;/4_E+6PD9[1B,KYA*X(/0D8
MP?7K0!UEKJ%G?27,=K=0SO;2F&=8W#&-P =K>AY%6:X>T\:1V>C>+M5O-*BM
MO[&O)(Y4M7W&X*HA#%MHY.X#D<#Z58?Q3J]KXDT72)M.LI3JT#SI*ERR"+8%
M+K]QMQ 8$'Y<^U '845YQ/\ $+78] UO65T*R^SZ+?RVUTAO&+.D9 8Q_)R>
M2?FQVX->BQR++$DB_==0P^AH =17)6'BV?5M4N[:P2S=K*_-I<VCR$7$:!]I
MFQW4]0.F.<YXK,D\:^)[E=?_ +,\.V<S:+=-%*KWI'FJJ*V$^3EB#WP!QU[
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M!A&S95=O<#&<CJ>*R+CQGX@:X\3P66BV)?0BI=I;QMLJ&/S.,)G<1V( 'J:
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M:JF^XU%$5 &#9XR3TK<_X5]X-_Z%71O_  "C_P */^%?>#?^A5T;_P  H_\
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M#WPZ\)Z'YNA:U=V5[ND2TU)0X"EG#1R<&,Y(RW^->FV/ACX<:FY2PT?PY<N
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MIFCQ8MCK?Q!\,Z]9^(_#@M-)9FE674E5WW$9V@ C@#N:[+_A7W@W_H5=&_\
M */_  JK_P (CX _M;^RO^$?T+[?Y'VC[/\ 8X]_E[MN[&.F>* /.X-(2+_A
M8&?$?A<_\)-G[/\ \34?NLL_W_E]'[=Q^-.N=.G/@KPIH=KXN\+@:7-NO[:3
M4@8+M P*@X )7KE2,'/M7IG_  K[P;_T*NC?^ 4?^%1S>!O ]N$,WAK1(P[A
M%+6<8!8]!TZF@#@/#FDV>FS^.HK[Q9X:-OXC$ACE@O%#(SB3JA/ 'F'C<>E4
MO[)9_@R_@B3Q)X4%PK@1S#5!M*B8REC\N<]!C'OGL/4/^%?>#?\ H5=&_P#
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M+Y_DXZ9XSZ5VQ(52S$  9)/:JFG:KI^KPR3:=>0W<4<AB:2%PRAQU&1QQD4
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MD[>N/>KM %'1;:YL]$L;6\$7VB"!(Y/*8LA*C&02 >WI5ZBB@ HHHH ****
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MD"I\ZN-AVC(.W'08ST;%9R>!M>3X:VGAG?IINH+T7!E\]]A47'G8_P!7G/\
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MX@\.M=:8\NHW\EQ#*#(BJKR^82PP>>,;1G']XT :GB$?\74\%8QG[/J'./\
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M5L\<1?S4>1"RN"3C;E?N\G'?TU9?$6N:G;:Q=>'+2TN!IMTUHEM.#ONW3'F
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M"*X1<YC<@'!_ BKE<CH^NZKJT_BBU\JRM+G3;L01.JM(K#RU;+<J2<'';\:
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M[^S8D61C';Q8;^+:"Q+.6/RCH![TE]X.O=1\ Z7HIO8[35=+$#VMW#ET6:$
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MM^=+O;.[A54,T3*UK)MVF1!\V>>0,@@_Q<UU%A:BQTZVLQ(\H@B2+S'.6;:
M,GW.* ."^#TS:KX=U'Q#=?/J.IZA,\[M]Y0IVI'[*H' [9KH/%'A"#7M(UN"
MWE^R7FIVT<+S@<$QDLA8=^6(/MQ5.Q\+:IX9U6_F\.W%FVFW\YN9=/O RB*4
M_>:-US@'^Z5/L16O<:?K%QI\Y74HH=0=HVB*1L88PCAMNW(+;L%2<C(/0=*
M.1\'>(_M&O/H7BFS%GXCANI)X&49@N#Y>UC$W?Y225/(S[<:.MHB_%WPFX4!
MFLK[) Y/$52VOAG4=0UZVU#6!:P1V%[)=P16[%S*[1A 2Q VJ!GY<9)QD\<W
MM2T&_O/&VD:Y%+;+;Z?#-%Y3;MT@E"Y.<8&-O3G/M0!D6TTEW\;[Z.8DQV.B
M((%/0&27+L/<[0/PKA;J\G#W>A G^SI?'D5NR_P^6Y\UH_IO&<>YKU;4-!F_
MX2>#Q%IK0B]6U:SGBF)"31%MR\@$AE;D'!R"1[C,/@&!_#4]@UU_Q,9M0.JF
M]$?W;O?O#A<_=& N,_=[YYH KZM,]I\9_#HA)'V[3;F&X [JA#IGZ$G\SZT?
M$":237O!>G$G[-<ZNLDH[,8U+*#[;L'\!6O!H5R_B&3Q%J,ML+V.S-I;1QY:
M.%2=S.2<$EB!Z8 QSR:R[?1M7\2>&;-M9NK?^U]/OQ=6=[#"5CD*'@E#SM8%
ME[9&".U '/\ C;5+O0_'6MS:>S(\OA&:=]O:2-V"/]1N(I-?4:1\(O!UU9_+
M/9S:=+"R]2S8#?\ ?09L^N37:0>%UN]7U+5M9$,UQ?68T_R8LE(K?DLN3@L6
M+$DX'88XR:-OX,NGL-$TC4+N*;2]&F2:$J#YEQY8(B5^P"\9QG<5'W>E %#P
M4!J^H>/IKX;S+JTMBP;_ )XQQJJK],,?S-7OA-?7&H?"W09[IV>40M'N;J51
MV1?T459F\,7MIJ&MS:-=001ZR 9Q*I)@EV[#*@'WLKCY3CD9SSBMO1=(M=!T
M6STFR4K;6D2Q)GJ0!U/N>I^M ''^+?&6L^'+76+YH["*.Q>,VUI(#)+=P_+O
MDRK?NQEB 2O!7G.:GN;K6'^,-I917\*V(T:2X6%K<G&9HU;D.,L<#!Z =CR:
MI:MX UG4++Q5IT>KV8L]<F^T+)+;LTR-A0(RV[&P;1C@D#-;4GAO5CXMTS7T
MU&T$L5BUC>*;=L,I=7S&-W!R,<Y_&@#;URZO[+1+RYTNS6\OHXR88'D"*[>Y
M)  [_A7-Z3XIO[SQ;>:"MQ87H735O;>[AB>--V\H5/S,&&<'*GU'6MCQAH4W
MB7PK?:1;W?V26X50LI7<.&#88=U.,'V)K)M?#6OQ^,(_$4]_IS2?V9]ADMXK
M=T08<N-I+$@9/).?IW !A6'COQ+-X7\.^);F'2Q9:A>QVMQ;QI)YF'E,8=6+
M8&./E(.>N1G Z2W\0ZA;^/;W0M6:SCM#9_;+"5(V4RH#B0,2Q&5XZ#D'/'2L
M>'P#JD/@+1O#8O;,R:=>1W)N"K8D"2^8!M[9)QU[>_$OBZWT?Q?JFDZ3;ZC$
MVK6EX?M"6LP9X8"A$Z/CE592$Y[LM '5>';R^U#1(+V_$(DN,RQK%&4Q$3E,
M@L3NVX)]SCM7-:;<ZU-\5?$%LU_;O:VUG;&.%K<_*K&0X!#\'(Y8@YXX&*[@
M      = *YM/#U_;>.KS7K6\MQ:WMK%#/!)&2^Z,MMVL#@ [N<@T <U/X[UV
M'X=:IX@6WT\WEEJ3VACVOY943B+(&<YYSUK4N-<\46OC2#07_LEEU"TDN+:4
M1R?Z,4900_S?O!AATV9/I5*7P#JLO@75?#IO;,27^H->>?M;"!IA*5V]^1C.
M>];MUH.HW7C72]?\RU6.SM9;=X<L2WF%22#CMM'&.?:@#'L?'5]'H5X=2AMV
MU.VUHZ,K6\3^7(^5Q($!+8VMG:"2=N >:UM"UG6[GQ)=Z=?6;2Z>+<36^H+9
M2VR[LX:)ED))/<$<8]ZQI/A[>W>DZW:S:C';W-YJYU>SN;=23:S?+M!!^\!M
MZ\9R>!71^'[+Q'&QG\1ZE9W$RIY<<=C"T<>,@EVW$Y8X'3 '/K0 >(=>DTV_
MTC2K-8SJ&JSM%"902D:(A>1R 03@#@9&21S7'P7&JZ;X]\:W4DUI)=VVCV\L
M3B%@C!?-8!EW9SP1PWO[5T_B[PQ=:W-I6I:7>1VFK:3.9K9YD+1N&&UT<#G#
M#N.:IVOA+59O$.L:GJE]9>7JFGI9RPVT+93 89#,W^V>W/M0!$?&&I_V3X(O
MQ%:8UZ2WCN8]C?(9(C(2AW<8(Q@@TFGZ]XKU;Q-K&G6R:/';Z5?PQ2M(LA:2
M%D#L%P>'P>I&/:JD'@?Q&=,\,65QJ^FA= NHGA,=LY\V.-&0;LM][!' ( Y/
M/&-_0- O]*\0Z_J-Q-;21:K,DRI'N!B*H$P2>N0 >U '.W/CG7;?P1XLUA;?
M3S>:-J,UJB[7\MD38,D9R3\Q/45KPZ_KEIXVTS2=32P:TU6UFE@%NCAX'CVD
MAF)PX(;J M9T_@35)_"GBC13>6:MKE]+=B4!L0B0J2N/XL;1SQU]N=B\T#4;
MGQ3H&MO+:I'I4$T<D0W$R>8J@D''&-H('.: ,&]\>:N/"E[XELX;/R+;4C9?
M8I8V,A43"')8-]_)#8QTX]Z]"B$_V5!,8Q<;!N* [-V.< \XS7D.E37UW#-K
MUAJO@ZXMKB[DO%_M".1)5;<=F\*^T.JX&=NX8[FO6M.N)KO3+2YN+<V\\L*2
M20DY,;$ E?P/% 'D\ESJU[\+?'TVI7T-SLN+Z'Y8"C90A 0=Q 7"@!<<>IKJ
M-/UW6]/\1>&]*OUL'L-6M)/)6%'$D#11JWS,3AP03T48/ZQ2>!=6_P"$?\3Z
M)%J-F;76+BXFA9H6#Q><VYMQSSCD #&<Y/I6C/X:U*?7?"VHF:T4:+'*DB#<
M?.\R,(2#CC &>_I[T 93>-]:O--M]9T6P:]MI+G;]A6PF\QX-Y4NLWW-V!NQ
MC';)/-=[<BX:UE%J\:7!4^6TJEE#=L@$$C\:XC1_!_B/099M*T_7;5?#3S/)
M'&\#&ZMT9BS1QN&"@9)PQ!(SP*[>XN(;2VEN;F5(8(D+R22-M5% R22>@ H
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M2Q7-NNEK"XG@:,F1I,C:0V< #G_/30H X'XI?<\'_P#8SV7\VI/%:ZFWQ/\
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MK*9!$QB"M)CY0YP,^YP:YKP)X;O?"FAR:;>7%O<9N))UEB!7[[%B"#Z$]<T
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ME9F^=2>#QGO[5GGQAK5GJ6AQWS69EO\ 4FL;NQA0N+4$.4_>J2-^%4D'KDX
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MX#;2N6!8 [<G!SG/R]*P=-U[Q'I7PZ\4:\+^UNKJTO[O'VBV/S%)-O9QQ@#
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M-TGQ#I6N/<)IMU]H-NYCFVQL!&XZJ20 &'IUK24$* QR<<G&,UP7PN_YG/\
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M]_Y#@GGYLD]!CG?N?%%S>ZJFF:=O@?\ L^*]EE6U:X*^86"*%!']TDD^P'J
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MAGT*.23^T((!<21M$R@(3M!#$8//IGH: .;E\$Z@_AGPOI"ZE;!M"N;>?S3
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M6K<CP_(71C9']]E2N#^\XX8_C5W7_".H7?B2'Q#H&M?V5J(@^S7 DMQ/%<1
MD@,N1@@DX.?:@#)N?&6M:3HNAS^*;631A</+'?W<,0E6!EP(S_$%5\DY.<8Q
M[U!XDN+V\'@2=;RRN[F36&,=S$,PNOER[6 !Z;<'&?;/>NK;1-5C6S\K5HYR
MD<JWB7EOO6Z,A4YPK )MVD <C!Q[UBP_#QK.TT&VL=2AACTF_DO]AM25=W+Y
M50'&Q!O( YZ#F@"H_C?4?#EOXS&M20W[:"L$L,L47D^:)ERJ,,G&&XSZ&M'5
M=:UGPQJ&@2:A<PWMGJEVEA<*D(0P32 [&C(/*9!!#9/0YI]QX#34=0\42:E>
MI/9Z_##%)!' 4:'RU(4ABQR><].H%3P>%;ZX71XM<U.&^ATF59X?+MS&TTB*
M51Y"6/(!)P ,G!]J .=CUZ'PQK7Q,UJ>,R):2VL@0'&]OLZ!5SVR2!3_ !'!
MJR>)/ <NH7T4_F:B3+$D(41R>2_W#UV]1\V3TYK7D\!+?2^*EU*^2>T\0A-\
M4<!1H2B!%(8L<XP#TZC\*KCP7K]P= _M#Q);SG1;@2Q2)8%7F 0I\Y,A&[!Z
MC'?@]@#H?%M_>Z3X2U;4M/>%;FSM);A/.C+J=BEL8!'7'_ZZYK4_&DNF6GAR
M;5+I]/L-0LA)-J26^]$N"J%4;@A%.YCDCL.1S75^(M+DUSP[J&E17"VYO;=[
M<RM'OVAU*DXR,G!]:S(O#VJ6]E8VBZC9SV\%B+.>WN+,M'/C #XW_*<#!'(.
M?I@ V-&FGN-&LYKJX@N)WB5GFM_]7(3_ !+R>#U'-<3)XH\3ZKI+:UX>L9+G
M;=ND-D8D$<\*2F-LR%@0Y"EL]!TP>IZ[PSH,/AGP[9Z/;R-)';*0'(QDEBQP
M.PR3@=ABN<LO VJZ3J%Y#I?B62VT"[G>>2P-L&DB+G+K%+GY023V..W/- $?
MB7Q)KWASQ);02-#)INK1FWL&*!6AO#C8DK$X*$9.0,\$<]];4-6OK/4]"\/"
MYC;4-065YKORL!4B4%BJ9QDEE R3@9)SCE-9\(?\)!!J\.I7,$T=W (+,?9R
M/L:]<CY^6W!6R-OW5]!5'4?!.J:AINBRMXAV^(-&8FVU-;7B164*RR1ECG<
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MKNC:O]FU.VMC9SO=P^>EW$6W'> RD-N);((Z^E %3X9+<)_PER74B2SKXBN
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MT9WC#N1@KOPQX]@,]#572?'VJW.FP:?>6\?]N_VO-I,SVZ90F)#(TB*2.J@
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M ,?4S\O\HSQC@#T '-2> ?#Z^'/"EO:A9E>4F9EF;+H#PB$^J($3_@- &/\
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MHX[[02>OO@"@#J-"UZQ\16#WNGM(T"S/"3)&4.Y#AN#R.?6M.O&+#4];\/\
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MOERO)[X'-=%:7]O>M,D3'S8'\N6-AAHVZX(]Q@@]".154:':?9%M6,CQ^?\
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M_$^+>:)949P4^5AD9!Y'![U1/B&R'BE?#NV?[<UJUV"8B(]@8*<,>IRPZ9H
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MTYC[G(;'SEO7GI5&U\8:OIVD:S:WEQ]OOK378]*MKDQ(C.LICVLRC:NY0Y]
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MK/2X+?4M0_M"[0$277DB+S.3@[5X'&!QZ5=HHH **** "BBB@ HHHH ****
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MS>;V3$9CWA.#G).3Z=JY&77/%&B6%MINJ2*+O4M92QL+Q_+:1;=\MO=5^0R
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MYC5PZO(JD'/3KVP: .MHK@=^OI\0Y?#G_"1W#6EUI9OO--O#YL#+*$*QG;@
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MF_[9$4 =3;7$-Y:PW-NXDAF021NO1E(R#^59<_B6T34Y=,M(;G4+V  SQ6B
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MWW]JJ%PWN,8/O6#9:GJWBJS\1WFGZI+82:??3V5G$D:,NZ(#YI-RDG<V>,C
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9FN:/\
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M2R=Y IP58]R",]Q745D1>((I?%<_A\6MP)X;1;MYCL\O:S%5'#$Y)#<$#I0
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M:2,9!QSVK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM8XI9=-@$:-O1"0AEW DEV'12, COS70:'I;S:]K>O749'V\QVULCC!%O&"
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M;V%GJ-JT5C=+&C(;[)PDFY3@%=N,8S\WMAZZOJ,/Q!DL)M25M+L-(%S>#RE
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M7NG7UO;?8VDAV/YL.=VUA(K9P>0>O/>MVUMQ:P",222'JSRMN9CW)_P& .P
MH X.Y\3ZQIB>,K(7'VZ_T\^9IYD15(0VXD^;: "%(;G')('<5IMK=R]A#K/]
MHO'I\&C-=7JI&G#E5="&(.&VA^.F"..16L?#-@=0UB^*L;G585@F<_PH$V@+
MZ>I]>/054N?!>GS^!G\*137$%F\"P&96!E(7'))!!R%P>.G'% '*ZM+K>I>
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MV$*B78RR*1OR$!9F) !QT'7JM1TI_#USK_BFQ6\O[ZZ2-OL0.5!10@P%&Y@
M2V.>^!DU@6,6JZ/<0OH'B0:TL]TAN+*YLP7VNX\QC*N&3:"2/,ST YX% &_#
MJM[>ZO>:8-1$5MH\*'4+]8T4R3,N[8H8%555PS'G[P QS7*76K:[K'PNTYYM
M4GBU+Q!J"6]L\")&5ADD.!]W./*4MD<^]=3=> K6ZFU[_B9W\=KK0)N+5"FQ
M9#'LW@[=V< '&<9'(-2MX(M6@T&(:A? :-GRB&4%P8_+P>/EPO VX(R<<\T
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MK1(Q9>2HV2 \R%QR6(QD=,YQVH W:*** "BBB@ HHHH **** "BBB@ HHHH
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M(8$$94'U!'US2F\%Z5/H=[I3F?R[^83WDV\&6X8,&.]B.AV@8   X&*Z*B@
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MOE36@XG_ 'HS'O0(Q4XR3@#EMQSGU.>IHH IZ7IT6DZ;!8PR2R)"@0/*06;
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M:GX4T[4O"4OAL--;6,B*A,##?@,&ZL#DDCDG.<FEF\,I+)<,NI7\:W%J+65
MR,&4%SGYE.&)D;D<<CC@5N44 <U?>"=/N#HTEE<W>F7&CQ&"TFM&7<L14*48
M.K!AA1U':KESX:M+Q=/%S/=3&RNUO07D!,LJ@@%^.@SD 8 ('I6S10 5B3>&
M8&U._O[:]N[.74(T2[^SLH\S8"JL"5)5MIQD$<8[C-;=% &&OA+28O[%2"%H
M+?1G:2UMXS^[W%2NYL@DD;F.<]22<U+IWAVUTW6]4U:.>XDGU&19)%D<%4(1
M4 4 #LHZYQSC&3G7HH Q]7\.6VLZGIE_/<7,4FG-(8UA8 /O7:P;()Z9&00>
M3S44GA6Q>/Q /.N1)KBE;F4.-Z#R_+ 3C@ =,YY)K=HH YJ3P3I\D&AP_:[U
M4T<DP[9 #)F/R_F^7^Z2!MVX[8J:7PG:W"F&YO+N>T-[]N^S2%-HD#^8 "%W
M;0V#C/;TR#OT4 5-4L(]5TJ[TZ626.*ZA>%WB(#JK @X)!P<&J,?AC3HM1TF
M\02 Z3:O:VD61L16"J3C&=VU0,YZ$ULT4 <E)\/=+ET34=+:[O\ ;?7AO6F\
MU?,BE,GF I\N.&]03V).!BU;>#;.W\21:\U]?S7R6OV9VED7$HW[LMA1SD#A
M<+P.*Z.B@#E/^$ T[_A&-2T$WM^UM?N[R2&1=Z[Y#(0/EQ]XGD@DC@G &+.I
M^#[749=,NDU"_M+_ $UG,%Y Z&0A_OA@RE2#Z;<#M@<5T5% &+=>&;2^BL4N
MKBZF-I>)>[G<$RR(#MW\8P"<X4 9 J[J6G'44ME%[=VOD7"3YMI-ADVG.QN#
ME#W'>KM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[9H_X3_PW_PB0\4"_+:/N"M.D+L4).W#*!N') Z=QZUR?C6>2'XDZ%:6V@W
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MCCA%4Q-Y8)[,,#U![YKUKPYI]KI7AZRL;*VFMK6&/$4,[$NBYR <\YYZ=NE
M&I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5@^)-"U'6UMA8>(;W1S$6WFU16\W.,9W#
MM@_G6]10!P7_  @?B+_HHNM_]^HO\*/^$#\1?]%%UO\ []1?X5WM% '!?\('
MXB_Z*+K?_?J+_"C_ (0/Q%_T476_^_47^%=[10!P7_"!^(O^BBZW_P!^HO\
M"C_A _$7_11=;_[]1?X5WM% '!?\('XB_P"BBZW_ -^HO\*ZS1-/N=+TJ*TO
M-3GU*="Q:ZG #ODDC('''3\*T:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;GCCC(.*Z":V@N(#!-!')"1@QN@9?R-/1%C1410J*,!5& !0!P86R?XZ3%Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^6F5.Q<K]WCI]*/+3&-BXZXQ3J* $P,8P,=,4U(8HF9HXT0N<L54#<?>GT4
M,6*-9&D6-!(W#,!R?J:/*C,HE,:^8!@/CG'IFGT4 -:*-G5V12ZY"L1R,]<4
MGE1A0H1<*, 8Z"GT4 -**3DJ"?7%4]6@OYM,N5TFX@MM0=0(IIHMZJ<]QD9X
MS^=7J* ,S1-,GTZUE:\N5NK^YD\ZYG6/8K/@* JY.%"JH R>F>I-:=%% #?+
MCP!L7 &!QTI)(HYE"RQHZ@YPPR,T^B@!K(KXW*#M.1D=#1L3:R[5PW48ZTZB
M@!NQ,YVKGUQ1Y:8QL7\J=10 QX8I8]DD2.F<[64$4I16ZJ#]13J* $"*#D*
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M*&-2SR.<!1ZDT 2T5G:9KVFZQ/=065SOGM&"W$+QM')$2,C<K $ CH<8-:-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7&_%C_DEOB#_KV_]F%=E7%?$^XL)/"-SHU[J^GZ8VIH8TFO92HP"I)
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M^($#SGR'1X\X/RY<XX8<'/(->97OCE?^$AUZY32_#>L6D^H&1));Y8%F1/\
M5[HF90Y']YE.23@D8KI=9\3:%XSD\(>*K;Q%H^DZIIKF26POYB0,D9&5YXV\
M<#(/:@#K/#/CS6]6N_'%M-IUO=3>'YFBM8K1&1KD@R  [F;D[!T]3UJEIWQ(
MU?\ X37P[HNH1V;#5K<FY@CB*2V,P!.QOG;/0<$ \YXZ5SNBRZ+I0\:'_A86
MB+<>(2TD=U!(4:!R7.=N>GS]CD8[]:H:7::+8:EX2OG^('AMGT-7C9$4J&5B
M3G[V68[CDG';CKD ZF]^)NN2:?XRU6PM[&&V\/7*VT=O<Q,SSG?M9F8,-OJ
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MF+8O;VZ.W(D9\AF(]>N/;'&2 :OB37/[#LK5HXUDNKV[BLK9'.%\R0X!8^@
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MC26DMMJVQ[BVNG9/*F4;?,0J#D$=5..1UJA?^ KD>![/P[IES;[X[M+R>YN
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M!\7B..UTB99[%GBLU+1OYV_ 8NS;=FW<2.O YYH ZK_A$/#/_0NZ3_X!1_\
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ME0&#3K&VLX2<F.WB6-<^N% K@X?B-,?!WAS6K\0Z?%J,KPWEYY3216[*64<
MY 9EX).!W]:[70KFYO-(BN+J>TN'=G*S6?\ JI(]YV,OS-U7:3R><T +_;FF
M_P!O#0_M0_M(P&X\C:<^6" 3G&.I'>M"N UL7S?%_35TY[>.X;0[@"2=2ZH/
M.CYV@@M],CKUJ73/%>NWWA6:X,%@-0L]5DTZ]N"VR"*..3:\^UF!P%YV[NM
M'=5F)X<T.+4/[0CT;3DO<[OM*VJ"3/KNQG-<SIGB;7-67Q38V!LI[_2F3[',
M]NZ)<!X]ZADW CGC<#@Y! JWHGB>\U_0O#=U9R6OVG407NE,+8C5 ?-P-^00
M^U.2>6% '0V>K65_>WUG;3%Y[%UCN%V,-C,H8#)&#P1TS5VN$;Q;K26_C@^7
M8>=H/S6_R/M=?)\WYOFR3VXQ3+/Q3XACU#PE)J TYK'7H]K10QN)(7\GS V\
MMA@<'C:,>IZT =]17GNI^-M631?%>KV*6D::!>-;"UGC8M,$"EF+!AC=N.W
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M6?;:YIMYK%WI-O="2^M$5YX@I^0-G'.,=CT-<AI7CR\U7P]X8*P6\6LZY-+
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MR74VDVDM]Y)NWA5IC <QEB.=O)XSTYH MT5R5WXAU&Y\1ZYI&GM;6S:5917
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M[2UALPL/V<C",LK *=_!R3DD'/M0!UFD:O8Z[I<.I:;.)[.;/ERA2 V"5/!
M/4&KM>.>#]<UOP]\-_"M]%]A;2Y+U;2:!HV,K+).R[P^X $$_=VGZ]AUNI^*
M=4N)];AT*,&;2W\E$>QEG%Q,$5RI92 @^8+ZYR>G4 [:BJ>DW<]_I%I=W5H]
MG<30J\MM)]Z)B.5/T-7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L'QCX?E\3>')=.@N4MI_-BFBD=-RAHY%<
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M3'&-\I+')QG@ #)SS@5TU9NK:]IVA_9/[0F:+[9<);08C9MTCD!1D XY/?%
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MN03P?:@# \3?VQ--X$O-0NK=UN-9MY)((X=HB<QN0%;.2 "0<]3@C'2O3JX
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MX&#TR3S@>A^%_"D/A2RO[>SFW_:+F2:+>,B%&8E8P,_=4L?^^CZUA+\/;]?
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MN9(I)V@1I9(CE&;:,E?;/2@"U5/4-4MM-6'SV8R3OY<$,:[GE;!;"COP"?0
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MYCB,4_E-M<2,SA@20V,8P,=: /0*S-:U^P\/P6\VH/*B7$Z6\92)G!=B H)
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M"&YM+:\C\NZMXIX\YVRH&&?H:DCC2&-8XT5$4855& !["G44 %%%% !1110
M4444 %%%% !5:YT^RO'5[JSMYV7[IEB5B/ID59HH ,8&!1110 4444 %%%%
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M8N'(+'=O&#\HQQ66G@>[70_$^F-J\)&O3S3/(+,CR?-4(P \SG@#'OZUVE%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZG4,J,_3?@H& R,GOR#4'C31K>V\):=X;TJ^:^U#Q;K7G7-[(FT3'<"SJ.R
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M]OV2.2>W3;;QQH,+%%R00HP"03R.W2@#KR,@@'!]:\V^'7BO7O%_B'Q T]W
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M/G\._$2YECEGUOPW+)$<QO)IA8I]"3Q78:;K]AJ.@VVLB>*&TG0.&DD4!<]
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MF@#C%T/XDJ9"NO\ AT&3[Y&FM\WUYYIDGAWXB2VZ6\FM>&WA0@K&VF$JI'3
MS@8KO;2^M+^)I+.YAN(U8HS1.& 8=02._(J.]U73]-7=?7UM;#:6S-*J<#J>
M3T'K0!PMSX<^(=XT;76M>&IS&<H9=++;3[9/%2MHGQ*>1)'\0>'F=/N,=.8E
M?H<\5TM[XKTBQUO3M'>\A:^OF/EQB0?*NTG<?8G '<EACO6S))'#$TLKJD:
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MZTV%41%MGWS1R\EQ(02!QMP.M6K?5]-N[DV]MJ%K-. 6,<<RLV <$X!Z \4
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MGO+^$*FUHUPB9)&1EV['HIK<CUG2YM..HQ:E9O8AMIN5G4QYW;<;LXSNX^M
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M+[>9*6_X"S'O72>#;F'5/%_BW4]^Z;[8+%%'/EQ0#;R>VYVD..^,UVVU2P;
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MN+U"(9[E-J+NRRY(7+C)')!ZXKN_#FG6EK#=WD$\MU/?S>=/=RKCSF "@J,
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MM0EAN;"*(B[:W4[8XT))_=E.<JO\3'<,YKU*VMXK2UBMK>,1PPH(XT7HJ@8
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M>#_1P&_UG&< ],XY ZD<T ;-%4+W6]-TZ1DN[R*)D3S'R?\ 5KV9O[H)X!.
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MJI<ZE9VBQ&:X4&;_ %2KEFDXR=JC);CG@4^ROK74K**\LITGMIEW1R1G(84
M6**R-9\0:7I-K=&]NQ'Y,)DE"$[D7!P21]W., G&3TK-\(7D]CX&TBXUZ^=[
MV[C$K&9BSLTF7" =20"!@#M0!U-%5K#4+34[;[393K-%N9"5[,IPRD'D$$$$
M'D5'>:M86$GEW-PJR;#(8U!9@@ZL0,D*/7I0!=KG_&&A7GB31'TJVN8+>&9T
M-PTL9<NBL&*#!&,XP3Z$UJ7&J6-M#!+)<IMG_P!3L^<R\9^4#);CGCMS5-O%
M>@K8_;3JUK]E,_V82^9\IER!M![G)QQ0!KKG:,XSCG'2EJN;^T&H?8#<1B[\
MDS^3N^;R\XW8],\9JM9:]I>HW"06EY'++)&9HU&?GC! WKG[RY(^8<<T :-%
M9S:]I:WD=H;V+S9)?(7J5,N"=F[IOP#\N<\=*T: "BBB@ HHHH **** "BBB
M@#%U/1KNYUNRU6SNXTDM8I(OL]Q$7C8.5RPP05<;<9YX)&.:BTKPS#8:[<:T
MZ6J7D\ @9;2#RD*AMV6Y)9L]SV'2M^B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^(MXL%OHEI
M=%X]*O-2CCU"0*2/*"LP1L=%=E53[$CO7:44 ><6NL1W'Q%\0:Q/9SI#HNE)
M#;H8B&96!F=B,?*2 @ Z^V<@8<>D367A7PKINHQR27VNZFM[J&(R3M#-<F+V
MRVT<]R>PX]CHH \QO]8L=!^).O@:Q86MWJ-G;H)=28QI;NH8 1G&'&#N*Y7G
M')SPM]I-GH5EX%\)6KRW-E]K^U/,J[O/$*F0=./FD9#Z #K@5TUGX9O;'3)-
M+6_LKFQ:21Q]LL3+(=[%CN.\*QRQY*_7-;.C:5;Z'HUGI=IN^SVL2Q)O.20!
MWH X!O$QT[6O&VJ7%O-/JVGJ8K*U\ML+;)$'# XP%9RQ)[[5')P*HB".T\&^
M O#OES-'=7:7-T1$?WOE SN,8_BEV@9ZCGIS7K=% 'F^N3)>^)]/UC1Y/-N7
MN3HNIZ9)S]HMO,92^WMM^9PW0J3SVJ/[<Z_$GQ!!J6H2:=)Y,$&F[+8O(UOM
MR_D'D9+YR-I/RKZ5Z910!AZ-+I.E/:^&K&*6WEBM/M*P.C'$9;!+/R"Q8DGG
M.236Y110!YUXJU6QN_B3X:T^YN8TLM-\Z_N'8_)YP79$I;H&!+-CK3_&GBB;
M4O!VOIX;\^7[-%&DMU C9 =P)/+X^8K'N)(Z9&.^/0J* .0\/6VCZE=6%_:7
M1OTL8"EGY,)CMK4$!2%!_C*\<EB!G[N>:GQ6OPOA,Z+%-LN=7GBLR1R8XG<"
M1V]%"A@2>.:[JB@#)LO#>A64D$]II=FCPJ!#(L2DH,?PGMQZ5YM<^)9+;PQX
MWU#[/--KTMU-:-&T; 6T(;RH03C&T!MPQU+$^I'K]% 'G#Z,EYJ_@[PU;I*N
MEZ39M>3ED*[]J^3&/8MN<^N/0U<\01VW_">>%]*BM1';1R3ZG(D,6!+, (TZ
M#D@R%B?1<FN[HH \R>]O[C5/B#JVFP3/J5K;?8+$",DKY4>[CU+22,0!UVUN
M>%&\.ZAX<T2QLT2^%HL<^2FXPS@$EY"?NR;B>OS9)..I'8T4 >0#62GP\\6Z
MTF^.^UO4)((7D4KMWM]GB7)[JB[O;-;K:/::C=>%]#T-5?1]!F2]FNH^4+QH
M5CC5NC,2Q9L= .>HKH]>T"ZUK5=&N%OH8K73KK[4;=X"YE<*RKEMPQC<2.#S
MBM^@#Q.36C?_  ND@,<[:MK]^+?596B8?9FDEVE3D?PQ@*%'0 'Z];/8KJ_Q
M#MV>%X](\/Z6#Y31D;I9OX,=\)&,CWQT)KOZ* /&5E^U?"^R2XCF1O$^MB2]
M;RVX220RL ,9/[M!'[G@5Z[<SR0Z9-<0P,TJ0LZ0XY)"Y"\=^U6:* /%9-1@
MU'X;Z'I82>YEUR_@_MBY,+961F\V5>GS-\A0 =  ..,]98ZK;VWQ-UY]:<P3
M)!;PZ4DBGYH2FZ3RL?>8R<$#)^51VKOJ* /.KJ33]'^(&B07D"Z;H4&G2SV2
MNFR(7CR?-GL'"$XS_?;'-1^-I(+5M$GAMQ9:->ZK]HU2X>V8J[*G[HRJ"#L+
M*O7'W1GW])HH \S\5R6=KX2UC4;:[FN-0UD1:8FH3KL7;(VW;&, !%5G;(Z]
M<DCB\=*M-5UGPUINBHO]A^'W^U27$?*-($*1QHP^\?F9F(Z<9Y-;^M:!=:OK
MNBWOVZ&.UTR=KC[,T!8RR%"@);<,;0Q(X/-;] 'C)O+R;X3ZOJMHERLNKZF;
MB_DCB8M%;O*%8 #D[8E4''3)YR#CO- M]*U'4+?5+>Y:_-M;F*UDBB\NVMD.
M 5C'J0!GEB ,<9P>JHH XKQU.)]8\*Z.Z2-#<ZA]JE"(6W+ N]4_%S'UXX-9
M"W[GXC>)(=4U&73YV6&"P"6Q>5[;;D^0V",ER=V%)R!Z#'IE% 'E_B.&TL-+
MMCX;+V.L^&64V=G)R;I945GBQDER^<$C)W#KWKTJUB2"TBBCA$**HQ&O1?:I
MJ* /'GO;^;X;>+M:TZ.Z%_J6H/)*\<9,D4'F"' [EEB0GCINKJ+&711:IKT$
M[ZC%I%E(UHMO 8[>W4)@JB]2Y48Y+$#CC//<T4 <+X7TJ/PW\/H]5U6V6YU)
M(7U*<M'N996#R%5[@@NPX[L?6N9LO#-W_9_@O0YA(+N\N&UC59PI!39F0)GM
M^\E&/<$U[!10!X_<W%\/#/Q"U71K>XCO'NA90B&(@Q6\.V+Y/<+YK8'3(]JZ
M*PN- CL[36HKB74;72K?%HEK;E(+;("?*O4R$'&"6(R>!DY[ZB@#@_"%FUAX
MHU/2[:5+_08L7]A.#N^R2REQ)"&[]2P'4!N>HJ3Q]>+'JWABQOO,71;F]=KU
MU1F5FC0M%&V >&?''?;BNXHH \N74-3OM>\<ZQ9V4PU*RTX66FQF([E"H9>?
M5F=QA?\ 9QVJYX,M](U?2-!07LM^+%4F%O' 8TBN ,F2;.29-Q8\GJ<[>,CT
M6B@#C/B7-+'X?LHV$G]FS:E;QZF\:D[;4ME\XYVG"@^Q-,\5W<=QX3U;5_#%
MN+G4[?3WAM;NWCSA&(W"-AUP!GY<\@=^*[:B@#SO29M!&BV.IQ7,VIVNC6QF
MMX+:W*10LJ$9*G):8Y(P23EB<#DU-X8M39^-M1LK*9+_ $&53JEO(#N^Q7,C
M%7C#?[09V ZCGUY[ZB@#B?B+=B+^P+.[WIH]WJ*KJ$BJ6!15++&V/X7<*#ZC
MCO62M]J&I>-/%>H6=E,M[IND"UTR-HB"6=3+N;/ +-Y8"]>,8X->F44 >426
M*ZG\,M(\):,6GO=1$+7\XR3;_,LD\LI[.6! !Y)/L<;&A:I;0>-?%)UMV34V
MN%@LX'0EGLP@*>4,?,"Q<G;WZ]*[^B@#SFZ2TLOB3HEA::<88=,TF2:TMHHL
M!I96\L D @!45LGMN[YKG[5+K6/ALUM'YQOO%>M$7$WE$;(VDRQP>RPQ@>G.
M.M>S44 >77$(L_$GB?7UMF-CX=TQ;6SCV$^=,%,[M[G<4R?[PSU%4) ^B:)\
M/;.XD:WT=-\U[<SP,T9N0NZ,N 00ID9V!/&0I[5[!10!YIXGL%G\+7L&F/=7
M&H^)+J"PDOYXR-T9/)"@#$:Q[\8 ').23DV[.*WB^)SPK#*;?0])"Q_NR<RS
M$L[Y QG;&H^K?EZ!10!Y;X;?2]2^'_V/63+$?$LUS<7,_P!Q4>3+_>/3:-BY
MZ;@![5U/@*34)]!,NK;)KZ*5[3[<JX^V11,PCE^A!)]\Y[UU-% 'G&K:A)#\
M59$U*^.GVZ:<JZ9*UN9 S.Q\TQG[HDX4<@G';GE-2T..ZU3POX>T^.ZBL_M4
MVL7TTP/FN4Z,YZAW>3/8C'08P/2** .(\#>7=:]XJU)86CWWPLXE\O:J0VZ^
M6H'U;><#L1ZBF:[?PVOQ0TG^V9/(TF'3Y);.27B(WA?:<GIN$?3/]XXKNJ*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +GC))SG. IQFN^T9[^32XWU*6VEN&9SYELI$;IO.Q@"3U3:>IY- %^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX4O%X7\2Z-?:TTYUJXDN#/'!M*LS*P+?,=V"HXXZMZYKT=$6-%1%"HHP%48
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2\H%TF8U!P2PSP >N>E-C\5^'9KBUMXM=TV2:[_X]T2Z1C+SCY<'GD$<=Q7
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MTZ52U&VMK#XH>%!I\,$+R:9>KB,!0X C*@XZC.3^=<7=:II]W^SQ?0WD\/\
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M DZEV0C(8+G.,$'Z54T/Q=I'B&_U&TL+N&22RG,! D&9,*I9E'4J"VW/3(H
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MYKB6XETVS>>4 22- I9P"",G&3R!^5)::YI5_=-:V>I6D]PJ[S'%,K-MSC.
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MTL\QGE$-N$C#%57Y%YP,*O?DY/>@#G]%:"/XP^)HHC&I?3K-F12!D@R#)'J
M1^E7?B@K/\,?$(52Q^QMP!GTKITM+:.7S4MXED_OA #^=3=: /-]3L-.O/$'
M@670$M3>03>:\MIMPMGY3!]Q7^$DJ!GJ3QWKE;G7=)NM$\-W-K<VMA:1>)XY
M3I^_,EN/.?>\[,25)))_A #8YKVNVLK6S#BUMH8 YW,(HPNX^IQUH^Q6OS_Z
M-#\[B1OW8^9AT8^I]Z /.].CTV?QY\1'=+9O]$M,E@.%,#;NO0'C/X5S DNK
MGP9\,(=-OX;?47$B6\TF&".+=U&1[' _IVKVLV-H69C:P9;[Q\L<_6F_V?9<
M?Z';\=/W2_X4 <YX!UNRU/17LT@6SU.QD:'4;-GW/'.#\S$DY8,<D,<YSUSF
MD^(>H6.G>'[62_MHYHWU&V1'F=DB@DW@K+(5(.U2,D=^!WKJ$M;>.4RI!$LA
MSEU0 G\:=+#%/$T4T:21MPR.H(/U!H \BBO[*77/B2DNIV]X9])@D60;0LFV
M&4,5 ZJ.!G)[ DFGH+*V\/\ PGDA\B-S<6_S+@$[K9M_YG&?>O5S:6S9W6\1
MW*%.4'('0?04TV%F0 ;2# Z#RQQ^E 'D]MK%DGA#XB:9K5Q!#K)N+YI8;A@K
MRHR8A*@_>7:%"X]!7H7@F>*X\"Z#)#*DB?V? NY&!&1&H(^H/%:TMC9SS>=-
M:P22["F]XP6VGJ,GM[5.JA5"J % P .U 'F_C 7EIK&MZKHFI6<DT%B@U71K
M\?N[B !B&5@<J<,X]">ON^#5+=?BOI%Y= 6(O?#(6*&=L-O:=#Y8SU89Z#FN
M^FL+.XE26>T@ED0Y5WC#%3Z@GI4K0QO(DC1HSIG8Q4$KGK@]J /(=.F@N?@I
MXATG5RIUN!KR.[A?_6M=M(SQ$#J2Q*;2.O&*O:5K2^&O&WD>,[N.VDNM"LX[
M>ZNG"Q%T#>>F\\9+L"?7 ]J],:RM'NUNFMH6N5&%F,8+@>@/6EN+2VNU5;FW
MBF56W*)$# 'U&>] 'E/B>WMXHO ]EX4DBTP-=70TYI065<PR;7PQR5).1G^\
M..U=CX!UNQU/1&M(X%L]2L9&AU"R9]SQS@_,Q)Y8,<D,<YSUSFNEDM;>9P\M
MO$[ 8#,@)%*EK;QRF5((ED/5U0 G\: .7^(>H6.G:#9R7]M'-&^HVR1O,[)%
M!)O!660J0=JD9(Z'@=\UP%_=S75W\3(-+U%;W4+G3K1XFM\ S*J.)/+"]0%^
M7()Z@9)KVF6&*XB:*:-)(VX9'4$'Z@TB011N72)%<J%+!0#@=!]!0!Q-CK7A
M;Q0-,O-!>VN-8@LY5M%B;Y[)6CP1(H/RC(5?F'7I6/X+UCPOJWA'P[I.H".7
M6].GC_XE[L1<QW:$AI"N<]2S%CQ@G->F06EM:M(UO;Q1&1MSF- NX^IQU-"6
MEM'<O<I;Q+<.,/*$ 9AZ$]30!YKH5S:?V!X[TSQ"\:7@OKM[I)B 7A=?W3C/
M52H 7_= JEITD^AZG\-)?$5PMM(FEW4,LMRX0*Y2,JC,>C8&.>X->K2V5I/<
M1W$MM#)-']R1XP67Z'J*=/:V]TJK<013*K!E$B!@".A&>] 'A^KWMA=?#OXF
MA9X6)UEI44D [3Y(5@#S@X.#WKM[\6=M\6O"J6H@B#Z9=H%CP,KF,J..W4C\
M:[AK.U965K:$JS%R"@P6]?K[T@LK0.KBUA#+C:1&,C'3% 'E&AR:;>?#^_TJ
MXUD:;=QZY*1,A4M:S?:RT3.IXP6"\'K_ "Z#0/$TVD'Q"?%[6$$FF- )]4ML
MB*Y#C"97G#C@$?[0[8KN&M+9UD5K>(K(<N"@^<^I]:KSZ7;OIDEA;Q06\+\;
M5A4J.<DA>F?0D'GG!H MPS1W$$<\,BR12*'1U.0RD9!!]*?4-I:PV-E!9VZ;
M(((UBC7/W548 _(5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 52U'5].TA(GU&]@M5E<1QF9PH=CT49ZGVJ[6#
MXST-O$7A+4-.B.VY:/S+9^A29#NC.>WS 4 :$>M:9+JCZ7'?0-?QKO>V#CS%
M7U*]0/>N5\2>)FBU7PS/IFKQC3KG4FM;P+L*$+&[-EB,K@KS@CWKEVUC69;K
M0?B!;V,FZ]B&D2613!.\?(S=P/M&1_ND'N:V/%]M9:7>^ =.GFB81:HNXS$9
M<B)\N0>Y8YSZF@#N-+U[2=:MI;C3-1MKN&%RDCQ2!@C#D@^E16_B71;J6:*'
M4[9Y(8O.=0_/E_WQZK[CBO,M;::ZU3XI6VE$37;6]@X@A8%I J'S  .I*@@_
M7%=%X?U'PEXIU_2=5TR_N]1U*VBDVAI#FU1UPPE& !S@ 'OR.A- %;7_ !X=
M4^&UUK_AS4#;30W*)@(K,4-QY0+!A\NY<L.XKM[#Q!H^J7US8V.I6MS=6W^N
MBBD#,G..0/?CZUXV^HV'_#/5QI[W,/VJWN_+G@9ANC8WV[:P[';SCTYKL-4F
MA_X6S8Q:?<6Z7$GAVXBAV.HYWH4']1]* .S7Q#H[:DFGC4;?[7(S*D>\9=E^
M\JGH2.X'(J$>+O#K7<=JNMV#3R3_ &9$6=26EP#L&#UY''N*\X\*WOAG7-!\
M/Z1J-S?-KNF30C^RV=EEAN8OE+X 'RCEB<XP3GFM_P "?V;=^*?&I7[+-,NL
M"08VLP B0!A]#NY]<T =Y<W5O96SW%U-'#!&,O)(P55^I-4[?7])NH[F2+4+
M?;:X^T;G"F'(R"X."HQZUS'Q)EGM(?#VH,&.F66L037^!D)&,@.W^RK$$_@>
MU5[N--2^*,.HZ7+'-;1:+-'?RQ,&1@S Q(2."?O,!Z#WH Z6'QCX:N+ZULH=
M=T^2YNE#01+.I,@/3'/.>WKVJSJ.OZ3I#[=0U"WMC@%O,?&T$X!;^Z">,G K
MQZVM=/U;X"Z#8:=]G?6GF@%H(L>:MP)AN;CD83<2?05M2:GHMIXD\6Z%XOU&
MXL?M]P980S%8[NV>)$"J0.2-I7 Y].<T >BW?B70["X>WN]6LH9DB\]XWF4,
ML>0-Q&>!EACUSQ5K3M2L=7L(K[3KJ*ZM9<[)8F#*<'!Y^M>>6L>F6?Q1\,VB
M*(5M_#TB0Q7+@RQ?.FT'/.[;GWZTO@OQ-H>@:%XCO-0U&"WLT\1W<:N#N WR
M?+PN>#R?2@#TRLQ?$.CO?K8KJ-N;ERRHF_[[+]Y5/0D=P.14NK+<SZ'?+8/B
MZDMI!;L#_&5.TY^N*X#P9KWAC6/#GAG2IH4EUO3/*C^P,A$UM/&-CR$=@/F;
M)XY]>* .Y_X2/1?L%Q?_ -J6GV2VD,4\WFC;$XQE6/8C(X/K3+WQ3H&G-MO-
M8L8&\GS]KSJ#Y?'S8STY'/?->7WNIV-CX5^*&E7-S''J,M[>2QVI/[QT>%"K
MA>I7@G/08YK5CNM+O/'W@7=/:S!M%G"@LIR2L8 ^I^8?G0!VDGC?PM%&9'\0
M::$ C8M]H7 #_<SSWZ_3FK=WXAT>PNUM;O4;>&9G6/:[@89ONJ3T!/8'DUQ^
MF1Z7+\8]>M2EHY&E6L:PD*< ,^5"^V%X^E<_97OA^XL]=\*^+[R\COSJ,[/8
M[F!O%>4R1-$ ,MD%0,'/ [4 >EWGBOP_I\ES'=ZS8PR6H!G1IES'G. 1V)P>
M.M5-9\;:-H]KI5PUW%+'JD\<5LZ/E65CR^X<;0,GWZ5S^ER6$?Q@U@2/ LD6
MBVRGS'4LN&?<"?7&,_A7(:7>VL/PM\ W3W$26UIXB4S2EP$A7S)P"QZ*.1U]
M10![?%(DT22QL'C=0RL.A!Z&H[N\MK&W:XNYXX85(!>1L#). /J3P!5"U\3:
M->ZV^C6]_&^HI;K<M!@AO+;&&Y&.XXZ\BN<\?3RZ?KWA#4[C(T:UU!_MK'[L
M;/&4B=O10S'D\#(H Z>'Q!I$]I<W2:E;""U.VX=Y HA/H^<;?QQ3=.\2:+J]
MT;73]4M;JX$*SF.*0,PC;&UL>AR/S'K7$:DL4OCOQ%JUI/$=,'APP7LJN/+:
M?<Q0$]"P3/T##UK<^&4=D?AWX>FMD@+C3XHW>,#(.,LI(_VLDCUH Z._U6QT
MQ5-[=1P[\[5)RS8ZX Y.._I7,>+=>N(K?PO?:+JB&TO]8M;:1H0DB3PN3G#8
M/IU!]:S]2U^T\,_%>6?7YUM=/OM+CBLKN;B)71V,D>[H"<J?P'M5'Q/)HMEX
M?\')ID45CIO_  DEM);HWR IO<EP#R%))/T(/>@#T'4-<TO2FVWU]# P3S"'
M;E4_O'T7W/%23ZK86UO#/)=1^5/CR64[O,R,_+C.[CGCMS7%:'J$.F^/O&%M
MKL\,#730W-K)<,%2:V$>W"D\$*<Y'JQ]:YW1-)N+?PMX;@36VT35TEO9M(:X
M0-&T!<?NG5NN4*D#J!]* /5%UK3&TU-16^@:S=BJ3*X*NV2,#U.01@>E%KK>
MEWNG2ZA;:A;26D182S"0!8ROW@Q/W2.^>E>63^(KB.W\*ZYK<!T[3H;R^M[Z
MXL"3"LS-M6=3@G8Q\SG_ &SZTOB+^R(= GUSP^US?:9)K5G=:Q<JS2)/$C9?
M:.X&$W$#'Y' !U,?B:2\^*5CIEEJ@FT^339II+8(HVN&0*V<;L$$X['M7<5Y
MN^NZ-J'QAT.YL=1M+A)-(N(Q+#*K DNC!<COC)QUKMM#\0:5XET[^T-'O4N[
M7>T?F(",,.H((!'_ ->@"DGB_2Y/%\OAQ9U^U0PK(Y)P-S' 0>IX)/IQ5QO$
M.CI?+9-J-LMPTGDJI<<R?W,]-W^SU]JY&6[2T^,&JPFX2"ZO-$@2S#]9'$DG
MW1WQD$^@YZ5S,<T&H? >309.-?A_T8V3-_I O!+D''7).&SZ$GUH ]9OM8T_
M36"WEW'$Q0R;2<D(.K$#D*.YZ"FQ:]I$]B][!JEG-:HP1IHIU=0QQA<@]3D<
M=>17G^IZS:^%OB$\U_JFGBXN=%ABG34)C"FY7;!1MI# G=N&..#SG%9LGV+P
MMX4\$7$6K?;]!TZYD2^O[!MZQNZ.JOQG"JSE?4 CO0!WVK>.-#TOPQ?:ZM[%
M<06FY&2)LL91TC(ZAOKTZ]*RM7\3O!XP\*O;ZO&FBWJ79NE.SR_W46X$N1D8
M)YYQP*YSQ-#H-YX \;:IX>FGOFO+:(W5X)"\<K)V7ME5ZD>HSSFM36=5TG4_
M'WP^FAO+6X@)O&1PX*D^2-I![_,, ^H]10!W&GZ[I6J::^HV.HVT]G&6#SI(
M-J%>NX]L>]1P>)-%N?M/EZI:_P"BJ'GWR!?+4]&;.,*?7I7E-_<N;+Q\^G$W
M"VVNVUW/!:L"[PKY328 _P!TY^AKIK&^\(:U?3Z]IFIRZA=QZ;)%+<O*=D,)
MYV29  );H#SP3VH Z_3_ !+HFK7GV33]5M+JX\D7'E12AF\LG ; [<C\QZU.
M^M:9%J@TQ[Z!;\QF46Q<>84'\6WKCWKF/A3'9-\-] FMT@,JV@C=T W YRRD
MCWY(I/'RR:1=:)XMMX9)7TNY\FYCB7+26TV$8 =R&V,![4 =%#XDT6XT^XU"
M'5+22SMB1-.LH*1D=0QZ#%5EU*T?Q.Y7Q#"4CL#))I@V'8-P/GL?O#@@8/'.
M:XK1].U33O%MYX:NXR]IK+IK4KH/DA.?W\0]09!&,=U<GK6N;BW'QV$?G1>:
M?#I7;N&<_:,X^N.: *'B/Q[_ &G\,]6UWPWJ!MKFUD*J0BLQ43>7DJPXW#)'
M<<5W%EX@T?4=2N-.LM2M;B\MAF:".0,R#..1]>/8UX[<:C9+\ ==TY[F(7D%
MW,DT!;YHV-X2 P[$CD#N,^E=K?7-BGQ?\-+;S6ZAM)N8U$;+@KNC*@8[<' H
M TOB7K&H^'O FH:SI=SY%U:!&4&-75MSJI!!'H3TQ6??>(-:\->+O#FFWEW'
MJ=CK;/#EH5CF@D4 [AMP&7GD8R/6D^-$\47PIUI))41I%B5%9@"Q\U.!ZUT&
MF>']#:ZMM<@C-U=+#MANI;E[@HI'.PNQ"Y]L4 6T\1:/)?I9+J-N;AY&B1-_
MWW7[R ]"PP<@<C%07'B_PY:SO!/KFGI*DJP,IN%RLC9PIYX/!XKR9]?TN[T;
MPI<P7,%A;P>)(W?3$Y^Q O+DS,<L'))/51\Q !QFNQ\,'3;WXI>. ?LTTF;%
ME# %OEAYP#Z,!GT(% &O9>-='U[3M9:VU6*Q2TDE@%U*RKLV@#S<-Q@,W&>N
M!ZUK6FHVEGX?T^YNM52YCDAC"WC +]I)4$, .[=<"O/M'U"RB\)_$6PFN(DN
M4O\ 5))(7;!5&SM)'8'/'KVZ56M-;M]#A^&VL:A*!H:Z/]E>Y',=O<-%'@N1
MTR%9<]N?>@#O-8US3+KPM<7=KXGMM,B9O+74 R-Y;AN5PW&[@C:>>:O7WB70
M]+EE@O\ 5[*WFAB\Z5)9E5D3(&XC/ RP'OFN \=W&@R?"?Q/=Z.D*6MY.LIN
M%X2ZF,D>YUS][IC(ZD'TK1OY]-_X71H\US);%'T*;R)'*X+>:I&TGOMW?K0!
MV,/B#1[C1UU>'4[5]/;@7*R@H3G&,^N>,=<\4B>(]&>RN;S^T[5+>U;9</)(
M$$+=</NQM/(X->5K)8Z#9ZO?&UMSHU[XIB;3YILBWMG &ZY^4C*!U('(!('.
M*=_:5C]H^*:-J:71GTV*2.5PJB4?96&Y<  KD@ CKQR<\@'I]KXHT*^U&/3[
M75[.6\DB$R0I*"S(1G./H0?IS5+1O%VG^)9M7M-,ND6>SG>W1R,[B$0EPO&5
M#/CWV^]<2USI\,'PH,<ULF&7&UE& UL0WYMP?>MWP!>6\>O>,M->91>G79I_
M()^?RS'%A\?W3CKTH VO#MYJ-EX96?Q/?123I*R_:3#Y'FJ6PA*=B>,#J<CC
M)K8L=2LM325[*X281/Y<FT\H^ =K#J#@C@^M87CF"SN=&MH;K59-*D:\B-K?
M)C$,XR4+!N""1C!ZYJOX&U'5+J36K/5X[.2[L[I4>_L@1%=DQKAL=G"A0P'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &[%VA=HVCH,<"AD5CEE!^HIU% #0B@Y"@'U I(X
M8HBQCC1"YW,54#<?4T^B@!OEQ\_(O)R>.]'EH#D(N1WQ3J* &"&)9FE$:"5A
M@N%&2/K2JB*<JJ@^PIU%  0""",@U5FMS'82PV44*,5(13\B9/K@?TJU10!S
MO@OP]+X:\,6&F77V:2YM(O)^T0@_O%SD=1D=>G-;[PQ2.CO&C,ARA902I]O2
MGT4 -*(6W%5)]<54U'38=2L)+*3"0S#;+M49*]P#V^O4=L'FKM% "*JHBHH
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M!'O2T4 )M&X-@9 QFDV+NW;1N]<<TZB@!OEIS\B\G)XZFCRT!!V+D=#BG44
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M4 1I!%'$(DB18QT55  _"E:*-X_+:-60_P )&1^5/HH :D:1QB-$54 P%48
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M'\*7RHQG"+SC/'6G44 -\M,8V+CTQ1Y:9SL7/TIU% $:00Q.SQQ(CO\ >95
M+?6G(B1C"*JC). ,<GDTZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BL1O&/AU998_[9M#Y+;9663<D9]&8?*OXFM.TOK34(3-9W,5Q
M$&*[XG#+D=1D<4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %5;W3-/U((+ZQMKH1YV>?$K[<]<9''05:HH RO\ A%_#_P#T
M M,_\!(_\*/^$7\/_P#0"TS_ ,!(_P#"M6B@#*_X1?P__P! +3/_  $C_P *
M/^$7\/\ _0"TS_P$C_PK5HH RO\ A%_#_P#T M,_\!(_\*/^$7\/_P#0"TS_
M ,!(_P#"M6B@#*_X1?P__P! +3/_  $C_P */^$7\/\ _0"TS_P$C_PK5HH
MR6\+>'F4JV@Z601@@V<?/Z4B>%?#L:JJ:#I:JHP +.,8_2M>B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW5>Q!]P01^%>3^ ;A?B3\1_$>L:V@NK3276'3[.8;HH0S. ^T\%L1]3W;V&
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M2>+XO"FM6$5K?W5B+RW,4QECD4YW(<J"&&UO4$#MTKE?V?@%\*ZXJ@ #6)0
M.WR1T >K/<P1L5>>-6'4,X!J165U#*05/((/!KQ/XXV\+^,O ):&,F6]=)"5
M'SKYD/!]1R?SKMO$7CJYT#QMI'A>VT1+M]2B+0R"Z\L*1G@@J<#CJ#T[$\$
M[>H8[NVEN'@CN(7FC^_&K@LOU'45Y[8?$"_\2^"/%<]MIT=EJVD>=!(GVHE
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_$6RN-6
M\$:EI-FL9NKV+RHS+*L:CD$DDG^6:ZJL;7_">A>*5MUUO38KT6Y8Q>82-F[&
M>A'7 _*@#A_"T>M>&/!&G:;'I6GW&KV$$L,4SZE&(OG?=]<<+D8[=:N^+=,G
M\3^%8?#EU)#+&;0-/>"XB+-<*GR8!.<%^2>.F.A)&A_PJ3P'_P!"W:_]]/\
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MK_WT_P#\50!?-W+KMM=VNH?9;#3[BV> Q&Y229BXP22IVJ ,\ MG/;'/F)\
M:A>>!M'\#W4]DEK8ZHUS-J*W*%)(,N0%7.[>?,/!  QU-=__ ,*D\!_]"W:_
M]]/_ /%4?\*D\!_]"W:_]]/_ /%4 84^C7P^,%UXGC^ROIS::UHF+J,.7V\'
M!/3(Q6#I?@34T^"6K>$+BYT^+4IKD3PM]J5HW =&QD=#\A'3N*[O_A4G@/\
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MIW'G^\<YZUI>#=1'_"2RZ7J6C3Z+K<=EN>W63S+:YC# >;&V<9R><\\C).*
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M.N!@@KQDD[0,]:L^)/".B^+;:*#6;0SK"2T++*R-&Q_B!4CGBO,O$5OJMO\
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M':+IOD+;6\H@MI/-M[>2XD>&%O5$9BHQDXXXSQBMVB@#F]7\!^'-<U==5OK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBLO6?$>C>'HXI-8U.VLEE.(_.D"EL=<#VR* -2BHX)X;JWCN+>5)89%#
MI)&P964\@@CJ*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQUXCNO#'A\7MG9O<2R3Q
M0!@R@1[W"[CN(SUX'KC.!735R?Q'TZ]U+P=+%I]K)=7$5S;S^3'C<ZI,C,!G
MJ< \4 8NJ7K6GQ7TB\-C?M+-H]Q_H:L'<L)$   8HO'?('J:Z33_ !EIVHZ%
M_::17,1%T;(VDJ 3"X#;?*P#C=GWQCDD#-9,JWMS\3-'U9M,O8K1-+GAD=H\
M^6[NK*IVYYPO.,@=,US$GA[6Y_#VJ2P:0\MU;>*)=7ALKI JWD!)&T9XR58\
M'D$=.E 'HFE>)[;4M:O=&DMKFRU*T197M[@+EHVZ.I1F!&>.N0:L>(QJ3>&M
M3&CD#4S:R?93Q_K-IV]>,Y]:RO"LB7LSWD/A-M"B$>QC<V\<4TC9!P A/R#'
M4]21@<5>UK4=0L-0TS[+IUQ=6;/(;QX "8D"X4[2<M\S#A<G@\<4 <GX/M](
M\3:%IEWIEQ=VNH6-Q'_:<3W$@F,B??28$_/EAG+?XBNHF\7:9"T+ 3RVTMVM
MDMU&@,?G,VT*#G+?-P2H(!SSP<<G<Z!J6H^*_$6O:!;3:>+K0WLT>9# ;F[)
M)238V"-H &X@=>.]7_!>G(=+T:.ZT/4HKG3H$CSJ&%2W95VDQJ.&8\X8+D@G
M+=B :EWX[TFSEU"*2*^:6PFC@ECCMR[,SA2-H'8!DR3@#<!U.*M0^+-/GL]9
MG2*[+:.[)=0>2?,R$#_*O?(/'K5'P)H]S8Z=>ZEJ4#0ZGJMY+=SQOUB!8A$_
M! M5;;0-0D\<>)I)(O+TC41:,\F>9BD95D ]"-H)],@=<@ T&U:UU3Q5I=E!
M=ZC!-':MJ'E(@6*>%@$'F9YX+# XY!]*L2^+=+BVN&DDMC=)9_:44>69F?8$
M!)RWS'!*@@8.>AQSIT[7+O7O&UU!9RV]S-9+9:9<2$*H"Q$J5/O)(Q]MHK5\
M&2R1>&](TO\ L2[LVM+>.*<7*!%C95P=IYWDGG(X[DCI0!?U3Q3I^EQW[LLU
MPNG1&6\,"@B!<;OF)(&<<[1EL8XY&:>H>.M.T^6138:Q<1QA2T]MI\DD8W $
M#<!C/S#CU.*YGPEH]VEE<:7K^C:C=7HU":XE,K*+.8M(664D'YQC;PP8@@<#
M'&R=>U"[UO9)X5UIDCF\NU9XXU@7G'G.=^[U/W<@=LF@#HIM;MXIX;58IY;Z
M6+SA:1J/,5/5LD*HSQR1D@@9K,C\=:-);Z/.K7'E:L':W<Q8 " LV[TP%/\
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M3RVL/GW*Q;<01X)W.S$*O ) )R1SC%<KXMU"PUC4O!T:G-O--_:K2;#O\B-
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M,Y'H:YG^S-27P=\/+/\ LR\^T:7?6LMZ@A.84CC=&)]>6'3.: /4F;8C-@G
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M;0[=Q5<;F)8@!1D#)/4@#)JKX9 DM);F/05T6&9@4MWB1)F 'WI A(!]!DD
M<]<#"\4Q:MH_C;2_%-AIEQJEHMI)87EM:X,R*S*ZNBDC=RN"* -6V\;:7=:4
M+T1722F].GBS>,"8W(.#&!G:3WSG;C)SP:E@\6VCWM_I\]I>6VH64 N7M)$5
MGDB/ =-K$,,\=>#UQ7/^([77=6CT'Q%!I<J2:9J(N?[-9E\YK=DV,3@E?,Y)
M"YZ<9S5B6PFU3QH_B9+2ZBM+72'LXUDA9)9Y'?<0$(W84#'(&2W' S0 ^+XE
MZ7)9:3J#:=JJ:=J;K%#=M I19&SM1@&+9.,9 (SQFM"T\9VMQ?:C8SZ=J5G=
MV-N+HP3Q*6EA)(#IM9LC((P<$=ZXJ/2=5C^&/@W33I=Y]ML-0M);F$1',:1R
M;G/H>,=#S^=;UU;W3?$K4-2^QW(L7\/_ &5;AHB%,HD=RO\ WR1ST[=: )(?
MBCH\L>E73V&JPZ=J3+'%?RVX$"R-]U6;=D'MD C/?@XU]7\6VVE0ZA.+&]O+
M?3?^/V:V"$0?*&.0S L0I#':#@'UXK@-'LYO%7P8T#PY;V5RDLZVWF3R1$1Q
M1)(',@?[IR%P "3EN0.<:'V*[T#Q7K<-[X,DUZSU.[-W9WD$,4A0LJAHY"Y&
MU01P?>@#>_X3.:Y\;Z;I5C82W.G7>F-?+<QM'^\4M&%8!F!"@,<]SD8'%6M2
M\<:?I=L;^>UNSI27'V:7445##&^_821NW;0_RE@I&:S)=/U+3_B#H>HKI)EM
MO[(>QD^Q!1%!(9$;G)&$P#@^W3M6'H.FWNB"X\-W_@A=0N%N)39ZJ8(G@DC=
MRRM,Q.Y2N[D $G'% '6W/CFUAU75=,M])U6\O--2.26."!?G5PQ!4LP&,+WQ
MG/&:HZCX]9E\*SZ/83W=IKDPQ(#&I"[&8H S#YN.<\#!YSBC38+JT^(/BN_E
ML;H6ES:VL<$HA)$C1JX8#'NPQZ]JYK3-&UFP\(> &?1[R2?1[P_;+9%'F("D
MBY ) (RPY![_ %H ];5BR!BI4D9VG&1[<<5YA;F#Q;K_ (KA\0:==PVME/$L
M-RTT:'3U2(.2&5R58DDDKGJ 3@8'IR%FC5F78Q )7.<'TKSNTT6^U23X@V,E
MM<VBZT2MG/-$0K@P"/=[<CH<'% '1)XQLUU/3+&YLKZT75 ?L-Q.J;)B!NV\
M,64D<@,!GZ\5RGQ/\00ZG\-M;>RM+Z6UB;R1?0L%BWJX5OX@S*#E2=I&?;FK
M?A/[5<+96%[X$&FZE:!5N;]X(A"-HP6B8'<S-CC XSG)QSSC:;X@M/A%J7@:
M30+^?4;<-%#<0JIAN$,N]7#9ZX/(Z_K@ ]/O->2SD>UMK&ZU"ZA@6>6&UV91
M#G;DNRC)VM@ YXK(_P"%CZ+);Z)/:PWUW'K(?[(8(,Y9 24.2,-E2,>O7 YK
M!U*UO=*\:3:S=>$9]:TW5+6!6CCBBFGLYHP1@J3C:0>2#C(JYJ-C>C7?!5Q'
MH;6T-G<W$UQ#:1 I;))&RJ#MX+98;MN><GIC(!KCQS;M&0FCZJ;J.R^W3VCQ
M)'+!%N8#<&<#<=K8 )Z>XK'\7WUMJT/@/6+*60P76M6K1G<RAHW1VY7IV'7T
MJ;Q$NM7GB;4+&;2KV\TJ73PMC]F95B,QW;_.)89Q\N <C&>":Q8M.U;_ (0K
MX?VDFC7T=QIFH6LEU&8P3''&C*SG!/&6&!U]J /5JY>Y\=:;:V#:HUM>-HZ3
M&%]214,*D-L+8W;]@;C<%QWZ<UTSKYD3+DKN4C(X(S7EMAH^L6_PMO/ <^F3
MMJ*QRV<%P(_]'EC=B5F\SHH ;)4_-D< T :_BW5)Y/&WAK1SID][IMRMU++"
MIB*76V-=O#. 0N\DAL#.",XK'M=,MCXWN?"$VCW]QH<&F[HH)YHY!$99GS*I
M,F0   N/G4 X SSLZAIMS9^-?!?D6EW<66DVES!<7*Q$A=T:*F>YSM.<9Q5F
MVANE^+5_J#6-TMC)I<5JEP8CL:19&8CUQAAST]Z (O"FI>&M$T#6IK)+^VMM
M/OF@O'O6:266<*@)&222<J !C)[<ULP^+;3^V)M+OK6ZTZYBLS??Z4$V-"#A
MFW(S 8/4'!KAI?#NMZAX;\806EG+#?RZ]_:E@MPNQ;A4,3*,GIGRSP<=LXKH
MY;K5O''AK4]-;1+W11<V,L#O?A03*ZE0$"DDJ,DEB!VP.3@ TD\968U73;&Z
MLKVT&J _89YU0),0-VWABRDCD!@/3KQ6[=W<%C9S7=U*L5O C22R,<!5 R2?
MPK@O"+7,YL;*\\"+INI6FT7-])!$(?E&"T3*=S,V.,# SG)QSTWC/1)O$?@W
M5M'MY1'/=6[)&Q.!NZ@'V)&#]: (4\8V:W6F17=E>V46J$)97%PJ!)7(RJ'#
M$HQ'(# 9Z=>*YRZ?_A)_B)JVA:MI%U/IT.GPI&C-%B$N[YF'SY!(5<$?,-O0
M=WWMIJ/BW1_#>FSZ9=V-W97UO<WYFCVI#Y.2=C]'W'@;<\')Q6AIL-U'\5-:
MOI+*Z2RN+&W@BN#$=CNA<L/;[PY/!H V-9O6\*>#;F[M[>>^_LVS+*CR@NX1
M>K,QYX&2>2>>":XG7M4FN[;X?:Q>6]W#/)J$/F("&\T- S$JB,0<GIW]A7=>
M*K*?4_"&M6%JF^XN;">&)<XW,T9 &?J:XJ>#4[O2_ 0.BZA$VFWD+W2/&"8T
M2$HS$ GC<>!UP,XH ZG3_&>GWB:P;J"ZTV72,&\BO%4,BLNY6&QF!! .,'/%
M20^++<^(+71;RQO+"[O(GEM/M 3;.%Y8 JS88#D@XXKCM7\.:GK>J^/[>"VF
MA&IVMHME/+&1'*\*MD9[#.!SUSQFMCPK/)J%W;-+X%_L2ZMP?M5Q-;Q*H;:1
MB%E.YLD]< 8SZB@#N*\Y\"Z7!XBM=:UJYEO&MKW4IQ8A+R5!' AV*4VL-N2K
M'BNJ\7W5_:^%=1_LJUGN=1D@>.VCA7)WD8!)Z #.>?2LGP_)=Z%X0TS1M+T*
M]FN;:U2+]^%AB$F/F9V8YQNR3M#'VH J^#?$TD$7B:PUN_,D6@WS0+>SGYGA
M(R@<C[SCIGJ>.];K>+K"&[FM;B"\@FCM/MH22+EXMVW( )(.>S 'VX..*U3P
M9J6B:'IDD/VC4[AM<75-9:T1?,E8Y^9%;@JC;2%]LUK^(+&Z;P-X@ET;1[P:
MA?VXAWSMONI@QVL<$D@*K,0N1WPH[@'0P^+=+GTS1;]3,(]9=([1#'\[%E+#
M([  $DU2A\8"7Q-K-C)9S6^GZ- 'N[N0#&\KOXP2<!!GID[AP,<X]OI6H2>.
M_#KMI5Q#I.EZ=(+56*[86;;&-Y!(W[ W S]X#U-+X:74;+3-0FU+0;EVU;5I
MWO49 Q6)MRCY1R4")&/?<< ]P#J+#Q':W[A?(N;=6M1>"2=5"&(]&W D#N<'
MD8YQ3+?Q5IUS=Z?"@F":BSK9S,@"S[5+DJ,[MN 3N( /&#R,\-/X8UR#X;>(
M-$T^.XN+07:C38)3MG:SW(SQ?-R!_K%4-R1]17<+JL\VE3W5EHMTA@MG:&.X
MC$;LX7Y8U3K[9X'3&>P!QVF>(M+TCQ#XH\0723>3<:C'I\8MXBX18R(S(V.
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ME07EO]KLYK;SI(?-0H9(\;E!],@C]*YG3=:T&WUKQ;<_8Y=/GL3$^J7$YXD
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MM%YS6\07=''TW.20JC.0,GG!QG!H TZ*I:/JMMKFDVVIV9<V]PF]-XP<5=H
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M"%^\&/0=:N6MOJ%GXT\0ZO<:=//)/'!;:<J8*M$BECELX3,CMG..@QFNPHH
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MP[XXJ.Y\.IJ>B:%9ZKHNIV]S8Z9$L&HV+8N+6X5=K)E6Y!P"."O7)'%>F44
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M7<13RVB$:JJ,2P*[2&[=^,UV]% #4W>6N\*&P,A3D ^U.HHH **** "BBB@
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M?4;2:%T&)) -\;AF&W! P>1CWXK+T_P?JGAU_ %G!927D6C&Y>]GB= JM,C
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M%\+?] .S_P"^*Z&B@#GO^$%\+?\ 0#L_^^*/^$%\+?\ 0#L_^^*Z&B@#GO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\
M%MSC3H=/%M=S"^GCAE,%L\H6$L/,+%0< IN'XUT%% 'G/Q<\(WWB#2M.U31
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG <EE*@?*=G0],\4 >GT5XUX1U+QSXQNO$5I%XI%HFEZKY4<KV<;N\89@4.
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M!5AU5E."I'H0#6A7FVF:!JW@W0+VXEU6QM+W5M:^V7KQ@LL22,,QP J=\AP
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MNUA]HC1(VN(A+& ' 7'23!VXSCGC((!['14-M"\%ND4ES+<NN<RRA0S<]]H
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M&#+*%#-]=H _("I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_$WA)?$MM8.VH3V.J:?)YMK?VH :-B,-\IR"I'45TE-22.0N$=6*-M8 YVG
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MD<UN44 <UXF\(CQ'_9]TFI7&G:OIS%K:^M5&5+ !P5.05.!P?3ZYY7X@Z?\
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MJX!/TR:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH43=AOF&=_SGGH>X-4;SX<6#1Z0^D:C?:1>Z5;BU@NK9@6:'^XX8$,,\_4T
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M %>WU&Z\1>,-?TJ*^GLK;1UAB'V?;ODED0N7)8'A1@ ="<YSQBO\(@R_#/3
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MKPM-?6P7[2\L5O"SC*HTCA=Q'H,D^^*S=3O]2\,^+O#UO]ON+[3]6E>TGCN
MI:.4+N61"JC&<$$=/0"NDUW1+'Q'HMUI.HQF2UN5VN <$8.00>Q! (^E4K/P
MT4O;"\U+49]2FT]&6U:5%7:6&TNVT?,^WC/3D\<T <YX+LIH_'OC-FU&[E$5
MY &5Q'B7-NN"V%'3MC'3O7H-86C^&AH^M:KJ:ZA<3R:G*LL\<BH%#*NT;< $
M< =<]*M:]I,VLZ:+:#4[O3I5E25+BU;# J<X([J>X[T >>^%KBZM/"GCV>RO
M[6PN%\27FRZNO]7'\T8)Z')QG P<G'!K4L-9U0^+-;TB.\OTM5TB.]MGO(D\
MV-RSJ2 1G:=H.'&0<\"MBZ\":;=>%KS0S/<1?:[HWLMU&0)#<&02;^F/O <8
MZ#%5YO"L6F:A=>)+K7+Z>Y_LXVLYG,:I* 6()"J,<MT7 ^ISD X\ZWXLLOAY
MH?CE]?DN2/(-Y8-;QB.:-W"'! W!\L#G./0#OJ>-=?UC2;'Q+?V>JN]QIS1O
M;0VB*T5NF%)6<L,%F)/R@D@%2 *D^'^@+JWPZ\/07]])/9VRQRO9E%&)$.X(
MYQDJK8.W@\#)(K4U#X<6M_'KUM_:^HPV.M2&:>UC*;5E( +@E=W\(XSCB@"/
M4+K6+KXE6^C0:U/:6%SH[W+)%%&61Q(BY1F4\X/\6[J>.A%[X?ZG?ZEH5W'J
M5R;JXL=1N;+[0RA6E6.0JK,  ,XQT%6(?"8A\1VNMG5;R6ZM[(V0$BH0Z%@Q
M+84<E@#Q@#IBK/AOPY'X;@O88KR>Y6[NY+QC,%!5Y#EL;0.,T 5?$EU=1:MI
M5O'J!@MIO-\RVMES=7# #:$X.%&26)P!\N3@URMAXF\13_#ZWU$PWM]+;:I+
M;WQM43[2;9'=<JH^4N,(#M[9QZUU^L>%EU37M/UF#4KNPO;.-X=]N$(DC?!*
MD.I'4#FJ.G>!ET>S6"PUO4(_+U![^,OL<*7#AD(*_,I\PDY.<@<C% %OP;J]
MKK>D37EEJ[ZG;-<,(WE0+)",+^[<8&"#GJ,X(//6J^M:S</XUTCPS;SO;)=6
M\UW/,@&\JF J*2#C)))/7 XQFM71="@T8WTJ.9+F_N#<W,A4*&<@+P!T&%'\
MR234.N>&H-9O=/U%+B6SU+3G9K:ZB ) 889&!&&4CJ/R(H YRTU'4Y=4\6>%
M[R_GD%C!'<VMZJH)?*D4G8WR[205(SC)!]>:N?"RW>'X<:&[74TPDLXRJ2;<
M1\=%P <?4FM:#PW'#%JC_:Y6O]3 %Q>;5W8"[5"KC  &<#GJ2<DU-X;T-/#>
MA6ND0W4MQ!:H(XFF"[@HZ X !_*@#E_BG_J/"/\ V,]C_-JL?%V.TD^%NN&[
MV[4A#QD]1(&&S'OG _&M;Q1X53Q0-/6;4+FU6PNX[V+R%0GS4SM)W*<@9Z4R
M[\'P:M<VTNMZA>:G%;2"6*UFV)!O'1F5%&XC_:)'M0!SNFZQK6KRPZ*S7L5Q
M9Z/9S7+6\D:2M/*K;B3)V7;T'<G/:IK#5_$9O?#WAK7+B*WU.Y@N)[RYM2N9
M%C("A>,*6# M@<;3C&>-;7_!4>KZW;ZW8ZM?:1JL47D-<6A4^;%G.UU8$'!Y
M'_ZJ9JW@.SU*STT1:A?6FI:;(TMMJ4;@S;G^^6R,,&[C&.PP.* *.HZAKWAN
MRM;"ZU!;V?4=8%K:3JJ++';LK. V0%+_ ",H.,<@\U6U"3Q=I.D^*;E[V2*R
MAT][K3Y9FBDGBE1"64X4AD) //(Z5M7_ (&LM5\./I6HWU]<3O,MS_:!D"SK
M,OW74@ +CH !C'U)I(_!CR:%?Z?J&O:C?S7MNUJ]W-LWI$PP510NT9SR<$DX
MR>!@ YV2^\0VUQX*N%\03O\ VVH@N8G@C,:9@+AT&,A@1U)()/3'%0:E>ZBF
MB_$S0KW49M0AT[3O,MYKA4$@$MN[%24500"O''>NLE\&)*GA]3J=T/[#(:W(
M1/G(0H-_R\_*<<8I7\%6L]]XBN+B]N94UZW6WNHOE4*BH4&P@9!PQZDT <J+
MC7_#4/@[4EUJ2\L-1FM=/N-/D@14C$J85HR!N&W'.2<U/'JGBOQ+H;ZSH#R1
MW0O)!;Q221"V,<<I0HX(+Y*J23UR>,"NFL?":P_V8M_J,^H1Z7@V<<J(H5@N
MU7;:!N8*2 >!R3C/-9\?P\@MM7O+BQUK4[33;Z8SW6F1.ODR.WWL$C<H;N%(
MSZB@"C&WB'6/'GB#28O$=Q96MG%9W$(C@B8KOWEDR5Y4X/OTYX(/H)&1@]*P
M['PTEAXIU'7DOIWDOXXXY8&5/+"Q@A,8&>,GOWK9FC,L$D:R/$74J'3&Y<CJ
M,Y&10!PWB^ZU'3_&7AJ_N]/M;G15O1;1LCMYT-Q,-BR$8P5&2,?[6?3$_P 1
MON>%?^QCLOYM6M9^&YA]D_M;6+K5?LD@EA$T<:#> 0K-L4;B,G';/.,@$2>(
MO#:>(O[/\R]GMA8WD=[&(54[I$SMSN!XYZ4 9WC;5[_11IUTEO?R:0'?^T'T
M] \T0V_(V.NS.2V.>!VR#RVLW)U>R\#7=GXDN;V"XUK8MS#L7S%(E92R[<;U
M "X(P"#Q7H5_I=Q=7MG>6^I2VT]LCH0$5DE#[<[U/N@(P16+-X L&TFRL[>\
MNK6:TU$ZDEU$$W>>Q8L=I4K@[R,8P.* .K12D:J79R  6;&3[G'%>3V&KW/A
M;1_B'KQO+J\DL=4E5(IRI5V\N((6PH/&0, @8'2O6(D\J)(]S/M4#<YR3CN3
MZUS2>"+ 7&N^=<W,UAK+-)<V+E?+#LH5F! W9(4=\ \]<8 ,K6M0U;PO-X:O
M_P"TYK^#4+Z&PO8953:QE'$B;0-N".G0@^O-=S-&98'C61XBRD!TQN7W&01G
M\*YVQ\(+ FF0WVI7.H6VE.'LXYU4%652J,Y &\J"0#QZG)P:Z6@#P]8Y_P#A
MG5[B6]N)WFN5.)B&"G[?R<@ DD\G)/X5VIU34] \?S65WJEQJ%C-H\NH&*6-
M%\J2-U!";5&%(/0Y/'4U*?AO:_\ "*S^'!K&HC3I)_-C3]WF$"7S=JG;R-_.
M3D]JV)/#"3^*;?7IKZ9YX;1K/R=B>6Z,06R,9R2!WH YG3;SQ;JUCX>UVQD<
MK=&*>^AGEB^SM;N,L$ &X,N1M).3@[LUWM[<K96%Q=NI98(FD('4A1G^E<IH
MGP]AT*Y6*VUO5&T>.7SH=*>13%&V=P&<;BH/(7./7-=BRJZ%&4,K#!!'!% '
MGFFWGBW5K'P]KMA(Y6Z,4]]%/+%]G:W<98( -P9<C:2<G'S9J'5-4U[2/'/_
M  CTVN/]DUKRSI]VRQ!K)@27C(V88N 0A;J>.<&MC1/A[#H5RL5MK>J-H\<O
MG0Z5)(IBC;.X#.-Q4'D+G'KFK6I^";;6-&U#3[V^N9)+VX6X-V @EB92"@0@
M87;C X[GU- &1X@M;AOBIX4B75+U$>SNR0I3&5$?."N,G<<G'TQ5=M3\4>)=
M.U*^T"6:&[M[^6WM5+Q"WQ%)L(D4@L=P!)[C(QC'/27WA,7]]HU_)JU\E]IB
MR1BXC$8:9)  X8;<#.T<J 1VQ5%OA]%'KE[?Z?KFJ:?:ZA+YU[8VTBB.9S]Y
M@2"4+=RI!]Q0!1\[7=3^(%]HK:Y<65I_9,-UMMHXBT3L[*0C%3Q\O4@GTQ7-
MS:EJFO\ @WP'?7NIW"W4NO):SO"%42['E4.5P1G]V#Z9SQ7HD7A=+?Q1<:]#
M>S)-+:+9B$(GEI&I)7 QG()/>LN/X=VL/AJPT6/5;Y1I]\+^UN0(_,CDW,W]
MW:1EVX([T =C$ACB1&D:0JH!=L9;W. !GZ"O//\ A)KJ'Q:VDZU>WNDWLFHX
MLC)&IM+VWWC;&K[3ARO7)!W<9P<5Z%#'Y4*1EWD**%WN<LV.Y]ZYV?P@MX!;
MWNHSW-@M_P#V@D$B+E7\PR!0X&=@8].N.,XXH P(]:U<Z5\0,ZG,9-(EE^Q2
M[(]T86 2 ?=P1N/<&K&EZ_?:UJ6@:+)>R0-/H,>J74T0423,Q50HXPHR68X&
M?N]!G-Z]\!QW5[KDL.L7UM:ZU&1=VL03:S^7Y>\,5W#C&0",XYXXJ*[^'EO+
M:Z*;/6-1L]1T>'[/;:A&4,ABP!L<;=K# '4?UH Q?%MKK-KH'ARUU/4H;R]3
MQ/:+%<B/'R>8=F]1@%@",XQG]:VM N]3M/'^LZ!=ZI/J%LEG!>0O<(@>,LSJ
MRY15!'R@CCBK=]X*AO[#3K:35+[?9WT>H&X;8TD\R'*ER5QCV  P !@"KEMX
M;6W\6W/B'[=.\]Q;);/"541A%)(QQG.2>_>@!WBNYNK3P[/-::A;Z?*'C'VF
M<9"*7 ;:,'+D9"C!RQ'%<OIVM:\^L^+M+L6N)I+73XKG3([]5#B5U? )'.TL
MJG#<CGI74^)O#L'B;218S7,]LT<T=Q#/ 1OCD1MRL,@@\]B*RQX$0ZAJ5^^N
M:F]SJ-D+2X?,:Y(# 2#"@ C<< <=\$T 9&A^)KG5HM4BTN]O1KEMISEM'U:-
M4DCN,?*_W1E2>.#@<=,U7T_QS''IVKWQO-0^WZ7IDD]UHVIQA)4E7!#@A1E3
MR,@X&1@#-=/-X02]N+B[OM1GEOI-/DTY+F-%C>.-^2PP,%\@'/08X R<R#PE
M;W5^U[J\YU&8V3V&7C5 87(+A@O4G YX [ 9- &19KXKDU+1[V"YE>PG0C4!
M<R0[2&4;7A"C*D$]#P1UR>:PO#)UNS\%>);O2[B]O[Z/6+I%A9D9V59P'925
MYDV!L9R,XX[5U'AWP,/#\D,?]O:I?:?:G_1+*Y=2D/IR "V.P)P/3(!#[?P0
MEG!J4-IK.HP1WE[]N15\O%O(9%D;;E>067&&SP2.YH ;X*UZTUYM0EL]4N[A
M(C&CV5]'LN+-_FW*XP#SQ@G/0\\53^*0<^']+$;*KG6K+:6&0#YHQD9&:Z'3
M- CL-6OM6EF,^H7J1QRR! B[(\[0%'^\<DDG\ !3/$OAR/Q+:6MM+>3VR6]S
M'=*80I+.AW+G<#QF@#G[.^U?3/'.L:)+K#7D)TA=1@DOE11!)O=""45?DX!]
ML50TK7=53Q1X5LVU*YO+?5;.X^U3O&JPRRQHK>9!\H8+DG'&T@C&>M='?>"[
M;4]:OM2N[ZY?[;IC:7-"H55\DDDXXR&RQYS52T\ +;W6A7,NOZI<3:,KQP%_
M+ ,3*%V$!/0#YOO>_3 !G6.MZM8W7BK0M0U&:XU2&6-M+D=(U+1386+ 50#M
M?(8D'I5J>_U2^\0W_AZWN;YO[-LX&>>!X4EDDDW_ #MN&, *, #&2<]JZ"[\
M-6%YXIT_Q#*K?;;*&2&,@\,'QU]<?-C_ 'C6=KW@J/5M=AURPU:^TC5(XO(>
M>T*D319SM=6!!P>A_P#K8 -'PN=;_P"$=M%\1>0=60%9V@(*L03AN. 2,$CU
MS6!XJO\ 48M1U*.WU25!#IIFMK6Q4&5)/F)EE+#:$X  )&<-P2*ZW3K"/3;&
M.UB>60)DM)*VYW8G+,Q[DDDUA7W@J&\U^_U2/5+^U&HVRVU[;PE-LRJ"%.2I
M*D!B/E(H O\ A/4I]8\'Z-J5T5-Q=V4,TI48!9D!.!VY-<U/;SR?&^$#4;M(
MQH33")2I4?Z0@*@%3@' SWXZUU/AS1$\.Z!9Z3'=3W4=K&(TDGV[MH& /E &
M  !_/)YJM>^&8KOQ3:>(([ZZMKF"W-K(D17;-$6#[6R"1\PZ@@^] '(PZ]K.
MM_#>^\:6.IR6]S%]HN;>TV*81%"[#RW!&265#DY!!/&!Q1IES/K?Q2TG45O;
MR"*[\,K>K;AE*INEC)3!7H>,GKQUK?3P);06NHZ;;:A<PZ-J,CR3V*A<#?\
M?5&QE5;N/<X(J[<^%+:7Q)8ZU;7=S9RVMJ;,Q0;0DL.X,$.5) R!RN#B@#C[
MOQ#K%E<:/<+JKWDEQKZV-RT"+]C\IY&41J2 2R@#++G#!@3VK:T[_DLNN?\
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MXL6A2I+:MMCW,54JN_Y>1@D<8H Z'1[*ZT_3(K6]U&749T+9N9D56<%B1D*
M. 0/PJ]110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445R'Q)OM1TSPI]LTR_DM)TN[="452'5Y50@Y&<8;L0:
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MJQINN0:A>W-@T,UK?VRJ\MM/MWA&SM<%205.",@]00<5XUIQF;4=,5\_V?\
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M(S7-?$O_ ))GXC_Z\9/Y5S]PVM^&M2\*WJZY=7MGJMQ%875E,B!$WQDJT6T
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MJ^HQDB>.W*08Z^:_R)_X\PK @\$:K<> [#PA<3VEEIJ01Q7<EN6>:8#!8#(
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M5W OE^3<;> SKL^]CC((XXJAHWP[L=#O!]DU753IB2^=%I3W -O&^=PP,;L
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MW2;[>XB:*13W5A@C\C6(O@G1Q:>'[8Q,RZ'();5B?F+!2,L>^20Q]2!71T4
M8NL>&X=9U72M0EO+J&33)3-"D.S:6*E3NW*2>"1U%,M?#$5GX@U76H=0O!<Z
MFD:2J?+*($!";1LSQD]2<]ZW:* ,CPQX>M_"N@P:/:7-Q/;0;O+-P5+ %BQ&
M549Y)J"Y\+H_B";6[/4KRQN[B!;>?RA&RR*I)4X=3@C)Y'X@UO4V.1)8UDC=
M71AD,IR#^- ',:GX!T;4= M-)0W-I]CF^T6UW;2[9XI<DF0.<Y8DDG/7-:FA
MZ(-%MW#W]YJ%S+CS;J\<-(P'0<   9. !W)ZDUJT4 <]K/A&WU37+37+>_O-
M-U2VC,'VFT*9DB)R4=75E89Y''!JBOP[TTZ%K6D2WVH30ZM<M=S.\B[DE+!M
MR$+P054\YZ5U]8TGB )XO@\/"SD:22T>[,X<;416"\CKR3C\#Z4 4;7P7#%K
MUMK5UJVHWM]#:M:LT[)ME1B"0RJH ' Z8]\U6T7X>6.A72_9=5U5M,CE\Z'2
MY+@&WB;.1@8W8!Y )QGGFNPI"0JEF( '))[4 4]7TJUUS1[O2[U6:VNHFBD"
MM@[2,<&LZR\+QP7%C->ZA=:B^GJ1:?: @$1*[=V$5<MMR,GL3C&33]7\1)I=
M]HUJEJ]T=5N1!$\;KA?E+EO4@*I/'M6W0!Q5E]B\9>*]/UM-+O($T=)D6:\M
MVA9I7(7:H/W@ &.>Q*XYS7:$9! ./<=J6B@#!7PI:MI6JZ;=W5S>6NIM(TRS
M;/E+CG;M48]NN*KZQX(T_5M'TO21=7=G9Z;)%);QVQ08:+[F2RG.*Z221(HV
MDD=411EF8X 'J361>>(!:>*=-T(6<DCWT4LOG*XVQK&!DD=>2R@?6@"C=^";
M6ZUNYU3^T]1ADO+5;6\BAD54N57(4M\N5(R>5(_GFO;?#ZSM+?0(8]6U,C0V
M+6I9HSG*[,-E.FWC QZ]>:Z^B@#F=>\%6NLZU;ZU;ZC?Z7J<,1@-S8R*IDBS
MG8P8$$9Y'%/NO!MG<2Z,ZWU]$=)E:>':ZL9)&!#,Y926)W-GD=:Z.B@#%TSP
MW#IGB#5=9CO+J6?4_+,\<FS8/+7:NW"@C XZFKFLZ6FM:/=Z9+/-!#=1-#(\
M.W=L8$$#<"!P?2KU% &,/#P3PLFA0ZI?PK%"D,5W$ZI.@3&W!"X[ =.1FI--
MT7[',MU=W]SJ-XL9B6XN0@**2"0JHJJ,D#)QDX&3P*U:* .3D\ V+6FO6::E
MJ4=IK4DLD\*NFU&DQYA3*'[V.^<=L9-67\'P27F@W3:E?&31%9;;_5X?<FP[
M_DY^7CC%="9$$HC+J)&!8+GD@8R<>G(_.JFFZI;:K'</;"4""=[=_-B9#O0X
M.-P&1[C@T ,US1;'Q%HUUI.I1>;:7*;74'!ZY!![$$ CZ5AV/@.UATR[L-1U
M?5M6BN+9[0&^G#&*)A@A< <D8^8Y/%=910!R-IX MK:]T6\DUK5[F?2$>.!I
M94&Z-@!L8*@XPHY&&/<GBDL?AY8:;J4\MIJ6IQ:;-.;A]*68?9C(3D\8W;2>
M2N<'OQQ77T4 <]'X2AAU/7-034KX3:RB)<#]WA BE5V?)Q@$CG-7_#^BP^'=
M"M-(MIYYH+5!'$TY4MM'0$J /TJ"3Q $\7P>'A:2-)+:/=F<.-J(K!>1UY)
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M"NZ,H5D;C&"%'0#&.,5>T+PO8>'KB_FLFG/VV<SNDCY5"0H(48'&%7KD\=:
M.:\,:KJ^N>%M 1]2D&K1WSB]=47$L4,KI)O&. P '&#N([ T_2-0\0:IX=\5
M7^GWIN+AKJY@T<3*@4"(; 1@ '+A^OH,UU&B^']/T""XBL8V7[1/)/*[-EF9
MV+'GL 6.!V^I).;I?@BRT?3=.LK+4-106$C212-(K,20PPP*[2,.W;J<]>:
M.?M_&?V7PA<>)+>XN[KS1#90:;=C]Y#>[V1T8@;NK)D<\*<=0*UK8ZR-4BO)
MK^[CTNVM)6OKBYC6,3R$#:8XB,HJ88Y(YR!\W)JY=^"-(O="N]*F-QMNKHWL
MERCA9O/W!A("!@,"!C Q@=*GE\,176BW>FWNI:A=_:X&MY+B611)Y;#! VJ%
M&>Y"Y/?.!0!@>"AXDUW0]$UF^UF>*)Y'N7@>!-US$^[8&( V@ IC YP3W&-[
MQ-K,^GG3M.L-AU/5+C[/;EQE8U"EI)".X503CN<"MJ"".VMXX(4"11($11T
M P!63KGAJVUV[TV\DNKNTNM.D:2":U<*PW+M93D$$$>V?>@#&TJ[O9?B+?Z=
M%JLUQINF6$?VA)=I)NI6)&2 .B+G:.!O^E5_!.IZGJUY+!J=]<1:KI;R1:I8
MN%V.[',4B<<1E=V,'GODC-:</@/3+9]2>WNK^)K^>.X=EF&4="A!4D<Y,:Y+
M;CU]36M8:+;V.HW>H^9+/>W:HDLTNW.Q,[5 4  #<QZ9Y^E &+\2+JYM_!L\
M-A<S6]_>S16=JT+;6,DKA!SVP"3Q@\56L9K@>(HO!VF7,L>GZ/91O>7)"F5M
MV1%"IQA1M4DD#.  ,')K?USP];:_]@^TSW,1L;H741@<*2X5EYR#QACTP1U!
M%1R^&;;^TKF_M+JZL9[J!(+@VS*/,5,["=RD@@,1D8.#[# !G^"=7N]4&NQS
MS-<6]CJLMI:SOC<Z*%R"1][#%AGOCUR:9X@U:ZT7QGH3/?2_V;>1W,<UML4C
M>D8="N!N+'##&3G(Q71:9IEEHVG0Z?I]NL%K",)&O;N22>22<DD\DFHK_1;+
M4M0TZ]NHR\NGR-+ #T#E2N2.^ 3B@#D]+U?6=:L=5LY;LVFJ1:V;>(0!3Y<2
M^6Y!R""H1B">Y/;(KGM4U:\DNO'WB.TN)K5+%5TVVN(U4NSQKQ&FX$<S2'<<
M=@!R<CTK3M!L-,U+4M0MT;[3J$HEF9FSR%5<+Z#"@^Y_#&:_@?2W\-0Z$)KM
M+:.Z%V9%D'F22"7S<L2,'+>U &;/X@OTUC3_  TTMPUU!IR76I7-M;^8[,?E
M5%P"JEF#$L> !QC.1D>(H-<G\-66B:A>W,-UK>LB"*))5,D-F269'8#YB(T;
M.#_%C) YZR[\'VD^N0ZQ:WU_I]XEN+5VM9%Q-$#D*X=6SCGG@\]:EO?"EA?7
MVE73S72-IOF^6J2\2>8 'WD@L<XZ@@\GGF@#EM1DEN_B5%:0W#I!H&DM)+>,
MJGR'F/+=-I?RTX&,?,3@@8,6E>*]6A\)>%;6YN)YM7UUI95N'@\QXK8$R;RB
M+\S",HHXQDY/ (/72^$]/EM=?@,EP&US=]KE#C> 8Q& IQP HXZ]ZK7G@C3[
MFWTA8KN^M+K2<_9+R"1?-4%0K [E*D$  C&. !@4 8.MZCKVB>&?$VKM=WEO
M 8HX]+BFV//YQRN\C! #.R83J IX7.*Z;1-.UJ&ZBO-2U>2:+[&D)LC$H"R
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M^U1HQ(EI \[J7VY51D\X/.!5/1M*U2VO!>7^KW$ZM:)#]B95V1L#R^X<LQ&
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M(&WUB[M7*-',X41R,1@E 20>F<@D'I0!Z)1573+>>TTRVM[JZ:ZN(XU66=@
M9&QRV!P,FK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6?J6CVFJW&GS78=C87 N85#87S I4$COC<<>]:%% &*
MOA?3UU75M2W7'VC5(UCF_>G:H5-@VCL<=_<^IJ"T\%Z39Z=I%B@G>'2IDGMQ
M))DEU0HI;UP#P.!D"NAHH PKCPEIES::[;OYX_MLG[9(LGSD; @"GL HX'UK
M5L+*'3K&*TMPWE1+M&YBQ/N2>M6*P]#U^76-4UJT-FL46F7*VPG2;>)7V!F&
M-HQMW*#UYSZ4 377A^VN-6?4XI[FTO)8!;S26[ >9&"2 <@\@DX(P>>M1_\
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M9(/!;B0C/?!((%5;6_OXM<?PM'=:GJ2:1;)+>3JP6>ZEE+,B&0D!%"C/4$\
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MUA$;N..]N#<S21W+K)O,GF'# Y W=A0!T-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS6\[O*+,?-N$BMNV C+= 2?Q-=C_ ,*P/_0]^-O_  ;?_84?\*P/_0]^-O\
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M%'&B?NDSA>K9R<G (Z\UL>%4\0P_VC!KK>9"L^ZQED9#,8B/NR;/ER#W'44
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MC.*[+PCJ<&KZ E[;:N-5@DED,=R5"MMW'"L !AE& >!TSWH W:*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 444V1Q%&SMNVJ,G:I8_@!R: '45E:-XFT7Q"URND
MZC#=M;,%F6,G,9.< @].A_*IK'6;#4;JZM;28R36K;)U\MAY;<'!)&,X(./0
MYH OT455U+4K/2-.GU#4)UM[2W3?+*W110!:HJA_;FE_V&NM&^@73&B$PN6;
M:FP]#D_6LZQ\<>&]1UM=&MM4C;4F!(M61T?A=QX8#''/Y^AH Z"BBB@ HHK-
MBU_2I]?GT**]B;5+>(32VPSN5#C!].X_,>M &E1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CN+>"ZA:&XACFB
M;[R2*&4_4&I** &QQI#&L<2*B*,*JC  ] *=110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %NBN0\/>([G5O'/B#3Q>VEUIUI!;26K6RC W[]P+ G<?E [=.@KKF8*I9B
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M.!N@Y_+-;/Q"GM)?@WX'-M)"VRYLED,9!PWV<Y!QWY&:Z^W\/_$NTBEBMH_
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MPM\1 CH+3X?A9,;P+*7#8Y&?EYITGAKXCRPQ0R6_@%XH@1&C6<I5,\G V\4
M-N5N$_:,L_MORV0T=Q8[ON?[>.V?O9]L5YU#]K_X9MUTS[A:-JP-CNZ>7YD>
M=O\ L[MWXYKTN[T'XFW\$<%XG@2YAC^Y'-:S.J<8X!&!Q2S:'\3KFUCM9QX%
MEMX\;(7MIF1<<# (P* 'W/AK1=+^$NIZG:6$$=]<>'&2:Y ^>4>3G+'N2><]
M^/2O+KFRLA\-_A@XMX0\VIL)6"C+@RX.3WX 'X"O4#H_Q1:Q^PD^!S:8QY!M
MYO+QG.-N,56/A;XB-&D9M/A^40DHILI<*3UP-O% &=HAM;#X^>.$QY%FFD*\
MBPC;@!(22 ._)Z>M<&VL:=-;> /[-NUBTZSUMA%#<3B2Y@0RJ2TS# 7=R0H
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MZC_^O76V.E:=IB.EA86MHK_?$$*QAOK@<TMKI6G6,K2VEA:V\C_>>*%4)^I
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MU;:M!YT)<;XMMV=Q8=5 ]3CJ/6@#V>\UO2M/G$%[J=G;2G!"33JAY.!P3W/
MK$UO5]2LO'_A;3H;A!I^HBZ$\7E L3'%N7YC[GMCI7#>,M6TRZL?B#!:S6UG
M,+=%N!(^^:]<0@H44G"H%P,@'/)XZG;N;RWNO&'PTFBN(Y4>"\PZN"&/V=0>
M>_- '76M_'!?:Q/=>(+.>TB=,0_(GV$;<%7;/.X\_-C'2N4T'Q@VMVFG>(&\
M4Z996LD\JW6G7#1 +'N=8P&X97PH/)(.3@#I5OP?Y$7C_P >K'Y:(MS:DA<
M#_1QD_GFLSP1HEKXJ^!5GI,S+LN(9E60<^6XF<JP]PP!_"@#T234+**6"*2\
MMTDN/]0C2J#+QGY1GGCTK+T[5+>TTV[N]1\1V-W;K=R 7(,<20KGY8B0<$J.
M,GDUA>"+Z^\3LE_K%LT5SI4+:=*CKPUUG$SCU&%3!_VF%</J"6I^#?C4 1;(
M]?N F,87_2DQCTXH ]EMM7TR]O;BRM=0M)[NV_U\$4RL\7^\H.1^-,EUW2(+
M@V\NJ64<P8J8WG4,& R1@GKCG%<E=06EE\8= 2UCA@#Z1=(5C 7<H>,J,#MU
M/YUR%BVEZGX6@\+2Z]H_^CZV]Q]LGO8UE=%N&<DQD[O,))7D8P<Y[4 >U!A+
M$&C<%6&59>1ST(KSFR\0^++Y?%LEO?:;NT.[DAABFLVQ,JKN^9@XP2.,@>^*
M]&151%1%"HHPH48 'M7EWA'1[#Q!K/CVUNI[AH'UATEA@N6C$B% "&VD<'!'
MOR* .P\.>+['6O!FG>(KMXM/BNX\E9Y H5P2" 3C/*G'J*U1K6E&TM[L:G9F
MVN6"03"==DK$X 4YP23Q@5POB&YLO"WC;P]#<7;:-H7]GS6MK/$J"*&;<AVL
M75@N47@\=#SUK%\0:;X=M_"]DVFW!O+&Y\4VTSW$S(T;N\B^9Y94 ;.N=O&0
MU 'IZ^(M$>U%TNL6#6[.T8E%RA4LOWAG.,COZ58?5=/CL4OGOK9;1\;)S*H1
ML],-G!S7(>(M(EM]?L9/"E[8:9K4-O/(MG-"!!>1LR&3<%P0VY4.X<U@:5K9
MN?$/@34;NQ&FZ7<6EU!#"6S%#=[L##=/F56V>H8XZT >EKK.EMIIU%=2LS8K
MG-R)U\L8Z_-G%%OK6E7=^]A;:E9S7B()'MXYU:15/0E0<@<C\Q7E7B6S"P?%
M.>$(=+>TB(Z%/M8B.\KVW<IGW([ULSP6=IXS^&QMHX8O,M[M?W8 W@VZGMUY
MY^M %Q[WQRGAJZD2YTR74H-0VP.+9PEY#M!V*N<@[R5W=,*3TYKOJ*S]>%XW
MA[4UT_=]M-I*+?;U\S8=N/QQ0 L6MZ5/?M81:G9O>*"3 LZEQCK\N<\=_2F+
MXAT1X)IUUC3VA@8++(+E"L9)P QSP3[UYUX9N?"_B+3?"I;7+F;4].>(PZ:C
M1)-!*J[7#(J!]@&[=DX('<XINN-::/XN?Q5#'N\+R7<4&K[7'EM<H2JW&W'*
MHY56YY89QE<D ]-O=6T[3;=;B^O[:VA<962:545N,\$GGBAM6TU%MF;4+4+=
M?\>Y,RXFXS\G/S<<\5P>KZW:Z=\3V_M;66TRQO=*C%A=YB\ER'<R+OD5@"<H
M>V0!UXK*O=)T&QM_ EKIA:XTXZXPADN2K>8C)(3MX&4+'CC![<$4 >C#Q3X>
M-A)?C7=,-G%)Y4DXNTV*_P#=+9P#[5<DU73HDMWDO[5%N1F M,H$HQGY>?FX
MYX[5Q&C66G/\5O&BR6]LP%I9$AD7C*2!OS 7/X5QNDI8W'@OX6->K#)&U^T+
M-+@@C;* ASVS@8H ]<;Q5H T:ZU=-8LIM/M0?.GAG615([94GGVZG-4!X@M]
M<T#2M1T[7K/3A<S0,V\QR[MV";?DC#G<!QR/2N0U/2H[;Q3X[ETF%8[%_#A2
M[2%<(;HK)M&!QNV8)_WAZU%JEW87?PV\!RQ3V\Q@U#2HRZL#L8;-RY[''44
M>GW^KZ;I84ZAJ%K:;@2//F5,@=3R>E.FU*PMQ;F:]MXQ<L%@WRJ/-)Z!>><^
MU<;HET(OB?XOM-6*+)-#;26?FXQ):JA#!<]@Y;/N:XJ#3TC\)>#X;R-'M'\6
M;;%90#FT+2[!SU4CD#I@B@#V73]7TW5DD?3=0M;Q(GV2-;S+($;T."<&GW&H
M65I-##<WEO#+.VR%)) K2-Z*">3["N.T!88/BYXKA@"1AK&R=D3 R1Y@SCZ8
M_2G?$R2.WM?#-U,ZQP0>(;.265SA8URPW$]AR.: .M&JZ<9;B(7]J9+8;IT\
MY<Q#U89^7\:@A\0:+<W<%I!J]A+<W$?FPPI<(7D3&=R@')&.XK@6U#3+[XA^
M+56YMIXI-"B"_,&63:9=V.S8[XZ?A63;06=OX ^%]Q%'#',VJ669% #$LCAN
M??H: /2O$VNVVDZ3>;=4LK._6W:2 3NN20#CY21G)&/K4/AS7EE\"Z+J^LWL
M$4EU90R2S2LL:L[("?0>O KC-.U:S6W^(UAKD\$6IM=W),=RP5I+8Q!8-N>J
MX& !W/O69H^N6VG1> ;F^U9K'29-"-JEY&8S'%=8C)5RZLJDJI&3@\$=,T >
MM#6]*-G;W8U.S-M<,$@F$Z[)6)P IS@DGC J6QU&QU. SV%Y;W<*N4,D$@=0
MPZC(/45Y-XATWP[;^%;=],N3>65SXHMIGN)71HW=Y%\SRRH V=<[>,@^E>MV
MME:6,;QV=K#;H[F1EAC"!F/5B!W/K0!!<:SI=I="UN-1M(;@E5$4DRJQ+?=&
M"<Y/;UHOM:TK3)$CO]2L[5WQM6>=4)R<#J?7BO.M=GO=$OM8U?39[;5]&?48
MO[3TF<8G@G!C4-$PZGB,A3[8J)M0TE]>\9Z#XJUU],-U<%A%,T2)<6K1*J[&
M="21@C"G@].<T >G7VIV&F1++?WMO:QM]UIY0@/?C)K*U;QEH>CS:7%<:A;9
MU*0+ WG+M*8),F[IMXZ]R17':=JNG>&?'L-KJ]R]II\VA6\6ESZDX0!4)\Q&
M8X <Y0D'GY1[4FK?V'I(\!/I82ST2'5I?)>1R(]K1R_,&8_=8DD$GD$8XQ0!
MW=K<&;Q'<A-;MIX/LT973T5"\1R?WA8')##  (QQ5A-:TJ6_^P1ZE9O>9(\A
M9U+Y'4;<YX[^E<%<&5_B'XM_L8H+^7PY&]OLP"929-I^N2OZ5E7K0:K\#_#\
M>DD#6(9+.*T5>)([Q'59..H8?O"WMDF@#TZZ\0Z+8_:/M>KV$'V8J)_-N47R
MBV=H;)XS@XSUP:T(Y(YHDEB=7C=0RNIR&!Z$'N*\[TVRTZ;XE>/1-;VSD6=G
MG<@. T4F[\^,UK_"R3S/A?X>8MNQ:!<YST)&/PQB@!_B,>,G-W<Z'=Z=9PVB
M[HH+FW,K79"Y.Y@PV+G@8!/&<\U';:QXB\4>$=$U/05LK">]B$\[WB-(D8Q]
MU5!!)).0?0'U%-\4>+-"%U+X<N->L;"1TQ>22W*1M%&W\*Y/WV'_ 'R#G^Z#
MO:9J6D/X?2\TV:$Z3!$1')'_ *L1QY!V^JC:>>G% &!X>OO%<FKZY9:E=:9>
M_88HEB:W@:%3.X+;6)9N I0G_?IVG7OB>Q\<1Z/JEU::E8W5F]R)K>U,#6S*
MP&TC<V5.>,G/!]#5KPO+%IOA(ZSJDL=H;YWU&ZDG8((_,.5#$\#:FQ?^ UC2
MZ="GQ,T;5M U&6;[;'+_ &I$MTTT3P!"8W()(7#D!<8')QWH Z6RUA]6U^_M
M;1@MGICB&>0#)EG*AB@] JE<]R6QQ@YI1:WJ?_"S9- F^S?V?_91O8]B'S-W
MFA,,2<'C/0#K[5F_#!9([7Q/%/G[0GB&\\W/4DE2#^((I^]/^%Y!-PW?\(YT
MSS_Q\T ;=UK#Z5XCLK&\8-:ZF62UEQ@QS*-WEGU#*"0>N5(YR*+76CJ>OZA:
MVTBI9Z65CN9>#OF*[B@)X 52I)ZY8#C!S@_$M'E;PA'!GSSXCM63'7 #EC]-
MN<T?#)9(T\613Y%POB.[+YZD'85/T*D8H AM_$E]XMU#5X/#_B*RLKBPO1!;
M0E8YDN8U5&=V'WB"6(!0C&VNI\.ZVNMV,S.@BN[2X>TNX0<A)4.#@]P1A@?1
MA7/?#Z6-]4\:A'5B-?ER <X_=QC^8/Y4WP.CGQIX\F7/V5M1B1/3S%A7?_-:
M .SN[ZTT^'SKRYAMXL[0\KA03Z9/>J5WXATNUT*;61?6LEDB,ZS),I1R,\!L
MX))&/K7-:S=/9_%WP^]\=NFS:?/!:NW"+=EE)&>@8H,#UY K-M(&MK_XF3P,
M%T>1 T>#^[\_[.?/([9R5S[Y]* -CPAJ>J>(8-+UN/7+6>TN+4/?:>J(WV>1
ME#*J,OS#&<$.3T[5JW'B[2(/%2>'&O;=+][<S$/( $.Y51",\LVXD#K@>XJ'
MX?,K_#GPV58$?V9;C(/<1J#61>7=O9?&VU:YGCA$V@-%%O8#>_VA?E7U/L.:
M )?"?BX26^HQ^(=8LH[E-9N;&V\QDA\Q8V"J%4GD_F>:ZK4-5T[2HA)J-_;6
MB-G#3RJ@..O4UX[>06<GPK^(UR8X6E_MF\_>X!;(E4KS[$\?6NANM:MM/^(M
MU'KFM-I=M?:7;FQN'\H0R*I?S$+2*P!RP.,C/&<\4 >E12QSPI+#(LD3J&1T
M.0P/0@CJ*Y ^(+K5?'6J>'+?4X=-?3X8GC1H@\ET77<6&X_<7@$#G.>16GX+
ML-,TSPK:6FC27$FFQE_L\D[;BREB<@]U.21[8[5A>(=$\+>.M7OM-O)/LFN:
M2R"*ZMYO+N8U9%=74]URQ&#GD'IF@#I=&NM1329I?$#VT5Q#-*KR1J8XO+5C
MM;YB< K@\DU<L=5T[5$D?3[ZVNEB;;(8)5?8?0X/!KR%M;UN/P);7.L7\MW9
M:5XD6";5(8PQGLX\@3$$$,!(5YP?N]SS5WQ+'IEYH/BC6/#&KW&LZG/IR)=R
M6\L;(8E=25/EJ!O*;\=\9]J /3(->T>Z>5+?5;&5H4WR!+A"47IN.#P/>G?V
MWI7V:WN?[3LO(N6V02_:%VRMG&%.<,<\<5S^DZKX0\1:MI6I:3+;W=_':LD)
MMY,M;0L!D2*#A1D 889R>.]>;PZII\/P6T"RDO(%NK;5HO.A+C?%MO"6+#JH
M QR<=1ZT >RW7B#1K&22.[U:Q@>(JLBRW"*4+<*"">,X./7%4#K5KI;Z[J&H
M^(;2:PMBC>2JJ#9 +RK$$EBQ!(!&>PKFM.L-(U'XN^)$GM;.Z5M.LW"NBN&R
M7);!X/\ "<_2J*)$+KXM0VZI_J5PB#N;/T'OF@#K1X@M]<T'2=1T[7K/3A<S
MP,V\QRE]V";?DC#G<!QR/2MB_P!9TO2MO]HZC:6F_P"[]HF5,\X[FO,M4N["
M[^'/@&6*>WF,&HZ5&75@=C#;N7/8XZBK-SJ>FQ>-O%ND>)M<;2H[Q8F@\XQ)
M%<6QA"E5:1#T;?P".6.!UH ]&N]5T[3U1KR_M;<2 LAFE5-P'4C)Z<C\ZLQ2
MQSPI-#(LD4BAD=#D,#R"#W%>9S:;<6#6$G@_5$6[L=(5?[.U<96[L][;23P5
M(P>>P*@XKM_"=]'J7A'2+R&S:RBEM(V2V8Y\I=HPN>XQT/<4 69M;TFWOELI
MM3LX[MF""%YU#ECR!C.<GL.])=Z[I%@\R7FJ65NT""242SJIC4G +9/ R<<U
MY!XKU?3;CPKXG%G/;V BUY#+:L^Z>:99X@\K;C\BX'  Z <\D5UMK%IM[\:K
MJ9([:=6T"&5& 5@29G&X?4$<^A]Z .Y&HV)T\:@+RW^Q%!(+GS5\LKZ[LXQ[
MURVB^))]3^(FK:;%J-M=Z9#8Q3PB!5.QV=E8%@22?E'^%>?:/J":=X3\#37+
MJN@PZY=K=-G]W&WFR^1N/0*&(// P#Z5V6D7VG3?&K6?LMU;.\VD6_\ JY%.
M]E=\].I V_AB@#5^(^N:CX9\$7VMZ9)$MQ:;"$FCWJX:15YY!_BJZR:[;W-H
MYU>RFBW;KB%[;RV,71F5M_&"0>AK!^-#*OPEUS<P&1"!D]3YR5T6F>'=/LM0
MBU2T>X,C6QA_>74DP96*MD;V./N]NN: +9UW1UL3?'5;$68?8;@W">6&]-V<
M9]JHW'C#1;7Q3'X?FOK=+QK9KAM\H4)\R*JG/\3;B0.N%]Q7E>IZA90?"GQ[
MITMS"M[_ &O>XMBP\SF8,#MZXQSGI78OJ5C'\8M.N7NX!!<^'72"3S!ME8W"
M$*I_B/L* .Q.NZ0+%KXZK8BT5_+,YN$\L-_=W9QGVHO-=TC3W=+W5+*V9(O.
M=9IU0JF0-QR>!E@,^XKQ_4M0LK?X8?$+3I;F%+TZQ?$6Q8>8090P.WKC'.>F
M*Z=X-(U7XO:89(K.[AG\.2,-P5UD_>H/HWR[OPS0!W-UKVCV/E?:]5LH/. :
M/S;A5W@]",GD'M4E[J^FZ:5%]J%K;%AN'G3*F1Z\GI7F*W>BKJ_C#PYXFUHZ
M2L]P2D#^3''/:-$JIY;.A/ 4C"G@].<U8U.TN],+WOAN_BDDL]%@COM'U@?\
M?%JH<H2W57P7!SQGK0!Z@CK(BNC!D8 JP.01ZTZJ&AW27WA_3;N.W>V2>UBD
M6"3[T8*@[3[CI5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KF?'&A:AXBT>WLM/^RADO(;AS<R,HQ&X; PK9SC
M%=-10!6LK&VL8=EM9V]KN^9T@0*N[\ ,_7%-73-/5Y'6QM@TD@E=A"N6<=&/
M')]ZY6R\:33?$J;0)H0FG30,MA<?\]IX6/GJ#[9Q_P!LSZUUUW>VMA!Y]W<1
MP19"[I& !)Z >I/I0 B6-I'<&X2U@6<DDR+& QSUYZTV/3+"&Z-U%8VT=R<@
MS+$H<_CC-8VL^-]#TCP\^L_;H+B#S/)C$4@.^7.-G'0@GG/2MV"[MKFU6Z@G
MCDMV!82HP*D#J<T 1R:;8S3R32V5L\LJ>7([1*6=/[I..1[5(]G:R2PRO;0M
M)#_JG* F/_=/;\*Y>+QC#'X1OO&-VS)I*([VT*@;GC#;58D_Q.>@Z ,.^34^
MCQ>(=6TFWU.]U3[#<7,8F2S@@1HH0PRJN6!9R!C)#+SG&* -PZ7IS(B&PM2B
M9VJ85PN3DXXXYI\=C:13M/':P),V<R+& QSUYKA[_6_$6FWGA-=3O(+<W6H7
M$%^D<06-T42LK MDJN%4]<XZFNOL-?T?5+&:^L=3M+BT@+"6:*962,@9.XYP
M,#GGM0!=@MX;:(16\,<48Z)&H4#\!0UO"\Z3M#&TT8(20J"R@]<'M5*UU_2+
MWSOLVI6LA@022@2#*(>C'T4]CTJO'XM\.RW=K:QZYISSW8S;QK<H3+R1\O//
M((]\4 :']G6)OOMWV*W^UXQY_E+YF/3=C-6:P+?Q?I-UXKN_#T=U%]KM8T9\
MN!EV+?(H[D!<G'3/UJ\FOZ1)J2Z<FI6IO&+!81*-S%?O #N1W Z4 6'T^RD\
MS?9V[>:P:3=$IWD< GCDT@TRP#(PL;8-']P^4N5[\<<527Q3H#W,=LFM6#3R
MSFW2-;A26E !*#GDX(X]QZU+K*ZK+:I!H\L-O/*^UKF:/S!"F"2P3(W-T &<
M<Y/3! +1L+,WPO3:0?:P-HG\L>9CTW8SBK%<5X;UCQ!;^(M:\/:W+%J4MC;Q
MW=O>00^494?<-C*"0&RIQBL_2/&-[J.C:!JUM?I=W6HWJ6]SIJQJ!!G/F 8&
M\&,<DL2"!T&X8 /1:RO$'AS2O%&ER:=J]HEQ;OTSPR'^\K=0?<5B0ZMJGB+4
M/$,.E7RV8TF?[) IB5Q-,$#,9,C.S+!0%P>"<\C&IX/\0IXK\)Z=K:Q>4;J,
MEX\YV.I*L![!E- !X:T2Z\.:;#I/VQ;RPMUV6[R)LF1!T5B.'QZX7\>M:(TS
M3U>1Q8VP>5Q)(PA7+N.C'CDCUJ/5_P"TFLO*TEH8[J5@@GF7<D*]W*Y&X\8
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MK6QNHG>QN#"?G&9,*I9@.NT%L9Z<5=MO$.C7D\L%MJEI++%'YKJLRY"?W_\
M=]^E &D    , 54N]+T^_7;>6%K<KNW8FA5^<8SR.N /RJK:>)M"O[J&VL]8
ML;B>9&DBCBG5BZJ2K$8/(!!&?8^E26>O:3J%XUI9ZE:SW"IYABCE!8KTW =Q
MGN.* +H@B$'D")!#MV>7M&W;TQCTIEI96MA!Y-G;0V\6<[(8PBY]<"N-^(?B
MT:1X?G;2=9MX-2AN88C&-CLVZ1%9.<@,%8G'7C-=M++'!$\LTBQQHI9W<X"@
M=23V% $5K86=CYGV2T@M_,;<_E1A-Q]3CJ:8-,T\/(XL;8/*XDD;R5R[CHQX
MY(]:CL-;TO4Y9(K&_MYY8U#LB."P4]&QUP>QZ&DM=<TJ]NA:VVH6\L[*76-)
M 2RC@L/4 D<CB@"PMC:)<&X2U@6<DDRB,!B3UYZTL5C:02M+#:P1R/D,Z1@$
M_4BF7NI66FHC7EU% )&VH';!<XS@#J3@$\>E.LKZTU*TCN[*YBN;>0926)PR
MMVX(]Z &'2]/:%(38VQBCSL0PKM7/7 QQ3KC3K&[,1N;.WF,)S$9(E;8?5<C
MC\*S[OQ=X<L!(;O7=.A$4@B??<H-KGG:>>#CG%6+K7]'L6A6ZU6RA::,RQ"2
M=1O0*6+#GE0 3GIQ0!/=:;87S*UW96UPR_=,L2N1],BK0&!@5F'Q'HHL;>]_
MM2U-M<*7AD$H(D4=2OJ!W]*G;5M/73X[_P"VVYM),>7,L@*/GIM(ZY[8H >^
MG6,C3,]G;LTX E)B4F3'3=QS^-#:=8M*TK6=N9&!#.8ER01@\X]*JCQ%HI@2
M?^U;(123>0C&90&ER!L'/+9(&.M.TSQ!H^M2SQ:7JEG>26[;9EMYE<H??!H
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M$=@:];D@AE8-)$CD="R@T@MH 6(@C!8$-\@Y!ZYH \STK4[.Y^+T3MJ]K?\
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MU"RN)8+<@LT06(S8'N%;/KS75Z!=^%O$/B:SUK2M6GU748[5HRZN,0PMSB0
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MBXE! Y"JH(8?0>E>FK;PI)YBPQJ_]X* ?SIL=K;PS23101)+)]]U0 M]3WH
MXGPC>6T/Q!\:V,DR+=RWL,J0D_.R?9T^8#TXZ]*36_L<?QAT&2_\A8SI5RL3
M3X \S>API/\ %C/OC-=V(T$AD"*'(P6QR1Z9ID]M!=1^7<0QS)G.V10PS]#0
M!XQ?02:39:]K.GQRIX;'B.VNB+500844":5%P05$F#TQ\GH*U=:32=<T?Q'J
MOA34+C5]6ET@P2S0R!E\L,&$9"@#>1OP,;L9]17JVU0FT*-N,8QQBF06\%K'
MY=O#'$F<[8U"C/T% 'G^AZCX1\4:QHFJV6JW%_J%I%(8HMZ@VJ,F'\U548'
M'/?&*XY7L(_@+--&UNL@UC?O4J#N%]P<^NS]/:O;X[2VB,ICMXD,IS)M0#>?
M?UH^R6V,?9XL=<;!0!3UV6-?#>I2M(HC^R2'>3QC8>]>7Z5>_8]-^%6H7$B_
MV-%;M#<2Y^2*=H D1?L.=RY/0FO8#'&8_+**4QC:1Q^5,-M 86A,,?E-]Y-H
MVGZB@#R/Q=:ZE/J7CR]\.%GADT:&*<P'/F7 8[@,=6$/7'/S"KFL^(O#FHZA
M\/+K3;ZR,"7ORJLBYA0P, K#^'G P>X]J]2BABMXEBAC2.->%1%  ^@%1QV5
MK"VZ*VA1MQ?*Q@'<>I^M 'D.I7FEJ?'/AB;7=(A&IWY8RZA=")X6>.,-\A'S
M*N!M((R1C@#-:VJ:I8^'_'.DR7^K26FB7&C+;V>H1LOE&42%F!8@@;EV'/&=
MM;,'AKQ%;7%Q"\VA:A;33R3"YOK1VG4,Q.U@#AMH(4<KP .,5TMAHME8Z/#I
MGDQRV\>3M>-=I))8D+C Y)P!P.U 'F-TVD>'KGPC>V$DW_")_P!K7$L]S,V8
MC,\>(Y,] F\O@\#/(XP:W?#VHZ;=?&#Q(;2[MI?/T^T*M%(&\PJ7#8(ZXX!]
M*[]X8I83#)&CQ$8*,H*D>F*2*WA@_P!3#''P!\B@<#H./2@#B+F[;3OC+"^I
M.(K*[T<P6$LAPGFB7=(@)Z,1M/N%'I7$^(;>.#P/X[GWQKI%UK<#V62-K'S8
MO-9/8L&Z?W37ML]O!=1&*XACFC)SMD4,/R-#00NBHT4;(OW5*@@?2@".UMK.
M")FM(8(XY,,3$H ?@ 'CKP /H*\W\)VL%[I/CQM.2VDU,:S?FVD4*71RF$(/
M;DG!]S7IZJJJ%50% P !Q3(X(8B3'$B$]=J@4 >5^%[[PMXBTWPQ;R:C=RZO
MILD7EZ9N"2VTR *^5"@[ -V<\$>_%9M]<Z5-9>,O"<_B#2+=;_5Y)#/?70BD
MAW%&<;"/FVE<*<@' Z 9/LJ6T$<[SI!&LTG#R*@#-]3WKC;3PQXBMC):SS:#
MJ%NTKR"[O+-FGPS%OF4':Q&<#D< <4 5M<ELD^)G@$0S0E3#?;&5A\RF)-IX
MZY[>M95I<W6C:O8OIM[;:UX>OM:>/['* +K3[AY'+E6!^95;>2#R![<UZ-IV
MCV>F:?:V<,*%+= B,4&>/H./H.!VJREG;1W!N$MX5F(P9 @#$>F>M 'DDL\K
M:#\3=+L7WZL^I33+:(?WKPF.+<0O7!4, >Y.*WM$U'PCXGUO1M6L=6N-0U"U
MBD,:%U!M8V3#^:JJ,#@#GOC%>@B-%D:0(H=L!F Y..F34<=I;1>9Y=O$GFG,
MFU -Y]_6@#R'0;);OX$:D^CV\,VI 7P4PJ#)@S/N4$<Y9 !CN,5M:=J'AKQ3
M>:7J>C:K<7^M6MO,;2'>H-KNC(82JJC R%7GC.,5Z/'#%""(XT3/7:H&:;%;
M00/(\,$<;2'<Y1 "Q]3CK0!X?=:YI,OP$BL9KJ%-5M9X%NK:9@)TG%TID9E/
M.3EB3[UZ?XZU"PMOA_JU[=6?]I6/V;+0)(0)58@?>7D+SDD=@:WS96IE>4VT
M)D?&YS&,M@Y&3WP0*F90RE6 *D8(/0T >4VFK6$GQ02:;6+>^BG\-R1A[3 C
M8B4$I%@DG"Y/+$CDG':UX3GO])UW0=)^W6FO:)<VDITR_0!;BUB55.V3'#+C
M:N>N<9KTA;:! H6&-0JE%PH&%]![4D-I;6[N\-O%&\G+LB %OKCK0!Q_B[5[
M"P\8>'8+EK:SN7CN6AU*Z8A(5PH=%&0I=N,;NF.ASBJ_PFNH)?#^J6\=QYLD
M.K7>\$89096(W# P3UQ@?2N[DABE*F2-'*-N7<H.T^H]Z5(TCW;$5=Q+' QD
M^M 'FNCQZ"?&?Q$CU9;+R_,A\T3A>(3;KNZ]L]??%8&B6?V"+X46>LA%N$:[
M;R[C 95,;&($'H0"@QZ@"O0-$\,W-IXGU[5-1BL9H]1N(YX0I+M"4C"=U'4#
M.173O!#(P:2*-F'0LH)H X2QEBT7XMZA;7JQ6MK=:7"NED@)&%1F,L:]L[F#
M$>F#7/:?I8.BW"QZPVCI-XIGG\/W(56B!V/@;3P8VQ* .^1CK7K<]M;W482X
M@CF0'(61 PSZ\TLMO#/%Y4L,<D?]QU!'Y4 >.:]J,U_X-;^W[.QBN+/Q-;0W
M=Q;\V]QADW2+GH-O!'J#[BMGQ!I;W'Q -SX86-+M/#]U'<O;X W, +=21QNW
M9(]E]JZ?Q?X<NM;TO3['3!:0I;7L%T1(2JXC<-M 53UQCV]ZZ&VMH;:$)#;Q
M0 _,R1* N>_0#/UH \N\+WWA;Q%I_AB%]1NYM7TUXO+TW<$EMI4 5]RA00@&
M<YX(]\"F^&-8T"?PQ=^&/%"QRZW#J,QGT^7(FN9C,9$9!U;.5P1Q@<\5ZHEM
M!'.\Z01K+)]^14 9OJ>]!MH#<"X,,?GA=HDVC=CTSUQ0!Q&DWEO:_%_Q1;3S
M)'/=VEB;>-CAI0JR;BHZD#OCI7!V^L:=#\'?#FGR7D*WEGJT'VF#<-\&VZ.2
MX_A'N<5[MY:>8)-B^8!MW8YQZ9J,6ELK,PMX@SN'8A!DL.A/O[T >8>);JXT
MK4/$&LZ'J%KJ-IYL7]K:'=8S(QCC"O"PY#,FS Z$CCGBO2-5TVWUO1;O3;M#
MY%W T,@/4!AC\Q4[6=L]PL[6\+3+]V0H"P^AZU-0!XK]MUD:!I'B.XAE%SX-
MG^QW@"9:Y7=Y4Y'J!&(W!Z$EO2M_X@P?9?@SJ\M\%CN[O9<S!R,B1Y4.WWVC
M"CV45Z28XRC(47:V=PQP<]<TDD4<H DC5P.<,,T <)JE_:6?Q>T.XN+F**&?
M1[B*%V88D<RQD*OJ2.PYKEI&L)/ ?Q4D+6[2-J5X-V02<1IMY_WLX]\U[)Y,
M7R?ND^3[GRCY?IZ4S[); $?9XL'J-@H K:'*)] TZ57$@>VC.X'.?E'>K]-1
M%C4*BA5'0 8 IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6)XI\3V7A321?7A)+R+%$@!^9V( ^@&<D_UQ6W7$
M_%<B/P+),W$<-[:22-V51.A)/L* &7WB<V?Q"L!)K"IH4VE37+(X54#K(B@[
ML;CUQC/4\5U-KKNE7ND#5K;4+>33R"?M <;.#@\^N>,>M<9<ZEIE[\8M!GCN
MK:5#H]P8WW#J9$P1GU ;!'4<CBN26^$/AG4[ZW:2:PT_QG-<WJVC9=+;<?G
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M)+.Z@F6>RLBCQ,&63:) 2".#C(&179:YJ:Z-HEYJ4D;2);1F1D49+ =0!W-
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MUA'61%=&#*PR&!R"/6EK/T&U@LM L+6U@FM[:*!$BBF)+H@'RAL\Y QUK0H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *0@$$$9![&EJO>7UMI\ FN9-B%@B@*69F/1549))] ,T 3[5SG:,_2@*
MHZ #/M60WBG18[;[1)>B.(7 M6:2-UVRG&$;(^4_,.#CK4\NIV=QJ$VBQWQA
MU(0&;8J_.J9QO7<"",G&>1F@"^D:1($C144= HP*4@$8(S7GG@'Q_IMQX7T*
MWUO786UN]5LB5L,[EVP"0, D8P..V*ZB*[M)?&<\$>N-)<QV0WZ6I4K&-_\
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M,CV;0R$#<%))S@=>M7-;O]77XFZ/HEMK-S;6%[9SS2)'%"2K)C&"T9..>^:
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MI6NA_%C74U&8QR7^GVGV0;"3<%/,#! !R02.!7H>!G..:,<T >':?>0+\'?
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MY*'9$/,/S-GTY' [TDMU9I+\+"DT"B,<[6 V VQ7GT^;CZ\5ZH  ,"B@#A/
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MG6L11/.C* ^8"RGS&+$_+T  XZFM*^G?3?!\,7B;Q#/8W1NMAOK<!'D(F.P
M ' 9=H(QT.*S?$0\'^+%O].\5Q0VDUE.T4%S,3"Q'!#0R'[W7! )Y'(KF[XZ
MJGP22#5YKBXG_M"(6CW"D32VZW*%&93SG8">><8S0!Z5?>+M!T[49=/N=01;
MR*'SF@5&=]N<<!023GL.>O'!J:'Q+HUQH,6MQ7\;Z=+@1S 'YB6VA0,9W;N-
MN,YXQFN8^U6I^-0N/-C,7_"/;!+D;=WG[L;NF=O./3FN0A>V3X8BXDFEADL?
M$INH66%I%1OM)*,ZKSY9![>HQF@#U.W\4Z+<ZA-8)?*EY"-TL$R-$Z#&[)#
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MQ<_ZQ1"JDKZ@$$<5K>.+?3KK08X-2N+FTB>YC\N\MFVO;2 Y23/8 @9)X -
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MW%SMR3A<#)/7L<<I=Z]:M\$6\.S0W,&LZ>;:"\MI('!C9;A,N6QMPW4'/.:
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MH2#T]10!U5%9.H>)-,TR6>*>69GMHQ+<""WDF\E#G!?8#MX!//89Z5#>^,=
ML%T]I]139J(W6C1HSB4;2W!4$=!QZ]J +VI:7#J2P,S&.XMI!-;SK]Z)\$9'
MJ""01W!-75W!1N(+8Y(& 36'#XOT>YTZWOK:6XGCGC:6-(K65Y-BMM8E NX
M$$<@>U:6EZI9:UIL&HZ=<I<6DZ[HY4Z$=/P.<C!Z4 +J%HU]9O;"=X4E&V1D
M^]M/4*?X2?7MVYY$MM;0V=K%:VT2Q00H(XXT& J@8  ],5!JNJV>BZ;-J%_(
MT5K NZ618V?8HZDA03CWJN_B+2X[_3K)[AA/J2,]H#$^V4*N\X;& 0O."0:
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MSNA&1A,;LX[8KSW6_&$VL^ ]%U^SN+S3?,U*U\U0&B4QO* 5+$#<-O4J<=:
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M6X@:(AU4!@ P!.".O3WZT -\/^-[768M;N;B&:QMM-NI8FDN(F152,+N+,>
M<ECCJ!CBM*V\4:;<:G;Z>QGM[FZC,MLES T7GJ.3LW#D@<E>H'.*\WNM(U74
M?"'CW0+2RNTU&76)[V$20LL<T?FQNH5R-K;@I& ?KBNBU5_^$SU'PE+IUO=1
M265^M]=-- \9MT5&#1MN ^8L57'L3T&: -SQ7XJ7PTVE1_99YGU"^BM0T<3.
MJ G+9QU.T' '.?I7/MKXTOXH:EY\^I36CZ-!<162)+*P=I'!VQ $@X49XX[U
M?^(L<PM_#EY';7$\5EKEM<7'D0M*R1@."VU020"PZ"H+*9F^+5_?O:W<=L^B
M0QB22V<+O$CL5SC&X CB@#I+?Q/I-YHMGJUM<&:UO2%MO+C8O*W/RA<9R-K9
M&.,$G !I^C^(-/UPW<=H\@GLY/*N8)HRDD38R RGL1R#T/8UY-IUMJ&G^"_"
MNIR:/J-Q!I5_>?;[)(72=8Y7DVR*O!. P/'8_6O1_"7]EW4E[J>E://9Q7(C
M#W-S$T<MR5!ZJ_S;5! !/7)QP* +FJ^*M,T<7+W+7#1V@!NI(8'D6W!&<N5'
M'!!(Z@$$\&D?Q9HZ:Q8:6;AS<ZA$9;0B%S',@7<2KXVGCGK7"E[?1?%'B'3/
M$6A:G>V^IW;7-G/:P231SHZ*IB8*< C;CGC'7C&=+Q/H \2:/9>&;2S&F7%C
M;+=1S>4QCM65<)$C 8;.<-C/R@\9(P ==!XCTVXT:/5DDE%I*P6)G@=6D).%
MVJ1N;)/&!SVJG_PFVBI!J<D\MQ;OI:A[R&6V?S(D(R'V@$E2 3D9%<=K&IZG
MXA\$:)JZ:#?+=:3?Q3ZAI:PO&[(JNC^4#C</FW+CM[BI[R32M6\)^)=0T;0;
MZ*2XTF:V^T3VLBS3NR$+&JMEF /4],D8SS@ Z1?'_A\W-G"T]Q&+V+S;:5[6
M01S?+N*HVW#-CL,G/'7BI(?'&ARZ=J=Z\MS FEG%['-:2I+",;@2A7=@CG..
ME<K=^88?AL1:79^RR(UQBUD_<@6Y0[_E^7YB!S576A(+GXKRM;W"0W&D1^3*
M\+JDA2WD#[6(P<$@<4 =A9^/_#U]J]IIL5U,L]XFZV>6W=(Y^,E4<C:Q'< ]
M>.M0:5XUMM9/B%)K:^M;?3KA[?S!;2;MJQH6;@'#98X'7 !Q6!+"GB?1? =I
MI\4IGL;JTO9W:%D%O'%'E@Q(X+'"@=\YZ#-6M!>73KSQU9W-E>K)-?S7<;"V
M<H\30H%*L!AB2",#)]J .@T?6='LO"6D7$%]=W5I<(D=G)/NDN+DD$CC&XM@
M$]. "3@"IT\7:.UKJ4SS31-I@S>PO _FPC&02@!)!'((R",\\5YWI=IJ.G:#
M\-]9:RO#;Z,LL&H6_D/YL7F1[/,*8W$*<YP#P:UM4LI+_P 0>)_$5I%.;%_#
MQT]-L+9N9B7;*KC+8!5<XZG Z&@#IK'QUH6H7FFVT$UQG4H_,M)7MI%BE.W?
MM#D;2P'49XP1UXJXWB73Q<B(?:'0W/V3SDA9H_.W;2A8#C!X)Z9XSGBN"99A
MX>^&,?V.\\RRFMC=*+63, 6W9&W_ "_+AB!S3I+:ZL?$C7_AF:_BDN-8*:CH
MEU"S02CS2'N$+#Y,@>9N!P>!UX(!Z%JVN6&B?9/M\DD:W=PEM$RQ,P,CG"J2
M <9/<\5%)XETR+5+S37DF%W:6XNI8_L\A_=$D!EP/FY!Z9Z5A_$J"=] T^ZA
MMYITL=5M+N988R[B-) 6(4<G YXK+@U#[5\3=0U-+'45L)?#Z1Q3O92A782R
M'&-N02#P" 3C@<C(!O6?Q"\.WSZ;Y%Q<&+4G$=M<&UD$3.<X0N5VAC@_+G-3
M>(M?LH++4[-9;LSV]L9)WLXW9K8$$J69>AXS@<XYQBO/K>"YC^%_@*U>QOA<
MV>K6<EQ#]DDWQ*DA+LPVY  /6M;3+V?P_K'C'3-4L[YGU.ZDO;&XBM9)4GC>
M-5"!E! *[0,''Y4 ;?@O7%B^'GAN:_FN+J]N[12J@-++,V,L?4^Y/'(YYJX_
MC_P[%I(U*2\D2W%U]CDW0.&BFR 4D&/D()'WL"O.]/6[T?0_!&L7NC:G<:=:
MZ;)87T,4$BS6S,482;.&*Y3!(XQ^%:OB2"SG\'>?H^@7EO%=:O:W&W[)(9IP
MLBEY63!8# /WN3CW% 'H>DZS9^(+2XDM!<JD4K6[B:%X&# #. P!Z$<UYE97
M.I/X;\=:FWB34;:?1M3NXK.1Y]Z(D2AD1E8$,"3CGDYKUP2H8?-R=FW=G!SC
MKTZUYMX T73[Z]\5-JNB*\DNO7%U;M?6)!:([=K*77IG- &]H'C,77AS1)M2
M@E_M>_L?M;6EM$6;8,;GQV7D8SZ@#-6YO'7AZ'2M,U-KUC9ZG(L5K*L#E68Y
MX)Q\IX/!P>#6;K]]-!XZL;.:QO(]/DL'VWEC:L\DLN\?N#(H)C7 #=5R<<@"
MN(TR.ZB^'O@BRETS4DGL/$"27$;6<A,:++*2QXZ ,O/3GKP: .W;XBV4VMZ-
M8VEEJ#1W[7&]Y+*52HB!!4*1N)W;<\<#K72:WI<FK:9+;0W]U83E3Y5S;2%6
MC;L<=&'L:YGQ49;;Q_X0U3[)=SVD27D4CV\#2;&D1-@(4'&2#R>/7%='K^MQ
MZ#IDEVUI=W<F#Y=O:P/*\C=A\H.![GB@#@?#NM:KJ.C7'@R[FO(_%EM*T-U=
M>:_R1]1=!NX*D;5[MCC&2-'XB"ZT/PUI']GZGJ,4IU*VMGF^U,7D1VPV[G&3
M]..V*SO%.C:CH2Z?XYT[S[[Q!#(!>P01NPO()" T*J 2H08*Y'&"3DU:^(E]
M_;7A319K&RU"1FU2UG:'[%+YD:*V6++MR,4 6O%KW-IXX\&65M?WT-K?3SQW
M,:7+XE5(]RYYSU[CD]Z=+-=#XU0:8+Z\%@VBM>FV^T/L,HFVYQGICMT]JA\8
MRM-X]\#W,-O=RP6UQ<23RQVTC+$K1;5+$+QDGO3I6?\ X7E;W8MKHVHT-K4W
M MW\L2F?=MWXQG'/6@"Q\6+N\TWP1+J&GWMS:745Q JR02E>'D56!'0\'O3_
M !3IVL:%H%SK'A_6;PW-A$T[VMX_GQ7**,LIW#<I(!P5(J#XO1S7/@.:TM;:
MYN;B6X@*16\#R,0LJLQPH/0 U9\5:W<ZKX>N]*\/:=?76H7\+6Z/+:R0Q0AQ
MM+N[J , DX&23VH 2W\3Z-KR^$;^2[O[6XU#,UI;PEQ'(_EMN20@;6"\\$CD
M UO:=XDT[5;[4;*T:=KG3F"W,;P.A0D9 ^8#.1R,9KB;K0CX<G^'6DPQW%Q'
MID[>?-% [*N864LQ (4%V[^M7_$FD:G;>.+6]TB)S!KMN=-U%TX\G;EDF_W@
MGF*#Z[10!IW>NZ)J%]X;E:^U&![N8R6*1I+$EQ\C<2?+@KCD X[&M*3Q+I\=
MR8O](=5N5M&FCA9HUF8A0A8#CE@">@/&<\5S_C"'RO$?@I;>UG:"UOV9_)@9
MEAC\ID!)4$*,D#FL2^MKJR\03ZGX8FOX+V75 E[HMS"SV]V/,"M.F1\GRC?O
M!QQCKU .RTV_TJ;Q9KJP7]Z]Y;Q0?:X)RZPP##;2@8 #(!)(R#Q4D7C#1Y;B
MQC\V:.._;;9SRPLD5PV,@*Q&,D<C.-W;-<??:9>ZMXF^(5E:QSPOJ&E06]K.
M\3I'(XCD# .1CJP!P>]1WBS>*O OA_0H;*ZMM6@N+07$<D#(;0PD>8Y)&,84
M[2#\V1B@#J;OX@:!:2ZE$TEY)+II NHXK*5VB!&[<0%^Z!SNZ<CFNBM+N"_L
MH+RUE66WGC66*1>C*PR"/P->?6I=->^(\K6MV([F.'R&-M)B;;;[#LX^;YN.
M,UT?P_62+X?Z#!-%+#-#8Q121RQE&1E4 @@@'K0!2M;N_3XN7FG2:A/-8G1D
MN8[=]H6-S,5., 9X7J<GD\UI>-K[4],\%ZK>Z-$TE_##NB"+N8<C<P'<A<D#
MVK'B+_\ "YKB?R+C[.=$2W$Y@?RS()F8KOQC."#UKI=?U"XTK1Y+VVM);N2.
M2/\ <0H6=U,BAMH'4[2<4 <KH$]AXAATW5/"OB2^N88YE-];SW;2LZX.0ZN2
M8V!P?EP#@\$8KHT\4Z5(-6VR3%M)(%XGV=]T>5W#C&6^7GC/%<'K6BZ9>>+]
M$UGPA;W-IKAOHS?&*WDA1K;K+YZL  <>OS$GOVGN)I-+\3>/K6:QOGDU2".6
MR,-L[I,!;;&^<#:N&'.XB@"UKWB.WC\6^"-7M]1N_P"R;^"ZE,<?F%9E\D-'
M^Z RS?-P,9R:Z;2O&>A:OIE[?P7GE16!(O%N8VA>W(&3O5@".*X73UGLK;X8
MZA<V-[%;:=9RV]XS6LF8':W5!N7&0"P(SC'O47BCP[JNLP^,=;TFSE9+O["(
M+<H4>\%NP9SM/.#]T9'S;>.",@&WJ.NM=?$[PA#;2ZE;PW$=V\L$RR11S*(L
MHVT\$@YX/(XR!Q6I8^)- T^S\0ZJE_J4]M;7K?;3/%*_V9PB[E1"NY4 P>!@
M9-8EYK<6O>.O!.HV5CJ9MX?M@G:2PE7R2\04!LKZ\$]!ZU?\%VRW-]XTM[NT
MF%O>:K(ZK/ Z+-$T2*2,@9!PPXH ZC^W;+R--F!F9-18+;;86)8E2PR,?+\H
M)R<=*R=)UO0X5U^^AU*^EC@O=MV+H28AEVJ/+C5@"!RN !R3Q69X TO5;/?8
M:K&_DZ"TEA8RO_RWC)#+)^$?EJ#_ +XK(M8+:>T\>0ZIIFH36-YJR-LCMY5=
MXR(D\R/"Y;:06XS]V@#M+S7].ETW5DNFO[-;2WW71$$BR1(X;#J5!)X5CE<X
MQ[46&LZ78^&]%DCNKFXANX(ELC(&DN+D%-P)'4MM&23TY)Q7(6"ZQ::3XJT^
M6^NM:TE--Q8WLUN3<,[*X\DD#,I'!SCC=CV%:T@OM.MOAOK<EI=M9:;I_P!B
MOXA _F6S/"B[RF-V RX)QP.: .X'C'11IVI7LD\L:Z8<7L3P/YL'&<L@&<8Y
M!'!'.:CL?&VB:AJ=E802W EOHC+:O);.D<V%W,$<C:Q Y(!XKD-;T^:^NO'&
MNVD%P;2[T/[! JPONNIMC\JN,D#<J@XP>?2I9A*9OAHPM+LBT_X^,6TG[G_1
MBGS_ "_+\W'- '6^+-<DT:QM(;7;]OU*[CL;7<,A7<\N1W"J&;'? '>K-_=-
MH^G0V]KON;Z9O*MDF<L9)#DEF/\ = RQ] .!T%<[\0()%UCP=J6";>UUE$F]
M%$JE%8^VX@?\"K3UGPWJFH:XNIZ?XDGTUEM_($:6D4P W9)!<'&?ESCKM'I0
M!E^!'U+6_ \WVW5+A[];ZZ1;S/S*RRL%.WIM&/N],<5N^$M?_P"$D\/0WSQK
M%<J[P742GA)D8JX'MD9'L17/?"G2=6TO0+P:G=W#A[VX,=O/;+$4_>OEQ@ G
M?D'GCTXJ7X6V[IH.JWQ!$.HZS>7D'_7-I,*?H=I/XT :F@ZJ_B+5M5NTD9;#
M3[MK&!%.!)(@'F2-ZC)V@=/E)[\2_P#"9:*&MF:>5;:ZF\B"[:%A!))D@*'Q
MCD@@'H>Q-<UX%TZY'A#Q1H7F&&^CU&]@WG@@R?,C_0AU-8\EM=:U\'K?P8;"
MY@UV-(+)H'A8")HY%S+OQMV;5W;@<'H.3B@#M(/%4>H^,M4\-?9;R-;6"(F<
M1.,L^_)##[JX488XR<XKG/ 'C6SM?!NBPZQ>WLUU<W,UN;N6.25!(9Y BO+@
M@,1C )Z8Z#%:-F\FE_%76Y+FUO##>Z?:^3.EN[QMY?F;\N!@$9'!.3GC.17(
MPP72_!/2[$Z??B]CU19&M_LDGF*HO#(3MVYQL.<T >H:KXFT[1_M!N/M$@M8
MQ+<FW@:7R$/.YMHXX!..N.<8JG>^//#]C+;1O=2RO=6QN[<06\DGG1@ Y0JN
M&X(X'/KBN1N9X-%\::]'KVC:G>V&L/'<65S:02RJ_P"Z6-HG5.A^7@$=#5T6
MPL_B!X16'29K.UM].N8C'% S1VQ?841G *@X!'7&: .C\0>+(-&\$3^)8;>>
MXB%L)X8Q$P)W#*[@>5'(SGI]>*YW7==:/Q9X(OC<WUO:W#70N+<K(BR$0$K^
MZQECN/'!)R,9XK=^(EG<ZA\.]>M;2%Y[B2S<)%&,LQZX [GVK O[PZAXI\ 7
ML-E?BW@:X,KO9R+Y8:#8I8%<KEN.<>O3F@#IK?QKH=QHU]JC7,D%O82^3=+<
M0/')$_&%*$;LG<N!CG-30^*M,EEU"%S<0W&GQK-<026[[UC;.&  .X'!Z9Z<
MUY_>75_8R^/+JUTB>Z$VH6KQB2Q:0&,+&KRHA&)"A!( SR >E6=/D,7CO6KM
M;;69;2[T2,1W5S:RYD96DSP5&WJ,+A>O"XYH ZJS^('AZ^ETQ8+BX,>I$):S
MM:R+$[D$A-Y&T,0#\N<_C6YJ&HVVF6ZS7+, \BQ1JJEF=V. H ZD_P#U^E>5
M10W,?PX^'MLUC>BXL]4LWN(OLLF^%4+;V8;<@#(Y/K7=^-K73]0T6"VU&*]-
MO+<IBXLMWFVK@$K*-H)&"!SC SS0!H1^(M/>TNKF1IH%M9Q;RI+"RN)"%(4+
MC+$[UQMSG/&:BM/%6E75Q?VSS/:W%A&);F*[0Q-'&1D/SP5X/(X'>O.[VV\4
M2>&[@R";78-'UB"Z@F2+RI]0MU3YQ@8W,N[ 8?>V]\5;U2PL_&/A77)/#6AW
M=O>S6!A^U7L+Q22$.KB%=_)!VG)^Z"1R<G !VT/B[2IK^.QS<QW$UNUS;QR6
MSJ;B->I0$9)_V>OM7/1>-=-\0?#R_P!5U0ZEI=DQFC>:WBD62-!*Z*590?FP
MHSC(!.#6EX>\41>)I[-TT*^M[N%#]I:\M&B^RDCE%9A\Q+8X7L,G' KBH([I
M/@=KFA-INH#48?M<1A^R299GG=E"<?/D$'*Y [T >FS:S96"6<&^:>>XCW00
MHIDED50,L1Z#(R3@9([D50G\<^'[?P_/K<EW(+*WE,$Y$#EX9 <%'7&4.2!S
MCJ/6N>+7&E>/M'\03PW#:1=:(-/:186/V:4.'!=<94-TR1U S6!XET>\D\,>
M/M1M[.[:/6;NV^Q6R6[F201^6&DV 9 8ACR.BY[B@#TBP\5Z5J6MR:1!).MV
ML7GH);=XUFC!P7C9@ ZY(Y'X<5:UFRN]1LUM;2_DL0[CSIX<>:$P<A"00"3@
M9QP,XYQ7,:@YF^*_A^ZB@N6MUTZYC>86[[%9RA4,V, G!X-;_B;7_P#A'M*-
MTMC=WLSL$BAMK=Y3N/=M@)"CJ3^63Q0!SWAA=8TCQKK.@/JEUJNFQ6<5U#+>
MOOE@D=F'EE\<@[2>>@Q^.+H/B*\U6TTZ*WN[T^+HK]$U6RF=ML2!_P!\6C/R
M+'L^ZP&<[1DDG/1>%M:@NY+FULM.U87TRM<W-[J%@]NDDF H^\/H HSA5Z\<
M\JFARW6F:%J<$5W!XZMKF,7<IC96ES(!.)3C!BV[BIZ8"A>N* .FM+RY\5^+
M/$ED+VZM;/2/+M;?[-*8R9V4L\C8^]C*@*<KP<@YJC8>++^^^&5OXPY^W:>C
MF^MT/R3K$Y648Z D*64]C@=,@VM/C?PCXN\43W-O<26FJ-'>VC0PM)OD";7B
M^4'YL@$#N&]C6?;Z/-X4^!&I6>HJ!>-I]U),@.<2S;R$]R"X7ZT >BVMS#>V
MD-U;N'AFC62-A_$I&0?R-2UD>%+&;2_"&BZ?<Y$]M8P0R ]F5 #^HK7H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***J:EJ=II-F;J\EV1[E10 69W8@*J@<DDD  4 6Z*QK3Q+976HW&FM%<6^
MHP0_:#:31XD>/H&3!(89XX/!X.*Y#PX[>-+[59[R35K6YL=9E%M-"[1+''$5
M B(Y7GG<I'.3[4 >D45S7BKQ2WAZ[T:UCLI[AM1O%@WQID(,%B/=B%.!]3]>
M>BUP:1\2O$+3?VG<Q'3K6:.SB62=U)+[MJ<[1P,]!GZB@#T:BL:#Q/IEWH]A
MJ=I*]Q%J 'V1(D)>4X)P >F #G. ,'-2:+X@L=>%TMJ9$GLYC!<V\R;)(7ZX
M(]QR",@]C0!JT5P/C[7QHFO:&-7EO+;PU,)5N;FU=TVS_+Y8D9,,$QNZ'D]>
M!6UHFFH[WTUMK%S?Z->PQ&T;[:TAC(+[PD@.[!RISDGMG H G\6>'6\3Z2FG
M_;/LJ">.9G$6\DHP=0.1@9 S6V@<(HD96?'S%1@$^PR<?G7DO@.^T_6OA]IK
MZOXGOQK=Y))!E-7E$V\S,B$1A\<#:?N]!DUZ+JU[/H_AUG0B>^")!!N_Y:SM
MA$S[%B,^@R: ->BN-^&^LWM_H5SI>L3&76=&N7LKMV/,F#E)/HRD<]\&NRH
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MA!.0N[:KD8)QSZ56N/B'HD$6I2+'J,PTR4QW8BLI"8L ,68$#"@'J>N#C.*
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M[@ Q#KG;U.,=Q6KH^KP7?BV/4=0LM:BUA[,V-HU[I;VL!YWD;LL-S%>I('&
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M>0K @YZ9J36-!L+V#2H)='U#0I88I9K*[T:%MUDS/GRV$0(RP()&""0W/()
M.[TZ_CU/3H+V%)$CF7<JRKM8>Q'8UE:IXML=+NKVV^SW5U+86PN[L6RJ?(B.
M<$[F&>%8X7)XZ=*D\('6&\*6!U[']I[#YQV!2WS':2HZ,5VDCL2:Y7Q.=7O=
M;\0Z;-I.HS6DFFA=-:S3$<SE'W^:X(Y!( 5CC&>"2* .ND\1V/DZ>]KYEY)J
M,7G6D, &^6/:&+_,0%4!EY8CJ!U(%5K3QGI%YHYU&-Y@!=&R-NT?[[[0#@Q;
M1U;/H<8YSCFN%T\:UX?/@_Q =!U.XMH-$72;ZUBAW7$) 0B01YR1N3![X'TK
M7\3/K-U'H'B6VT.[:+3M2,[Z<J#[2T+1E"Y0'[X+$A<YP1G!S@ Z&+Q?:OJ5
MYILFGZA#?VEK]KDMY$3)BS@%6#%3GGH>Q[\4#QII;:7HFI*ER;369HX+601C
MAY/NAAG(S@\^U<U873ZS\4]1D6TN;3SO#<:HETFQ\&9^2O5>>QYXK!MH]6;P
M3X+TG_A'M6%UH^K6AO UOM"B,MDJ3]X8YW#CWR0* .]M]4T9/&&M^4FH'4K6
MTB-T"DA0QY;;L3N>O*CGUIFE_$+1M5MEO(8=0CL6M6N1>2VK"$@-M*!AG+Y(
M^49].O%4+43P_$OQ#?R6-ZMK+IL$4<HMG*NZ%RR@@<GYATZ]JQ;#0-7O?@-:
MZ+#921:M;1QM]DNXRF]XIA)L.[@A@N/3F@#N+7Q59S:X=&N;>ZL+XP&YCCNE
M4"6,'!965B..X)!'I7'>-_$,>IV/ARYL8]12UFUNT6"[5BD,ZF49R V2I R"
MRX.,CJ,SVT,/BK2KZ"P\&2:#?26$\#7=[9)"T3O&5"QL/F89.21Q@>IK&N+C
M5;WP+X:T=O#>KQZEI-_8K=1"U.S;"P!=7^ZP(7/!.,\XZT >O,2%)"EB!T'4
MUS,GCK2HO#=_KK0W?V/3[A[>Z'EC?&Z-M;C/(!XXS73*2R@E2I(S@]17C>IV
M>K1^"/''AQ-"U.:]NM1N;B!X[<F*2*20,K*_0G'&T9.>V,D 'HE]XRTZQUW^
MQ3;W\]^;4W:10VS-O3<%PIZ$Y/T&#DBEM/&>D7GAQ-;1YD@:;[.(7C(F\[?L
M\K9UW[N,?TK%C^TM\4['4GTZ^CM1H+V[R-;L564RHX0D C.U3_+KQ7*+I6MQ
MZ#'?V^E7LDFF^*IM4>R:%DDGMV=\,@8#<V&R!0!T=CJ#R_&BX66.^LT30#))
M!=RY0'SU^=<,R 8&.#V.:Z >---%YIT,T-W!!J;;;&[DC BN&QD 8)8$CD;@
M,]JY6[AO/$OCJ[GMM,U*VL[WPU+8+=7-LT0CE>0D9#8(Q],_A@T>$2)8-,TO
M4/ #6NL:>8UFO9K&/[.ICQF6.7JS$#C;DY/H,T =)8>/-,U34C96=GJDKI>O
M92R"S8)#(JY)<_P@].?3L.:T/%6MMX<\,:AJZ6DETUI"T@B0@9P,Y))' []\
M= :Q/A_%<6\WB=;FSNK?[1K=Q=0F>!HQ)$P0*P)'^R>.M:OC:QN=3\#:[8V<
M1EN9[&:.*,=78H< ?6@#D==U>634_ 6JW"WUNTMRXFA!8B7_ $=B,1H2#D].
M,UUFG>,=+O[34YY%N;)M+?9>0W<6R2+Y0P.!G(((QC.:Y:Z:\O;CP#.-(U.-
M+*<M<![5\Q+Y!3+  X^8XYYXSTYJCJ^A:KK-Y\0X;*RG62]:QFLFN(62.X,"
MH67+ #DIMYZY]* .[M?%-I/KR:+<6UW8WTL)G@CN44"9 <$J58C([J<$>E6/
M$BEO#.IE9)8W2UE=7AD:-E8(2"&4@BN=\+7-IJU_;W,7@:71KFW5O/N+RQ2$
MQDC!2)ARV3W  P#GD@5T7B,L/#6I*D4LLDEK(B1Q1L[,Q4@  #UH \DDU74-
M*^'/A'7-+UG4)_$%Y+ C6LU[)<"]W9WJ8W8@?50,5VUG+]E^+FN^9<2BV71X
M)V625F1#YC[B 3A1A1TJQ\-M*BL?!6CK<:7]EU*"V6*<S6WER!AP>2,FJ<R:
ME%\2-?OK/3IY"VB)#:O)"PAEG1I&V%L8Q\R\YQ0!M:?XTTW4+O3(%ANXEU6)
MYK":6,;+A5&XXP20=ISA@#BJ$WQ+T6*SO[L6NJ26^GW36UW(MFV("N,LV<84
M;OKP>,5RU@FJ7&N^!M6FT37&FMO/34'GAV".1X"N%3("(&Z$ #&.2<T]K*_?
MP+\0K,:9J'VC4-1NY+2,VDF9ED50A''0D'Z=Z /5D=9$5T8,K $$="*=5'1B
M3HECN22-A @9)$*,I"@$$'D5>H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***QO$OB2T\+:8M_>P7,L)E2+]P@8
MJ68*"<D<9(H V:*Y7_A.(1K4VCMHNKK?B#[1;PF),W4>[;N4[\+@]=Y7&1FG
M6_CO3+C04U3[/>([7PT[[&Z*)A<[]GEGG:#GONQCO0!U%%<R?&MLMKK<CZ;J
M'VG12OVRT14:0*4WAEP^U@5YZYXZ5;3Q/;2Z5H^H0VEU+'JK(MO&GEEAO4N"
MWSXP%!)P3@"@#;HKB/B[&'^%NN,2X:.$,I5RO.X#MUZ]*OVGC>RE\1V^AW.G
MZE8S72,UG-=P!([K:,D(<D@XYPP!Q0!U%%<O>>.M.L8[>[FMKO\ LN>Y%JNH
M@(8@Y8J"1NW[2P(W;<=^A!K<U74[;1M*N=2O'*6UM&9)"!DX'I[T 7**QE\1
MPQ?;CJ-I<:=%9VPNI)K@H4,9W<@HS9(VG(^G7-5D\7VJ7VFV][8WMBFIG;9S
M7"ILD?&0AVL2K$<@,!GIUXH Z*BN!\.3V^E^.?B#-<3>5:6[VDKO*Y(1?L^Y
MCD]N2:H^)]5.I^(O UPNG7]M'-J:M%+,5".AC<X*AB5)^4X8 X^A% 'IE%8O
MB[6YO#GA34M7M[1KJ2U@:01A@HX'4Y(X'?'/H*XO7M0EEUCX?ZK=6MY'.]Q(
M'BR&:3-NQR%1BO)/'0^N!0!Z=17*)X^L1I&M7UQIVHV\FBL1>VCQH94&W>&&
MUBI!7G.ZG0>.;.6U>YETW4[>%O(6U>:  7C3?<6+GYCGKG&.O3F@#J:*P8/%
M4$FK7&D36-W;:G%!]I2VD\O,\><;D8,5.#P02"/IS51/'NF2>'=(UU+6]-EJ
MEPEO$=B;HV=]B[QNZ9],T =316#?>*K:TO=1M(+2ZO9M-@6XO%MPO[I6!*CY
MF&6(4G [#W&>/\2ZY9ZO-X&U^TCO!;RZJ/+!5MTB&)R,("<Y./>@#TZBL30?
M$T&NW6HV?V*[L;W3Y%2XMKI5#*'7<C JS @CW[5G^(O$]]I/BSP]I%MID]S'
MJ#3-(\;Q@L$B8[%#,.<E22<<# SG@ UM?T&V\0V"6MQ/<V[13+/#/;2;)(I%
MZ,#R.YX((J+3O#\EK-'-?ZSJ&JR1',7VKRE6,X(R%C103@GDYZ\8KBM/UI?#
M?C+Q[,NGZC?QPRVLK1VP#F-/(W,Q+L!U). <GL*Z'5=<T"]F\)W-Q:W5R+^Y
M2;39HP51)&C)4M\P_A)X(/TH ZZL/0_#::'J&JW:7UQ<-J4_VB990F%? 7Y=
MJ@@8 &#FFOXI@^TSI;V-W<PV]XEE-/#L*QRL5'(+!L#>,G'YUKWM[;Z=8SWM
MW*(K>",R2.>BJ!DF@">BN=7Q? NN6ND7>G7UI=WL+RV8F\O%QL&64%7.& YP
MV*K:?X]L=3W1V^FZC]K2^:QDLW6(3(ZKN9F&_ 0#^+/TS0!U=17-O'=6[P3!
MC&XPP5BN1Z9'-8^I^)X+":^A@LKN_EL(1/=K:A/W2D$@'<PRQ )"C)QCID9Y
M+5]7M9_'W@C6[%+JYAO;"\DCBC!+2#9&4 4D!3\QY. ,\F@#TE$6-%1%"HHP
MJJ, #T%+7+0>/-,E\/W>JRVUY;FTO/L,UI(B^<L^Y5"<,5.2ZX.<<]:GC\86
MI?689[&]ANM(B2:XMRJLS(REE9"K$$84]QC% '145R-E\0;"]ET0_P!G:E!:
MZR%%K=S1*(S(4WB,_-NS@'G&"1P35K4/&EC8+JTB6MW=0:1C[=+ JD1';N(P
M6!8JI!..@/<\4 =)16$GBBWN+>R:TL[N>XO(6GAM@$5_*! WDLP4+\RXYYR,
M=\3^'?$5EXFTY[NS$L9BF>WGAF4"2&5#AD8 D9'L2.: -:BBB@ HHHH ****
M "BBB@ HHHH **** "LO7=&;6[*.V35-0TXI*LOFV$HC=L9^4D@Y4YZ>PK4H
MH KV-E!IUC#9VR;(84"("23CU)/)/J3R:L444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8D
M?AN./QA+XD^VW!GDM1:& A/+$88L/X<YR3SFMNBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0^)5G>:CX2-I86
MDUU<-=V\@CB7)VI*CL?0<*:Z^B@#C)X;I_BK8:HME=&P32);=I_).U9&D1PI
M'7HI[<=*YRVA\2:;HFJ?8]+OU%SXGDNKA(E"SO92-DM%D\,< =0P&>G!KU:B
M@#@_!^G7EEXU\42RZ)<V=A?BUD@>9D8';%M8,0Q)8GD]>^3ZL\$Z#=:;KNIV
M,DB2:3HUQ)'I8!R5$P61E/N@.T'T<UV.L:6FLZ5/I\EU=VJS  S6DQBE3!!^
M5ATZ4[2],M](L$L[;S"BDLSRN7>1B<EF8\LQ/))H Q/B'I-[KO@#6=,TZ'SK
MN>#;%'N"[B&!QD\=JIWMI/XKU[P[<I8W=G:Z7,]W.]U'Y;[]A18U!Y/+9)'R
MX'!.:[.B@#RKPKIVH:-:1^%[_P %)<W=JYC@U<PQ-;21;B5D=B=V0#]T DX[
M9X]"\0IYF@7L9T[^TE>/:]G@?OE)PRC) SC-:=% 'DS^"=2N](\0^']'N]03
MP_=Z<HM(=2W V]R'SY:%OF\O  /4<\$\UM7UKJ/B^Q\,VEQIEU8W-C?P7M\T
MZ;5B,(.51NC[FP 5SP23CI7?T4 >7ZEX:U37+GXC6D5M-;C5X[<64TJE4E,<
M05AGL-PQSV.>:=?7.N:X/![GPOJ<-QIVHQR7J,L:JF(G5BK%L,N3D'I^/%>G
M44 87C33KG5O!&MZ?9Q^9=7%E+'$F0-S%3@9/K7+7,6I7MYX$N3HU_"FGRLU
MTKH"8E\@Q@G:3_$>@R<#) KT:B@#R_4]-U.9_B4(],O&_M>WCCL2(C^^86_E
MG'I\WKCCFM#7]'U6_P#"'A>[L+25K[1;FVNY+%\(\HC4JZ#/&[!.#G''O7H%
M% ''?V?-K_CS3->6VN+6TTZRFBS<1F-Y9)2HV[3SA0"2>F2,9YKB[?3?$$?P
M]T+P\/#FH&\TG5('G;Y CJDY?,9+?,".<G 'KZ^RT4 >7ZS/<VGC779K+1M;
M>*]M(+>[DTR.&?<X5N6#.-DBJP ZC!R0<BGS117=IX*CT/2-2BL]'U$"X@F@
M*R6R)&R?..Y^93QG(.:ZB7P7:_VI=7]EJFK:>]W)YMQ%:7.(Y7P 6*L#@D #
M*XZ5NV5E!I]LMO;JP0$DEF+,Q/)+,>22>YH Y;P_:W</Q&\67LUG<1VEZEH+
M>9T(60QHROCTP2.O7M1XMM-0'B[PGJ]IIT][!8RW*SK 5W+YD6U3\Q QGJ<\
M5V-% 'GMM:7Z:SX_N'TZ[$>HQQ"T/E$^<5@\L@>GS>N/7I5"/3-33P[\.K8Z
M9>>=I5Q"UZHB/[D)"R$GUY(Z9XKU&B@#S+6=#O)==GU?0+34=*\1"]1&:,'[
M)?PAP"\O\'W,]<-D< \5V'C31;CQ#X-U72K1U2YN("L1;IO!! /L2,?C6[10
M!POAF[N+R6![GP*='NK52UW.\$6W=M(Q 5.YB3WP!C/).*SY['6+'Q)9>-[+
M3+B2ZOG-KJ.FK$ ZVW\#9_YZ+M!//.[ . #7I5% 'GJRZUX7\<ZS>1Z#?ZKI
M>N>3/"]F%WP2K&$*2!V7 ( .>WYXM:C;:I/X_P#"5_/82E+6WNUNY(5+1PM*
MJ;%SU;[I&0/?BNXHH \L6'Q+I^G>*9=-TR]$EWKZW0"(!+):$1J[1;N ^%.
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MEO;ILB08 R2?4DD\DD\DGDDYJ:@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$]<M+_X+>(+[[*DMQX0UR-X_+!S]GD*D ?4=O[R^XX /?[&Z-[8PW1@E@\U
MXCFV[U!]=I(_6K!( ))P!WKS#Q/X@O\ _A-_!?A.WGFMK._C\^[DA<H\BJIP
M@<<J/E.<$'D5R]WXCU34?"'Q,T.YOKITT.=EM;CS#YAB9W41NW5@-O?DYY-
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M;W&J726]VT:)B0%');[OWOE^F>H-7'T.6Q^)WANSFUK5+QAIUVWG3S_,<.A
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MCBC4L[L< "@!+6VALK."TMT"0P1K'&H[*HP!^0J:BB@ HHHH **** "BBB@
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MV+U[K>%F%P,;9%90 K * , # Z<G-RT\/6L%U+=W4TVH7<L'V9IKO83Y6<E
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MM+,97BS.XPK/DXR"><\D]JUO^%=Z+_PBMOX>:2\:UM9OM%K-YH$UO)N+;D<
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M;I"C2,J\!I9"['ZLQ)-2U!9VPL[2.W$LLNP?ZR9]SL>I)-3T %%%% !1110
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M!%:ZSJ5Y::T+B*[M[N?S0K)'O$B \)SP0 !TXH [73;J]NDN3>Z<;(QW#QQ
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MLT)>(.)=L:G=EB?O'&%QCKGL-!2^CT*SBU.[AO+Z./RY[B'[LCKP3]>.??-
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MF3K<6[-<%F\Q1A68L#G XQTQVJQ<>%;*76+C5;>>[LKN[C6*Z:UEV"X5>%W
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M !D9#A5;<>,?=/ %8%Q;7,O@WQ]?MJ^K?:-)U2[-BPOI!Y7EI&R]#\P[8;(
MZ 9.>^TCX?>'M"U$WFGV\\8#F2.V-R[01.>K)&3M!Y/...V*F'@G1AINJZ?M
MNC;:K*\UXAN7_>NW#'.<C( Z8Z4 ;&FSO<Z7:3R$%Y84=L>I4$U:J"SM8[&R
MAM(2YBA0(F]BQP.!DGDU/0 4444 %%%% !1110 4444 %%%% !1110 4444
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MY7[8J88Y^8;3C#9KJH;"/3?BO_9L$]VUGJ.B2RW,4MS(X>1954/R3@X8CC%
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MLQCVSS0!Z]7/ZIXBGT[Q?H.BBS1X-5\\?:/-(:,QQE\;<<YXYSZ\5SNFW/\
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MI<N#)'NE&&YPQ^1>3SQ70O91VGC.V\'P3$V TU[V*&^GDD\Z1IB&&=V6V@#
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MP3.T]01V!YZUMWO@/PYJ%UJ-Q<V+N=27;=H+B18Y3C 8H&V[@.C8R/6NDHH
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M6&I6R7%M)@LC9'(.001R"#T(Y%7:S_[2%[9Z@VDM%<W-LSPJKMA#,JYVEAG
MR0#Z<^E %:U\+Z?;7,%P\E[=O;G,/VR\DF6,XQD!F(W?[1Y]ZDD\.Z;)K_\
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M4@]>M='<^$M#O-&DTFXL%DLY9?/=6D?>TF<[R^=V[/\ %G- '#V<<T.M>/\
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MEPL=SH]P[1-*P ^:/!"YPIP>V*W%\&:$D<4(M9C:PLK1VC74K6ZD'(_=%MF
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M(-NC2ONAQTV/NW+^!J1_!N@/I%MI1L,65O*)HXDFD7]X#D.2&RS9YR23F@#
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M^$/!=[865MK*0:2CW6DW$@5KA3%%^\3.067GK_?/<UV$/@OP_;KJ(BL"IU)
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MA410 ![ 4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JCJVD6&N:>]AJ5N+BT<@O$S$*V#D9P>>>?PJ]10!EGP]
MIAU.'4C YO8(O)CG,SEE3^[G=T_G4FEZ)I^BBX&GV_DBXE,TPWLV^0]6.2>3
MW/>M"B@#.U/0=*UF:UEU&QBN9+1R\#..4)&#^!'4=#4 \+:,O]H8M&']H_\
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M.;=YT8=AYN[[V\YRV>^2<]ZTJ* *NGZ?:Z5916=E&8K:)0L<>]F"*!@ 9)P
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M[: ,L48VHK.6P/3))-3444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU;_H<=8_[\6G_P 8KH:* ,W3--O+%Y&NM;O=1# !5N8X5">X\N-?US6E110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,@=<?49]1UK2'C+5-"7QA!JLL.H2Z+]G>WE2+R?,\]?E5@"<8;C/I0!Z'02
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M:^MGM%G1W4;=Z9(VM@>X/?/2NSHH AM;=;2TBMU=W$:!=\C99L=R>Y-3444
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M#F2..3=@*<GJI(R>:T9_"Y?Q3I.L6]W'!#IEN]M%:B#(*/M!^;=QC:,<<>]
M&_*SK"[1IOD"DJI.,GL,UY_X8\:'4)-U[JLL5]9VDDNJ:1=6ZQ2Q.H!S&-H)
M0?-W;@KDUW]Q$9[:6$.4,B%0PZC(QFN;B\(/<:KI>H:Q>PW\^FP20Q2+:^4\
MH==C>8=QW<9X  R2: .>N_%.NV_P[M_':7*NA5+J;3/+7R_(9@-JMC>'"D'<
M202#QC@>C12+-"DJ9VNH89]#7'6W@$P: ?#3ZH9O#PEW+;/!^^$>_?Y1EW8*
M9X^[G'&>]=H!@8'2@#SK1%OG\8>///U2XGCMVB18W5,;3;[@.%R "QQC'ODY
MK&\,:GK>A^#/ -W'?Q-87L]OI\EEY QMD# /O^]N!&>P[8XR>W'A.>#7];U.
MTU9HDU9$\VW: .JR+'Y8;.0<8YQQR.N.*H+X!G3PWX>T9=739HEU%<Q2FUYD
M,>=H8;^G)SC]* ,WQAXIUK0K/7;^._C\W3YHC;V5O$)8S"=F?/;;E&;<V!N7
MH, ][DZWTGQKAA&J7"6ZZ&TZPA4*C]^@91E?XMHR>O'!%)J/PWFO['Q%IR^(
M)H;#6K@W30BV5FCE.TGYB<E<J/EXQCKZ[$GA6X?Q18:\FL2K<P69L[D&%#]H
MC+A^/[AW#L#Q^= '13(\D#I'*T3LI"R* 2I]0""/SKQ1C>2_L\3W=U?37<D]
MTK8F"\-]OY.0,G)Y.<^U>W5P1^'$W_"%W'A9-=?["\_F0EK52T2B;SMO!&X[
MNY[=AUH F76]7T;QW)INJ7\=[8S:5+J"A+<1F!HW *K@Y*D-W).1UJM8ZQXO
MU.UT#6K"TFFM[UXI+NUD^SK"EO(,[HV#>9N4$=?O<\#I6[/X8FNO%MMKT]]$
MWE63V3VXMCM='(+'._CD#\/7K6;H/@2^T%TLH_$UW+X?AD\R#37A3<@SN"&7
M[Q0'MQZ=,@@':UXQHUQXGTCX;7FO:1J5JEOIUW>SO826P87"+.Y?=)G*G&<8
M';WX]GKC+?P))!H]WH+:L7T.ZGDEDA^SXF*NY=X_-#8VDDC[N<$C/>@ T_Q%
M<^*_$%]IVGW<FG06-E;3NZ1HTCR3J74?."-JJ!GC))ZC'.?IWBW6-2\/GS[B
MTLKNPUE]+U*Y QN"?Q0H0V7;* +@]3@5O3^%'@\3'7M%O([&YEMUMKF&2W\V
M*9%^X=H92&7H"#TXQ5&Y\ +]ETXZ?JDEKJ%GJ$FHM=/")!--)N$A9,@<AB!@
M\#% &'-XPUU/!WC2YANA]JT2X9;>>YM0'>/8K@.@V@-\W7'U%:5UK'B#25TV
M&ZU2WN+G7KJ&"T"VH062["TISG]YP.,XY/IQ3YOAY/-8^);0Z_*T>O,&F\RV
M0E#M56(P1D_*,= /0]:T]<\'G7="TZTEU%[?4=-ECGM;^"( I*@P#L)(((ZC
M/- &-IMO<VWQKO$N;U[L'0(S&\B*K!?/;@[0 ><\X'7\:Z/QEXA'A3PCJ.M>
M4)6MHQY:,<!G9@JY]MS#/M5/3O"M_!XN'B._UO[3<FP%D\45JL4; .7R.6(Y
M/3/KSC@;.NZ+9^(M#O-(U!"UK=1F-PIP1W!'N" 1[B@#F]6U;6/"VK^'FNK[
M^T+'5+M=/N$>%$,4S@E'C*@?+D$$-N.,<U2\,6MV/BGXQ+:E.ZQBQWJ8X\2
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M[GU-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-8%A,[P*?-7[08^0.%..NW\,5K:]/XD\))I^J7OB.2]TM=0":@/L<,?EV\A
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ML"V]U/#!M41JK*-JEC\V&;DD]NPQ45UX%:5="N;35I;35M'A^SPWB0AA+%@
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M/M[ X XXX&(=.^'[:3>7$-EKU[%H,\S3OI(1"@9CEE$A&X(3U48[\\FNTHH
MYK_A%9;/7M1U31]2-B=3"F[A:$2H748$B<C:^.O4'C(JNW@6W@?PZ-.NVM8-
M"9F@C,>\R,RE6+G(SD,3QCDDUUM% ',ZGX1>X\41^(M+U273;\P?9KC$2RQW
M$0.0&4]&!Z,*RE^&OE:<L,6OWHN8M7;5H+AHHSLE8MD%< ,"&.<_ACI7=T4
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MY/( !YSR ?:K/AWPQJ&D/&VI^)+W6%MUVVJ3QH@B&,9)49=L<;F/0GUKI:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4M5U*+2=/DNY5:0KA8XD^]*YX5%]R<#_ZU4M=U
M'7;%X!HV@1ZHK@^87OEM_+/&.JG.>?RKG]1O?%!UA;N3PA+=0P6R^0L>H0!8
MY73]XQW$$D9* X' 8C[U &_X/UV3Q-X2T[6I8%@>[B\PQ*V0O)&,_A6W7F'P
MYU37X/A3HQT_PV+J2,".-9+Y(A+'\Q,@.#CG VD ]Z]"TFYO[O3HYM3T];"[
M8G?;K.)@O)Q\P SD8/3O0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *0@,"",@\&EHH K:?IUII.GPV%A D%K"NV.).BCT%6:** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pacb-20231231xexx1028005.jpg
<TEXT>
begin 644 pacb-20231231xexx1028005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" __!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>G"Y>ZO2D5K*(;B80NT<4AQA6< J#R.IXR,]17(7$T1UOX9NA^2".7S2 <1
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MNT(EBC$,14>6RD;"6Y)##=S[4 >C450U+6;+2GMH[EV,]U(8[>&-"[RL 6(
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MZAJ9FN8X-.?R[Q)+.598#C.6CV[@,'.<8Q6@VOZ>EIIUT7F,6HNJ6Q6!R7+
ML,@#(X!.3C@4 :=%%<]XAUF2WU71]!M'\N\U65\RCK%#&NZ1A[GY5'NV>V*
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M5)HRDA(8=^5'!Z8KI=0\3:;ILMS'*T\C6B"2Y^SP/+Y"D9!?:#CCG'7'.,4
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M>;##CY1)@@.?4@'CL,YY.,<WK'Q#TVT\%7/B+3XY[I8Y3;>68'5HIMP3;(I
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M*)0JY.3]2>YJ>HK:YCN[:.XA+&.0;EW(5./H0"/QJ6@ HHHH **** "BBB@
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M.DN+:0VMXUJ%,L3!)E$&Q\$C##/!Q5?P+IFI6VI3Z3J&7LO#4CVMA,6R9A(
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M1M_%"6P-MY5E*DZ3X^7:X&"F[GDX /.".- P:I%XS\"MJ,-S/<VFFSQ7]S'
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M;P23S.L<4:EW=C@*H&237!>#;/4-*\2-8V5_?ZAX;^Q%XCJ,+++9R;E B#L
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M:+8)VC'.0<DCK@C.#D"2TE;7O&_C'[+;SQFZT*W2%+B,Q,V1* 2K<KR>X!H
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MTD$DBQ,DICP%FV8)1N3@<CISWH ]:HK L/%FGWNNC11%>0W+0&>%IX"B3H"
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M^7.2RX.1G./?% 'J]%<U?^,M)T2XL-.DCOY;BZMFEMHXK=Y&D5%!(!_B;!'
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M+'+$* ,CJ1U%<[K/Q @M_"5OK6E6MQ<BXNTL]I0*87,@C8.">H.0 ,Y..W-
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MC=MZ'/6KGB\ZAK7A"*^M]$O(Q%JEK=+:^3_I#Q)(I9S&.=W7Y>N ,^@]!HH
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M_<'[,8_FX_O<<?7I5[3X;J#Q;XZNY+&\6"]CM_LS_9WQ-LA*-MX_O''OU'%
M'1Q^)["YT_3;JQ6:\.I1>=:PP@!Y$P"3\Q 4#(SDCD@=2!4F@>(K+Q%;W,EJ
MLT4MK.UM<V\ZA9(9%ZJP!(].02#ZUYC::1JNDZ%X+U2;PW/J<>FV,EAJ.FM
M&FC#%2'1&X8@H.G8_7'<V6H'3=$FU.S\(W-JD\Z*EC;V\:7# D*9)%4X&,GC
M.0!D]<  ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBL[6];L?#VF/J&H2%(594557<SNQPJJ.Y).*
M-&BL.+Q-&-4LM.O--U"QN;TL+<3HC*^U"Y^>-F4$!3P2#[=:W* "BBN?\+>,
M-,\6Z1<ZG8+<0VUO.\$ANH_+(* $GKTP?\<4 =!145M<PWEI#=6\@D@F19(W
M'1E(R#^1J6@ HHI&)5&8*6(&0HQD^W- "T5@>%/&&F>,;2ZN=,6X5+6<V\HG
M0*0X )Z$^M;] !1110 45SVB>,M-U[7=4T:VBN8KW3"!<I,@ !)(&""0>E=#
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNO1O'8ZN-3B>2RR3B5I APXZECD_3 '?H+?P[=0^.+CQ&]_"R3V269MEMR"
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MCD]:M@Y ///J* *VFVTUGIMO;7%P+B:*,*TH38&(]%YP/Q/U-6J** "BBB@
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M..!ZUS\7AC6X-!;1(_$,3VCQ-"9)K'=,B-P0K!PO .!E3CC.: *=WKTMC?\
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M/?3V;7!M^)A'*$W;<X4D$>HXZ5L>*O%;Z)KT%I?WTVD:=/:@V^HBW$D)N"S
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ME'_".*LPO5M#=\Q%8_+#!>&/4Y/;T-:U>:W$DNA?%FYO;V^GO8;?PQ-<9D1
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MPI&ZY#Q%6\SY2>C$Y'O0!WE%<%X3NO$^N:EJ4USKL2VNF:U<6C0)9I^_B50
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MMSCMG&: /6:*\^\2>*[G3/$EYIM]J4^B1RI&-*O'@1K6=RN6$CE3M;=D8R.
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MH 3\W3 &/4T]->U;2?&M[IVIWZWEG9^'UU!O+MUC+2!V5F[]=A.,X&: .YI
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M,^P$ N22 HR0,DC)Z9I=(UVSULW:VRW"26DHAGCGA:-D?:&Q@]>"#D<'/!-
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M658-7E><P/$K+%*ZA6;/!/"\#.![UU%->1(P"[JH)"@L<<DX _$T <@W@/\
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MM@8*22-PX8\ C/?TH P-/O/%NH)X?U>S:=X+KRY+^*X-N(/)D7):+:2X*Y&
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M86PM!>VZ(?.A'\+HP*GGGZ_ACI=,T]=,L5M_/FN),EI)YR"\KGJS8 'X
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M;5(!$DS*<KYO)+ $ X& 2.0: .*LH=6U3QOH*G49+"_E\(HUQ<+$KR!C*A;
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M5+^RNY?BY96L&ISPR_\ ".RA[ORT:7'VA.1\NP'ISM(Z\=ZZSQ-X>B\3:/\
M8)+F6V99HYXIX@"T<B,&4X((/(Z&JJ>%I$\40:^=5FDN8;)K+;)&I#JS!RQQ
MCG<!TP .,4 <7=>*?$,7PDUC4EU0C5-+OY;/[5Y*9F5)Q'DKC:#M/8=16UXP
M\2W.A:Z$U"YOM-T66U40:E;0++'%<%F!$V58@8V8XQ][/M/+\/(YO"FJ>'WU
M:X^SZC=M=RR")=ZLSB1@O;&X#MZUK7_A^[O9;H_VL5BO+5;6XA>W5T(&[+J"
M?E8AB.<C@<4 :]@YDTZUD:=)V:)"9HSE9,@?,#Z'K5BJNF:?;Z3I5IIMHI6W
MM(4@B#')"J !D_05:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ***YGQGKEQI%OI-I:2>3<ZKJ,-@L^T'R0V2S
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M,_\ L@\GVKA-(UG4U\8:%I_]H7MQ::CIDTDTUPBA994V?O8@0&4?,>" I!&
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M1GUB[\.?$*:#6-3E?1=0LGN++S @6"2+YI4R%!/R?,,GH"* .WIKML1F"EB
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MD$=W=+/]D%D(!L$(B#;@H&W/!.<Y_2I[_P /:?J.N:9J]S&6N]-\SR#GCYP
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ML5T;=G>1BN0P4G"[>@QRW.:U5\#6:Z7KNG_VEJ!AUN626[),6[=(H5]OR<9
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MOKQ;M[3['L!C\L1[BPP"F<[B3G/Z4 <+I/BW59?#?AC3[B]D:[U'5I]/FOB
M',43R>V [!57..Y/6MB:]U/2O'%UX=BU"Z>QO-)>]MY'822VLJ-M8!G!RIR#
M\V<&M"/X>:4GA]=(:ZOG2*\-];W#.@FMYRQ;>C!0.I/4$<XK2B\-Q+/=7<]]
M=7&H7%N+4W;B,/'%DG:@"A1R23P<G'H, &%\-XM4U#P[I/B#4M=O;N2ZL KV
MTFT1!MV0X &=V!@G/.3TX T_$UQ*NJZ/;+?RQPS-+YEC:Y%Q=D+\NU@1L52<
ML20.@)YP='P[H4'AK0[;2+6XN)K:V79$;@J6"^F5 S5;6O"UMK.K:=JGVV]L
MKVQ#K'+:.H+(^-R,&4@@X'N.QH \^F\0Z^WPSN+Q=5N8;VSUPV(D8(S/&+D1
MA7..2 <94C..M=):_P!HV?Q)N-!DUF_NK.]T=KLF9EW0RB4)F,JH"C#=,8R*
ML'X;:7_9%WI:ZCJJVMS??;F7SE8K)OWX!93QN&><D]R:TKK0H+37F\5276H3
M75M8-;F&-48/&#O("A,EB0#P>O% '*Z-J^IR:/=>%[S4;AO$EOJ@LWN=V':)
MB9%F Z >2K8&,97'>O0[B9;*QEF(9U@C+D9RQ"C/Y\5R_AZWM==\33>,%TRY
MLR]FEG ;N$Q2N-Q9F*GH.54'KPW;%=>1D8- 'ED^MZP_PIC\=V^I2C4E07K0
M;\V[1[^8=G3 7C=][(SFM#3(C=_&&\N?M-XBOHMM<")I3A=TC_+CL.!QZYK9
MM_ 6G6UC)I<=U>?V(\WG?V82AA!W;R@.W>$W<[=V.W0D5>N/"]M/XH7Q!'>7
MMO=_9A;2)#(HCE0,67<"I.023P1GH<CB@#RZTEU+2/AG=^(+'5KJ"2QUF8I;
M1[1%(K7FU@X(RV0Q[C'&.Y/9WU[JNO\ B7Q!H]C+)"-,CA2,Q79@99)(]_F'
M"G<.0 #Q\IX.>+;?#S3V\*7/AQM2U(V-Q<&X<[HM^XR>8<'R^F[GI4FK^ [3
M5-:BUF'5=5TW4A$()KFQF6,W"#H'&T@_4 ?H, '/74GBG^VO!>DZAKS07-]#
M>1:@;#849HX^'4E,AN><\ ]!Q7H6FVLEAIMO:S7<UY)#&$:XFQOD([G  S6/
M+X/LGU31K^.\O87TA9!;HCJRMY@PY<LI9BPZDG.>>M=%0!YA!K&JZY\,;[QI
M:ZG<6VH1"YNH(0W[E(X7<")DZ-E4Y)YRW!' I=68Z]XL^'.I--=6QU"&>8QQ
MR8\K-MNPO'!YP:Z5? EA'%J%G!>7L.E:A*TMSIR,GE,6^^ 2NY5;N P')QC-
M7-2\+6VHZSI6I_;+NWETO?\ 98X/+$:[UVMD%#GY>.O% '-'3L_&X?Z9>#&@
M^;Q+_P!/'W>GW?:JEK=^*O%'AV/7]%NHK>[-T[Q^=>%8!$DI4Q/&$(^ZIRWW
ML\Y X'8GPS"?%O\ PDGV^]%W]E^R>5F/RO*W[]N-F>O?.:RXOAUIMMJ]S=VN
MHZK;V5W,9[C2XKC%K*Y^\2N,@'N 0#TZ<4 9L$.L:S\0/$VF'Q)J%M:60L9X
M4A$8*[@[%<[?NG&#W/&3QS4DU764TKXD$:S=>=I3.UG+MCW1@6XD"@;<8R?3
M/OGFNSL?#<%AXEU'78[V[>XU!8TGB<IY>$!"8 4$8R>_?G-46\#V;0^((CJ.
MH%==S]K^:+C*[#M^3CY>._Y\T <]:W>KV&M^!KB36KRZ3686CN[>7;Y?%OYB
ME0!D$$=<DGO5/6->UA].\6%=0N+3Q%9:AY6E6D1Y>+Y/*VQ'(DWY8DD''/3%
M=B_@VV>307.HW^[1!BUYB^;Y-GS_ "<_+QQC\ZX>W43:EJ+S:OXST34KF\ED
M:PMK5Y8NN%*MY3J0553G=@>P% 'JEA%-#801W,\D\P0;Y)=NXGOG: OY 58J
MCHRWZ:-:+J<GF7HC E<@ D^X7C/KCC.<<5>H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y7QSK5QI4&BVMM*T
M#:KJL%@\Z]8T;);;GHQ"[0>V<]J .JHKAIIK[1OB+8:)!?7DFFZQ93OMEE,K
MVTL6#O5GW'!# 8.1FH/AC!J.I^'-*\0ZCKVI74[Q3QO!)(/);]ZP#%<9+#'7
M/?'0 4 >@44'IZ5Y'(^KW/A3QW?/XBU59]'U"[-FR3!=OEQHRAL#E>VWIR>,
MT >N45YS]JU*S\2>"KXZM>S?VT'2\MY''DG]P9!L0#"X(ZCG'4FL_6-7U"T2
M+4;/5;R\D_X2&.![J-REJ(FFV& 1EL/@'!8+U!^;(H ]6K$\/>(T\03:M$MG
M-:MIMZUFZRLI+$*K9^4D8^;UKEVM-2UGXC>(-);Q%JMK9P6MI<1+;2*A1F9\
M@';]WY>1C)[GBL+2]7\OQAK^@///I\>IZ_(!J"-M^98HB(58=';GD\8! R3P
M >P5'-<0VZJTTBH&=8UW'JS' 'U)-<;J-U=W7C0>&+9G^SP:8MV5.H2P22%I
M&3/F*&<[=O3(^]SG KF]:TK5X8/!MKX@U,W5[%X@6#S;6Z<9B,;LN_ 7]X!C
MYL9Q]30!Z;]LNO[;^Q?V?+]D^S>;]MWKLW[L>7MSNSCG/2KM<4DU['\67TH:
ME=FQ;0/.2)G!$<GG!-PR.3@=6SW]:XV*_P!;B^&5MXG;Q!J4E]:ZF8U5I1Y<
MB?;#$5=0/FRI[],#&* /9Z*X35]1F_X3+5+#5;ZYL-/73$ETYX)6BWOEO,;*
MGYG!V84YX[<FMCP*NL'P=I\VORW#ZI-&))UG"AD)_AP ,<8.#R"30!T=%9/B
MAYXO"FK2VUS+;3Q6DLD<L6-RLJDC&0?2O/O-UB#2?A]JD?B#4OM&K-;6MT'D
M#1LLEN6+;",;P5R&.3D\YZ4 >KT5YQ;7E[I&L^-M*.OS1VUI8PW5M=Z@_G?9
M7='W')Y*Y4''Y4ND7EZGCNPTOS]4%A>Z+)(XNYV+22*R 2J"Q:,D,>./H"*
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M \G'(P>]:?BZ[NOM7B+[-J=[++9Z8)8;>RD,(L7"NWF2L& 8MA<*<G"],'-
M'>R7$,,D,<DBJ\SE(U)Y=@I; _!2?PJM!>74NK7=I)I\L5M"B-%=EU*S%LY
M .1MP.OK7G-RKZWXB^&5]=W-R)[VQGDF,4[QC=]F5B0%( .6/([<=*U[:ZU&
M3QMXTL#JMWY,%C;26PRO[@LLA.P8QV')!- '>45Y#IU]K$/A;P%X@?7=0GNK
M^^MK6YBDES%)'+N# KCEN =QR<^V -;6]4OCJOB^UO+Z[LY[6UCDT5+>1E\S
M,9.54?ZQC(,%2#T QSR >D4V21(8GEE<)&BEF9C@ #J367X8BU"+PUIW]K2S
M2:BUNCW)EVY60J"R_* , Y'^-8WQ2B$OPRU_+RILM'<>7(4S@=#@\CU'0T =
M;&ZRQK(AW(P#*?4&G5P)O)(O$?AKPM'<W4=I<V,MY/)]H?S)2H4+&'SN R2Q
MP1T Z9S<\+W]_;^-/$?ANXN)KJSLE@N;2:9B\B+*#F-F/+8*G!.3CJ30!V58
MOB#Q'!H6@:EJJP27JZ>I,T4#*&7"ACG)'0$'N>>E;+#<I7)&1C(.#7C5O9)!
M\+/B'()KERMYJ4($MP[C ;@D$G+<?>ZF@#V"TN!=V4%R%VB:-9 I.<9&<5-7
MG-JU]H_B[P9&FJWL\&K6DT=S;S/F(>7"KH43&%P>..HZYZU6LIO$WBOPU#XA
MTJ_@L[PW+RJ\VH2"%8TD8&)X0A7&T8)ZYYS0!Z?6!XG\50^%Q8-<:?>70OKJ
M.SA-MY?^M?.U3O=<9QUZ5OUY_P#%?S/L7A7RMOF?\))9;-W3.6QGVH Z"R\7
M6EQXB_L"[M+S3M3:'SXH;I4Q,@ZE&1F4X[C.?:N@KS70$DUCXJ7MQXC=8=;T
M>$QV%I"N(FMGX\]6)RY.2IZ!>G6IY9=;\67'B:#3KK[+<6%VUG:.M_)!Y#+&
MK!V14(D!9B?FR,#  Y) /0ZC>XA2>.!I%$LH8HA/+ 8R1],C\Z\YU_5]8T=K
M6YUY;V?2CIL:3W^B3-BTN?F\R5D7!9#\I!((&T\<FD%M!?\ Q1\.W":A<W$<
MN@22K/'<NJR8>+# 9X#=2._?- 'I=4M+O+J]MGDN]/EL9%F=!'(ZL656(#Y4
M]".<5P_A.SU/6=4UV:[\2:MMTS79X88TD0*R"-/E<;<$?-P,  C/<UG:=XFU
M.W\(6:3ZC.\]]XF?2VO)2"\<1E<<<8!VIM'&!G- 'JQ( ))P!4<$\5U;Q7$#
MK)#*@='7HRD9!'X5P_BG0[BQ\.>+&.MW<EA-I4LL%G),[20R(C%F$A8L5/RY
M7I^!Q5&TN[BRT[P/H-G+(5U6R:>0RWDD;-Y<,9\M9 &91\V<+C[O;)H ]*K$
M?Q&J>-(O#;64P>2S>\6Y++L(5E4@ '.<MWQ^-<=J%YXD\*V0T^\U.)EU76;:
MSL91.T\UG#*3NW.ZC<1M8*3GKSG%6TTY-/\ C58".XNI(WT.<A;B=I=I$L><
M%B3SQQG'% 'H-8=QXC_XG%SI>G:=<:A<VB(]UY3HBQ;QE5R[#+$#.!VQDC(K
M<KS_ ,0^%]8'B.[\2^"M6B@U;"0W]A<C=;W1505#?W6VLN#[CD<Y .JTSQ!:
MZEH\NIO'-9PQ221R+=*$9"C%6R 3W!K6KQ[Q%KH\5_"N]N)[*?2]1LM6AMKV
MU28@+.)XPW((W ALC/?Z UUANGN_B"?"IN;N.QL]+%V=MRZRSN\A7)D!WX4#
ML>K<]!0!VM4-:U,:-HM[J;6\MPMK"TS1Q%0Q51DXW$#H*\W7Q9J^GB\T"XO9
M',?B.#2H]1?'F""5=XR>A<*-N[_:!ZUT6N:3<Z7HWBI_[7FGL+C29C#8W#M(
M\3K&P=E=F+%3E>.@- '4:/J"ZOHEAJ21F-;RVCN A.2H=0V,^V:NUYM\/-27
MQ!;:?:S7%U9/H^G6T8L!*T9G5HD(G;!PR'HH'ONZ@#TF@#G]8\60Z-XATK1I
M--O9Y]49UMGA\O82BAFSN<$8!]*NZUK/]BV\$S6-S=++/'!B IE6D<(N=S#C
M+"N4\9?+\3?AZYX43WJY]S!Q70^*^=-LE[G4[+ ]<7$9/Z T ;BDL@)4J2,E
M3VJGJ=Y=64$+VNGRWSO.D;)&ZJ41C@N=QZ <XZUQK0:AJOQ)UW2)-=U.&P73
M[>9([>41E&9G'RD#(' ]SW..#B1:_K5U\+O"&J/JERMW+JEO;7#H0#.GV@QG
M<<9Y"\X(SDYS0!ZM]HA^TBV\Q?.*>9LSSMSC/TS4E>?V=BI^-&LR">YW+I5O
M* ;A]N2\@QC.-O'W>G4]ZK>%=<N/^$@T_2/$#:GI^OA)#)'-*TEKJ.%Y>$YV
MC'WMH P"1@XX /2:Q+7Q&ESXOO?#QLIHI;6V2Y\YV7;(K,5&T D]CUQ]*VZ\
M[GTYM4^+VKVWVZ[M$.B6^YK23RY#^]DQANH]>/Y9! /1**\PT'6K_5/ _A22
M^U>X-Q/<S12PP BXOQ&9%"JP(V_=5F;(& <D9Y-+U+Q)=>%?$<5E]HNKO3]=
M>WBMY+G$S6RF-VB$N?O;6<!LD^_0T >GTV1BD;,J-(P!(1<9;V&2!^9KE/ ^
MM66L+J36EQJ*R13*LUAJ6_SK)MOW3N).#@D')ZGZ#K: ,;PMXAC\4Z!%JT5M
M);)))+'Y4A!9=DC)SCC^&MFO$=-M-3LOA%-XDTW7[^TNM-FN[B*W5E^SN%N)
M"RNF/FSSR3QQBNK&H:KXMUC6M/@=K8V5O;"-4OY+9XGEB\SS#L0[^3C#<?(>
M.30!Z'17G<%]K\^L:7X7U*ZMKB\CTM[F[DMKR2V%Q()?+R'1-W !) QR?08J
MCJJ^*M%T70[6]\0-]I;Q)!:B2VDWLUM(V524L@+,!U[$8SG- 'J5%<3X?>\T
M_P"(NM:(^I7E[9_88+R,7<GF-&[,ZL%/8':#CH.V*[:@#"U;Q$]G?RZ;IU@V
MH:A#:_;'MUD$?[O<5 !(.6)!P/8Y(XS5/BVY@\):CK][X>U"T2T5Y!:RM&)7
MB50V\C=A>_!Y&#Q6)9:;&?C1J[?:+L%=+MYABY?&3+)QC/*_[/3VK/6\O;KX
M<_$A+V]GNS;7.HV\3S$$K&L(VJ,   9["@#TG3KP:AIEI>JA07$*2A2<[=R@
MX_6K->>6^I7ES=^&_#D! B?0EO'47;VS2D;$ #HI;C).!C.1S@8,$EYXBT--
M'\.:IJD<DVIZN\"7<,Q>6*T"^8(V<JI\P\+NQG!SUYH Z^W\1I/XQNO#ILIH
MY;>T6[\YV7;(K,5&T D]0>N.G2MNN TBQ6P^,^IQI/<2HVAPNHGE:0H/.<8#
M,22,@GDGJ>U=_0 45YKJ%S>Z;X@\3Z)/J=_F]LDN]&<7#;D<GRS&ISU$K)@'
MLPSQ5KP?JMQXCT_08)+BZCO-/20ZJ//;=YR$Q;'YY#.&<9[)CH<4 =A::A-*
M+][VQ>QBM9F1))9%(FC !\P8/ Z\'GBJ6H>)XK#Q!H>E?9)I1JYD$5RK*$79
M&7Y&=V2!Z8YZUYYJTUY??#KXD17VHWEQ]BU"XCA=I2I5%CC(3Y<#;R>.ASS6
MKK=@4U[X=VL%U<QEY;G]\9#(ZYM3G!;/X>E 'I=%<9X)N+N+7/%6C3WUS>0:
M=>QBWDNI/,D59(E<J6/) ).,UV= !16!XPN&M]"!34SIQDN(8_,1"\D@+C,<
M8'.]AE01R,Y]QQR:IJT3_$*S2[U"T33["*ZLUFF$TL#-#(Q&YBW!* XR<9XQ
M0!ZA17DTTNNZ/H_@SQ/'K^H7<E]+96][9S.##*DR@95<<."0=W)/4U/:V&M^
M(!XQC_X2K5K>33M1D2R:*14"D1(P#X7E<G[HP.3U)X /4J*\ELM8UKQ-<> V
MEU>]LEUC3KIKQ+8JF61%PZ\<$DD\YQGC'6MW1FFU;Q/KGARZU/46@T*WM8(Y
M%N6CFF>2,LTSLF"QZ =N"<<T =[17DCZMXAO?AY=ZF;VZ?4/#FJ2PW#0.8_M
M]O!(/,W!<#)3/(YRIQC-='JWB%H]*USQ3ILTD]I8:;FV3S&\J64IYFXKG! 5
MHQG_ 'O2@#N*Q/%OB-?"GAVXUB2RFNXX-NY(F4$98*"<GIDCID^U8-K9>((-
M1TG68=2B_LXQ$WZ2ZA).+I64%6C4H%1L\X7 .<8KD/$,\_B;X&7?B>ZOKK[5
M=D3>4D["%$\\*(MF=I  ')&[(SF@#VBBCM10 45Q&GW,WBSQ'XHLIKV\M8M,
MFCM+9+6=HF0E-QE.TC<23P&R,+TY.>7M_$.OZQHG@V6;5;BUNI]8DTZ[>W"J
MLX3S 7QCJ=@]LYXH ]?HJCH^G-I.F1637UW?&,M_I%XX>5LL3R0!G&<?0"KU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ+@*I4,P Z@''! ]173T4 <O_P ('I8L]$MUNM15M&R+6=;DB3:5V,I..A4
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MPP)'+,QR9&"@$DGKD]ZI>$_$*^*O#=MK"VK6HG:1?)9PQ79(R<D?[N?QK:H
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M 4>%M)6S34=3DL19W>K71NIH3C<@P%0-C(W;0"<'[S-UH L>*KG[)X5U.?\
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M\B[,''3(W'D"L)--,VK:D][;^-M+U"YO))#'I4TGV609PC*P)3)4+G<1SGH
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M@L2<$X'4X-"[U76A\+-=E&JWL-WINO/9PR+<%G$8N40(SGYG #$9)R:] N?
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M:6LIGM9/.(EMW)+;D<<@Y)ZYZUM:)H5MH5HT,$UU<2.=TMQ>3M--(>@W,W/
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M@@8QSG?T3X?:-X?NQ-8RZAY,;,]O9RW;O;V['.62,\ \GDYQFM/0O#MIX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA:XST,41!6)?7)5<^@![D5K)H]JFORZT#-]KDMQ;,#*Q38&W#"9P#D]:T**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\)?XNN?(D$GDW.J%XI,'HR[>0>XKLZ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHILC%(V94:0@9"+C+>PR0* '45S7A?QWHGBZZO[73))A<V+!9XIH]C#)(X]1
MD$5I:;K4>IWE];1VEU$;*7R97E0!2^ V%()SPP.>G/K0!IT45G:UK=GH6CWV
MIW;.T%E&9)EA&]P/I0!HT5AS>+=(MO"L'B.YG>&PGB22/?&?,;>!M4*.2QST
M%9UC\0]*O?%J>&6L]2MM3<,=D]OA1M4,?F!(Z'\^/3(!UM%%% !137D2-=SN
MJC(&6..2< ?B2!6-;^*=.N?%]YX8C6X_M"TMUN9"8B(]K8QANY^8?Y!H VZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *SM=O)+#0[NX@Q]HV;( >\K':@_%BHK1K+UG1Y-7-H
M!J$]JEO.D^R)4(D93E0VX'C.#QCH* /)/%=DGPL^(?A_Q5:!ET>[B33=1P.F
MU0H8^^U0WN8SZUTNK>*;[0=+\/Z3IL2?\)!XEN6E4S+N6V$C;W9AWV!P /\
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MO)/J7]I&7=+'=[57S(F8M&<* /N%1P.U96I>#4U*'4;5]3N19ZA;):SP.JR
M(H/S*6&0YW'YCGMQD9K?L+&WTS3K:PM$V6UM$L,29SM50 !^0H L4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.U2;S<XQ]XC&,'\Z /,+7P;INB_%'0;_ .'^H&2WGD8ZE;03>;%# ,9W,"<
M] K'.0,=.,SP_967VWQ5X,\8/JL<UWJ;7<5O!$3]MRP(96"$YRJG.0.?8UZ!
M_P (1XY_Z*==?^"J+_XJC_A"/'/_ $4ZZ_\ !5%_\50!RKW4'ACXP>(H/%EM
M-)HVOVD<4$\D+2HX55&P[0?]H''<#US4_CE+;2?''PYU*.SDLM%MBT0S"P$(
M^7:I4#*G'8\]?0UT?_"$>.?^BG77_@JB_P#BJ/\ A"/'/_13KK_P51?_ !5
M''^"9<-\69I8Y8!<RSRQ+/&8V93YV.#S_$!CU(%=-\$[.TM_ACI\D\$4=S!+
M/)(TJ /$Q=ADYY7Y OX5:_X0CQS_ -%.NO\ P51?_%4?\(1XY_Z*==?^"J+_
M .*H \RT&RNKGX#>-[*&VE>Z;4O/6$(=YCW0G<!UQA6_(UI>/KJ/4?@[X)BM
M5EDDAGM Z^4P(V0$.<$<@$@$],\5W?\ PA'CG_HIUU_X*HO_ (JC_A"/'/\
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MR>*.-MKCRT!&=BY W$GU)-=W_P (1XY_Z*==?^"J+_XJC_A"/'/_ $4ZZ_\
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MN/H,D#/K7=44 >0:U!=:EJ?Q-MM+'G74T-B\,:-@S^6G[Q5(ZG VG'<@5O\
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M/_2=HY8*5)&."17LE% 'D=K?6\?B+QZS7-U.EWI%NT-Q<0E?. CE!(^4+C)
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MQ-XDTN"Z-N\TI87"6I=+>1HUE8@*A<+M!RP')XSS7.^.75?$W@P\D1:F9)"
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M+:7$TTAG26^$,@8QKYGSG:HX([\#)%7[6^\*^(+>^U6STC5+UH=-GCNI+H7
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M^W:C'^ZQ!]J74?'GAK2[F]MKK4<7%D%-Q%'#)(R!LXX53G[ISCIWQ7FT/R?
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MN73;<ZC:VJJ7EB'F0R8^;@\JWY&N6\:WDFHZ5X[TXV5U:W2-^ZM;6S;_ $M
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MD=S"'\J097>A0D>N" 14] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !11574-0M=+LVNKR810J0N<$DL3A5 ')))
M  '))H M45CVOB;3;F\N;+=/%>6T0FDMI8'63RST=5QEAGC*YYXZU5T7QOH7
MB&YMX-,N)IS<1/+&_P!FD5"JMM/S%< ^QYP1ZB@#HJ*Y#XC:W=:!X?MKR)KB
M*S-[%'J%Q;+ND@MCG>R^G(49ZC/'.*?HB17%]:ZOHFO7&H:$]M*)(6N3< 29
M0JP9LOG 8%23C(X% '65GZ[I*:[H=YI<EQ-;I<QF,RP$!U^F>/P[CBL]_&V@
MQ^'YM=:ZE&G03-!++]FDS&X;:05V[AAN,XKG=0\0+H/Q6NUO+V^DLFT1)DM(
MU>;]X9F!*1J"<[5Y('3.: -^VT#6)%6'6O$ U"U4@F*.R2 R8.0'()R,@<*%
MS].*Z.L.S\7:+J&CVNJ65V;FWNY/)@$:,7>3!)3;C(8!6)!Q@ GI5#Q#K^B7
M'A:[GO;_ %+3[1;A8))[>.6*:.0.OR\+E03A<]"#UYH ZNBLW4-9L[&X2S<S
M27<T;.L%O&9)-@X+8 X ) R>_ R:\\T/7+*7X;:Q=ZWK>K161U:XB2]B>7[0
MB"8>6-V"R]EY ZXXS0!ZK161J7B33M*NFM)FFDN8[<W4D4$+2,D(.-Y ' R#
M[G!P#BJUUXUT"SATR:6]8QZHNZS>.%W$HV[A@@=<=NIZ8S0!T%%<[I?C?0]8
MO[6QM9;H75U"T\4<MG+'E%;:QRR@<$8ZUK6>J6M_=7MO;F0R6<HBFW1,H#E0
MV 2,-P0>,]10!<HHKC/BI>WFE_#O5-3T^[GM;RU5&BEA<J03(H.1T/!/6@#L
MZ*Y+4/%,7A[5/#FBM!>W#:AYA>;RI)B%2)F.",EF+!>!G R>.*ZPL%0N<X S
MTY_*@!:*Y?0M;T6'1+F]M=3OKRV;4)(MUT'>3SF?'E(I ; 8X QQ^M;>G:K;
MZI]I$"S(]M+Y,R31-&ROM5L8(YX8'(R.: +M%8^K>)])T._L[+4+AXI[TL(%
M$+L'*@D@$ C/'3J21@<TS3?%FCZG87UY%<M#%I[LEV+J)H&@(&X[U< @8YH
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M$MK$PQCD;PN0V W/4#.#0!U-%<_<>-_#UMIFGZD^HJ;+4)5AMIDC=E9R<8)
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MJIB(3@$;<<CH>>,9]5HH \\A@%E\2O#ZII\EI;6^AR6Y1(V:.!B\96/>!MR
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M%]X1$3<?ER0V68@#D#%<EI\EY<ZWX#U-]+UMI(//CO0]D\4=O(T!41I'@*B
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MJBL^RU9+[4]0L5M+R)K)D4S30E8YMR[LQM_%CH?0UH4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<W?>%KF379]7TS7[[39[E$2XC1(
MY8Y F0I"NIVGD]#^%=)10!2T[3ET^)\SS7,\K;IKB;&^0XP,[0   .@ 'YFK
MM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ>+2[0VR1N9Y(B(I-V>$;^(C'/ID4 7:*** "BBFNZQJ6=@JCNQP* '4444
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MV:4+N/)!W#L<CG)X'%<7<3^ G^'R>#K6YUVWM#,)YI_[+D:25\YR?EP.@[=
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M*_B]CJ5VPCCL2RD1XD!23 ;Y.@[8P?7-;7C;PY)XCL;-;'4SINK6=P+JPN
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M/>IHM=MY-4O;!H+B)[.-99Y90HC5&W;3NSSG:WTQSBN5^&'$OC0=QXFO./\
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M .QHKA=5\1ZA866H:G#<R207.IPZ;81E8]L>76.20$@9.[S,;B1\H[&I8O\
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M !1110 4444 %%%% !1110 4444 %9?B/15\1Z!=Z1)<R6\-W&8I7B +;3U
MSD"M2J6K7\FF:7/>0V-S?21 $6UL 9'R0. 2!WS^% &1?^$(KZVTAFOIX]1T
MAMUG?(JAU^7:RL,896 P1QGVHN/"$5W9:REQ>RM>:Q!]FNKH(H(BVE0B+T4
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MNU#11GS$4J&VD.06&X'&<T :NJZ;#K&C7FEW1;R+R!X)2AP=K*5)'OS7/_\
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MR6Z21F/RP\<H<J?F!P>-@P01U-8"_#NTM7TF;3=2O+&ZTY[AQ-$L9\SSVW2
MJRE1D],#BM#7O&-IH-ZEFVFZOJ$QC$C+IUDT_E@D@;L=,X./H:NWVOV]BUA
MT%Q+>WV3!9QA?-.!EB<D* HZDG&2!U(H Y]_AQ:OX;UK0O[6OS::M=/<2EMA
M:/<VY@IV]SW.35G6_!/]JZC8ZM:ZS>Z;K-K#]G^VVP7][%G.UT(*D9Y'O6G'
MXITIM"N]8EG,%M9LZ70E&'A=#AD8#/S9[#.<C&<BG6'B""\U'^SIK:YLKUH/
MM$<%T%#21YP6&UB."0""<C(R.: +>F:>FF6*6RS33ODM)/.VZ25CU9CP,_0
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MJ\8,3J=R\ AL*!U(.!TK6FOY(M7M;%;"YDCGC=VND \J(KC"L<YR<\<=JNT
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M81G"(!]T98MU)R<YX&*OA_P9/H?EK+XBU/48;92ME%=["L'!4$X +D D#)P
M>E;UU?R6^I6-HEA<S)=%P]Q&!Y<&U<C?DY&>@P#S5V@#$\+>'$\+:1_9L-Y-
M<PB5Y5:95# NQ9A\H'&2:S/&NHV-Y:W/A&2UN+F_U2T988UMW:/YCM#,X&U=
MI^8Y/ 'J1GKJ* ,&^\(Z7J/@\>&;A)/L*PI$K*V'4IC:X/\ >! .?7K6?!X%
M\W1[W3]:U[4M7%S;/:+).54PQL.=NT<MP/F;)X^N>NKF;CQI;P>(;G0UTK5)
M[ZW@%PZPQHP\HG 8?/SSVZ^U %:V\"M#J6CZC-X@U&XN],A>!&=8P'C8*-I
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MT5EDC523EP"/F![$],&NMKA_B+.NLZ!J?A2TCN'U2ZBB\I?(?8P,JY._&W@
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M78JL@4+&F6))VC)49QQ7-CQ)XAG^'&CWZZK-#??VXMC+(8XR98_M)CPX ZX
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M!+]GVAF (8#+*<<@5J6ENUK:10-/).8U"^9( &;'K@ ?I0!Y'I]O]FC\2?#
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MTNC,7LWF$;S1J81)L8_,",D\\G!ZUW/B/PU!XCCL2]Y=6=S8W(N;:XMBN]'
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MD4X.>E '4VT)M[=(C-+,5_Y:2D%C]< 5+4%G;M:VD<#W$URZCYIIB"[GN3@
M?@  .PJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHKCOB9=W]AX2^UZ=?SV<R7=LFZ+'S*\J*0>,XP3T(H [&
MBO/9;74(?B6NB+K^J&QO]*>ZF5I0661)57,9Q^[R&YVX]L5AR:SJ]OX!U!QJ
MMX]SI?B/^SX;EI3YCPBX1,.>C':Q&30!Z]17&7%[?1?%5K""[<6TF@R7(AD<
MF(3"95#X[<<<5D^%M7DNM9M]%UU]8TS7A:2)<6UQ.[17IPN9H7!VC&"<+C&X
M\<< 'HL%Q%<QF2&19$#LA*G(W*Q5A^!!'X5)7!_""V$7P]LIO-G=I9+C<))6
M<#$\@X!/!/?UJEXFURYT?Q!?KKCZG9:7,\0T_5K.5C!;?*H*3(IXR^[YF!R&
M&",4 >DUB:UXC31=5T>QDLYI?[3N?LZ3*RA(VVEN><]%/0?C6-IES<W'Q"\4
MZ9)>7+64=G:RQ1^<W[MG$FXJ<Y&<#H:XZ&[O]=\(_#6XNK^8WMQJ9WW7!DSL
MF&1D8S@=P?I0![+17E\LNM:!KGB70$UW4+JU_L-M4M+FX=7FMI S*4W$<@D9
M&1QCCUJ#SM9@T?P!JJ>(-1-SJKVUK=*[AHV62 L6V$8W@KD,<G/7/2@#U9R5
M1F"EB!D*._M5"QU)YM(MKW4;5M-EFVJUO,ZLR.S;54D<$DD?G7):*U_;>+?%
M>@?VO?S6T-K;W-O+/())(6</NVLP/'R@X(P.U<O))<ZUX ^'%_?WMW)=7&KV
MRRR"=E+[C(23@]?E&#V[4 >RT5EZU(UAX8OGBU!+%H;5]EY<?.(B%X=L_>QU
MYZUQ^B:A?0>/],T]9M1-C=Z/),XOI2QED1T E56),>0Q^7C_ '1B@#J/%/BB
MV\)Z:FH7EG>7$#2I$3;!"59CA<AF7N>U.37Y_P"T;.TN-!U.V%T[1I/(8&C5
M@C/AMDC$9"G!QUQ7-?&3<? #;" WVZUP2,@'S5[5T5NNNV=[=76J7=K=6:6N
M8TM;=H<."2V0SODD8QSV- &[17E4FKZK<_"5?'5OJ=PFK+&;TH)2;<H'.83'
M]W;M^7.-V1G.:N2KJGB'Q_<Z8->U73[*;0X+U8[9U1X9&D88!V_[(SQD^N.*
M /2:I/>7*ZU%9#3Y6M7@:1KP.NQ&! "$9SD@YSTXK@E?Q'XMLM:FTF]%K>V>
MHS6EK*;]XUA\I@N'B5"K[L9.[/WN,8%:<5]J0^*&F6DVH,]M/H<D\EO$P,'F
MB2,;EX!(Y."<]: .WHKR6ZU77;S0+MH;^]A\6QZR8%LXI#@1>:  (SE=GE'=
MO([9S6U-!J-S\3I-"?7]36P.A).RQNJ,7\XH2"JC!( .1SUP0.* /0*YIO&*
M'Q/=>'X=%U.>]MH5G?88 AC8X!!:4=^W6H/AOJ%[J/@V)[^Y>ZN(+FXMC/)]
M^18Y652WJ< <UAI'?R?&_6!87-M XT:#<9[=I01O/0!UQ^9H [C3-5;49+F*
M73[NQEMV"LESY>6!&0RE&8$=1UZ@UH5SR:;JEYX=NK#4=6,&IN\S1W=F3&47
M>WEL%W'@ K\I)KG?AUJUYKK3-J=[+]NTJ)+22V29RL_!(NB#]X2 Y7MU/I@
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MINKF3XNPVL>HW#6%QH$DZPK)^[#^=&H=1TS@]3GK6Q?>%;34)=1\V[O5M]2
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MQ7E&NQR:K\*]#\075_=37MW=V5S-B=O*)>9#L$>=H"Y &!GY>O)S[!MW1[)
M&R,-D<'UXKCO^%8Z$-.?35N-333#.L\=DEXPBA8-N^0=0,]L\=L'F@".PN'\
M5>+?%.GW5U>6\.EO#;6\=M</"R[H]QD)4C))/&<@!>G)SS^@>*]5U9?"VBZI
M=2*UW=WUO<W41,37/V;A0&&"NXD$XP3L/K7=3^%;)]7;5;6YO+&^DA6":6WD
M&9T7[H<,&!([-][WJ'4_ VA:GH5GI+6\EO#9.)+26WE*2P./XU?KN.223G).
M3S0!S'C*UU#PUX*UJ:W\0WLLB7D$]H/.<26L;RHI0MN)=3\^-W]*V+R>Y7XL
M6-C'>7*6MSH\\DD(E)3>LB ,%/ (!/:M)O!NE3>&[O0[DW5U!>#_ $B:XN&>
M:1AC#%SSD8&.PP.*BM?!.GVVK6NJF\U*?4+:!H$N9KHLQ5B#\W8]!QC;WQF@
M#SI[C5D^$L_B0:_JIU*PU"00N;EMI47?E[77HX*GHV<=L"NLE:Z\/_$JR@CU
M'4+NVOM,N9IX+F<R*9(RA#(O1#\Q&% 'M6H? &DGPQ-X=,]Z=-FF,SIYHW%B
M^\_-C.-W/_UJT9?#=M-K]EK4MU=/>6<30Q$LH7:V-P("\YP/Z8H XO1QXA\1
M>'M"\36>IPVT[NEU=2OJ$K0R1G/F1&';L7'08Y&WJ3DU6FAU"^_X6$)-?U=!
MIDA>T\JZ,?EL+<./NXXS_#T]0:ZK3_AWH>EZJ]Y9O?QP--]H_L\73?9!+G.\
M1=,YY'8''' JVO@^Q3^VL75Y_P 3G/VSYU^;*[>/E^7Y>./Y\T <7*G]M^)?
MAG?WLUS]HOM-GDF:*YDCRWV=&R K#;RQSC&>ASBF>+=4OK32?$&JZ?JM]=7-
MEJD02YBE:*"U7S(D-OLW8E(W'<=N/FY.5Q7:/X(TJ2VT6$RWH.C*4LY$G*.L
M94(4++C(*@#UXZU4N_AOH5Y#JEN[WZVVI3?:9K>.Z98UE+!BZKT!) /.10!G
M?V?"_P <IG,ET#_8,<V%N9 -WVAATW8VX ^7[O?'-8C^)M4T7PCXON/[0N)9
MX?$;6,%Q.V\V\;&)<C/ "AB0,8S7?OX4TY]<M-8WW:WEM;BV#+<-^]C#;@).
M?FPW//7OFH8/!6D1V&KV$ZS7=KJ\SSWD5PX(>1L988 *G@=.F!C% &-K!N_#
M7C'PU'87E[)9ZK+)9W5O/</-R$++*N\G:1@YQP1VKD;N?5H_AYXGUP>(-6-[
MI&K7*VA^TD*%CF"@,!]\$<8.1Z <Y].L?#-M9SVT\MW>7LUI&T5K)=.KF!6
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MVE!&=VXD]>O''I6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* ///^%2P_\ 0[^-?_!M_P#84?\ "I8?^AW\:_\ @V_^PKT.B@#SS_A4L/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4456U"^M]+TVZO[I]EO;1--(P&<*HR>/PH LT5Q1^)^C+
MJMGI;6&L+J%Y%YT%LUDPD=.3G:3D?=;KZ5TFA:U;>(-*34;2.XCA=W0+<1&-
MP48JP*GD<@C\* -&BBB@ HHHH **** "BBB@ HK#\5>*].\':4NHZFMPT#RB
M)1!'O8N<X&,]\&MM3N4,5*Y&<'J* %HKG9/&>F/J\^DZ;'<ZK?6__'Q'8H&$
M/L[L50'KQNSQTJYH?B&UU\7GV:"ZA:SG^SSI<Q>6RR  E?? (Y''/!- &M11
M10 44A.%)P3CL*XY/B;H+^%]4\1*E]_9^FW'V:5O(^9GRHPHSR 6')Q0!V5%
M06]W#<6MO<(^([A5:/>-I.1D#![X[5EZ1XJT[6];U?2+03_:=)D6.X\R(JN6
M!QM/?H?_ -5 &W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZV0 2P.$5L# P3G.>U8MBVK^%?"WP]\,Z/>O:ZAK<QFO,1(Y\IB'<G<IP0&
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MYA,5W?6L:$K<GH6W*<*.#COSUQBO0-*BNH=)M8[ZZ%W=K$OFSJH42-CD@
M5@:OX&@UNUU*PO=0GDTW49HY9;9E4^7L" "-NJ@B-<YSWQC-=3&BQ1K&BA44
M!5 [ 4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<R0EYH73(3:"3D<'<2 OWNG% '4451L=7LM1GG@MWD\Z *98Y87B90V=I(<
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M]2,8YSBI+/Q=IDFC:3?WD_V4ZC)%!$LD;KNF=<A!D<]^>GO0!OT444 %%%%
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MM<ZEHX(VF/:X:)@#]T,R9'LWO7J5% 'DDEQK\^H:'XUM+66*?7(?[,DMB/\
MCW1TW0R,/02!V)Z[7 K:\;1VFF3>!K*-E2*UUB' 8\K&L3KN/MDJ,^]>@T4
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MB0E#&0H7&2QR,*.PHU3P[=W_ (PT77([V&.+3$F00-"6,@E !^;<,8VC'!H
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M"*!CJN3T&>:]0HH X#Q):WVG^.+._P!)B,B:_:MIEPR@%8Y%R\<Q]<)YOU
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M&(]3OR,_XTM]!HVG77@.'3;0V.GKJDL\<4[-N"-&^)"'Y4,Q!&?4=#Q7JU%
M'E%Z1=ZE\6+>UQ++<:?$(DCY,C"U93M]2#@''?BNIT/Q+H\/A'PY)/(Y6X^S
MV4!^SN<SE!@=.,$$;N@((S7744 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYN<9_'%9>I+?KX;^&Q::">X;4+4Q%D**H-L^ W))QZ\9]J /5Z*\^_X3?4-
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MA@^R,J[@5RQW*>1CJ.N>U/TS5?$VL:;H>NV263VFH2))/9N-IAMG!(8/GYG
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M/!'<V\D$R!XI%*.IZ,I&"*YO6H(KWQ)H.BQ1(L,+MJ,ZJH "18$:_C(ZD?\
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M5AJ?B1?%%K:SVK76E7$+F:X-J;<VLJC(ZL=RMT]0>]=8S*B,[L%51DDG  H
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M,KD9!QCK6]29&2,C([4 <POAO4SXRM/$,NI6TC0Z>]D\0MBN_<X<L#O.!D
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M3^5MLI2_RYWKM(*^V?6NMK'\4Z++XC\-7VCQ7:6OVR(PO*T7F;5/7 W#G\:
M,"/5[ZRF\,>'8[M&N]2@>5KDP@>3#'&I(5>A8D@ GCJ<&J=]XLUO2V\6Z3)+
M;27VDZ<=2L[IX.)H=K':Z@@!@RD9'!ZX[5L7_A">\70KR/48X=8T;(@NEMSY
M<B%0KHZ;LX8#LV1VI+SP=+?VNO23WT0U+6;3[%)<+;G9##M90J)OS_$QR6Y)
M]!B@"SX3DUZ\L8=2U:^M)H+RT@EB@A@*&)BN6RV?FSD=A5WQ+=W]CH4]QIS6
MJ3J4S+=N%CB0L [DD@<+DXSR14^B6$NE:'9:?-<)</:P)#YJ1^6&"@ ';DX/
M'K5'Q;X>D\2Z,EG#?&RGBN(KF*;R_,4/&P8!DR-RY'3- &7X:\0W>H>*->T>
M:=KFVLX8)[>>6W,,A$@;((P 1E>" .#WZUP\'_)OGAO_ *^[3_TJ%=]I_A34
M[+Q-J&N/KD<L]]:1PRQ_8PJ!TW8(^;.WYC\N<_[7:LY?AY=)X T_PJNM0[;*
M>.5;DV9RP23S "OF>O4YZ=J .\KG_&<4<?@7Q,Z(%:33KAG('WCY)&3^  _"
MM] P10Y!?'S$# )^E9OB'3)M:\/W^EPW*6QO('@:5XC)M5U*D@;ASSZT 9?@
MV/=\./#<B1)+/%I=N\(<X&_R0!SVX)&?>L33?%>JCQ)X:L+F\ANO[5BG6\6*
M']U!-''OQ%(.' (*GENG:NDTWP[):>"8_#=S?>:J67V(7,,?E-LV; V-S?-C
MG.:PK+P%JEO+X9EF\11NV@AXH1'8! \31^7@C<</C^+I_L^H!!)X@\1VGC*?
MPK<W5N+F\*3Z7=^2H3R 290ZYY< 8 '7(/ S71:MXU\-^'KQ;'5]:M[:Z\L/
MLE.&(/ / [X-9NK^![C6-,D\[58X]:^VK=P:G':D-!L/R*JE^@7*XS@Y)(R2
M:ZR".46\8NGCEG"@.Z1[%8^H!)Q^9H \XUW4)]+^-1O(-/N+]XO"[L8+<J'(
M%QGC<1GIT'//2K/P[BBM]&UWQK+<PR1ZU(U^T%L2R0(@/R9(&7Z[N!R*W6\+
M7C?$%/%/]IPA5L38?9?LI_U?F;\[]_WL]\8]J9I_@YM)UO4YK"^C31]3;S+G
M2Y+?<HD(P[1L&&W<.HP10!EV6O>++Y-!U6SL)+BTOWC:\MFCC5(8)%R'C??N
M)7(SG.[G 7I46ES7EMXJ^),^G1PR7L;VS0I.^Q"XM5QN/85=\/>"M7T$PZ?_
M ,)/+<:!;.&M[-K91*J@Y6-I<Y*@X[#(XZ<4E[X FU >+4GU<+'XA6,'RK8J
MT!1 B\[SN& ,C SSTH CT?Q)J%SXQ30QJ*WEO<Z0UXMU]FVA)E=5/ED !X_F
MR.O3J:QO"GB#4]*^'=I?3W;7UYJ&JR6D(>,9$CW,@+'D;N 2%X' '%=+9^$=
M5C\4:=KU[KT<T]M9-9RQQ60C21"RL-OS';RHSU]MM4D^&Y/A2Y\/S:S(;<73
M76GS10A)+20R&0,3D[R&)_N\?F !+CQ/KWALZU>ZO93W&B6EC]J@N95CCD\X
M''DD(QR#D$-@8YSFJ'B6/5FU'P'=:A?1S>=J\32PI"%6.0Q.0$/7:!N'S9)X
M.1TK>B\(:AJ6C7NG^*M<.JBYMVM@8;9;=45L9; )R^0#D\#' Y.:/_"#Z[/;
MZ#!?>)89ET6[2>"1;#:\BJC* Y\P@G#8R .^03T .\K@(P3\>[K:0#_PC28)
M&<?Z0:[^N8C\+7B?$&3Q2=3A*O9"Q^R_93Q&'WYW[_O9[XQ[4 <GH&O:EHGA
MOQ/JUW>M?S)KDUG$DD8&Z0RI"C$@C@9'R\<"NCM+OQ:OB!K9H'DTR:U9A=W4
M$:FWG'0;4?+(1^(]:A_X5XDVF>(=)N]3>33=6NI;M(TA"26\KN'W;\G=M901
MP.^<]KVB:#XBLTSJ_B8:G+%&4MC]C$2@D8WR -EVQQU Y/?D '(VWC#Q6_@C
MPYXI:ZL'%Y=103V?V<@.))2F=^<J1QC ^N:Z&VUK7['QIJ&A7DUOJ6=).I6W
ME0>25<.4\K[QR"<8).:@3X>W<?@;2?#*ZU#MTZYCG6X-D<OLDWJ"OF<<]3GI
MZ5IW?A6]NO%<VNKJT<32:4VFB-+8Y7+;O,#;^H;MCI^= %'P7XJ;Q'=Q@:LD
MDT=LW]H:;/ (9[:?*8 7@[!\XYSVYKMSG!QUKF;7PM,_B2PUW4[JVFOK*VD@
M66VMO):;?C)D^8YQCA>@))]JZ*>(3V\L)9E$B%2RG!&1C(/K0!Y];>+-9@UC
MPY!>7-O/)J5U+;7UO!%NAMV"LRB.4#!9=H# D]^!4,_B#Q9/:^,Y(-1T^$Z#
M,YBQ9EO-581)L(+_ "YZ$\GGC&.;5I\.]3M['P_:MXD4KH=QYEL4L%7='M9<
M-ECE\-][IZJ:T$\%WJV_BJ(ZM ?[?+EC]C/[C=&(^/WGS?*/;G\J &V_BFZU
MO5=%TFS=;2:\TE=6NI0H9HXV*JJ(#QDLQY(. O3G(K?#A+B/4/&274JS3+KC
MAI%3:&_=1X..QQC/O4A\"7UK-H6H:9K,4&K:59#3WF>T+175N,85TW@@Y&<A
MNM:OACPU=:!>ZQ<W&IK=G4[HW3*MOY81BJJ<?,>/E'_U^M $7Q(_Y)KXC_[!
M\O\ Z":R=/U;7-+\1>%=/N[JUGL-8M)%$$<!4V[11*X(?.6R,@Y ^@KI_%&C
M2>(O#5_H\=TMM]LA:%I6B\S:I&#@9'/XUF2^$[V;5_#-^VJ0 Z(DB;!:']_O
M383GS/EX'OS0!B#Q1XHU;2(-=T"PEN4>Y.RR,<8CEMQ(5)\PN&#X&[/3/&#U
M-J+4_%>J>-=?T>TU'3[:WTUK21&:T+%DD#,R'Y^I ^][# &:=IO@34]'N[BT
MT_Q+)#X=GF:8Z>;93)'N.61)<Y522>V1GCGFMC2_#EUI_B_6=<?4(I8]36%6
MMQ;E3'Y2E5PV\YZG/'Y4 <V?$_BC5M(37/#]C+<J;IA'9&.,1S0+(4/[PN&#
MX!;/0=,'J8(+;7;OXB^.$T/4+6PFVV#&2XMS-D^2V%QD #U//L*T[#P)JFD7
MMU;:;XED@\/7,SS-IYME:2/><ND<N<JI)/;(SQSS6D?#6H6GB;5=9TO4X(?[
M4CB6>.XM3)L:-2JLA#KV/((/]* .83QSK<WA/0_$LOD6MHM[]CUJ)8MWE8D,
M9E1B>%W 9SGAO;GMK&\N[SQ'J2I,ITZT6.$+L&3.1N?YO0*T?XEO2L+4QX7\
M*^%4\)WLID%Y;S1Q6S9::\9LE\8'WV9_;D\=*W/"FBGP]X7T_3'D,LT,0\^5
MCDO(>7;/?+$T 2>)=;C\.>&M1UF6,R+9P-+Y8.-Y X&>V3@5GP'Q);7^GW5Q
M=VESIDEN[Z@-FPP.%!4Q8Y9<Y!#$GOFMC5]+M=<T>\TN]4M;7<30R '!P1C(
M]ZP/#GA?6=+2WMM6\1G5+*T79;1?91$Q&-H\ULG?@'';GDY., &++XMUM_A\
M/'5K)"85!N3IK1C:;8.1C?\ >$FWYL],\;>]:@\17T/CO2K6>X3^Q-8L7FLB
M8@'$R@,49O382P[Y!':HK;P#-:^';CPNFJ*?#TLC;83 ?/CB9MS1"3=C&<C)
M7(!(]"-?Q3X3M?$^DVMB\C6WV6XBGADBX9-IPP&.F4++^/M0!E3>)=1AM]*C
M5FFGUN[E%H4B7=';*K.& ) 9BBJ>>F[H<8.9J_B+QEHOA?Q1>301QC3U2;3[
MRZA3,Z$?,K(CX#*?XNA]*Z7Q7X4'B*PLUM+Y],O]/F$]C=PH&\E@",%3P5(.
M"*H:AX/U?6?">I:5JGB%9[R_C$+W(LPL<<8.<)&&')R<DDY_ "@!D6LZ]8^-
M]%T_4+JUN+/6+6>18HH"AMWC"MPV3N!#8Y YYP.E9TWBS6;&_P!%^U7-O)->
MZQ_9]W9P1[X8$8OLQ*!_K %4D$]SP*W[GPO>W7B+0=7?4X =)BEB,2VI'F^8
MH5CGS/E^Z,=?QK"@^&^I0:-I.ECQ*#!I&HK>VA-B-QPS'$AW_,?G/(Q[@]@!
MTVM>*KS6/&-A:ZC86RZ,L3P2?9"Q8-"9-I!;\">>G %4;K6-5U[4/AM?17WV
M-=362>6%(PR"3[,S9YY(Y( ]\\FNE@\)7L&I^);T:K"S:VD:;6M#^YV1^6#P
M_P W'7IS^54X_ =W;Z7X6@M]9C2[\/DK%.;3*RH8S&04W\':>N>O:@"";Q=<
M#Q9<Z'<:BNEWZ742V=O=0 17MO\ )N97/5SEP ",' P>:[ZN1UCP==:[:3Z=
MJ6HP7%A)=+<1LUK^_@ 8-M1]V 3@_-C@$C&*ZZ@#S^VN[ZW^*7B26ZU-S8V6
MG6\WD^4,+'F0E1^6<]3^50W?BW6[;P!;>.5>%[=@ES-IOEC MV8#"OU\P*0<
MG@D'@5T4GA:0^,;K6X[]5MKVT2VN[-H WF!"V,/GY00Q!&#]169;> 9H?#?_
M  BTNJ+-X?$@*Q- ?/\ )#[_ "3)NP1GC.W.WCWH [6.198DD0Y5U# ^QKB+
MW4_$][X\U'P[IVH6%I!'I\=W%.]H9&0L[+@C?AC\O7@ =C7<@   # ':O/,W
M<GQKU%;"[MHY%T2 .DT9<']Z_HP((R/S_&@!-'\7:[J7AQ&NVLK.\LM7DTS5
M+G.%4)G+1*WWF8E !SR3P:6S\0^)=6\->)_[,EC?5-(O9(K5I[4J;A%17"NA
MQAB&(XQSCBKDWP_DC@TR73M6$&I6>H2ZC)<36_F1W$LH82%HPPQPV!@\ ?C4
MEE9VW@%]:UC6O$*&RU&[69C+ $"2LJKR1G/W1C@8&<YZT 6--\12Z^GAR32[
ML-%=VYN[MFC!/E@ ;?\ 9;S"!]%?TKJZY'P)H=GIT.IZG9I(D&IW;S6Z/D;(
M-Q*A0>BEF=P/22NNH \YU+Q9K.F7=F\US;M++K<=C+90Q^9%' [[%+2 ?++@
MJV">_P!VM"V_Y+7J'_8 @_\ 1\E4O^%;ZBNCQZ6GB0"VMM3&HVA:R#.K"4R8
MD;?\_)/(V^^>E;\'AJ[A\:S^(CJ43^;8)9>0UMSA6+!BP?&<L<C 'TH S?A;
M_P BK=?]A6]_]'M6UXNU:[T3P[-?VEO+,T<D8E\J/S'CB+@2.%_B*J2<>WI3
M/"/AV?PQI<]E-?1W8DN9;@.L!BP9&+$8W-GD\5H:M:7MY:QKI]\MG<1RI()&
MB\Q2 >5*Y&01QUH X?5/&-W%\/\ 6/$>B:[::E%;-&UK+Y2YP2H9)5&,-DD]
M%[<>N]J.N7MCX_TK2_-0Z?>65Q/(I3YE:/9C!]/F/%4[KX>6]_IOB:">XCAG
MUX1^:UK#L2-D'RL%).3GDG(S[=:EA\):M-XDTG7-3UR&XGL8)8)(HK+RXY%?
M;G&6)!^7DY.>P% $6E:KXDU_1M(\0Z9+:^3>3J\EC*H"K:DD9#CYO, P?3.1
MBL$/K,/B3XC76D7MO:/;/!/NE@\TN5M5(7&0 #CD\GFMS0? VI: ?[-MO$<A
M\.)*9(K VP\U%+;O*\W/W,^V<'&15J/PA>QW7BF?^U8"=>4 C[(?W&(_+'_+
M3YOE^G/Y4 ;7AW4WUKPSI6JR(L;WEI%<,B]%+(&('YUH"*,3&;8/,*A2V.<#
M)Q^IK.\.:3)H7AS3])DN5N396Z0+*L?E[E4  D9/.!ZUHRB0Q,(71),?*SJ6
M /N 1G\Z .!^$,4<WPZA21 Z_;KEL$=Q.Q!_ @&HM4\6:SI=U;237-NTKZW'
M8RV4,?F1QV[OL4M(!\LN"&P3W^[71>"?"\_A'0O[*EU".]02R2K(MN8B"[%B
M#\S9Y/M6 ?AOJ(T<:4GB0"U@U,:C:[K(,ZMYOF$2-O\ GY)Y&WWSTH F\3^(
MM=\-^)K>W>6&73=51K?3WV*IAO"1L61B>4(R<@9XQSWW]1\2Z5X5M+./Q'K-
MO#<3*<22+L$I7&XA1G Y'%5-6\'MKUKJT&JWD5R+NW%O:L;<@VH'.X8;EBP5
MB1MY4=@*V-%L;VQTBWM-3OTU&YA4(;GR?+,@'&2-S<^ISSZ4 </XSU&*[\5?
M#W4-/'VV*6ZGDA\I@/,4P\$%B!T]:7P.C>)?'&K^-)-MFZPG2CIN298BC@DS
M< ;N!@#(P>M=#X@\+7>M>(=#U2'4H;9=)E>5(6M3)YA9=I!.\8&,]J+CPG-%
MXO\ ^$BTC44L9YXA%?P/;^9%=@?=8@,I5QR,\\<?4 PY_$WB;5=,NM4\.6<D
M[0WDD-O:&./RITCE,;;G+!E8[6((P!P,'K5M&9_C4CE"CGPSDH3R#]HZ'%+;
M^!]5TS5KXZ/XFDL]&OYVN)['[,KO&[\OY4A/R9^AQVK1E\*32>,6UP:@L<#:
M8=-^S+ 0RH6W;A)O^]GVH P+;Q9K,&L^'(+RYMYY-2NI;:^MX(MT-NP5F41R
M@8++MPP)/?@55TW7+_0IO'^LW]\]Y%IMT<0F,+NQ"A10?X1DX_4Y-7K3X=ZG
M;6/AZU;Q(A70KCS+8I8*NZ/:RX;+'+X;[W3U4UIGP,LM[XC6XOS)I6N_-/:"
M$!U<QA"1)GI@ @8R#CGU (H=3\4VNNV+3VTEQI$L4AOY)(HXOLK!<JT>')92
M<C!R1US7*>,-2U/Q)\'Y_$!NDAM;N6&1;+R@0L/VA0F6Z[^ 2>G48[UV'A[P
MKK>FK#:ZQXE;5=/MEV00FU6)F&-H\UP27P#[<\G-8TGPTU,>$KKPG!XC1=$:
M17MEDLM\T"B02;"^\!E!!Q\H/OCB@#T>N!\7_P#)5/A[_P!=+_\ ]$"N[B5U
MB19'#N!\S!<9/KCM7-ZYX6O-7\5Z'KD6IPVXTAI6C@:U+^9YB!6RV\=AQ@?G
M0!@6.HWVG^.O'=]>ZB\UGI=M;2F#RA_JQ%))M4]L$GZYJY9ZQXMN+G0[V&RD
MN+*]V_;HGCC1+='7(>-M^Y@IQD')(Z8K2/A GQ/K.I-?!K#6+>.&\LF@R6V(
MR##YX!#'(QGWJIX<\':UH8@L)_%$M[HMH1]EMFM564*OW%>4'+*O'  S@#IQ
M0!A2^)O%LGACQ9JL>H:?')H-_<QJHLR1.D2J=IR_RY!/.2<GJ,5KKK^NVWBC
MPP+JXM9+#7DE!M4@*FV*Q>8I#YRW3!R![ 4]? MX/#WB;26UB C7;F>=Y19D
M>3YH"L /,YP!Q_6K4_A*]GO?#%R=4@#:&&X%H?WY:/RS_P M/E^4^_/Y4 9V
MC^+I]3\2'2Y]16QU2&\E6?2;F$(7MP6"-$QY<D!6)!/?@<5WM<E+X/N=0N-*
M;5=0M[H:9>B[MYEMBD_!)5"^X\<@'CY@!]:O>'4UM+_6!J>H?;;0W&ZS<VPA
M,:G.8QC[RJ-H#'J<T 7=?N;^ST"^N-+2V:]CB+1"Z?9$#ZL>P R>W2N8TSQ1
M?OXMO]'BG.J0+I(U"VD>#R6=]Y3:IP R' (8#\36_P"+/#__  E'AF\T?[6]
MH;@+MF5=VTJP89'<97D=QFL<>#M6D\1-K=QXA!NI=+;3Y1#9B-1\Q963YB5P
M3G!))]1V (?!?BIO$=Y&!JR/-';-_:&FSP"&>VN,I@!>#L'SCG/;FNX/3CK7
M,6WA:9_$>GZ[J=U;3WUC;R0++;VWDM-OP"9/F.0,'"] 23[5T<\0GMY(2S*)
M%*EE.",C&0?6@#SZW\6:S;ZQX=AO+FWFEU&[DM;ZV@BW0V[!691'*!@LNT!@
M2>_ J*?Q!XLG@\9O!J.GP'096,1%F6\U5A$FP@OQGH3R>>,8YLVGPZU.WT_P
M_:-XD4KH=SYEL4L%7='M9<-ECE\-][IZJ:T4\&7JP^*H_P"UH#_;Y8D_8S^X
MW1B/C]Y\WRCVY_*@!EMXJNM<U30])LW6TFO=)75KJ4*&,<;;55$!XR68\D'
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M YX^]UP: .KHKB+G4=>TS5K/0KB_:_NM0:XN5GM+:*)X8$" (H=MI.Y_O'/
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M:"<M@$X./K@U1^*$^K2>']-6\T^U@B_M>T^>*[,ASYGH8U_G0!Z9&XEC5U#
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M*58L=PZ[F/ ZG/M77T4 %<HGA&\M;O6OL&L^1::Q,9[A&MM\L;LH5C&^X <
M8W*V#75T4 <'XJ/AV'P\?A_"/]-N+%8[&R1') SM1]V,#:R[B2>-I-=CIEA%
MI6EVMA 6,=O$L89CDM@=2>Y/4GU-4]$\06.ORZ@+-)U:PN3:3>=$4.\ ,< \
MX^8=<5KT <WXM\+S>*$TU$U!;1;"^BOE_<>86DCSM!^8?+SR.OO2>+O"\_BK
M3+2R.HI:B"XCN6=;??N=#D<%A@9[<_6NEHH Y'6_!M]?:[;Z_I.O/I.K+ +:
MXD2V$L5Q&#D!HV/4$G!S3[WP?<74^ASC5V,NEW#73230!VN)&!5BV&4 88X
M''&.!BNKIKNL:,[L%51DLQP * '4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8/C.-)?"]Q'(H='E@5E89!!
MF3(-;U9FO:7+K.F&RBNQ;!G1V?RMY^5@PQR!U44 <#X7U:7P9#K_ (/E!EN=
M,D$FCHYYGAG;$2Y[[9&VD]L^U.\#:<='^(WC.SB<2S1VEB7EDX\V4QNS.W^\
MQ)/UKL[KPK87_B;2_$-V@?4=/ADB1U7"MNQR1ST^;'/&XU0@\&%-?U[5)]1:
M0:W MO<PK#L"JJ%%V'.0<$\G- &%IWB76(_$/A2VFU/[<FJ>?'>F.%1;>8L9
M<>0^U68 @C.6!'?-/E\8ZGI'_"=SWDT=TNCRP):)Y815\R-2 <<D;G&<GH.U
M+<>#XO#VF:+J&I^*;P6WAPGR9!;)A82GE[2%4DG! W<].@ZU-HVAVOB*[\;O
M=*)]'UJ>*.*1&XE18$4LA]FR ?53Z4 7K9O%T'B.V*QW-SI4L$@N1?&V1HI0
M,H8_*.2">"#G'7-9OA/Q-<:[?Q:?=ZQ=V6LQV[B_TNZMXXWCDP,20_)\R YQ
MRV003[ZVB>#[_38A#J'B>^U2""-H[2.:-$\G*E=S,HS(P4D D]SQ5BU\*R?V
MKI.HZGJ O;C2HWCMI1 (W;>NTF1LG<<9Z!1DYQTH XGPTGB7_A3\VI:/K5U)
MJB2W4R1RQQ2"0K<2%ARF2S#/))YQVXKL--UL^([W1Y-+OI#I[V/VRZ!1#O#_
M "QHWR\$D29QC[A'>J]G%IGPRT5AJ&L7+:9)=LMLC6Y;R3([/M^12QY)Y/L.
M.]KP-H-OHFD7,L%L]M_:%W+=B&3(,2.Q*)@_=PN#M[%C0!CZU?CP';Z)IQDO
M[/PW!:&&34+6!93%(NT)YF5;:I&XY ZXKL-"G>YT&QGDOHKYWA5FNH<;)CC[
MPQQ@U#?Z9>SZB+NTU%(4,!@DMYK?S8Y!G.2-RG(R1UQR<@T_P_H=KX;T&TTB
MS+&"V4JI;&2222>..I/ H TCT-?/^C7EY=?!_P .^%YH8;+3=;FFM3JTCEUB
M/GNP4I@89B"%).*]]N%E>!U@D6.4C"NR;@/PR,_G7)Z5\/K*R\!R>#[VX-_I
MI5U1GC"2+N8OG(.,ACD' QCO0 _5[^709/#GAO3A<%KI7B62/RS*(X8P3M\P
MA=Q^7DYXSQ6;/_PGB>'?$(2>2*ZM3YVE3RI \MPFTEHY$0%<@C (QG(]ZN7W
M@2?4M$T^TNO$%V=1TR026.J)&JS1D#!W<X<$<'IGOFM[0])N=,AD>_U2;4[Z
M7 DN98UCR!G:JHH 4#)]\D\T 9&F>(#KL>CWMA?2BR-A]NN_E0E@1A4;Y>"6
M$F=N/]61WK'L-8\7:UI>BZ]I45PZW4B2W%I*;86_V=NH5@?,#J,<D\D'('0=
M1X;\+6/ABVO8++<8[JZDN"K=$#'.Q?11DX'N?6L;1OA_+HDYM;7Q%??\(^)3
M*FDLB%5R=VSS,;MF?X>,]#G)R 9$^J>*+M_&Z1:^+8:*^^V,=I&2?W DVG<#
M\N3@]_<=]"U\3:I=:YX%/VC;;:YI\MQ=6X1=H=84<;3C<.7/?TK23P=*C>)6
M&IY.O?ZW-O\ ZKY/+^7YO[OKGGGVJ&3P-*++PVMIK$EO>Z!&8;>Y%NK!XB@1
ME9"<9(4<^HZ4 9 \8ZI86GB033FZEMM;BTVR9XT!02^6 3C:#C>3SC. ">];
MND'Q/%XH>.Z6YFT.2VW"2]-N)HIP>@\K@H1ZC(/M53_A7%E-I^OV5]J5Y=0Z
MS.+B0G:K12 +AU('W@5!].V,5J>'O#NH:6XEU;Q#=ZS+&GEP&:)(Q&O<X4?,
MQP!N))^F3D Z&N"\7ZSJ^G'Q!+;ZKY)LM/%S96UG$LKY579FN-R$*I*@#D9
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MI)C(L$ABV>8%)7><+G'&?:J.A:=<Z3H]O876H27[P*$6XE0*[*.F['4^_?\
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M%9F57W#D$!<8'!&.^2>[K#\)>'3X5T&+2%O&NH8G=HW>,*PWN7(.#@\L:W*
M/-_&GB/6M&M?$=Y;:HHET\1RVMK:PK*BQX4M]H++\I8EL ,#C!%:&H:EKMS\
M0K+1K35%M+&[TF2Z(6W5WC<.BY!;.3\QZ\<]#1J/PZ%^GB*V37+N"PUQC+-;
M+$AV2E0"P8C.WY1\O'3K6E#X4GA\26.M-JSS36EBUEMD@'SJS!BQP1SD#&.
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M2F1RQR[O+=7V,5;:<X(ZCZT <B? ,;>']=T=M5N##K5S+<W#^6FY6DQO"\8
MX'7.*J^)C8:MIY\!.+NZU&6*']X+9U6- P_?>8!M!4+GKR<#OBN[K&USQ%!H
M-QI<5Q;7$@U&\2SCDC"[4=\XW9(., ] >E &K;V\5I;16T"".&)!'&B]%4#
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MW D C'RN.".@KG-.UOQ$/ WA/Q//K]S-<7.H0V]Q;F.,12QR3%&R N=V.AR
M,<"NXM_!:P:^FN/KFJ3:@++[')([1XD7=N!*A !@GH !ZYYS63X=V4?A73?#
MR:IJ(M-/N$N87_=;RROO4$[,$!O:@"";6;KPU\0+F'6=3F?1K^Q>YL3(%"P2
M19::/@ GY<,,GH"*W-'T^XNO#<$6MR33S3_OIHY6QMW'<(CMQD*"%(/7!SG-
M8FL?8/&6M6NAOI]Y(=)OTN+FXGMVCC78I(VL0 ^\D+@?PECV%=O0!PGC/7[K
M0M:234/[2M_#[VH O[!-_P!EN-QRTJ@$[=NW'!&<Y![=?I4HGT>RE%TEV'@1
MOM"'*RY4?,/8]?QJEJ&@R7M_<746J7-NMS;+:S0*B/&5!8[@&4X;YR,YQTR#
MBK=CI4&EZ+;Z5I[/;P6T*PPD89E51@=003QWH \D\(Z%K'BKX,1Z#:FQMK.[
MN9UENI)&:14%PS';&%QGC'+5T^OR7FEIJ-C9:K<E-.T=39VUECS(&56_>S,W
MRX.U<*3SAL*:Z7PGX7M_"&C+I5I>75S;*[.GVG864LQ8\JH[D]:J7_@>UO=:
MU/45U+4+9=4MUM[ZW@= DP52JG)4LI )'RD9_/(!SD^L:[J=Q\/1%K$UF-;L
MY'O%ABC(+"VW[ERIP<DXSD=.#BK<4^LW>KZAX:CU&]N'TJT@#722QPRR22!F
M\QOEY    ''7.>,:=KX"M[5O#K+J^I,V@HR6I8QG<"FPAODZ;>.,>O7FI-=\
M$0:OKL6MV>JZAI.IK%Y$D]BZCSH\Y"NK @X[''\A0!STUWXNAU'P1IVI:PMO
M>WK74&H"T2-XW*1,5<97AL8./N@_PG&#FZQ=:FW@[XC:1<ZO>7"Z3_J+AF59
M61X5?8Q4#(R2.@R..E=S-X.M9+_1+M+Z]C?2&D>$!E;S'D!#M(64EB<G/(Y.
M:B;P-8RCQ&MQ>WDR:^NVZ1B@"X38"F%!!"@=<]* +^FM_97A.*XEFGN%AM!,
M2Y!8@)G P!Z5Q%WKVM1_"ZW\=PZE(UZJ)>2VAV_9WB9P##MQQA3PWWLCDUZ#
MI.F?V7I45C)=W%[L4(9;G:68 8 (4 8P .!]<DDUA6W@&QM=-.C+>W;:%YWG
M+IS["B_-O\O=C=Y>[G;GVSCB@#'E?7-;\>ZII-OXCO;"S&FV]Y"(XHB\3,[9
M7E>GR\YR??'!Z+QEX=B\3:-%IYOY+"\6X2>RNH_O1SH"RD#OP&X],U/!X:BM
M_%MSXB6^NFGN+=;=X#L\K8I)7'R[L@D]^]6-;T5-;AM4:[NK1[:X%Q'+;,%<
M,%8#J",?,<@C!Z'B@#C-$\1Z]8^)[#PUXVL(3>SK)_9VKV9_=W!5?F!'\+;?
MI].AJA<^(=;C^&'B[45U2<7VEZE=0VUQM3<$CD"JI&W!X]J[>+PUYFLVFJZE
MJ$]_<60<6JNB(D1889L*!EB.,G@ G %9%[\-[.\MM:LCJ^I1:=JTSW$UG&R!
M$E<@LRG;NY(^Z25YZ4 9VI6=SJ?Q<A@@U*XL&?PV2\]NJF3'V@<*6! YQS@_
MAUJG::_XIAT'4[207.KSZ+K/V6ZFM$5;BXM-@;*CIY@W*"!SC..>:["?PFK:
MO::M;:I>0:A;VGV(S8C<31;MV&4KC.1G(Q3E\*0064$-E?7=K/%>-?/<J59Y
MY65E8R97!!#'@ 8P,8P* .-UKQ/)+\*M=USP]XBNI'MYQY;R1J)H.8U:&0,N
M01EN>O(.3WZ6?4Y]6^($_AQ+F6VM;*P6ZF,+;7F=V(4;NH50,\8R2.PP5O\
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M-O&V=PQQNV@\A<XSUS4]SX#L+V;Q$]U>WLJ:_&D=U&2@"!%VJ4PN00/4GWH
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M\X]CU_&KM4]*TRUT;2;33+)"EM:Q+#$I.2%48&3W-7* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-?UT:%:Q.EA=ZA<
M3/LBM;-0TCX&2<$@8 ZG/IZTS7?$+Z(\"KH>KZEYH)SI\"R!,8^]EAC.?TK/
MUWPG9^,K>QU&6?5M*OXH<V\D$YAEMR^"0R@D9R "/;K0!M:+J4VK::EW/IEW
MISLQ'V>["B0 '&2%) S]:T*XC0?$VK67A%9=7T^^U>_M;Z;3Y'TV!6:;RV9?
M-VD@ ';@^]=5I.HG5=.CO&L;RQ+DCR+R,)*N"1R 2.<9Z]* +M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6-?\ AV._U=-1&IZI;.(O)>*VNBD4
MBY)Y7G!Y/(P?>MFB@"&TM(+&UCMK:,1PQC"J/\\GOGO4U%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!RS9/J>,^@H U+Z^M=-LIKR]G2"VA4O)(YP% HL;VWU+3[:^LY!+;7,2S12
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M;EAO5%R3AQGAR!TQSU[8\%]K>EW_ ,1-0T?[ /L=Y]ID%VCOY@2W1B@"D8)
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M==I>6<S+N42+_"PXRI!(-:FG:M9ZL+HV<C/]EN'M9LQLNV1,;AR!GKU'%7:
M.:30;ZYU[^W[\6@OH;-K2U@B=FC3<07<L5!). ,8X /7-2^"="NO#'A*QT6[
MFAG>S4H)8@0'&20<'H><=ZT])U:SUS3(=1T^1I+68$H[(R$X)!X8 CD'M5V@
M#F[O0;Z;QY9>((Y+?[/;6<EKY+%@S;V5BV<8&-HXKGG\!:S_ &7=0Q:A9)</
MX@.MHK*S1/EMWDR#@D X.1W X&*]%HH Y;0?#FJZ9XLUK6+R_M)H]42 O'%
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MJOH1[@X/X5AP^%M2O(-%M==OK:Z@TB=+A'AB97N9(U(C9\DA<9R0,Y('('!
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M5<8V*A)XZY)))SZ8 S/#?@V/P[X8N]&CO9G\\RJD^?GBC.1&JG_87 ^N3WH
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M98V"@E1N&UOD'7(Y[XYT_&&@2^)O#-SI<%Y]DED9'20IO7*.&PRY&5.,$>]
M&)IWBF_NO$6KZ/'=VMTD&G)>VMX+9E4DLRD$;L.N5R&4]^IJK'XUU>3P?X.U
MK99B36+ZVMKJ/RFP%E8@E/FX(QWS6I9>%=57Q?)KU_JEK*+C3ELKB"&U*#AF
M8;"7.!\W?)^G;&@^'NNQZ!HNC/KME]GT:_BN;5Q9MN=(V) D^?D\@?+COUH
MN:#/JT_Q)\7PW&H12VMJEHBQ& C"-'(P53NXP6.20<^U<SX/UK6] ^'O@N[1
M[%M,N;J*QDMS$QE(ED9?,#[L @X^7;^/IW,/AK4;/Q;J^LVFH6_DZG#")8)+
M<EA)&A12&#<*<Y(P3QU%8\7@#48?!6@^'EU*U+:3>Q70G,#?O!&^\+MW<9)P
M3DT :D.MZKK^H:[;Z)/:VZZ5-]E5KB$R>=.$#-G##:@W!>.>I]JPH_'^KZMI
M_A*[TNWLX#K%S):7,5PC,89$5]Q!!&0"A.,9([C/&]!X9U'2/$.JZEHUW:I#
MJQ62XM[F-F$<X&/,0@C((ZJ<9(ZBJ?\ P@4EG!X8M],O(DAT2X:Y8SQEFN'<
M,')P1MR78]^OM0 ]=9\1Z=XI\-:)JDNFS'4(;IKB2VA=?FB *[<MP"&&1CJ#
MS67X8N/%5Q:>,YK74+.YOH-6N(H$GM6VLZ1Q!1PXVK@ 8[=<FNFU3P_=W_C+
M1-<CNH$ATQ)T,+1DM)YH /S9XQM&.#533].'@NXU_5-0UFUBT6\O&OCYL>QH
MI)-BD,Y;&W(&!@')ZT 1:1XIO-=T/PU/92VPO-18F[5H&Q$L8/G?+NR"KX3D
MGEA39[Q]+^+UI:1\6^LZ:YD0=/.A;A_KL8J?HOI2^"M'L$UC7M?TZ0R6.H71
M-IALQXPOFO'[/("??8".*FCTXZO\2!K8YL]+LFM(7[23NV9"/4*JJN?4D?PF
M@"]XDU^32;G2-.M1&;[5;K[/"TH)6-0I9W(!&< <#(R2*RF\1ZO8>)[[PY=-
M:RW!TYM0L+ORBJL%.UDD4-U!P<@C(-:GBKPT?$$=A/;70M-2TVY6ZM)RF]0P
MX*LN1E6'!P14/_".7=SJEUK5Y-;?VD]B;&W6-6,4*$[F)R<L2<>G  ]20#FK
M#QEXE;1_"&N79TTV>LW4-I-:Q0N'4RAL2!RV."!\NWIW->C7/_'K-_N-_*N(
M7P)J*>%?#.BKJ-KNT2\AN?-,+?OA%G"XW?+G/)R:[6\2>6RECMVC69D*JT@)
M4$]R!UH \3T?2-4\6? 71/#NG:5)YD[@B_FDC6* +.S%Q\V\G *X"]S7<>*/
M$6M:!!J\B36D4>GV*SV:R(9I+TJI:0LJMN11@#..ISG'%;/@?P[<^$_"EGH=
MQ=170M RI-'&4W L6Y!)]?6LG5/!&J7NH>)VM]8@BLM?M1#(LEL7EA(B,8"M
MN V\YP1W.,$YH 9J7B;7Y=;\-6.E#3XDUNQFN UQ&[F%TC1AG##</GZ8'3K4
M&E2^)&^*$EGJ&IVCM!HL,KQQ6S",,TC!PF7R,E <G/&!CBK]OX0U6+5?"]]+
MJ5I(=$M9+=U%NR^<'55)'S';@(/7//X7YO#EX/'8\16E_#'%+9):7%O)"69@
MCEP5;<,9W8.0>/T ,.T\<ZA'H6K7%[%:R7T&O-H]HL2LD;,71$9LDG&6+'GM
MBNBMO^$GBUFYMKAK&?3VM1)!>",HR3YP4:/<25QR#D>G/6L _#N6[\.Z]I5[
MJ2*^HZF^IV]S;QE6MI2P9>"><%1Z9!/2MS1=.\20*TVMZM:7ETD9CA6WMS%%
MVR[C<2S' Z8 YP.: .4A\=^()_ OA76XX=/:[U;4H[.>)E=5 :5U&TY.WA<9
M.>N:TK/Q'XET_P 77?AW5X;"^FET][[3I;16A#E3@Q,&9L')'S9Z?IS^M^'[
MSPMX'\'Z(;Z"6>W\0VJQ7'E$*2TCL,KN[$]CVKKK[PC<:U=:C?:A>+!=W&FR
M:;;FU!(MT?EGR<%F)V^F N.Y- &=IGBW5&\3Z)I5U/97)U*SF>;R(B%MIXPI
M**X8JX&X@@'((Z\XK*N/&GBN/PIKNOAM)":+J,UO)"('/VA(Y I ._Y#C)S\
MV3Z=]>S\%ZY%J'AF]N-8L2^BP26WEPV157C9%7CYSAOE'/3T'JR3P#J,O@[Q
M#H#:E:[M8O)KHSB!L1"5MS+MW<XQP<B@![W.K3?&.&VCU"-;(:(;A8&@)P&G
M0,,AA\QVCYN@]*Z6>R339-4UFWMS<WTEO\L:@ N$#%4&!U))Y.3SZ "LQ_#.
MH_\ "7V'B"'4+>-X]/\ L%U$8"V]-X?*'<-IR,<YX-=#?P37.G74%M.;>>6)
MTCF SY;$$!OP/- '+>#O%+^)I(YH-4LKJ$6Y-W;+"8I[6XRN%*EB=OWQR.J]
M35;XD^>)_"'V41F?^WX?+\TD+GRI>N.<5HV?A:8^++;Q%?&S2^@M7MG>SC*?
M:MQ7YGSV&WA><9Z\5:\5>'Y]>CTR2TNH[>ZTV^2]B\V,NCLJLNU@"" 0QY%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5#<6EM>*BW-O%.L;B1!*@;:XZ,,]"/6IJ* ,O1O#VFZ#:
MQ0V4 W1QF,3R8:5DW%MI?J1DGBM2BB@ HHHH **** "LO6?#VFZ[;2PWD WR
M((S/'A90@8-M#]0,@<5J44 0VUI;6:NMM;Q0*[F1Q$@4,QZL<=2?6IJ** "B
MBB@ HHHH *Q[KPQI%YJ$-Y+9QAXVE=D50$F,B;&,BXP_R\<UL44 -CCCAB2*
M)%2-%"JBC 4#H .PIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117'^+
M?%RZ7K%AH%M>VUG=W<;3SWERRA+2W4X+X/!8GY5!XSDGI@@'8451TA[6;38Y
M[+4#J$$OS"Y\X2B3MD$<=N@P/:KU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH \\_P"%+>$?34__  /D_P :/^%+>$?34_\ P/D_QKT.B@#SS_A2WA'TU/\
M\#Y/\:/^%+>$?34__ ^3_&O0Z* ///\ A2WA'TU/_P #Y/\ &C_A2WA'TU/_
M ,#Y/\:]#HH Y/PY\.M \+:H=0TT7GGF,Q_OKIY%P<9X)QVKK*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***Y+Q;X_L_!VI:997NG7T[:G)Y5L]OY9!?*C!W,,<N* .MHKE]'\=Z;
MJOB:Z\-RV]WI^LVR[VM;M5RZX!RK(S*PP0>N?R-:.N>)=-\/2Z;'J$WEMJ-V
MMI!_OL#@GVX S[B@#7HIKNL:,[L%11EF8X 'J:Y+2_'D?B*>X/AW1[S4K&W<
MQO?!DBB=AU$>]@7^N />@#KZ*Y*X\>VMMH&L:O)I6HK'I,WDW<#HBRJ0J,2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O&/CGO_ .$B\!>7M\S^T&V[NF=\.,^U>SUS'B;P+I?B
MR_L+S4Y[SS+!_,M1#($$;94D_=Y.5'7/2@#.TCP#+#\0+OQIJ^H1W.H2Q^5!
M!;Q&.*%=H7J22QP/;J?;'%_%FP'BS1]4OH(K]KG2)0+!HK64QD1Y\]MX7:,G
M(Z_\L1ZU[-) TEHT'VB569-OG+M#CW'&,_A5'3=$BTK0TTF"YN6@1"B/*5=U
M7TR5P?Q!ZT >=:EXHNO&'[/%_JMDQ-^;/RKL)U#*P$WYIN;Z-6U\%7MV^$^B
M_9]ORB42 =0_FOG/^>F*U_"7@+2/!<-U!I+W?V:Y.98)Y0Z%NF<8X../?\!4
M=A\/].T6XN'T+4-2TB"X?S);6TE0PENY"R(VW_@.* (/B?%$GPS\3/&BAY+8
MF0@<L<*.?? 'Z5QFD_\ )K$G_8.N/_1KUZ1?^$=.U#P]<Z)(]REI=$FY99<R
M3$XR6=@23P/P '3BJD/@+3(/!S>%([J^&DLI3R_,7<%)+%=VW."2?>@#B/A/
M;ZZ_A+P:XFMGT,?:A)"D3"0.3*%+MDAE^]V')'6JOCL!?VA?!*J  (%  [?/
M)7J7AKPY9^%-&BTG3Y9VLX2?*29@Q3)+'!P#U)/.:SM5\!:7K'BFS\1W5S>C
M4;, 6[I(H6, D@;=N#R3USUH \YLVD3]JBZ&HYRUH19;NF/)'W?P$GXYKVN:
M**5 LR*RAE8!AQN!!4_4$"L/Q#X,T?Q++:7-['+'?V9#6U];R&.>(]>&'\B"
M*GM/#R0W$,][J-_J4D!S#]K=-L9Z9"HJJ3[D$CM0!)XG_P"13UG_ *\9_P#T
M U\\:18:O=?L\W$T=Y!_9$%XTMW9+$4EF174D"4D@<X.-G;KVKZ1U.P35--N
M+&666**XC:.0Q$!BI&",D''!KD;?X4>'[?0#H(N-3;2&E\U[,W1".V0>2 &(
MR <9Q0!YS\1-2T[5?V>-!NM)M'M++[5%'' [;C'L$B$9[\J>>_6E^+ZS+:?#
MJ:;/]F(4$Q/W0V(CS_P$-CZ&O5==^'VA>(- M-"N(YH-*M2K16MJPC4$ @'.
M,]SW[YZU?N_"NEZEX;70-3B-]8JBH!.1N 484@J!@CU'- &3\56B7X7>(3,1
ML^RD#/\ >)&W]<5YMH/@J;Q=\)/"MFVI2:=KUJ+B\TR4D@B,2#KCD#YHR".1
MQ7IUSX"L-1L+?3M4U+4]1TVW962SN)DV-M^Z'*J'<#T9C[YK1U/PO8:G=Z==
ME[BUGTU76T>UD\ORMVT'CH1A0,$$8SQ0!YIX7\4>-;+7KOP=XJM$EUG^SYI-
M-U! -SX' R.""5'/!RO/L?LY-%_PB&KHW_'XNHDS;OO8,:;<_B'_ %KTVQ\.
M6MIK#ZQ//<7VI-#Y"W-R5RD><[5"*J@$\GC)[FLY_ 6EQ:[<:UI5S>Z1?77_
M !\O8R*%G/JR.K*3UYQGD^M &]>Q1>1<2[%\[R&7=CG;@\?3->1?L]_\DUUC
M_L(2_P#HF.O4H= @@MKI%NKMKBZ4+-=NX:5@,X&2,*!DX   R2!DUE^&_ .E
M^$]*N],T>ZOH+6Z8NZM(KD,0 6!*\'  H \E^"-OK4OA:%[*:#^S4U\->0^4
M3*P\I,$-G&T-M)&.V<]J]BUU+*]M["V$<4MLVHB&6/:"AX<,I'0]2#^-9^A?
M#?3/#.GSV.C:EJUG;3OYDB1W"\M@#()7(. .GI6A!X.L[72M/TZVOM0BAL9S
M<1L)0SO(69BSLRDMR[=>#GF@#Q7Q!9:C\'-6U2TM4EN?"6OP2PQKG/D2LA &
M?49_X$ON.-WXIM)'\:_ KWN?[,$D7EEONB7SOF_]IYKUW7-"L/$>BSZ5J<7G
M6TRX;LP(Z,#V(/.:A\1^%](\5Z;]@UBT6XA#;T.2KQM_>5AR#0!J3QQ36\D4
MZJ\+J5=7'!4CD'VQ7BWQ368_&;P*ML\<<Q9=C2(74'S>,@$$C\17IEOX3C2*
M.WO=8U74;5,8M[N9"IQTW%55G'LQ(/?-5==\ :5XA\06>MWMS?"^LB#:M%*J
M"+!W# V\\^N: +'A9;RRT>!-?DA;59+RZ0.J;0^99'&P'D*44''H!7DEQX>\
M7?#:&7Q'X&U%=2\+3+]L:QEYV1$;L[3U&,?,I!P.1Q7L$'A6W37(-7N-0U&\
MN;='2(7$P,:;A@D( !G'>J=KX#L;+0O["MM2U6/23'Y3VGGJP92,,-S*74'G
M(5@.3C% &EX5U>#7O"FEZI;6_P!FAN;='6#M'QC:/88P*\I^":RP^/O'D6H9
M_M'[2I;?]X_O)=Q^F2OZ5[1:6EO86<-I:PI#;P((XXT& J@8 %8M]X/TVZU]
M=>MGN-/U?R_*>[M&4-*G'RNK!E8<#J,\#T% 'F/C]9IOVAO!B6&3<I%$TNSJ
M(A)(6S_P#?4!34I/VF->729K6&\_L]=CW432)_J8NH5@?Q_2O5])\(Z9I.KW
M6LYFN]6N@%EO;I@TA4=%& %5>!PH%4X/ .EV_C&7Q6EU?'5IEV22&1=K+M"[
M=NW&,*!QZ4 :?A>&ZB\,:5_:(_XF(LX4N6(^8N%YS^);\Z\G\0M)'^U!H#:C
MG[(;<"TW?=YCD Q[^9G]*]OK#\2>$='\5P0)JENQEMW\RWN(G,<L#>J,.1T'
MMP/2@#8FBBFB,<R*\9QE6'!YX_6N/\<):ZYCPS=)>-9RP--=FUMY)2,Y6('8
M#C+Y<?\ 7+'>MBV\-(DD+7VJZEJ:P,'B2[D3:K#D,0BKN(/(W9P1GKS5C3]$
MCT[4[Z_2\NY9+U@TJS,I4$# VX48 '&!Q^/- 'F?P(UR>/3]3\&ZEN2^T>9C
M&D@*MY3-R,'GAO7^^*K>#/\ DY3QC_UY-_Z%!7?1_#[28?&4GBN*XODU:7B1
MUD4*Z[0NTKMP1@#\L]>:BM_AUI=GXEN_$5M?ZG#JMX"L\Z3+\X..-NW&/E7M
MVH V=?NH3I&JV8<&<6$LI3T4JP!/U(/Y&O,/@E_R1G5O^N]S_P"BEKT2#P=:
M0MJTAU#499]4B6&XGEF#-L4, JY7"CYVZ#O4&@^ M,\-Z#=:+I=U?16-R6+J
M9%8@L &()7(R * /*_@Q#K\G@:T;3Y[<:<NO WD7E-YS+B/HV<8SM)&.@//:
MKOC")X/VC_"37*[;%H46VXP@;]YP/?<1^8KT_P )>#=-\%6$MCI$ER+620RF
M*9PX#D $@XST4=\59\0^%]*\46L,.IVY9H)!+;SQN4E@<=&1AR#P/RH X+]H
M-HA\,\28WM?1"//][#=/PS7)_$B.^ATCX51W>1?(8UD\S.1(!!G=^/6O7)O!
M-AJ%_97FLWE[J[6+;[:.\9/+C?\ O;410S>[9IOB?P)I?BZ]L;K4YKS?8.7M
MEAD""-B02>G)^4=<]* /,[>>3Q/\>+>T\8!-/O='7=IEM "8[D@E@V\G)[,!
MCG;C@@Y[GQ;X/T_QO?ZSI5\ K'3[1[><#+0R![G##^1'<5I>(O .C>*+S3K[
M4#<B_P!/.8+N"3RY1SD9(&.",CCCGUK4M=$%MK$NIG4+R6::)(9%D9-A5"Q7
M@*,8+L<CUH \F^&NN:W:>*[3P)XCA?[=H_FM!.3D/#L( SW'(VGT..,5)IG_
M "=1K'_7@O\ Z)BKUB?0M/N->M-;>$#4+6-X4F7@E&ZJ?49Y'ISZFL:#P#I=
MOXQE\5)=7W]K2KLDD,B[67 7;MVXQA1^5 &-\0[2#Q7%=^'94O&A@M6DWV]M
M)*/M3#]T&**<;1EB#UWJ>U4?@9XDEU3P?)HE]N74-$D^S.C\,(^=F1[89?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M72+#31>*J;[BY6XVI;>BO\OWCU"C)QR<#F@"UJ>A6VL:#+HU])/+:S)Y<OS
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MZ$9\A+D&1!(,KGY<?7GCWK1A\3ZC=1Z.;30C,^I6AN_^/H*L"83 9BOWCO'
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M@X-8%I\.M L-';2;,ZE;Z>V[-O%J4ZKSUZ/T- 'GOQ_N(+OPCX>GM'5H'O\
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M[K8MN$4LX/)W'!4Y[XZ<5K>(/#>G>+=1U/2-2BW03Z= 58#YHV\R7#+Z$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMU:0M,T)4M\DB*"W1L9 (X'KQK?\*CLO^AM\7_\ @U_^QH_X5'9?]#;XO_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:/ R.I').:71;K6O%OABU\1V&M&RN);MI!"Z@P) DK*8V7&22JY+9SNZ$#H
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MH(& H.U2!QC)'!Z4 >GT5YUJNJ^)_!]GX@U>X(GTF*Q\VUBNIA)+'<;@N,J
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M."54GD@=<?F*JV=_)=WM];O8W5NMK(J++,H"3@J#N3!Y SCG'-<*8I;OXJZ
MZZO<2QOH,DH>&13&_P \62N1C#=2>IXYIKZQK:67Q& U>?S=)R]E*8X\Q@6X
MD"XVX(R?3/O0!Z317FUIJ&MV6I^!KN;6KBZCUJ/RKNVD1!&/]'\P,N%W Y')
M).<]NE5-8\2:R=+\5RQZC+9Z]I^HF#3;) I,D7R>7B,@^9Y@+'.#CMC% 'JE
M%5[&.:*QA2YFDFF"#?)(%#$^^T ?D!5B@ HHHH **** "BBB@ HHHH ****
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M==2^=+I:R+Y!;_OG<%]@>0,'(XK0L/!%GI_CG4/%L=]>/>WT?E31.4\K8 H
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MPIW.N.AYZ>].TGQ78:KK%UHYBN;/5;9!+)9W2!7V'HZE259<\9!- &[7)Q^
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MB#3%HW!_A;&#^.".HKOZ* .8L?!<$>FW=GK&IW^MBY@:V=[YP2L1ZJH4#&<
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MVMO&(XHUZ*H& *Q7\'P#4M3N[74M0M%U0AKR&%TVR,%"Y!92R$J,?*1[8/-
M')>&?&&H^+)O"VFWDKVQO-+EOKQX#Y;3LDGE!5(Y4$Y<[<'IVSG-\4W^HMX;
M^(?AV[O;F:+28(I[6YWXD:.52WE.P^\ 01SR1US7H5[X.TRX_LI[0RZ=<:2-
MEE-:;08T(VE,,"&4@#((_6EE\'Z;<Z1J]A=-/.=7!%[<NP$LGRA1R  -H
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MPVIM A,?EM&2&.0$SDD Y!_2@#S32Y+_ $K]GNZU6PU6]@O$2>19/,#X(N)
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M.DCUBUM]3U.ST[5B[7-C!(GE;W'S,N4++GK@'!],<4 =)HG_ " -._Z]8O\
MT$5?JMI]DFG:=;V4<DLB01B-6E;<Q X&35F@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE?'&M7&EV^C6=M*T
M$FK:I#8-.OWHD;)8KG^(A<#TSGM0!?'B-3XU_P"$:-E,LGV$WHN&9=C*'"8
M!)ZGOCI6W7G0LTTOXQNT=[,(SX;D<-=S-*(B)UR=SDG'&<$^M4],U/4(/$7@
MH1ZAJ%U;ZFEPEU=3R$17I$)<21Q,3L&1D8"\'H10!Z;%<0S231QR*SPN$D /
MW&VAL'\&!_&I*\ATV\?POX<^(.LVLUPUQ:ZS/%&9[AY%7<(5#L"2"1NSD@G
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MR;=/^0A;>5ORX^[R<XQS]15J_BU7PSXU\.30ZW?WUKJ\[VMW:73AD!\LN'C
M V8VG(':@#T*BO*9=7U"VD\-WUKJM[??:]>%I<7P<K:W$;M(-B1%B,*  & '
M*Y!.35S5=;N=*\430^(&U.RM9]0B.GZK;3,UIY8*?N)54X4DAE)8<[CR * /
M2J1B50D*6(&0HQD^W-><M)K_ (N'B(:7=BTNK+4)+.TD%_)$(#&%P6B5"KAC
MDG=G(.!C%7=.U"\\0>,+K1;^\9$TS3;:246,[Q+<3R@EG#J0Q0   =/FR>V
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MB:X5U"VX"Y!(/)R>.*\ZU-/%.E:;X6L;_P 0L;R37$LII;1PV^%E=E#DJ"7
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MK4TM;RZ^V>1'=$)#+O#ED&.,D9P<CTQ77Q1"&%(E+%44*"[%B<>I/)/O3Z*
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MO^$GTB2_^R-:%+F:W,3.'(,;E2<CCM6J]U!%<PVSRJ)I@QC3NP7&3^&1^8H
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M4&6=N@H J:/I,6BZ1#IMO//)%"NV-YBI<#W( S]3SZUA6WP^TVUTS6=.CO\
M4?LNL/))=QF1,%I/OE?D^7(XXXKK:* .>?PA:27&B3M?7QDT8$6AW)W78=WR
M<_+Q_P#7YK.L1%XN\3V&LS:'?62:.)TBDU"#RI'E?"_*,G*A0QSZLN.AKLJ*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KE?&^KS:;'H=I'.UNFIZI#933J=K(C!F(4]BVT+GJ-QQSBNJK
M,U_0-.\3:1+IFJ0>;;2$-PQ5D8<AE(Y!'K0!SNL6$GA_3O$-R/%EQ8VMQ;*T
M N-UPUDP^5G0LQ9MQ9?E[$\=:HZ1-?)\1I]($FI6MA<:$+D0W-V99%D$NSS/
MF+;"0>@/8$\UN+X#T=M O=(NY+Z_BO45)Y[RZ>69@IR@#D\!3R .,\]S2P>$
M-*TS5(=<,NISWMM;&W,LES),TB9W891G=@\@8QWQF@#S5)-<B^#MAXWC\1ZJ
M^K68$WER7!,,R^<5*.G1L@]3D] ,# '<QR7,OQ:O-.EO+LV4V@K/]G\YE6-V
MF*DKM(VG '(Y]ZS_ (<>%_,\ :1::PFHQ_9W,LFG7:&-!()"RDAE#$9PV,E<
M]J[%?#UHOB=O$(EN/MS6XM3EQL\H-N"[<?WCG/7WH \X\)1Q6/PBTZ1-5N[%
M[F_,)\N221YO]*<>3$N[Y&<9&Y<'J3TS6[X<N[W_ (2+QKID[7*6MM#;2V]O
M<7!G:'S(G+#<2>NT' ) .<5IGX<Z"=*?35^VI +H7<&VZ?-M(&+ Q<_)RS'\
M?I5NU\%Z79ZA?7\$U\MU?0+#<2-=,Y<*" QW9!;!(R>G;% ' VMQ=VGP>\#3
MVE[<6S&[L8G$,A42(TH!5L=1CM71>-GD@NQIVEW5]-XAUA]MG$E[-'%:1JH#
MRLJ,!M7!;D<L<<UL'P+I1\/Z?H?G7@L;"5)K=1*-RLARGS8R0#R,_P"%3?\
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MD$@ECC\[Y@0^\?-C. W/_P!:M"3PY:R^(;77)+BY:^MH3 C;P%*'!8%0,')
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MVP(6)@5\PC_6=<?/D8Z 5Z=-X=M9O$D6O&:X6]B@-LFUQL$9()7;CN0#GK5
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M/<C8W(V.JG XH XNQNKSQ1X+U_7?[2O;34H+B[%KY-PR+;>23L0H#M;A06W
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M-+\TD"-*"J$DDL5!'+<G(KI+SX>:%=Z3I=@/ML!TH8LKJ&Z=9X!@ A7SG!
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METQ[FXGM]/U>2&V^T2M(R1E$8+N8DD L<9-=I0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ%<&34(!#>(MS(D<X"[070$ L!P#C]:?;^"](M;G2;B(70ETJ-HK1FN7;8K
M!@<GYL@ <]@,8Q70T4 <XW@G2&LM7M,W8CU:3S;LBY<,S\?,#GY3\H''&!BN
MA1!'&J+G:H &3D_F:=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<!\6IY++PW8W<-_=63#4K
M>.22"Z>']VS88,58<8]:[^N%^*=M=7V@6%M965U=S+J5O.R6\+/A$;+$X&.G
M:@#+UG5X;/Q/X<@\(:W-J%W<7JQWMBM^UW&;7!WR-N9O+V\8((SGO7IU>:>.
M[&Y\72:-%H.E7L.I6]]'-_:DULUN+6,9W?,X#-GCY0"#7=PZF\NN7.FG3[Q$
M@A247;H!#(6)^56SRPQR* -"O(?CM?W^DV&A7.G:E?V4DU[Y,IMKN2(,F,X(
M5@/QKUZO)?CCI&IZ[8:):Z7IEY?207GG2B&!F"IC')QC\* (].UC4K3XZ+H.
MAZE=ZCH+6OF7L<URURMJ^UCP[$E>0G&?XB/IV,/Q%T2>>VV"Y^PW5\=/@U J
MOD23C^$'=NP2" VW!(ZUT$5K;/ILD5G"+6.9"!MA\LC(QG;@$'ZUXY\/?#D]
MA8CPMXE\):G<W5C?&:UN2[_8L9R) V[:",L> 20?7- ';ZA\5-#TW5=7TN6S
MU22^TM0\L$%N)&=>#E<-TP023@ =>>*Y3Q;XEO\ 6OB5X8T&)-6MM)O[&29X
M82L4LIDB?#_>_@X.&Z%3P>*T_"^E7]O\<?%6K3Z==Q65W D=O<O P1RHC# '
M'^R?KBE\1Z;J$WQW\,:M%I]Y)IUG:213W*0,41F64 9 Y^\O(Z9H UH?&>D^
M&K2\TD2:KJZZ!#&-1OODD,6[.-Y+ LV 2=H. .>:O:W\1-!T$:++=//):ZP0
M+6ZA4-'SMY;D$## ]*\]F\-:QH8^)6GG3KV[?Q ?,TZ6"!I%EWF3*LP&$*[Q
MG<1T)IFN^#M8T_2_AGIHL+F];2+I9K]H(FD6)=Z,PR!SC##CTH [>Y^*FC66
M@76M76FZQ!:6M[]BD$UJ$??C(.UF!P?S]0*E3XG:2VOC16T[5TOI;<7-K&UJ
M,W2'IL&[(Z'[P4#!SC%9OQKTO4-;\ ?8=+L;F\NI+J-Q'#$6.!G)/I^-9DVG
M:C)\;O#FM+IE]_9MOI @FN/LS[4D*R?*>,_Q+],T =7I?Q*\/ZGX3U#Q&7N+
M2ST^1HKI+F/$D;C'RX4G))8 8/>IM+\>:9J?B1=!-M=VE]+:K>0"<1E9XCT9
M61V'X'%>:^&=-\1:-\/_ !LD?AJ6YOKF^,UM9WMJ66:-B!NV,,-@9.WV'%2^
M&]%UZ+XJ^'=:NM#U=+=M)$,\UP%.R7#!LA6VQKD\*,8&,+VH ZV?XOZ%!!K$
MO]FZQ)_8\PAO1';J?*.XKDG?MQD8ZY] >:Z&\\9:5:V6CW$;2W+ZSM^P00J/
M,GW*&R Q   ())(Q7D \/:X=!^*$/]BZCYFKWJRV*FV?,Z^<YR..."#SBK^K
M:'XBT[3/ASXCL-)O+N70K9(+VP2,^<ORJK84\GHP_(]* /0+;XE^'[CPS<:Z
M6N88K>Z-G);R1CSO/XQ&%!(+'(Z''OP:U]'\2V>L:CJ&FK%/:ZAI[(+FUN N
M]0Z[E8%692"/0_6O/_B1I.J^+? ]M?:'H5W:SVFHI?"SF0133@*0S;5.0V2.
MIW'!]L]5X.@L;JXGUJW\.:CI=U<1*D\NI,_G2$?PX9B2!CJ<=L=\ '/?%+QC
MJ=AK>@^$-#N#:7VL3(LMVHRT,3.$&WW)W<]MO'7CJ;GP7;C27@TW4M3L[X1D
M1WOVV5WWX^\X9B'YZ@CZ8KF?B=X*U/4]<T+Q;H4(N=0T>5&DM"P4SQJX<!2>
M,@[N.^?;!@^)5]J_B+PM;1^%+;Q%;ZR;A#L2"XM2B8.X,V%3KCN?:@#KKGQ'
M;^&;;0M)OA-=ZO>HL,5M 0SRLJC>V6(  [DD4R+XA>'W\/:GK4T\EM#I<K07
ML,J?O890VW85!.220!@D'UKD-6\+ZII_C;P-XD>&[N[?3[4VM^%+W$L3E&^<
M@;F8%G.2,]*R;+0/$>E^'?B!KEOH0N[C6]0,EGIUW ')B\UCYC1-U.'R%(S\
MO2@#T;2_'.FZKXC?P\UO=VE^;474:S;"LT3?Q(T;L._J#7+?!S4;^^G\6Q7M
M_=W:6VJM%#]IG>4QH"V "Q.!Q6)X9T;7+?XL:/K5UHFKI:R:0(IIKD*Q63!W
M;MK$(,]$&,#&%'2M#X;Q:GX7MO&E_>Z%JC&6_>[MX$MCYEPA)QL!QD\].M '
MKE<C\3)9(? EVT4LD3&XM5W1N5.#<1@C(YY!(KJX9#-!'(8WC+J&V.,,N1T/
MO7)?%#_D0KK_ *^K/_TIBH ROB=;?V-X'B;2[F]LG2^@0/;W<J-AY &!(;)R
M#WI?'5GKNGZIH][X6NKIKV%9I7LI;J1XKM$"YC*EB-Q!.#C.?S%KXK6MW?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW
M7M$MO$6CRZ9=O+'#(T;EH2 P*.KJ1D$=5':M*B@"O9V\EK;B*6\GNW!)\V<(
M&/M\BJ/TJQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+%X;C7Q)'KD^H7
MMS<Q120PI+Y82-'920 J G[HZDUM44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV^]Y?&Y03SC./:D'A1!XV;Q3_:-S]J-K]C\G:GE^3OWX^[G.>^: .@55484
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M_1YKJ=/T:6TU&6^NM4N[^9HA%&)EC58ESD[0BCECC).?NBJ<?A1(_&DOB?\
MM&Y-U);"T,)5/+\H-N ^[G.>^: '>++Y[#0VM[02+=7T@MH?(C+.I?)=U4<D
MJ@=_^ UQOA2:V\+_ !*O-#M;6XM-(UN 75E'/ T02XB4+(JA@,Y4!C]*[R?1
M6N/$5KJ[7\X^S1/'';;4\OY\;FZ9W?*!G/ SZFJ7B;PG%XENM+N7U"ZLYM-N
M/M$#VP3._IR64\8ZCH: ,/5O^2W^'?\ L%77_H0HT#_DL_C#_KRLO_06K;N/
M"8N?%MEXC?5+H75G UND:I'Y95OO9&W.3]:KKX+DA\3:AKUMX@U"WN[]$CF5
M(X2FU!A0 R'&.>_>@#0\6:+9^)/#EWH]W=-;+<; LR-AHWW@QL/^!@?7I7&V
M'B#Q'X<U[2M#\<6<-[#<7(AT[6[7@-,0559$_A8@D9]^_)KJ)?"/VK3[VWO-
M:U*>>ZFAE-WF-)(A$X=%3:H4 ,">G\1J23PP]]?6,^K:I/?QV$PN+>%HDC7S
M0"%=]H&XC)QC SSCI0!J:Q_R!+__ *]I/_037"_#=]<'POT46]OIS0?9/E,D
M[AB,GJ A'ZUWNHVC7^GSV@G>#SD,9D0 L 1@XR",UEZ%X9'A_P +Q:#::C<M
M##&8X9I%0R(I)]%P>O<4 >;:5_R:Q)_V#[C_ -&O7<Z,/$)T[PZ&_L\Z>8X_
MM(0-O\OR3CKQ][;FHX/A[;6_@)_!R:K>_P!G,C1[RL?FA&8L1G;CJ3VJZ?"M
MTVE1Z8WB/4OLBQK$RK' K/& !M+"/(R!@D8- ',:[<ZA:_&A+C2K**^ND\,2
M,D$DYBWXGS@-M;DG YP.>HJ]\+K:WNM/U+Q.+OS[_6KGS+R,1^6+9TR/)VDD
M@KD@D]>#6XWA-&\:1^)QJ-RMS':FS6 *GE>5NW8^[G.>^:6W\)0V'B.^UG3;
M^ZLS?X:ZM4"&&20<>9M*Y#'N01GO0!R'@+^V\>-O[).GY_X22^V_:@_W_E_N
M]NE=+XJ\X?"G7!<\7/\ 8L_G#C[_ ))+9QWSFC1_!4NA'4#8>(=03[?>27LX
M:*!OWKXW$9CX' XJKXJMX]&^'>MZ8UQ>WU[?65V%D:$R23RNC8!V+@=54# &
M !VH Z70O^1>TW_KUB_] %:%4=%1H]!TY'4JRVT8*D8(.T<5>H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUU)3!8@FYDDC>-8L=0Q<#!'<=15G2O$VDZU<O;65RQN$B2<Q2PO$YC;[K@.
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M#[XQS[A7+^)/!R>(-9L]0EDM)TMH7B%EJ%H+FW)8@[PNY</QC//':@#RR_\
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M7$PQ'G^]@9QUJCHC>&;CXB>-Y]:CTV6*6>V^S27D:,K@18;86&#R,'%>LT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNC;3);DEU7)*G@@>A.>O;]: .NHKD&UF_CUK1_#$5S";RYM'NY[KR<>7$N%
M5<D;B6ZDD  \<U/X:\07MWK^N>'M4$37NE/$RW$2E5GAD4LAVY.&&"#V]* .
MH)P,GI6:^O:<GB"/0FF8:C)"TZQ>6V"@P"=V-O<=ZYSXISWUMX,:2QO/LQ-U
M;QR83)='E12N<\#GGUZ51UB+4O\ A:6@1075N+PZ3=@W$D)*+\\?(0-S]-P]
M?:@#M]5U2UT72Y]1O6=;:!0SF.-G8#('"J"3UJV"&4$=",UYI<^-?$%M\-O$
M.J;[%M5T2^FLGD,#>7,$<+N"[OE)# ]2,BM?Q+XN.C>(;?3KN^CTFVN+426U
M]<0%X99]Q!C=L@*  #U&=W48Y .UHJO8M.^GVS7)0W#1*93&<KNP,X]LU8H
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M85TE% %#1-*CT/0K#2HI7ECL[=(%DD^\P4 9/Y5?HHH **** "BBB@ HHHH
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M=J ,7XS?\DDU[_<B_P#1R5F7IF\8_$K2--NH!I+>'BNHA)G#3788 #R]OR[
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MB\9*GO@D ]QD9ZC-JN%^(\\VB^'-*U=)WENM,U*W?S6 #2*S>6ZG: ,,KD$
M5W5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672369806784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,323,701,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,951,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366096192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364592272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 179,911<span></span>
</td>
<td class="nump">$ 325,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">451,505<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">36,615<span></span>
</td>
<td class="nump">18,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">56,676<span></span>
</td>
<td class="nump">50,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,040<span></span>
</td>
<td class="nump">10,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">742,047<span></span>
</td>
<td class="nump">852,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">36,432<span></span>
</td>
<td class="nump">41,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">32,593<span></span>
</td>
<td class="nump">39,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">456,984<span></span>
</td>
<td class="nump">410,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">462,261<span></span>
</td>
<td class="nump">409,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">13,274<span></span>
</td>
<td class="nump">10,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,746,013<span></span>
</td>
<td class="nump">1,767,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,062<span></span>
</td>
<td class="nump">12,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">45,708<span></span>
</td>
<td class="nump">32,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">16,342<span></span>
</td>
<td class="nump">30,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">9,591<span></span>
</td>
<td class="nump">8,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">8,326<span></span>
</td>
<td class="nump">7,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">95,029<span></span>
</td>
<td class="nump">263,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, non-current</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">31,606<span></span>
</td>
<td class="nump">41,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="nump">892,243<span></span>
</td>
<td class="nump">896,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,044,709<span></span>
</td>
<td class="nump">1,204,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized 50,000 shares; No shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized 1,000,000 shares; issued and outstanding 267,744 and 226,505 shares at December&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,539,892<span></span>
</td>
<td class="nump">2,099,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">219<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,839,075)<span></span>
</td>
<td class="num">(1,532,340)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">701,304<span></span>
</td>
<td class="nump">562,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,746,013<span></span>
</td>
<td class="nump">$ 1,767,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364603248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672369810384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
<td class="nump">$ 130,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">733<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContracts', window );">Loss on purchase commitment</a></td>
<td class="nump">3,436<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">147,741<span></span>
</td>
<td class="nump">79,269<span></span>
</td>
<td class="nump">71,653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">52,780<span></span>
</td>
<td class="nump">49,035<span></span>
</td>
<td class="nump">58,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">187,170<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="nump">112,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">169,818<span></span>
</td>
<td class="nump">160,854<span></span>
</td>
<td class="nump">124,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="nump">9,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">15,060<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">6,157<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">387,247<span></span>
</td>
<td class="nump">356,231<span></span>
</td>
<td class="nump">269,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(334,467)<span></span>
</td>
<td class="num">(307,196)<span></span>
</td>
<td class="num">(210,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss from Continuation Advances from Illumina</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(2,033)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(14,343)<span></span>
</td>
<td class="num">(14,690)<span></span>
</td>
<td class="num">(12,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(318,159)<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
<td class="num">(274,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,649)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(306,735)<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
<td class="num">(181,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="num">(3,678)<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (301,751)<span></span>
</td>
<td class="num">$ (317,926)<span></span>
</td>
<td class="num">$ (182,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeLossPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Earnings Per Share, Basic, Other Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">224,550<span></span>
</td>
<td class="nump">204,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">224,550<span></span>
</td>
<td class="nump">204,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 183,872<span></span>
</td>
<td class="nump">$ 108,699<span></span>
</td>
<td class="nump">$ 113,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of product revenue</a></td>
<td class="nump">127,568<span></span>
</td>
<td class="nump">60,932<span></span>
</td>
<td class="nump">56,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">16,649<span></span>
</td>
<td class="nump">19,605<span></span>
</td>
<td class="nump">17,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostOfOperatingRevenue', window );">Cost of service and other revenue</a></td>
<td class="nump">$ 14,754<span></span>
</td>
<td class="nump">$ 13,899<span></span>
</td>
<td class="nump">$ 14,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Losses recognized in the current period on contracts which are expected to generate losses, which are probable and can be reasonably estimated, in a future period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 605<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481187/605-35-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostOfOperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other costs incurred during the reporting period related to other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostOfOperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672369895280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 335,491<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 1,372,083<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="num">$ (1,036,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(181,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(1,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">31,806<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">31,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs</a></td>
<td class="nump">294,845<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">294,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition</a></td>
<td class="nump">237,885<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">237,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">73,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">790,987<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">2,009,945<span></span>
</td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">(1,218,092)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(314,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(314,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(3,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">11,230<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">11,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">78,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 562,904<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">2,099,782<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
<td class="num">(1,532,340)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">226,505,000<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">15,319<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">15,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs</a></td>
<td class="nump">189,200<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">189,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition</a></td>
<td class="nump">76,642<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">76,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 72,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock following milestone achievement (in shares)</a></td>
<td class="nump">8,988,391<span></span>
</td>
<td class="nump">8,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock following milestone achievement</a></td>
<td class="nump">$ 84,761<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">84,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with liquidity event bonus plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 701,304<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 2,539,892<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="num">$ (1,839,075)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">267,744,000<span></span>
</td>
<td class="nump">267,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363029936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
<td class="num">$ (181,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss (gain) from Continuation Advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">9,480<span></span>
</td>
<td class="nump">7,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense', window );">Amortization of intangible assets</a></td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">6,810<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
<td class="nump">4,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">72,118<span></span>
</td>
<td class="nump">78,613<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Merger-related compensation expense</a></td>
<td class="nump">3,395<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium and accretion of discount on marketable securities, net</a></td>
<td class="num">(12,840)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="nump">4,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">15,060<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">10,584<span></span>
</td>
<td class="nump">6,027<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(17,829)<span></span>
</td>
<td class="nump">5,455<span></span>
</td>
<td class="num">(7,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(13,841)<span></span>
</td>
<td class="num">(33,906)<span></span>
</td>
<td class="num">(13,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(8,984)<span></span>
</td>
<td class="num">(12,324)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">6,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">13,103<span></span>
</td>
<td class="num">(3,651)<span></span>
</td>
<td class="nump">15,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Deferred revenue</a></td>
<td class="num">(10,420)<span></span>
</td>
<td class="num">(3,734)<span></span>
</td>
<td class="nump">25,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liabilities</a></td>
<td class="num">(8,759)<span></span>
</td>
<td class="num">(7,724)<span></span>
</td>
<td class="num">(4,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncreaseDecreaseInContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="num">(14,882)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(259,173)<span></span>
</td>
<td class="num">(263,211)<span></span>
</td>
<td class="num">(111,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(8,843)<span></span>
</td>
<td class="num">(16,750)<span></span>
</td>
<td class="num">(5,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(179)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(756,567)<span></span>
</td>
<td class="num">(442,788)<span></span>
</td>
<td class="num">(988,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">212,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">769,521<span></span>
</td>
<td class="nump">575,800<span></span>
</td>
<td class="nump">422,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) in investing activities</a></td>
<td class="nump">4,604<span></span>
</td>
<td class="nump">116,083<span></span>
</td>
<td class="num">(678,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProceedsFromRepaymentsOfContractTermination', window );">Continuation Advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Senior Notes, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">895,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts', window );">Proceeds from issuance of common stock under equity offerings, net of issuance costs</a></td>
<td class="nump">189,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">294,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock from equity plans</a></td>
<td class="nump">15,319<span></span>
</td>
<td class="nump">11,230<span></span>
</td>
<td class="nump">31,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(7,375)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(86,411)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes payable principal payoff</a></td>
<td class="num">(1,842)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">108,891<span></span>
</td>
<td class="nump">9,622<span></span>
</td>
<td class="nump">1,169,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(145,678)<span></span>
</td>
<td class="num">(137,506)<span></span>
</td>
<td class="nump">379,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">328,311<span></span>
</td>
<td class="nump">465,817<span></span>
</td>
<td class="nump">85,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">182,633<span></span>
</td>
<td class="nump">328,311<span></span>
</td>
<td class="nump">465,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">179,911<span></span>
</td>
<td class="nump">325,089<span></span>
</td>
<td class="nump">460,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash at end of period</a></td>
<td class="nump">2,722<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">5,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">14,049<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible Senior Notes exchange</a></td>
<td class="nump">441,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_LiquidityBonusEventMember', window );">Liquidity Bonus Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_MilestoneAchievementMember', window );">Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">84,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for purchase of business acquisition, net of cash acquired</a></td>
<td class="num">(102)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(319,793)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember', window );">Apton And Omniome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_TransferOfInventoryToPropertyAndEquipment', window );">Inventory transferred to property and equipment</a></td>
<td class="nump">3,984<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property and equipment transferred to inventory</a></td>
<td class="num">(7,022)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and liability additions and modifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember', window );">Apton And Omniome | Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">$ 76,642<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 237,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) and research development expense in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncreaseDecreaseInContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncreaseDecreaseInContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock under equity offerings, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromRepaymentsOfContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (Repayments of) Contract Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromRepaymentsOfContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_TransferOfInventoryToPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of Inventory to Property and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_TransferOfInventoryToPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTransfersAndChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_LiquidityBonusEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_LiquidityBonusEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonAndOmniomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368558016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB</span><span style="background-color:#ffffff;color:#333333;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on creating some of the world's most advanced sequencing systems to provide our customers the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the fair value of contingent consideration, the valuation of acquired intangible assets, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2023. Actual results could differ materially from these estimates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Functional Currency</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2023, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. For the years ended December&#160;31, 2022 and 2021, one customer accounted for approximately 12%, and 13% of our total revenue, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, 49% and 57% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2023, one customer represented approximately 10% of our net accounts receivable. As of December&#160;31, 2022, one customer represented approximately 10% of our net accounts receivable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory, Net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense in our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, and Other Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and capitalized in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill in the second quarter of each year, or more frequently if indicators of potential impairment exist. We generally perform annual impairment testing of IPR&amp;D in the fourth quarter of each year, or more frequently if indicators of potential impairment exist.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale debt securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of COVID-19 or other epidemics or pandemics, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP")  based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_118" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 10. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires entities to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. This authoritative guidance will be effective for us in fiscal year 2025, with early adoption permitted. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364882448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS ACQUISITIONS</a></td>
<td class="text">BUSINESS ACQUISITIONS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apton Biosystems</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, we acquired Apton Biosystems, Inc. (&#8220;Apton&#8221;), a California-based genomics company focused on developing a high throughput short-read sequencer using highly differentiated optics and image processing, paired with novel clustering and chemistry (the &#8220;Apton acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, all outstanding equity securities of Apton were cancelled in exchange for shares of our common stock with a fair value of $76.6 million, cash of $0.2 million, and contingent consideration with a preliminary estimated fair value of $18.5 million. Excluded from consideration transferred was $1.3 million attributable to accelerated share-based compensation expense. The fair value of the 6,121,571 common shares issued was determined based on the closing market price of our common stock on the acquisition date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Apton acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the 5-year anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the twenty trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on preliminary estimates of their respective fair values at the date of the completion of the Apton acquisition, and such allocation is subject to adjustment for up to one year after the close of the acquisition as additional </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information is obtained. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred, based on the preliminary estimated fair values were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation is preliminary, primarily due to the pending finalization of review of various tax attributes. We continue to collect information regarding certain estimates and assumptions, including potential liabilities and contingencies. We will record adjustments to the fair value of the assets acquired, liabilities assumed and goodwill within the twelve months measurement period, if necessary. During the year ended December&#160;31, 2023, we recorded a measurement period adjustment of $1.6&#160;million to decrease goodwill, and a corresponding $2.0&#160;million increase in intangible assets and $0.4&#160;million decrease in the deferred tax liability on the consolidated balance sheets, and a $0.7&#160;million increase to our benefit from income taxes on the consolidated statements of operations and comprehensive loss. The measurement period adjustment was due to new information that became available to us upon the completion of the valuation assessment of the in-process research and development and the tax provision.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred costs related to the Apton acquisition of approximately $9.0&#160;million during the year ended December&#160;31, 2023, which are included in merger-related expenses on the consolidated statement of operations and comprehensive loss. Merger-related expenses include $2.8&#160;million relating to a liquidity event bonus plan that was treated as a separate transaction and included the issuance of 168,621 shares of common stock that were issued with a fair value of $2.1&#160;million based on the closing market price of our common stock on the acquisition date. As a result, the total shares issued in connection with the Apton acquisition were 6.3&#160;million shares of common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $52.3&#160;million, based on preliminary estimates, which is primarily attributable to the synergies expected to occur from the integration of Apton and is not deductible for income tax purposes. We preliminarily allocated $55.0 million of the purchase price to acquired in-process research and development ("IPR&amp;D"). The fair value of the IPR&amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as assumed revenue projections and discount rate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omniome, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021, we completed our acquisition of Omniome, Inc. (&#8220;Omniome&#8221;), a San Diego-based company, to obtain their proprietary short-read DNA sequencing platform capable of delivering high accuracy (the &#8220;Omniome acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Omniome acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $315.7&#160;million in cash, 8,911,580 shares of our common stock with a fair value of $249.4&#160;million and contingent consideration with a fair value of $168.6&#160;million. The fair value of the 8,911,580 common shares issued was determined based on the closing market price of PacBio&#8217;s common shares on the acquisition date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, approximately $18.9&#160;million, comprised of $7.4&#160;million of cash, 226,811 shares of our common stock with a fair value of $6.3&#160;million, and $5.2&#160;million related to contingent consideration, was accounted for as a one-time post-acquisition share-based compensation expense. This share-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition the contingent consideration of $200&#160;million (composed of $100&#160;million in cash and $100&#160;million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $100&#160;million in shares of our common stock to be issued as part of the milestone, $4.1&#160;million was attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction. Upon achievement of the milestone, shares will be issued not in excess of an amount equal to 19.9% of our outstanding shares of common stock on the date of closing (prior to the issuance of any shares issued in connection with the transaction or the related private placement), less 11,500,000 shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive Loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a scenario-based method that considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio&#8217;s credit spread. On September 20, 2023, we achieved the commercial milestone in connection with the acquisition of Omniome. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_103" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i02b9487756a44f62beca493d5cd6fd6a_103" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5. Financial Instruments</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on amounts paid and shares issued to former Omniome securityholders during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition is as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash paid</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of share consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Share-based compensation expense excluded from consideration transferred</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. As of December&#160;31, 2021, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we recorded a measurement period adjustment of $1.6&#160;million to decrease goodwill and a corresponding $0.4&#160;million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $1.2&#160;million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to Note 9 &#8211; Income Taxes, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2021 for more information. There were no measurement period adjustments recorded in the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred costs related to the Omniome acquisition of approximately $12.0&#160;million during the twelve months ended December&#160;31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income. No significant merger-related costs were incurred during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of 2020, giving effect on a pro forma basis to the purchase accounting adjustments such as $12.0&#160;million of PacBio acquisition-related costs, $18.9&#160;million of share-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $91.0&#160;million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $16.7&#160;million of Omniome&#8217;s acquisition-related costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of 2020 or the results of future operations of the combined business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the unaudited pro forma financial information:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma total revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma net (loss) income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(278,451)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma net (loss) income per share - basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.27)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Revenues of $0 and a net loss of $15.6&#160;million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Circulomics, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, we acquired Circulomics Inc. (&#8220;Circulomics&#8221;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows (the &#8220;Circulomics acquisition&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $29.5&#160;million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the Circulomics acquisition. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $19.3&#160;million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes. We recorded $11.4&#160;million for the fair value of acquired intangible assets, which consists of developed technology and customer relationships.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672371659856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVITAE COLLABORATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SignificantAgreementsAbstract', window );"><strong>Invitae Collaboration Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_InvitaeCollaborationTextBlock', window );">INVITAE COLLABORATION</a></td>
<td class="text">INVITAE COLLABORATION<div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Invitae Corporation (&#8220;Invitae&#8221;). The Amended and Restated Agreement amended and restated the existing Development and Commercialization Agreement, effective as of January 12, 2021, as amended by Amendment No. 1 to Development and Commercialization Agreement, entered into on June 3, 2021, by and between us and Invitae (together, the &#8220;Original Agreement&#8221;). Unless otherwise agreed in writing or terminated in accordance with the Amended and Restated Agreement, the term of the Amended and Restated Agreement shall continue until June 30, 2028 (&#8220;Term&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Original Agreement, Invitae provided certain funding to us to develop products relating to production-scale high-throughput sequencing (&#8220;Program Products&#8221;). If Program Products were to become commercially available, Invitae had the right to purchase the Program Products at preferred pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended and Restated Agreement, we will continue to receive feedback, input and insight from Invitae in connection with the intended development of our new sequencing systems; however, such feedback will not be contractually required, and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. Our development plans for such new sequencing systems will be at our discretion and pursuant to our own internal processes and programs. Invitae will not be contractually obligated to reimburse us for development costs under the Amended and Restated Agreement. There can be no assurances that the in-development sequencing systems will continue to be developed, be successfully developed or become available for commercial sale.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the non-refundable payments received from Invitae pursuant to the Original Agreement of $23.5 million, we will provide Invitae with credits in connection with Invitae&#8217;s anticipated purchase of certain currently sequencing systems (instruments, consumables and service contracts). The credits will expire on June 30, 2025 (&#8220;Credit Expiration Date&#8221;). Subject to certain conditions, Invitae will also be entitled to most favored pricing for the Company&#8217;s Sequel IIe systems and certain in-development systems through the Term. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Invitae may terminate the Amended and Restated Agreement if the other party remains in material breach of the Amended and Restated Agreement following a cure period to remedy the material breach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated Agreement was deemed a contract modification and accounted for on a prospective basis in accordance with ASC Topic 606. We will recognize proportionate amounts of the transaction price, including payments made by Invitae to us pursuant to the Original Agreement, in revenue as the remaining performance obligations are s</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atisfied, which is when Invitae places purchase orders for certain sequencing platforms and the associated goods or services are delivered. Any remaining unused credits will be recognized when they expire.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invitae purchased certain instruments and consumables under the terms of the Amended and Restated Agreement, for which $10.5 million and $3.7 million of revenue was recognized as product revenue during the years ended December&#160;31, 2023 and 2022, respectively, on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, $8.0 million of deferred revenue, current, and $2.9 million of deferred revenue, non-current, is recorded on the consolidated balance sheet relating to all future performance obligations under the Amended and Restated Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_InvitaeCollaborationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and Commercialization Of Significant Agreements Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_InvitaeCollaborationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SignificantAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and Commercialization Of Significant Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SignificantAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672371663376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TERMINATION OF MERGER WITH ILLUMINA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerTerminationAbstract', window );"><strong>Termination of Merger with Illumina [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerTerminationTextBlock', window );">TERMINATION OF MERGER WITH ILLUMINA</a></td>
<td class="text">TERMINATION OF MERGER WITH ILLUMINA<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the &#8220;Illumina Merger Agreement&#8221;) with Illumina, Inc. (&#8220;Illumina&#8221;) and FC Ops Corp., a wholly owned subsidiary of Illumina (&#8220;Illumina Merger Sub&#8221;). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the &#8220;Termination Agreement&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Continuation Advances from Illumina</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Termination Agreement, Illumina paid us cash payments (&#8220;Continuation Advances&#8221;) totaling $52 million. Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March&#160;31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February&#160;15, 2028, $52.0&#160;million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-operating expense in the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerTerminationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Termination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerTerminationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerTerminationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerTerminationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366846976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Omniome acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Apton acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities measured at fair value </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration, which was incurred in connection with the acquisition of Apton, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the 5-year anniversary of the closing date of the acquisition. As of December 31, 2023, the key input used in the determination of the fair value included projected revenues of the Company relating to the high-throughput short-read products and services leveraging Apton's technology. A decrease in the projected revenues would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- credit rating, which ranges from 7.8% to 8.2%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2023, we achieved the commercial milestone in connection with the acquisition of Omniome. Consequently, former Omniome securityholders were entitled to receive as milestone consideration, among other things, an aggregate of approximately $100.9&#160;million in cash and approximately 9.0&#160;million shares of our common stock, representing $95.9&#160;million divided by the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that was two days </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediately prior to the achievement of the milestone. The $95.9&#160;million represents the $100.0&#160;million that was to be paid in shares of our common stock offset by $4.1&#160;million attributable to stock options issued by PacBio in replacement of Omniome&#8217;s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the achievement of the commercial milestone, $101.3&#160;million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December&#160;31, 2023. Additionally, 8,988,391 shares were issued at a value of $84.8&#160;million to the former Omniome securityholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the achievement of the milestone, the contingent consideration liability incurred in connection with the acquisition of Omniome was no longer considered a Level 3 liability at December&#160;31, 2023. There were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis for the year ended December&#160;31, 2023, and our valuation techniques did not change compared to the prior year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the year ended December&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-727">Change in estimated fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Achievement of milestone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as the Change in fair value of contingent consideration in the consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,720)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through 5 years </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net on the consolidated statement of operations and comprehensive loss was $32.8&#160;million and $9.2&#160;million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366794256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text">BALANCE SHEET COMPONENTS<span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of capitalizable costs that have been incurred for the construction of long-lived assets and is primarily comprised of amounts that will be classified as lab equipment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense during the years ended December&#160;31, 2023, 2022, and 2021 was $11.5 million, $9.5 million, and $7.2 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the goodwill balance was $462.3 million and $410.0 million, respectively. Goodwill preliminarily increased by $52.3 million, due to the Apton acquisition, of which $11.3 million relates to a deferred income tax liability. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2023, noting no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include acquired IPR&amp;D of $55.0 million as a result of the Apton acquisition in August 2023. As of December&#160;31, 2023, the research and development project had not been completed or abandoned and, therefore, the IPR&amp;D intangible asset is not currently subject to amortization. During the year ended December&#160;31, 2023, acquired IPR&amp;D of $400.0 million as a result of the Omniome acquisition in September 2021 was completed and became subject to amortization. IPR&amp;D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for IPR&amp;D impairment in the third quarter of 2023, noting no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired definite-lived intangible assets as of December&#160;31, 2023 (in thousands, except years):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated <br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,555)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangibles was $8.3 million, $0.9 million and $0.4&#160;million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. For the years ended December&#160;31, 2023,  2022, and 2021 amortization expense of intangibles in cost of revenue was $2.0&#160;million, $0.7 million, and $0.3&#160;million, respectively.  For the years ended December&#160;31, 2023, 2022, and 2021, amortization expense of intangibles in operating expenses was $6.3 million, $0.2 million, and $0.1&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The definite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional services and legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had a total of $21.9 million of deferred revenue, $16.3 million of which was recorded as deferred revenue, current and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae, as described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_97" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3. Invitae Collaboration</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as deferred service contract revenues. The deferred revenue, non-current balance of $5.6 million primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae and deferred service contract revenues and is scheduled to be recognized in the next 5 years. The deferred revenue, non-current balance includes $2.9 million that was reclassified from deferred revenue, current to deferred revenue, non-current following receipt of a non-cancellable order from Invitae during the year ended December&#160;31, 2023 for partial utilization of the available credits, which is expected to be recognized in revenue after 12 months from December&#160;31, 2023. Revenue recorded in the year ended December&#160;31, 2023 includes $18.9 million of previously deferred revenue that was included in deferred revenue, current as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#8217;s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month and before the 43</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the carrying value of term loans outstanding was $0.5 million, recorded as part of other liabilities, current on the consolidated balance sheet. The interest expense was $0.3 million for the year ended December&#160;31, 2023, which was included as part of interest expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the future principal payments remaining on term loans was the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Liabilities, Current</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities, current, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366685232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE SENIOR NOTES</a></td>
<td class="text">CONVERTIBLE SENIOR NOTES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2030 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221;) in exchange for $441.0 million principal amount of the 2028 Notes (the &#8220;Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December&#160;15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0 million in connection with the Exchange Transaction during the year ended December&#160;31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5 million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $7.3 million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our consolidated balance sheets and are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5 million on the 2028 Notes in connection with the Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the Exchange Transaction, $459.0 million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt premium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes for the years ended December&#160;31, 2023, 2022, and 2021 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the estimated fair value (Level 2) of the 2030 Notes was $410.5 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;9, 2021, we entered into an investment agreement (the &#8220;Investment Agreement&#8221;) with SB Northstar LP (the &#8220;Purchaser&#8221;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900.0 million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021. As discussed above, in June 2023 we completed an exchange of $441.0 million in aggregate principal amount of our 2028 Notes for $441.0 million aggregate principal amount of the 2030 Notes, leaving approximately $459.0 million in aggregate principal amount of 2028 Notes outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are governed by an indenture (the &#8220;2028 Indenture&#8221;) between the Company and U.S. Bank National Association, as trustee. The 2028 Notes bear interest at a rate of 1.50% per annum. Interest on the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028 Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The 2028 Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption, or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2028 Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the 2028 Notes (which is equal to an initial conversion price of $43.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2028 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 20, 2026, the 2028 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2028 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2028 Indenture), the holders of the 2028 Notes may require that we repurchase all or part of the principal amount of the 2028 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2028 Notes under the 2028 Indenture. The 2028 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2028 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2028 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2028 Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2028 Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the 2028 Notes shall be subject to acceleration as provided for in the 2028 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2028 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2028 Notes were not issued at a premium; therefore, the 2028 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2028 Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the 2028 Notes on our consolidated balance sheets and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">896,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the estimated fair value (Level 2) of the 2028 Notes was $395.4 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366761856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $18.1 million in right-of-use assets and liabilities on our consolidated balance sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 6.8%. The weighted-average remaining lease term for our operating leases as of December&#160;31, 2023 was 3.8 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $12.1 million and $11.2&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, and were included in operating cash flows. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $10.4 million and $10.5 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_28" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancellable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchase orders and contractual obligations are approximately $109.9 million as of December&#160;31, 2023, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a loss on purchase commitment of $3.4 million for the year ended December&#160;31, 2023, which was recorded as part of accrued expenses on the consolidated balance sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to a supply agreement with a third-party vendor, for which we do not expect to have related sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a long-term supply agreement, which was amended in October 2022 (the &#8220;Supply Agreement&#8221;), for the purchase of certain products with a semiconductor manufacturer (&#8220;Supplier&#8221;). The Supply Agreement provides for minimum purchase commitments through 2026 on our part in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid our Supplier a deposit of $9.0 million in November 2022 and an additional deposit of $6.0 million in 2023, for a total of $15.0 million (the &#8220;Deposit&#8221;). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. As of December&#160;31, 2023, $3.0 million related to the Deposit was included in prepaid expenses and other current assets in the consolidated balance sheets and $12.0 million related to the Deposit was included in other long-term assets in the consolidated balance sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-20/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-30/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366846976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes both in the United States and certain foreign jurisdictions in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for Global Intangible Low-taxed Income as a period cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022, and 2021 income/(loss) before taxes from U.S. operations were ($318.9) million, ($315.7) million, and ($275.4) million, respectively, and income/(loss) before taxes from foreign operations was $0.7 million, $1.8 million, and $0.8 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision (Benefit) for Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit) Provision for Income Taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,649)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory tax rate </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State tax rate, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and experimental expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of indebtedness income and interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(525,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(445,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,527)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we maintained a valuation allowance against our net deferred tax assets which totaled $525.7 million, including net operating loss carryforwards and research and development credits of $435.5 million and $83.9 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. A deferred income tax benefit of $11.4&#160;million for the year ended December&#160;31, 2023, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, the Company's valuation allowance increased to $525.7 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. For the year ended December&#160;31, 2022, the Company's valuation allowance increased to $445.6 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had a net operating loss carryforward for federal income tax purposes of approximately $1,709.3 million, of which $788.1 million is subject to expiration beginning in 2024. We had a total state net operating loss carryforward of approximately $1,171.8 million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have federal credits of approximately $57.7 million, which will begin to expire in 2024 if not utilized and state research credits of approximately $49.8 million, which have no expiration date. These tax credits are subject to the same limitations discussed above. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our total unrecognized tax benefit was $14.6 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2023 and 2022, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December&#160;31, 2020 to present and December 31, 2019 to present, respectively. In addition, all the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366810032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December&#160;31, 2023 and 2022, there were no shares of preferred stock issued or outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Underwritten Public Equity Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an underwriting agreement, relating to the public offering of 19,430,000 shares of our common stock, $0.001 par value per share, at a price to the public of $4.47 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2,914,500 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in August 2020. In total, we sold 22.3&#160;million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9&#160;million, excluding approximately $0.3&#160;million of offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into an underwriting agreement, relating to the public offering of 6,096,112 shares of our common stock, $0.001 par value per share, at a price to the public of $14.25 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 914,416 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#8217; option, closed in November 2020. In total, we sold 7.0&#160;million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deducting the underwriting discount were approximately $93.9&#160;million, excluding approximately $0.3 million of offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, for the year ended December&#160;31, 2021, we issued 29.4 million shares of our common stock through our two underwritten public offerings with an average offering price of $6.40. The total net proceeds to us from the two offerings, after deducting the underwriting commission and offering expenses, were approximately $187.2 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into an underwriting agreement, relating to the public offering of 17.5&#160;million shares of our common stock, $0.001 par value per share, at a price to the public of $10.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2.6&#160;million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold 20.1&#160;million shares of our common stock. We paid a commission equal to 5.75% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $189.7&#160;million, excluding approximately $0.5&#160;million of offering expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement of Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of 11,214,953 shares of common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300 million. The transaction closed on September&#160;20, 2021. We registered the private placement shares for resale following the closing of the merger.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) allow for the issuance of stock options, restricted units and awards, and performance-based awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2020, the Board of Directors (the &#8220;Board&#8221;) adopted the Inducement Plan and reserved 2,500,000 shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April&#160;18, 2021 and November&#160;22, 2021, the Board amended the Inducement Plan to reserve an additional 750,000 and 360,000 shares, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, was assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio&#8217;s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to 0.259204639. We reserved 2,494,128 shares of our common stock for issuance pursuant to equity awards under the Omniome Plan. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, stockholders approved an amendment to the 2020 Plan, and we reserved an additional 18,000,000 shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had 12.8&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-based stock options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,618</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,119)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(910)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,008</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based stock options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance condition was achieved during the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of the outstanding options presented in the tables above as of December&#160;31, 2023, totaled $31.8 million, and had a weighted-average remaining contractual life of 5.9 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $9.81, our closing stock price on the last trading day of our fourth quarter of 2023 and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2023. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and exercisable options as of December&#160;31, 2023, totaled 10,039,742 shares, had an aggregate intrinsic value of $30.0&#160;million, a weighted-average exercise price per share of $9.70, and a weighted-average remaining contractual life of 5.2 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested and expected to vest options as of December&#160;31, 2023, totaled 13,026,464 shares, had an aggregate intrinsic value of $31.6 million, a weighted-average exercise price per share of $10.81, and a weighted-average remaining contractual life of 5.8 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2023, 2022, and 2021 was $8.8 million, $5.0 million, and $146.1 million, respectively. The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all options granted was $7.32 in 2023, $5.93 in 2022, and $18.36 in 2021, each determined by the Black-Scholes option valuation method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Restricted Stock Unit (RSU) represents one equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs are time-based and vest over four years at a rate of 25% annually. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. The fair value of these RSUs is </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis.  RSUs that are expected to vest are net of estimated future forfeitures. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue PSUs for which the number of shares issuable in the third year of the performance period is based on performance relative to specified revenue targets and continued employment through the vesting period.  Maximum achievement of the revenue goal under the PSUs will result in up to 200% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under PSUs will result in no shares subject to the PSUs becoming eligible to vest.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the time-based RSUs and PSUs activity for the year ended December&#160;31, 2023 (shares in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units (RSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Stock Units (PSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,141</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,730)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,638)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,308</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested related to RSUs and PSUs during the years ended December&#160;31, 2023, 2022, and 2021 was $39.3 million, $39.2 million, and $9.2 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all RSUs and PSUs granted was $9.65 in 2023, $10.15 in 2022, and $35.33 in 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, a total of 29.5&#160;million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will be terminated and a new offering period will come into place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lesser of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP&#8217;s administrator. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,735,058</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, 1,878,168 shares, and 1,913,968 shares of common stock were purchased under the ESPP, respectivel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y. As of December&#160;31, 2023, 12,197,447 sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares of our common stock remain available for issuance under our ESPP.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense consists of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - stock-settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - cash-settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, $0.6 million and $0.7 million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit of share-based compensation expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Fair Value</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term &#8211; The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Volatility &#8211; The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Dividend &#8211; We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-Free Interest Rate &#8211; The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 - 4.6</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77% - 78%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 76%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67% - 80%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73% &#8211; 4.60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.41% &#8211; 3.66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05% &#8211; 1.10%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from option exercises for the years ended December&#160;31, 2023, 2022, and 2021 was $6.5 million, $3.4 million and $25.4 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESPP </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79% - 97%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 97%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67% - 68%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9% - 5.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6% - 3.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1% - 0.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received through the ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was $8.8 million, $7.8 million, and $6.4 million, respectively.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, $101.9 million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of 2.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366752272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the convertible senior notes, using the if-converted method, and outstanding equity awards using the treasury stock method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the consolidated statements of operations and comprehensive loss (in thousands, except per share amounts): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,136</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,690</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,690</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,246</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,291</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,419</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_94" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2. Business Acquisitions</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the contingently issuable shares would be due upon the achievement of a milestone. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_118" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 10. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on RSUs with time-based vesting and RSUs with performance-based vesting.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366647216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND GEOGRAPHIC INFORMATION</a></td>
<td class="text">SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East, and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363017584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
<td class="num">$ (181,223)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364615424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672371026320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the fair value of contingent consideration, the valuation of acquired intangible assets, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2023. Actual results could differ materially from these estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Functional Currency</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Restricted Cash, and Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration and Other Risks</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2023, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#8217; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. We have not experienced any significant credit losses to date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. For the years ended December&#160;31, 2022 and 2021, one customer accounted for approximately 12%, and 13% of our total revenue, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, 49% and 57% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2023, one customer represented approximately 10% of our net accounts receivable. As of December&#160;31, 2022, one customer represented approximately 10% of our net accounts receivable. </span></div>We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory, Net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#8220;FIFO&#8221;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></div>We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense in our consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill, Intangible Assets, and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, and Other Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and capitalized in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill in the second quarter of each year, or more frequently if indicators of potential impairment exist. We generally perform annual impairment testing of IPR&amp;D in the fourth quarter of each year, or more frequently if indicators of potential impairment exist.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the IPR&amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;D with the carrying value. If the carrying amount of the IPR&amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue and Shipping and Handling</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to shipping and handling are included in cost of revenues for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Credit Losses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade accounts receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#8217;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale debt securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div>Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of COVID-19 or other epidemics or pandemics, or other customer-specific factors.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. </span></div>We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP")  based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i02b9487756a44f62beca493d5cd6fd6a_118" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 10. Stockholders&#8217; Equity</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information regarding share-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div>Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Pending Adoption</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU requires entities to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. This authoritative guidance will be effective for us in fiscal year 2025, with early adoption permitted. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div>The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Standards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479391/326-20-30-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-3C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479366/326-20-35-8A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-3D<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479175/326-30-30-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479148/326-30-35-13A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479391/326-20-30-4A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479148/326-30-35-7A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-7<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-17<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -SubTopic 20<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483530/326-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366647216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Estimated Useful Lives of The Major Classes of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368567936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text">The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred, based on the preliminary estimated fair values were as follows (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Unaudited Pro Forma Financial Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the unaudited pro forma financial information:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma total revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma net (loss) income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(278,451)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pro forma net (loss) income per share - basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.27)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock', window );">Total Consideration Transferred for Acquisition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition is as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash paid</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of share consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Share-based compensation expense excluded from consideration transferred</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Major Classes of Assets and Liabilities Allocated to Total Fair Value of The Consideration Transferred</a></td>
<td class="text">As of December&#160;31, 2021, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, details of total considerations transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368569456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets measured at fair value </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Omniome acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration - Apton acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities measured at fair value </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock', window );">Changes in The Estimated Fair Value of Contingent Consideration Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the year ended December&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-727">Change in estimated fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Achievement of milestone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance as of December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,958&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,911&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,720)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and investments </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through 5 years </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in the estimated fair value of contingent consideration liabilities table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364518912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,381&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Definite-Lived Intangible Assets from Business Acquisitions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired definite-lived intangible assets as of December&#160;31, 2023 (in thousands, except years):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated <br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,555)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchase commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional services and legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Changes in Reserve for Product Warranties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Future Principal Payments , Fiscal Year Maturity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the future principal payments remaining on term loans was the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities, Current</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities, current, consisted of the following components: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,233&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (S-X 210.12-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364613424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Net Carrying Amount</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt premium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">896,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes for the years ended December&#160;31, 2023, 2022, and 2021 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366952544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of operating lease liabilities </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Description [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LesseeOperatingLeaseDescriptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364807424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Income Tax Rate</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory tax rate </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State tax rate, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Reconciliation of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): <div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and experimental expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation of indebtedness income and interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(525,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(445,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,527)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109,350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefit Accounts</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our total unrecognized tax benefit was $14.6 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken in prior year </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in balance related to tax positions taken during current year </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,554&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit) Provision for Income Taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,424)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,649)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364105968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,618</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,119)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(910)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,008</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Time-Based RSUs Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the time-based RSUs and PSUs activity for the year ended December&#160;31, 2023 (shares in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units (RSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance Stock Units (PSUs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PSU</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,535</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,141</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,730)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,638)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,308</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense consists of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - stock-settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger-related expenses - cash-settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 - 4.6</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77% - 78%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 76%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67% - 80%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73% &#8211; 4.60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.41% &#8211; 3.66%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05% &#8211; 1.10%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Purchase Plan</a></td>
<td class="text">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 - 2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79% - 97%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% - 97%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67% - 68%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9% - 5.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6% - 3.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1% - 0.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364619344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(306,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing basic net loss per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in computing diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,629</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,136</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,063</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,690</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,690</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,246</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,291</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,419</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672371008160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East, and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of Revenue by Category</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672370046960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StandardProductWarrantyPeriod', window );">Product warranty period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Customer One | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer One | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Domestic Customers | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StandardProductWarrantyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StandardProductWarrantyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_DomesticCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_DomesticCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672369698208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672359868016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2023 </div>
<div>USD ($) </div>
<div>d </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,042,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,129,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,118,000<span></span>
</td>
<td class="nump">78,613,000<span></span>
</td>
<td class="nump">$ 80,728,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="nump">$ 411,539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,912,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with liquidity event bonus plan (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,550,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred', window );">Less: Share-based compensation expense excluded from consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod', window );">Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Decrease to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Increase in intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability', window );">Decrease in deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit', window );">Decrease (increase) to our benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Merger related transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Merger-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with Apton liquidity event bonus plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, acquired during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan', window );">Issuance of common stock in connection with liquidity event bonus plan (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger', window );">Percentage of outstanding shares of common to be issued in merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Achievement of Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">$ 100,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 172,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,911,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Decrease to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability', window );">Decrease in deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit', window );">Decrease (increase) to our benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,923,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance', window );">Income tax benefit from reduction in deferred tax assets valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts', window );">Pro forma adjustment related to acquiree's acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Since the date of acquisition, revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Since the date of acquisition, net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | Omniome Stock Awards Related to Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | Achievement of Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger', window );">Percentage of outstanding shares of common to be issued in merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts', window );">Issuance of common stock in Private Placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Closing Date Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax benefit from reduction in deferred tax assets valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common to be issued in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pro forma adjustment to reflect acquiree's acquisition-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense excluded from consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Average Trading Period, Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in private placement net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OmniomeStockAwardsRelatedToAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OmniomeStockAwardsRelatedToAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364897808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 20, 2021</div></th>
<th class="th"><div>Jul. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 462,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other assets, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 462,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="nump">390,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember', window );">Circulomics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Allocation of purchase price to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, operating lease right of use assets net recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_CirculomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363091408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Total Consideration Transferred for The Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2023</div></th>
<th class="th"><div>Sep. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Less: Share-based compensation expense excluded from consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (72,118)<span></span>
</td>
<td class="num">$ (78,613)<span></span>
</td>
<td class="num">$ (80,728)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">$ 100,900<span></span>
</td>
<td class="nump">$ 315,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of share consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Less: Share-based compensation expense excluded from consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363071776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS ACQUISITIONS - Unaudited Pro Forma Financial Information (Details) - Omniome, Inc - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business Acquisition, Pro Forma Revenue</a></td>
<td class="nump">$ 130,513<span></span>
</td>
<td class="nump">$ 78,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business Acquisition, Pro Forma Net Income (Loss)</a></td>
<td class="num">$ (278,451)<span></span>
</td>
<td class="nump">$ 17,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Pro forma net (loss) income per share - basic (in usd per share)</a></td>
<td class="num">$ (1.27)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Pro forma net (loss) income per share - diluted (in usd per share)</a></td>
<td class="num">$ (1.27)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364538960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVITAE COLLABORATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems', window );"><strong>Development and Commercialization of Significant Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
<td class="nump">$ 130,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,342<span></span>
</td>
<td class="nump">30,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems', window );"><strong>Development and Commercialization of Significant Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,872<span></span>
</td>
<td class="nump">108,699<span></span>
</td>
<td class="nump">$ 113,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember', window );">Invitae Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems', window );"><strong>Development and Commercialization of Significant Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AmountOfAgreementPaymentReceivedUponExecution', window );">Amount of agreement payment received upon execution</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AmountOfAgreementPaymentReceivedUponExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of agreement payment received upon execution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AmountOfAgreementPaymentReceivedUponExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and Commercialization Agreement Transactions [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_InvitaeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_InvitaeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363109472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TERMINATION OF MERGER WITH ILLUMINA - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerTerminationLineItems', window );"><strong>Merger Termination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss (gain) from Continuation Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace', window );">Possible Continuation Advances payable</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty', window );">Period in which company must repay continuation advances if change-of-control transaction is entered into with third party</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction', window );">Equity or debt financing that must be raised in a single transaction</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pacb_IlluminaFcOpsCorpMember', window );">Illumina, FC Ops Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerTerminationLineItems', window );"><strong>Merger Termination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Loss (gain) from Continuation Advances</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_MergerTerminationLineItems', window );"><strong>Merger Termination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Period in Which Company must Repay Continuation Advances if Change-of-Control Transaction is Entered into with Third Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_MergerTerminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Termination [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_MergerTerminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pacb_IlluminaFcOpsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pacb_IlluminaFcOpsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672360134912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 179,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">451,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">634,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">70,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">109,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">88,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">352,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">70,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">72,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">70,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">109,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">451,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">561,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">109,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">88,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">352,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">19,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LongTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LongTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShortTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShortTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=pacb_CashAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672359959616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2023 </div>
<div>USD ($) </div>
<div>d </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod', window );">Business acquisition, anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock following milestone achievement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,988,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock following milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,800<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="nump">$ 100,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,911,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition</a></td>
<td class="nump">$ 95,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,121,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Valuation, Income Approach | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Valuation, Income Approach | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Liability, Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Contingent Consideration, Revenue Achievement Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Average Trading Period, Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368616112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Changes in Estimated Fair Value of Contingent Consideration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">$ 18,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of contingent consideration<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in estimated fair value</a></td>
<td class="nump">$ 15,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance as of December 31, 2022</a></td>
<td class="nump">172,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration', window );">Achievement of milestone</a></td>
<td class="nump">186,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance as of December 31, 2023</a></td>
<td class="nump">$ 19,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364919600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 561,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember', window );">Total cash, cash equivalents, and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">631,197<span></span>
</td>
<td class="nump">$ 777,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">864<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(4,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">631,416<span></span>
</td>
<td class="nump">772,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">179,958<span></span>
</td>
<td class="nump">325,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">179,911<span></span>
</td>
<td class="nump">325,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">70,172<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">70,172<span></span>
</td>
<td class="nump">137,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">109,786<span></span>
</td>
<td class="nump">20,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">109,739<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">451,239<span></span>
</td>
<td class="nump">451,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(585)<span></span>
</td>
<td class="num">(4,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">451,505<span></span>
</td>
<td class="nump">447,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="nump">127,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="nump">127,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">88,263<span></span>
</td>
<td class="nump">49,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">88,579<span></span>
</td>
<td class="nump">49,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">353,029<span></span>
</td>
<td class="nump">274,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(3,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">352,979<span></span>
</td>
<td class="nump">270,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_ShortTermRestrictedCashMember', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pacb_LongTermRestrictedCashMember', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 2,422<span></span>
</td>
<td class="nump">$ 2,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_CashCashEquivalentsAndInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_CashAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_ShortTermRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_ShortTermRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pacb_LongTermRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pacb_LongTermRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364500480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Due in one year or less</a></td>
<td class="nump">$ 465,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Due after one year through 5 years</a></td>
<td class="nump">96,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">$ 561,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368116544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Components of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Purchased materials</a></td>
<td class="nump">$ 20,168<span></span>
</td>
<td class="nump">$ 24,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">23,436<span></span>
</td>
<td class="nump">14,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">13,072<span></span>
</td>
<td class="nump">12,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 56,676<span></span>
</td>
<td class="nump">$ 50,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672369929408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Components of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 111,226<span></span>
</td>
<td class="nump">$ 106,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(74,794)<span></span>
</td>
<td class="num">(64,988)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">36,432<span></span>
</td>
<td class="nump">41,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember', window );">Laboratory equipment and machinery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">44,907<span></span>
</td>
<td class="nump">38,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">35,226<span></span>
</td>
<td class="nump">34,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">19,528<span></span>
</td>
<td class="nump">18,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,628<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,594<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 4,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pacb_LaboratoryEquipmentAndMachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364442544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,463<span></span>
</td>
<td class="nump">$ 9,480<span></span>
</td>
<td class="nump">$ 7,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,261<span></span>
</td>
<td class="nump">409,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,157<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,342<span></span>
</td>
<td class="nump">30,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ContractWithCustomerLiabilityNoncurrentReclassification', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfFeeToPrepayDebt', window );">Percentage of fee to prepay debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Term loans outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_CostOfRevenueMember', window );">Cost Of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 390,665<span></span>
</td>
<td class="nump">462,300<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Short term debt acquired</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt acquired</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">43 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc | In-Process Research and Development Indefinite Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets include acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, acquired during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod', window );">Deferred service revenue, noncurrent, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractWithCustomerLiabilityNoncurrentReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Noncurrent, Reclassification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractWithCustomerLiabilityNoncurrentReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfFeeToPrepayDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fee of the outstanding debt to prepay the debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfFeeToPrepayDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_CostOfRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_CostOfRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364647088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Definite-Lived Intangible Assets from Business Acquisitions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 411,539<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 401,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 411,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 401,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368482816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 27,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">27,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2029 and thereafter</a></td>
<td class="nump">264,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 401,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364647120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries and benefits</a></td>
<td class="nump">$ 29,337<span></span>
</td>
<td class="nump">$ 17,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AccruedTenantImprovementsCurrent', window );">Accrued interest payable</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Accrued purchase commitments</a></td>
<td class="nump">2,613<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AccruedProductDevelopmentCostsCurrent', window );">Accrued product development costs</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services and legal fees</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyAccrualPresentValue', window );">Inventory accrual</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty accrual</a></td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 45,708<span></span>
</td>
<td class="nump">$ 32,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedProductDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedProductDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedTenantImprovementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Tenant Improvements, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedTenantImprovementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyAccrualPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of the accrual for product liability loss contingencies as of the balance sheet date (if the accrual qualifies for discounting).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyAccrualPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364842352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Additions charged to cost of product revenue</a></td>
<td class="nump">8,227<span></span>
</td>
<td class="nump">3,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Repairs and replacements</a></td>
<td class="num">(5,197)<span></span>
</td>
<td class="num">(2,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at end of period</a></td>
<td class="nump">$ 4,681<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368558016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Future Principal Payments , Fiscal Year Maturity (Details) - Omniome, Inc<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672369611920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Other Liabilities, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent', window );">Accrued Employee Stock Purchase Plan</a></td>
<td class="nump">$ 3,715<span></span>
</td>
<td class="nump">$ 3,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">1,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,121<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">$ 8,326<span></span>
</td>
<td class="nump">$ 7,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Employee Stock Purchase Plan Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672360334064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,033<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,626<span></span>
</td>
<td class="nump">896,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0229885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Convertible Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Debt Conversion Terms One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Debt Conversion Terms Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,617<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.046512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Debt Conversion Terms One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Debt Conversion Terms Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Paid accrued but unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentAdditionalInterestInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentDebtDefaultCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentDebtDefaultCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentInterestInTheEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentInterestInTheEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672370031104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 441,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized debt issuance costs</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(6,907)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">434,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">459,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(1,374)<span></span>
</td>
<td class="num">(3,317)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 457,626<span></span>
</td>
<td class="nump">$ 896,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368554176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 3,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">10,133<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">11,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 10,605<span></span>
</td>
<td class="nump">$ 14,117<span></span>
</td>
<td class="nump">$ 12,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672359938960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,593,000<span></span>
</td>
<td class="nump">$ 39,763,000<span></span>
</td>
<td class="nump">$ 32,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="nump">11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations', window );">Additional liability associated with indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Loss on purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDeposits', window );">Payments for deposits to Supplier</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember', window );">Omniome, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Liability Associated With Indemnification Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 330<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_OmniomeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672367989152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 12,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">12,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">12,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">9,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">46,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">41,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetClassificationAbstract', window );"><strong>Balance Sheet Classification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">9,591<span></span>
</td>
<td class="nump">$ 8,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">31,606<span></span>
</td>
<td class="nump">$ 41,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 41,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Classification [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672360224096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition', window );">Probability of benefit realized upon settlement uncertain tax position</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">(Loss) income before taxes from U.S. operations</a></td>
<td class="num">$ (318,900)<span></span>
</td>
<td class="num">$ (315,700)<span></span>
</td>
<td class="num">$ (275,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">525,703<span></span>
</td>
<td class="nump">445,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">435,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">83,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">14,554<span></span>
</td>
<td class="nump">10,410<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
<td class="nump">$ 5,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Income before taxes from foreign operations</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,709,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">788,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">57,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,171,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 49,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OperatingLossCarryforwardsAmountSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Amount Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OperatingLossCarryforwardsAmountSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probability of benefit Realized Upon Settlement Uncertain Tax Position</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368621184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Provision (Benefit) for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(9,956)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(83,742)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,468)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(11,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,649)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) Provision for Income Taxes</a></td>
<td class="num">$ (11,424)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (93,649)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672360206816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Federal Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(25.10%)<span></span>
</td>
<td class="num">(4.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit', window );">Tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent', window );">Merger Expenses</a></td>
<td class="num">(0.001)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_EffectiveIncomeTaxRateReconciliationTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_EffectiveIncomeTaxRateReconciliationTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363091648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 435,488<span></span>
</td>
<td class="nump">$ 400,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">83,922<span></span>
</td>
<td class="nump">71,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and experimental expenses</a></td>
<td class="nump">63,196<span></span>
</td>
<td class="nump">34,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Accruals and reserves</a></td>
<td class="nump">16,872<span></span>
</td>
<td class="nump">13,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense', window );">Cancellation of indebtedness income and interest expense</a></td>
<td class="nump">14,907<span></span>
</td>
<td class="nump">4,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">18,584<span></span>
</td>
<td class="nump">17,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="nump">9,510<span></span>
</td>
<td class="nump">11,537<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">642,479<span></span>
</td>
<td class="nump">554,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(525,703)<span></span>
</td>
<td class="num">(445,574)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets:</a></td>
<td class="nump">116,776<span></span>
</td>
<td class="nump">108,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(109,488)<span></span>
</td>
<td class="num">(98,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(548)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DeferredTaxLiabilitiesRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(7,491)<span></span>
</td>
<td class="num">(9,157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(117,527)<span></span>
</td>
<td class="num">(109,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="num">$ (751)<span></span>
</td>
<td class="num">$ (835)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Deferred Expense, Capitalized Research and Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672367983888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Unrecognized Tax Benefit Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
<td class="nump">$ 5,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase in balance related to tax positions taken in prior year</a></td>
<td class="nump">2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase in balance related to tax positions taken during current year</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">2,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease in balance related to tax positions taken in prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 14,554<span></span>
</td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672355734640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>period </div>
<div>$ / shares </div>
<div>vote </div>
<div>offering </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>offering </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 02, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting right of common stock share holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned', window );">Voting right of common stock share holders, number of votes | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingShares', window );">Public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OfferingShareAmountMaximum', window );">Common stock offering price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod', window );">Public offering, option to purchase additional shares, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares', window );">Public offering, option to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering', window );">Commissions, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,744,000<span></span>
</td>
<td class="nump">226,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock from equity plans | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,319<span></span>
</td>
<td class="nump">$ 11,230<span></span>
</td>
<td class="nump">$ 31,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 146,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation cost capitalized in inventory | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingShares', window );">Public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,096,112<span></span>
</td>
<td class="nump">19,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OfferingShareAmountMaximum', window );">Common stock offering price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.25<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod', window );">Public offering, option to purchase additional shares, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares', window );">Public offering, option to purchase additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,416<span></span>
</td>
<td class="nump">2,914,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in Private Placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering', window );">Commissions, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,900<span></span>
</td>
<td class="nump">$ 93,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_NumberOfOfferings', window );">Number of offerings | offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember', window );">Shelf Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedAndPerformanceBasedOptionsMember', window );">Time-Based and Performance-Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,039,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired, weighted average exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,026,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShareInstrumentNumberOfSharesConversionRatio', window );">Ratio of number of shares into which the share instrument may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSUs) | Share-based Compensation Award, Tranche One, Two, Three and Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember', window );">Time Based Restricted Stock Units PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal', window );">Amount eligible to vest upon achievement of goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember', window );">Time Based Restricted Stock Units RSUs and Performance Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested related to RSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,300<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="nump">$ 10.15<span></span>
</td>
<td class="nump">$ 35.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock reserved for issuance (in shares)</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_InducementEquityIncentivePlan2020Member', window );">2020 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember', window );">Omniome Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.259204639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_TwoThousandTenEquityIncentivePlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,197,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
<td class="nump">$ 25.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_NumberOfPurchasePeriods', window );">Number of purchase periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PurchasePeriodOfEmployeeStockPurchasePlan', window );">Purchase period of ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased', window );">Percentage of fair market value at which stock can be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common stock used to determine annual plan increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock purchased under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,058<span></span>
</td>
<td class="nump">1,878,168<span></span>
</td>
<td class="nump">1,913,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pacb_PrivatePlacementOfCommonStockMember', window );">Private Placement of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,214,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock from equity plans | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in Private Placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes Per Share Owned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The relative number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_NumberOfOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Offerings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_NumberOfOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_NumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of purchase periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_NumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OfferingShareAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Share Amount Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OfferingShareAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value at which stock can be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Option to Purchase Additional Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PurchasePeriodOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase period of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PurchasePeriodOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareInstrumentNumberOfSharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares into which the share instrument may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareInstrumentNumberOfSharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pacb_ShelfOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedAndPerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedAndPerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_InducementEquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_InducementEquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_TwoThousandTenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_TwoThousandTenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pacb_PrivatePlacementOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pacb_PrivatePlacementOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364683024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember', window );">Time-Based Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">14,618,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">419,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(1,119,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(910,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">13,008,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">11.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">17.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(251,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Omniome Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">4.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_OmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672363732784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of RSUs and PSUs Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">8,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">7,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(2,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">11,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="nump">9.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">14.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">13.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share) | $ / shares</a></td>
<td class="nump">9.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">9.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending, outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672371028944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 72,118<span></span>
</td>
<td class="nump">$ 78,613<span></span>
</td>
<td class="nump">$ 80,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">5,399<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">6,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">22,435<span></span>
</td>
<td class="nump">30,676<span></span>
</td>
<td class="nump">20,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">44,284<span></span>
</td>
<td class="nump">43,135<span></span>
</td>
<td class="nump">35,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesStockSettledMember', window );">Merger-related expenses - stock-settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesMilestoneMember', window );">Merger-related expenses - milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">72,118<span></span>
</td>
<td class="nump">78,613<span></span>
</td>
<td class="nump">73,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesCashSettledMember', window );">Merger-related expenses - cash-settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesStockSettledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesStockSettledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesCashSettledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_MergerRelatedExpensesCashSettledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368181456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="nump">$ 18.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">3.66%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 5.93<span></span>
</td>
<td class="nump">$ 15.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672365152960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in usd per share)</a></td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
<td class="nump">$ 25.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672370874032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (306,735)<span></span>
</td>
<td class="num">$ (314,248)<span></span>
</td>
<td class="num">$ (181,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing basic net (loss) income per share (in shares)</a></td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">224,550<span></span>
</td>
<td class="nump">204,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (in usd per share)</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing diluted net (loss) income per share (in shares)</a></td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">224,550<span></span>
</td>
<td class="nump">204,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (in usd per share)</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672370916976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Antidilutive Shares Excluded From Computation Of Diluted Net Loss Income Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">31,063<span></span>
</td>
<td class="nump">20,690<span></span>
</td>
<td class="nump">20,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">27,246<span></span>
</td>
<td class="nump">27,291<span></span>
</td>
<td class="nump">21,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672366780224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details) - 12 months ended Dec. 31, 2023<br></strong></div></th>
<th class="th"><div>unit</div></th>
<th class="th"><div>segment</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672364014576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
<td class="nump">$ 130,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">105,410<span></span>
</td>
<td class="nump">69,561<span></span>
</td>
<td class="nump">64,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe, Middle East, and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">40,658<span></span>
</td>
<td class="nump">22,598<span></span>
</td>
<td class="nump">30,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia-Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 54,453<span></span>
</td>
<td class="nump">$ 36,145<span></span>
</td>
<td class="nump">$ 35,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139672368103840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION Summary of Revenue by Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 200,521<span></span>
</td>
<td class="nump">$ 128,304<span></span>
</td>
<td class="nump">$ 130,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">183,872<span></span>
</td>
<td class="nump">108,699<span></span>
</td>
<td class="nump">113,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_InstrumentMember', window );">Instrument revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">120,451<span></span>
</td>
<td class="nump">48,719<span></span>
</td>
<td class="nump">61,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ConsumableMember', window );">Consumable revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">63,421<span></span>
</td>
<td class="nump">59,980<span></span>
</td>
<td class="nump">52,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 16,649<span></span>
</td>
<td class="nump">$ 19,605<span></span>
</td>
<td class="nump">$ 17,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_InstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_InstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ConsumableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ConsumableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>98
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!YKC6M<OO(=/\"N?X)^US[",(/$U#=<3,LVPK)H$6VIU6)5)\,\R"8ML%=,
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M$%<)N='ST,+@/*<1J-,8"DTDI]=,D+$HGT9E9E"5D)8;1PU3:(>!+Y/C*/F
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MZ^'0=F1R5#N,?3DA-'("KYW\ ,M15PW'CN_)3^9U9L@EF#BV?FW'O0B S2+
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M4HITG].3R;VIR-5Y"9$)7&* 06N%6ZUH4F<?8[VSOGR0_)]_9-R>@8?L<.2
MP;3)[6Y4#!'PD22YV#,N(_5YX1:/BG6WP_Q)&0VE$&Z9PF @;P&!T8YH@.9Q
M1OHP?5Y;;K#&38^CJ0;,&E+L3L,D%(-$]Y=B5N1Q+GM6XF#I.@Q7UE@3U7&H
M(J^SE@U)[M.A8A''9QTO DB-#="#((K_:>?34Z&ZC;!)R8WCEJHIH\H?6\S_
M(O7$+#5FV/(G5!(!Q:]:T2L<I].GL/JI"G$(*>(*M0-8P->C[9'6; 1EG!D#
M<\=G"F*C@ M-.4IK,"$9"@BR^G.M1'5$Y03?QKW'#!(%'I!H27#EIF"HSY@
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M'*Y.^CJT!92*>R2;&X>-R'@&KA^@T@5=+NT,H98$;I:B"J'0 1K[.IB.&AE
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MB"*5T?(\^@5;Q!DQC6EVW-MB&D[0!N$-/.R6A&I58Z=!DQF67-#WY$]!+FW
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MZ63\N/M'F,;>O>2/$JRU$QE$A8&_,P__MB;9>M9VFTX![Z3QOGZ@VUWA>EY
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M1Y?LBS0D&]VG3U_)LXUU7WQ)%,372AM_/BI#J-]-ISXKJ9)^8FLR>%)85\F
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MRP:T/C54JM6  [1/P.$_4$L#!!0    ( (F#7%AX5([QE X  &$M   9
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M_("]57FY-.QEGHITF\ 5\-0P%M2,W09'*?XLD@$+?8\%PR \0B]L! V)7GB
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M[*=@*GC>>'O'+Z>236$RL[X3X9A3:QB$* R.Q;-Y$,[')W1O&"(]C\0%MRI
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M!@&Y15.&QI2GJ?1!JMP=3S:1:*U9!_*0#0>C,"2]@]*&]S,$@,("M+?>[#>
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M7+T>(%2\<O=J</GS3^.ST<LG1#AI13AYBOJ/V^S_("?^KN#S7ORN$(*Y=84
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M\J1OR*)M@4?;%YRT \O4#G8>4BC;&0B)A;PGK5&@P-TL:0-9M&,R!N6TUJ:
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MT)"E6JVF>@R5=;K1UY05Z!-5\JV!. _$IC97FB"=[G_DV4-Q!9I?K*-XC?Y
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MLFP;&H]P\:ZHLL0!W_8>\ZZ7X198.S>A]G&9DPPVAO$%:O8JA?2,S[OGX"T
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M)V'[+/:G4WP63-IGH1_"N+?]Z#!$M>[O(]N;[6$J %L\,SMF=%9&+<A)S"X
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MKU-TG:^;*%[;;K/G2O<N.RSUSP*$"=#/<\[5<6(V&'X_R1M02P,$%     @
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MF,?I&L'B\/)+F-+&*DQ&1.E&Z+=B2BJS=J9N:2]VME6R'FS8P8:DV\+:(T7
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M9"IG_%;E6R162%[53+0LN,:6J\]O3Q!4=EI?BG=91ED80BR#6-L$(P#!Y#E
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MLF@",U9$O_%NE+CWRH\NX)R;+#4HRU9/%%VQ$$<[C/O'U,8>6M;(_F7F*E/
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MVI(*-DN[8(9,\N#LQU<O7IQ].JZ*72&$=CYI>1;'X7AEW^@$,B.$EK9DJV5
MSBT;R"$$Q A<\JRA!:\NZ9>9&<\_\HQGR1^@6X?-P=#?&@;G'KN&4W+_.HQ2
MN3X]_$3Z&V]'.EWE]@,8[K/?>/+'KCF&/(S1N#X]1N/'K$69!*=/$Z;H65 _
M=A$,"R)C&Q)"-+-3(I<"F,UV4$."<_DF=J4"6RIX=OR=.*XXMTQ\/; %#5K"
M0A89VC2U$=?0V[C50]_T(OFAK'C3]\ 4PNS_.PBXXMO7D^H+W&-JZQ< B(/
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MRXX#JGEBFHF197VM+Z6A1Z(>;NA51F4=:'TEI=E-;(+].S_\%U!+ P04
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ME=7K:-718FU?).=":U'89LH9D$ZS .:70NBF8PYHGZ@O_P=02P,$%     @
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MLX([JK,F<ES8I,R,HEU.=F9\?3?]-'EXO+WZ;0*SR?3V[@&F=X^3&70>V;Q
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M:4IZLZ#?$FKG0-]W2MG3PB5H?W33OP%02P,$%     @ B8-<6%G=GV53!@
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M/UO3MEN?S-LW;\%4+BH-!=^BJW<S0)U5^XZT"R/W3>_>2(,O03/=X=/+E37
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M,!5(%FE*Q<L))'PQ\+"W/G##'N?*'/"'_9P^PBVH^WPJ],RO6"*60B89SY"
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M"!I.0N]@,I2 5I4HFJE-G42,W$G$4_?\*?Z6+-=+JYZ@L0.4%D%I#$KC4)J
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MZB&^,;(8;\5&B[F=$(]"X[RQRP2_"$ :!SR?"J'7&_. \ANC_P]02P,$%
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M40(1RW)$UY"IB5RMPY2%ZM&6N>C57#*#*$%TCD_8[$0GX6HE(#FB I4K,"(
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M-3']HL3A5*G4WNDH:\=I\I.N8;VBH,(=A:;S*^5].M4$DD(U.Q2-H]!TTI3
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M401)^U#UP>P.K%6O36TO)/_^C'>7#5&7/4>5^M 7L+V>F6^^N7B&>ZE^Z 3
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M%8S+1ABWL -.VG7V&@5_,Z'[%:S^7U#2_3_ P*!B8- 8F ELF!#6NQ7E5$1
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M_/O928A""14/>TG\<<_Q.3>YU]&6BR>9 RCT7% F1U:N5'EFVS+-H<#RA)?
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MW%S?7S],[\#\X]W=(YA^^3S[\G#W\#@'[\&4ICG-2"8XH$LP8U(Z3+P G"W
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MFR1*-_R,W";S-JG,Y5VE@M)\*"V TBB4QE TU21U$FE;[S-%V- X$DKSH;0
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M6?$._<BDLM?B< ED#EP/4/<CQN3SB7XMKS_#!/\#4$L#!!0    ( (F#7%B
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M;89+KG1KM<-$?\M0F WZ?<RY>IF8_EI]'<,_4$L#!!0    ( (F#7%C5V.[
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M_U9A,,5% FAA>BEF><D*E;I O\9+(;GZ^_WNRK$V[76;ZI:\$"5.8&2IGA/
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M;+V=6V_;.A:%_PKA.1CT )U8=SN=)$!C\=)!;VC:,P^#>5!LQA9J2QY)3GJ
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MR(2Z&E :A=(8E,:A-(&BZ9)5KD8XQ,[:T$<CH+082J-0&H/2.)0F4#1=@LH
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M5@*.?S>B5O5.';A[_:;^M3 /9EZP) /.?M&96O:LMH5F9(YSIG[P]7>R,50
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M"1,U+2H^E2466RW.Z!9?S)J2!-P/%T,@MN&L"I)46N.* =P&^2<V'$],LY,
MJ9WK=>U\B9WEN4[7+E!.[)VTC2K:1DK:OJ-XCXJ=/1:]!1(K549- 3)J3,6U
MQ(SM#C-],\=Q7<_I$*,,Z=A%IPFLQ9Y7L><IV;L6#5^YIM(-B,4*!*'8:)_$
MXCL@*M])O3Y'MNOV%IERX&._<IU@@2:P%N'CBO"QDO!;@8AHN 6B3Q%MXX/H
MAW=YB0TI7HD2W&1?1OZX1_[8[G_@RAB.Y5XG6* )K,7]I.)^HN3>QVM,!<W/
M-3;;R\JM3T;UI$?U"82.U:D%\[Y9MXQ*@";VR)ETJJ@R^'=2 \VZVS:5Y)R'
M(=WGW' L\$59H$!H/A3S",L;:O.UB<]?-_'541V[NG2AM3EL*!:HY/ ^I3@D
MFS3OH1JK2\X?[)$#Q5[375XR,].!/1[[9F/;[G1>06G5W-'=26/(]KRM>MZ6
M<MZ7+_4LV7VT25]I6TKT9NR]7F1>&C5#A^->QR*QZAD%ZMF\=Y746@@J6_O9
M%[P2;,12)K1J'ZUHOE:T0!=:.P>U_H&./D$*=6J,N58T7RM:H NMG95: 4&U
M!'I/-UI"MNJC9T[L?@'1I%)*WG6B!;K0VKS7$@JJ-=0W!>>? =LO_\$A!YP
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MP5B?_*)JGJN!XEO;3JZXTLVIO2ST'PX0)D _7W.N7@9F@N8OS.('4$L#!!0
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M#\)LJ[S?S:T*Y?6W6.B'<=IAM=@1$GK)0$?#9^*,1VD_PUJ]0C]HL3\N8UK
M9Y=9UU9:W*.8$)_$7M#%M1B&(2%Q.,![$DD\*DG#U;5J91/L<HZC..ZV,)N=
MEQ!,!G!/$H?'->X&>FRUX:O"WKP:[XLZ82_M"YK-,$W2  \ GB0-CVO:1_X$
M91Q9H'UIFH#@=O$L5MB/_ &ZDX+A<0GK;GII/IDG8CW9PV $NB])DSA,<9?:
M8I9B,M0!3M*%Q[7+LD:+T[>L%;BO3Q/HF,3O"H#5T$L#,B!E^*1E>%S,E@.X
M;U'%M)4Y[GUD36+2J['%*@FZ^\H].UZ8L]T7*C>\4C#K:W#SWL7@+X_'I>-
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M"K0\>2MO.,F+TZY'PCE)B\LE#B),Y0OB]SDA_.5&=E"??X[_ U!+ P04
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M$7TDBT3>LM476A+* PQ9(O)7L"IMG0X(%T*RM'16$:1Q5KR3IS(1:PXPV.&
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M-CT]O0]N<!*K@'FVDS32^^.?;0@)U-!T0Z]?&B#W'M]SL(]OW.&&L@>^Q%B
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M0%O\79"].'I&BLHK8S_4X,]L83EJ1Z0DJ50N,/SMR",I2^4)]O%/Y]3JWZF
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MCPYKM>;T=D&I\E8%%_7(7RA5?0R">K:@!:DORXH*C>2E+(C273D/ZDI2DM5
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M]?*7Y??.R0UUP;F^K1B>_@)02P,$%     @ B8-<6(:F8T@, @  82L  !,
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MZ9^UZS]02P$"% ,4    " ")@UQ8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (F#7%B[$:91[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( (F#7%B97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ B8-<6 J]6#$B"   (3$  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( (F#7%C^[WEU/ (  +T%   8              " @680  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " ")@UQ8F3\<2O(&  #4
M'@  &               @('8$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ B8-<6$B&4WID P  [0\  !@              ("! !H
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (F#7%BKI*UC
M+P@  (\K   8              " @9H=  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " ")@UQ8"WZI'KL(  !S1   &
M@('_)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ B8-<
M6.G"A/MV#   Q4<  !@              ("!\"X  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( (F#7%@V6.I3/"4  )AW   8
M      " @9P[  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" ")@UQ84F6EJ542  #=/0  &               @($.80  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ B8-<6%;=U4]_!P  ?A,  !D
M             ("!F7,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " ")@UQ8P7-!)50$   ."@  &0              @(%/>P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (F#7%AX5([QE X
M &$M   9              " @=I_  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ B8-<6*8+5Z!6#0  K"0  !D              ("!
MI8X  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " ")@UQ8
MH]'-BUD/   V0P  &0              @($RG   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( (F#7%A8U-Z4^ P  /,B   9
M      " @<*K  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ B8-<6.=[QD%K#0  P28  !D              ("!\;@  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ")@UQ86@8?;?84  "F2
M&0              @(&3Q@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( (F#7%C^?COPHP0  *(+   9              " @<#;  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ B8-<6/HAJ#J5
M!   $PH  !D              ("!FN   'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " ")@UQ8S\VW9UT"  ""!@  &0
M@(%FY0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (F#
M7%AD.J)K0P(  (H&   9              " @?KG  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ B8-<6#N!J1+R(@  >'8  !D
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M=#(V+GAM;%!+ 0(4 Q0    ( (F#7%C=_($VTP,  *$*   9
M  " @8PE 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MB8-<6+:3_3,Z P  ] 8  !D              ("!EBD! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " ")@UQ86=V?95,&  "2$   &0
M            @($'+0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( (F#7%BM&B-!'08  -81   9              " @9$S 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ B8-<6%&84 V< P
MX @  !D              ("!Y3D! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " ")@UQ8R#00X'$#  #8!P  &0              @(&X
M/0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( (F#7%BD
MSO#=? 0  *L?   9              " @6!! 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ B8-<6.DQ[YJP P  RA0  !D
M     ("!$T8! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (F#7%AT_/95. 0  $$6   9              "
M@<QG 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ B8-<
M6.IQ3!*V!   =QL  !D              ("!.VP! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " ")@UQ8&/':R*8-  !6F0  &0
M        @($H<0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( (F#7%B2+$I]-P<  +=#   9              " @05_ 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ B8-<6$J8'96% P  /@H
M !D              ("!<X8! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " ")@UQ8><=N)ZD'   *-@  &0              @($OB@$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( (F#7%@_6.Z]
MB0(  )(%   9              " @0^2 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ B8-<6%TF,J.I @  _ 8  !D
M ("!SY0! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " ")
M@UQ8[]^H&$ $  "^%@  &0              @(&OEP$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (F#7%A0S>-B+ D  &59   9
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M970U,BYX;6Q02P$"% ,4    " ")@UQ8SC5Z\T8"  #.!   &0
M    @(%KLP$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M (F#7%B[62,<M (   H'   9              " @>BU 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ B8-<6.^)]QHN#0  )K(  !D
M             ("!T[@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " ")@UQ8=6JY"3D#  #A"P  &0              @($XQ@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( (F#7%C%>TOODP,
M (P.   9              " @:C) 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ B8-<6-"''4=J!0  ?"(  !D              ("!
M<LT! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " ")@UQ8
MS>)#<KX#  #Q#@  &0              @($3TP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (F#7%BM)X<(804  *D?   9
M      " @0C7 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ B8-<6 [/%@]! P  CPL  !D              ("!H-P! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ")@UQ88HK2,I@#  #.#
M&0              @($8X $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( (F#7%B;>V!:4P0  , .   9              " @>?C 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ B8-<6*C2;D!C
M P  &0L  !D              ("!<>@! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " ")@UQ8!9D7>YH<  !.MP$ &0
M@($+[ $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( (F#
M7%@&2B(H3@0   L5   9              " @=P( @!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ B8-<6)\]Z%?#!   ;!4  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( (F#7%BFE:!%3 ,  &@,   9
M  " @=(D @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
MB8-<6!#U-V@\ @  $P4  !D              ("!52@" 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " ")@UQ8*F[49,0#   B$0  &0
M            @('(*@( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( (F#7%@:->E__P,  )(4   9              " @<,N @!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ B8-<6#6:>0QJ P
M=1<   T              ( !^3(" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" ")@UQ8EXJ[',     3 @  "P              @ &.-@( 7W)E;',O+G)E
M;'-02P$"% ,4    " ")@UQ8'0N[E\4%  #6,0  #P              @ %W
M-P( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ B8-<6&?\4D), @  :"P
M !H              ( !:3T" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ B8-<6(:F8T@, @  82L  !,              ( ![3\"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %, 4P"\%@  *D("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>353</ContextCount>
  <ElementCount>486</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - BUSINESS ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS</Role>
      <ShortName>BUSINESS ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - INVITAE COLLABORATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INVITAECOLLABORATION</Role>
      <ShortName>INVITAE COLLABORATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - TERMINATION OF MERGER WITH ILLUMINA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINA</Role>
      <ShortName>TERMINATION OF MERGER WITH ILLUMINA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - CONVERTIBLE SENIOR NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - BUSINESS ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables</Role>
      <ShortName>BUSINESS ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/INCOMETAXES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - BUSINESS ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - BUSINESS ACQUISITIONS - Total Consideration Transferred for The Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Total Consideration Transferred for The Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - BUSINESS ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails</Role>
      <ShortName>BUSINESS ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - INVITAE COLLABORATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails</Role>
      <ShortName>INVITAE COLLABORATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - TERMINATION OF MERGER WITH ILLUMINA - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails</Role>
      <ShortName>TERMINATION OF MERGER WITH ILLUMINA - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - FINANCIAL INSTRUMENTS - Changes in Estimated Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Changes in Estimated Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - BALANCE SHEET COMPONENTS - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - BALANCE SHEET COMPONENTS - Components of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Components of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - BALANCE SHEET COMPONENTS - Definite-Lived Intangible Assets from Business Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Definite-Lived Intangible Assets from Business Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - BALANCE SHEET COMPONENTS - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - BALANCE SHEET COMPONENTS - Future Principal Payments , Fiscal Year Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Future Principal Payments , Fiscal Year Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - BALANCE SHEET COMPONENTS - Other Liabilities, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Other Liabilities, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - INCOME TAXES - Provision (Benefit) for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Provision (Benefit) for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - INCOME TAXES - Reconciliation of Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - INCOME TAXES - Reconciliation of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefit Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Unrecognized Tax Benefit Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of RSUs and PSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of RSUs and PSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - NET LOSS PER SHARE - Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - NET LOSS PER SHARE - Antidilutive Shares Excluded From Computation Of Diluted Net Loss Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Antidilutive Shares Excluded From Computation Of Diluted Net Loss Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pacb-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Summary of Revenue by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION Summary of Revenue by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="pacb-20231231.htm">pacb-20231231.htm</File>
    <File>pacb-20231231.xsd</File>
    <File>pacb-20231231_cal.xml</File>
    <File>pacb-20231231_def.xml</File>
    <File>pacb-20231231_lab.xml</File>
    <File>pacb-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pacb-20231231_g1.jpg</File>
    <File>pacb-20231231_g2.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="1243">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pacb-20231231.htm": {
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "pacb-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "pacb-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pacb-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pacb-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 415,
   "keyCustom": 71,
   "axisStandard": 27,
   "axisCustom": 1,
   "memberStandard": 44,
   "memberCustom": 49,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 353,
   "entityCount": 1,
   "segmentCount": 100,
   "elementCount": 815,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1243,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://www.pacificbiosciences.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.pacificbiosciences.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000008 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS",
     "longName": "0000009 - Disclosure - BUSINESS ACQUISITIONS",
     "shortName": "BUSINESS ACQUISITIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.pacificbiosciences.com/role/INVITAECOLLABORATION",
     "longName": "0000010 - Disclosure - INVITAE COLLABORATION",
     "shortName": "INVITAE COLLABORATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:InvitaeCollaborationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:InvitaeCollaborationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINA",
     "longName": "0000011 - Disclosure - TERMINATION OF MERGER WITH ILLUMINA",
     "shortName": "TERMINATION OF MERGER WITH ILLUMINA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:MergerTerminationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:MergerTerminationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS",
     "longName": "0000012 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS",
     "longName": "0000013 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES",
     "longName": "0000014 - Disclosure - CONVERTIBLE SENIOR NOTES",
     "shortName": "CONVERTIBLE SENIOR NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000015 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXES",
     "longName": "0000016 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.pacificbiosciences.com/role/StockholdersEquity",
     "longName": "0000017 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE",
     "longName": "0000018 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION",
     "longName": "0000019 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-353",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-353",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy",
     "longName": "9954471 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policy)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables",
     "longName": "9954473 - Disclosure - BUSINESS ACQUISITIONS (Tables)",
     "shortName": "BUSINESS ACQUISITIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9954474 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
     "longName": "9954475 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables",
     "longName": "9954476 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)",
     "shortName": "CONVERTIBLE SENIOR NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9954477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESTables",
     "longName": "9954478 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9954479 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables",
     "longName": "9954480 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables",
     "longName": "9954481 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954482 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES- Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:StandardProductWarrantyPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
     "longName": "9954483 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of The Major Classes of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
     "longName": "9954484 - Disclosure - BUSINESS ACQUISITIONS - Narrative (Details)",
     "shortName": "BUSINESS ACQUISITIONS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
     "longName": "9954485 - Disclosure - BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)",
     "shortName": "BUSINESS ACQUISITIONS - Schedule of Business Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
     "longName": "9954486 - Disclosure - BUSINESS ACQUISITIONS - Total Consideration Transferred for The Acquisition (Details)",
     "shortName": "BUSINESS ACQUISITIONS - Total Consideration Transferred for The Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails",
     "longName": "9954487 - Disclosure - BUSINESS ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)",
     "shortName": "BUSINESS ACQUISITIONS - Unaudited Pro Forma Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
     "longName": "9954488 - Disclosure - INVITAE COLLABORATION - Narrative (Details)",
     "shortName": "INVITAE COLLABORATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "pacb:AmountOfAgreementPaymentReceivedUponExecution",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails",
     "longName": "9954489 - Disclosure - TERMINATION OF MERGER WITH ILLUMINA - Narrative (Details)",
     "shortName": "TERMINATION OF MERGER WITH ILLUMINA - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:GainLossOnContractTermination",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:GainLossOnContractTermination",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954490 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "longName": "9954491 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
     "longName": "9954492 - Disclosure - FINANCIAL INSTRUMENTS - Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails",
     "longName": "9954493 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Summary of Cash, Cash Equivalents and Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails",
     "longName": "9954494 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails",
     "longName": "9954495 - Disclosure - BALANCE SHEET COMPONENTS - Components of Inventory (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Components of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
     "longName": "9954496 - Disclosure - BALANCE SHEET COMPONENTS - Components of Property and Equipment, Net (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Components of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
     "longName": "9954497 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentForAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails",
     "longName": "9954498 - Disclosure - BALANCE SHEET COMPONENTS - Definite-Lived Intangible Assets from Business Acquisitions (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Definite-Lived Intangible Assets from Business Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails",
     "longName": "9954499 - Disclosure - BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails",
     "longName": "9954500 - Disclosure - BALANCE SHEET COMPONENTS - Accrued Expenses (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails",
     "longName": "9954501 - Disclosure - BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Changes in Reserve for Product Warranties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
     "longName": "9954502 - Disclosure - BALANCE SHEET COMPONENTS - Future Principal Payments , Fiscal Year Maturity (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Future Principal Payments , Fiscal Year Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails",
     "longName": "9954503 - Disclosure - BALANCE SHEET COMPONENTS - Other Liabilities, Current (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Other Liabilities, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
     "longName": "9954504 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-226",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
     "longName": "9954505 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
     "longName": "9954506 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "longName": "9954507 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
     "longName": "9954508 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9954509 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails",
     "longName": "9954510 - Disclosure - INCOME TAXES - Provision (Benefit) for Income Taxes (Details)",
     "shortName": "INCOME TAXES - Provision (Benefit) for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails",
     "longName": "9954511 - Disclosure - INCOME TAXES - Reconciliation of Federal Income Tax Rate (Details)",
     "shortName": "INCOME TAXES - Reconciliation of Federal Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954512 - Disclosure - INCOME TAXES - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "INCOME TAXES - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails",
     "longName": "9954513 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefit Accounts (Details)",
     "shortName": "INCOME TAXES - Reconciliation of Unrecognized Tax Benefit Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9954514 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
     "longName": "9954515 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Summary of Stock Option Activity (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-270",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-270",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
     "longName": "9954516 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Summary of RSUs and PSUs Activity (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Summary of RSUs and PSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-283",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-283",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9954517 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-295",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
     "longName": "9954518 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Options (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-316",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
     "longName": "9954519 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-292",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9954520 - Disclosure - NET LOSS PER SHARE - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails",
     "longName": "9954521 - Disclosure - NET LOSS PER SHARE - Antidilutive Shares Excluded From Computation Of Diluted Net Loss Income Per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Antidilutive Shares Excluded From Computation Of Diluted Net Loss Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-332",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-332",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails",
     "longName": "9954522 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
     "longName": "9954523 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-338",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails",
     "longName": "9954524 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Summary of Revenue by Category (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION Summary of Revenue by Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "pacb_A2028ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "A2028ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 Convertible Senior Notes",
        "label": "2028 Convertible Senior Notes [Member]",
        "documentation": "Convertible Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2030ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "A2030ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 Convertible Senior Notes",
        "label": "2030 Convertible Senior Notes [Member]",
        "documentation": "2030 Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r800"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "pacb_AccruedEmployeeStockPurchasePlanLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AccruedEmployeeStockPurchasePlanLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Employee Stock Purchase Plan",
        "label": "Accrued Employee Stock Purchase Plan Liability, Current",
        "documentation": "Accrued Employee Stock Purchase Plan Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "pacb_AccruedProductDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AccruedProductDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued product development costs",
        "label": "Accrued Product Development Costs, Current",
        "documentation": "Accrued Product Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional services and legal fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "pacb_AccruedTenantImprovementsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AccruedTenantImprovementsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest payable",
        "label": "Accrued Tenant Improvements, Current",
        "documentation": "Accrued Tenant Improvements, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r225",
      "r652"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r138",
      "r230",
      "r648",
      "r671",
      "r672"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21",
      "r46",
      "r561",
      "r564",
      "r600",
      "r667",
      "r668",
      "r916",
      "r917",
      "r918",
      "r931",
      "r932",
      "r933"
     ]
    },
    "pacb_AchievementOfMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AchievementOfMilestoneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Milestone",
        "label": "Achievement Of Milestone [Member]",
        "documentation": "Upon achievement of a milestone."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AdditionalLiabilityAssociatedWithIndemnificationObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional liability associated with indemnification obligations",
        "label": "Additional Liability Associated With Indemnification Obligations",
        "documentation": "Additional Liability Associated With Indemnification Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r800",
      "r1015"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r681",
      "r931",
      "r932",
      "r933",
      "r995",
      "r1017"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r473"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r836",
      "r846",
      "r872"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r839",
      "r849",
      "r875"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r840",
      "r850",
      "r867",
      "r876",
      "r880",
      "r888"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "negatedTerseLabel": "Less: Share-based compensation expense excluded from consideration transferred",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r514"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r432",
      "r586",
      "r924"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r76"
     ]
    },
    "pacb_AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of intangible assets and research development expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) and research development expense in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AmountOfAgreementPaymentReceivedUponExecution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AmountOfAgreementPaymentReceivedUponExecution",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of agreement payment received upon execution",
        "label": "Amount Of Agreement Payment Received Upon Execution",
        "documentation": "Amount of agreement payment received upon execution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "pacb_AptonAndOmniomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AptonAndOmniomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apton And Omniome",
        "label": "Apton And Omniome [Member]",
        "documentation": "Apton And Omniome"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AptonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AptonMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apton",
        "label": "Apton [Member]",
        "documentation": "Apton"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaPacificMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AsiaPacificMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific",
        "label": "Asia Pacific [Member]",
        "documentation": "Region of Asia Pacific."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r229",
      "r254",
      "r288",
      "r296",
      "r301",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r556",
      "r558",
      "r577",
      "r643",
      "r708",
      "r800",
      "r813",
      "r955",
      "r956",
      "r999"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r233",
      "r254",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r556",
      "r558",
      "r577",
      "r800",
      "r955",
      "r956",
      "r999"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "pacb_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.pacificbiosciences.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r832"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.pacificbiosciences.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r832"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r832"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r364",
      "r642"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total investments",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r364",
      "r637",
      "r937"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r364"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through 5 years",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r313",
      "r364"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "pacb_BalanceSheetClassificationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BalanceSheetClassificationAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification",
        "label": "Balance Sheet Classification [Abstract]",
        "documentation": "Balance Sheet Classification [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_BalanceSheetComponentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BalanceSheetComponentsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components [Line Items]",
        "label": "Balance Sheet Components [Line Items]",
        "documentation": "Balance Sheet Components [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r793",
      "r794"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r550",
      "r793",
      "r794"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger related transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma net (loss) income per share - basic (in usd per share)",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma net (loss) income per share - diluted (in usd per share)",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Pro Forma Financial Information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Pro Forma Revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration transferred",
        "totalLabel": "Total consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r18"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share consideration",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of contingent consideration",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r106",
      "r553"
     ]
    },
    "pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationConsiderationTransferredRevenueAchievementMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "label": "Business Combination, Consideration Transferred, Revenue Achievement Milestone",
        "documentation": "Milestone Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r923"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Contingent consideration",
        "periodStartLabel": "Beginning balance as of December 31, 2022",
        "periodEndLabel": "Ending balance as of December 31, 2023",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r107",
      "r554"
     ]
    },
    "pacb_BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anniversary",
        "label": "Business Combination, Contingent Consideration, Liability, Closing Date Period",
        "documentation": "Business Combination, Contingent Consideration, Liability, Closing Date Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability, current",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r107"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rates",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, anniversary",
        "label": "Business Combination, Contingent Consideration Liability, Measurement Period",
        "documentation": "Business Combination, Contingent Consideration Liability, Measurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability, non-current",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r107"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS ACQUISITIONS",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r551"
     ]
    },
    "pacb_BusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination",
        "label": "Business Combination [Member]",
        "documentation": "Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Since the date of acquisition, net loss",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Since the date of acquisition, revenues",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in deferred tax liability",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Decrease (increase) to our benefit from income taxes",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Income Tax Expense (Benefit)",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Income Tax Expense (Benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in intangible assets",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term debt acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred income tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of purchase price to intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, non-current",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration transferred",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "pacb_BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Business Combination, Recognized Identifiable Assets Operating lease right-of-use assets, net Acquired and Liabilities Assumed Operating Lease Right of use assets Net",
        "documentation": "The amount of property, operating lease right of use assets net recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r222",
      "r768"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents:",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Investments",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "pacb_CashAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CashAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market funds",
        "label": "Cash And Money Market Funds [Member]",
        "documentation": "Cash and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CashCashEquivalentsAndInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CashCashEquivalentsAndInvestmentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash, cash equivalents, and investments",
        "label": "Cash Cash Equivalents And Investments [Member]",
        "documentation": "Cash, Cash Equivalents and Investments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r152",
      "r251"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r152"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "pacb_ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in The Estimated Fair Value of Contingent Consideration Liabilities",
        "label": "Changes in the estimated fair value of contingent consideration liabilities [Table Text Block]",
        "documentation": "Changes in the estimated fair value of contingent consideration liabilities table."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CirculomicsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CirculomicsIncMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Circulomics, Inc",
        "label": "Circulomics Inc [Member]",
        "documentation": "Circulomics Inc. (\u201cCirculomics\u201d), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r996"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r118",
      "r644",
      "r695"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Line Items]",
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]",
        "documentation": "Commitments and Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, dividends declared (in usd per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r803",
      "r804",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r931",
      "r932",
      "r995",
      "r1014",
      "r1017"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r696"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r129",
      "r696",
      "r714",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized 1,000,000 shares; issued and outstanding 267,744 and 226,505 shares at December\u00a031, 2023 and December\u00a031, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r647",
      "r800"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting right of common stock share holders",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "pacb_CommonStockVotingRightsNumberOfVotesPerShareOwned": {
     "xbrltype": "positiveIntegerItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CommonStockVotingRightsNumberOfVotesPerShareOwned",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting right of common stock share holders, number of votes",
        "label": "Common Stock, Voting Rights, Number Of Votes Per Share Owned",
        "documentation": "Common Stock, Voting Rights, Number Of Votes Per Share Owned"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r235",
      "r237",
      "r243",
      "r638",
      "r657"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r948",
      "r949"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r309",
      "r752"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r309",
      "r673",
      "r752"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r309",
      "r752",
      "r897"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration and Other Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r198"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r309"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r111",
      "r112",
      "r309",
      "r752"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ConsumableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ConsumableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumable revenue",
        "label": "Consumable [Member]",
        "documentation": "Consumable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Possible Continuation Advances payable",
        "label": "Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place",
        "documentation": "Continuation Advances Payable Per Agreement To Repay Advance If Change In Control Transaction Or Single Equity Or Debt Financing Takes Place"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r461"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets",
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r461"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets",
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r461"
     ]
    },
    "pacb_ContractWithCustomerLiabilityNoncurrentReclassification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ContractWithCustomerLiabilityNoncurrentReclassification",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract With Customer, Liability, Noncurrent, Reclassification",
        "documentation": "Contract With Customer, Liability, Noncurrent, Reclassification"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ContractWithCustomerLiabilityNoncurrentRecognitionPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred service revenue, noncurrent, recognition period",
        "label": "Contract with Customer, Liability, Noncurrent, Recognition Period",
        "documentation": "Contract with Customer, Liability, Noncurrent, Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued purchase commitments",
        "label": "Contractual Obligation, to be Paid, Year One",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Principal Payments , Fiscal Year Maturity",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of convertible debt",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r411",
      "r412",
      "r422",
      "r423",
      "r424",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon conversion of convertible senior notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes, net, non-current",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "pacb_ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes",
        "label": "Convertible Senior Notes [Member]",
        "documentation": "Convertible Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r792",
      "r1013"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Cost, Amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r254",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r577",
      "r955"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue:",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_CostOfRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CostOfRevenueMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Of Revenue",
        "label": "Cost Of Revenue [Member]",
        "documentation": "Cost Of Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue and Shipping and Handling",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r536",
      "r542",
      "r928"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r309"
     ]
    },
    "pacb_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One",
        "label": "Customer One [Member]",
        "documentation": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "pacb_DebtConversionTermsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtConversionTermsOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms One",
        "label": "Debt Conversion Terms One [Member]",
        "documentation": "Debt Conversion Terms One"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtConversionTermsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtConversionTermsTwoMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms Two",
        "label": "Debt Conversion Terms Two [Member]",
        "documentation": "Debt Conversion Terms Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE SENIOR NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r252",
      "r410",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r426",
      "r433",
      "r434",
      "r436"
     ]
    },
    "pacb_DebtInstrumentAdditionalInterestInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentAdditionalInterestInEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest in the event of default",
        "label": "Debt Instrument, Additional Interest in the Event of Default",
        "documentation": "Debt Instrument, Additional Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r124",
      "r125",
      "r183",
      "r185",
      "r257",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r587",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r926"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r185",
      "r437"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r413"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r84",
      "r167",
      "r168",
      "r413"
     ]
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentDebtDefaultCalendarDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentDebtDefaultCalendarDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, debt default, calendar days",
        "label": "Debt Instrument, Debt Default, Calendar Days",
        "documentation": "Debt Instrument, Debt Default, Calendar Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of notes",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r411",
      "r587",
      "r782",
      "r783"
     ]
    },
    "pacb_DebtInstrumentInterestInTheEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentInterestInTheEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest in the event of default",
        "label": "Debt Instrument, Interest in the Event of Default",
        "documentation": "Debt Instrument, Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r114",
      "r439",
      "r587"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r412"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r435",
      "r587",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r926"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r257",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r587",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r926"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid accrued but unpaid interest",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentRedemptionPriceConsecutiveTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, consecutive trading days",
        "label": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentRedemptionPricePercentageOfConversionPrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, percentage of conversion price",
        "label": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "documentation": "Debt Instrument, Redemption Price, Percentage of Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentRedemptionPriceTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DebtInstrumentRedemptionPriceTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, trading days",
        "label": "Debt Instrument, Redemption Price, Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r84",
      "r85",
      "r113",
      "r114",
      "r116",
      "r119",
      "r166",
      "r168",
      "r257",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r435",
      "r587",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r926"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt issuance costs",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r958"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r992",
      "r993"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r928",
      "r992"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Deferred income tax benefit",
        "totalLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r174",
      "r204",
      "r541",
      "r542",
      "r928"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r184",
      "r530"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r992",
      "r993"
     ]
    },
    "pacb_DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of indebtedness income and interest expense",
        "label": "Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense",
        "documentation": "Deferred Tax Asset, Cancellation Of Indebtedness Income And Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and experimental expenses",
        "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Deferred Tax Assets Deferred Expense, Capitalized Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liabilities, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r990"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r991"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r991"
     ]
    },
    "pacb_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "documentation": "Deferred Tax Liabilities, Right-of-use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits, current",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r77"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "pacb_DevelopmentAndCommercializationAgreementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DevelopmentAndCommercializationAgreementTransactionsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Commercialization of Significant Agreements Transactions [Line Items]",
        "label": "Development and Commercialization of Significant Agreements Transactions [Line Items]",
        "documentation": "Development and Commercialization Agreement Transactions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r832"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r832",
      "r868"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DomesticCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "DomesticCustomersMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Customers",
        "label": "Domestic Customers [Member]",
        "documentation": "Domestic Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in usd per share)",
        "verboseLabel": "Basic net (loss) income per share (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r274",
      "r276",
      "r277",
      "r278",
      "r282",
      "r569",
      "r570",
      "r639",
      "r658",
      "r775"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, Other Disclosure [Abstract]",
        "verboseLabel": "Denominator:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in usd per share)",
        "verboseLabel": "Diluted net (loss) income per share (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r276",
      "r277",
      "r278",
      "r282",
      "r569",
      "r570",
      "r639",
      "r658",
      "r775"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r279",
      "r280",
      "r281"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r522",
      "r544"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r994"
     ]
    },
    "pacb_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expense, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r994"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r994"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State tax rate, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r994"
     ]
    },
    "pacb_EffectiveIncomeTaxRateReconciliationTaxCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Salaries and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation cost capitalized in inventory",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r217",
      "r239",
      "r240",
      "r241",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r270",
      "r283",
      "r346",
      "r347",
      "r455",
      "r507",
      "r508",
      "r509",
      "r537",
      "r538",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r600",
      "r667",
      "r668",
      "r669",
      "r681",
      "r735"
     ]
    },
    "pacb_EquityIncentivePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "EquityIncentivePlan2020Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "label": "Equity Incentive Plan2020 [Member]",
        "documentation": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r836",
      "r846",
      "r872"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r833",
      "r843",
      "r869"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe, Middle East, and Africa",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "pacb_ExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ExchangeRatio",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "label": "Exchange Ratio",
        "documentation": "The relative number of new shares that will be given to existing shareholders of a company that has been acquired or that has merged with another."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ExchangeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ExchangeTransactionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Transaction",
        "label": "Exchange Transaction [Member]",
        "documentation": "Exchange Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r576"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572",
      "r576"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r108",
      "r110",
      "r180"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r572",
      "r604",
      "r605",
      "r606",
      "r782",
      "r783",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r464",
      "r469",
      "r572",
      "r604",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r464",
      "r469",
      "r572",
      "r605",
      "r782",
      "r783",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r572",
      "r606",
      "r782",
      "r783",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Achievement of milestone",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration",
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in estimated fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r604",
      "r605",
      "r606",
      "r782",
      "r783",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r32"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r593",
      "r799"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r352",
      "r353",
      "r354",
      "r355",
      "r360",
      "r368",
      "r369",
      "r370",
      "r435",
      "r453",
      "r566",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r656",
      "r779",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_FinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "FinancialInstrumentsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Line Items]",
        "label": "Financial Instruments [Line Items]",
        "documentation": "Financial Instruments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_FinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "FinancialInstrumentsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Table]",
        "label": "Financial Instruments [Table]",
        "documentation": "Financial Instruments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r380"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r379",
      "r380",
      "r382",
      "r634",
      "r635"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r635"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r634"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r840",
      "r850",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r840",
      "r850",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r840",
      "r850",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r840",
      "r850",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r840",
      "r850",
      "r876"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnContractTermination",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from Continuation Advances from Illumina",
        "negatedLabel": "Loss (gain) from Continuation Advances",
        "label": "Gain (Loss) on Contract Termination",
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r82",
      "r83"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r375",
      "r636",
      "r780",
      "r800",
      "r945",
      "r947"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, acquired during period",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r780"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Intangible Assets, and Other Long-Lived Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r69"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease to goodwill",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r946"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r254",
      "r288",
      "r295",
      "r300",
      "r303",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r577",
      "r777",
      "r955"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819",
      "r832"
     ]
    },
    "pacb_IlluminaFcOpsCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "IlluminaFcOpsCorpMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Illumina, FC Ops Corp",
        "label": "Illumina Fc Ops Corp [Member]",
        "documentation": "Illumina, FC Ops Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "InProcessResearchAndDevelopmentIndefiniteLivedMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Process Research and Development Indefinite Lived",
        "label": "In Process Research And Development Indefinite Lived [Member]",
        "documentation": "In-process research and development indefinite lived"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeApproachValuationTechniqueMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation, Income Approach",
        "label": "Valuation, Income Approach [Member]",
        "documentation": "Valuation approach converting future amounts to single current discounted amount."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) income before taxes from U.S. operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r543"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before benefit from income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r140",
      "r189",
      "r288",
      "r295",
      "r300",
      "r303",
      "r640",
      "r654",
      "r777"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income before taxes from foreign operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r543"
     ]
    },
    "pacb_IncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "IncomeLossPerShareAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income Loss per Share Abstrct",
        "documentation": "Income Loss per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r719"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r719"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit from reduction in deferred tax assets valuation allowance",
        "label": "Income tax benefit from reduction in deferred tax assets valuation allowance",
        "documentation": "Income tax benefit from reduction in deferred tax assets valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r517",
      "r523",
      "r528",
      "r534",
      "r539",
      "r545",
      "r546",
      "r547",
      "r680"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/INCOMETAXESProvisionBenefitforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit from income taxes",
        "totalLabel": "(Benefit) Provision for Income Taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r206",
      "r269",
      "r270",
      "r292",
      "r521",
      "r540",
      "r659"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r519",
      "r520",
      "r528",
      "r529",
      "r533",
      "r535",
      "r677"
     ]
    },
    "pacb_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "pacb_IncreaseDecreaseInContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "IncreaseDecreaseInContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Contingent consideration liability",
        "label": "Increase (Decrease) In Contingent Consideration Liability",
        "documentation": "Increase (Decrease) In Contingent Consideration Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liability",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r381"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets include acquired IPR&amp;D",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r159"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r840",
      "r850",
      "r867",
      "r876",
      "r880",
      "r888"
     ]
    },
    "pacb_InducementEquityIncentivePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "InducementEquityIncentivePlan2020Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Inducement Equity Incentive Plan",
        "label": "Inducement Equity Incentive Plan2020 [Member]",
        "documentation": "2020 Inducement Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r892"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r892"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r892"
     ]
    },
    "pacb_InstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "InstrumentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instrument revenue",
        "label": "Instrument [Member]",
        "documentation": "Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r74"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r192",
      "r242",
      "r291",
      "r585",
      "r720",
      "r811",
      "r1016"
     ]
    },
    "us-gaap_InterestExpenseBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Borrowings",
        "documentation": "Aggregate amount of interest expense on all borrowings."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r430",
      "r440",
      "r784",
      "r785"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r431",
      "r784",
      "r785"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r249",
      "r250"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r770"
     ]
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitment",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory, net",
        "totalLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r769",
      "r800"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Net",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r221",
      "r231",
      "r371",
      "r372",
      "r374",
      "r632",
      "r773"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r772"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r771"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory provision",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premium and accretion of discount on marketable securities, net",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total investments",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_InvitaeCollaborationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "InvitaeCollaborationTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVITAE COLLABORATION",
        "label": "Invitae Collaboration [Text Block]",
        "documentation": "Development and Commercialization Of Significant Agreements Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_InvitaeCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "InvitaeCorporationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invitae Corporation",
        "label": "Invitae Corporation [Member]",
        "documentation": "Invitae Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_LaboratoryEquipmentAndMachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "LaboratoryEquipmentAndMachineryMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment and machinery",
        "label": "Laboratory Equipment And Machinery [Member]",
        "documentation": "Laboratory Equipment And Machinery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "pacb_LesseeOperatingLeaseDescriptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "LesseeOperatingLeaseDescriptionTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Leases",
        "label": "Lessee, Operating Lease, Description [Table Text Block]",
        "documentation": "Lessee, Operating Lease, Description [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r254",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r557",
      "r558",
      "r559",
      "r577",
      "r694",
      "r776",
      "r813",
      "r955",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r186",
      "r650",
      "r800",
      "r927",
      "r943",
      "r998"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r220",
      "r254",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r557",
      "r558",
      "r559",
      "r577",
      "r800",
      "r955",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "pacb_LiquidityBonusEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "LiquidityBonusEventMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity Bonus Event",
        "label": "Liquidity Bonus Event [Member]",
        "documentation": "Liquidity Bonus Event"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total",
        "terseLabel": "Aggregate outstanding balance",
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r185",
      "r423",
      "r438",
      "r782",
      "r783",
      "r1010"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r257",
      "r428"
     ]
    },
    "pacb_LongTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "LongTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Long Term Restricted Cash Fair Value Disclosure",
        "documentation": "Long-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_LongTermRestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "LongTermRestrictedCashMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Long Term Restricted Cash [Member]",
        "documentation": "Long-Term Restricted Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r81"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394"
     ]
    },
    "us-gaap_LossOnContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossOnContracts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitment",
        "label": "Loss on Contracts",
        "documentation": "Losses recognized in the current period on contracts which are expected to generate losses, which are probable and can be reasonably estimated, in a future period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r456"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r789",
      "r959",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r390",
      "r391",
      "r392",
      "r470",
      "r631",
      "r666",
      "r686",
      "r687",
      "r740",
      "r742",
      "r744",
      "r745",
      "r747",
      "r762",
      "r763",
      "r778",
      "r786",
      "r795",
      "r802",
      "r957",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Risk Free Interest Rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity or debt financing that must be raised in a single transaction",
        "label": "Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction",
        "documentation": "Merger Agreement, Continuation Advances Repayable, Minimum Company must Raise in Equity or Debt Financing in a Single Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period in which company must repay continuation advances if change-of-control transaction is entered into with third party",
        "label": "Merger Agreement, Period in Which Company must Repay Continuation Advances if Change-of-Control Transaction is Entered into with Third Party",
        "documentation": "Merger Agreement, Period in Which Company must Repay Continuation Advances if Change-of-Control Transaction is Entered into with Third Party"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerRelatedExpensesCashSettledMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerRelatedExpensesCashSettledMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses - cash-settled",
        "label": "Merger Related Expenses Cash Settled [Member]",
        "documentation": "Merger-related expenses - cash-settled"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerRelatedExpensesMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerRelatedExpensesMilestoneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses - milestone",
        "label": "Merger Related Expenses Milestone [Member]",
        "documentation": "Merger-related expenses - milestone."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerRelatedExpensesStockSettledMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerRelatedExpensesStockSettledMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related expenses - stock-settled",
        "label": "Merger Related Expenses Stock Settled [Member]",
        "documentation": "Merger-related expenses - stock-settled."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerTerminationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerTerminationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination of Merger with Illumina [Abstract]",
        "label": "Termination of Merger with Illumina [Abstract]",
        "documentation": "Merger Termination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerTerminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerTerminationLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Termination [Line Items]",
        "label": "Merger Termination [Line Items]",
        "documentation": "Merger Termination [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerTerminationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerTerminationTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINANarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Termination [Table]",
        "label": "Merger Termination [Table]",
        "documentation": "Merger Termination [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MergerTerminationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MergerTerminationTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/TERMINATIONOFMERGERWITHILLUMINA"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TERMINATION OF MERGER WITH ILLUMINA",
        "label": "Merger Termination [Text Block]",
        "documentation": "Merger Termination"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_MilestoneAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "MilestoneAchievementMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "documentation": "Milestone Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r390",
      "r391",
      "r392",
      "r470",
      "r631",
      "r666",
      "r686",
      "r687",
      "r740",
      "r742",
      "r744",
      "r745",
      "r747",
      "r762",
      "r763",
      "r778",
      "r786",
      "r795",
      "r802",
      "r957",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r789",
      "r959",
      "r1011",
      "r1012"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r154",
      "r190",
      "r218",
      "r234",
      "r236",
      "r241",
      "r254",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r275",
      "r288",
      "r295",
      "r300",
      "r303",
      "r345",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r570",
      "r577",
      "r655",
      "r716",
      "r733",
      "r734",
      "r777",
      "r811",
      "r955"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Pronouncements Pending Adoption",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r840",
      "r850",
      "r867",
      "r876"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashMergerRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related compensation expense",
        "label": "Noncash Merger Related Costs",
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas",
        "label": "North America [Member]",
        "documentation": "Continent of North America."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes exchange",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loans outstanding",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r185",
      "r1010"
     ]
    },
    "pacb_NumberOfOfferings": {
     "xbrltype": "positiveIntegerItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "NumberOfOfferings",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of offerings",
        "label": "Number Of Offerings",
        "documentation": "Number Of Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_NumberOfPurchasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "NumberOfPurchasePeriods",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of purchase periods",
        "label": "Number Of Purchase Periods",
        "documentation": "Number of purchase periods."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "pacb_OfferingShareAmountMaximum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "OfferingShareAmountMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering price (in usd per share)",
        "label": "Offering Share Amount Maximum",
        "documentation": "Offering Share Amount Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OmniomeIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "OmniomeIncMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniome, Inc",
        "label": "Omniome Inc [Member]",
        "documentation": "Omniome, Inc. (\u201cOmniome\u201d), a San Diego-based company developing a highly differentiated, proprietary short-read DNA sequencing platform capable of delivering high accuracy."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OmniomePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "OmniomePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniome Plan",
        "label": "Omniome Plan [Member]",
        "documentation": "Omniome Plan."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OmniomeStockAwardsRelatedToAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "OmniomeStockAwardsRelatedToAcquisitionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniome Stock Awards Related to Acquisition",
        "label": "Omniome Stock Awards Related To Acquisition [Member]",
        "documentation": "Omniome stock awards in connection with the acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expense",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r295",
      "r300",
      "r303",
      "r777"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r799"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability",
        "verboseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeasesDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r595"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r799"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r799"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "pacb_OperatingLossCarryforwardsAmountSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "OperatingLossCarryforwardsAmountSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, subject to expiration",
        "label": "Operating Loss Carryforwards, Amount Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Amount Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options To Purchase Common Stock",
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options to purchase common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r178",
      "r674",
      "r675"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "verboseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r20",
      "r179"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostOfOperatingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCostOfOperatingRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of service and other revenue",
        "label": "Other Cost of Operating Revenue",
        "documentation": "Other costs incurred during the reporting period related to other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Liabilities, Current",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, current",
        "totalLabel": "Other liabilities, current",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r800"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, non-current",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r80"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r838",
      "r848",
      "r874"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r841",
      "r851",
      "r877"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r841",
      "r851",
      "r877"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "pacb_PaymentsForContingentConsiderationRevenueAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PaymentsForContingentConsiderationRevenueAchievementMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "label": "Payments For Contingent Consideration, Revenue Achievement Milestone",
        "documentation": "Payments For Contingent Consideration, Revenue Achievement Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForDeposits",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for deposits to Supplier",
        "label": "Payments for Deposits",
        "documentation": "The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r922"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent payments",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of offering expense",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash paid",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r552"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for purchase of business acquisition, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "pacb_PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions, percentage of gross proceeds",
        "label": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering",
        "documentation": "Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At-the-market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PercentageOfFairMarketValueAtWhichStockCanBePurchased": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PercentageOfFairMarketValueAtWhichStockCanBePurchased",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fair market value at which stock can be purchased",
        "label": "Percentage Of Fair Market Value At Which Stock Can Be Purchased",
        "documentation": "Percentage of fair market value at which stock can be purchased."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PercentageOfFeeToPrepayDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PercentageOfFeeToPrepayDebt",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fee to prepay debt",
        "label": "Percentage of fee to prepay debt",
        "documentation": "Percentage of fee of the outstanding debt to prepay the debt."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of common to be issued in merger",
        "label": "Percentage of outstanding shares of common to be issued in merger",
        "documentation": "Percentage of outstanding shares of common to be issued in merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Units (PSUs)",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r442"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r696"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in share)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r442"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r696",
      "r714",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized 50,000 shares; No shares issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r646",
      "r800"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "pacb_PrivatePlacementOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PrivatePlacementOfCommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement of Common Stock",
        "label": "Private Placement Of Common Stock [Member]",
        "documentation": "Private Placement of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma adjustment related to acquiree's acquisition-related costs",
        "label": "Pro forma adjustment related to acquiree's acquisition-related costs",
        "documentation": "Pro forma adjustment to reflect acquiree's acquisition-related costs."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of benefit realized upon settlement uncertain tax position",
        "label": "Probability Of Benefit Realized Upon Settlement Uncertain Tax Position",
        "documentation": "Probability of benefit Realized Upon Settlement Uncertain Tax Position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Convertible Senior Notes, net of issuance costs",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from equity plans",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "pacb_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock, Net of Issuance Costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under equity offerings, net of issuance costs",
        "label": "Proceeds from issuance of common stock under equity offerings, net of issuance costs",
        "documentation": "Proceeds from issuance of common stock under equity offerings, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r938"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r920"
     ]
    },
    "pacb_ProceedsFromRepaymentsOfContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ProceedsFromRepaymentsOfContractTermination",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuation Advances",
        "label": "Proceeds from (Repayments of) Contract Termination",
        "documentation": "Proceeds from (Repayments of) Contract Termination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of investments",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r245",
      "r312",
      "r344"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r27"
     ]
    },
    "us-gaap_ProductLiabilityContingencyAccrualPresentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductLiabilityContingencyAccrualPresentValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory accrual",
        "label": "Product Liability Contingency, Accrual, Present Value",
        "documentation": "Present value of the accrual for product liability loss contingencies as of the balance sheet date (if the accrual qualifies for discounting)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r633",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r765",
      "r787",
      "r801",
      "r900",
      "r951",
      "r952",
      "r959",
      "r1011"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r395",
      "r397",
      "r400"
     ]
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warranty accrual",
        "label": "Product Warranty Accrual, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r953",
      "r954"
     ]
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyAccrualPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repairs and replacements",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions charged to cost of product revenue",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r633",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r765",
      "r787",
      "r801",
      "r900",
      "r951",
      "r952",
      "r959",
      "r1011"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r224",
      "r653"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r641",
      "r653",
      "r800"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r199",
      "r203",
      "r651"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives of The Major Classes of Property and Equipment",
        "verboseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTransfersAndChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment transferred to inventory",
        "label": "Property, Plant and Equipment, Transfers and Changes",
        "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering, option to purchase additional shares, period",
        "label": "Public Offering, Option to Purchase Additional Shares, Period",
        "documentation": "Public Offering, Option to Purchase Additional Shares, Period"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicOfferingOptionToPurchaseAdditionalSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PublicOfferingOptionToPurchaseAdditionalSharesShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering, option to purchase additional shares (in shares)",
        "label": "Public Offering, Option to Purchase Additional Shares, Shares",
        "documentation": "Public Offering, Option to Purchase Additional Shares, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PublicOfferingShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering (in shares)",
        "label": "Public Offering, Shares",
        "documentation": "Public Offering, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PublicStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PublicStockOfferingMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "documentation": "Public Stock Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_PurchasePeriodOfEmployeeStockPurchasePlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "PurchasePeriodOfEmployeeStockPurchasePlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase period of ESPP",
        "label": "Purchase Period Of Employee Stock Purchase Plan",
        "documentation": "Purchase period of employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r390",
      "r391",
      "r392",
      "r463",
      "r470",
      "r500",
      "r501",
      "r502",
      "r607",
      "r631",
      "r666",
      "r686",
      "r687",
      "r740",
      "r742",
      "r744",
      "r745",
      "r747",
      "r762",
      "r763",
      "r778",
      "r786",
      "r795",
      "r802",
      "r805",
      "r950",
      "r957",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r390",
      "r391",
      "r392",
      "r463",
      "r470",
      "r500",
      "r501",
      "r502",
      "r607",
      "r631",
      "r666",
      "r686",
      "r687",
      "r740",
      "r742",
      "r744",
      "r745",
      "r747",
      "r762",
      "r763",
      "r778",
      "r786",
      "r795",
      "r802",
      "r805",
      "r950",
      "r957",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "pacb_RecentlyAdoptedAccountingStandardsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "RecentlyAdoptedAccountingStandardsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards",
        "label": "Recently Adopted Accounting Standards [Policy Text Block]",
        "documentation": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r833",
      "r843",
      "r869"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable principal payoff",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r516",
      "r1007"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r834",
      "r844",
      "r870"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r835",
      "r845",
      "r871"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r842",
      "r852",
      "r878"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash at end of period",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r181",
      "r222",
      "r251",
      "r645"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r194",
      "r251"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r925"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r169",
      "r649",
      "r670",
      "r672",
      "r679",
      "r697",
      "r800"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r270",
      "r346",
      "r347",
      "r507",
      "r508",
      "r509",
      "r537",
      "r538",
      "r560",
      "r562",
      "r563",
      "r565",
      "r568",
      "r667",
      "r669",
      "r681",
      "r1017"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r294",
      "r298",
      "r299",
      "r305",
      "r307",
      "r309",
      "r459",
      "r460",
      "r633"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographic Location",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r764",
      "r774"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset and liability additions and modifications",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r799"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue, Net",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r896"
     ]
    },
    "pacb_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive Shares Excluded from Computation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "pacb_ScheduleOfBalanceSheetComponentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ScheduleOfBalanceSheetComponentsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Components [Table]",
        "label": "Schedule of Balance Sheet Components [Table]",
        "documentation": "Schedule of Balance Sheet Components [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Consideration Transferred for Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition Consideration Transferred [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, details of total considerations transferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSDefiniteLivedIntangibleAssetsfromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSFuturePrincipalPaymentsFiscalYearMaturityDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSScheduleofBusinessAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTotalConsiderationTransferredforTheAcquisitionDetails",
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSUnauditedProFormaFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r550"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash, Cash Equivalents and Investments",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Carrying Amount",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r84",
      "r85",
      "r113",
      "r114",
      "r116",
      "r119",
      "r166",
      "r168",
      "r782",
      "r784",
      "r930"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "pacb_ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ScheduleOfDevelopmentAndCommercializationAgreementTransactionsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INVITAECOLLABORATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Development and Commercialization Agreement Transactions [Table]",
        "label": "Schedule of Development and Commercialization Agreement Transactions [Table]",
        "documentation": "Schedule of Development and Commercialization Agreement Transactions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation of Federal Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue by Category",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-Lived Intangible Assets from Business Acquisitions",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "pacb_ScheduleOfInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "documentation": "Schedule of Interest Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r135",
      "r136",
      "r137"
     ]
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Reserve for Product Warranties",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSComponentsofPropertyandEquipmentNetDetails",
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofTheMajorClassesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Classes of Assets and Liabilities Allocated to Total Fair Value of The Consideration Transferred",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r139"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Time-Based RSUs Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Purchase Plan",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation of Unrecognized Tax Benefit Accounts",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r989"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Future Amortization Expense Of Acquisition-Related Intangible Assets With Definite Lives",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r307",
      "r308",
      "r683",
      "r684",
      "r685",
      "r741",
      "r743",
      "r746",
      "r748",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r766",
      "r788",
      "r805",
      "r959",
      "r1011"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r293",
      "r297",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ServiceAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ServiceAndOtherMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONSummaryofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service and other revenue",
        "label": "Service And Other [Member]",
        "documentation": "Service and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount eligible to vest upon achievement of goal",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning (in shares)",
        "periodEndLabel": "Outstanding, ending (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning, outstanding (in dollars per share)",
        "periodEndLabel": "Ending, outstanding (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested related to RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional common stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock remain available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercisable, number (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in usd per share)",
        "periodEndLabel": "Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average exercise price (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding common stock used to determine annual plan increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options expired, weighted average exercise price (in usd per share)",
        "verboseLabel": "Expired (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "pacb_ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Award, Tranche One, Two, Three and Four",
        "label": "Share Based Compensation Award Tranche One Two Three And Four [Member]",
        "documentation": "Share-based Compensation Award, Tranche One, Two, Three and Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r478",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r510",
      "r511",
      "r512",
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ShareInstrumentNumberOfSharesConversionRatio": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ShareInstrumentNumberOfSharesConversionRatio",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ratio of number of shares into which the share instrument may be converted",
        "label": "Share Instrument, Number of Shares, Conversion Ratio",
        "documentation": "Number of shares into which the share instrument may be converted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in usd per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ShelfOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ShelfOfferingMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Offering",
        "label": "Shelf Offering [Member]",
        "documentation": "Shelf Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSOtherLiabilitiesCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term loan",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r183",
      "r800",
      "r1009"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r914"
     ]
    },
    "pacb_ShortTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ShortTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Short-Term Restricted Cash Fair Value Disclosure",
        "documentation": "Short-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ShortTermRestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "ShortTermRestrictedCashMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Short Term Restricted Cash [Member]",
        "documentation": "Short Term Restricted Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SignificantAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "SignificantAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invitae Collaboration Arrangement [Abstract]",
        "label": "Invitae Collaboration Arrangement [Abstract]",
        "documentation": "Development and Commercialization Of Significant Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StandardProductWarrantyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StandardProductWarrantyPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product warranty period",
        "label": "Standard Product Warranty, Period",
        "documentation": "Standard Product Warranty, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r44",
      "r217",
      "r239",
      "r240",
      "r241",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r270",
      "r283",
      "r346",
      "r347",
      "r455",
      "r507",
      "r508",
      "r509",
      "r537",
      "r538",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r600",
      "r667",
      "r668",
      "r669",
      "r681",
      "r735"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r216",
      "r307",
      "r308",
      "r683",
      "r684",
      "r685",
      "r741",
      "r743",
      "r746",
      "r748",
      "r751",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r766",
      "r788",
      "r805",
      "r959",
      "r1011"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r283",
      "r633",
      "r676",
      "r682",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r715",
      "r717",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r735",
      "r806"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r283",
      "r633",
      "r676",
      "r682",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r715",
      "r717",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r735",
      "r806"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r837",
      "r847",
      "r873"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockBasedCompensationExpenseExcludedFromConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockBasedCompensationExpenseExcludedFromConsiderationTransferred",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Share-based compensation expense excluded from consideration transferred",
        "label": "Stock-based compensation expense excluded from consideration transferred",
        "documentation": "Stock-based compensation expense excluded from consideration transferred."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREAntidilutiveSharesExcludedFromComputationOfDilutedNetLossIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity awards",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockIssuedDuringPeriodAverageTradingPeriodAcquisition",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average trading period",
        "label": "Stock Issued During Period, Average Trading Period, Acquisition",
        "documentation": "Stock Issued During Period, Average Trading Period, Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in Private Placement, net of issuance costs",
        "label": "Issuance of common stock in Private Placement, net of issuance costs",
        "documentation": "Value of stock issued in private placement net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in acquisition (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r169"
     ]
    },
    "pacb_StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with liquidity event bonus plan (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan",
        "documentation": "Stock Issued During Period, Shares, Acquisitions, Liquidity Bonus Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchased under plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r92",
      "r128",
      "r129",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock following milestone achievement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs (in shares)",
        "terseLabel": "Issuance of common stock in Private Placement, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r128",
      "r129",
      "r169",
      "r678",
      "r735",
      "r749"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r128",
      "r129",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r128",
      "r129",
      "r169",
      "r484"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in acquisition",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r44",
      "r169"
     ]
    },
    "pacb_StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with Apton liquidity event bonus plan",
        "label": "Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan",
        "documentation": "Stock Issued During Period, Value, Acquisitions, Liquidity Bonus Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock following milestone achievement",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in Private Placement/Underwritten Public Offering, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r128",
      "r129",
      "r169",
      "r681",
      "r735",
      "r749",
      "r812"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r128",
      "r129",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BUSINESSACQUISITIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options issued",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r44",
      "r169"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets",
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132",
      "r133",
      "r155",
      "r698",
      "r714",
      "r736",
      "r737",
      "r800",
      "r813",
      "r927",
      "r943",
      "r998",
      "r1017"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockholdersEquityLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity [Line Items]",
        "label": "Stockholders' Equity [Line Items]",
        "documentation": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r253",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r567",
      "r738",
      "r739",
      "r750"
     ]
    },
    "pacb_StockholdersEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "StockholdersEquityTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity [Table]",
        "label": "Stockholders' Equity [Table]",
        "documentation": "Stockholders' Equity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SupplementalBalanceSheetComponentsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "SupplementalBalanceSheetComponentsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components [Abstract]",
        "label": "Balance Sheet Components [Abstract]",
        "documentation": "Supplemental Balance Sheet Components Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "pacb_TimeBasedAndPerformanceBasedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TimeBasedAndPerformanceBasedOptionsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-Based and Performance-Based Options",
        "label": "Time Based And Performance Based Options [Member]",
        "documentation": "Time-based and performance-based options"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsPSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TimeBasedRestrictedStockUnitsPSUMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Based Restricted Stock Units PSU",
        "label": "Time Based Restricted Stock Units PSU [Member]",
        "documentation": "Time Based Restricted Stock Units PSU"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Based Restricted Stock Units RSUs and Performance Units",
        "label": "Time Based Restricted Stock Units RSUs And Performance Units [Member]",
        "documentation": "Time Based Restricted Stock Units RSUs And Performance Units"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofRSUsandPSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Time Based Restricted Stock Units Rsus [Member]",
        "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TimeBasedStockOptionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYSummaryofStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-Based Stock Option",
        "label": "Time Based Stock Option [Member]",
        "documentation": "Time-based stock option"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pacificbiosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TransferOfInventoryToPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TransferOfInventoryToPropertyAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory transferred to property and equipment",
        "label": "Transfer of Inventory to Property and Equipment",
        "documentation": "Transfer of Inventory to Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Option, Eligible Item or Group [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r435",
      "r453",
      "r566",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r656",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "pacb_TwoThousandTenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "TwoThousandTenEquityIncentivePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan",
        "label": "Two Thousand Ten Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Ten Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government &amp; agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r525"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in balance related to tax positions taken in prior year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in balance related to tax positions taken during current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in balance related to tax positions taken in prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "pacb_UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20231231",
     "localname": "UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSSummaryofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government &amp; agency securities",
        "label": "Us Government Corporations And Agencies Securities Not Included With Cash And Cash Equivalents [Member]",
        "documentation": "US Government Corporations and Agencies Securities, , Not Included with Cash and Cash Equivalents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r196",
      "r197",
      "r200",
      "r201"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted-average shares used in computing diluted net (loss) income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r278"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares used in computing basic net (loss) income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r278"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computation of basic and diluted net loss per share",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageRateOfTimeDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageRateOfTimeDepositsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share:",
        "label": "Weighted Average Rate of Time Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480637/718-40-25-10"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-4A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "330",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "SubTopic": "20",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483530/326-20-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-4A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-5A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479366/326-20-35-8A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-17"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3C"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479175/326-30-30-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-13A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-7A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3C"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-20/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-30/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "605",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481187/605-35-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(S-X 210.12-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001299130-24-000054-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-24-000054-xbrl.zip
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M:W?W+7] @NKJ<9>%&G=-1,160[0G9 HLE(.:@-P]0PYJD'??1,3ON2N.O2:
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MGY#Y%(5[QB6ZE;K%OKSH!6MP3%?^(.Z2WHPSU4V3,HPEAI5"%5'2+$)-#-C
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M+=5GKM-7<VE/ IO\!(67519MHF,RMB2HCHV\'J3TG3)+S,MT'$'WK.#$=0R
MUXNWW$.+=!<*$\W#(#<F\YG@MG434"/9XV)M1L]';#UZ0U]JU=BOXKR9C$;'
M.E -2)=3\$5U]!F\DJOJG4Z+ACKZ9'J396R<(QUE= EO(E*6 :I/SG^O$\P$
M1M2'-&?DE8%03&ALG+]#G=]Y_KA,9*Q(CI[)4%)(<Z?=PDKRG5:0I"9?S8&*
M0SQN1,>"VGC0=<;Y:MH,*5+>I5<2'+WZA_(Y7^HPR\*_VGA2^]RO48;5#1W?
M#>90N_-O7,RR\V\SO^U]"&DNA& R\"@7A<V]/S&+Q>:>Z9PZAW$1UJ=S7-BS
MUL4C,T^IV0K>CQDX,CZ][,'J%H0C4?41I7',2#1SSF[CYK$F&;#JS2XHEU:G
MO-??<(W;5=(&932 FD(Y.$ -,M%M*@1GM\D)OU^'=>%520F_X9::P$0)[ZS+
M3CXQ@=_F?A?AAEJE0!=S%95) ZP6&3,)"K#CL=++1O^)L7T,\<\I10$9B4=X
M^#?>N4<[80W)M&QRN(4$/TX*^WS7A<2_MM]LO0Y@.+&.;0U115)ZP;_NM;?V
MS"5J#33]G0ZA8YQ9:K\BG$ID4ZB%QPU15H0Q!72KI)J^-KZ@DV2+^[:GLB$?
M1PBOL7>0Q$_2@FH\,,FLGU!G;RM9_Z#CHS2(9/($)J5%,:"&;#QPZMM"3P=1
M21D ,,5=]_!#["=3=0Z)0/RG$VB58WR %D?59#8UY;+&N!01^&YC8T;P G'J
M:8_2D.@(:6GIT"OC'AH!</^P.?OHLTA*!&9X'?T;]2WXM!EX/7O0/2NB*DZO
MGPO!E<(8WA_6IN]:VO K,Q#84I]E$J=@PV7?6\$Q3!L8/%&"$J2!HR4H@2@X
MO3@#%;[[9H_>@G\=;&^W"=RN,N1MAS/./FJY4<Z6.Z56#4)OT;1$'#O'#/$X
M=9\VS'BAA![T-$(UN[\Z;35X7XP'Y<)6L-:^\]TLU^6NPQ$8,+KRC3>CNU Z
M194Q=R-#J-<.[RM33[P)CV[F QGWW%>21!&LZ1P-A)@['@)FS@?2>Q6V$\'+
ML%ZTD& OF#Q-BS/J;-X_J/> 2B,-/9I#W<W]HHP43VF8\BDC)-?,D:CU 9#@
M A=,F*Y.PM[ +S0?-J'+K> "O3&]8,Y\;=J1;MI8&0>84&OK"G0N;8X6"1O6
M$0MDLESU+\V1+*;*D!;S@Q/-]V\"MU?)@^I!UY%9BHY?)/=M1J@)P=$:HW+L
MB4M(N0*S6A)GZ[,\FG?5VK4V2FICY:C<=$D+6G\<8M(9=G;?UXZ1K169V_)Q
M_J*]@@7Z]*&N' C8N]9<MX?(Z'..*N9U;&I=]>&\OLK6(%? R*#;&YA2W/3N
MTRJ5.78)LX)Q3,Y(P.J&VP? 4/P=,PXZ<Y%<.(P/<I(('?Z1YTJ;#=1:0I?Y
MU^$#75[DTITKJ6@^50Z*L_[<XPH?Q PCLN8-N$QHN1E631N83&>='R.-*S'S
M2!1G'F6N39\:W6MLXK8$,!I)%_:8?!NWKUYS9,XIT)6J,K +Z5>,(B-RX]_H
M9PN<#P[G8MM"\-TP,,Z<#-9 FO!IH7:&(S-#C%7W4G  J+=Z@KP OZ $DK$E
M:>K$;FG+D'3+<9/J1 P"L5S&1INXA:>H4FY[EIK#.:EKBNDZ9#:J>YI5C\O
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M-F^@&5X(*EFQ]5<F3WT6L[.IHL$'1+R)PE8WURQ+8O9JI1'FUWS.2#D(&-T
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MA1F&* ;70I\05[&&*$%5"W/VK=W9D1OF!59%KCPV!#413=TZ)!Y7[#F#LF3
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MH\+7_+!=[8703XOC$<H4+M6B.3= %EP4P='+==4L6Q)O=(F@KO?3:B+5! V
MB!U8)%FHM*D(HT#,LHK>8P/!L&VMBX8CNE#IE+MEGHK;5N[T*OJG 1._.(&)
M'_T1'AM,?+*!'] 03<DS:D$@9<R1E#0T15B036ES/ 5.RIC#-7?KY%,YS1T@
MGZ*?5H%+YW2N/>"<7K?U,FE>9?>B[F-1U[2FZFYYQC"VT1[8TSP]8%)E;MZ'
M<T4.SDT(,0+J/#-6'CH^5>1V1K< 9*ZVY8@5^>1+/OQ<(M$BZ&@(C&/TF5)
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MF$:!QF^J/O#HZ?/9R\S'3(H UV6]YHW3R'2Z9N;P8/L^-HC 5TJK3+YD1 O
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MW[C49=LNT7G!J-BLV_O4K'WQVU,-XQ^^AO'T(-!C#1&)@?%:T5'PRY1?;M&
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MRR01NC!F($C4K@UV(W6H[Q9/N)0\?<E5,777A0,9?B'**+1B@A%MUQ^$8XV
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M6@VU0R_"J29;>D?%WV/E\ B4@BG])^!:J>22G&L")0,%/Y7PZBWY*'? G!&
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M@OE(;A$_PUGQ@WHY:6RIJ-Z,"7O(.B5K$69'%E?F(\=%JCT9D\10Y7()L\Y
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M?G.:\0>;\;QQ-G7XTW)*2@P[ B >*SWF^%E#T^>G]VF6'VZ6\ZI8G*C;9*9
MG"BG1!K1E8*C&#G-N&%&=-))R._X34XS_[#[&Y@RA4\P=1OSKNB^50GO<B9D
M_@CT<\.>V'7$/$*"/BXM5V255(^1E+GB5BOJJY6H2;DKE,QB^0W=]+0\'O3
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M*[#<\)2<G^/(2;U-P4!SJV=XH+NU=X(/E?8,G2$DY=G,QCI(I^L,7G(QOJL
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MR@_H:@5U-3(^]7)6A4><2T^9L:<'@].F^\%%LSI&26EU49>G;0AA 6N%A2<
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M737$!&RI7PKWPRMR+BT<WC3!=/3"3? N O$:TR[E[21YK >SF']PZ8=RK+E
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MNW^+?$ZU(:&3*0^.5KMQFG[G6)-BE[TE22/PF'.-L7CL^[Q'&_#VA+2N#Y@
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MIH*3XY0:HUW^1)Y\.TA%K&+Y-;)"*=(@9L\I\;R6KOHUE;TBY5.<(5 NF&-
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M! OM;!M>#*(<3+NPI7Q1F/TM-"Z(K*%;$<F8^VL(^L**>M0M'\E<4=6KG'^
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MY80?W^N%A<!TH2@;37,(OH3%(=F@V0'B[\=DWUV,'+RABU.]R_1P2NGJ!S#
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M(J32PS&\4'AU3BW+QM_=>D=?Q,',Z$ARJA[F$*-W<QQ%SCUP.=W(4<%^H]:
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MS!(N&0YN:F&Q!V<>!N<?%;36L;&@21>M<3(?X8(5;&7X,/-Y$=WBLC.96N9
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M1YO'  3M%)B%^_=V7]V[P/G%IU8DM[\AG2[Y=@E?.D_-CJ1P"9 K*K?4@R)
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M[_"FA7]-I402S*?%/N'1C\/\O*JKT^Z:I_WB:?'\Q@][7*TWS!'S]+$^[IA
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MJ;Y8\D8WC<D_^J+^KVU;S9X\*829T :KG+'T:\=L2AQC^DXYH$!;!D^BIHK
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M"M^U^&7W>".NC.]"M,/?,7,KN31M,'&8:)D$>CF*$OT7E$0M4N_8]-UD[A#
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M=1#<ETTD]GM7:%4_EBG,/!8<RX6>&&++P5H,WF-&"84+TT[6"V;9,^V!96L
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MP!?QM1,XY&@.ZYFJ.<Y=@&?3\T)UI:FIX9S E0LMX9/32S^Q/^ $WC*<7+I
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M269.X4.3-,A'Q<C:8^N,5 *JP)\@V0[:6<UF 7["68#_K6<!GD9F%N!IZ2S
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M+M)V8 =<H$D6SLUUX+4>E!#6J4\DOTRLVG<H_?V>W=>.I+ $[@$R ?(D]<K
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M2EUXE]3O@X>C%YBH"<Z^O:;Q,Z@7LYVO3%M'0C-M:?AW3+?](JD;X!#)9F%
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MC@0KX1E#'_^3)U+\T3W<!X\<QP8A0D'$ZG_J&6# >@(QG$P0ZG>:ARN@]L%
M'0[,NN[&MH47W^\$FS=)2AF,6\*<!;UD&CA%_^IKM?3P%VP-QO>()GOY9^B;
MH$CR2NJ67KDV6?RO)$,U-[WE. H@(Z@,P&F3Z'.M1H38)QI%8"2PAWR0N-13
M<:9?=,HO(C9OO<4?7W OR:?8FZNK*/Y!W9X9(B$L%H@B561:G2^0=ZB>W\8
M,0?T';&:P.+E;S&\SLMVL]5Q9OKQKTQ_ V_.$0]3C>.E%U_SSMI#VEF7^J:
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MH<<#TW^IR5+<8%$-! T.#@X:=32>U78I\7ZL1+4Q(LEB+&C]Q'EI7=)F,Y#
M7,N-O%=Y_-\,M'RM*WMB/B,3 "Q*YUQ;RN1-U(:S>[V)*4BRC4=*Z/MA&4GO
M2Z3$?. NTL"/>!$9C&8.JK,.]8*)J=_)S7Q<1^*-6VJMNMVG76>/GF?VJ,X$
M'70F:"=#[1%+E.BNWV/<$!6-'=(]=O[;#!1EZ'50K[[4#JJT]D,J[8?4B1\K
MWE&6+6G?,%NB#3-N8_$F_USZ6;\,C82F?K!KL.0PODD-8&#CRNRJ#N<.K%D<
MSA76]G M#4^CYF*?<0E/9@TV=H:*QW6%5,X-Z_=3=1SX/WE(1XYE*7G5ZS6:
M=S>I[+G&))Y7"L $#,N<;+L-03*L-E<@>5LUA<[8&JE6&BQ<G45FTGRK)%U(
MJ*HIJZIC<BT3C#XGR@,_C<NKU4\51 N*&;X\^_KMW\%W?/OAE9L5:>9S$'/O
MAS(!0RNRF)5*DV-F#=O.92>ES%J/3J2!@9@0Q"<KCZ;BL".7WU(V!2AW+"O,
M["?VJ!2)CLK2R"D,9>GIM8Z0EOB'II83!:.^C^*P3FN+)@VI@^I9S':^ +_/
MS+)1)@L$V_Z'S"_6XDO[UC0'!:?^2+<'1^@QDU#^=GA+-K<Q7[Y.\2!=FUA"
M0\53KD7?<S"#ZG#L'89C]XC&E@5<"Z*<8X \SS:7G\T"8>8IU%%:(KU Q/CJ
M2O/X.J&QE+%I(O^+$D*+\[6BPHP_EF65+,2L%%X#3R5KDNM&*)BF W3KWDQ*
M4@Q+*]J7/OU<Y'<^U4+J=[O\)C*1R*HAIF+_UKJH<J&%J6C19+IW'DU5D#7G
MX91G9!$>;)I]3+HG?)HK:_63)8C#0",1$83 "ZX350B8LC*UB?728^:ZB)5'
M)\-SFK5FT^U6*Z83G5:6,#%] -OBR%9<-R/5 K/D3!S-#'D)86^!&Q(67BR+
MF%L3T2DPKT>PX9B_*4Z9S5*D%G) V=48KX@*+BBF?[$$H4*3J!FY0X_^$W9+
MO#EUN@)QQQOFK-VOFE\;OZZ83GB=O';VG@WR&7Y@)H,,C]Y]C'$8(QG7SM_!
MRKMP?O_]Z[IA(54_$8T1@[6 /-Z]U ?BDP -A+*AW6RU#J8_>>_K_EWR2>;*
M1T?OSF&Y8%6IR+70;P[URLM1'%97OR/$6N?(^M)..OG9)+4Z=X)AUZ\Q[)YP
M)JS"0Q$/9,3CQE$I3ZHA;=!JC#KEO]H[=]AN-(>;<X>[_[S;[-_=HCKWEM <
M5610XW"GI*7=NU,VK+&*P[(&*T@-Y3B]+\EYB9;P$/2/U"_$+4//TDDN"0.(
M04->[1"UVCY@LLJ7C"FS.]GDK<=P5OR4VONPP-B;_+B(@82FQ[*PR40IL"@>
MDS=VV^H)!G]V&1:W=H^WIY5MIW?3[]_=+-C55\SH?Y6ZX'+1=ZHK+>FB=XG+
M;]WLWO=Q7]]_"FRYYM80SM/@K&(Z]:<7Y*=NRP7NL]>F4]T=O[C5QNP-43-4
M!78DD:!/L12F+$.?XT#+9'I4" QUCQQP%/VY%R1_.3KNZ##1,CF^\+S%&R2'
MDW"*__F8T<))>NK%,8::L;(,O$JN8 8G_U?Z)ES.CZ<1^9_X6& *. Q%[,%Q
MIF[SZ%UK,')'K9:.+.FEON-0S6UN! 7N7C=S-^JAYH:GP V]1^"&UM&[3KOG
M-H>CBG##TS5)SL*?*DGGI>K,[+2]WTY+F?D0:7^+)CB_C.+TNXKGUB'N2^KM
MHW?=7LOM-7NW)?5RDKLWP;^+'?E<Z6:+S+P+NND W70';KM]:Q%Y1W3S=.W_
MDXEI]Y\HT'!C+.0)K2Z!?<3EKK;/(9+]%G&IS_&;.<;/*A67>%_R[X*%T'?[
MK5M+S>J8R\^>?+9(S;LDGQZX6T-W,.Q7A'R>MGT9IE%\?7.1^90MA2TBTYP>
MD/J^--X_>M<#$3FX-8W7AF5ER&6+B+P-N0R 7)IN9WCK %1M3VZY\*^Q6G@^
M#E18J#!1=KWG9,<$P7,U$;:(2SG9CWRP)^'T"YXJI]5N:"D,,3#K-KO-BE@*
MM:%Y[U+T'JAH!%34=-MU///>Z8!B*\?8/X#E]FGLTVPBS-S5MN=^PO2;.3X,
M[AO"+])VKPFN>//6XK$V,BM#%UO$XZYTT:H273Q=:_)[E"((W-T9CKN5BST9
M:M\6M+R%VN^UC]X-NFVP'@=WI/=W+N6KNEWYS(AL6VCS-D36.7HW[ &1#;J5
M)[*G:W9^C;%A7.9Q8XG8@F<+AFI#^_US-3"V>O%\EE\#+TS!_?JHCW/_J%:/
M\T3=3KLB=DAMGSZ ^WYWY-,[>M=MN;UA;<;>-P%\,7@;@?)H&BW\[CB:'2.>
M$ENUMY"F3SF:M46:FH/]'<_U&[[DR^S/1)'-L2\_]+$PS^V-.A6)8]71T'L7
MIW=*/P.@GY$[Z%>%?IZN0?I[%%[48= [#X.NECI_CL+)S1RWX=&[MMMMUZ;I
MTZ&EO4*G=TE+(Z2E465HZ>G:J6<%K*ZD+@6]45V3/D4.?8%K]O&7C&GX:Q1-
MK_P@V),%^DVLI.^[H^%=Q<%JX_3QZ6AKP=/=TU$+??ZFV^Y6I;;XZ1JI^HIJ
MFW0_\7E3TL9FHW[;;?>K4N17VYSW+B)O2BO88-0<N:/;IY5JFW);[)-J/P/C
ML=?5GS>+=&9E>C=VI/K=HW>MCMN^LV1J;40^/MULBW#>!=WTJ,*SUQY6A&Z>
MKM'(!4]K9.2V[=VB[J0BV]\=C6*_+1\ZD^]4Q[4O5_>!J]U!M^\V6[=.6>QU
M'8]D3-?L\US99Z<*M7W99T#LTQ^XS=MWVMX[^SP%_Z(<5_!WWQO[@9_ZTFMV
MGD:3'Y=1@$-1!.;=P2Q$>GTS2+K5NL$.G/\T6F*4O&KH@UN7]G0M)PT_&&3T
M4$,0'L3-&0B2A7=-8-4U\N!3Q%K;$4#E*Q/!S>K%^]C1VG.;_5OGBJL3X:BI
M_RE0_X[X+[>C?NS$;;O-.D[S$#HK7BH+YJ#.\NTM[O$ +>O]9C0_H,H(=]"\
M-<W76;_*T,YV87DWM-.2BN^JH @]71O_@YJI& <URVQAUS3UUHG /1&ZX</X
MF+_YZ>7I,H&=J%ASPO4-^: -=D/?[72?D-7\[,EH&[3U/9!1!T$1W.ZH-C\?
MNJ',"GH9R5I;I+?I);LM+W2/WHW LJAKT9X._>S52W9;^ND=O1NZPSO++-66
MZ9;ZM!(!6INF-ZE1N[U7UD?2[[2K E]<&Z,/4Z1V>\(9'+T;N.U.W7][[[E6
M^ 2L$&4DW'/B3Q4/'C9B]+JV0F\H0]\O$WA\DIQ&\[$?TJEFIWUJ'_9F"V/F
M_U+3XW^I."IAE.'1.RJ-:+^MB'E1FZ?W+F/OBK"VBV',0@W:;G-4-U<\+#ZB
M9<36((EW)I%O;9<,FT?O1CVW>?MI1C50XD$3VA8)?7M":QV]:_<[;J=S5]V]
M%2I(/1CC>#75!?=P?*N8PE,V6VZ3[KIQ1].P??2NY_8Z58&^J^W?QTUXW9R0
M.M0%4)NZE8@Y6(*VCMW>>]SAYDR#?<@CM]>KY\X\'?JZ^_##.OK:%-H:]NXL
MM%5'@6]3A%#;O'=>B7!S>8O(MBVWWZQ*-KDV=Q^K&N'F-#0@M/#FH"HNTY.V
M=&D1V J7J-"/8I"FJ6(PQMK(O5TP09\L0@CCE/K/>++2=;,O2PR/W@U';;?=
MK4K&N;9C'R*,<)<D-$(2ZKO]855(Z F;JZN%7K61>G?%7K9E423S4?/HW:!7
MU\(^'>+8LZ#KQF;GJ(7QU7K4XD.5$M0E!/=<0K O_6-KEMOL=MU!LRX?>-Y$
MMGOYP+Y$1DFL=K/KMH9WU0)X[Y4#>@5RG!V@H <'Z=F^R<>"#]IC94]7I9U&
M\[F?XG0\A@:;Z(3#9*-ZVUMR[:LJ?B7^F] /_G*4QDNUZF":1>,,%7O)AE^[
M\,HBF][!/FXKP?>59K<^A][:<ZB0D*C<]Y\NPY=A_RG"_KL[9G]X?+]'!_&;
M^C\?=MRPKJ!+\#Y=Y\4FN?)5Q>>77JPVFN1GGS^M3E*5MQ#1?/7B+_%YZJ5J
M^M]>L%394\58:AJAT]\LY]:MIW=?ZQD<O6LVFLW5Z,K*#YR%%SL_\7%O##_0
MW=8 B=7GBI-E>AG%\/FILY;\$B219.^1PC;A$94EV<OV=26&&[BC?'E;!V;?
MY?)&1^]Z3;=9$D]:Y19>[MM]CWL_P<,;.DN297$S)64NANF!)&YWSCNNZ\LR
M35(PG8$_]EE<:^_%[2<=;WIH[0=9UPT/#9SPS]%VLMR9<!V?SL>)8B?*5N1L
MD?S/->VWEQ0BE;Q[45JKV:U:55J=*;[W>-PM2>;9%S(^L'V%\88HO#N7HZ1R
M %^PIW7?:MZ%NW%7:ZE=C=K5N(VK89'=+0WY5O/.'8V[7-R(LG;-?3T-L=@P
M5ITSV>YWGV5V]/8]MF[I@>RPL+6&] ZKHU;8@3OHKG9FK9X_'O@]4_H-#_F6
M'LL]'S*X+.UVW^TU5_N-UWHE7NI\4!,U'ZN8[9A.RW7:S7:';J'T5VW7@6\N
M%#SHIPJN:Q?FAL6OYN;%&%V]T"YR357@.VL?Y0&J6;?31 ^9?% 1FGBZY:DG
ML$ \6"\ V]F?'ONA,_$6/A9EU:6I^TFZ["B_PDF>A:=\CGNK-W"]VFZO,W*'
MHUN7Q=2UJY6AGFW3!>Z(>@9(/<W1R!W<OJBJKE[=/H]E.5\&&,5P(BKTGT3S
M1:PN59B T>CX(?Q=.2^#*$E>U6U3>\K3['"IL/O4/MHS.MG?X5P_J_3+[+OW
MJXP9P%MOM^ZJ@+4V+.^'9%[>2HHFL&KXTZV)9T\Q.SIZUW4'_54/=(7-:]OT
M+J3K5,W\B?],^J7VXH@5*;J&([ZIU(,W33]Z<0BGD%BG^X$/=U\F:#<QWC@$
M2[4YN TCU$9J=:AI5_EZ#]1$/5>]3MOM=%>CUP].34_7:.66JV1MT6K=@75G
M)JQ=&<S3P/?FBO;1NT$3>Q%OC?56]V$=-*EMB1_< :EUCM[U^FUW= "D]G2-
MWM6&6$Q0[2&M=^S1XJUA;XHSC98(^D(7<PNFJL@![C[P^2X/Y-"ER^ZMQ"?A
M] YD39< 3+M]M]FZ-0;)'=[C(_D=-<_6/'N?G=EWP[,]XMG^P&W>V8"XQ^)9
MLA]>IXB=I LZX%]ZN7,OOO!#>F\_SR\3!1<0WQ%%M)K;2*)-[85*.=X$$PM>
M>&W7TJ]9PVQVUVO@$P#*B!@K]0U<I(KQ4W 2WF,OP;F,D1_^S6^VQZ/N<##H
M];UN=]9OC]7$ZXXZT]YDVI]-^][_('0:8=K]QVOOW993O(^;=-+(22\5(4DC
M+5-D<^:'7CCQR26''U#K<:-0;&31ICRPVX,W+J*$<H9O8A5X6*7T]LJ?II=:
ME%C?$@9K9E_QQK"$9;K^*X]']:T>+&70+=1;6?_&5:)0VG[C.!5(OG1IVK(7
MWH4Z'L?*^W'LS6!C;[S@RKM.4"[80@ D@'W8Q7-Z*/Z#TWAL_MN\A-WY;P#N
M#8I<)YHYV%J/I&ZS8O&.'UD<#TJ9^.O)Z=FGLU/G_=F7\].SCY]//YX[7SXY
MIR>_GWWZ\NWSV8GKG'T^;:QEX&KMYM061>=& .$-"98K?(!<T%P&S<'DV8Y;
M1.P#NG4CBTBKP\8";Y&H-_H/;Z=^L@B\ZS=^2.ND+[V59XD 0T8L*'4Z0/YU
MQJ.-)O.IA CDS?+K!OSJ]>K/>\-&J]LN_56ST2K]^;I'M=J-YK#\*^L>M?[G
MW6;_B2^JN_%16V(]&\.(K=[*YTJ\(&:\![7^5[B1Z/7ORHL3YR.(UJPFV>FT
MW)Q9O>-Y/(:W-VCT=DM)^2$80M$2'C)-7$?]FB@PXD'><+FVX\W!5T@WE,Q8
M?O:N/D(E+QPKT.]DD]N:C []E-KU*>UP2JU]!,4!IS"_\8RS-[L0Q<V3$X^%
MO/,D5G9'&1H.6C8K285?XVBZG*1ZXM[>F9@G&YU]4E'6_N8HJXBB3W$T+YOU
M=A9.@B4>QDF2*/C_] ;%ANW^T;O6L.,.!U6IZ'Z E$?-'(? '(/'9XX!,$=S
MZ/9'MZ[SKIFC9HZ[9([AXS/'$)BCU2EME3[H7J JFX7G*O[I3Q3C*5!3T#H#
M\4FV<^S#(:/'YQ#$S.B[_6[=)?1TR*K5?'2ZZC1IV&S_]H*WIJOJT%7K\>D*
MNR0&;K-9%;B,.XWSC"JIT+DD]U9*/%_N]%Q*UBO +FV,BS?=7ONNQH!5NHZT
MIL7UM-A^?&+$@3?MX5WT\M3$>-C$V'E\8L0*_ Y(QKNNOZ]"M\_!)#)/HR3%
M6JN[2&@^=G*P<M]_!BE(33^++:G(?63QDY2X6[)X>(Y?9G^-HBGU2G $[^,O
M$;,?U"*&+U,Q)/PY4/@'^-S)/((S^!?]?&_YB]T4[8';NSWP877R%L^>S+;D
MPQZ!S/I'[_I-=]1Y0JGC9T]E6Q)+CT!E VP==SN]JLBR9Y!FTJH_J=--=Y1N
M$J P9![I?0@OQ##?FR$P\=IU![V[@E*HP_^/3S[;TDIW23^8ENRXP]L7M=3T
M4QWZV1(/OT/ZZ39)_HR&5:&?9^"+VP84*F9O\O^S]^[-B2/9ONA74;#WG%,=
M(;M!O*LGB*!<57V\;XWM6Z[>'>?^LT.&Q-8T2(PD[/)\^KO6RDPIA21 (&P)
M\D2<V=4&I'RL]^.W_K5R<)ZHXX:V^^A@"YP=!"P,M'=>+%&4:= &]][\(*.U
M0X!SPT%9\4_M&56 D+9D>7:EI#2Q( Y;6Y/*"9'*EAS,_J32;HS:S;(04K0G
MO/76L1?=@-M>KOS)DQT@OL9BX838R*Y=X&*:%H_RUI4YQZ"P2NT Z9N=]L'$
MK[V6ZE#,%I5Z*,ETD63ZND[RE$AFBVK=2#(;Y]-V>B<ZG[;Z]8\3$6_6=9#'
M<6_WC?1@_UL'1T[J"L<SI[*=?-]]R6P _N_0M'IE=5EJ*JLIE>WD-N]+94.@
MLI;9ZYY-32*]UQI44N__[J-CO?2]V;Z#=\X3J7^+NJ=CO:-3+<H?W69CU+7,
M_B ](*5J"/UZ&,1[ZOI#:*S5&'6&9K-=ED>N::RF-+9%TQ]"8Q;(L8$YZ%5?
MCIWNI)&HQL#X\G/)W&#/[H-=S.AS_/T9)%Z^LX#9_N2):@^G8/+/O25F773E
M8>%.6'Z08W?Z.3Y&P9:%A2NV&0[Z9JM?EG2MF9X^30K:VK]:)@EA<^"P;<*F
M-0F=#@EM[3HMDX2POZEE5:B$]0Q*$._A$@+3>&0NF'9S4LOV=.&X3A#Z-"!$
M-P86U,SW; [/?_R=GRBVR23.<U_F0$3/WM <M*K2,*,KRHZOHH]$2Y@ [#7-
MP>&])IJ6JD-+6W3UD6@)VY:LC@G_OR*T= 9>]#^8_\C\"YKAQ:8&XU>W7Y/
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M?]) :==<RUZ.PW==*]+.,G=W"0QLZ\?N(OY<1O)E/\?^'9J9-,MHEMF=9?:
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M9S9;L]-\N]F: ZRDZO7-?B>-&%=V7N+MZ. T)LB4?RRU8HX,W;2-,W::SCG
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MQ7AKCY)1'9NF2D;8?.I\)3.%^44A*L9G6 /771I_K#\T+@/#A%9RA=+PB."
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M\#"NC++%0#K*7!OY-S6KH%CV"KI>-BC1]IDO8L$@$=WI0BE[" 1PILQ%X:W
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M6:64PG2!79S6-L(PMS1Y2#WLJ).HUV$!J)WOU07UB5$!#@C%;1YJ^^/V+;<
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M5_O1N-]6[,-VFV)[1LJJ$+#=-B8;R[XSNHB\N;U%F:F#Z>V!.;32MIP&JM-
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MN-01D38X_T^(2+)6JH:(=#KAU9/"JUZHLM$+7P*R]"6RU U9-KC/3RB@!E)
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MG*/IK9"CO2+KFYM ]E,!O05PSXEI6 J\&^['L=F>2HMH/0V7#&!G?P5P Q;
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M6?/D>"F9EC9HA(4)"2-9@Y[:ZF85P8Q%*@78H7CTB6=U;+<1VP?JW+)TIU2
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M.R EZE4']4Z*>:7IJT,N?+NM+/95C?N56G8VK+ FNZF?^5K[\HR6>\*L]XK
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M^5"AWFV!4&]M$^IYF/"PL$UD_&NX\,B6/F\T%)EZ\0WBA>/01/C91O@G+K&
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M:HD*AZ/:X:GR:OISI*' S4@%<R9Z"GFB;U!$7KR$?AIV#,@IP\&A-+[OFN.
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M*#[.>,(G_[N0MU5+NUN[FUJU_6'Z\SLXO@/W'.6P[$<'O9@.L)>0ULSZ!!0
MEX5[A?U/PWL2GD'UG"<JE&:<.-@0"+S7S#8Y2![L=6Y.YLJKD<YLRAYWPO=
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MYP?0D  V"5"E_B4<=H777MX)[N(W%#K,H#%J9P^3V&]:EM&P%QQF$,HM&K"
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M"1JDO:]-Y0?9&;>//W"+K9N6\!1&;Q-FIEB5WL4C 7;NP/D9X[$<<WVX/6P
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M8%B??D[@T0/'0;1;C5%7[;8KT.>^OD+FVWI"U[90I.RD);N0[,4@CDKL3+(
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M. T(V(_,,EZ1-<(?7!0_NTRTFJ$^(3P'SN&M?Y@!;%_T(YB:+B.>Q+G4#*
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MJ5"<HC&/=ENX-!EXW!IW#(D;4R^2>A&:M&0%"S4S4E!%V^/-_=FY?R&;"6+
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MM$@V6J/Q8H AM71Y[FZ$_AT"(\*R!ZSD2]R6N-POD&+E?/CSTJ.IX-$TUW#
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MQEMDYF!;=]JK O(<KI%L^@H:4>0OD98+ADL31!+!3]^1P]0=)KDE!_;HT?<
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M>,3BWH(][SQ.#8N?) ;E.5OB\NO:V45?UCO):'C9%;"">+*(9U]0>+L1SWJ
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MR9NW5F@:>1VA<8HGY/>Z7#%<UMNL4MQF#?V*38\%ZBO#_XF[/Y5RLM?O!3J
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MQ 95SBZTUB"11[/#[N7E[Y/<_5ZU=A\;?X2).;7=_;62\  !AE)(HU\MTNB
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M0%S!.G]$A*K2\'<%.G,Y0!)':V#86'@MG6BQ4O]RRUX#C$4D41^:"Y&YBM3
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MVI_-(RSI^!5VDM[EHL:6WJEMI2--'&-.7FWGS_?2._K8VX?;X*WO(^K(YLW
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MA>T!\)8@O?_2GL]-%VWOEB#:[8FV4;0+KP?3#V5<2,.FQ<Q%],MBMB&E5]]
M?$4$<4Z93V_2G!B,J$$]_XEUM>YR- VIF1+G$XC1/XGG!L?C]*2=OG9BDG'V
M*-Z9[R63G;[#-S!3@\$3OC/AAU=[.4,X0B:</1/-7F"'J>',)TMXSD1:T*)?
M^ [LB=',=LE8,, V#/"_&T'S(&>E433[%L2DYQFC*?..?/K&8A%*9)AH#91J
M>)(Q&G&(,\H)0\M:&M@W':E< C*E #M*^_R?---CC+ Y(/2#?$]\&)(PD]P%
MQ#7]'A^)=WLVTKIIC6QG@;EDC/T<,@%' A-63 NNP#'":Y /$? G)UQ/"/ 3
M&1-/$58&G4X4M$=&<VCETE@A&;M'B]_S.B5PCP-</$8U!F\G^!S:%)0^#4'F
M M68O<"R9#H.<1<<611NP!D_$PO\WEED<7#QP$I[7J);')-E5#RQ)4H1!J+;
M:WJW5SV[VRN.W1S_?V>;6XPJW>[9Q9YZQ%:N#>RQAG#@CJ\I<GY?M-E+E>K7
MCU??):7;^OO?E&[[4_+?K[?WWYEL?OCQ_?OP_E\Y8Q4'G%BZNKJQ+=+*'.S!
MY-'114^W'-$S$**GP:)GOZ29+GD>X,6&MP1S1*J+3+F+%(FAU84A"M.AX2YJ
M&8;596B=*?J[\?N@@*R(N;>"#8\AD3&VV*'>WWBC%<U,71>6"2Z&7TSJ.DZ-
MV01-7GPX)3IV 7V;0Y9H_M*7&$MO:CNP*N-6WHVI6F ZL[$WN"2=3BF1:;6T
M%N@=I:7U>F7$N%.]ZFX>%_, R,>;I0+=SYP^5XXXA+*/0,11XA7E5_%LEG=T
M,[Z 5_DQZ#_!#$*U3T&;M15=LU5D8^\GBCGG^?GMXVXAFF/P3_I4/K@?I,NI
M ZK#A'?>MJ3?B.6\I9ZV'(8WN"Y 30'726 NFV,)IW]D)/;5H%>Z.$HNY?%6
ML@[KA<E)-!3M=S-( QK)([S5HPMOH4Z$.CF2.CEV.XX"NB;6LZIXH:_0->%R
M1I=2:)GU6CD=\Z6>BN7X(Q**Y4042[7\E._F:$IF1/IJ./,,[A5Z8[,TC"^C
MT!SKUNIWT!-2FI,20;;/UB;'/]X^^G%2+_LX21P,B8.A,@Z&[F[_N+J7;K]*
MP\?'V_N;JW_5YGSHGS>W?TC#;]^DNZO[A]N;!^GSOZ3'WZX>KJ2[>_CWYO%!
M9AE1Q, D/^*XMB6]3FV7G=;0TS".DX,G-C/[E=8Y/+UA#@[,QUMZ/-L)+K)-
M/'5*!JCDF$\F2Y\=XGG2T/O3M%R9WAQ7&.P[.B)V5C6GAU%XQF0[^'[)<Y:$
M7C0S7C$UT "QY5CD[1R6?H(9WG1$S[3;)4W/@HMFTL)^A7OAD>[RB8W=3\D"
M\1OY2J;YO?3]I@5[:XZ7-!=)\GMB&O"PD;$P1O3X3,;C+5RMV._TZ(R=P]&S
MN0U94'@;7(<99?0\S(7[^=CQ:3RWV&5'8S0O;"S9- /+QQG"<B#<%8L?^7E^
M08I<)$--EI[QA ^U#CV <PTP//SE=9/KZZ9M5F2UZ87L_,Y[PQF.V=@7K'4=
MNY$^@2*C^<]&1*5G=IH)BHCM-4R,N"XV[F7'B6/;(MES!H+!8;S1O<0E-)GP
M86]?.J#A<!6 K&CBF@O_-T?&8<4!F(@*(X6G,YZ0?;)'43AYP\'Q@JN)Z<SI
M1W@%Y:0<*X8C E()UHLGX(7$AIG)2N^3&U(J$,/<>./TC@FP-ATH2[X-EP-&
M^&(Z'G 'CM>>9.>;Y!54%__SY'RX$&DK2E_8&:=D9U0RG6.+O W0.PY3.$$=
M"\_#X)D7$WL&:AU%&!-U+FHFGIR1Z-3G@^6%VH]I(BO(^76I&,/:JW%>X5.;
M9(W6H%-.A@6VL^RMKR+,^RBMW=)00I7P*&70:NOIMQ1]%"Y5*562#?#P@[2R
MRD?*\LWGT?1F39D+QFD+3.4 )[*;(W^5?T#.U5+;Y1TSY*:Q\FJ4<H65UYE7
M>1)C5F;MV*_L;_7XE69Y3T+ ?AF!,R2G!CF3F1CH;;R[<TQK9"[ 64Y<L!;+
MHMCZ5()"SB[\4R(I<4!4"8%4_07<D!)5F14\[F6G2R&;A'!FFD/]I6]F7L**
MF$U<(<2L8**\V4"563LA8*LI8-?D ]1?Q!8YP(](W.2O0N0*MLJ?2%.9U:N$
MT&TX)6P2L/^PIY;TM06"=@;#,ZSRD[V/8+D:IC,W+/\,XK-M.&/\X <4W'V$
M(&LM(AO.!&<7.Y!Y;6T^(5Z/+U[_0'HSYM(?+>G*,4>NW00!Z\M1(49/B]C/
M+G8B9R%(A2#=6I#^9EB6,96&+>EW8T;3#'<\2!:25$C2(R[6;O0L1*D0I5N+
MTGO#&F/.\4-+^F:^P$Q<3YBEU=I"(4P++=:N%"W$J1"GVQ]1&8X[1>K[UI*^
MV],=Q8^0I$*2'O/8:'MB%D)4"-&MA>@_#6_Z)MTZ8_OO?U,UY1/YKQ"C5=H_
M(48++=9.Y"P$J1"D6PO2;\O1F_0P-1:F8PL16J6=$R*TT&)M2<A"> KAN;7P
M_&*\F&/I.YDUZW1I;6%83;9.2,^"*((A)1?9_GV*%X$XI@RRD4 ^/-GC-_B_
MJ3>?7?S_4$L#!!0    ( (J#7%CO'O/91QL  ,,G 0 1    <&%C8BTR,#(S
M,3(S,2YX<V3M/6N3XS:.W_,K>'U5=]FJ\?1CWG.9;+G=[HGJNFV?[4ZR]R5%
M2[3-1):\HM33WE]_!*FG]: DVS$O]E:VIFV+ $B (  "T ]_?UG9Z)EXC+K.
MEXOKUU<7B#BF:U%G\>7B:7K?^7CQ]Q^_^^Z'?^MT?KT=/Z [UPQ6Q/%1SR/8
M)Q;Z1OTE\I<$_>)Z?]!GC$8V]N>NM^IT?A3#>NYZX]'%TD<W5S=OH\>B7[W/
M;S]>?2*?R*Q#R'NS\_;*?->9W;S_T+EZ3V:?WGZ<O_TPLUXM/G^<O\.8?)AU
M/GR<7W?>XH]7'6Q]XL]>OWOWWKQZ=_/V_4P ?6&?F;DD*XSXU!SV^85]N5CZ
M_OKSY>6W;]]>?WOSVO46ES=75]>7OSX^3,2C%^&S-G7^R#S],O/LZ/DWE_#S
M##,2/;[&YBSS./^"SJDYHRXS*5]'PEZ;[HH/OGESS?^+Q@%4RX]'II&\NY0_
MIA^E%211A_F8(XJ>MWROXV_6A%T7#^*_7\+O0--5Y^JZ<W.=&ZH>>=.Y>M.!
M^6#?]^@L\,D]Y_@=F>/ YO,*G'\&V.8K02PN3C8!@<D\D/K9Q]Z"^ .\(HRO
M'FFTG#]^AQ#PFZ[6KN<C)P=DCME,$,\\7PR[0%(V'EP3^T+DX4D6,2'W_"6Q
M?0:?.O#I]0NS+B[K8PU89X'QNA'F]!B)/?RF"04I0;_^].G3Y0M(;C$%A5(E
MGN_ GYWK&\[H!FC+Q+,^;OZI$XW;!PW)KFU&0S1N1QH*=UR9+*A&BL]L5S+B
M[=N8C'!D(S**U5M-7D0#@ GOFB!DQ'R]<)\O+4+K[+_MQ^&/)CLN X285A.<
MT>/P1P%.[#BN+\;#-^%WZS5UYJ[\@G\%LOHY$M@QF4>G1^Y *] *XI_/V#,]
MUU:HD,NUYZZ)YU/"TH>A +#TR/S+!1R)G4A!_[;VR&M.2?1(#D%VU\'/' -A
M_+@0\WU()A2! ,'[<L$X'VPBETCG^5MDWG3^? AUZ%]B]C:>-9T]'T+L__<3
M-['==.)\B!G8;:0>AD_Y[XA:7RYZ+K?E+Q!\]S0VZAA3 KL<%L&-(">B^..5
M^-\UZB0.0 >)43]<;C^[!25@Q!HZ/XJ_MS=W.#A\I&+@UO+4'I?=387#PB^C
M9:Q8W&Y@4=]PP+D1E#1?YQP$Y9+?9)=< $ I"">T_#W78:Y-+7 [;[$-YN%D
M28C/VLA[&2@E0]YP+DSX$I)X$R2@4 @+26!GWOALA#T^JR7Q*:=SCXS*PE5R
M[6U]KJ'O,[#_=J)<C%>+N?,A/_P$:0P[5L]=\5DNB</H,WEPV8[;KP$>)9??
M57$Y083<.4I0(8X+99 AP'9F^WSBN^8?2]>VB,?Z_PRHO]D?JPM@*]G[OCY[
MT^#_X]\_WEQ_^"\DT9SY.N]AMKRWW6][W+D)2"47/]3G(D!% NP)<6TX_MH=
M&/_;G1K#07=P-S&^#HQ[H]<=3+N]WO!I,#4&7T?#!Z-G]"?-&=@(NI*7'\$Z
MI<RT719XA'](@T<</DHA0 D&%*$X(;[>/DV,07\RZ?;^Y\F8&+!"+?A7"$7)
MIT_;?(K H#2<$V*&,?C9F';[O>'#0_=V.!;RVIP9A5!4S+B^VF9&" 9EX)P0
M,Z;]\:,Q$+,>WC_VQU_[XU^,Z4_&P\,3?-^<+RJ 2A9=;[,H!1$-[Y&$B0 H
MBJ">$,/N^70'/:/[8 PFT_'38W\P;:'*"J$H67.SS9H8#$K!.2%FW'8?^/S[
MDY_Z_6EO^#@:#MJQHP2.DB%O<F>+!(0$))2 .B&>](:#G_OCJ7'[T)_T!\9P
M/!A.VUAK)7"4/'F[S9,4("0A(0'JI'CR^&A,A7;@ABE?$#!$^X-V9G05,"5W
MWN6Y$T,31G,&W@FQR!CPE>A/N[^V84EZL)(%[_,V&(Q&8O@)K?@^0CPM0CG7
M'[;7/PWD/T\O5#/H3Q^&D\FH/Y[\U!WWFS-A&X"2 SG7G4-   )Q&$@ .:'U
MG_2_@OKERO=K?_AUW!W]9/2,P?UP_-C2-50!5/(GY[*'$,4!D<!$*: GQ*\F
M8:R1:U.SA5YK@:."JY\^O7O[]D/.L6P:,$/?2U2G="W5A!%3/+-)B\!V"QQ*
M9N=<U>;,EJA.B=E% <ZV3*V I61>WJTM"IF>(H>*XC9M.50!2\FAG)-;& DZ
M10X5AW):[Z(J:$HNY9S=LO#0*3*J.+[3EE&5T)2,RKG$93&CTV14:;RG/;=4
M()4LRWG1E8&D4^1;*BC4ED]Y$$J^Y'SK='3I%-DPF0Y[__W3\.&N/Y[TN?4T
M_4=;;I1"4C(E[U"G0,4Y0@+D*;)H*X#4EC_%8%3,^9B[$\]'HTZ1*8HH4NM-
M5 NLDFFY8(8Z1'6*3&P26AA@#])2G\D=\3&U#QS(R&%3LGSGD ;?V1%2]'V(
M]BP,Q>SI,Y^N("WRB9%Y8#_P-6/N?+HDC_AWU^O9F#'X8B2+DS;8L>#>9 WI
MDW^*^.R!/J7 Y<(PC6-H'133B22A2% *"::<5B2(12&U\&5$KT@,CRD^26DM
M"J#MKJ)J055*1B[\4QR@.W6%4[38T/3""FSBSF\#1AW"6-?D<LX$SKVRM18F
M):OS,:025D?H8!M'"%$*XUD"HBBXZV,;,N^I%=;!3#WLL#GQ/&+-78\KQD.)
M1#O42AG)A:_*9$3@1QD"4(H"Q$D0Y\)9;/*\>W(P%* 2BY^1T- %WU,'.R;%
M=JHD=:_2T@BC4DAR ;,R(8G1@C6 !&(48T[7WYZD:!3EO>]N%M2"JF1Q0>RM
M(+O^Y,T"18K\[MQLBD#)V%S\KD9._LFSN>A^=1*L5MC;N/,N]WA\*+5]H'A&
M;0K]+1X)AN6UL'^/J?<SM@/B.GA,S,#SJ+.XQ8RRUC)Q4&I4 O0I%V,LOB_F
M5J0D"8Q(293P!%-DH8@NA'T$E"%!&N+' 48Q=4B0=Q:[<&%W5RFUH"K%(!>U
M+!.#L^;87NS>$CL+PMVJ.**2;,LYMZA]+O5\QAG;>J_<WH4 I6#4JRR"6U9)
M!:).*K245@-SE-"RY6F<16E+[4.--_P? FW/V(;2;ZYM#>>9,%\4@A_FM*F-
M5BDVN0AEC6,%,+^2Y>TI L0QDR+A+"PYKO%MY6'3#[#]B/W $Z>Q9&:6D=UG
MOFYPT\0=M0G_]O#RM$?*E")7,_,M*W()@2BA,.ZRL"V&,9D=3F<'"#UYR2S.
M@X/.,:XCNV# "CF^ZVW:AT":XU!*2_T,O Y*,(%DQ+C._"[D1='-UH"TOWS;
M&:-2%O)1TKJR4'PK]@IQ[&?IB)=M#Y=C]> J.9T/=99S^K0]G>(5OY,H"-P5
M<[O0YR8_Y<>A# C,/7=5<*'5WK8X  U*"<E%2BLD)**D(TA!"2U1A 2H*;QR
M.]L*R4(F7FO #3#27;F>3_\E2.V_K(G#N!>;6KHQL>'A;<;#&Q?2DK%OJ3LP
ME4JYS#<K*I?+E/\MB$5I:E%(K@CD)01W0HH+I%B\S"*B.DP3.8MOM-Y=T_0"
M8H6KNF^Q*X&N$)=W5[FP;H6XA#@BP3@S-V5E1J&U,9^;]PSN*3?YK,#T?P'K
MP %O<=^&;0.42C'(A76K+-LD@!>B%K?^(7*48#_+1[QL4K^./.J8=(WM$=Z(
M2, ]7W)L_X-@+PPJ[-OW;8Q7*2FY.&^%I(2G2HP>1?C1*R1)0$!#%%$Y.\K)
MZ@W])?%2EV:]P/-VR4QMA44I#+6[5T'J*>!*WP.^0B&ZDV1[<;GA[AYP3;A*
MUM9N@G7R'G#QBB>YFP/B]_@";:BSX/9UL,,F;HU)R>V"IEJEW$ZGB4+\*D*)
M),ZS#!1PACM+A$_0#TWG@TE "1XE_^N7+V?Y'^&+G<739'YI+?(^]'E]X$HV
M-RQY/FOVTK5/MIS4>E.ZXBH0.]839Y_'5\KQ-ZG&[A#@"U^:X"P>"-XE /"G
M4*44I5S\4R5*:;4AJ7N%)'WB4B1%8;9YO0R.QF0B2>=9'@_$^=^N]93(WZ[/
M,JFC3*8:/.PCB;T<F)+[N<AWIF_$J9]EJ:4=>>XSA5=6WQ*'HX#W31L.YP&9
MXI<=SJ7&&%0<+>KUG^%HC 9]'R+ZFPA%2EQ((#MU9H^)Z3HFM:D@R9W?$\BF
MM&-VC+&_E_W:!(^2\;EP]!;CL\A -X?H4JQ'@/',_2Q7[HBLT^/K4U0Q< A!
MJ(E2*1.YP+-2)B+,0AI*:A'.\I%AUI/C\6\6#OV78%BH5;NF";;10<2C'D:E
M=.0BT4KI2",6$A*B1A'NDY2-?(>HW:VZ&C"5_,V%HROZ3YVZJ9=?[SC16C2*
M'ZX!4=?D"[3+C6,[-$I.YT+1E9Q.Y6@+I$AB11':LP!D.3.>/,$!/.+_'%(
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MB"5\@&A MCE?@SY2.\'4EKDE)U638Z )"%W/@>(J7^B)MQ"/WFZ21T)/7M0
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M9*9 12)8_9O8_2/21:KR[PU0^K:50X[MN6Z_4&PK.)GB2.UWDE6!T#0R61#
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M<WGUPR6?(./&T0K_^-W_ 5!+ P04    " "*@UQ8ZW[+\<DM  !VU@$ %0
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M4QR9Y)R2#"&[4',2 FDK5VAK%QQ5,9$%C,?:( X:R45HOEA1O"(S!7D$1>,
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M-#[*4DA,L<;H"I+P:=,*.GK(J*4JEBMG6U^,/]+0AJ1Z#^/H_J>FQ^-&RS)
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M0S+TV_'CD'EN?613QW2Q6ZP'IYTN)2H'M&,0H.XX/@HB8Y+<:L]HR*U/[>Z
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MT^]%:]<Z.G>TBS@/JT[WY^#-*P##D'_#JRCG0,^UQ%.<8MTEF"*=4#4/THX
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M>J7GC=.:H\N]G3^\)_1:0_,']$*^>K1,5=0"E& 60L@94-IL U-6BM;U&)L
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M%&V#+?]W%,/-,.TG&)_/S[B>3=*@F66(S=D2*?"K$#TGSNL$0KJ03.T=_UY
MSYX!]<3=(H"*X"8%'2"^U]\*4=$L/RNK/\FO($Q[3"@C-7!B/6YO,L>$ )TA
MGLK J<^:AMHN]8.@#H(3]<3>X$1 @P3&,+D,_P2?%6-1$^U+0J/1B 2=,Z(,
M!<U9\,;ZRBRX!>'9ZWP;D=[5L*F2,?%^-!S=/* 6Z%*R40C ]44FB@'JT;ZA
M@4C.E14^X3=J1UGO1_3L]5]1X'?I8+=_X1?FR2+1L#^\0)!7!8PO((_&,/N]
M3_X;3'#?&GM\/AYEX^^=?'!UI>0+A3SHUC<C?*_$ JFCB4!,DD@PZ-VJ9(B(
MOMP11A^K.Y$-E_/LB?A45'V7Q:X.BQ'R_*UZ 4,H%YH4C\Z@,A#N*)ZF2@H2
MLL*MUT4O6!#<5:\L60'E0-BSG8B77!!MG;_^'J;77*P4I+*41:)H*+TV?""!
MEP5'KK.@$D+U3(\; )Z]FA\OSB7*K97>>:U\_@H<(CW)R,</):"&$IY.Q_UP
M,2UEL9]&'_P817(9M0E6>@?2D\1<*HDOAKCH) '<KH#Z8)VIG>-5"?JS)]0^
M5+B$BMLGIZQ8Q]%7WQ\4Q'AT3OP 3B%>C%%%,#E*_W4QF19)KK'.7F86C#>1
ME*IM7)^WQ+LH"'AAP/KD1?T4E[9+VD/8=A]<6Y/O^^!)DW*/.RM;H.XIY017
MZ,_JS$LTVY38A4$?5T>P6D!R*E1/LUP)Y]GOG+5$O80%C[XO[XI5KUZJ#S ^
M/4->7EV/>"2C#))$57!%X8E+QA">?(9RM<_AP;X^#SSCV>JUINR6Z'3K^X'7
M?CQ$G^X2V L_Z<<>N,@\"$9X5FC?>Y%Q+PQ C.?HY=G($ZU=1;,4R.[47E5/
MH]HR;K"GWP;UJC^XF$+J2<B*!]Q:()22'FXEL9)E$ISU64G%1*B]GZ^ <IC*
M?XR<&V3-+>5D9\:\ZD]*?Z>+\;4+\!RHS39WZ5EH?^"I0UR6D3C0R4@\CG2L
M?2^T$<!G>SRT5\>2K6/KB\1_06F0"NGH*XS]9WA_461UDCODDY.+:>D>6HI)
M9QM=Y%Q%(34"]2@7I@*Q/'9YQ9Q:RKF%VN&9C0#NGCP-M3W:E:8:'$DKP,YW
MS#N8>SR6#BN@B5&E4XI@C%AJ.#$@4@R64<BULU8VA/@#4JN*ME8>>/_^VRU)
MXO;[9[O^I:?34?SS;#1 ")/7_WW1GWZ_B7"[GJ5+/GTG?4H?6E6[WJ045(HI
M*$)U28"1:$UY)2P![SE:/,9EYFJ7;+3N31JH4=E ()E3],6!41*L*>^0D\J%
MX&DXV-ZDF^CS@=ZDFXAQW[U)[RQA]A:5V,UH6-ZQKH%?5!:42N@U<.?0:\#%
M^.0TB<+@-V+@LGID[%Y 3Z1[Z4:*7L69K07>PJ.^B6G>'6X=4)NT,MW$A5H&
M:+<M31LH[K;G5$WJ.Z-$2?9S&2TAS8"A<6U*;;YW1&@!V9E@@=<N0]LA%5;T
M.=T7$S81=INKD_/1L+.XYOT=@Z,LRZR(CKCU29D2+E%98H2EDAO\KJD=2[D#
M8@]^R?;*N7M3LH5D&S15/$JI$Z(??/#]=#Q\Z;_TIWXP!Y<%$Y*J3*+.L91^
M"1*8#81)'C)+64I3NPCP7D"'0(%Z$F_PYA_%>'%^T56[KKH>7@!5QDETM8D.
M)0=4.D^L+EDW"MUOL!%-ZMKIMVN#.PB:--%$@Z#\1YCB6B$M@CAS5"I2D94W
MQ&LH>99=MK!(1"G.8D[>I%2[?]ER)(= A@HR;E"*CBP<@Y_ *YC]^WAX-TCS
M<308O!F-__+CU).:H0AD)A!+YQX92R%Q<B0SK926W.M0>\O8$.*3N)+9)C[1
M4B4-K(]KYM#=V&O0:!EEG8F0#K$E98AS0$N/)W Q"1JA=I[9?7AVSXVFREQM
MF&ZGB1:M=>ZLNI>IM%&P@"]%,$1Z4'CFV4@<,U189Q6SM4^758'O0V7$EE)O
M8&G<S/B.2GDJ=4*OV^)YZC1:RDI$ EKKC,8RZ-MS&IY[ OTNM?]X63<P-%IG
MJKKL2C%C)LYZM*,<FF96!.1U=W\<5*@_?>[@,IIW2<ZGQ(<&[0\ZP1U/)A>0
M7B'^X></,.Z/YK?3BPMRZ(8UXNIG5?K>*@TF6J(@."*-M<1I] P2PW=4HHQS
MJ#] <6.8ATW+UGIKT%UA!>1_^L$%K$!L3)(T&2 @T 24"HV (",0(5*BD3DA
M?.U*Q<U1_I!$JZ6U!MT:[GTUWL-?W8\F/4^9HMIS8AW'MR$D2X(( 0U,84+,
MPB95O3OF6LA^2#YMHYT&_2#N8_T52*V!9XT;JNZJ3)RTQ(/$4UQS&QQ$$+I^
M9LL:P'Y(!FVAFP8=).ZE^;5VGY,>2S)$11W1942M9"Z2X/$K(X2(+OEL;>U^
M$&N#^R&)M*6.&C1RN(_Q-W!R9E+.#(C-3J TI"%>E-X#3..[D"C-KG88<UUL
M/R25MM-0B\805\[IY--HQ?5P]P*$VV;=1Y@M ^8C;&8K_ AQ]'FFR6ZQ/1\L
M\\E;8KC01%K&T97E@A@9LD["0?*US\36:SILZCXI1K1HEW'O-C_[/LIQ,9BI
MYV+,*8$EX#3"5:7[:)"44!8XPYU>,U:[&F<SA(=-QX;::M$ X[Z-_RY:;BE$
M0P/AUJ(=01&H3\82!CP4@R+D7#^]?P. /R2U*NBJ>C.!M4W3MWW\&O?L[R]&
MPXO)AX$?]J(TEDJ=B0&-_DX(C.!;4EZ);#G7DIG;0QQ6#15_/(C#)-).55.S
MF<%]P._8J$MP)YU1(A$-5O2:\1]&H3.=/'$Y4^6SE-[I;2BU!H8?CU&U%=.B
MT'G)Q;U.%'\/#%IZ)?J;')[(DF?BM6/*^QP8;Q(4NR==HG*R$,5C0+FH".0B
M=$6!!*LR429%04&!9PTZ^CR0++3CPL^7?G+V9C#Z:W*37=O5>UY]Z$[*/%>L
MH5UUI]5<07246$]EF0^I</M/B20?LW9((0?-"M[>-JKN-!SW&HMK@ER:(1HJ
MB&41=STC'62&5GD#=^F)5'=NHL\'JCLW$>-3J>Y<# 6Z=D9U-4K!>'S7*8('
M&XG490PJ1RM'*&7 !2&S;S7.Z1:4)U+1N9%R5TQ>VD;(#?(DE\$J7XX!YCGH
MZP!L5-?Y(+C]U'A64>4:]-A>#WLA# C/349S43% @Y8'A_8SCV@_4YX$"*UL
M[>#(GHCR0 7H?GBRB?@K\J/S@%[V<6L=C,[[<8)>U[SB1.ID''!-C"Y-Q:@S
MQ%$!Q'M?)@"4>I3\D*6Y\M-W[TY6UL"HIO@JEEMT@$[.A_W1.5R!"0+IZ94G
M0(-&W]@FXL"@9P@V69I54MRLI<O;GWQ0>MQ*;+7?R:,O4US9,,U!S1$9D64$
M9DBF.1!9VC,Z9XIWSSS-WE@=Q5J*7/KQ!Z7-[078H*[A]"),^JGOQ]]/_0!.
M9JV.NM.%VQ*KR9)D7]H[>VM(D#034%;C\JG14#UNLPK, =CM=03=@@%7<-[[
M<_SRT]@/)SX6^<XIOP["1J;[P^CVU)^ECCIODZ2-+EK4Q3V,-"@;=5:61 .Q
M=$ATQ$H%) CO=.36,E7]<G-/;'FHA<N^R+*)"FK;"TM&1,^//!N<<1P!B2#+
M""]<OC<A$%NZ3[CDP=]N +?"9ECYB#W44E=6QJBZ)&O;]#=OGUY_Q5-RCBHF
MIJA4:,@8APL%SQ 5SR0H<-$H[MWM>J 5^EWYB,/2;QU)UGY_W_4',$&+%8[B
M61^^=F;0'):7T4M18/F$L*PN<\RTQU.348MV;.)JO>O?U<\X+ U7DF6;NN9R
M[?5A//K:3Y!>?/]C NEX>#F8^0C7_W56QKCH@8L.26 4712CRBRS$H JPU9(
MY."Y\H%S7SM!?7.43Z*;QC;W08T5TZ"AQLVR;1L\M:6.5;#2*;D,8 FE73\Z
MNQQDMBF[V@U7]EPBWUIC]U;);R+N%KV[KB<-EXS?8<0M[P;$3Z--I2-]9-J(
M0(R34#)'2K R<Y*B%\[BRZ5Y[:OD%NLX>";N7?D-SL7[Y]*+1%U**A+(Z+%)
M37D918,;NZ)"4^E#K#Y \UY NZ?8_G6^9&A\'84UV!Y?P9<QQ/X,2PA21A&+
M%<]QJXX9C?J2K:<\%UR:;,/M?-RMR7/]^3^Y\GAU5-QH9E<"YZ43R/]T0$[R
M\7#JAY_[80!'DPE,)T?#]!$F@(\[>X5.PV#TI6L#/!^)'IF33G)/**,)?4..
MCH,%(,HQAJZ_R3[*M9RP+4#\P%S:J?X:]#5Z@UOC,,+;DLG\L0PF.<DHJ [X
M]57UF #)I05B3"H[IT(?QC-%?+26>\:UJI[<NB:T'YA\+978HJG0\KX@+"09
M;.#$XZY+I"FM_8141$2AA= >%U][WO13Z=CRY)A4044-6@2]1[F@$-[!^#.,
M/T+7D?CE:#)%?S=)=$EP<=&7:W/-(RFCF="J8\JGD$R^/4)U^_#"*C _Z5-)
M40V:_Q2W8%+D >@9O/Y6EG[1GYP5T9WD5Q"F/8M,EH8Y0JG.Y0H.B+. &R1D
M3\%QPUGMGE(/@OK)J,J*:] 2Z'CX%682NYPZ?=,<+//C1A?#*9J!'\9PWK\X
M[_&8I%7X'AB@95H'TR1(Z]#7H*PT3Z=6UXX;/ +F3_8U5VZ##D-+;HE+) 1E
M@ZLH)4\HM[&?Z7&,?LJLZNGE6?GR>(BKNRAOUHJ_\K;O0W_0GWYG/26I$L&6
M!JR<$RF4(\X)3JCQ(G*3192UVQ_O:&D_>?\D2=2@@5)YO8?X*]__->Y/X=7H
MKV'/FN!YYGB0<)%*GW%'K$&I6?3'4PPZ25F[_=]=%#\9N*UJ6O1(>@49QN.R
MZ"*23_[;/(3S H:HH6E/^"AH9+@^R[HRYT!*QVH25=:(S]&<:E]U/@#I)X^J
M*JU%%Z*NC_22Q2^*D"_3"7I"!;0H3)FQPWVA?R(N"4HT-<$X90U4'XNY-KB?
M1&NDR!:]B>XVL+B$/>_K=2D0Y@-C (!>NQ!$.N#$6RH)1_P2?Y@CK7U'M3ZZ
M@[]0;Z2HG8QA.HJ=7S3!5Q/Z7[NRB6Q,5CDI(C1G:.SE3 (P3[1,-@'-:.[5
MKO]>!]=3Z"!31Z\/TF=+I32X$;^+<6'XX4O48PYAJ$P)]:6C"L6%V^SQ*^]L
M",%*)VO?#-P+Z >BRF/5T" 'YRZX#V/XXOMI8=O-3;I24U<.X=FM:\]Y*15'
MRXY#:3CDK$'441##/.ZYS$IC:MM+CT/Z [&JNN)V>I9]\-]G>Z;@+D?'B=)E
M8(:*M#368@5@#BY:YWCMT->#H'X@$FVCC@:WVDL!CB\@+>)<90M-/@M=LHM2
MB)S(D'$++9X%0) L2> JMY\[>1?7C\6:;932X%;[+L9%RN*_^M.SE^C>HB,[
MVQ1[,@&7"(=H04MO.1^(-\82[20/EHH,MOZ-T=KP?B :U5%1@QONR_5W64"X
M-W:QD1Z:9]%2KD@0*J+%9BCZGQ&%P2!**[3!']>.&BU%<K <J2#XBM?273[B
M<MK>=Q738S;$!%*5JQ?<"XW4Q%,O" 6C&8<4D[Q5I;TBC73S9Q\<,W:A@P8W
MQTNDT@TYO!B/NW*VJX,S!R,\98$@P4M+6RT)NH@"S71PFIEL1/7FCFN#.S@V
MM55/@UO5]:.DO0PR^N 3<49[(H6PQ*H02'2!&X:GJ>2UDZ[61W?P\>5&BFK@
M8ZU .DO/62Z8I+(SG*']E541#/J''H(@W@?%0L@*JF<5;X[R4,N3:RFF0<1Y
M8:!]&LT;>B%V)/ST>VF<7O*X2J?PKD*CIPS-3J<2Z!2\[-:6!*T207M'9R:I
M,=6=]O71/9G=J9JN1SM1U"XH=;L"J ?"6B>3)LIXC=LGGOLVXMDL@I/::#R5
MJ[<^?A#4CT>@K=32X&+C#L!%VEV9>%KRYU!8\Y^D7LPYH3MIB'(9BE&7":(,
M!$I"/60\@&/M/GR;X/OQV%1+60VN,)8P?Y''C*:<DC1$PPD8%HED3!(OT8 4
MTB6M(;M@:N=TW(?GQR/.8Y71P*Y&&42 -'F#0IHU/CKZZON#<JU29E[A=TXA
M7HP[873%%EQ[I9PIU:HQ$:D](U9P36A(4603C5.U';9-,1X^H5HJK<$]QW6\
M[_QTCJR["IZ]&6C+O?2#P>2^A?30+\D\N40"^KM$&DC$,EX\4 V@I91,53__
M:@#_H>BX&_4VN#U97V8](T+T#)UDFP0CL@1;O):,</PCC<'+"+(R$=='=_!L
M:Z2H!H6!*Y#.:O67"P9D%@D4$(,>+?JQ,9*0DR,L1I4M$R%4GY&V.<I#C5G5
M4DSMYC#7]]>/EYOJK+KJ=G\CE@6/MD0^ MC2F3P0SYT@R4&FRNEHDE_K%F^#
MASZ9+:>: D<[D'Z+,-0UJ CO*XRG)=;1F8 Z@+>14I*5*1=/R1!;MERCN8S)
M2Q5M;&@]W8)SL)2IK8J6>TF9+%JZQA0N7TZ1_&.(3YG-RCS)&<K4T5EX8_';
MLVX.FK+@<LZ$1H8>!7.NN*TET@$J@C,IZ_5:.U<"=+"$VIO66D2E'EI&#[PJ
M)0>,!%\V4/">6-PUB7+".5#2 :M^X?(0J(.E5ANUM A271ZZ9?^\26F!:TLR
M6V)L1!M?QUPZ6D7"O)$Y,2KB[0G4U8*92^ </E<JJ:)%E&D&[<UH_%">U1+A
M]$Q0$B3CI:-5F<#.)'%.EOTQ6IV8I-S4SA;8"O"/PK0=J+-!-.FZH_!^-(7+
M4@4N><A"!(*FGR((IHQT,)9P2_'50><5=.ULW%58#IY!5930("YT_;Q=[*=(
M\RZ9;QF7E3+,^L0)S1JYG'(B-FA-P',;T*\,&G)#HV@-B =/I98J:Y#(N[YT
M>L*70*Q7)&>.SJ@H+@%G>'Q3 S)Q!X'[RN1:']W!\ZJ1HAKD]!:8Y?_%R?SJ
M!] 5D:,$^K%T>"RI#UV3XVO?N/:;'] C':6[^<MQ<)%PE:^_Q:YQU$<_A=?H
MOJ)0#<_>,L<)J-*511M'K =#N+&>.L>LOCWC=VM:[G:%SSZ(_H0)T2!TL=5J
M>U11IAQS1-@(1'*)6T27[F$B!"'Q,$BU*]&W OQCDW,C=34(=VP'7BD7,H @
MUI1SHAL-+94F,0L3J58V5&^949%KCY-6EV!PXU./\%P=C[_C7O)//[B 'O,Z
M9AJ[L7EX2$O</GPVF63'*)<"? JUKS_6 G80;UI=\3=QQV^Q\?9+8[775#$@
M#GBIU0R*^-),.%CM7-#,L5S[I7D(T[-G1E6A-W##3R^^?!ETZ_6#18^VXV$>
MC<]G?4VO%5@QT-$3#J5%:01$&$0B1D!*!O=7"+5#-FM">_84::&")G6Q4Q@C
MFS_X?D*/K><=]Z:45WI7O'O@G@3\6T1)E9)BGH&J7_UZ \(>--]"57<*7!\O
MYP;I%(MESF<:7&68#=,2![TT A^,)A=CN)0%%9I;8S@1@HHB"XNG'GB2K>,N
MT)1EKGTWM2WF9[^E[%1I%>,LW3U_-VDXP[B,D)IW/_XT6E2]W2AXXQPHVDVT
MF/5H4.D0\11-C*!_0F6P(H*[%1]9D7^Q]B-WSXS=JG+47 ]M,KZ65T0N5M#E
M7G>QE$DO**#.YDA,:3L@/57$TA@[<43*!,NB^A7G!OA^$((U5UV#.L5;(\5.
MPA3%6P+5BT!=N0NYT07GJJ>)M!E/ZY()J4H;'*-*?VW'B R<F@CXQE0?T+0%
MW!^,A+M2;(.(;)>95!)0<+OM9302>(9$LB\%3ID:XL$;DIP,U!G%<JY=DG']
M^3\8:QXM^A:-0<K%_@(+R^ATY*2)*1=P$J@F0>$:F;)1))%P\ZQ>F7/M^3\8
M#1XM^I7)7__^VRW)H4_P9_>#[OM%,A\A_U+^_<?'XTLI_O777W]#NZV?^S'T
M1Y/8AV&$R=_BZ/RW3I@G'W\_>G_\_Q]].CYY?_3^U>GQ[^^/WQR_/'K_Z>CE
MRY,_WG\Z?O_[AY.WQR^/7Y^^]^.RVWV%5X![X6!R$_.D?XY>\$.&]5;/^^UJ
MO3?E,'_H#?[L;N7P;0K#!.G7+=R;TXOS<S_^?I)/^Y^'!7.Q?&:]7)&G'T:#
M/BY@<N4'9DZ]%X81[6-)XI*9.&8<248XFCR7.8:UG)P-'[R5#[?>LSYUB4C:
M,N&#5T0FP+</E$>S3F42J' 97YLR8K/B C]53OOR@\'=K:FYIF]X:JVDO<Q7
M^Z4((DW_7O902/_X=3J^@*MOCH93?$=>SV)DN%/ Y[M>\R-B4+BQ0RDT*BKZ
MV)_\^>+["WS'SW#1?QY]ZT]ZDH'VM!RZ69;V_;8,FP-&.(@DHS7:A-KU^ ]A
MJLBP,Q33.%X$(/A=&$Y*M=DVC'L$$6['EVHJI$70\@Z^!;I7G4FQ%KX>*LU?
M#*;-B7,36TW[:4$7<FLI2VRHJAI]D"X5U+$/VC":E> \$8%N'9%6&F)C5J3,
M7.. (&FJ79F\'[K,/OJ)LF43+31@26G9,/D(7V%X429MO>N\DQ[-0L4D 4$Q
M*).==1EG%8AEAK'DJ.'.5:;&4B![<+^JZNNVE[VUL.\R8.L1B'<'",UQ)8@^
MX'\(-8ZB!0>9^%2XCYAXH"J)ZB,Q5F$Y,!Y4$7G%S6 RGO;>^?\:C1?=[R?=
MOJ=$HJQ,3Q20.9'<>N*"500$U6"!LF#6*MW$C[^F?/S3E>*7/_D@S<T*0JYX
M#U#0O/?G<))O8)J3>QU0FUB4#S!@)9#=FH\U-#1J)=[*K_MJ<, Y10B4<)T"
MD8;A'F0T(\JZ8*Q*P9JUDJ.>ELY7V( [4_DF4JVHZFYG6T Y&5Z>,\$DRX4@
MAH:N,Q?N7]8DHJ@7+*C 57HP)+K\HW=W4E>4]ZB:L"K:9QT:7$T)_\=+>LXQ
M::!9>S0\F*2.R*PU\;X+L0D1N !I;M?(KU#@B@<\>S76$-Q.G/+OG_"O=IN.
METQGT348RAXW'>:(5381YBE$FFU,U>OV[H%SD#98;36T*$NZ#:T F[\-ZT#;
M5:#O"M:3B?$]3H4/46-+^>]B$[D&42#MG?>)\&@R>I "][?2U\5H"([)Z(1K
MOHFTIL;F\;SFS-A$["T8,3_E[D"<GWJX6BMMEWF;&)&16>)9%(2JF!P*@>?J
M\;P'(#V!B,YCU7>;%A5EWR"\=P?6!SR+2\[_9V ]K;+ %R&4L<^:2(:G:0!\
M.S15X)T53KGF5P#7\.R.%#N[TJZNA@84>7]1A'22/\*7T7A:C*O3V57WI(>+
M]%E+2K(OP\%UC,0IFXD2BIK,/9I>U=.O5J(Y8'I44D'MR,'IU ^3'Z</XU&Z
MB--_E7RBX?3[K-:_)UA2#EPB--*$VUL&8H/1)&3K<QG?$VZ?*JMR7>Y[S %J
MO;)L5X:%GT#RW6MTPL_]%-(?$\@7@[?]KS 9Y4]G,//V![X,6QGE1>J\OY8U
MOZ-TO0H(]Y;@5UNZ6Z8$/E@(<?7:2,F,+<URO7>F6$42^<T5R9&&$""*7#W)
MZ6%46U^FQS-(%V5ZQ^I2D"YV$;G*@<M2'>T<D9)[8LN!;Q*+*J@ 3-7N'K(N
MMM;)A(TX<N>JO84J]IU"6&*E'TL-1^?+1LTD=QI(SL6QH-D0%QDG3D2AN 0=
MV5KW\P]<U%P^<-<1P;:J'&TKTLH7<AV(N<NX#HR*UZ_7'KW["]='"O^V^K:0
M7$-%<NN8MU*2+"/N8*Z4/=,4">24N,G9:K;6/K]O!=YS>UI7?YL(K'8"#$KJ
M_.)\#@2$2M+2XI('6\HS-7' *%&!EM A"]ZMY?@^E/MR_:&[O71[M-A'-616
M,8PQN\/_=@V(TU88C2Z34MZ5N!LEH<P+BHS%TG4N!;=6-X\'$Y>^/6OE/5IF
MNRQ[OQ:\9Y&GZ- >I,)#J6Q+)!@J"%<IJW)+3ZLG)*X!ZR#-HE9J:3%Q=^7J
MK^+[ZT!L='&Z!KS]7*!65^W:W1"VT\M.>VY<0371.^6T+]$]W&6#8<2#YH1Z
M9CBUW&A6^PIM;]1YX(+U*3!G$W4T8$S7..%L-$C'YU_&HZ^=>[](,:*,"LN"
M)D!C)C*;1*PWGJ1H#*1HN9"U&QW? V?W%ZW5U3=J(_L&-VF72UVD#J(YK'-@
M1("51 JTB!$")SERKCUPEU3M;(Q;$ Y/_=O(N$DRSOF7B^EL5-=U6-)[!Q:7
MB(XO+?4A0$*TE@B?O)( 09GJ[<Z70SD\"M20>0-+= 'K=)2G?_DR%'Z*;EH9
M$MBUXIF#5"YKF2,E+OK2]3]+$BQ7A#DG,G="BMNYU]6(<2^PPZ5)/7TTR/=\
M<S%&.9<&+J7!R[?RU>(P Z,"4R80;PPZ;L'BSL9R)BQ+)]&L2D[5'IVW&LWA
MT:.2Y!MT0%JY\L4U;X9>9IFR0,LLMC(]P5$@5J&I;0)(!S)*&7?FCUS!>D(L
MJ7./6%L5*XW.1KD:+_XX/7[_^O3TZ.7_]\?QZ7%)*JC2$&FMSZV:%['Y2BIE
M,[RXF""5)I.CB+J?+-8PYY:G@@:70VD&H/'T")%8R4KZJ,LL6254]:*-^_#4
MRV!8\I3)B^_7_C0++@*:UT)91JCF74-G08*F'+TN/#P592G2VAFDFV+<549#
M-9ZLSF5HH)1]YS3<([TND,1+S676@0 KJ=F&6N*T9D0;32553J18N\7M"BC[
M#_2W4/^HOAH:>-G+8)4OQ["P!-<!V"C$_R"X_03XJZAR#7ILKX>]$$9HS[)!
MNT:5 <<2O$/[D&>BG023F,RJ^FWBGHCR0#A_/SS91/RUT]J/ODQ'P[FK%[SS
M5BE)6+2!2)H8;I;H]+D@A. !4?#TD#%\^T-W[P55EO>H@K!JE\*?G _[H_,R
M47"1ZZ6X-,&AQY]*F^)D*;&:(S\54R%37*RU:VGN]B<?E/JV$EOU3A1]M'H&
MH_-^G%P!HDYI&SPG6FK<9T!DX@0$DD3T24=A&%^O)^RR3S\H76XMOB9![Z6C
MW*]=!:.>#(W4E_[AC$AGH$R!,23%B,Y/$#X(5?F@?1#4#V'+UU7-[KAS+;Z[
M#L!V'0_N![>WO@<UE;H>9;;42)L>" \ C=[&<O=+M"CG7(RF]'!"@X4&2R7S
M@MOJ4U/W0YF'^R'LE3&;***ZI1_/^C!+$3G)[_H#F* QNTB<#8HF,%(3(;-#
M!T<[$H)*!&(,C"K-C&;KF?[W/&4OC0YJ:F340IR5T[^OBA!X3DZ+!/A4[HG4
M#H]*%3@)"<VJ*!B-MP<,//>BJ(:&Q.-%6_&B_$ZZ^QHP#J\X:B/AKRJN>83D
M&A9'"4MIH%$0&6)IC"(#\9K:THO'@@-)95XK$6;?"ERK.*J&_C816/7NP-=K
M16(RU$<;2=(\$)F91 <V*A)ERE'E&'-:Z]+S>=37;"3VE?4UF\BL06;JY4S6
MDL P_5Y2H_#D+G/=NVQMH[+VF1,:$ZZ3&DVL]9&@F0!99V5$KIUI="^@@SY5
MZZND00K2+4R+>HTU0#5RQY<"VH\+7E%Q2W*;ZTB]@<N]')R@@7E@@E@0BD@6
M#)YID1,>0+F8=:*T]M:Q0RH\X%KOF@F;"+M-KOOY:-C-BEPDSUJ%A@V>98"P
MB$S.$&_0P!$^19.H4I#K!UEN@=B]AUU!.7=3E;>0; -[X>@O/TZ7 :+,HW0:
M!!%*&ER:]<1RF@EH9:,"EF2LW:WG!H ?PAYXO,COZE]M;2^>^3&\\!-(A>8H
M)S^3][@8QEW%U8OO5[_SP7\OW^M6<+6,82I9LZ6Y]_P-66=-C<R'%NO9C_6Q
M!4UN&Z!/1<<-CJHF:W-.!V6<)L9)3:37F7ANT(=CW C0WF51?2S6L^'M Z;2
M$Z?M)JJM?4DQ3]'H3O\.XN0C#$I7OT^C:P?,HIVP,#DJ1&8RH)6AC2]].B3)
MW%#A&)7N=MW'_5DO:SUU]R;6_I6\)(FFOH8:6&X+2P7E%OK#3FPW[X%0A),,
MXS&DF1U[/)S"&";3^>!O%%OYHC-G3#)11Q&(,Q&(#"P1&Z@DCFL1) HQ5F]Z
M4!'^D\C]>5NE!&!?2FW S_F[.IF_.O@&S]<&D]_'H\FDAV\D5THFPES(I24V
M(F66$P$J"<H9<[EV2<U#F Z(257%WS!Q^R;3EUUHO^W[T!\@UWL*?6WA$"/S
MI5S3HNOE!;K.B?)HF4Q,06WW]!$P#XA$K954,==LWFL;#^X[UL3K;^5+>/TM
M#BX2I#<HOU6;:B\FJIG,^$)$E8CD*"W<."U18+BG7C)U.YMH9:_S+:$< (WV
MH),&E?O= F;'ZZN+<6D.W[5N[ZS2&W&B'F3CE J.>$GQQ"V#1KQ";T=*!DQK
M;XVOO3^M#>X Z-16(14OUSK>;V#*S4=%7\NZNLRYZH'"HY@+0U1I>H#;)R4!
MO6<BM%7<)1#A]IFW8D.J@^< :+0O[52,WMZSA'L/YY>#$?Z=SZ_0I9W/GX#
M>."9$VTLOA<6W84 U!.(HK1VLUS<OM;;B%Z;H3EL<C74S%UJZ>WMJ+L[[-%7
MA/T9\-U(5]^[DEQ/,TZS1X%%+\O4-6[1XU2,.,%TRM[G9./ZQM/&SS\4^NQ
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M,B:9F*D>O'^.,Z$WX<G6,Z$W4<JRMCY/:29T B&C4XDPX21N^YD2FZ(@*L=
M@PC<I%;7C,]U)O1&ZE]S)O0F:FC8*6KUH,5U /Z<";VQ*C>>]?L8/>R%,$YX
MJV6*).I22&5H(-8X3BC32601J(RMLNJ?QTSHMCS91/S5)\5=&W/LG$Q!2$E8
MF= B06?B.,\D6*T]4^@%L/42V9_X3.B-Y+UJ)O0FPJK83G+Y<&-!*3>E_MRQ
MTN%54$]L1*\0\-CCRBC)8;U.(\]A)O2CU;>5V&J_>,N'&@L#6J-5K*Q'<T5E
M1URT"?^H?#:61B_6JU-^+C.A'ZW+K<778*YOS<S<EWYRAC\H76V_^D'7;H(F
M*Z*ECG!A+)'>".)$:5@:P>00&/[;-CJEVZSH21"RCE_ZA%2_F][:S5+.@[*2
M188>FV)E]EP):R8O")/*F:QYX'P'64<_2!W"4Z%\35(T\* 614(]Y1@(AJ^@
M%527MIF4N,P8P7,'?Y"=T'ZMV9V/J,,Z(.8\2IQ/_;PN90O#Z>PW3Z9G92!"
M5AX8FA\T=*.L@B%.LT024&8I\T+:'=RK5ES1 5'P":F^08OFFJM;TGD'?]AS
MP04MM2!1VDBD98 O,1KNADN>-)?1^AV,R*B\JI\$;T6!!J-::Z[P^K(2OJY:
ME%(SH7R90*A)X#H2FQFGT:04W%/>MG_2N96R&XP;?.2R+HO6ERWO/4Q[(*R+
M"@TK82@N"[+'!0I#=%820!@)\HF$"AY:RD\.5U5VQ<[8+5[-#^/1%QA/OY>.
M'--Y#.1+N5+O"49!9:Z(CZ4[$!>.>&UH:>EL/),LUY^XNY.%_>1W0R+4;NN]
MX0I/OG15R<//;\%/X&/_\]GT)/\QF?\47]U[1?#@W^YYG[)0,1"3N2#2J'(K
M&2)A5G /RJ-[O5YMS--:UP&\$D]0JANQI4%O\YJ[0^=DOQ_->D4L/.^>U"E8
M$R-)DE(B<W2D7,V3S)1/PCGM@GS"1\3211W N_ T";";?NQ;!,2OFG,7R>HD
M2PY;J95*"D\\931)T4%6(&@23]GT>;J]V)\*FQ^K[-6=V'>8??]I-/6#53U8
M\FC\Z>Q&'4K==/S'/;QY?GX%F>PB8=\;)T"Z1"SP,E*I=/WGS)*$_F12*8 *
MK:Y:GT3"OJ0"F-5H BF01'H>B,NJW"JBI40I\\G47O^S3-C?A"=;)^QOHI2G
MGK"OT"5%FQO=5%I&4"44G(T<#9+ ;?"EGLK2]B_8LTK8WTC]:R;L;Z*&O>1?
MKP/P9\+^QJK<.!'[,7K8"V&"#CI2(0C(B)Y.:>V"YB'^D9I,':4.>#@,HCPR
M8;\M3S81?^V\X3M)S%%[YQ53)'=3R+P!$LHLD6P,]9;[S&X/ZWK&N=\;2?[>
MW.]-Q-8@I?*#_]X-D;OLE;)8.\S+L#/SUB*%2<A9HS>(7 Z9XU=*Y!B]DIK5
M3K!X"-.3($0=L[2J^'>3<;O*GRQ7(]/OQVC8CF$RG<SZ$AX-4]=WL)A427A.
MP:,A)4N.O>CF?Y>)0PR2\@J<"SOH3/-8^ =$NGTIM:&)\LCNSD9DD7/01$%F
M1)J,4DPYD>P3)%FJ;X3?'R6?06/NW;!P6]4UR-E=L^TAHG& KP:A+)?<-"[Q
M];":4# I93 AY=J>]_/L0+D%D1JH8C>YL*L[AB.YE8Y.$ _=U _&2& EKY&I
M++VG(N@=9+4^FT;NN]F%-E/+RDS3'=Z)_#'T%ZD_[=)8NHY=;W")P]B_,3NR
M\E7(1L]L?@/R> GLXN)#2.$TU8HHG]"DCSH11Q,GPEFI&/<FN%;ID4_CXH-3
M#RQS8HSF9?V&V%3"K=D 94IF<7L<\H]Y\;$)3[:_^-A *4_]XL/FZ+*%3"P%
M%!Q/$C=LDTE.5' \& 07NXA//JN+CTW4O^;%QR9JV$L<>QV /R\^-E;EQ@'M
MQ^AA/ZVM J<L:$$T*]YG-H%X8X% !B^,3ES(5L4YS^/BHRU/-A%_\XN/1*V$
MP#6"<>@54(J.B$[H8@:G=*;",[9>LY3G</&QD>3OO?C81&P-(]O7C\.%DS!O
MQ]U#?RZG"(Y0EQ&B0N_2*J"X8H'NH!81H%7$^AY83X(6=8S3VDK8,4_>PW0V
MQ*(TO>X%Q4/D7I!LK2'2H$BLL9S0E)UF+&2N:GLS:X/[03CS>(7LQHI8X%RT
M2_\ XT70LA][U JP-@62J4&#6^*VZ+LYXF!5QH-3<[>#QL7W8CQL'M533\,N
M(6O@?=4?7$PA]:05664TPC(7I84ZP\.:!D^8!#S'?<[,[""^] #*'Y-2CU'1
MREN)1B'EX_?_//YT]/KER=NW1R]./AZ5B.I[/RZ!\:^P1=AXK<^M&AK>?"5;
MAG\[D_<56C"#45<N>C0L=U+G97RG'_3_9S;&ZC.:U>6'W1V#[\9>3:X1D24+
M ?VF*#T2,4N+]C&'DHLJ?9"@<@AKN15;P=AN4.AE\.DQ&&;QJ&0@<V[+7)"2
M5J#P+;&,E=JJ+ -5TDFMUQ)#!3"M@\$[9LW-8:([UM6^0\>3\;3WSO_7:/SR
M8C)%BW$\Z>(60O"L@W$D9($V8P)&/&>:\&BIM(QZO5Z2$G[\M>,2_W1U5"Y_
M\JX#Q/M1^JB:\"L:[ 7->W^.4KB!:1[Q6 ?4)K'A!YBQ$LANX\ U-#1J)=Z=
MZ9X))9(#3[P-;M8_S88LB9+&:D,I]VHM _IIZ7Q%2'=G*M]$JK6CM\?#K_VI
MAY>C\9?1+,-C'H[4R8AH-1 !$0].JP,)W#(2$O $PN< ?"T[8]43=N?G5)3^
MJ+;H*D;HRC+1O2H#8T_&IS#^VH_0,;9T*=99<I(]M<6%<\3I4&JW=/ :SR/K
MUPK$/?#6+GOV#W>*;ZV BI&2:W@FN/PYHLF<]^N JGB.KP2R^W-\>QW=57@E
M 5<^R5># P5!Z<3+F(Q2C>4C[G]9D6Y\-(V9.[-6\XJGI?5[3O(=*7T3N3:(
ML<^!+6:A2%UN(=%4,3D3J3DGN*Q(@'D!P3*O;>VVV#< [/:(KZ24VQ5)CY9H
M[>DR1^>CB^'T)%^>6O-BJ8\0H71G_^-+2>Z&>%%$W./&E=59$K,J@0\;BQ$B
M$+A1"L7@J/%KV6\;/79W&M]G;*B=)AI<V,[OC=^@Y%Z.AM,QBN%?_>G9P@H^
M'L;!1>H//Y>&./B_TDVX%R$#BQQM8H2.D%4BGE%*\&5Q$+)/^O;<HJTWCD?
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M8-1F 80'C6\).JC$0K;$)!&\1>^5B]H!G^<UM;XM3S81?_.I]<88;IEPA 7
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M&4X_A._S)PJJ<(DF%B@F.V(;U^!8T)!Y"2G3%)&WCG3>'?\,]+VW6-?H>.]
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MO(E _SY$QY7*NG6YEK5 CI-BM*^6'G=%V5/$#8V]Z60V^%A#FXM++<&<$L&
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MFC<7^^A[9XEN?,9QI*#TZG9MR=0>0](;1CIH0+K+;'L.1\N<G5:8R6DHM:I
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MW; :]VTFR@+'/"(W?7T]F<RC*#&R* -"\8(F:12"-\Z *(59Q[RRO/VCGC5
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M5(6[A(>6^WEGGQ(= Z5B@8!%$T8O0@G,9-GZGO$92&?"AI:";YWJ^&$RCLO
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MS'C12O '.Y0Z[[6OKL;7H]E IFB*"@R$S^23Q6!J'KT').,3B>(,7>O+[R;
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M248!RG !41CB7:COE)DJ0I;MUO)S0YZGHGL4^V-RN/U,MP62S^-5/ZM'9\K
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MZQL&H&,P20.Y-$(Z=1,A*'KB4.^1;A1@VF1J*3_2M@_!CI&'<7)VBAD@G;Z
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M['[^(2?FKF17>^\DR.X'?VEJ KY!</RV0(?H.R8!@3V$*.$-DIG V1,T7^L
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M1Z0N//*N;NA"H0T^9UT^RL3*\[B0N<:S*(#MA)QR]O7;2@M_54F$*O:G[CK
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M&[5@-L"$K-764*)AR'U"YB?5]$IXV.]QN_#K%;4*'2DO:G8>/0V^E,@H9)7
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MD5 D$NK IA]KTQ] PO>W]I\Q_=0H+/R !B>?2</"\4F94=C,,X!*^K_35%I
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MP.O FJIU/!W';S360@O=[=N1S_'ZIA]61>W5**\F# #[Y$D;55_[:P9T3]3
M.CFG'6Q+S'H:)COS2USX00DCO3+Z]!0 _J:UBFO4C9^K5ESZ*O>S4([DGT"=
MC1 8WIL1H3^CPLZ<Q/4ZC?W\)R'S"]S>!OT6YT@UB(?B$STL1#1HY?7[ D3;
ML)-<-R[&\IF8Y%7>K\,* *"SG-;_#*'J_PM>&&ID6(MP^8VQJ15S9N'N8N:
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M',+OSVXV7:2O;*LT?8$8UXB_7!^";?<3$U2"N]0$N8WQCH8U_.X%]:C!S?3
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M?/6PJ7]31M$?<>D<7CB@]C]02P,$%     @ BH-<6&:59MX@?P$ $P 0 !4
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M9@#LU,#;"IR=3,YY VZGAGLO4'?R"4=^3^YQT82>O<L?U*E^+<YE4:@#@SK
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MSA25U4+7!]1F2*\>'H-!5L?OGB^:ZJ0&+\*F3E]MNV#5S==?VR(_8< 2G]$
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M)!*(G(C .!8AY(&@C,4)(E&XJO(*KT>ZM^4D1IRPG6JZQ_Y6S0%8YW^M\'>
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MY-5!W4;R5DM@>5;^Q$6N LO:/"Q>?I3_3.^R5>AQ+XJ%#QG"B=P>^B&,?2^
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MV5NOZ\J+,8X\&D#?21*Y_\7*/>J&T F%RU"8)(+K1\P:3KZX;TDC/K@6H*=
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M/L+2F$G)I&] #"!SVIZP \K$Y-$3<EM15KEA6?J4,I58- B8D=5Q&H]11LC
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M'!&!,",<H9'K+LRT,OJI_'ZP; 6_:JLNC9ZE;%:;:9HU&)F[!^<LCU#[Z7)
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MR2;2O7N7E8FFV^!LXK*S"UH=>&#HZ+K(TNH,.&-?TC_53V5C[B6NX_JN2V"
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MPB6^PS%R82QB!)'G8(@]+X"(1TZ2<(3"(-;AMKY)YD9AK9Q@*RBH)=4CJ5Y
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M^!Z/?!@$"8*(>0)B5_Y!HLB)$H$$"XQ"1XQFGQOU=\M0;L2'(B]@*14 6PW
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MF '%?$XH?T$5G_T1)R[?<T*AP[H]ISYH]AJ7Q6KQ79G]S7EZ'#,>$<2@B(,
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MZZK>X*YJ\QL0**+0(\)G E$MNCTWT>Q(].@]PM=!#6W[\-4PB"VA-OHMS#2
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M]@=LC&,N!X"%) H"SC)(4)!*4R,,8.+))RS->,A8RD-I@=@5>.X-V3CEE5V
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M JOL:YK!#!/) SBEU&.28@.CSKU=DTR-6]MB_G]-1XT_M*@V,03G(#4(N7
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MPU1BB%"6PC01H30>/*P.EU).8AOGDMFT4^.*6EH[?Y APF9.'?>X#4P8VPK
MM<3M/J:UT."76FR'.8]V.#GRCAA..JJ+PPZ(0S^%Y=W]RTQ\6:S^5#X,^:,Z
M@2M55>^;):M]\?)GNLY?M==C%WNPC=*+0H003D*8XL2'2'@>)$DF8,:0H#Z-
MLI!RV^H3UP@T-=KZL7EY6>C88[FC9[O0FY6HO-RJLD+>**F]H:)1$Y"MGO:U
M*ZY:5#,^''.I!F9*7>!"Z3(#M3;@=F]1M@J!G49[D50#!'"ZPM=A;8RKQ!F]
M9(8+\$Y5TG R;H]\U(]/*H^AO%T^//'/<M9GE2:T+>)Q)U05<SF]Y!KYDRY/
MI'<&+;>U;@2VVQ4E$1.4^AG,,B^ R/.%:MOEPRP*XH01/R"!44K/(-)-C<EK
M_51RC]00;%5LU\*1K+Y3$^SIV3[ELDB:=+[FW=S^[BLY--'O%G$M%Y%O%U&H
M17QM%I'N%I'N+6*K_VW=GQ"8;+9'6%>+#-GW7-^1TF9=KK.NY_!W1XFT0V'?
MF5WK?-+Q4FZ'PFLO#W>P27H&+S8S?WC;_OA_<CEI09_>OO)7B;:.960AP7%"
M(">J$7G&$IAR'$'!8D8\2CPN[!)%C*:=VF>Y]?7="JM-]F\W_^@7XFB&OMD>
MR3VF W\@KX'3/A#2"AU7<9%FDXX;)FD%Q%'4I-W=/78>)V)F]ICPH2#+LG)7
M?:^ZC=W0IUS^I#[UO^4+^?U=+?F<IUD6T<2#-.9<I<E&, U]"E%,@\@+8NYQ
M:KS?<"/3U.AL*YA=VS:7JV2P0Q@?^X%I[W00X_X&KJ64BF_4:H&67F"KV/AK
M9F']C[]V(]G\NU?G^X57Q\YD=PM8IZ'N:*KQS'.WV.P9Y8Z'[F>*?^=K(J5@
M36KX#96/\F:A]@>?N,AIOIYG..0TQ@*&"8D@2CB!64I32'F6>;'/_3BQBOV_
M/.74OEDM"0&K1+0SN0U0-C.WW6(W\#>G$19L*T/\TD:R%MCAP:PY.HY,;8,)
M1S6SS0$X-+$M[NP;"Y*M=TE/7^034\7ZREV^%R"/^C"A+(,H36)(DEC(73X3
M*(KD+^S*;IV;:&JD<E_D2YJ_D 4@6K[JQ'1M>Q9Z%E?3F(_KT1H\RB-;M[(5
M56U^RIU%BIL"X2R,X\PT(P=N="M['*IQX?I^G%"EDWRL<TN:PWG!0Q5QP6""
M/0\BCWLP"8(49@&+&:(!3PFV(823LTR-#6KQZ@Q!.PHX#:/9^W\U. .__#=U
MQF2#SQ!Q")T8.'KO3\\QZDO?J>;A&]]]<=_TD1O&Y,-1_I [97Y7W!>K5_D-
MY'.:A5$89A2& 94[#,)2F/IA @D.,N21%'E99I<X<GJBJ;WT=;Y#+>P,:'$E
MI* 1V#99Y R^W53@$K6!V: _8#U20[K1N"(IY,S (Z>#=*MWG ARX7K[%! 5
M:WY#UQNR6+S=DYS]HSR1M&:=&6(WZM08H9WP !HU@-(#O)9_!^?R)LWS1RQ!
M[V:.8?$>F$MZ0CU \DD_"'OEI%A.-5JJ2C\(VADL/4?H65V</G&V6? [47MF
MRR]2G<\_)44LR>+CIEROGB5;J)3ZU?+Q:_[*6650Z3"*>123R*,TA#@0/D2I
M0)!DB8"AAR+$ Q^1Q.B8T(TX4^/ 1AOE$&GT >IQ 8U&8*M255Y#*@6U5DWU
MC2IRS3(NXLI%-=MOC;=4 ]/G"*MD7Z'<";BNJI5?)\RXE<N= '=4Q=S-J+T;
MG*E0=FVG,LX^O/U><G:[O'O1IVOM&/:MQT1N-4/B\P@RBB4M1SR!&8X1I"2(
M(D+]+&&)#2W;BS U*M9I(V*Q^K-^M5>-Z+U3=WHLBQFQ#@OVP&2J6JUIK!OQ
M0?8&?E$:@'SY-[!5HIV<,U#7M9X@NFO)9BO V/W:>@)THIE;WY%<',!]7"U?
M>;'.)=%6/Y9R&W1?Y)3[<Q%S*C)IG@8XXA!A/X*$Q9(6>8"#2)!4$"OSU'CF
MR='?5C[PH@0$<G% J784X)=\"=AJL2#2NMG^UK)UK?F*]#G+<X3SV(=[+;&;
MO^@%T)(/==QG@-4@YW]=\[[C@: !'-TGA"8##,9BWY5+QY_3E..4(0(#CAE$
M+(M@BOP8,@]3$:"$A;'5,:+QS%-C,?V*Y:U7C+9?,;I[Q738F7,*JY?#&879
M@SP5"OO>B>\0%+:/U7@45L\[-0K;AZ,'A1T,T(_"I,E'.6=Z,_P;66\*;>7=
M%_REZN>F-L0?R6)1WHF;5Y(OU&;XRZKX01;\!Z?UY7/*O3#D(8$H5L7V)+7!
MA(D81C%#*(TR^8=G0V].I)H:]>T446ZJJ@R%5L:.Y=RLF!D#CKX. [-CHT_E
M0-AI- ,MG;2#4&NEUDD3ZDZ9&=@J"L6J@$I5=RSJ%&]'#.M&IE'9URF,A\SL
M=G W'1(_D#*G6Q\5I2$.5$.A(!,4HDB$, T\ 7U*1$90B(E_57_$O=FFQK):
MN.MZ(^ZC:<:4SC :F %/]474LH[2%?$D*@/U1-R?ZUT[(IY4^U(_Q-,W]3Q_
M4*'<]^1-GPT&TCZ+1>C#.,(I1!X1,)//C:IUR.,H\XF(K(RU]N!38X,'7CR#
MQ8HLY;?<MNSQ2? ,_?\](1G:LZ_$ K5<#AWU)[1UY8)O#SVN<_V$4D=N\U/7
M7%F%HCIT_(T35<>*W:EN"9M"=5U6?%#^OEQE)2]>U8RWRY?-6C536-)\D>O0
MH0]O^O:/"U*6GU;/)%_.DS1,@HQQ:0RDRG].4DC")(32$$AXQ!-$D57)P*$$
MG1IS:/F %A#\48G8M[2%ZR4UXZ I+-3 ?&:U1OWK90P$H.L*&Z[%?)^:' .!
M?;:*QU#S]=S8"<'562O?%J#]3M9\?U+=!F=7GKR<X\P/:.1Y,"6!-.,"R>Y)
M1CU(L.]CD?HAYIE=%]D^8MCPPCC=9K6$EEO!/O@;[A 'QG3HC6,C?KNNM=(
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MY]GF&=3Q$5Z6)=+>03#D'$MK)U7'+SB :89#CJ(T28A5R6[CF:=F";4$KU_
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M1"@6<<HAP7$*49AD$,>)_*>?)%D6!WX@M+JRG1U];L) $0@;"O5DPGG0^F7
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M>%Z4"L08#"*&(<I2# DG"<0B"U'$:!*'Q,P^UIUZ;M*DID\J0C7)H# N9V
MNZX=.P:84R@^>ZIO0$MW5:- VITUSGO:7=J:IG@YLR"U)Y[8+C0%Y-3:,Q[!
M]IIAS;9T\U^X*/!J\UJ)1KQ<!!&)_3A&,":)E$\",YCRC,$DR#(OXJG'0F&>
M]7Y^,I---&'2>]-X"6\ V>6_KP6H*3"]3S@/LI_Z$<XH#(2GFB6F"&9QYL'$
M"U L BR\T#=-@'<%\?CY[QV ^8HYAE;WAN9:L$86ZC^4BQ\7K/(A?ORUD4 I
M&5Z3#5JZ04.XRSN:/F"<7<V<G63B&YD^1D\O8GJ?OK)#T+WXE*_DELCQ\MNZ
MS _:W$4L2U&49="G:021%X40$RKU11I''DE]*9:-<EET)IVEIMAF:.VH!BW9
MQBT&C19 3Z"XAG5\\7(MHO:]BC0@<MW!J&_*M^EKI '"Q6Y'.N_:BJ0U_=?/
M]5*^4:IN"9O71239#%C(H>"I+Q7"+(:I3Z3]RE$0QUXLA."+C>J;IBN CJ<P
M$C>[B<;;''7+O;)#YW_\CS3PD_\->$6OJ9 YA32)A!3B&4R4[Q"EG,(TC1(8
M1WXF<!3P.,K,=>SK@/VW*2IU!L]8<)3ZPH<>58VVL!]*=3H*H(BYG_#("SU,
M3=5I%VC.NY34&2!US[IKH!GY9*L)N@&WFTV1D^VFJLBX68-OV*W[]3((SLZN
MDPDF/JDN,7AZ+EU\TNX4DJ=;ON&?\Q?.[E;2$'K,Y2+6=]]?\#_71=655Q7@
M^+!^POE*'E%1$F<40Y]P:4YCAB!)");_24@2AFDB0J-;&</YYZ8NU^3#BGZP
M9V 7N5+Q4'>4KFJ\@#]K/@RU9]-5TA,N(V(_LN1Q#[NQ4+($SY'$,IU]4G%F
M"<VQK+,=QCIU33E[ZR8ZW_/R7^]>'^1(5:6W$#$_0#&&E&=2Z+$JC]V/H<\$
MBPG* L*08:[:I;GF)N .2 6*5J!(M:JCUP>QGL1R!-S(TLD2,YN4LR$TW.68
M79QIZJ2R(9;/9)$-OF)IP:N8/W(<\W>K_):/E?/@W>O^D6_X5?WJ]B]<L$\X
M+_Z!EULES;9/SU5_115>J));'GCQY"]\[*6I1Q)I9J58E9GV(4ZDU96F6,2I
MGZ$L,<J.'8_4N0FLECA0Y;#EJRKLSS#>;\2%U33[9K%<8SM&+P5I=_@$Y/4@
MF+OA%53,W@#%+JCX!1V&;\#N(U \.S1$1U\65P;M>(1.:QB/#OB)@3W^C->4
M=OZ\+LM/$J:Z^>,V7SW>/S>-'\MW7*R+?8,$+J>7IYZ<(U_AXO5NPY]*U1-2
M)56OEW*FQS;B81%FQ ^B-%-U7E0B4415,\=$*KF,Q%'* Q8G)G[G$6F=FP-;
M,0E(Q4W;$P&H[UB>/%59Y8UBSJ;<]#@KK7?\S&3]1CY_FL+7ORD^?Z\7;<\J
MV//:+N^^4+8*,CUD;Q<(YKID]JB+X+3N]CB4OD'Q[E$A/U\!?-PI+4HF?^'%
M(R^^\Z6*@VLRGTJ5=_^#;S9+SII:==(4\4B(,4P3/X0HHBG, A%#II*-0NS%
MG&@E&QG,.3=[HZ8:%C79@#=T U@5S8!E3;M!A6!-Z/LE^4B CBR1:X)!0W&;
MZ5E6539 0[1-T65-2 W*+[N'=J)"S%=^KF;EF,U0ZBW,K#G4="6:S7@[*-9L
M^*IES'%MFY0/ZUOZ_[:Y.D$.?>B+E'E!1BB'D9<AB+P@@"GR(Q@0X<4QCN-8
M^(L5?U14ZNG]@W-J;8BLWA#=F<?;#]_:HFMKH=(CVHLD7)%K&"4[B+B>]NT&
MQ8F*FC2TJFO_AMK3^SB'(;.ZT+B*GAV<;]I 6EWV3V)JM5^T$S:?UZM'Y>10
M&17O7K_@S;;J9=/&=:I&LPD7"<38\R#*$@I3$0F8B#0+22 XB;")-[M_NKEI
MB(I:J,@%BMX;\"DO*5[6)0A;VJWC:@>0UY,X[O <6=RX@M)8\.@AY$CJ#$PV
MJ<C18_Q8WFB^96&8WC^M<FD(5W%0E=^U;/2H1K35(;JM>1IE)*$QAT&@6E+$
M7&HX'L<0^]C#(H@RRK3DCO',<Q-!#>U-!_N:^IV9U1[=-0,&9I716FC8JV,A
M/+)0Z@7WX0!<&^/5"&4#$W8LM"<R9%O4J]AQ@&O4\Q60<FVE6D5+L/_*-S_!
MYJ?4YO?\N.HT9(->KX%K-.!T9JX-GP?&KM4 -@=#[3!=/2I?ZGM<%*]B753S
MW3ZMMZO-CRWYI_PN'M;2X,YKU^I"I"Q.&$4P0:KW=,H1E)]= #-&4(BD<BH2
M_=YO%@3,[IAH60!+=:U%NTS<@+)F0)T7?,>"B2"S6"&=4V-<W,<^/':05S>)
M[P\AKSD #0OJ,/DX%?(F)\FX*S#5@>)^)0R/%'L8^T\6BW$G/&#LN3X\9ZX8
MQ^*X^5:L*>>LNK6[*\NMR@FZ%^_73T_K5776?>6;>]'^1=4!+!>I"+P,"0*C
M)&,0!3Z'F"<A3 )&/>ZEE/) ^[BQ(&!NQTW+0A,PT9"J/+&T8J/1[:J_;E=R
M8?Z25N2&K\#SEBQSVJ0(RN<%+^3"RUVZXE66[6XHJM@V$)0VJZIQ1(V\5F/[
M> ^6Z:ZS3#4';3WKKS7XNP?>3P"^P2DU\B),=$H]2'-&W=1)4T<LUW_5:U+9
M.(Q5FC1>RK\_YRJMMHH)4(EYRAB26IMZ3%)8Y>R=W2FNC*,KH.X]R6S&G>XD
MNX+K@Y/LFG$LDP#;V,6[U?-V4W[F+WP9M/VQ42@\U14[HW$($44$DM@GT$L2
MC_IQB/S$J,AXSUQS.Y\JVD!@F*K7@Z6>-]X10B.?"OO0:U4%31%Z QK '/9]
M-,#$569=STS39M$-LWR2,:?QBF6MUE:[;L(5F@\:8<9Q*#7:E%,/HIA%$",>
M0(\'&0I9& IL5&SZ_#1SDPM[2[$AT[!.ZWDL]83#]0A-YM!H*!Q!&O2#X*H.
MZ_E)IJV_VLOH2=W5_J<MK%P5E'2[8E_6*_[Z!1?_XIM/TA KV^LUGX6<AS%D
M1.H'""4>S# CD*8LI1Z)0R_3JJ\Z/-7<)$ 5D*C*Q3TI<L%312\0BF #@Z<?
M70V[TAEF(\N$"BY)**@H!36IH*+5YD:L'S<#D] 9?A,9?SV?G2O330N27B.M
M?X3IS#$M3@X,+[TW+,1H9;4I@XVS#UOEJOI6U2RZ?9'R^I$_%)CM?[>_$UN(
M( U8@%1TO?P/\K /"0\1Q$'($A1@GOI46[[:T3 WP=N0"S8UO4;53*]9"@UA
M/#[ (TOI.GZAY@#4+(":7M7@H\:]86/_>ZO $<M%,)#LXR_&1")_K$4Q.Q6N
M@[/WN+ <>KISY#K>#PZ8*X>RK%)!?W*V7?)[<519MVW-\/J@"K<]\%^;=Y+I
M?RT$#9$\=A(89U*WEV9\ C,5.A>G&<\H(YE(C$I\F1(PMS/G_4^5^UT%%WWG
M)2]>.!#KXKA =&Z:YFN\+GH.@C'1'OL :DA7%Q,GY;=WY(,_*P: X@!4++@L
MG&N)GJNZ#:;33UN-P1*<DQH+MN.X[ACS40@5*OC".]U+0DIBDDDM.Y':-T0!
MCV$F_PLQCQ./"!K0V*CEL]'L<Q-]5;^3O-/OA+<TC]-+YMR"Z(F]T6 >6>8-
M=93943]Q4YD>U$;O*W-N[IFTENF!1;^[3-\@-MZ%[=,3+E[OQ8_\<96+G$I1
M>DNI"GI2ZN1ZF5.IG%0B=>%'+(Y"[L,DY"%$GHAA&LM_<LI3+R9)F*3Z(4@&
M$\]-L#6D@WL!.L2#/?6@);]1-TS\DR8+HN-8& ?FL96YN2!LXC48!^FI7 7N
M$#?T#IC#UN\2,!AO0C^ .9>'QK_%^]:EP@J.2_Z!U_]_MSHM&_Y]O5Q^J@-D
M%P'' C.<01:0!*),U7-!\C\L"W D#P3A9\Q$Y36<?VYG0TL^^*UEX'=E^W=Y
M^/] S07X4_$!&D8,4W=-ETE/$1X1_)%/C!%PMRFZ98.>NT):1K-/71S+!IHS
M!:^LAC$3A9RRA2H-SC[^XG2K=.U[(46NG.'3:N]1TY!I6@/-38)5!(,=Q: E
M^4;NF/5FM=8UV/50[)=+S@$<60H-8R>U)Y>N1R. S@B:DM._/:Y?_J<<IY$Q
ME.U%B][HDP@2(T9;L6'VDIF08#Q??&AT\[J21'WW\DG^KERP($HII2$4.)&F
M<H(8)+2*@P[CE#,<:!8/Z)UE;I*C);2MK%&3"BI:]61&/ZC]LL(95&,[[6Q0
MTA8(6BCT" +Y?BT(Y ][0= _ZB0"0(NQ=N/K/6SA+GO(GWA53/QVI3H\BW7Q
MI/(HJE_=UW6;V^AFRJGP? (%E<81"D4$<9#YT.?*C89(X!$MN\ALVKF)!$5X
M4WU=A9YU:&]^VU!OX+[17P(-]]@HP(XL0!3-H$;O]A!3<("I372D/K@&GK%1
M0)XJ94Y]P&3W 3]W/N#ZM^N!#]C,&V8,5:\O3'^TZ3QAQAP>^,',WW;=V>Z/
MDHOM\G,N^$)^.[''LQ#ZOFH/&HI4A; ',*%8A(F(PS#QW+2SVT\Z-P'_L=SD
M3U6QHII&H(@$O[6M4WYWU:JN [N>*\LUF",+]=ZF=#==<*?H0G<*T>BMYSI3
MSJ3?W"D(^DWFSKQ[1:/G;C>1;_*S:8Y@0:-()(F 8<2(*@GAPU0D'HR$[Z?R
M)YJ%6BDT&G/-3NS4GMRZ<I=%.]T+B.J)%D<XC7V'>J[S4:<YDOO,.@U<7/;<
MO3#3],UW^UD^VX5WX!7+0KI<BAZ^KV6C/.2[J+BVBN^'+5<53S_)[VP1AFF0
MI6D"8QSR1H$),@&YX'[H8>:33"M'Q): N4D5^9TEAA5T32'7DS!C CFRV*E)
MOP&=BEB*^IM]#.Z-*B="N!1*.;NIR^\J'AS6V[5$SU4%7M/IIZW):PG.295>
MVW&N:)?Y;KBUVKOCUFJ-57B_W9120U,Y$O_%\\>?TF)I,B<^_N(%S4O^K<@I
M7S#,PXA03QIQG*@8-P^F*0F@1P03/LVBP(\7=>+8CPTN-IJ:U334FXB!8Q[&
MDPCO^&.^6BE)0/"R<E,I\W!;5MX44"J^#<W$J3X&$F*&D8=@%L<"HD1^%@0+
M N,@"5*?84K2H/D8/JXTVUS,]E-H.1A1::^H_K?["C2-@OFMZX0&AF4+UONV
MYVJ'^QO0\K_+46P1 !4$CENR3K=F+ONS3D#U],U:IUN*LYU;)YS>I1*T0,1/
M4XQ"Z 6!TEE0 %-.0L@YP@$+F)!_,^[W?3+-W(RU6JS4ES"T0Z>+0^0JF3]3
M$7W&!U0W(E5U089J43D2K9-(PCD(+C,Y<Z58^,Y?^&K+5<G'C[_DUEOAY?MM
MN5D_R5WX[O7O?/U8X.>?.;U5,9-'><&$X"1&/((^D_]!OL]@ZHD,>F',411R
M*4V,?,A7T#([ =/)*&[84NK,G@?P66T#8Y%SS7+IR:6)%F%DX=5B7E6I;?D
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M%H$_*Y8-H[K'^3@T':IOO>03^DMW?M"]F^BF[;G+ZJX;M7&G>)(K_K3>JIO
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MP?,VGX>>M)_]HH]_JIQ9Y@8$=>\*=C" !U5_3P+1/@?N!*BQD/8;:-  '3C
M?0%J0-J$"/F+*B1N!PJH4 $5+/\.7Y79L3G[KVNZXWG^7YFQ7O"FJSND?[P-
M<9/J.6^*_[$^];;$3)RRVN3Q=,H+W$D.<FD!TSK3,.%9+ @+8,1C#)'(",P2
M3F&6>91Y*8TS*4NGR$H=HG1N^M>.NCK,=:*TTL'UU'-*SV*51E:8'"2'[M(_
M._S>@/W*SR7]4W=5WCK#<Y#.?X\D3EVXG>5I:D]HX17XP.LPWP?\J_;GM[]H
M?/F=*,#OO.1R\)^W*_:!O_#ENNI&4H5H+7 69MQ' :18]73RD@2F49A YI.
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M^8XW_!N7'\!JLPAHR+B?9)#Z*%9[5D B(@1IY/%("$%X8A0X:TK W#9V2S'
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MPJ77$];S7-"1A7S+-.AP?0/V?(,NXZ#FO*U<S:I*U1T>0</]#6CX/VS JB"
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M\&2VA.M,]$B6P77129(#_D>ZC!LG.44$CQ%"$$%4+_Q\@:1FXMA>S^1J2FD
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M\K7+&QY3,6Q>LB?X["GL!C)++\6V([2A)IBD"'.E?%\:3GP$2;3*+E/'!7H
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M<&A,DC09("#0898*'9X@(Q A4J*1.2%\[0?GKZ=RV$Y4#8"TE@;;Q>AJ&Y[
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M@/&?=SIR:YFJ?D/[(E4#QSQUU/\05'5U,?0A=6VR#V>783U=>VU;;7#&<61
M!%E&DZ*XO F!V-)BR24/_F&WS@T'U<8E!H9'947.JDMU:&S<OS([^H9"77,1
M$U-4*CQMC4/!@&?(!<\D*'#1*.[=P[=R&["Q<8F!#Z$>L5%'JD-CX]?Q!!;H
MDL$!BA*^=2?VF@TOHY>BL.$3LF%U&>VJ/4G J$5'+7&UW>7WYC6&=7/[1$<E
MN;;@M#SN8F,U5Q#1F;.>2N1 *.)B2B3YF+6S*COHK8?OQU<UCNI_[F0%]W8_
M 3< D1-8EDN,3_/9MW&"].[';PM(Q]/3ZZGI![BEOJW>JU]?<6! %QC%$,^H
M,@"X)!W+N#\2.7BN?.#<UWYE\WHJ&\GU[XB+QUTS^E12&S"\TQ?$!D]M:78@
M6)DA428 AC)\24;@(+--V=7N3K;#E.:^P-.WMI]MR?(:T3?Q-/7><X?R5F$:
M\?R^Q]3%[+7RE#XR;40@QDDH%44EO9TY2=$+9W$K:U[[AKL//H;UX-\8QX,#
MH0$S^@LZOH71T^GA;-IQ< 'SRW7X.Q*)NI141$_'&B(UY64<(AY!B@I-I0]1
MUD;ULP0-:V:'Q\NL+^6]'HENA<0I?"Y55%6P^!YP[3A>41^"E%'$$DAS/%9B
MQKBZ5/PJSP67)MOP\'' WM"[N_ZPAK YI.VLFJ%3'@>7I476?W>$G^9CU.'T
M\QB#N(/% I:+@VDZ0\TB>5_>8]P^F7WM1FU\+P\<8129DTYR3RBCB4C@&+M;
M *(<8RYYDWU\,'QWTZW?[D0,&_@V@\,WU64#Q_('-.+3"!]+^?)9&7%WFE&P
M':-WI3!B B27%H@QJ=AXA3&B9XKX:"WWC&M5O?![2]*&;>37#'#[5&@#.-W0
M+HN%)(,-G'@\'8@TI5>PD(J(*+00VJ.P6&58MMAYKSD45E!7 Z [03FBT'Z%
M^6>8GT$W]>-PME@N1C9)#/A0&-&7TA+-(RG#1='O9<JGD$R&ZHG&3<0,VT^O
M.>C545H#Z"M!UZ+(#S#N.OI>1'4U7GQ9E?>_A[ <6=PUTC!'*-6Y5"H <1;0
MD$/V%!PWG-5N]_@B4<-VU&L.C765N&_T?%%QJL<W6 EZ)=F3^^Y%F8R\B+.K
MZ1*]Y4]SN!Q?78YX3-(JW'H&:!DBR#0)TCH,YR@K\Y&HU;63/#N0.6Q+ON8
MW+>BFT@(/5&14Q)=*$WDNSSB0TG/UQB88S"X>L=W^*5\>3Q%>5QU3ZZ>_B<?
MQSZ,)^/E#S92DBH1;&DCSSF10CGBG."$&B\B-UE$67LDQ!NQ-FP/P>9V38N
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M*Y?-QF25DR)"<X;.<,XD /-$RV03T(SN<.UV#MO0U=I8QSJ8>!%Z>RJHB;S
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M71S\UVX&ZNX_KWXGM8&R:DDE7 HN_/<GH*-<Y$(Y2:P#@=!!_*"* TE.9XO
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M9-57]M%>8IH9;D,D3)C2)"='@LYK*#W(1+(BJPRUR\&WIV[@)O[#0[(G138
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M[6Z*2XH4).[$D$P9<\")]5X1R(91SY('5KWGQ@YT_J$F\+T&:8]RZ'TKL8%
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M Y"Z$<UU*2&Z>#H'1@182:1 +P])YF62%=<>N$NJ=GG, Q*&/07[ALX^\FX
M+JNF-S!_R(;TWD$W. @T+4\C@(1H+1$^>24!@C*UK<\&4H;M3MLW?&K(OR$8
MG<_R\G<4[#&J:/IYC-YE-PAHS91R6<LRO,_%TME!9$F"Y8HPYT3F3DCQL!Z\
M&JB>)6S8=J]O!;%ZNFD <!^NYM/QLLQ;F:8/X^_EJ^L#&XP*3)E O#$8S@2+
M%ICE3%B63J+;F9RJW:)E,S7#-DKM&UJ5M-  GC9*ZO9J7DIFK,+8!4VS*16)
MDMB .P0W30@!HLC5>PJ\3-6PI^.P*8;=5-,RV*[OT#.,,LN4!1H)PWU(I*-
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MCYN8?7Z#88D?II^_K-Z5OY;;/WV[K2U[3&3/_M>3$'*1.D6P14A05M=2CIB
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MYK//CS(2968I6 O<%/**<ZG'%AT%Z$9S)KWF]ZMQ'P'44U\9UT+U@:=F6NC
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M@_#E_UGXVD<EO</LSEZR6+07G&[XHLMZ.)J$8)4 $P(W242F=.M@<B!IPUY
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M*) ^B:B(06..Z\3W.RES%[T/F92YBZ@[N T?F.^'F;G,ZA)!:<G>UGR E\I
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MLGRI]AF7,R>=KI[^I>#5UFZEY):4+OOM#R@I[U)J2>(2*;MV]*ZRTRXN O@
M B ("#B]"8X$#G,&$8?G 45C/::!YGE^G:*Y;5^JZS#U!XDG U@+LKN!$^^W
MFQE8\]GLS/_G9CA;=+)8#KX0QGAF\HNH7,WBG4':,:#*1(XE8<ZF5%AG-FRE
MXL3#LL*>E.=\HP#*OYS&VVP*,$)3QPFR)N6)U3;?  6!*#B @DNFA"L]6&KK
MINK:JB*B[P"G_>50.TEY?CT>3J[CN[%?Y<V\#$E8JE%D-"[G+5@; DJ2":>U
M29AU*YU^NG)[2#A :I-2+*PM_Q<L[WWT(:(GU$2!=-89+@0&=?$<Z.-)>*R-
MZSC&N<O7*@Y2[>48ZH?-#1Q(YU]C#D#&G]]'.XN7P\]?YN?ITRR>S69Q/I!$
M$N<Q0XI$4(+\LLE)*E#D@C.?J/:I=#3_XH;:]&[V%/ZD+TDT!ZM_QDQ-#&??
MX*>?%V_]<Q%X;G"SZFLS$-+FDKR$ A8JCRIPP#DAD:(:2Z6BQ\4?+.^ZQS9M
M6A_@*RROUO%X&;/O</N'N;*3#'0(0IGD4,R#2WF(!EEJ.#(8&Q<XU9243H3O
MNL<Z2<X&\'BHO!K XZK;TNSM9'J9U<D3%J((&@EG<U."G/3W7"+,C,3$6IML
MZ<=(3[90ITS[.&@ZA-L-@.6Q,N2KHH&6A."D'<(Z-TGU!.(<"2$*%<D3HZ-*
MQ;,$SW=19PY)#0.T,\]K1X3W?7;?#ZT;CH;S'^!'3OPPOS/YYW#^Y=TX1 AY
MT] OKR+=:/AY\2M@6TK$QD00=A2CW'(WMTF%?Z0 )I4DS7S'%_K[;Z+.4))^
MH754P31@MBYNIOX+*,\]"8,D(Y>))J1B<(CG]H*&<(K 6<00>KNHE2E]S#W;
M19WA)$<ZZ0[C>0.H>6QX[Y1D0',*+H],E ;GUBKY#BH1C+R-)GAMX?]+0V?#
M5NH,&JEQ[.W'_09 ]&Z<>\I/IC_>#J?7MSIQS[S<)7R0&%=:!H9,(! Q2)(C
M!A%02#PF!3$LT^6+Z;9NJ\XLDN. J[14&@#:@\CB=?PZF0WGP")N%6<L(F>8
MRP,,+-)86^0-C1$8)./3^8 E8[G;;52:2W+T@&XOMC> G-M]+]*[LU<WT^DB
MK>8<=LQ&E P%ID@>D9%:(IH25AH;KDCY!Y%K-E)I"LEQT',XZYO#SX?)V*_H
M,!B[R(5!R6.#./&Y[T^"^$Q%1Y.G1A4_US;MI=*4D1HHVE, I]"^>&/QXOTS
M^653GZOA-?#8CL,G6&(ZM\/Q_,<DO;*S+V]'D[]F64"/_<M9/_6<Y?9UO$+0
MGGA9I8*4.^$U@!Q@GZN;!8W@PZF$N+62"6,,_.84*TA?#I+@4[=NR>N;>V98
M@KG&CJ!D,<T%E (9RR#\%@I8H9@(L70+GUWV=TIEJ+O@JEM@6T!F#;@"[R,<
M07%#Z/Z O@]@#:[^BJ-O\0_@]!<X_H(EBLN $G8<<0BQD$X!_.88E,/"\JA*
MWR+LN]>Z..T//4];"QU#E"<$V7]%.[WZ:S)0W%(LI$0V,5!]2SUR-B0D0R2.
M*^>L*]W[8\<MUGVJUAQ ]Q'<J>$2@!8'1%(-AQ)& A@)WCX$D-K#H:0<E4H9
MH).7#K=VWF3=YW!M8G-GX9T8.M].;J8#XS06B4E$K(!3 7X'!T("^CC&FAC)
MN"A=5K+K'NNV!VP2FSN+[M2@.?P6!QP;D3#-]Y"YOUD4%)G<GMI9CXW$5'I>
M.B[:=8]UZEO:AN:NHCLA:)XE^.8=D<DRSBU;] 8U.34(+HSG @E#O556PCGA
M*^'ST4;K5,HT"]+]A7A"2!U@'+&+.=HS1",NG0#_VCDX*Y+5U#LE1?&6OAWW
M5J>ZIED\[B2J8DT:>H+@IW%8/06(X<UWGU_B+;OYNQ"B)8RCP&D>/&,B<IH%
M%*6.GF MK2I]Y;W71NN4[K0%SB)"/+35>:^E8EAJ#IZS0 J'!%;?YX?!F".E
M"=7&YQX[I>\?#BD5*U[-<W2\E1!$U2$?BQOCW^PH=_[_^"7&^:N1G<WNBG#O
MF!3!80!F).1S>0E/RB/#8D0A$&)QE"GX)\C:4!J]_5MU\XG]7\STP?(&7+@-
MJG!;9!*LESQH"QIA%\\X$](J842)%LS38$3QXHR7=U3Q16UIX7<S2OM(HEU<
M/2@[P1BH24$CEUN,<0+'MY5)H*2%\IX)B-5+QP1;-U7QR6P==.TICW8!-@"O
M+X:8NUL*!V1("7H"QAXYP[4V6"KI2[OVASA3_;QWK0.FG7A_T@W^BE4_#9X\
M.F^GEFQ 3K&:["D_[^K)_NMP/+S[ !2\N3K[OV4:/+ZT7&'.=]YYH?*[=V/X
M=+RRW]?XWM0*DC"QX+@(A[A3#FG")8K@BH=DA K%K_A>V,Y! =C=NK>=>K#!
MW$E*T&*B'V=1(4.=1EYXF2*S05K2*=QZNG+=:J)2XGP42AW$O ;\C[O]G]W,
MOTRF^5UL;O)F"9:))(ZP$4!*L 2"3,M04A)3&B@O/\9E_4XJ!DJ'B?;9(ZR#
M^=PD6FYG9G/0(.,ITB* &V8,!V])$>0QE49BQ>W3_JT]X*6%KHDEY+P5.GLP
MO0'PP*[C;#[TK[)K-/VQ:O@GA,'*\MP*1'/$1?3(6HD1EI+81"S%H?C J'4;
M:0TV^\CXZ5.9@QG> &H^@A#BV3B\A[\Y^O]NIL-9&/HLEA4Y41'#*8, /]?J
M<.X2LA'B?6L-M<EB&5CI8NHM6ZJ;0NX%226%4+M'RX-C_?W]BS2GF9:!@K!)
M'H=#7>[ISY"GVBA,B!>R6__Q=:M73,<5\6'*L*VVW"^F$[?*\)RGW^(XIN'\
M,MI1'D']Z>MD_#'.YZ.XG&^^BM:!VHO)LN%M[@0I>'(!@;: ^BB5ITAXBRQ3
MV*G@->V(D,/VT88_O"<")G7$T< IMN1=;K7P%IBZO-B[&8X_K](_D_'LMY@F
MT_B Q[>G]X 9D8(#:QJ9!+VE,B#X@$'8:0A/08V%*'W"';#=-HS=80 ]MM0:
M .CKU6>SX[!X6?VG'=TLQ38:3?[*:?A!9%RQ&#6B(M<J* V>8S "&<(D:*$@
MKGASS@[;JG@_41QPI:70 +#N$]R@1J_L=/H#-.8O.PVS <3$BGC*D91!05!,
M-'B-(G>"$%QC(904I4._S;NIV(BS.(P*\;RVQ[:9C.7URL<;]]_1SZ\F;[Y_
M'2X-\L!SK#47# C*]X$T$F2L](A23KB0 O/$.[EI>WR\8F/.LKY9WXQOP"P!
MJU[!5X?SA^2M*C(%]YI$:Y$$C8!H-D$TZY1 TAH.T2S!1)2^>W]A.Q5[<A8W
M3*6XW@" ;H_J.QZM1@2N0IE!#J4#"1$9X6,N3(C(6NX1:()7F"K!:>EJV"U;
MJMB LS='J03WJY; WA+T:3R-?O)YG,-?(&=%Q^R.OHLXMJ-<1'PV#K=#*<^\
MG][$,'!8.X4U1H;#2<Z#SF\=/%ABEX*B&"(-4]HO/V"[%?MX%H?AL:36@+W;
M0.H@1 ZG?IZ!&@.8;0_J9I*D\-L8J?'46%NZ0>R&K53LX7DL8.W$[09 LT<"
MY2W\=OAY/ C!,&=\ I.="X6#@4!%&(N\L@DXH#'H2?VLUVJW-;M^MI#UVD=H
M[??@>U!O=C&=?!O.8.65)@+]#Y-^1<KGNGVCOYJZ/6@\0J&=3]@3(B@ *9B<
M[K+(:@]QI2>!&()9Y*4?A/=0:'?WP&=9I;[);<4^8I''7$CG((C.Z6.=E$4A
MQ1@T"YB1TOV67MY1(U41!^+BJ84K*(4&#MDML= Z WY?/A^CI<XF% W'<$XP
M!_QD$3%+%,&1$E*\P=<!VVVDLJ(P&H\EOX:@^C:"J.QHDP)J'J1.0%!P!*A2
M*2#'&4?42N"JDT'Q\NVXN^RLKCD\&E V +2@U!K"XJ/:IDVT&7">B8+HG()[
MF_5;(\/ SPVY=I-B&X(KW39IE_W5-8RU<5E<@@VA<Q59;:9*,16X08%HB/,<
M1'Q.&(7@ &+*)98HZRO+_/+.ZO8^K(W(@E)K"(N;R"%*>D%20I@ZB/J%CLAP
MB/H%U9X%3DDD?1G'0]#76W?#VN@K(:<&>B)M(D-%981R 47F.>(X.*2IQD@)
M88SVW/E0.N/<I)'K*QXIP??VGT4_2'Q=1C\9^^%HN%A^DI[ZN7D =YD4WRY?
MZB_1MS>]1TCW8<H)^&8,*:Y<;@TLD,7YJ8)SF/G<&=CVD_;O)=WW)J7H\S/E
M1[Q]S/^S^8K_V8V]R7/:'OWE@< ,NZ $.*YP#G"+@2,^.602)S31W*>VM+DK
ML.UV$X>[(.RI:3RV/!MP_KJ0O#X B[-!U"HX#IXM8;F;LI;Y0*(,\60L39P:
MJF@%[&[:;[OYQ;Y!6T2"3132=*'VU1<[_@Q_H4NYM23&DL0#2CHMQHH)I/,,
M\L2==!QS0V/IXIK")+3KI?:-ZK[D7+]I8A?J[XHM!](Z$R*<-C&7CO"(08DY
MTRAR2:4,VEC<K7_B3I^M&X27QEW/;#^1D_[#)/O_-_#7W"BNXL./7T @O]E9
M#*\FU_DG2]V;S.:#)"5G1. \? 9\'8X5LE%*%)AU7%"O+2U=25V>BKKS"&K:
MSQZE7?MMR;[D_Q&GG^-T]9N+./6YYZ"W1M- />(T9T92\DAK05 ,Q$A+HL+1
M%K.O77=5=T)!-?/;B]!.Q#J?S[_$Z5GX[YO9LH?P0"GI< 3'/3#)\BMI#V&F
M8B@J1:/A.O"GC]:/8G^?[K/N\(*:%O8@B34<;ZV[XQA *)F\"@2Q*"S$DIX@
M*UE +$3@IW<BFN-X ^MV5W=&P7$Q>+!T3CJ]_RP:M./PH$M_/YG^CA\]7M)_
M'RX<HZ^FBYKD]HN*Q(1XGF^EB4E(*$,5#RX:7+H@L<?\_S,F?XCS^SLZP96G
MCB-J?'XQRS6RBXR#M%Y9'$U,?5V;K]M/NQG[73"QM:/"OA)HXK!]1LU++_U%
M8I3(@*2'$X,+9<&3,!X%XUW(_TO%"^=WV%X;E92'HV(;W H)J$WTK7W./;L$
M6<).OPR(-R08(U$$GN64*D,."]!;'64NQ7/,]H[ E[?81MUD_R@L**CZN>]G
MU-W^8!7@O[)?A_-E([%;"L_&X77\%D>3KSG*RLFJV0""*<(DN+K U9RM$@X9
MQSR*21L1'.%:ZFT.7\']M%$P60R*M2350*9FG?8](7P0L24I"844SC&=)!9I
M^#]$:#(.DZ!5\:DQ';;51MGD4<SA(0)ISP2^RE>8H]$RI93>08SFYC&,XVS5
MBN!!^X%;@IG627MKD6#9J39:(L?SM-:D-?-,)QGE7N9O][W4O6 YCNGK64*G
M8?8>WA@!P;==#5ZX4N(\L,2X1<RJW+.6$60)_%:$2*4!_R1%=GP[N3,==>]B
M:AK6?D5>^Q;QA7#OR>S/@7*<VGS3A D&)\;I@%SN#"H-)X%0*TT*^[F;&[]9
M]UKE2"YE&8ZW:#]_GTYFLT%(FBB7*%+Y*."!$^0"T.,D."E*L>2>GM/E+>!B
M)W4O2(YGPW9G>P-O9;I4N!ECP9@JA8SQ$OR)""01P9$,1C%K,?RZ=R3M69W8
MVZSFX\'J0($T,?E[';<&3FF'K65(60ENJI<8S*R+8'6%<$X:77Y4U+I]5&K!
M='P@[<KSMJS3@P/Z]\DD_#4<C9:ACQU_SA4[2QJ?_GZ@(^8AL8187-R!<X&L
MP1Y)2SSQ\#\A2'\@VV_3[;XF*'2A=@19MF;V'I!\,9V ZSG_<3&RXSG0_>8_
M-\-%TG(@E8\X6H>LS944).3F[%@BG42*#K25\])55SMNL=TG >6A649.58'X
M-/)Y0-WE\/.7^7GZ-+O5KFAUE")&)'7PN?-M0#IHAC2S@4N*(S8[QYDO?*_=
M(O]]D-07HYLR8W=,>Q0L^R")Q 8E;#'B$/P@ P$/DIABGPP)T8:>;-:Z_;1;
M<U_"0!TL@4/Q=-6S:S<0GCLI?)Y/PG*'$PU656.-/!6:,W![G>TQUMP52%6J
MX,N?=#MQO:!)JE'$N;Y!\IGW>99 3S6<W;YYO!+./7APA I.AQ...55&G5>(
M,Y4@V(5C4B6LI*!$QE#ZRJ;'"LXGY?H;>#Y[\]V/;L)P_'DYS&)VL9Q8!S_(
M0U+L]7"\^.N7<7XS'<\N)Z/1VV41SH!(IH7P'GF2$XT1/ A+\O 4JI-F*1?]
MERZ2ZINF=BM)=\'F4YO;%!(:N*_8U**>10NA4X#(WJC%+-C<: ^BJF1$"'G6
MJ!2E*[@/&0C0&P[;PDO'^0*["&]O#$(X/ISDKHW3><^S4Z;Y3C#7.=Z,\A5A
M[F=_ =^>7BQV<'4_3S2[W];&_#H[!<& <DJ0H\RBF(3R7A.?4FD[7&+?=9.,
MIXCQ_F#1KE%>3_.J#?H:JKVB7G "L0G/@802"6)1'I"%4-0+22(N/GRCS,[K
M)C9_'G4H XTF7BULH/MUW,4,6.'!=501,9GT<FPFG(L!$2"8!$4P":53^B7V
M73<[>XKJT!\LFL@!;_3[7&(F/S;G+@]?-$$!$TE PC(X &U*FI=NU':(T]Y;
MYO<4(;N3\ YTVM^,CY+X^WAU_NI__^/\_>LWEQ_?_)]/[Z[^]<%.<YG?MT,:
ML798M7#R;E<Z"J7G[C,?Y^EA?>UE'&5+LGA5LZC =;D"]\+^6/2>N,N2:*^P
MD%2AA*G(HWP],@1.?$D)H32%0)Z6JAZ>O#]HQP?=JWZ<3_R_OTQ&8%AF^6YX
M_N/*NE$<N$ 43SZ/,<[/,R6G2#MID6?!ABB%Q8QN0]Q+'ZC\ O9X$'ETN5J"
MVPW$68M^F9DE2QHR!R?C!8>^#V<#3#&S"8-!MMIE(Q^0\]H@JDS VB;G56EO
M\<4-U8%:.7E/^F)^ TAZ0L/KR34X$@,CDF-*4D2I-XAKX9"-02/B<P?V0*G4
MI;-1:S=2UT@5%/33OC@'<[WVTQ,(2;X!=RY&UB]8M##CU[F3+RC<'_':Q>F
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MJ?;N:9W&!F1U_& +'FI=C/4AF=IH.[\>#R?7"PI6N^>)FFC 11<Q/ZE4!HX
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M['IR,YX/F'<R<8L1-?F"SUF9>RD:%$$D$<X4''7I*J,B&V_Q\.\;<V6!OP<
MVG^S\_'-[W^\^7!U]N'U[V_.?[\\N_C'NU?O/KP]O_SC[.K=^8</=CJUF5^'
MS&'8\1.EYRT<0F&A1.['^#F_%[N,7R?@I(X_WZ75C)+)<N914"P@SF5"3OB
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M;[3*]"HO@5S@[SHO$P6_4(#4=6-_DY?TP_?I,E_E2W6:5\TRU^52PS(KI29
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MW1K8'_I?*T2'_T.08W< T8#])8R<!CO%T MEFJMZR$)BQ2R88RL2/) &728
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M.L-7H $W.:J;L+(3U&V^1MO&V@^^JD<T?DO./\B& M0D" ?"IWNZ\I!":=/
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MLE62*??R:9\-AW02^8=1'#(Z^\X<&PD#+^F.Z.T05G3:G#W\':?#7[.?$\@
M,@#18!=_(=HH12PDZ\K9(ZKFW>M:"_ND7^@+#<@P>'X1:$8V%\ <3? 7:%D
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M>BE$DG^>RQ^+4+7"UAM;"_L41NOG,XI&!<S&73VTAP[?Q;(2A9QWDK4)@K#
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M:Y@4Z6+'W)(:.KE<B2C&]]S"4JQ[C"ATQUUT.E]-@M=4D \W9=EXAT%-&G2
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M>KL3..CIIQ!@PN3GT5_R&)RCH1STIJ: N!9/E/R[A4B*5:UM<85_*SGNGCM
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MZ>M^-T5N9]!F9!E^T1PV5*7T)5,)G9?]HA2SD8BX!0C=>XYDYJU,TV-$;1%
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M.=WPQS^"UUQ2K2$YSBY,0^X^+68#,KD;B&"7=T<_^/>U+YQ\M?:%DV[[PLE
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MYG 4(G#GNU^4;4-"U ^S]E\:#XG^<WIY]@O^]^W\W?E/_P]02P,$%     @
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M'W)J:I_KO+&ZR7.4ZRP!EVFR;GJW$'I1 K5(7), HD2$E)1@_\<DZ*S=!+Z
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MYA!7FC1KO&$KG9OW#1%YYY]];P*>$M%<KYIL:?9<_!>-I\V\X?4O4$L#!!0
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M[>KZJ]^)6/M^:HDW1[3UY1 > '2%71_RG4^NRI_^ZZ\3]]79?P!02P,$%
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M+!,/HD>8$$&0M<9US_%*-)&@<(GF=+6_<)/)XP>>/G]5+6(0G2YO7>W.MF8
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MQ8KL49!P]"D3(IR?"0U"2E7PP$!/G5;$#8TYD!<F:$<+@J77;63W'(DE@B'
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M0 =4,[JJCFGB[4\QV.V ]=N/NJB0=&*D]"X:I;Q)]A;@J.(AG$PF6')&YZI
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M]HP=EQ\A=L$ 8_D=E;O;>L7&$_?<FAYD9J*C#XOJ!0MML(Q+'7M5N0SW8 P
MBEI+:-.IRE:A@_0&5CH!2-D)K_"&LIZ#Y$:T_EA$B",USINT*PR?..G>.,GS
MSW)I%'(*Y7L(8;!+F@F!"SP.X6JM6A6?,&189N;OK5_KEJQ'05>EXJKRSKH>
M\(E;[I=;0LS=H[)Y-S@4L(MSR<;D.QFJ*=!4=\*O;O1E=&.M$U=&$NV@/Z-@
M@8)>WHNYS5VT-9FO5&R5IX9%BZ%6"ZKNGGCEGN-P-?+>YU\E'II"AX7VTN0^
M156!2&8U^_1<*^*,(4_L9^^ 3 _YCTM7?%RU'FX;LG^"_V_ @IV!-;(R[47_
M668"XW^K2Q-SH3>,K^>Y:\>.UA'?' <?GOCFGOFF5C*PZZ>M-X!Z;5-;(N0A
M]X(M=WY UMDDNL>G'#?>R>ZW\-P<F+SA$$^)]HV(>%^B\HEC;,YY]9;?5CMA
M]R=#WFOIDSOAM'=O"[)UU;XCIM '*E!_XQ/_QQOL$I"*Q8G*:4UTTQOW7,<L
M1_!H\+^I\8=34#03_MEMX.$1;.<^[F$!LRD2_V"WO0/:WN=%LOP;W/CJU<I?
M]P;[*W];-^KK@\'+_8.-AGU.,^99 UTL&(-?GKUX5C,VJ:*3O6B?:.['6W/I
MP?0*+PY5.BJR)2KJZ?TE&_8.NM[D'?)..)';?W2#2P.RM_39 2GZV]N*QJ6W
MM]-.GBC'-Z7.S"J)_+Y]%QM4JN\>-!8)QLX=F74:Z405<'F\P32P(3!8:I'=
MLY=!#Y>['8ISG5)=99M^7(9^XN:;<#,'J:6Y[_:%]/ G9KX;9MX>2Z&3LH-M
M%'=OU5#?< ;=IOLY^8H;,MO#BEJ>8Y-)^&=29.F[_P502P$"% ,4    " "*
M@UQ8<^B-=84P P"X(2  $0              @ $     <&%C8BTR,#(S,3(S
M,2YH=&U02P$"% ,4    " "*@UQ8[Q[SV4<;  ##)P$ $0
M@ &T, , <&%C8BTR,#(S,3(S,2YX<V102P$"% ,4    " "*@UQ8ZW[+\<DM
M  !VU@$ %0              @ $J3 , <&%C8BTR,#(S,3(S,5]C86PN>&UL
M4$L! A0#%     @ BH-<6%JFZ<QWG@  !/8& !4              ( !)GH#
M '!A8V(M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( (J#7%@/$G<6TAD
M * :   4              "  = 8! !P86-B+3(P,C,Q,C,Q7V<Q+FIP9U!+
M 0(4 Q0    ( (J#7%CR<'"%WC$  !PR   4              "  =0R! !P
M86-B+3(P,C,Q,C,Q7V<R+F=I9E!+ 0(4 Q0    ( (J#7%AFE6;>('\! !,
M$  5              "  >1D! !P86-B+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"
M% ,4    " "*@UQ8MINGYU_H  "RP H %0              @ $WY 4 <&%C
M8BTR,#(S,3(S,5]P<F4N>&UL4$L! A0#%     @ BH-<6)$\8+"D00  Q.<
M !D              ( !R<P& '!A8V(M,C R,S$R,S%X97AX,3 R."YH=&U0
M2P$"% ,4    " "*@UQ8=?8\.MD#  #W*@  &               @ &D#@<
M<&%C8BTR,#(S,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @ BH-<6-J7NNOA
M P  ?0\  !@              ( !LQ(' '!A8V(M,C R,S$R,S%X97AX,C,Q
M+FAT;5!+ 0(4 Q0    ( (J#7%ANE2)=\ <  &4F   8              "
M <H6!P!P86-B+3(P,C,Q,C,Q>&5X>#,Q,2YH=&U02P$"% ,4    " "*@UQ8
MA$LWT? '  !\)@  &               @ 'P'@< <&%C8BTR,#(S,3(S,7AE
M>'@S,3(N:'1M4$L! A0#%     @ BH-<6*5<[Z]\!   +1$  !@
M     ( !%B<' '!A8V(M,C R,S$R,S%X97AX,S(Q+FAT;5!+ 0(4 Q0    (
M (J#7%B$X0I/@@0  !P1   8              "  <@K!P!P86-B+3(P,C,Q
M,C,Q>&5X>#,R,BYH=&U02P$"% ,4    " "*@UQ8VXE'BX(9  !4E@  &
M            @ & , < <&%C8BTR,#(S,3(S,7AE>'@Y-S$N:'1M4$L%!@
0   0 !  /P0  #A*!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>pacb-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pacb="http://www.pacificbiosciences.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pacb-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonAndOmniomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:LiquidityBonusEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OmniomeStockAwardsRelatedToAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:CirculomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-03</startDate>
            <endDate>2021-06-03</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:InvitaeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pacb:IlluminaFcOpsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:UsGovernmentCorporationsAndAgenciesSecuritiesNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:CashCashEquivalentsAndInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:ShortTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pacb:LongTermRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pacb:LaboratoryEquipmentAndMachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:OmniomeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2010-10-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pacb:ShelfOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pacb:PrivatePlacementOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-02</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-18</startDate>
            <endDate>2021-04-18</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-20</startDate>
            <endDate>2021-09-20</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-20</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-22</startDate>
            <endDate>2022-05-22</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:InducementEquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:OmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedAndPerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">pacb:ShareBasedCompensationAwardTrancheOneTwoThreeAndFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRSUsAndPerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:TwoThousandTenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesStockSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:MergerRelatedExpensesCashSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="unit">
        <measure>pacb:unit</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="vote">
        <measure>pacb:vote</measure>
    </unit>
    <unit id="offering">
        <measure>pacb:offering</measure>
    </unit>
    <unit id="period">
        <measure>pacb:period</measure>
    </unit>
    <unit id="segment">
        <measure>pacb:segment</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-32">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001299130</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityFilerCategory contextRef="c-1" id="f-36">Large Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-727">http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-245"
      decimals="7"
      id="f-1017"
      unitRef="number">0.0229885</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-221"
      decimals="7"
      id="f-1018"
      unitRef="number">0.046512</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-34899</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">94025</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">521-8000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">3323701933</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">267951880</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">Portions of the registrant&#x2019;s definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-37">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-38">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-39">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">179911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">325089000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">451505000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">447229000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">36615000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">18786000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">56676000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">50381000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">17040000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">10289000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">742047000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">852074000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">36432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">41580000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">32593000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">39763000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">2422000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">456984000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">410245000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">462261000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">409974000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">13274000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">10528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">1746013000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">1767086000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">15062000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">12028000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">45708000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">32596000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">16342000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">30498000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">9591000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">8886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">8326000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">7233000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">95029000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">263335000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">5530000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">1794000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">31606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">41070000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">892243000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">896683000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">751000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">1300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">1044709000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">1204182000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-94" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-95" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-98" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-99" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-102" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="3"
      id="f-106"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="3"
      id="f-107"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-108" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-109" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-110" unitRef="shares">267744000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-111" unitRef="shares">267744000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-112" unitRef="shares">226505000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-113" unitRef="shares">226505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">268000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">227000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">2539892000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">2099782000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">219000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-4765000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">-1839075000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-1532340000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">701304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">562904000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-124" unitRef="usd">1746013000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">1767086000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-126" unitRef="usd">183872000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">108699000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-128" unitRef="usd">113505000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-129" unitRef="usd">16649000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-10" decimals="-3" id="f-130" unitRef="usd">19605000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-11" decimals="-3" id="f-131" unitRef="usd">17008000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-133" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-134" unitRef="usd">130513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">127568000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">60932000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-8" decimals="-3" id="f-137" unitRef="usd">56358000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:OtherCostOfOperatingRevenue contextRef="c-9" decimals="-3" id="f-138" unitRef="usd">14754000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue contextRef="c-10" decimals="-3" id="f-139" unitRef="usd">13899000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue contextRef="c-11" decimals="-3" id="f-140" unitRef="usd">14989000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">1983000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-12" decimals="-3" id="f-142" unitRef="usd">733000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">306000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:LossOnContracts contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">3436000</us-gaap:LossOnContracts>
    <us-gaap:LossOnContracts contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">3705000</us-gaap:LossOnContracts>
    <us-gaap:LossOnContracts contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">0</us-gaap:LossOnContracts>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">147741000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-12" decimals="-3" id="f-148" unitRef="usd">79269000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-13" decimals="-3" id="f-149" unitRef="usd">71653000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">52780000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-12" decimals="-3" id="f-151" unitRef="usd">49035000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-13" decimals="-3" id="f-152" unitRef="usd">58860000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">187170000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-3" id="f-154" unitRef="usd">193000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-155" unitRef="usd">112899000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">169818000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-157" unitRef="usd">160854000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-158" unitRef="usd">124124000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">9042000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-12" decimals="-3" id="f-160" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-13" decimals="-3" id="f-161" unitRef="usd">31129000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">15060000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-12" decimals="-3" id="f-163" unitRef="usd">2377000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">1143000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">6157000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">387247000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="-3" id="f-169" unitRef="usd">356231000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-170" unitRef="usd">269295000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">-334467000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-172" unitRef="usd">-307196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-173" unitRef="usd">-210435000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnContractTermination contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-12" decimals="-3" id="f-175" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-13" decimals="-3" id="f-176" unitRef="usd">-52000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-2033000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-12" decimals="-3" id="f-178" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-13" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">14343000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="-3" id="f-181" unitRef="usd">14690000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-13" decimals="-3" id="f-182" unitRef="usd">12530000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">32684000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-184" unitRef="usd">7638000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-185" unitRef="usd">93000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-318159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-187" unitRef="usd">-314248000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-188" unitRef="usd">-274872000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-11424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-190" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-191" unitRef="usd">-93649000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-193" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-194" unitRef="usd">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">4984000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-196" unitRef="usd">-3678000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-197" unitRef="usd">-1172000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-301751000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-199" unitRef="usd">-317926000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-200" unitRef="usd">-182395000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-201"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-202"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-203"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-204"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-205"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-207" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-3" id="f-208" unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-209" unitRef="shares">204136000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-210" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-3" id="f-211" unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-212" unitRef="shares">204136000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-213" unitRef="shares">192294000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-214" unitRef="usd">192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-215" unitRef="usd">1372083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-216" unitRef="usd">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-217" unitRef="usd">-1036869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-218" unitRef="usd">335491000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-3" id="f-219" unitRef="usd">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-220" unitRef="usd">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-3" id="f-221" unitRef="usd">-1172000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-222" unitRef="usd">-1172000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-21" decimals="-3" id="f-223" unitRef="shares">8557000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-21" decimals="-3" id="f-224" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-22" decimals="-3" id="f-225" unitRef="usd">31797000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-3" id="f-226" unitRef="usd">31806000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-21" decimals="-3" id="f-227" unitRef="shares">11215000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-228" unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-229" unitRef="usd">294834000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-230" unitRef="usd">294845000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-21" decimals="-3" id="f-231" unitRef="shares">8912000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-21" decimals="-3" id="f-232" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-22" decimals="-3" id="f-233" unitRef="usd">237876000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-13" decimals="-3" id="f-234" unitRef="usd">237885000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-22" decimals="-3" id="f-235" unitRef="usd">73355000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-236" unitRef="usd">73355000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-23" decimals="-3" id="f-237" unitRef="shares">220978000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-238" unitRef="usd">221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-239" unitRef="usd">2009945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-240" unitRef="usd">-1087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-241" unitRef="usd">-1218092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-242" unitRef="usd">790987000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-243" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-244" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-29" decimals="-3" id="f-245" unitRef="usd">-3678000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-246" unitRef="usd">-3678000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-30" decimals="-3" id="f-247" unitRef="shares">5527000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="-3" id="f-248" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-31" decimals="-3" id="f-249" unitRef="usd">11224000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="-3" id="f-250" unitRef="usd">11230000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-31" decimals="-3" id="f-251" unitRef="usd">78613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-252" unitRef="usd">78613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="-3" id="f-253" unitRef="shares">226505000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-254" unitRef="usd">227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-255" unitRef="usd">2099782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-256" unitRef="usd">-4765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-257" unitRef="usd">-1532340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-258" unitRef="usd">562904000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-259" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-37" decimals="-3" id="f-261" unitRef="usd">4984000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">4984000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-38" decimals="-3" id="f-263" unitRef="shares">8988000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-38" decimals="-3" id="f-264" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-39" decimals="-3" id="f-265" unitRef="usd">84752000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">84761000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-38" decimals="-3" id="f-267" unitRef="shares">6121000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-38" decimals="-3" id="f-268" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-39" decimals="-3" id="f-269" unitRef="usd">76636000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">76642000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan contextRef="c-38" decimals="-3" id="f-271" unitRef="shares">169000</pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan>
    <pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan contextRef="c-39" decimals="-3" id="f-272" unitRef="usd">2111000</pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan>
    <pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">2111000</pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-38" decimals="-3" id="f-274" unitRef="shares">20125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-3" id="f-275" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-39" decimals="-3" id="f-276" unitRef="usd">189180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">189200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-38" decimals="-3" id="f-278" unitRef="shares">5836000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-38" decimals="-3" id="f-279" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-39" decimals="-3" id="f-280" unitRef="usd">15313000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">15319000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-3" id="f-282" unitRef="usd">72118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">72118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-40" decimals="-3" id="f-284" unitRef="shares">267744000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-285" unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-286" unitRef="usd">2539892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-287" unitRef="usd">219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-288" unitRef="usd">-1839075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-289" unitRef="usd">701304000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-291" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-292" unitRef="usd">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnContractTermination contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-12" decimals="-3" id="f-294" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-13" decimals="-3" id="f-295" unitRef="usd">-52000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">11463000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-3" id="f-297" unitRef="usd">9480000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-3" id="f-298" unitRef="usd">7199000</us-gaap:Depreciation>
    <pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">8261000</pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense>
    <pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense contextRef="c-12" decimals="-3" id="f-300" unitRef="usd">913000</pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense>
    <pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense contextRef="c-13" decimals="-3" id="f-301" unitRef="usd">381000</pacb:AmortizationOfIntangibleAssetsAndResearchDevelopmentExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">6810000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-12" decimals="-3" id="f-303" unitRef="usd">6925000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-13" decimals="-3" id="f-304" unitRef="usd">4005000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">72118000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-306" unitRef="usd">78613000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-307" unitRef="usd">73355000</us-gaap:ShareBasedCompensation>
    <us-gaap:NoncashMergerRelatedCosts contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">3395000</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts contextRef="c-12" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts contextRef="c-13" decimals="-3" id="f-310" unitRef="usd">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">-2033000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-12" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-13" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">12840000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-12" decimals="-3" id="f-315" unitRef="usd">244000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-13" decimals="-3" id="f-316" unitRef="usd">-4011000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">15060000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-12" decimals="-3" id="f-318" unitRef="usd">2377000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-13" decimals="-3" id="f-319" unitRef="usd">1143000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">10584000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-12" decimals="-3" id="f-321" unitRef="usd">6027000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-13" decimals="-3" id="f-322" unitRef="usd">678000</us-gaap:InventoryWriteDown>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-11424000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-325" unitRef="usd">-93649000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">1059000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-12" decimals="-3" id="f-327" unitRef="usd">918000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-13" decimals="-3" id="f-328" unitRef="usd">593000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">17829000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-330" unitRef="usd">-5455000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-3" id="f-331" unitRef="usd">7166000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">13841000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-3" id="f-333" unitRef="usd">33906000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-3" id="f-334" unitRef="usd">13109000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">8984000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-336" unitRef="usd">12324000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-337" unitRef="usd">1024000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">206000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-3" id="f-339" unitRef="usd">1025000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-340" unitRef="usd">6363000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">13103000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-12" decimals="-3" id="f-342" unitRef="usd">-3651000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-13" decimals="-3" id="f-343" unitRef="usd">15320000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">10420000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-12" decimals="-3" id="f-345" unitRef="usd">3734000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-13" decimals="-3" id="f-346" unitRef="usd">-25736000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">8759000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-3" id="f-348" unitRef="usd">7724000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-3" id="f-349" unitRef="usd">4990000</us-gaap:OperatingLeasePayments>
    <pacb:IncreaseDecreaseInContingentConsiderationLiability contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">14882000</pacb:IncreaseDecreaseInContingentConsiderationLiability>
    <pacb:IncreaseDecreaseInContingentConsiderationLiability contextRef="c-12" decimals="-3" id="f-351" unitRef="usd">0</pacb:IncreaseDecreaseInContingentConsiderationLiability>
    <pacb:IncreaseDecreaseInContingentConsiderationLiability contextRef="c-13" decimals="-3" id="f-352" unitRef="usd">0</pacb:IncreaseDecreaseInContingentConsiderationLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">2449000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-12" decimals="-3" id="f-354" unitRef="usd">887000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-13" decimals="-3" id="f-355" unitRef="usd">-803000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">-259173000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-357" unitRef="usd">-263211000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-358" unitRef="usd">-111180000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">8843000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-360" unitRef="usd">16750000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-361" unitRef="usd">5931000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-12" decimals="-3" id="f-363" unitRef="usd">179000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-13" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-44" decimals="-3" id="f-365" unitRef="usd">102000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-45" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-46" decimals="-3" id="f-367" unitRef="usd">319793000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">756567000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-12" decimals="-3" id="f-369" unitRef="usd">442788000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-13" decimals="-3" id="f-370" unitRef="usd">988046000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">595000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-12" decimals="-3" id="f-372" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-3" id="f-373" unitRef="usd">212734000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">769521000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-12" decimals="-3" id="f-375" unitRef="usd">575800000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-13" decimals="-3" id="f-376" unitRef="usd">422505000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">4604000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-378" unitRef="usd">116083000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-379" unitRef="usd">-678531000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <pacb:ProceedsFromRepaymentsOfContractTermination contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">0</pacb:ProceedsFromRepaymentsOfContractTermination>
    <pacb:ProceedsFromRepaymentsOfContractTermination contextRef="c-12" decimals="-3" id="f-381" unitRef="usd">0</pacb:ProceedsFromRepaymentsOfContractTermination>
    <pacb:ProceedsFromRepaymentsOfContractTermination contextRef="c-13" decimals="-3" id="f-382" unitRef="usd">-52000000</pacb:ProceedsFromRepaymentsOfContractTermination>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-12" decimals="-3" id="f-384" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-13" decimals="-3" id="f-385" unitRef="usd">895536000</us-gaap:ProceedsFromConvertibleDebt>
    <pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">189200000</pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts>
    <pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts contextRef="c-12" decimals="-3" id="f-387" unitRef="usd">0</pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts>
    <pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts contextRef="c-13" decimals="-3" id="f-388" unitRef="usd">294845000</pacb:ProceedsFromIssuanceOfCommonStockUnderEquityOfferingsNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">15319000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-390" unitRef="usd">11230000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-3" id="f-391" unitRef="usd">31806000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">7375000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-12" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-13" decimals="-3" id="f-394" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">86411000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-12" decimals="-3" id="f-396" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-13" decimals="-3" id="f-397" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">1842000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-12" decimals="-3" id="f-399" unitRef="usd">1608000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-13" decimals="-3" id="f-400" unitRef="usd">361000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-12" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-13" decimals="-3" id="f-403" unitRef="usd">-245000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">108891000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-405" unitRef="usd">9622000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-406" unitRef="usd">1169581000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">-145678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-408" unitRef="usd">-137506000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-409" unitRef="usd">379870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-410" unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-411" unitRef="usd">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-412" unitRef="usd">85947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-413" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-414" unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-415" unitRef="usd">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-416" unitRef="usd">179911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-417" unitRef="usd">325089000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-27" decimals="-3" id="f-418" unitRef="usd">460725000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-419" unitRef="usd">2722000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-420" unitRef="usd">3222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-27" decimals="-3" id="f-421" unitRef="usd">5092000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-422" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-423" unitRef="usd">328311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-424" unitRef="usd">465817000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">15687000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-3" id="f-426" unitRef="usd">14049000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-427" unitRef="usd">6928000</us-gaap:InterestPaidNet>
    <pacb:TransferOfInventoryToPropertyAndEquipment contextRef="c-47" decimals="-3" id="f-428" unitRef="usd">3984000</pacb:TransferOfInventoryToPropertyAndEquipment>
    <pacb:TransferOfInventoryToPropertyAndEquipment contextRef="c-48" decimals="-3" id="f-429" unitRef="usd">2812000</pacb:TransferOfInventoryToPropertyAndEquipment>
    <pacb:TransferOfInventoryToPropertyAndEquipment contextRef="c-49" decimals="-3" id="f-430" unitRef="usd">2586000</pacb:TransferOfInventoryToPropertyAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-47" decimals="-3" id="f-431" unitRef="usd">-7022000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-48" decimals="-3" id="f-432" unitRef="usd">-715000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-49" decimals="-3" id="f-433" unitRef="usd">-383000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-47" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-48" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-49" decimals="-3" id="f-436" unitRef="usd">2576000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-50" decimals="-3" id="f-437" unitRef="usd">76642000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-51" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-52" decimals="-3" id="f-439" unitRef="usd">237885000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-53" decimals="-3" id="f-440" unitRef="usd">2111000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-54" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-55" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:NotesIssued1 contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">441000000</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1 contextRef="c-12" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1 contextRef="c-13" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:StockIssued1 contextRef="c-56" decimals="-3" id="f-446" unitRef="usd">84761000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-57" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-58" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-449">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#333333;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on creating some of the world's most advanced sequencing systems to provide our customers the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in this report to &#x201c;PacBio,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;our&#x201d; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the fair value of contingent consideration, the valuation of acquired intangible assets, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2023. Actual results could differ materially from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Functional Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2023, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#x2019; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. We have not experienced any significant credit losses to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. For the years ended December&#160;31, 2022 and 2021, one customer accounted for approximately 12%, and 13% of our total revenue, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, 49% and 57% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2023, one customer represented approximately 10% of our net accounts receivable. As of December&#160;31, 2022, one customer represented approximately 10% of our net accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#x201c;FIFO&#x201d;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives of the major classes of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense in our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets, and Other Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and capitalized in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill in the second quarter of each year, or more frequently if indicators of potential impairment exist. We generally perform annual impairment testing of IPR&amp;amp;D in the fourth quarter of each year, or more frequently if indicators of potential impairment exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the IPR&amp;amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;amp;D with the carrying value. If the carrying amount of the IPR&amp;amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of COVID-19 or other epidemics or pandemics, or other customer-specific factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP")  based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_118" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10. Stockholders&#x2019; Equity&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to shipping and handling are included in cost of revenues for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU requires entities to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. This authoritative guidance will be effective for us in fiscal year 2025, with early adoption permitted. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-451">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the fair value of contingent consideration, the valuation of acquired intangible assets, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of December&#160;31, 2023. Actual results could differ materially from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Functional Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. dollar is the functional currency of our international operations. We remeasure foreign subsidiaries monetary assets and liabilities to the U.S. dollar and record net gains or losses from remeasurement in other income, net, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities, and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-454">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of interest-bearing investments and trade receivables. We maintain cash, cash equivalents, and investments with various major financial institutions. The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing. At December&#160;31, 2023, most of our cash was deposited with U.S. financial institutions. Our investment policy generally restricts the amount of credit exposure to any one issuer. There is no limit to the percentage of the portfolio that may be maintained in securities issued by the U.S. Treasury and U.S. Government Agencies, or other securities fully backed by U.S. Treasury or Government agencies. We have not experienced significant credit losses from financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade receivables are derived from revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers&#x2019; financial condition and, generally, require no collateral from our customers. The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review our trade receivables including consideration of factors such as historical experience, the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. We have not experienced any significant credit losses to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, or other customer-specific factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, no single customer accounted for 10% or greater of our total revenue. For the years ended December&#160;31, 2022 and 2021, one customer accounted for approximately 12%, and 13% of our total revenue, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, 49% and 57% of our accounts receivable were from domestic customers, respectively. As of December&#160;31, 2023, one customer represented approximately 10% of our net accounts receivable. As of December&#160;31, 2022, one customer represented approximately 10% of our net accounts receivable. &lt;/span&gt;&lt;/div&gt;We currently purchase several key parts and components used in the manufacture of our products from a limited number of suppliers. Generally, we have been able to obtain an adequate supply of such parts and components but in certain instances have incurred additional costs to secure a supply of constrained material. An extended interruption in the supply of parts and components currently obtained from our suppliers could adversely affect our business and consolidated financial statements.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="2" id="f-455" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-60" decimals="2" id="f-456" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="2" id="f-457" unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="2" id="f-458" unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-459" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-460" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out (&#x201c;FIFO&#x201d;) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances. Cost includes depreciation, labor, material, and overhead costs, including product and process technology costs. Determining net realizable value of inventories involves numerous judgements, including projecting future average selling prices, sales volumes, and costs to complete products in work in process inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make inventory purchases and commitments to meet future shipment schedules based on forecasted demand for our products. The business environment in which we operate is subject to rapid changes in technology and customer demand. We perform a detailed assessment of inventory each period, which includes a review of, among other factors, demand requirements, product life cycle and development plans, component cost trends, product pricing, product expiration, and quality issues. Based on our analysis, we record adjustments to inventory for potentially excess, obsolete, or impaired goods, when appropriate, to report inventory at net realizable value. Inventory adjustments may be required if actual demand, component costs, supplier arrangements, or product life cycles differ from our estimates. Any such adjustments would result in a charge to our results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-462">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, reviewed regularly for impairment, and depreciated over the estimated useful lives of the assets, using the straight-line method. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred. Transfers of assets between property and equipment, net, and inventory are transferred at standard cost and recognized at carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-463">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated useful lives of the major classes of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and machinery &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-65" id="f-464">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-66" id="f-465">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-67" id="f-466">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-68" id="f-467">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-69" id="f-468">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-70" id="f-469">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-71" id="f-470">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-72" id="f-471">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-472">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-473">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. Operating lease expense is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period incurred.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-474">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, contingent consideration can be earned by the sellers upon completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration. These estimates require significant management judgment, including probabilities of achieving certain future milestones. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in operating expense in our consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-475">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets, and Other Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and capitalized in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is assessed for impairment and then amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually. We perform annual impairment testing of goodwill in the second quarter of each year, or more frequently if indicators of potential impairment exist. We generally perform annual impairment testing of IPR&amp;amp;D in the fourth quarter of each year, or more frequently if indicators of potential impairment exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the IPR&amp;amp;D impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount. The qualitative factors include, but are not limited to, macroeconomic conditions, industry-specific conditions, and company-specific conditions. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of the IPR&amp;amp;D is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the IPR&amp;amp;D with the carrying value. If the carrying amount of the IPR&amp;amp;D exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles assets include our acquired developed technology and customer relationships. We capitalize finite-lived intangibles assets and generally amortize them on a straight-line basis over the estimated useful lives. We regularly review the carrying amount and useful lives of our finite-lived assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-476" unitRef="unit">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-477">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of our instruments and related consumables; service and other revenue consist primarily of revenue earned from product maintenance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for a contract with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Revenues are recognized when control of the promised goods are transferred to our customers, or services are performed, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into contracts with customers that include a combination of promised products and services, resulting in arrangements containing multiple performance obligations. We determine whether each product or service is distinct, in order to identify the performance obligations in the contract and allocate the contract transaction price among the distinct performance obligations. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Therefore, instrument revenue is recognized upon transfer of control of the asset to the customer, which is generally upon delivery for sales made to our non-distributor customers and upon shipment for sales made to our distributor customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for contracts with multiple performance obligations is allocated between separate performance obligations based on their individual standalone selling price. We determine the best estimate of standalone selling price using average selling prices over a 12-month period combined with an assessment of current market conditions. If the standalone selling price is not directly observable, we rely on estimates by considering multiple factors including, but not limited to, overall market conditions, including geographic or regional specific factors, internal costs, profit objectives, pricing practices, and other observable inputs. We recognize revenues as performance obligations are satisfied by transferring control of the product or service to the customer or over the term of a product maintenance agreement with a customer. Our revenue arrangements generally do not provide a right of return. Revenue is recorded net of discounts and sales taxes collected on behalf of governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our agreements provide options to customers which can be exercised at a future date, such as the option to purchase our product at discounted prices, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal standalone selling prices, we would likely determine that the option is not a material right and, therefore, account for it when the customer exercises the option. If the standalone selling price of the option is not directly observable, an estimated standalone selling price is utilized which considers adjustments for discounts that the customer could receive without exercising the option and the likelihood that the option will be exercised. We may also utilize the alternative approach to estimate the standalone selling price, available pursuant to the applicable accounting guidance, to the extent we conclude the applicable criteria for using the alternative approach has been met. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we generally provide a one-year warranty on instruments. We accrue the cost of the assurance warranty when revenue of the instrument is recognized. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee sales commissions are generally recorded as selling, general, and administrative expense when incurred as the amortization period for such costs, if capitalized, would have been one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <pacb:StandardProductWarrantyPeriod contextRef="c-1" id="f-478">P1Y</pacb:StandardProductWarrantyPeriod>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-479">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue reflects the direct cost of product components, third-party manufacturing services, and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain, and support our instruments, consumables, and services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing overhead is predominantly comprised of labor and facility costs. We capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support our installed customer base. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to shipping and handling are included in cost of revenues for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-480">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists primarily of expenses for personnel engaged in the development of our core technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, partner development costs, facilities costs, and other related overhead. We expense research and development costs during the period in which the costs are incurred. We defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for credit losses is based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as the age of the accounts receivable balances, customer creditworthiness, customer industry, and current and forecasted economic conditions that may affect a customer&#x2019;s ability to pay. Credit loss expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities. We regularly assess whether our securities in an unrealized loss position are credit related. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income. Unrealized losses that are not credit related are included in accumulated other comprehensive income (loss). The unrealized losses on our investments are mainly attributable to government securities, including U.S. government and U.S. agency bond securities, impacted by movements in market rates and not due to issuer credit risk. We have the ability to hold and do not intend to sell the investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;Although we have historically not experienced significant credit losses, our exposure to credit losses may increase if our customers are adversely affected by changes in economic pressures or uncertainty associated with local or global economic recessions, disruptions associated with the evolution of COVID-19 or other epidemics or pandemics, or other customer-specific factors.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. The effect of a change in tax rates on the deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized. &lt;/span&gt;&lt;/div&gt;We regularly review our positions taken relative to income taxes. To the extent our tax positions are more likely than not going to result in additional taxes, we accrue the estimated amount of tax related to such uncertain positions.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-483">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize share-based compensation expense for share-based payments, including stock options, restricted stock units, performance stock units and stock issued under our employee stock purchase plan ("ESPP")  based on the grant-date fair value. We estimate the fair value of stock options and ESPP using an option-pricing model. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_118" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10. Stockholders&#x2019; Equity&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information regarding share-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-484">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of outstanding stock options, restricted stock units, and common stock issuable pursuant to our ESPP, using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <pacb:RecentlyAdoptedAccountingStandardsPolicyTextBlock contextRef="c-1" id="f-486">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued Accounting Standards Update ("ASU") No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU provides specific guidance on how to recognize contract assets and contract liabilities related to revenue contracts with customers acquired in a business combination. This amendment improves comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. We adopted this ASU on January 1, 2023. The adoption of this guidance did not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</pacb:RecentlyAdoptedAccountingStandardsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-487">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU requires entities to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. This authoritative guidance will be effective for us in fiscal year 2025, with early adoption permitted. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-488">BUSINESS ACQUISITIONS&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Apton Biosystems&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2023, we acquired Apton Biosystems, Inc. (&#x201c;Apton&#x201d;), a California-based genomics company focused on developing a high throughput short-read sequencer using highly differentiated optics and image processing, paired with novel clustering and chemistry (the &#x201c;Apton acquisition&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Apton acquisition, all outstanding equity securities of Apton were cancelled in exchange for shares of our common stock with a fair value of $76.6 million, cash of $0.2 million, and contingent consideration with a preliminary estimated fair value of $18.5 million. Excluded from consideration transferred was $1.3 million attributable to accelerated share-based compensation expense. The fair value of the 6,121,571 common shares issued was determined based on the closing market price of our common stock on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Apton acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the 5-year anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the twenty trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on preliminary estimates of their respective fair values at the date of the completion of the Apton acquisition, and such allocation is subject to adjustment for up to one year after the close of the acquisition as additional &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;information is obtained. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred, based on the preliminary estimated fair values were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price allocation is preliminary, primarily due to the pending finalization of review of various tax attributes. We continue to collect information regarding certain estimates and assumptions, including potential liabilities and contingencies. We will record adjustments to the fair value of the assets acquired, liabilities assumed and goodwill within the twelve months measurement period, if necessary. During the year ended December&#160;31, 2023, we recorded a measurement period adjustment of $1.6&#160;million to decrease goodwill, and a corresponding $2.0&#160;million increase in intangible assets and $0.4&#160;million decrease in the deferred tax liability on the consolidated balance sheets, and a $0.7&#160;million increase to our benefit from income taxes on the consolidated statements of operations and comprehensive loss. The measurement period adjustment was due to new information that became available to us upon the completion of the valuation assessment of the in-process research and development and the tax provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred costs related to the Apton acquisition of approximately $9.0&#160;million during the year ended December&#160;31, 2023, which are included in merger-related expenses on the consolidated statement of operations and comprehensive loss. Merger-related expenses include $2.8&#160;million relating to a liquidity event bonus plan that was treated as a separate transaction and included the issuance of 168,621 shares of common stock that were issued with a fair value of $2.1&#160;million based on the closing market price of our common stock on the acquisition date. As a result, the total shares issued in connection with the Apton acquisition were 6.3&#160;million shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $52.3&#160;million, based on preliminary estimates, which is primarily attributable to the synergies expected to occur from the integration of Apton and is not deductible for income tax purposes. We preliminarily allocated $55.0 million of the purchase price to acquired in-process research and development ("IPR&amp;amp;D"). The fair value of the IPR&amp;amp;D was determined, with the assistance of a third-party valuation firm, using an income approach based on a forecast of expected future cash flows. Expected future cash flows utilize significant assumptions such as assumed revenue projections and discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Omniome, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021, we completed our acquisition of Omniome, Inc. (&#x201c;Omniome&#x201d;), a San Diego-based company, to obtain their proprietary short-read DNA sequencing platform capable of delivering high accuracy (the &#x201c;Omniome acquisition&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Omniome acquisition, all outstanding equity securities of Omniome were cancelled in exchange for approximately $315.7&#160;million in cash, 8,911,580 shares of our common stock with a fair value of $249.4&#160;million and contingent consideration with a fair value of $168.6&#160;million. The fair value of the 8,911,580 common shares issued was determined based on the closing market price of PacBio&#x2019;s common shares on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, approximately $18.9&#160;million, comprised of $7.4&#160;million of cash, 226,811 shares of our common stock with a fair value of $6.3&#160;million, and $5.2&#160;million related to contingent consideration, was accounted for as a one-time post-acquisition share-based compensation expense. This share-based compensation expense was due to accelerated vesting of Omniome stock awards in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition the contingent consideration of $200&#160;million (composed of $100&#160;million in cash and $100&#160;million in shares of our common stock) is due upon the achievement of a milestone, defined as the first commercial shipment to a customer of a nucleotide sequencing platform, comprising both an instrument and related consumables, that utilizes SBB technology. The number of shares of stock to be issued will be determined using the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that is two days immediately prior to the achievement of the milestone. Of the $100&#160;million in shares of our common stock to be issued as part of the milestone, $4.1&#160;million was attributable to stock options issued by PacBio in replacement of Omniome&#x2019;s unvested options as part of the transaction. Upon achievement of the milestone, shares will be issued not in excess of an amount equal to 19.9% of our outstanding shares of common stock on the date of closing (prior to the issuance of any shares issued in connection with the transaction or the related private placement), less 11,500,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our Consolidated Statements of Operations and Comprehensive Loss. The fair value of the contingent consideration liability is calculated, with the assistance from a third-party valuation firm, using a scenario-based method that considers a range of possible outcomes and their assigned probabilities of occurrence. The potential outcomes are discounted to present value at a discount rate equal to the sum of the term-matched risk-free-interest rate plus PacBio&#x2019;s credit spread. On September 20, 2023, we achieved the commercial milestone in connection with the acquisition of Omniome. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_103" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_103" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5. Financial Instruments&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on amounts paid and shares issued to former Omniome securityholders during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash paid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of share consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Share-based compensation expense excluded from consideration transferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was accounted for as a business combination and, accordingly, the total fair value of the consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values on the acquisition date. As of December&#160;31, 2021, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, we recorded a measurement period adjustment of $1.6&#160;million to decrease goodwill and a corresponding $0.4&#160;million to decrease the deferred tax liability on the Consolidated Balance Sheet, and a $1.2&#160;million decrease to our benefit from income taxes on the Consolidated Statements of Operations and Comprehensive (Loss) Income. The measurement period adjustment was due to new information that became available to us upon the completion of the IRC Section 382 Tax Study, where we identified additional net operating losses that are available to us from acquired assets. Refer to Note 9 &#x2013; Income Taxes, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December&#160;31, 2021 for more information. There were no measurement period adjustments recorded in the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill recognized was primarily attributable to the assembled workforce and synergies that are expected to occur from the integration of Omniome and is not deductible for income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred costs related to the Omniome acquisition of approximately $12.0&#160;million during the twelve months ended December&#160;31, 2021, which are included in merger-related costs on the Consolidated Statement of Operations and Comprehensive (Loss) Income. No significant merger-related costs were incurred during the twelve months ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if Omniome had been acquired as of the beginning of 2020, giving effect on a pro forma basis to the purchase accounting adjustments such as $12.0&#160;million of PacBio acquisition-related costs, $18.9&#160;million of share-based compensation expense related to acceleration of certain Omniome stock options not attributable to pre-combination service, and a $91.0&#160;million one-time income tax benefit from the reduction of our deferred tax asset valuation allowance resulting from the Omniome acquisition, as well as a pro forma adjustment to reflect $16.7&#160;million of Omniome&#x2019;s acquisition-related costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of the consolidated results of the combined business had the acquisition actually occurred at the beginning of 2020 or the results of future operations of the combined business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the unaudited pro forma financial information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pro forma total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pro forma net (loss) income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(278,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pro forma net (loss) income per share - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the results of operations for Omniome beginning September 20, 2021. Revenues of $0 and a net loss of $15.6&#160;million from the acquired Omniome business have been included in our Consolidated Statement of Operations and Comprehensive (Loss) Income for the twelve months ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Circulomics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, we acquired Circulomics Inc. (&#x201c;Circulomics&#x201d;), a Maryland-based biotechnology company focused on delivering highly differentiated sample preparation products that enable genomic workflows (the &#x201c;Circulomics acquisition&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We paid $29.5&#160;million in cash in exchange for all outstanding shares of common stock of Circulomics. We allocated the consideration transferred to the identifiable assets acquired and liabilities assumed based on their respective fair values at the date of the completion of the Circulomics acquisition. The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the value of consideration paid over the aggregate fair value of those net assets has been recorded as goodwill. We recognized goodwill of $19.3&#160;million, which is primarily attributable to the synergies expected from capabilities in extraction and sample preparation and is not deductible for income tax purposes. We recorded $11.4&#160;million for the fair value of acquired intangible assets, which consists of developed technology and customer relationships.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-74" decimals="-5" id="f-489" unitRef="usd">76600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-74" decimals="-5" id="f-490" unitRef="usd">200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-75" decimals="-5" id="f-491" unitRef="usd">18500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred contextRef="c-74" decimals="-5" id="f-492" unitRef="usd">1300000</pacb:StockBasedCompensationExpenseExcludedFromConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-74"
      decimals="INF"
      id="f-493"
      unitRef="shares">6121571</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-76" decimals="-5" id="f-494" unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone contextRef="c-74" decimals="-5" id="f-495" unitRef="usd">50000000</pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone>
    <pacb:BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod contextRef="c-75" id="f-496">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityClosingDatePeriod>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-74" decimals="INF" id="f-497" unitRef="d">20</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger contextRef="c-77" decimals="3" id="f-498" unitRef="number">0.199</pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-499">The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred, based on the preliminary estimated fair values were as follows (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-75" decimals="-3" id="f-500" unitRef="usd">97000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-75" decimals="-3" id="f-501" unitRef="usd">55000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-75" decimals="-3" id="f-502" unitRef="usd">52287000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-75" decimals="-3" id="f-503" unitRef="usd">153000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-75" decimals="-3" id="f-504" unitRef="usd">11338000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-75" decimals="-3" id="f-505" unitRef="usd">2191000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-75" decimals="-3" id="f-506" unitRef="usd">94008000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-78" decimals="-5" id="f-507" unitRef="usd">-1600000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles contextRef="c-78" decimals="-5" id="f-508" unitRef="usd">2000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability contextRef="c-78" decimals="-5" id="f-509" unitRef="usd">-400000</pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability>
    <pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit contextRef="c-78" decimals="-5" id="f-510" unitRef="usd">-700000</pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-79" decimals="-5" id="f-511" unitRef="usd">9000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized contextRef="c-78" decimals="-5" id="f-512" unitRef="usd">2800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan contextRef="c-80" decimals="0" id="f-513" unitRef="shares">168621</pacb:StockIssuedDuringPeriodSharesAcquisitionsLiquidityBonusPlan>
    <pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan contextRef="c-78" decimals="-5" id="f-514" unitRef="usd">2100000</pacb:StockIssuedDuringPeriodValueAcquisitionsLiquidityBonusPlan>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-78" decimals="-5" id="f-515" unitRef="shares">6300000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-78" decimals="-5" id="f-516" unitRef="usd">52300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-75" decimals="-5" id="f-517" unitRef="usd">55000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-81" decimals="-5" id="f-518" unitRef="usd">315700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-81"
      decimals="INF"
      id="f-519"
      unitRef="shares">8911580</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-81" decimals="-5" id="f-520" unitRef="usd">249400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-81" decimals="-5" id="f-521" unitRef="usd">168600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-81"
      decimals="INF"
      id="f-522"
      unitRef="shares">8911580</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-82" decimals="-5" id="f-523" unitRef="usd">18900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-82" decimals="-5" id="f-524" unitRef="usd">7400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-82"
      decimals="INF"
      id="f-525"
      unitRef="shares">226811</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-82" decimals="-5" id="f-526" unitRef="usd">6300000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-82" decimals="-5" id="f-527" unitRef="usd">5200000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-83" decimals="-8" id="f-528" unitRef="usd">200000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-84" decimals="-8" id="f-529" unitRef="usd">100000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-84" decimals="-8" id="f-530" unitRef="usd">100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-74" decimals="INF" id="f-531" unitRef="d">20</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-84" decimals="-8" id="f-532" unitRef="usd">100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-84" decimals="-5" id="f-533" unitRef="usd">4100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger contextRef="c-84" decimals="3" id="f-534" unitRef="number">0.199</pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger>
    <pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts contextRef="c-84" decimals="INF" id="f-535" unitRef="usd">11500000</pacb:StockIssuedDuringPeriodInPrivatePlacementNetOfIssuanceCosts>
    <pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash paid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of share consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Share-based compensation expense excluded from consideration transferred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfBusinessAcquisitionsByAcquisitionConsiderationTransferredTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-81" decimals="-3" id="f-537" unitRef="usd">315703000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-81" decimals="-3" id="f-538" unitRef="usd">249435000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-81" decimals="-3" id="f-539" unitRef="usd">168574000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-81" decimals="-3" id="f-540" unitRef="usd">18923000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-81" decimals="-3" id="f-541" unitRef="usd">714789000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-542">As of December&#160;31, 2021, the major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;390,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The major classes of assets and liabilities to which we have allocated the total fair value of the consideration transferred were as follows (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-85" decimals="-3" id="f-543" unitRef="usd">15338000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-544" unitRef="usd">6123000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <pacb:BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet contextRef="c-85" decimals="-3" id="f-545" unitRef="usd">18095000</pacb:BusinessCombinationRecognizedIdentifiableAssetsOperatingLeaseRightOfUseAssetsNetAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-85" decimals="-3" id="f-546" unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-85" decimals="-3" id="f-547" unitRef="usd">390665000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-85" decimals="-3" id="f-548" unitRef="usd">3203000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-85" decimals="-3" id="f-549" unitRef="usd">91814000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-85" decimals="-3" id="f-550" unitRef="usd">26821000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-85" decimals="-3" id="f-551" unitRef="usd">714789000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-86" decimals="-5" id="f-552" unitRef="usd">-1600000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability contextRef="c-86" decimals="-5" id="f-553" unitRef="usd">-400000</pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability>
    <pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit contextRef="c-86" decimals="-5" id="f-554" unitRef="usd">1200000</pacb:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-86" decimals="-5" id="f-555" unitRef="usd">12000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-86" decimals="-5" id="f-556" unitRef="usd">12000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-81" decimals="-5" id="f-557" unitRef="usd">18900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <pacb:IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance contextRef="c-81" decimals="-5" id="f-558" unitRef="usd">91000000</pacb:IncomeTaxBenefitFromReductionInDeferredTaxAssetsValuationAllowance>
    <pacb:ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts contextRef="c-81" decimals="-5" id="f-559" unitRef="usd">16700000</pacb:ProFormaAdjustmentRelatedToAcquireeSAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-560">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the unaudited pro forma financial information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pro forma total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pro forma net (loss) income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(278,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pro forma net (loss) income per share - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-86" decimals="-3" id="f-561" unitRef="usd">130513000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-87" decimals="-3" id="f-562" unitRef="usd">78893000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-86" decimals="-3" id="f-563" unitRef="usd">-278451000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-87" decimals="-3" id="f-564" unitRef="usd">17510000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-86"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">-1.27</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-86"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">-1.27</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-87"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">0.09</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-87"
      decimals="2"
      id="f-568"
      unitRef="usdPerShare">0.09</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c-86" decimals="-5" id="f-569" unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c-86" decimals="-5" id="f-570" unitRef="usd">15600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-88" decimals="-5" id="f-571" unitRef="usd">29500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-89" decimals="-3" id="f-572" unitRef="usd">987000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-89" decimals="-3" id="f-573" unitRef="usd">214000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-89" decimals="-3" id="f-574" unitRef="usd">11360000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill contextRef="c-89" decimals="-3" id="f-575" unitRef="usd">19309000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-89" decimals="-3" id="f-576" unitRef="usd">467000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-89" decimals="-3" id="f-577" unitRef="usd">2672000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-89" decimals="-3" id="f-578" unitRef="usd">118000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-89" decimals="-3" id="f-579" unitRef="usd">29547000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-89" decimals="-5" id="f-580" unitRef="usd">19300000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-90" decimals="-5" id="f-581" unitRef="usd">11400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <pacb:InvitaeCollaborationTextBlock contextRef="c-1" id="f-582">INVITAE COLLABORATION&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, we entered into an Amended and Restated Development and Commercialization Agreement (the &#x201c;Amended and Restated Agreement&#x201d;) with Invitae Corporation (&#x201c;Invitae&#x201d;). The Amended and Restated Agreement amended and restated the existing Development and Commercialization Agreement, effective as of January 12, 2021, as amended by Amendment No. 1 to Development and Commercialization Agreement, entered into on June 3, 2021, by and between us and Invitae (together, the &#x201c;Original Agreement&#x201d;). Unless otherwise agreed in writing or terminated in accordance with the Amended and Restated Agreement, the term of the Amended and Restated Agreement shall continue until June 30, 2028 (&#x201c;Term&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Original Agreement, Invitae provided certain funding to us to develop products relating to production-scale high-throughput sequencing (&#x201c;Program Products&#x201d;). If Program Products were to become commercially available, Invitae had the right to purchase the Program Products at preferred pricing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Amended and Restated Agreement, we will continue to receive feedback, input and insight from Invitae in connection with the intended development of our new sequencing systems; however, such feedback will not be contractually required, and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. Our development plans for such new sequencing systems will be at our discretion and pursuant to our own internal processes and programs. Invitae will not be contractually obligated to reimburse us for development costs under the Amended and Restated Agreement. There can be no assurances that the in-development sequencing systems will continue to be developed, be successfully developed or become available for commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration of the non-refundable payments received from Invitae pursuant to the Original Agreement of $23.5 million, we will provide Invitae with credits in connection with Invitae&#x2019;s anticipated purchase of certain currently sequencing systems (instruments, consumables and service contracts). The credits will expire on June 30, 2025 (&#x201c;Credit Expiration Date&#x201d;). Subject to certain conditions, Invitae will also be entitled to most favored pricing for the Company&#x2019;s Sequel IIe systems and certain in-development systems through the Term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Invitae may terminate the Amended and Restated Agreement if the other party remains in material breach of the Amended and Restated Agreement following a cure period to remedy the material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated Agreement was deemed a contract modification and accounted for on a prospective basis in accordance with ASC Topic 606. We will recognize proportionate amounts of the transaction price, including payments made by Invitae to us pursuant to the Original Agreement, in revenue as the remaining performance obligations are s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;atisfied, which is when Invitae places purchase orders for certain sequencing platforms and the associated goods or services are delivered. Any remaining unused credits will be recognized when they expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Invitae purchased certain instruments and consumables under the terms of the Amended and Restated Agreement, for which $10.5 million and $3.7 million of revenue was recognized as product revenue during the years ended December&#160;31, 2023 and 2022, respectively, on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, $8.0 million of deferred revenue, current, and $2.9 million of deferred revenue, non-current, is recorded on the consolidated balance sheet relating to all future performance obligations under the Amended and Restated Agreement.&lt;/span&gt;&lt;/div&gt;</pacb:InvitaeCollaborationTextBlock>
    <pacb:AmountOfAgreementPaymentReceivedUponExecution contextRef="c-91" decimals="-5" id="f-583" unitRef="usd">23500000</pacb:AmountOfAgreementPaymentReceivedUponExecution>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-92" decimals="-5" id="f-584" unitRef="usd">10500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-93" decimals="-5" id="f-585" unitRef="usd">3700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-94" decimals="-5" id="f-586" unitRef="usd">8000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <pacb:ContractWithCustomerLiabilityNoncurrentReclassification contextRef="c-4" decimals="-5" id="f-587" unitRef="usd">2900000</pacb:ContractWithCustomerLiabilityNoncurrentReclassification>
    <pacb:MergerTerminationTextBlock contextRef="c-1" id="f-588">TERMINATION OF MERGER WITH ILLUMINA&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the &#x201c;Illumina Merger Agreement&#x201d;) with Illumina, Inc. (&#x201c;Illumina&#x201d;) and FC Ops Corp., a wholly owned subsidiary of Illumina (&#x201c;Illumina Merger Sub&#x201d;). On January 2, 2020, we, Illumina and Illumina Merger Sub, entered into an agreement to terminate the Merger Agreement (the &#x201c;Termination Agreement&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Continuation Advances from Illumina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Termination Agreement, Illumina paid us cash payments (&#x201c;Continuation Advances&#x201d;) totaling $52 million. Up to the full $52.0 million of Continuation Advances paid to us were repayable without interest to Illumina if, within two years of March&#160;31, 2020, we entered into, or consummated a Change of Control Transaction or raised at least $100 million in a single equity or debt financing (that may have multiple closings), with the amount repayable dependent on the amount raised by us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Resulting from the issuance and sale of $900 million of 1.50% Convertible Senior Notes due February&#160;15, 2028, $52.0&#160;million of Continuation Advances were paid without interest to Illumina in February 2021 and recorded a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;non-operating expense in the consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</pacb:MergerTerminationTextBlock>
    <us-gaap:GainLossOnContractTermination contextRef="c-95" decimals="-6" id="f-589" unitRef="usd">-52000000</us-gaap:GainLossOnContractTermination>
    <pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace contextRef="c-96" decimals="-5" id="f-590" unitRef="usd">52000000</pacb:ContinuationAdvancesPayablePerAgreementToRepayAdvanceIfChangeInControlTransactionOrSingleEquityOrDebtFinancingTakesPlace>
    <pacb:MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty contextRef="c-97" id="f-591">P2Y</pacb:MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty>
    <pacb:MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction contextRef="c-97" decimals="-8" id="f-592" unitRef="usd">100000000</pacb:MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-98" decimals="-8" id="f-593" unitRef="usd">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-98" decimals="4" id="f-594" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnContractTermination contextRef="c-99" decimals="-5" id="f-595" unitRef="usd">-52000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-596">FINANCIAL INSTRUMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;775,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration - Omniome acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration - Apton acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify contingent consideration, which was incurred in connection with the acquisition of Apton, within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the 5-year anniversary of the closing date of the acquisition. As of December 31, 2023, the key input used in the determination of the fair value included projected revenues of the Company relating to the high-throughput short-read products and services leveraging Apton's technology. A decrease in the projected revenues would result in a decrease in the fair value of the liability. The discount rates used are the sum of the U.S. risk-free rate and the estimated subordinated credit spread for B- credit rating, which ranges from 7.8% to 8.2%. Changes in our estimated subordinated credit spread can result in changes in the fair value of the contingent consideration liability, where a lower credit spread may result in an increased liability valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2023, we achieved the commercial milestone in connection with the acquisition of Omniome. Consequently, former Omniome securityholders were entitled to receive as milestone consideration, among other things, an aggregate of approximately $100.9&#160;million in cash and approximately 9.0&#160;million shares of our common stock, representing $95.9&#160;million divided by the volume-weighted average of the trading prices of our common stock for the twenty trading days ending with and including the trading day that was two days &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immediately prior to the achievement of the milestone. The $95.9&#160;million represents the $100.0&#160;million that was to be paid in shares of our common stock offset by $4.1&#160;million attributable to stock options issued by PacBio in replacement of Omniome&#x2019;s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the achievement of the commercial milestone, $101.3&#160;million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December&#160;31, 2023. Additionally, 8,988,391 shares were issued at a value of $84.8&#160;million to the former Omniome securityholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the achievement of the milestone, the contingent consideration liability incurred in connection with the acquisition of Omniome was no longer considered a Level 3 liability at December&#160;31, 2023. There were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis for the year ended December&#160;31, 2023, and our valuation techniques did not change compared to the prior year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability for the year ended December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-727"&gt;Change in estimated fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Achievement of milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the fair value are recorded as the Change in fair value of contingent consideration in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and our valuation techniques did not change compared to the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;772,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through 5 years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment income included in other income, net on the consolidated statement of operations and comprehensive loss was $32.8&#160;million and $9.2&#160;million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-597">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;775,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration - Omniome acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration - Apton acquisition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-599" unitRef="usd">70172000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-600" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-601" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-602" unitRef="usd">70172000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-603" unitRef="usd">137636000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-604" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-605" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-606" unitRef="usd">137636000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-607" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-608" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-609" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-610" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-112" decimals="-3" id="f-611" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-113" decimals="-3" id="f-612" unitRef="usd">166453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-114" decimals="-3" id="f-613" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-614" unitRef="usd">166453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-616" unitRef="usd">109739000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-118" decimals="-3" id="f-617" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-119" decimals="-3" id="f-618" unitRef="usd">109739000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-120" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-620" unitRef="usd">21000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-621" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-622" unitRef="usd">21000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-623" unitRef="usd">70172000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-624" unitRef="usd">109739000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-625" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-626" unitRef="usd">179911000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-627" unitRef="usd">137636000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-628" unitRef="usd">187453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-629" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-630" unitRef="usd">325089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-130" decimals="-3" id="f-631" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-131" decimals="-3" id="f-632" unitRef="usd">9947000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-132" decimals="-3" id="f-633" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-133" decimals="-3" id="f-634" unitRef="usd">9947000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-134" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-135" decimals="-3" id="f-636" unitRef="usd">127302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-136" decimals="-3" id="f-637" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-137" decimals="-3" id="f-638" unitRef="usd">127302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-138" decimals="-3" id="f-639" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-139" decimals="-3" id="f-640" unitRef="usd">88579000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-140" decimals="-3" id="f-641" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-141" decimals="-3" id="f-642" unitRef="usd">88579000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-142" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-143" decimals="-3" id="f-644" unitRef="usd">49491000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-144" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-145" decimals="-3" id="f-646" unitRef="usd">49491000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-146" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-147" decimals="-3" id="f-648" unitRef="usd">352979000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-148" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-149" decimals="-3" id="f-650" unitRef="usd">352979000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-151" decimals="-3" id="f-652" unitRef="usd">270436000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-152" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-153" decimals="-3" id="f-654" unitRef="usd">270436000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-655" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-656" unitRef="usd">451505000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-657" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-658" unitRef="usd">451505000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-660" unitRef="usd">447229000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-662" unitRef="usd">447229000</us-gaap:InvestmentsFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-124" decimals="-3" id="f-663" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-125" decimals="-3" id="f-664" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-126" decimals="-3" id="f-665" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-666" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-127" decimals="-3" id="f-667" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-128" decimals="-3" id="f-668" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-129" decimals="-3" id="f-669" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-5" decimals="-3" id="f-670" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-124" decimals="-3" id="f-671" unitRef="usd">2422000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-125" decimals="-3" id="f-672" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-126" decimals="-3" id="f-673" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-674" unitRef="usd">2422000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-127" decimals="-3" id="f-675" unitRef="usd">2922000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-128" decimals="-3" id="f-676" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-129" decimals="-3" id="f-677" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-5" decimals="-3" id="f-678" unitRef="usd">2922000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-679" unitRef="usd">72894000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-680" unitRef="usd">561244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-681" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-682" unitRef="usd">634138000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-683" unitRef="usd">140858000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-684" unitRef="usd">634682000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-685" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-686" unitRef="usd">775540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-154" decimals="-3" id="f-687" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-155" decimals="-3" id="f-688" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-156" decimals="-3" id="f-689" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-157" decimals="-3" id="f-690" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-158" decimals="-3" id="f-691" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-159" decimals="-3" id="f-692" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-160" decimals="-3" id="f-693" unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-161" decimals="-3" id="f-694" unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-162" decimals="-3" id="f-695" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-163" decimals="-3" id="f-696" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-164" decimals="-3" id="f-697" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-79" decimals="-3" id="f-698" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-165" decimals="-3" id="f-699" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-166" decimals="-3" id="f-700" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-167" decimals="-3" id="f-701" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-168" decimals="-3" id="f-702" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-124" decimals="-3" id="f-703" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-125" decimals="-3" id="f-704" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-126" decimals="-3" id="f-705" unitRef="usd">19550000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">19550000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-127" decimals="-3" id="f-707" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-128" decimals="-3" id="f-708" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-129" decimals="-3" id="f-709" unitRef="usd">172094000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-5" decimals="-3" id="f-710" unitRef="usd">172094000</us-gaap:LiabilitiesFairValueDisclosure>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-4" id="f-711">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-169" decimals="3" id="f-712" unitRef="number">0.078</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-170" decimals="3" id="f-713" unitRef="number">0.082</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-171" decimals="-5" id="f-714" unitRef="usd">100900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-171"
      decimals="-5"
      id="f-715"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-171" decimals="-5" id="f-716" unitRef="usd">95900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-74" decimals="INF" id="f-717" unitRef="d">20</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-171" decimals="-5" id="f-718" unitRef="usd">95900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-172" decimals="-5" id="f-719" unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-173" decimals="-5" id="f-720" unitRef="usd">4100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <pacb:PaymentsForContingentConsiderationRevenueAchievementMilestone contextRef="c-174" decimals="-5" id="f-721" unitRef="usd">101300000</pacb:PaymentsForContingentConsiderationRevenueAchievementMilestone>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c-1" decimals="0" id="f-722" unitRef="shares">8988391</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-1" decimals="-5" id="f-723" unitRef="usd">84800000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <pacb:ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock contextRef="c-1" id="f-724">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability for the year ended December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-727"&gt;Change in estimated fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Achievement of milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ChangesInTheEstimatedFairValueOfContingentConsiderationLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-129" decimals="-3" id="f-725" unitRef="usd">172094000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-1" decimals="-3" id="f-726" unitRef="usd">18450000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-728" unitRef="usd">15060000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <pacb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration contextRef="c-175" decimals="-3" id="f-729" unitRef="usd">186054000</pacb:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-126" decimals="-3" id="f-730" unitRef="usd">19550000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-731">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;325,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;772,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-176" decimals="-3" id="f-732" unitRef="usd">70172000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-176" decimals="-3" id="f-733" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-176" decimals="-3" id="f-734" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-176" decimals="-3" id="f-735" unitRef="usd">70172000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-177" decimals="-3" id="f-736" unitRef="usd">109786000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-177" decimals="-3" id="f-737" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-177" decimals="-3" id="f-738" unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-177" decimals="-3" id="f-739" unitRef="usd">109739000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-178" decimals="-3" id="f-740" unitRef="usd">179958000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-178" decimals="-3" id="f-741" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-178" decimals="-3" id="f-742" unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-178" decimals="-3" id="f-743" unitRef="usd">179911000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-179" decimals="-3" id="f-744" unitRef="usd">9947000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-179" decimals="-3" id="f-745" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-179" decimals="-3" id="f-746" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-179" decimals="-3" id="f-747" unitRef="usd">9947000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-180" decimals="-3" id="f-748" unitRef="usd">88263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-180" decimals="-3" id="f-749" unitRef="usd">373000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-180" decimals="-3" id="f-750" unitRef="usd">57000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-180" decimals="-3" id="f-751" unitRef="usd">88579000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-181" decimals="-3" id="f-752" unitRef="usd">353029000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-181" decimals="-3" id="f-753" unitRef="usd">478000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-181" decimals="-3" id="f-754" unitRef="usd">528000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-181" decimals="-3" id="f-755" unitRef="usd">352979000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-182" decimals="-3" id="f-756" unitRef="usd">451239000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-182" decimals="-3" id="f-757" unitRef="usd">851000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-182" decimals="-3" id="f-758" unitRef="usd">585000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-182" decimals="-3" id="f-759" unitRef="usd">451505000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-183" decimals="-3" id="f-760" unitRef="usd">631197000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-183" decimals="-3" id="f-761" unitRef="usd">864000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-183" decimals="-3" id="f-762" unitRef="usd">645000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-183" decimals="-3" id="f-763" unitRef="usd">631416000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-184" decimals="-3" id="f-764" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-184" decimals="-3" id="f-765" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-185" decimals="-3" id="f-766" unitRef="usd">2422000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-185" decimals="-3" id="f-767" unitRef="usd">2422000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-186" decimals="-3" id="f-768" unitRef="usd">137636000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-186" decimals="-3" id="f-769" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-186" decimals="-3" id="f-770" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-186" decimals="-3" id="f-771" unitRef="usd">137636000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-187" decimals="-3" id="f-772" unitRef="usd">166514000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-187" decimals="-3" id="f-773" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-187" decimals="-3" id="f-774" unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-187" decimals="-3" id="f-775" unitRef="usd">166453000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-188" decimals="-3" id="f-776" unitRef="usd">20994000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-188" decimals="-3" id="f-777" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-188" decimals="-3" id="f-778" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-188" decimals="-3" id="f-779" unitRef="usd">21000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-189" decimals="-3" id="f-780" unitRef="usd">325144000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-189" decimals="-3" id="f-781" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-189" decimals="-3" id="f-782" unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-189" decimals="-3" id="f-783" unitRef="usd">325089000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-190" decimals="-3" id="f-784" unitRef="usd">127626000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-190" decimals="-3" id="f-785" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-190" decimals="-3" id="f-786" unitRef="usd">333000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-190" decimals="-3" id="f-787" unitRef="usd">127302000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-191" decimals="-3" id="f-788" unitRef="usd">49998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-191" decimals="-3" id="f-789" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-191" decimals="-3" id="f-790" unitRef="usd">507000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-191" decimals="-3" id="f-791" unitRef="usd">49491000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-192" decimals="-3" id="f-792" unitRef="usd">274315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-192" decimals="-3" id="f-793" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-192" decimals="-3" id="f-794" unitRef="usd">3880000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-192" decimals="-3" id="f-795" unitRef="usd">270436000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-193" decimals="-3" id="f-796" unitRef="usd">451939000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-193" decimals="-3" id="f-797" unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-193" decimals="-3" id="f-798" unitRef="usd">4720000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-193" decimals="-3" id="f-799" unitRef="usd">447229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-194" decimals="-3" id="f-800" unitRef="usd">777083000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-194" decimals="-3" id="f-801" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-194" decimals="-3" id="f-802" unitRef="usd">4781000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-194" decimals="-3" id="f-803" unitRef="usd">772318000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-195" decimals="-3" id="f-804" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-195" decimals="-3" id="f-805" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-196" decimals="-3" id="f-806" unitRef="usd">2922000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-196" decimals="-3" id="f-807" unitRef="usd">2922000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-808">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through 5 years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-809" unitRef="usd">465181000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-810" unitRef="usd">96063000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-811" unitRef="usd">561244000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-5" id="f-812" unitRef="usd">32800000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-12" decimals="-5" id="f-813" unitRef="usd">9200000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-814">BALANCE SHEET COMPONENTS&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and machinery &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress consists of capitalizable costs that have been incurred for the construction of long-lived assets and is primarily comprised of amounts that will be classified as lab equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense during the years ended December&#160;31, 2023, 2022, and 2021 was $11.5 million, $9.5 million, and $7.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill and intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the goodwill balance was $462.3 million and $410.0 million, respectively. Goodwill preliminarily increased by $52.3 million, due to the Apton acquisition, of which $11.3 million relates to a deferred income tax liability. Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2023, noting no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include acquired IPR&amp;amp;D of $55.0 million as a result of the Apton acquisition in August 2023. As of December&#160;31, 2023, the research and development project had not been completed or abandoned and, therefore, the IPR&amp;amp;D intangible asset is not currently subject to amortization. During the year ended December&#160;31, 2023, acquired IPR&amp;amp;D of $400.0 million as a result of the Omniome acquisition in September 2021 was completed and became subject to amortization. IPR&amp;amp;D is reviewed for impairment at least annually, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for IPR&amp;amp;D impairment in the third quarter of 2023, noting no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired definite-lived intangible assets as of December&#160;31, 2023 (in thousands, except years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangibles was $8.3 million, $0.9 million and $0.4&#160;million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. For the years ended December&#160;31, 2023,  2022, and 2021 amortization expense of intangibles in cost of revenue was $2.0&#160;million, $0.7 million, and $0.3&#160;million, respectively.  For the years ended December&#160;31, 2023, 2022, and 2021, amortization expense of intangibles in operating expenses was $6.3 million, $0.2 million, and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The definite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchase commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued product development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional services and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. There were no material changes in estimates for the periods presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had a total of $21.9 million of deferred revenue, $16.3 million of which was recorded as deferred revenue, current and primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae, as described in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_97" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 3. Invitae Collaboration&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as well as deferred service contract revenues. The deferred revenue, non-current balance of $5.6 million primarily relates to future performance obligations under the Amended and Restated Agreement with Invitae and deferred service contract revenues and is scheduled to be recognized in the next 5 years. The deferred revenue, non-current balance includes $2.9 million that was reclassified from deferred revenue, current to deferred revenue, non-current following receipt of a non-cancellable order from Invitae during the year ended December&#160;31, 2023 for partial utilization of the available credits, which is expected to be recognized in revenue after 12 months from December&#160;31, 2023. Revenue recorded in the year ended December&#160;31, 2023 includes $18.9 million of previously deferred revenue that was included in deferred revenue, current as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Omniome, we acquired $1.3 million in short-term debt and $3.0 million in long-term debt relating to a term loan facility that Omniome obtained in April 2020. Borrowings on the term loan facility were used to fund Omniome&#x2019;s purchases of equipment, which serves as collateral. Each term loan has a term of 43 months and bears a fixed interest rate of approximately 17% annually. The fee for the elective option to prepay all, but not less than all, of the borrowed amounts at any time after the 24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; month and before the 43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;rd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; month after the commencement date, is 4% of the outstanding loan balance. Payments are made in equal monthly installments including principal and interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the carrying value of term loans outstanding was $0.5 million, recorded as part of other liabilities, current on the consolidated balance sheet. The interest expense was $0.3 million for the year ended December&#160;31, 2023, which was included as part of interest expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the future principal payments remaining on term loans was the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Liabilities, Current&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities, current, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-815">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-816" unitRef="usd">20168000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-5" decimals="-3" id="f-817" unitRef="usd">24139000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-818" unitRef="usd">23436000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-3" id="f-819" unitRef="usd">14062000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-820" unitRef="usd">13072000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-3" id="f-821" unitRef="usd">12180000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-822" unitRef="usd">56676000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-823" unitRef="usd">50381000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-197" decimals="-3" id="f-824" unitRef="usd">44907000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-198" decimals="-3" id="f-825" unitRef="usd">38998000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-199" decimals="-3" id="f-826" unitRef="usd">35226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-200" decimals="-3" id="f-827" unitRef="usd">34129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-201" decimals="-3" id="f-828" unitRef="usd">19528000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-202" decimals="-3" id="f-829" unitRef="usd">18438000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-830" unitRef="usd">6628000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-203" decimals="-3" id="f-831" unitRef="usd">6879000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-204" decimals="-3" id="f-832" unitRef="usd">3594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-205" decimals="-3" id="f-833" unitRef="usd">3426000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-206" decimals="-3" id="f-834" unitRef="usd">1343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-207" decimals="-3" id="f-835" unitRef="usd">4698000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-836" unitRef="usd">111226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-837" unitRef="usd">106568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-838" unitRef="usd">74794000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-839" unitRef="usd">64988000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-840" unitRef="usd">36432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-841" unitRef="usd">41580000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-842" unitRef="usd">11500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-843" unitRef="usd">9500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-844" unitRef="usd">7200000</us-gaap:Depreciation>
    <us-gaap:Goodwill contextRef="c-157" decimals="-5" id="f-845" unitRef="usd">462300000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-161" decimals="-5" id="f-846" unitRef="usd">410000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-78" decimals="-5" id="f-847" unitRef="usd">52300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-78" decimals="-5" id="f-848" unitRef="usd">11300000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-75" decimals="-5" id="f-849" unitRef="usd">55000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-208" decimals="-8" id="f-850" unitRef="usd">400000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-851">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired definite-lived intangible assets as of December&#160;31, 2023 (in thousands, except years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-209" id="f-852">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-209" decimals="-3" id="f-853" unitRef="usd">411179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-209" decimals="-3" id="f-854" unitRef="usd">9195000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-209" decimals="-3" id="f-855" unitRef="usd">401984000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-210" id="f-856">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-210" decimals="-3" id="f-857" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-210" decimals="-3" id="f-858" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-210" decimals="-3" id="f-859" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-860" unitRef="usd">411539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-861" unitRef="usd">9555000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-862" unitRef="usd">401984000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AdjustmentForAmortization contextRef="c-1" decimals="-5" id="f-863" unitRef="usd">8300000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-12" decimals="-5" id="f-864" unitRef="usd">900000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-13" decimals="-5" id="f-865" unitRef="usd">400000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-211" decimals="-5" id="f-866" unitRef="usd">2000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-212" decimals="-5" id="f-867" unitRef="usd">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-213" decimals="-5" id="f-868" unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-214" decimals="-5" id="f-869" unitRef="usd">6300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-215" decimals="-5" id="f-870" unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-216" decimals="-5" id="f-871" unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-872">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of acquisition-related intangible assets with definite lives is estimated as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-873" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-874" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-875" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-876" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-877" unitRef="usd">27412000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-878" unitRef="usd">264924000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-879" unitRef="usd">401984000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-880">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchase commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued product development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional services and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-881" unitRef="usd">29337000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-882" unitRef="usd">17432000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pacb:AccruedTenantImprovementsCurrent contextRef="c-4" decimals="-3" id="f-883" unitRef="usd">2834000</pacb:AccruedTenantImprovementsCurrent>
    <pacb:AccruedTenantImprovementsCurrent contextRef="c-5" decimals="-3" id="f-884" unitRef="usd">5100000</pacb:AccruedTenantImprovementsCurrent>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-885" unitRef="usd">2613000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c-5" decimals="-3" id="f-886" unitRef="usd">3705000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <pacb:AccruedProductDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-887" unitRef="usd">1033000</pacb:AccruedProductDevelopmentCostsCurrent>
    <pacb:AccruedProductDevelopmentCostsCurrent contextRef="c-5" decimals="-3" id="f-888" unitRef="usd">2326000</pacb:AccruedProductDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-889" unitRef="usd">2641000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-890" unitRef="usd">1005000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ProductLiabilityContingencyAccrualPresentValue contextRef="c-4" decimals="-3" id="f-891" unitRef="usd">353000</us-gaap:ProductLiabilityContingencyAccrualPresentValue>
    <us-gaap:ProductLiabilityContingencyAccrualPresentValue contextRef="c-5" decimals="-3" id="f-892" unitRef="usd">332000</us-gaap:ProductLiabilityContingencyAccrualPresentValue>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-4" decimals="-3" id="f-893" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-5" decimals="-3" id="f-894" unitRef="usd">1651000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-895" unitRef="usd">2216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-896" unitRef="usd">1045000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-897" unitRef="usd">45708000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-898" unitRef="usd">32596000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="c-1" id="f-899">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="c-5" decimals="-3" id="f-900" unitRef="usd">1651000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-27" decimals="-3" id="f-901" unitRef="usd">594000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-1" decimals="-3" id="f-902" unitRef="usd">8227000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-12" decimals="-3" id="f-903" unitRef="usd">3199000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-1" decimals="-3" id="f-904" unitRef="usd">5197000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-12" decimals="-3" id="f-905" unitRef="usd">2142000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual contextRef="c-4" decimals="-3" id="f-906" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-5" decimals="-3" id="f-907" unitRef="usd">1651000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ContractWithCustomerLiability contextRef="c-217" decimals="-5" id="f-908" unitRef="usd">21900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-217" decimals="-5" id="f-909" unitRef="usd">16300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-217" decimals="-5" id="f-910" unitRef="usd">5600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod contextRef="c-218" id="f-911">P5Y</pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod>
    <pacb:ContractWithCustomerLiabilityNoncurrentReclassification contextRef="c-4" decimals="-5" id="f-912" unitRef="usd">2900000</pacb:ContractWithCustomerLiabilityNoncurrentReclassification>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-218" decimals="-5" id="f-913" unitRef="usd">18900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c-85" decimals="-5" id="f-914" unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt contextRef="c-85" decimals="-5" id="f-915" unitRef="usd">3000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:DebtInstrumentTerm contextRef="c-81" id="f-916">P43M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-85" decimals="2" id="f-917" unitRef="number">0.17</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <pacb:PercentageOfFeeToPrepayDebt contextRef="c-1" decimals="2" id="f-918" unitRef="number">0.04</pacb:PercentageOfFeeToPrepayDebt>
    <us-gaap:NotesPayable contextRef="c-4" decimals="-5" id="f-919" unitRef="usd">500000</us-gaap:NotesPayable>
    <us-gaap:InterestExpenseBorrowings contextRef="c-1" decimals="-5" id="f-920" unitRef="usd">300000</us-gaap:InterestExpenseBorrowings>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="c-1" id="f-921">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the future principal payments remaining on term loans was the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-157" decimals="-3" id="f-922" unitRef="usd">490000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt contextRef="c-157" decimals="-3" id="f-923" unitRef="usd">490000</us-gaap:LongTermDebt>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-924">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities, current, consisted of the following components: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent contextRef="c-4" decimals="-3" id="f-925" unitRef="usd">3715000</pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent>
    <pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent contextRef="c-5" decimals="-3" id="f-926" unitRef="usd">3638000</pacb:AccruedEmployeeStockPurchasePlanLiabilityCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c-4" decimals="-3" id="f-927" unitRef="usd">490000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-5" decimals="-3" id="f-928" unitRef="usd">1842000</us-gaap:ShortTermBorrowings>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-929" unitRef="usd">4121000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-930" unitRef="usd">1753000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-931" unitRef="usd">8326000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-932" unitRef="usd">7233000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-933">CONVERTIBLE SENIOR NOTES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2030 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 1.50% Convertible Senior Notes due 2028 (the &#x201c;2028 Notes&#x201d;), pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#x201c;2030 Notes&#x201d;) in exchange for $441.0 million principal amount of the 2028 Notes (the &#x201c;Exchange Transaction&#x201d;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are governed by an indenture (the &#x201c;2030 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December&#160;15, 2030, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after June 20, 2028, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0 million in connection with the Exchange Transaction during the year ended December&#160;31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5 million related to the respective portion of the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2030 Notes of approximately $7.3 million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our consolidated balance sheets and are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5 million on the 2028 Notes in connection with the Exchange Transaction on June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the Exchange Transaction, $459.0 million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes for the years ended December&#160;31, 2023, 2022, and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the estimated fair value (Level 2) of the 2030 Notes was $410.5 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;9, 2021, we entered into an investment agreement (the &#x201c;Investment Agreement&#x201d;) with SB Northstar LP (the &#x201c;Purchaser&#x201d;), a subsidiary of SoftBank Group Corp., relating to the issuance and sale to the Purchaser of $900.0 million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February&#160;16, 2021. As discussed above, in June 2023 we completed an exchange of $441.0 million in aggregate principal amount of our 2028 Notes for $441.0 million aggregate principal amount of the 2030 Notes, leaving approximately $459.0 million in aggregate principal amount of 2028 Notes outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Notes are governed by an indenture (the &#x201c;2028 Indenture&#x201d;) between the Company and U.S. Bank National Association, as trustee. The 2028 Notes bear interest at a rate of 1.50% per annum. Interest on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028 Notes is payable semi-annually in arrears on February 15 and August 15 and commenced on August 15, 2021. The 2028 Notes will mature on February&#160;15, 2028, subject to earlier conversion, redemption, or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2028 Notes are convertible into shares of our common stock based on an initial conversion rate of 22.9885 shares of common stock per $1,000 principal amount of the 2028 Notes (which is equal to an initial conversion price of $43.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2028 Notes, we may elect to settle such conversion obligation in shares of our common stock, cash or a combination of shares of our common stock and cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after February 20, 2026, the 2028 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2028 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2028 Indenture), the holders of the 2028 Notes may require that we repurchase all or part of the principal amount of the 2028 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2028 Notes under the 2028 Indenture. The 2028 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2028 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2028 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2028 Notes outstanding for each day from, and including, the 181st calendar day to, and including, the 360th calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2028 Indenture). On the 361st day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361st day), the 2028 Notes shall be subject to acceleration as provided for in the 2028 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2028 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2028 Notes were not issued at a premium; therefore, the 2028 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2028 Notes including unpaid interest to the maturity date in the event of a Fundamental Change is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2028 Notes of approximately $4.5 million, which were recorded as debt issuance cost and are presented as a reduction to the 2028 Notes on our consolidated balance sheets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;896,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the estimated fair value (Level 2) of the 2028 Notes was $395.4 million. The fair value of the Notes is estimated using a pricing model that is primarily affected by the trading price of our common stock and market interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-219" decimals="4" id="f-934" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-220" decimals="-5" id="f-935" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-220" decimals="5" id="f-936" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-219" decimals="-5" id="f-937" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-220" decimals="5" id="f-938" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-220"
      decimals="2"
      id="f-939"
      unitRef="usdPerShare">21.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice contextRef="c-221" decimals="2" id="f-940" unitRef="number">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays contextRef="c-221" id="f-941">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays contextRef="c-221" id="f-942">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-221" decimals="2" id="f-943" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-221" decimals="2" id="f-944" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-221" id="f-945">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-221" decimals="4" id="f-946" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-222" id="f-947">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-221" id="f-948">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-221" decimals="4" id="f-949" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-223" id="f-950">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-221" id="f-951">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-224" id="f-952">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-224" id="f-953">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-225" decimals="-5" id="f-954" unitRef="usd">-2000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-226" decimals="-5" id="f-955" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-227" decimals="-5" id="f-956" unitRef="usd">7300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-228" decimals="3" id="f-957" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-229" decimals="-5" id="f-958" unitRef="usd">2500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:LongTermDebt contextRef="c-230" decimals="-5" id="f-959" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-960">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2028 Notes is included as convertible senior notes, net, non-current in the consolidated balance sheets as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;896,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-227" decimals="-3" id="f-961" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-231" decimals="-3" id="f-962" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-227" decimals="-3" id="f-963" unitRef="usd">524000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-231" decimals="-3" id="f-964" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-227" decimals="-3" id="f-965" unitRef="usd">6907000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-231" decimals="-3" id="f-966" unitRef="usd">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt contextRef="c-227" decimals="-3" id="f-967" unitRef="usd">434617000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-231" decimals="-3" id="f-968" unitRef="usd">0</us-gaap:LongTermDebt>
    <pacb:ScheduleOfInterestExpenseTableTextBlock contextRef="c-1" id="f-969">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes for the years ended December&#160;31, 2023, 2022, and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-232" decimals="-3" id="f-970" unitRef="usd">3032000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-233" decimals="-3" id="f-971" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-234" decimals="-3" id="f-972" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-232" decimals="-3" id="f-973" unitRef="usd">463000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-233" decimals="-3" id="f-974" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-234" decimals="-3" id="f-975" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-232" decimals="-3" id="f-976" unitRef="usd">3495000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-233" decimals="-3" id="f-977" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-234" decimals="-3" id="f-978" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-228" decimals="-5" id="f-979" unitRef="usd">410500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-235" decimals="-8" id="f-980" unitRef="usd">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-219" decimals="-5" id="f-981" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-220" decimals="-5" id="f-982" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt contextRef="c-230" decimals="-5" id="f-983" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-235" decimals="4" id="f-984" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-235"
      decimals="2"
      id="f-985"
      unitRef="usdPerShare">43.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice contextRef="c-236" decimals="2" id="f-986" unitRef="number">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays contextRef="c-236" id="f-987">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays contextRef="c-236" id="f-988">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-236" decimals="2" id="f-989" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-237" id="f-990">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-237" decimals="4" id="f-991" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-238" id="f-992">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-237" id="f-993">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-237" decimals="4" id="f-994" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-239" id="f-995">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-237" id="f-996">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-240" id="f-997">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-240" id="f-998">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-230" decimals="-5" id="f-999" unitRef="usd">4500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-230"
      decimals="3"
      id="f-1000"
      unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-226" decimals="-3" id="f-1001" unitRef="usd">459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-241" decimals="-3" id="f-1002" unitRef="usd">900000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-226" decimals="-3" id="f-1003" unitRef="usd">1374000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-241" decimals="-3" id="f-1004" unitRef="usd">3317000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt contextRef="c-226" decimals="-3" id="f-1005" unitRef="usd">457626000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-241" decimals="-3" id="f-1006" unitRef="usd">896683000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-242" decimals="-3" id="f-1007" unitRef="usd">10133000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-243" decimals="-3" id="f-1008" unitRef="usd">13500000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-244" decimals="-3" id="f-1009" unitRef="usd">11812000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-242" decimals="-3" id="f-1010" unitRef="usd">472000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-243" decimals="-3" id="f-1011" unitRef="usd">617000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-244" decimals="-3" id="f-1012" unitRef="usd">532000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-242" decimals="-3" id="f-1013" unitRef="usd">10605000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-243" decimals="-3" id="f-1014" unitRef="usd">14117000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-244" decimals="-3" id="f-1015" unitRef="usd">12344000</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-230" decimals="-5" id="f-1016" unitRef="usd">395400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-1019">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. In connection with the acquisition of Omniome, we acquired $18.1 million in right-of-use assets and liabilities on our consolidated balance sheets. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of our operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 6.8%. The weighted-average remaining lease term for our operating leases as of December&#160;31, 2023 was 3.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the present value of operating lease liabilities was $12.1 million and $11.2&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, and were included in operating cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $10.4 million and $10.5 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see subsection titled &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_28" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceedings&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part I, Item 3 of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we enter into agreements to purchase goods or services or license intellectual property, certain of which are not cancellable without penalty. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to ongoing minimum royalty payments, some of which are subject to adjustment, may be terminated under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our purchase orders and contractual obligations are approximately $109.9 million as of December&#160;31, 2023, which consist of open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule and adjust our requirements based on our business needs prior to the delivery of goods or performance of services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized a loss on purchase commitment of $3.4 million for the year ended December&#160;31, 2023, which was recorded as part of accrued expenses on the consolidated balance sheet and is included in the aforementioned purchase orders and contractual obligations amount. The purchase commitment loss is based on an estimate of future excess inventory related to a supply agreement with a third-party vendor, for which we do not expect to have related sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a long-term supply agreement, which was amended in October 2022 (the &#x201c;Supply Agreement&#x201d;), for the purchase of certain products with a semiconductor manufacturer (&#x201c;Supplier&#x201d;). The Supply Agreement provides for minimum purchase commitments through 2026 on our part in exchange for guaranteed capacity at Supplier. We are responsible for providing certain materials to allow our Supplier to perform its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We paid our Supplier a deposit of $9.0 million in November 2022 and an additional deposit of $6.0 million in 2023, for a total of $15.0 million (the &#x201c;Deposit&#x201d;). The Deposit is fully refundable to us, in accordance with the Supply Agreement, if we meet the minimum volume purchase commitment for the applicable year. As of December&#160;31, 2023, $3.0 million related to the Deposit was included in prepaid expenses and other current assets in the consolidated balance sheets and $12.0 million related to the Deposit was included in other long-term assets in the consolidated balance sheets, as we believe it is probable the minimum volume purchase commitment level will be achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:OperatingLeaseLiability contextRef="c-85" decimals="-5" id="f-1020" unitRef="usd">18100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-85" decimals="-5" id="f-1021" unitRef="usd">18100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <pacb:LesseeOperatingLeaseDescriptionTableTextBlock contextRef="c-1" id="f-1022">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of our operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:LesseeOperatingLeaseDescriptionTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1023" unitRef="usd">12082000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-1024" unitRef="usd">12307000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-1025" unitRef="usd">12412000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-1026" unitRef="usd">9930000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-1027" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-1028" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-1029" unitRef="usd">46731000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-1030" unitRef="usd">5534000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1031" unitRef="usd">41197000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-1032" unitRef="usd">9591000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-1033" unitRef="usd">31606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1034" unitRef="usd">41197000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1035" unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1036">P3Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PaymentsForRent contextRef="c-1" decimals="-5" id="f-1037" unitRef="usd">12100000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c-12" decimals="-5" id="f-1038" unitRef="usd">11200000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-1039" unitRef="usd">10400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-5" id="f-1040" unitRef="usd">10500000</us-gaap:OperatingLeaseCost>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations contextRef="c-4" decimals="INF" id="f-1041" unitRef="usd">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <us-gaap:PurchaseObligation contextRef="c-4" decimals="-5" id="f-1042" unitRef="usd">109900000</us-gaap:PurchaseObligation>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-1" decimals="-5" id="f-1043" unitRef="usd">3400000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:PaymentsForDeposits contextRef="c-246" decimals="-5" id="f-1044" unitRef="usd">9000000</us-gaap:PaymentsForDeposits>
    <us-gaap:PaymentsForDeposits contextRef="c-1" decimals="-5" id="f-1045" unitRef="usd">6000000</us-gaap:PaymentsForDeposits>
    <us-gaap:PaymentsForDeposits contextRef="c-247" decimals="-5" id="f-1046" unitRef="usd">15000000</us-gaap:PaymentsForDeposits>
    <us-gaap:DepositsAssetsCurrent contextRef="c-4" decimals="-5" id="f-1047" unitRef="usd">3000000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c-4" decimals="-5" id="f-1048" unitRef="usd">12000000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1049">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income taxes both in the United States and certain foreign jurisdictions in which we operate, and we use estimates in determining our provisions for income taxes. Significant management judgement is required in determining our provision for income taxes, deferred tax assets and liabilities, and valuation allowances recorded against net deferred tax assets in accordance with U.S. GAAP. These estimates and judgements occur in the calculation of tax credits, benefits, and deductions, and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease to our tax provision in the current or subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the sustainability assertion have changed and the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for Global Intangible Low-taxed Income as a period cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023, 2022, and 2021 income/(loss) before taxes from U.S. operations were ($318.9) million, ($315.7) million, and ($275.4) million, respectively, and income/(loss) before taxes from foreign operations was $0.7 million, $1.8 million, and $0.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provision (Benefit) for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Benefit) Provision for Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statutory tax rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State tax rate, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and experimental expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancellation of indebtedness income and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(525,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(445,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(98,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, we maintained a valuation allowance against our net deferred tax assets which totaled $525.7 million, including net operating loss carryforwards and research and development credits of $435.5 million and $83.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. A deferred income tax benefit of $11.4&#160;million for the year ended December&#160;31, 2023, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Apton acquisition. We maintain a valuation allowance on the net deferred tax assets of our U.S. entities as we have concluded that it is more likely than not that we will not realize our deferred tax assets. Accordingly, this benefit from income taxes is reflected on our consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, the Company's valuation allowance increased to $525.7 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. For the year ended December&#160;31, 2022, the Company's valuation allowance increased to $445.6 million, primarily because of an increase in our net operating losses, credits, and capitalized research and experimental expenses that were fully offset by a valuation allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had a net operating loss carryforward for federal income tax purposes of approximately $1,709.3 million, of which $788.1 million is subject to expiration beginning in 2024. We had a total state net operating loss carryforward of approximately $1,171.8 million, which are subject to annual expirations. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have federal credits of approximately $57.7 million, which will begin to expire in 2024 if not utilized and state research credits of approximately $49.8 million, which have no expiration date. These tax credits are subject to the same limitations discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our total unrecognized tax benefit was $14.6 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2023 and 2022, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. If total unrecognized tax benefits were realized in the future, it would not result in any tax benefit as we currently have a full valuation allowance. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December&#160;31, 2020 to present and December 31, 2019 to present, respectively. In addition, all the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition contextRef="c-1" decimals="2" id="f-1050" unitRef="number">0.50</pacb:ProbabilityOfBenefitRealizedUponSettlementUncertainTaxPosition>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-5" id="f-1051" unitRef="usd">-318900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-5" id="f-1052" unitRef="usd">-315700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-5" id="f-1053" unitRef="usd">-275400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-5" id="f-1054" unitRef="usd">700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-5" id="f-1055" unitRef="usd">1800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-5" id="f-1056" unitRef="usd">800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1057">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Benefit) Provision for Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1058" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1059" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1060" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1061" unitRef="usd">-9956000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1062" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1063" unitRef="usd">-83742000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1064" unitRef="usd">-1468000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1065" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1066" unitRef="usd">-9907000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1067" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1068" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1069" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1070" unitRef="usd">-11424000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1071" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1072" unitRef="usd">-93649000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1073" unitRef="usd">-11424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1074" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1075" unitRef="usd">-93649000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1076">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying the statutory income tax rate of 21% to pretax loss as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statutory tax rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State tax rate, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1077" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="3" id="f-1078" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="3" id="f-1079" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1080" unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="3" id="f-1081" unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="3" id="f-1082" unitRef="number">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1083" unitRef="number">-0.200</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="3" id="f-1084" unitRef="number">-0.251</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="3" id="f-1085" unitRef="number">-0.049</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit contextRef="c-1" decimals="3" id="f-1086" unitRef="number">0.020</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit contextRef="c-12" decimals="3" id="f-1087" unitRef="number">0.022</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <pacb:EffectiveIncomeTaxRateReconciliationTaxCredit contextRef="c-13" decimals="3" id="f-1088" unitRef="number">0.025</pacb:EffectiveIncomeTaxRateReconciliationTaxCredit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1089" unitRef="number">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="3" id="f-1090" unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="3" id="f-1091" unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent contextRef="c-1" decimals="3" id="f-1092" unitRef="number">-0.001</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent contextRef="c-12" decimals="3" id="f-1093" unitRef="number">0</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent contextRef="c-13" decimals="3" id="f-1094" unitRef="number">-0.009</pacb:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1095" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-12" decimals="3" id="f-1096" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-13" decimals="3" id="f-1097" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1098" unitRef="number">0.036</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-1099" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-1100" unitRef="number">0.340</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1101">Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands): &lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and experimental expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancellation of indebtedness income and interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(525,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(445,574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(98,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-1102" unitRef="usd">435488000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-1103" unitRef="usd">400629000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-1104" unitRef="usd">83922000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-1105" unitRef="usd">71526000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-1106" unitRef="usd">63196000</pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-5" decimals="-3" id="f-1107" unitRef="usd">34863000</pacb:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="c-4" decimals="-3" id="f-1108" unitRef="usd">16872000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense contextRef="c-5" decimals="-3" id="f-1109" unitRef="usd">13830000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense contextRef="c-4" decimals="-3" id="f-1110" unitRef="usd">14907000</pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense>
    <pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense contextRef="c-5" decimals="-3" id="f-1111" unitRef="usd">4587000</pacb:DeferredTaxAssetCancellationOfIndebtednessIncomeAndInterestExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-1112" unitRef="usd">18584000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-1113" unitRef="usd">17117000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pacb:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1114" unitRef="usd">9510000</pacb:DeferredTaxAssetsOperatingLeaseLiabilities>
    <pacb:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1115" unitRef="usd">11537000</pacb:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-1116" unitRef="usd">642479000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1117" unitRef="usd">554089000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-1118" unitRef="usd">525703000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1119" unitRef="usd">445574000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-1120" unitRef="usd">116776000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1121" unitRef="usd">108515000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-1122" unitRef="usd">109488000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-1123" unitRef="usd">98931000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-1124" unitRef="usd">548000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1125" unitRef="usd">1262000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <pacb:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-4" decimals="-3" id="f-1126" unitRef="usd">7491000</pacb:DeferredTaxLiabilitiesRightOfUseAssets>
    <pacb:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-5" decimals="-3" id="f-1127" unitRef="usd">9157000</pacb:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-1128" unitRef="usd">117527000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-1129" unitRef="usd">109350000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-1130" unitRef="usd">751000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-1131" unitRef="usd">835000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-1132" unitRef="usd">525700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-4" decimals="-5" id="f-1133" unitRef="usd">435500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-4" decimals="-5" id="f-1134" unitRef="usd">83900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1135" unitRef="usd">-11400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-1136" unitRef="usd">525700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-1137" unitRef="usd">445600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-248" decimals="-5" id="f-1138" unitRef="usd">1709300000</us-gaap:OperatingLossCarryforwards>
    <pacb:OperatingLossCarryforwardsAmountSubjectToExpiration contextRef="c-248" decimals="-5" id="f-1139" unitRef="usd">788100000</pacb:OperatingLossCarryforwardsAmountSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-249" decimals="-5" id="f-1140" unitRef="usd">1171800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-248" decimals="-5" id="f-1141" unitRef="usd">57700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-249" decimals="-5" id="f-1142" unitRef="usd">49800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1143">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our total unrecognized tax benefit was $14.6 million. A reconciliation of the beginning and ending unrecognized tax benefit balance is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken in prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase in balance related to tax positions taken during current year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-1144" unitRef="usd">14600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-3" id="f-1145" unitRef="usd">5954000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1146" unitRef="usd">189000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-1147" unitRef="usd">2192000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-3" id="f-1148" unitRef="usd">8335000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1149" unitRef="usd">10000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-1150" unitRef="usd">2085000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-1151" unitRef="usd">10410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1152" unitRef="usd">2044000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1153" unitRef="usd">2100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-1154" unitRef="usd">14554000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-5" id="f-1155" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-5" id="f-1156" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1157">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December&#160;31, 2023 and 2022, there were no shares of preferred stock issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Underwritten Public Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we entered into an underwriting agreement, relating to the public offering of 19,430,000 shares of our common stock, $0.001 par value per share, at a price to the public of $4.47 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2,914,500 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#x2019; option, closed in August 2020. In total, we sold 22.3&#160;million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $93.9&#160;million, excluding approximately $0.3&#160;million of offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, we entered into an underwriting agreement, relating to the public offering of 6,096,112 shares of our common stock, $0.001 par value per share, at a price to the public of $14.25 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 914,416 shares of our common stock, which was subsequently exercised in full, and the offering including the sale of shares of common stock subject to the underwriters&#x2019; option, closed in November 2020. In total, we sold 7.0&#160;million shares of our common stock. We paid a commission equal to 6% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deducting the underwriting discount were approximately $93.9&#160;million, excluding approximately $0.3 million of offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, for the year ended December&#160;31, 2021, we issued 29.4 million shares of our common stock through our two underwritten public offerings with an average offering price of $6.40. The total net proceeds to us from the two offerings, after deducting the underwriting commission and offering expenses, were approximately $187.2 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we entered into an underwriting agreement, relating to the public offering of 17.5&#160;million shares of our common stock, $0.001 par value per share, at a price to the public of $10.00 per share. Under the terms of the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to an additional 2.6&#160;million shares of our common stock, which was subsequently exercised in full, and the offering, including the sale of shares of common stock subject to the underwriters' option, closed in January 2023. In total, we sold 20.1&#160;million shares of our common stock. We paid a commission equal to 5.75% of the gross proceeds from the sale of shares of our common stock. The total net proceeds to us from the offering after deducting the underwriting discount were approximately $189.7&#160;million, excluding approximately $0.5&#160;million of offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Private Placement of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2021, in connection with the Omniome acquisition, we entered into a purchase agreement with certain qualified institutional buyers and institutional accredited investors, pursuant to which we agreed to sell an aggregate of 11,214,953 shares of common stock, at a price of $26.75 per share, for aggregate gross proceeds of approximately $300 million. The transaction closed on September&#160;20, 2021. We registered the private placement shares for resale following the closing of the merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), the 2020 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), and the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;) allow for the issuance of stock options, restricted units and awards, and performance-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;2, 2020, the Board of Directors (the &#x201c;Board&#x201d;) adopted the Inducement Plan and reserved 2,500,000 shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April&#160;18, 2021 and November&#160;22, 2021, the Board amended the Inducement Plan to reserve an additional 750,000 and 360,000 shares, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;20, 2021, in connection with the acquisition of Omniome, we adopted the Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;). Under the Omniome Merger Agreement, each unvested option to purchase Omniome common stock, granted under the Omniome Plan held by employees continuing with us, was assumed by PacBio and converted into an option to purchase shares of our common stock. The terms and conditions of the converted options are substantially the same (including vesting and exercisability), except that (A) the assumed options cover shares of PacBio&#x2019;s common stock; (B) the number of shares of our common stock subject to the assumed option is equal to the product of (i) the number of shares of Omniome common stock subject to the corresponding unvested option, multiplied by (ii) the exchange ratio (as defined below), with any resulting fractional share rounded down to the nearest whole share; and (C) the exercise price per share of the assumed options is equal to the quotient of (i) the exercise price per share of the corresponding unvested option to purchase shares of Omniome common stock, divided by (ii) the exchange ratio (as defined below), with any resulting fractional cent rounded up to the nearest whole cent. The exchange ratio was equal to 0.259204639. We reserved 2,494,128 shares of our common stock for issuance pursuant to equity awards under the Omniome Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 25, 2022, stockholders approved an amendment to the 2020 Plan, and we reserved an additional 18,000,000 shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had 12.8&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Time-based stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(910)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-based stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance condition was achieved during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of the outstanding options presented in the tables above as of December&#160;31, 2023, totaled $31.8 million, and had a weighted-average remaining contractual life of 5.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of outstanding options represents the total pre-tax intrinsic value (i.e. the difference between $9.81, our closing stock price on the last trading day of our fourth quarter of 2023 and the option exercise price multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December&#160;31, 2023. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vested and exercisable options as of December&#160;31, 2023, totaled 10,039,742 shares, had an aggregate intrinsic value of $30.0&#160;million, a weighted-average exercise price per share of $9.70, and a weighted-average remaining contractual life of 5.2 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vested and expected to vest options as of December&#160;31, 2023, totaled 13,026,464 shares, had an aggregate intrinsic value of $31.6 million, a weighted-average exercise price per share of $10.81, and a weighted-average remaining contractual life of 5.8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2023, 2022, and 2021 was $8.8 million, $5.0 million, and $146.1 million, respectively. The total intrinsic value of options exercised represents the difference between our closing stock price on the exercise date and the option exercise price, multiplied by the number of in-the-money options exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all options granted was $7.32 in 2023, $5.93 in 2022, and $18.36 in 2021, each determined by the Black-Scholes option valuation method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Restricted Stock Unit (RSU) represents one equivalent share of our common stock to be issued after satisfying the applicable continued service-based vesting criteria over a specified period. These RSUs are time-based and vest over four years at a rate of 25% annually. The RSUs do not entitle participants to the rights of holders of common stock, such as voting rights, until the shares are issued. The fair value of these RSUs is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the closing price of our common stock on the date of grant. We measure compensation expense for these RSUs at fair value on the date of grant and recognize the expense over the expected vesting period on a straight-line basis.  RSUs that are expected to vest are net of estimated future forfeitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue PSUs for which the number of shares issuable in the third year of the performance period is based on performance relative to specified revenue targets and continued employment through the vesting period.  Maximum achievement of the revenue goal under the PSUs will result in up to 200% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under PSUs will result in no shares subject to the PSUs becoming eligible to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the time-based RSUs and PSUs activity for the year ended December&#160;31, 2023 (shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance Stock Units (PSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,535&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,141&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,730)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,308&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of shares vested related to RSUs and PSUs during the years ended December&#160;31, 2023, 2022, and 2021 was $39.3 million, $39.2 million, and $9.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all RSUs and PSUs granted was $9.65 in 2023, $10.15 in 2022, and $35.33 in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, a total of 29.5&#160;million shares of our common stock have been reserved for issuance under our 2010 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will be terminated and a new offering period will come into place. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each fiscal year equal to the lesser of 2% of the common shares then outstanding, 4,000,000 shares, or an amount determined by the ESPP&#x2019;s administrator. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022, and 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,735,058&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares, 1,878,168 shares, and 1,913,968 shares of common stock were purchased under the ESPP, respectivel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y. As of December&#160;31, 2023, 12,197,447 sh&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares of our common stock remain available for issuance under our ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses - stock-settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses - milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses - cash-settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, $0.6 million and $0.7 million of share-based compensation cost was capitalized in inventory, net, on our consolidated balance sheets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit of share-based compensation expense was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Determining Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of share options granted using the Black-Scholes valuation method and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSU awards granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Term &#x2013; The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock options and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Volatility &#x2013; The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Dividend &#x2013; We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate &#x2013; The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is amortized on a straight-line basis over the requisite service period of the awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference observable market prices of similar or identical instruments in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1 - 4.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67% - 80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.73% &#x2013; 4.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.41% &#x2013; 3.66%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05% &#x2013; 1.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from option exercises for the years ended December&#160;31, 2023, 2022, and 2021 was $6.5 million, $3.4 million and $25.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ESPP &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of shares to be issued under the ESPP using the Black-Scholes option pricing model. The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67% - 68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6% - 3.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1% - 0.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received through the ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was $8.8 million, $7.8 million, and $6.4 million, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, $101.9 million of total unrecognized compensation expense related to stock options, restricted stock, and ESPP shares was expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-250"
      decimals="INF"
      id="f-1158"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-250"
      decimals="3"
      id="f-1159"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-250"
      decimals="INF"
      id="f-1160"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-250"
      decimals="3"
      id="f-1161"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-4"
      decimals="INF"
      id="f-1162"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-4"
      decimals="INF"
      id="f-1163"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-5"
      decimals="INF"
      id="f-1164"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-5"
      decimals="INF"
      id="f-1165"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-1166"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockVotingRights contextRef="c-1" id="f-1167">one</us-gaap:CommonStockVotingRights>
    <pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned contextRef="c-1" decimals="INF" id="f-1168" unitRef="vote">1</pacb:CommonStockVotingRightsNumberOfVotesPerShareOwned>
    <pacb:PublicOfferingShares
      contextRef="c-251"
      decimals="-4"
      id="f-1169"
      unitRef="shares">19430000</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-252"
      decimals="3"
      id="f-1170"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="c-252"
      decimals="2"
      id="f-1171"
      unitRef="usdPerShare">4.47</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod contextRef="c-251" id="f-1172">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="c-251"
      decimals="-2"
      id="f-1173"
      unitRef="shares">2914500</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-251"
      decimals="-5"
      id="f-1174"
      unitRef="shares">22300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="c-251"
      decimals="2"
      id="f-1175"
      unitRef="number">0.06</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="c-251" decimals="-5" id="f-1176" unitRef="usd">93900000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-252" decimals="-5" id="f-1177" unitRef="usd">300000</us-gaap:DeferredOfferingCosts>
    <pacb:PublicOfferingShares
      contextRef="c-253"
      decimals="0"
      id="f-1178"
      unitRef="shares">6096112</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-254"
      decimals="3"
      id="f-1179"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="c-254"
      decimals="2"
      id="f-1180"
      unitRef="usdPerShare">14.25</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod contextRef="c-253" id="f-1181">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="c-253"
      decimals="0"
      id="f-1182"
      unitRef="shares">914416</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-253"
      decimals="-5"
      id="f-1183"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="c-253"
      decimals="2"
      id="f-1184"
      unitRef="number">0.06</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="c-253" decimals="-5" id="f-1185" unitRef="usd">93900000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-254" decimals="-5" id="f-1186" unitRef="usd">300000</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-255"
      decimals="-5"
      id="f-1187"
      unitRef="shares">29400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pacb:NumberOfOfferings
      contextRef="c-255"
      decimals="INF"
      id="f-1188"
      unitRef="offering">2</pacb:NumberOfOfferings>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-256"
      decimals="2"
      id="f-1189"
      unitRef="usdPerShare">6.40</us-gaap:SharesIssuedPricePerShare>
    <pacb:NumberOfOfferings
      contextRef="c-257"
      decimals="INF"
      id="f-1190"
      unitRef="offering">2</pacb:NumberOfOfferings>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="c-255" decimals="-5" id="f-1191" unitRef="usd">187200000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <pacb:PublicOfferingShares
      contextRef="c-258"
      decimals="-5"
      id="f-1192"
      unitRef="shares">17500000</pacb:PublicOfferingShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-259"
      decimals="3"
      id="f-1193"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pacb:OfferingShareAmountMaximum
      contextRef="c-259"
      decimals="2"
      id="f-1194"
      unitRef="usdPerShare">10.00</pacb:OfferingShareAmountMaximum>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod contextRef="c-258" id="f-1195">P30D</pacb:PublicOfferingOptionToPurchaseAdditionalSharesPeriod>
    <pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares
      contextRef="c-258"
      decimals="-5"
      id="f-1196"
      unitRef="shares">2600000</pacb:PublicOfferingOptionToPurchaseAdditionalSharesShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-260"
      decimals="-5"
      id="f-1197"
      unitRef="shares">20100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering
      contextRef="c-258"
      decimals="4"
      id="f-1198"
      unitRef="number">0.0575</pacb:PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering>
    <pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="c-258" decimals="-5" id="f-1199" unitRef="usd">189700000</pacb:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-258" decimals="-5" id="f-1200" unitRef="usd">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-261"
      decimals="0"
      id="f-1201"
      unitRef="shares">11214953</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-261"
      decimals="2"
      id="f-1202"
      unitRef="usdPerShare">26.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-262" decimals="-8" id="f-1203" unitRef="usd">300000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-263"
      decimals="-5"
      id="f-1204"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-264"
      decimals="-4"
      id="f-1205"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-265"
      decimals="-4"
      id="f-1206"
      unitRef="shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pacb:ExchangeRatio
      contextRef="c-266"
      decimals="INF"
      id="f-1207"
      unitRef="number">0.259204639</pacb:ExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-267"
      decimals="0"
      id="f-1208"
      unitRef="shares">2494128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-268"
      decimals="-6"
      id="f-1209"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-269"
      decimals="-5"
      id="f-1210"
      unitRef="shares">12800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1211">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes time-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(910)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes performance-based stock option activity for all of our equity compensation plans for the year ended December&#160;31, 2023 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-270"
      decimals="-3"
      id="f-1212"
      unitRef="shares">14618000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-270"
      decimals="2"
      id="f-1213"
      unitRef="usdPerShare">10.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-271"
      decimals="-3"
      id="f-1214"
      unitRef="shares">419000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1215"
      unitRef="usdPerShare">11.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-271"
      decimals="-3"
      id="f-1216"
      unitRef="shares">1119000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1217"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-271"
      decimals="-3"
      id="f-1218"
      unitRef="shares">910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-271"
      decimals="2"
      id="f-1219"
      unitRef="usdPerShare">17.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-272"
      decimals="-3"
      id="f-1220"
      unitRef="shares">13008000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-1221"
      unitRef="usdPerShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-273"
      decimals="0"
      id="f-1222"
      unitRef="shares">258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-273"
      decimals="2"
      id="f-1223"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-274"
      decimals="-3"
      id="f-1224"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-1225"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-274"
      decimals="-3"
      id="f-1226"
      unitRef="shares">251000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-1227"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-275"
      decimals="0"
      id="f-1228"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-275"
      decimals="2"
      id="f-1229"
      unitRef="usdPerShare">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-276"
      decimals="0"
      id="f-1230"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-276"
      decimals="2"
      id="f-1231"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-277" decimals="-5" id="f-1232" unitRef="usd">31800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-278" id="f-1233">P5Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharePrice
      contextRef="c-279"
      decimals="2"
      id="f-1234"
      unitRef="usdPerShare">9.81</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-277"
      decimals="0"
      id="f-1235"
      unitRef="shares">10039742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="-5" id="f-1236" unitRef="shares">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-278"
      decimals="2"
      id="f-1237"
      unitRef="usdPerShare">9.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1238">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-277"
      decimals="0"
      id="f-1239"
      unitRef="shares">13026464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-5" id="f-1240" unitRef="usd">31600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1241"
      unitRef="usdPerShare">10.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1242">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-1243" unitRef="usd">8800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-5" id="f-1244" unitRef="usd">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-5" id="f-1245" unitRef="usd">146100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1246"
      unitRef="usdPerShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-1247"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-1248"
      unitRef="usdPerShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pacb:ShareInstrumentNumberOfSharesConversionRatio
      contextRef="c-280"
      decimals="0"
      id="f-1249"
      unitRef="shares">1</pacb:ShareInstrumentNumberOfSharesConversionRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-280" id="f-1250">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-281"
      decimals="2"
      id="f-1251"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal
      contextRef="c-282"
      decimals="2"
      id="f-1252"
      unitRef="number">2</pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-1253">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the time-based RSUs and PSUs activity for the year ended December&#160;31, 2023 (shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance Stock Units (PSUs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,535&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,141&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,730)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,308&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-283"
      decimals="-3"
      id="f-1254"
      unitRef="shares">8535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-284"
      decimals="-3"
      id="f-1255"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1256"
      unitRef="usdPerShare">15.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-284"
      decimals="2"
      id="f-1257"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-280"
      decimals="-3"
      id="f-1258"
      unitRef="shares">7141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-274"
      decimals="-3"
      id="f-1259"
      unitRef="shares">564000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-280"
      decimals="2"
      id="f-1260"
      unitRef="usdPerShare">9.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-274"
      decimals="2"
      id="f-1261"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-280"
      decimals="-3"
      id="f-1262"
      unitRef="shares">2730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-274"
      decimals="-3"
      id="f-1263"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-280"
      decimals="2"
      id="f-1264"
      unitRef="usdPerShare">14.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-274"
      decimals="2"
      id="f-1265"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-280"
      decimals="-3"
      id="f-1266"
      unitRef="shares">1638000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-274"
      decimals="-3"
      id="f-1267"
      unitRef="shares">23000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-280"
      decimals="2"
      id="f-1268"
      unitRef="usdPerShare">13.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-274"
      decimals="2"
      id="f-1269"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-285"
      decimals="-3"
      id="f-1270"
      unitRef="shares">11308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-286"
      decimals="-3"
      id="f-1271"
      unitRef="shares">541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-285"
      decimals="2"
      id="f-1272"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-286"
      decimals="2"
      id="f-1273"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-287" decimals="-5" id="f-1274" unitRef="usd">39300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-288" decimals="-5" id="f-1275" unitRef="usd">39200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-289" decimals="-5" id="f-1276" unitRef="usd">9200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-287"
      decimals="2"
      id="f-1277"
      unitRef="usdPerShare">9.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-288"
      decimals="2"
      id="f-1278"
      unitRef="usdPerShare">10.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-289"
      decimals="2"
      id="f-1279"
      unitRef="usdPerShare">35.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-290"
      decimals="-5"
      id="f-1280"
      unitRef="shares">29500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pacb:NumberOfPurchasePeriods
      contextRef="c-291"
      decimals="INF"
      id="f-1281"
      unitRef="period">4</pacb:NumberOfPurchasePeriods>
    <pacb:PurchasePeriodOfEmployeeStockPurchasePlan contextRef="c-292" id="f-1282">P6M</pacb:PurchasePeriodOfEmployeeStockPurchasePlan>
    <pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased
      contextRef="c-292"
      decimals="2"
      id="f-1283"
      unitRef="number">0.85</pacb:PercentageOfFairMarketValueAtWhichStockCanBePurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-292"
      decimals="2"
      id="f-1284"
      unitRef="number">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-291"
      decimals="-6"
      id="f-1285"
      unitRef="shares">4000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c-292"
      decimals="0"
      id="f-1286"
      unitRef="shares">1735058</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c-293"
      decimals="0"
      id="f-1287"
      unitRef="shares">1878168</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c-294"
      decimals="0"
      id="f-1288"
      unitRef="shares">1913968</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-291"
      decimals="0"
      id="f-1289"
      unitRef="shares">12197447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1290">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses - stock-settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses - milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Merger-related expenses - cash-settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-295" decimals="-3" id="f-1291" unitRef="usd">5399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-296" decimals="-3" id="f-1292" unitRef="usd">4802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-297" decimals="-3" id="f-1293" unitRef="usd">6126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-298" decimals="-3" id="f-1294" unitRef="usd">22435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-299" decimals="-3" id="f-1295" unitRef="usd">30676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-300" decimals="-3" id="f-1296" unitRef="usd">20275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-301" decimals="-3" id="f-1297" unitRef="usd">44284000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-302" decimals="-3" id="f-1298" unitRef="usd">43135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-303" decimals="-3" id="f-1299" unitRef="usd">35403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-304" decimals="-3" id="f-1300" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-305" decimals="-3" id="f-1301" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-306" decimals="-3" id="f-1302" unitRef="usd">6349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-307" decimals="-3" id="f-1303" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-308" decimals="-3" id="f-1304" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-309" decimals="-3" id="f-1305" unitRef="usd">5202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-310" decimals="-3" id="f-1306" unitRef="usd">72118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-311" decimals="-3" id="f-1307" unitRef="usd">78613000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-312" decimals="-3" id="f-1308" unitRef="usd">73355000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-313" decimals="-3" id="f-1309" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-314" decimals="-3" id="f-1310" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-315" decimals="-3" id="f-1311" unitRef="usd">7373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-1312" unitRef="usd">72118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-1313" unitRef="usd">78613000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-1314" unitRef="usd">80728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1315" unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-12" decimals="-5" id="f-1316" unitRef="usd">700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-13"
      decimals="INF"
      id="f-1317"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-1"
      decimals="INF"
      id="f-1318"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-12"
      decimals="INF"
      id="f-1319"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1320">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1 - 4.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67% - 80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.73% &#x2013; 4.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.41% &#x2013; 3.66%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05% &#x2013; 1.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-316" id="f-1321">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-317" id="f-1322">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-318" id="f-1323">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-319" id="f-1324">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-320"
      decimals="2"
      id="f-1325"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-321"
      decimals="2"
      id="f-1326"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-322"
      decimals="2"
      id="f-1327"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-323"
      decimals="2"
      id="f-1328"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-318"
      decimals="2"
      id="f-1329"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-319"
      decimals="2"
      id="f-1330"
      unitRef="number">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-316"
      decimals="4"
      id="f-1331"
      unitRef="number">0.0373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-316"
      decimals="4"
      id="f-1332"
      unitRef="number">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-317"
      decimals="4"
      id="f-1333"
      unitRef="number">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-317"
      decimals="4"
      id="f-1334"
      unitRef="number">0.0366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-324"
      decimals="4"
      id="f-1335"
      unitRef="number">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-324"
      decimals="4"
      id="f-1336"
      unitRef="number">0.0110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="4" id="f-1337" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-12" decimals="4" id="f-1338" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-13" decimals="4" id="f-1339" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-316"
      decimals="2"
      id="f-1340"
      unitRef="usdPerShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-317"
      decimals="2"
      id="f-1341"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-324"
      decimals="2"
      id="f-1342"
      unitRef="usdPerShare">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-316" decimals="-5" id="f-1343" unitRef="usd">6500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-317" decimals="-5" id="f-1344" unitRef="usd">3400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-324" decimals="-5" id="f-1345" unitRef="usd">25400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1346">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5 - 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67% - 68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6% - 3.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1% - 0.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-325" id="f-1347">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-326" id="f-1348">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-327" id="f-1349">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-328" id="f-1350">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-329" id="f-1351">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-330" id="f-1352">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-325"
      decimals="2"
      id="f-1353"
      unitRef="number">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-326"
      decimals="2"
      id="f-1354"
      unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-327"
      decimals="2"
      id="f-1355"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-328"
      decimals="2"
      id="f-1356"
      unitRef="number">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-329"
      decimals="2"
      id="f-1357"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-330"
      decimals="2"
      id="f-1358"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-292"
      decimals="4"
      id="f-1359"
      unitRef="number">0.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-292"
      decimals="4"
      id="f-1360"
      unitRef="number">0.055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-293"
      decimals="3"
      id="f-1361"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-293"
      decimals="3"
      id="f-1362"
      unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-294"
      decimals="3"
      id="f-1363"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-294"
      decimals="3"
      id="f-1364"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="4" id="f-1365" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-12" decimals="4" id="f-1366" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-13" decimals="4" id="f-1367" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-292"
      decimals="2"
      id="f-1368"
      unitRef="usdPerShare">5.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-293"
      decimals="2"
      id="f-1369"
      unitRef="usdPerShare">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-294"
      decimals="2"
      id="f-1370"
      unitRef="usdPerShare">25.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-292" decimals="-5" id="f-1371" unitRef="usd">8800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-293" decimals="-5" id="f-1372" unitRef="usd">7800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-294" decimals="-5" id="f-1373" unitRef="usd">6400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-279" decimals="-5" id="f-1374" unitRef="usd">101900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-331" id="f-1375">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1376">NET LOSS PER SHARE&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the convertible senior notes, using the if-converted method, and outstanding equity awards using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the consolidated statements of operations and comprehensive loss (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(181,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_94" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2. Business Acquisitions&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the contingently issuable shares would be due upon the achievement of a milestone. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i02b9487756a44f62beca493d5cd6fd6a_118" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10. Stockholders&#x2019; Equity&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for detailed information on RSUs with time-based vesting and RSUs with performance-based vesting.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1377">&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(306,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(181,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253,629&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1378" unitRef="usd">-306735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-1379" unitRef="usd">-314248000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-1380" unitRef="usd">-181223000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1381" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-12"
      decimals="-3"
      id="f-1382"
      unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-13"
      decimals="-3"
      id="f-1383"
      unitRef="shares">204136000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1384"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-1385"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-1386"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1387" unitRef="shares">253629000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-12"
      decimals="-3"
      id="f-1388"
      unitRef="shares">224550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-13"
      decimals="-3"
      id="f-1389"
      unitRef="shares">204136000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1390"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-1391"
      unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-1392"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1393">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the convertible senior notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,690&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-332"
      decimals="-3"
      id="f-1394"
      unitRef="shares">31063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-333"
      decimals="-3"
      id="f-1395"
      unitRef="shares">20690000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-334"
      decimals="-3"
      id="f-1396"
      unitRef="shares">20690000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-335"
      decimals="-3"
      id="f-1397"
      unitRef="shares">27246000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-336"
      decimals="-3"
      id="f-1398"
      unitRef="shares">27291000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-337"
      decimals="-3"
      id="f-1399"
      unitRef="shares">21419000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1400">SEGMENT AND GEOGRAPHIC INFORMATION&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East, and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1401"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1402">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East, and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-338" decimals="-3" id="f-1403" unitRef="usd">105410000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-339" decimals="-3" id="f-1404" unitRef="usd">69561000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-340" decimals="-3" id="f-1405" unitRef="usd">64521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-341" decimals="-3" id="f-1406" unitRef="usd">40658000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-342" decimals="-3" id="f-1407" unitRef="usd">22598000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-343" decimals="-3" id="f-1408" unitRef="usd">30271000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-344" decimals="-3" id="f-1409" unitRef="usd">54453000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-345" decimals="-3" id="f-1410" unitRef="usd">36145000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-346" decimals="-3" id="f-1411" unitRef="usd">35721000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-1412" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-1413" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-1414" unitRef="usd">130513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-1415">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-347" decimals="-3" id="f-1416" unitRef="usd">120451000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-348" decimals="-3" id="f-1417" unitRef="usd">48719000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-349" decimals="-3" id="f-1418" unitRef="usd">61324000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-350" decimals="-3" id="f-1419" unitRef="usd">63421000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-351" decimals="-3" id="f-1420" unitRef="usd">59980000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-352" decimals="-3" id="f-1421" unitRef="usd">52181000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-1422" unitRef="usd">183872000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-1423" unitRef="usd">108699000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-1424" unitRef="usd">113505000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-1425" unitRef="usd">16649000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-10" decimals="-3" id="f-1426" unitRef="usd">19605000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-11" decimals="-3" id="f-1427" unitRef="usd">17008000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-1428" unitRef="usd">200521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-1429" unitRef="usd">128304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-1430" unitRef="usd">130513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-353" id="f-1431">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-353" id="f-1432">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-353" id="f-1433">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-353" id="f-1434">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
